<SEC-DOCUMENT>0000885590-22-000039.txt : 20220809
<SEC-HEADER>0000885590-22-000039.hdr.sgml : 20220809
<ACCEPTANCE-DATETIME>20220809164004
ACCESSION NUMBER:		0000885590-22-000039
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		119
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220809
DATE AS OF CHANGE:		20220809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bausch Health Companies Inc.
		CENTRAL INDEX KEY:			0000885590
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14956
		FILM NUMBER:		221148995

	BUSINESS ADDRESS:	
		STREET 1:		2150 ST. ELZEAR BLVD. WEST
		STREET 2:		LAVAL
		CITY:			QUEBEC
		STATE:			A8
		ZIP:			H7L 4A8
		BUSINESS PHONE:		514-744-6792

	MAIL ADDRESS:	
		STREET 1:		2150 ST. ELZEAR BLVD. WEST
		STREET 2:		LAVAL
		CITY:			QUEBEC
		STATE:			A8
		ZIP:			H7L 4A8

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Valeant Pharmaceuticals International, Inc.
		DATE OF NAME CHANGE:	20100928

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOVAIL Corp
		DATE OF NAME CHANGE:	20100416

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOVAIL CORP INTERNATIONAL
		DATE OF NAME CHANGE:	19960522
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>bhc-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:08e728a9-955b-42e6-9f9e-75e33d236c1d,g:6cf439ae-5822-43c6-a8ac-f8ebfd7ee7fe,d:762fba229369426294c4424c2015a01a--><html xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:bhc="http://www.bauschhealth.com/20220630" xmlns:srt="http://fasb.org/srt/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bhc-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80L2ZyYWc6MWVlZGJkODU2ZWY3NGFhYTgyYTBkNTJkY2UwMmU4NjUvdGFibGU6MDNiMGIxYmZmZTk3NDA1NWJkZDQzM2U5OTRhNTZjMWIvdGFibGVyYW5nZTowM2IwYjFiZmZlOTc0MDU1YmRkNDMzZTk5NGE1NmMxYl8zLTEtMS0xLTExNjc3MQ_d69b7289-8e80-43bd-a97f-35fc29539696">0000885590</ix:nonNumeric><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80L2ZyYWc6MWVlZGJkODU2ZWY3NGFhYTgyYTBkNTJkY2UwMmU4NjUvdGFibGU6MDNiMGIxYmZmZTk3NDA1NWJkZDQzM2U5OTRhNTZjMWIvdGFibGVyYW5nZTowM2IwYjFiZmZlOTc0MDU1YmRkNDMzZTk5NGE1NmMxYl80LTEtMS0xLTExNjc3MQ_b6e379ce-4e41-4598-9193-cce44af6e39f">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80L2ZyYWc6MWVlZGJkODU2ZWY3NGFhYTgyYTBkNTJkY2UwMmU4NjUvdGFibGU6MDNiMGIxYmZmZTk3NDA1NWJkZDQzM2U5OTRhNTZjMWIvdGFibGVyYW5nZTowM2IwYjFiZmZlOTc0MDU1YmRkNDMzZTk5NGE1NmMxYl81LTEtMS0xLTExNjc3MQ_d97853aa-7076-4374-aebb-c4e49112b963">2022</ix:nonNumeric><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80L2ZyYWc6MWVlZGJkODU2ZWY3NGFhYTgyYTBkNTJkY2UwMmU4NjUvdGFibGU6MDNiMGIxYmZmZTk3NDA1NWJkZDQzM2U5OTRhNTZjMWIvdGFibGVyYW5nZTowM2IwYjFiZmZlOTc0MDU1YmRkNDMzZTk5NGE1NmMxYl82LTEtMS0xLTExNjc3MQ_821d3229-1618-4c07-ae1e-f7b80e265b9b">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80L2ZyYWc6MWVlZGJkODU2ZWY3NGFhYTgyYTBkNTJkY2UwMmU4NjUvdGFibGU6MDNiMGIxYmZmZTk3NDA1NWJkZDQzM2U5OTRhNTZjMWIvdGFibGVyYW5nZTowM2IwYjFiZmZlOTc0MDU1YmRkNDMzZTk5NGE1NmMxYl83LTEtMS0xLTExNjc3MQ_a933cb89-c2a3-4458-9e61-cb3045dacf36">FALSE</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i1b39d2ccabe247cca573ab8370a379ba_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xOTQwL2ZyYWc6YzY0MDA0ODM4ZWE3NGUwMTkxMmRlMTY2NTJiNzllYzkvdGFibGU6NzNkNWQ0Mzk4ZGM1NDQ1N2JhN2M0MjZhYWY1Yjg5NmYvdGFibGVyYW5nZTo3M2Q1ZDQzOThkYzU0NDU3YmE3YzQyNmFhZjViODk2Zl8wLTEtMS0xLTEyODA2MA_b8f2dbc5-bf30-4ef7-9ebc-064c38ef7ef6">0.5</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ia07ca095cb3c4d2989e3bb13b2aa76e4_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xOTQwL2ZyYWc6YzY0MDA0ODM4ZWE3NGUwMTkxMmRlMTY2NTJiNzllYzkvdGFibGU6ZDI1YzNkYjFlMmQ5NDVmMDgxMjZkYmUwMjk3MzVlMDgvdGFibGVyYW5nZTpkMjVjM2RiMWUyZDk0NWYwODEyNmRiZTAyOTczNWUwOF8wLTEtMS0xLTEyODEwOQ_d879cf74-18ce-44b2-989e-f074ee14afb9">0.5</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ib6f49645538a4fd882535c15503691a1_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xOTQwL2ZyYWc6YzY0MDA0ODM4ZWE3NGUwMTkxMmRlMTY2NTJiNzllYzkvdGFibGU6ZTA5ZTYwMDdkOTY3NDRkNWFhMGMwMjQ4NGQxYzNkZTIvdGFibGVyYW5nZTplMDllNjAwN2Q5Njc0NGQ1YWEwYzAyNDg0ZDFjM2RlMl8wLTEtMS0xLTEyODE5Nw_375bdfc6-2be1-4880-aa65-2f13cf8cb6b4">0.5</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i8b237fbee2f7460db22b0481466222cf_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xOTQwL2ZyYWc6YzY0MDA0ODM4ZWE3NGUwMTkxMmRlMTY2NTJiNzllYzkvdGFibGU6YThkYzcwNjcxMzUyNDEzM2FjZGU1ZmVlMWE3MWE5NWIvdGFibGVyYW5nZTphOGRjNzA2NzEzNTI0MTMzYWNkZTVmZWUxYTcxYTk1Yl8wLTEtMS0xLTEyODI4Mg_eb5c6b8d-2128-4d43-8c4e-923d0e69dc80">0.5</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bhc-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e1813544ece4aedbf13459cd893081d_I20220804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5375b8e373564a36aaf52188e7d12cf6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic162a3439c8c430c97c3765d64ade238_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4dcf9828b6146d280f1c8faa0decc1b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2aeffa8d800d40419ffca17d6354a930_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77051dd59400460d84de895305bdc503_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice79c5989bb147d780b5ce3edbaaa033_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8b6d4b376e54c96b6861f58b066f558_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4e2c9d81976431390f8ae34842a6dec_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e13e115ca834d5c8178e3e30589f645_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="iecf0a43ebd03491a8cd2f55d19444acd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95b6dd1dfae14edfa03b4da8db2e5244_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd553c3824724691bb7773ce70306e33_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd7c9074c6584fea8bf7d00e43ce6c43_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c3a44068c7b46ba80b46ad12a02d69c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4391dfc5122a436f9abd2091fc12ec77_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3b6d9e41bb6491cbf140d6d7a14372b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4c2ca217eb1474a9e4606fb8ac62dc8_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0faf02d0dab04ba2a12aed2a72ddb539_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6ef01f8c2d44283b8c7b657548358e5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3678a5f161a2409b8cb49dac580a2b3e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07f07a50d8c848a5b09b20937a317971_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87b5d05e9653487da8ca7e66ab3fba48_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8730ee88d2bc423b9151cc9c2820d19d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36716f0b028846cb85d4eb4230d3d560_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dc7cc39fb2243a28ac5a77266758826_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b5d37c24d0e41cb994b6d343566c79e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i916cf2185b2841f8a9e4fd0d5fec5a62_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43b9c3f038194349830beac9c871e79d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dfaea77d3414998bbda1fdaa74c3687_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58298d9eca31468d856c6a8af9ac695d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i737ae3f3c29c44eda0e06a604ac5d478_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id66ae7f7283b4cb5b860cc7e725569c3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4373a86e3f3641b1b628310fe43e6cc4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc5bc84b42294f459a348f63c3726c9c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6daf46a421eb422cab6a685d448b4571_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06d85523749f4a83b2b4c231d9c4dcda_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57be2e142e074165b286ea861bf03454_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3059ef14d774d44a01059d4de19473d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i030001e1f73a4abcb80a144774c1d968_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76f8e88b904b44a792fab696eda910bf_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i774f5c7dc8fe4f20874a5a05070d8148_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i167c3eb2b5a24484aae6de79b43072b9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22ce8f1c4aba43659ab73d3c120bd01f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f0bb2a47484474cbd31c19016dce90b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadf2cdcdd456462bb8b4d9279093e8ad_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2238c74c755346c79d5d762dfe2cd6aa_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f2ab9065125401bb73c3a17f98f4c57_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94793ac34eb24e699f57a3960e391e71_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6618ebcc4884ef78540a8090e1935b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87abd59869d7404c8d073f59e57b3927_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb17c62b32e2446fbb119cdb52d7cf3f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a5f744b0e03413c9fa836c080e97ee8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i989da2ed6f4b41c18402f75e75411454_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16963925dad9481f931247cb3748b170_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4677f0249548444e9357645b49193bd4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29d13958e0ae471a9601cbcfbee2a354_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f62a1dbada6412d9a70817c07d9551c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4af951a869647b7a15353420cc9a86f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba4b227c13d94a3c8b88f5359bdef6ad_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2226daa2ed09422d853e54bab742c402_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ca51f98774641caa2fa73733729ac9b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6241ec65cd5841d28d2b1250bb5b5996_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12c22386ccd746679fcffe88ce0ac211_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i628fbe5e0c6641f0821414b9534fdfbc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f53aee8e3d54f4c9d733db6eaab6639_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83ec1ba0169043a5b8ee5935b00c293f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5e21899f1044f7fa7cb214f91d5655c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i168fd2ab08394dc88509e23e01fe1f09_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54f5ce0b0a044bc88c6f3917442a0aee_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8ecdccc3b9849ea91d1b8d126581ab7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4bd722a099c434c96732e1638d0eef9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if281e8e8aeee4142a78388f4196a2cb4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9b445a9016e474ea5b82e795dd9171f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab6dfe2f976644e99955a0681d7c0c9c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="country"><xbrli:measure>bhc:country</xbrli:measure></xbrli:unit><xbrli:context id="i1508df3b43b1420ea4df39c0ed271596_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1419e3c9d7064ed0ae3e2c5034298ca9_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdd2e805422643dfb113cf804f616871_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d34ce2c08d1460f808a069165908113_D20220601-20220601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i929d5ea1c5624f61b981d629befc7a9d_I20220601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1441c284542b4be69c98952b98de6886_I20220601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd3c0b53338441d68bc503e5527d1220_D20220601-20220601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id112e4cb690043fba76b75855a318fed_D20220601-20220601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bhc:IPOAndOverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5351c87dd28040558ca2b56602428e56_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41079230ec4f4c298b2e78b68dbf4675_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a1cc3e19bb5406f9f7bb16e324efb73_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4154c578f14243c9b9bf1af4b506141a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c45771f0e2f47988c015be717b2f0b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41e06bd172a5482eaf50c7db24abc26a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa9af24c349540cc966f28ac5d9956ed_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53c5043ff3cf49cd84342b026a1ccd23_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc6e7bacd9e74e10ab66ecc0b3c66513_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib43f03b9a4c24364af00b0bee48970f3_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib720c993198b4897b6de065be0d2db71_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0903c200bb4544e59a69d3d41e660f9c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c259ae988c6479faf350e58d008e78c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i635febccfe0048d18fbd37689e3cd69d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i415e68faef7f4ba28dd9ac453dcd2665_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1bf4e809b854d01bce396823e6d1480_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3635e4095c1b4cbf852ec17575d58b30_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f09824df81c4936b5ccd49a133e7471_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ca0942470cf47b0a264c45f0187b74c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9595e765516542c0911edc919a2de08e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9607524bf3464d7c9cddb1ba970385e3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i340db29595784ee08b18b8bab8b169b8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2c856c4b2614789b5fd854b8955fd6d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60bf28905a394c1890a5d2e6ceb0cfcf_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6269a678f67b4ecf9db4720dcce9ef03_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4887e1b949fa47e0995174f52a3c62f4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cc2ce2251ff4d70a86c4ce36ba413dd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38ce7e9873ed48928d8f66267a5181b9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c8105ccfc3c4797a29a70cd4dd59ad9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c02e9fd592b472e98bf4f6aa3087550_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i543391a7e8714bbfafcedd3cb1ad5539_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e5553f78cf642b4a35f59e0c0a41f82_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e4b08ae397c4999b5a89bd9886028e8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i946fa40358f2484eb2b268a38b324c08_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88092f2a3121475ea6f4d62c541f5263_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3691b4d8ff64742b92e7f95b3ab5725_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic98d97b553c347bba74a30a630426fa0_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60aea4fd35f0463c9e764ebeb3fc9833_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:AssetImpairmentChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b7ebf59aac94b30b7f7b423b41e117c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:AssetImpairmentChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52c2c4c1d1a5416b9c90de8eeb79bb48_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c73de91dfce436faf9fe431bbdc6487_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ee589a448d54140b1753817a06b38e6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73006e60a9e74841887814ddcaca7dc1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99ee9e6ccc2443c0b6ca3d2b22341738_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3945140cd4d9458eafb0336b8c0878ac_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationAndInitialPublicOfferingCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i571cafc77df6419e8f7ad8e88a7f5d22_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationAndInitialPublicOfferingCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1d5ed0948004c6da2b0030b9c2d5c61_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cce3ab850c54369b71be99818c2eadc_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd4d5e497f284e3bb6f031694e5e632b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20f3c15d038f4d9a95a41ec1632623ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id78b9bd044e04128813ea5234fe8bbef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic88bcecca27f4caf845d3357626418ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb74f1a8f9f947d5b4d8a76565d7e64a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61bd5fedea3e409b8e2fc3fcc1946608_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if25b6bb0d9734b1da12ac4c00dfb2152_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic835863b5091449ea80b36560fc1e6a3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8379b2caaf1244258cefe506e215e56c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9145c463e6ca4724adb2d0d6582fec23_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1b5f54af20f4de8bfeeea70bfb7ff42_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c974af31735487dabbddfa5989251cd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie63c790d802547cea65c40ded8c158fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a344934b62143ffb69252e4cddaf7f0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaabfd7c03ce9402ea41cfcee705244c4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombToBeDistributedToOtherLegalEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i189afe61ed934a13beac41e9a8e72d03_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3cc2ca14e8e4aa5b2cdb9d9edc76003_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="appeal"><xbrli:measure>bhc:appeal</xbrli:measure></xbrli:unit><xbrli:context id="i80db1e595e9640d1885c3342cd690c01_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54705085633648acb51a31a97ced439a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iece67921157f4e1a974430192b9d3bb2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74f9e7451c5d4e35be2c1947c78de1e3_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea270cf4c54447e083b7f756deb2b619_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id174b5ac9dab4a9795348c9cab5bd884_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5970569842e447ca7e924e7d2d9c57b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadd5508489ab4388a28166622ded71ec_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2748f8a48f1c4077a65379baa42188c9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e40ec51c8e14dcf8242bf19258f7e98_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56a275573f694076bcb43a832f0ec8ed_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5073339adb074151bb1c3f96161a4030_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b891f480d594aed8e806f205699bb48_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29a580e8bc224076a70259444452e1ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79fc8f975e3d4b62a88faa67e904f40e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96796514e5f543db98cc98707c804220_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1483a64c418348fa85a7a2e2d92d9a71_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0beb279eb94a4ed9a49020c90d93ed68_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i518e98f1651849d6aa762c450415511f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8726b33a91484a12951301843f01bde5_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a487257cff84ebb8f7de444b4ebbe8e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id76bfb01eac947359aab3481b8c4cc1a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="rate"><xbrli:measure>bhc:rate</xbrli:measure></xbrli:unit><xbrli:context id="i8a317605867040149a9dee38efc52b70_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85f23aaeb4ab4696888e25b5585acb6d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bhc:MeasurementInputWeightedAverageDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieac99a0231e043b7a6cf8a6875d75f4a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ed8d150a9e04ca1951e0567580a1c34_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i605f016464d646fabfb72ea00b5aa146_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26184bc3f87e42b8af77e4f35e46cdae_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6085cb4d390c424680c3eafd241edadf_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5faaf2aaa33e43408f0747441c0e1404_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61fbe90e93374904b5398ecb0a93c67f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a23787efe874f5c8d650b7fef441ddb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdab7f29e78845a9b4b14d6cdf3e20d7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b1968cf2be247feb9dd0cc924d8f8c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic83fa38af9914b0993c6039b714e49b9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19b47b5930ac4a57b58e47cb7fb6bc97_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0408adaddad474dbeeab55bfaf37b13_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43736d02e7b34234a0989ae49e2de7e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c83dd8e105e4a4692fb8791ce3bd76a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idda5195bfad44f2d9f625be80dcbf677_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ead88a7e4a8400f82d1ed2f6fed1364_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic81756cf7add4054878a13b141b160aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida1c327408524e2b9da48b8046b1596c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddcfbc0128c04d5d9a4a4a24b7c58559_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b3901031b674c118620c5be45160bef_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30cfd27625d04204b5b2e2739311e5d9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cc006d888334261a3b145852eb7937f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ff241de36bb4d838d517bfa74e1000c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idda6bfc9237c4952a9c07b6cd1fb8aa6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f2123e8bcd8437b81c7aee9a2cf5046_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86923f0a7d294df0951a3efb41cfb120_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb4539c0cd93410f8877606829a28dbd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b9c8e4e54e14c11a2541b80edd0ce79_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70c6f0d3c53c4ae0b8bac9c750c52401_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife7ba88747a44275adc038a9f0579315_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0e2720588804bb59fc95044cb42a692_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88df2b54d58543dd9380c146b625dca4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i382fa2f0b4d84cefb5705374b83054c8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife45351a90c740ae923457acb3f6c195_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5108829d89c48d8b0cb4fec084de93a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6009ca6df304f4ab8d03e57a2f270b8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a80fbad02df47ffb3f0b027e0c7052a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafb5fd0adbea424d95cb70b136e7d1c2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d31c842cea74aa198d8cb6778701a57_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i754ebf26cb214d2a9e08dde9805eca10_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff73055417e147b7bd096e9578313bc1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2b016ed329f478591978619289e8da6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dc4af5c709c464682b201a4d8b84132_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92e5ef7f7dc14944b76087572c2ba682_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief312576a3114c0aaed496cc8a87eb3b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e70d8f7f02147b4a2ff2c867e6566d2_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86bd562069224eb1a2aa48a2a7c117a3_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c7b76190d5140fd9da04108a1ed24e5_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i430a37ccee354cf9b59987d97e781a8f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86a04889bcf044b38603f4f4ca1d8de4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i864ee40a0f6549cab4f16fffdd93c3fd_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecd0285b18fe41da9fc167864657bccb_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b0f083a6d9044aaa355608d9d198fb8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7f5bfb1314341ee926c9b0fc40e54e2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f643780bb9448ef9016e16f6b89c2c1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f56f31b09064a848920713fa0661b76_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i647555e6b2b54c909b5caeb1da998334_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5607e58e61534749aa9df1f4280fb05a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4284138a323449c291086d55ad27a489_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcb19cddd3134b4d8f4ea965f330d69a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31f42e923b084ff0a4f4fbc812d7be7f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie53716daef0b4224954a5c9de0faef7a_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if80b04373ab14c578c53ef3c8014d242_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:ReportingUnitsExcludingOrthoDermatologicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e3ff28c3d904d4bb50e1f6b60dc5774_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i128de9e46d854032ac8fdb6fcc689f05_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie76f7d931cfe4a698fa9381288d5e165_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefe6bc2fdd6b4faa87a273eecb773668_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i448fd15a1c2c4081960f6912ee1d7df8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48edc6c592494439969797a031f0a38a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifede6e1372dd4ddb9ca2270e1f8b8a13_D20210630-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-30</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i495d40d3ed894092a5e407185421dded_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0b5d00c327249b888e21da2766eda53_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib56d8698081a436cb05434bb225f22eb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="reporting_unit"><xbrli:measure>bhc:reporting_unit</xbrli:measure></xbrli:unit><xbrli:context id="i15ce718b5f734e61a6ad0bdd28c54691_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a8c0ca7ff6d40f5a4b99dd032ce969d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56c650b8e02f446bbdb4b9a650860424_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i161c125a316c41338df59b517707ec98_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6fc6e77709e4c859b776fc4a4a569d6_D20220506-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-06</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09575f835d044c72a01f338fc66e8824_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fd9c089632f4f5f8b22cfa9e437b633_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a6c26cc64df4c86826a5f9b2862ceec_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied74a18a6e8c464cbf9706fc4935c4ab_D20220506-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-06</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08e5c94f206e49029306d4605cb23f7b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc599dddc6874659a5df85bf6a360251_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie564ee44d1b6403eb498a73450791f9f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc66dfaa572849969745a0c5f0b68d37_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i793328a205eb4096950273313b00bd65_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fa6b74354994e99b127ae89877febc7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0edf0a7a93de4224aba9d200f79ca4dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2335f26e5e14e98a36115419811c130_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c45bbfd4f504c27b6226cc0c73a33f9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieadee1866a824ef498fe7b558d0181c4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40aff33e8b24488a834a063a1529422b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafc837c840c1423691e83ffca1191fb0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cbc2b4901924769a731d568c6814714_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f38d4ca2bf94b95844417747e708aa1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7c9cb43c0384e9db889a190dda21497_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b1a4f289c1e48948d7f02b9bee8c3b7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf103131598445f68811c80a255e6f67_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52543bc3134e4d3ab18b8abb808ab987_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfe50f19787342d2a1eba96ea86a16dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d8d5f877595471594e7cd0d8a9a9bb3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0abb0ba205745ee88868776020e8f2c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i833d75561bf74683841f8a1a38848570_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cea3fe80b2940b89f52022162775e03_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28a10e63f05e408188f20f7b9cdcf496_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia55753b63d414228b384e230c86e775f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a25c3e0cf7640eb931b7c3c9e6872cd_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee049418c13b4e299a8c83e2be11bc55_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8a3b188d15b4912ba75bc9ee39e79b0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a975e0e21154064a6bcc406c36b62b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee91cc92408044d795d6bcf969858eb1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f324ee7a47e4543b63557fd35984d09_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9165a4c4fa4438b9df24cf0a0792346_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if803056461c6486db832367a43895632_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i398c1b11a4d14d1a9a22642a4366b4f3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13687ae43098477691509c97baced059_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7141189be3804bae89bd5a07b8eed649_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic76bf6c1d1e74dbdac6341facf5d2281_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2065ef23dc6d4584b71fd6c1feee2ce9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia157a13c8e7444d9a15b0ef900f499ac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55d39b6dbdc64a07aafafbab0a66b4cf_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4db4028fafd541e2adcdd0f2a8acb446_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14f52e507b3c4725b4e1096cc5b3092f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b92a3adf20a4c61a5df00eff00b36d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c2ba2913e7c4009a057680b01952716_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa56bff66e564adaa6394ca261106b7c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeef119d45684adb8aeab24feb20d75c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8fbf55e1f7641c9a02ee367f63c49ea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5eee7cc73d847faac3aa9d22d79a2c3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c1392391ca546758b079e1238c10a9f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie97aa1338630440fa931939603c3afa8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bhc:SeniorSecuredCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a193ea233134644af3474c6d58858b2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70293a619f5141b8baf60127b5cdb2d3_I20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dee274036df4695a83fc9e2f921cd2a_D20180601-20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3f9fb93db3f4b06852f02dd6bfe37ae_I20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd3b61934fa0481cb903c6cad1023951_I20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id684a5f342be4a9dacf6da92dfbae334_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie870cb7bef5c4e1f80f119d7291d6694_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6da3d0cbf2d147fc8ed6d47a33114b1b_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if697bdbf4b2341c28c62cc63991814b1_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic821cb350682455fb80a7cf379859436_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3317da9d69b44a5a0f5530521c43d9a_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib41ea84450c549cdbd5dd7eb01cb3125_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b5b14287deb4a36811e3567b40c972b_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e01c970675a436bbf061ef17c476e22_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:CanadianBankersAcceptanceRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1101765767e40daa36e42e2d05de9aa_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:CanadianBankersAcceptanceRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdc5cac429d2406fad6f5db1a981f8e5_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:EuropeInterbankOfferedRateEURIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8243ac81d9d44639387960613fa815a_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e609a7fc5194c08831552ad31cb3326_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i084c2ea2f89c4a93a0688cf9fa993c87_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDORAndEURIBORRatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3357e0f78c5d4623aa4578bb9c5bfb71_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDORAndEURIBORRatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e66748d2095465691388b65def844ec_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84a6900222c6444eaa2f43c56b21657f_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ce4074fb09e40f88a53999eaedb2071_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia63076c25e4a4832b2cbf2122f93d974_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31d884d227e045f3b2a89fc5ec26f5bf_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88238e27384b4699bca91ad69cb37063_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b587afb6b2449d6abebb3e8259edaf4_D20220630-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i317f673a636e4cfbbe6308e053f9a1b1_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i222693060eda48fcb8a8ff27a64972c7_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1be7401b40834ec4b9897f7ca08a3bcc_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:NewRestatedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if65afec1ca9042d88f04d82fb68476c8_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0459e2e91fe04b5099b8551dc212bb5b_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i025e4c51c5f2476eaa7e7b81b3dd925e_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf0a3be8d6bd4202945aa5df250dec6c_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13fb480b68044eeba4d131527e8279e9_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5197b5b99efa4eb8bf8f5a69128f60d6_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id57f7f9d4d2d4e3e9eb4720166ca7a73_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:CanadianBankersAcceptanceRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37e23f9713ba4df0a3897cb703b32626_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:CanadianBankersAcceptanceRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b4a82c59de848fd933f25769865c682_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:EuropeInterbankOfferedRateEURIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic57a642f15b64fba9bd4ead705bdcd69_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SONIARateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i745d6bb83b7948309a5bca9ce9967c7f_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SONIARateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i794772c7b0a94cb4ae0831e44b12025a_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if00b75865db04bb2a36148fc758260df_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fa8451ab2b24a2f9856257a3e56525b_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97fcf2fb2a11462b97034820ecfbea20_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89435b8df34c4e929c8786a5809ae39d_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6eb7b9d116404dcbb45abb5c29aab3db_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia79343ddb46b49649e9595a3a81569bf_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f27835a65de4739ba485d7737c8fcf1_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4503aad9ff7046f7b027b10d33ee0a67_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62be326ed1094f42a72cf8f28f3824e9_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bcd09daf6ff45d1be1768c23751ced6_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i586f734bb9414bcab81efe9583058179_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54647254f8ae45e6b7709b92695601f7_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86c83d00da024414839c7b0495b95f61_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife48262157f54a9f9411801fa38bef33_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31491c26d42f4c55a76225f7c3e1437b_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:BLCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib72d5c0c9cae4427a65ac12763613c50_D20220630-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22e56e38486147d28bc2898f73182eef_I20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if19b6a01b94c43baac9f6b2e2576cb33_D20210608-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueMarch2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2801d5faaff4cff805188a7408a18d9_I20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueMarch2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id15e04f207ca454ab4b3869196ecb3aa_D20210608-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ba95d1a1d8a4e50be9c80b6091f5c9f_D20210608-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i670946275ba0478c9fa99c66c759a07f_D20210608-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88c94d8d653b41e2bece3ba32629f570_I20220210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaa9e9d10abf4341b32b2669fa6bd9c5_D20220210-20220210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-10</xbrli:startDate><xbrli:endDate>2022-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib171e1f6ad134f1e8a838ae91f96bdc6_D20220210-20220210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-10</xbrli:startDate><xbrli:endDate>2022-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icacf3f32142f4f7793bba94c9b3e3ebe_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib86afa84ce1b41d5b48258b10accd8f9_I20220118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.00SeniorNotesdueDecember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00eb5a1c1bb64566b2473aca50a87f8b_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib99e0e69c7014f3db279170c3e995c4c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79deb0713cde44578625b28d0e656766_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0acce2b828944f6db85708f4bd37bcd0_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b39d2ccabe247cca573ab8370a379ba_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia07ca095cb3c4d2989e3bb13b2aa76e4_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6f49645538a4fd882535c15503691a1_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b237fbee2f7460db22b0481466222cf_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cd8cb835ea2462f98e5d1fadf8a2bf3_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0860bb9611a474495df2c84fca443ea_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba8a2efe71f24a6fa3f18d4fe8dc0568_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i666ce213d28248b1853cff9f08dadf3c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9f1c1de00ee4efcb8697ec7c3c5c449_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ffeb2497315442bb679da042122c643_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b4bf4e8fe81409981be4a7ea9e8c8b8_I20140531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fcb725d105e49e7b841b1a1b6ea5845_D20180430-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-30</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6c3216122874ca2a63bc8576f858181_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ddb299f73684060bea0bc507f71ef99_I20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d0bb60ae16b4974b67f6d117230127a_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d3dfe74f4714b7a933c87137684aa03_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6202db2af2b4bafa11ccccaaf34418a_I20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9090a13c2aa6459eaac11b6d545fcbe2_I20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f3765198c384eddb84bb962d8f1d47c_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i224371ec19ea4a1fab4ab9edec1c44b2_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82c8f4dd25114f83975b0eb530968e3c_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6be3a30d81ad44bdaad72c4d270fd4a4_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i515efea05dbc4414985b6f9579a6bbce_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33dd60c60854413ab4b719ac057cf817_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc3fb9c24a1a42d6a1abed1c7e372f2a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4690e57d623418889d484725bb730c7_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41c4ed7db4b34d4bbdc90c34f51f1caa_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie919cd08314e401e805d15dfd8c4b7f9_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id624e9058a214f69b2edf512f1e9c531_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79b44039ced246f8b01d5c45ecee92be_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7f366437a554f0881430dd47c95e590_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8324a3a87b5b4431a240a863bcd109e7_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i162c7abaff6441bcaafdcb7c3786380f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia50d9a9309cc4eeabfd8a0b7ec06cbb9_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd76194575be490ba80170f4fdd8bdeb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c788daa389d46c7ab261260e329fa06_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2a52a76022341358c404e2fb242b953_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd6d0843d657451284d1138fc8962e1a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4c50767d19044e08e9feb4b807a2916_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc74e57032d14542b4caf11d925a446c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6dc26b569a743babd2022197af82304_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i451c05ed9bb34dfd81236d9bd495bdd4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i697b06c7bfab4c66b24bd5ee7d182aff_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icac063b2f1aa4b21b334538c17b2df50_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ROTCPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i557729c1fe0b4b1480972c1737bd0a7f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ROTCPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie92ec71133c44dfc990b249053e5e02b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:SeparationPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadcde18252cb48d884cbe14183aa9c67_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:SeparationPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68d73c7e5e384257812c2170febe4778_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f24f78b6a854ff5ad91cc5ccdd5b4af_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab029c733228479b92d1b8a6e2205965_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd8a8752f1f749c88cde59232457ef50_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd08efb021e240aebc5ee605feba929f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i720ba0ebf9c2430f814fa6947f648cee_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25c764472afe40a994fbab76db8f8203_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i488260ae8425453ebec7df5c26c9c934_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdc7a899aaa242abbfc3fb10b5125784_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib81ba7780e6c4af981ed3d93789a7a30_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bhc:MilestonePaymentRelatedToCertainProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib67e20cff1f34666a7bda60fe85e0092_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb9c38f8768a42babfa04ab70b2ba49b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c6c606001c0400cac53065471f71ff1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib34295b40b53420292196a9f2aa2100a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib34421622cb84c04846df6c8e22ebbed_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b78053555ef422d9b068388d75f6068_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d86e8e57d7e44a4bdcd3c9f0a800e7d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9065eee32f34d6fa02a0d1a52cb32c9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie62c44e3a5424b748e2e6a9534f2057c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30507c6e944f444ebabb56848a53aea3_D20151001-20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="case"><xbrli:measure>bhc:case</xbrli:measure></xbrli:unit><xbrli:context id="ie30ec1de778c473aa24992db460e51ab_D20191216-20191216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-16</xbrli:startDate><xbrli:endDate>2019-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74040cd3e59640bf9752be2e23b0ac69_D20220630-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:RestrictedCashAndOtherSettlementDepositsCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4102d9065afe4932a90e498521bfa3cb_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="group"><xbrli:measure>bhc:group</xbrli:measure></xbrli:unit><xbrli:context id="ib9028ff993434533b2b5623750bbd556_D20150101-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5274caaee15944b38fc2385088096f35_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="action"><xbrli:measure>bhc:action</xbrli:measure></xbrli:unit><xbrli:context id="icb691d8ec4ac4d71aee1342723827741_D20200804-20200804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-04</xbrli:startDate><xbrli:endDate>2020-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="i757e35cf9f3d40a4b5c93f8ca62f5f21_I20190215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="entity"><xbrli:measure>bhc:entity</xbrli:measure></xbrli:unit><xbrli:context id="iaf7e31cd823147eabf32516dee47b2d9_I20210317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d58819753a6484caa4ffdf910353903_D20160527-20160916"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:RICOClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-05-27</xbrli:startDate><xbrli:endDate>2016-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4305560891084775b5a8f280c90557dd_D20171207-20171207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-07</xbrli:startDate><xbrli:endDate>2017-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="insurance_policy_period"><xbrli:measure>bhc:insurance_policy_period</xbrli:measure></xbrli:unit><xbrli:context id="i74c5348c904e49149ebdc8edaa5089a9_I20210720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="insured"><xbrli:measure>bhc:insured</xbrli:measure></xbrli:unit><xbrli:context id="iddba8dcdaa5c416aba241e33eece7d94_D20210720-20210720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-20</xbrli:startDate><xbrli:endDate>2021-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59952c7ec62348a0bf0304c3e9c4aa1f_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26aebd3fd2cf4b1b9c6310ad6e35e2e8_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b5eea4e2b054fe9b33f5a1c2468e6be_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bacfb7cad21454aa0b7847ed301e366_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1b9c6e509b24bc380ee524ca05ae442_D20210726-20210726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-26</xbrli:startDate><xbrli:endDate>2021-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a2d38205ea946e095aed8012d8b17c2_D20200326-20200326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:NorwichPharmaceuticalsIncLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-26</xbrli:startDate><xbrli:endDate>2020-03-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ccb1877ab504b0da10aae4fbd2023a4_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PerrigoIsraelPharmaceuticalsLtdLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0c3cf86c7f3419099a730b07b8db1b8_D20220721-20220721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:TaroPharmaceuticalsIncLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-21</xbrli:startDate><xbrli:endDate>2022-07-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ada237c7e9e4db3b48af8ba931e7f96_D20200501-20200501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PadagisLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19fa8a54dc9d4942b1269451e77f4405_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:MSNLaboratoriesPrivateLtdLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i163c3bd2391743dca52453bf7bb54c2d_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="defendant"><xbrli:measure>bhc:defendant</xbrli:measure></xbrli:unit><xbrli:context id="ic0fbaa5244774f8785a4c3159850c238_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fa2cc2f25c840c8aa8cd8f821e0e024_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">bhc:DefaultJudgementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i535a21de35094309b7dde211b4cc6c75_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">bhc:DeclaratoryJudgementActionLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e13b85e78034bd58a4c8e9b49e1b7f8_D20220809-20220809"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-09</xbrli:startDate><xbrli:endDate>2022-08-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i699127da9e51419abf9760aca1b136de_D20220202-20220202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LumifyParagraphIVProceedingsSlaybackANDALitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-02</xbrli:startDate><xbrli:endDate>2022-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9baba49f62e74a14aed75dbbd081c3b4_D20220202-20220202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LumifyParagraphIVProceedingsLupinANDALitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-02</xbrli:startDate><xbrli:endDate>2022-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifac3480ee2d142bf905b63b471677601_D20180801-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PatentInfringementLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic187ba4416b64839ad042a51d60bfdd1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ApotexIncLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>bhc:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="ibf92d71d956242d2ae34c263d78aac0a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife18e9be510b4194a3a4277ad67e7250_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">bhc:PendingLitigationAgreedStipulationsOfDismissalSubmittedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8381d2aef44c4cb6bbf760cd8d3e40b8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i768a63ca14b44cf0a9b21c5ad06e8cea_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0c00ea3613744deacee586a7d91e4c2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-BC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibed3ef3f1abe40969ae83f8df49eaddc_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i256a9238c6d447949e96e0113ba7913c_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1614b745c4246e89dd4a1987611b15c_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3da2b3029b9e49809af6f64595c73392_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:DoctorsAllergyFormulaLLCLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i521280a2735e43e2bc975a7b850cdd00_D20190128-20190128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LitigationwithFormerSalixCEOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-28</xbrli:startDate><xbrli:endDate>2019-01-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99a74cae63104c7b82e2b04e1ad12241_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i135087334a5d4c22bfa9b973191edec2_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33f1397d8a6c4970be8e3744fa05b614_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa70c909ebed4960ac5793fab0872d29_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1fd4b8f2dca420587be152cd56a71f1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6165a9798c56425cb4efb5a5f6723bfc_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bd4de5a193d4a029240767ca5a07233_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife570419c7bf420eb1abf7c964aaca40_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3029344c603341c39ead09035d7dfa4d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dd827b38d174dab9b133e198c4a8961_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58ecd7a903984152b7f6c2ae9bec8334_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib91d44ce63944098b3420f5c3736b8a9_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc157eb51cba40e89c5c61507c69e6e5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66c6b838e58742c0aec7f7e50a13b045_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ffd9a91d95843f5b57ffc1c00e8f083_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dba412bc4484690b009184d4ba468c6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52b7ac6f51a042f3af9aea0cd5d38c09_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i641af432b0f64dcb834dccbe69309abd_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if41baecc67df46e3909a38e74cfc03c7_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4ade95eb6964658bc80338e46f307dc_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7050fd087c144698ee6de6deb8f7b08_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56f9693a8c8e416f9524496f13d18f13_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i457d6b1c8dad41d797d6f3caa45e3c46_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c0e69d16e47492cba77b50588ee0475_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8193e2fcad6a491c9c98e5dadc6de63a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabd877b8ef23452c8e9fb08b70c21536_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7fcbc8743ff4d28a9642d1d245a31c3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia26aedc76fcf44ae81e064729f28caf3_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i341826d4665e4f9691c35f15ba5167d5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i120c5c3448804817954acd3db4e441ce_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f6e559fe09a4393a2f7b2d796409368_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1917cf604f114f61a3027f48b8e509ba_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i304de3dee0ca46afbd4d773d5b73caeb_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5bdd34908934731b3f7ed30e692ca37_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib94cfde72d4a4cceaa45cabf3b8613fe_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i697b4e937dcf4444a2da425da4f9da4a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bf870b296aa434ba035c90e0472f7b5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37722f9f64464a7789b7776cda56802e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68e196aa912c4a06b50fe1a7ff07c9c3_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1535a26028ca41d681e4eb89f1cab0ef_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ac012d36aa744d285111dd5bfa0f49b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1532aea43eb6489e973b019623e7468c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40ac48836f7b4475b5d15a50602624db_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3591c7e9bf84e3b97a9bfacbd8fc4c0_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9945eced06dd4de19098303f4b0695b2_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6fdf97ea30640ada7e3f06ac163c2d4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i363714d873034daabe033fe4530323c5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18def26b9d7f4f769191fbb1b702e4e8_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dde17363f0241f99f397e9fc622e2dd_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e6d327e99e94ae6ac9c9222edaffe89_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2c6d5fc0df14fdd8c5d865fdd5a471f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5244d54181f2446bb8ba651b7b0fbad7_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id527f274d97e461ab64689a5373f4d81_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b3c647fe76d46f0bc12c314d43c29b1_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4daa40222c247d590b95cd5d1197454_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00857c1731c645e18fc5b267ac5193c4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id70a3d87ffc848f3a702d8181bb0aac1_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9098718d68eb4191b04c1220647b46ac_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98252b07170a475c86a2d0a8454ebb3e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d0cc468650a4f8eb079db9c1f1d724f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb0c495400cf41aaabcb4ebdf8cc8c54_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52b3e89147934577b98cf490c2dc6e6d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad533e12c8984d1aabaf4ca2ea7f295f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8a84b3f2b824ca7bb450377f0288abe_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id997cc25c0184d418316a9c77c4792d5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i175f3c9ffed049e683076ff08bfebbbd_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia439123672ce49b5b793b5103844ab11_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3a10c843c354c3eb832c610df7c4cec_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i094e2621cd8646149b22d5835913eff4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8d1a68df38d4361a9ac80a5d0b7650d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f1a30d7d1d8412cb4ef23629b723985_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55e9e9d493b84ce3b937b48d26431696_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia453e822304242f5817dad90b1b13517_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf81fc999e7d4614a4ac10b31038913c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie523d947f1fa44f2a62fe53506efc11d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45ab7ba925334c48973d75b0c877af73_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic38842b1d031468aaa7b2c3123e44ef8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i636acc71a6ad4a25a53a6db7c8380b4c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71427b5dcdf84da295d3722e33c25b53_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieda5739af68749139a002f6bbc8b7968_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cc095d5494b464eba663d1927c92206_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ff22abce45548b7ae5bae24b04a665a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6117b7192764a0b83f96ffa1cb7174b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66e4cb2eef1c497aba28c323a09b369d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7885ad991d8747f994509e41120e1156_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i033175b733ff4d76ac19b4af757b2c72_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a94cf1fdbb647919430b66b2c3f4818_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa1d61d59efe430d99d872a21dbbb93f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58fa049f1be9491d86f8e95d6a2c5777_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie753b580b8874261b8650c0a68ba8d70_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5c02cb63e5b4aa3a0984f648ed39900_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecf369ea76514f31b38a239710bbca0f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8530b669e5514873aea052a84f77f1e8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13a41399fcd14f7c86e4befc31b9bed4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96c50519eebe43e28fe0e6f1d4c9fcf4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96c60e82572346049ef163998e5a970d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0da421ef8e5c446692c399776ebed030_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0702da316be6440e840ce3f2f1780427_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddbe6a4096ff457cb62338fc9c69d310_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie25fd17d002a4da395da4369a027c307_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4ef1ddaae604d258905581fe15e36d0_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5239df425024a3e9d3b04b6422f8d1c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i425a979e48b04f06b178c9b31d745920_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1b2fa78c45a42dd8e6d9fc4f37b7f8f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd114af7b13347929658a839ced9cb43_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c7ae506423648cf912c0b4dafc6bb92_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fa22ed31f5d47d78586f590cb5b2296_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if81393d129bb4f80a2217b7c9d4c8957_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08b72bf14f6c499fbdab27dad66f293c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2e2aafd1b5e4899a9552e3dacb16fce_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffba9783b7fe44a6935ad5a994bbbee4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id62f002563a345a4b90b427b6746a4ba_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff8125862d7c4fa8b63656e4caef3fea_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1843b2170f054dfda4d14d6b65d9e07e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i875a6c5886a44cbe9f224b9739a1d650_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife0400651f12423ea171a23fe5b7b728_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9906ce0703774a55b40a2d2cbed1fa6f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ba7a99462cd4381a45f105bbdc6d784_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39805184860940d5bd360342cd8f0cf6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf03874e602d4ffa881dc7e9af5ec89f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic07dceb99d094428b0107fdfd7ea2ded_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b8d25aa564b48688828b7b52a248072_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa7024726e6548129771c398104f4234_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09631ce9f39243a38774112d96ca119c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36c7f7595c284373909f23141e52949e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4105a97cccf946db9ca58a8b45433ea7_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57f06f60daf14282b059eb9c693125a2_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05e092a9ec4e49c6a71e8efa4a8d7087_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4002b0e7cb584f409ca3835643a996ce_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ecff54947c94ec5a731ac192a3eac6f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie837436aa8784d168ff0c0b936ad7cbe_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5f965033d67432c81edaee2da1a1977_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bde276d18e442d082198091776c5340_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i406023bd6e5f421284bd2cc748d58de8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86081bcd6aa54f46bf54174fe6157caf_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d9741cc605c4351b5b3308c245d8cae_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bfae50f3756423ca86237fa9b199c6f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie00839f31b7c419293449f6db9edd59a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64314cb261074ff9adb800d48da61982_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i895071e19f56442e8979c066881d9317_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia36c07693d1f4df588ce2d80fa89ff6e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib42a147c0c7b4941bae23485591fe3e2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c9e5781756f4250be2a94d03142b737_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98b834d54e804d5ea61ab8adaffb5153_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fbc6006e021429bb57b14e5be7faea9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a5341f0ece54bcca5e06f9dbc2c5aa7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4be2243ad7b746ff8509e04bcc66e578_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28cd923a4f904a5da05278a0549bb209_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a79025dcf9b4067a64a869b30e5d82f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85da69a1931c49e8b2e5ce17cb63defa_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c72a40331c64039b9c3787b46aac39c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf5411fb6d544cfd8fd5bf410f862cbc_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5a9a936aaad4510ab5bf3d9d20d705c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73af0e3646d5483ab230a7ecb7d39952_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia56d626754214d8bb30c6d8a7af45bde_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18484995d42c4a828a942edcda3b3121_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13c03a791f84448bb0b7d082960d3002_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ed7a35687114a9980b0c5849d0ae283_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id15af34d73934993bcabdfba417f3137_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id018321b208247d78d77fe559ea5026b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04f8b4bf53f849b2a0c2101807367a6e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99757cb9fe65492481f94c5710ab5f19_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib382d5d0d22742d48bc99e77c138c9e1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20309133d4fc442aa35447c20bd22671_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>bhc:product</xbrli:measure></xbrli:unit><xbrli:context id="i2cfaca18cad64ba8b05f366fe634d9ef_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4deb7698e4954a5b8d104244e7a7dc24_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9362d500d1bd48e4b930877c7401396e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i456aa1b7ef8e4440b7cb8b6579de00b4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5171d1e65dcd4cbdb5cc14e47de1aa9b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9ff5741a13c41598bd951eb6df22a49_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9c0f8ff2e5749af9aff83169945c02a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43c8fbd8ff914b6ca19f0386f21d064b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14ff28c4ec8a4de49643e94dca541c07_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia381cdacc8be46eca693495fb7945846_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe893c791888473889bea0f1c91bcd39_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia641b1adcc574ee0ab038b7fa110e50a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7834297d0db94dfe9f7141a9f3078f4d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i591e4832b4f54fbb9d7adb9df692f736_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ed4f56387c146ce93bc623b05db992f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f1990f6b2cd456e92b332bb89de592f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60c79a94ccae45868e7311a72fb1d515_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i884265fef55745918deccdac9bcfa489_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i069927ecb29c4fe080759394b3c8dc0c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ced9f4e29364491b1408b971112bc7c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdc9dc66188149c59e6c7ce0524d38b6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bf2b6a85341450abb18712f9efb5eda_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7053004fc5084f679e0978de05d595ea_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31517ff0a8fc467a97fb7a044c926728_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70de35ed376b493a9c17e9a01ab991c0_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib63abbc4e400433b9f6ec4a807834bce_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60d3cf48dd964670a527396a7fe4eb90_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73244b3c309e4530819a1d26aa067e4b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie300b629f5f74f4a92f1b3212fe0f30e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6948cd6efdde4ea5884d6a6035885001_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idce9b5dcada741cfa3553faf07a2ab29_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17e0e178db084c9caca62884ab5d8e93_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e2d85cd6a68443cb41d6924d9e95324_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42b0806f1ff343be83a859afbca2a621_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i443d6ce9e17f413aa131fd871f9a563c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i084806bf6a674211835a0bd79f97abba_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a390cca570a48afb39f787bcd7cada6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i869eb22b61c947cda0c17505c748ba31_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99dbbb9db6434a699d016c9c43e9044f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icce4f70058be4e0b99727594cbdf1550_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e85ab61967049ef95c26fe225814698_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i007fd7d6bf5e4f9e867874fad1935ed7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5eb5ee1718564d8b976f1851830b7dbd_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i059deee3380c481ca365b22d8012a26f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcc32b6fa5394db2a95a6046a14c34da_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb02cd70b47347f8b7ffdf5647ef00c0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7079eca37c44de7aacc67bf6c5a6511_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b1368ef6dc84e9b8b1bacbf9cd7dd96_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib74d8519f3d64c62a7f44ecee5857716_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefa92bbaed9340e4a7f6b8cfcdecb6ef_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70e4a3d5230a4ff8b71fd4c1597f8ffe_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b528c8c45d94928a7607bd144197d86_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if74073e3926d4398abab160d9cbb64e6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c750ce60d174c2d8ea17243fca49290_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i420e7b1dee5c49dbb3ab84d5bf60a017_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id551f20a7c294526a90193e44a7d481b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e57a428831244d0addaf1c93da509e0_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f42c8f52d064fceaa8822b15b9cebc7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cf345d189714dc1bec54dec30d5fe8a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i648582730a944818a8954c08f4676c96_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i227c1b875ad04673a4bb23d3cb69932a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i640e2ab4eb224f69a463e994c0e65ae1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ba3dd5c6bf14d8ea672f7543ae52430_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i555a31f9bb61484a89ccf486fcac5905_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83b432d29b6b47c8a7c436116ed24dae_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i762fba229369426294c4424c2015a01a_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 45.00pt 36.00pt 45.00pt"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGV4dHJlZ2lvbjozNThjNTVjZWE3NDI0MDU2OWJmODA0NDAzN2FhZTNjNl8xOTgx_c0d716aa-0942-4eee-bbf5-68a5bcbe17b1">10-Q</ix:nonNumeric></span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.798%"><tr><td style="width:0.1%"></td><td style="width:2.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGFibGU6ODhjYzg5Y2VlZDJiNGI5YzkyMmQ5ZWZhMWNmZjVjOTQvdGFibGVyYW5nZTo4OGNjODljZWVkMmI0YjljOTIyZDllZmExY2ZmNWM5NF8wLTAtMS0xLTExNjc3MQ_d1847283-c435-482c-93b9-b8402c2b3d44">&#9746;</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-align:right;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Quarterly Period Ended</span></div></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGFibGU6ODhjYzg5Y2VlZDJiNGI5YzkyMmQ5ZWZhMWNmZjVjOTQvdGFibGVyYW5nZTo4OGNjODljZWVkMmI0YjljOTIyZDllZmExY2ZmNWM5NF8xLTItMS0xLTExNjc3MQ_639f6896-eb93-456b-9643-fbf57d770174">June 30, 2022</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGFibGU6ODhjYzg5Y2VlZDJiNGI5YzkyMmQ5ZWZhMWNmZjVjOTQvdGFibGVyYW5nZTo4OGNjODljZWVkMmI0YjljOTIyZDllZmExY2ZmNWM5NF8zLTAtMS0xLTExNjc3MQ_8a9e695c-b9ba-4406-963c-9a1c631a37b8">&#9744;</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the transition period from&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">           &#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> to&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">           &#160;</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGV4dHJlZ2lvbjozNThjNTVjZWE3NDI0MDU2OWJmODA0NDAzN2FhZTNjNl8xOTc0_44129916-4470-42c6-b2ce-20d4aa4e0a09">001-14956</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGV4dHJlZ2lvbjozNThjNTVjZWE3NDI0MDU2OWJmODA0NDAzN2FhZTNjNl8xOTc3_7b4614ba-3825-43e7-aac1-2be282949561">Bausch Health Companies Inc.</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.816%"><tr><td style="width:1.0%"></td><td style="width:22.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.330%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGFibGU6MzY3YmU0M2FlOTUzNDhkMTgzYTg0NWEwYzM5OTQ2OGYvdGFibGVyYW5nZTozNjdiZTQzYWU5NTM0OGQxODNhODQ1YTBjMzk5NDY4Zl8wLTAtMS0xLTExNjc3MQ_fde2cbb2-227a-4b13-8c02-654174d102d7">British Columbia</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGFibGU6MzY3YmU0M2FlOTUzNDhkMTgzYTg0NWEwYzM5OTQ2OGYvdGFibGVyYW5nZTozNjdiZTQzYWU5NTM0OGQxODNhODQ1YTBjMzk5NDY4Zl8wLTQtMS0xLTExNjc3MQ_602185dc-4b13-4e16-bda4-0db9807f16cd">Canada</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGFibGU6MzY3YmU0M2FlOTUzNDhkMTgzYTg0NWEwYzM5OTQ2OGYvdGFibGVyYW5nZTozNjdiZTQzYWU5NTM0OGQxODNhODQ1YTBjMzk5NDY4Zl8wLTctMS0xLTExNjc3MQ_74582c99-b736-495f-aae7-37e7e65af777">98-0448205</ix:nonNumeric></span></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGV4dHJlZ2lvbjozNThjNTVjZWE3NDI0MDU2OWJmODA0NDAzN2FhZTNjNl8xOTcw_326bd7ed-bb14-40bc-aa61-88735af69f99">2150 St. Elz&#233;ar Blvd. West</ix:nonNumeric>, <ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGV4dHJlZ2lvbjozNThjNTVjZWE3NDI0MDU2OWJmODA0NDAzN2FhZTNjNl8xOTgy_64d825b3-c761-4eec-81d1-228a0a97b724">Laval</ix:nonNumeric>, <ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGV4dHJlZ2lvbjozNThjNTVjZWE3NDI0MDU2OWJmODA0NDAzN2FhZTNjNl8xOTc4_b29b1b26-1b8e-445e-8360-e56bac138d50">Qu&#233;bec</ix:nonNumeric>, <ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGV4dHJlZ2lvbjozNThjNTVjZWE3NDI0MDU2OWJmODA0NDAzN2FhZTNjNl8xOTc1_9cf39bbb-2073-4a65-836b-a0cb7a88e166">Canada</ix:nonNumeric> <ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGV4dHJlZ2lvbjozNThjNTVjZWE3NDI0MDU2OWJmODA0NDAzN2FhZTNjNl8xOTc2_62eb6f1f-d0cf-4502-9a28-48586566fe66">H7L 4A8</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices) (Zip Code)</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGV4dHJlZ2lvbjozNThjNTVjZWE3NDI0MDU2OWJmODA0NDAzN2FhZTNjNl8xOTgz_786a22af-5b2c-4963-8929-cb14d831cca2">514</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGV4dHJlZ2lvbjozNThjNTVjZWE3NDI0MDU2OWJmODA0NDAzN2FhZTNjNl8xOTc5_002944d5-e602-46b5-9fbf-aa37277cc0e9">744-6792</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.522%"><tr><td style="width:1.0%"></td><td style="width:29.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.921%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGFibGU6NWIzYTZiMGVmMzliNDNhMmE5NTUyMDZlNzU4NTQ2OWMvdGFibGVyYW5nZTo1YjNhNmIwZWYzOWI0M2EyYTk1NTIwNmU3NTg1NDY5Y18xLTAtMS0xLTExNjc3MQ_5b9d0be1-9a17-409a-8e53-84b33bbcab66">Common Shares, No Par Value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGFibGU6NWIzYTZiMGVmMzliNDNhMmE5NTUyMDZlNzU4NTQ2OWMvdGFibGVyYW5nZTo1YjNhNmIwZWYzOWI0M2EyYTk1NTIwNmU3NTg1NDY5Y18xLTEtMS0xLTExNjc3MQ_3bac0764-9892-4791-850d-ca917ea7bed9">BHC</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGFibGU6NWIzYTZiMGVmMzliNDNhMmE5NTUyMDZlNzU4NTQ2OWMvdGFibGVyYW5nZTo1YjNhNmIwZWYzOWI0M2EyYTk1NTIwNmU3NTg1NDY5Y18xLTItMS0xLTExNjc3MQ_5723fd09-c43f-4597-bd9a-b4846d9ae4be">New York Stock Exchange</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Toronto Stock Exchange</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or&#160;15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or&#160;for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. <ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGV4dHJlZ2lvbjozNThjNTVjZWE3NDI0MDU2OWJmODA0NDAzN2FhZTNjNl8xOTcx_adb177cf-67c4-4974-a10f-d836a1ce2586">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or&#160;for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGV4dHJlZ2lvbjozNThjNTVjZWE3NDI0MDU2OWJmODA0NDAzN2FhZTNjNl8xOTcy_255be64d-0743-4677-8a18-3734be2e202b">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.451%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGFibGU6YzM4ODk0MTk2YmIzNGJiYzlmNjAzMGQ2MzAwYTg2MDMvdGFibGVyYW5nZTpjMzg4OTQxOTZiYjM0YmJjOWY2MDMwZDYzMDBhODYwM18wLTAtMS0xLTExNjc3MQ_741dffe8-bf4d-4c78-a1a1-83ab6013b05d">Large accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGFibGU6YzM4ODk0MTk2YmIzNGJiYzlmNjAzMGQ2MzAwYTg2MDMvdGFibGVyYW5nZTpjMzg4OTQxOTZiYjM0YmJjOWY2MDMwZDYzMDBhODYwM18wLTctMS0xLTExNjc3MQ_b7e0c557-3ebf-40a3-b348-01b5bbad17b9">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGFibGU6YzM4ODk0MTk2YmIzNGJiYzlmNjAzMGQ2MzAwYTg2MDMvdGFibGVyYW5nZTpjMzg4OTQxOTZiYjM0YmJjOWY2MDMwZDYzMDBhODYwM18wLTktMS0xLTExNjc3MQ_9ba2c89d-314f-44e4-b268-682072026e90">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as&#160;defined in Rule&#160;12b-2 of the Exchange Act). Yes &#9744; No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGV4dHJlZ2lvbjozNThjNTVjZWE3NDI0MDU2OWJmODA0NDAzN2FhZTNjNl8xOTgw_864582ec-f50b-4eca-af5e-c7798369f97c">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable&#160;date.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common shares, no par value&#160;&#8212; <ix:nonFraction unitRef="shares" contextRef="i9e1813544ece4aedbf13459cd893081d_I20220804" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGV4dHJlZ2lvbjozNThjNTVjZWE3NDI0MDU2OWJmODA0NDAzN2FhZTNjNl8xOTI5_89f966e2-c4df-416c-aa1c-4863f3510bb4">361,728,490</ix:nonFraction> shares outstanding as of August 4, 2022.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i762fba229369426294c4424c2015a01a_7"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 45.00pt 36.00pt 45.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="margin-bottom:16pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE QUARTERLY PERIOD ENDED JUNE&#160;30, 2022 </span></div><div style="margin-bottom:16pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.118%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part&#160;I.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Consolidated <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_19">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_22">Consolidated Balance Sheets as of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_22"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_22">June 30</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_22">, 2022 and December&#160;31, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_22">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_25">Consolidated Statements of Operations for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_25">and six </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_25">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_25">June 30</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_25">, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_25">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_28">Consolidated Statements of Comprehensive Loss for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_28">and six </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_28">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_28">June 30</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_28">, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_28">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_31">Consolidated Statements of Shareholders&#8217; Equity (Deficit) for the three and six months ended June 30, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_31">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_34">Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_34">six</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_34"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_34">June 30</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_34">, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_34">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_37">Notes to the Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_37">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_103">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_103">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_217">Quantitative and&#160;Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-align:right;text-indent:-27pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_217">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_220">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_220">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part&#160;II</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_229">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_229">99</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_232">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_232">99</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_235">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:40.5pt;text-align:right;text-indent:-40.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_235">102</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_238">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_238">102</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_241">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_241">102</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_244">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_244">102</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_247">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_247">102</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i762fba229369426294c4424c2015a01a_250">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i762fba229369426294c4424c2015a01a_250">105</a></span></div></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i762fba229369426294c4424c2015a01a_10"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE QUARTERLY PERIOD ENDED JUNE&#160;30, 2022 </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Introductory Note</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except where the context otherwise requires, all references in this Quarterly Report on Form&#160;10-Q for the quarterly period ended June&#160;30, 2022 (this &#8220;Form&#160;10-Q&#8221;) to&#160;the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221; or similar words or phrases are to Bausch Health Companies&#160;Inc. and its subsidiaries, taken together. In this Form&#160;10-Q, references to&#160;&#8220;$&#8221; are to United&#160;States (&#8220;U.S.&#8221;) dollars, references to &#8220;&#8364;&#8221; are to euros and references to &#8220;CAD&#8221; are to Canadian dollars. Unless otherwise indicated, the statistical and financial data contained in this Form&#160;10-Q are presented as of June&#160;30, 2022.</span></div><div id="i762fba229369426294c4424c2015a01a_13"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caution regarding forward-looking information and statements and &#8220;Safe-Harbor&#8221; statements under the U.S.&#160;Private Securities Litigation Reform Act of&#160;1995 and applicable Canadian securities laws:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">To the extent any statements made in this Form&#160;10-Q contain information that is not historical, these statements are forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information within the meaning defined under applicable Canadian securities laws (collectively, &#8220;forward-looking statements&#8221;).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">These forward-looking statements relate to, among other things: our business strategy, business plans and prospects and forecasts and changes thereto; product pipeline, prospective products and product approvals, expected launches of new products, product development and future performance and results of current and anticipated products; anticipated revenues for our products; expected research and development (&#8220;R&amp;D&#8221;) and marketing spend; our expected primary cash and working capital requirements for 2022 and beyond; the Company&#8217;s plans for continued improvement in operational efficiency and the anticipated impact of such plans; our liquidity and our ability to satisfy our debt maturities as they become due; our ability to reduce debt levels; our ability to comply with the financial and other covenants contained in our Fourth Amended and Restated Credit and Guaranty Agreement dated as of June 1, 2018 (the &#8220;Restated Credit Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">), as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018 (the &#8220;2018 Restated Credit Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">) and the Second Amendment (the &#8220;Second Amendment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">) to the 2018 Restated Credit Agreement, dated as of May 10, 2022 (as so amended, and as may be further amended, supplemented or otherwise modified from time to time in accordance with the terms thereof, the &#8220;2022 Amended Credit Agreement&#8221;), and senior notes indentures; the ability of our subsidiary, Bausch + Lomb Corporation (&#8220;Bausch + Lomb&#8221;), to comply with the financial and other covenants contained in its Credit and Guaranty Agreement (the &#8220;B+L Credit Agreement&#8221;, and the credit facilities thereunder, the &#8220;B+L Credit Facilities&#8221;), dated as of May 10, 2022; the impact of our distribution, fulfillment and other third-party arrangements; proposed pricing actions; exposure to foreign currency exchange rate changes and interest rate changes; the outcome of contingencies, such as litigation, subpoenas, investigations, reviews, audits and regulatory proceedings; the anticipated impact of the adoption of new accounting standards; general market conditions; our expectations regarding our financial performance, including revenues, expenses, gross margins and income&#160;taxes; our impairment assessments, including the assumptions used therein and the results thereof; the anticipated impact of the evolving COVID-19 pandemic and related responses from governments and private sector participants on the Company, its supply chain, third-party suppliers, project development timelines, costs, revenues, margins, liquidity and financial condition, the anticipated timing, speed and magnitude of recovery from these COVID-19 pandemic related impacts and the Company&#8217;s planned actions and responses to this pandemic; the anticipated impact from the ongoing conflict between Russia and Ukraine; and the Company&#8217;s plan to separate its eye health business, including the structure and timing of completing such separation transaction.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements can generally be identified by the use of words such as &#8220;believe&#8221;, &#8220;anticipate&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;estimate&#8221;, &#8220;plan&#8221;, &#8220;continue&#8221;, &#8220;will&#8221;, &#8220;may&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;should&#8221;, &#8220;target&#8221;, &#8220;potential&#8221;, &#8220;opportunity&#8221;, &#8220;designed&#8221;, &#8220;create&#8221;, &#8220;predict&#8221;, &#8220;project&#8221;, &#8220;forecast&#8221;, &#8220;seek&#8221;, &#8220;strive&#8221;, &#8220;ongoing&#8221;, &#8220;decrease&#8221; or &#8220;increase&#8221; and variations or other similar expressions. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements may not be appropriate for other purposes. All of the statements in this Form&#160;10-Q that contain forward-looking statements are qualified by these cautionary statements. These statements are based upon the current expectations and beliefs of management. Although we believe that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making such forward-looking statements, including, but not limited to, factors and assumptions regarding the items previously outlined, those factors, risks and uncertainties outlined below and the assumption that none of these factors, risks and uncertainties will cause actual results or events to differ materially from those described in such forward-looking statements. Actual results may differ materially from those expressed or implied in </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">such statements. Important factors, risks and uncertainties that could cause actual results to differ materially from these expectations include, among other things, the&#160;following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, the fear of that pandemic, the availability and effectiveness of vaccines for COVID-19 (including with respect to current or future variants and subvariants), COVID-19 vaccine immunization rates, the emergence of variant and subvariant strains of COVID-19, the resurgence of the COVID-19 virus and variant and subvariant strains thereof (including, but not limited to, the recent resurgence of COVID-19 cases) and any resulting reinstitution of lockdowns and other restrictions, the evolving reaction of governments, private sector participants and the public to that pandemic, and the potential effects and economic impact of the pandemic and the reaction to it, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a significant adverse impact on the Company, including, but not limited to, its supply chain, third-party suppliers, project development timelines, employee base, liquidity, stock price, financial condition, costs (which may increase) and revenue and margins (both of which may decrease);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the challenges the Company faces as a result of the closing of the initial public offering (&#8220;IPO&#8221;) of Bausch + Lomb (the &#8220;B+L IPO&#8221;), including the transitional services being provided by and to Bausch + Lomb, any potential, actual or perceived conflict of interest of some of our directors and officers because of their equity ownership in Bausch + Lomb and/or because they also serve as directors or officers of Bausch + Lomb and our ability to timely consolidate the financial results of the Bausch + Lomb business; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">with respect to the Company's proposed plan to spinoff Bausch + Lomb, the risks and uncertainties include, but are not limited to, the expected benefits and costs of the spinoff, the expected timing of completion of the spinoff and its terms (including the Company&#8217;s expectation that the spinoff will be completed following the expiry of customary lock-ups related to the B+L IPO and achievement of targeted debt leverage ratios, subject to receipt of applicable shareholder and other necessary approvals), the Company&#8217;s ability to complete the spinoff considering the various conditions to the completion of the spinoff (some of which are outside the Company&#8217;s control, including conditions related to regulatory matters and applicable shareholder and stock exchange approvals), that market or other conditions are no longer favorable to completing the spinoff, that the previously announced planned IPO of the Company&#8217;s aesthetics medical device business, Global Solta (the &#8220;Solta IPO&#8221;) has been suspended, that the Norwich Legal Decision (see &#8220;Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Paragraph IV Proceedings&#8221; of Note 18, &#8220;LEGAL PROCEEDINGS&#8221; to our unaudited interim Consolidated Financial Statements) may affect the timing of, or our ability to complete the B+L Separation, that applicable shareholder, stock exchange, regulatory or other approvals is not obtained on the terms or timelines anticipated or at all, business disruption during the pendency of, or following, the spinoff, diversion of management time on separation transaction-related issues, retention of existing management team members, the reaction of customers and other parties to the separation transaction, the qualification of the separation transaction as a tax-free transaction for Canadian and/or U.S. federal income tax purposes (including whether or not an advance ruling from the Canada Revenue Agency and/or the Internal Revenue Service will be sought or obtained), the ability of the Company and the separated entity to satisfy the conditions required to maintain the tax-free status of the spinoff (some of which are beyond their control), other potential tax or other liabilities that may arise as a result of the spinoff, the potential dissynergy costs resulting from the spinoff, the impact of the spinoff on relationships with customers, suppliers, employees and other business counterparties, general economic conditions, conditions in the markets the Company is engaged in, behavior of customers, suppliers and competitors, technological developments, as well as legal and regulatory rules affecting the Company&#8217;s business. In particular, the Company can offer no assurance that any spinoff will occur at all, or that any such transaction will occur on the timelines anticipated by the Company; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">ongoing litigation and potential additional litigation, claims, challenges and/or regulatory investigations challenging or otherwise relating to the B+L IPO and the spinoff and the costs, expenses, use of resources, diversion of management time and efforts, liability and damages that may result therefrom;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the expense, timing and outcome of legal and governmental proceedings, investigations and information requests relating to, among other matters, our past distribution, marketing, pricing, disclosure and accounting practices (including with respect to our former relationship with Philidor Rx Services, LLC (&#8220;Philidor&#8221;)), including a number of pending non-class securities litigations (including certain pending opt-out actions in the U.S. related to the previously settled securities class action (which remains subject to an objector&#8217;s petition for rehearing of its appeal of the Court&#8217;s final approval order) and certain opt-out actions in Canada relating to the recently settled class action in Canada), certain pending lawsuits and other claims, investigations or proceedings that may be initiated or that may be asserted;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">potential additional litigation and regulatory investigations (and any costs, expenses, use of resources, diversion of management time and efforts, liability and damages that may result therefrom), negative publicity and reputational </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">harm on our Company, products and business that may result from the past and ongoing public scrutiny of our past distribution, marketing, pricing, disclosure and accounting practices and from our former relationship with Philidor;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the past and ongoing scrutiny of our legacy business practices, including with respect to pricing, and any pricing controls or price adjustments that may be sought or imposed on our products as a result thereof; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">pricing decisions that we have implemented, or may in the future elect to implement, such as the Patient Access and Pricing Committee&#8217;s historic practice of limiting the average annual price increase for our branded prescription pharmaceutical products to single digits, or any future pricing actions we may take in 2022 or beyond following review by our Patient Access and Pricing Committee (which is responsible for the pricing of our drugs);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">legislative or policy efforts, including those that may be introduced and passed by the U.S. Congress, designed to reduce patient out-of-pocket costs for medicines, which could result in new mandatory rebates and discounts or other pricing restrictions, controls or regulations (including mandatory price reductions);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">ongoing oversight and review of our products and facilities by regulatory and governmental agencies, including periodic audits by the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) and equivalent agencies outside of the U.S. and the results thereof;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">actions by the FDA or other regulatory authorities with respect to our products or facilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with the legal and regulatory requirements of our marketed products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our substantial debt (and potential additional future indebtedness) and current and future debt service obligations, our ability to reduce our outstanding debt levels and the resulting impact on our financial condition, cash flows and results of operations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with the financial and other covenants contained in our senior notes indentures, the 2027 Revolving Credit Facility (as defined below), the 2022 Amended Credit Agreement, the B+L Credit Agreement and other current or future credit and/or debt agreements, including the ability of Bausch + Lomb to comply with its covenants and obligations under the B+L Credit Agreement, restrictions and prohibitions such covenants impose or may impose on the way we conduct our business, including prohibitions on incurring additional debt if certain financial covenants are not met, limitations on the amount of additional obligations we are able to incur pursuant to other covenants, our ability to draw under our 2027 Revolving Credit Facility, Bausch + Lomb&#8217;s ability to draw down under the revolving credit facility under the B+L Credit Agreement and restrictions on our ability to make certain investments and other restricted payments;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">any default under the terms of our senior notes indentures or the 2022 Amended Credit Agreement (and other current or future credit and/or debt agreements) and our ability, if any, to cure or obtain waivers of such default;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">any downgrade by rating agencies in our credit ratings, which may impact, among other things, our ability to raise debt and the cost of capital for additional debt issuances;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">any reductions in, or changes in the assumptions used in, our forecasts for fiscal year 2022 or beyond, including as a result of the impacts of the COVID-19 pandemic on our business and operations, which could lead to, among other things: (i) a failure to meet the financial and/or other covenants contained in the 2022 Amended Credit Agreement, senior notes indentures and/or the B+L Credit Agreement (and other current or future credit and/or debt agreements) and/or (ii) impairment in the goodwill associated with certain of our reporting units or impairment charges related to certain of our products or other intangible assets, which impairments could be material;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the assumptions used in connection with our impairment analyses or assessments, which would lead to a change in such impairment analyses and assessments and which could result in an impairment in the goodwill associated with any of our reporting units or impairment charges related to certain of our products or other intangible assets;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the uncertainties associated with the acquisition and launch of new products, assets and businesses, including, but not limited to, our ability to provide the time, resources, expertise and funds required for the commercial launch of new products, the acceptance and demand for new products, and the impact of competitive products and&#160;pricing, which could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability or inability to extend the profitable life of our products, including through line extensions and other life-cycle programs;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to retain, motivate and recruit directors, executives and other key&#160;employees;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to implement effective succession planning for our executives and key employees;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to stabilize and reposition our Ortho Dermatologics business to generate additional value, including the success of recently launched products and the approval of pipeline products (and the timing of such approvals);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to achieve anticipated revenues for our products, including changes in anticipated marketing spend on such products and launch of competing products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to achieve anticipated market acceptance for our products, including acceptance of the pricing, effectiveness of promotional efforts, reputation of our products and launch of competing products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the challenges and difficulties associated with managing a large complex business, which has, in the past, grown rapidly;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to compete against companies that are larger and have greater financial, technical and human resources than we do, as well as other competitive factors, such as technological advances achieved, patents obtained and new products introduced by our competitors;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively operate and grow our businesses in light of the challenges that the Company has faced and market conditions, including with respect to its substantial debt, pending investigations and legal proceedings, scrutiny of our past pricing and other practices, limitations on the way we conduct business imposed by the covenants contained in our 2022 Amended Credit Agreement, the B+L Credit Agreement, our senior notes indentures and the agreements governing our other indebtedness, and the impacts of the COVID-19 pandemic;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our products are reimbursed by government authorities, pharmacy benefit managers (&#8220;PBMs&#8221;) and other third-party payors; the impact our distribution, pricing and other practices may have on the decisions of such government authorities, PBMs and other third-party payors to reimburse our products; the impact of obtaining or maintaining such reimbursement on the price and sales of our products; and the launch and implementation of any new pharma-care or dental-care program or related spending by the Canadian federal government;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the inclusion of our products on formularies or our ability to achieve favorable formulary status, as well as the impact on the price and sales of our products in connection therewith;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the consolidation of wholesalers, retail drug chains and other customer groups and the impact of such industry consolidation on our business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain strong relationships with physicians and other healthcare professionals;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our eligibility for benefits under tax treaties and the availability of low effective tax rates for the business profits of certain of our subsidiaries;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the implementation of the Organisation for Economic Co-operation and Development Inclusive Framework on Base Erosion and Profit Shifting, including the global minimum corporate tax rate, by the countries in which we operate; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of any audits by taxation authorities, which outcomes may differ from the estimates and assumptions that we may use in determining our consolidated tax provisions and accruals;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the actions of our third-party partners or service providers of research, development, manufacturing, marketing, distribution or other services, including their compliance with applicable laws and contracts, which actions may be beyond our control or influence, and the impact of such actions on our Company;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the risks associated with the international scope of our operations, including our presence in emerging markets and the challenges we face when entering and operating in new and different geographic markets (including the challenges created by new and different regulatory regimes in such countries and the need to comply with applicable anti-bribery and economic sanctions laws and regulations);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">adverse global economic conditions, including rates of inflation, and credit markets and foreign currency exchange uncertainty and volatility in certain of the countries in which we do&#160;business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the trade conflict between the U.S. and China;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the ongoing conflict between Russia and Ukraine and the export controls, sanctions and other restrictive actions that have been or may be imposed by the U.S., Canada and other countries against governmental and other entities in Russia, Belarus and parts of Ukraine;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the United States-Mexico-Canada Agreement (&#8220;USMCA&#8221;) and any potential changes to other trade agreements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, maintain and license sufficient intellectual property rights over our products and enforce and defend against challenges to such intellectual property (such as in connection with the filing by Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;) of its Abbreviated New Drug Application (&#8220;ANDA&#8221;) for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets and the Company&#8217;s related lawsuit filed against Norwich in connection therewith) and the impact of the Norwich matter on, among other things, our business results, financial results, and the proposed separation of B+L;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully appeal the decision of the U.S. District Court for the District of Delaware in the Company&#8217;s lawsuit against Norwich in connection with Norwich&#8217;s ANDA and challenge Norwich&#8217;s ability to achieve a modified ANDA that avoids an injunction [expected to be issued] by the District Court and omits the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> hepatic encephalopathy (&#8220;HE&#8221;) indication and HE safety data;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the fact that a substantial amount of our revenues are derived from the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">product line, and that we may be materially impacted by the entry of a generic rifaximin product earlier than January 2028;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the introduction of generic, biosimilar or other competitors of our branded products and other products, including the introduction of products that compete against our products that do not have patent or data exclusivity rights;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify, finance, acquire, close and integrate acquisition targets successfully and on a timely basis and the difficulties, challenges, time and resources associated with the integration of acquired companies, businesses and products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">any divestitures of our assets or businesses and our ability to successfully complete any such divestitures on commercially reasonable terms and on a timely basis, or at all, and the impact of any such divestitures on our Company, including the reduction in the size or scope of our business or market share, loss of revenue, any loss on sale, including any resultant impairments of goodwill or other assets, or any adverse tax consequences suffered as a result of any such divestitures;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the expense, timing and outcome of pending or future legal and governmental proceedings, arbitrations, investigations, subpoenas, tax and other regulatory audits, examinations, reviews and regulatory proceedings against us or relating to us and settlements thereof;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to negotiate the terms of or obtain court approval for the settlement of certain legal and regulatory proceedings;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain components, raw materials or finished products supplied by third&#160;parties (some of which may be single-sourced) and other manufacturing and related supply difficulties, interruptions and delays;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the disruption of delivery of our products and the routine flow of manufactured goods;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">economic factors over which the Company has no control, including changes in inflation, interest rates, foreign currency rates, and the potential effect of such factors on revenues, expenses and resulting margins;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">interest rate risks associated with our floating rate debt borrowings;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively distribute our products and the effectiveness and success of our distribution arrangements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively promote our own products and those of our co-promotion partners;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our fulfillment arrangements with Walgreen Co., including market acceptance of, or market reaction to, such arrangements (including by customers, doctors, patients, PBMs, third-party payors and governmental agencies), and the continued compliance of such arrangements with applicable laws;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to secure and maintain third-party research, development, manufacturing, licensing, marketing or distribution arrangements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that our products could cause, or be alleged to cause, personal injury and adverse effects, leading to potential lawsuits, product liability claims and damages and/or recalls or withdrawals of products from the&#160;market;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the mandatory or voluntary recall or withdrawal of our products from the market and the costs associated therewith;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vi</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of, and our ability to obtain and maintain, adequate insurance coverage and/or our ability to cover or insure against the total amount of the claims and liabilities we face, whether through third-party insurance or self-insurance;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our indemnity agreements, which may result in an obligation to indemnify or reimburse the relevant counterparty, which amounts may be material;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the difficulty in predicting the expense, timing and outcome within our legal and regulatory environment, including with respect to approvals by the FDA, Health Canada, European Medicines Agency (&#8220;EMA&#8221;) and similar agencies in other countries, legal and regulatory proceedings and settlements thereof, the protection afforded by our patents and other intellectual and proprietary property, successful generic challenges to our products and infringement or alleged infringement of the intellectual property of&#160;others;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the results of continuing safety and efficacy studies by industry and government agencies;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the success of preclinical and clinical trials for our drug development pipeline or delays in clinical trials that adversely impact the timely commercialization of our pipeline products, as well as other factors impacting the commercial success of our products, which could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties around the successful improvement and modification of our existing products and development of new products, which may require significant expenditures and efforts;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the results of management reviews of our research and development portfolio (including following the receipt of clinical results or feedback from the FDA or other regulatory authorities), which could result in terminations of specific projects which, in turn, could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the seasonality of sales of certain of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">declines in the pricing and sales volume of certain of our products that are distributed or marketed by third parties, over which we have no or limited control;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">compliance by the Company or our third-party partners and service providers (over whom we may have limited influence), or the failure of our Company or these third parties to comply, with health care &#8220;fraud and abuse&#8221; laws and other extensive regulation of our marketing, promotional and business practices (including with respect to pricing), worldwide anti-bribery laws (including the U.S. Foreign Corrupt Practices Act and the Canadian Corruption of Foreign Public Officials Act), worldwide economic sanctions and/or export laws, worldwide environmental laws and regulation and privacy and security regulations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the impacts of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 and potential amendment thereof and other legislative and regulatory health care reforms in the countries in which we operate, including with respect to recent government inquiries on pricing;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of any changes in or reforms to the legislation, laws, rules, regulation and guidance that apply to the Company and its businesses and products or the enactment of any new or proposed legislation, laws, rules, regulations or guidance that will impact or apply to the Company or its businesses or products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of changes in federal laws and policy that may be undertaken under the current administration;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">illegal distribution or sale of counterfeit versions of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">any plans for the Company's aesthetic medical business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">interruptions, breakdowns or breaches in our information technology systems; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risks in Item 1A. &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed on February 23, 2022, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">risks under Item 1A. &#8220;Risk Factors&#8221; of Part II of this Form 10-Q </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and risks detailed from time to time in our other filings with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and the Canadian Securities Administrators (the&#160;&#8220;CSA&#8221;), as well as our ability to anticipate and manage the risks associated with the&#160;foregoing.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed on February 23, 2022,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">under Item&#160;1A. &#8220;Risk Factors&#8221;, u</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">nder Item 1A. &#8220;Risk Factors&#8221; of Part II of this Form 10-Q </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and in the Company&#8217;s other filings with the SEC and the CSA. When relying on our forward-looking statements to make decisions with respect to the Company, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. These forward-looking statements speak only as of the date made. We undertake no obligation to update or </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">revise any of these forward-looking statements to reflect events or circumstances after the date of this Form&#160;10-Q or&#160;to reflect actual outcomes, except as required by law. We caution that, as it is not possible to predict or identify all relevant factors that may impact forward-looking statements, the foregoing list of important factors that may affect future results is not exhaustive and should not be considered a complete statement of all potential risks and uncertainties.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">viii</span></div></div></div><div id="i762fba229369426294c4424c2015a01a_16"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i762fba229369426294c4424c2015a01a_19"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Financial Statements</span></div><div id="i762fba229369426294c4424c2015a01a_22"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions, except share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:9pt;margin-top:5pt;padding-left:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:36pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMy0xLTEtMS0xMTY3NzE_997ae05b-ef98-4f53-a96c-09bc01c4fac9">659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMy0zLTEtMS0xMTY3NzE_fc8841ed-f51a-4550-8ca7-f9c50e3b837f">582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="bhc:RestrictedCashAndOtherSettlementDepositsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfNC0xLTEtMS0xMTY3NzE_8d75d951-9aa3-4b49-8a64-fbb61e8dd119"><ix:nonFraction unitRef="usd" contextRef="i5375b8e373564a36aaf52188e7d12cf6_I20220630" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfNC0xLTEtMS0xMTY3NzE_981787f7-d593-4a2a-80bf-09aa335c6bc1">1,220</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="bhc:RestrictedCashAndOtherSettlementDepositsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfNC0zLTEtMS0xMTY3NzE_53b4ae8a-19aa-47c6-9a53-cdae7ffbddda">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfNS0xLTEtMS0xMTY3NzE_18a1f447-e364-487c-89f1-4a488785e6a8">1,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfNS0zLTEtMS0xMTY3NzE_8d9b3d5f-5b13-48cf-864f-c7eddafdc67e">1,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfNi0xLTEtMS0xMTY3NzE_47fd1d95-8c92-4d7b-8baa-6b41cdfe3bd9">1,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfNi0zLTEtMS0xMTY3NzE_08b1b8a2-dfda-49f2-b8f3-fe0599e7e9b0">993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfNy0xLTEtMS0xMTY3NzE_6f50fe9d-cdd6-4543-9541-b3d19c837848">820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfNy0zLTEtMS0xMTY3NzE_ed64b646-70d4-450a-b5f7-77835715a9cc">720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfOC0xLTEtMS0xMTY3NzE_e62739b1-3188-4a08-a4dd-1a69503ddf5a">5,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfOC0zLTEtMS0xMTY3NzE_a325b64d-887d-496c-a7c6-4ac3487ea170">5,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfOS0xLTEtMS0xMTY3NzE_464d13ee-c7fb-4a48-9c6a-03ca30036a46">1,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfOS0zLTEtMS0xMTY3NzE_3cb3b855-bc8e-4801-8f56-9dd35ba73ea7">1,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTAtMS0xLTEtMTE2Nzcx_de58aca2-c80f-41ac-885d-7f156fdddbad">6,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTAtMy0xLTEtMTE2Nzcx_606c3d57-4f49-47e0-8814-cb3e8f4d3dd0">6,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTEtMS0xLTEtMTE2Nzcx_f34825b3-d8df-4889-99e4-b69c9ffe7985">12,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTEtMy0xLTEtMTE2Nzcx_9a3d3849-3ccc-4175-bc3d-96cee3acb58e">12,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTItMS0xLTEtMTE2Nzcx_c42010a4-36b7-40a2-9490-81c0f3e7fbe9">2,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTItMy0xLTEtMTE2Nzcx_394dd9df-89dd-4318-a471-d62710aa6ff2">2,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTMtMS0xLTEtMTE2Nzcx_63173ba3-631d-4b4b-a2c3-0b2dd5fcb3d7">338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTMtMy0xLTEtMTE2Nzcx_1d12c085-b786-449e-9155-c39132cc89c6">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTQtMS0xLTEtMTE2Nzcx_0cf35d5d-ef69-43d8-9b02-da16b8ed2942">28,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTQtMy0xLTEtMTE2Nzcx_2ef6c77f-a71b-4cd8-bfa6-fd0ae347753b">29,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTctMS0xLTEtMTE2Nzcx_51c20494-2228-4b97-af94-da9920a6ab99">536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTctMy0xLTEtMTE2Nzcx_eb4410d6-ada5-49cd-9914-fd7e9048682f">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTgtMS0xLTEtMTE2Nzcx_239d40d3-97f9-4ecf-97af-b817ff36c6e0">4,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTgtMy0xLTEtMTE2Nzcx_0a43202c-93a9-4b55-b55e-0ba951c3377a">4,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTktMS0xLTEtMTE2Nzcx_8a3823f4-c321-48d6-bbd4-bd859fd0c74f">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTktMy0xLTEtMTE2Nzcx_880002bb-0e34-4b08-87fc-16d21a4091bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjAtMS0xLTEtMTE2Nzcx_e5da6758-3877-4cdf-b7fd-c2873c77ef21">4,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjAtMy0xLTEtMTE2Nzcx_7a128c27-9855-4a80-a490-06c8e00f11f4">5,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationNoncurrentLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjEtMS0xLTEtMTE2Nzcx_ef2232ca-ff5e-47e2-a22d-833e0b832e51">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationNoncurrentLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjEtMy0xLTEtMTE2Nzcx_78c5e3c2-b8df-4a8b-ad0e-c34dfd872d28">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjItMS0xLTEtMTE2Nzcx_57a23c32-977b-4f74-9d77-3da783492712">21,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjItMy0xLTEtMTE2Nzcx_8224d1c3-6ef4-4eba-99a0-d9ff368f4455">22,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjMtMS0xLTEtMTE2Nzcx_a4fafc25-6b77-40a7-b3e4-75bf8b881e87">545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjMtMy0xLTEtMTE2Nzcx_1aab534c-613a-4d43-820a-56b67ef0a72e">529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjQtMS0xLTEtMTE2Nzcx_fdc86dc9-a94a-48fb-a443-75c9f74812ac">524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjQtMy0xLTEtMTE2Nzcx_3787d279-feab-431f-8aab-827b92d0a0db">653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjUtMS0xLTEtMTE2Nzcx_c5380731-604d-4bc8-93e7-fa79ca611bf6">27,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjUtMy0xLTEtMTE2Nzcx_c2665d52-dd23-45d4-adaf-68b7b2eaa0de">29,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjYtMS0xLTEtMTE2Nzcx_83c1f003-7967-469e-bbbb-4d36a568f0d8"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjYtMy0xLTEtMTE2Nzcx_8888a4d0-bff2-403e-a230-a32fb84da00b"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity (Deficit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares, no par value, unlimited shares authorized, <ix:nonFraction unitRef="shares" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjgtMC0xLTEtMTE2NzcxL3RleHRyZWdpb246NmY4ZGZiZTRlZTgxNDE5M2EwZmExN2UxZDUzOTI3MjlfNjI_3064d1ee-8594-422e-9564-108449f285ef"><ix:nonFraction unitRef="shares" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjgtMC0xLTEtMTE2NzcxL3RleHRyZWdpb246NmY4ZGZiZTRlZTgxNDE5M2EwZmExN2UxZDUzOTI3MjlfNjI_9e190418-35af-4f9a-8be6-a466cc084ecf">361,571,921</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjgtMC0xLTEtMTE2NzcxL3RleHRyZWdpb246NmY4ZGZiZTRlZTgxNDE5M2EwZmExN2UxZDUzOTI3MjlfNjk_12888894-2992-41c9-81e0-1d5804f28f57"><ix:nonFraction unitRef="shares" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjgtMC0xLTEtMTE2NzcxL3RleHRyZWdpb246NmY4ZGZiZTRlZTgxNDE5M2EwZmExN2UxZDUzOTI3MjlfNjk_14f7c61d-66ac-407b-800d-e244445ef48c">359,405,748</ix:nonFraction></ix:nonFraction> issued and outstanding at June 30, 2022 and December&#160;31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjgtMS0xLTEtMTE2Nzcx_af534d1c-47fd-4c8b-a981-8dfcf7726896">10,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjgtMy0xLTEtMTE2Nzcx_1656e81c-895b-4fa5-a72f-75af0aa49eb8">10,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjktMS0xLTEtMTE2Nzcx_fba1293b-929e-468a-935e-4b63acbfc1c1">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjktMy0xLTEtMTE2Nzcx_356e2087-82fb-4b3d-80d9-c0becd61a026">462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMzAtMS0xLTEtMTE2Nzcx_bdce2dd6-7219-4d1a-95f2-3a4e0a290544">9,175</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMzAtMy0xLTEtMTE2Nzcx_54b9a009-3093-4ef7-98dc-46754f40ab40">8,961</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMzEtMS0xLTEtMTE2Nzcx_0f83a48b-0a7f-43c1-bd9b-c9c2af396721">2,002</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMzEtMy0xLTEtMTE2Nzcx_b0bcc346-9005-4af5-9007-4486b65c26ea">1,924</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Bausch Health Companies Inc. shareholders&#8217; deficit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMzItMS0xLTEtMTE2Nzcx_c55ec8be-106e-4e18-9e88-ba105372ecf7">693</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMzItMy0xLTEtMTE2Nzcx_8b1693ce-1767-4256-8e55-a344c41a8e41">106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMzMtMS0xLTEtMTE2Nzcx_31ad8aa1-8025-491f-9e5c-ad36dc045568">946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMzMtMy0xLTEtMTE2Nzcx_199136d7-cb2b-43e9-ad62-feae61344e5a">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity (deficit)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMzQtMS0xLTEtMTE2Nzcx_8d5c0988-4b03-421d-b467-0d83d27083ee">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMzQtMy0xLTEtMTE2Nzcx_5a51434b-a89c-43b3-9e4a-2f53cc0fb595">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity (deficit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMzUtMS0xLTEtMTE2Nzcx_75e1dbd8-33c6-4d58-b1a4-a688ab0aefa2">28,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMzUtMy0xLTEtMTE2Nzcx_42dd55d6-8ac5-4fab-a85b-0b9630419866">29,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i762fba229369426294c4424c2015a01a_25"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:59.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic162a3439c8c430c97c3765d64ade238_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMy0xLTEtMS0xMTY3NzE_ef9583e0-8b70-4609-876a-23d1b57cad09">1,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4dcf9828b6146d280f1c8faa0decc1b_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMy0zLTEtMS0xMTY3NzE_ac2c2309-ef74-4366-90ed-91bddef6b9ff">2,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aeffa8d800d40419ffca17d6354a930_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMy01LTEtMS0xMTY3NzE_013c921e-8819-4b69-b87e-4c64de76f7f7">3,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77051dd59400460d84de895305bdc503_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMy03LTEtMS0xMTY3NzE_04800d87-2ff6-47ed-802f-95c0ec503c3e">4,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice79c5989bb147d780b5ce3edbaaa033_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfNC0xLTEtMS0xMTY3NzE_5df293fe-7527-4608-beea-a70838fc6bce">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8b6d4b376e54c96b6861f58b066f558_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfNC0zLTEtMS0xMTY3NzE_ef4a4487-0857-4723-a032-3aeea06f705a">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e2c9d81976431390f8ae34842a6dec_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfNC01LTEtMS0xMTY3NzE_f2ad2392-771f-406c-939d-4e0e4568784a">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e13e115ca834d5c8178e3e30589f645_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfNC03LTEtMS0xMTY3NzE_984c8dd4-8fec-4cfc-9edf-cc46b3c88fb3">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfNS0xLTEtMS0xMTY3NzE_5ea575e0-17e3-401c-8847-badaf2328bb8">1,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfNS0zLTEtMS0xMTY3NzE_c93dbbfb-760b-4c78-977f-2c4558618707">2,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfNS01LTEtMS0xMTY3NzE_494706b9-6291-4811-8235-74d9af6e3b82">3,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfNS03LTEtMS0xMTY3NzE_58838485-b147-4496-b150-d8b521ab3d5f">4,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(excluding amortization and impairments of intangible assets)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic162a3439c8c430c97c3765d64ade238_D20220401-20220630" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfNy0xLTEtMS0xMTY3NzE_39be0924-dee5-4386-bb5b-481a1363cd25">570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4dcf9828b6146d280f1c8faa0decc1b_D20210401-20210630" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfNy0zLTEtMS0xMTY3NzE_4e67dfde-6f6c-40ff-a297-67621747233c">604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aeffa8d800d40419ffca17d6354a930_D20220101-20220630" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfNy01LTEtMS0xMTY3NzE_60c51fa6-0bc7-4313-8779-a90796dece1a">1,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77051dd59400460d84de895305bdc503_D20210101-20210630" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfNy03LTEtMS0xMTY3NzE_d75a8b24-adba-4954-89d0-fb03ac808851">1,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice79c5989bb147d780b5ce3edbaaa033_D20220401-20220630" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfOC0xLTEtMS0xMTY3NzE_1601d5ad-1154-4734-af8c-d196f9938b62">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8b6d4b376e54c96b6861f58b066f558_D20210401-20210630" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfOC0zLTEtMS0xMTY3NzE_c875298f-1691-4505-affe-f5cf536b88eb">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e2c9d81976431390f8ae34842a6dec_D20220101-20220630" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfOC01LTEtMS0xMTY3NzE_79d8000a-2507-465b-9cad-9e43d6308140">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e13e115ca834d5c8178e3e30589f645_D20210101-20210630" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfOC03LTEtMS0xMTY3NzE_0bd65f30-a4bb-4e66-9e5d-4fab736436ff">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfOS0xLTEtMS0xMTY3NzE_64a9ec71-583d-4416-bedd-1457e44b09de">676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfOS0zLTEtMS0xMTY3NzE_0c848359-d598-451b-b6a0-9bc81359f819">685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfOS01LTEtMS0xMTY3NzE_0908b017-3ef3-4422-a67f-b1a2d45d851c">1,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfOS03LTEtMS0xMTY3NzE_ba1d1e58-757a-47d8-97f6-65acfda3c362">1,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTAtMS0xLTEtMTE2Nzcx_afb73e69-bd1f-4f39-94b1-a6adf1192da8">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTAtMy0xLTEtMTE2Nzcx_f0e16aa0-945c-46f6-9261-c9a62970eccd">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTAtNS0xLTEtMTE2Nzcx_7584b161-7cea-489e-96f8-0a6c21a00d3f">254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTAtNy0xLTEtMTE2Nzcx_915e24c7-8607-403c-b393-60e01a94414a">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTEtMS0xLTEtMTE2Nzcx_484599de-de9e-4f9a-8339-d638ee7ac137">302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTEtMy0xLTEtMTE2Nzcx_8d4f913b-bb97-4614-8024-4c261b1dd3db">360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTEtNS0xLTEtMTE2Nzcx_64d4c39f-3499-4b75-bd58-50ed61038efe">612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTEtNy0xLTEtMTE2Nzcx_da9d57c5-33e3-4781-9c7a-38963472bb13">717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTItMS0xLTEtMTE2Nzcx_32c4e933-017f-472f-a765-6022739c7cea">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTItMy0xLTEtMTE2Nzcx_279427eb-841d-4632-a91a-014071c61913">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTItNS0xLTEtMTE2Nzcx_a9fa993d-831a-407e-817e-8fd13a6b2db0">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTItNy0xLTEtMTE2Nzcx_131b6c2c-0816-4843-aa9b-ef03a3e40028">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTMtMS0xLTEtMTE2Nzcx_f662062c-bd60-41ce-ae6b-d8aead6a5bb9">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTMtMy0xLTEtMTE2Nzcx_ce722cc3-fc29-46ef-8bb0-1b515dba99f4">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTMtNS0xLTEtMTE2Nzcx_162d5a32-4c7c-455c-9ec3-f600333f2e71">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTMtNy0xLTEtMTE2Nzcx_5feeb2b0-2520-4880-8323-c2a99cfc9e7a">195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTQtMS0xLTEtMTE2Nzcx_16546a82-44af-4381-a4fd-27c894d440f8">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTQtMy0xLTEtMTE2Nzcx_a25573f5-135f-4b31-858e-76cd053e4e4d">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTQtNS0xLTEtMTE2Nzcx_902dde1f-df34-4c6a-9b56-4a78098afdf1">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTQtNy0xLTEtMTE2Nzcx_d8768424-beee-44f1-a9ea-a449c152d4fb">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTUtMS0xLTEtMTE2Nzcx_0d55e3f5-eb29-4ee4-b424-d7faaf9a0606">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTUtMy0xLTEtMTE2Nzcx_e3c5a001-8a65-4470-97fd-ddd971c9b37a">542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTUtNS0xLTEtMTE2Nzcx_7e56f0b8-8cf5-4d8e-8b5b-40a4b19e1dc5">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTUtNy0xLTEtMTE2Nzcx_71507c22-d235-4061-8042-e2f12a3470cf">512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTYtMS0xLTEtMTE2Nzcx_4fc57d15-b083-4291-a791-da6d66ea773b">1,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTYtMy0xLTEtMTE2Nzcx_c93f3268-51f7-41f5-929b-a22aa20dcba2">2,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTYtNS0xLTEtMTE2Nzcx_a4eefa07-8462-47da-9e1b-9e88ce8547d2">3,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTYtNy0xLTEtMTE2Nzcx_0e8f1976-16da-438e-8e77-0d51ac41206b">4,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTctMS0xLTEtMTE2Nzcx_793a794c-68c4-417c-b1be-76d01cafde98">161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTctMy0xLTEtMTE2Nzcx_49489d5e-a3c9-4ec8-a5b1-6cae807f95fe">270</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTctNS0xLTEtMTE2Nzcx_a3d5bc30-1eb6-4560-a37d-ed509167042b">446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTctNy0xLTEtMTE2Nzcx_cb30c889-df79-43f5-9705-84733a99df47">491</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTgtMS0xLTEtMTE2Nzcx_e9afe573-ebc8-41a7-bc19-0584ed2e3650">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTgtMy0xLTEtMTE2Nzcx_4b32d011-b10c-46dd-8253-4b61228ee10c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTgtNS0xLTEtMTE2Nzcx_d9949348-6437-46b3-a756-54cda4a8835d">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTgtNy0xLTEtMTE2Nzcx_7a8be7ac-9955-495f-a4a6-874d590ae828">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTktMS0xLTEtMTE2Nzcx_8d851b2b-8c6d-45e3-9747-24f900f80fa8">410</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTktMy0xLTEtMTE2Nzcx_80ffcc72-c5f5-4206-bbbe-06953e60f68f">364</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTktNS0xLTEtMTE2Nzcx_dce77335-5e0d-479a-acf5-72d045d7cdb1">772</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTktNy0xLTEtMTE2Nzcx_e628eb2b-7e73-43eb-ac88-70985a06a0a3">732</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjAtMS0xLTEtMTE2Nzcx_baf9ec75-9902-436b-be76-7688e0cc7172">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjAtMy0xLTEtMTE2Nzcx_e3b78bfe-1a5c-4c5a-bb03-8e7c9fb78a2c">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjAtNS0xLTEtMTE2Nzcx_9b1ef3f8-fd9b-4a6d-9b85-50dc9cf4ff45">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjAtNy0xLTEtMTE2Nzcx_14988bbb-6588-4d2c-90d3-b74f5595800a">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjEtMS0xLTEtMTE2Nzcx_a0f56511-c13b-4ae3-8543-75005f248c9f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjEtMy0xLTEtMTE2Nzcx_ff8c8198-cf8f-4119-b532-0c462337e5b3">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjEtNS0xLTEtMTE2Nzcx_6c8255fd-17cc-4649-98dc-ff8a02f3c314">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjEtNy0xLTEtMTE2Nzcx_b93d9763-f184-46e4-a844-cb00c027c63d">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjItMS0xLTEtMTE2Nzcx_3cefb2c9-0381-4cee-bfe2-7f08b4721abe">129</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjItMy0xLTEtMTE2Nzcx_3e04ccba-951d-431a-aa41-4f689123db04">670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjItNS0xLTEtMTE2Nzcx_e68f6c51-cc5e-4a56-b7dd-b6a0e512e6ed">211</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjItNy0xLTEtMTE2Nzcx_e8fefd88-91c4-48a9-bdfb-cf9e49f7ed71">1,261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Provision for) benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjMtMS0xLTEtMTE2Nzcx_4637021d-c524-40dd-a168-9576c9048232">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjMtMy0xLTEtMTE2Nzcx_42ef07c9-1a84-43e4-9863-a0170c872091">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjMtNS0xLTEtMTE2Nzcx_416f30b3-9a64-4644-a285-a8b8bba4ace0">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjMtNy0xLTEtMTE2Nzcx_13d3a34e-9e11-4829-83ec-d9a6b17f2c12">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjQtMS0xLTEtMTE2Nzcx_b68eb744-63f6-43f6-961a-201aeb01d4e6">139</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjQtMy0xLTEtMTE2Nzcx_ee37169c-eeaf-4efe-8ef1-3b209ae9df30">593</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjQtNS0xLTEtMTE2Nzcx_06a52c19-f9ad-41f6-b950-462b277b14c1">205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjQtNy0xLTEtMTE2Nzcx_6c7a05a8-bd5b-484c-838b-da9d46099cce">1,200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjUtMS0xLTEtMTE2Nzcx_a892606f-1229-4e7a-983c-04b8a2727ac3">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjUtMy0xLTEtMTE2Nzcx_cfba24e2-5f0d-4045-95f2-00b9e218865e">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjUtNS0xLTEtMTE2Nzcx_3d5b8969-bc2c-42e7-bdea-0635ae3de0bf">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjUtNy0xLTEtMTE2Nzcx_82662cbc-2eaa-4799-8a46-393e9783cca9">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjYtMS0xLTEtMTE2Nzcx_57dd0348-335f-4a1b-a8d7-e869af4321f7">145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjYtMy0xLTEtMTE2Nzcx_fe833a24-cb57-4846-b159-9c93f8a02bfb">595</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjYtNS0xLTEtMTE2Nzcx_626b24fb-a5f3-449f-91fd-533d99be2982">214</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjYtNy0xLTEtMTE2Nzcx_11d3e26c-18ea-41a6-b270-6d88cd86215c">1,205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted loss per share attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjktMS0xLTEtMTE2Nzcx_265ff4c3-528e-46a9-825e-7224c3c45718"><ix:nonFraction unitRef="usdPerShare" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjktMS0xLTEtMTE2Nzcx_9cb90fc5-b0ab-44c2-bd7a-caeeb5a4b82f">0.40</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjktMy0xLTEtMTE2Nzcx_2cdeda4b-46b6-4bef-a17a-7faac1a766ff"><ix:nonFraction unitRef="usdPerShare" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjktMy0xLTEtMTE2Nzcx_4f6e992a-5796-469f-8860-200a94372aa2">1.66</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjktNS0xLTEtMTE2Nzcx_04b936c4-5ce7-4780-aae9-48ca049ea687"><ix:nonFraction unitRef="usdPerShare" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjktNS0xLTEtMTE2Nzcx_ec2ad1d5-0e9f-4569-a10e-d11f55843f6c">0.59</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjktNy0xLTEtMTE2Nzcx_0365dda3-80f9-4b69-9099-b0f4ad685600"><ix:nonFraction unitRef="usdPerShare" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjktNy0xLTEtMTE2Nzcx_53ac96a1-7d4f-4861-99f2-521b57f21ebc">3.37</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted weighted-average common shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMzMtMS0xLTEtMTE2Nzcx_3d856aa6-170a-4ffe-b302-9769db5dfec9"><ix:nonFraction unitRef="shares" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMzMtMS0xLTEtMTE2Nzcx_9641a01e-051d-4ebe-86b5-6c7e5d9b8a5e">362.2</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMzMtMy0xLTEtMTE2Nzcx_0e735f3f-38c7-4f88-982d-c539356f7eeb"><ix:nonFraction unitRef="shares" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMzMtMy0xLTEtMTE2Nzcx_55194c8f-ea06-4c98-9298-a7f78d9f03c4">359.1</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMzMtNS0xLTEtMTE2Nzcx_1189b2fe-8ce8-4805-83e9-4426af4badf4"><ix:nonFraction unitRef="shares" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMzMtNS0xLTEtMTE2Nzcx_50c56646-02e7-4ac0-a842-c089656bec94">361.5</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMzMtNy0xLTEtMTE2Nzcx_7bad3fef-e6f1-4b42-945d-48da57025ff2"><ix:nonFraction unitRef="shares" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMzMtNy0xLTEtMTE2Nzcx_d87b09cc-e1da-4796-9cc5-866df4e19191">358.0</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i762fba229369426294c4424c2015a01a_28"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.727%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfMi0xLTEtMS0xMTY3NzE_492095ad-84cb-4d8a-bf5b-6af693218ed4">139</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfMi0zLTEtMS0xMTY3NzE_f4d0d311-17f6-4627-a7d7-a5a41fe568ac">593</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfMi01LTEtMS0xMTY3NzE_a3ae049e-5a90-4a73-a135-b1afacb81399">205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfMi03LTEtMS0xMTY3NzE_24bf3689-6530-4c62-a691-799e2b0d2651">1,200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNC0xLTEtMS0xMTY3NzE_0ffa44ad-bc91-4ccd-87fc-6de00ee53e91">166</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNC0zLTEtMS0xMTY3NzE_9ea14d5b-616d-4412-a297-defbc4eeb047">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNC01LTEtMS0xMTY3NzE_0375685b-0110-4f17-b7bb-7ebbf08cd344">222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNC03LTEtMS0xMTY3NzE_6ccc4f26-7d24-4261-9ae3-35f61790ebe9">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and postretirement benefit plan adjustments, net of income taxes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNS0xLTEtMS0xMTY3NzE_792454dd-0c43-498f-a831-09b7e86a8055">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNS0zLTEtMS0xMTY3NzE_1bf7d769-ae8b-43cd-be2d-205cdb90e155">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNS01LTEtMS0xMTY3NzE_c5d42ad7-2391-42a1-8361-9950251e2e71">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNS03LTEtMS0xMTY3NzE_08df6fc7-ffff-4bc1-8dc6-6395f14d5ff5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNi0xLTEtMS0xMTY3NzE_8ede0585-f362-4bbd-98fe-99891289d1b5">165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNi0zLTEtMS0xMTY3NzE_5750c630-857c-40f9-9634-f21f4e663b3c">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNi01LTEtMS0xMTY3NzE_9ae2dcca-d712-4cd5-9338-335e68501187">215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNi03LTEtMS0xMTY3NzE_84836560-765d-4699-bba9-293754a82b36">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNy0xLTEtMS0xMTY3NzE_6d56be83-9101-4f6b-8c76-2d46d13fcbd2">304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNy0zLTEtMS0xMTY3NzE_23fa0e48-17c6-444b-a930-3b6fb7addf53">518</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNy01LTEtMS0xMTY3NzE_2c1ce1f7-6d88-4a25-8fdb-066ea5a943f8">420</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNy03LTEtMS0xMTY3NzE_7336cefb-7ce2-4a1e-941c-67830c2248f5">1,248</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfOC0xLTEtMS0xMTY3NzE_87e76db1-c06c-45b4-bb4e-0bd59c894481">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfOC0zLTEtMS0xMTY3NzE_8a881a41-e02b-4d3d-a52b-c43f6d72a0c2">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfOC01LTEtMS0xMTY3NzE_d1c7dfa7-dc30-4118-b95c-ff9f91c9a14b">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfOC03LTEtMS0xMTY3NzE_da7aecb7-5bca-4ab2-b263-bb8f122aed20">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfOS0xLTEtMS0xMTY3NzE_fcd8db59-1777-4270-8299-cad33295fc22">310</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfOS0zLTEtMS0xMTY3NzE_9503c9ad-a4a0-4cf4-adc1-8e8b78eb2f28">521</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfOS01LTEtMS0xMTY3NzE_f32ba1ab-c428-4f8c-a740-4914949905e6">429</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfOS03LTEtMS0xMTY3NzE_ca85afe6-42cc-4ff7-8a9d-eecd7ca8c2bb">1,254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i762fba229369426294c4424c2015a01a_31"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY (DEFICIT)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.001%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch Health Companies&#160;Inc. Shareholders&#8217; Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Bausch Health<br/>Companies&#160;Inc.<br/>Shareholders&#8217;<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Non-<br/>controlling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total<br/>Equity<br/>(Deficit)</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances, April 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iecf0a43ebd03491a8cd2f55d19444acd_I20220331" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNC0yLTEtMS0xMTY3NzE_c8c5b255-4228-4e3d-8e76-47f018ac6e5d">361.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf0a43ebd03491a8cd2f55d19444acd_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNC00LTEtMS0xMTY3NzE_7e34bce2-4d5f-4a4b-b8c7-49bcf458b919">10,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95b6dd1dfae14edfa03b4da8db2e5244_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNC02LTEtMS0xMTY3NzE_9d045c3e-c67b-4740-bc52-10b318a1af9b">415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd553c3824724691bb7773ce70306e33_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNC04LTEtMS0xMTY3NzE_659124e5-769b-40d5-a73a-0fd5ef00a995">9,030</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd7c9074c6584fea8bf7d00e43ce6c43_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNC0xMC0xLTEtMTE2Nzcx_be9b8ddf-c6bc-4ee4-a034-1c714df428f1">1,974</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c3a44068c7b46ba80b46ad12a02d69c_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNC0xMi0xLTEtMTE2Nzcx_0700bc7c-ed06-4a80-a2fa-efae232454e3">216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4391dfc5122a436f9abd2091fc12ec77_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNC0xNC0xLTEtMTE2Nzcx_eb2d16a4-8306-4eb8-81b2-4af43574035a">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3b6d9e41bb6491cbf140d6d7a14372b_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNC0xNi0xLTEtMTE2Nzcx_3b89533f-469d-446f-812c-d2a3d82279b7">141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from B+L initial public offering, net of costs (Note 2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c2ca217eb1474a9e4606fb8ac62dc8_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNS02LTEtMS0xMzQ0MzM_c42ffd46-5fb1-4143-98f6-4e46b5a3a23c">327</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faf02d0dab04ba2a12aed2a72ddb539_D20220401-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNS0xMC0xLTEtMTM0NDMz_71a341ee-a083-4e91-849d-973311cb04a0">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ef01f8c2d44283b8c7b657548358e5_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNS0xMi0xLTEtMTM0NDMz_ece42765-5d8a-40ca-8b6d-391aa57e1e9c">190</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3678a5f161a2409b8cb49dac580a2b3e_D20220401-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNS0xNC0xLTEtMTM0NDMz_e0905762-4f39-40cd-ad73-aa8884abd91b">865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNS0xNi0xLTEtMTM0NDMz_aa7a2203-5ccd-4545-973e-98b1879c670e">675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issued under share-based compensation plans</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07f07a50d8c848a5b09b20937a317971_D20220401-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNS0yLTEtMS0xMTY3NzE_aea2d7c2-5f5e-4198-ae3b-53d91a86b0a1">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07f07a50d8c848a5b09b20937a317971_D20220401-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNS00LTEtMS0xMTY3NzE_17f8d124-f8df-4f3e-8b2a-d589f350a5f5">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c2ca217eb1474a9e4606fb8ac62dc8_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNS02LTEtMS0xMTY3NzE_754fdf85-a4a8-4e0b-bcb2-36402927af15">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ef01f8c2d44283b8c7b657548358e5_D20220401-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNS0xMi0xLTEtMTE2Nzcx_83311d63-e425-45d8-aec8-d6395b9042b8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNS0xNi0xLTEtMTE2Nzcx_a7ea9ead-326c-4c4c-8ef5-e0d1810d1060">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c2ca217eb1474a9e4606fb8ac62dc8_D20220401-20220630" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNi02LTEtMS0xMTY3NzE_789c6aef-b358-4077-a381-1f750cbd705c">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ef01f8c2d44283b8c7b657548358e5_D20220401-20220630" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNi0xMi0xLTEtMTE2Nzcx_1489f350-8afb-4f8e-b4b0-91947b0538ea">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNi0xNi0xLTEtMTE2Nzcx_cc063f31-2170-4458-8e0c-497504456013">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee withholding taxes related to share-based awards</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c2ca217eb1474a9e4606fb8ac62dc8_D20220401-20220630" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNy02LTEtMS0xMTY3NzE_89aca76f-d5db-4d48-a426-515e89143be5">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ef01f8c2d44283b8c7b657548358e5_D20220401-20220630" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNy0xMi0xLTEtMTE2Nzcx_6bbb263a-673a-40f6-8a1a-9aa4921e5145">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNy0xNi0xLTEtMTE2Nzcx_f03bc072-4dee-4199-b66b-4b68769ec8f2">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87b5d05e9653487da8ca7e66ab3fba48_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTAtOC0xLTEtMTE2Nzcx_54440090-11eb-4d40-acfd-60249cfb2145">145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ef01f8c2d44283b8c7b657548358e5_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTAtMTItMS0xLTExNjc3MQ_3678f9dc-f50b-4a29-a315-111699704a53">145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3678a5f161a2409b8cb49dac580a2b3e_D20220401-20220630" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTAtMTQtMS0xLTExNjc3MQ_52410789-0b16-4580-b7dc-dddecb55748e">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTAtMTYtMS0xLTExNjc3MQ_67b7cb2c-32e1-461a-bf91-f95eb8cdabd5">139</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0faf02d0dab04ba2a12aed2a72ddb539_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTEtMTAtMS0xLTExNjc3MQ_0eea0c62-b715-4f2b-9dc5-8c26e2cf657b">165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6ef01f8c2d44283b8c7b657548358e5_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTEtMTItMS0xLTExNjc3MQ_1cde1689-5956-49bc-ae77-b4ba1ec101d2">165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTEtMTYtMS0xLTExNjc3MQ_d0ad01e3-b31f-424f-8610-f74a25e97218">165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances, June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8730ee88d2bc423b9151cc9c2820d19d_I20220630" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTItMi0xLTEtMTE2Nzcx_82e5ae47-dde7-43f6-91be-7c8bdccfe8f1">361.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8730ee88d2bc423b9151cc9c2820d19d_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTItNC0xLTEtMTE2Nzcx_ed628313-2d35-4ef6-b0e8-3534b1dfde9e">10,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36716f0b028846cb85d4eb4230d3d560_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTItNi0xLTEtMTE2Nzcx_7e6d7c47-af7d-4f29-8cdf-579d7c726f26">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2dc7cc39fb2243a28ac5a77266758826_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTItOC0xLTEtMTE2Nzcx_05b54485-f38d-4070-bde0-f904af00ec12">9,175</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b5d37c24d0e41cb994b6d343566c79e_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTItMTAtMS0xLTExNjc3MQ_9f2c6ea3-9641-417f-b8be-b1f4b0d212ac">2,002</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i916cf2185b2841f8a9e4fd0d5fec5a62_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTItMTItMS0xLTExNjc3MQ_14301a9a-ca3d-45d6-aaee-3dff794db790">693</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43b9c3f038194349830beac9c871e79d_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTItMTQtMS0xLTExNjc3MQ_cfa44828-c33b-4428-a0d1-cce197e5555a">946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTItMTYtMS0xLTExNjc3MQ_64a5f283-7ac2-44d5-b2d0-d087912d6f6b">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="45" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances, April 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6dfaea77d3414998bbda1fdaa74c3687_I20210331" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTUtMi0xLTEtMTE2Nzcx_195c88ed-70c4-4f26-b557-d0c79b3eb6e1">358.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dfaea77d3414998bbda1fdaa74c3687_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTUtNC0xLTEtMTE2Nzcx_a3b1a2ec-834f-4811-abf2-2a43c12438df">10,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58298d9eca31468d856c6a8af9ac695d_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTUtNi0xLTEtMTE2Nzcx_bf67d10b-6622-41d8-8a2c-37267050cd65">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i737ae3f3c29c44eda0e06a604ac5d478_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTUtOC0xLTEtMTE2Nzcx_565f2a0d-8615-406b-a4db-2dce07502db0">8,623</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id66ae7f7283b4cb5b860cc7e725569c3_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTUtMTAtMS0xLTExNjc3MQ_6b85e22c-f6fb-4088-9ada-628bdf248985">2,256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4373a86e3f3641b1b628310fe43e6cc4_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTUtMTItMS0xLTExNjc3MQ_64312a4d-c563-4692-88ce-a2b880e72095">197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc5bc84b42294f459a348f63c3726c9c_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTUtMTQtMS0xLTExNjc3MQ_3973b2ac-7333-4e85-a20a-ed457db5d6bf">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6daf46a421eb422cab6a685d448b4571_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTUtMTYtMS0xLTExNjc3MQ_66e3c984-54e5-4eaa-9207-91fcccefc806">124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issued under share-based compensation plans</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06d85523749f4a83b2b4c231d9c4dcda_D20210401-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTYtMi0xLTEtMTE2Nzcx_720c4dd4-0239-4a75-8d74-989807d8f3c0">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06d85523749f4a83b2b4c231d9c4dcda_D20210401-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTYtNC0xLTEtMTE2Nzcx_031bf44c-3210-446d-8b1a-77b869c6f2cc">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57be2e142e074165b286ea861bf03454_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTYtNi0xLTEtMTE2Nzcx_484f2072-f518-425e-8f76-7eaaed186ad3">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3059ef14d774d44a01059d4de19473d_D20210401-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTctMTItMS0xLTEyMTgyMg_c5c016a8-de04-4d66-9706-0d540a463443">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTYtMTYtMS0xLTExNjc3MQ_e8bedd62-dad4-427d-a77f-1a28232e401a">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57be2e142e074165b286ea861bf03454_D20210401-20210630" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTctNi0xLTEtMTE2Nzcx_19557708-ac2a-44f5-85b8-8e0aec6c193a">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3059ef14d774d44a01059d4de19473d_D20210401-20210630" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTctMTItMS0xLTExNjc3MQ_db598485-cfb6-481e-83e9-212d2b1cc024">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTctMTYtMS0xLTExNjc3MQ_e8ef9333-2a05-4286-b104-eb2df99f7e7c">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee withholding taxes related to share-based awards</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57be2e142e074165b286ea861bf03454_D20210401-20210630" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTgtNi0xLTEtMTE2Nzcx_2b11c421-5527-4eab-a70c-2c358a90e34b">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3059ef14d774d44a01059d4de19473d_D20210401-20210630" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTgtMTItMS0xLTExNjc3MQ_a727f27f-0534-489e-b14c-1f04d4a19760">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTgtMTYtMS0xLTExNjc3MQ_5340191c-588e-4e14-b22b-2381c1046d43">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i030001e1f73a4abcb80a144774c1d968_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjAtOC0xLTEtMTE2Nzcx_92827d7d-1095-4e1e-bc2b-bb3396216c9b">595</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3059ef14d774d44a01059d4de19473d_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjAtMTItMS0xLTExNjc3MQ_c5623cb2-385a-4059-a67f-5827cf0cd53b">595</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f8e88b904b44a792fab696eda910bf_D20210401-20210630" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjAtMTQtMS0xLTExNjc3MQ_7ca8f616-fb24-4ebf-a422-131724c93f41">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjAtMTYtMS0xLTExNjc3MQ_7ff7ed11-1af8-4952-b065-2024d8afaf8c">593</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i774f5c7dc8fe4f20874a5a05070d8148_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjEtMTAtMS0xLTExNjc3MQ_89a16aa5-96fb-4312-80bc-58f20f06f263">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3059ef14d774d44a01059d4de19473d_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjEtMTItMS0xLTExNjc3MQ_d038c152-0dbc-4915-bb5d-a74e8fcd6640">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f8e88b904b44a792fab696eda910bf_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjEtMTQtMS0xLTExNjc3MQ_680733d7-8614-4d70-8e18-6ecd57b1545a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjEtMTYtMS0xLTExNjc3MQ_4ac305a4-05e5-4480-beb4-caaed2f21d9e">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances, June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i167c3eb2b5a24484aae6de79b43072b9_I20210630" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjItMi0xLTEtMTE2Nzcx_40ad60e4-be31-46ec-9510-ee016fdbee3b">358.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167c3eb2b5a24484aae6de79b43072b9_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjItNC0xLTEtMTE2Nzcx_c80969bb-3152-4a0b-ab6c-76f58a4663f8">10,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22ce8f1c4aba43659ab73d3c120bd01f_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjItNi0xLTEtMTE2Nzcx_b7cefb00-342f-47e2-bb40-08e26763aee3">413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f0bb2a47484474cbd31c19016dce90b_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjItOC0xLTEtMTE2Nzcx_6d05eecb-2dbd-4150-ad6c-8d4f5eef4e35">9,218</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iadf2cdcdd456462bb8b4d9279093e8ad_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjItMTAtMS0xLTExNjc3MQ_bc9d0bee-c6fa-4abf-b3b8-b125e4c6d361">2,182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2238c74c755346c79d5d762dfe2cd6aa_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjItMTItMS0xLTExNjc3MQ_942a843b-145b-4c5f-8914-5e107a51c0b1">687</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f2ab9065125401bb73c3a17f98f4c57_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjItMTQtMS0xLTExNjc3MQ_1f2cbda1-0a3f-4016-9362-6417ad35238c">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94793ac34eb24e699f57a3960e391e71_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjItMTYtMS0xLTExNjc3MQ_88bc9716-fef9-4a02-9eda-f325f7805771">611</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances, January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic6618ebcc4884ef78540a8090e1935b4_I20211231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjUtMi0xLTEtMTE2Nzcx_96789b84-8501-4554-8ef2-4ee937de32f8">359.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6618ebcc4884ef78540a8090e1935b4_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjUtNC0xLTEtMTE2Nzcx_7d634a18-7636-4ea9-b703-e39eceeaebf1">10,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87abd59869d7404c8d073f59e57b3927_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjUtNi0xLTEtMTE2Nzcx_14d66a33-c724-42ff-875f-089317e5f3c7">462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb17c62b32e2446fbb119cdb52d7cf3f_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjUtOC0xLTEtMTE2Nzcx_109ff350-fc08-4f5f-bd1b-beffdc4e1b53">8,961</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a5f744b0e03413c9fa836c080e97ee8_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjUtMTAtMS0xLTExNjc3MQ_d6501eaa-d003-491e-bcad-b0ec6b387b10">1,924</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i989da2ed6f4b41c18402f75e75411454_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjUtMTItMS0xLTExNjc3MQ_4019286b-4444-4e7c-ae00-67bd1a54dea9">106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16963925dad9481f931247cb3748b170_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjUtMTQtMS0xLTExNjc3MQ_6ea9d881-395d-4dd6-824b-35257faecb87">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjUtMTYtMS0xLTExNjc3MQ_31c0c217-0a9b-4e04-8f5f-d6827e05b657">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from B+L initial public offering, net of costs (Note 2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4677f0249548444e9357645b49193bd4_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjgtNi0xLTEtMTM0NDM2_533f6bfe-44de-46f7-ac21-e419bbab1d1a">327</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d13958e0ae471a9601cbcfbee2a354_D20220101-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjgtMTAtMS0xLTEzNDQzNg_32b4dde8-8d86-4e63-b52c-2825981d34f8">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f62a1dbada6412d9a70817c07d9551c_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjgtMTItMS0xLTEzNDQzNg_e8d5d3dd-5316-4b30-866d-7e5a7fb11e5d">190</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4af951a869647b7a15353420cc9a86f_D20220101-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjgtMTQtMS0xLTEzNDQzNg_230f93aa-b8cd-4414-9012-ecab6084c7d9">865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjgtMTYtMS0xLTEzNDQzNg_aaec5848-c47e-4cc2-b414-c706892336eb">675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issued under share-based compensation plans</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba4b227c13d94a3c8b88f5359bdef6ad_D20220101-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjYtMi0xLTEtMTE2Nzcx_e69e8269-e81d-4a69-8100-a69224a19480">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba4b227c13d94a3c8b88f5359bdef6ad_D20220101-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjYtNC0xLTEtMTE2Nzcx_4a0715ac-5a06-4f19-b80f-ee26171a1796">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4677f0249548444e9357645b49193bd4_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjYtNi0xLTEtMTE2Nzcx_4962b567-a2d1-46d3-a9a8-8efc4dcedabe">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f62a1dbada6412d9a70817c07d9551c_D20220101-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjYtMTItMS0xLTExNjc3MQ_ad225cc4-b299-4b63-a75f-dcc53ac885b4">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjYtMTYtMS0xLTExNjc3MQ_c8725f25-07e3-41a7-846c-48549cb91753">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4677f0249548444e9357645b49193bd4_D20220101-20220630" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjctNi0xLTEtMTE2Nzcx_8e1d1688-dd01-4ac2-b411-6db2b47dc0f9">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f62a1dbada6412d9a70817c07d9551c_D20220101-20220630" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjctMTItMS0xLTExNjc3MQ_264bfd17-0d79-485e-b45c-881f8fe3888a">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjctMTYtMS0xLTExNjc3MQ_d181423c-a520-4b5c-ae27-0f2ea1ab5777">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee withholding taxes related to share-based awards</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4677f0249548444e9357645b49193bd4_D20220101-20220630" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjgtNi0xLTEtMTE2Nzcx_7804103e-e9b8-4925-b843-d5f8e5b67a33">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f62a1dbada6412d9a70817c07d9551c_D20220101-20220630" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjgtMTItMS0xLTExNjc3MQ_3781235b-6f92-4b37-8f3c-3136728192d6">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjgtMTYtMS0xLTExNjc3MQ_1a1bdbb3-0ea2-4eac-ac09-82229bf2e2e1">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2226daa2ed09422d853e54bab742c402_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjktOC0xLTEtMTE2Nzcx_e3395e58-a805-4979-8faa-432bd5946a88">214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f62a1dbada6412d9a70817c07d9551c_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjktMTItMS0xLTExNjc3MQ_d1f8c909-c772-4749-a6d0-3ad79b1901eb">214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4af951a869647b7a15353420cc9a86f_D20220101-20220630" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjktMTQtMS0xLTExNjc3MQ_99d3671a-9017-40ae-9e2d-a88d98fd1849">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjktMTYtMS0xLTExNjc3MQ_e3da109c-9c8e-42e3-a9ce-d8fb5db72798">205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29d13958e0ae471a9601cbcfbee2a354_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzAtMTAtMS0xLTExNjc3MQ_6f9afd4e-58f5-4db1-a32e-5fa8196d9c6c">215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f62a1dbada6412d9a70817c07d9551c_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzAtMTItMS0xLTExNjc3MQ_8a2922bf-79b4-427f-a07d-6ce4db63c5ee">215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzAtMTYtMS0xLTExNjc3MQ_74528bd1-e6f5-49c6-acd3-16b8945314ea">215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances, June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8730ee88d2bc423b9151cc9c2820d19d_I20220630" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzEtMi0xLTEtMTE2Nzcx_b27ffb71-ad4a-48bc-976f-aa33ced0d8da">361.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8730ee88d2bc423b9151cc9c2820d19d_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzEtNC0xLTEtMTE2Nzcx_9befad24-6202-45c8-b9cc-d5eedda0b07f">10,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36716f0b028846cb85d4eb4230d3d560_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzEtNi0xLTEtMTE2Nzcx_a7232a3b-7745-4ddb-9875-083f9fb2a9d7">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2dc7cc39fb2243a28ac5a77266758826_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzEtOC0xLTEtMTE2Nzcx_3a14636f-0863-44e9-842a-8210788a064f">9,175</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b5d37c24d0e41cb994b6d343566c79e_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzEtMTAtMS0xLTExNjc3MQ_f2822713-b2a7-4ef4-a6a7-ba16a6eb79ae">2,002</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i916cf2185b2841f8a9e4fd0d5fec5a62_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzEtMTItMS0xLTExNjc3MQ_7c50225b-6edf-4294-85e4-915d5cd0189c">693</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43b9c3f038194349830beac9c871e79d_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzEtMTQtMS0xLTExNjc3MQ_fd6d58a4-a488-4b47-a3e0-6d39db5689a8">946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzEtMTYtMS0xLTExNjc3MQ_8a4c2ae4-50ba-4e68-a160-d2e2a3a9e986">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances, January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1ca51f98774641caa2fa73733729ac9b_I20201231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzQtMi0xLTEtMTE2Nzcx_fd8c7fb2-18a2-4182-bcd0-edf5a4260cc7">355.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca51f98774641caa2fa73733729ac9b_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzQtNC0xLTEtMTE2Nzcx_012a6036-ca0f-4eb7-9d27-f11993a47f4b">10,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6241ec65cd5841d28d2b1250bb5b5996_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzQtNi0xLTEtMTE2Nzcx_74faa725-82cf-486b-aa0f-66ef92c04845">454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12c22386ccd746679fcffe88ce0ac211_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzQtOC0xLTEtMTE2Nzcx_64831593-65a8-45c9-a58b-448628492607">8,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i628fbe5e0c6641f0821414b9534fdfbc_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzQtMTAtMS0xLTExNjc3MQ_364acc46-a88d-4e54-a119-bdd83664dd07">2,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f53aee8e3d54f4c9d733db6eaab6639_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzQtMTItMS0xLTExNjc3MQ_f5f352a0-6ded-47ce-a480-c3c9be026848">535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83ec1ba0169043a5b8ee5935b00c293f_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzQtMTQtMS0xLTExNjc3MQ_755a9ea6-4f3b-4e93-8c2f-68868cd00020">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e21899f1044f7fa7cb214f91d5655c_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzQtMTYtMS0xLTExNjc3MQ_a564f562-31e9-4e24-b861-e889b10ba697">605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issued under share-based compensation plans</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i168fd2ab08394dc88509e23e01fe1f09_D20210101-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzUtMi0xLTEtMTE2Nzcx_2febf823-cb02-4618-9424-4a029f3d08dd">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i168fd2ab08394dc88509e23e01fe1f09_D20210101-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzUtNC0xLTEtMTE2Nzcx_b605c41d-8fbe-42aa-bf11-379113844127">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54f5ce0b0a044bc88c6f3917442a0aee_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzUtNi0xLTEtMTE2Nzcx_45375620-1977-461e-9d63-36c28e540452">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ecdccc3b9849ea91d1b8d126581ab7_D20210101-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzUtMTItMS0xLTExNjc3MQ_ace75714-84c9-4f86-b435-500003f4905c">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzUtMTYtMS0xLTExNjc3MQ_a3a07d65-e5ae-4e68-857d-a3a717a310cf">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54f5ce0b0a044bc88c6f3917442a0aee_D20210101-20210630" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzYtNi0xLTEtMTE2Nzcx_5ca80fa2-0306-4753-b852-95481830b0f9">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ecdccc3b9849ea91d1b8d126581ab7_D20210101-20210630" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzYtMTItMS0xLTExNjc3MQ_52ee561c-5b57-459b-b299-d5d283dabe49">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzYtMTYtMS0xLTExNjc3MQ_7c1d1618-b52c-4ca9-bffe-ed4f78ee86b0">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee withholding taxes related to share-based awards</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54f5ce0b0a044bc88c6f3917442a0aee_D20210101-20210630" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzctNi0xLTEtMTE2Nzcx_0410f434-0be1-472c-8d40-94a951d73a1f">45</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ecdccc3b9849ea91d1b8d126581ab7_D20210101-20210630" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzctMTItMS0xLTExNjc3MQ_94a1f390-9a74-441d-b97c-4017939df5fd">45</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzctMTYtMS0xLTExNjc3MQ_2a31a403-8cff-4203-a1d8-99f8d114ff45">45</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4bd722a099c434c96732e1638d0eef9_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzgtOC0xLTEtMTE2Nzcx_39538422-44d3-4314-bf14-91c29e1af5ed"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzgtOC0xLTEtMTE2Nzcx_ce9cc730-46dc-4484-b836-fab046e2159f">1,205</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ecdccc3b9849ea91d1b8d126581ab7_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzgtMTItMS0xLTExNjc3MQ_3209d732-4da6-410b-a37e-5d9c2b9c57d5">1,205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if281e8e8aeee4142a78388f4196a2cb4_D20210101-20210630" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzgtMTQtMS0xLTExNjc3MQ_844c130f-5146-4abb-9097-bf34f8d98761">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzgtMTYtMS0xLTExNjc3MQ_729913d2-ac19-4799-90c1-a9ae567a3350">1,200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9b445a9016e474ea5b82e795dd9171f_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzktMTAtMS0xLTExNjc3MQ_7cd1ae0e-1cda-4d7e-b4de-7b0c06160ece">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ecdccc3b9849ea91d1b8d126581ab7_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzktMTItMS0xLTExNjc3MQ_c81f84e1-c1e6-42dd-a17a-b02d71eb74ac">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if281e8e8aeee4142a78388f4196a2cb4_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNDEtMTQtMS0xLTEyMTgzMQ_66bc15a0-484b-47a9-b08e-c8d53e1ffadc">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzktMTYtMS0xLTExNjc3MQ_34dd5dc6-507c-4184-b593-eef224df72eb">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances, June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i167c3eb2b5a24484aae6de79b43072b9_I20210630" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNDAtMi0xLTEtMTE2Nzcx_f55dc603-5d6a-4c4a-a533-0f66a04bf8b2">358.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i167c3eb2b5a24484aae6de79b43072b9_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNDAtNC0xLTEtMTE2Nzcx_5bae49a5-5cd8-4d64-8754-1f84eacb65ea">10,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22ce8f1c4aba43659ab73d3c120bd01f_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNDAtNi0xLTEtMTE2Nzcx_76397726-bbb8-44db-a1ba-79219a397151">413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f0bb2a47484474cbd31c19016dce90b_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNDAtOC0xLTEtMTE2Nzcx_c4dbc7bd-be74-4242-8801-a91c90d79b56">9,218</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iadf2cdcdd456462bb8b4d9279093e8ad_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNDAtMTAtMS0xLTExNjc3MQ_82580eeb-3ced-434a-acb1-b061ef60d395">2,182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2238c74c755346c79d5d762dfe2cd6aa_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNDAtMTItMS0xLTExNjc3MQ_728ebbdb-c08d-4193-a0be-6185a022dab4">687</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f2ab9065125401bb73c3a17f98f4c57_I20210630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNDAtMTQtMS0xLTExNjc3MQ_94cbc5e8-6656-43f2-a546-8c133e315fc5">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94793ac34eb24e699f57a3960e391e71_I20210630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNDAtMTYtMS0xLTExNjc3MQ_f9f867cb-86b4-4471-8e34-70fb9409e216">611</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i762fba229369426294c4424c2015a01a_34"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 22.50pt 54.00pt"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:81.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows From Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMy0xLTEtMS0xMTY3NzE_a3ae049e-5a90-4a73-a135-b1afacb81399">205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMy0zLTEtMS0xMTY3NzE_24bf3689-6530-4c62-a691-799e2b0d2651">1,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNS0xLTEtMS0xMTY3NzE_32cdbbba-0334-4963-9865-222528b15e64">699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNS0zLTEtMS0xMTY3NzE_c47a37d0-8359-49d9-bda6-0c25bdc8c1ff">807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization and write-off of debt premiums, discounts and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNi0xLTEtMS0xMTY3NzE_0966aa06-10cd-45d4-a4e0-0c2814dd872d">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNi0zLTEtMS0xMTY3NzE_9c62dbd2-6b02-4d06-8d94-2ea735480bf6">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNy0xLTEtMS0xMTY3NzE_162d5a32-4c7c-455c-9ec3-f600333f2e71">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNy0zLTEtMS0xMTY3NzE_5feeb2b0-2520-4880-8323-c2a99cfc9e7a">195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfOC0xLTEtMS0xMTY3NzE_a9fa993d-831a-407e-817e-8fd13a6b2db0">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfOC0zLTEtMS0xMTY3NzE_131b6c2c-0816-4843-aa9b-ef03a3e40028">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfOS0xLTEtMS0xMTY3NzE_6b7dd1dc-1f3e-4585-a9c0-5c904398c100">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfOS0zLTEtMS0xMTY3NzE_9372386c-84f1-4e8d-a89e-402db54ee3af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allowances for losses on trade receivable and inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="bhc:AllowancesForLossesOnAccountsReceivableAndInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTAtMS0xLTEtMTE2Nzcx_94bdf0fd-99b0-451b-b155-897628847786">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="bhc:AllowancesForLossesOnAccountsReceivableAndInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTAtMy0xLTEtMTE2Nzcx_cf3b1bd5-6f26-415c-a7f2-cece70d6348c">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="bhc:DeferredIncomeTaxNoncashExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTEtMS0xLTEtMTE2Nzcx_46f185a2-ab02-45b5-a448-66991799a37f">99</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="bhc:DeferredIncomeTaxNoncashExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTEtMy0xLTEtMTE2Nzcx_801162d5-efaf-45e6-80ab-d18e9eb4fe56">120</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net gain on sale of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTItMS0xLTEtMTE2Nzcx_d3f271b2-63da-4c26-ab85-4d2c67e5e228">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTItMy0xLTEtMTE2Nzcx_6d6e15f5-3405-4487-a774-3c849eca8d57">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to accrued legal settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="bhc:GainLossRelatedToLitigationSettlementGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTMtMS0xLTEtMTE2Nzcx_c67fbc03-eb32-4d24-a4e4-e600cf001f0e">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="bhc:GainLossRelatedToLitigationSettlementGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTMtMy0xLTEtMTE2Nzcx_590ceaae-0c5b-452d-b47d-79a51c26321c">532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of accrued legal settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTQtMS0xLTEtMTE2Nzcx_e840382a-52c3-4a02-bb3a-28d52bf83354">360</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTQtMy0xLTEtMTE2Nzcx_5b4defd1-2699-4b0a-b8a1-bac6cce041f6">129</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTUtMS0xLTEtMTE2Nzcx_0666c920-edcf-4f10-9667-e7f317dd9176">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTUtMy0xLTEtMTE2Nzcx_027da782-d243-4ec8-ab94-8b2d35100e50">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTYtMS0xLTEtMTE2Nzcx_f3c471fc-fd51-4788-9e0f-b97a10090b7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTYtMy0xLTEtMTE2Nzcx_b0e835c2-21fd-454d-9eaa-fab368703ed4">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain excluded from hedge effectiveness</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="bhc:DerivativeGainExcludedComponent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTctMS0xLTEtMTE2Nzcx_9d153f0d-fd00-49e4-9d63-ad9e004445e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="bhc:DerivativeGainExcludedComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTctMy0xLTEtMTE2Nzcx_40ae2e30-1579-4771-9a8f-c9e7fee229ab">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gain) loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTgtMS0xLTEtMTE2Nzcx_8a817854-8661-453b-893a-a17b889b9e82">113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTgtMy0xLTEtMTE2Nzcx_d072985a-d3f1-43e3-bf0f-0a5b45692d9d">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of contingent consideration adjustments, including accretion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTktMS0xLTEtMTE2Nzcx_0f7320d0-4385-4e82-bda2-556511480d78">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTktMy0xLTEtMTE2Nzcx_ca15da75-cefb-4281-b739-639183ade66e">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjAtMS0xLTEtMTE2Nzcx_50c8095c-90ed-485e-a459-0107cb0d8e11">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjAtMy0xLTEtMTE2Nzcx_ec651cc5-92db-4ff5-b1f9-53aa23acdc03">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjItMS0xLTEtMTE2Nzcx_b577d0dd-8756-4eb0-a822-65108f4d4a7f">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjItMy0xLTEtMTE2Nzcx_2db211c8-b901-4492-8cf3-19d1cae5084e">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjMtMS0xLTEtMTE2Nzcx_21691c0c-3077-470d-8fa3-98f964c60d66">138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjMtMy0xLTEtMTE2Nzcx_096a860d-5099-4149-8f03-41ee7f9cb107">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjQtMS0xLTEtMTE2Nzcx_fea8db59-5261-45fb-a3ef-ea8f4f112bbd">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjQtMy0xLTEtMTE2Nzcx_a1755a9b-7772-46b0-884b-6967fa58ba37">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjUtMS0xLTEtMTE2Nzcx_4290c570-22e1-436c-a2d5-a854ba87e5c8">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjUtMy0xLTEtMTE2Nzcx_7f0fd06e-e707-418e-a9ad-61aa2597018f">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjYtMS0xLTEtMTE2Nzcx_27b240c9-6600-4d48-b1a4-f5da0902b889">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjYtMy0xLTEtMTE2Nzcx_a2c1b9ef-e81f-4248-82ba-d0d4ada3005d">838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows From Investing Activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjgtMS0xLTEtMTE2Nzcx_942dc476-0251-454f-a050-c7a7bb1b3c2d">98</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjgtMy0xLTEtMTE2Nzcx_c2aa58f7-7040-4d2c-8b11-481d45d0a9e6">128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for intangible and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjktMS0xLTEtMTE2Nzcx_4b1879af-6735-4663-a289-721b60d65bc5">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjktMy0xLTEtMTE2Nzcx_044298bd-ca4e-4582-84d3-bca8b7b4c1bb">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMzAtMS0xLTEtMTE2Nzcx_08ca6630-bd0b-43e6-8dc9-1648317089d9">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMzAtMy0xLTEtMTE2Nzcx_c866abf9-f8a3-482b-aa97-f4b8ca83aa14">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMzEtMS0xLTEtMTE2Nzcx_a3e3a905-d5ad-4c6d-af2f-1305a5ba2d84">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMzEtMy0xLTEtMTE2Nzcx_97647781-2e2a-47da-b2c9-42f04ef7cfea">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of assets and businesses, net of costs to sell</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMzItMS0xLTEtMTE2Nzcx_83285002-36a2-476a-81d6-505ab1ce3fc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMzItMy0xLTEtMTE2Nzcx_f28ef311-c93d-47b4-ac2f-bf819a9b8cac">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest settlements from cross-currency swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="bhc:InterestSettlementOnCrossCurrencySwaps" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMzMtMS0xLTEtMTE2Nzcx_448a5338-962f-4f08-a1f9-2860243f5f8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="bhc:InterestSettlementOnCrossCurrencySwaps" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMzMtMy0xLTEtMTE2Nzcx_330d1eb6-d828-402d-8b4f-9f1676a40d3a">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMzQtMS0xLTEtMTE2Nzcx_8fe607dc-51bd-4047-af8d-f9ce493c5614">114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMzQtMy0xLTEtMTE2Nzcx_0576911a-1ade-4291-9dfd-3f1b5e903407">99</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows From Financing Activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of long-term debt, net of discounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMzYtMS0xLTEtMTE2Nzcx_50a53d3e-51d3-4ab4-afad-37dc0c905409">6,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMzYtMy0xLTEtMTE2Nzcx_41010b66-7b07-4d33-98f6-fe03c4cc9c07">1,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayments of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMzctMS0xLTEtMTE2Nzcx_109aa529-119a-4b23-9ad2-f8b0ff5aab28">7,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMzctMy0xLTEtMTE2Nzcx_38ad36b6-b1dd-41fa-be6d-ebcb25da4425">2,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net proceeds from B+L initial public offering, net of costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="bhc:ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDAtMS0xLTEtMTIzMjE5_f6b8668a-f535-4c97-bec6-aaf860a38d55">675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="bhc:ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDAtMy0xLTEtMTIzMjE5_622174bd-b7ce-4aa9-9f66-cf8ce8022c38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of employee withholding taxes related to share-based awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDAtMS0xLTEtMTE2Nzcx_b05551f3-2b5a-4cb7-b01c-5b43ec8fa5a4">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDAtMy0xLTEtMTE2Nzcx_836ccb73-9cb8-4f29-93cc-f1b50874666b">45</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDEtMS0xLTEtMTE2Nzcx_b8cc507e-65e4-4ead-8872-b7353e0148bc">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDEtMy0xLTEtMTE2Nzcx_5140593c-80ae-4172-837c-9b90194469da">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDItMS0xLTEtMTE2Nzcx_f53ee2ac-93a5-4082-8664-470126697fef">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDItMy0xLTEtMTE2Nzcx_9463f43b-2cdc-4c3f-8f68-05de9ba3803e">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDMtMS0xLTEtMTE2Nzcx_0eb62768-52d6-4a07-8d5e-8b969351de24">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDMtMy0xLTEtMTE2Nzcx_3335a195-c6d7-4215-80a3-0891b639932d">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDQtMS0xLTEtMTE2Nzcx_5488b2db-fdbe-4e9a-8cf1-09685da7725d">162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDQtMy0xLTEtMTE2Nzcx_115d0136-a210-406d-ace7-487108f40fd6">631</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and other</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDUtMS0xLTEtMTE2Nzcx_13cb9949-cd44-46f0-ba1a-3c5bcf25046e">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDUtMy0xLTEtMTE2Nzcx_d4c6638f-e334-4757-a3de-a1eaf802ad20">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents, restricted cash and other settlement deposits</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDYtMS0xLTEtMTE2Nzcx_57476996-b6c4-42f0-9566-3ae435830f08">240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDYtMy0xLTEtMTE2Nzcx_281fd155-dca9-41b9-ac97-4de9c2a03887">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, restricted cash and other settlement deposits, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDctMS0xLTEtMTE2Nzcx_a612bf12-ec8d-40c2-b57f-5e9c0779a666">2,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e21899f1044f7fa7cb214f91d5655c_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDctMy0xLTEtMTE2Nzcx_5f94229b-e21c-47dc-9b11-4bd46ecc39bb">1,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash, cash equivalents, restricted cash and other settlement deposits, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDgtMS0xLTEtMTE2Nzcx_ce107062-4a68-4144-926b-585087c73f0a">1,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94793ac34eb24e699f57a3960e391e71_I20210630" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDgtMy0xLTEtMTE2Nzcx_c9465487-4375-4a30-b048-235ab646dd32">1,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDktMS0xLTEtMTE2Nzcx_0840c291-597f-42c4-9a5e-783f46312794">659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94793ac34eb24e699f57a3960e391e71_I20210630" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDktMy0xLTEtMTE2Nzcx_b535cf7c-2c0b-43d1-a77d-e34932936151">642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="bhc:RestrictedCashAndOtherSettlementDepositsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNTAtMS0xLTEtMTE2Nzcx_6ae4c475-c6b9-42fd-a8a9-26eff370c9e9">1,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94793ac34eb24e699f57a3960e391e71_I20210630" decimals="-6" name="bhc:RestrictedCashAndOtherSettlementDepositsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNTAtMy0xLTEtMTE2Nzcx_f2bcd6a9-227a-4843-9d21-6d6225b53a2b">1,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents, held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNTEtMS0xLTEtMTE2Nzcx_7a332666-cc97-4f32-9d35-cd68b97eb32b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94793ac34eb24e699f57a3960e391e71_I20210630" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNTEtMy0xLTEtMTE2Nzcx_8fc8cef0-f5d4-44ca-a424-376a96bd2823">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash, cash equivalents, restricted cash and other settlement deposits, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNTItMS0xLTEtMTE2Nzcx_1d51e992-62a5-48c7-8eb7-45bdab115f38">1,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94793ac34eb24e699f57a3960e391e71_I20210630" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNTItMy0xLTEtMTE2Nzcx_98a7b717-cabe-4458-bc23-bc73b6c8ab40">1,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i762fba229369426294c4424c2015a01a_37"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i762fba229369426294c4424c2015a01a_40"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80MC9mcmFnOjMzMmVjNTIzMWExMzQ0NTNiM2UzMzM3ZjE2MzY5NzYwL3RleHRyZWdpb246MzMyZWM1MjMxYTEzNDQ1M2IzZTMzMzdmMTYzNjk3NjBfNTg5_95088a49-85ed-4cb8-9669-26379f399ef6" continuedAt="i7764472d20a749818530aafbf7ee9bd0" escape="true">DESCRIPTION OF BUSINESS </ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7764472d20a749818530aafbf7ee9bd0">Bausch Health Companies Inc. (the&#160;&#8220;Company&#8221; or &#8220;Bausch Health&#8221;) is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (&#8220;GI&#8221;) and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (&#8220;OTC&#8221;) products and medical aesthetic devices and, through its approximately <ix:nonFraction unitRef="number" contextRef="iab6dfe2f976644e99955a0681d7c0c9c_I20220630" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80MC9mcmFnOjMzMmVjNTIzMWExMzQ0NTNiM2UzMzM3ZjE2MzY5NzYwL3RleHRyZWdpb246MzMyZWM1MjMxYTEzNDQ1M2IzZTMzMzdmMTYzNjk3NjBfNDM5ODA0NjUxMjE5Ng_0df7e40a-91b9-4651-b416-a83e5e186cb7">90</ix:nonFraction>% ownership of Bausch + Lomb Corporation (&#8220;Bausch + Lomb&#8221;), branded, and branded generic pharmaceuticals, OTC products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment) in the therapeutic area of eye health. The Company's products are marketed directly or indirectly in approximately <ix:nonFraction unitRef="country" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-2" name="us-gaap:NumberOfCountriesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80MC9mcmFnOjMzMmVjNTIzMWExMzQ0NTNiM2UzMzM3ZjE2MzY5NzYwL3RleHRyZWdpb246MzMyZWM1MjMxYTEzNDQ1M2IzZTMzMzdmMTYzNjk3NjBfNTc0_fb152f90-fbd2-4ead-8e81-75100d6abcd1">100</ix:nonFraction> countries.</ix:continuation></span></div><div id="i762fba229369426294c4424c2015a01a_43"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80My9mcmFnOjA5ZDllMmE3ZWIwZDQ3NWU5NTk4ZGI1ZGY4NzQ2MDZiL3RleHRyZWdpb246MDlkOWUyYTdlYjBkNDc1ZTk1OThkYjVkZjg3NDYwNmJfNzk3MQ_788d70e9-5f6b-4ad5-91c8-ad05053e2a40" continuedAt="i594cf373b074464d875b8535e1f8e39d" escape="true">SIGNIFICANT ACCOUNTING POLICIES </ix:nonNumeric></span></div><ix:continuation id="i594cf373b074464d875b8535e1f8e39d" continuedAt="ie041588eeec4470d8f3ac315869b9eca"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80My9mcmFnOjA5ZDllMmE3ZWIwZDQ3NWU5NTk4ZGI1ZGY4NzQ2MDZiL3RleHRyZWdpb246MDlkOWUyYTdlYjBkNDc1ZTk1OThkYjVkZjg3NDYwNmJfNzk3Mw_382df0ef-311f-403a-b3f2-a0d23ce5d96e" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared by the Company in U.S. dollars and in accordance with&#160;U.S. generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;) for interim financial reporting, which do not conform in all respects to the requirements of U.S.&#160;GAAP for annual financial statements. Accordingly, these notes to the unaudited Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements prepared in accordance with U.S.&#160;GAAP that are contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the U.S. Securities and Exchange Commission (the&#160;&#8220;SEC&#8221;) and the Canadian Securities Administrators (the&#160;&#8220;CSA&#8221;) on February&#160;23, 2022. The unaudited Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#8217;s audited Consolidated Financial Statements for the year ended December&#160;31, 2021. The unaudited Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statement of the Company&#8217;s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full&#160;year.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation of the Bausch + Lomb Eye Health Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, the Company announced its intentions to separate its eye health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc. (the &#8220;B+L Separation&#8221;). In January 2022, the Company completed the internal organizational design and structure of the new eye health entity, Bausch + Lomb, as previously announced. The registration statement related to the initial public offering (&#8220;IPO&#8221;) of Bausch + Lomb (the &#8220;B+L IPO&#8221;) was declared effective on May 5, 2022, and Bausch + Lomb&#8217;s common stock began trading on the New York Stock Exchange and the Toronto Stock Exchange, in each case under the ticker symbol &#8220;BLCO&#8221; on May 6, 2022. Prior to the effectiveness of the registration statement, Bausch + Lomb was an indirect wholly-owned subsidiary of the Company. On May 10, 2022, a wholly owned subsidiary of the Company (the &#8220;Selling Shareholder&#8221;) sold <ix:nonFraction unitRef="shares" contextRef="i1508df3b43b1420ea4df39c0ed271596_D20220510-20220510" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80My9mcmFnOjA5ZDllMmE3ZWIwZDQ3NWU5NTk4ZGI1ZGY4NzQ2MDZiL3RleHRyZWdpb246MDlkOWUyYTdlYjBkNDc1ZTk1OThkYjVkZjg3NDYwNmJfMjczMg_4b7676ee-6040-4ca6-b150-30103e9398da">35,000,000</ix:nonFraction> common shares of Bausch + Lomb, at an offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1419e3c9d7064ed0ae3e2c5034298ca9_I20220510" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80My9mcmFnOjA5ZDllMmE3ZWIwZDQ3NWU5NTk4ZGI1ZGY4NzQ2MDZiL3RleHRyZWdpb246MDlkOWUyYTdlYjBkNDc1ZTk1OThkYjVkZjg3NDYwNmJfMjc5MQ_93957a5d-69b7-4c7e-a1ea-c8ae03c076c8">18.00</ix:nonFraction> per share, pursuant to the B+L IPO. In addition, the Selling Shareholder granted the underwriters an option for a period of <ix:nonNumeric contextRef="ifdd2e805422643dfb113cf804f616871_D20220510-20220510" name="bhc:SaleOfStockOverAllotmentTerm" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80My9mcmFnOjA5ZDllMmE3ZWIwZDQ3NWU5NTk4ZGI1ZGY4NzQ2MDZiL3RleHRyZWdpb246MDlkOWUyYTdlYjBkNDc1ZTk1OThkYjVkZjg3NDYwNmJfMTI2NDQzODM3MzgyOTQ_ba661f57-6693-44ab-ab64-f38cdf4a3fdd">30</ix:nonNumeric> days from the date of the B+L IPO to purchase up to an additional <ix:nonFraction unitRef="shares" contextRef="ifdd2e805422643dfb113cf804f616871_D20220510-20220510" decimals="INF" name="bhc:SaleOfStockNumberOfAdditionalSharesAvailableForIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80My9mcmFnOjA5ZDllMmE3ZWIwZDQ3NWU5NTk4ZGI1ZGY4NzQ2MDZiL3RleHRyZWdpb246MDlkOWUyYTdlYjBkNDc1ZTk1OThkYjVkZjg3NDYwNmJfMTI2NDQzODM3MzgzMDg_227fd18d-adfd-45c5-995e-fe6bc15c829b">5,250,000</ix:nonFraction> common shares to cover over-allotments at the IPO price less underwriting commissions. On May 31, 2022, the underwriters partially exercised the over-allotment option granted by the Selling Shareholder and, on June 1, 2022, the Selling Shareholder sold an additional <ix:nonFraction unitRef="shares" contextRef="i0d34ce2c08d1460f808a069165908113_D20220601-20220601" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80My9mcmFnOjA5ZDllMmE3ZWIwZDQ3NWU5NTk4ZGI1ZGY4NzQ2MDZiL3RleHRyZWdpb246MDlkOWUyYTdlYjBkNDc1ZTk1OThkYjVkZjg3NDYwNmJfNDk0NzgwMjMzNDEwMQ_5ed7353a-5ac7-4351-b9c7-d48dde801532">4,550,357</ix:nonFraction> common shares of Bausch + Lomb at an offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i929d5ea1c5624f61b981d629befc7a9d_I20220601" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80My9mcmFnOjA5ZDllMmE3ZWIwZDQ3NWU5NTk4ZGI1ZGY4NzQ2MDZiL3RleHRyZWdpb246MDlkOWUyYTdlYjBkNDc1ZTk1OThkYjVkZjg3NDYwNmJfNDk0NzgwMjMzNDExMw_bec8c855-a7a4-4c38-a744-31c3c270e4fb">18.00</ix:nonFraction> per share (less applicable underwriting discount). The remainder of the over-allotment option granted to the underwriters expired.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the closing of the B+L IPO and after giving effect to the partial exercise of the over-allotment option, Bausch Health directly or indirectly holds <ix:nonFraction unitRef="shares" contextRef="i1441c284542b4be69c98952b98de6886_I20220601" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80My9mcmFnOjA5ZDllMmE3ZWIwZDQ3NWU5NTk4ZGI1ZGY4NzQ2MDZiL3RleHRyZWdpb246MDlkOWUyYTdlYjBkNDc1ZTk1OThkYjVkZjg3NDYwNmJfNDk0NzgwMjM0MzQzNQ_6c478be7-6c72-48e8-94ea-0b9690842de0">310,449,643</ix:nonFraction> Bausch + Lomb common shares, which represent approximately <ix:nonFraction unitRef="number" contextRef="ifd3c0b53338441d68bc503e5527d1220_D20220601-20220601" decimals="3" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80My9mcmFnOjA5ZDllMmE3ZWIwZDQ3NWU5NTk4ZGI1ZGY4NzQ2MDZiL3RleHRyZWdpb246MDlkOWUyYTdlYjBkNDc1ZTk1OThkYjVkZjg3NDYwNmJfNDk0NzgwMjMzNDA5NA_6ac80cfa-da14-4ddf-8ed7-a6f1b749da3c">88.7</ix:nonFraction>% of Bausch + Lomb&#8217;s outstanding common shares. The aggregate net proceeds from the B+L IPO and the partial exercise of the over-allotment option by the underwriters, after deducting underwriting commissions were approximately $<ix:nonFraction unitRef="usd" contextRef="id112e4cb690043fba76b75855a318fed_D20220601-20220601" decimals="-6" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80My9mcmFnOjA5ZDllMmE3ZWIwZDQ3NWU5NTk4ZGI1ZGY4NzQ2MDZiL3RleHRyZWdpb246MDlkOWUyYTdlYjBkNDc1ZTk1OThkYjVkZjg3NDYwNmJfMTA5OTUxMTYyOTI1ODc_3db3e860-dbb2-4d34-b3ad-53aa729b4aaa">675</ix:nonFraction>&#160;million. The Company remains committed to completing the B+L Separation and believes the separation makes strategic sense. The completion of the B+L Separation is subject to the expiry of customary lockups related to the B+L IPO, the achievement of targeted debt leverage ratios and the receipt of applicable shareholder and other necessary approvals. The Company continues to evaluate the factors and considerations related to completing the B+L Separation and effect of the Norwich Legal Decision (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 18, &#8220;LEGAL PROCEEDINGS&#8221;) on the B+L Separation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The B+L IPO established two separate companies that include: (i) a fully integrated eye health company which consists of the Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals businesses and (ii) a diversified pharmaceutical company which includes the Company&#8217;s Salix, International (formerly International Rx), Diversified (dentistry, neurology, medical dermatology and generics pharmaceutical) products, and Solta aesthetic medical device businesses. Other than the </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="ie041588eeec4470d8f3ac315869b9eca" continuedAt="i349b8053bcaa4bac80339f59563af9bd"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effects of the B+L IPO described above, these unaudited Consolidated Financial Statements do not include any adjustments to give effect to the B+L Separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impacts of COVID-19 Pandemic </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unprecedented nature of the COVID-19 pandemic has, and continues to, adversely impact the global economy. The COVID-19 pandemic and the reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which these events may continue to impact the Company&#8217;s business, financial condition, cash flows and results of operations, in particular, will depend on future developments which are highly uncertain and many of which are outside the Company&#8217;s control. Such developments include the availability and effectiveness of vaccines for the COVID-19 virus, the ultimate geographic spread and duration of the pandemic, COVID-19 vaccine immunization rates, the extent and duration of a resurgence of the COVID-19 virus and variant strains thereof, such as the delta and omicron variants, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus and the economic impact of the pandemic and the reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company&#8217;s business, financial condition, cash flows and results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing. Although it is difficult to predict the broad macroeconomic effects that the COVID-19 pandemic will have on industries or individual companies, the Company has assessed the possible effects and outcomes of the pandemic on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand and currently believes that its estimates are reasonable. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Initial Public Offering of Solta Medical Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2021, the Company announced its intentions to conduct an IPO of its aesthetic medical device business, Solta Medical (formerly Global Solta) (the &#8220;Solta IPO&#8221;). In January 2022, the Company completed the internal organizational design and structure of the new Solta Medical entity, Solta Medical Corporation (&#8220;Solta&#8221;). On June 16, 2022, as a result of challenging market conditions and other factors, the Company announced it was suspending its plans for the Solta IPO. Solta will remain part of Bausch Health, as the Company plans to revisit alternate paths for its Solta medical aesthetic devices business.</span></div><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80My9mcmFnOjA5ZDllMmE3ZWIwZDQ3NWU5NTk4ZGI1ZGY4NzQ2MDZiL3RleHRyZWdpb246MDlkOWUyYTdlYjBkNDc1ZTk1OThkYjVkZjg3NDYwNmJfNzk2Nw_45cbe1a1-f149-431a-b815-de106ae3fff2" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the unaudited Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Consolidated Financial Statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the differences could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#8217;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#8217;s results of operations and financial position could be materially impacted.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80My9mcmFnOjA5ZDllMmE3ZWIwZDQ3NWU5NTk4ZGI1ZGY4NzQ2MDZiL3RleHRyZWdpb246MDlkOWUyYTdlYjBkNDc1ZTk1OThkYjVkZjg3NDYwNmJfNzk2Mw_5dd4e25d-6383-4102-b01d-c00c3dd0f7e4" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80My9mcmFnOjA5ZDllMmE3ZWIwZDQ3NWU5NTk4ZGI1ZGY4NzQ2MDZiL3RleHRyZWdpb246MDlkOWUyYTdlYjBkNDc1ZTk1OThkYjVkZjg3NDYwNmJfNzk3OA_f9ab2aea-ddae-473e-867f-a1ecb2a42ed5" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Reportable Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2022, the Company operates in the following reportable segments: (i) Salix, (ii) International (formerly International Rx), (iii) Diversified Products, (iv) Solta Medical, and (v) Bausch + Lomb. Prior to the first quarter of 2022, the Company operated in the following reportable segments: (i) Salix, (ii) International Rx, (iii) Ortho </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i349b8053bcaa4bac80339f59563af9bd">Dermatologics, (iv) Diversified Products and (v) Bausch + Lomb. Prior period presentations have been recast to conform to the current segment reporting structure. See Note 19, &#8220;SEGMENT INFORMATION&#8221; for additional information.</ix:continuation></span></div><div id="i762fba229369426294c4424c2015a01a_46"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RleHRyZWdpb246NzgxZTk0MGE3OTBkNGRmMWFlMjA0NDg3ZGIwNWY4MTFfNTY3OA_69a94a54-16fc-47c1-917e-763f7f395bad" continuedAt="i71f9c7cc26d742799a1a33e0c2004a94" escape="true"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RleHRyZWdpb246NzgxZTk0MGE3OTBkNGRmMWFlMjA0NDg3ZGIwNWY4MTFfNTcxNQ_d5d02c40-9c6b-41fb-b03e-6acffd212561" continuedAt="i85f74b6b763f451ab9ff73958cbde0e7" escape="true">REVENUE RECOGNITION </ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i71f9c7cc26d742799a1a33e0c2004a94" continuedAt="i98d3809fb1304dbdb0f4d1920219d235"><ix:continuation id="i85f74b6b763f451ab9ff73958cbde0e7"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, principally in the therapeutic areas of GI, dermatology, and eye health, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics medical devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 19, &#8220;SEGMENT INFORMATION&#8221; for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160;The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company&#8217;s products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#8217;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics.</span></div></ix:continuation><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RleHRyZWdpb246NzgxZTk0MGE3OTBkNGRmMWFlMjA0NDg3ZGIwNWY4MTFfNTcwMw_a75e584e-d008-42fa-b907-4f7adcaf1020" continuedAt="i583d47c01bc849e4826debfcd22f35a2" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the activity and ending balances of the Company&#8217;s variable consideration provisions for the six months ended June 30, 2022 and 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5351c87dd28040558ca2b56602428e56_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfMi0yLTEtMS0xMTY3NzE_5100fc6f-374b-4b42-ab5a-9f32e7ee0924">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41079230ec4f4c298b2e78b68dbf4675_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfMi00LTEtMS0xMTY3NzE_41797b9e-06d9-41bb-9110-68cf199d7f0f">482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a1cc3e19bb5406f9f7bb16e324efb73_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfMi02LTEtMS0xMTY3NzE_d64ac83a-1999-4b8d-ac58-2fe5b24df4b0">944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4154c578f14243c9b9bf1af4b506141a_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfMi04LTEtMS0xMTY3NzE_a5b3ccf7-c398-4fb2-9da6-d779f6da91c3">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c45771f0e2f47988c015be717b2f0b1_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfMi0xMC0xLTEtMTE2Nzcx_b03c87db-8d52-4287-ad7f-610205d8b479">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfMi0xMi0xLTEtMTE2Nzcx_af0c7f47-5740-4f34-b75c-adecd723d453">1,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41e06bd172a5482eaf50c7db24abc26a_D20220101-20220630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfMy0yLTEtMS0xMTY3NzE_4d094508-dc47-4070-85f0-70273959c341">278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa9af24c349540cc966f28ac5d9956ed_D20220101-20220630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfMy00LTEtMS0xMTY3NzE_7019e352-a324-475e-9557-e85f30e278b2">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53c5043ff3cf49cd84342b026a1ccd23_D20220101-20220630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfMy02LTEtMS0xMTY3NzE_fe3cbe6c-480f-4d3c-9669-d9835e7f16b3">1,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc6e7bacd9e74e10ab66ecc0b3c66513_D20220101-20220630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfMy04LTEtMS0xMTY3NzE_732d15e3-58e0-4e16-af7c-7aa63750f3ab">1,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib43f03b9a4c24364af00b0bee48970f3_D20220101-20220630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfMy0xMC0xLTEtMTE2Nzcx_5b4655bd-76fa-4dd9-b8b2-b3a964a985ac">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfMy0xMi0xLTEtMTE2Nzcx_68291ec4-72ac-489f-92bd-e0e933eb63f9">2,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41e06bd172a5482eaf50c7db24abc26a_D20220101-20220630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfNC0yLTEtMS0xMTY3NzE_c0230cc1-f48a-487a-8a6d-cd4e63f3ba60">303</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa9af24c349540cc966f28ac5d9956ed_D20220101-20220630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfNC00LTEtMS0xMTY3NzE_79bf2fd5-51f9-4502-bc0f-543c3975d525">107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53c5043ff3cf49cd84342b026a1ccd23_D20220101-20220630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfNC02LTEtMS0xMTY3NzE_d75bee4c-9da3-4460-8994-2e33554200c5">1,170</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc6e7bacd9e74e10ab66ecc0b3c66513_D20220101-20220630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfNC04LTEtMS0xMTY3NzE_48e11a6d-2398-4c56-8aa3-ddb998134441">976</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib43f03b9a4c24364af00b0bee48970f3_D20220101-20220630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfNC0xMC0xLTEtMTE2Nzcx_25e1ed01-71d7-402e-be99-29196eb8e09a">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfNC0xMi0xLTEtMTE2Nzcx_b6b207cf-c524-40f4-b020-3f2f0476625f">2,602</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib720c993198b4897b6de065be0d2db71_I20220630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfNS0yLTEtMS0xMTY3NzE_acea96a5-e722-4774-8075-3f51f086aa53">197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0903c200bb4544e59a69d3d41e660f9c_I20220630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfNS00LTEtMS0xMTY3NzE_f6bfe366-4d65-4d3e-b5ba-7ce7aed50b50">435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c259ae988c6479faf350e58d008e78c_I20220630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfNS02LTEtMS0xMTY3NzE_7ab23ba5-3c83-48ab-a900-f28ab9e41661">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i635febccfe0048d18fbd37689e3cd69d_I20220630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfNS04LTEtMS0xMTY3NzE_a43d3b25-3876-4e3b-8a9a-9b4c1bbdfdb5">222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i415e68faef7f4ba28dd9ac453dcd2665_I20220630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfNS0xMC0xLTEtMTE2Nzcx_94c4a97f-d272-44e4-b267-dc2f6f5f5705">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfNS0xMi0xLTEtMTE2Nzcx_992cee0b-8c61-484b-9941-237d0eaa4676">1,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $<ix:nonFraction unitRef="usd" contextRef="id1bf4e809b854d01bce396823e6d1480_I20220630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RleHRyZWdpb246NzgxZTk0MGE3OTBkNGRmMWFlMjA0NDg3ZGIwNWY4MTFfNDEwMA_aa9ef620-2b24-48e2-b592-9defb04040b0">48</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3635e4095c1b4cbf852ec17575d58b30_I20220101" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RleHRyZWdpb246NzgxZTk0MGE3OTBkNGRmMWFlMjA0NDg3ZGIwNWY4MTFfNDEwNw_a649caeb-6e57-4129-9a93-a606cf9039c8">36</ix:nonFraction>&#160;million as of June 30, 2022 and January 1, 2022, respectively, which are reflected as a reduction of Trade receivables, net in the Consolidated Balance Sheets. There were <ix:nonFraction unitRef="usd" contextRef="i4f09824df81c4936b5ccd49a133e7471_D20220101-20220630" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RleHRyZWdpb246NzgxZTk0MGE3OTBkNGRmMWFlMjA0NDg3ZGIwNWY4MTFfNDI1Ng_6d721fb9-6da1-47ae-a661-b76249cb99e7">no</ix:nonFraction> price appreciation credits during the six months ended June 30, 2022.</span></div></ix:nonNumeric></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i98d3809fb1304dbdb0f4d1920219d235"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><ix:continuation id="i583d47c01bc849e4826debfcd22f35a2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ca0942470cf47b0a264c45f0187b74c_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfMi0yLTEtMS0xMTY3NzE_f125d6c5-7427-4e92-aa7c-d770f257a2f1">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9595e765516542c0911edc919a2de08e_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfMi00LTEtMS0xMTY3NzE_e77f8fc3-e095-4de8-acf8-bf46e04c2519">575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9607524bf3464d7c9cddb1ba970385e3_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfMi02LTEtMS0xMTY3NzE_041ac836-40d1-4ce3-8bbc-0f372b786de2">779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i340db29595784ee08b18b8bab8b169b8_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfMi04LTEtMS0xMTY3NzE_ed3c4a63-84fd-4102-bf0b-a4c80858b8ae">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2c856c4b2614789b5fd854b8955fd6d_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfMi0xMC0xLTEtMTE2Nzcx_6c468e29-612d-43d8-99f4-f4c5c4f3efee">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e21899f1044f7fa7cb214f91d5655c_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfMi0xMi0xLTEtMTE2Nzcx_fe577601-29a8-4215-acaa-49fc124b0da7">1,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60bf28905a394c1890a5d2e6ceb0cfcf_D20210101-20210630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfMy0yLTEtMS0xMTY3NzE_81a9bb44-1a83-4ca0-81d8-5400b377c2f4">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6269a678f67b4ecf9db4720dcce9ef03_D20210101-20210630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfMy00LTEtMS0xMTY3NzE_62a6202e-8c10-48d8-a7a1-79bcd232fc8a">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4887e1b949fa47e0995174f52a3c62f4_D20210101-20210630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfMy02LTEtMS0xMTY3NzE_247b40d0-975a-4618-b256-dc9fcc4543c7">1,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cc2ce2251ff4d70a86c4ce36ba413dd_D20210101-20210630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfMy04LTEtMS0xMTY3NzE_bf954a14-c7b3-4d51-92bc-1df568fb6eb8">993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ce7e9873ed48928d8f66267a5181b9_D20210101-20210630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfMy0xMC0xLTEtMTE2Nzcx_f07439e7-1049-46b5-88cc-a94963f64bf3">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfMy0xMi0xLTEtMTE2Nzcx_a158a323-e0bb-4a03-a3b1-ea14eb72a886">2,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60bf28905a394c1890a5d2e6ceb0cfcf_D20210101-20210630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfNC0yLTEtMS0xMTY3NzE_d8f6453e-364a-4456-b974-dc6bc9bf6f67">296</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6269a678f67b4ecf9db4720dcce9ef03_D20210101-20210630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfNC00LTEtMS0xMTY3NzE_4464eacc-b45b-407f-a1fd-313bc8af9c50">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4887e1b949fa47e0995174f52a3c62f4_D20210101-20210630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfNC02LTEtMS0xMTY3NzE_0da2917d-7cfc-4c85-a858-9317f6fb1608">1,025</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cc2ce2251ff4d70a86c4ce36ba413dd_D20210101-20210630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfNC04LTEtMS0xMTY3NzE_0b1fe9e6-4654-4b0d-bb48-a87a0e723ecf">1,012</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38ce7e9873ed48928d8f66267a5181b9_D20210101-20210630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfNC0xMC0xLTEtMTE2Nzcx_b06e81ff-4b12-4f9d-980b-a9fe54d6850c">94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfNC0xMi0xLTEtMTE2Nzcx_c64dba04-a74b-43f7-b9d4-f7d638be3be5">2,546</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c8105ccfc3c4797a29a70cd4dd59ad9_I20210630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfNS0yLTEtMS0xMTY3NzE_7576ca59-e279-45bb-b73e-7d91dd79d14e">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c02e9fd592b472e98bf4f6aa3087550_I20210630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfNS00LTEtMS0xMTY3NzE_406da637-fc6d-4716-8a89-dcdff63e8283">533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i543391a7e8714bbfafcedd3cb1ad5539_I20210630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfNS02LTEtMS0xMTY3NzE_bc095620-b984-4e86-9be6-0f7571e01492">981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e5553f78cf642b4a35f59e0c0a41f82_I20210630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfNS04LTEtMS0xMTY3NzE_db22b539-2272-4496-9915-473409b9e22e">165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e4b08ae397c4999b5a89bd9886028e8_I20210630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfNS0xMC0xLTEtMTE2Nzcx_85b78dcf-04b8-4cc6-b2f6-08df988beefb">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94793ac34eb24e699f57a3960e391e71_I20210630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfNS0xMi0xLTEtMTE2Nzcx_29d24dd4-570e-4212-b995-a301f7f68741">1,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $<ix:nonFraction unitRef="usd" contextRef="i946fa40358f2484eb2b268a38b324c08_I20210630" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RleHRyZWdpb246NzgxZTk0MGE3OTBkNGRmMWFlMjA0NDg3ZGIwNWY4MTFfNDQxMg_b00917e9-4608-4dbb-8935-a2062e343d94">41</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i88092f2a3121475ea6f4d62c541f5263_I20210101" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RleHRyZWdpb246NzgxZTk0MGE3OTBkNGRmMWFlMjA0NDg3ZGIwNWY4MTFfNDQxOQ_b325f12d-d0f7-48aa-a829-8864c212ce09">32</ix:nonFraction>&#160;million as of June 30, 2021 and January 1, 2021, respectively. Included as a reduction of Distribution fees in the table above are price appreciation credits of approximately $<ix:nonFraction unitRef="usd" contextRef="ic3691b4d8ff64742b92e7f95b3ab5725_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RleHRyZWdpb246NzgxZTk0MGE3OTBkNGRmMWFlMjA0NDg3ZGIwNWY4MTFfNDU3Mg_3153c712-fb0e-422d-bccd-270640d225b1">1</ix:nonFraction>&#160;million during the six months ended June 30, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Contract Liabilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allowance for Credit Losses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collateral (if any), and any relevant current and reasonably supportable future economic factors.&#160;Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses. <ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RleHRyZWdpb246NzgxZTk0MGE3OTBkNGRmMWFlMjA0NDg3ZGIwNWY4MTFfNTY4NA_1507d060-7749-4fdb-be77-28a701890b1b" continuedAt="i105012695cdc474480d762e315944d0b" escape="true">The activity in the allowance for credit losses for trade receivables for the six months ended June 30, 2022 and 2021 is as follows.</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><ix:continuation id="i105012695cdc474480d762e315944d0b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.830%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjU5NTFiZDZlYTYzMTQ2ZTg4MzNmNWIyYmI1MzI1Y2NkL3RhYmxlcmFuZ2U6NTk1MWJkNmVhNjMxNDZlODgzM2Y1YjJiYjUzMjVjY2RfMS0xLTEtMS0xMTY3NzE_88543d5c-d1fd-471e-93c1-360c38b1606c">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e21899f1044f7fa7cb214f91d5655c_I20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjU5NTFiZDZlYTYzMTQ2ZTg4MzNmNWIyYmI1MzI1Y2NkL3RhYmxlcmFuZ2U6NTk1MWJkNmVhNjMxNDZlODgzM2Y1YjJiYjUzMjVjY2RfMS0zLTEtMS0xMTY3NzE_e5d99b51-ca0f-4a91-a675-efccf43d379b">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjU5NTFiZDZlYTYzMTQ2ZTg4MzNmNWIyYmI1MzI1Y2NkL3RhYmxlcmFuZ2U6NTk1MWJkNmVhNjMxNDZlODgzM2Y1YjJiYjUzMjVjY2RfMi0xLTEtMS0xMTY3NzE_498b35b2-b400-4c7e-b202-00831dfb4890">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjU5NTFiZDZlYTYzMTQ2ZTg4MzNmNWIyYmI1MzI1Y2NkL3RhYmxlcmFuZ2U6NTk1MWJkNmVhNjMxNDZlODgzM2Y1YjJiYjUzMjVjY2RfMi0zLTEtMS0xMTY3NzE_14d3d0d2-d1e9-4eb3-a28f-093b610cdbbb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjU5NTFiZDZlYTYzMTQ2ZTg4MzNmNWIyYmI1MzI1Y2NkL3RhYmxlcmFuZ2U6NTk1MWJkNmVhNjMxNDZlODgzM2Y1YjJiYjUzMjVjY2RfMy0xLTEtMS0xMTY3NzE_5478e79f-3796-44a6-bd85-fcfb20e3ef13">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjU5NTFiZDZlYTYzMTQ2ZTg4MzNmNWIyYmI1MzI1Y2NkL3RhYmxlcmFuZ2U6NTk1MWJkNmVhNjMxNDZlODgzM2Y1YjJiYjUzMjVjY2RfMy0zLTEtMS0xMTY3NzE_de2b3138-f57e-489d-ba32-ee50ae91810a">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjU5NTFiZDZlYTYzMTQ2ZTg4MzNmNWIyYmI1MzI1Y2NkL3RhYmxlcmFuZ2U6NTk1MWJkNmVhNjMxNDZlODgzM2Y1YjJiYjUzMjVjY2RfNC0xLTEtMS0xMTY3NzE_996a67ff-25a4-4943-9628-3fe4cafa5265">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjU5NTFiZDZlYTYzMTQ2ZTg4MzNmNWIyYmI1MzI1Y2NkL3RhYmxlcmFuZ2U6NTk1MWJkNmVhNjMxNDZlODgzM2Y1YjJiYjUzMjVjY2RfNC0zLTEtMS0xMTY3NzE_85940645-b95b-4cf9-ad63-2e525ad5f9c7">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="bhc:AccountsReceivableAllowanceForForeignExchangeAndOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjU5NTFiZDZlYTYzMTQ2ZTg4MzNmNWIyYmI1MzI1Y2NkL3RhYmxlcmFuZ2U6NTk1MWJkNmVhNjMxNDZlODgzM2Y1YjJiYjUzMjVjY2RfNS0xLTEtMS0xMTY3NzE_99ae996a-2af9-4611-b8c4-740788c2bbe7">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="bhc:AccountsReceivableAllowanceForForeignExchangeAndOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjU5NTFiZDZlYTYzMTQ2ZTg4MzNmNWIyYmI1MzI1Y2NkL3RhYmxlcmFuZ2U6NTk1MWJkNmVhNjMxNDZlODgzM2Y1YjJiYjUzMjVjY2RfNS0zLTEtMS0xMTY3NzE_160a3a87-c3de-485c-ad7a-28aa231ba732">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjU5NTFiZDZlYTYzMTQ2ZTg4MzNmNWIyYmI1MzI1Y2NkL3RhYmxlcmFuZ2U6NTk1MWJkNmVhNjMxNDZlODgzM2Y1YjJiYjUzMjVjY2RfNi0xLTEtMS0xMTY3NzE_098491e0-095d-4b98-8414-17380587dc11">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94793ac34eb24e699f57a3960e391e71_I20210630" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjU5NTFiZDZlYTYzMTQ2ZTg4MzNmNWIyYmI1MzI1Y2NkL3RhYmxlcmFuZ2U6NTk1MWJkNmVhNjMxNDZlODgzM2Y1YjJiYjUzMjVjY2RfNi0zLTEtMS0xMTY3NzE_f18c70a8-30e7-4a14-9188-30234ff6021e">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i762fba229369426294c4424c2015a01a_49"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80OS9mcmFnOjdlMTM0ZjI4ZDdiYzRmNjE4MWJiYTI2MDMwMDU1ODMzL3RleHRyZWdpb246N2UxMzRmMjhkN2JjNGY2MTgxYmJhMjYwMzAwNTU4MzNfMjQ0Ng_ec5fc26b-a708-4f4f-b41e-4eaae65a2331" continuedAt="i1366361d464543fcb408a1e7fc213744" escape="true">LICENSING AGREEMENTS AND DIVESTITURE</ix:nonNumeric></span></div><ix:continuation id="i1366361d464543fcb408a1e7fc213744" continuedAt="i164d8a079be6432494f77c899d0c8a6d"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early stage development that target unique conditions. The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by regulatory agencies, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain. The commitment periods under these agreements vary and include customary termination provisions. Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred. Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture of Amoun Pharmaceutical Company S.A.E. (&#8220;Amoun&#8221;)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, the Company announced that it and certain of its affiliates had entered into a definitive agreement to sell all of its equity interests in Amoun for total gross consideration of approximately $<ix:nonFraction unitRef="usd" contextRef="ic98d97b553c347bba74a30a630426fa0_D20210331-20210331" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80OS9mcmFnOjdlMTM0ZjI4ZDdiYzRmNjE4MWJiYTI2MDMwMDU1ODMzL3RleHRyZWdpb246N2UxMzRmMjhkN2JjNGY2MTgxYmJhMjYwMzAwNTU4MzNfMTI1MQ_e6397307-9e20-43e5-a588-7c8bdbec12b3">740</ix:nonFraction>&#160;million (including the assignment to the purchasing entity of an intercompany loan granted by the Company to Amoun), subject to certain adjustments (the &#8220;Amoun Sale&#8221;). The Amoun Sale closed on July 26, 2021. As part of the Amoun Sale, cash generated by Amoun during the period from the locked-box date of January 1, 2021 through closing was for the benefit of the purchasing entity, subject to working capital during such period. Amoun manufactures, markets and distributes branded generics of human and animal health products. The Amoun business was part of the International segment (previously included within the former Bausch + Lomb/International Rx segment) and was reclassified as held for sale as of December 31, 2020. As a result of meeting the criteria for held for sale classification, the carrying value of the Amoun business, was adjusted to its estimated fair value, less </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i164d8a079be6432494f77c899d0c8a6d">costs to sell, and the Company recognized impairment losses of $<ix:nonFraction unitRef="usd" contextRef="i60aea4fd35f0463c9e764ebeb3fc9833_D20210401-20210630" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80OS9mcmFnOjdlMTM0ZjI4ZDdiYzRmNjE4MWJiYTI2MDMwMDU1ODMzL3RleHRyZWdpb246N2UxMzRmMjhkN2JjNGY2MTgxYmJhMjYwMzAwNTU4MzNfMjE5Mw_97aefc48-c09b-48f6-95ac-4c203ec96e57">20</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4b7ebf59aac94b30b7f7b423b41e117c_D20210101-20210630" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80OS9mcmFnOjdlMTM0ZjI4ZDdiYzRmNjE4MWJiYTI2MDMwMDU1ODMzL3RleHRyZWdpb246N2UxMzRmMjhkN2JjNGY2MTgxYmJhMjYwMzAwNTU4MzNfMjc0ODc3OTA3MTkxMA_60f46e5e-9369-4f85-b545-6cfbbfac4a3e">88</ix:nonFraction>&#160;million during the three and six months ended June 30, 2021, respectively, included within Asset impairments, including loss on assets held for sale in the Consolidated Statements of Operations. Revenues associated with Amoun were $<ix:nonFraction unitRef="usd" contextRef="i52c2c4c1d1a5416b9c90de8eeb79bb48_D20210401-20210630" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80OS9mcmFnOjdlMTM0ZjI4ZDdiYzRmNjE4MWJiYTI2MDMwMDU1ODMzL3RleHRyZWdpb246N2UxMzRmMjhkN2JjNGY2MTgxYmJhMjYwMzAwNTU4MzNfMjM5OA_447ca86c-a47b-484f-833a-0d293240b419">70</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8c73de91dfce436faf9fe431bbdc6487_D20210101-20210630" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80OS9mcmFnOjdlMTM0ZjI4ZDdiYzRmNjE4MWJiYTI2MDMwMDU1ODMzL3RleHRyZWdpb246N2UxMzRmMjhkN2JjNGY2MTgxYmJhMjYwMzAwNTU4MzNfNzE0NjgyNTU4MzI4OQ_3ac4c551-e89b-4daa-9575-423a1dc15b7e">137</ix:nonFraction>&#160;million for the three and six months ended June 30, 2021, respectively.</ix:continuation></span></div><div id="i762fba229369426294c4424c2015a01a_52"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="bhc:RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81Mi9mcmFnOjg3MDgxMWIzZDgyZDRjM2I5YWQ4Nzg5ZmNkNmQ4ODhkL3RleHRyZWdpb246ODcwODExYjNkODJkNGMzYjlhZDg3ODlmY2Q2ZDg4OGRfMjM2Nw_22a8f82e-6661-4cfb-be56-16d494b4f7c7" continuedAt="if4fff108ff7d4e25a94af6933410b1df" escape="true">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS </ix:nonNumeric></span></div><ix:continuation id="if4fff108ff7d4e25a94af6933410b1df"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and Integration Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates opportunities to improve its operating results and implement cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The liability associated with restructuring and integration costs as of June 30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i1ee589a448d54140b1753817a06b38e6_I20220630" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81Mi9mcmFnOjg3MDgxMWIzZDgyZDRjM2I5YWQ4Nzg5ZmNkNmQ4ODhkL3RleHRyZWdpb246ODcwODExYjNkODJkNGMzYjlhZDg3ODlmY2Q2ZDg4OGRfNzA5_b3864989-cf2d-49e1-851d-e7215891fb30">30</ix:nonFraction> million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $<ix:nonFraction unitRef="usd" contextRef="i73006e60a9e74841887814ddcaca7dc1_D20220101-20220630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81Mi9mcmFnOjg3MDgxMWIzZDgyZDRjM2I5YWQ4Nzg5ZmNkNmQ4ODhkL3RleHRyZWdpb246ODcwODExYjNkODJkNGMzYjlhZDg3ODlmY2Q2ZDg4OGRfNzM0_ca3600d9-dd30-429d-a2ea-1033409d411d">25</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i99ee9e6ccc2443c0b6ca3d2b22341738_D20210101-20210630" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81Mi9mcmFnOjg3MDgxMWIzZDgyZDRjM2I5YWQ4Nzg5ZmNkNmQ4ODhkL3RleHRyZWdpb246ODcwODExYjNkODJkNGMzYjlhZDg3ODlmY2Q2ZDg4OGRfNzQx_00ab6b20-ec29-49a3-a436-2891a9591ddf">6</ix:nonFraction>&#160;million of restructuring and integration costs and made payments of $<ix:nonFraction unitRef="usd" contextRef="i73006e60a9e74841887814ddcaca7dc1_D20220101-20220630" decimals="-6" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81Mi9mcmFnOjg3MDgxMWIzZDgyZDRjM2I5YWQ4Nzg5ZmNkNmQ4ODhkL3RleHRyZWdpb246ODcwODExYjNkODJkNGMzYjlhZDg3ODlmY2Q2ZDg4OGRfODA0_6a275d79-2abf-4e97-a326-a72ee8e2d770">15</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i99ee9e6ccc2443c0b6ca3d2b22341738_D20210101-20210630" decimals="-6" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81Mi9mcmFnOjg3MDgxMWIzZDgyZDRjM2I5YWQ4Nzg5ZmNkNmQ4ODhkL3RleHRyZWdpb246ODcwODExYjNkODJkNGMzYjlhZDg3ODlmY2Q2ZDg4OGRfODEx_b7d5fca7-748f-492e-a306-144fda0d0b93">9</ix:nonFraction>&#160;million during the six months ended June 30, 2022 and 2021, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation Costs, Separation-related Costs, IPO Costs and IPO-related Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred, and expects to continue to incur costs associated with activities to effectuate the B+L Separation. The Company also incurred costs associated with activities to effectuate the Solta IPO, which was suspended in June 2022. These B+L Separation and Solta IPO activities include: (i) separating the Bausch + Lomb and Solta Medical businesses from the remainder of the Company, (ii) completing the B+L IPO and preparing for the suspended Solta IPO and (iii) completing the actions necessary for Bausch + Lomb to become an independent publicly traded entity. Separation and IPO costs are incremental costs directly related to the ongoing B+L Separation and the suspended Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing a new board of directors and related board committees for the Bausch + Lomb and Solta Medical entities. Included in Restructuring, integration, separation and IPO costs for the six months ended June 30, 2022 and 2021 are Separation and IPO costs of $<ix:nonFraction unitRef="usd" contextRef="i3945140cd4d9458eafb0336b8c0878ac_D20220101-20220630" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81Mi9mcmFnOjg3MDgxMWIzZDgyZDRjM2I5YWQ4Nzg5ZmNkNmQ4ODhkL3RleHRyZWdpb246ODcwODExYjNkODJkNGMzYjlhZDg3ODlmY2Q2ZDg4OGRfMTY4OQ_118b35e5-a7c1-4987-8b76-ac5ccbdc7101">23</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i571cafc77df6419e8f7ad8e88a7f5d22_D20210101-20210630" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81Mi9mcmFnOjg3MDgxMWIzZDgyZDRjM2I5YWQ4Nzg5ZmNkNmQ4ODhkL3RleHRyZWdpb246ODcwODExYjNkODJkNGMzYjlhZDg3ODlmY2Q2ZDg4OGRfMTY5Ng_5eb1a778-03b5-43c4-85ac-880b6345db00">15</ix:nonFraction>&#160;million, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also incurred Separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation and the suspended Solta IPO and will continue to incur incremental costs indirectly related with the B+L Separation. Separation-related and IPO-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. Included in Selling, general and administrative for the six months ended June 30, 2022 and 2021 are Separation-related and IPO-related costs of $<ix:nonFraction unitRef="usd" contextRef="i3945140cd4d9458eafb0336b8c0878ac_D20220101-20220630" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81Mi9mcmFnOjg3MDgxMWIzZDgyZDRjM2I5YWQ4Nzg5ZmNkNmQ4ODhkL3RleHRyZWdpb246ODcwODExYjNkODJkNGMzYjlhZDg3ODlmY2Q2ZDg4OGRfMjIxNA_348848e2-3282-480a-a7bd-8083c75701b5">64</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i571cafc77df6419e8f7ad8e88a7f5d22_D20210101-20210630" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81Mi9mcmFnOjg3MDgxMWIzZDgyZDRjM2I5YWQ4Nzg5ZmNkNmQ4ODhkL3RleHRyZWdpb246ODcwODExYjNkODJkNGMzYjlhZDg3ODlmY2Q2ZDg4OGRfMjIyMQ_b8bacb2e-2c10-457f-b2aa-decd50a99061">55</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent and timing of future charges of these costs to complete the B+L Separation cannot be reasonably estimated at this time and could be material.</span></div></ix:continuation><div id="i762fba229369426294c4424c2015a01a_55"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfNjE5Mw_0f947b82-f7e1-428d-b4a4-72e98cffd1f2" continuedAt="i502273dcf9cb4ac1a7896caca636ae86" escape="true">FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="i502273dcf9cb4ac1a7896caca636ae86" continuedAt="i73807e111ef94367afc584effe1ebcaf"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are estimated based on valuation techniques and inputs categorized as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1&#160;&#8212;&#160;Quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2&#160;&#8212;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;&#160;and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or&#160;estimation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the&#160;instrument.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i73807e111ef94367afc584effe1ebcaf" continuedAt="i7ff8e88bfd474df6825e3d0314ba90f8"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfNjIwMw_31abf95c-0c30-4948-b80d-c081dbbf0840" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.196%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1d5ed0948004c6da2b0030b9c2d5c61_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfMy0yLTEtMS0xMTY3NzE_c1eddc22-d1e9-413c-8fea-faf801db5ae1">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5375b8e373564a36aaf52188e7d12cf6_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfMy00LTEtMS0xMTY3NzE_15e5b0da-fe12-427b-8e5e-6d5e7160a07d">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cce3ab850c54369b71be99818c2eadc_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfMy02LTEtMS0xMTY3NzE_c14a94be-2181-4cba-bf45-c93f5cb1b04b">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4d5e497f284e3bb6f031694e5e632b_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfMy04LTEtMS0xMTY3NzE_b6d7c2a1-dedd-46e8-bf56-4472c7cfe014">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f3c15d038f4d9a95a41ec1632623ff_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfMy0xMC0xLTEtMTE2Nzcx_9c9e39f9-4062-4f65-9ee4-2bc0b56c3207">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id78b9bd044e04128813ea5234fe8bbef_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfMy0xMi0xLTEtMTE2Nzcx_23b72d1f-81ee-4bb4-8345-48ed6f0f8390">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic88bcecca27f4caf845d3357626418ff_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfMy0xNC0xLTEtMTE2Nzcx_347be691-543f-4e5d-bc7d-81a2953579f0">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb74f1a8f9f947d5b4d8a76565d7e64a_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfMy0xNi0xLTEtMTE2Nzcx_64891a3b-c7eb-4cb4-8bba-b3806000bca9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1d5ed0948004c6da2b0030b9c2d5c61_I20220630" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNC0yLTEtMS0xMTY3NzE_fd030ee6-ac6e-4183-af44-f458c1a9273c">1,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="bhc:RestrictedCashAndOtherSettlementDepositsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNC00LTEtMS0xMTY3NzE_8d75d951-9aa3-4b49-8a64-fbb61e8dd119"><ix:nonFraction unitRef="usd" contextRef="i5375b8e373564a36aaf52188e7d12cf6_I20220630" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNC00LTEtMS0xMTY3NzE_981787f7-d593-4a2a-80bf-09aa335c6bc1">1,220</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cce3ab850c54369b71be99818c2eadc_I20220630" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNC02LTEtMS0xMTY3NzE_4b9bcc46-fe96-4f58-a675-cbf6b8c388e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4d5e497f284e3bb6f031694e5e632b_I20220630" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNC04LTEtMS0xMTY3NzE_55f444b0-a4a7-420b-bc90-792c6efd2c02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f3c15d038f4d9a95a41ec1632623ff_I20211231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNC0xMC0xLTEtMTE2Nzcx_996fa8f9-4313-4d78-8df4-a6b9b0557fd4">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id78b9bd044e04128813ea5234fe8bbef_I20211231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNC0xMi0xLTEtMTE2Nzcx_aff94ebe-1931-4fcd-a54b-d0058299e342">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic88bcecca27f4caf845d3357626418ff_I20211231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNC0xNC0xLTEtMTE2Nzcx_81a9adb0-a240-4e51-87a4-907fd133a8c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb74f1a8f9f947d5b4d8a76565d7e64a_I20211231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNC0xNi0xLTEtMTE2Nzcx_9eb29989-2578-4402-8a77-60fc23f2239f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61bd5fedea3e409b8e2fc3fcc1946608_I20220630" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNS0yLTEtMS0xMTY3NzE_34c9bed8-3b3d-4d66-aa5a-74757cf4fd0a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if25b6bb0d9734b1da12ac4c00dfb2152_I20220630" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNS00LTEtMS0xMTY3NzE_2494ee5f-e901-432d-970c-245e90a132d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic835863b5091449ea80b36560fc1e6a3_I20220630" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNS02LTEtMS0xMTY3NzE_4d104241-c35a-4bf1-b43e-373482fb647a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8379b2caaf1244258cefe506e215e56c_I20220630" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNS04LTEtMS0xMTY3NzE_f077c82a-0567-459b-9a5a-e20831758798">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9145c463e6ca4724adb2d0d6582fec23_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNS0xMC0xLTEtMTE2Nzcx_75785c8b-2ffe-4b2a-bf93-ffbb965746fa">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1b5f54af20f4de8bfeeea70bfb7ff42_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNS0xMi0xLTEtMTE2Nzcx_911ac0e6-d0ff-4a8e-8b88-5595fa56b155">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c974af31735487dabbddfa5989251cd_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNS0xNC0xLTEtMTE2Nzcx_cc3b8814-2cd0-45bb-8ddb-9346c188fa08">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie63c790d802547cea65c40ded8c158fb_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNS0xNi0xLTEtMTE2Nzcx_27a448e4-53b6-4508-a209-b843f530f358">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1d5ed0948004c6da2b0030b9c2d5c61_I20220630" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNy0yLTEtMS0xMTY3NzE_6621adc3-c675-4941-9e74-f5cdb69ecd3b">225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5375b8e373564a36aaf52188e7d12cf6_I20220630" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNy00LTEtMS0xMTY3NzE_0dc6701e-2f88-4778-a5bd-ea0eaaf8820b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cce3ab850c54369b71be99818c2eadc_I20220630" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNy02LTEtMS0xMTY3NzE_751b6e7d-a545-46a5-919a-9a930a257275">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4d5e497f284e3bb6f031694e5e632b_I20220630" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNy04LTEtMS0xMTY3NzE_daa99a7b-27dc-4686-9a00-ff653008b968">225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f3c15d038f4d9a95a41ec1632623ff_I20211231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNy0xMC0xLTEtMTE2Nzcx_df572509-2d2c-4916-ae09-bffade871898">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id78b9bd044e04128813ea5234fe8bbef_I20211231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNy0xMi0xLTEtMTE2Nzcx_606d7d96-acdf-4e2f-9cea-75faf6a66c60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic88bcecca27f4caf845d3357626418ff_I20211231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNy0xNC0xLTEtMTE2Nzcx_ab87c328-83b3-4af8-b14e-cac97d9e84d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb74f1a8f9f947d5b4d8a76565d7e64a_I20211231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNy0xNi0xLTEtMTE2Nzcx_6fa7473f-1cdb-41ea-b51e-6facb1670c68">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61bd5fedea3e409b8e2fc3fcc1946608_I20220630" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfOC0yLTEtMS0xMTY3NzE_1dbf0ffb-7ebf-4e61-9d71-e26eb996f689">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if25b6bb0d9734b1da12ac4c00dfb2152_I20220630" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfOC00LTEtMS0xMTY3NzE_4a50a9bd-f8f1-46e5-a3c5-931e96e4b5a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic835863b5091449ea80b36560fc1e6a3_I20220630" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfOC02LTEtMS0xMTY3NzE_997385bd-b340-4c5d-b884-ad73e5aa29de">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8379b2caaf1244258cefe506e215e56c_I20220630" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfOC04LTEtMS0xMTY3NzE_3f0e3a59-d3b2-44ac-8f45-388eba126246">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9145c463e6ca4724adb2d0d6582fec23_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfOC0xMC0xLTEtMTE2Nzcx_4c7562db-a05c-4377-b3d8-8cf4011d1122">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1b5f54af20f4de8bfeeea70bfb7ff42_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfOC0xMi0xLTEtMTE2Nzcx_78b6f76f-60f0-40b8-8b2d-ae59c6693f20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c974af31735487dabbddfa5989251cd_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfOC0xNC0xLTEtMTE2Nzcx_a9894b89-a677-4545-b02a-70b942eec1b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie63c790d802547cea65c40ded8c158fb_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfOC0xNi0xLTEtMTE2Nzcx_bd8e2faa-9b3f-43ee-ad37-1ab0286686e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of <ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="bhc:HighlyLiquidInvestmentsMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfMTQyOA_57b142c2-e33a-46cc-ae85-cc0fc83d5fb2">three months</ix:nonNumeric> or less when&#160;purchased, and are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature. Cash, cash equivalents and restricted cash and other settlements as presented in the Consolidated Balance Sheet as of June 30, 2022 includes $<ix:nonFraction unitRef="usd" contextRef="i2a344934b62143ffb69252e4cddaf7f0_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfNDM5ODA0NjUxODg1Ng_a8606383-961f-4f5a-8999-36fd2719f6a4">446</ix:nonFraction>&#160;million of cash, cash equivalents and restricted cash held by legal entities of Bausch + Lomb, of which approximately $<ix:nonFraction unitRef="usd" contextRef="iaabfd7c03ce9402ea41cfcee705244c4_I20220630" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfNDM5ODA0NjUxOTI0OA_70496a95-2be4-4cda-95ba-00de6c54da1f">92</ix:nonFraction>&#160;million was due to be distributed to other legal entities owned by the Company in connection with the separation of Bausch +Lomb. Cash otherwise held by Bausch + Lomb legal entities and any future cash from the operations, investing and financing activities of Bausch + Lomb, is expected to be retained by Bausch + Lomb entities and are generally not available to support the operations, investing and financing activities of other legal entities, including Bausch + Lomb&#8217;s parent company unless paid as a dividend which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to  Bausch + Lomb&#8217;s shareholders. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, Restricted cash and other settlement deposits includes $<ix:nonFraction unitRef="usd" contextRef="i189afe61ed934a13beac41e9a8e72d03_D20220101-20220630" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfMTY1NA_2c513c1c-498e-41e6-bfac-f9bb5d1fdfc1">1,210</ix:nonFraction>&#160;million of payments into an escrow fund under the terms of a settlement agreement regarding certain U.S. securities litigation (which settlement agreement is subject to <ix:nonFraction unitRef="appeal" contextRef="ia3cc2ca14e8e4aa5b2cdb9d9edc76003_I20220630" decimals="INF" name="bhc:LitigationSettlementNumberOfObjectorsAppeals" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfMTgxOA_bf860801-834f-459a-9262-3cafd2f089ff">one</ix:nonFraction> objector&#8217;s appeal of the final court approval of the agreement), and is reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to its short-term nature. These payments will remain in escrow until resolution of the appeal of the final court approval of the settlement agreement, as discussed in Note 18, &#8220;LEGAL PROCEEDINGS&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers into or out of Level 3 during the six months ended June 30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cross-currency Swaps</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into cross-currency swaps, with aggregate notional amounts of $<ix:nonFraction unitRef="usd" contextRef="i80db1e595e9640d1885c3342cd690c01_I20191231" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfMjM0MA_97593055-8ef9-4e97-81b3-33a425117d2a">1,250</ix:nonFraction> million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its Consolidated Financial Statements from fluctuation in exchange rates. The euro-denominated net investment being hedged was the Company&#8217;s investment in certain euro-denominated subsidiaries. The Company unwound these cross-currency swaps during November 2021. As a result, there were no assets or liabilities related to the cross-currency swaps included in the Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021.</span></div><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfNjE4Mw_ee889a21-e09b-4f7c-96dc-cec67465be81" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of hedging instruments on the Consolidated Statements of Comprehensive Loss and the Consolidated Statements of Operations for the three and six months ended June 30, 2022 and 2021:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54705085633648acb51a31a97ced439a_D20220401-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjQ4MTc1N2U0N2JhNDQ3NTg5MmViY2VkNmY1MzgzNDc3L3RhYmxlcmFuZ2U6NDgxNzU3ZTQ3YmE0NDc1ODkyZWJjZWQ2ZjUzODM0NzdfMi0yLTEtMS0xMjAyMjk_8f80ccf5-6e30-4372-ad40-2832ff0a946d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iece67921157f4e1a974430192b9d3bb2_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjQ4MTc1N2U0N2JhNDQ3NTg5MmViY2VkNmY1MzgzNDc3L3RhYmxlcmFuZ2U6NDgxNzU3ZTQ3YmE0NDc1ODkyZWJjZWQ2ZjUzODM0NzdfMi00LTEtMS0xMjAyMzE_92f0d6f6-1677-49c9-815d-ccea9ac4a5a4">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74f9e7451c5d4e35be2c1947c78de1e3_D20220101-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjQ4MTc1N2U0N2JhNDQ3NTg5MmViY2VkNmY1MzgzNDc3L3RhYmxlcmFuZ2U6NDgxNzU3ZTQ3YmE0NDc1ODkyZWJjZWQ2ZjUzODM0NzdfMi0yLTEtMS0xMTY3NzE_bcf0b58a-2f68-4306-b680-e6fdb514456e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea270cf4c54447e083b7f756deb2b619_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjQ4MTc1N2U0N2JhNDQ3NTg5MmViY2VkNmY1MzgzNDc3L3RhYmxlcmFuZ2U6NDgxNzU3ZTQ3YmE0NDc1ODkyZWJjZWQ2ZjUzODM0NzdfMi00LTEtMS0xMTY3NzE_0529a68b-529a-4093-a5d5-d2414c6dc601">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain excluded from assessment of hedge effectiveness</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id174b5ac9dab4a9795348c9cab5bd884_D20220401-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjQ4MTc1N2U0N2JhNDQ3NTg5MmViY2VkNmY1MzgzNDc3L3RhYmxlcmFuZ2U6NDgxNzU3ZTQ3YmE0NDc1ODkyZWJjZWQ2ZjUzODM0NzdfMy0yLTEtMS0xMjAyMjk_364b73fb-4be0-4c7e-91e0-ac87256c205f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5970569842e447ca7e924e7d2d9c57b_D20210401-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjQ4MTc1N2U0N2JhNDQ3NTg5MmViY2VkNmY1MzgzNDc3L3RhYmxlcmFuZ2U6NDgxNzU3ZTQ3YmE0NDc1ODkyZWJjZWQ2ZjUzODM0NzdfMy00LTEtMS0xMjAyMzE_f7fa0853-e344-4578-98b6-a389d6f01c7b">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadd5508489ab4388a28166622ded71ec_D20220101-20220630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjQ4MTc1N2U0N2JhNDQ3NTg5MmViY2VkNmY1MzgzNDc3L3RhYmxlcmFuZ2U6NDgxNzU3ZTQ3YmE0NDc1ODkyZWJjZWQ2ZjUzODM0NzdfMy0yLTEtMS0xMTY3NzE_02867c34-1162-43d6-87ec-19e144535c61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2748f8a48f1c4077a65379baa42188c9_D20210101-20210630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjQ4MTc1N2U0N2JhNDQ3NTg5MmViY2VkNmY1MzgzNDc3L3RhYmxlcmFuZ2U6NDgxNzU3ZTQ3YmE0NDc1ODkyZWJjZWQ2ZjUzODM0NzdfMy00LTEtMS0xMTY3NzE_9cbaaafa-dd35-44b1-a8f8-fff5155c4f42">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of gain of excluded component</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No portion of the cross-currency swaps was ineffective for the six months ended June 30, 2021. During the six months ended June 30, 2022 and 2021, the Company received $<ix:nonFraction unitRef="usd" contextRef="i9e40ec51c8e14dcf8242bf19258f7e98_D20220101-20220630" decimals="-6" name="us-gaap:PaymentsForProceedsFromHedgeInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfMzIyNw_941a4221-06ef-40d6-9e49-d96165870c21">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i56a275573f694076bcb43a832f0ec8ed_D20210101-20210630" decimals="-6" name="us-gaap:PaymentsForProceedsFromHedgeInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfMzIzNA_65dbaadf-248b-4d9b-a4ca-1dd22455b45b">11</ix:nonFraction>&#160;million, respectively, in interest settlements which are reported as investing activities in the Consolidated Statements of Cash Flows.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i7ff8e88bfd474df6825e3d0314ba90f8" continuedAt="if893bc3e1c014706b4bb7138d82241c5"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Contracts</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2020, the Company has been entering into foreign currency exchange contracts. As of June 30, 2022, these contracts had an aggregate outstanding notional amount of $<ix:nonFraction unitRef="usd" contextRef="i5073339adb074151bb1c3f96161a4030_I20220630" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfMzU1Mw_826d4972-d484-4f3c-b490-317512a1eef7">332</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. The Company&#8217;s foreign currency exchange contracts are economically hedging the foreign exchange exposure on certain of the Company&#8217;s intercompany balances. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other. Settlements of the Company&#8217;s foreign currency exchange contracts are reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other and reported as operating activities in the Consolidated Statements of Cash Flows. </span></div><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfNjE4NA_0ccc5085-b551-417b-9b00-0e14312f94a8" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company&#8217;s foreign exchange contracts as included in the Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.443%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b891f480d594aed8e806f205699bb48_I20220630" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjRmYmExYmNlYjk2NDQzZmZiMDk0NWRjMzY2ODYzMTRjL3RhYmxlcmFuZ2U6NGZiYTFiY2ViOTY0NDNmZmIwOTQ1ZGMzNjY4NjMxNGNfMS0xLTEtMS0xMTY3NzE_e6f6fbd5-03f2-4e87-85af-08b48b9f9a09">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a580e8bc224076a70259444452e1ae_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjRmYmExYmNlYjk2NDQzZmZiMDk0NWRjMzY2ODYzMTRjL3RhYmxlcmFuZ2U6NGZiYTFiY2ViOTY0NDNmZmIwOTQ1ZGMzNjY4NjMxNGNfMS0zLTEtMS0xMTY3NzE_0f5275ea-cdcc-4798-867f-52791e796a24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79fc8f975e3d4b62a88faa67e904f40e_I20220630" decimals="-6" sign="-" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjRmYmExYmNlYjk2NDQzZmZiMDk0NWRjMzY2ODYzMTRjL3RhYmxlcmFuZ2U6NGZiYTFiY2ViOTY0NDNmZmIwOTQ1ZGMzNjY4NjMxNGNfMi0xLTEtMS0xMTY3NzE_ca1881a0-cd5c-469c-920a-7b81f088e4db">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96796514e5f543db98cc98707c804220_I20211231" decimals="-6" sign="-" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjRmYmExYmNlYjk2NDQzZmZiMDk0NWRjMzY2ODYzMTRjL3RhYmxlcmFuZ2U6NGZiYTFiY2ViOTY0NDNmZmIwOTQ1ZGMzNjY4NjMxNGNfMi0zLTEtMS0xMTY3NzE_f58b27c9-75aa-4283-86e6-8c55c39812e1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5073339adb074151bb1c3f96161a4030_I20220630" decimals="-6" sign="-" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjRmYmExYmNlYjk2NDQzZmZiMDk0NWRjMzY2ODYzMTRjL3RhYmxlcmFuZ2U6NGZiYTFiY2ViOTY0NDNmZmIwOTQ1ZGMzNjY4NjMxNGNfMy0xLTEtMS0xMTY3NzE_7e18f023-b0d1-460f-80e1-152f6e532896">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1483a64c418348fa85a7a2e2d92d9a71_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjRmYmExYmNlYjk2NDQzZmZiMDk0NWRjMzY2ODYzMTRjL3RhYmxlcmFuZ2U6NGZiYTFiY2ViOTY0NDNmZmIwOTQ1ZGMzNjY4NjMxNGNfMy0zLTEtMS0xMTY3NzE_23a78e39-bf0e-4b2d-b92d-ed3db0fd5271">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfNjE5OA_c2100729-df99-4a30-89c0-8bc29c0ec34b" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of the Company&#8217;s foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for the three and six months ended June 30, 2022 and 2021:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.982%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.366%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) related to changes in fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0beb279eb94a4ed9a49020c90d93ed68_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjM4ODBiMzU3YTk0OTQxNmI5NjYyYjg4MGYwYmEzNDg1L3RhYmxlcmFuZ2U6Mzg4MGIzNTdhOTQ5NDE2Yjk2NjJiODgwZjBiYTM0ODVfMi0xLTEtMS0xMjAyMzU_08fb83c6-4517-46c8-90aa-2fa0fcb9d7e5">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i518e98f1651849d6aa762c450415511f_D20210401-20210630" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjM4ODBiMzU3YTk0OTQxNmI5NjYyYjg4MGYwYmEzNDg1L3RhYmxlcmFuZ2U6Mzg4MGIzNTdhOTQ5NDE2Yjk2NjJiODgwZjBiYTM0ODVfMi0zLTEtMS0xMjAyMzc_54e2ea95-1ebd-4698-ba8c-47cc93b9dd8c">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8726b33a91484a12951301843f01bde5_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjM4ODBiMzU3YTk0OTQxNmI5NjYyYjg4MGYwYmEzNDg1L3RhYmxlcmFuZ2U6Mzg4MGIzNTdhOTQ5NDE2Yjk2NjJiODgwZjBiYTM0ODVfMi0xLTEtMS0xMTY3NzE_1e411b3a-03cf-4733-84bb-fc1fe0495db0">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a487257cff84ebb8f7de444b4ebbe8e_D20210101-20210630" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjM4ODBiMzU3YTk0OTQxNmI5NjYyYjg4MGYwYmEzNDg1L3RhYmxlcmFuZ2U6Mzg4MGIzNTdhOTQ5NDE2Yjk2NjJiODgwZjBiYTM0ODVfMi0zLTEtMS0xMTY3NzE_c3936fe7-bea3-464a-a3c6-a04555a3433d">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) related to settlements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0beb279eb94a4ed9a49020c90d93ed68_D20220401-20220630" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjM4ODBiMzU3YTk0OTQxNmI5NjYyYjg4MGYwYmEzNDg1L3RhYmxlcmFuZ2U6Mzg4MGIzNTdhOTQ5NDE2Yjk2NjJiODgwZjBiYTM0ODVfMy0xLTEtMS0xMjAyMzU_e8c1216c-2b58-47e9-a234-b8cb0a446cc6">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i518e98f1651849d6aa762c450415511f_D20210401-20210630" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjM4ODBiMzU3YTk0OTQxNmI5NjYyYjg4MGYwYmEzNDg1L3RhYmxlcmFuZ2U6Mzg4MGIzNTdhOTQ5NDE2Yjk2NjJiODgwZjBiYTM0ODVfMy0zLTEtMS0xMjAyMzc_266efef8-5dcb-4334-acaa-d320a0a9f5aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8726b33a91484a12951301843f01bde5_D20220101-20220630" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjM4ODBiMzU3YTk0OTQxNmI5NjYyYjg4MGYwYmEzNDg1L3RhYmxlcmFuZ2U6Mzg4MGIzNTdhOTQ5NDE2Yjk2NjJiODgwZjBiYTM0ODVfMy0xLTEtMS0xMTY3NzE_e003e362-fd19-48b0-81ab-4cd73a5a7b06">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a487257cff84ebb8f7de444b4ebbe8e_D20210101-20210630" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjM4ODBiMzU3YTk0OTQxNmI5NjYyYjg4MGYwYmEzNDg1L3RhYmxlcmFuZ2U6Mzg4MGIzNTdhOTQ5NDE2Yjk2NjJiODgwZjBiYTM0ODVfMy0zLTEtMS0xMTY3NzE_8c7b010b-f367-44f8-a454-20dcdd8d9ee9">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related Contingent Consideration Obligations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level&#160;3) inputs. These inputs may include: (i)&#160;the estimated amount and timing of projected cash flows, (ii)&#160;the probability of the achievement of the factor(s) on which the contingency is based and (iii)&#160;the risk-adjusted discount rate used to present value the probability-weighted cash&#160;flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At June&#160;30, 2022, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from <ix:nonFraction unitRef="rate" contextRef="id76bfb01eac947359aab3481b8c4cc1a_I20220630" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfNTYxMQ_f72b8550-8921-45af-957c-9fc1a0a30ce3">6</ix:nonFraction>% to <ix:nonFraction unitRef="rate" contextRef="i8a317605867040149a9dee38efc52b70_I20220630" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfNTYxNw_b0b5cada-120a-47da-a9ac-21efef4784b8">18</ix:nonFraction>%, and a weighted average risk-adjusted discount rate of <ix:nonFraction unitRef="rate" contextRef="i85f23aaeb4ab4696888e25b5585acb6d_I20220630" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfNTY3NQ_ed8fc8a7-9b3c-4298-904c-95d5daf91c5e">7</ix:nonFraction>%. The weighted average risk-adjusted discount rate was calculated by weighting each contract&#8217;s relative fair value at June&#160;30, 2022.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="if893bc3e1c014706b4bb7138d82241c5"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfNjE4Ng_c0def7cd-7536-4484-a782-7e0bb35f690b" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the six months ended June 30, 2022 and 2021: </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.534%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfMS00LTEtMS0xMTY3NzE_ab148daa-003d-4c64-a24d-a0da7be43c9f">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e21899f1044f7fa7cb214f91d5655c_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfMS04LTEtMS0xMTY3NzE_179b4c77-1828-4056-8e2e-66295d3ecd20">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to Acquisition-related contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion for the time value of money</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac99a0231e043b7a6cf8a6875d75f4a_D20220101-20220630" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfMy0yLTEtMS0xMTY3NzE_66306116-2c9d-4ab4-95bd-9339bc8c40f0">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ed8d150a9e04ca1951e0567580a1c34_D20210101-20210630" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfMy02LTEtMS0xMTY3NzE_8b214d23-3b28-4dbf-918b-e12f83af097f">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments due to changes in estimates of other future payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i605f016464d646fabfb72ea00b5aa146_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfNC0yLTEtMS0xMTY3NzE_a172f46a-e23f-4df0-bd38-b8e69316b714">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26184bc3f87e42b8af77e4f35e46cdae_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfNC02LTEtMS0xMTY3NzE_4b50c1a6-e137-4ee4-af70-10dab4382b43">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfNS00LTEtMS0xMTY3NzE_d5eb74e7-22ca-4d00-83bb-5b0597e9d3e4">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfNS04LTEtMS0xMTY3NzE_8b19c1de-3115-42f7-ac05-743ceede3c3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfNi00LTEtMS0xMTY3NzE_2e895fe8-c2db-418a-a219-42a95fbc5311">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfNi04LTEtMS0xMTY3NzE_d7973bd8-c47c-4cbc-9660-ba31edde0a84">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment included in other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfNy00LTEtMS0xMjIwODk_64277667-d0be-44a7-934e-2fb5f7fa5bb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfNy04LTEtMS0xMjIwOTE_3eb77943-3bcc-4368-babe-3c28f12b8728">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfOC00LTEtMS0xMTY3NzE_1c25086d-95f7-4abd-86c7-8d4afd5cb3e3">225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94793ac34eb24e699f57a3960e391e71_I20210630" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfOC04LTEtMS0xMTY3NzE_4f10cd73-1c09-4161-a552-20cf4eb0a757">280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfOS00LTEtMS0xMTY3NzE_b8959187-4e7b-4451-bc83-656e3891c4aa">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94793ac34eb24e699f57a3960e391e71_I20210630" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfOS04LTEtMS0xMTY3NzE_771877af-8b40-4884-a7c1-14ad462317be">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfMTAtNC0xLTEtMTE2Nzcx_c766bba0-52be-48d1-bc6c-b336b172e5ff">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94793ac34eb24e699f57a3960e391e71_I20210630" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfMTAtOC0xLTEtMTE2Nzcx_5d33a300-d535-4c95-9a71-7a7a685b2d3e">206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Long-term Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of long-term debt as of June&#160;30, 2022 and December&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i6085cb4d390c424680c3eafd241edadf_I20220630" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfNjA2MA_5e0f4a48-3547-4f50-a1f6-a14fce693590">16,141</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5faaf2aaa33e43408f0747441c0e1404_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfNjA2Nw_2ccdcdbc-35f9-4ef5-ae9f-a3eb97dbd81d">22,689</ix:nonFraction> million, respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div></ix:continuation><div id="i762fba229369426294c4424c2015a01a_58"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81OC9mcmFnOmE5ZjZjZDYyMzg3ZDRjNWFhNGIwZDRjNWQ0YTYxNjU1L3RleHRyZWdpb246YTlmNmNkNjIzODdkNGM1YWE0YjBkNGM1ZDRhNjE2NTVfNTQ_a2e7a75d-eeb5-4314-aa47-2ff5121bab82" continuedAt="if934fa17ad414b5f86a90d7c349bc87f" escape="true">INVENTORIES</ix:nonNumeric></span></div><ix:continuation id="if934fa17ad414b5f86a90d7c349bc87f"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81OC9mcmFnOmE5ZjZjZDYyMzg3ZDRjNWFhNGIwZDRjNWQ0YTYxNjU1L3RleHRyZWdpb246YTlmNmNkNjIzODdkNGM1YWE0YjBkNGM1ZDRhNjE2NTVfNjA_0b01a7c7-ca5f-4ebc-ac9d-925f9c8dc601" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consist of:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:InventoryRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81OC9mcmFnOmE5ZjZjZDYyMzg3ZDRjNWFhNGIwZDRjNWQ0YTYxNjU1L3RhYmxlOjkyNjU0ZTZlZTQ1NDQyZTQ4MjNhNjRjOTQ2ZmU4OGQxL3RhYmxlcmFuZ2U6OTI2NTRlNmVlNDU0NDJlNDgyM2E2NGM5NDZmZTg4ZDFfMS0yLTEtMS0xMTY3NzE_634259c1-cc61-4526-89ba-6e21ff4e0755">301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:InventoryRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81OC9mcmFnOmE5ZjZjZDYyMzg3ZDRjNWFhNGIwZDRjNWQ0YTYxNjU1L3RhYmxlOjkyNjU0ZTZlZTQ1NDQyZTQ4MjNhNjRjOTQ2ZmU4OGQxL3RhYmxlcmFuZ2U6OTI2NTRlNmVlNDU0NDJlNDgyM2E2NGM5NDZmZTg4ZDFfMS00LTEtMS0xMTY3NzE_da128153-bf8e-4031-ba5f-1e28fa2d9be9">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:InventoryWorkInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81OC9mcmFnOmE5ZjZjZDYyMzg3ZDRjNWFhNGIwZDRjNWQ0YTYxNjU1L3RhYmxlOjkyNjU0ZTZlZTQ1NDQyZTQ4MjNhNjRjOTQ2ZmU4OGQxL3RhYmxlcmFuZ2U6OTI2NTRlNmVlNDU0NDJlNDgyM2E2NGM5NDZmZTg4ZDFfMi0yLTEtMS0xMTY3NzE_bd05fe95-6d75-4e46-b9c8-cedf8d45dd17">124</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:InventoryWorkInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81OC9mcmFnOmE5ZjZjZDYyMzg3ZDRjNWFhNGIwZDRjNWQ0YTYxNjU1L3RhYmxlOjkyNjU0ZTZlZTQ1NDQyZTQ4MjNhNjRjOTQ2ZmU4OGQxL3RhYmxlcmFuZ2U6OTI2NTRlNmVlNDU0NDJlNDgyM2E2NGM5NDZmZTg4ZDFfMi00LTEtMS0xMTY3NzE_ad9d1f41-0c97-415a-8cf1-5e3e53d59f39">112</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81OC9mcmFnOmE5ZjZjZDYyMzg3ZDRjNWFhNGIwZDRjNWQ0YTYxNjU1L3RhYmxlOjkyNjU0ZTZlZTQ1NDQyZTQ4MjNhNjRjOTQ2ZmU4OGQxL3RhYmxlcmFuZ2U6OTI2NTRlNmVlNDU0NDJlNDgyM2E2NGM5NDZmZTg4ZDFfMy0yLTEtMS0xMTY3NzE_2b84c980-8c33-4dc8-92e1-348feeefd461">648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81OC9mcmFnOmE5ZjZjZDYyMzg3ZDRjNWFhNGIwZDRjNWQ0YTYxNjU1L3RhYmxlOjkyNjU0ZTZlZTQ1NDQyZTQ4MjNhNjRjOTQ2ZmU4OGQxL3RhYmxlcmFuZ2U6OTI2NTRlNmVlNDU0NDJlNDgyM2E2NGM5NDZmZTg4ZDFfMy00LTEtMS0xMTY3NzE_61b037f8-7462-40ce-87dc-71ccefa23d20">602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81OC9mcmFnOmE5ZjZjZDYyMzg3ZDRjNWFhNGIwZDRjNWQ0YTYxNjU1L3RhYmxlOjkyNjU0ZTZlZTQ1NDQyZTQ4MjNhNjRjOTQ2ZmU4OGQxL3RhYmxlcmFuZ2U6OTI2NTRlNmVlNDU0NDJlNDgyM2E2NGM5NDZmZTg4ZDFfNC0yLTEtMS0xMTY3NzE_90402397-5019-46e1-8e7b-d47d41e8127c">1,073</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:InventoryGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81OC9mcmFnOmE5ZjZjZDYyMzg3ZDRjNWFhNGIwZDRjNWQ0YTYxNjU1L3RhYmxlOjkyNjU0ZTZlZTQ1NDQyZTQ4MjNhNjRjOTQ2ZmU4OGQxL3RhYmxlcmFuZ2U6OTI2NTRlNmVlNDU0NDJlNDgyM2E2NGM5NDZmZTg4ZDFfNC00LTEtMS0xMTY3NzE_1497570f-83dc-41ca-b07c-d3c139b0f91a">993</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i762fba229369426294c4424c2015a01a_61"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTczMTI_b8f44b8e-bf56-4aad-b698-9e6f65bbab50" continuedAt="i76b5333411564b2aa83208cde4a42c31" escape="true">INTANGIBLE ASSETS AND GOODWILL</ix:nonNumeric></span></div><ix:continuation id="i76b5333411564b2aa83208cde4a42c31" continuedAt="iea2f71e24b404568844d473603397cad"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTcyODg_c4d95367-0528-4f77-b0e8-2a2521ead687" escape="true"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTczMTg_b0551f8f-de10-451d-8d66-146ba6baea1a" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets consist of: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61fbe90e93374904b5398ecb0a93c67f_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfMy0yLTEtMS0xMTY3NzE_24cfca27-f79c-49a4-84cd-569692ba714e">20,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61fbe90e93374904b5398ecb0a93c67f_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfMy00LTEtMS0xMTY3NzE_ba2f6d03-6ddd-459c-988a-c023dc343890">16,695</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61fbe90e93374904b5398ecb0a93c67f_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfMy02LTEtMS0xMTY3NzE_e44ed9ca-8f6a-436c-941e-60f7b4b106f9">4,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a23787efe874f5c8d650b7fef441ddb_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfMy04LTEtMS0xMTY3NzE_9c14dbd1-092d-4e84-bcce-fa617500d1f7">20,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a23787efe874f5c8d650b7fef441ddb_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfMy0xMC0xLTEtMTE2Nzcx_69c0efcd-194b-4aac-bdd3-fb65b5c272a9">16,169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a23787efe874f5c8d650b7fef441ddb_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfMy0xMi0xLTEtMTE2Nzcx_3f95178f-42eb-4f54-bdd6-2e940b13d060">4,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdab7f29e78845a9b4b14d6cdf3e20d7_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNC0yLTEtMS0xMTY3NzE_46baf8af-a3d7-4aee-9bab-1ea4f540577d">897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdab7f29e78845a9b4b14d6cdf3e20d7_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNC00LTEtMS0xMTY3NzE_5cdea3ac-2f88-41a7-8d62-77ceed74eb44">506</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdab7f29e78845a9b4b14d6cdf3e20d7_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNC02LTEtMS0xMTY3NzE_08f4c253-df85-4cbb-930c-fc9c000f5f78">391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1968cf2be247feb9dd0cc924d8f8c8_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNC04LTEtMS0xMTY3NzE_c066b21f-eb9a-4d9b-ba87-35cfb73ba126">902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b1968cf2be247feb9dd0cc924d8f8c8_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNC0xMC0xLTEtMTE2Nzcx_9a4f61e6-28d1-4460-bbf9-52ec1cc6c93e">473</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1968cf2be247feb9dd0cc924d8f8c8_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNC0xMi0xLTEtMTE2Nzcx_d089d04a-405c-4400-b53c-b2f35675e978">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic83fa38af9914b0993c6039b714e49b9_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNS0yLTEtMS0xMTY3NzE_1cc64a42-213e-4a27-92ca-4ed66acfc582">3,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic83fa38af9914b0993c6039b714e49b9_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNS00LTEtMS0xMTY3NzE_e899a10d-6bab-4ef2-b76e-41a2c5b01fcf">3,197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic83fa38af9914b0993c6039b714e49b9_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNS02LTEtMS0xMTY3NzE_ba3f0c45-7bfb-4c4b-9bdd-cd101d85786c">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19b47b5930ac4a57b58e47cb7fb6bc97_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNS04LTEtMS0xMTY3NzE_45fd140c-48e9-46b6-8a79-862cfa1e2180">3,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19b47b5930ac4a57b58e47cb7fb6bc97_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNS0xMC0xLTEtMTE2Nzcx_7b360540-e063-4738-b3a5-000a010d018c">3,174</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19b47b5930ac4a57b58e47cb7fb6bc97_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNS0xMi0xLTEtMTE2Nzcx_580e62b5-e9ca-46e8-97c2-17a1fb1ab67a">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0408adaddad474dbeeab55bfaf37b13_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNi0yLTEtMS0xMTY3NzE_4f8233b0-9d03-423b-9930-3191dbb38471">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0408adaddad474dbeeab55bfaf37b13_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNi00LTEtMS0xMTY3NzE_c15815a1-9a98-4daa-a6f5-d1cd339a2c42">146</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0408adaddad474dbeeab55bfaf37b13_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNi02LTEtMS0xMTY3NzE_486f730a-965e-4ae1-8412-37db1929a972">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43736d02e7b34234a0989ae49e2de7e9_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNi04LTEtMS0xMTY3NzE_1999232d-375a-461c-9cd3-25fd4c00be2e">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43736d02e7b34234a0989ae49e2de7e9_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNi0xMC0xLTEtMTE2Nzcx_923a1a41-e0d6-4791-bcda-9f0901ad2793">158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43736d02e7b34234a0989ae49e2de7e9_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNi0xMi0xLTEtMTE2Nzcx_380a36ae-b393-45bd-b58a-4bac80f5c3d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c83dd8e105e4a4692fb8791ce3bd76a_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNy0yLTEtMS0xMTY3NzE_50ed7734-7cfb-4b17-96af-b430f62aff98">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c83dd8e105e4a4692fb8791ce3bd76a_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNy00LTEtMS0xMTY3NzE_4f73861e-75e3-42ed-a669-c8301beae220">196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c83dd8e105e4a4692fb8791ce3bd76a_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNy02LTEtMS0xMTY3NzE_b4c42f5d-ac75-42d4-8c05-f8c62bad1b92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idda5195bfad44f2d9f625be80dcbf677_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNy04LTEtMS0xMTY3NzE_6c6ef65d-1ad1-4203-9bd3-b0401e6951f6">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idda5195bfad44f2d9f625be80dcbf677_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNy0xMC0xLTEtMTE2Nzcx_e1ab15af-3be6-4b15-8592-b0d442e3eb9e">206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idda5195bfad44f2d9f625be80dcbf677_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNy0xMi0xLTEtMTE2Nzcx_ad2bf552-9b47-4a8c-9013-cb0b482eb017">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfOC0yLTEtMS0xMTY3NzE_1fee7e70-e23e-4ef7-be96-fede84fefc9b">25,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfOC00LTEtMS0xMTY3NzE_721c2a36-a168-4861-a4bb-530749d8f6ac">20,740</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfOC02LTEtMS0xMTY3NzE_bd527f6d-ff54-4ec1-ad25-28f2de086adb">4,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfOC04LTEtMS0xMTY3NzE_8b2255d4-0ee1-4c91-acc6-ad4b1820ed47">25,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfOC0xMC0xLTEtMTE2Nzcx_0173fc77-9544-4e12-b8f7-753587e9e4d5">20,180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfOC0xMi0xLTEtMTE2Nzcx_f7edb4f7-6cce-44ef-b476-0c682cd4d2f4">5,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bausch + Lomb Trademark</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ead88a7e4a8400f82d1ed2f6fed1364_I20220630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfOS0yLTEtMS0xMTY3NzE_7abd519c-ee16-40d7-b8b7-153a9c2f326e">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ead88a7e4a8400f82d1ed2f6fed1364_I20220630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfOS02LTEtMS0xMTY3NzE_d5dfeb6b-cdab-4587-ae07-cef1dc3ca515">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic81756cf7add4054878a13b141b160aa_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfOS04LTEtMS0xMTY3NzE_8d68d24f-3c37-4626-95c1-591e3dff1c73">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic81756cf7add4054878a13b141b160aa_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfOS0xMi0xLTEtMTE2Nzcx_46b37554-776e-4ca4-92a5-8b5efda4c06b">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfMTAtMi0xLTEtMTE2Nzcx_955e1ed5-eb5d-48be-a808-e2d6bbd525c5">27,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfMTAtNC0xLTEtMTE2Nzcx_595f76fb-e9bf-4231-a1aa-86f25eb73fca">20,740</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfMTAtNi0xLTEtMTE2Nzcx_769e1663-5b38-4b0f-a523-0cdb31ddfe7f">6,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfMTAtOC0xLTEtMTE2Nzcx_8be05b70-80c7-483a-a0cf-2d873fef0dfb">27,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfMTAtMTAtMS0xLTExNjc3MQ_b6efcca7-9564-4a47-8839-4166b40cb4bd">20,180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfMTAtMTItMS0xLTExNjc3MQ_9d03ecee-81e0-437e-b14a-8a8956e41eea">6,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments in the Consolidated Statement of Operations. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="iea2f71e24b404568844d473603397cad" continuedAt="i80bc1ec582da4884abbe48a9139b2b3b"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale, for the six months ended June 30, 2022 were $<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNjY3_d8c3dbc5-749b-4e52-be43-f8bfba8029b2">14</ix:nonFraction>&#160;million and include: (i) impairments of $<ix:nonFraction unitRef="usd" contextRef="ida1c327408524e2b9da48b8046b1596c_D20220101-20220630" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNzAy_92e568ba-1a02-4a9b-8a65-0455fed27edc">10</ix:nonFraction>&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines and (ii) impairments of $<ix:nonFraction unitRef="usd" contextRef="iddcfbc0128c04d5d9a4a4a24b7c58559_D20220101-20220630" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfODA3_d8da742b-72f6-43b3-aab5-43c54368133f">4</ix:nonFraction>&#160;million, in aggregate, related to the discontinuance of certain product lines.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale, for the six months ended June 30, 2021 were $<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfOTU1_021b373a-2ff8-476b-b9ee-2d6361d947a0">195</ix:nonFraction>&#160;million and include: (i) $<ix:nonFraction unitRef="usd" contextRef="i6b3901031b674c118620c5be45160bef_D20210101-20210630" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfOTc1_5b07dd81-91e8-4381-b44d-b341db753a0c">96</ix:nonFraction>&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines, (ii) an adjustment of $<ix:nonFraction unitRef="usd" contextRef="i8c73de91dfce436faf9fe431bbdc6487_D20210101-20210630" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTExNA_cd8d596a-d599-43e1-85a1-044d6abe93de">88</ix:nonFraction>&#160;million due to the loss on assets held for sale in connection with the Amoun Sale and (iii) impairments of $<ix:nonFraction unitRef="usd" contextRef="i30cfd27625d04204b5b2e2739311e5d9_D20210101-20210630" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTIxNg_841ccbd8-41ae-4fc9-8a1a-6fdc0189ad88">11</ix:nonFraction>&#160;million, in aggregate, related to the discontinuance of certain product lines. </span></div><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTczMDk_794fef19-e4a0-4f98-a2e6-6855cdee4cba" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense of finite-lived intangible assets for the remainder of 2022 and each of the five succeeding years ending December&#160;31 and thereafter is as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.833%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFlZWQ4ZjA0ZmE0MTRlOTU4ZDE5NTM1YTJkZGVmZWM0L3RhYmxlcmFuZ2U6MWVlZDhmMDRmYTQxNGU5NThkMTk1MzVhMmRkZWZlYzRfMS0yLTEtMS0xMTY3NzE_667abb0c-b7bc-49a6-8b4c-b7fc6577c22e">565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFlZWQ4ZjA0ZmE0MTRlOTU4ZDE5NTM1YTJkZGVmZWM0L3RhYmxlcmFuZ2U6MWVlZDhmMDRmYTQxNGU5NThkMTk1MzVhMmRkZWZlYzRfMS00LTEtMS0xMTY3NzE_98394a78-da4a-4c3a-9b72-852c11fcc52b">1,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFlZWQ4ZjA0ZmE0MTRlOTU4ZDE5NTM1YTJkZGVmZWM0L3RhYmxlcmFuZ2U6MWVlZDhmMDRmYTQxNGU5NThkMTk1MzVhMmRkZWZlYzRfMS02LTEtMS0xMTY3NzE_0e6894a4-d4cb-4010-9436-92671fb69c09">898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFlZWQ4ZjA0ZmE0MTRlOTU4ZDE5NTM1YTJkZGVmZWM0L3RhYmxlcmFuZ2U6MWVlZDhmMDRmYTQxNGU5NThkMTk1MzVhMmRkZWZlYzRfMS04LTEtMS0xMTY3NzE_ff105633-3269-4505-bcbe-f740c5ea5fca">792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFlZWQ4ZjA0ZmE0MTRlOTU4ZDE5NTM1YTJkZGVmZWM0L3RhYmxlcmFuZ2U6MWVlZDhmMDRmYTQxNGU5NThkMTk1MzVhMmRkZWZlYzRfMS0xMC0xLTEtMTE2Nzcx_fa443dfa-0c2e-48c0-9515-e6f66307ad2f">664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFlZWQ4ZjA0ZmE0MTRlOTU4ZDE5NTM1YTJkZGVmZWM0L3RhYmxlcmFuZ2U6MWVlZDhmMDRmYTQxNGU5NThkMTk1MzVhMmRkZWZlYzRfMS0xMi0xLTEtMTE2Nzcx_12444ce1-9321-40f2-9c46-dca2d546b62a">627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFlZWQ4ZjA0ZmE0MTRlOTU4ZDE5NTM1YTJkZGVmZWM0L3RhYmxlcmFuZ2U6MWVlZDhmMDRmYTQxNGU5NThkMTk1MzVhMmRkZWZlYzRfMS0xNC0xLTEtMTE2Nzcx_bae84cc4-0293-446b-a1a6-c8c304759a77">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFlZWQ4ZjA0ZmE0MTRlOTU4ZDE5NTM1YTJkZGVmZWM0L3RhYmxlcmFuZ2U6MWVlZDhmMDRmYTQxNGU5NThkMTk1MzVhMmRkZWZlYzRfMS0xNi0xLTEtMTE2Nzcx_634cb060-5435-4b90-a563-1ed97c9c8d2b">4,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net includes finite-lived intangible assets related to the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> branded products with a carrying value of approximately $<ix:nonFraction unitRef="usd" contextRef="i6cc006d888334261a3b145852eb7937f_I20220630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU2NjQ4OA_1ad3b102-3842-48c4-ab47-84f7fb989889">2,963</ix:nonFraction>&#160;million as of June 30, 2022, and a remaining estimated life of <ix:nonNumeric contextRef="i9ff241de36bb4d838d517bfa74e1000c_D20220101-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU2NjUwNA_f913a7d7-6ead-4992-a4c8-b25da6e0dd34">66</ix:nonNumeric> months. Amortization expense related to these intangible assets amounts to approximately $<ix:nonFraction unitRef="usd" contextRef="i9ff241de36bb4d838d517bfa74e1000c_D20220101-20220630" decimals="-6" name="bhc:AnnualAmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU2NjUxMw_f014ef8e-dcc5-49d2-8070-0aec3b16875a">539</ix:nonFraction>&#160;million annually. While the Company intends to appeal the Norwich Legal Decision (see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 18, &#8220;LEGAL PROCEEDINGS&#8221;), it is possible that this and other potential future developments: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">may adversely impact the estimated future cash flows associated with these brands, which could result in an impairment of the value of these intangible assets in one or more future periods. Any such impairment could be material to the Company&#8217;s results of operations in the period in which it occurs; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">may result in shortened useful lives of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets, which would increase amortization expense in future periods.</span></div><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTczMTU_0747c71b-1bed-4fc4-b3ba-0276fdb077d6" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill during the six months ended June 30, 2022 and the year ended December&#160;31, 2021 were as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.298%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bausch + Lomb/ International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idda6bfc9237c4952a9c07b6cd1fb8aa6_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMS0yLTEtMS0xMTY3NzE_aceddf60-b3ee-44f2-851c-4ea6692276eb">5,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f2123e8bcd8437b81c7aee9a2cf5046_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMS00LTEtMS0xMjEzMDk_827f8bc7-7f07-472d-98d7-fd9afe17d016">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86923f0a7d294df0951a3efb41cfb120_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMS02LTEtMS0xMTY3NzE_4c0acf57-81a9-4f42-9186-d99ca4db27b0">3,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb4539c0cd93410f8877606829a28dbd_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMS04LTEtMS0xMjEzMDc_2e70a917-d5bc-44f3-bf43-1feec77c8de7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b9c8e4e54e14c11a2541b80edd0ce79_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMS0xMC0xLTEtMTE2Nzcx_c02a6546-3dad-42c7-8cb4-31acdb1f3bee">1,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70c6f0d3c53c4ae0b8bac9c750c52401_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMS0xMi0xLTEtMTIxMzA1_f127c3d2-0f0d-46aa-aafc-d98ba08d79f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife7ba88747a44275adc038a9f0579315_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMS0xNC0xLTEtMTE2Nzcx_3b545c64-7eb5-4893-b9d2-98d8a99a5b63">2,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e21899f1044f7fa7cb214f91d5655c_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMS0xNi0xLTEtMTE2Nzcx_af16a9ba-d30f-42d8-92d0-b6b1fe5f3431">13,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0e2720588804bb59fc95044cb42a692_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMi0yLTEtMS0xMTY3NzE_54daefcf-9005-4818-93af-85bf2d7301e0">5,704</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88df2b54d58543dd9380c146b625dca4_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMi00LTEtMS0xMTY3NzE_3729ef3f-5ed3-4dbb-bc33-a481e24a2513">5,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i382fa2f0b4d84cefb5705374b83054c8_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMi02LTEtMS0xMzQxNjA_aea95a18-7dff-4c2f-ab2e-411a2f5ffa87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife45351a90c740ae923457acb3f6c195_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMi04LTEtMS0xMTY3NzE_578aae25-b07a-4d71-8715-42d029024bbc">887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5108829d89c48d8b0cb4fec084de93a_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMi0xMC0xLTEtMTM0MTc2_d9164ead-f25f-43d0-a058-ebf8fa187b24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6009ca6df304f4ab8d03e57a2f270b8_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMi0xMi0xLTEtMTM0MTgw_30915294-7845-4d47-bcfe-de808c039112">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a80fbad02df47ffb3f0b027e0c7052a_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMi0xNC0xLTEtMTE2Nzcx_1004a734-c142-4247-9095-364dfd836c14">578</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafb5fd0adbea424d95cb70b136e7d1c2_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMi0xNi0xLTEtMTE2Nzcx_50761b88-9c85-47bc-99a2-e1e4bf97a856">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e2720588804bb59fc95044cb42a692_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMy0yLTEtMS0xMTY3NzE_c956b6bb-352b-4872-9f10-eb67a162a94c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88df2b54d58543dd9380c146b625dca4_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMy00LTEtMS0xMzQxNTQ_7306bb4c-7bbe-4981-8580-957bd9c6ccab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i382fa2f0b4d84cefb5705374b83054c8_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMy02LTEtMS0xMzQxNjA_13ef198d-9db1-48b8-b8a4-29d461b71ddc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife45351a90c740ae923457acb3f6c195_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMy04LTEtMS0xMzQxNzA_5b65e24b-4004-46dd-8540-09b16c881cba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5108829d89c48d8b0cb4fec084de93a_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMy0xMC0xLTEtMTE2Nzcx_af80a5f4-dd35-4d80-bf97-c031d4ac6734">469</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6009ca6df304f4ab8d03e57a2f270b8_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMy0xMi0xLTEtMTM0MTg0_c1cab5c5-2a4d-4a44-ae19-1649b9fc6225">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a80fbad02df47ffb3f0b027e0c7052a_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMy0xNC0xLTEtMTM0MTg4_7376321e-b069-4ab4-a869-a51f0cf1a148">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iafb5fd0adbea424d95cb70b136e7d1c2_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMy0xNi0xLTEtMTE2Nzcx_731be0c1-abee-40f1-b293-5b9c89a5ab74">469</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e2720588804bb59fc95044cb42a692_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNC0yLTEtMS0xMTY3NzE_a37a30e0-41a9-45ad-acf5-23676a8e40e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88df2b54d58543dd9380c146b625dca4_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNC00LTEtMS0xMTY3NzE_ad69ca4e-cfb1-4a7b-acae-56dca647728f">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i382fa2f0b4d84cefb5705374b83054c8_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNC02LTEtMS0xMzQxNjA_da0306a0-54fe-4837-bb9a-7893c4a40b76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife45351a90c740ae923457acb3f6c195_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNC04LTEtMS0xMTY3NzE_922ad61e-727d-4cf7-9e3c-53ce53644bf9">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5108829d89c48d8b0cb4fec084de93a_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNC0xMC0xLTEtMTM0MTky_45107137-eb69-4bc4-a67d-a61e64197633">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6009ca6df304f4ab8d03e57a2f270b8_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNC0xMi0xLTEtMTM0MTk1_b23a1ebf-4b21-4799-9f72-e3dc344db1b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a80fbad02df47ffb3f0b027e0c7052a_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNC0xNC0xLTEtMTE2Nzcx_0b8b59ef-6757-4715-a3ee-5a1de8205916">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iafb5fd0adbea424d95cb70b136e7d1c2_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNC0xNi0xLTEtMTE2Nzcx_5ddb33bf-cbad-4ff5-abcc-a0ffd5d947e0">118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d31c842cea74aa198d8cb6778701a57_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNS0yLTEtMS0xMTY3NzE_a4743322-8b5e-457d-ba7d-e8ea0207bad9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i754ebf26cb214d2a9e08dde9805eca10_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNS00LTEtMS0xMTY3NzE_1d666e3b-6cbb-4540-bdb3-4741707b3dc5">5,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff73055417e147b7bd096e9578313bc1_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNS02LTEtMS0xMTY3NzE_e5d77127-ba07-4b6f-ad67-c047b35c06a3">3,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b016ed329f478591978619289e8da6_I20211231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNS04LTEtMS0xMTY3NzE_f085d6dd-1b09-45a2-a47b-c407be299a18">825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dc4af5c709c464682b201a4d8b84132_I20211231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNS0xMC0xLTEtMTE2Nzcx_3f51a00a-d259-49a2-b60c-34489c786527">798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92e5ef7f7dc14944b76087572c2ba682_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNS0xMi0xLTEtMTE2Nzcx_8b05c06f-b902-4244-97fd-bd51e2d0ece9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief312576a3114c0aaed496cc8a87eb3b_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNS0xNC0xLTEtMTE2Nzcx_90446531-7b88-4d82-833e-179cf1275b4e">2,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNS0xNi0xLTEtMTE2Nzcx_4b242745-09b9-4f6d-9e2a-d951673e9f2a">12,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e70d8f7f02147b4a2ff2c867e6566d2_D20220101-20220630" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNi0yLTEtMS0xMTY3NzE_c90b8105-bc40-43cc-8596-b113ce6904b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86bd562069224eb1a2aa48a2a7c117a3_D20220101-20220630" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNi00LTEtMS0xMzQxNTY_f748d824-6526-406d-bbab-778e46cb8be3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c7b76190d5140fd9da04108a1ed24e5_D20220101-20220630" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNi02LTEtMS0xMzQxNjM_db2d8096-354a-4ef2-9d41-a585866ba258">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i430a37ccee354cf9b59987d97e781a8f_D20220101-20220630" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNi04LTEtMS0xMzQxNzM_1c59658d-c667-4b8c-a08c-db40cf15beb3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86a04889bcf044b38603f4f4ca1d8de4_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNi0xMC0xLTEtMTE2Nzcx_c2d88dff-5fb6-422c-a452-032db00eef2b">798</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i864ee40a0f6549cab4f16fffdd93c3fd_D20220101-20220630" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNi0xMi0xLTEtMTE2Nzcx_4fb9e982-4273-4ad1-8427-42b498fa0e24">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecd0285b18fe41da9fc167864657bccb_D20220101-20220630" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNi0xNC0xLTEtMTE2Nzcx_98135135-10ae-4260-87cf-40991eabfb74">683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNi0xNi0xLTEtMTE2Nzcx_7c87dd22-1382-44f3-b86b-6a129bb45070">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e70d8f7f02147b4a2ff2c867e6566d2_D20220101-20220630" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy0yLTEtMS0xMzg3NzU_713a9985-1ada-47e2-be51-b35987e7b796">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86bd562069224eb1a2aa48a2a7c117a3_D20220101-20220630" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy00LTEtMS0xMzg3NzU_963541d9-7fb6-471d-831b-aa5cdbd7594a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c7b76190d5140fd9da04108a1ed24e5_D20220101-20220630" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy02LTEtMS0xMzg3NzU_9b67fb4f-7e50-4dd4-8a08-d0a1612159ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i430a37ccee354cf9b59987d97e781a8f_D20220101-20220630" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy04LTEtMS0xMzg3NzU_bb614671-94d3-4ec5-8271-64636bc60c65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86a04889bcf044b38603f4f4ca1d8de4_D20220101-20220630" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy0xMC0xLTEtMTM4Nzc1_c641a328-6cce-4362-85de-0a9dbf086aeb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i864ee40a0f6549cab4f16fffdd93c3fd_D20220101-20220630" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy0xMi0xLTEtMTM4Nzc1_726f1a7d-95bd-44b2-8b44-c9d0f97f0877">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecd0285b18fe41da9fc167864657bccb_D20220101-20220630" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy0xNC0xLTEtMTM4Mzgx_af17a4f6-742a-48f4-9b09-b217782856f2">83</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy0xNi0xLTEtMTM4Mzgz_91d8656d-c6f6-4a7c-8b8e-f450aa416830">83</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e70d8f7f02147b4a2ff2c867e6566d2_D20220101-20220630" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy0yLTEtMS0xMTY3NzE_073dfc52-4932-45d6-bac1-96469e6d985f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86bd562069224eb1a2aa48a2a7c117a3_D20220101-20220630" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy00LTEtMS0xMTY3NzE_6e37d92d-ecfd-4f52-b987-86de9285da3d">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c7b76190d5140fd9da04108a1ed24e5_D20220101-20220630" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy02LTEtMS0xMzQxNjc_2e92d7b1-7bf5-4de1-bcbd-d1f03ef89a28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i430a37ccee354cf9b59987d97e781a8f_D20220101-20220630" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy04LTEtMS0xMTY3NzE_abff59fa-8656-41a9-b490-3c74a749a748">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86a04889bcf044b38603f4f4ca1d8de4_D20220101-20220630" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy0xMC0xLTEtMTM0MTk5_eb987980-e972-41cd-abcc-5b0f9b6a7ebb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i864ee40a0f6549cab4f16fffdd93c3fd_D20220101-20220630" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy0xMi0xLTEtMTM0MjAz_5fbcab4f-a8e5-450f-b1b2-bd5664668482">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecd0285b18fe41da9fc167864657bccb_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy0xNC0xLTEtMTE2Nzcx_a37c538e-0e88-42d9-8651-6c315c9246f6">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy0xNi0xLTEtMTE2Nzcx_0add01c3-78fe-48a5-a801-4f556b32559b">108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b0f083a6d9044aaa355608d9d198fb8_I20220630" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfOC0yLTEtMS0xMTY3NzE_8ac784fb-a4f5-4abb-affe-4c788c9b466e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f5bfb1314341ee926c9b0fc40e54e2_I20220630" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfOC00LTEtMS0xMTY3NzE_42de14a4-c329-4775-8961-eea616dda11c">5,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f643780bb9448ef9016e16f6b89c2c1_I20220630" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfOC02LTEtMS0xMTY3NzE_bc560474-bec0-47f2-ba76-170634ec2cfc">3,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f56f31b09064a848920713fa0661b76_I20220630" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfOC04LTEtMS0xMTY3NzE_8ab1820c-9f1a-4623-a54f-e219907f7870">773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i647555e6b2b54c909b5caeb1da998334_I20220630" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfOC0xMC0xLTEtMTE2Nzcx_af4f8838-3ad7-4b3f-94de-f2763a93e947">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5607e58e61534749aa9df1f4280fb05a_I20220630" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfOC0xMi0xLTEtMTE2Nzcx_d6f72512-55f4-4506-9f18-1e9b52ea70cc">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4284138a323449c291086d55ad27a489_I20220630" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfOC0xNC0xLTEtMTE2Nzcx_9db850e1-20f2-4c2a-81a1-12923796acfe">2,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfOC0xNi0xLTEtMTE2Nzcx_18aa0cae-cfe5-4c37-a7f4-ffc9a9999b32">12,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit (Step 1).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair value of a reporting unit using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The quantitative fair value test is performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit&#8217;s terminal value. </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i80bc1ec582da4884abbe48a9139b2b3b" continuedAt="i116cdc9e3e6a4938a9713b84687b76a4"><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To forecast a reporting unit&#8217;s cash flows the Company takes into consideration economic conditions and trends, estimated future operating results, management&#8217;s and a market participant&#8217;s view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts are based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected loss of exclusivity to the Company&#8217;s product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company&#8217;s control could have a positive or negative impact on achieving its targets. Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and such change could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Quarter 2021 - Realignment of Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2021, the Company began operating in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International, (iv) Ortho Dermatologics and (v) Diversified Products. The Bausch + Lomb segment consisted of the: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. The Salix segment consisted of the Salix reporting unit. The International segment consisted of the International (formerly International Rx) reporting unit. The Ortho Dermatologics segment consisted of the: (i) Ortho Dermatologics and (ii) Global Solta reporting units. The Diversified Products segment consisted of the: (i) Neurology and Other, (ii) Generics and (iii) Dentistry reporting units. This realignment in segment structure resulted in a change in the Company&#8217;s former International reporting unit, which was divided between the International Bausch + Lomb reporting unit and International reporting unit. In addition, as part of the realignment of segment structure, certain products historically included in the Generics reporting unit were included in the U.S. Bausch + Lomb reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of this realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. Goodwill previously reported in the former International reporting unit was reassigned to the International Bausch + Lomb and International reporting units, and a portion of goodwill previously reported in the former Generics reporting unit was reassigned to the U.S. Bausch + Lomb reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the change in reporting units, the Company performed a qualitative fair value assessment for its former: (i) International and (ii) Generics reporting units. Based on the qualitative fair value assessment performed, Management believed that it was more likely than not that the carrying values of its former: (i) International and (ii) Generics reporting units were less than their respective fair values and therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately following the change in reporting units, as a result of the change in composition of the net assets for its: (i) International Bausch + Lomb, (ii) International and (iii) Generics reporting units, the Company performed a quantitative fair value test. The quantitative fair value test utilized a range of long-term growth rates of <ix:nonFraction unitRef="number" contextRef="ifcb19cddd3134b4d8f4ea965f330d69a_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNjkyMA_306f68e8-d981-4260-8277-4f8ea41ad9a3">1.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i31f42e923b084ff0a4f4fbc812d7be7f_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNjkyNg_c66961ec-1ca5-4e7f-b9bf-e91021147c39">3.0</ix:nonFraction>% and a range of discount rates between <ix:nonFraction unitRef="number" contextRef="ifcb19cddd3134b4d8f4ea965f330d69a_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNjk2Nw_c12f2c69-5406-46e6-93cf-d94d76deffd9">11.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i31f42e923b084ff0a4f4fbc812d7be7f_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNjk3NA_a42bfe6c-8519-4eb3-bd04-f4b81aadf0cc">12.25</ix:nonFraction>%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than <ix:nonFraction unitRef="number" contextRef="i6daf46a421eb422cab6a685d448b4571_I20210331" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNzE1Mw_6e68e2a0-3e03-4075-85f7-d3d2c933f23a">40</ix:nonFraction>%, and, therefore, there was <ix:nonFraction unitRef="usd" contextRef="ie53716daef0b4224954a5c9de0faef7a_D20210331-20210331" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNzE4Mw_f9e6040e-2eb5-42de-ae3f-2b7cc3657cce">no</ix:nonFraction> impairment to goodwill. In addition, as the U.S. Bausch + Lomb reporting unit had a change in composition of its net assets related to certain products historically included in the Generics reporting unit now being included in the U.S. Bausch + Lomb reporting unit, the Company performed a qualitative assessment of this reporting unit. Based on the qualitative fair value assessment performed, Management believed that it was more likely than not that the carrying value of its current U.S. Bausch + Lomb reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Interim Goodwill Impairment Testing</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the interim periods of 2021, with the exception of the Ortho Dermatologics reporting unit, no events occurred, or circumstances changed that would indicate that the fair value of any other reporting unit might be below its carrying value and therefore, <ix:nonFraction unitRef="usd" contextRef="if80b04373ab14c578c53ef3c8014d242_D20210101-20211231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfODEwNg_813adfb0-6021-476c-8b3f-42803cda3fbc">no</ix:nonFraction> impairments were recorded.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, management identified launches of certain Ortho Dermatologics products which were not going to achieve their trajectories as forecasted once the social restrictions associated with the COVID-19 pandemic began to ease in the U.S. and offices of health care professionals could reopen. In addition, insurance coverage pressures within the U.S. continued to persist limiting patient access to topical acne and psoriasis products. In light of these developments, during the first quarter of 2021, the Company began taking steps to: (i) redirect its R&amp;D spend to eliminate projects it had identified as high cost and high risk, (ii) redirect a portion of its marketing and product development outside the U.S. to geographies where there is better patient access and (iii) reduce its cost structure to be more competitive. As a result, during the three months ended March 31, 2021, the Company revised its long-term forecasts for the Ortho Dermatologics reporting unit. Management believed that these events were indicators that there was less headroom as of March 31, 2021 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2020). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed. The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the first quarter of 2021 to reflect the </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i116cdc9e3e6a4938a9713b84687b76a4" continuedAt="i072d505114444239b90cc5e9066deef7"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business changes previously discussed, including a range of potential outcomes, along with a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="i9e3ff28c3d904d4bb50e1f6b60dc5774_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfOTcyNA_2c6a7d11-3dbd-49af-b866-dfae05941972">1.0</ix:nonFraction>% and a range of discount rates between <ix:nonFraction unitRef="number" contextRef="i128de9e46d854032ac8fdb6fcc689f05_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfOTc2NQ_b8d2e8d6-36b4-40a1-879b-1f4a5ceb059f">9.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ie76f7d931cfe4a698fa9381288d5e165_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfOTc3Mg_793941d8-9f3c-4fe8-a677-12103e427129">10.0</ix:nonFraction>%. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at March 31, 2021, and the Company recognized a goodwill impairment of $<ix:nonFraction unitRef="usd" contextRef="iefe6bc2fdd6b4faa87a273eecb773668_D20210331-20210331" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfOTk3NQ_12e95d28-3dc1-4eb9-a347-5e8499008dd2">469</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Quarter 2021 - Realignment of Bausch + Lomb Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the second quarter of 2021, the Company changed the way it reviews the financial information of its Bausch + Lomb segment. Beginning in the second quarter of 2021, management no longer reviews the financial information of its Bausch + Lomb segment on a geographic basis, but instead reviews this financial information on a business line basis. This change created a change in the reporting units of the Bausch + Lomb segment. After the change, under its business line view, the Bausch + Lomb segment consisted of the global: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. Prior to the second quarter of 2021, under the geographic view, the Bausch + Lomb segment consisted of the former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. As a result of the realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. The change in Bausch + Lomb reporting units did not impact the reported revenues and segment profits of the Bausch + Lomb segment for any prior periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the change in its Bausch + Lomb reporting units, the Company performed a qualitative fair value assessment for its former reporting units. Based on the qualitative fair value assessment, management believed that it was more likely than not that the carrying values of its former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units were less than their respective fair values and, therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the change in composition of net assets, the Company performed a quantitative fair value test of its new: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units immediately following the change in the Bausch + Lomb segment. The quantitative fair value test utilized long-term growth rates of <ix:nonFraction unitRef="number" contextRef="i448fd15a1c2c4081960f6912ee1d7df8_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTIwMjI_e16e65ed-94ac-4e23-8bdd-79907f5e0520">2.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i48edc6c592494439969797a031f0a38a_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTIwMjk_b0a3c68b-75d6-43e3-b03f-a02e5aeb6d44">3.0</ix:nonFraction>% and a range of discount rates between <ix:nonFraction unitRef="number" contextRef="i448fd15a1c2c4081960f6912ee1d7df8_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTIwNzA_1a9c1345-944c-4f1a-8822-c0d9177f327f"><ix:nonFraction unitRef="number" contextRef="i448fd15a1c2c4081960f6912ee1d7df8_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTIwNzA_7950944b-0de6-4147-86b8-60bc8a56e3d5">7.0</ix:nonFraction></ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i48edc6c592494439969797a031f0a38a_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTIwNzc_0e596b0b-d60f-4d2f-ab04-3a3b1eb7c348"><ix:nonFraction unitRef="number" contextRef="i48edc6c592494439969797a031f0a38a_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTIwNzc_2528fa11-bb6d-4da4-b549-4d216aa68c48">10.0</ix:nonFraction></ix:nonFraction>%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than <ix:nonFraction unitRef="number" contextRef="i94793ac34eb24e699f57a3960e391e71_I20210630" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTIyNTY_50b297c2-dc87-47b6-bec4-bd0638427208"><ix:nonFraction unitRef="number" contextRef="i94793ac34eb24e699f57a3960e391e71_I20210630" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTIyNTY_646c7933-9f8c-4d7f-9976-805441528149">45</ix:nonFraction></ix:nonFraction>%, and, therefore, there was <ix:nonFraction unitRef="usd" contextRef="ifede6e1372dd4ddb9ca2270e1f8b8a13_D20210630-20210630" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTIyODY_4e30aec0-14c0-4653-879b-2e9b1ef5cc38">no</ix:nonFraction> impairment to goodwill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Annual Goodwill Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2021 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2021, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2021, the Company considered, among other matters, the limited headroom as a result of the impairment to the goodwill of the Ortho Dermatologics reporting unit when last tested (March 31, 2021) and macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The Company believed that these facts and circumstances may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2021, utilizing a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="i495d40d3ed894092a5e407185421dded_I20211001" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTM3NDA_6b9e2006-43d6-4d25-85ef-be8d9a7f6375">1.0</ix:nonFraction>% and a discount rate of <ix:nonFraction unitRef="number" contextRef="i495d40d3ed894092a5e407185421dded_I20211001" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTM3NjY_a6bc8c26-1d83-4b58-9e9f-4eea582ee488">9.0</ix:nonFraction>%, in estimation of the fair value of this reporting unit. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately <ix:nonFraction unitRef="number" contextRef="i495d40d3ed894092a5e407185421dded_I20211001" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTM5NDQ_5348fec6-c6f5-4ed4-a622-65a5ef9cd7fa">10</ix:nonFraction>% greater than its carrying value and as a result there was <ix:nonFraction unitRef="usd" contextRef="ie0b5d00c327249b888e21da2766eda53_D20211001-20211001" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTQwMDU_ec85910e-8b7c-4eb5-9112-a458c5c1cc38">no</ix:nonFraction> impairment to the goodwill of the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Quarter 2022 - Realignment of Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2022, the Company began operating in the following reportable segments: (i) Salix, (ii) International, (iii) Diversified Products, (iv) Solta Medical and (v) Bausch + Lomb. The Salix segment consists of the Salix reporting unit. The International segment consists of the International reporting unit. The Diversified Products segment consists of the: (i) Neurology and Other, (ii) Generics, (iii) Ortho Dermatologics and (iv) Dentistry reporting units. The Solta Medical segment consists of the Solta reporting unit. The Bausch + Lomb segment consists of the: (i) Vision Care (formerly Vision Care / Consumer Products), (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. As such, the new segment structure does not impact the Company&#8217;s reporting units but realigns the <ix:nonFraction unitRef="reporting_unit" contextRef="ib56d8698081a436cb05434bb225f22eb_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTQ5MDg_a73c9ec3-34c2-4c08-b35e-27b75b06d5cd">two</ix:nonFraction> reporting units of the former Ortho Dermatologics segment whereby the Ortho Dermatologics reporting unit is now part of the current Diversified Products segment and the Solta reporting unit is now its own operating and reportable segment, and therefore management concluded that a quantitative fair value test was not required. See Note 19, &#8220;SEGMENT INFORMATION&#8221; for additional information.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i072d505114444239b90cc5e9066deef7" continuedAt="if422b4806f16485397d4e7f2314bddba"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">March 31, 2022 Interim Assessment of Goodwill</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, macroeconomic factors had impacted interest rates and the U.S. inflation rate was higher than previously expected. Given the limited headroom of the Ortho Dermatologics reporting unit as calculated on October 1, 2021, the Company believed that these facts and circumstances suggest the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the first quarter of 2022 and utilized a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="i15ce718b5f734e61a6ad0bdd28c54691_I20220331" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTYwODc_e508ec14-3c9d-440c-bff4-b339ccf8ec7c">1</ix:nonFraction>% and a discount rate of <ix:nonFraction unitRef="number" contextRef="i15ce718b5f734e61a6ad0bdd28c54691_I20220331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTYxMTM_75db041b-8318-4293-838e-b84d3c33cfef">9</ix:nonFraction>%. The discount rate contemplates changes in the current macroeconomic conditions noting certain inputs such as the risk free rate increased over the three months ended March 31, 2022, and was offset by decreases in other reporting unit specific risks during the same period. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was less than <ix:nonFraction unitRef="number" contextRef="i15ce718b5f734e61a6ad0bdd28c54691_I20220331" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTY1MDU_51dbc716-dfd3-4bde-8e15-df17ab407df2">2</ix:nonFraction>% greater than its carrying value and as a result there was <ix:nonFraction unitRef="usd" contextRef="i5a8c0ca7ff6d40f5a4b99dd032ce969d_D20220101-20220331" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTY1NjY_7717e669-b410-4732-b1f5-a139a3fd9196">no</ix:nonFraction> impairment to the goodwill of the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">June 30, 2022 Interim Assessment of Goodwill </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ortho Dermatologics</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to monitor the market conditions impacting the Ortho Dermatologics reporting unit. During the three months ended June 30, 2022, increases in interest rates and, to a lesser extent, higher than expected inflation in the U.S. and other macroeconomic factors impacted key assumptions used to value the Ortho Dermatologics reporting unit at March 31, 2022 (the last time goodwill of the Ortho Dermatologics reporting unit was tested). Given the limited headroom of the Ortho Dermatologics reporting unit as calculated on March 31, 2022, the Company believed that these facts and circumstances suggest the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the second quarter of 2022 which reflect current market conditions and current trends in business performance. The Company&#8217;s latest discounted cash flow model for the Ortho Dermatologics reporting unit includes a range of potential outcomes for, among other matters, macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The quantitative fair value test utilized a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="i56c650b8e02f446bbdb4b9a650860424_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU1NTc5MA_bfb6f9c0-30a6-420d-b384-f718655a2814">1</ix:nonFraction>% and a discount rate of <ix:nonFraction unitRef="number" contextRef="i56c650b8e02f446bbdb4b9a650860424_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU1NTc5NA_ee4e3b40-6fcf-4485-b1d4-4ac46ad9e8f6">10</ix:nonFraction>%. The discount rate has increased <ix:nonFraction unitRef="number" contextRef="i56c650b8e02f446bbdb4b9a650860424_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU2MjM4Ng_9bd1164b-4fdc-443d-a093-ab4af5057c73">1</ix:nonFraction>% since the assessment performed at March 31, 2022, as a result of changes in current macroeconomic conditions, including an increase in the risk free rate during the three months ended June 30, 2022. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at June 30, 2022, and the Company recognized a goodwill impairment of $<ix:nonFraction unitRef="usd" contextRef="i161c125a316c41338df59b517707ec98_D20220401-20220630" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU1NTc5OQ_5b0d41c3-c57d-4517-bf0e-7946e2467788">83</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch + Lomb Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period May 6, 2022 (the time Bausch + Lomb&#8217;s stock began trading publicly) through June 30, 2022, equity and bond markets were negatively impacted by various macroeconomic and geopolitical factors including, but not limited to: rising inflation rates in the U.S. and abroad, uncertainties created by the Russia/Ukraine conflict, interest rate volatility, COVID-19 related lockdowns and supply issues. The decline in the equity markets negatively impacted the market price for Bausch + Lomb&#8217;s common stock which at June 30, 2022 was trading below its IPO offering price. The Company believed that these facts and circumstances suggest the fair value of the <ix:nonFraction unitRef="reporting_unit" contextRef="id6fc6e77709e4c859b776fc4a4a569d6_D20220506-20220630" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU1NTg1Mw_8d11154a-6828-462f-8d23-502a4c9a55cc">three</ix:nonFraction> reporting units of the Bausch + Lomb segment could be less than their respective carrying amounts. Therefore, separate quantitative fair value tests were performed for the Vision Care, Surgical and Ophthalmic reporting units of the Bausch + Lomb segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value tests utilized Bausch + Lomb&#8217;s most recent cash flow projections for each of the reporting units and utilized long-term growth rates of <ix:nonFraction unitRef="number" contextRef="i09575f835d044c72a01f338fc66e8824_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU1NTgxMg_727ea1ec-389d-486e-b3b1-2d0bebdf5261">2</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i9fd9c089632f4f5f8b22cfa9e437b633_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU1NTg1MA_5ccdad5d-b272-498b-8ef2-da941e150058">3</ix:nonFraction>% and discount rates of <ix:nonFraction unitRef="number" contextRef="i09575f835d044c72a01f338fc66e8824_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU1NTgxNg_37bd09af-00ef-4b79-bbf3-c45a7820aec3">9.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i9fd9c089632f4f5f8b22cfa9e437b633_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU1NTgyMg_0a4476a8-b59b-40d7-ab36-d4610968a2f2">11.5</ix:nonFraction>%. After completing the testing, the fair value of each of these reporting units exceeded their respective carrying values by more than <ix:nonFraction unitRef="number" contextRef="i1a6c26cc64df4c86826a5f9b2862ceec_I20220630" decimals="INF" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU1NTgzNw_274a70cc-d598-4175-808f-ce7d155a9fee">25</ix:nonFraction>%, and, therefore, there was <ix:nonFraction unitRef="usd" contextRef="ied74a18a6e8c464cbf9706fc4935c4ab_D20220506-20220630" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU1NTgyOA_2e23f23b-fd8f-49ca-8773-402e8805b73a">no</ix:nonFraction> impairment to goodwill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the interim periods of 2022, with the exception of the Ortho Dermatologics reporting unit and the reporting units of the Bausch + Lomb segment, no events occurred, or circumstances changed that would indicate that the fair value of any other reporting unit might be below its carrying value and therefore, <ix:nonFraction unitRef="usd" contextRef="i08e5c94f206e49029306d4605cb23f7b_D20220401-20220630" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU1NTg0MQ_fe4ceff3-5400-4b3c-afe7-cfa336134a23">no</ix:nonFraction> impairment to those reporting units was recorded. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated goodwill impairment charges through June&#160;30, 2022 were $<ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTcyODE_57e65cff-d36c-47c3-8179-c80d6dabaa5c">4,263</ix:nonFraction> million.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="if422b4806f16485397d4e7f2314bddba"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other events occurred or circumstances changed during the period October 1, 2021 (the last time goodwill was tested for all other reporting units) through June 30, 2022 that would indicate that the fair value of any reporting unit, other than the Ortho Dermatologics reporting unit, might be below its carrying value.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately <ix:nonFraction unitRef="number" contextRef="icc599dddc6874659a5df85bf6a360251_D20220101-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU2NjUyOA_c0d0ebb1-99fe-4d1f-a661-a629dcaadb08">80</ix:nonFraction>% of Salix segment&#8217;s revenue for the six months ended June 30, 2022, or $<ix:nonFraction unitRef="usd" contextRef="ie564ee44d1b6403eb498a73450791f9f_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU2NjUzMw_0163723c-6722-448a-9109-c66c797c06cb">775</ix:nonFraction>&#160;million was derived from the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line. While the Company intends to appeal the Norwich Legal Decision (see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 18, &#8220;LEGAL PROCEEDINGS&#8221;), it is possible that this and other potential future developments, may adversely impact the estimated fair value of the Salix segment, in one or more future periods. Any such impairment could be material to the Company&#8217;s results of operations in the period in which it occurs.</span></div></ix:continuation><div id="i762fba229369426294c4424c2015a01a_64"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RleHRyZWdpb246NzE4NDZkYjNiM2U2NDk0ZWI5MTlkOGUzZmU3NTk1OWVfOTg_640991fb-383c-4e2d-8ad2-dd579137e09e" continuedAt="ided131e5db014537869c63c7f8d726f9" escape="true">ACCRUED AND OTHER CURRENT LIABILITIES</ix:nonNumeric></span></div><ix:continuation id="ided131e5db014537869c63c7f8d726f9"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RleHRyZWdpb246NzE4NDZkYjNiM2U2NDk0ZWI5MTlkOGUzZmU3NTk1OWVfOTQ_bcc6ac58-0f0a-4b9e-a8f6-f758704772b1" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matters and related fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="bhc:Legalsettlementsandrelatedfees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfMS0yLTEtMS0xMTY3NzE_8c6b69ea-ec16-4c32-8d4d-2c8fa77fffd1">1,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="bhc:Legalsettlementsandrelatedfees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfMS00LTEtMS0xMTY3NzE_c9c00d84-bd12-4b58-9157-08664cc988f3">1,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="bhc:AccruedProductRebateCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfMi0yLTEtMS0xMTY3NzE_7002aefa-006e-4dc2-a5a1-35715ae92962">962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="bhc:AccruedProductRebateCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfMi00LTEtMS0xMTY3NzE_6ebea32b-8ed4-48de-b716-745d7153f5be">908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="bhc:AccruedProductReturnCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfMy0yLTEtMS0xMTY3NzE_00f2715b-af6e-4291-8394-64c55abb1a2a">435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="bhc:AccruedProductReturnCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfMy00LTEtMS0xMTY3NzE_fabec835-18b1-4326-87ab-e78eaf834670">482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfNC0yLTEtMS0xMTY3NzE_d6455143-e14b-40b0-9a7a-40dd9e6cf063">326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfNC00LTEtMS0xMTY3NzE_b56dd5f3-d1ff-417c-9161-50de15f4356e">328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefit costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfNS0yLTEtMS0xMTY3NzE_239d2157-84c1-415e-9229-e0e62450cdf9">277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfNS00LTEtMS0xMTY3NzE_95adf48f-a1a2-47f9-b2d8-0a3df99f72d8">336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfNi0yLTEtMS0xMTY3NzE_f823d353-86fb-4a0a-bf4c-442382492ce2">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfNi00LTEtMS0xMTY3NzE_372ce993-77b2-4ff7-929a-74fdda82b12c">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfNy0yLTEtMS0xMTY3NzE_6d5c5a4c-cdff-4a4f-b27c-caba32e8bbbc">716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfNy00LTEtMS0xMTY3NzE_c3c611dd-ca14-48db-a731-66923dd3bfbd">749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfOC0yLTEtMS0xMTY3NzE_79eac357-94c9-4dd9-9f66-aba08982e569">4,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfOC00LTEtMS0xMTY3NzE_4921d5b6-39f2-4493-80da-b93b70e51d15">4,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="i762fba229369426294c4424c2015a01a_67"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTgzMjI_999c6708-2271-41c0-96f0-712c0b085915" continuedAt="i647166f6e8284873945e5929e430cffb" escape="true">FINANCING ARRANGEMENTS</ix:nonNumeric></span></div><ix:continuation id="i647166f6e8284873945e5929e430cffb" continuedAt="i0d8e73f1700a451bb4b7912ddfee12ad"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTgzNDM_2a38f690-4b24-47a1-9c03-3977b7155099" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs consist of the following: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2018 Restated Credit Agreement</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc66dfaa572849969745a0c5f0b68d37_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMy00LTEtMS0xMTY3NzE_00158290-b0ab-4400-9a34-86ee8323eaca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc66dfaa572849969745a0c5f0b68d37_I20220630" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMy02LTEtMS0xMTY3NzE_3b1e15c6-a9f0-4c0d-96e6-131dc233d47a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i793328a205eb4096950273313b00bd65_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMy04LTEtMS0xMTY3NzE_ea056399-cd19-4495-92f5-244d18e4e599">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i793328a205eb4096950273313b00bd65_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMy0xMC0xLTEtMTE2Nzcx_e3adc799-38a0-4442-a0ba-6b04b3eaa5ff">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa6b74354994e99b127ae89877febc7_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNC00LTEtMS0xMTY3NzE_e91478c3-3570-4c9e-bbd5-9c5514b77f0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa6b74354994e99b127ae89877febc7_I20220630" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNC02LTEtMS0xMTY3NzE_e498d01f-3e16-4453-b882-488f6d30ac82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0edf0a7a93de4224aba9d200f79ca4dd_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNC04LTEtMS0xMTY3NzE_0eeb4d2f-a868-4d9d-aa3b-7be89dfb2a5d">2,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0edf0a7a93de4224aba9d200f79ca4dd_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNC0xMC0xLTEtMTE2Nzcx_c295f055-4712-47e3-be2d-fd48bceec5c7">2,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2335f26e5e14e98a36115419811c130_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNS00LTEtMS0xMTY3NzE_9061ff98-d31f-4541-8e67-3de968464faa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2335f26e5e14e98a36115419811c130_I20220630" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNS02LTEtMS0xMTY3NzE_dedcac5a-c598-4739-9018-c12328be9613">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c45bbfd4f504c27b6226cc0c73a33f9_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNS04LTEtMS0xMTY3NzE_85c66296-e29d-4ef9-b0be-e61db411cdb0">994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c45bbfd4f504c27b6226cc0c73a33f9_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNS0xMC0xLTEtMTE2Nzcx_7fad7743-c55e-4fa6-aee5-77144fe67d6d">984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2022 Amended Credit Agreement</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieadee1866a824ef498fe7b558d0181c4_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNi00LTEtMS0xMjI4NDU_3668bb82-7a88-4a18-832f-8e828a718dac">425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieadee1866a824ef498fe7b558d0181c4_I20220630" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNi02LTEtMS0xMjI4NDc_2a486171-8988-4156-9aac-a12a561b9ff6">425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40aff33e8b24488a834a063a1529422b_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNi04LTEtMS0xMjI4NDk_725f246a-127f-4061-91b8-9c5992cc4ca4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40aff33e8b24488a834a063a1529422b_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNi0xMC0xLTEtMTIyODUx_2ac6c6fd-fd0d-4920-9977-c4fa2f0b719c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafc837c840c1423691e83ffca1191fb0_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNy00LTEtMS0xMjI4NDU_41378132-69ea-485c-9aff-f10d493b75ee">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafc837c840c1423691e83ffca1191fb0_I20220630" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNy02LTEtMS0xMjI4NDc_acc69f58-21d3-42b3-addf-f875027feb58">2,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cbc2b4901924769a731d568c6814714_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNy04LTEtMS0xMjI4NDk_99bf6191-18ea-41d6-814e-76cf2906d1ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cbc2b4901924769a731d568c6814714_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNy0xMC0xLTEtMTIyODUx_62d6d378-78df-4723-a2a4-d3f96a38b488">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">B+L Credit Facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B+L Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f38d4ca2bf94b95844417747e708aa1_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTEtNC0xLTEtMTI3OTky_ce6e1cd9-510f-4484-818a-b9ea4c777d3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f38d4ca2bf94b95844417747e708aa1_I20220630" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTEtNi0xLTEtMTI3OTky_dc962bc2-ca0c-4ed0-ad93-985d5a1d9c0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7c9cb43c0384e9db889a190dda21497_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTEtOC0xLTEtMTI3OTky_9fe22b7d-659f-4d23-bebf-52ee747d2af7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7c9cb43c0384e9db889a190dda21497_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTEtMTAtMS0xLTEyNzk5Mg_59329de5-9745-4749-87f7-ec9cc590514f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B+L Term Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b1a4f289c1e48948d7f02b9bee8c3b7_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfOS00LTEtMS0xMjEzMTg_92b0859d-5278-4c56-9a6b-90a2eb5c9146">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b1a4f289c1e48948d7f02b9bee8c3b7_I20220630" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfOS02LTEtMS0xMjEzMjA_305a5e45-f832-442c-9e91-24816d53d8db">2,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf103131598445f68811c80a255e6f67_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfOS04LTEtMS0xMjEzMjI_f67e6bcb-5c27-4b04-add2-be6a002c7c31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf103131598445f68811c80a255e6f67_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfOS0xMC0xLTEtMTIxMzI0_d59f04ac-9d82-478f-bf98-d747162544c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i52543bc3134e4d3ab18b8abb808ab987_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNy0wLTEtMS0xMTY3NzEvdGV4dHJlZ2lvbjoyMGI1OTY0NDA0MWM0YzJhYmYwNTZlNGNlY2Y0ZTZiMF80_4f825db4-43da-4032-a96b-ee010edf2aea">5.50</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52543bc3134e4d3ab18b8abb808ab987_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNy00LTEtMS0xMTY3NzE_700cfea7-010f-47c0-8d9c-06a513ce53be">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52543bc3134e4d3ab18b8abb808ab987_I20220630" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNy02LTEtMS0xMTY3NzE_bb72e34f-fe5a-4211-a23e-7045a60439d3">1,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfe50f19787342d2a1eba96ea86a16dc_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNy04LTEtMS0xMTY3NzE_aa33ab7a-254e-4dd9-aaff-b24c50f665c7">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfe50f19787342d2a1eba96ea86a16dc_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNy0xMC0xLTEtMTE2Nzcx_afaf1632-54a4-4a45-a5dc-dc1aa13990a7">1,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0d8d5f877595471594e7cd0d8a9a9bb3_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfOC0wLTEtMS0xMTY3NzEvdGV4dHJlZ2lvbjo3MjEzZDE2NDAzY2I0NjEwODU0Yzg0M2Q4MmFmYjJiZV80_ec593a12-0ac5-47b7-98fe-8f585ddf4849">6.125</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8d5f877595471594e7cd0d8a9a9bb3_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfOC00LTEtMS0xMTY3NzE_0093d71b-1aba-493f-baa8-d6dd28687783">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d8d5f877595471594e7cd0d8a9a9bb3_I20220630" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfOC02LTEtMS0xMTY3NzE_42c6af13-c050-46bd-9225-d500ab6cc8d8">986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0abb0ba205745ee88868776020e8f2c_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfOC04LTEtMS0xMTY3NzE_09bb5bc8-0f48-4861-8d22-329e3919806d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0abb0ba205745ee88868776020e8f2c_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfOC0xMC0xLTEtMTE2Nzcx_8b70bfc6-99b9-4200-a99d-0279b9f238fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i833d75561bf74683841f8a1a38848570_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfOS0wLTEtMS0xMTY3NzEvdGV4dHJlZ2lvbjo3YzZmNzIwNDgyNmM0OTMzOTJmMzA1YWVkMTM0ZjE2NV80_7b9fe8d9-7281-401b-85b1-80499ccf1a1d">5.75</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i833d75561bf74683841f8a1a38848570_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfOS00LTEtMS0xMTY3NzE_aaa66a53-be18-4769-aa84-c2bbdc1bb912">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i833d75561bf74683841f8a1a38848570_I20220630" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfOS02LTEtMS0xMTY3NzE_fdd018de-68ef-4758-908d-8d2f86c4324f">496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cea3fe80b2940b89f52022162775e03_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfOS04LTEtMS0xMTY3NzE_88f3302f-057e-4797-b512-4fe1079545c0">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cea3fe80b2940b89f52022162775e03_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfOS0xMC0xLTEtMTE2Nzcx_6e795e78-27d6-47d5-ad85-26e0242e0083">495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i28a10e63f05e408188f20f7b9cdcf496_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTAtMC0xLTEtMTE2NzcxL3RleHRyZWdpb246OThmYmE1ZDc0YjQ0NDdlMDkxY2ViMzM5M2E1MDA3Y2JfNA_c9e1efa3-7451-4382-a856-5ac7cab4d1da">4.875</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28a10e63f05e408188f20f7b9cdcf496_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTAtNC0xLTEtMTE2Nzcx_65b5061f-3e1d-4dbc-8a9a-940e293a28d1">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28a10e63f05e408188f20f7b9cdcf496_I20220630" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTAtNi0xLTEtMTE2Nzcx_e7f63134-1f08-4ddb-b50d-d897b9b35a8f">1,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia55753b63d414228b384e230c86e775f_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTAtOC0xLTEtMTE2Nzcx_0d42fb2a-8ac1-46b6-a14b-1fcbb8d0d021">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia55753b63d414228b384e230c86e775f_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTAtMTAtMS0xLTExNjc3MQ_794a2e1f-0a6b-43d3-8984-e758eddb315e">1,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4a25c3e0cf7640eb931b7c3c9e6872cd_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTItMC0xLTEtMTE2NzcxL3RleHRyZWdpb246YzY3YWJjMGY3NzZmNDMxNTllZWRkMDNhMjhiOTIxNTJfNA_9e1acd8b-cfa0-4db7-bb06-c5400f730ed7">6.125</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a25c3e0cf7640eb931b7c3c9e6872cd_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTItNC0xLTEtMTE2Nzcx_9a054a5d-a35b-4719-94b9-9d381dd42254">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a25c3e0cf7640eb931b7c3c9e6872cd_I20220630" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTItNi0xLTEtMTE2Nzcx_2f9ff543-c268-43d4-8824-b074a2f3c535">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee049418c13b4e299a8c83e2be11bc55_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTItOC0xLTEtMTE2Nzcx_9d93fecf-d24c-4e8f-965c-003aa7e5d1e1">2,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee049418c13b4e299a8c83e2be11bc55_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTItMTAtMS0xLTExNjc3MQ_04f8afa3-7437-4e26-92b9-2bf52217c615">2,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic8a3b188d15b4912ba75bc9ee39e79b0_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTMtMC0xLTEtMTE2NzcxL3RleHRyZWdpb246ZDZlYTZlYmQ2ODVhNDJkYjgzOTFkNmMxNDliOWFkMzBfNA_4dd0bfe5-6957-444f-bc9c-d37ff813a5df">9.00</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8a3b188d15b4912ba75bc9ee39e79b0_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTMtNC0xLTEtMTE2Nzcx_b1cd3548-ade3-47ed-a4c8-c65ce681acfa">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8a3b188d15b4912ba75bc9ee39e79b0_I20220630" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTMtNi0xLTEtMTE2Nzcx_67831e43-9b3c-4fb9-a1ed-233edae0f894">1,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a975e0e21154064a6bcc406c36b62b5_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTMtOC0xLTEtMTE2Nzcx_43134513-6c89-4297-aa4f-77ea9958274c">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a975e0e21154064a6bcc406c36b62b5_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTMtMTAtMS0xLTExNjc3MQ_11d53e1e-4de3-485b-9a53-8de700e146b2">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iee91cc92408044d795d6bcf969858eb1_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTQtMC0xLTEtMTE2NzcxL3RleHRyZWdpb246ZDZjMTFiZTQ1MjAyNDAxY2E3ZTZjZTE2NTc2YTY4OWFfNA_6159fe7e-5a4d-47d0-8615-ee473767d10b">9.25</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee91cc92408044d795d6bcf969858eb1_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTQtNC0xLTEtMTE2Nzcx_da6425d1-5e16-4f1f-9b0e-0963151d2c8e">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee91cc92408044d795d6bcf969858eb1_I20220630" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTQtNi0xLTEtMTE2Nzcx_a426789f-4565-40c3-923e-af572e596dba">1,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f324ee7a47e4543b63557fd35984d09_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTQtOC0xLTEtMTE2Nzcx_e7b60115-c3cf-4c2c-8a22-07e357613008">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f324ee7a47e4543b63557fd35984d09_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTQtMTAtMS0xLTExNjc3MQ_f74a65a8-ea8f-49c8-b002-dbe7f9f2d9b6">1,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if9165a4c4fa4438b9df24cf0a0792346_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTUtMC0xLTEtMTE2NzcxL3RleHRyZWdpb246YmNmMGFmNGU2ZGQxNDI2NTllZDBlNjQxZjRmZjY5MzlfNA_25d1f2ca-e1f4-427d-bf12-c428f437810e">8.50</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9165a4c4fa4438b9df24cf0a0792346_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTUtNC0xLTEtMTE2Nzcx_7b4c7fde-9790-4459-ad92-43afb29b59a4">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9165a4c4fa4438b9df24cf0a0792346_I20220630" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTUtNi0xLTEtMTE2Nzcx_a88195af-1ae0-49d8-90c0-25511e502380">1,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if803056461c6486db832367a43895632_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTUtOC0xLTEtMTE2Nzcx_92b605e5-7a09-4c65-90d1-f53b7f32c2a6">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if803056461c6486db832367a43895632_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTUtMTAtMS0xLTExNjc3MQ_82d4f366-69a6-4e24-bb5f-3b9dd2bb0f6d">1,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i398c1b11a4d14d1a9a22642a4366b4f3_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTYtMC0xLTEtMTE2NzcxL3RleHRyZWdpb246NmYxZjU2ODdlYjQ4NDEyODk2YjVmOTZiZTFiNmZiNTlfNA_22476f51-8372-4654-8002-69b8755dd8c3">7.00</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i398c1b11a4d14d1a9a22642a4366b4f3_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTYtNC0xLTEtMTE2Nzcx_1c7cbc3e-1027-4979-8772-103020be8d1e">748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i398c1b11a4d14d1a9a22642a4366b4f3_I20220630" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTYtNi0xLTEtMTE2Nzcx_ac15610d-42cf-46e1-8d5e-135041b8f72f">742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13687ae43098477691509c97baced059_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTYtOC0xLTEtMTE2Nzcx_ca9a6d0c-772f-4dfb-98fa-e7d0b563a183">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13687ae43098477691509c97baced059_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTYtMTAtMS0xLTExNjc3MQ_93103f1a-714e-4373-9730-521214431581">743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7141189be3804bae89bd5a07b8eed649_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTctMC0xLTEtMTE2NzcxL3RleHRyZWdpb246NTNmNDYwZjgxZjUzNDg5ODkxMTA2NThhOTZlNDVjYzhfNA_8cdafb00-4b6a-4123-89a5-68f4fae9eff5">5.00</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7141189be3804bae89bd5a07b8eed649_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTctNC0xLTEtMTE2Nzcx_38c64721-8a09-492c-8700-c3366ec90295">1,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7141189be3804bae89bd5a07b8eed649_I20220630" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTctNi0xLTEtMTE2Nzcx_365c34e5-95f9-48e6-a319-e6664bb44f2d">1,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic76bf6c1d1e74dbdac6341facf5d2281_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTctOC0xLTEtMTE2Nzcx_70c82755-8ff2-441f-a9e1-3a6e36a485f7">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic76bf6c1d1e74dbdac6341facf5d2281_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTctMTAtMS0xLTExNjc3MQ_e939766e-ada8-4271-8226-ed71246ec882">1,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2065ef23dc6d4584b71fd6c1feee2ce9_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTgtMC0xLTEtMTE2NzcxL3RleHRyZWdpb246NDY2NzNhZTUxZDU0NDM0YzgzN2Y3ZGRjYjlmYmYwNjBfNA_d4648c0e-ab15-4519-9988-0017e997dc8f">6.25</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2065ef23dc6d4584b71fd6c1feee2ce9_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTgtNC0xLTEtMTE2Nzcx_f786c7db-1a91-416d-ac02-85cefb1e9b40">1,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2065ef23dc6d4584b71fd6c1feee2ce9_I20220630" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTgtNi0xLTEtMTE2Nzcx_6f7243cb-e49d-4ef4-a21c-6e44e00f07c6">1,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia157a13c8e7444d9a15b0ef900f499ac_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTgtOC0xLTEtMTE2Nzcx_281cf3fe-2d63-4332-9e41-fd9b1ba074e0">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia157a13c8e7444d9a15b0ef900f499ac_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTgtMTAtMS0xLTExNjc3MQ_28d63bb2-1095-4782-8eb3-d9ca6eea3dd5">1,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i55d39b6dbdc64a07aafafbab0a66b4cf_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTktMC0xLTEtMTE2Nzcx_39606137-d83d-48a2-b04e-f8570f8c94ae">5.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55d39b6dbdc64a07aafafbab0a66b4cf_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTktNC0xLTEtMTE2Nzcx_60e1c338-629d-4adb-affa-645a0ff05e35">834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55d39b6dbdc64a07aafafbab0a66b4cf_I20220630" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTktNi0xLTEtMTE2Nzcx_2c82f34e-f5a7-4d40-b06c-19abf42c99aa">826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4db4028fafd541e2adcdd0f2a8acb446_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTktOC0xLTEtMTE2Nzcx_8dbcb600-9a50-40e9-8843-df930118b330">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4db4028fafd541e2adcdd0f2a8acb446_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTktMTAtMS0xLTExNjc3MQ_ca8b1a39-2aab-45e1-aea8-593fe5cec48e">990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i14f52e507b3c4725b4e1096cc5b3092f_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjAtMC0xLTEtMTE2NzcxL3RleHRyZWdpb246YWUzZTU3NzliZDMxNGRmOThmNWMxMzRiOTA1NTllODJfNA_ce0da611-c867-4b59-9531-e12ab308b455">7.25</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14f52e507b3c4725b4e1096cc5b3092f_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjAtNC0xLTEtMTE2Nzcx_78bad7cd-98e8-4641-a92a-5e0e0a2ae9d3">745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14f52e507b3c4725b4e1096cc5b3092f_I20220630" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjAtNi0xLTEtMTE2Nzcx_851a4a3e-d4be-4c68-a701-96da59f058b8">738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b92a3adf20a4c61a5df00eff00b36d1_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjAtOC0xLTEtMTE2Nzcx_a7c5efdc-7884-426d-8559-68245e4df86e">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b92a3adf20a4c61a5df00eff00b36d1_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjAtMTAtMS0xLTExNjc3MQ_eeafc356-47ba-46a1-9676-a0d18251d194">742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c2ba2913e7c4009a057680b01952716_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjEtMC0xLTEtMTE2NzcxL3RleHRyZWdpb246NmE2ZmRlNWY4MjMwNGJlYmJiNDc5MzM4NGI5ZmNjODNfNA_5f27e4f0-694b-4e64-9adb-edd30a396022">5.25</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c2ba2913e7c4009a057680b01952716_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjEtNC0xLTEtMTE2Nzcx_8054216b-4e3b-4cd5-ab90-6211454c6748">1,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c2ba2913e7c4009a057680b01952716_I20220630" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjEtNi0xLTEtMTE2Nzcx_7a777636-83b0-4792-bd50-4c78fcdd6a49">1,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa56bff66e564adaa6394ca261106b7c_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjEtOC0xLTEtMTE2Nzcx_607bda83-f84b-4264-a49b-95906a864a10">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa56bff66e564adaa6394ca261106b7c_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjEtMTAtMS0xLTExNjc3MQ_37d6f8fa-2f76-4ce5-843a-cf179b71b9d8">1,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifeef119d45684adb8aeab24feb20d75c_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjItMC0xLTEtMTE2Nzcx_1061ffc6-26dc-483c-ad96-711f4609da07">5.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeef119d45684adb8aeab24feb20d75c_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjItNC0xLTEtMTE2Nzcx_fe783962-d0c3-4b2f-95e6-1d44f3d72238">909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeef119d45684adb8aeab24feb20d75c_I20220630" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjItNi0xLTEtMTE2Nzcx_f26bae09-42d1-4026-b284-c8cf5b7ac3b8">900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fbf55e1f7641c9a02ee367f63c49ea_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjItOC0xLTEtMTE2Nzcx_fc2b8df1-f06d-4ab6-82e1-8b25ff922bea">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fbf55e1f7641c9a02ee367f63c49ea_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjItMTAtMS0xLTExNjc3MQ_918e2fb0-b254-46d4-9fec-15f8c4c71b77">989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5eee7cc73d847faac3aa9d22d79a2c3_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjMtNC0xLTEtMTE2Nzcx_c4195bba-34d8-45ff-a293-4bf2dbe8555c">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5eee7cc73d847faac3aa9d22d79a2c3_I20220630" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjMtNi0xLTEtMTE2Nzcx_76ba8597-ee0f-456e-aa2c-544460770505">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c1392391ca546758b079e1238c10a9f_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjMtOC0xLTEtMTE2Nzcx_eee81544-9ff1-4aff-aba8-311da86e03ee">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c1392391ca546758b079e1238c10a9f_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjMtMTAtMS0xLTExNjc3MQ_e2f107fd-8397-4bd5-945f-f8d6649b2cb4">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjQtNC0xLTEtMTE2Nzcx_655598b4-bb64-453a-ad37-8e40749cd543"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjQtNC0xLTEtMTE2Nzcx_e84a93f4-ffeb-43fb-9e35-5cb13074f5ac">22,056</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjQtNi0xLTEtMTE2Nzcx_bf245a58-e5d7-4786-a02a-b66a5f8fe6c9">21,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjQtOC0xLTEtMTE2Nzcx_fea7d0b2-a5d8-4ee2-8e62-e3902da16977">22,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjQtMTAtMS0xLTExNjc3MQ_1b8a0475-ed6c-4f79-9b61-54d2df1253b9">22,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjUtNi0xLTEtMTE2Nzcx_8a3823f4-c321-48d6-bbd4-bd859fd0c74f">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjUtMTAtMS0xLTExNjc3MQ_880002bb-0e34-4b08-87fc-16d21a4091bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjYtNi0xLTEtMTE2Nzcx_26912b6b-596b-4781-9229-996b8bbd826c">21,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjYtMTAtMS0xLTExNjc3MQ_c87c6b67-0e74-410b-9a51-099bd26ce45a">22,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Covenant Compliance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities (as defined below), the B+L Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes (as defined and described in the table above) and Senior Unsecured Notes (as defined and described in the table above) contain customary affirmative and negative covenants and specified events of default. These affirmative and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company&#8217;s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. As of June&#160;30, 2022, the amount available for restricted payments under the &#8220;builder basket&#8221; in the Company&#8217;s most restrictive indentures (as defined by those indentures) was approximately $<ix:nonFraction unitRef="usd" contextRef="ie97aa1338630440fa931939603c3afa8_I20220630" decimals="-6" name="bhc:DebtInstrumentCovenantAmountAvailableForRestrictedPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTIwMQ_ea17b170-9646-43e7-9dfa-3d80382429da">14,100</ix:nonFraction>&#160;million (although such availability is subject to the Company&#8217;s compliance with a <ix:nonFraction unitRef="number" contextRef="i9a193ea233134644af3474c6d58858b2_I20220630" decimals="INF" name="bhc:DebtInstrumentCovenantTermsFixedChargeCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTI3OA_96f993f0-ac3d-4039-bfa1-1d2cbf22d400">2.00</ix:nonFraction>:1.00 fixed charge coverage ratio). The 2027 Revolving Credit Facility (as defined below) also contains a financial </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i0d8e73f1700a451bb4b7912ddfee12ad" continuedAt="i6a4f0817458e4920bb8e42fde222ad02"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">maintenance covenant that, requires the Company to maintain a first lien net leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="i9a193ea233134644af3474c6d58858b2_I20220630" decimals="INF" name="bhc:DebtInstrumentCovenantComplianceSecuredLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTU3NQ_5f32d9d2-6750-4552-bae7-76d2be6f819a">4.00</ix:nonFraction>:1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast for the next twelve months from the date of issuance of these financial statements, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations over that same period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to take steps to improve its operating results to seek to ensure continual compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company&#8217;s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the 2018 Restated Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the &#8220;Senior Secured Credit Facilities&#8221; under the Company&#8217;s Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018 (the &#8220;2018 Restated Credit Agreement&#8221;) with a syndicate of financial institutions and investors as lenders. Prior to the 2022 Amended Credit Agreement (as defined below), the 2018 Restated Credit Agreement provided for a revolving credit facility of $<ix:nonFraction unitRef="usd" contextRef="i70293a619f5141b8baf60127b5cdb2d3_I20180601" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMzA3NA_6c57f4d9-134a-4723-aecb-2d87d322a8ea">1,225</ix:nonFraction> million, maturing on the earlier of June 1, 2023 and the date that is <ix:nonNumeric contextRef="i3dee274036df4695a83fc9e2f921cd2a_D20180601-20180601" name="bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMzEzOQ_3301bd7e-612e-45d3-945a-050bc9490e5c">91</ix:nonNumeric> calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and Bausch Health Americas, Inc. (&#8220;BHA&#8221;) in an aggregate principal amount in excess of $<ix:nonFraction unitRef="usd" contextRef="i70293a619f5141b8baf60127b5cdb2d3_I20180601" decimals="INF" name="bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMzMyNQ_37d36644-6e67-4c3e-8b0d-9833c3c814d8">1,000</ix:nonFraction> million (the &#8220;2023 Revolving Credit Facility&#8221;) and term loan facilities of original principal amounts of $<ix:nonFraction unitRef="usd" contextRef="ia3f9fb93db3f4b06852f02dd6bfe37ae_I20180601" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMzQyNQ_e52410a1-70f9-480d-8eef-12d30ff820de">4,565</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icd3b61934fa0481cb903c6cad1023951_I20180601" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMzQzMg_9f3f23fe-fb36-45dd-808f-ca5f3d6df8f8">1,500</ix:nonFraction> million, maturing in June 2025 (the &#8220;June 2025 Term Loan B Facility&#8221;) and November 2025 (the &#8220;November 2025 Term Loan B Facility&#8221;), respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the 2022 Amended Credit Agreement</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, the Company and certain of its subsidiaries as guarantors entered into a Second Amendment (the &#8220;Second Amendment&#8221;) to the Fourth Amended and Restated Credit and Guaranty Agreement (as amended by the Second Amendment, the &#8220;2022 Amended Credit Agreement&#8221;). The 2022 Amended Credit Agreement provides for a new term loan facility with an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="id684a5f342be4a9dacf6da92dfbae334_I20220510" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjE0MQ_27239958-d136-4f64-8d22-a0db2f391ac7">2,500</ix:nonFraction>&#160;million (the &#8220;2027 Term Loan B Facility&#8221;) maturing on February 1, 2027 and a new revolving credit facility of $<ix:nonFraction unitRef="usd" contextRef="ie870cb7bef5c4e1f80f119d7291d6694_I20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjE1Nw_d1b51b10-3b4d-4e77-beb7-a7764755668d">975</ix:nonFraction>&#160;million (the &#8220;2027 Revolving Credit Facility&#8221;) that will mature on the earlier of February 1, 2027 and the date that is <ix:nonNumeric contextRef="i6da3d0cbf2d147fc8ed6d47a33114b1b_D20220510-20220510" name="bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjIzOA_6d17ee68-ba0d-48d0-9465-16423984f55e">91</ix:nonNumeric> calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and BHA in an aggregate principal amount in excess of $<ix:nonFraction unitRef="usd" contextRef="ie870cb7bef5c4e1f80f119d7291d6694_I20220510" decimals="INF" name="bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjE3MQ_68696f45-5680-41ce-9192-3ed90071d07a">1,000</ix:nonFraction>&#160;million. Borrowings under the 2027 Revolving Credit Facility can be made in U.S. dollars, Canadian dollars or Euros. After giving effect to the Second Amendment, the 2023 Revolving Credit Facility, June 2025 Term Loan B Facility and November 2025 Term Loan B Facility were refinanced (such refinancing, the &#8220;Credit Agreement Refinancing&#8221;), along with certain of the Company&#8217;s existing senior notes, using net proceeds from the borrowings under the 2027 Term Loan B Facility, the B+L IPO and the B+L Debt Financing (as defined below) and available cash on hand. As of June 30, 2022, the Company had drawn $<ix:nonFraction unitRef="usd" contextRef="ieadee1866a824ef498fe7b558d0181c4_I20220630" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTA5OTUxMTYzNTQzNzg_b0f3a3ff-2bc4-4cdf-97dc-52ce5702ee8d">425</ix:nonFraction>&#160;million on the 2027 Revolving Credit Facility. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2027 Term Loan B Facility bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) a forward-looking term rate determined by reference to the financing rate for borrowing U.S. dollars overnight collateralized by U.S. Treasury securities (&#8220;term SOFR rate&#8221;) for the interest period relevant to such borrowing</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or (b) a base rate determined by reference to the highest of: (i) the prime rate (as defined in the 2022 Amended Credit Agreement), (ii) the federal funds effective rate plus 1/2 of 1.00% and (iii) the term SOFR rate for a period of one month plus <ix:nonFraction unitRef="number" contextRef="if697bdbf4b2341c28c62cc63991814b1_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjYwODYyNw_abae4672-a8e4-4313-8397-43902c425e13">1.00</ix:nonFraction>% (or if such rate shall not be ascertainable, <ix:nonFraction unitRef="number" contextRef="ic821cb350682455fb80a7cf379859436_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjYwODYzNA_6d7ae543-4755-4f16-b9bf-3ef7be46b866">1.50</ix:nonFraction>%) (provided, however, that the term SOFR rate with respect to the 2027 Term Loan B Facility shall at no time be less than <ix:nonFraction unitRef="number" contextRef="id3317da9d69b44a5a0f5530521c43d9a_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjYwODY0MQ_6542402c-79c3-4f1a-9875-da4c466958a3">0.50</ix:nonFraction>% per annum), in each case, plus an applicable margin. Borrowings under the 2027 Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) the term SOFR rate (provided, however, that the term SOFR rate with respect to the 2027 Revolving Credit Facility shall at no time be less than <ix:nonFraction unitRef="number" contextRef="ib41ea84450c549cdbd5dd7eb01cb3125_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjYwODY0OA_bdf853d0-a1aa-4ba4-8206-bd377d230555">0.00</ix:nonFraction>% per annum) or (b) a base rate determined by reference to the highest of: (x) the prime rate (as defined in the 2022 Amended Credit Agreement), (y) the federal funds effective rate plus 1/2 of 1.00% or (z) the term SOFR rate for a period of one month plus <ix:nonFraction unitRef="number" contextRef="i1b5b14287deb4a36811e3567b40c972b_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjYwODY1Ng_c14e6971-d5c4-4167-8c85-9055eab64063">1.00</ix:nonFraction>%, (ii) Canadian dollars bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) the bankers&#8217; acceptance rate for Canadian dollar deposits in the Toronto interbank market (the &#8220;BA rate&#8221;) for the interest period relevant to such borrowing (provided, however, that the BA rate shall at no time be less than <ix:nonFraction unitRef="number" contextRef="i3e01c970675a436bbf061ef17c476e22_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjYwODY2Mw_e6c56912-2bc1-47ba-946e-d7c98c23ab02">0.00</ix:nonFraction>% per annum) or (b) a prime rate determined by reference to the higher of: (x) the rate of interest last quoted by The Wall Street Journal as the &#8220;Canadian Prime Rate&#8221; or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (y) the one month BA rate calculated daily plus <ix:nonFraction unitRef="number" contextRef="id1101765767e40daa36e42e2d05de9aa_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjYwODY3MQ_1cd9ccae-e3ac-47d4-a175-aa2068555d66">1.00</ix:nonFraction>% (provided, however, that the prime rate shall at no time be less than <ix:nonFraction unitRef="number" contextRef="i3e01c970675a436bbf061ef17c476e22_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjYwODY4Mg_17acd3da-4b76-4b6c-8e5c-e1bbecb74071">0.00</ix:nonFraction>% per annum) and (iii) euros bear interest at a rate per annum </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i6a4f0817458e4920bb8e42fde222ad02" continuedAt="i74453b7ed71a4a3286f19751dec08ade"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equal to a term benchmark rate determined by reference to the cost of funds for euro deposits (&#8220;EURIBOR&#8221;) for the interest period relevant to such borrowing (provided, however, that such rate, shall at no time be less than <ix:nonFraction unitRef="number" contextRef="ifdc5cac429d2406fad6f5db1a981f8e5_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTA5OTUxMTYzNDUyMjk_2660f3ec-e3fd-4cf3-b872-72232fe44c94">0.00</ix:nonFraction>% per annum in each case, plus an applicable margin). Term SOFR rate loans are subject to a credit spread adjustment ranging from <ix:nonFraction unitRef="number" contextRef="ib41ea84450c549cdbd5dd7eb01cb3125_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTA5OTUxMTYzNDUyNDM_4c34329b-4028-44f9-9eba-016903071f7f">0.10</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="ia8243ac81d9d44639387960613fa815a_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTA5OTUxMTYzNDUyNTA_3e7148d6-be76-4750-8fc7-59bd5f47c1eb">0.25</ix:nonFraction>%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margin for borrowings under the 2027 Term Loan B Facility is <ix:nonFraction unitRef="number" contextRef="ic821cb350682455fb80a7cf379859436_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjMzMTY_1c9fcd0d-2d2e-4131-b634-6c61dfba59b2">5.25</ix:nonFraction>% for term SOFR rate loans and <ix:nonFraction unitRef="number" contextRef="i6e609a7fc5194c08831552ad31cb3326_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjMzMjM_fb184b32-df2d-4dc6-8998-b32ac99eee47">4.25</ix:nonFraction>% for U.S. dollar base rate loans. The applicable interest rate margin for borrowings under the 2027 Revolving Credit Facility ranges from <ix:nonFraction unitRef="number" contextRef="i084c2ea2f89c4a93a0688cf9fa993c87_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjMzMzM_a4776bc3-b9d8-4627-9da5-d8949660f9ac">4.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i3357e0f78c5d4623aa4578bb9c5bfb71_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjMzNDA_b7bbae5c-30c8-44b5-adf2-f28bad61ee59">5.25</ix:nonFraction>% for term SOFR rate loans, BA rate loans and EURIBOR loans and</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i8e66748d2095465691388b65def844ec_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjMzNDc_57a32710-f7a4-457c-bb5b-94d7117fcf51">3.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i84a6900222c6444eaa2f43c56b21657f_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjMzNTQ_38f68088-cc0d-413d-ad34-98a9f8f22b51">4.25</ix:nonFraction>% for U.S. dollar base rate loans and Canadian prime rate loans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is required to pay commitment fees of <ix:nonFraction unitRef="number" contextRef="i8ce4074fb09e40f88a53999eaedb2071_D20220510-20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjMzNjE_f9d2e64d-835b-4e10-a2f9-db7816f45e52">0.25</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="ia63076c25e4a4832b2cbf2122f93d974_D20220510-20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjMzNjg_1d1fea2e-3016-4460-b046-3645e9ded4b5">0.50</ix:nonFraction>% per annum with respect to the unutilized commitments under the 2027 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on term SOFR rate borrowings under the 2027 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency fees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the 2022 Amended Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i) <ix:nonFraction unitRef="number" contextRef="i31d884d227e045f3b2a89fc5ec26f5bf_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjMzNzY_da48dc1c-dd26-431f-bdfe-fb555c32e6ec">100</ix:nonFraction>% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, and net proceeds thresholds), (ii) <ix:nonFraction unitRef="number" contextRef="i31d884d227e045f3b2a89fc5ec26f5bf_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjMzODI_984b877e-6403-4328-b308-251fe8319e92">100</ix:nonFraction>% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the 2022 Amended Credit Agreement), (iii) <ix:nonFraction unitRef="number" contextRef="i31d884d227e045f3b2a89fc5ec26f5bf_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjMzODg_9c8f8a82-3c0a-447e-867e-4dcd3ba2ff2b">50</ix:nonFraction>% of Excess Cash Flow (as defined in the 2022 Amended Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) <ix:nonFraction unitRef="number" contextRef="i31d884d227e045f3b2a89fc5ec26f5bf_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjMzOTM_bb9aa219-272e-485e-a301-a6f3f0bfdc2e">100</ix:nonFraction>% of net cash proceeds from asset sales (subject to reinvestment rights, and net proceeds thresholds). These mandatory prepayments may be used to satisfy future amortization. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for the 2027 Term Loan B Facility is <ix:nonFraction unitRef="number" contextRef="id684a5f342be4a9dacf6da92dfbae334_I20220510" decimals="INF" name="bhc:DebtInstrumentAnnualAmortizationRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjMzOTk_3f636865-05cf-4f3c-92e3-145872c01d6b">5.00</ix:nonFraction>% per annum, or $<ix:nonFraction unitRef="usd" contextRef="i88238e27384b4699bca91ad69cb37063_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentPeriodicPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjYxNDc4OQ_88b8bd92-cb3e-4d7c-bcab-487d92bbb255">125</ix:nonFraction>&#160;million, payable in quarterly installments beginning on September 30, 2022. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of June 30, 2022, the remaining mandatory quarterly amortization payments for the 2027 Term Loan B Facility were $<ix:nonFraction unitRef="usd" contextRef="i6b587afb6b2449d6abebb3e8259edaf4_D20220630-20220630" decimals="-6" name="bhc:DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjYwODY5MA_d12e1946-ac26-4642-8626-5710bcfdd724">563</ix:nonFraction>&#160;million through December 2026.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Amended Credit Agreement permits the incurrence of incremental credit facility borrowings up to the greater of $<ix:nonFraction unitRef="usd" contextRef="ie870cb7bef5c4e1f80f119d7291d6694_I20220510" decimals="INF" name="bhc:LineOfCreditFacilityThresholdForIncrementalBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjM0MDY_d92a8d39-d08a-48b3-8d2b-f0fce6e87edd">1,000</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="number" contextRef="i6da3d0cbf2d147fc8ed6d47a33114b1b_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjM0MjI_94281e5a-6988-4c19-9b7a-625c42aeba53">40</ix:nonFraction>% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the 2022 Amended Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="i317f673a636e4cfbbe6308e053f9a1b1_I20220510" decimals="INF" name="bhc:DebtInstrumentCovenantTermsSecuredLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjM0Mjc_be549c70-119e-49b4-a3e7-d72653acf6d9">3.50</ix:nonFraction>:1.00, and, in the case of unsecured debt, either a total leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="i222693060eda48fcb8a8ff27a64972c7_I20220510" decimals="INF" name="bhc:DebtInstrumentCovenantTotalLeverageRatioMaximum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjM0MzM_3d1994b7-2c9b-4869-9070-b7b9798b034d">6.50</ix:nonFraction>:1.00 or an interest coverage ratio of not less than <ix:nonFraction unitRef="number" contextRef="ie870cb7bef5c4e1f80f119d7291d6694_I20220510" decimals="INF" name="bhc:DebtInstrumentCovenantInterestCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjM0Mzk_c310da9b-eed9-4fbc-8e2e-67772dc35f2b">2.00</ix:nonFraction>:1.00.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Amended Credit Agreement provides that Bausch + Lomb shall initially be a &#8220;restricted&#8221; subsidiary subject to the terms of the 2022 Amended Credit Agreement covenants, but does not require Bausch + Lomb to guarantee the obligations under the 2022 Amended Credit Agreement. The 2022 Amended Credit Agreement permits the Company to designate Bausch + Lomb as an &#8220;unrestricted&#8221; subsidiary under the 2022 Amended Credit Agreement and no longer subject to the terms of the covenants thereunder provided that no event of default is continuing or will result from such designation and the total leverage ratio of Remainco (as defined in the 2022 Amended Credit Agreement) will not be greater than <ix:nonFraction unitRef="number" contextRef="i1be7401b40834ec4b9897f7ca08a3bcc_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentCovenantTotalLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjYwODU1Nw_dafaa01a-bd5a-44ee-a80a-57c4e4363dc0">7.60</ix:nonFraction>:1.00 on a pro forma basis. The Credit Agreement Refinancing contains provisions designed to facilitate the B+L Separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the B+L Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, Bausch + Lomb entered into a credit agreement (the &#8220;B+L Credit Agreement&#8221;, and the credit facilities thereunder, the &#8220;B+L Credit Facilities&#8221;) providing for term loans of $<ix:nonFraction unitRef="usd" contextRef="if65afec1ca9042d88f04d82fb68476c8_I20220510" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTA5OTUxMTYzNTg4MDA_0b233580-b87a-4af0-a86e-84d54629a70f">2,500</ix:nonFraction>&#160;million with a <ix:nonNumeric contextRef="i0459e2e91fe04b5099b8551dc212bb5b_D20220510-20220510" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjYwODU2OA_ad24caa4-8d3a-4dd7-bc1d-77faabe3cac7">five-year</ix:nonNumeric> term to maturity (the &#8220;B+L Term Facility&#8221;) and a <ix:nonNumeric contextRef="i025e4c51c5f2476eaa7e7b81b3dd925e_D20220510-20220510" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjYwODU4MQ_d813b513-c08d-4c72-8232-afc4a745f84e">five-year</ix:nonNumeric> revolving credit facility of $<ix:nonFraction unitRef="usd" contextRef="iaf0a3be8d6bd4202945aa5df250dec6c_I20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTA5OTUxMTYzNTg4Mjk_21a7dc62-e14d-4e77-8e2b-3f16be208dd2">500</ix:nonFraction>&#160;million (the &#8220;B+L Revolving Credit Facility&#8221; and such financing, the &#8220;B+L Debt Financing&#8221;). The B+L Credit Facilities are secured by substantially all of the assets of Bausch + Lomb and its material, wholly-owned Canadian, U.S., Dutch and Irish subsidiaries, subject to certain exceptions. The term loans are denominated in U.S. dollars, and borrowings under the revolving credit facility will be made available in U.S. dollars, euros, pounds sterling and Canadian dollars. As of June 30, 2022, the B+L Revolving Credit Facility remains undrawn.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The B+L Revolving Credit Facility is a source of funding for Bausch + Lomb and its subsidiaries only. Absent the making of a dividend, which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to Bausch + Lomb&#8217;s shareholders, proceeds from the B+L Revolving Credit Facility are not available to fund the operations, investing and financing activities of Bausch Health.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Borrowings under the B+L Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either: (a) the term SOFR rate for the interest period relevant to such borrowing or (b) a base rate, determined by reference to the highest of: (i) the prime rate (as defined in the B+L Credit Agreement), (ii) the federal funds </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i74453b7ed71a4a3286f19751dec08ade" continuedAt="ia01365bcdecb48eba1ee3d98b33c0b6e"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">effective rate plus 1/2 of 1.00% and (iii) the term SOFR rate for a period of one month plus <ix:nonFraction unitRef="number" contextRef="i13fb480b68044eeba4d131527e8279e9_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxODkyNDg_00b4c14e-927f-4dc1-bcfe-07399ef6a33b">1.00</ix:nonFraction>% (or if such rate shall not be ascertainable, <ix:nonFraction unitRef="number" contextRef="i13fb480b68044eeba4d131527e8279e9_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxODkyNTU_eb86fe24-02c4-494b-a593-0ec33756ebf4">1.00</ix:nonFraction>%) (provided, however, that the term SOFR rate with respect to the B+L Revolving Credit Facility shall at no time be less than <ix:nonFraction unitRef="number" contextRef="i5197b5b99efa4eb8bf8f5a69128f60d6_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxODkyNjI_840ab0ad-35d4-43ea-9911-775905b0cf4f">0.00</ix:nonFraction>% per annum), (ii) Canadian dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either: (a) the BA rate for the interest period relevant to such borrowing (provided, however, that the BA rate shall at no time be less than <ix:nonFraction unitRef="number" contextRef="id57f7f9d4d2d4e3e9eb4720166ca7a73_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxODkyNzA_b8ff4670-c41d-48bd-9544-fdef64727f24">0.00</ix:nonFraction>% per annum) or (b) prime rate determined by reference to the higher of: (x) the rate of interest last quoted by The Wall Street Journal as the &#8220;Canadian Prime Rate&#8221; or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (y) the one month BA rate calculated daily plus <ix:nonFraction unitRef="number" contextRef="i37e23f9713ba4df0a3897cb703b32626_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxODkyNzg_2e850384-03e7-4e27-8b51-3704159568dd">1.00</ix:nonFraction>% (provided, however, that the prime rate shall at no time be less than <ix:nonFraction unitRef="number" contextRef="id57f7f9d4d2d4e3e9eb4720166ca7a73_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxODkyODU_73886149-3898-4ce0-9509-ea0f43790574">0.00</ix:nonFraction>% per annum), (iii) euros bear interest at a rate per annum equal to EURIBOR for the interest period relevant to such borrowing (provided, however, that such rate shall at no time be less than <ix:nonFraction unitRef="number" contextRef="i9b4a82c59de848fd933f25769865c682_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxODkyOTM_db3d09fa-3c2d-4623-922b-d82acbac968d">0.00</ix:nonFraction>% per annum) and (iv) pounds sterling bear interest at a rate per annum equal to the effective overnight interest rate for unsecured transaction in the Sterling Overnight Index Average (&#8220;SONIA&#8221;) (provided, however, that such rate, shall at no time be no less than <ix:nonFraction unitRef="number" contextRef="ic57a642f15b64fba9bd4ead705bdcd69_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjE4Nw_6244ee6b-5502-45e3-9b6a-dd341999e188">0.00</ix:nonFraction>% per annum, in each case, plus an applicable margin. Term SOFR rate loans are subject to a credit spread adjustment of <ix:nonFraction unitRef="number" contextRef="i13fb480b68044eeba4d131527e8279e9_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjIwMw_3a61f4c1-a009-4b49-923c-527bf07e06fb">0.10</ix:nonFraction>% and sterling loans are subject to a credit spread adjustment of <ix:nonFraction unitRef="number" contextRef="i745d6bb83b7948309a5bca9ce9967c7f_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxODkzMDE_dbea80a6-dd2d-4dbd-8770-3964e83d6680">0.0326</ix:nonFraction>%.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for borrowings under the B+L Revolving Credit Facility are: (i) between <ix:nonFraction unitRef="number" contextRef="i794772c7b0a94cb4ae0831e44b12025a_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjIxMA_e4bb6ddd-9665-4b15-8a0a-e951b17392b4">0.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="if00b75865db04bb2a36148fc758260df_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjIxNw_217c779a-6468-4c6e-a6aa-05abf68e9537">1.75</ix:nonFraction>% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between <ix:nonFraction unitRef="number" contextRef="i9fa8451ab2b24a2f9856257a3e56525b_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjIyNA_6a24ef68-ce41-4bce-b6eb-521bc91f496a">1.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i97fcf2fb2a11462b97034820ecfbea20_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjIzMQ_bb746617-94b4-4a6b-ac97-0085639a5264">2.75</ix:nonFraction>% with respect to term SOFR rate, EURIBOR, SONIA or BA rate borrowings based on Bausch + Lomb&#8217;s total net leverage ratio and (ii) after: (x) Bausch + Lomb&#8217;s senior unsecured non-credit-enhanced long term indebtedness for borrowed money receives an investment grade rating from at least two of S&amp;P, Moody&#8217;s and Fitch and (y) the B+L Term Loan Facility has been repaid in full in cash (the &#8220;IG Trigger&#8221;), between <ix:nonFraction unitRef="number" contextRef="i89435b8df34c4e929c8786a5809ae39d_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjI2OQ_e12c7263-83fd-4ac7-8bcd-64bba8b032f7">0.015</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i6eb7b9d116404dcbb45abb5c29aab3db_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjI3Nw_e0dec408-20b9-468e-a743-556931bbb866">0.475</ix:nonFraction>% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between <ix:nonFraction unitRef="number" contextRef="ia79343ddb46b49649e9595a3a81569bf_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjI4NQ_d95d7ac3-6353-4fee-a9e1-4950ef9b1bbb">1.015</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i7f27835a65de4739ba485d7737c8fcf1_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjI5Mw_938aa31c-19ab-4130-8ae8-da1abc482ae4">1.475</ix:nonFraction>% with respect to term SOFR rate, EURIBOR, SONIA or BA rate borrowings based on Bausch + Lomb&#8217;s debt rating. In addition, Bausch + Lomb is required to pay commitment fees of <ix:nonFraction unitRef="number" contextRef="i025e4c51c5f2476eaa7e7b81b3dd925e_D20220510-20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjMwMQ_cc7b32eb-6ce7-4dd8-9d03-4af83abe4510">0.25</ix:nonFraction>% per annum in respect of the unutilized commitments under the B+L Revolving Credit Facility, payable quarterly in arrears until the IG Trigger and a facility fee between <ix:nonFraction unitRef="number" contextRef="i4503aad9ff7046f7b027b10d33ee0a67_D20220510-20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjMwOA_b9e9e5d2-be5b-4fc5-a5b0-23c8288edc23">0.110</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i62be326ed1094f42a72cf8f28f3824e9_D20220510-20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjMxNg_2302187a-89be-4008-9ac3-aa0db3e4a556">0.275</ix:nonFraction>% of the total revolving commitments, whether used or unused, based on Bausch + Lomb&#8217;s debt rating and payable quarterly in arrears. Bausch + Lomb is also required to pay letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on term SOFR rate borrowings under the B+L Revolving Credit Facility on a per annum basis, payable quarterly in arrears, as well as customary fronting fees for the issuance of letters of credit and agency fees. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the B+L Term Facility bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either (i) the term SOFR rate for the interest period relevant to such borrowing (provided, however, that the term SOFR rate with respect to the B+L Term Facility shall at no time be less than <ix:nonFraction unitRef="number" contextRef="i3bcd09daf6ff45d1be1768c23751ced6_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxODkzMTA_6375df9d-5cb1-4bfe-beef-c837912d4639">0.50</ix:nonFraction>% per annum), plus an applicable margin of <ix:nonFraction unitRef="number" contextRef="i586f734bb9414bcab81efe9583058179_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjMyNA_e88dbb61-a4e0-4fad-91ae-0d17a4cf8123">3.25</ix:nonFraction>% or (ii) a base rate determined by reference to the highest of (x) the prime rate (as defined in the B+L Credit Agreement), (y) the federal funds effective rate plus 1/2 of 1.00% and (z) the term SOFR rate for a period of one month plus <ix:nonFraction unitRef="number" contextRef="i54647254f8ae45e6b7709b92695601f7_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxODkzMTc_2818c5e2-b798-4de0-baf2-d7bc8ade184f">1.00</ix:nonFraction>% (or if such rate shall not be ascertainable, <ix:nonFraction unitRef="number" contextRef="i54647254f8ae45e6b7709b92695601f7_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjMzMQ_f8005209-62b5-4119-9f37-510707c32972">2.25</ix:nonFraction>%) (provided, however, that the base rate with respect to the B+L Term Facility shall at no time be less than <ix:nonFraction unitRef="number" contextRef="i86c83d00da024414839c7b0495b95f61_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjMzOA_5d108e42-d904-40e5-9d47-a905ac26b3b9">0.50</ix:nonFraction>% per annum), plus an applicable margin of <ix:nonFraction unitRef="number" contextRef="ife48262157f54a9f9411801fa38bef33_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxODkzMjQ_94b3cf49-48ff-4e08-8f36-b762f24bc9ba">2.25</ix:nonFraction>%. Term SOFR rate loans are subject to a credit spread adjustment of <ix:nonFraction unitRef="number" contextRef="i586f734bb9414bcab81efe9583058179_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjM1Mg_ca5f85e0-2aa1-48c2-a610-f14fe8584b3e">0.10</ix:nonFraction>%.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the B+L Credit Agreement, Bausch + Lomb is required to make mandatory prepayments of the loans under the B+L Term Facility under certain circumstances, including from: (i) <ix:nonFraction unitRef="number" contextRef="i31491c26d42f4c55a76225f7c3e1437b_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjM1OQ_7e55f696-94f9-4c8a-b691-a13f95d21edf">100</ix:nonFraction>% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii) <ix:nonFraction unitRef="number" contextRef="i31491c26d42f4c55a76225f7c3e1437b_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjM2NQ_e247ccb9-84ff-4984-a237-42bf00cecc17">100</ix:nonFraction>% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the B+L Credit Agreement), (iii) <ix:nonFraction unitRef="number" contextRef="i31491c26d42f4c55a76225f7c3e1437b_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjM3MQ_37114c86-462e-4c36-b023-9b3b7855be60">50</ix:nonFraction>% of Excess Cash Flow (as defined in the B+L Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) <ix:nonFraction unitRef="number" contextRef="i31491c26d42f4c55a76225f7c3e1437b_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjM3Ng_b2a8a6f7-5aef-4613-912c-24832f26a76f">100</ix:nonFraction>% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for the B+L Term Facility is <ix:nonFraction unitRef="number" contextRef="if65afec1ca9042d88f04d82fb68476c8_I20220510" decimals="INF" name="bhc:DebtInstrumentAnnualAmortizationRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjM4Mg_993b69fe-cd99-4dc6-a168-bd0fc4d4739c">1.00</ix:nonFraction>% per annum, or $<ix:nonFraction unitRef="usd" contextRef="i0459e2e91fe04b5099b8551dc212bb5b_D20220510-20220510" decimals="-6" name="us-gaap:DebtInstrumentPeriodicPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjYxNDgwMw_1b54cf0d-edbb-49d9-a477-1a613fa2a278">25</ix:nonFraction>&#160;million, payable in quarterly installments beginning on September 30, 2022. Bausch + Lomb may direct that prepayments be applied to such amortization payments in order of maturity. As of June 30, 2022, the remaining mandatory quarterly amortization payments for the B+L Term Facility were $<ix:nonFraction unitRef="usd" contextRef="ib72d5c0c9cae4427a65ac12763613c50_D20220630-20220630" decimals="-6" name="bhc:DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxODkzMzE_6c4f3cc5-1997-4e0e-b668-641809e3f4f9">119</ix:nonFraction>&#160;million through March 2027. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Notes</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes are guaranteed by each of the Company&#8217;s subsidiaries that is a guarantor under the 2022 Amended Credit Agreement and existing Senior Unsecured Notes (together, the &#8220;Note Guarantors&#8221;). In connection with the closing of the B+L IPO, the redemption of the Company&#8217;s <ix:nonFraction unitRef="number" contextRef="i4a25c3e0cf7640eb931b7c3c9e6872cd_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjYwMA_efd04024-0db0-43bf-aca9-c226b191bd71">6.125</ix:nonFraction>% Senior Unsecured Notes due 2025 (the &#8220;April 2025 Unsecured Notes&#8221; and the related indenture, the &#8220;April 2025 Unsecured Notes Indenture&#8221;) (as discussed below) and the related release in respect of the 2018 Restated Credit Agreement, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="ia01365bcdecb48eba1ee3d98b33c0b6e" continuedAt="ia5da145a04ee4d8f82ebd236635a94b0"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#8217;s obligations under the 2022 Amended Credit Agreement under the terms of the indentures governing the Senior Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#8217;s and Note Guarantors&#8217; respective existing and future unsubordinated indebtedness and senior to the Company&#8217;s and Note Guarantors&#8217; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pari passu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#8217;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#8217;s debt that is secured by assets that are not collateral.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#8217;s notes, in whole or in part, at a purchase price equal to <ix:nonFraction unitRef="number" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="INF" name="bhc:DebtInstrumentRedemptionPricePercentageChangeinControl" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTI1ODM_6c6bc2d7-d159-4e42-8e8f-010a3c1e85ac">101</ix:nonFraction>% of the principal amount thereof plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i22e56e38486147d28bc2898f73182eef_I20210608" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTI2NTI_6dc00983-a1ae-4cb9-9c50-593d0880d301">4.875</ix:nonFraction>% Senior Secured Notes due 2028 - June 2021 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i22e56e38486147d28bc2898f73182eef_I20210608" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTI3NTg_b4fb28f6-d72b-48f0-a4f2-9e1cc794f1fa">1,600</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i22e56e38486147d28bc2898f73182eef_I20210608" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTI3OTE_6dc00983-a1ae-4cb9-9c50-593d0880d301">4.875</ix:nonFraction>% Senior Secured Notes due June 2028 (the &#8220;June 2028 Secured Notes&#8221;) in a private placement. The proceeds and cash on hand were used to: (i) repurchase a portion and redeem the remainder of $<ix:nonFraction unitRef="usd" contextRef="if19b6a01b94c43baac9f6b2e2576cb33_D20210608-20210608" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTI5ODI_5a1b174d-e660-4b90-a032-a6dde21ad8dd">1,600</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="ib2801d5faaff4cff805188a7408a18d9_I20210608" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTI5ODg_c476163a-0678-4e23-8cdb-48f702b47be6">7.00</ix:nonFraction>% Senior Secured Notes due 2024 (the &#8220;March 2024 Secured Notes&#8221;), representing the remaining outstanding principal balance of the March 2024 Secured Notes and (ii) pay all fees and expenses associated with these transactions (collectively, the &#8220;June 2021 Refinancing Transactions&#8221;). The June 2021 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="id15e04f207ca454ab4b3869196ecb3aa_D20210608-20210608" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTM0MjA_b9b1c377-dbf9-4728-b6d0-dfc09f96e266">38</ix:nonFraction>&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value. Interest on the June 2028 Secured Notes is payable semi-annually in arrears on each June 1 and December 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2028 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after June 1, 2024, at the redemption prices set forth in the June 2028 Secured Notes indenture. The Company may redeem some or all of the June 2028 Secured Notes prior to June 1, 2024 at a price equal to <ix:nonFraction unitRef="number" contextRef="i7ba95d1a1d8a4e50be9c80b6091f5c9f_D20210608-20210608" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTM5NzU_fd5ddf17-c62d-473b-86af-4ee73867a5be">100</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of the redemption plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to June 1, 2024, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="i670946275ba0478c9fa99c66c759a07f_D20210608-20210608" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTQyMDA_e865fe7d-6b46-4e07-94c2-64f9d568d44e">40</ix:nonFraction>% of the aggregate principal amount of the June 2028 Secured Notes using the net proceeds of certain equity offerings at the redemption price set forth in the June 2028 Secured Notes indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i88c94d8d653b41e2bece3ba32629f570_I20220210" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTQzOTU_47492366-f3fa-42c2-9545-df649840edea">6.125</ix:nonFraction>% Senior Secured Notes due 2027 - February 2022 Financing</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2022, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i88c94d8d653b41e2bece3ba32629f570_I20220210" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxOTAwOTg_e0b080fd-263e-47b4-ae6a-c7f62ddb42d9">1,000</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i88c94d8d653b41e2bece3ba32629f570_I20220210" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTQ1MzY_c168c7c3-681d-4b66-a997-f9eb3ea4e43c">6.125</ix:nonFraction>% Senior Secured Notes due February 2027 (the &#8220;February 2027 Secured Notes&#8221;). The proceeds from the February 2027 Secured Notes, along with proceeds from the B+L IPO, the 2027 Term Loans and the B+L Debt Financing and cash on hand, were used to redeem the April 2025 Unsecured Notes and the Credit Agreement Refinancing as discussed below. The February 2027 Secured Notes accrue interest at a rate of <ix:nonFraction unitRef="number" contextRef="i88c94d8d653b41e2bece3ba32629f570_I20220210" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTUwMzM_c168c7c3-681d-4b66-a997-f9eb3ea4e43c">6.125</ix:nonFraction>% per year, payable semi-annually in arrears on each February and August. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The February 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after February 2024, at the redemption prices set forth in the indenture. The Company may redeem some or all of the February 2027 Secured Notes prior to February 2024 at a price equal to <ix:nonFraction unitRef="number" contextRef="iaaa9e9d10abf4341b32b2669fa6bd9c5_D20220210-20220210" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTU0MTI_e3ab605e-9d2a-4cf3-bba5-d6c09c87507d">100</ix:nonFraction>% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. Prior to February 2024, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="ib171e1f6ad134f1e8a838ae91f96bdc6_D20220210-20220210" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTU1Mjk_b2ac9acc-02f8-40f5-830a-435cf4316cff">40</ix:nonFraction>% of the aggregate principal amount of the February 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Unsecured Notes issued by the Company are the Company&#8217;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the 2022 Amended Credit Agreement. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the 2022 Amended Credit Agreement. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes. In connection with the closing of the B+L IPO, the discharge of the April 2025 Unsecured Notes Indenture and the related release in respect of the 2018 Restated Credit Agreement, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="ia5da145a04ee4d8f82ebd236635a94b0" continuedAt="ie9f111b695db479aa540a109ac973741"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to <ix:nonFraction unitRef="number" contextRef="icacf3f32142f4f7793bba94c9b3e3ebe_D20220101-20220630" decimals="INF" name="bhc:DebtInstrumentRedemptionPricePercentageChangeinControl" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTY5MDE_a2391dab-72b7-4aed-b768-3fc663c56134">101</ix:nonFraction>% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Redemption of April 2025 Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, the Company issued conditional notices of redemption to redeem: (i) all of the April 2025 Unsecured Notes conditioned upon the completion of the Credit Agreement Refinancing and (ii) $<ix:nonFraction unitRef="usd" contextRef="ib86afa84ce1b41d5b48258b10accd8f9_I20220118" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTA5OTUxMTYzNTk3MTY_fb2b55b8-dfee-42d1-ae2d-31a1df53a4aa">370</ix:nonFraction>&#160;million in aggregate principal amount of the Company&#8217;s outstanding <ix:nonFraction unitRef="number" contextRef="ib86afa84ce1b41d5b48258b10accd8f9_I20220118" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTA5OTUxMTYzNTk3NDY_5dfba276-c56c-4e9e-807d-8a631a1ec9d5">9.000</ix:nonFraction>% Senior Unsecured Notes due 2025 (the &#8220;December 2025 Unsecured Notes&#8221;) conditioned upon the receipt of aggregate proceeds of at least $<ix:nonFraction unitRef="usd" contextRef="ib86afa84ce1b41d5b48258b10accd8f9_I20220118" decimals="INF" name="bhc:DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDk0NzgwMjQyNDM0NQ_8102f749-be57-4a58-b20a-fcb7b0635187">7,000</ix:nonFraction>&#160;million from: (a) the B+L IPO, (b) the B+L Debt Financing, (c) the Credit Agreement Refinancing and (d) the issuance of the February 2027 Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of the B+L IPO, the conditions of the redemption of its April 2025 Unsecured Notes were satisfied and the Company discharged the April 2025 Unsecured Notes Indenture using: (i) the net proceeds from the issuance of the February 2027 Secured Notes, (ii) the net proceeds from the B+L IPO, (iii) the net proceeds from the borrowings under the B+L Debt Financing and (iv) cash on hand. On May 10, 2022, the Company caused sufficient funds for the redemption in full of its April 2025 Unsecured Notes at a redemption price of <ix:nonFraction unitRef="number" contextRef="i00eb5a1c1bb64566b2473aca50a87f8b_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTA5OTUxMTYzNTk3NjI_7754858d-e9ea-48f4-bb6e-684b4dd62d41">101.021</ix:nonFraction>% of the principal amount then outstanding to be irrevocably deposited with the Bank of New York Mellon, N.A., as trustee under the April 2025 Unsecured Notes Indenture, and the April 2025 Unsecured Notes Indenture was discharged. The April 2025 Unsecured Notes were redeemed on May 16, 2022. The redemption was accounted for as an extinguishment of debt. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, the Company notified the Trustee and holders of its outstanding December 2025 Unsecured Notes that the conditions to its previously announced redemption would not be satisfied, and the conditional redemption was cancelled.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of the B+L IPO, the discharge of the April 2025 Unsecured Notes Indenture and the related release in respect of the 2018 Restated Credit Agreement as described above, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Stated Rate of Interest</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average stated rate of interest for the Company&#8217;s outstanding debt obligations as of June&#160;30, 2022 and December&#160;31, 2021 was <ix:nonFraction unitRef="number" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTcxNjg_014c20bc-9cb8-421c-b32a-c2fd8d3bc880">6.34</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTcxNzU_64d5e06c-6853-4823-b404-a4ae43074ab3">5.88</ix:nonFraction>%, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gain (Loss) on Extinguishment of Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022, the Company repurchased and retired, outstanding Senior Unsecured Notes with an aggregate par value of $<ix:nonFraction unitRef="usd" contextRef="ib99e0e69c7014f3db279170c3e995c4c_I20220630" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDk0NzgwMjQyNjM5MA_c5b957b2-ccd9-4a0d-b8de-706a6ed64b23">481</ix:nonFraction>&#160;million in the open market, for an aggregate cost of $<ix:nonFraction unitRef="usd" contextRef="i79deb0713cde44578625b28d0e656766_D20220401-20220630" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDk0NzgwMjQyNjQzOQ_ae5e8775-e854-4861-86fc-f01bf9fc7c94">300</ix:nonFraction>&#160;million. In connection with these repurchases, the Company recognized a gain of $<ix:nonFraction unitRef="usd" contextRef="i79deb0713cde44578625b28d0e656766_D20220401-20220630" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDk0NzgwMjQyNjUxNQ_c924c56b-1ad5-4de1-80b8-c4aab5b66244">176</ix:nonFraction>&#160;million on extinguishment of debt which represents the differences between the amounts paid to settle the extinguished debt and its carrying value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the repayment of: (i) June 2025 Term Loan B Facility, (ii) November 2025 Term Loan B Facility, (iii) 2023 Revolving Credit Facility and (iv) redemption of April 2025 Unsecured Notes the Company incurred a loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i0acce2b828944f6db85708f4bd37bcd0_D20220510-20220510" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNzE0NjgyNTY4MzA0OQ_66688355-bac8-4832-bede-0d3cfa6e1a66">63</ix:nonFraction>&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may, from time to time, purchase outstanding debt for cash in open market purchases or privately negotiated transactions. Such repurchases or exchanges, if any, will depend on prevailing market conditions, future liquidity requirements, contractual restrictions and other factors. </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="ie9f111b695db479aa540a109ac973741"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTgzMzM_e0aeeeee-c5e4-42b1-848f-36cd0f3ea76f" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of debt obligations for the remainder of 2022, the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:90.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjI4MDRiNTk1NmYzOTQxYjM4YTI0NzA5MmM0YmJhYWFiL3RhYmxlcmFuZ2U6MjgwNGI1OTU2ZjM5NDFiMzhhMjQ3MDkyYzRiYmFhYWJfMS0xLTEtMS0xMTY3NzE_4335977c-2ece-4af3-bf19-0cdcf6db4990">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjI4MDRiNTk1NmYzOTQxYjM4YTI0NzA5MmM0YmJhYWFiL3RhYmxlcmFuZ2U6MjgwNGI1OTU2ZjM5NDFiMzhhMjQ3MDkyYzRiYmFhYWJfMi0xLTEtMS0xMTY3NzE_a7c2b9cd-4fa2-4093-91cc-3f003064f8bd">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjI4MDRiNTk1NmYzOTQxYjM4YTI0NzA5MmM0YmJhYWFiL3RhYmxlcmFuZ2U6MjgwNGI1OTU2ZjM5NDFiMzhhMjQ3MDkyYzRiYmFhYWJfMy0xLTEtMS0xMTY3NzE_c9cd00d7-79ec-48da-8ae6-3e7afd461003">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjI4MDRiNTk1NmYzOTQxYjM4YTI0NzA5MmM0YmJhYWFiL3RhYmxlcmFuZ2U6MjgwNGI1OTU2ZjM5NDFiMzhhMjQ3MDkyYzRiYmFhYWJfNC0xLTEtMS0xMTY3NzE_ca48ada5-69ed-447b-9540-eeef34eabc80">3,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjI4MDRiNTk1NmYzOTQxYjM4YTI0NzA5MmM0YmJhYWFiL3RhYmxlcmFuZ2U6MjgwNGI1OTU2ZjM5NDFiMzhhMjQ3MDkyYzRiYmFhYWJfNS0xLTEtMS0xMTY3NzE_5b46250a-e438-45fa-bab3-33ddda1ed98b">1,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjI4MDRiNTk1NmYzOTQxYjM4YTI0NzA5MmM0YmJhYWFiL3RhYmxlcmFuZ2U6MjgwNGI1OTU2ZjM5NDFiMzhhMjQ3MDkyYzRiYmFhYWJfNi0xLTEtMS0xMTY3NzE_59f51e73-4de7-42a2-94e3-0149c11f1b9b">8,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjI4MDRiNTk1NmYzOTQxYjM4YTI0NzA5MmM0YmJhYWFiL3RhYmxlcmFuZ2U6MjgwNGI1OTU2ZjM5NDFiMzhhMjQ3MDkyYzRiYmFhYWJfNy0xLTEtMS0xMTY3NzE_23172efd-3c7a-4a31-9eaa-f6b965f543ac">8,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjI4MDRiNTk1NmYzOTQxYjM4YTI0NzA5MmM0YmJhYWFiL3RhYmxlcmFuZ2U6MjgwNGI1OTU2ZjM5NDFiMzhhMjQ3MDkyYzRiYmFhYWJfOC0xLTEtMS0xMTY3NzE_655598b4-bb64-453a-ad37-8e40749cd543"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjI4MDRiNTk1NmYzOTQxYjM4YTI0NzA5MmM0YmJhYWFiL3RhYmxlcmFuZ2U6MjgwNGI1OTU2ZjM5NDFiMzhhMjQ3MDkyYzRiYmFhYWJfOC0xLTEtMS0xMTY3NzE_e84a93f4-ffeb-43fb-9e35-5cb13074f5ac">22,056</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized premiums, discounts and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjI4MDRiNTk1NmYzOTQxYjM4YTI0NzA5MmM0YmJhYWFiL3RhYmxlcmFuZ2U6MjgwNGI1OTU2ZjM5NDFiMzhhMjQ3MDkyYzRiYmFhYWJfOS0xLTEtMS0xMTY3NzE_70eda85e-f33c-4bc8-ad71-d42a2f824bea">242</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjI4MDRiNTk1NmYzOTQxYjM4YTI0NzA5MmM0YmJhYWFiL3RhYmxlcmFuZ2U6MjgwNGI1OTU2ZjM5NDFiMzhhMjQ3MDkyYzRiYmFhYWJfMTAtMS0xLTEtMTE2Nzcx_bf245a58-e5d7-4786-a02a-b66a5f8fe6c9">21,814</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i762fba229369426294c4424c2015a01a_73"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RleHRyZWdpb246NjQyNjA1YzE4OGQ4NGYwZGIxNzVlZWVmZTIwOWU3MmFfNDAw_8f5bd8eb-e0dd-42f2-b7fd-c6de6b4e590f" continuedAt="i0f6c073a81674e21998565712e2a272f" escape="true">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</ix:nonNumeric></span></div><ix:continuation id="i0f6c073a81674e21998565712e2a272f"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which covers certain U.S. employees and employees in certain other countries. <ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RleHRyZWdpb246NjQyNjA1YzE4OGQ4NGYwZGIxNzVlZWVmZTIwOWU3MmFfMzk2_9da17f62-df9f-4661-ad6f-b724504e49b4" continuedAt="ic7f8d222c17f4b3da05c438ffaf10a30" escape="true">Net periodic (benefit) cost for the Company&#8217;s defined benefit pension plans and postretirement benefit plan for the six months ended June 30, 2022 and 2021 consists of: </ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><ix:continuation id="ic7f8d222c17f4b3da05c438ffaf10a30"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.980%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Postretirement<br/>Benefit<br/>Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cd8cb835ea2462f98e5d1fadf8a2bf3_D20220101-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfMy0yLTEtMS0xMTY3NzE_951c4457-404d-4ecc-a5ec-d9fea1cb9a23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0860bb9611a474495df2c84fca443ea_D20210101-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfMy00LTEtMS0xMTY3NzE_f7bb4dc2-c510-4429-9155-5a6bfe750435">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba8a2efe71f24a6fa3f18d4fe8dc0568_D20220101-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfMy02LTEtMS0xMTY3NzE_7681ac87-3d09-40d4-b456-3573726fabc9">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i666ce213d28248b1853cff9f08dadf3c_D20210101-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfMy04LTEtMS0xMTY3NzE_f13407b8-84c9-41c2-a9f4-620831ed12fe">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9f1c1de00ee4efcb8697ec7c3c5c449_D20220101-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfMy0xMC0xLTEtMTE2Nzcx_ee293c7a-df99-434f-a320-9621fb4f10dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ffeb2497315442bb679da042122c643_D20210101-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfMy0xMi0xLTEtMTE2Nzcx_f24277a8-b59f-4bf3-98b5-5eaf3b7e1a20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cd8cb835ea2462f98e5d1fadf8a2bf3_D20220101-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNC0yLTEtMS0xMTY3NzE_a3ff0156-b054-48b9-bcb1-293bfd52b0cc">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0860bb9611a474495df2c84fca443ea_D20210101-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNC00LTEtMS0xMTY3NzE_a722a3b7-e583-4360-b388-f91da35aadac">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba8a2efe71f24a6fa3f18d4fe8dc0568_D20220101-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNC02LTEtMS0xMTY3NzE_d40c0da8-1c56-4ecf-8ecd-bceab5aca095">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i666ce213d28248b1853cff9f08dadf3c_D20210101-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNC04LTEtMS0xMTY3NzE_7bc2842a-6cb7-4841-a18b-b094e8116ef0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9f1c1de00ee4efcb8697ec7c3c5c449_D20220101-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNC0xMC0xLTEtMTE2Nzcx_1afb30fe-85aa-489d-a662-1c96727f7014">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ffeb2497315442bb679da042122c643_D20210101-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNC0xMi0xLTEtMTE2Nzcx_33e2c670-b545-480f-9e99-a2d66d393fdb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cd8cb835ea2462f98e5d1fadf8a2bf3_D20220101-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNS0yLTEtMS0xMTY3NzE_9629d066-3f60-4abd-b365-a30c78e213cf">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0860bb9611a474495df2c84fca443ea_D20210101-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNS00LTEtMS0xMTY3NzE_6b721bba-1ec5-4d2e-b6f7-73eb3e87c05e">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba8a2efe71f24a6fa3f18d4fe8dc0568_D20220101-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNS02LTEtMS0xMTY3NzE_7f0df28a-c257-47b8-83f6-713c4e113379">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i666ce213d28248b1853cff9f08dadf3c_D20210101-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNS04LTEtMS0xMTY3NzE_c4a7f091-52ad-4b52-b8aa-84d38429cd40">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9f1c1de00ee4efcb8697ec7c3c5c449_D20220101-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNS0xMC0xLTEtMTE2Nzcx_510ac8f6-7e40-40fc-8119-a6718dd120c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ffeb2497315442bb679da042122c643_D20210101-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNS0xMi0xLTEtMTE2Nzcx_98610e0c-5242-425a-84fc-6258db19470a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cd8cb835ea2462f98e5d1fadf8a2bf3_D20220101-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNi0yLTEtMS0xMTY3NzE_5bbf4e88-dcdb-4a2f-946f-b9365e5de330">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0860bb9611a474495df2c84fca443ea_D20210101-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNi00LTEtMS0xMTY3NzE_778449ac-5671-4525-a7a4-3b6f625cf3a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba8a2efe71f24a6fa3f18d4fe8dc0568_D20220101-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNi02LTEtMS0xMTY3NzE_9fa6f21a-0847-49ee-9654-4e4f55e64f6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i666ce213d28248b1853cff9f08dadf3c_D20210101-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNi04LTEtMS0xMTY3NzE_0b699156-0a56-4d5c-bcac-465bcca82bf2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9f1c1de00ee4efcb8697ec7c3c5c449_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNi0xMC0xLTEtMTE2Nzcx_9e55a6cb-1cf8-41b1-85b8-c80b0fe271be">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ffeb2497315442bb679da042122c643_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNi0xMi0xLTEtMTE2Nzcx_5f33135b-738b-4b43-9df2-c5191e52e30c">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cd8cb835ea2462f98e5d1fadf8a2bf3_D20220101-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNy0yLTEtMS0xMjIzNzk_4888db5d-b90a-4f7c-8375-dfb068b30e86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0860bb9611a474495df2c84fca443ea_D20210101-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNy00LTEtMS0xMjIzNzk_9ce816ee-7b6b-4305-9ee6-a9ed6657ef5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba8a2efe71f24a6fa3f18d4fe8dc0568_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNy02LTEtMS0xMjIzNzk_06680c91-a004-44d6-9f9b-e336f8ed7e28">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i666ce213d28248b1853cff9f08dadf3c_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNy04LTEtMS0xMjIzNzk_be808ffe-f3d5-438f-b948-e0a31177ec17">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9f1c1de00ee4efcb8697ec7c3c5c449_D20220101-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNy0xMC0xLTEtMTIyMzc5_8c19076e-0d2d-45e3-a109-9dd34f16cca1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ffeb2497315442bb679da042122c643_D20210101-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNy0xMi0xLTEtMTIyMzc5_ee79ee03-a5ab-4d3b-af10-09cb293d6511">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4cd8cb835ea2462f98e5d1fadf8a2bf3_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNy0yLTEtMS0xMTY3NzE_3e2a4bc8-ce22-47fb-9ec0-eb77592d43ca">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0860bb9611a474495df2c84fca443ea_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNy00LTEtMS0xMTY3NzE_2518e503-73ed-448e-b761-16ffaa375c97">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba8a2efe71f24a6fa3f18d4fe8dc0568_D20220101-20220630" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNy02LTEtMS0xMTY3NzE_f6a8f77b-f90c-4288-a10a-824f8b04fecf">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i666ce213d28248b1853cff9f08dadf3c_D20210101-20210630" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNy04LTEtMS0xMTY3NzE_7083a531-2561-4ae0-8df5-d2ce7e471c54">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9f1c1de00ee4efcb8697ec7c3c5c449_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNy0xMC0xLTEtMTE2Nzcx_5ede15fd-accb-40ae-9104-46a2e7c00274">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ffeb2497315442bb679da042122c643_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNy0xMi0xLTEtMTE2Nzcx_e67da3c2-1f58-4812-8593-d804e3a51256">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i762fba229369426294c4424c2015a01a_76"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDUyNg_37becd6f-3978-464d-b411-3ac9cf84be66" continuedAt="ied73b59734e94ab4a475840a8526fb86" escape="true">SHARE-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="ied73b59734e94ab4a475840a8526fb86" continuedAt="i88b10a834b6d4eb9b694afaaee6438e3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bausch Health&#8217;s Long-Term Incentive Plan</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2014, shareholders approved the Company&#8217;s 2014 Omnibus Incentive Plan (the &#8220;2014 Plan&#8221;) which replaced the Company&#8217;s 2011 Omnibus Incentive Plan (the &#8220;2011 Plan&#8221;) for future equity awards granted by the Company. The Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan was equal to <ix:nonFraction unitRef="shares" contextRef="i1b4bf4e8fe81409981be4a7ea9e8c8b8_I20140531" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDQ0_3886ecae-3f56-4d50-aa50-c71be74c8043">18,000,000</ix:nonFraction> common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or surrendered under the 2011 Plan and the Company&#8217;s 2007 Equity Compensation Plan. The Company registered <ix:nonFraction unitRef="shares" contextRef="i1b4bf4e8fe81409981be4a7ea9e8c8b8_I20140531" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfODA0_8435523d-a697-414c-8b8c-dd14adea8d22">20,000,000</ix:nonFraction> common shares for issuance under the 2014 Plan. The 2014 Plan was amended and restated effective April 30, 2018 and April 28, 2020 to, among other things, increase the number of common shares authorized for issuance under the 2014 Plan. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective June 21, 2022, the Company further amended and restated the 2014 Plan, as subsequently amended and restated (the &#8220;Amended and Restated 2014 Plan&#8221;). Such amendment and restatement increased the number of common shares authorized for issuance under the Amended and Restated 2014 Plan by an additional <ix:nonFraction unitRef="shares" contextRef="i8fcb725d105e49e7b841b1a1b6ea5845_D20180430-20180430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfMTE3Mg_4782b447-a80e-4fd3-9f6e-e846454337a1">11,500,000</ix:nonFraction> common shares, among other things.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately <ix:nonFraction unitRef="shares" contextRef="ib6c3216122874ca2a63bc8576f858181_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfMzAxOA_91e75de6-0bac-4663-9b57-87b4259ce14f">21,627,000</ix:nonFraction> common shares were available for future grants under the Amended and Restated 2014 Plan as of June&#160;30, 2022. The Company uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i88b10a834b6d4eb9b694afaaee6438e3" continuedAt="i014f84240dbd4ce3ad45ca82375d9817"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with the Company&#8217;s focus on improving its tangible capital usage and allocation while maintaining focus on improving total shareholder return over the long-term. The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based restricted share units (&#8220;RSUs&#8221;) and performance-based RSUs. Performance-based RSUs are comprised of awards that: (i) vest upon achievement of certain share price appreciation conditions that are based on total shareholder return (&#8220;TSR&#8221;), (ii) vest upon attainment of certain performance targets that are based on the Company&#8217;s return on tangible capital (&#8220;ROTC&#8221;) and (iii) vest fully or partially upon attainment of certain goals that are linked to the B+L Separation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bausch + Lomb Long-Term Incentive Plan</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb participated in Bausch Health&#8217;s long-term incentive program prior to the establishment of the Bausch + Lomb Incentive Plan. Effective May 5, 2022, Bausch + Lomb established the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the &#8220;B+L Plan&#8221;). A total of <ix:nonFraction unitRef="shares" contextRef="i9ddb299f73684060bea0bc507f71ef99_I20220505" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfMTE1NDQ4NzIwOTgyODk_43818a37-efab-4132-b748-0b27a7d595cd">28,000,000</ix:nonFraction> common shares of Bausch + Lomb are authorized under the B+L Plan. The B+L Plan provides for the grant of various types of awards including RSUs, stock appreciation rights, stock options, performance-based awards and cash awards. Under the Plan, the exercise price of awards, if any, is set on the grant date and may not be less than the fair market value per share on that date. Generally, stock options have a term of <ix:nonNumeric contextRef="i5d0bb60ae16b4974b67f6d117230127a_D20220505-20220505" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfMTE1NDQ4NzIwOTgzMDA_bbc43858-f4ee-4c70-b44a-0e2ff072119a">ten years</ix:nonNumeric> and a <ix:nonNumeric contextRef="i5d0bb60ae16b4974b67f6d117230127a_D20220505-20220505" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfMTE1NDQ4NzIwOTgzMjU_5821f7fd-2da9-4c23-a710-96afac0caadf">three-year</ix:nonNumeric> vesting period, subject to limited exceptions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2022, in connection with the B+L IPO, </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb granted certain awards to certain eligible recipients (the &#8220;IPO Founder Grants&#8221;). Eligible recipients are individuals employed by Bausch + Lomb or employed by an affiliate of Bausch + Lomb. Approximately <ix:nonFraction unitRef="shares" contextRef="i1d3dfe74f4714b7a933c87137684aa03_D20220505-20220505" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDk0NzgwMjMzMjI4OQ_ba68fccf-139b-4e05-93bb-d8a764df7945">3,900,000</ix:nonFraction> IPO Founder Grants were issued to </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb executive officers and were awarded <ix:nonFraction unitRef="number" contextRef="id6202db2af2b4bafa11ccccaaf34418a_I20220505" decimals="INF" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDk0NzgwMjMzMjMxOA_4c4eb670-8f49-4fc0-995e-8a7bfe279f03">50</ix:nonFraction>% in the form of stock options and <ix:nonFraction unitRef="number" contextRef="i9090a13c2aa6459eaac11b6d545fcbe2_I20220505" decimals="INF" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDk0NzgwMjMzMjMxMw_094e920b-fd9b-4003-93c7-8d4b0c6709bf">50</ix:nonFraction>% in the form of RSUs. Additionally, </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb granted approximately <ix:nonFraction unitRef="shares" contextRef="i9f3765198c384eddb84bb962d8f1d47c_D20220505-20220505" decimals="-5" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDk0NzgwMjMzMjMwMQ_cfc568ef-6b23-4d5c-a141-21e62b2de662">5,700,000</ix:nonFraction> stock options and RSUs to non-executive eligible recipients, of which approximately <ix:nonFraction unitRef="shares" contextRef="i224371ec19ea4a1fab4ab9edec1c44b2_D20220505-20220505" decimals="-5" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDk0NzgwMjMzNjA0MA_ab2a90a8-1ef3-4df9-ba5c-2dcfc89747de">4,300,000</ix:nonFraction> were IPO Founder Grants. The options have a <ix:nonNumeric contextRef="i82c8f4dd25114f83975b0eb530968e3c_D20220505-20220505" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDM5ODA0NjUyMTg4Mg_e0cdd94d-3e77-4e06-84ab-33e0cbf290a5">three-year</ix:nonNumeric> graded vesting period and the RSUs vest <ix:nonFraction unitRef="number" contextRef="i6be3a30d81ad44bdaad72c4d270fd4a4_D20220505-20220505" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDM5ODA0NjUyMTg4NA_e30fe6d3-2cc3-4db8-b103-e1a3bcf8808b">50</ix:nonFraction>% in the second year and <ix:nonFraction unitRef="number" contextRef="i515efea05dbc4414985b6f9579a6bbce_D20220505-20220505" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDM5ODA0NjUyMTg4OQ_198b09a2-4987-4117-80c3-b0fcca6300a9">50</ix:nonFraction>% in the third year after the grant. Vesting of the IPO Founder Grants are contingent on the completion of the B+L Separation and expense recognition will begin near the time of the B+L Separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately <ix:nonFraction unitRef="shares" contextRef="i2a344934b62143ffb69252e4cddaf7f0_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDM5ODA0NjUxNzcyOQ_ad22c7c3-f33d-4160-b293-a7e3a3085e7e">18,400,000</ix:nonFraction> Bausch + Lomb common shares were available for future grants as of June&#160;30, 2022 under the B+L Plan. Bausch + Lomb uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans.</span></div><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDUxOQ_c46949b2-edb7-4b67-822f-402f86553f44" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components and classification of Bausch Health share-based compensation expenses related to stock options and RSUs for the three and six months ended June 30, 2022 and 2021: </span></div><div style="margin-bottom:6pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33dd60c60854413ab4b719ac057cf817_D20220401-20220630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfMi0yLTEtMS0xMjAyNDE_108da141-ec19-4bf5-9dcf-0a9741f029ab">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc3fb9c24a1a42d6a1abed1c7e372f2a_D20210401-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfMi00LTEtMS0xMjAyNDM_e4e738b6-8331-4906-8c93-cd661021a8d3">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4690e57d623418889d484725bb730c7_D20220101-20220630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfMi0yLTEtMS0xMTY3NzE_f67b568d-bf74-416a-9778-987e05e30499">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c4ed7db4b34d4bbdc90c34f51f1caa_D20210101-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfMi00LTEtMS0xMTY3NzE_2b67bc57-b046-4e57-8ba6-69a465514af2">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie919cd08314e401e805d15dfd8c4b7f9_D20220401-20220630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfMy0yLTEtMS0xMjAyNDE_da88e60f-8dea-41d0-b564-eb86a2330d00">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id624e9058a214f69b2edf512f1e9c531_D20210401-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfMy00LTEtMS0xMjAyNDM_ac0fe041-06ce-4fe8-8e3b-82346e3a5b98">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79b44039ced246f8b01d5c45ecee92be_D20220101-20220630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfMy0yLTEtMS0xMTY3NzE_ad739d8a-ae38-46ca-a3db-325ccdc0eecb">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7f366437a554f0881430dd47c95e590_D20210101-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfMy00LTEtMS0xMTY3NzE_b9d14dbd-fd8f-4ede-856a-76d76ae2cda7">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfNC0yLTEtMS0xMjAyNDE_42657412-958e-48cf-b6d9-8dbd3f7ef77d">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfNC00LTEtMS0xMjAyNDM_ee60ce02-3d39-4eb7-a8a3-22a16584b9b1">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfNC0yLTEtMS0xMTY3NzE_af8b9ade-268c-42d2-b244-b2e8041dcc95">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfNC00LTEtMS0xMTY3NzE_5c92d8f6-c107-4525-97c0-9fd5529d0cce">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8324a3a87b5b4431a240a863bcd109e7_D20220401-20220630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfNi0yLTEtMS0xMjAyNDU_a00fd3cf-c7d2-4dd4-8eca-2da8d2ec616b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i162c7abaff6441bcaafdcb7c3786380f_D20210401-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfNi00LTEtMS0xMjAyNDc_722d63da-57da-4eb8-918b-1c7bf0f129f8">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia50d9a9309cc4eeabfd8a0b7ec06cbb9_D20220101-20220630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfNi0yLTEtMS0xMTY3NzE_75096a1c-7ea5-4bb3-91c7-a0baa7fbe8cc">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd76194575be490ba80170f4fdd8bdeb_D20210101-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfNi00LTEtMS0xMTY3NzE_b3bea723-1997-4f71-b330-fa12bf32607c">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c788daa389d46c7ab261260e329fa06_D20220401-20220630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfNy0yLTEtMS0xMjAyNDU_c2b41a77-cc3b-4f15-97a5-4c3fb0c50af7">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2a52a76022341358c404e2fb242b953_D20210401-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfNy00LTEtMS0xMjAyNDc_fa86bb97-17b9-47d2-87db-331bfdfed3f6">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd6d0843d657451284d1138fc8962e1a_D20220101-20220630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfNy0yLTEtMS0xMTY3NzE_c41dda70-6c78-43c9-8139-343fcc363d17">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c50767d19044e08e9feb4b807a2916_D20210101-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfNy00LTEtMS0xMTY3NzE_0b85bd8f-4dcc-427b-a38b-1c001ee240d5">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfOC0yLTEtMS0xMjAyNDU_15e6f0e1-a676-4420-9e62-3ced831457de">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfOC00LTEtMS0xMjAyNDc_877cfe85-2aec-409d-b968-be50c55ffaaf">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfOC0yLTEtMS0xMTY3NzE_97dac505-8655-4d87-bda6-862bc1a0eaac">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfOC00LTEtMS0xMTY3NzE_21c2189f-1e04-4fe5-82e7-0784b7439795">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i014f84240dbd4ce3ad45ca82375d9817"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDUyMQ_80bc7d8f-0169-4ad5-ad6f-1419783aa23b" escape="true"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based awards granted for the six months ended June 30, 2022 and 2021 consist of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch Health Share-Based Awards</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id4690e57d623418889d484725bb730c7_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMi0xLTEtMS0xMTY3NzE_2d6fb243-e071-4a89-985e-b9b1f12694a2">2,570,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41c4ed7db4b34d4bbdc90c34f51f1caa_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMi0zLTEtMS0xMTY3NzE_4aae76d3-d248-4bc8-a2ee-2e61afb92a02">1,466,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id4690e57d623418889d484725bb730c7_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMy0xLTEtMS0xMTY3NzE_39a84018-1b5c-4af7-a57b-a7fe5bafadfe">23.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i41c4ed7db4b34d4bbdc90c34f51f1caa_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMy0zLTEtMS0xMTY3NzE_c92ebda6-f435-41f5-ba69-7428cc444d7d">32.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id4690e57d623418889d484725bb730c7_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfNC0xLTEtMS0xMTY3NzE_ea780b5c-b8a7-4140-a15b-eafa2be154e7">6.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i41c4ed7db4b34d4bbdc90c34f51f1caa_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfNC0zLTEtMS0xMTY3NzE_d139a035-010a-434c-801c-1506ed5a5e31">11.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time-based RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc74e57032d14542b4caf11d925a446c_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfNi0xLTEtMS0xMTY3NzE_d38a60b6-c8f0-49b4-8911-b8f0d5ae495c">2,680,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6dc26b569a743babd2022197af82304_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfNi0zLTEtMS0xMTY3NzE_b7da8077-5719-43ee-9c92-7bb7a0d0096e">2,861,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifc74e57032d14542b4caf11d925a446c_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfNy0xLTEtMS0xMTY3NzE_4c7dae97-3b71-46a9-9e26-1c1bba2ff93f">18.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie6dc26b569a743babd2022197af82304_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfNy0zLTEtMS0xMTY3NzE_3dc0cace-2778-46c5-97ca-36b315f108e0">32.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TSR performance-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i451c05ed9bb34dfd81236d9bd495bdd4_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfOS0xLTEtMS0xMTY3NzE_6528c2f0-fac4-4e1f-adb8-7d050b647b26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i697b06c7bfab4c66b24bd5ee7d182aff_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfOS0zLTEtMS0xMTY3NzE_12f0dcde-191c-4d9c-a2eb-6cb0c71dff17">400,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i451c05ed9bb34dfd81236d9bd495bdd4_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMTAtMS0xLTEtMTE2Nzcx_3d045d91-b7a6-43b9-94ef-8b3d29b0ea22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i697b06c7bfab4c66b24bd5ee7d182aff_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMTAtMy0xLTEtMTE2Nzcx_56da59fb-f913-4382-9485-a4e2ddebf015">56.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROTC performance-based RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icac063b2f1aa4b21b334538c17b2df50_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMTItMS0xLTEtMTE2Nzcx_f3859bd1-a8ac-40e0-b129-5a64174b2a28">369,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i557729c1fe0b4b1480972c1737bd0a7f_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMTItMy0xLTEtMTE2Nzcx_85756cc2-46c6-47b6-bcdb-081acb90329f">413,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icac063b2f1aa4b21b334538c17b2df50_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMTMtMS0xLTEtMTE2Nzcx_41d1a3b1-07fe-4d49-ba8b-8d89c35cbc1f">9.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i557729c1fe0b4b1480972c1737bd0a7f_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMTMtMy0xLTEtMTE2Nzcx_08a1f559-b324-4b52-be71-04cd801573b3">31.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B+L Separation performance-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie92ec71133c44dfc990b249053e5e02b_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMTUtMS0xLTEtMTE2Nzcx_5d283e8c-5325-45b5-8230-96dfa145d40a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iadcde18252cb48d884cbe14183aa9c67_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMTUtMy0xLTEtMTE2Nzcx_861fcef3-3f76-436f-b826-12d9d168c19a">132,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie92ec71133c44dfc990b249053e5e02b_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMTYtMS0xLTEtMTE2Nzcx_77dc22b6-49e1-43ea-86e0-951638665a2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iadcde18252cb48d884cbe14183aa9c67_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMTYtMy0xLTEtMTE2Nzcx_31354c4e-4221-4779-b1cf-a27173ce075a">32.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch+ Lomb Share-Based Awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i68d73c7e5e384257812c2170febe4778_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMjAtMS0xLTEtMTIxNzk0_f42b27d4-6285-4d06-be48-fd7c0eeca745">6,455,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f24f78b6a854ff5ad91cc5ccdd5b4af_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMjAtMy0xLTEtMTIxNzk2_e66f10b1-d590-4fb3-8ea6-85d675483e12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i68d73c7e5e384257812c2170febe4778_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMjEtMS0xLTEtMTIxNzk0_3ec64800-8e95-4ec6-b515-93637d7a9a09">18.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f24f78b6a854ff5ad91cc5ccdd5b4af_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMjEtMy0xLTEtMTIxNzk2_e44b030f-dad0-44e6-bcdc-0a1de62d3e00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i68d73c7e5e384257812c2170febe4778_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMjItMS0xLTEtMTIxNzk0_bedfce7f-ab32-4e77-8bc8-7b20065d19e3">4.55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f24f78b6a854ff5ad91cc5ccdd5b4af_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMjItMy0xLTEtMTIxNzk2_a0b1d757-0600-482a-ab4e-1f34e44afde6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab029c733228479b92d1b8a6e2205965_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMjQtMS0xLTEtMTIxNzk4_f1ca2d36-1562-41c8-8868-4be8596b4ce8">3,207,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd8a8752f1f749c88cde59232457ef50_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMjQtMy0xLTEtMTIxODAw_0f51090c-3155-4c88-8125-97268134449c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iab029c733228479b92d1b8a6e2205965_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMjUtMS0xLTEtMTIxNzk4_bf6ed556-ba91-4055-8095-8cc05613c071">17.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idd8a8752f1f749c88cde59232457ef50_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMjUtMy0xLTEtMTIxODAw_00f75942-8ea4-4baa-8a36-6bb1d425a22d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the remaining unrecognized compensation expenses related to all outstanding non-vested stock options, time-based RSUs and performance-based RSUs under the Amended and Restated 2014 Plan amounted to $<ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDQ0OQ_09271ad4-cb2c-4f01-ad94-972d20d2f8d3">139</ix:nonFraction> million, which will be amortized over a weighted-average period of <ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDUxMQ_a6694321-1f79-452a-98c3-e937d0a72f5a">1.74</ix:nonNumeric> years.</span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the remaining unrecognized compensation expenses related to all outstanding non-vested stock options, time-based RSUs and performance-based RSUs under the B+L Plan amounted to $<ix:nonFraction unitRef="usd" contextRef="i2a344934b62143ffb69252e4cddaf7f0_I20220630" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDM5ODA0NjUyMjA2OQ_648384a3-105c-42a6-a289-d53c6ac73cc2">59</ix:nonFraction>&#160;million, which will be amortized over a weighted-average period of <ix:nonNumeric contextRef="idd08efb021e240aebc5ee605feba929f_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDM5ODA0NjUyMjA4Mg_88d94ed2-acea-4ba6-87b7-e6fee161a5dd">1.77</ix:nonNumeric> years.</span></div></ix:continuation><div id="i762fba229369426294c4424c2015a01a_79"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83OS9mcmFnOjNkYTE3YjEwMzlhOTQ2MDE4Y2E3MjY5NWJhZTIxYmUzL3RleHRyZWdpb246M2RhMTdiMTAzOWE5NDYwMThjYTcyNjk1YmFlMjFiZTNfNDcy_5e6a25f1-41fc-463e-931f-b8ccf8d4cf0b" continuedAt="i056055d77177462c9dadb2c2aa760a5d" escape="true">ACCUMULATED OTHER COMPREHENSIVE LOSS</ix:nonNumeric></span></div><ix:continuation id="i056055d77177462c9dadb2c2aa760a5d"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83OS9mcmFnOjNkYTE3YjEwMzlhOTQ2MDE4Y2E3MjY5NWJhZTIxYmUzL3RleHRyZWdpb246M2RhMTdiMTAzOWE5NDYwMThjYTcyNjk1YmFlMjFiZTNfNDY5_41b248bb-b16a-44eb-8169-a52383c64cb4" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss consists of: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:69.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i720ba0ebf9c2430f814fa6947f648cee_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83OS9mcmFnOjNkYTE3YjEwMzlhOTQ2MDE4Y2E3MjY5NWJhZTIxYmUzL3RhYmxlOjIzOTJkZDRiMTk1ZjQ1NGFiZDBhMjNhNWZlM2RjZmUyL3RhYmxlcmFuZ2U6MjM5MmRkNGIxOTVmNDU0YWJkMGEyM2E1ZmUzZGNmZTJfMS0yLTEtMS0xMTY3NzE_1b052883-d339-492c-81ba-78b87c622788">1,990</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25c764472afe40a994fbab76db8f8203_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83OS9mcmFnOjNkYTE3YjEwMzlhOTQ2MDE4Y2E3MjY5NWJhZTIxYmUzL3RhYmxlOjIzOTJkZDRiMTk1ZjQ1NGFiZDBhMjNhNWZlM2RjZmUyL3RhYmxlcmFuZ2U6MjM5MmRkNGIxOTVmNDU0YWJkMGEyM2E1ZmUzZGNmZTJfMS00LTEtMS0xMTY3NzE_19c2bd0f-fb38-45fd-a911-ccf2bc8d0f03">1,905</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and postretirement benefit plan adjustments, net of income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i488260ae8425453ebec7df5c26c9c934_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83OS9mcmFnOjNkYTE3YjEwMzlhOTQ2MDE4Y2E3MjY5NWJhZTIxYmUzL3RhYmxlOjIzOTJkZDRiMTk1ZjQ1NGFiZDBhMjNhNWZlM2RjZmUyL3RhYmxlcmFuZ2U6MjM5MmRkNGIxOTVmNDU0YWJkMGEyM2E1ZmUzZGNmZTJfMi0yLTEtMS0xMTY3NzE_24ccea8d-1c6a-4e7c-ac38-18a1ebbd445d">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibdc7a899aaa242abbfc3fb10b5125784_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83OS9mcmFnOjNkYTE3YjEwMzlhOTQ2MDE4Y2E3MjY5NWJhZTIxYmUzL3RhYmxlOjIzOTJkZDRiMTk1ZjQ1NGFiZDBhMjNhNWZlM2RjZmUyL3RhYmxlcmFuZ2U6MjM5MmRkNGIxOTVmNDU0YWJkMGEyM2E1ZmUzZGNmZTJfMi00LTEtMS0xMTY3NzE_404fdaac-68e5-4b9a-b345-681ff8465fac">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b5d37c24d0e41cb994b6d343566c79e_I20220630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83OS9mcmFnOjNkYTE3YjEwMzlhOTQ2MDE4Y2E3MjY5NWJhZTIxYmUzL3RhYmxlOjIzOTJkZDRiMTk1ZjQ1NGFiZDBhMjNhNWZlM2RjZmUyL3RhYmxlcmFuZ2U6MjM5MmRkNGIxOTVmNDU0YWJkMGEyM2E1ZmUzZGNmZTJfMy0yLTEtMS0xMTY3NzE_a6365efa-767b-4759-a008-1bb45c85dc59">2,002</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a5f744b0e03413c9fa836c080e97ee8_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83OS9mcmFnOjNkYTE3YjEwMzlhOTQ2MDE4Y2E3MjY5NWJhZTIxYmUzL3RhYmxlOjIzOTJkZDRiMTk1ZjQ1NGFiZDBhMjNhNWZlM2RjZmUyL3RhYmxlcmFuZ2U6MjM5MmRkNGIxOTVmNDU0YWJkMGEyM2E1ZmUzZGNmZTJfMy00LTEtMS0xMTY3NzE_e15d9fd0-8e01-45f4-bfbd-35ba569f3eec">1,924</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company&#8217;s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company&#8217;s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the change in the Company&#8217;s ownership interest in Bausch + Lomb, the carrying amount of accumulated other comprehensive income was adjusted to reflect the change in the ownership interest in Bausch + Lomb through a corresponding credit of $<ix:nonFraction unitRef="usd" contextRef="i0faf02d0dab04ba2a12aed2a72ddb539_D20220401-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83OS9mcmFnOjNkYTE3YjEwMzlhOTQ2MDE4Y2E3MjY5NWJhZTIxYmUzL3RleHRyZWdpb246M2RhMTdiMTAzOWE5NDYwMThjYTcyNjk1YmFlMjFiZTNfNDM5ODA0NjUxMzQ1NA_0098220a-dd76-420a-9400-1f4697defbbb">137</ix:nonFraction>&#160;million to equity attributable to the Company.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i762fba229369426294c4424c2015a01a_82"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84Mi9mcmFnOjQ0MjdhMDc3NjQ2YzRmNTI4YjY3ZWQzMDE4NDI1YmMwL3RleHRyZWdpb246NDQyN2EwNzc2NDZjNGY1MjhiNjdlZDMwMTg0MjViYzBfMjM2_81e044af-f032-42c7-8d17-6df80c01121b" continuedAt="id15b131f70e844649cb14066b6fb0717" escape="true">RESEARCH AND DEVELOPMENT</ix:nonNumeric></span></div><ix:continuation id="id15b131f70e844649cb14066b6fb0717"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. <ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84Mi9mcmFnOjQ0MjdhMDc3NjQ2YzRmNTI4YjY3ZWQzMDE4NDI1YmMwL3RleHRyZWdpb246NDQyN2EwNzc2NDZjNGY1MjhiNjdlZDMwMTg0MjViYzBfMjMz_8cb9616a-2b46-4e93-8b8a-14207a8da998" continuedAt="i7b241f3964e94774872e28a57c6a593b" escape="true">Research and development costs consist of:</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><ix:continuation id="i7b241f3964e94774872e28a57c6a593b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product related research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseProductRelated" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84Mi9mcmFnOjQ0MjdhMDc3NjQ2YzRmNTI4YjY3ZWQzMDE4NDI1YmMwL3RhYmxlOjVkMzJmZTFiN2JkNDRhNjJiOGFlZDQ1ZDZmMWQyNmQ3L3RhYmxlcmFuZ2U6NWQzMmZlMWI3YmQ0NGE2MmI4YWVkNDVkNmYxZDI2ZDdfMi0yLTEtMS0xMTY3NzE_6bb3674e-496a-4f08-a553-c3335f953bb9">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseProductRelated" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84Mi9mcmFnOjQ0MjdhMDc3NjQ2YzRmNTI4YjY3ZWQzMDE4NDI1YmMwL3RhYmxlOjVkMzJmZTFiN2JkNDRhNjJiOGFlZDQ1ZDZmMWQyNmQ3L3RhYmxlcmFuZ2U6NWQzMmZlMWI3YmQ0NGE2MmI4YWVkNDVkNmYxZDI2ZDdfMi00LTEtMS0xMTY3NzE_86a9170c-834c-4fa0-b09e-bea8ebd5384f">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseProductRelated" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84Mi9mcmFnOjQ0MjdhMDc3NjQ2YzRmNTI4YjY3ZWQzMDE4NDI1YmMwL3RhYmxlOjVkMzJmZTFiN2JkNDRhNjJiOGFlZDQ1ZDZmMWQyNmQ3L3RhYmxlcmFuZ2U6NWQzMmZlMWI3YmQ0NGE2MmI4YWVkNDVkNmYxZDI2ZDdfMi02LTEtMS0xMTY3NzE_2d4db56e-4d25-4abe-b255-b15583aa5780">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseProductRelated" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84Mi9mcmFnOjQ0MjdhMDc3NjQ2YzRmNTI4YjY3ZWQzMDE4NDI1YmMwL3RhYmxlOjVkMzJmZTFiN2JkNDRhNjJiOGFlZDQ1ZDZmMWQyNmQ3L3RhYmxlcmFuZ2U6NWQzMmZlMWI3YmQ0NGE2MmI4YWVkNDVkNmYxZDI2ZDdfMi04LTEtMS0xMTY3NzE_8a46a1f6-5721-45fe-912e-d62178ee2457">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseQualityAssurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84Mi9mcmFnOjQ0MjdhMDc3NjQ2YzRmNTI4YjY3ZWQzMDE4NDI1YmMwL3RhYmxlOjVkMzJmZTFiN2JkNDRhNjJiOGFlZDQ1ZDZmMWQyNmQ3L3RhYmxlcmFuZ2U6NWQzMmZlMWI3YmQ0NGE2MmI4YWVkNDVkNmYxZDI2ZDdfMy0yLTEtMS0xMTY3NzE_93e7fe58-64f1-4265-9fa9-b37ce9644806">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseQualityAssurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84Mi9mcmFnOjQ0MjdhMDc3NjQ2YzRmNTI4YjY3ZWQzMDE4NDI1YmMwL3RhYmxlOjVkMzJmZTFiN2JkNDRhNjJiOGFlZDQ1ZDZmMWQyNmQ3L3RhYmxlcmFuZ2U6NWQzMmZlMWI3YmQ0NGE2MmI4YWVkNDVkNmYxZDI2ZDdfMy00LTEtMS0xMTY3NzE_673a2e51-33dc-4654-bc9b-162df899486c">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseQualityAssurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84Mi9mcmFnOjQ0MjdhMDc3NjQ2YzRmNTI4YjY3ZWQzMDE4NDI1YmMwL3RhYmxlOjVkMzJmZTFiN2JkNDRhNjJiOGFlZDQ1ZDZmMWQyNmQ3L3RhYmxlcmFuZ2U6NWQzMmZlMWI3YmQ0NGE2MmI4YWVkNDVkNmYxZDI2ZDdfMy02LTEtMS0xMTY3NzE_382c68a8-2c88-4f21-8077-c94489567ee8">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseQualityAssurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84Mi9mcmFnOjQ0MjdhMDc3NjQ2YzRmNTI4YjY3ZWQzMDE4NDI1YmMwL3RhYmxlOjVkMzJmZTFiN2JkNDRhNjJiOGFlZDQ1ZDZmMWQyNmQ3L3RhYmxlcmFuZ2U6NWQzMmZlMWI3YmQ0NGE2MmI4YWVkNDVkNmYxZDI2ZDdfMy04LTEtMS0xMTY3NzE_fca173df-17b0-42f6-979b-971074f67072">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84Mi9mcmFnOjQ0MjdhMDc3NjQ2YzRmNTI4YjY3ZWQzMDE4NDI1YmMwL3RhYmxlOjVkMzJmZTFiN2JkNDRhNjJiOGFlZDQ1ZDZmMWQyNmQ3L3RhYmxlcmFuZ2U6NWQzMmZlMWI3YmQ0NGE2MmI4YWVkNDVkNmYxZDI2ZDdfNC0yLTEtMS0xMTY3NzE_9dbc4cbc-ce5b-42f1-8a69-60094195ece2">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84Mi9mcmFnOjQ0MjdhMDc3NjQ2YzRmNTI4YjY3ZWQzMDE4NDI1YmMwL3RhYmxlOjVkMzJmZTFiN2JkNDRhNjJiOGFlZDQ1ZDZmMWQyNmQ3L3RhYmxlcmFuZ2U6NWQzMmZlMWI3YmQ0NGE2MmI4YWVkNDVkNmYxZDI2ZDdfNC00LTEtMS0xMTY3NzE_7bf9f4a6-c33f-4271-a1b3-906a87af4b5c">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84Mi9mcmFnOjQ0MjdhMDc3NjQ2YzRmNTI4YjY3ZWQzMDE4NDI1YmMwL3RhYmxlOjVkMzJmZTFiN2JkNDRhNjJiOGFlZDQ1ZDZmMWQyNmQ3L3RhYmxlcmFuZ2U6NWQzMmZlMWI3YmQ0NGE2MmI4YWVkNDVkNmYxZDI2ZDdfNC02LTEtMS0xMTY3NzE_71284e67-a92e-4f03-bf1f-b895ea05438d">254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84Mi9mcmFnOjQ0MjdhMDc3NjQ2YzRmNTI4YjY3ZWQzMDE4NDI1YmMwL3RhYmxlOjVkMzJmZTFiN2JkNDRhNjJiOGFlZDQ1ZDZmMWQyNmQ3L3RhYmxlcmFuZ2U6NWQzMmZlMWI3YmQ0NGE2MmI4YWVkNDVkNmYxZDI2ZDdfNC04LTEtMS0xMTY3NzE_c0f4e492-620a-48ba-9cf5-1e6803516b9e">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i762fba229369426294c4424c2015a01a_85"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RleHRyZWdpb246ZmIzMWE0OTI2NjZjNDA0NmFlYzI0ZGYyODE2NTk3OTRfMTg0_6ee773b7-84a1-42c4-874f-9ed4d943e68c" continuedAt="i52e3a6a2e6a14b9090a305d5e19be7a9" escape="true">OTHER EXPENSE, NET</ix:nonNumeric></span></div><ix:continuation id="i52e3a6a2e6a14b9090a305d5e19be7a9"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RleHRyZWdpb246ZmIzMWE0OTI2NjZjNDA0NmFlYzI0ZGYyODE2NTk3OTRfMTg4_9da40bad-541f-4ab1-abf3-cd33103013a0" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net consists of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfMi0yLTEtMS0xMTY3NzE_a09cb18f-f801-43ba-959d-ec591450f370">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfMi00LTEtMS0xMTY3NzE_12e4bdeb-f7ff-4175-a1bd-0004203d2ac6">532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfMi02LTEtMS0xMTY3NzE_436e184c-3c4d-456f-9dfa-91ec2802e7e7">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfMi04LTEtMS0xMTY3NzE_a1a0114f-abf0-48c2-b491-394ee95718a7">532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfMy0yLTEtMS0xMTY3NzE_2aa2654e-7cd6-491c-b0f1-51183bf8b27c">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfMy00LTEtMS0xMTY3NzE_39f10095-dc32-4b23-89a5-476309619af0">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfMy02LTEtMS0xMTY3NzE_e50f58a5-dea5-43d2-9a65-e15b9d2e02ca">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfMy04LTEtMS0xMTY3NzE_4497e3cd-718e-4d44-b14b-dbb883664c3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNC0yLTEtMS0xMTY3NzE_4b55f6e8-7ac8-4d95-8654-e26255a171bb">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNC00LTEtMS0xMTY3NzE_d2ea90f5-df73-463f-8c77-b8e78b0d6c92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNC02LTEtMS0xMTY3NzE_80a47af6-bab3-4ab5-98a5-375b0e357f36">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNC04LTEtMS0xMTY3NzE_8e3f9498-a069-4f2a-890b-53a060107584">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNS0yLTEtMS0xMTY3NzE_aa23b410-ca45-4537-ae32-e23807de6579">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNS00LTEtMS0xMTY3NzE_e4b4bb2e-7aff-4776-a77f-37bd90886230">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNS02LTEtMS0xMTY3NzE_ca019d33-a6c9-463a-a4ab-abada5810eb3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNS04LTEtMS0xMTY3NzE_c189f441-1f0c-418c-9125-bb84203dd09b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, Net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" sign="-" name="bhc:OtherIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNi0yLTEtMS0xMzAyODM_593f3fb2-5756-4ba9-9fb2-75bfd8d995fe">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="bhc:OtherIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNi00LTEtMS0xMzAyODM_267e93a7-cb18-46ff-9b63-5195708bf973">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="bhc:OtherIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNi02LTEtMS0xMzAyOTY_e7e31749-063a-45e5-8e3f-57aa2e18adb7">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="bhc:OtherIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNi04LTEtMS0xMzAyOTY_c923a648-c182-4e5b-bb35-ec805aaf7d70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNi0yLTEtMS0xMTY3NzE_b3f37eb3-5a02-4986-8d05-37d01127f9a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNi00LTEtMS0xMTY3NzE_75b7f2a0-71b1-4b8f-8852-1b7399d898d2">542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNi02LTEtMS0xMTY3NzE_1e1deec3-03ca-4c8d-aa23-6f4ba0e32cb5">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNi04LTEtMS0xMTY3NzE_60168dbf-70e8-463b-96ea-b4907baf58bc">512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of assets, net for the six months ended June 30, 2021, includes $<ix:nonFraction unitRef="usd" contextRef="ib81ba7780e6c4af981ed3d93789a7a30_D20210101-20210630" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RleHRyZWdpb246ZmIzMWE0OTI2NjZjNDA0NmFlYzI0ZGYyODE2NTk3OTRfMTA3_91dd3738-5d61-4bc5-ab6c-4c899f7a5a45">25</ix:nonFraction>&#160;million related to the achievement of a milestone related to a certain product.</span></div></ix:continuation><div id="i762fba229369426294c4424c2015a01a_88"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfNzc3NQ_1ff392c0-e648-494e-ba41-6151751e6f08" continuedAt="i92f36984680047fe8f9a1d618aa431f4" escape="true">INCOME TAXES </ix:nonNumeric></span></div><ix:continuation id="i92f36984680047fe8f9a1d618aa431f4" continuedAt="i6dc9ed166e5c4c15a85c2ebcddfaddf0"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For interim financial statement purposes, U.S. GAAP income tax expense/benefit related to ordinary income is determined by applying an estimated annual effective income tax rate against a company&#8217;s ordinary income. Income tax expense/benefit related to items not characterized as ordinary income is recognized as a discrete item when incurred. The estimation of the Company&#8217;s income tax provision requires the use of management forecasts and other estimates, application of statutory income tax rates, and an evaluation of valuation allowances. The Company&#8217;s estimated annual effective income tax rate may be revised, if necessary, in each interim period.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Benefit from income taxes for the six months ended June 30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfNzA2_416f30b3-9a64-4644-a285-a8b8bba4ace0">6</ix:nonFraction> million and included: (i) $<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfNzI3_f8ccd1ef-6be3-45a8-9c92-1bb29e3709a3">16</ix:nonFraction>&#160;million of income tax expense for the Company&#8217;s ordinary loss for the six months ended June 30, 2022 and (ii) $<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfODA0_9618e443-288a-4f92-973b-67f7ea9af17d">22</ix:nonFraction> million of net income tax benefit for discrete items, which includes: (a) $<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationTaxContingencies" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfODcz_08432671-2606-476b-bc66-af4eeb890c26">39</ix:nonFraction>&#160;million of net income tax benefit recognized for changes in uncertain tax positions and (b) a $<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="bhc:EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfOTc3_939d8797-e807-4e87-9b3b-7784bd3b2957">16</ix:nonFraction>&#160;million tax provision associated with filing certain tax returns.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefit from income taxes for the six months ended June 30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfMTA2OQ_13d3a34e-9e11-4829-83ec-d9a6b17f2c12">61</ix:nonFraction> million and included: (i) $<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfMTA5MA_e6a0e4f3-1c26-414b-a786-4b2f2fcb93f4">50</ix:nonFraction> million of income tax benefit for the Company&#8217;s ordinary loss for the six months ended June 30, 2021 and (ii) $<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfNDM5ODA0NjUxOTY5Nw_7a3ba589-ece2-43b3-b96f-aa2b00611b5a">11</ix:nonFraction>&#160;million of net income tax provision for discrete items, which includes: (a) a $<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="bhc:EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfMTE2Mw_d211c3ec-e361-42cf-b9d1-9b59da299fa0">54</ix:nonFraction>&#160;million of net income tax benefit associated with certain legal settlements, (b) a $<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="bhc:EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfNDM5ODA0NjUxOTcxMA_71af2cff-0adf-4c6d-ad69-4b500d9fb526">46</ix:nonFraction>&#160;million tax provision related to potential and recognized withholding tax on intercompany dividends, (c) a $<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfMTI2NQ_73936c75-0377-4e97-bed1-95cd97186285">7</ix:nonFraction>&#160;million tax benefit related to a deduction for stock compensation and (d) a $<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="bhc:EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfNDM5ODA0NjUxOTcyMw_74780f33-7c3e-4645-a28c-d2653492ff7b">4</ix:nonFraction>&#160;million tax provision associated with the filing of certain tax returns. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made. The valuation allowance against deferred tax assets was $<ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfMjIyOQ_ccea87ff-d07f-4ddd-8f25-a3c98a1ded68">2,277</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfMjIzNg_77fc97e6-9571-42d3-8331-439ecb27dad3">2,222</ix:nonFraction> million as of June&#160;30, 2022 and December&#160;31, 2021, respectively. The increase was primarily due to losses in Canada. The Company will continue to assess the need for a valuation allowance on an ongoing basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8, 2021, the Organisation for Economic Co-operation and Development (&#8220;OECD&#8221;)/G20 inclusive framework on Base Erosion and Profit Shifting (the &#8220;Inclusive Framework&#8221;) published a statement updating and finalizing the key </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i6dc9ed166e5c4c15a85c2ebcddfaddf0"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">components of a two-pillar plan on global tax reform originally agreed on July 1, 2021, and a timetable for implementation by 2023. The timetable for implementation has since been extended to 2024. The Inclusive Framework plan has now been agreed to by 141 OECD members, including several countries which did not agree to the initial plan. Under pillar one, taxing rights over multinational businesses with global turnover above &#8364;20 billion and a profit margin above 10% will generally be re-allocated to market jurisdictions. Under pillar two, the Inclusive Framework has agreed on a global minimum corporate tax rate of 15% for companies with revenue above &#8364;750 million, calculated on a country-by-country basis. On October 30, 2021, the G20 formally endorsed the new global minimum corporate tax rate rules. The Inclusive Framework agreement must now be implemented by the OECD Members who have agreed to the plan, effective in 2023. On December 20, 2021, the OECD published model rules to implement the pillar two rules, which are generally consistent with agreements reached by the Inclusive Framework in October 2021. Some further guidance on the plan and rules has been published, with additional guidance expected to be published in 2023. The Company will continue to monitor the implementation of the Inclusive Framework agreement by the countries in which we operate. While the Company is unable to predict when and how the Inclusive Framework agreement will be enacted into law in these countries, it is possible that the implementation of the Inclusive Framework agreement, including the global minimum corporate tax rate could have a material effect on the Company&#8217;s liability for corporate taxes and the Company&#8217;s consolidated effective tax rate. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December&#160;31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfNDMwMQ_c949fd5e-7b2d-41ab-89db-452eb2518add">840</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfNDMwOA_3b9ea76a-54b9-4dae-9edf-8b1a93514c60">927</ix:nonFraction> million of unrecognized tax benefits, which included $<ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfNDM1Ng_6457c059-7e04-4daf-9d4d-9912fd76ffe0">44</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfNDM2Mw_ddc03417-4529-4fcf-9f28-c7a732905909">41</ix:nonFraction> million of interest and penalties, respectively. Of the total unrecognized tax benefits as of June&#160;30, 2022, $<ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfNDQ1Ng_d3d07bb1-8c8c-462a-a014-b1385f6cad20">179</ix:nonFraction> million would reduce the Company&#8217;s effective tax rate, if recognized. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits at June&#160;30, 2022 could decrease by approximately $<ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfNDY2Mg_6ef876a2-6466-4ae2-896e-1cd2a3e8736d">14</ix:nonFraction> million in the next 12 months as a result of the resolution of certain tax audits and other events.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to be under examination by the Canada Revenue Agency. The Company&#8217;s position as of June&#160;30, 2022 with regard to proposed audit adjustments was updated to reflect an updated assessment received for 2015 which would primarily result in a loss of tax attributes that are subject to a full valuation allowance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company undertook an internal restructuring in the form of what is commonly known as a Granite Trust transaction, which resulted in a recorded capital loss (the &#8220;2017 capital loss&#8221;). In the U.S., the 2014 tax year remains open to the extent of the portion of the 2017 capital loss carried back to that year. The Internal Revenue Service (&#8220;IRS&#8221;) is continuing its examination of the Company&#8217;s annual tax filings for 2015 and 2016 and the Company&#8217;s short period tax return for the period ended September 8, 2017, which was filed as a result of the Company&#8217;s internal restructuring efforts during 2017. In 2021, the Company received a notice of proposed adjustment from the IRS that would disallow the 2017 capital loss. The Company intends to contest any proposed tax deficiency through the IRS administrative appeals process, and if necessary, appropriate litigation. If the Company were ultimately unsuccessful in defending its position, and all or a substantial portion of the 2017 capital loss deduction were disallowed, the Company estimates, in a worst-case scenario, that it could be liable for additional income taxes (excluding penalties and interest) of up to $<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfNjM4Ng_964e858b-ae12-44a9-9fda-2e9dc8d78ff6">2,100</ix:nonFraction>&#160;million, which could have an adverse effect on the Company&#8217;s financial condition and results of operations. The Company intends to vigorously defend its position, including through appropriate litigation, if necessary, and ultimately believes it will sustain its deduction of the 2017 capital loss, and, accordingly, no income tax provision has been recorded. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2015 through 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries in Germany are under audit for tax years 2014 through 2016. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#8217;s Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company settled its audit with the Australian Taxation Office for various years beginning in 2011 through 2017 with no material adjustments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain affiliates of the Company in regions outside of Canada, the U.S., Germany and Australia are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#8217;s Consolidated Financial Statements.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i762fba229369426294c4424c2015a01a_91"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RleHRyZWdpb246MzU4MWUyYzAzNWE5NDVmOGFkNDJhZGIwMTc4MTAwNGNfOTY0_1d2a2287-7033-48e9-b56e-0d7456270ab0" continuedAt="i7c8ed9589a6348d1b4a408dbbebbeefc" escape="true">LOSS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i7c8ed9589a6348d1b4a408dbbebbeefc" continuedAt="i06448bd672684d9184721c7cd81c77bc"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RleHRyZWdpb246MzU4MWUyYzAzNWE5NDVmOGFkNDJhZGIwMTc4MTAwNGNfOTYx_8f2460d7-6714-4339-a3ad-6ac59216dd9b" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share attributable to Bausch Health Companies Inc. were calculated as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.977%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.575%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfMi0xLTEtMS0xMTY3NzE_fdcb755b-b8d7-43eb-afb3-5324abaf372b">145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfMi0zLTEtMS0xMTY3NzE_6ec4e541-60ea-47a2-9ee6-91260de85c51">595</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfMi01LTEtMS0xMTY3NzE_b62f4ba4-306b-4bc2-8d47-76dd85df3344">214</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4bd722a099c434c96732e1638d0eef9_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfMi03LTEtMS0xMTY3NzE_39538422-44d3-4314-bf14-91c29e1af5ed"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfMi03LTEtMS0xMTY3NzE_ce9cc730-46dc-4484-b836-fab046e2159f">1,205</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfMy0xLTEtMS0xMTY3NzE_3d856aa6-170a-4ffe-b302-9769db5dfec9"><ix:nonFraction unitRef="shares" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfMy0xLTEtMS0xMTY3NzE_9641a01e-051d-4ebe-86b5-6c7e5d9b8a5e">362.2</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfMy0zLTEtMS0xMTY3NzE_0e735f3f-38c7-4f88-982d-c539356f7eeb"><ix:nonFraction unitRef="shares" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfMy0zLTEtMS0xMTY3NzE_55194c8f-ea06-4c98-9298-a7f78d9f03c4">359.1</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfMy01LTEtMS0xMTY3NzE_1189b2fe-8ce8-4805-83e9-4426af4badf4"><ix:nonFraction unitRef="shares" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfMy01LTEtMS0xMTY3NzE_50c56646-02e7-4ac0-a842-c089656bec94">361.5</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfMy03LTEtMS0xMTY3NzE_7bad3fef-e6f1-4b42-945d-48da57025ff2"><ix:nonFraction unitRef="shares" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfMy03LTEtMS0xMTY3NzE_d87b09cc-e1da-4796-9cc5-866df4e19191">358.0</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to Bausch Health</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Companies Inc.</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfNy0xLTEtMS0xMTY3NzE_265ff4c3-528e-46a9-825e-7224c3c45718"><ix:nonFraction unitRef="usdPerShare" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfNy0xLTEtMS0xMTY3NzE_9cb90fc5-b0ab-44c2-bd7a-caeeb5a4b82f">0.40</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfNy0zLTEtMS0xMTY3NzE_2cdeda4b-46b6-4bef-a17a-7faac1a766ff"><ix:nonFraction unitRef="usdPerShare" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfNy0zLTEtMS0xMTY3NzE_4f6e992a-5796-469f-8860-200a94372aa2">1.66</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfNy01LTEtMS0xMTY3NzE_04b936c4-5ce7-4780-aae9-48ca049ea687"><ix:nonFraction unitRef="usdPerShare" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfNy01LTEtMS0xMTY3NzE_ec2ad1d5-0e9f-4569-a10e-d11f55843f6c">0.59</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfNy03LTEtMS0xMTY3NzE_0365dda3-80f9-4b69-9099-b0f4ad685600"><ix:nonFraction unitRef="usdPerShare" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfNy03LTEtMS0xMTY3NzE_53ac96a1-7d4f-4861-99f2-521b57f21ebc">3.37</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2022 and 2021, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately <ix:nonFraction unitRef="shares" contextRef="ib67e20cff1f34666a7bda60fe85e0092_D20220401-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RleHRyZWdpb246MzU4MWUyYzAzNWE5NDVmOGFkNDJhZGIwMTc4MTAwNGNfNDMx_962f85b0-7352-4d34-9737-0b51cf0b0272">1,184,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="icb9c38f8768a42babfa04ab70b2ba49b_D20210401-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RleHRyZWdpb246MzU4MWUyYzAzNWE5NDVmOGFkNDJhZGIwMTc4MTAwNGNfNDM4_1b784ce0-620a-4c94-b153-a6c0acf95931">4,558,000</ix:nonFraction> common shares for the three months ended June 30, 2022 and 2021, respectively, and approximately <ix:nonFraction unitRef="shares" contextRef="i7c6c606001c0400cac53065471f71ff1_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RleHRyZWdpb246MzU4MWUyYzAzNWE5NDVmOGFkNDJhZGIwMTc4MTAwNGNfNzE0NjgyNTU4MTY2Nw_149401fe-6d1f-46b0-af44-8327c954a5e1">2,392,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ib34295b40b53420292196a9f2aa2100a_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RleHRyZWdpb246MzU4MWUyYzAzNWE5NDVmOGFkNDJhZGIwMTc4MTAwNGNfNzE0NjgyNTU4MTY1MA_2e3d3e63-6795-4451-b89f-528682e52cb8">5,608,000</ix:nonFraction> common shares for the six months ended June 30, 2022 and 2021, respectively.</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i06448bd672684d9184721c7cd81c77bc">During the three and six months ended June 30, 2022, time-based RSUs, performance-based RSUs and stock options to purchase approximately <ix:nonFraction unitRef="shares" contextRef="ib34421622cb84c04846df6c8e22ebbed_D20220401-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RleHRyZWdpb246MzU4MWUyYzAzNWE5NDVmOGFkNDJhZGIwMTc4MTAwNGNfNTgw_1d9f66e9-f4d7-4542-a4ce-1d5d9465f31b">15,372,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i3b78053555ef422d9b068388d75f6068_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RleHRyZWdpb246MzU4MWUyYzAzNWE5NDVmOGFkNDJhZGIwMTc4MTAwNGNfNTg3_4f7cce33-636f-48e3-b76d-69a24f7f0e61">13,771,000</ix:nonFraction> common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During the three and six months ended June 30, 2021, time-based RSUs, performance-based RSUs and stock options to purchase approximately <ix:nonFraction unitRef="shares" contextRef="i5d86e8e57d7e44a4bdcd3c9f0a800e7d_D20210401-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RleHRyZWdpb246MzU4MWUyYzAzNWE5NDVmOGFkNDJhZGIwMTc4MTAwNGNfNzE0NjgyNTU4MjA4Mw_8bb48755-4dfe-4db1-ad82-1968133fee20">3,929,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="if9065eee32f34d6fa02a0d1a52cb32c9_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RleHRyZWdpb246MzU4MWUyYzAzNWE5NDVmOGFkNDJhZGIwMTc4MTAwNGNfNzE0NjgyNTU4MjEwOQ_c55abcbc-2e90-4e6d-84f8-1448ab299929">4,110,000</ix:nonFraction> common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During the three months ended June 30, 2022, an additional <ix:nonFraction unitRef="shares" contextRef="ie62c44e3a5424b748e2e6a9534f2057c_D20220401-20220630" decimals="-3" name="bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RleHRyZWdpb246MzU4MWUyYzAzNWE5NDVmOGFkNDJhZGIwMTc4MTAwNGNfNzk3_265b33bc-ddcf-458b-b81f-c39824d787fd"><ix:nonFraction unitRef="shares" contextRef="ie62c44e3a5424b748e2e6a9534f2057c_D20220401-20220630" decimals="-3" name="bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RleHRyZWdpb246MzU4MWUyYzAzNWE5NDVmOGFkNDJhZGIwMTc4MTAwNGNfNzk3_ea6fd886-f28e-4256-afc9-244ea2bf6738">156,000</ix:nonFraction></ix:nonFraction> performance-based RSUs were not included in the computation of diluted earnings per share as the required performance conditions had not been met.</ix:continuation> </span></div><div id="i762fba229369426294c4424c2015a01a_94"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNTM4NzA_c178d63d-4e48-4459-bdfd-08f4f1458956" continuedAt="ie8e9e144d9524b18aa298e58f8dba10e" escape="true">LEGAL PROCEEDINGS</ix:nonNumeric></span></div><ix:continuation id="ie8e9e144d9524b18aa298e58f8dba10e" continuedAt="i42cb17a3ea0c431db726fc2eec962a30"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC and the CSA on February 23, 2022. Except as described below, there have been no material updates or developments with respect to any such proceedings or actions during the six months ended June 30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued. As of June 30, 2022, the Company&#8217;s Consolidated Balance Sheets includes accrued current loss contingencies of $<ix:nonFraction unitRef="usd" contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630" decimals="-6" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTM2Ng_74d2bd22-940d-41f9-96f4-09b8e245e46f">1,536</ix:nonFraction> million related to matters which are both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company&#8217;s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental and Regulatory Inquiries</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above, during the three months ended June 30, 2022, there have been no material updates or developments with respect to certain other proceedings or actions as described under &#8220;Governmental and Regulatory Inquiries&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC and the CSA on February 23, 2022. These matters include:</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i42cb17a3ea0c431db726fc2eec962a30" continuedAt="i7ead560ad7db48c9ae33b289ab7bd87e"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation by the U.S. Attorney&#8217;s Office for the District of Massachusetts - re OraPharma</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company received a subpoena from the U.S. Attorney&#8217;s Office for the District of Massachusetts, requesting materials including documents concerning the sales, marketing, coverage and reimbursement of Arestin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including related support services, and other matters. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is cooperating with this investigation. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities and RICO Class Actions and Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation - Opt-Out Litigation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658). On January 31, 2021, the District Court issued an order granting final approval of this settlement. On February 4, 2021, Timber Hill LLC (&#8220;Timber Hill&#8221;) filed a notice of appeal of the Court&#8217;s final approval order, which overruled its objections to the allocation of settlement proceeds as between common stock and options. On March 1, 2021, Cathy Lochridge filed a notice of appeal of the Court&#8217;s final approval order, which overruled her objections as to the attorneys&#8217; fees awarded to class counsel. On October 14, 2021, Timber Hill dismissed its appeal of the final approval order. On December 20, 2021, the Third Circuit denied Lochridge&#8217;s appeal. On January 3, 2022, Lochridge filed a petition for rehearing of the appeal en banc. On May 12, 2022, the Third Circuit denied Lochridge&#8217;s petition for rehearing en banc. The deadline for Lochridge to file a petition for a writ of certiorari with the U.S. Supreme Court is August 10, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2015, <ix:nonFraction unitRef="case" contextRef="i30507c6e944f444ebabb56848a53aea3_D20151001-20151031" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNDI0MQ_5e28abd5-12f3-4905-8f7d-9f9f81ec4bb7">four</ix:nonFraction> putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#8217;s business and prospects, including relating to drug pricing, the Company&#8217;s use of specialty pharmacies, and the Company&#8217;s relationship with Philidor Rx Services, LLC (&#8220;Philidor&#8221;). On May 31, 2016, the court entered an order consolidating the <ix:nonFraction unitRef="case" contextRef="i30507c6e944f444ebabb56848a53aea3_D20151001-20151031" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNDc4Mg_4fd37d49-fc2a-4f1c-a337-b62a56b6dd8e">four</ix:nonFraction> actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658. On December 16, 2019, the Company, the current or former officers and directors, ValueAct, and the underwriters announced that they agreed to resolve the securities action for $<ix:nonFraction unitRef="usd" contextRef="ie30ec1de778c473aa24992db460e51ab_D20191216-20191216" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNTA4Mg_69865adc-a65d-4fb9-a376-2160fe315ad2">1,210</ix:nonFraction> million, subject to final court approval. This settlement received final approval from the court on January 31, 2021 and will resolve and discharge all claims against the Company in the class action. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. The settlement remains subject to appeal of the final court approval (as such appeal is further described above). In order to qualify for a settlement payment all persons and entities that purchased or otherwise acquired the Company securities during the class period must have submitted a proof of claim and release form by May 6, 2020. The settlement payments have been paid into an escrow account in accordance with the payment schedule outlined in the settlement agreement. These payments, less certain settlement expenses and attorneys&#8217; fees, will remain in escrow until resolution of the appeal of the final court approval of the settlement agreement. The opt-out litigations discussed below remain ongoing. As of June 30, 2022, Restricted cash and other settlement deposits includes an aggregate $<ix:nonFraction unitRef="usd" contextRef="i74040cd3e59640bf9752be2e23b0ac69_D20220630-20220630" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNjI0NA_29fd8a47-6897-47f5-8faf-531cb436ba68">1,210</ix:nonFraction>&#160;million of: (i) payments in the escrow fund and (ii) certain disbursements for settlement expenses and attorney&#8217;s fees. Disbursements for attorney&#8217;s fees remain refundable until resolution of the appeal of the final court approval of the settlement agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 18-cv-10246), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company&#8217;s common stock during the period January 4, 2013 through August 11, 2016. On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 15-cv-07658). On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the consolidated putative class action, <ix:nonFraction unitRef="group" contextRef="i4102d9065afe4932a90e498521bfa3cb_D20220101-20220630" decimals="INF" name="bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNzYxNg_3536b414-9086-4ca5-a293-f59d0c97557f">thirty-seven</ix:nonFraction> groups of individual investors in the Company&#8217;s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. These actions were captioned previously in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on February 23, 2022. <ix:nonFraction unitRef="case" contextRef="i4102d9065afe4932a90e498521bfa3cb_D20220101-20220630" decimals="INF" name="us-gaap:LossContingencyClaimsDismissedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfODA2OQ_ebd0fa9f-3d2d-443b-821f-851b374233fb">Sixteen</ix:nonFraction> of the <ix:nonFraction unitRef="group" contextRef="i4102d9065afe4932a90e498521bfa3cb_D20220101-20220630" decimals="INF" name="bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfODA3OQ_3536b414-9086-4ca5-a293-f59d0c97557f">thirty-seven</ix:nonFraction> opt-out actions have been dismissed; and the total number of remaining opt-out actions pending in the District of New Jersey is <ix:nonFraction unitRef="group" contextRef="i4102d9065afe4932a90e498521bfa3cb_D20220101-20220630" decimals="INF" name="bhc:LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfODIxMA_7ef32d51-0696-498e-a1e2-fca20ba7facb">twenty-one</ix:nonFraction> actions.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i7ead560ad7db48c9ae33b289ab7bd87e" continuedAt="i9a440dc65b7f456784a2fc4cb10d4827"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These individual shareholder actions assert claims under Sections 10(b), and 20(a) of the Exchange Act. Certain of these individual actions assert additional claims, including claims under Section 18 of the Exchange Act, Sections 11, 12(a)(2), and 15 of the Securities Act, common law fraud, negligent misrepresentation, and claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act. These claims are based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss were filed in many of these individual actions and the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud, and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) opt-out action, closing the case. On September 10, 2019, the Court granted defendants&#8217; motion to dismiss all claims in the Bahaa Aly v. Valeant Pharmaceuticals International, Inc. (&#8220;Aly&#8221;) (Case No. 18-cv-17393) opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. On June 16, 2021, the Court of Appeals granted plaintiffs&#8217; appeal in the Aly action. This action has been remanded to the District Court. On June 19, 2020, the Court entered stipulations of voluntary dismissal in the Catalyst, Mississippi, Connecticut, and Delaware actions. On July 13, 2020, the Court entered a stipulation of voluntary dismissal in the NYCERS action. On December 30, 2020, the Court entered a stipulation of voluntary dismissal in the BlueMountain action. On February 18, 2021, and March 10, 2021, the Court entered stipulations of voluntary dismissal in the T. Rowe, BloombergSen, Principal Funds, Pentwater, Lord Abbett, Equity Trustees, and UC Regents actions. On April 30, 2021, the Court entered a stipulation of voluntary dismissal in the Florida SBA action. On July 20, 2021, the Court entered a stipulation of voluntary dismissal in the Janus action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery in the opt-out actions has concluded. Motions for summary judgment were filed on August 1, 2022 but have not yet been fully briefed. Trial dates have not been set in any of the opt-out actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it in the remaining individual opt-out complaints and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canadian Securities Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, <ix:nonFraction unitRef="case" contextRef="ib9028ff993434533b2b5623750bbd556_D20150101-20151231" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTA3NTg_3fae8ff6-5565-4305-a5d0-dabc101cf9ac">six</ix:nonFraction> putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec. The Company is also aware of <ix:nonFraction unitRef="action" contextRef="i5274caaee15944b38fc2385088096f35_D20220101-20220630" decimals="INF" name="bhc:LossContingencyNewClaimsFiledButNotYetServedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTA5NzY_af1c1cdf-b0fc-4d92-ba97-456b9e8cd57f">two</ix:nonFraction> additional putative class actions that were filed with the applicable court but which have not been served on the Company and the factual allegations made in these actions are substantially similar to those outlined herein. These actions were captioned previously in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on February 23, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these putative class actions, other than the Catucci action in the Quebec Superior Court, was discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec Securities Act and authorized the class proceeding. On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a hearing on November 11, 2019, the court approved a settlement in the Catucci action between the class members and the Company&#8217;s auditors and the action was dismissed as against them. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2020, the Company entered into a settlement agreement with the plaintiffs in Catucci, on behalf of the class, pursuant to which it agreed to resolve the Catucci action for the amount of CAD <ix:nonFraction unitRef="cad" contextRef="icb691d8ec4ac4d71aee1342723827741_D20200804-20200804" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTI1Mzk_20ed8e8d-29d5-449d-a870-2efe4bc5f965">94,000,000</ix:nonFraction> plus payment of an additional amount to cover notice and settlement administration costs and disbursements. As part of the settlement, the Company and the other defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. Court approval of the settlement was granted after a hearing on November 16, 2020. The Catucci action has now been dismissed against the Company, its current and former directors and officers, its underwriters and its insurers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action. On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i9a440dc65b7f456784a2fc4cb10d4827" continuedAt="ibfa889742a734dba8823f1152b77f086"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, <ix:nonFraction unitRef="entity" contextRef="i757e35cf9f3d40a4b5c93f8ca62f5f21_I20190215" decimals="INF" name="bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTM5NjM_60f54884-00c7-45f6-ad89-204b378b24eb">one</ix:nonFraction> of the entities which exercised its opt-out rights, the California State Teachers&#8217; Retirement System (&#8220;CalSTRS&#8221;), served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers&#8217; Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt-out proceedings. On that same date, CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2020, the Quebec Superior Court granted the applications of CalSTRS and BlackRock for leave to pursue their respective actions asserting claims under the Quebec Securities Act. On June 16, 2020, the Quebec Court of Appeal granted the defendants leave to appeal that decision. The appeal was heard on September 29, 2021 and, by judgment dated October 29, 2021, the appeals were dismissed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8 and 9, 2020, respectively, CalSTRS amended its proceedings to, among other things, include a new alleged misrepresentation concerning the accounting treatment of &#8220;price appreciation credits&#8221; in respect of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the period covered by the claims. A hearing was held on February 17, 2021 with respect to whether CalSTRS would be permitted to file the proposed amended proceedings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2021, the Quebec Superior Court granted the Company&#8217;s application to strike the new allegations from its Quebec Securities Act claim, but permitted the amendments to its claim under the Quebec Civil Code. On December 8, 2021, CalSTRS delivered its amended pleadings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2021, <ix:nonFraction unitRef="entity" contextRef="iaf7e31cd823147eabf32516dee47b2d9_I20210317" decimals="INF" name="bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTU5NDk_c570bfa3-3102-40f1-a7e0-80b4cc25503a">four</ix:nonFraction> additional opt-outs from the Catucci class issued a Statement of Claim in the Ontario Superior Court of Justice. That proceeding is captioned The Bank of Korea et al. v. Valeant Pharmaceuticals International Inc. et al. (Court File No. 21-006589666-0000). In addition, these plaintiffs also served and filed a motion for leave to pursue claims under the Ontario Securities Act. The allegations in this proceeding are similar to those made by the plaintiffs in the Catucci class action and the plaintiffs in the opt-out actions described above. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Securities and RICO Class Actions and Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above, during the three months ended June 30, 2022, there have been no material updates or developments with respect to certain other proceedings or actions as described under &#8220;Securities and RICO Class Actions and Related Matters&#8221; in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC and the CSA on February 23, 2022. Such matters include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RICO Class Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between May 27, 2016 and September 16, 2016, <ix:nonFraction unitRef="action" contextRef="i5d58819753a6484caa4ffdf910353903_D20160527-20160916" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTY2OTk_83a49df5-c5bf-4ce9-afb6-8b64aca5ecd9">three</ix:nonFraction> actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties (these actions were subsequently consolidated), alleging claims under the federal Racketeer Influenced Corrupt Organizations Act (&#8220;RICO&#8221;) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company-branded drugs between January 2, 2013 and November 9, 2015.&#160;The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding: (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured&#8217;s consent to renew the prescription.&#160;The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute.&#160;On August 4, 2021, the Company executed a stipulation of settlement for this action and, on August 17, 2021, the Court preliminarily approved the settlement. On December 6, 2021 the Special Master overseeing this litigation issued a report and recommendation recommending final approval of the settlement, and on February 22, 2022 the settlement was approved by the district court. The time to appeal the district court&#8217;s final approval order expired on March 24, 2022, and the settlement has resolved and discharged all claims against the Company in this action. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Coverage Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during <ix:nonFraction unitRef="insurance_policy_period" contextRef="i4305560891084775b5a8f280c90557dd_D20171207-20171207" decimals="INF" name="bhc:LossContingencyNumberOfInsurancePolicyPeriods" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTkxNTU_d32ffc72-8e69-45be-bcb2-e2bcc772b693">two</ix:nonFraction> distinct policy periods, (i) 2013-14 and (ii) 2015-16. The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; Case No. 3:18-CV-00493). </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="ibfa889742a734dba8823f1152b77f086" continuedAt="ib4f18396ce76411ea530b5ee8fe7dd5d"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the lawsuit, the Company seeks coverage for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (the &#8220;Allergan Securities Litigation&#8221;) (under the 2013-2014 coverage period) and (ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and the SEC Investigation and certain of the other investigations described under &#8220;Complete or Inactive Matters&#8221; in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021 and under &#8220;Governmental and Regulatory Inquiries&#8221; and &#8220;Complete or Inactive Matters&#8221; in Note 21, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC and the CSA on February 19, 2020 (under the 2015-2016 coverage period).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021, the Company entered into settlement agreements with the insurers in the 2015-2016 coverage period in which the Company agreed to resolve its claims for insurance coverage in connection with the U.S. Securities Litigation and the Canadian Securities Litigation and related opt-out litigation and related investigations matters described above. On that same day, the Company entered into settlement agreements with <ix:nonFraction unitRef="insured" contextRef="i74c5348c904e49149ebdc8edaa5089a9_I20210720" decimals="INF" name="bhc:LossContingencySettlementAgreementsNumberOfInsurers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMjExMjY_7b61bb05-d121-468b-962b-7d96aae65aea">two</ix:nonFraction> of its insurers in the 2013-2014 coverage period in which the Company agreed to resolve its claims against those <ix:nonFraction unitRef="insured" contextRef="i74c5348c904e49149ebdc8edaa5089a9_I20210720" decimals="INF" name="bhc:LossContingencySettlementAgreementsNumberOfInsurers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMjEyNDI_5214f792-e4f1-42f2-bec4-53c336d66d16">two</ix:nonFraction> insurers only for insurance coverage in connection with the Allergan Securities Litigation. As a result of all of the settlement agreements entered into with the insurers on July 20, 2021, the Company has received an aggregate sum of $<ix:nonFraction unitRef="usd" contextRef="iddba8dcdaa5c416aba241e33eece7d94_D20210720-20210720" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMjE0Nzk_a0c7cdee-c6ae-4df7-a93f-83b15c637a10">213</ix:nonFraction>&#160;million. The Company&#8217;s insurance claims with respect to the Allergan Securities Litigation against the remaining insurers in the 2013-2014 coverage period remain pending.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Hound Partners Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP, and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County that asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. The Company disputes the claims and intends to vigorously defend this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between August 2019 and July 2020, <ix:nonFraction unitRef="case" contextRef="i59952c7ec62348a0bf0304c3e9c4aa1f_D20190801-20200730" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMjIyMDM_31df8750-a0da-44aa-8634-7426078b73c6">eight</ix:nonFraction> (8) putative antitrust class actions and <ix:nonFraction unitRef="case" contextRef="i26aebd3fd2cf4b1b9c6310ad6e35e2e8_D20190801-20200730" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMjIyNDc_171eb3cd-1f31-4f31-b4b6-2ed8b147e728">four</ix:nonFraction> (4) non-class complaints naming the Company, Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., and Santarus, Inc. (for purposes of this subsection, collectively, the &#8220;Company&#8221;), among other defendants, were filed or transferred to the Northern District of California. <ix:nonFraction unitRef="case" contextRef="i9b5eea4e2b054fe9b33f5a1c2468e6be_D20190801-20200730" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMjI1MjY_b9c33cf0-40d5-44ad-84ad-383477aeda0b">Three</ix:nonFraction> (3) of the class actions were filed by plaintiffs seeking to represent a class of direct purchasers. The purported classes of direct purchasers filed a consolidated first amended complaint and a motion for class certification in April 2020. The court certified a direct purchaser class in August 2020. The putative class action complaints filed by end payer purchasers have all been voluntarily dismissed. <ix:nonFraction unitRef="case" contextRef="i2bacfb7cad21454aa0b7847ed301e366_D20190801-20200730" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMjI5MzU_95e24895-f921-4fa4-9eda-bf20079bebcc">Three</ix:nonFraction> (3) of the non-class complaints were filed by direct purchasers. The fourth non-class complaint, asserting claims based on both direct and indirect purchases, was filed by an insurer plaintiff in July 2020 and subsequently amended in September 2020. In December 2020, the court denied the Company&#8217;s motion to dismiss as to the insurer plaintiff&#8217;s direct claims but dismissed the insurer plaintiff&#8217;s indirect claims. On February 2, 2021, the insurer plaintiff&#8217;s motion for leave to amend its complaint was denied.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These actions were consolidated and coordinated in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822-WHA (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The lawsuits alleged that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or grant any other company a license to do so. The complaints alleged that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. Both the class and non-class plaintiffs sought damages under federal antitrust laws for claims based on direct purchases.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2021, the insurer plaintiff filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#8220;State Court Action&#8221;) (discussed in further detail below, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see Glumetza State-Law Insurer Litigations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Defendants&#8217; demurrer in the State Court Action was heard on September 22, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 26, 2021, the Company reached an agreement in principle and, thereafter, on September 14, 2021, executed a final settlement agreement to resolve the class plaintiffs&#8217; claims for $<ix:nonFraction unitRef="usd" contextRef="ib1b9c6e509b24bc380ee524ca05ae442_D20210726-20210726" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMjQ2ODQ_90951482-6df4-41df-b7b3-9c93bb76e44a">300</ix:nonFraction>&#160;million, subject to court approval. On August 1, 2021, the Company also reached an agreement in principle to resolve the non-class direct purchaser plaintiffs&#8217; claims, described above, for additional consideration. A final settlement agreement with the non-class direct purchaser plaintiffs was executed on August 6, 2021. As part of the settlements, the Company admitted no liability as to the claims against it and denied all allegations of wrongdoing. On September 20, 2021, the insurer plaintiff voluntarily dismissed its claims in the consolidated </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="ib4f18396ce76411ea530b5ee8fe7dd5d" continuedAt="i92baaec4459e4672bbb29ea3036a87b0"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">federal action. By stipulation, the insurer plaintiff has asserted its direct opt-out claims in the State Court Action, resulting in the consolidation of all of its opt-out claims in the State Court Action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 22, 2021, the court granted preliminary approval of the class settlement agreement and vacated the October 2021 trial date and all other pre-trial deadlines in the consolidated actions. On February 3, 2022, the court granted final approval of the class settlement and ordered dismissal of the class plaintiffs&#8217; claims. The deadline to appeal the final approval of the class settlement has now passed, and the settlements have resolved and discharged all asserted class and direct purchaser non-class claims against the Company in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pricing Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries, Oceanside Pharmaceuticals, Inc. (&#8220;Oceanside&#8221;), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (&#8220;Bausch Health US&#8221;), and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (&#8220;Bausch Health Americas&#8221;) (for the purposes of this paragraph, collectively, the &#8220;Company&#8221;), are defendants in multidistrict antitrust litigation (&#8220;MDL&#8221;) entitled In re: Generic Pharmaceuticals Pricing Antitrust Litigation, pending in the United States District Court for the Eastern District of Pennsylvania (MDL 2724, 16- MD-2724). The lawsuits seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company&#8217;s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals. The lawsuits, which have been brought as putative class actions by direct purchasers, end payers, and indirect resellers, and as direct actions by direct purchasers, end payers, insurers, States, and various Counties, Cities, and Towns, have been consolidated into the MDL. There are also additional, separate complaints which have been consolidated in the same MDL that do not name the Company or any of its subsidiaries as a defendant. There are cases pending in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed in the cases. The cases have been placed in deferred status. The Company disputes the claims against it and continues to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Bausch Health Companies Inc. and certain U.S. and Canadian subsidiaries (for the purposes of this paragraph, collectively the &#8220;Company&#8221;) have been named as defendants in a proposed class proceeding entitled Kathryn Eaton v. Teva Canada Limited, et al. in the Federal Court in Toronto, Ontario, Canada (Court File No. T-607-20). The plaintiff seeks to certify a proposed class action on behalf of persons in Canada who purchased generic drugs in the private sector, alleging that the Company and other defendants violated the Competition Act by conspiring to allocate the market, fix prices, and maintain the supply of generic drugs, and seeking damages under federal law. The proposed class action contains similar allegations to the In re: Generic Pharmaceuticals Pricing Antitrust Litigation pending in the United States Court for the Eastern District of Pennsylvania. The Company disputes the claims against it and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These lawsuits cover products of both Bausch + Lomb and the Company&#8217;s businesses. It is anticipated that Bausch + Lomb and the Company will split the fees and expenses associated with defending these claims, as well as any potential damages or other liabilities awarded in or otherwise arising from these claims, in the manner set forth in the Master Separation Agreement between Bausch Health and Bausch + Lomb.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza State-Law Insurer Litigations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2021, the insurer plaintiff from the federal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822- WHA (N.D. Cal.) (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) (discussed in further detail above) filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#8220;State Court Action&#8221;). The State Court Action alleges that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or grant any other company a license to do so. The State Court Action alleges that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. On September 20, 2021, the parties stipulated that the insurer plaintiff&#8217;s direct opt-out claims from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, discussed above, were deemed asserted in the State Court Action. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defendants&#8217; demurrer in the State Court Action was heard on September 22, 2021. On November 29, 2021, the court denied the motion in part and granted it in part as to certain state law claims, with leave to amend. The insurer plaintiff did not amend the complaint. Defendants&#8217; answers were filed on February 3, 2022. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 5, 2022, Health Care Service Corporation filed an action with similar substantive allegations and similar indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others. Defendants&#8217; answers were filed on June 17, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims and intends to vigorously defend these matters.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i92baaec4459e4672bbb29ea3036a87b0" continuedAt="i5b5e0727c11f40f38f195b4c7deda60c"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation/Paragraph IV Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company (and/or certain of its affiliates) is also party to certain patent infringement proceedings in the United States and Canada, including as arising from claims filed by the Company (or that the Company anticipates filing within the required time periods) in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers respecting their pending applications for generic versions of certain products sold by or on behalf of the Company, including Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 550mg, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Injection, Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Nuvessa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Canada, or other similar suits.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2020, the Company and Alfasigma S.p.A. (&#8220;Alfasigma&#8221;) received a Notice of Paragraph IV Certification from Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;), in which Norwich asserted that the U.S. patents listed in the FDA&#8217;s Orange Book for the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Norwich&#8217;s generic rifaximin tablets, 550 mg, for which an Abbreviated New Drug Application (&#8220;ANDA&#8221;) has been filed by Norwich. The Company, through its subsidiaries Salix Pharmaceuticals, Inc. and Bausch Health Ireland Limited, holds the New Drug Application for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and owns or exclusively licenses (from Alfasigma) these patents.&#160;On March 26, 2020, certain of the Company&#8217;s subsidiaries and Alfasigma filed suit against Norwich in the U.S. District Court for the District of Delaware (Case No. 20-cv-00430) pursuant to the Hatch-Waxman Act, alleging infringement by Norwich of one or more claims of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a <ix:nonNumeric contextRef="i6a2d38205ea946e095aed8012d8b17c2_D20200326-20200326" name="bhc:GainContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMzIxOTI_780e8878-f081-4967-8572-78919899e862">30</ix:nonNumeric>-month stay of the approval of Norwich&#8217;s ANDA for rifaximin tablets, 550 mg. Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is protected by 26 patents covering the composition of matter and the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange&#160;Book. Trial in this matter was held in March 2022. The court issued an Oral Order on July 28, 2022 indicating that the court will find certain U.S. Patents protecting the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets for the reduction in risk of hepatic encephalopathy (&#8220;HE&#8221;) recurrence valid and infringed and U.S. Patents protecting the composition, and use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for treating inflammatory bowel syndrome with diarrhea (&#8220;IBS-D&#8221;) invalid (the &#8220;Norwich Legal Decision&#8221;). The Company remains confident in the strength of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to appeal the court&#8217;s decision and vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (now Padagis LLC) (&#8220;Padagis&#8221;), in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotene) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#8217; generic lotion, for which an ANDA has been filed by Padagis. On August 28, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a <ix:nonNumeric contextRef="i0ccb1877ab504b0da10aae4fbd2023a4_D20200828-20200828" name="bhc:GainContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMzM1MTI_0cb4251d-48cc-49fa-81a6-15b559ce59d6">30</ix:nonNumeric>-month stay of the approval of the Padagis ANDA. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described below, regarding Padagis&#8217; ANDA for generic Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion. The court scheduled a trial to begin on October 4, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company received a Notice of Paragraph IV Certification from Taro Pharmaceuticals Inc. (&#8220;Taro&#8221;), in which Taro asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotene) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use, sale, offer for sale, or importation of Taro&#8217;s generic lotion, for which an ANDA has been filed by Taro. On July 21, 2022, the Company filed suit against Taro pursuant to the Hatch-Waxman Act, alleging infringement by Taro of one or more claims of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents and triggering a <ix:nonNumeric contextRef="ie0c3cf86c7f3419099a730b07b8db1b8_D20220721-20220721" name="bhc:GainContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNDM5ODA0NjYxNzkzMg_f9dd2de9-17a8-469e-90f2-a512c9693eba">30</ix:nonNumeric>-month stay of the approval of the Taro ANDA. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains confident in the strength of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Padagis, in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#8217; generic halobetasol propionate lotion, for which an ANDA has been filed by Padagis. On May 1, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents, thereby triggering a <ix:nonNumeric contextRef="i3ada237c7e9e4db3b48af8ba931e7f96_D20200501-20200501" name="bhc:GainContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMzQ2MTY_a036df32-25d8-45ff-8b81-8b7c036d6622">30</ix:nonNumeric>-month stay of the approval of the Padagis ANDA for halobetasol propionate lotion. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described above, regarding Padagis&#8217; ANDA for generic Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotene) lotion. The court scheduled a trial to </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i5b5e0727c11f40f38f195b4c7deda60c" continuedAt="i5da0a254faa547e0987d8f2802a2f576"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">begin on October 4, 2022. The Company remains confident in the strength of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company commenced litigation against MSN Laboratories Private Ltd. (&#8220;MSN&#8221;) and Mylan Pharmaceuticals Inc., (&#8220;Mylan&#8221;) alleging patent infringement by MSN&#8217;s and Mylan&#8217;s filing of their ANDA for generic Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) 3mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from each of MSN and Mylan, in which they had each asserted that the U.S. patents listed in the FDA&#8217;s Orange Book for the Company&#8217;s Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 3 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of their respective generic plecanatide tablets, 3 mg. The filing of these suits triggered a <ix:nonNumeric contextRef="i19fa8a54dc9d4942b1269451e77f4405_D20210401-20210430" name="bhc:GainContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMzU4NTA_67b66515-22ad-4ec7-8894-7000f871e32b">30</ix:nonNumeric>-month stay of the approval of the MSN and Mylan ANDAs for plecanatide tablets. The Company remains confident in the strength of the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> AREDS Patent Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AREDS and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AREDS 2 are over the counter eye vitamin formulas for those with moderate-to-advanced age-related degeneration (&#8220;AMD&#8221;). The PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> U.S. formulation patent expired in March 2021, but a patent covering methods of using the formulation remains in force into 2026. Bausch + Lomb Incorporated (&#8220;B&amp;L Inc.&#8221;) has filed patent infringement proceedings against <ix:nonFraction unitRef="defendant" contextRef="i163c3bd2391743dca52453bf7bb54c2d_D20210301-20210331" decimals="INF" name="bhc:GainContingencyNumberOfDefendants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTE1NDQ4NzIxODAyNzA_bf3895d1-00b4-4022-9d9c-2e830721039d">16</ix:nonFraction> defendants claiming infringement of these patents and, in certain circumstances, related unfair competition and false advertising causes of action. <ix:nonFraction unitRef="defendant" contextRef="ic0fbaa5244774f8785a4c3159850c238_D20220101-20220630" decimals="INF" name="bhc:GainContingencyNumberOfDefendants" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTE1NDQ4NzIxODAyNzM_d5547064-4758-4074-8c4a-432256a15194">Twelve</ix:nonFraction> of these proceedings were subsequently settled; <ix:nonFraction unitRef="defendant" contextRef="i9fa2cc2f25c840c8aa8cd8f821e0e024_D20220101-20220630" decimals="INF" name="bhc:GainContingencyNumberOfDefendants" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTE1NDQ4NzIxODAyOTY_15f1fca9-c6f1-479b-a964-9276f7242158">two</ix:nonFraction> resulted in a default. <ix:nonFraction unitRef="defendant" contextRef="i535a21de35094309b7dde211b4cc6c75_D20220101-20220630" decimals="INF" name="bhc:GainContingencyNumberOfDefendants" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTE1NDQ4NzIxODAzMTA_5250d590-f37a-41c7-bb82-df8aa11437f0">One</ix:nonFraction> defendant filed a declaratory judgment action after B&amp;L Inc. filed its suit, seeking declaratory judgment related to patent claims as well as false advertising and unfair competition claims. As of the date of this filing, there are <ix:nonFraction unitRef="defendant" contextRef="i5e13b85e78034bd58a4c8e9b49e1b7f8_D20220809-20220809" decimals="INF" name="bhc:GainContingencyNumberOfDefendants" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNDM5ODA0NjU5OTk1Mw_971fcd40-6dc5-4d52-84c1-981bb61aa6af">two</ix:nonFraction> ongoing actions: (1) Bausch &amp; Lomb Inc. &amp; PF Consumer Healthcare 1 LLC v. ZeaVision LLC, C.A. No. 6:20-cv-06452-CJS (W.D.N.Y.); and (2) Bausch &amp; Lomb Inc. &amp; PF Consumer Healthcare 1 LLC v. SBH Holdings LLC, C.A. No. 20-cv-01463-VAC-CJB (D. Del.). Bausch + Lomb remains confident in the strength of these patents and B&amp;L Inc. intends to continue to vigorously pursue these matters and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation against Certain Ocuvite and PreserVision </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2021, ZeaVision, LLC (&#8220;ZeaVision&#8221;) filed a complaint for patent infringement against certain of the Ocuvite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products in the Eastern District of Missouri (Case No. 4:21-cv-00739-RWS). On June 29, 2021, ZeaVision amended its complaint to assert a second patent against certain of the Ocuvite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products. On November 16, 2021, ZeaVision filed an additional complaint for patent infringement to assert a third patent against certain of the PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products (Case No. 4:21-cv-01352-RWS). On March 1, 2022, the cases were consolidated. On March 10, 2022, the court granted Bausch + Lomb&#8217;s motion to stay all proceedings pending inter partes review. On July 1, 2022, ZeaVision filed a motion to partially lift the stay to allow Case No. 4:21-cv-01352-RWS to proceed, and Bausch + Lomb opposed the motion. The Company disputes the claims and intends to vigorously defend this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2021, B&amp;L Inc. received a Notice of Paragraph IV Certification from Slayback Pharma LLC (&#8220;Slayback&#8221;), in which Slayback asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brimonidine tartrate solution) drops (the &#8220;Lumify Patents&#8221;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Slayback&#8217;s generic drops, for which an ANDA has been filed by Slayback. B&amp;L Inc., through its affiliate Bausch + Lomb Ireland Limited, exclusively licenses the Lumify Patents from Eye Therapies, LLC (&#8220;Eye Therapies&#8221;). On September 10, 2021, B&amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Slayback pursuant to the Hatch-Waxman Act, alleging infringement by Slayback of one or more claims of the Lumify Patents, thereby triggering a <ix:nonNumeric contextRef="i699127da9e51419abf9760aca1b136de_D20220202-20220202" name="bhc:GainContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTE1NDQ4NzIxODAyNDg_7277846d-9ac8-4c6e-8826-cd6ef79655a2">30</ix:nonNumeric>-month stay of the approval of the Slayback ANDA.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2022, B&amp;L Inc. received a Notice of Paragraph IV Certification from Lupin Ltd. (&#8220;Lupin&#8221;), in which Lupin asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brimonidine tartrate solution) drops (the &#8220;Lumify Patents&#8221;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Lupin&#8217;s generic brimonidine tartrate solution, for which its ANDA No. 216716 has been filed by Lupin. On February 2, 2022, B&amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Lupin pursuant to the Hatch-Waxman Act, alleging patent infringement by Lupin of one or more claims of the Lumify Patents, thereby triggering a <ix:nonNumeric contextRef="i9baba49f62e74a14aed75dbbd081c3b4_D20220202-20220202" name="bhc:GainContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTE1NDQ4NzIxODAzMjA_c011a54c-bbd7-4fde-ab16-e893becda9a9">30</ix:nonNumeric>-month stay of the approval of the Lupin ANDA.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B&amp;L Inc. remains confident in the strength of the Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related patents and B&amp;L Inc. intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Parties Review Proceedings at the U.S. Patent and Trademark Office</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i5da0a254faa547e0987d8f2802a2f576" continuedAt="i44b304d4219946b8a730c03e277c7e5a"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patents covering the Company&#8217;s branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review (&#8220;IPR&#8221;) at the U.S. Patent &amp; Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution. IPR challenges have been brought against patents covering the Company&#8217;s branded pharmaceutical products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following Acrux DDS&#8217;s IPR petition, the U.S. Patent and Trial Appeal Board (&#8220;PTAB&#8221;), in May 2017, instituted inter partes review for an Orange Book-listed patent covering Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (U.S. Patent No. 7,214,506 (the &#8220;&#8216;506 Patent&#8221;)) and, on June 6, 2018, issued a written determination invalidating such patent. An appeal of this decision was filed on August 7, 2018. On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings. As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion. The &#8216;506 Patent, therefore, remains valid and enforceable and expires in 2026. Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is covered by sixteen Orange Book-listed patents owned by the Company or its licensor, which expire in the years 2028 through 2035. In August and September 2018, the Company received notices of the filing of a number of ANDAs with paragraph IV certification, and has timely filed patent infringement suits against these ANDA filers, and, in addition, the Company has also commenced certain patent infringement proceedings in Canada against <ix:nonFraction unitRef="defendant" contextRef="ifac3480ee2d142bf905b63b471677601_D20180801-20180930" decimals="INF" name="bhc:GainContingencyNumberOfDefendants" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNDM5ODA0NjYxNzkzOQ_96489087-5d98-41de-bd8a-1c8144be7172">four</ix:nonFraction> separate defendants. All cases in U.S. regarding Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been settled. In Canada, <ix:nonFraction unitRef="lawsuit" contextRef="ic187ba4416b64839ad042a51d60bfdd1_D20220101-20220630" decimals="INF" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNDM5ODA0NjYxNzk0OA_72af89c0-331b-41ef-afff-a0187c0327c7">two</ix:nonFraction> lawsuits remain pending against Apotex Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mylan has filed IPR petitions for certain U.S. patents listed in the FDA Orange Book for Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide). On March 21, 2022, Mylan filed a petition for IPR of U.S. Patent No. 7,041,786. On June 10, 2022, Mylan filed petitions for IPR of U.S. Patent Nos. 9,610,321, 9,616,097, 9,919,024, and 9,925,231. The Company remains confident in the strength of these patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Products Liability Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2016, the Company has been named in a number of product liability lawsuits involving the Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> body powder product acquired in September 2012 from Johnson &amp; Johnson; due to dismissals, twenty-nine (<ix:nonFraction unitRef="case" contextRef="ibf92d71d956242d2ae34c263d78aac0a_I20220630" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMzk5MDc_1c368664-822a-42c2-a268-92b5d820923e">29</ix:nonFraction>) of such product liability suits currently remain pending. In three (<ix:nonFraction unitRef="case" contextRef="ife18e9be510b4194a3a4277ad67e7250_I20220630" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTE1NDQ4NzIxODAzMzA_b3b7a130-d773-4569-b6c1-72bac74e4163">3</ix:nonFraction>) cases pending in the Atlantic County, New Jersey Multi-County Litigation, agreed stipulations of dismissal have been entered by the Court, thus dismissing the Company from those cases. Potential liability (including its attorneys&#8217; fees and costs) arising out of these remaining suits is subject to full indemnification obligations of Johnson &amp; Johnson owed to the Company and its affiliates, and legal fees and costs will be paid by Johnson &amp; Johnson. Twenty-eight (<ix:nonFraction unitRef="case" contextRef="i8381d2aef44c4cb6bbf760cd8d3e40b8_I20220630" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNDAyNTA_07b30fd2-16ac-4324-8db7-6b10ac588779">28</ix:nonFraction>) of these lawsuits filed by individual plaintiffs allege that the use of Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> caused the plaintiffs to develop ovarian cancer, mesothelioma or breast cancer. The allegations in these cases include failure to warn, design defect, manufacturing defect, negligence, gross negligence, breach of express and implied warranties, civil conspiracy concert in action, negligent misrepresentation, wrongful death, loss of consortium and/or punitive damages. The damages sought include compensatory damages, including medical expenses, lost wages or earning capacity, loss of consortium and/or compensation for pain and suffering, mental anguish anxiety and discomfort, physical impairment and loss of enjoyment of life. Plaintiffs also seek pre- and post-judgment interest, exemplary and punitive damages, and attorneys&#8217; fees. Additionally, <ix:nonFraction unitRef="case" contextRef="i768a63ca14b44cf0a9b21c5ad06e8cea_I20220630" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNDEwOTc_d2dc7c05-8f8c-4359-aeda-5e85cd09df7d">two</ix:nonFraction> proposed class actions have been filed in Canada against the Company and various Johnson &amp; Johnson entities (<ix:nonFraction unitRef="case" contextRef="ic0c00ea3613744deacee586a7d91e4c2_I20220630" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNDEyMDk_af16dcab-ee2f-4bc0-bf9e-059020e2d77d">one</ix:nonFraction> in the Supreme Court of British Columbia and <ix:nonFraction unitRef="case" contextRef="ibed3ef3f1abe40969ae83f8df49eaddc_I20220630" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNDEyNTc_0e2842cf-536b-4aba-996d-24758fc8cd07">one</ix:nonFraction> in the Superior Court of Quebec), on behalf of persons who have purchased or used Johnson &amp; Johnson&#8217;s Baby Powder or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The class actions allege the use of the product increases certain health risks (British Columbia) or negligence in failing to properly test, failing to warn of health risks, and failing to remove the products from the market in a timely manner (Quebec). The plaintiffs in these actions are seeking awards of general, special, compensatory and punitive damages. On November 17, 2020, the British Columbia court issued a judgment declining to certify a class as to the Company or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and at this time no appeal of that judgment has been filed. </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2021, the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plaintiff in the British Columbia class action filed a Second Amended Notice of Civil Claim and Application</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for Certification, removing the Company as a defendant; as a result, the British Columbia class action is concluded</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as to the Company.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson, through one or more subsidiaries, has purported to have completed a Texas divisional merger with respect to any talc liabilities at Johnson &amp; Johnson Consumer, Inc. (&#8220;JJCI&#8221;). LTL Management, LLC (&#8220;LTL&#8221;), the resulting entity of the divisional merger, assumed JJCI&#8217;s talc liabilities and thereafter filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the Western District of North Carolina. Pursuant to court orders entered in November 2021, the case was transferred to the United States District Court for the District of New Jersey (the &#8220;Bankruptcy Court&#8221;), and substantially all cases related to Johnson &amp; Johnson&#8217;s talc liability were stayed for a period of sixty (<ix:nonNumeric contextRef="i256a9238c6d447949e96e0113ba7913c_D20211101-20211130" name="bhc:LossContingencyStayOfApprovalPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNDI5MTg_a57f332b-19e8-4932-83e6-f338d8b6bc8c">60</ix:nonNumeric>) days pursuant to a preliminary injunction. Notwithstanding the divisional merger and LTL&#8217;s bankruptcy case, the Company and its affiliates continue to have indemnification claims and rights against Johnson &amp; Johnson and LTL pursuant to the terms of the indemnification agreement entered into between JJCI and its affiliates and the Company and its affiliates, which indemnification agreement remains in effect. As a result, it is the Company&#8217;s current expectation that it will not incur any material impairments with respect to its indemnification claims as a result of the divisional merger or the bankruptcy. In </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i44b304d4219946b8a730c03e277c7e5a" continuedAt="i13372ed28013489faafa230b67776b36"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 2021, certain talc claimants filed motions to dismiss the bankruptcy case. Shortly thereafter, LTL filed a motion in the Bankruptcy Court to extend the <ix:nonNumeric contextRef="ie1614b745c4246e89dd4a1987611b15c_D20211201-20211231" name="bhc:LossContingencyStayOfApprovalMotionToExtendPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNDM2OTc_70622136-a239-4736-a19f-3f4e39391cdf">60</ix:nonNumeric>-day preliminary injunction. On February 25, 2022, the Bankruptcy Court entered orders denying the motions to dismiss and extending the preliminary injunction staying substantially all cases subject to the indemnification agreement related to Johnson &amp; Johnson&#8217;s talc liability through at least June 29, 2022. The order denying the motions to dismiss and the order extending the preliminary injunction are subject to appeal and the bankruptcy court certified their appeals directly to the United States Court of Appeals for the Third Circuit. On May 11, 2022, the Third Circuit granted authorization for the parties to proceed with their direct appeals and on June 24, 2022, set an expedited briefing schedule to conclude on September 6, 2022. Further, pursuant to a court order dated March 18, 2022, the Bankruptcy Court directed certain talc claimants and LTL to mediate the issues related to the case in the hopes of achieving a global resolution. The Bankruptcy Court has also ordered separate mediation with respect to certain consumer protection claims against LTL by various state attorneys general. On May 4, 2022, the Bankruptcy Court extended LTL&#8217;s exclusive period to file a chapter 11 plan until September 9, 2022, which the talc claimants have challenged by filing a motion to terminate the exclusivity period and requesting a hearing on such motion for September 14, 2022. On July 26, 2022, the Bankruptcy Court held a hearing to consider alternative paths to case resolution, and on July 28, 2022, authorized an abbreviated estimation process designed to determine the extent of the debtor&#8217;s aggregate liability. Additionally, the Bankruptcy Court identified its proposed independent expert who will issue a report forecasting and estimating the volume and value of claims. Thereafter, the Bankruptcy Court will direct the parties to reconvene for mediation. On July 28, 2022, the Bankruptcy Court also ruled that it would leave in place the stay and injunction enjoining talc product liability cases from proceeding until at least the completion of the estimation process. Following the Bankruptcy Court&#8217;s July 28 ruling, on August 2, 2022, LTL filed a motion to extend its exclusivity period until 30 days after the issuance of the independent expert&#8217;s report, with a hearing on such motion requested for August 23, 2022. To the extent that any cases proceed during the pendency of the bankruptcy case, it is the Company&#8217;s expectation that Johnson &amp; Johnson, in accordance with the indemnification agreement, will continue to vigorously defend the Company in each of the remaining actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation - New Jersey Declaratory Judgment Lawsu</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">it</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 24, 2022, the Company and Bausch + Lomb were named in a declaratory judgment action in the Superior </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Court of New Jersey, Somerset County, Chancery Division, brought by certain individual investors in the Company&#8217;s common shares and debt securities who are also maintaining individual securities fraud claims against the Company and certain current or former officers and directors as part of the U.S. Securities Litigation. This newly filed action seeks a declaratory judgment that the transfer of the Company assets to Bausch + Lomb would constitute a voidable transfer under New Jersey&#8217;s Uniform Voidable Transactions Act and that Bausch + Lomb would become liable for damages awarded against the Company in the individual opt-out actions. The declaratory judgment action alleges that a transfer of assets from the Company to Bausch + Lomb would leave the Company with inadequate financial resources to satisfy these plaintiffs&#8217; alleged securities fraud damages in the underlying individual opt-out actions. None of the plaintiffs in this declaratory judgment action have obtained a judgment against the Company in the underlying individual opt-out actions and the Company disputes the claims against it in those underlying actions. The underlying individual opt-out actions assert claims under Sections 10(b) and 20(a) of the Exchange Act, and certain actions assert claims under Section 18 of the Exchange Act. The allegations in those underlying individual opt out actions are made against the Company and several of its former officers and directors only and relate to, among other things, allegedly false and misleading statements made during the 2013-2016 time period by the Company and/or failures to disclose information about the Company&#8217;s business and prospects including relating to drug pricing and the use of specialty pharmacies. On March 31, 2022, the Company and Bausch + Lomb removed the action to the U.S. District Court for the District of New Jersey. As a result, the New Jersey Superior Court action is closed and the case is now pending in the District of New Jersey (Case No. 22-cv-01823). On April 29, 2022, Plaintiffs filed a motion to remand. That motion is fully briefed and pending as of June 30, 2022. Other proceedings are in abeyance pending resolution of Plaintiffs&#8217; remand motion. Both the Company and Bausch + Lomb dispute the claims in this declaratory judgment action and intend to vigorously defend this matter. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Proposition 65 Related Matter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson &amp; Johnson (Gutierrez, et al. v. Johnson &amp; Johnson, et al., Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the California Safe Cosmetics Act. This lawsuit was served on Bausch Health US in June 2019 and was subsequently removed to the United States District Court for the Southern District of California, where it is currently pending. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. Bausch Health US filed a motion to dismiss Plaintiffs&#8217; claims, which was granted in April 2020 without prejudice. In May 2020, Plaintiffs filed an amended complaint and in June 2020, filed a motion for leave to amend the complaint further, which was granted. In August 2020, Plaintiffs filed </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i13372ed28013489faafa230b67776b36" continuedAt="i28df8b56d85f40d4af9f7b03d80a9fa4"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Fifth Amended Complaint. On January 22, 2021, the Court granted the motion to dismiss with prejudice. On February 19, 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit Court of Appeals. On July 1, 2021, Appellants (Plaintiffs) filed their opening brief; Appellees&#8217; response briefs were filed on October 8, 2021. This matter was stayed by the Ninth Circuit on December 7, 2021, due to the preliminary injunction entered by the Bankruptcy Court in the LTL bankruptcy proceeding. This stay included Appellants&#8217; reply brief deadline, which was previously due to be filed on or before December 2, 2021. On March 9, 2022, the Ninth Circuit issued an order extending the stay through July 29, 2022. On July 29, 2022, Johnson &amp; Johnson filed a status report in the Gutierrez appeal, outlining the developments since the last status report and the imposition of the current stay. Johnson &amp; Johnson noted that following a July 26, 2022, hearing, the Bankruptcy Court left the preliminary injunction in place, and accordingly, asked the Ninth Circuit if Johnson &amp; Johnson could have until December 19, 2022, to provide the next status report while the stay remains in place in this action. They also indicated they will inform the court if the status of the bankruptcy stay changes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Mexico Attorney General Consumer Protection Action</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US were named in an action brought by State of New Mexico ex rel. Hector H. Balderas, Attorney General of New Mexico, in the County of Santa Fe New Mexico First Judicial District Court (New Mexico ex rel. Balderas v. Johnson &amp; Johnson, et al., Civil Action No. D-101-CV-2020-00013, filed on January 2, 2020), alleging consumer protection claims against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer, Inc., the Company and Bausch Health US related to Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its alleged causal link to mesothelioma and other cancers. In April 2020, Bausch Health US filed a motion to dismiss, which in September 2020, the Court granted in part as to the New Mexico Medicaid Fraud Act and New Mexico Fraud Against Taxpayers Act claims and denied as to all other claims. The State of New Mexico brings claims against all defendants under the New Mexico Unfair Practices Act and other common law and equitable causes of action, alleging defendants engaged in wrongful marketing, sale and promotion of talcum powder products. The lawsuit seeks to recover the cost of the talcum powder products as well as the cost of treating asbestos-related cancers allegedly caused by those products. Bausch Health US filed its answer on November 16, 2020. On December 30, 2020 Johnson &amp; Johnson filed a Motion for Partial Judgment on the Pleadings and on January 4, 2021, Bausch Health US filed a joinder to that motion, which was denied on March 8, 2021. Trial is scheduled to begin on March 6, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 14, 2022, LTL filed an adversary proceeding in the Bankruptcy Court (Case No. 21-30589, Adv. Pro. No. 22-01231) against the State of New Mexico ex rel. Hector H. Balderas, Attorney General, and a motion seeking an injunction barring the State of New Mexico from continuing to prosecute the action while the bankruptcy case is pending. On July 20, 2022, the Bankruptcy Court entered a consent order pursuant to which, among other things, a hearing on the injunction is scheduled for August 23, 2022, and the action is stayed pending further order on the injunction motion. The one exception is that the parties in the New Mexico case may continue to litigate the scheduling order extension in that case which has been scheduled for hearing August 24, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above, during the three months ended June 30, 2022, there have been no material updates or developments with respect to certain proceedings or actions as described under &#8220;General Civil Actions&#8221; in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021. These matters include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Doctors Allergy Formula Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, Doctors Allergy Formula, LLC (&#8220;Doctors Allergy&#8221;), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, asserting breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas.&#160;Doctors Allergy claims its damages are not less than $<ix:nonFraction unitRef="usd" contextRef="i3da2b3029b9e49809af6f64595c73392_D20180401-20180430" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNTIyMjc_659e0c74-0a33-4ff7-bd15-b6c6cc11e161">23</ix:nonFraction> million. Bausch Health Americas has asserted counterclaims against Doctors Allergy. Bausch Health Americas filed a motion seeking an order granting Bausch Health Americas summary judgment on its counterclaims against Plaintiff and dismissing Plaintiff&#8217;s claims against it. The motion was fully briefed as of May 2021. The Court held a hearing on the motion on January 25, 2022. The motion remains pending. Bausch Health Americas disputes the claims against it and intends to continue to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation with Former Salix CEO</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, asserting claims for breach of contract and declaratory relief. On November 19, 2021, Logan amended her complaint to add a claim for breach of the implied covenant of good faith and fair dealing. The lawsuit arises out of the contractual termination </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i28df8b56d85f40d4af9f7b03d80a9fa4"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of approximately $<ix:nonFraction unitRef="usd" contextRef="i521280a2735e43e2bc975a7b850cdd00_D20190128-20190128" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNTMxNTA_3a9df1cb-7b5c-4abf-9962-7872858ace85">30</ix:nonFraction> million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd. Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification. On June 20, 2019, the Court entered an order staying the claim for declaratory relief pending the final resolution of the breach of contract claim. Trial is scheduled to commence on April 10, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it in each of these matters and intends to vigorously defend the matters.</span></div></ix:continuation><div id="i762fba229369426294c4424c2015a01a_97"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RleHRyZWdpb246ODZkOGIyZDAzM2QxNDQzN2IzMmE4YzM5MDAxNWE3MTZfNDI0OQ_559e4b24-3553-4246-a558-f9242ea3f58f" continuedAt="ia6ec50ec98d543f3b40a28c2a257c5db" escape="true">SEGMENT INFORMATION</ix:nonNumeric></span></div><ix:continuation id="ia6ec50ec98d543f3b40a28c2a257c5db" continuedAt="i458dcf6113cf4db0b92eade0375daed8"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company&#8217;s previously announced plan to separate its Solta business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., the Company had begun managing its operations in a manner which was consistent with the organizational structure of the two separate entities as proposed by the Solta IPO. As a result, during the first quarter of 2022, the Company&#8217;s Chief Executive Officer (&#8220;CEO&#8221;), who is the Company&#8217;s Chief Operating Decision Maker, commenced managing the business differently through changes in its operating and reportable segments, which necessitated a realignment of the Company&#8217;s historical segment structure. This realignment is consistent with how the Company&#8217;s CEO currently: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports. Pursuant to these changes, effective in the first quarter of 2022, the Company operates in the following reportable segments: (i) Salix, (ii) International (formerly International Rx), (iii) Diversified Products, (iv) Solta Medical and (v) Bausch + Lomb. The new segment structure does not impact the Company&#8217;s reporting units but realigns the <ix:nonFraction unitRef="reporting_unit" contextRef="i86a04889bcf044b38603f4f4ca1d8de4_D20220101-20220630" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RleHRyZWdpb246ODZkOGIyZDAzM2QxNDQzN2IzMmE4YzM5MDAxNWE3MTZfMTI3NQ_86be53b1-7d0e-478a-ac21-c919f2b85868">two</ix:nonFraction> reporting units of the former Ortho Dermatologics segment whereby its medical dermatology reporting unit (Ortho Dermatologics) is now part of the current Diversified Products segment and the Solta reporting unit is now the sole reporting unit of the new Solta Medical segment. Prior period presentation of segment revenues and segment profits has been recast to conform to the current segment reporting structure.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2022, the Company announced it was suspending plans for the Solta IPO; however, the Company is continuing to manage and operate the business in its current reportable segment structure. See Note 2, &#8220;SIGNIFICANT ACCOUNTING POLICIES&#8221; for additional information.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief description of the Company&#8217;s segments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales in the U.S. of GI products. Sales of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line represented <ix:nonFraction unitRef="number" contextRef="i99a74cae63104c7b82e2b04e1ad12241_D20220401-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RleHRyZWdpb246ODZkOGIyZDAzM2QxNDQzN2IzMmE4YzM5MDAxNWE3MTZfNTQ5NzU1ODE0NTM5OQ_48e2ec32-727c-4d1e-a465-40ba5260532d">81</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="icc599dddc6874659a5df85bf6a360251_D20220101-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RleHRyZWdpb246ODZkOGIyZDAzM2QxNDQzN2IzMmE4YzM5MDAxNWE3MTZfNTQ5NzU1ODE0NTQwNg_60a6b859-9b21-490c-a959-f84539184724">80</ix:nonFraction>% of the Salix segment&#8217;s revenues for the three and six months ended June 30, 2022, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified Products segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological) products and (iv) dentistry products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Solta Medical segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Solta aesthetic medical devices. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Bausch + Lomb segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment profit is based on operating income after the elimination of intercompany transactions, including between Bausch + Lomb and other segments. Certain costs, such as Amortization of intangible assets, Asset impairments, Goodwill impairments, Restructuring, integration, separation and IPO costs and Other (income) expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#8217;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i458dcf6113cf4db0b92eade0375daed8" continuedAt="i526c1edc66094cfc88a035d6ad1884f7"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Revenues and Profits</span></div><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RleHRyZWdpb246ODZkOGIyZDAzM2QxNDQzN2IzMmE4YzM5MDAxNWE3MTZfNDIzOQ_bf91692c-10b0-45a3-ab4d-152519c286b3" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenues and profits were as&#160;follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135087334a5d4c22bfa9b973191edec2_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNC0xLTEtMS0xMTY3NzE_ae373f9d-c006-497e-83e1-d0b261c86275">501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33f1397d8a6c4970be8e3744fa05b614_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNC0zLTEtMS0xMTY3NzE_124941ac-f317-43e4-bab8-99905ff47095">516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa70c909ebed4960ac5793fab0872d29_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNC01LTEtMS0xMTY3NzE_174dafb2-8f33-4143-bd10-747a5ca5d72d">965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1fd4b8f2dca420587be152cd56a71f1_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNC03LTEtMS0xMTY3NzE_1ee00fea-3a6f-4e7f-9622-b777a098833b">988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6165a9798c56425cb4efb5a5f6723bfc_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNS0xLTEtMS0xMTY3NzE_9d893038-5aa3-4a48-bfcf-1a375cb49b13">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bd4de5a193d4a029240767ca5a07233_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNS0zLTEtMS0xMTY3NzE_e5641113-fb86-47cd-bf24-a1ff59f4d9e7">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife570419c7bf420eb1abf7c964aaca40_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNS01LTEtMS0xMTY3NzE_c94354a8-3fbd-464f-87c1-46b9c8339cdb">477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3029344c603341c39ead09035d7dfa4d_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNS03LTEtMS0xMTY3NzE_a45bf3ba-9915-4d26-9a27-243567f3d2b7">619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd827b38d174dab9b133e198c4a8961_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNS0xLTEtMS0xMjU4Mjc_2662d752-fe8b-413e-9bea-414a260a8413">235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58ecd7a903984152b7f6c2ae9bec8334_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNS0zLTEtMS0xMjU4MzA_cddb7ce7-4c8a-45bd-95ac-894dc6865a33">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib91d44ce63944098b3420f5c3736b8a9_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNS01LTEtMS0xMjU4MzI_a999feec-c3e8-4427-b34c-aeabcbe244de">484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc157eb51cba40e89c5c61507c69e6e5_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNS03LTEtMS0xMjU4MzQ_04ebe07e-dd18-4894-9a51-6c4ff4b780a4">560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66c6b838e58742c0aec7f7e50a13b045_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNi0xLTEtMS0xMTY3NzE_709d3bc7-f064-4282-ab64-95014e57fe3a">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ffd9a91d95843f5b57ffc1c00e8f083_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNi0zLTEtMS0xMTY3NzE_2d3789d1-7f7d-456c-9148-d82bed309342">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dba412bc4484690b009184d4ba468c6_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNi01LTEtMS0xMTY3NzE_93d1d15b-d165-4691-b11a-a536ea556563">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b7ac6f51a042f3af9aea0cd5d38c09_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNi03LTEtMS0xMTY3NzE_907ec7d4-16d6-49a2-9eb4-f6a0fe53c340">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i641af432b0f64dcb834dccbe69309abd_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfOC0xLTEtMS0xMjU3ODk_a56d5eaa-f7b7-482d-b17f-4db0633f6945">941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if41baecc67df46e3909a38e74cfc03c7_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfOC0zLTEtMS0xMjU3OTc_6f123455-1136-409e-9685-5cdf8eec7b35">934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ade95eb6964658bc80338e46f307dc_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfOC01LTEtMS0xMjU4MDA_bb7d3346-d373-465e-9690-3171cc07f24b">1,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7050fd087c144698ee6de6deb8f7b08_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfOC03LTEtMS0xMjU4MDM_2d4670d8-1460-4c0c-aa1e-d2c26373088c">1,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56f9693a8c8e416f9524496f13d18f13_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfOC0xLTEtMS0xMTY3NzE_c858ecf9-b1ac-42a1-a5f2-1f91c782b100">1,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i457d6b1c8dad41d797d6f3caa45e3c46_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfOC0zLTEtMS0xMTY3NzE_bdbcbb62-c652-4e6e-811c-f4d2a9046700">2,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c0e69d16e47492cba77b50588ee0475_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfOC01LTEtMS0xMTY3NzE_a5102e2a-0791-4090-a603-b5dfd077a224">3,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8193e2fcad6a491c9c98e5dadc6de63a_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfOC03LTEtMS0xMTY3NzE_46e8e764-dce0-4905-a2e9-88a668210c4a">4,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135087334a5d4c22bfa9b973191edec2_D20220401-20220630" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTEtMS0xLTEtMTE2Nzcx_cd3aaa67-d714-41ef-8083-d5939c54da5f">354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33f1397d8a6c4970be8e3744fa05b614_D20210401-20210630" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTEtMy0xLTEtMTE2Nzcx_0294ac48-f975-4279-a3a6-677b9cbb9210">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa70c909ebed4960ac5793fab0872d29_D20220101-20220630" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTEtNS0xLTEtMTE2Nzcx_50ad9540-7ea7-48b6-9735-41cdf2c666f0">676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1fd4b8f2dca420587be152cd56a71f1_D20210101-20210630" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTEtNy0xLTEtMTE2Nzcx_ae50fc4d-0a5f-4c6c-af9f-98ca1ca1b42b">697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6165a9798c56425cb4efb5a5f6723bfc_D20220401-20220630" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTItMS0xLTEtMTE2Nzcx_5918dd2c-c9e6-4c7c-a421-14a51a37fbb8">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bd4de5a193d4a029240767ca5a07233_D20210401-20210630" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTItMy0xLTEtMTE2Nzcx_72f2feac-5354-4aac-ad7c-60358a978f0e">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife570419c7bf420eb1abf7c964aaca40_D20220101-20220630" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTItNS0xLTEtMTE2Nzcx_d4214b5c-8979-4dfb-a0f5-03bca7abf2c6">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3029344c603341c39ead09035d7dfa4d_D20210101-20210630" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTItNy0xLTEtMTE2Nzcx_0176654c-0094-40e1-ab81-61b2dc6e6a08">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd827b38d174dab9b133e198c4a8961_D20220401-20220630" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTMtMS0xLTEtMTI1OTAx_b8dc43b0-f0db-40cd-a8d6-56362baf4515">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58ecd7a903984152b7f6c2ae9bec8334_D20210401-20210630" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTMtMy0xLTEtMTI1OTAx_381141be-cb71-4e25-821c-cac750df0f86">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib91d44ce63944098b3420f5c3736b8a9_D20220101-20220630" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTMtNS0xLTEtMTI1OTAx_fc97d941-7f01-40eb-81e8-9b335d1ea7e1">299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc157eb51cba40e89c5c61507c69e6e5_D20210101-20210630" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTMtNy0xLTEtMTI1OTAx_ddde3be9-c9af-47f8-9f98-ed28cc738a30">362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66c6b838e58742c0aec7f7e50a13b045_D20220401-20220630" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTQtMS0xLTEtMTMzNzYx_979f1d13-1c8a-4b74-ab10-a339326b57df">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ffd9a91d95843f5b57ffc1c00e8f083_D20210401-20210630" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTQtMy0xLTEtMTMzNzYx_296e3b78-9443-408b-a2d0-17219376d8bb">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dba412bc4484690b009184d4ba468c6_D20220101-20220630" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTQtNS0xLTEtMTMzNzYx_c544a1bb-99d4-460d-8fa3-c2d0debee42d">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b7ac6f51a042f3af9aea0cd5d38c09_D20210101-20210630" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTQtNy0xLTEtMTMzNzYx_68552a99-b7d8-4c07-a746-1753bede8d8c">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i641af432b0f64dcb834dccbe69309abd_D20220401-20220630" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTQtMS0xLTEtMTI1ODg4_b926d799-861e-45eb-ade4-49b0e9db7974">208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if41baecc67df46e3909a38e74cfc03c7_D20210401-20210630" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTQtMy0xLTEtMTI1ODg4_80a32614-f76f-49f3-b8b2-fa37dcec8d2e">213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ade95eb6964658bc80338e46f307dc_D20220101-20220630" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTQtNS0xLTEtMTI1ODg4_4dd2629b-1591-42fd-af39-966e463b7547">414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7050fd087c144698ee6de6deb8f7b08_D20210101-20210630" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTQtNy0xLTEtMTI1ODg4_eeb7aa80-441a-4e39-a1d9-a60e815024b1">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56f9693a8c8e416f9524496f13d18f13_D20220401-20220630" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTUtMS0xLTEtMTE2Nzcx_f02b98c1-65a3-453b-8489-ae70241cdc8a">789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i457d6b1c8dad41d797d6f3caa45e3c46_D20210401-20210630" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTUtMy0xLTEtMTE2Nzcx_ca0f95d3-1aad-44f1-90a0-c253dcdb2154">887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c0e69d16e47492cba77b50588ee0475_D20220101-20220630" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTUtNS0xLTEtMTE2Nzcx_29cf7f4d-ba18-464b-b426-b1929a125bff">1,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8193e2fcad6a491c9c98e5dadc6de63a_D20210101-20210630" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTUtNy0xLTEtMTE2Nzcx_65c09029-aafd-4167-9e3f-ac7c8614662b">1,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabd877b8ef23452c8e9fb08b70c21536_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTYtMS0xLTEtMTE2Nzcx_cda87e4d-2c85-4f6c-bac7-15aa72163917">202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7fcbc8743ff4d28a9642d1d245a31c3_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTYtMy0xLTEtMTE2Nzcx_6a51e6bd-c25f-4037-8478-ec868f3bea3d">199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia26aedc76fcf44ae81e064729f28caf3_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTYtNS0xLTEtMTE2Nzcx_d9f4bcf3-827f-43d1-84ca-d485d327303e">396</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i341826d4665e4f9691c35f15ba5167d5_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTYtNy0xLTEtMTE2Nzcx_334c4573-a78c-41ac-8be8-9cb395f8aabe">380</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTctMS0xLTEtMTE2Nzcx_229f0dc4-dac3-4dd4-8d92-ddc720df547c">302</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTctMy0xLTEtMTE2Nzcx_03e245f8-e3e6-42cb-a84f-896b29c947e5">360</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTctNS0xLTEtMTE2Nzcx_8a93b5f5-271e-438b-919b-8ca70ca54b51">612</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTctNy0xLTEtMTE2Nzcx_3d173568-1200-4bb0-84cc-a4bdf033fc68">717</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTgtMS0xLTEtMTE2Nzcx_812d6f6e-eace-4391-ac93-dd99be3fa990">83</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTgtMy0xLTEtMTE2Nzcx_97111cbb-dfc8-4943-bb3f-000866a3fa61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTgtNS0xLTEtMTE2Nzcx_17e7d943-5d86-4f98-8a56-da42bf98546c">83</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTgtNy0xLTEtMTE2Nzcx_46f60fae-6baf-4be7-b740-7487f6762616">469</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTktMS0xLTEtMTE2Nzcx_54319a37-5277-494f-b4b7-f658880cb127">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTktMy0xLTEtMTE2Nzcx_0272940b-af82-4b7b-8adf-ac088858a186">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTktNS0xLTEtMTE2Nzcx_8abfa467-9428-4b09-8962-83ad00984b3f">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTktNy0xLTEtMTE2Nzcx_3d3f6336-3e44-46b5-85e3-7117d98953e0">195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjAtMS0xLTEtMTE2Nzcx_3c0e84a4-d26c-45b6-bcf4-233f168ef30a">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjAtMy0xLTEtMTE2Nzcx_856d72c8-b8ab-46df-99f8-e0c9d665fb8c">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjAtNS0xLTEtMTE2Nzcx_a343e766-b0eb-4f96-a3e8-346b24b1509c">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjAtNy0xLTEtMTE2Nzcx_3897d03b-b729-40ac-9a57-19f303af4a73">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjEtMS0xLTEtMTE2Nzcx_1db2cb9c-4d71-41f3-b861-b05be39c883d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjEtMy0xLTEtMTE2Nzcx_6864c787-a728-46f1-ae8c-3bd32c05f62e">542</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjEtNS0xLTEtMTE2Nzcx_4a23adbb-982e-4136-a434-b2bc8bb6b9ef">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjEtNy0xLTEtMTE2Nzcx_64d3ca97-9da4-456b-96b1-27a26dedeeb2">512</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjItMS0xLTEtMTE2Nzcx_cda0c98f-d578-4432-b049-8eb359a4862b">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjItMy0xLTEtMTE2Nzcx_e133e0e1-10ee-470e-a702-a1785ebfa360">270</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjItNS0xLTEtMTE2Nzcx_71f78b7d-43bb-4d70-8980-5458de714a1c">446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjItNy0xLTEtMTE2Nzcx_3ff38a6d-521a-4f61-8590-f691b519f152">491</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjMtMS0xLTEtMTE2Nzcx_e7b58578-7dc9-4d91-9d28-a81de21ebd29">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjMtMy0xLTEtMTE2Nzcx_87190d3c-b5cf-4e9e-a534-b91399b4cdab">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjMtNS0xLTEtMTE2Nzcx_ee72c7e2-0833-48fb-bfab-b1fc79dad7a4">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjMtNy0xLTEtMTE2Nzcx_1e05124a-6e5d-4e85-b835-e72619c3eb55">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjQtMS0xLTEtMTE2Nzcx_5c5fba05-dac3-4363-99c0-7dcb48a973df">410</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjQtMy0xLTEtMTE2Nzcx_2d3aa0d8-ba07-4670-a767-c78e865fd92c">364</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjQtNS0xLTEtMTE2Nzcx_d13bf50d-4ad0-4f65-aa83-c5c69f58c662">772</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjQtNy0xLTEtMTE2Nzcx_ee80a332-dc87-45df-948f-c9b92098cf4d">732</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjUtMS0xLTEtMTE2Nzcx_6cd87c3f-84a3-462e-b5d5-3280b5f15ce4">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjUtMy0xLTEtMTE2Nzcx_52153aeb-8063-4608-b4e5-81ab5472de8e">45</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjUtNS0xLTEtMTE2Nzcx_68631b75-8797-45b3-bf17-acfd5c4baae1">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjUtNy0xLTEtMTE2Nzcx_57548523-6bd8-4bc7-9dca-34edbdb902d5">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjYtMS0xLTEtMTE2Nzcx_2069bc1a-6c16-4422-85aa-ae93ad8872ff">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjYtMy0xLTEtMTE2Nzcx_138b63cf-a6d2-46a1-8fe8-4f286cc11bb6">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjYtNS0xLTEtMTE2Nzcx_cd734b99-f6b8-42d4-9807-55ba392ac83d">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjYtNy0xLTEtMTE2Nzcx_3a0ea119-994d-486a-98eb-bffb617a802e">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjctMS0xLTEtMTE2Nzcx_ab05a49b-41da-4d35-ba41-3f1e3a556b5d">129</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjctMy0xLTEtMTE2Nzcx_30401f94-70cc-47bb-849b-76243771c5be">670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjctNS0xLTEtMTE2Nzcx_80827dcf-2190-4517-92b6-382e9601f7ac">211</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjctNy0xLTEtMTE2Nzcx_f2274eef-e55b-4805-982c-fd1f1b1cb13b">1,261</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i526c1edc66094cfc88a035d6ad1884f7" continuedAt="i940697eb330a49dda412da1ff39d86dd"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues by Segment and Product Category </span></div><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RleHRyZWdpb246ODZkOGIyZDAzM2QxNDQzN2IzMmE4YzM5MDAxNWE3MTZfNDIwNw_69807aff-6c47-4843-bba3-39978ab7479a" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by segment and product category were as&#160;follows:</span></div><div style="margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i120c5c3448804817954acd3db4e441ce_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMi0xLTEtMS0xMTY3NzE_bda8bbe2-92d4-4e1b-9f0a-7645f948a16d">501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6e559fe09a4393a2f7b2d796409368_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMi0zLTEtMS0xMTY3NzE_68982229-3893-4987-ae51-951807a92a7a">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1917cf604f114f61a3027f48b8e509ba_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMi01LTEtMS0xMTY3NzE_4dee3819-6e7c-41fa-b6ce-87204771b1c9">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i304de3dee0ca46afbd4d773d5b73caeb_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMi03LTEtMS0xMTY3NzE_3090211a-2780-4f93-8feb-6a7d13dae659">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5bdd34908934731b3f7ed30e692ca37_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMi05LTEtMS0xMTY3NzE_fc5353e4-61d8-4c0d-9038-04b229ff6e29">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib94cfde72d4a4cceaa45cabf3b8613fe_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMi0xMS0xLTEtMTE2Nzcx_ddbefafb-ad06-4e39-bbdb-9fbd89872391">884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i697b4e937dcf4444a2da425da4f9da4a_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMy0xLTEtMS0xMTY3NzE_f63b41b5-2c9b-4577-a636-f9f787289c6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bf870b296aa434ba035c90e0472f7b5_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMy0zLTEtMS0xMTY3NzE_31b2a64e-039f-450e-9fde-a9abd5464a2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37722f9f64464a7789b7776cda56802e_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMy01LTEtMS0xMTY3NzE_eff6dc1f-9c6f-41d6-80c2-a66dc50920e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68e196aa912c4a06b50fe1a7ff07c9c3_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMy03LTEtMS0xMTY3NzE_5b70ba4f-3d98-452e-9bb0-81bb9eae1796">57</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1535a26028ca41d681e4eb89f1cab0ef_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMy05LTEtMS0xMTY3NzE_3263e72a-cd97-4b8c-8cd5-4f417383f53d">392</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ac012d36aa744d285111dd5bfa0f49b_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMy0xMS0xLTEtMTE2Nzcx_2ce10cf1-82c1-449b-af7b-6774922489cb">449</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1532aea43eb6489e973b019623e7468c_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNC0xLTEtMS0xMTY3NzE_3397beaf-0948-47a0-871f-e7c1c47650db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40ac48836f7b4475b5d15a50602624db_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNC0zLTEtMS0xMTY3NzE_c0e177fe-dbd9-4e02-9064-76a9bc9e4aa9">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3591c7e9bf84e3b97a9bfacbd8fc4c0_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNC01LTEtMS0xMTY3NzE_ab9b89da-173c-4a5c-9420-28dc33148e1e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9945eced06dd4de19098303f4b0695b2_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNC03LTEtMS0xMTY3NzE_19a05855-4ab1-4c1e-9fc0-68133e0812e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6fdf97ea30640ada7e3f06ac163c2d4_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNC05LTEtMS0xMTY3NzE_23323842-6263-485c-920e-8d69be7c2d16">364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i363714d873034daabe033fe4530323c5_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNC0xMS0xLTEtMTE2Nzcx_4e4c5997-8263-4d90-8565-937e1350b6e1">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18def26b9d7f4f769191fbb1b702e4e8_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNS0xLTEtMS0xMTY3NzE_98a07482-b702-4d17-b4d2-7a7040431304">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dde17363f0241f99f397e9fc622e2dd_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNS0zLTEtMS0xMTY3NzE_53dd7d19-0ca9-4aef-814d-91147c622069">122</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6d327e99e94ae6ac9c9222edaffe89_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNS01LTEtMS0xMTY3NzE_b6b44cf2-81cd-4623-b8d6-d6cdbd227c68">31</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2c6d5fc0df14fdd8c5d865fdd5a471f_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNS03LTEtMS0xMTY3NzE_08c12985-09aa-46a6-a99d-ae32d8947dc2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5244d54181f2446bb8ba651b7b0fbad7_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNS05LTEtMS0xMTY3NzE_92567e2d-8060-4002-ace6-6a6e1678b03d">61</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id527f274d97e461ab64689a5373f4d81_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNS0xMS0xLTEtMTE2Nzcx_c6f68e75-1dde-4bec-bec9-1960c32c1a42">214</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3c647fe76d46f0bc12c314d43c29b1_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNi0xLTEtMS0xMTY3NzE_288ce851-9c36-429b-a813-0b475246a839">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4daa40222c247d590b95cd5d1197454_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNi0zLTEtMS0xMTY3NzE_1d9cf92f-6548-46d0-820e-4e7216cddf6c">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00857c1731c645e18fc5b267ac5193c4_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNi01LTEtMS0xMTY3NzE_8af81b68-c37d-4bc2-8bfe-8edcbce3735b">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id70a3d87ffc848f3a702d8181bb0aac1_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNi03LTEtMS0xMTY3NzE_7a26b107-8f3b-4bec-a63c-a6947ccb8a50">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9098718d68eb4191b04c1220647b46ac_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNi05LTEtMS0xMTY3NzE_35d737c7-1988-4bb0-a099-9e571deee3cf">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98252b07170a475c86a2d0a8454ebb3e_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNi0xMS0xLTEtMTE2Nzcx_8737fdf3-b7f6-409e-a342-653e6934585a">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d0cc468650a4f8eb079db9c1f1d724f_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNy0xLTEtMS0xMTY3NzE_1858ba28-beaa-48e5-9574-76bab7a2dc2f">501</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb0c495400cf41aaabcb4ebdf8cc8c54_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNy0zLTEtMS0xMTY3NzE_f718e38e-265b-47b0-890c-a1c0907408d1">233</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b3e89147934577b98cf490c2dc6e6d_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNy01LTEtMS0xMTY3NzE_4ec1471e-6d55-4e0e-8d2f-c123082c49bc">235</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad533e12c8984d1aabaf4ca2ea7f295f_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNy03LTEtMS0xMTY3NzE_1158312b-8e5e-48e1-8ee6-d2258966bf37">57</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8a84b3f2b824ca7bb450377f0288abe_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNy05LTEtMS0xMTY3NzE_b0373f60-3692-4173-835d-31518fe0ea0d">941</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNy0xMS0xLTEtMTE2Nzcx_af3d1a41-6ee1-40f3-8da0-4890cec65df3">1,967</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id997cc25c0184d418316a9c77c4792d5_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTAtMS0xLTEtMTE2Nzcx_d340eb31-7cf0-46b2-9950-2af08dc452bf">514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i175f3c9ffed049e683076ff08bfebbbd_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTAtMy0xLTEtMTE2Nzcx_bc3c8dda-31da-480e-8a91-5e87b9079825">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia439123672ce49b5b793b5103844ab11_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTAtNS0xLTEtMTE2Nzcx_c9e1bb91-c473-4f0b-ac50-c97f35b4f603">223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3a10c843c354c3eb832c610df7c4cec_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTAtNy0xLTEtMTE2Nzcx_8b4d4ac4-62e2-429d-b220-85578080caeb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i094e2621cd8646149b22d5835913eff4_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTAtOS0xLTEtMTE2Nzcx_48b0a06b-cff8-42c8-9a0c-3e1938cb45d2">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8d1a68df38d4361a9ac80a5d0b7650d_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTAtMTEtMS0xLTExNjc3MQ_3f06222f-8705-4c65-a4c4-301fc488a10f">942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f1a30d7d1d8412cb4ef23629b723985_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTEtMS0xLTEtMTE2Nzcx_ef047b2a-7309-42cb-88df-40b23aef54a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55e9e9d493b84ce3b937b48d26431696_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTEtMy0xLTEtMTE2Nzcx_55e92d37-619b-4952-8ceb-a7da1f43c139">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia453e822304242f5817dad90b1b13517_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTEtNS0xLTEtMTE2Nzcx_fd26091d-65d8-4121-b8a1-b525cb175cac">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf81fc999e7d4614a4ac10b31038913c_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTEtNy0xLTEtMTE2Nzcx_8fa4644d-0ca3-4bd3-8b49-921df4f0b425">73</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie523d947f1fa44f2a62fe53506efc11d_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTEtOS0xLTEtMTE2Nzcx_50f3876a-3e68-4039-98c7-f0e81b7e3a62">397</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45ab7ba925334c48973d75b0c877af73_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTEtMTEtMS0xLTExNjc3MQ_9d0b9f50-80ff-448a-8f22-85dcea6084be">470</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic38842b1d031468aaa7b2c3123e44ef8_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTItMS0xLTEtMTE2Nzcx_d7cb240d-09af-42c7-a08a-4d0abfacc2d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i636acc71a6ad4a25a53a6db7c8380b4c_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTItMy0xLTEtMTE2Nzcx_321138be-569e-4168-b923-4ec5e4b313da">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71427b5dcdf84da295d3722e33c25b53_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTItNS0xLTEtMTE2Nzcx_0bdb3fab-7f2a-4ced-b366-207279c120e3">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieda5739af68749139a002f6bbc8b7968_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTItNy0xLTEtMTE2Nzcx_215b7eca-33fe-49b1-af67-6b175a996745">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cc095d5494b464eba663d1927c92206_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTItOS0xLTEtMTE2Nzcx_42b10a94-45d3-4c9b-9b53-58afb9491362">325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ff22abce45548b7ae5bae24b04a665a_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTItMTEtMS0xLTExNjc3MQ_9cc5dd2f-5266-4838-8778-7ed9d86d6e9b">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6117b7192764a0b83f96ffa1cb7174b_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTMtMS0xLTEtMTE2Nzcx_45bff8fd-49f3-4c5a-b168-b735e38aedd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66e4cb2eef1c497aba28c323a09b369d_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTMtMy0xLTEtMTE2Nzcx_eb785002-8a1e-485c-b50c-be3f5098002c">206</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7885ad991d8747f994509e41120e1156_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTMtNS0xLTEtMTE2Nzcx_5b4b219b-09e7-4108-98d0-45797b521246">31</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i033175b733ff4d76ac19b4af757b2c72_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTMtNy0xLTEtMTE2Nzcx_477375fe-dbdb-4af4-bdf8-74181dcce6e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a94cf1fdbb647919430b66b2c3f4818_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTMtOS0xLTEtMTE2Nzcx_b0cdb3a0-b333-488e-8be0-96cd20f16dc4">68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa1d61d59efe430d99d872a21dbbb93f_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTMtMTEtMS0xLTExNjc3MQ_1fde9fb9-ebd5-49b2-a00a-6d32f8f9ea37">305</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58fa049f1be9491d86f8e95d6a2c5777_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTQtMS0xLTEtMTE2Nzcx_a4e6d993-9422-44ff-b7ae-583f478c2b37">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie753b580b8874261b8650c0a68ba8d70_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTQtMy0xLTEtMTE2Nzcx_b705fc3d-30f0-46b0-abee-686800dbece1">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5c02cb63e5b4aa3a0984f648ed39900_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTQtNS0xLTEtMTE2Nzcx_0a5c1884-00ad-4fe7-9f82-906e4c915161">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf369ea76514f31b38a239710bbca0f_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTQtNy0xLTEtMTE2Nzcx_e17170c5-941c-496c-b00e-7b677e6336ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8530b669e5514873aea052a84f77f1e8_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTQtOS0xLTEtMTE2Nzcx_a31855be-c52e-4116-b2ae-9854e5432518">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a41399fcd14f7c86e4befc31b9bed4_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTQtMTEtMS0xLTExNjc3MQ_40819100-2337-47f7-9731-36fb5850b393">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96c50519eebe43e28fe0e6f1d4c9fcf4_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTUtMS0xLTEtMTE2Nzcx_6d75aa30-9468-4f70-abbe-37b1d3183cc3">516</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96c60e82572346049ef163998e5a970d_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTUtMy0xLTEtMTE2Nzcx_99258768-9b72-41a1-8b21-2e2e616dd93e">313</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0da421ef8e5c446692c399776ebed030_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTUtNS0xLTEtMTE2Nzcx_9f18191f-0a84-472d-a8bf-c04bc189bb01">264</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0702da316be6440e840ce3f2f1780427_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTUtNy0xLTEtMTE2Nzcx_dbae25e0-627f-48f6-9c46-87b238381119">73</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddbe6a4096ff457cb62338fc9c69d310_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTUtOS0xLTEtMTE2Nzcx_fc3077ae-1b13-4be0-8b2c-6978b9828d38">934</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTUtMTEtMS0xLTExNjc3MQ_1ea2f6ce-3fbe-4128-976e-34ea68ae43fa">2,100</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie25fd17d002a4da395da4369a027c307_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTgtMS0xLTEtMTIwMjUx_451b208f-9c08-48f1-98c3-489020f7ab02">965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4ef1ddaae604d258905581fe15e36d0_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTgtMy0xLTEtMTIwMjUx_40b7bfa5-0877-4fce-87d8-b3d30333e12f">134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5239df425024a3e9d3b04b6422f8d1c_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTgtNS0xLTEtMTIwMjUx_fa283c57-6605-4346-aec5-92c1de1ca313">402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i425a979e48b04f06b178c9b31d745920_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTgtNy0xLTEtMTIwMjUx_3a54f786-a17b-4ee0-ae79-1e3895162431">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1b2fa78c45a42dd8e6d9fc4f37b7f8f_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTgtOS0xLTEtMTIwMjUx_d1201ad8-50ff-449d-b209-2e986c8e0ddd">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd114af7b13347929658a839ced9cb43_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTgtMTEtMS0xLTEyMDI1MQ_3df6b0ee-7ad6-4b8c-bd2d-eed2923db96f">1,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c7ae506423648cf912c0b4dafc6bb92_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTktMS0xLTEtMTIwMjUx_cbe67007-efa0-4519-930a-7f55be796059">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fa22ed31f5d47d78586f590cb5b2296_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTktMy0xLTEtMTIwMjUx_9631a82f-53c2-461e-b39b-d7ebcadef455">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if81393d129bb4f80a2217b7c9d4c8957_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTktNS0xLTEtMTIwMjUx_42990302-79bf-4a22-9b73-f18d4141bb63">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08b72bf14f6c499fbdab27dad66f293c_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTktNy0xLTEtMTIwMjUx_6f68fc23-e7f1-4335-8237-99db267062e5">129</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e2aafd1b5e4899a9552e3dacb16fce_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTktOS0xLTEtMTIwMjUx_3971c81a-1b1c-42de-94a0-28510081f644">778</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffba9783b7fe44a6935ad5a994bbbee4_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTktMTEtMS0xLTEyMDI1MQ_a7a0f14d-08ae-48af-9179-fe201f554f5f">907</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id62f002563a345a4b90b427b6746a4ba_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjAtMS0xLTEtMTIwMjUx_7b11a988-44a9-4795-be5e-3bcd17e72dac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff8125862d7c4fa8b63656e4caef3fea_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjAtMy0xLTEtMTIwMjUx_d0fd2be5-222b-41b5-871e-4ebdb19fe274">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1843b2170f054dfda4d14d6b65d9e07e_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjAtNS0xLTEtMTIwMjUx_53c3b653-c61f-4fc7-8591-da522e4d4ab9">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i875a6c5886a44cbe9f224b9739a1d650_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjAtNy0xLTEtMTIwMjUx_5bddb27a-06d5-4231-8970-2d92e478c98e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife0400651f12423ea171a23fe5b7b728_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjAtOS0xLTEtMTIwMjUx_a6de463a-317f-417d-9673-7d69aeb4296b">699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9906ce0703774a55b40a2d2cbed1fa6f_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjAtMTEtMS0xLTEyMDI1MQ_5ef6c6b7-fd33-4670-b740-9955cb44b118">775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ba7a99462cd4381a45f105bbdc6d784_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjEtMS0xLTEtMTIwMjUx_ff126052-30bc-4d11-84ec-fa204ce8b1e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39805184860940d5bd360342cd8f0cf6_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjEtMy0xLTEtMTIwMjUx_eb9e0a3a-c6f6-476b-ab67-c116652411e1">255</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf03874e602d4ffa881dc7e9af5ec89f_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjEtNS0xLTEtMTIwMjUx_d35912ee-d022-4b55-8419-4126fbd5bc4f">67</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic07dceb99d094428b0107fdfd7ea2ded_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjEtNy0xLTEtMTIwMjUx_ff7cb827-4e72-4be4-8351-562fe54642fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b8d25aa564b48688828b7b52a248072_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjEtOS0xLTEtMTIwMjUx_e5cb3c7c-6d9d-437d-9bbb-bc0f66c900db">113</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7024726e6548129771c398104f4234_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjEtMTEtMS0xLTEyMDI1MQ_7c6a1660-fbbd-4346-9e15-db872909c3bb">435</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09631ce9f39243a38774112d96ca119c_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjItMS0xLTEtMTIwMjUx_62d46704-b5a2-49a8-a0d5-a60ddb283805">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36c7f7595c284373909f23141e52949e_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjItMy0xLTEtMTIwMjUx_b6aac767-0ae1-4777-95be-bde0ab4cf9bb">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4105a97cccf946db9ca58a8b45433ea7_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjItNS0xLTEtMTIwMjUx_84cd1077-f2cf-4154-b37d-75fe92e90ec5">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i57f06f60daf14282b059eb9c693125a2_D20220101-20220630" xsi:nil="true" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjItNy0xLTEtMTIwMjUx_c20f214e-b352-4717-a43f-6e3c7789ec8c"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05e092a9ec4e49c6a71e8efa4a8d7087_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjItOS0xLTEtMTIwMjUx_bfe6d5b8-6fde-4bca-8bac-db03aef252e8">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4002b0e7cb584f409ca3835643a996ce_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjItMTEtMS0xLTEyMDI1MQ_30b3a77d-63f6-45ca-bc63-a24a312a743b">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c7b76190d5140fd9da04108a1ed24e5_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjMtMS0xLTEtMTIwMjUx_362e336b-dae4-4e40-b2f8-3f46054001eb">965</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i430a37ccee354cf9b59987d97e781a8f_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjMtMy0xLTEtMTIwMjUx_6e69c83e-20c5-4fe0-9b15-678cad3c3338">477</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecd0285b18fe41da9fc167864657bccb_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjMtNS0xLTEtMTIwMjUx_acaa3093-000a-4166-a879-d2616866772c">484</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i864ee40a0f6549cab4f16fffdd93c3fd_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjMtNy0xLTEtMTIwMjUx_cb2da099-891e-4ceb-92d3-b8ded43c1d20">129</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86bd562069224eb1a2aa48a2a7c117a3_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjMtOS0xLTEtMTIwMjUx_db98482a-faf4-4715-892a-6e11818b82b6">1,830</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjMtMTEtMS0xLTEyMDI1MQ_e1046a74-5d4b-4b0f-a811-4163ad3a224b">3,885</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ecff54947c94ec5a731ac192a3eac6f_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjYtMS0xLTEtMTIwMjUz_aa0971e4-e45c-488c-a3c2-7511dd09733c">984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie837436aa8784d168ff0c0b936ad7cbe_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjYtMy0xLTEtMTIwMjUz_76bd7c2a-b9a2-4ae2-9b55-da91a14e5eda">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5f965033d67432c81edaee2da1a1977_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjYtNS0xLTEtMTIwMjUz_208b5bcf-04ba-4840-a0a0-12ad005d12b0">465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bde276d18e442d082198091776c5340_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjYtNy0xLTEtMTIwMjUz_23269b90-9119-4d8c-941b-7b038bf78ba6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406023bd6e5f421284bd2cc748d58de8_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjYtOS0xLTEtMTIwMjUz_cf624fa8-af18-4fef-9a8b-89f1a2cda153">259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86081bcd6aa54f46bf54174fe6157caf_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjYtMTEtMS0xLTEyMDI1Mw_e6df5cf3-eb96-49b3-89f3-60bcdae1a1ed">1,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d9741cc605c4351b5b3308c245d8cae_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjctMS0xLTEtMTIwMjUz_35c6b019-4bf0-4b5e-b097-461cbbf74ef8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bfae50f3756423ca86237fa9b199c6f_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjctMy0xLTEtMTIwMjUz_d07f6312-ab68-44fe-b1e2-a9dc1a245456">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie00839f31b7c419293449f6db9edd59a_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjctNS0xLTEtMTIwMjUz_176d90ad-d770-4ac0-90a6-ee4656ad09aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64314cb261074ff9adb800d48da61982_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjctNy0xLTEtMTIwMjUz_c8b2a975-0fd2-4273-aca0-ef866ed9439d">145</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i895071e19f56442e8979c066881d9317_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjctOS0xLTEtMTIwMjUz_728681d2-bb2b-42d5-91b9-8ee14eb0c66e">779</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia36c07693d1f4df588ce2d80fa89ff6e_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjctMTEtMS0xLTEyMDI1Mw_6475b61c-cd91-452d-8162-d78da67d1cc6">924</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib42a147c0c7b4941bae23485591fe3e2_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjgtMS0xLTEtMTIwMjUz_fa2b41f0-75bc-40d3-a113-77bf4216768c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9e5781756f4250be2a94d03142b737_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjgtMy0xLTEtMTIwMjUz_858281b7-5ecc-4bfa-bd9b-e77377cd9e42">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98b834d54e804d5ea61ab8adaffb5153_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjgtNS0xLTEtMTIwMjUz_0c6a1d19-21f1-4726-a57f-70658c1e698e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fbc6006e021429bb57b14e5be7faea9_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjgtNy0xLTEtMTIwMjUz_a9f7a9df-28cc-47b7-9ded-a616f55dfb02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a5341f0ece54bcca5e06f9dbc2c5aa7_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjgtOS0xLTEtMTIwMjUz_a9955295-e5bf-4ec7-8732-398352d9376f">645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be2243ad7b746ff8509e04bcc66e578_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjgtMTEtMS0xLTEyMDI1Mw_0a93bc00-2dd8-40e5-bb74-61039a796780">706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28cd923a4f904a5da05278a0549bb209_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjktMS0xLTEtMTIwMjUz_edb7063a-772f-46de-b91d-272702e8ebae">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a79025dcf9b4067a64a869b30e5d82f_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjktMy0xLTEtMTIwMjUz_5076d355-4344-4ed8-9a33-58a425b9ec35">418</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85da69a1931c49e8b2e5ce17cb63defa_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjktNS0xLTEtMTIwMjUz_6c67f1ab-f0e4-42a3-bf25-6ef342cd3a67">78</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c72a40331c64039b9c3787b46aac39c_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjktNy0xLTEtMTIwMjUz_5392a353-aea5-4af7-986f-a96136d05704">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf5411fb6d544cfd8fd5bf410f862cbc_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjktOS0xLTEtMTIwMjUz_8c50d5ec-7590-4b9e-8084-96e15431b96b">119</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5a9a936aaad4510ab5bf3d9d20d705c_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjktMTEtMS0xLTEyMDI1Mw_bd8907ec-0afb-40ab-8f13-9a7eae8ddd6d">615</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73af0e3646d5483ab230a7ecb7d39952_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMzAtMS0xLTEtMTIwMjUz_221a775d-43d5-4889-b502-349d23b192ae">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia56d626754214d8bb30c6d8a7af45bde_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMzAtMy0xLTEtMTIwMjUz_3740ed77-8988-4794-944a-c4f862b59bd2">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18484995d42c4a828a942edcda3b3121_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMzAtNS0xLTEtMTIwMjUz_8729a268-e5d6-4e2b-a157-be1ce80096f1">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13c03a791f84448bb0b7d082960d3002_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMzAtNy0xLTEtMTIwMjUz_7384102c-2d65-4cae-bb99-44a98ae35a68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ed7a35687114a9980b0c5849d0ae283_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMzAtOS0xLTEtMTIwMjUz_c922de73-e6d1-4ae7-aaaa-b536624b8d79">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id15af34d73934993bcabdfba417f3137_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMzAtMTEtMS0xLTEyMDI1Mw_27f627f9-607a-426f-9f0a-34166fb7036e">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id018321b208247d78d77fe559ea5026b_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMzEtMS0xLTEtMTIwMjUz_0e818661-df85-4000-873a-794b5c3c4da0">988</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04f8b4bf53f849b2a0c2101807367a6e_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMzEtMy0xLTEtMTIwMjUz_2ebec953-a97f-497e-9222-0ee3fbbccd81">619</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99757cb9fe65492481f94c5710ab5f19_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMzEtNS0xLTEtMTIwMjUz_cb7c6b2f-00ba-4eb7-8569-c1c5ac27d941">560</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib382d5d0d22742d48bc99e77c138c9e1_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMzEtNy0xLTEtMTIwMjUz_872c324b-699f-4e25-b146-cd0691502725">145</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20309133d4fc442aa35447c20bd22671_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMzEtOS0xLTEtMTIwMjUz_749db3b2-f03b-4427-8b4f-cd85d6d17467">1,815</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMzEtMTEtMS0xLTEyMDI1Mw_e97b4887-4c01-42cd-b17b-d68dfd33f3cd">4,127</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The top <ix:nonFraction unitRef="product" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="INF" name="bhc:ConcentrationRiskNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RleHRyZWdpb246ODZkOGIyZDAzM2QxNDQzN2IzMmE4YzM5MDAxNWE3MTZfMzgxMw_663e2b7d-0b86-46b6-8700-a6126593587a"><ix:nonFraction unitRef="product" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="INF" name="bhc:ConcentrationRiskNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RleHRyZWdpb246ODZkOGIyZDAzM2QxNDQzN2IzMmE4YzM5MDAxNWE3MTZfMzgxMw_f61456e1-87f5-4f3c-b0ed-57a8abf89429">ten</ix:nonFraction></ix:nonFraction> products for the six months ended June 30, 2022 and 2021 represented <ix:nonFraction unitRef="number" contextRef="i2cfaca18cad64ba8b05f366fe634d9ef_D20220101-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RleHRyZWdpb246ODZkOGIyZDAzM2QxNDQzN2IzMmE4YzM5MDAxNWE3MTZfMzg0OA_41a44d96-a4ae-4d51-a630-dbff65a093d6">48</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i4deb7698e4954a5b8d104244e7a7dc24_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RleHRyZWdpb246ODZkOGIyZDAzM2QxNDQzN2IzMmE4YzM5MDAxNWE3MTZfMzg1NQ_3df4630f-534c-450e-bd88-e3f708ef57f2">43</ix:nonFraction>% of total revenues for the six months ended June 30, 2022 and 2021, respectively.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i940697eb330a49dda412da1ff39d86dd"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information</span></div><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RleHRyZWdpb246ODZkOGIyZDAzM2QxNDQzN2IzMmE4YzM5MDAxNWE3MTZfNDI0NQ_9bbf1d77-f9fa-4f2b-90ef-cdc94b1342ed" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are attributed to a geographic region based on the location of the customer and were as&#160;follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9362d500d1bd48e4b930877c7401396e_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMi0xLTEtMS0xMTY3NzE_c34706c7-3abe-4d49-861c-57d2c3f007f1">1,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i456aa1b7ef8e4440b7cb8b6579de00b4_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMi0zLTEtMS0xMTY3NzE_3f31c9a3-baa7-4807-a015-9ac85c246769">1,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5171d1e65dcd4cbdb5cc14e47de1aa9b_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMi01LTEtMS0xMTY3NzE_07876f8a-74b2-402d-a6dd-68c8ce9f6e63">2,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9ff5741a13c41598bd951eb6df22a49_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMi03LTEtMS0xMTY3NzE_7ce513bd-ba68-4f77-885e-94b1a402f4e6">2,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c0f8ff2e5749af9aff83169945c02a_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMy0xLTEtMS0xMTY3NzE_4a7fe09e-12de-4947-b848-86ae2034c4b4">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43c8fbd8ff914b6ca19f0386f21d064b_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMy0zLTEtMS0xMTY3NzE_1c25c747-16e7-4f68-aa1b-c2edc7b4d8df">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14ff28c4ec8a4de49643e94dca541c07_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMy01LTEtMS0xMTY3NzE_9e8e002e-21b4-4bfc-9552-4bea5d5b3745">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia381cdacc8be46eca693495fb7945846_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMy03LTEtMS0xMTY3NzE_0987c3b2-6172-451d-af02-158c3ca37374">229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe893c791888473889bea0f1c91bcd39_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfNC0xLTEtMS0xMTY3NzE_1eca24f2-758f-45c6-a58f-5a99d73c01f1">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia641b1adcc574ee0ab038b7fa110e50a_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfNC0zLTEtMS0xMTY3NzE_ae38732a-0c42-43ac-b3b3-4f0bb8ab66b5">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7834297d0db94dfe9f7141a9f3078f4d_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfNC01LTEtMS0xMTY3NzE_f399425c-19e0-4783-ad00-3b5ce1087e48">166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591e4832b4f54fbb9d7adb9df692f736_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfNC03LTEtMS0xMTY3NzE_36cca8b1-7d47-4517-8700-49248628e006">163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ed4f56387c146ce93bc623b05db992f_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfNS0xLTEtMS0xMTY3NzE_0eab6f88-810e-4bac-b4d0-1a402efa54be">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1990f6b2cd456e92b332bb89de592f_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfNS0zLTEtMS0xMTY3NzE_e8332418-b999-4093-8719-b0aa2e441ed3">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60c79a94ccae45868e7311a72fb1d515_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfNS01LTEtMS0xMTY3NzE_2af1d1b8-0bdd-4cb8-a723-3cfffc17f341">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884265fef55745918deccdac9bcfa489_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfNS03LTEtMS0xMTY3NzE_8e72c82c-314c-421e-b0b0-f79876965bbc">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i069927ecb29c4fe080759394b3c8dc0c_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfNi0xLTEtMS0xMTY3NzE_1680506e-fee2-4688-b573-bd12a2bb1a70">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ced9f4e29364491b1408b971112bc7c_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfNi0zLTEtMS0xMTY3NzE_2b36cc30-7b59-4a1b-88af-60e22ff6939e">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdc9dc66188149c59e6c7ce0524d38b6_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfNi01LTEtMS0xMTY3NzE_245b9ec2-ef99-4a18-8125-95d1b9fdad44">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bf2b6a85341450abb18712f9efb5eda_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfNi03LTEtMS0xMTY3NzE_b5e6ec90-43b0-49d0-8dd3-6e4685d451eb">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7053004fc5084f679e0978de05d595ea_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfOC0xLTEtMS0xMjAyNTc_f54d26fa-5ea5-4c1b-9902-65df1f9d3d7d">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31517ff0a8fc467a97fb7a044c926728_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfOC0zLTEtMS0xMjAyNTc_ba79a3f7-81d1-446f-885a-1bd266934712">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70de35ed376b493a9c17e9a01ab991c0_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfNy01LTEtMS0xMTY3NzE_47243fde-5986-4f02-98e3-1ce443a9ef6d">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63abbc4e400433b9f6ec4a807834bce_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfNy03LTEtMS0xMTY3NzE_5bb86458-969d-4393-9ac0-f9b13dc41cc4">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60d3cf48dd964670a527396a7fe4eb90_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfOC0xLTEtMS0xMTY3NzE_8ebf242e-70ca-4a3c-9c8c-483b6c638caf">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73244b3c309e4530819a1d26aa067e4b_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfOC0zLTEtMS0xMTY3NzE_56ad4409-083c-4fb1-afcd-f9791914833b">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie300b629f5f74f4a92f1b3212fe0f30e_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfOC01LTEtMS0xMTY3NzE_0704be8a-5b1b-482a-8839-1c59fbd0c8b7">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6948cd6efdde4ea5884d6a6035885001_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfOC03LTEtMS0xMTY3NzE_698bda67-2aad-468c-9ad4-e2ceed1df946">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idce9b5dcada741cfa3553faf07a2ab29_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfOS0xLTEtMS0xMTY3NzE_67817234-d96a-4219-8430-924d843afca5">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17e0e178db084c9caca62884ab5d8e93_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfOS0zLTEtMS0xMTY3NzE_5c60cff2-4293-4db1-b511-8b992c30507e">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e2d85cd6a68443cb41d6924d9e95324_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfOS01LTEtMS0xMTY3NzE_804adf56-181a-4bd9-89ab-bf00735c6aa6">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42b0806f1ff343be83a859afbca2a621_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfOS03LTEtMS0xMTY3NzE_d4d424ed-f757-4cf0-bf53-a9a529eb4f25">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i443d6ce9e17f413aa131fd871f9a563c_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTAtMS0xLTEtMTE2Nzcx_2a15964a-5266-4ba5-b92a-357171235392">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i084806bf6a674211835a0bd79f97abba_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTAtMy0xLTEtMTE2Nzcx_3a05883d-82f0-41ff-8333-7d9553c80dc9">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a390cca570a48afb39f787bcd7cada6_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTAtNS0xLTEtMTE2Nzcx_5af733fa-67ae-4ec1-9f8f-8e9d4d5f4bf6">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i869eb22b61c947cda0c17505c748ba31_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTAtNy0xLTEtMTE2Nzcx_66f7a0b3-cebb-434a-aad1-9776547cb29c">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99dbbb9db6434a699d016c9c43e9044f_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTEtMS0xLTEtMTE2Nzcx_f9814006-3010-4de7-9809-e63ac9823570">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icce4f70058be4e0b99727594cbdf1550_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTEtMy0xLTEtMTE2Nzcx_6420318e-4f4c-414b-b20c-edf7aa35fd71">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e85ab61967049ef95c26fe225814698_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTEtNS0xLTEtMTE2Nzcx_78ab9e09-7ad8-4df7-af35-c9c053e4516f">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i007fd7d6bf5e4f9e867874fad1935ed7_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTEtNy0xLTEtMTE2Nzcx_11e2386b-e92e-4e67-8cea-66bacb62a478">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eb5ee1718564d8b976f1851830b7dbd_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTItMS0xLTEtMTE2Nzcx_7ce3c18e-d49f-4a21-ad80-73b76086355e">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i059deee3380c481ca365b22d8012a26f_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTItMy0xLTEtMTE2Nzcx_8b959554-be91-4cfe-9cbe-c90a50930346">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcc32b6fa5394db2a95a6046a14c34da_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTItNS0xLTEtMTE2Nzcx_d8b58977-8210-4f0e-984c-32a58fd911f9">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb02cd70b47347f8b7ffdf5647ef00c0_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTItNy0xLTEtMTE2Nzcx_f4de623b-df91-493b-9fc9-d8013c21ad3f">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7079eca37c44de7aacc67bf6c5a6511_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTMtMS0xLTEtMTE2Nzcx_bc185f28-efe5-41a0-965f-42736d8ef7dd">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b1368ef6dc84e9b8b1bacbf9cd7dd96_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTMtMy0xLTEtMTE2Nzcx_6491dcb6-040c-4db9-8af0-7d8f8319ecd7">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib74d8519f3d64c62a7f44ecee5857716_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTMtNS0xLTEtMTE2Nzcx_8a92935c-f541-4b26-b58e-2d4a07a9de31">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefa92bbaed9340e4a7f6b8cfcdecb6ef_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTMtNy0xLTEtMTE2Nzcx_e4231835-c271-4d5f-bbcf-96023a3020ae">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e4a3d5230a4ff8b71fd4c1597f8ffe_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTUtMS0xLTEtMTIwMjU3_d14096cc-d4ae-47cd-b46e-843b216c095b">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b528c8c45d94928a7607bd144197d86_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTUtMy0xLTEtMTIwMjU3_f5671031-56fa-4517-9acc-18444dc71f2d">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if74073e3926d4398abab160d9cbb64e6_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTQtNS0xLTEtMTE2Nzcx_f1789ff2-cf7f-4004-b19e-c7942f3c529e">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c750ce60d174c2d8ea17243fca49290_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTQtNy0xLTEtMTE2Nzcx_bab293a7-ef61-464b-9d81-7196f1f15bed">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i420e7b1dee5c49dbb3ab84d5bf60a017_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTUtMS0xLTEtMTE2Nzcx_bf9e6436-c715-4413-bed8-c61cabbaf459">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id551f20a7c294526a90193e44a7d481b_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTUtMy0xLTEtMTE2Nzcx_5cfabef9-1113-4f0a-b3b1-3020c774867a">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e57a428831244d0addaf1c93da509e0_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTUtNS0xLTEtMTE2Nzcx_7e844d4f-57b0-45a6-b668-05edd857c05f">426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f42c8f52d064fceaa8822b15b9cebc7_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTUtNy0xLTEtMTE2Nzcx_1eb81315-e1d5-4beb-bf59-56434e113ace">568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTYtMS0xLTEtMTE2Nzcx_ed537a04-1468-43a1-9b6b-31fb1b3bed10">1,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTYtMy0xLTEtMTE2Nzcx_3c8ddb0e-3681-4c8e-83f4-aa19a2f9111b">2,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTYtNS0xLTEtMTE2Nzcx_cc84c395-63a2-413f-b3ad-5fb50ae16a99">3,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTYtNy0xLTEtMTE2Nzcx_a464da9d-3847-4436-ae0a-592a10d1f5b9">4,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made and are reflected in the table above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers</span></div><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RleHRyZWdpb246ODZkOGIyZDAzM2QxNDQzN2IzMmE4YzM5MDAxNWE3MTZfNDI0OA_903bfadd-acb3-4269-8f61-96a60ee7c787" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that accounted for 10% or more of total revenues were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0cf345d189714dc1bec54dec30d5fe8a_D20220101-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjRhN2Q5ODA3ODdmZTQzMzA5ZmJjYzIwYTNmNTk1NjdhL3RhYmxlcmFuZ2U6NGE3ZDk4MDc4N2ZlNDMzMDlmYmNjMjBhM2Y1OTU2N2FfMi0xLTEtMS0xMTY3NzE_56ae6aeb-0157-4a85-8ff2-c33515db1f7f">16</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i648582730a944818a8954c08f4676c96_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjRhN2Q5ODA3ODdmZTQzMzA5ZmJjYzIwYTNmNTk1NjdhL3RhYmxlcmFuZ2U6NGE3ZDk4MDc4N2ZlNDMzMDlmYmNjMjBhM2Y1OTU2N2FfMi0zLTEtMS0xMTY3NzE_052fa874-247f-4560-93ed-c345016f0609">17</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation (including McKesson Specialty)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i227c1b875ad04673a4bb23d3cb69932a_D20220101-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjRhN2Q5ODA3ODdmZTQzMzA5ZmJjYzIwYTNmNTk1NjdhL3RhYmxlcmFuZ2U6NGE3ZDk4MDc4N2ZlNDMzMDlmYmNjMjBhM2Y1OTU2N2FfMy0xLTEtMS0xMTY3NzE_4fb62638-dc55-418e-a3fc-c8aa5f1662b7">13</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i640e2ab4eb224f69a463e994c0e65ae1_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjRhN2Q5ODA3ODdmZTQzMzA5ZmJjYzIwYTNmNTk1NjdhL3RhYmxlcmFuZ2U6NGE3ZDk4MDc4N2ZlNDMzMDlmYmNjMjBhM2Y1OTU2N2FfMy0zLTEtMS0xMTY3NzE_2ea2e8cf-30b7-4a1c-b3fd-fd817144475a">16</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health,&#160;Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ba3dd5c6bf14d8ea672f7543ae52430_D20220101-20220630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjRhN2Q5ODA3ODdmZTQzMzA5ZmJjYzIwYTNmNTk1NjdhL3RhYmxlcmFuZ2U6NGE3ZDk4MDc4N2ZlNDMzMDlmYmNjMjBhM2Y1OTU2N2FfNC0xLTEtMS0xMTY3NzE_de1e9c67-8c19-418c-82a7-0d8ff6077375">11</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i555a31f9bb61484a89ccf486fcac5905_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjRhN2Q5ODA3ODdmZTQzMzA5ZmJjYzIwYTNmNTk1NjdhL3RhYmxlcmFuZ2U6NGE3ZDk4MDc4N2ZlNDMzMDlmYmNjMjBhM2Y1OTU2N2FfNC0zLTEtMS0xMTY3NzE_76d80014-78d5-4b01-abdc-4a72db333dbf">12</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i762fba229369426294c4424c2015a01a_100"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xMDAvZnJhZzo4M2U5NTA5NTAyY2E0MTg3YTUwN2U0MGVjZGZhNjFhMy90ZXh0cmVnaW9uOjgzZTk1MDk1MDJjYTQxODdhNTA3ZTQwZWNkZmE2MWEzXzExNTQ0ODcyMTIwOTE4_3dd67c32-f40c-4849-a1bd-c516d86d4555" continuedAt="iff3e4b031870404388550f7777333fbf" escape="true">SUBSEQUENT EVENT </ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="iff3e4b031870404388550f7777333fbf" continuedAt="ibfa4ed5de25f4edf8661be8e5ae318a3">Cross-Currency Swaps</ix:continuation></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibfa4ed5de25f4edf8661be8e5ae318a3">During July 2022, the Company entered into cross-currency swaps, with aggregate notional amounts of $<ix:nonFraction unitRef="usd" contextRef="i83b432d29b6b47c8a7c436116ed24dae_I20220731" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xMDAvZnJhZzo4M2U5NTA5NTAyY2E0MTg3YTUwN2U0MGVjZGZhNjFhMy90ZXh0cmVnaW9uOjgzZTk1MDk1MDJjYTQxODdhNTA3ZTQwZWNkZmE2MWEzXzExNTQ0ODcyMTIwOTIw_2c62f5bd-68ab-4403-b290-ca54bdaafe51">1,000</ix:nonFraction>&#160;million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its Consolidated Financial Statements from adverse movements in exchange rates. The euro-denominated net investment being hedged is the Company&#8217;s investment in certain Bausch + Lomb euro-denominated subsidiaries.</ix:continuation> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="i762fba229369426294c4424c2015a01a_103"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of&#160;Operations</span></div><div id="i762fba229369426294c4424c2015a01a_106"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTRODUCTION</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless the context otherwise indicates, as used in this &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company,&#8221; and similar terms refer to Bausch Health Companies Inc. and its subsidiaries. This &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; has been updated through August&#160;9, 2022 and should be read in conjunction with the unaudited interim Consolidated Financial Statements and the related notes (the &#8220;Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">) included elsewhere in this Quarterly Report on Form 10-Q for the quarterly period ended June&#160;30, 2022 (this &#8220;Form 10-Q&#8221;). The matters discussed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contain certain forward-looking statements within the meaning of Section 27A of The Securities Act of 1933, as amended, and Section 21E of The Securities Exchange Act of 1934, as amended, and that may be forward-looking information within the meaning defined under applicable Canadian securities laws (collectively &#8220;Forward-Looking Statements&#8221;). See &#8220;Forward-Looking Statements&#8221; at the end of this Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations..</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our accompanying unaudited interim Consolidated Financial Statements as of June&#160;30, 2022 and for the three and six months ended June 30, 2022 and 2021 have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) for interim financial statements, and should be read in conjunction with our Consolidated Financial Statements for the year ended December&#160;31, 2021, which were included in our Annual Report on Form 10-K filed on February&#160;23, 2022. In our opinion, the unaudited interim Consolidated Financial Statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for a fair statement of the financial condition, results of operations and cash flows for the periods indicated. Additional company information is available on SEDAR at </span><span style="color:#0027ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.sedar.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> and on the SEC website at&#160;</span><span style="color:#0027ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. All currency amounts are expressed in U.S.&#160;dollars, unless otherwise noted. Certain defined terms used herein have the meaning ascribed to them in the Financial Statements. </span></div><div id="i762fba229369426294c4424c2015a01a_109"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global company whose mission is to improve people&#8217;s lives with our health care products. We develop, manufacture and market, primarily in the therapeutic areas of gastroenterology (&#8220;GI&#8221;) and dermatology, and eye health, a broad range of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) over-the-counter (&#8220;OTC&#8221;) products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in approximately 100 countries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of products falls into five operating and reportable segments: (i) Salix, (ii) International (formerly International Rx), (iii) Diversified Products, (iv) Solta Medical and (v) Bausch + Lomb. These segments are discussed in detail in Note 19, &#8220;SEGMENT INFORMATION&#8221; to our unaudited Consolidated Financial Statements. The following is a brief description of the Company&#8217;s segments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales in the U.S. of GI products. Sales of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line represented 81% and 80% of the Salix segment&#8217;s revenues for the three and six months ended June 30, 2022, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified Products segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological) products and (iv) dentistry products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Solta Medical segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Solta aesthetic medical devices.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Bausch + Lomb segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022, the Company changed its segment structure. The new segment structure resulted in a change to the Company&#8217;s former Ortho Dermatologics segment whereby its medical dermatology business (Ortho Dermatologics) is now managed by the Chief Operating Decision Maker (&#8220;CODM&#8221;) as part of the Diversified Products segment and the Solta Medical business is now managed by the CODM as its own operating and reportable segment. Prior period presentation of segment revenues and segment profits has been recast to conform to the current reporting structure. </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="i762fba229369426294c4424c2015a01a_112"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Focus on Value</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we implemented a multi-year plan designed to transform and bring out value in our Company. The multi-year plan increased our focus on, among other factors, our: product portfolio, infrastructure, geographic footprint, capital structure and risk management.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since that time, we have been executing and continue to execute on our commitments to transform the Company and generate value. As discussed below, under the multi-year plan, we have taken actions that among other things included: (i) divesting non-core assets, (ii) making strategic investments in our core businesses and (iii) making measurable progress in improving our capital structure. These measures gave us operating flexibility and put us in a strong position to unlock the additional value to be found in our specific businesses. We believe that these and other actions we have taken to transform our Company, have helped to focus our operations, and improve our capital structure. These positive actions also presented us with an opportunity to unlock potential value across our portfolio of assets by separating our pharmaceutical and eye health businesses. Although management believes the B+L Separation (as defined below) will bring out additional value, there can be no assurance that it will be successful in doing so.</span></div><div id="i762fba229369426294c4424c2015a01a_118"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation of the Bausch + Lomb Eye Health Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, we announced our plan to separate our eye health business consisting of our Bausch + Lomb Global Vision Care (formerly Vision Care/Consumer Health), Global Surgical and Global Ophthalmic Pharmaceuticals businesses into an independent publicly traded entity, Bausch + Lomb from the remainder of Bausch Health Companies Inc. (the &#8220;B+L Separation&#8221;). In January 2022, we completed the internal organizational design and structure of the new eye health entity. The registration statement related to the B+L IPO was declared effective on May 5, 2022, and Bausch + Lomb&#8217;s common stock began trading on the New York Stock Exchange and the Toronto Stock Exchange, in each case under the ticker symbol &#8220;BLCO&#8221; on May 6, 2022. Prior to the effectiveness of the registration statement, Bausch + Lomb was an indirect wholly-owned subsidiary of the Company. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, a wholly owned subsidiary of the Company (the &#8220;Selling Shareholder&#8221;) sold 35,000,000 common shares of Bausch + Lomb, at an offering price of $18.00 per share, pursuant to the B+L IPO. In addition, the Selling Shareholder granted the underwriters an option for a period of 30 days from the date of the B+L IPO to purchase up to an additional 5,250,000 common shares to cover over-allotments at the IPO offering price less underwriting commissions. On May 31, 2022, the underwriters partially exercised the over-allotment option granted by the Selling Shareholder and, on June 1, 2022, the Selling Shareholder sold an additional 4,550,357 common shares of Bausch + Lomb at an offering price of $18.00 per share (less applicable underwriting discount). The remainder of the over-allotment option granted to the underwriters expired.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the closing of the B+L IPO and after giving effect to the partial exercise of the over-allotment option, the Company directly or indirectly holds 310,449,643 Bausch + Lomb common shares, which represents approximately 88.7% of Bausch + Lomb&#8217;s outstanding common shares. The aggregate net proceeds from the B+L IPO and the partial exercise of the over-allotment option by the underwriters, after deducting underwriting commissions were approximately $675&#160;million. The Company remains committed to completing the B+L Separation as soon as is practical and believes the B+L Separation makes strategic sense. The completion of the B+L Separation is subject to the expiry of customary lockups related to the B+L IPO, the achievement of targeted debt leverage ratios and the receipt of applicable shareholder and other necessary approvals. The Company continues to evaluate the factors and considerations related to completing the B+L Separation and the effect of the Norwich Legal Decision (see &#8220;Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Paragraph IV Proceedings&#8221; of Note 18, &#8220;LEGAL PROCEEDINGS&#8221; to our unaudited interim Consolidated Financial Statements) on the B+L Separation.&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The B+L Separation will establish two separate, independent companies:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Bausch + Lomb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - a fully integrated, &#8220;pure play&#8221; eye health company built on the iconic Bausch + Lomb brand and long history of innovation; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Bausch Pharma</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - a diversified pharmaceutical company with leading positions in gastroenterology, hepatology, dermatology, neurology and international pharmaceuticals, and aesthetic medical devices. The remaining pharmaceutical entity will comprise a diversified portfolio of our leading durable brands across the Salix, International, dentistry, neurology, medical dermatology and generics, and aesthetic medical devices businesses. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the B+L Separation will result in two highly attractive but dissimilar businesses. As independent entities, management believes that each company will be better positioned to individually focus on its core businesses to drive additional growth, more effectively allocate capital and better manage its respective capital needs. Further, the B+L Separation will allow us and the market to compare the operating results of each entity with other &#8220;pure play&#8221; peer companies. Although management believes the B+L Separation will bring out additional value, there can be no assurance that it will be successful in doing so.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time of our announcement of the B+L Separation, we emphasized that it is important that the post-separation entities be well capitalized, with appropriate leverage and with access to additional capital, if and when needed, to provide each entity with the ability to independently allocate capital to areas that will strengthen their own competitive positions in their respective lines of business and position each entity for sustainable growth. Therefore, we see the appropriate capitalization and leverage of these businesses post-separation as a key to maximizing value across our portfolio of assets and, so, it is a primary objective of our plan of separation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in further detail below, the proceeds from the B+L IPO, along with those from the offering of the February 2027 Secured Notes, the B+L Debt Financing and the 2027 Term Loans (each as defined below), along with cash on hand, were used to repay and refinance a portion of our existing debt. In addition, we intend to use the proceeds from any potential future offers of Bausch + Lomb common shares to further repay, to the extent possible, a portion of our existing debt, thereby improving our capitalization and leverage. We believe the B+L Separation, if consummated, provides us with an attractive opportunity for liquidity to support the appropriate capitalization and leverage of the Bausch + Lomb entity and the remainder of Bausch Health Companies Inc., which we refer to as &#8220;Bausch Pharma&#8221; and which will assume a new name upon completion of the B+L Separation. However, management will also continue to explore additional alternatives in order to properly capitalize the two entities. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have previously stated that all options for achieving the appropriate capitalization and leverage for these entities post-separation were being considered. Management remains focused on the capitalizations of the post-separation entities and has considered and continues to consider alternative means of achieving this, including dispositions from our existing business that we believe represent attractive opportunities for the Company and are in line with our plan of separation. This informed our decision to divest Amoun Pharmaceutical Company S.A.E. (&#8220;Amoun&#8221;) on July 26, 2021 and, as discussed below, use the net proceeds to repay certain debt obligations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the capitalization and leverage ratios of each entity, there are considerations, approvals and conditions, including market conditions, that will determine the ultimate timing and structure of the B+L Separation, including regulatory approvals, final approval by our board of directors, any shareholder vote requirements that may be applicable, compliance with U.S. and Canadian securities laws and stock exchange rules, receipt of any applicable opinions and/or rulings with respect to the Canadian and U.S. federal income tax treatment of the B+L Separation and determination of the pro forma capitalization of each of the two entities post separation. The failure to satisfy all of the required conditions could delay the completion of the B+L Separation for a significant period of time or prevent it from occurring at all. We will need to complete a number of additional steps that will depend on the ultimate structure of the transactions (in addition to obtaining the regulatory approvals and satisfying the conditions described above) before we can complete the B+L Separation. As a result, there can be no assurance as to the timing of the completion of the B+L Separation or its structure or terms, and the information in this Form 10-Q relating to each transaction is preliminary and may change as the transactions progress and any such changes and their impact on the Company, or any of the companies that result from the consummation of the B+L Separation, may be material.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Solta Medical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2022, the Company announced it was suspending its previously announced plans to pursue an IPO of our Solta aesthetic medical device business (&#8220;Solta Medical&#8221;) (the &#8220;Solta IPO&#8221;). By the end of 2021, we had substantially completed the internal objectives necessary to facilitate the Solta IPO, however, we believe that the interests of the Company and its stakeholders, including shareholders and creditors, are best served in the near-term by focusing on driving Solta&#8217;s revenue, profitability and cash flow while also achieving key operational and regulatory milestones, and as such, Solta will remain as part of Bausch Health and continue to contribute to the Company&#8217;s performance, including the deleveraging of the Company&#8217;s balance sheet. The Company will revisit alternative paths for Solta in the future. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 1A. &#8220;Risk Factors &#8212; Risk Relating to the B+L Separation and the Solta IPO&#8221; of our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC and the CSA on February&#160;23, 2022, for additional risks relating to the B+L Separation and the formerly planned Solta IPO.</span></div><div id="i762fba229369426294c4424c2015a01a_121"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Setting Up Our Company to Unlock Value</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To position ourselves to unlock the value we see in our individual businesses, we have sought to right-size our portfolio of assets and provide financial flexibility. The Company has focused on the following growth drivers, that remain a focus of our growth strategies today:</span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">on May 10, 2022 in connection with the B+L IPO, the Company completed a series of transactions in which among other things: (i) Bausch + Lomb entered into a new credit facility, (ii) the Company repaid certain amounts outstanding under its existing term B loans, (iii) the Company refinanced the remaining amounts outstanding under its then existing credit facilities and (iv) the Company discharged the indenture governing its 6.125% Senior Unsecured Notes (as defined and described in the table in Note 10, &#8220;FINANCING ARRANGEMENTS,&#8221; to our </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="padding-left:40.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unaudited Consolidated Financial Statements) due 2025 (the &#8220;April 2025 Unsecured Notes&#8221; and the related indenture the &#8220;April 2025 Unsecured Notes Indenture&#8221;). We believe these transactions bring us one step closer to meeting our commitment to properly capitalize the two entities post-separation while improving our overall capitalization and leverage. These actions are discussed in more detail below in &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt &#8212; Long-term Debt&#8221;;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">divested non-core assets in order to narrow the Company&#8217;s activities to our core businesses where we believe we have an existing and sustainable competitive edge and the ability to generate operational efficiencies. To date, we received approximately $4,100 million in net proceeds from these divestitures, which includes the sale of Amoun as discussed below, on July 26, 2021;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">made strategic investments in our core businesses in order to support recent revenue growth and prepare for additional growth opportunities we plan to capitalize on for our core businesses;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">made measurable progress in improving our capital structure as we have repaid approximately $10,600&#160;million in long-term debt obligations (net of additional borrowings, amounts refinanced and excluding the $1,210 million financing of the U.S. Securities Litigation settlement discussed below) during the period of January 1, 2016 through June 30, 2022, using the proceeds from the divestiture of non-core assets, proceeds from the B+L IPO, cash on hand, and cash from operations, including from a focus on working capital management; and </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">resolved many of the Company&#8217;s legacy litigation matters originating back to 2015 and prior, including the most significant legacy legal matter, the U.S. Securities Litigation settlement, significantly reducing related possible disruptions and other uncertainties to our operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that these and other actions we have taken to transform our Company, have helped focus our operations, unlocked value across our product portfolios, improved our capital structure and mitigated certain risks associated with legacy litigation matters. We believe that these measures, along with our continued commitment to improving people&#8217;s lives through our health products, help position us to unlock potential value across our portfolio of assets by separating our eye health and pharmaceutical businesses. Although management believes the B+L Separation will unlock additional value, there can be no assurance that it will be successful in doing so.</span></div><div id="i762fba229369426294c4424c2015a01a_124"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Divest Assets to Improve Our Capital Structure and Simplify Our Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to better focus on our core businesses, we continue to evaluate opportunities to simplify our operations and improve our capital structure, including dispositions of various assets. For example, on July 26, 2021, we completed the sale of Amoun for total gross consideration of approximately $740&#160;million, subject to certain adjustments (the &#8220;Amoun Sale&#8221;). Amoun manufactures, markets and distributes branded generics of human and animal health products. The Amoun business was part of the International segment (previously included within the former Bausch + Lomb/International segment). Revenues associated with Amoun were $137&#160;million for the six months ended June 30, 2021 and $157&#160;million for the period of January 1, 2021 through July 26, 2021. On July 30, 2021 and August 3, 2021, the Company made aggregate payments of $600&#160;million, to repay $469&#160;million of its June 2025 Term Loan B Facility and $131&#160;million of its November 2025 Term Loan B Facility&#8221; (each as defined below), using the proceeds from the Amoun Sale and cash on hand.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to consider further dispositions of various assets in line with this strategy. While we anticipate that any future divestiture activities will be on non-core assets, we will consider dispositions in core areas that we believe represent attractive opportunities for the Company. See Note 4, &#8220;LICENSING AGREEMENTS AND DIVESTITURE&#8221; to our unaudited interim Consolidated Financial Statements for additional information.</span></div><div id="i762fba229369426294c4424c2015a01a_127"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Focus on Core Businesses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In line with this focus on our core businesses we have: (i) directed capital allocation to drive growth within these core businesses, (ii) made measurable progress in effectively managing our capital structure, (iii) increased our efforts to improve patient access and (iv) continued to invest in sustainable growth drivers to position us for long-term growth.</span></div><div id="i762fba229369426294c4424c2015a01a_130"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Direct Capital Allocation to Drive Growth Within Our Core Businesses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our capital allocation is driven by our long-term growth strategies. We have been aggressively allocating resources to our core businesses globally through: (i) R&amp;D investment, (ii) strategic licensing agreements and (iii) strategic investments in our infrastructure. The outcome of this process allows us to better drive value in our product portfolio and generate operational efficiencies.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i762fba229369426294c4424c2015a01a_136"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">R&amp;D Investment</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We search for new product opportunities through internal development and strategic licensing agreements, that, if successful, will allow us to leverage our commercial footprint, particularly our sales force, and supplement our existing product portfolio and address specific unmet needs in the market. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal R&amp;D organization focuses on the development of products through clinical trials. As of December 31, 2021, approximately 1,300 dedicated R&amp;D and quality assurance employees in 25 R&amp;D facilities were involved in our R&amp;D efforts internally. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, we have approximately 160 projects in our global pipeline. Certain core internal R&amp;D projects that have received a significant portion of our R&amp;D investment in current and prior periods are listed below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gastrointestinal</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10pt">Rifaximin - Top line results from a Phase 2 study for the treatment of overt hepatic encephalopathy with a new formulation (SSD IR) of rifaximin showed a treatment benefit. Patients receiving 40 mg twice daily showed a statistically significant separation from placebo. The top line results from this Phase 2 study will help inform further research on potential new indications for rifaximin. A Phase 3 study has commenced (RED-C) with patients actively enrolling for the prevention of the first episode of Overt Hepatic Encephalopathy.</span></div><div style="text-align:justify;text-indent:4.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10pt">Rifaximin - Rifaximin recently received orphan drug designation for sickle cell disease. A phase 2 study with novel dosage formulation is currently enrolling patients for the treatment of sickle cell disease.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Rifaximin - Development of a fit for purpose Patient Reported Outcomes tool for small intestinal bacterial overgrowth, or &#8220;SIBO&#8221;, is continuing in 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Rifaximin - We have entered into an agreement with Cedars Sinai Medical Center to evaluate a new formulation of rifaximin for the treatment of IBS-D. Two preclinical studies have been completed. A Proof of Concept study, that was paused due to COVID-19 pandemic related factors, has recommenced and is fully enrolled. Based on recent FDA comments dated February 10, 2022, the program is being assessed and related timelines reviewed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Envive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In October 2020, we launched, on a limited basis, a probiotic supplement that was developed to address gastrointestinal disturbances. In April 2021, we expanded the launch to additional territories in the U.S.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Amiselimod (S1P modulator) - We commenced a Phase 2 study during the first half of 2021 to evaluate Amiselimod (S1P modulator) for the treatment of mild to moderate ulcerative colitis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dermatology</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(tazarotene) Lotion, 0.045% - In June 2020, we launched this acne product containing lower concentration of tazarotene in a lotion form to help reduce irritation while maintaining efficacy. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Internal Development Project (&#8220;IDP&#8221;) 120 - An acne product with a fixed combination of mutually incompatible ingredients: benzoyl peroxide and tretinoin. Phase 3 clinical studies have been completed and met the primary endpoints. We are currently evaluating next steps for this project. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">IDP-126 - An acne product with a fixed combination of benzoyl peroxide, clindamycin phosphate and adapalene. Phase 3 clinical studies initiated in December 2019 were paused due to COVID-19 pandemic related factors, but resumed in June 2020. Both Phase 3 studies have been completed and have met their primary endpoints. A comparative bridging safety and efficacy study was delayed until 2021 due to COVID-19. The bridging study has completed enrollment in July 2022. We anticipate filing a New Drug Application (&#8220;NDA&#8221;) in the fourth quarter of 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solta Medical</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Clear + Brilliant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Touch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Next generation Clear + Brilliant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;laser that is designed to deliver a customized and more comprehensive treatment protocol by providing patients of all ages and skin types the benefits of two wavelengths. This product was launched in the U.S. in March 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">SiHy Daily - A silicone hydrogel daily disposable contact lens designed to provide clear vision throughout the day. In September 2018, we launched SiHy Daily in Japan under the branded name AQUALOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY. In August 2020, we launched SiHy Daily in the U.S. under the branded name Bausch + Lomb INFUSE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SiHy Daily Disposable contact lens. In the fourth quarter of 2020, SiHy Daily was launched in Australia, Hong Kong and </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada under the branded name Bausch + Lomb Ultra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY. SiHy Daily has also received regulatory approval in China, New Zealand, Japan, South Korea, Europe, Singapore and Malaysia, where it will be branded as Bausch + Lomb Ultra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY, and in the second quarter of 2021, we launched SiHy Daily in South Korea and Singapore as Bausch + Lomb Ultra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">LUMIFY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brimonidine tartrate ophthalmic solution, 0.025%) - An OTC eye drop developed as an ocular redness reliever. We launched this product in the U.S. in May 2018 and received Canadian approval in May 2022. Currently, we have several new line formulations under development. The first Phase 3 study in support of these line extensions has initiated. Additional studies are expected to commence in the second half of 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday for Astigmatism - A daily disposable contact lens for astigmatic patients. The Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday contact lens incorporates Surface Active Technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to provide a dehydration barrier.&#160;The Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday for Astigmatism also includes evolved peri-ballast geometry to deliver stability and comfort for the astigmatic patient.&#160;We launched this product in December 2016 and launched an extended power range and further extended power ranges in each of the years 2017 through 2020. Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday for Astigmatism has also received regulatory approval in China.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10pt">New Ophthalmic Viscosurgical Device (&#8220;OVD&#8221;) product - A formulation to protect corneal endothelium during phacoemulsification process during a cataract surgery and to help chamber maintenance and lubrication during IOL delivery. A clinical study report was completed for the cohesive OVD product (StableVisc&#8482;) during the second quarter of 2022. FDA approval is expected in the fourth quarter of 2022 and launch is expected in the first quarter of 2023. In addition, in March 2021, we received Premarket Approval from the FDA for Clearvisc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> dispersive OVD, which we launched in the U.S. in June 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Bausch + Lomb is expanding its portfolio of premium IOLs built on the enVista</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform with Monofocal Plus, EDOF and Trifocal optical designs for presbyopia correction. Bausch + Lomb expects that they will be commercialized together with a new preloaded inserter with two options: non-Toric, as well as Toric for astigmatism patients. Bausch + Lomb anticipates launching Monofocal Plus, Trifocal and EDOF optical designs for presbyopia in 2023, 2024 and 2025/2026, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> monthly silicone hydrogel lens - Specifically designed to address the lifestyle and vision needs of patients with MoistureSeal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology, which maintains 95% of contact lens moisture for a full 16 hours. In the second quarter of 2020, Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> received a seven day extended wear indication approval from the European Union and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">received regulatory approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from the National</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Products Administration in China.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Multifocal for Astigmatism contact lens - The first and only multifocal toric lens available as a standard offering in the eye care professional&#8217;s fit set. The new monthly silicone hydrogel lens, which was specifically designed to address the lifestyle and vision needs of patients with both astigmatism and presbyopia, combines the Company&#8217;s unique 3-Zone Progressive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;multifocal design with the stability of its OpticAlign</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;toric with MoistureSeal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology to provide eye care professionals and their patients an advanced contact lens technology that offers the convenience of same-day fitting during the initial lens exam.&#160;Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Multifocal for Astigmatism was launched in June 2019 and received European Union regulatory approval in the second quarter of 2020. In July 2021, we launched an extended parameter range of this product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Renu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced Multi-Purpose Solution (&#8220;MPS&#8221;) - Contains a triple disinfectant system that kills 99.9% of germs tested, and has a dual surfactant system that provides up to 20 hours of moisture. Renu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced MPS is FDA cleared with indications for use to condition, clean, remove protein, disinfect, rinse and store soft contact lenses including those composed of silicone hydrogels. Prior to 2022, Renu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced MPS was launched in India, Mexico, Korea, Turkey and Greece and gained regulatory approvals in Indonesia, Malaysia, Singapore, the European Union, Belarus and China. In 2022, Renu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced MPS was launched in Taiwan, Czech Republic, Israel, Poland and Slovakia. We anticipate launches in China, Taiwan, Argentina and the Latin America region during 2022 and launches in additional regions in 2023 and 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Zen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Multifocal Scleral Lens for presbyopia - In January 2019, we launched this product in the U.S. exclusively available with Zenlens</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Zen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> RC scleral lenses and will allow eye care professionals to fit presbyopic patients with regular and irregular corneas and those with ocular surface disease, such as dry eye. The Zen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Multifocal Scleral Lens incorporates decentered optics, enabling the near power to be positioned over the visual axis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Tangible</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hydra-PEG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - A high-water polymer coating that is bonded to the surface of a contact lens and designed to address contact lens discomfort and dry eye. We launched this product in the U.S. in March 2019. Tangible</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hydra-PEG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> coating technology in combination with our Boston</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> materials and Zenlens</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> family of scleral lenses </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will help eye care professionals provide a better lens wearing experience for their patients with challenging vision needs.</span></div><div id="i762fba229369426294c4424c2015a01a_139"></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Strategic Licensing Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To supplement our internal R&amp;D initiatives and to build-out and refresh our product portfolio, we also search for opportunities to augment our pipeline through arrangements that allow us to gain access to unique products and investigational treatments, by strategically aligning ourselves with other innovative product solutions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company will enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early stage development that target unique conditions. The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by the FDA or other regulators, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain. Under certain agreements, the Company may be required to make payments contingent upon the achievement of specific developmental, regulatory, or commercial milestones.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we announced that we had entered into two exclusive license agreements which present us with unique developmental opportunities to address the unmet need of treatment for myopia in children. The first of these two licensing agreements is with Eyenovia, Inc. for the development and commercialization in the United States and Canada of an investigational microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression, also known as nearsightedness, in children ages 3-12. We expect to complete enrollment for a Phase 3 study during the first quarter of 2023. If approved by the FDA, we believe this investigational product could potentially change the treatment paradigm for the reduction of myopia progression in children. The second is an exclusive global licensing agreement with BHVI for a myopia control contact lens design developed by BHVI. The Company plans to pair BHVI&#8217;s novel contact lens design with our leading contact lens technologies to develop potential contact lens treatments designed to slow the progression of myopia in children.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we announced that we had acquired an exclusive license from Novaliq GmbH for the commercialization and development in the U.S. and Canada of the investigational treatment NOV03 (perfluorohexyloctane), a first-in-class investigational drug with a novel mechanism of action to treat dry eye diseases (&#8220;DED&#8221;) associated with Meibomian gland dysfunction (&#8220;MGD&#8221;). In an Open Label Safety study, NOV03 has achieved its enrollment target. In April 2021, we announced statistically significant topline data from the first of two Phase 3 studies and in September 2021, we announced statistically significant topline data from the second Phase 3 study. The NDA was filed in June 2022, and if approved, Bausch + Lomb anticipates launching in the U.S. in 2023. If approved by the FDA, we believe the addition of this investigational treatment for DED will help build upon Bausch + Lomb's strong portfolio of integrated eye health products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, we acquired an exclusive license from Clearside Biomedical, Inc. (&#8220;Clearside&#8221;) for the commercialization and development of Xipere</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (triamcinolone acetonide suprachoroidal injectable suspension) in the U.S. and Canada. Xipere</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for suprachoroidal administration via Clearside&#8217;s proprietary SCS Microinjector</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In October 2021, the FDA approved Xipere</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for suprachoroidal use for the treatment of macular edema associated with uveitis. We launched Xipere</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the U.S. in the first quarter of 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, we entered into an exclusive licensing agreement with Mitsubishi Tanabe Pharma Corporation to develop and commercialize MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate receptor that plays a role in autoimmune diseases, such as inflammatory bowel disease and ulcerative colitis. We have completed a thorough QTC study, which evaluated the cardiac safety profile of the compound. Topline results were positive and we commenced a Phase 2 study in the first half of 2021.</span></div><div id="i762fba229369426294c4424c2015a01a_142"></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Strategic Investments in our Infrastructure</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In support of our core businesses, we have and continue to make strategic investments in our infrastructure, the most significant of which are at our Waterford facility in Ireland, our Rochester facility in New York and our Lynchburg facility in Virginia, both of which support our Bausch + Lomb business. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To meet the forecasted demand for our Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday range of contact lenses, in July 2017, we placed into service a $175 million multi-year strategic expansion project of the Waterford facility. The emphasis of the expansion project was to: (i) develop new technology to manufacture, automatically inspect and package contact lenses, (ii) bring that technology to full validation and (iii) increase the size of the Waterford facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To address the expected global demand for our Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> range of contact lenses, in December 2017, we completed a multi-year, $220 million strategic upgrade to our Rochester facility. The upgrade increased production capacity in support of our Bausch + Lomb Ultra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and SiHy Daily AQUALOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product lines and better supports the </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">production of other well-established contact lenses, such as our PureVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PureVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 (SVS, Toric, and Multifocal), SofLens</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 38 and SilSoft</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To address the expected global demand for our SiHy Daily disposable contact lenses, in November 2018, we initiated $300 million of additional expansion projects to add multiple production lines to our Rochester and Waterford facilities. The first phase of the production line installation program has been completed, and in the first half of 2022, we commenced commercial production of certain of our latest contact lenses, at both our Rochester and Waterford facilities. We expect to complete the expansion programs at our Rochester and Waterford facilities in the second half of 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further help us meet the anticipated demand of our contact lenses, in 2020, we initiated an expansion of the Company's Lynchburg distribution center. The new facility is expected to create new jobs over the next five years and expand the overall site to 200,000 square feet, which will provide distribution capabilities for medical devices, primarily contact lens products, and be the main point of distribution for these products in the U.S. This expansion program is expected to be completed in the second half of 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we announced plans to invest an additional $90 million to increase capacity at our Waterford facility to meet the expected demand for our Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday range of daily disposable contact lenses. The new production lines are expected to be completed in 2023. If completed as planned, the recently announced expansion of our Waterford facility will be the fifth major expansion of our Bausch + Lomb manufacturing facilities in support of our efforts to increase market share in the contact lens market in the seven years ending 2023. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the investments in our Waterford, Rochester and Lynchburg facilities and related expansion of labor forces further demonstrates the growth potential we see in our Bausch + Lomb products and our eye health business.</span></div><div id="i762fba229369426294c4424c2015a01a_145"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effectively Managing Our Capital Structure  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the B+L Separation, we have emphasized that it is important that the post-separation entities be well capitalized, with appropriate leverage and access to additional capital, if and when needed, to provide each entity with the ability to independently allocate capital to areas that will strengthen their own competitive positions in their respective lines of business and position each entity for sustainable growth. Therefore, we see the appropriate capitalization and leverage of these entities post-separation as a key to bringing out the maximum value across our portfolio of assets and, so, it is a primary objective of our plan of separation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Debt Repayments and Other Financing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, our executive team committed to improving our Company&#8217;s capital structure and, since that time, we have been executing and continue to execute on that commitment. As a result of a series of debt repayments and transactions since making that commitment, the Company positioned itself to execute on the B+L IPO, while at the same time progressing toward providing the appropriate capitalization and leverage of these businesses to effect the B+L Separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we continue to effectively manage our capital structure by: (i) executing on our plan for the B+L Separation, including the B+L IPO which completed its initial closing on May 10, 2022, (ii) reducing our debt through repayments, (iii) extending the maturities of debt through refinancing and (iv) focusing on our credit ratings. During the six months ended June 30, 2022, we have reduced the aggregate principal amount of our debt obligations by approximately $800 million as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Notes Issuance and Credit Agreement Refinancing - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we continued to take actions in support of our commitment to improve our liquidity and reduce our leverage. These actions included:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On February 10, 2022, the Company issued $1,000 million aggregate principal amount of 6.125% Senior Secured Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due February 2027 (the &#8220;February 2027 Secured Notes&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On May 10, 2022: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As previously discussed, the Company completed the initial closing of the B+L IPO. The aggregate net proceeds from the B+L IPO and the partial exercise of the over-allotment option by the underwriters, after deducting underwriting commissions were approximately $675&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company entered into the 2022 Amended Credit Agreement as discussed in further detail below, under &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt &#8212; Long-term Debt&#8221;. The 2022 Amended Credit Agreement consists of new term loans of $2,500 million and a revolving credit facility of $975 million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bausch + Lomb entered into the B+L Credit Agreement as defined and discussed in further detail below under &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt &#8212; Long-term Debt&#8221;. The B+L Credit Agreement </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:58.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provides for a five-year term loan facility in an initial principal amount of $2,500 million and also provides for a five-year revolving credit facility of $500 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds from these transactions, along with cash on hand, allowed us to: (i) repay certain amounts outstanding under our then existing June 2025 Term Loan Facility and November 2025 Term Loan Facility, (ii) replace our existing revolving credit facility which was to have matured in 2023, with revolving credit facilities that mature in 2027, (iii) redeem in full all of our outstanding April 2025 Unsecured Notes and (iv) replace our then remaining amounts outstanding under our June 2025 Term Loan Facility and November 2025 Term Loan Facility with term loan facilities that expire in 2027. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Early Extinguishment of Debt - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During June 2022, through a series of transactions we repurchased and retired, outstanding senior unsecured notes with an aggregate par value of $481 million in the open market for approximately $300 million using: (i) the net proceeds from the partial exercise of the over-allotment option in the B+L IPO by the underwriters, after deducting underwriting commissions, (ii) amounts available under our revolving credit facility and (iii) cash on hand. The senior unsecured notes retired had maturities of January 2028 through February 2031 and had a weighted average interest rate of approximately 5.35%. As a result of these transactions, we recognized a gain on the extinguishment of debt of approximately $176 million, net of write-offs of debt premiums, discounts and deferred issuance costs, representing the differences between the amounts paid to retire the senior unsecured notes and their carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The repayment of the (i) June 2025 Term Loan B Facility, (ii) November 2025 Term Loan B Facility, (iii) 2023 Revolving Credit Facility and (iv) redemption of April 2025 Senior Unsecured notes were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $63&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value. As a result of these transactions and the open market repurchases, the Company realized a net gain on early extinguishment of $113 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Debt Repayments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the impact of the $1,210 million financing of the U.S. Securities Litigation settlement (discussed in the subsequent section titled &#8220;Off-Balance Sheet Arrangements and Contractual Obligations&#8221;) we have repaid (net of additional borrowings) approximately $10,600&#160;million of long-term debt during the period January 1, 2016 through June 30, 2022 using the net cash proceeds from divestitures of non-core assets, the B+L IPO, cash on hand, cash from operations, including from our focus on working capital management.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe these transactions bring us closer to meeting our commitment to properly capitalize the two entities post-separation while improving our overall capitalization and leverage. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Consolidated Financial Statements and &#8220;Liquidity and Capital Resources: Long-term Debt&#8221; below for additional discussion of these matters. Cash requirements for future debt repayments including interest can be found in &#8220;Management&#8217;s Discussion and Analysis - Off-Balance Sheet Arrangements and Contractual Obligations.&#8221;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Continue to Manage our Capital Structure</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor our capital structure and to evaluate other opportunities to simplify our business and improve our capital structure, giving us the ability to better focus on our core businesses and prepare us for post-separation. Also, the Company regularly evaluates market conditions, its liquidity profile and various financing alternatives for opportunities to enhance its capital structure. If the Company determines that conditions are favorable, the Company may refinance or repurchase existing debt or issue additional debt, equity or equity-linked securities.</span></div><div id="i762fba229369426294c4424c2015a01a_148"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improve Patient Access</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Improving patient access to our products, as well as making them more affordable, is a key element of our business strategy.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Access and Pricing Committee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our Patient Access and Pricing Committee is responsible for setting, changing and monitoring the pricing of our products and evaluating contract arrangements that determine the placement of our products on drug formularies. The Patient Access and Pricing Committee considers new to market product pricing, price changes and their impact across channels on patient accessibility and affordability. Since its inception in 2016, the Patient Access and Pricing Committee has limited the average annual price increase for our branded prescription pharmaceutical products to single digits. Future pricing changes and programs could affect the average realized pricing for our products and may have a significant impact on our revenues and profits.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch Health Patient Assistance Program - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the face of the COVID-19 pandemic, some people have financial obstacles that keep them from obtaining and continuing their prescribed treatments. We are committed to supporting patients who have lost employment health benefits due to the COVID-19 pandemic, and because it is essential that our patients continue their prescribed treatments, we are proud to offer certain of our prescription medicines through our Bausch Health Patient Assistance Program. The purpose of the Bausch Health Patient Assistance Program is to provide eligible unemployed patients in the U.S., who meet stated qualifications and have lost their health insurance due to the COVID-19 pandemic, with certain of our prescription products where their financial circumstances or insurance status would otherwise interfere with their ability to access such products. If approved, patients receive their Bausch Health Companies Inc. prescription product(s) at no cost to them for up to one year, and may be able to reapply to the program annually if they continue to meet eligibility requirements and have a valid prescription.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash-pay Prescription Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In February 2019, we launched Dermatology.com, a cash-pay product acquisition program offering certain branded Ortho Dermatologics products directly to patients. In March 2020, the name Dermatology.com was removed as the cash-pay product program name, with the name Dermatology.com limited to only online usage, including future digital teledermatology and e-commerce offerings. The cash-pay program is designed to address the affordability and availability of certain branded dermatology products, when insurers and pharmacy benefit managers are no longer offering those branded prescription pharmaceutical products under their designated pharmacy benefit offerings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Walgreens Fulfillment Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In the beginning of 2016, we launched a brand fulfillment arrangement with Walgreen Co. (&#8220;Walgreens&#8221;). Under the terms of the brand fulfillment arrangement, as amended in July 2019, we made certain dermatology and ophthalmology products available to eligible patients through patient access and co-pay assistance programs at Walgreens U.S. retail pharmacy locations, as well as participating independent retail pharmacies.</span></div><div id="i762fba229369426294c4424c2015a01a_151"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invest in Sustainable Growth Drivers to Position us for Long-Term Growth</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are constantly challenged by the changing dynamics of our industry to innovate and bring new products to market. We have divested certain businesses where we saw limited growth opportunities, so that we can be more aggressive in redirecting our R&amp;D spend and other corporate investments to innovate within our core businesses where we believe we can be most profitable and where we aim to be an industry leader. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we have a well-established product portfolio that is diversified within our core businesses and provides a sustainable revenue stream to fund our operations. However, our future success is also dependent upon our ability to continually refresh our pipeline, to provide a rotation of product launches that meet new and changing demands and replace other products that have lost momentum. We believe we have a robust pipeline that not only provides for the next generation of our existing products, but is also poised to bring new products to market.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leveraging our Salix Infrastructure - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strongly believe in our GI product portfolio and we have implemented initiatives, including increasing our marketing presence and identifying additional opportunities outside our existing GI portfolio, to further capitalize on the value of the infrastructure we have built around these products to extend our market share. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2017, we hired approximately 250 trained and experienced sales force representatives and managers to create, bolster and sustain deep relationships with primary care physicians (&#8220;PCP&#8221;). With approximately 70% of IBS-D patients initially presenting symptoms to a PCP, we continue to believe that the dedicated PCP sales force is well positioned to reach more patients in need of IBS-D treatment. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales force has been successful in delivering consistent growth in demand for our GI products, demonstrated by our growth in Salix revenues of 32% when comparing 2021 to 2017. We continue to seek ways to bring out further value through leveraging our existing sales force including the following opportunities:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, we completed the acquisition of certain assets of Synergy Pharmaceuticals Inc. (&#8220;Synergy&#8221;), whereby we acquired the worldwide rights to the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product, a once-daily tablet for adults with chronic idiopathic constipation, or CIC and irritable bowel syndrome with constipation, or IBS-C. We believe that the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product complements our existing Salix products and allows us to effectively leverage our existing GI sales force. In order to drive growth of the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product, we have increased the number of sales force representatives for the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product. We believe this has been successful as Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues were $47 million and $49 million for the six months ended June 30, 2022 and 2021, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licensing Arrangement - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, in April 2019, we entered into a licensing agreement to develop and commercialize MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate receptor that plays a role in autoimmune diseases, such as inflammatory bowel disease and ulcerative colitis. This license presents a unique developmental opportunity to address unmet needs of individuals suffering with certain </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GI and liver diseases and, if developed and approval is obtained from the FDA, will allow us to further utilize our existing sales force and infrastructure to extend our market share in the future and create value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Next Generation Formulations - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line increased approximately 11%, 2% and 22% in 2021, 2020 and 2019, respectively. For the six months ended June 30, 2022 and 2021, Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product revenues were $775 million and $768 million respectively, an increase of $7 million or 1%. In order to extend growth in Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we continue to directly invest in next generation formulations of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and rifaximin, the principal semi-synthetic antibiotic used in our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product. In addition to three R&amp;D programs in progress, we have another R&amp;D program planned for a next generation formulation of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) which would address a new indication.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the acquisition and licensing opportunities discussed above will be accretive to our business by providing us access to products and investigational compounds that are a natural pairing to our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> business, allowing us to effectively leverage our existing infrastructure and sales force. We believe these opportunities, coupled with our investment in next generation formulations, will allow our GI franchise to continue to further extend market share.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Our Solta Aesthetic Medical Device Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Next generation Thermage FLX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a fourth-generation non-invasive treatment option using a radio frequency platform designed to optimize key functional characteristics and improve patient outcomes, has been on sale since 2017 in the U.S., Hong Kong, Japan, Korea, Taiwan, Philippines, Singapore, Indonesia, Malaysia, China, Thailand, Vietnam, Australia and various parts of Europe as part of our Solta aesthetic medical devices portfolio. We plan to continue to expand into other regions, paced by country-specific regulatory registrations. Next generation Thermage FLX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues were $154&#160;million and $142&#160;million for the years 2021 and 2020, respectively. Consistent with our business strategy to continually update and improve our technology, in 2021, we launched, in the U.S., our next generation Clear + Brilliant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Touch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> system which is designed to deliver a customized and more comprehensive treatment protocol by providing patients of all ages and skin types the benefits of two wavelengths. The launch of our next generation Clear + Brilliant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Touch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> system in the U.S. is expected to serve as a foundation for future launches in Asia and Europe.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reposition the Ortho Dermatologics Business to Generate Additional Value - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Ortho Dermatologics business continues to work towards improving the treatment options for medical dermatology patients needing topical acne and psoriasis products. We continue to explore additional strategic e-commerce and partnership expansion opportunities which can enable increased accessibility for patients and we continue to invest in our on-market products and evaluate various opportunities for our key medical dermatology pipeline products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In support of the complete dermatology portfolio, we continue to take a number of actions that we believe will help our efforts to stabilize our dermatology business. These actions include: (i) building on our legacy brands to improve and meet today&#8217;s physician relevance and customer service, (ii) making key investments in our core medical device and dermatological products portfolios, (iii) optimizing our go to market strategy by building on our relationships with prescribers of our products to balance our sales portfolio with the business&#8217; profitability, (iv) refocusing our operational and promotional resources and (v) improving patient access to our Ortho Dermatologics products through our cash-pay prescription program previously discussed. In addition, we made significant investments to build out our psoriasis and acne portfolios as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Psoriasis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In response to the increasing number of reported cases of psoriasis in the U.S., we launched Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in June 2019 and launched Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in November 2018, which align well with our topical portfolio of psoriasis treatments. Although we continue to support a diverse portfolio of topical and injectable biologics, in order to provide a diverse choice of psoriasis treatments to doctors and patients, we believe some patients prefer topical products as an alternative to injectable biologics.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acne</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In support of our established acne product portfolio, we have developed and launched several products, which include Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(tazarotene) Lotion (launched in the U.S. in June 2020), Altreno</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(launched in the U.S. in October 2018), the first lotion (rather than a gel or cream) product containing tretinoin for the treatment of acne, and Retin-A Micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 0.06% (launched in the U.S. in January 2018). As previously discussed, we also have a unique acne project in our pipeline (IDP-126) that, if approved by the FDA, we believe will further innovate and advance the treatment of acne.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invest in our Bausch + Lomb Business - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a fully integrated eye health business with a legacy of over 165 years, Bausch + Lomb has an established line of contact lenses, intraocular lenses and other medical devices, surgical systems and devices, vitamin and mineral supplements, lens care products, prescription eye-medications and other consumer products that positions us to compete in all areas of the eye health market. As part of our global Bausch + Lomb business strategy, we continually look for key trends in the eye health market to meet changing consumer/patient needs and identify areas for investment to extend our market share through new launches and effective pricing. </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, there is an increasing rate of myopia, and importantly, myopia is a potential risk factor for glaucoma, macular degeneration and retinal detachment. We continue to see increased demand for new eye health products that address conditions brought on by factors such as increased screen time, lack of outdoor activities and academic pressures, as well as conditions brought on by an aging population (for example, as more and more baby-boomers in the U.S. are reaching the age of 65). To extend our market share in eye health, we continually seek to identify new products tailored to address these key trends for development internally with our own R&amp;D team to generate organic growth. Recent product launches include Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday daily disposable contact lenses, the next generation of Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contact lenses, SiHy Daily contact lenses (branded as AQUALOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY in Japan, Bausch + Lomb INFUSE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SiHy Daily Disposable in the U.S. and Bausch + Lomb Ultra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY in Australia, Hong Kong, Canada and South Korea and Singapore), Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (an eye redness treatment), Vyzulta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (a pressure lowering eye drop for patients with angle glaucoma or ocular hypertension), Ocuvite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Eye Performance (vitamins to protect the eye from stressors such as sunlight and blue light emitted from digital devices) and SimplifEYE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (preloaded intraocular lens injector platform for enVista intraocular lens). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also license selective molecules or technology in leveraging our own R&amp;D expertise through development, as well as seek out external product development opportunities. As previously discussed, we acquired a global exclusive license for a myopia control contact lens design developed by BHVI, which we plan to pair with our leading contact lens technologies to develop potential contact lens treatments designed to slow the progression of myopia in children, and exclusive licenses for the commercialization and development in the U.S. and Canada of: (i) a microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression in children ages 3-12; (ii) Xipere</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which was approved by the FDA in October 2021 and launched in the first quarter of 2022, and is the first treatment available in the U.S. that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis; and (iii) NOV03, an investigational drug with a novel mechanism of action to treat DED associated with MGD which has demonstrated statistically significant topline data in two Phase 3 studies. We also acquired the U.S. rights to EM-100, which was launched in February 2021 as Alaway</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Preservative-Free and is the first OTC preservative-free formulation eye drop for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair, and dander in adults and children 3 years of age and older. We believe investments in these investigational treatments, if approved by the FDA, will complement, and help build upon our strong portfolio of integrated eye health products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, we have also made strategic investments in our infrastructure, the most significant of which were at our Waterford facility in Ireland to meet the forecasted demand for our Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday lenses, our Rochester facility in New York to address the expected global demand for our Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contact lens and our Lynchburg facility in Virginia to be our main point of distribution for medical devices in the U.S. During late 2018, we began investing in additional expansion projects at the Waterford and Rochester facilities in order to address the expected global demand for our SiHy Daily disposable contact lenses, which we launched in Japan in September 2018, under the branded name AQUALOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY, in the U.S. in August 2020, under the branded name Bausch + Lomb INFUSE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SiHy Daily Disposable contact lens, and in Australia, Hong Kong and Canada in the fourth quarter of 2020 and in South Korea and Singapore in the second quarter of 2021, under the branded name Bausch + Lomb Ultra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our recent product launches, licensing arrangements and the investments in our Waterford, Rochester and Lynchburg facilities demonstrate the growth potential we see in our Bausch + Lomb products and our eye health business and that these investments will position us to further extend our market share in the eye health market.</span></div><div id="i762fba229369426294c4424c2015a01a_154"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Trends</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the actions previously outlined, the events described below have affected and may affect our business trends. The matters discussed in this section contain forward-looking statements. Please see &#8220;Forward-Looking Statements&#8221; at the end of Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations for additional information.</span></div><div id="i762fba229369426294c4424c2015a01a_157"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Russia-Ukraine War</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Russia invaded Ukraine. As military activity and sanctions against Russia, Belarus and specific areas of Ukraine have continued, the war has increasingly affected economic and global financial markets and exacerbated ongoing economic challenges, including issues such as rising inflation and global supply-chain disruption. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues attributable to Russia for the six months ended June 30, 2022 and 2021 were $63&#160;million and $64&#160;million, respectively. Our revenues attributable to Ukraine for the six months ended June 30, 2022 and 2021 were $3 million and $5 million, respectively. Our revenues attributable to Belarus for the six months ended June 30, 2022 and 2021 were $4 million in each period. As the geopolitical situation in Eastern Europe continues to intensify, political events and sanctions are continually changing, and we continue to assess the impact that the Russia-Ukraine war has had and will have on our businesses. These impacts may include but are not limited to: (i) interruptions or stoppage of production, (ii) damage or loss of inventories, (iii) supply-chain and product distribution disruptions in Eastern Europe, (iv) volatility in commodity prices </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and currencies, (v) disruption in banking systems and capital markets, (vi) reductions in sales and earnings of business in affected areas, (vii) increased costs and (viii) cyberattacks.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, these challenges have not yet had a material impact on our operations; however, we anticipate that the ongoing conflict in this region and the sanctions and other actions by the global community in response will continue to hinder our ability to conduct business with customers and vendors in this region. For example, we expect to experience further disruption and delays in the supply of our products to our customers in Russia, Belarus and Ukraine. We may also experience further decreased demand for our products in these countries as a result of the conflict and invasion. In addition, we expect to experience difficulties in collecting receivables from such customers. If we continue to be hampered in our ability to conduct business with new or existing customers and vendors in this region, our business, and operations, including our revenues, profitability and cash flows, could be adversely impacted. Furthermore, if the sanctions and other retaliatory measures imposed by the global community change, we may be required to cease or suspend our operations in the region or, should the conflict worsen, we may voluntarily elect to do so. We cannot provide assurance that current sanctions or potential future changes in these sanctions or other measures will not have a material impact on our operations in Russia, Belarus and Ukraine. The disruption to or suspension of our business and operations in Russia, Belarus and Ukraine may have a material adverse impact on our business, financial condition, cash flows and results of operations. We will continue to monitor the impacts of the Russia-Ukraine war on macroeconomic conditions and continually assess the effect these matters may have on our businesses. </span></div><div id="i762fba229369426294c4424c2015a01a_160"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impacts of COVID-19 Pandemic </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unprecedented nature of the COVID-19 pandemic has, and continues to, adversely impact the global economy. The COVID-19 pandemic and the reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions. Our revenues were most negatively impacted during our second quarter of 2020 by certain social restrictions and other precautionary measures taken in response to the COVID-19 pandemic. However, as governments began lifting social restrictions, allowing offices of certain health care providers to reopen and certain surgeries and elective medical procedures to proceed, the negative trend in the revenues of certain businesses began to level off and stabilize prior to our third quarter of 2020. After the launch of effective vaccines in December 2020, infection rates began to decline, signaling the beginning of a recovery from the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues gradually returned to pre-pandemic levels for many of our businesses and geographies throughout 2021. However, in some regions, including China (as further described below), we continue to experience negative impacts of the COVID-19 pandemic on our business in those regions. The rates of recovery for each business will vary by geography and will be dependent upon, among other things, the availability and effectiveness of vaccines for the COVID-19 virus and variant and subvariant strains thereof, government responses, rates of economic recovery, precautionary measures taken by patients and customers, the rate at which remaining social restrictions are lifted and, once lifted, the presumption that social restrictions will not be materially reenacted in the event of a resurgence of the virus or variant and subvariant strains thereof and other actions taken in response to the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outbreak of the omicron variant in China in 2022 has resulted in government enforced lockdowns and other social restrictions, which impacted our ability to conduct business as usual in certain regions in China, particularly Shanghai. The lockdowns in China have impacted the demand for certain products, particularly our consumer, vision care and Solta products, as shelter in place orders limit the demand and need for the use of contact lenses and related products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as well as for aesthetic medical treatments. Our revenues in China for the six months ended June 30, 2022 and 2021 were $177 million and $229 million, respectively, a decrease of $52 million and, in part, reflects the impact of the surge of the omicron variant in China. Additionally, government enforced lockdowns have caused certain businesses to suspend operations, creating distribution and other logistic issues for the distribution of our products and the sourcing for a limited number of raw materials. Through the date of this filing, we have dealt with these issues in China with only a minimal impact on our manufacturing and distribution processes. However, as the impacts of global reaction to the COVID-19 pandemic remains a fluid situation, we continue to monitor the impacts on our businesses of the COVID-19 virus and variant and subvariant strains thereof in order to timely address new issues if and when they arise.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a further discussion of these and other COVID-19 related risks, see Item 1A. &#8220;Risk Factors &#8212; Risk Relating to COVID-19&#8221; of our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC and the CSA on February&#160;23, 2022.</span></div><div id="i762fba229369426294c4424c2015a01a_163"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Tax Reform</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, U.S. President Joseph Biden proposed changes to the U.S. tax system. Since that date, both houses of Congress have released their own proposals for changes to the U.S. tax system, which differ in a number of respects from the </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President&#8217;s proposal. The proposals under discussion have included changes to the U.S. corporate tax system that would increase U.S. corporate tax rates, although the most recent proposals do not include any such rate increase, and changes that would raise the tax rate on and make other changes to the taxation of Global Intangible Low Tax Income earned by foreign subsidiaries. Also under consideration are modifications to the Base Erosion and Anti-Abuse Tax, which would tax certain payments, including some that are related to inventory, made to affiliates that are subject to an effective tax rate of less than specified rates. Certain proposals also include limitations on the participation exemption for foreign dividends received and interest expense. In addition, certain proposals include limitations on the deduction of interest expense and carryforwards of unused interest expense, as well as an excise tax on certain pharmaceutical products that are non-compliant with the proposed drug pricing legislation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict which, if any, U.S. tax reform proposals will be enacted into law, and what effects any enacted legislation might have on our liability for U.S. corporate tax. However, it is possible that the enactment of changes in the U.S. corporate tax system could have a material adverse effect on our liability for U.S. corporate tax and our consolidated effective tax rate.</span></div><div id="i762fba229369426294c4424c2015a01a_166"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global Minimum Corporate Tax Rate</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8, 2021, the Organisation for Economic Co-operation and Development (&#8220;OECD&#8221;)/G20 inclusive framework on Base Erosion and Profit Shifting (the &#8220;Inclusive Framework&#8221;) published a statement updating and finalizing the key components of a two-pillar plan on global tax reform originally agreed on July 1, 2021, and a timetable for implementation by 2023. The timetable for implementation has since been extended to 2024. The Inclusive Framework plan has now been agreed to by 141 OECD members, including several countries which did not agree to the initial plan. Under pillar one, a portion of the residual profits of multinational businesses with global turnover above &#8364;20 billion and a profit margin above 10% will be allocated to market countries where such allocated profits would be taxed. Under pillar two, the Inclusive Framework has agreed on a global minimum corporate tax rate of 15% for companies with revenue above &#8364;750 million, calculated on a country-by-country basis. On October 30, 2021, the G20 formally endorsed the new global minimum corporate tax rate rules. The Inclusive Framework agreement must now be implemented by the OECD Members who have agreed to the plan, effective in 2024. On December 20, 2021, the OECD published model rules to implement the pillar two rules, which are generally consistent with the agreement reached by the Inclusive Framework in October 2021. Some further guidance on the plan and the related rules has been published, with additional guidance expected to be published in 2023. We will continue to monitor the implementation of the Inclusive Framework agreement by the countries in which we operate. While we are unable to predict when and how the Inclusive Framework agreement will be enacted into law in these countries, and it is possible that the implementation of the Inclusive Framework agreement, including the global minimum corporate tax rate could have a material effect on our liability for corporate taxes and our consolidated effective tax rate.</span></div><div id="i762fba229369426294c4424c2015a01a_169"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Reform</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal and state governments continue to propose and pass legislation designed to regulate the health care industry. In March&#160;2010, the Patient Protection and Affordable Care Act (the &#8220;ACA&#8221;) was enacted in the U.S.&#160;The ACA contains several provisions that impact our business, including: (i) an increase in the minimum Medicaid rebate to states participating in the Medicaid program, (ii) the extension of the Medicaid rebates to Managed Care Organizations that dispense drugs to Medicaid beneficiaries, (iii) the expansion of the 340(B) Public Health Services drug pricing program, which provides outpatient drugs at reduced rates, to include additional hospitals, clinics and health care centers and (iv) a fee payable to the federal government based on our prior-calendar-year share relative to other companies of branded prescription drug sales to specified government programs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in 2013, federal subsidies began to be phased in for brand-name prescription drugs filled in the Medicare Part D coverage gap. The ACA also included provisions designed to increase the number of Americans covered by health insurance. In 2014, the ACA&#8217;s private health insurance exchanges began to operate. The ACA also allows states to expand Medicaid coverage with most of the expansion&#8217;s cost paid for by the federal government.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2021 and 2020, we incurred costs of $13 million and $21 million, respectively, related to the annual fee assessed on prescription drug manufacturers and importers that sell branded prescription drugs to specified U.S.&#160;government programs (e.g.,&#160;Medicare and Medicaid). For 2021 and 2020, we also incurred costs of $94 million and $131 million, respectively, on Medicare Part&#160;D utilization incurred by beneficiaries whose prescription drug costs cause them to be subject to the Medicare Part&#160;D coverage gap (i.e.,&#160;the &#8220;donut&#160;hole&#8221;). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we faced uncertainties due to federal legislative and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the ACA. However, we believe there is low likelihood of repeal of the ACA, given the failure of the Senate&#8217;s multiple attempts to repeal various combinations of ACA provisions and the change in the U.S. Presidential administration. There is no assurance that any replacement or administrative modifications of the ACA will not adversely affect our business and financial results, particularly if the replacing legislation reduces incentives for employer-</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sponsored insurance coverage, and we cannot predict how future federal or state legislative or administrative changes relating to the reform will affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the U.S. Department of Health and Human Services announced a preliminary plan to allow for the importation of certain lower-cost drugs from Canada. The preliminary plan excludes insulin, biological drugs, controlled substances and intravenous drugs. The preliminary plan relies on individual states to develop proposals for safe importation of those drugs from Canada and submit those proposals to the federal government for approval. Although the preliminary plan has some support from the prior administration, at this time, studies to evaluate the related costs and benefits, evaluate the reasonableness of the logistics, and measure the public reaction of such a plan have not been performed. While we do not believe this will have a significant impact on our future cash flows, we cannot provide assurance as to the effect or impact of such a plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Government of Canada (Health Canada) published in the Canada Gazette the new pricing regulation for patented drugs. These regulations were scheduled to become effective on July 1, 2021, but have been delayed until July 1, 2022. The new regulations will, among other things, change the mechanics of establishing the pricing for products submitted for approval after August 21, 2019 and the number and composition of reference countries used to determine if a drug&#8217;s price is excessive. While we do not believe this will have a significant impact on our future cash flows, as additional facts materialize, we cannot provide assurance as to the ultimate content, timing, effect or impact of such regulations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, former U.S. President Donald Trump signed four Executive Orders related to drug pricing, including orders addressing: (i) Part D rebate reform, (ii) the provision of deeply discounted insulin and/or an EpiPen to patients of Federally Qualified Health Centers, (iii) drug importation from Canada and (iv) most favored nation pricing for Medicare. In November 2020, former U.S. President Donald Trump announced the Most Favored Nation Model for Medicare Part B Payment which was to be implemented by the Centers for Medicare &amp; Medicaid Services Innovation on January 1, 2021; however, it has not been implemented, as it is currently being challenged in court. It is also uncertain whether the Biden administration intends to reverse these measures or adopt similar policy initiatives.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, as part of a series of drug pricing-related rules issued by the Trump Administration, the Center for Medicare &amp; Medicaid Services issued a Final Rule that makes significant modifications to the Medicaid Drug Rebate Program regulations in several areas, including with respect to the definition of key terms &#8220;line extension&#8221; and &#8220;new formulation&#8221; and best price reporting relating to certain value-based purchasing arrangements (which took effect on January 1, 2022) and the price reporting treatment of manufacturer-sponsored patient benefit programs (which take effect on January 1, 2023).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the U.S. Congress enacted the American Rescue Plan Act of 2021. One of the provisions included within the American Rescue Plan Act of 2021 eliminated the Maximum Rebate Amount for Single Source drugs and Innovator Multiple Source drugs in the Medicaid Drug Rebate Program. We are currently reviewing this legislation, the impact of which is uncertain at this time.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption of legislation at the federal or state level could materially affect demand for, or pricing of, our products. Additionally, U.S. President Joseph Biden and several members of the current U.S. Congress have indicated that lowering drug prices is a legislative and political priority. Other legislative efforts relating to drug pricing have been enacted and others have been proposed at the U.S. federal and state levels. For instance, certain states have enacted legislation related to prescription drug pricing transparency. Several states have passed importation legislation and Florida is working with the U.S. government to implement an importation program from Canada. We also anticipate that Congress, state legislatures and third-party payors may continue to review and assess alternative health care delivery and payment systems and may in the future propose and adopt legislation or policy changes or implementations affecting additional fundamental changes in the health care delivery system. We continually review newly enacted and proposed U.S. federal and state legislation, as well as proposed rulemaking and guidance published by the Department of Health and Human Services and the FDA; however, at this time, it is unclear the effect these matters may have on our businesses.</span></div><div id="i762fba229369426294c4424c2015a01a_172"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Competition and Loss of Exclusivity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our products face the expiration of their patent or regulatory exclusivity in 2022 or in later years, following which we anticipate generic competition of these products. In addition, in certain cases, as a result of negotiated settlements of some of our patent infringement proceedings against generic competitors, we have granted licenses to such generic companies, which will permit them to enter the market with their generic products prior to the expiration of our applicable patent or regulatory exclusivity. Finally, for certain of our products that lost patent or regulatory exclusivity in prior years, we anticipate that generic competitors may launch in 2022 or in later years. Following a loss of exclusivity (&#8220;LOE&#8221;) of and/or generic competition for a product, we would anticipate that product sales for such product would decrease significantly shortly following the LOE or entry of a generic competitor. Where we have the rights, we may elect to launch an authorized generic (&#8220;AG&#8221;) of such product (either ourselves or through a third-party) prior to, upon or following generic entry, which </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may mitigate the anticipated decrease in product sales; however, even with launch of an authorized generic, the decline in product sales of such product would still be expected to be significant, and the effect on our future revenues could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of our products already face generic competition. Prior to and during 2021, in the U.S., these products include, among others, Ammonul</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Benzaclin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bepreve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bupap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cuprimine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Demser</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Edecrin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Elidel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Istalol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Isuprel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Locoid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lotion, Lotemax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gel, Lotemax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Suspension, Mephyton</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Migranal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MoviPrep</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Nitropress</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Solodyn</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Syprine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Timoptic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Ocudose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tablet, Virazole</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Wellbutrin&#160;XL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Xenazine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zegerid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Zovirax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cream. In Canada, these products include, among others, Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Wellbutrin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;XL and Zovirax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ointment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 LOE Branded Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Branded products that began facing generic competition in the U.S. during 2021 included Lotemax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gel, Bepreve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Clindagel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and certain other products. These products accounted for less than 1% of our total revenues in 2020. We believe the entry into the market of generic competition generally would have an adverse impact on the volume and/or pricing of the affected products, however we are unable to predict the magnitude or timing of this impact.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 through 2026 LOE Branded Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Based on current patent expiration dates, settlement agreements and/or competitive information, we have identified branded products that we believe could begin facing potential LOE and/or generic competition in the U.S. during the years 2022 through 2026. These products and year of expected LOE include, but are not limited to, Noritate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2022), Targretin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gel (2022), Xerese</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2022)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and certain other products that are subject to settlement agreements which could impact their exclusivity during the years 2022 through 2026.&#160;In aggregate, these products accounted for 2% of our total revenues in 2021. These dates may change based on, among other things, successful challenge to our patents, settlement of existing or future patent litigation and at-risk generic launches. We believe the entry into the market of generic competition generally would have an adverse impact on the volume and/or pricing of the affected products, however we are unable to predict the magnitude or timing of this impact.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, for a number of our products (including Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 200mg and 550mg, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Injection in the U.S. and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Canada), we have commenced (or anticipate commencing) and have (or may have) ongoing infringement proceedings against potential generic competitors in the U.S. and Canada. If we are not successful in these proceedings, we may face increased generic competition for these products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Lotion, 0.01% (Glenmark)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In December 2019, the Company announced that it had reached an agreement to resolve&#160;the&#160;outstanding&#160;intellectual&#160;property&#160;litigation&#160;with&#160;Glenmark&#160;Pharmaceuticals,&#160;Ltd. (&#8220;Glenmark&#8221;). Under the terms of the agreement, the Company will grant Glenmark a non-exclusive license to its intellectual property relating to Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. and, beginning in 2026 (or earlier under certain circumstances), Glenmark will have the option to market a royalty-free generic version of Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lotion, should it receive approval from the FDA. The parties have agreed to dismiss all litigation related to Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lotion, and all intellectual property protecting Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lotion remains intact.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Lotion, 0.01% (Padagis) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (now Padagis LLC) (&#8220;Padagis&#8221;), in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#8217; generic halobetasol propionate lotion, for which an Abbreviated New Drug Application (&#8220;ANDA&#8221;) has been filed by Padagis. On May 1, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA for halobetasol propionate lotion.&#160;On September 3, 2020, this action was consolidated with the action between the Company and Padagis described below, regarding Padagis&#8217; ANDA for generic Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotene) lotion. A trial in the consolidated action has been scheduled for October 4, 2022. The Company remains confident in the strength of the Bryhali&#174; patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Lotion (Padagis) - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Padagis, in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotene) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#8217; generic lotion, for which an ANDA has been filed by Padagis. On August 28, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described above, regarding Padagis&#8217; ANDA for generic Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion. A trial in the consolidated action has been scheduled for October 4, 2022. We remain confident in the strength of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will vigorously defend our intellectual property.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Lotion (Taro)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In June 2022, the Company received a Notice of Paragraph IV Certification from Taro Pharmaceuticals Inc. (&#8220;Taro&#8221;), in which Taro asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotene) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use, sale, offer for sale, or importation of Taro&#8217;s generic lotion, for which an ANDA has been filed by Taro. On July 21, 2022, the Company filed suit against Taro pursuant to the Hatch-Waxman Act, alleging infringement by Taro of one or more claims of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents and triggering a 30-month stay of the approval of the Taro ANDA. We remain confident in the strength of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will vigorously defend our intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> 550mg Patent Litigation (Actavis) - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2016, the Company initiated litigation against Actavis Laboratories FL, Inc. (&#8220;Actavis&#8221;), which alleged infringement by Actavis of one or more claims of each of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents. On September 12, 2018, we announced that we had reached an agreement with Actavis that resolved the existing litigation and eliminated the pending challenges to our intellectual property protecting Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets. As part of the agreement, the parties agreed to dismiss all litigation related to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin), Actavis acknowledged the validity of the licensed patents for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets and all intellectual property protecting Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets will remain intact and enforceable until expiry in 2029. The agreement also grants Actavis a non-exclusive license to the intellectual property relating to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets in the United States beginning January 1, 2028 (or earlier under certain circumstances). The Company will not make any financial payments or other transfers of value as part of the agreement. In addition, under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Actavis will have the option to: (i) market a royalty-free generic version of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tablets, 550 mg, should it receive approval from the FDA on its ANDA, or (ii) market an authorized generic version of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tablets, 550 mg, in which case, we will receive a share of the economics from Actavis on its sales of such an authorized generic. Actavis will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed before January 1, 2028.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">550mg Patent Litigation (Sandoz) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In October 2019, the Company announced that it and its licensor, Alfasigma, had commenced litigation against Sandoz Inc. (&#8220;Sandoz&#8221;), a Novartis division, alleging patent infringement of 14 patents by Sandoz&#8217;s filing of its ANDA for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets. On May 6, 2020, the Company announced that an agreement had been reached with Sandoz that resolved this litigation. Under the terms of the agreement, the parties agreed to dismiss all litigation related to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(rifaximin), Sandoz acknowledged the validity of the licensed patents for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(rifaximin) 550 mg tablets and all intellectual property protecting Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(rifaximin) 550 mg tablets will remain intact and enforceable until expiry in October 2029. The agreement also grants Sandoz a non-exclusive license to the intellectual property relating to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(rifaximin) 550 mg tablets in the United States beginning January 1, 2028 (or earlier under certain circumstances). Under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Sandoz will have the right to market a royalty-free generic version of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(rifaximin) 550 mg tablets, should it receive approval from the FDA on its ANDA. Sandoz will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed in the U.S. before January 1, 2028. The Company did not make any financial payments or other transfers of value as part of this agreement with Sandoz.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">550mg Patent Litigation (Norwich) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- On March 26, 2020, the Company and its licensor, Alfasigma, filed suit against Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;), alleging infringement by Norwich of one or more claims of the 23 Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents by Norwich&#8217;s filing of its ANDA for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets. On November 13, 2020, an additional three patents alleged to be infringed by Norwich were added to the suit. Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 550mg is protected by 26 patents covering the composition of matter and the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange&#160;Book. Trial in this matter was held in March 2022. The court issued an Oral Order on July 28, 2022 indicating that the court will find certain U.S. Patents protecting the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets for the reduction in risk of hepatic encephalopathy (&#8220;HE&#8221;) recurrence valid and infringed and U.S. Patents protecting the composition, and use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for treating inflammatory bowel syndrome with diarrhea (&#8220;IBS-D&#8221;) invalid. The Company remains confident in the strength of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to appeal the court&#8217;s judgment and vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">200mg and 550mg Patent Litigation (Sun) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In April 2019, the Company and its licensor, Alfasigma, commenced litigation against Sun Pharmaceutical Industries Ltd. (&#8220;Sun&#8221;), alleging patent infringement by Sun&#8217;s filing of its ANDA for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from Sun, in which Sun asserted that the U.S. patents listed in the FDA&#8217;s Orange Book for the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 200 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of Sun&#8217;s generic rifaximin tablets, 200 mg. Subsequently, on August 10, 2020, the Company received an additional Notice of Paragraph IV Certification from Sun, in which Sun asserted that the U.S. patents listed in the FDA&#8217;s Orange Book for the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of Sun&#8217;s generic rifaximin tablets, 550 mg, for which an ANDA had been filed by </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sun. On September 22, 2020, the Company announced that an agreement had been reached with Sun that resolved the outstanding intellectual property disputes with Sun regarding Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets. Under the terms of the agreement, the parties agreed to dismiss all litigation related to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) and all intellectual property protecting Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets will remain intact and enforceable until expiry in July and October 2029, respectively. The agreement also grants Sun a non-exclusive license to the intellectual property relating to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets in the U.S. beginning January 1, 2028 (or earlier under certain circumstances). Under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Sun will have the right to market royalty-free generic versions of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets, should it receive approval from the FDA on its ANDAs. Sun will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed in the U.S. before January 1, 2028. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Tablets Patent Litigation (Actavis)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - On December 6, 2016, the Company initiated litigation against Actavis, which alleged infringement by Actavis of one or more claims of U.S.&#160;Patent No. 8,524,276 (the &#8220;&#8216;276 Patent&#8221;), which protects the formulation of RELISTOR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets. Actavis had challenged the validity of such patent and alleged non-infringement by its generic version of such product. In July 2019, we announced that the U.S. District Court of New Jersey had upheld the validity of, and determined that Actavis infringed, the &#8216;276 Patent, expiring in March 2031. Actavis appealed this decision to the U.S. Court of Appeals for the Federal Circuit. In March 2021, the Company and Actavis reached a settlement agreement and the appeal was dismissed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Injection Patent Litigation (Gland)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - On February 22, 2022, the Company commenced litigation against Gland Pharma Limited (&#8220;Gland&#8221;) alleging patent infringement by Gland&#8217;s filing of its ANDA No. 216836, referencing Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (methynaltrexone bromide injection, vials) and its ANDA No. 216965, referencing Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (methynaltrexone bromide injection, pre-filled syringes). This suit had been filed following receipt of two Notices of Paragraph IV Certification from Gland, in which it had asserted that the U.S. patents listed in the FDA&#8217;s Orange Book for the Company&#8217;s Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> methynaltrexone bromide injection, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of its generic methynaltrexone bromide injection. The filing of this suit triggered a 30-month stay of the approval of the Gland ANDA for its methynaltrexone bromide injection. The Company remains confident in the strength of the Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> 3mg Tablets Patent Litigation (MSN and Mylan)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In March 2021, the Company received Notices of Paragraph IV Certification from MSN Laboratories Private Ltd. (&#8220;MSN&#8221;) and Mylan Pharmaceuticals Inc., (&#8220;Mylan&#8221;) in which MSN and Mylan asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) 3mg tablets, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of their generic plecanatide tablets, for which each of MSN and Mylan had filed an ANDA. In April 2021, the Company filed suit against MSN and Mylan, alleging infringement of one or more claims of the patents listed for Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. The Company remains confident in the strength of the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Ophthalmic Solution Patent Litigation (Slayback)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - On August 16, 2021, the Company received a Notice of Paragraph IV Certification from Slayback Pharma LLC (&#8220;Slayback&#8221;), in which Slayback asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brimonidine tartrate solution) drops (the &#8220;Lumify Patents&#8221;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Slayback&#8217;s generic drops, for which an ANDA has been filed by Slayback. The Company, through its affiliate Bausch + Lomb Ireland Limited, exclusively licenses the Lumify Patents from Eye Therapies, LLC (&#8220;Eye Therapies&#8221;). On September 10, 2021, B&amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Slayback pursuant to the Hatch-Waxman Act, alleging infringement by Slayback of one or more claims of the Lumify Patents, thereby triggering a 30-month stay of the approval of the Slayback ANDA. The Company remains confident in the strength of the Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Ophthalmic Solution Patent Litigation (Lupin)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; On January 20, 2022, B&amp;L Inc. received a Notice of Paragraph IV Certification from Lupin Ltd. (&#8220;Lupin&#8221;), in which Lupin asserted that certain of the Lumify Patents are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Lupin&#8217;s generic brimonidine tartrate solution, for which its ANDA No. 216716 has been filed by Lupin. On February 2, 2022, B&amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Lupin pursuant to the Hatch-Waxman Act, alleging patent infringement by Lupin of one or more claims of the Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of the Lupin ANDA. As noted above, the Company remains confident in the strength of the Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Competition to Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, a generic competitor launched a product which will directly compete with our Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tablet product. As disclosed in our prior filings, the Company initiated various infringement proceedings </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">against this generic competitor. The Court construed the claims of the asserted patents on August 2, 2019 and, on October 24, 2019, the Company agreed to a judgment that the asserted patents did not cover the generic tablets under the Court&#8217;s claim construction, while reserving its right to appeal the claim construction. On November 22, 2019, the Company filed a Notice of Appeal with respect to the claim construction in the Court of Appeals for the Federal Circuit. On December 18, 2020, the Court of Appeals for the Federal Circuit affirmed the District Court&#8217;s claim construction. The ultimate impact of this generic competitor on our future revenues cannot be predicted; however, Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tablet revenues for the six months ended June 30, 2022 and 2021 were approximately $7 million and $5 million, respectively, and for the years 2021, 2020 and 2019 were approximately $10&#160;million, $15&#160;million and $20&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Competition to Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2018, the U.S. Patent and Trial Appeal Board (&#8220;PTAB&#8221;) completed its inter partes review for an Orange Book-listed patent covering Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (U.S. Patent No 7,214,506 (the &#8220;&#8216;506 Patent&#8221;)) and issued a written determination invalidating such patent.&#160;On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings.&#160;As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion. The &#8216;506 Patent, therefore, remains valid and enforceable and expires in 2026. Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues for the six months ended June 30, 2022 and 2021 were approximately $54 million and $50 million, respectively, and for the years 2021, 2020 and 2019 were approximately $100 million, $111 million and $110 million, respectively. Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is covered by fourteen additional Orange Book-listed patents owned by the Company or its licensor, which expire in the years 2028 through 2035. In August and September 2018, the Company received notices of the filing of a number of ANDAs with paragraph IV certification, and has timely filed patent infringement suits against these ANDA filers, and, in addition, the Company has also commenced certain patent infringement proceedings in Canada against three separate defendants. All cases in the U.S. regarding Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been settled. In Canada, two lawsuits remain pending against Apotex, Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AREDS and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AREDS 2 are over the counter eye vitamin formulas for those with moderate-to-advanced age-related degeneration (&#8220;AMD&#8221;). The PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> U.S. formulation patent expired in March 2021, but a patent covering methods of using the formulation remains in force into 2026. The Company has filed patent infringement proceedings against 16 defendants claiming infringement of these patents and, in certain circumstances, related unfair competition and false advertising causes of action. Twelve of these proceedings were subsequently settled; two resulted in entry of a default. One defendant filed a declaratory judgment action after the Company filed its suit, seeking declaratory judgment related to patent claims as well as false advertising and unfair competition claims. As of the date of this filing, there are two ongoing matters. The Company remains confident in the strength of these patents and will continue to vigorously pursue these matters and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 18, &#8220;LEGAL PROCEEDINGS&#8221; to our unaudited interim Consolidated Financial Statements elsewhere in this Form 10-Q, as well as Note 20, &#8220;LEGAL PROCEEDINGS&#8221; of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC and the CSA on February&#160;23, 2022 for further details regarding certain infringement proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks of generic competition are a fact of the health care industry and are not specific to our operations or product portfolio. These risks are not avoidable, but we believe they are manageable. To manage these risks, our leadership team continually evaluates the impact that generic competition may have on future profitability and operations. In addition to aggressively defending the Company&#8217;s patents and other intellectual property, our leadership team makes operational and investment decisions regarding these products and businesses at risk, not the least of which are decisions regarding our pipeline. Our leadership team actively manages the Company&#8217;s pipeline in order to identify innovative and realizable projects aligned with our core businesses that are expected to provide incremental and sustainable revenues and growth into the future. We believe that our current pipeline is strong enough to meet these objectives and provide future sources of revenues, in our core businesses, sufficient enough to sustain our growth and corporate health as other products in our established portfolio face generic competition and lose momentum.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we have a well-established product portfolio that is diversified within our core businesses. We also believe that we have a robust pipeline that not only provides for the next generation of our existing products, but also brings new solutions into the market.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 1A &#8220;Risk Factors&#8221; of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC and the CSA on February&#160;23, 2022,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information on our competition risks.</span></div><div id="i762fba229369426294c4424c2015a01a_175"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, our products, devices and facilities are the subject of ongoing oversight and review by regulatory and governmental agencies, including general, for cause and pre-approval inspections by the relevant competent authorities where we have business operations. Through the date of this filing, all of our global operations and facilities have the relevant operational good manufacturing practices certificates and all Company products and operating sites are in good </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compliance standing with all relevant notified bodies and global health authorities. Further, all sites under FDA jurisdiction are rated as either No Action Indicated (where there was no Form 483 observation) or Voluntary Action Indicated (&#8220;VAI&#8221;) (where there was a Form 483 with one or more observations). In the case of VAI inspection outcomes, the FDA has accepted our responses to the issues cited, which will be verified when the agency makes its next inspection of those specific facilities. </span></div><div id="i762fba229369426294c4424c2015a01a_178"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL PERFORMANCE HIGHLIGHTS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides selected unaudited financial information for the three and six months ended June 30, 2022 and 2021: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.179%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.089%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,885&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(242)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(270)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(491)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(670)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,261)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(595)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Performance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of the Three Months Ended June 30, 2022 Compared to the Three Months Ended June 30, 2021 </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for the three months ended June 30, 2022 and 2021 was $1,967 million and $2,100 million, respectively, a decrease of $133 million, or 6%. The decrease was primarily due to: (i) the impact of our divestiture of Amoun on July 26, 2021, (ii) a decrease in net volumes in our Diversified Products, Salix and Solta segments, offset by an increase in net volumes in our Bausch + Lomb segment and (iii) the unfavorable impact of foreign currencies, primarily in Europe and Asia. These decreases were partially offset by an increase in net realized pricing, primarily in our Bausch + Lomb segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income for the three months ended June 30, 2022 was $161 million as compared to an operating loss of $270&#160;million for the three months ended June 30, 2021, an increase in our operating results of $431 million and reflects, among other factors:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in contribution (Product sales revenue less Cost of goods sold, excluding amortization and impairments of intangible assets) of $95 million primarily due to: (i) the decrease in revenues as previously discussed and (ii) higher manufacturing variances, primarily as a result of inflationary pressures related to certain manufacturing costs;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in selling, general and administrative (&#8220;SG&amp;A&#8221;) of $9 million primarily attributable to: (i) the impact of our divestiture of Amoun on July 26, 2021 and (ii) the favorable impact of foreign currencies partially offset by: (i) higher selling, advertising and promotion expenses, (ii) higher compensation expense and (iii) an increase in separation-related and IPO-related costs;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in R&amp;D of $12 million primarily attributable to lower R&amp;D spend in 2021, as certain R&amp;D activities and clinical trials which were suspended in response to the COVID-19 pandemic in 2020 and did not normalize until later in 2021;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in Goodwill impairments of $83 million. During the three months ended June 30, 2022, we recognized an $83 million impairment to the goodwill of the Ortho Dermatologics reporting unit primarily driven by an increase in the discount rate due to changes in market conditions;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Amortization of intangible assets of $58 million primarily attributable to fully amortized intangible assets no longer being amortized in 2022;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Asset impairments, including loss on assets held for sale of $41 million primarily attributable to an adjustment to the loss on assets held for sale in connection with the Amoun Sale during 2021; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in Restructuring, integration, separation and IPO costs of $26 million primarily attributable to an increase in Separation costs and IPO costs associated with the B+L Separation, the B+L IPO completed on May 10, 2022 and the Solta IPO which was suspended in June 2022; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a favorable change in Other expense, net of $542 million, primarily attributable to higher adjustments related to the settlements of certain litigation matters during the three months ended June 30, 2021.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income for the three months ended June 30, 2022 was $161 million as compared to an operating loss of $270&#160;million for the three months ended June 30, 2021 and included non-cash charges for Depreciation and amortization of intangible assets of $347 million and $404 million, Goodwill impairments of $83 million and $0, Asset impairments, including loss on assets held for sale, of $6 million and $47 million and Share-based compensation of $26&#160;million and $31&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before income taxes for the three months ended June 30, 2022 and 2021 was $129 million and $670&#160;million, respectively, a decrease of $541 million. The decrease in our Loss before income taxes is primarily attributable to: (i) the increase in our operating results of $431 million, as previously discussed and (ii) the favorable change in Gain (loss) on extinguishment of debt of $158&#160;million, partially offset by an increase in Interest expense of $46 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to Bausch Health Companies Inc. for the three months ended June 30, 2022 and 2021 was $145&#160;million and $595&#160;million, respectively, an increase in our results of $450 million. The increase in our results was primarily due to the decrease in our Loss before income taxes of $541 million, as previously discussed, partially offset by an unfavorable change in income taxes of $87 million.</span></div><div id="i762fba229369426294c4424c2015a01a_181"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of the Six Months Ended June 30, 2022 Compared to the Six Months Ended June 30, 2021 </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for the six months ended June 30, 2022 and 2021 was $3,885 million and $4,127 million, respectively, a decrease of $242 million, or 6%. The decrease was primarily due to: (i) the impact of our divestiture of Amoun on July 26, 2021, (ii) the unfavorable impact of foreign currencies and (iii) a decrease in net volumes primarily attributable to our Diversified Products, Salix and Solta segments partially offset by an increase in volumes in our Bausch + Lomb segment. These decreases were partially offset by an increase in net realized pricing, primarily in our Salix and International segments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income for the six months ended June 30, 2022 was $446 million and operating loss for the six months ended June 30, 2021 was $491 million, an increase in our operating results of $937 million and reflects, among other factors:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in contribution of $179 million primarily due to: (i) the decrease in revenues as previously discussed and (ii) higher manufacturing variances, primarily as a result of inflationary pressures related to certain manufacturing costs;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in SG&amp;A of $7 million primarily attributable to: (i) higher advertising and promotion expenses, (ii) higher compensation expense and (iii) an increase in separation-related and IPO-related costs partially offset by: (i) the impact of our divestiture of Amoun on July 26, 2021 and (ii) the favorable impact of foreign currencies;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in R&amp;D of $27 million primarily attributable to lower R&amp;D spend in 2021, as certain R&amp;D activities and clinical trials which were suspended in response to the COVID-19 pandemic in 2020 and did not normalize until later in 2021;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Amortization of intangible assets of $105 million primarily attributable to fully amortized intangible assets no longer being amortized in 2022;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Goodwill impairments of $386 million. Goodwill impairments associated with our Ortho Dermatologics reporting unit were $83 million and $469 million for the six months ended June 30, 2022 and 2021, respectively;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Asset impairments, including loss on assets held for sale of $181 million, primarily attributable to an adjustment to the loss on assets held for sale in connection with the Amoun Sale during 2021; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in Restructuring, integration, separation and IPO costs of $27 million primarily attributable to an increase in Separation costs and IPO costs associated with the B+L Separation, the B+L IPO completed on May 10, 2022 and the Solta IPO which was suspended in June 2022; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a favorable change in Other expense, net of $510 million primarily attributable to higher adjustments related to the settlements of certain litigation matters during the six months ended June 30, 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income for the six months ended June 30, 2022 was $446 million and operating loss for the six months ended June 30, 2021 was $491 million, and included non-cash charges for Depreciation and amortization of intangible assets of $699 million and $807 million, Asset impairments, including loss on assets held for sale of $14 million and $195 million, Goodwill impairments of $83 million and $469 million and Share-based compensation of $58 million and $62&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before income taxes for the six months ended June 30, 2022 and 2021 was $211 million and $1,261&#160;million, respectively, a decrease of $1,050 million. The decrease in our Loss before income taxes is primarily attributable to: (i) the increase in our operating results of $937 million, as previously discussed, and (ii) the favorable change in Gain (loss) on </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">extinguishment of debt of $163 million partially offset by: (i) an increase in Interest expense of $40 million and (ii) the unfavorable net change in Foreign exchange and other of $11 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to Bausch Health Companies Inc. for the six months ended June 30, 2022 and 2021 was $214&#160;million and $1,205 million, respectively, an increase in our results of $991 million. The increase in our results was primarily due to the decrease in our Loss before income taxes of $1,050 million, as previously discussed, partially offset by a decrease in Benefit from income taxes of $55 million.</span></div><div id="i762fba229369426294c4424c2015a01a_184"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unaudited operating results for the three and six months ended June 30, 2022 and 2021 were as follows:</span></div><div style="margin-bottom:0.8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:44.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.268%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.003%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.153%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,079&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,967&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(133)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,885&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(242)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of goods sold (excluding amortization and impairments of intangible assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(386)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(542)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(510)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,806&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(564)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,439&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,179)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(270)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(491)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">937&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(364)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(772)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(732)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain (loss) on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(670)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,261)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Provision for) benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(593)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(205)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,200)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">995&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(595)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,205)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="i762fba229369426294c4424c2015a01a_187"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three Months Ended June 30, 2022 Compared to the Three Months Ended June 30, 2021 </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, principally in the therapeutic areas of GI, dermatology, and eye health, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics medical devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues were $1,967 million and $2,100 million for the three months ended June 30, 2022 and 2021, respectively, a decrease of $133 million, or 6%. The decrease was due to: (i) the impact of divestitures and discontinuations of $74 million, primarily attributable to our divestiture of Amoun on July 26, 2021, (ii) the unfavorable impact of foreign currencies of $61 million, primarily in Europe and Asia and (iii) a decrease in volumes of $17 million primarily due to decreases in our Salix, Diversified Products and Solta segments offset by increases in volumes in our Bausch + Lomb segment. These decreases were partially offset by an increase in net realized pricing of $19&#160;million, primarily in our Bausch + Lomb segment. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our segment revenues and segment profits for the three months ended June 30, 2022, are discussed in further detail in the respective subsequent section &#8220; &#8212; Reportable Segment Revenues and Profits&#8221;.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Discounts and Allowances, Chargebacks and Distribution Fees</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at net product sales.&#160;Provisions for these deductions are recognized concurrently with the recognition of gross product sales. These provisions include cash discounts and allowances, chargebacks, and distribution fees, which are paid or credited to direct customers, as well as rebates and returns, which can be paid or credited to direct and indirect customers. As more fully discussed in Note 3, &#8220;REVENUE RECOGNITION&#8221; to our unaudited interim Consolidated Financial Statements, the Company continually monitors the provisions for these deductions and evaluates the estimates used as additional information becomes available. Price appreciation credits are generated when we increase a product&#8217;s wholesaler acquisition cost (&#8220;WAC&#8221;) under our contracts with certain wholesalers. Under such contracts, we are entitled to credits from such wholesalers for the impact of that WAC increase on inventory on hand at the wholesalers. In wholesaler contracts, such credits are offset against the total distribution service fees we pay on all of our products to each such wholesaler. In addition, some payor contracts require discounting if a price increase or series of price increases in a contract period exceeds a negotiated threshold. Provision balances relating to amounts payable to direct customers are netted against trade receivables and balances relating to indirect customers are included in accrued liabilities. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively manage these offerings, focusing on the incremental costs of our patient assistance programs, the level of discounting to non-retail accounts and identifying opportunities to minimize product returns. We also concentrate on managing our relationships with our payors and wholesalers, reviewing the ranges of our offerings and being disciplined as to the amount and type of incentives we negotiate. Provisions recorded to reduce gross product sales to net product sales and revenues for the three months ended June 30, 2022 and 2021 were as follows: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.021%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,489&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions to reduce gross product sales to net product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Returns</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,454&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,413&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash discounts and allowances, returns, rebates, chargebacks and distribution fees as a percentage of gross product sales were 42.8% and 40.5% for the three months ended June 30, 2022 and 2021, respectively, an increase of 2.3 percentage points and includes: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discounts and allowances as a percentage of gross product sales were lower primarily driven by lower gross product sales and lower discount rates for certain generic products, such as Tobramycin / Dexamethasone, Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG and Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG partially offset by: (i) higher gross sales for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG and (ii) the impact of higher gross product sales and discount rates for other generics, such as Trimethoprim and Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">returns as a percentage of gross product sales were unchanged. Over the last several years, the Company has increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including, but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving the sales return experience. The year over year comparison is also favorably impacted by the recall of certain Bausch + Lomb consumer products as a result of a quality issue at a third-party supplier during the three months ended June 30, 2021, as discussed below. These factors driving our lower return experience were partially offset by charges in our International segment of approximately $11 million during the three months ended June 30, 2022, to reflect a change in estimated future returns in one market, driven by lower estimated demand following the easing of local COVID lockdown restrictions and a change of distributors;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">rebates as a percentage of gross product sales were higher primarily due to an increase in gross product sales and higher rebate rates for certain branded products, such as Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Aplenzin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by lower gross product sales and lower rebate rates for certain branded products, such as Wellbutrin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Retin-A Microsphere.06, Bepreve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and lower sales of our generic product Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">chargebacks as a percentage of gross product sales were higher primarily due to higher chargeback rates for certain branded products, such as Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SLX and Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and certain generic products such as Ofloxacin, Nifediac and Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG partially offset by lower gross product sales and lower chargeback rates for certain generic products, such as Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG and for certain branded products such as Mysoline</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Atavin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distribution service fees as a percentage of gross product sales were higher primarily due to higher gross product sales and changes in the year over year customer mix for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. There were no price appreciation credits for the three months ended June 30, 2022 and 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold (excluding amortization and impairments of intangible assets)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold primarily includes: manufacturing and packaging; the cost of products we purchase from third parties; royalty payments we make to third parties; depreciation of manufacturing facilities and equipment; and lower of cost or market adjustments to inventories. Cost of goods sold typically vary between periods as a result of product mix, volume, royalties, changes in foreign currency and inflation. Cost of goods sold excludes the amortization and impairments of intangible assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold was $570 million and $604 million for the three months ended June 30, 2022 and 2021, respectively, a decrease of $34 million, or 6%. The decrease was primarily driven by: (i) the impact of the divestiture of Amoun on July 26, 2021, (ii) the decrease in volumes previously discussed and (iii) the favorable impact of foreign currencies. These decreases were partially offset by higher manufacturing variances, primarily as a result of inflationary pressures related to certain manufacturing costs, partially offset by the impact of manufacturing variances incurred in 2021 related to a quality issue at a third-party supplier, as discussed below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, B&amp;L Inc. was notified by a third-party supplier of sterilization services for its lens care solution bottles and caps at its Milan, Italy facility, of inconsistencies in the sterilization data versus certificates of conformance previously submitted to B&amp;L Inc. by that supplier. Based on B&amp;L Inc.&#8217;s internal Health and Safety Analysis, it was determined that this issue did not affect the safety or performance of any of its products and was limited to a specific number of lots for certain Consumer products within our Bausch + Lomb segment. However, out of an abundance of caution and working with the appropriate notified body and responsible health authorities, B&amp;L Inc. has contained and/or recalled down to the consumer level the limited number of affected lots of products resulting in $7&#160;million of manufacturing variances and $6 million of returns during the three months ended June 30, 2021. Further, although B&amp;L Inc.&#8217;s Greenville, South Carolina facility increased production to support some of the demand in the near term, due to the limited availability of qualified materials, production at the Milan facility could not keep up with demand which negatively impacted our sales for the affected products in this region during the three months ended June 30, 2021. At this time, B&amp;L Inc. has removed this supplier from its Approved Supplier List and qualified another sterilization supplier, who, along with an existing secondary supplier, will provide bottle sterilization, thereby allowing the Milan facility to return to full production capacity. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold as a percentage of product sales revenue were 29.3% and 29.1% for the three months ended June 30, 2022 and 2021, respectively, an increase of 0.2 percentage points.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses primarily include: employee compensation associated with sales and marketing, finance, legal, information technology, human resources and other administrative functions; certain outside legal fees and consultancy costs; product promotion expenses; overhead and occupancy costs; depreciation of corporate facilities and equipment; and other general and administrative costs. The Company has also incurred Separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation and the suspended Solta IPO and will continue to incur incremental costs indirectly related with the B+L Separation. Separation-related and IPO-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses were $676 million and $685 million for the three months ended June 30, 2022 and 2021, respectively, a decrease of $9 million, or 1%. The decrease was primarily attributable to: (i) the impact of our divestiture of Amoun on July 26, 2021, (ii) lower compensation expense and (iii) the favorable impact of foreign currencies partially offset by: (i) higher selling, advertising and promotion expenses and (ii) an increase in separation-related and IPO-related costs.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Research and development are costs related to our product development and quality assurance programs. Expenses related to product development include: employee compensation costs; overhead and occupancy costs; depreciation of research and development facilities and equipment; clinical trial costs; clinical manufacturing and scale-up costs; and other third-party development costs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards and include: employee compensation costs; overhead and occupancy costs; amortization of software; and other third-party costs. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses were $127 million and $115 million for the three months ended June 30, 2022 and 2021, respectively, an increase of $12 million, or 10%. R&amp;D expenses as a percentage of Product sales were approximately 7% and 6% for the three months ended June 30, 2022 and 2021, respectively. The increase was primarily attributable to: (i) lower R&amp;D spend in 2021, as certain R&amp;D activities and clinical trials which were suspended in response to the COVID-19 pandemic in 2020 and did not normalize until later in 2021, as discussed below, and (ii) higher spend on certain Solta and Salix projects. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2020, due to the COVID-19 pandemic, certain of our R&amp;D activities were limited and others, including new patient enrollments in clinical trials, were temporarily paused, as most trial sites were not able to accept new patients due to government-mandated shutdowns. During our third quarter of 2020, many of these trial sites began to reopen. During 2021, the pace of new patient enrollments and the increase these activities and related R&amp;D spend gradually increased until they approached a normalized spend rate toward the end of 2021. As of the date of this filing, we have not had to make material changes to our development timelines and the pause in our clinical trials has not had a material impact on our operating results; however, a resurgence of COVID-19 could result in unanticipated delays in our ability to conduct new patient enrollments and create other delays which could have a significant adverse effect on our future operating results.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization of Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives, generally 2 to 20 years. Management continually assesses the useful lives related to the Company&#8217;s long-lived assets to reflect the most current assumptions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets was $302 million and $360 million for the three months ended June 30, 2022 and 2021, respectively, a decrease of $58 million. The decrease was primarily attributable to fully amortized intangible assets no longer being amortized in 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net includes finite-lived intangible assets related to our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> branded products. The aggregate carrying value of our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intangible assets is approximately $2,963&#160;million as of June 30, 2022, and have remaining useful lives of 66 months. Amortization expense related to these intangible assets is approximately $539&#160;million annually. While we intend to appeal the Norwich Legal Decision (see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 18, &#8220;LEGAL PROCEEDINGS&#8221; to our unaudited interim Consolidated Financial Statements), it is possible that this and other potential future developments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">may adversely impact the estimated future cash flows of our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brands, which could result in an impairment of the value of these intangible assets in one or more future periods. Any such impairment could be material to the Company&#8217;s results of operations in the period in which it occurs; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">may result in shortened useful lives of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets, which would increase amortization expense in future periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our unaudited interim Consolidated Financial Statements for further details related to our intangible assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill Impairments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill impairments were $83 million and $0 for the three months ended June 30, 2022 and 2021, respectively, an increase of $83 million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to monitor the market conditions impacting the Ortho Dermatologics reporting unit. During the three months ended June 30, 2022, increases in interest rates and, to a lesser extent, higher than expected inflation in the U.S. and other macroeconomic factors impacted key assumptions used to value the Ortho Dermatologics reporting unit at </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2022 (the last time goodwill of the Ortho Dermatologics reporting unit was tested). Given the limited headroom of the Ortho Dermatologics reporting unit as calculated on March 31, 2022, the Company believed that these facts and circumstances suggest the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022, the quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the second quarter of 2022 which reflect current market conditions and current trends in business performance. Our latest discounted cash flow model for the Ortho Dermatologics reporting unit includes a range of potential outcomes for, among other matters, macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The quantitative fair value test utilized a long-term growth rate of 1% and a discount rate of 10%. The discount rate has increased 1% since the assessment performed at March 31, 2022, as a result of changes in current macroeconomic conditions, including an increase in the risk free rate during the three months ended June 30, 2022. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at June 30, 2022, and we recognized a goodwill impairment of $83&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 80% of our Salix segment revenues is derived from our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line. While we intend to appeal the Norwich Legal Decision (see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 18, &#8220;LEGAL PROCEEDINGS&#8221; to our unaudited interim Consolidated Financial Statements), it is possible that this and other potential future developments may adversely impact the estimated fair value of the Salix segment, in one or more future periods. Any such impairment could be material to the Company&#8217;s results of operations in the period in which it occurs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our unaudited interim Consolidated Financial Statements for further details related to our goodwill. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Impairments, Including Loss on Assets Held for Sale</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments in the Consolidated Statement of Operations. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale were $6 million and $47 million for the three months ended June 30, 2022 and 2021, respectively, a decrease of $41 million. Asset impairments, including loss on assets held for sale for the three months ended June 30, 2022 of $6 million was primarily related to changes in forecasted revenues and production costs of a neurology product. Asset impairments, including loss on assets held for sale for the three months ended June 30, 2021 of $47 million include: (i) impairments of $25 million due to decreases in forecasted sales of a certain product line in our Diversified Products segment, (ii) an adjustment of $20 million to the loss of assets held for sale in connection with the Amoun Sale and (iii) impairments of $2 million, in aggregate, related to the discontinuance of certain product lines. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our unaudited interim Consolidated Financial Statements for further details related to our intangible assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring, Integration, Separation and IPO Costs </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, integration separation and IPO costs were $35 million and $9 million for the three months ended June 30, 2022 and 2021, respectively, an increase of $26 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring and Integration Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates opportunities to improve its operating results and implement cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and integration costs were $22 million and $3 million for the three months ended June 30, 2022 and 2021, respectively. The Company continues to evaluate opportunities to streamline its operations and identify additional cost savings globally. Although a specific plan does not exist at this time, the Company may identify and take additional exit and cost-rationalization restructuring actions in the future, the costs of which could be material. </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation and IPO Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred, and expects to continue to incur costs associated with activities to effectuate the B+L Separation. The Company also incurred costs associated with activities to effectuate the Solta IPO, which was suspended in June 2022. These B+L Separation and Solta IPO activities include: (i) separating the Bausch + Lomb and Solta Medical businesses from the remainder of the Company, (ii) completing the B+L IPO and preparing for the suspended Solta IPO and (iii) completing the actions necessary for Bausch + Lomb to become an independent publicly traded entity. Separation and IPO costs are incremental costs directly related to the ongoing B+L Separation and the suspended Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing a new board of directors and related board committees for the Bausch + Lomb and Solta Medical entities. Separation and IPO costs were $13&#160;million and $6 million for the three months ended June 30, 2022 and 2021, respectively. The extent and timing of future charges of these costs to complete the B+L Separation cannot be reasonably estimated at this time and could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 5, &#8220;RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS&#8221; to our unaudited interim Consolidated Financial Statements for further details regarding these actions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other expense, net</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net for the three months ended June 30, 2022 and 2021 consists of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, Net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Operating Income and Expense</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense primarily consists of interest payments due, amortization of debt premiums, discounts and deferred issuance costs on indebtedness under our credit facilities and notes and the amortization of amounts excluded from the assessment of hedge effectiveness over the term of the Company&#8217;s cross-currency swaps during 2021. In November 2021, we entered into a transaction to unwind our cross-currency swaps. In July 2022, we entered into new cross-currency swaps with aggregate notional amounts of $1,000&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was $410 million and $364 million, and included non-cash amortization and write-offs of debt premiums, discounts and deferred issuance costs of $50 million and $12 million, for the three months ended June 30, 2022 and 2021, respectively. Interest expense for the three months ended June 30, 2022 increased $46 million, or 13%, as compared to the three months ended June 30, 2021, primarily attributable to the higher interest rates partially offset by the impact of lower outstanding debt balances. The weighted average stated rate of interest as of June&#160;30, 2022 and 2021 was 6.34% and 5.85%, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Consolidated Financial Statements for further details.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain (Loss) on Extinguishment of Debt </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) on extinguishment of debt represents the differences between the amounts paid to settle extinguished debts and the carrying value of the related extinguished debt. The gain on extinguishment of debt was $113 million for the three months ended June 30, 2022 as compared to a loss on extinguishment of debt of $45 million for the three months ended June 30, 2021. </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain on extinguishment of debt for the three months ended June 30, 2022 includes $176 million of gains associated with the early retirement of senior unsecured notes as discussed below, partially offset by $63 million of losses associated with the refinancing and modification to certain debt obligations completed in connection with the B+L IPO, as discussed in further detail below, under &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt&#8221; and represents the differences between the amounts paid to settle the extinguished debt and its carrying value.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During June 2022, through a series of transactions we repurchased and retired, outstanding senior unsecured notes with an aggregate par value of $481 million in the open market for approximately $300 million using: (i) the net proceeds from the partial exercise of the over-allotment option in the B+L IPO by the underwriters, after deducting underwriting commissions, (ii) amounts available under our revolving credit facility and (iii) cash on hand. The senior unsecured notes retired had maturities of January 2028 through February 2031 and had a weighted average interest rate of approximately 5.35%. As a result of these transactions, we recognized a gain on the extinguishment of debt of approximately $176 million, net of write-offs of debt premiums, discounts and deferred issuance costs, representing the differences between the amounts paid to retire the senior unsecured notes and their carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loss on extinguishment of debt of $45 million for the three months ended June 30, 2021 is primarily associated with refinancing transactions during the three months ended June 30, 2021 and represents the differences between the amounts paid to settle the extinguished debt and its carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Consolidated Financial Statements for further details.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange and Other </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange and other primarily includes: (i) translation gains/losses on intercompany loans and third-party liabilities and (ii) the gain/loss due to foreign currency exchange contracts. Foreign exchange and other was a gain of $4&#160;million and $7&#160;million for the three months ended June 30, 2022 and 2021, respectively, an unfavorable net change of $3&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes was $10 million for the three months ended June 30, 2022 and compares to a benefit for income taxes of $77 million for the three months ended June 30, 2021, an unfavorable change of $87&#160;million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate for the three months ended June 30, 2022 differs from the statutory Canadian income tax rate primarily due to: (i) the recording of valuation allowance on entities for which no tax benefit of losses is expected, (ii) the tax benefit generated from our annualized mix of earnings by jurisdiction and (iii) the discrete treatment of certain tax matters, primarily related to: (a) adjustments for book to income tax return provisions, (b) a tax deduction for stock compensation and (c) changes in uncertain tax positions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate for the three months ended June 30, 2021 differs from the statutory Canadian income tax rate primarily due to: (i) the tax benefit generated from our annualized mix of earnings by jurisdiction, (ii) the recording of valuation allowance on entities for which no tax benefit of losses is expected and (iii) the discrete treatment of certain tax matters, primarily related to: (a) potential and recognized withholding taxes on intercompany dividends, (b) adjustments for book to income tax return provisions, (c) tax deduction for stock compensation and (d) changes in uncertain tax positions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 16, &#8220;INCOME TAXES&#8221; to our unaudited interim Consolidated Financial Statements for further details.</span></div><div id="i762fba229369426294c4424c2015a01a_190"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segment Revenues and Profits</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief description of the Company&#8217;s segments: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.15pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales in the U.S. of GI products. Sales of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line represented 81% and 80% of the Salix segment&#8217;s revenues for the three and six months ended June 30, 2022, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified Products segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological) products and (iv) dentistry products.</span></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Solta Medical segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Solta aesthetic medical devices.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Bausch + Lomb segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment profit is based on operating income after the elimination of intercompany transactions, including between Bausch + Lomb and other segments. Certain costs, such as Amortization of intangible assets, Asset impairments, Goodwill impairments, Restructuring, integration, separation and IPO costs and Other (income) expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. See Note 19, &#8220;SEGMENT INFORMATION&#8221; to our unaudited interim Consolidated Financial Statements for a reconciliation of segment profit to Loss before income taxes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment revenues, segment revenues as a percentage of total revenues, and the period-over-period changes in segment revenues for the three months ended June 30, 2022 and 2021. The following table also presents segment profits, segment profits as a percentage of segment revenues and the period-over-period changes in segment profits for the three months ended June 30, 2022 and 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.542%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.090%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Profits / Segment Profit Margins</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Organic Revenues and Organic Growth Rates (non-GAAP)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organic revenue and organic revenue change are non-GAAP measures. Non-GAAP measures are not standardized measures under the financial reporting framework used to prepare the Company&#8217;s financial statements and might not be comparable to similar financial measures disclosed by other issuers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organic revenue and change in organic revenue (non-GAAP), are defined as GAAP Revenue and changes in GAAP revenue (the most directly comparable GAAP financial measures), respectively, adjusted for changes in foreign currency exchange rates (if applicable) and excluding the impact of recent acquisitions, divestitures and discontinuations, as defined further below. Organic revenue (non-GAAP) is impacted by changes in product volumes and price. The price component is made up of two key drivers: (i) changes in product gross selling price and (ii) changes in sales deductions. The Company uses organic revenue (non-GAAP) and organic revenue changes (non-GAAP) to assess performance of its reportable segments, and the Company in total without the impact of foreign currency exchange fluctuations and recent acquisitions, divestitures and product discontinuations. The Company believes that providing these measures is useful to investors as they provide a supplemental period-to-period comparison.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adjustments to GAAP Revenue and changes in GAAP revenue to determine Organic Revenue (non-GAAP) and changes in Organic Revenue (non-GAAP) are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency exchange rates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Although changes in foreign currency exchange rates are part of our business, they are not within management&#8217;s control. Changes in foreign currency exchange rates, however, can mask positive or negative trends in the underlying business performance. The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions, divestitures and discontinuations:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In order to present period-over-period organic revenues (non-GAAP) on a comparable basis, revenues associated with acquisitions, divestitures and discontinuations are adjusted to include only revenues from those businesses and assets owned during both periods. Accordingly, organic revenue growth (non-GAAP) excludes from the current period, all revenues attributable to each acquisition for twelve months subsequent to the day of acquisition, as there are no revenues from those businesses and assets included in the comparable prior period. Organic revenue growth (non-GAAP) excludes from the prior period (but not the current period), all revenues attributable to each divestiture and discontinuance during the twelve months prior to the day of divestiture or discontinuance, as there are no revenues from those businesses and assets included in the comparable current period. There were no acquisitions during the twelve month period ended June&#160;30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of GAAP revenues to organic revenues (non-GAAP) and the period-over-period changes in organic revenue (non-GAAP) for the three months ended June 30, 2022 and 2021 by segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.006%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Change in<br/>Organic Revenue (Non-GAAP)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Revenue<br/>as<br/>Reported</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Changes in Exchange Rates</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Organic Revenue (Non-GAAP)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Revenue<br/>as<br/>Reported</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Divestitures and Discontinuations</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Organic Revenue (Non-GAAP)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,967&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,028&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,026&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Salix Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salix Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Salix segment includes our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line. Revenues from our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line accounted for approximately 81% and 78% of the Salix segment revenues for the three months ended June 30, 2022 and 2021, respectively. No other single product group represents 10% or more of the Salix segment product sales. Salix segment revenue for the three months ended June 30, 2022 and 2021 was $501 million and $516 million, respectively, a decrease of $15 million, or 3%. The decrease is primarily driven by a decrease in volumes of $20 million primarily attributable to: (i) unfavorable inventory balancing of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by our wholesalers and (ii) the impact of generic competition as certain products, such as Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, lost exclusivity, partially offset by an increase in net realized pricing of $5 million, primarily driven by Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salix Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Salix segment profit for the three months ended June 30, 2022 and 2021 was $354&#160;million and $370&#160;million, respectively, a decrease of $16&#160;million, or 4%. The decrease was primarily driven by: (i) a decrease in contribution primarily attributable to the net decrease in revenues, as previously discussed, and (ii) higher advertising and promotion expenses primarily associated with Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> partially offset by a decrease in litigation costs and an increase in R&amp;D.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">International Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The International segment has a diversified product line with no single product group representing 10% or more of its product sales. The International segment revenue was $233 million and $313 million for the three months ended June 30, 2022 and 2021, respectively, a decrease of $80 million, or 26%. The decrease was primarily attributable to: (i) the impact of divestitures and discontinuations of $71 million, primarily attributable to our divestiture of Amoun on July 26, 2021 and (ii) the unfavorable impact of foreign currencies of $15 million, primarily in Europe. These decreases were partially offset by an increase in volumes of $1 million, which included charges of $11 million representing a change in estimated future returns in one market, driven by lower estimated demand following the easing of local COVID-19 lockdown restrictions as well as a change of distributors, and an increase in net realized pricing of $7 million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The International segment profit for the three months ended June 30, 2022 and 2021 was $66 million and $103&#160;million, respectively, a decrease of $37 million, or 36%. The decrease was primarily attributable to: (i) our divestiture of Amoun on July 26, 2021 and (ii) lower contribution primarily attributable to the unfavorable impact of foreign currencies and by higher manufacturing variances, primarily as a result of inflationary pressures related to certain manufacturing costs. These decreases were partially offset by lower selling expenses.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Diversified Products Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversified Products Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Diversified Products segment revenue for the three months ended June 30, 2022 and 2021 was $235 million and $264 million, respectively, a decrease of $29 million, or 11%. The decrease was primarily driven by: (i) a decrease in volume of $17 million and (ii) a decrease in net realized pricing of $12 million, primarily in our Neurology and Other business and Ortho Dermatologics business. The decrease in volume was primarily attributable to our Neurology and Other business primarily due to: (i) unfavorable inventory balancing of our Wellbutrin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product by our wholesalers and (ii) lower demand for Ativan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Mysoline</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversified Products Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Diversified Products segment profit for the three months ended June 30, 2022 and 2021 was $141 million and $162&#160;million, respectively, a decrease of $21 million, or 13%. The decrease was primarily driven by the decrease in contribution primarily attributable to the net decrease in revenues, as previously discussed, partially offset by lower general and administrative expenses, primarily due to lower litigation costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Solta Medical Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solta Medical Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Solta Medical segment includes the Thermage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product line, which accounted for approximately 71% of the Solta segment revenues for the three months ended June 30, 2022. No other single product group represents 10% or more of the Solta segment revenues. The Solta Medical segment revenue for the three months ended June 30, 2022 and 2021 was $57&#160;million and $73&#160;million, respectively, a decrease of $16&#160;million, or 22%. The decrease was primarily attributable to a decrease in volume of $20&#160;million, primarily driven by the impact of the COVID-19 pandemic in China, partially offset by an increase in net realized pricing of $4&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solta Medical Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Solta Medical segment profit for the three months ended June 30, 2022 and 2021 was $20 million and $39&#160;million, respectively, a decrease of $19 million, or 49%. The decrease was primarily driven by: (i) the decrease in contribution primarily driven by the decrease in revenues, as previously discussed, and (ii) an increase in R&amp;D.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Bausch + Lomb Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bausch + Lomb segment has a diversified product line with no single product group representing 10% or more of its product sales. The Bausch + Lomb segment revenue was $941 million and $934 million for the three months ended June 30, 2022 and 2021, respectively, an increase of $7 million, or 1%. The increase was attributable to increases in volumes of $41 million and net realized pricing of $15 million. The increase in volume was due to: (i) the Vision Care business, primarily attributable to: (a) increased demand for certain consumer eye health products including Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and (b) the impact of a quality issue in 2021 related to a third-party supplier of sterilization services for certain lens care solution bottles and caps, as previously discussed, and (ii) increased demand of consumables and intraocular lenses within our Surgical business, partially offset by: (i) a decrease in volume in our international contact lens business, primarily driven by the impact of the COVID-19 pandemic in China and (ii) a decrease in volume in our U.S. Ophthalmic Pharmaceuticals business, primarily driven by the impact of generic competition on certain products that had previously lost exclusivity, such as Lotemax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gel, Lotemax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Suspension and Bepreve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The overall increases in revenues and net realized pricing were partially offset by: (i) the unfavorable impact of foreign currencies across all our international businesses of $46 million primarily in Europe and Asia and (ii) the impact of divestitures and discontinuations of $3 million, related to the discontinuation of certain products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bausch + Lomb segment profit for the three months ended June 30, 2022 and 2021 was $208&#160;million and $213&#160;million, respectively, a decrease of $5 million, or 2%. The decrease was primarily driven by: (i) higher SG&amp;A expenses within U.S. Consumer and Surgical, (ii) the unfavorable impact of foreign currencies and (iii) higher manufacturing variances, primarily as a result of inflationary pressures related to certain manufacturing costs, partially offset by the impact of manufacturing variances incurred in 2021 related to a quality issue at a third-party supplier, as previously discussed. These decreases were partially offset by the increase in revenues, as previously discussed.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="i762fba229369426294c4424c2015a01a_193"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Six Months Ended June 30, 2022 Compared to the Six Months Ended June 30, 2021 </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue was $3,885 million and $4,127 million for the six months ended June 30, 2022 and 2021, respectively, a decrease of $242 million, or 6%. The decrease was due to: (i) the impact of divestitures and discontinuations of $146&#160;million, primarily attributable to our divestiture of Amoun on July 26, 2021, (ii) a decrease in volumes of $73 million primarily in our Diversified, Salix and Solta segments partially offset by an increase in volumes in our Bausch + Lomb segment and (iii) the unfavorable impact of foreign currencies of $102 million primarily in Europe and Asia. These decreases were partially offset by an increase in net realized pricing of $79&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our segment revenues and segment profits for the six months ended June 30, 2022, are discussed in further detail in the respective subsequent section &#8220; &#8212; Reportable Segment Revenues and Profits&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Discounts and Allowances, Chargebacks and Distribution Fees</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions recorded to reduce gross product sales to net product sales and revenues for the six months ended June 30, 2022 and 2021 were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.020%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,555&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,792&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions to reduce gross product sales to net product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Returns</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,710&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,713&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,845&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,079&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,885&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash discounts and allowances, returns, rebates, chargebacks and distribution fees as a percentage of gross product sales were 41.3% and 39.9% for the six months ended June 30, 2022 and 2021, respectively, an increase of 1.4 percentage points and includes:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discounts and allowances as a percentage of gross product sales were lower primarily due to lower gross product sales for certain generic products, such as Timoptic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG, Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG, Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AG and Migranal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">returns as a percentage of gross product sales were lower primarily due to: (i) the result of the Company&#8217;s improving return experience and (ii) the favorable year over year impact due to the recall of certain Bausch + Lomb consumer products as a result of a quality issue at a third-party supplier during the three months ended June 30, 2021, as previously discussed. Over the last several years, the Company has increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including, but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving the sales return experience. These factors driving our lower return experience were partially offset by charges in our International segment of approximately $11 million during the six months ended June 30, 2022, to reflect a change in estimated future returns in one market, driven by lower estimated demand following the easing of local COVID-19 lockdown restrictions and a change of distributors;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">rebates as a percentage of gross product sales were higher primarily due the impact of an increase in gross product sales of certain branded products with higher rebate rates, such as Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Aplenzin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Prolensa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by lower gross product sales and lower rebate rates for certain branded products such as Wellbutrin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Retin-A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Microsphere .06% and Retin-A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Microsphere .08%, and the generic product Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">chargebacks as a percentage of gross product sales were higher primarily due to higher chargeback rates for certain products such as Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SLX, Ofloxacin and Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by lower chargeback rates and gross product sales for certain generic products such as Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG and Targretin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG and certain branded products such as Mysoline</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Ativan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distribution service fees as a percentage of gross product sales were unchanged. Price appreciation credits are offset against the distribution service fees when due to wholesalers. Price appreciation credits were $0 and $1 million for the six months ended June 30, 2022 and 2021, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold (excluding amortization and impairments of intangible assets)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold was $1,113 million and $1,168 million for the six months ended June 30, 2022 and 2021, respectively, a decrease of $55 million, or 5%. The decrease was primarily driven by: (i) the impact of the divestiture of Amoun on July 26, 2021, (ii) the net decrease in volumes, as previously discussed, and (iii) the favorable impact of foreign currencies. These decreases were partially offset by higher manufacturing variances, primarily as a result of inflationary pressures related to certain manufacturing costs, partially offset by the impact of manufacturing variances incurred in 2021 related to a quality issue at a third-party supplier, as previously discussed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold as a percentage of product sales revenue was 28.9% and 28.6% for the six months ended June 30, 2022 and 2021, respectively, an increase of 0.3 percentage points. Costs of goods sold as a percentage of Product sales revenue was unfavorably impacted by higher manufacturing variances as previously discussed, partially offset by the increase in net realized pricing, as previously discussed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses were $1,298 million and $1,291 million for the six months ended June 30, 2022 and 2021, respectively, an increase of $7 million, or 1%. The decrease was primarily attributable to: (i) higher selling, advertising and promotion expenses and (ii) an increase in separation-related and IPO-related costs partially offset by: (i) the impact of our divestiture of Amoun on July 26, 2021 and (ii) the favorable impact of foreign currencies. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses were $254 million and $227 million for the six months ended June 30, 2022 and 2021, respectively, an increase of $27 million, or 12%. R&amp;D expenses as a percentage of Product sales were approximately 7% and 6% for the six months ended June 30, 2022 and 2021, respectively. The increase was primarily due to: (i) the result of lower R&amp;D spend in early 2021 as certain R&amp;D activities and clinical trials which were suspended in response to the COVID-19 pandemic in 2020 and did not normalize until later in 2021, as previously discussed, and (ii) higher spend on certain Bausch + Lomb and Salix projects</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization of Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets was $612 million and $717 million for the six months ended June 30, 2022 and 2021, respectively, a decrease of $105 million, or 15%. The decrease was primarily attributable to fully amortized intangible assets no longer being amortized in 2022. </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net includes finite-lived intangible assets related to our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> branded products. The aggregate carrying value of our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets is approximately $2,963&#160;million as of June 30, 2022, and have remaining useful lives of 66 months. Amortization expense related to these intangible assets is approximately $539&#160;million annually. While we intend to appeal the Norwich Legal Decision (see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 18, &#8220;LEGAL PROCEEDINGS&#8221; to our unaudited interim Consolidated Financial Statements), it is possible that this and other potential future developments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">may adversely impact the estimated future cash flows of our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brands, which could result in an impairment of the value of these intangible assets in one or more future periods. Any such impairment could be material to the Company&#8217;s results of operations in the period in which it occurs; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">may result in shortened useful lives of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets, which would increase amortization expense in future periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our unaudited interim Consolidated Financial Statements for further details related to our intangible assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill Impairments </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill impairments were $83 million for the six months ended June 2022, related to our Ortho Dermatologics unit as previously discussed, and for the six months ended June 30, 2021 were $469 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, the Company believed that increases in interest rates and other macroeconomic factors during the three months ended June 30, 2022, impacted key assumptions used to value the Ortho Dermatologics reporting unit at March 31, 2022 (the last time goodwill of the Ortho Dermatologics reporting unit was tested) and therefore the Company performed a quantitative fair value test for the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022, the quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the second quarter of 2022 which reflect current market conditions and current trends in business performance. Our latest discounted cash flow model for the Ortho Dermatologics reporting unit includes a range of potential outcomes for, among other matters, macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The quantitative fair value test utilized a long-term growth rate of 1% and a discount rate of 10%. The discount rate has increased 1% since the assessment performed at March 31, 2022, as a result of changes in current macroeconomic conditions, including an increase in the risk free rate during the three months ended June 30, 2022. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at June 30, 2022, and we recognized a goodwill impairment of $83&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, management identified launches of certain Ortho Dermatologics products which were not going to achieve their trajectories as forecasted once the social restrictions associated with the COVID-19 pandemic began to ease in the U.S. and offices of health care professionals could reopen. In addition, insurance coverage pressures within the U.S. continued to persist limiting patient access to topical acne and psoriasis products. In light of these developments, during the first quarter of 2021, the Company began taking steps to: (i) redirect its R&amp;D spend to eliminate projects it had identified as high cost and high risk, (ii) redirect a portion of its marketing and product development outside the U.S. to geographies where there is better patient access and (iii) reduce its cost structure to be more competitive. As a result, during the three months ended March 31, 2021, the Company revised its long-term forecasts for the Ortho Dermatologics reporting unit. Management believed that these events were indicators that there was less headroom as of March 31, 2021 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2020). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed. The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the first quarter of 2021 to reflect the business changes previously discussed, including a range of potential outcomes, along with a long-term growth rate of 1.0% and a range of discount rates between 9.0% and 10.0%. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at March 31, 2021, and the Company recognized a goodwill impairment of $469&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 80% of our Salix segment revenues is derived from our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line. While we intend to appeal the Norwich Legal Decision (see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 18, &#8220;LEGAL PROCEEDINGS&#8221; to our unaudited interim Consolidated Financial Statements), it is possible that this and other potential future developments may adversely impact the estimated fair value of the Salix segment, in one or more future periods. Any such impairment could be material to the Company&#8217;s results of operations in the period in which it occurs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our unaudited interim Consolidated Financial Statements for further details related to our goodwill.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Impairments, Including Loss on Assets Held for Sale</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale were $14 million and $195 million for the six months ended June 30, 2022 and 2021, respectively, a decrease of $181 million. Asset impairments, including loss on assets held for sale for the six months ended June 30, 2022 includes: (i) impairments of $10&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines and (ii) impairments of $4&#160;million, in aggregate, related to the discontinuance of certain product lines. Asset impairments, including loss on assets held for sale for the six months ended June 30, 2021 include: (i) impairments of $96&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines, (ii) an adjustment of $88&#160;million to the loss on assets held for sale in connection with the Amoun Sale and (iii) impairments of $11 million, in aggregate, related to the discontinuance of certain product lines.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our unaudited interim Consolidated Financial Statements for further details related to our intangible assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring, Integration, Separation and IPO Costs </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, integration, separation and IPO costs were $48 million and $21 million for the six months ended June 30, 2022 and 2021, respectively, an increase of $27 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring and Integration Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and integration costs were $25 million and $6&#160;million for the six months ended June 30, 2022 and 2021, respectively, an increase of $19 million. The Company continues to evaluate opportunities to streamline its operations and identify additional cost savings globally. Although a specific plan does not exist at this time, the Company may identify and take additional exit and cost-rationalization restructuring actions in the future, the costs of which could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation and IPO Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separation and IPO costs were $23&#160;million and $15&#160;million for the six months ended June 30, 2022 and 2021, respectively. The extent and timing of future charges of these costs to complete the B+L Separation cannot be reasonably estimated at this time and could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 5, &#8220;RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS&#8221; to our unaudited interim Consolidated Financial Statements for further details regarding these actions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Expense, Net </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net for the six months ended June 30, 2022 and 2021 consists of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, Net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Operating Income and Expense</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was $772 million and $732 million and included non-cash amortization and write-offs of debt premiums, discounts and deferred issuance costs of $64 million and $25 million for the six months ended June 30, 2022 and 2021, respectively. Interest expense increased $40 million, or 5%, primarily due to higher interest rates partially offset by lower outstanding principal balances. The weighted average stated rate of interest as of June&#160;30, 2022 and 2021 was 6.34% and 5.85%, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain (Loss) on Extinguishment of Debt </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain on extinguishment of debt was $113 million for the six months ended June 30, 2022 as compared to a loss on extinguishment of debt of $50 million for the six months ended June 30, 2021.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain on extinguishment of debt for the six months ended June 30, 2022 includes $176 million of gains associated with the early retirement of senior unsecured notes as previously discussed, partially offset by $63 million of losses associated with the refinancing and modification to certain debt obligations completed in connection with the B+L IPO, as discussed in further detail below, under &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt&#8221; and represents the differences between the amounts paid to settle the extinguished debt and its carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loss on extinguishment of debt of $50 million for the six months ended June 30, 2021 is primarily associated with refinancing transactions during the six months ended June 30, 2021 and represents the differences between the amounts paid to settle the extinguished debt and its carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Consolidated Financial Statements for further details.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange and Other </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange and other was a loss of $3 million and a gain of $8 million for the six months ended June 30, 2022 and 2021, respectively, an unfavorable net change of $11 million primarily due to: (i) translation gains/losses on intercompany loans and third-party liabilities and (ii) the gain/loss due to foreign currency exchange contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefit from income taxes was $6 million and $61 million for the six months ended June 30, 2022 and 2021, respectively, an unfavorable change of $55 million. Our effective income tax rate for the six months ended June 30, 2022 differs from the statutory Canadian income tax rate primarily due to: (i) the recording of valuation allowance on entities for which no tax benefit of losses is expected, (ii) the tax benefit generated from our annualized mix of earnings by jurisdiction and (iii) the discrete treatment of certain tax matters, primarily related to: (a) changes in uncertain tax positions, (b) adjustments for book to income tax return provisions and (c) a tax deduction for stock compensation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate for the six months ended June 30, 2021 differs from the statutory Canadian income tax rate primarily due to: (i) the tax benefit generated from our annualized mix of earnings by jurisdiction, (ii) the recording of valuation allowance on entities for which no tax benefit of losses is expected and (iii) the discrete treatment of certain tax matters, primarily related to: (a) the release of a valuation allowance, (b) tax law changes, (c) adjustments for book to income tax return provisions, (d) changes in uncertain tax positions and (e) a tax deduction for stock compensation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 16, &#8220;INCOME TAXES&#8221; to our unaudited interim Consolidated Financial Statements for further details.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="i762fba229369426294c4424c2015a01a_196"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segment Revenues and Profits</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment revenues, segment revenues as a percentage of total revenues, and the year-over-year changes in segment revenues for the six months ended June 30, 2022 and 2021. The following table also presents segment profits, segment profits as a percentage of segment revenues and the year-over-year changes in segment profits for the six months ended June 30, 2022 and 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.989%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,885&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(242)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Profits / Segment Profit Margins</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,601&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,803&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents organic revenue (non-GAAP) and the year-over-year changes in organic revenue (non-GAAP) for the six months ended June 30, 2022 and 2021 by segment. Organic revenues (non-GAAP) and organic growth (non-GAAP) rates are defined in the previous section titled &#8220;Reportable Segment Revenues and Profits&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.221%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.006%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Change in<br/>Organic Revenue (Non-GAAP)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Revenue<br/>as<br/>Reported</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Changes in Exchange Rates</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Organic Revenue (Non-GAAP)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Revenue<br/>as<br/>Reported</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Divestitures and Discontinuations</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Organic Revenue (Non-GAAP)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,815&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,885&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,987&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,981&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Salix Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salix Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Salix segment includes the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product line. Revenues from our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line accounted for approximately 80% and 78% of the Salix segment revenues for the six months ended June 30, 2022 and 2021, respectively. No other single product group represents 10% or more of the Salix segment product sales. The Salix segment revenue for the six months ended June 30, 2022 and 2021 was $965 million and $988 million, respectively, a decrease of $23 million, or 2%. The decrease was primarily attributable to decreases in volume of $72 million, primarily attributable to: (i) unfavorable inventory balancing of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by our wholesalers and (ii) the impact of generic competition as certain products, such as Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, lost exclusivity, partially offset by an increase in net realized pricing of $49 million, primarily attributable to our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line. </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salix Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Salix segment profit for the six months ended June 30, 2022 and 2021 was $676 million and $697&#160;million, respectively, a decrease of $21 million, or 3%. The decrease was primarily driven by: (i) a decrease in contribution primarily attributable to the net decrease in revenues, as previously discussed, and (ii) higher selling, advertising and promotion expenses primarily associated with Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by lower litigation costs. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">International Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The International segment has a diversified product line with no single product group representing 10% or more of its product sales. The International segment revenue was $477 million and $619 million for the six months ended June 30, 2022 and 2021, respectively, a decrease of $142 million, or 23%. The decrease was primarily attributable to: (i) the impact of divestitures and discontinuations of $140&#160;million, primarily attributable to our divestiture of Amoun on July 26, 2021 and (ii) the unfavorable impact of foreign currencies of $27 million, primarily in Canada and Europe. This decrease was partially offset by: (i) an increase in net realized pricing of $16 million and (ii) an increase in volumes of $9 million. The increase in volumes is primarily attributable to Europe and was partially offset by charges for approximately $11 million of returns in connection with a change in certain distribution agreements representing a change in estimated future returns in one market, driven by lower estimated demand following the easing of local COVID-19 lockdown restrictions as well as a change of distributors.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The International segment profit for the six months ended June 30, 2022 and 2021 was $157 million and $212 million, respectively, a decrease of $55 million, or 26%. The decrease was primarily driven by the decrease in contribution primarily attributable to the impact of the divestiture of Amoun on July 26, 2021 partially offset by the increases net realized pricing, as previously discussed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Diversified Products Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversified Products Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Diversified Products segment revenue for the six months ended June 30, 2022 and 2021 was $484 million and $560&#160;million, respectively, a decrease of $76 million, or 14%. The decrease was primarily driven by: (i) a decrease in net realized pricing of $3 million and (ii) a decrease in volume of $73 million. The decrease in volume was primarily attributable to our Neurology and Other business, including: (i) decreases in Ativan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Mysoline</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Pepcid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attributable to the favorable impact of mail order programs in 2021 not recurring in 2022, (ii) a decrease in Wellbutrin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attributable to a decrease in demand and the unfavorable impacts of inventory rebalancing by our distributors and (iii) the impacts of more generic competitors.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversified Products Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Diversified Products segment profit for the six months ended June 30, 2022 and 2021 was $299 million and $362 million, respectively, a decrease of $63 million, or 17% and was primarily driven by the decrease in revenues, as previously discussed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Solta Medical Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solta Medical Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Solta Medical segment includes the Thermage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line, which accounted for approximately 74% of the Solta segment revenues for the six months ended June 30, 2022. No other single product group represents 10% or more of the Solta segment revenues. The Solta Medical segment revenue for the six months ended June 30, 2022 and 2021 was $129 million and $145 million, respectively, a decrease of $16 million, or 11%. The decrease was primarily attributable to a decrease in volume of $25 million, primarily driven by the impact of the COVID-19 pandemic in China partially offset by an increase in net realized pricing of $9 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solta Medical Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Solta Medical segment profit for the six months ended June 30, 2022 and 2021 was $55 million and $80 million, respectively, a decrease of $25 million, or 31%. The decrease was primarily driven by the decrease in revenues as discussed above.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Bausch + Lomb Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bausch + Lomb segment revenue was $1,830 million and $1,815 million for the six months ended June 30, 2022 and 2021, respectively, an increase of $15 million, or 1%. The increase was primarily attributable to: (i) an increase in volumes across all of our Bausch + Lomb businesses of $88 million and net realized pricing of $8 million. The increase in volumes was primarily driven by: (i) our Vision Care business, primarily attributable to: (a) increased demand for certain consumer eye health products including Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and (b) the impact of a quality issue in 2021 related to a third-party supplier of sterilization services for certain lens care solution bottles and caps, as previously discussed, and (ii) increased demand of consumables and intraocular lenses within our Surgical business, partially offset by a decrease in volume in our international contact lens business, primarily driven by the impact of the COVID-19 pandemic in China. These increases were partially offset by: (i) the unfavorable impact of foreign currencies across all Bausch + Lomb&#8217;s international businesses of $75 million, primarily in Europe and Asia and (ii) the impact of divestitures and discontinuations of $6 million, related to the discontinuation of certain products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bausch + Lomb segment profit for the six months ended June 30, 2022 and 2021 was $414&#160;million and $452 million, respectively, a decrease of $38 million, or 8%. The decrease was primarily driven by: (i) higher SG&amp;A expenses within U.S. Consumer and Surgical, (ii) the unfavorable impact of foreign currencies and (iii) higher manufacturing variances, primarily as a result of inflationary pressures related to certain manufacturing costs, partially offset by the impact of manufacturing variances incurred in 2021 related to a quality issue at a third-party supplier, as previously discussed. These decreases were partially offset by the increase in revenues, as previously discussed. </span></div><div id="i762fba229369426294c4424c2015a01a_199"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:69.838%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,200)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash provided by operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,497)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by operating activities before changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(502)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(276)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(778)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(631)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate on cash and cash equivalents and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents, restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(342)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, restricted cash and other settlement deposits, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, restricted cash and other settlement deposits, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,879&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,918&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities was $60 million for the six months ended June 30, 2022, as compared to $838 million for the six months ended June 30, 2021, a decrease of $778 million. The decrease was attributable to: (i) the decrease in Cash provided by operating activities before changes in operating assets and liabilities and (ii) Changes in operating assets and liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities before changes in operating assets and liabilities was $165 million and $667 million for the six months ended June 30, 2022 and 2021, respectively, a decrease of $502 million. The decrease is primarily attributable to payments of accrued legal settlements related to the Glumetza Antitrust Litigation and a RICO class action matter during 2022 and an increase in payments for Separation costs, Separation-related costs, IPO costs and IPO-related costs in 2022 as compared to 2021. </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities resulted in a net decrease in cash of $105 million for the six months ended June 30, 2022, as compared to a net increase of $171 million for the six months ended June 30, 2021, respectively, a decrease of $276 million. During the six months ended June 30, 2022, Changes in operating assets and liabilities was positively impacted by: (i) an increase in inventories of $138 million and (ii) the timing of other payments in the ordinary course of business of $74&#160;million, partially offset by the collection of trade receivables of $107 million. During the six months ended June 30, 2021, Changes in operating assets and liabilities was positively impacted by: (i) the timing of other payments in the ordinary course of business of $254&#160;million and (ii) an increase in accrued interest due to timing of payments of $12&#160;million and was partially offset by: (i) an increase in trade receivables of $48 million and (ii) an increase in inventories of $47 million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $114 million for the six months ended June 30, 2022 and was primarily driven by Purchases of property, plant and equipment of $98 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $99 million for the six months ended June 30, 2021 and was primarily driven by Purchases of property, plant and equipment of $128 million partially offset by: (i) Proceeds from sale of assets and businesses, net of costs to sell of $25 million and (ii) Interest settlements from cross-currency swaps of $11 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities was $162 million for the six months ended June 30, 2022 and was primarily driven by: (i) the issuance of long-term debt, net of discounts, of $6,320 million related to the February 2027 Secured Notes, 2027 Term Loan B Facility, draws on the 2027 Revolving Credit Facility and the B+L Term Loan Facility and (ii) net proceeds from the B+L IPO of $675 million, partially offset by the repayment of long-term debt of $7,083 million related to: (i) the repayment of the outstanding balance under our 2023 Revolving Credit Facility, (ii) the repayment of the outstanding balance of our 6.125% Senior Unsecured Notes, (iii) the repayment of the outstanding balances under our 2025 Term Loan B Facilities and (iv) the repurchase and retirement of certain outstanding Senior Secured Notes in the open market with an aggregate par value of $481 million for approximately $300 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities was $631 million for the six months ended June 30, 2021 and was primarily driven by the repayments of debt of $2,100 million which consisted of: (i) $1,600 million of 7.00% Senior Secured Notes due 2024 as part of the 2021 Refinancing Transactions and (ii) the aggregate prepayments of $500 million of Senior Secured and Senior Unsecured Notes using cash on hand and cash from operations. Issuance of long-term debt, net of discounts of $1,579 million primarily includes the proceeds of $1,583 million from the issuance of $1,600 million in principal amount of 4.875% Senior Secured Notes due June 2028.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Consolidated Financial Statements for additional information regarding the financing activities described above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Sources of Liquidity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity are our cash and cash equivalents, cash collected from customers, funds as available from our revolving credit facility, issuances of long-term debt and issuances of equity and equity-linked securities. We believe these sources will be sufficient to meet our current liquidity needs for at least the twelve months following the issuance of this Form 10-Q.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly evaluates market conditions, its liquidity profile, and various financing alternatives for opportunities to enhance its capital structure. If opportunities are favorable, the Company may refinance or repurchase existing debt or issue equity or equity-linked securities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash and other settlements as presented in the Consolidated Balance Sheet as of June 30, 2022 includes $446 million of cash, cash equivalents and restricted cash held by legal entities of Bausch + Lomb of which approximately $92 million was due to be distributed to other legal entities owned by the Company in connection with the B+L Separation. Cash otherwise held by Bausch + Lomb legal entities and any future cash from the operations, investing and financing activities of Bausch + Lomb, is expected to be retained by Bausch + Lomb entities and are generally not available to support the operations, investing and financing activities of other legal entities, including Bausch + Lomb&#8217;s parent company unless paid as a dividend which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to  Bausch + Lomb&#8217;s shareholders. </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-term Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt, net of unamortized premiums, discounts and issuance costs was $21,814 million and $22,654 million as of June&#160;30, 2022 and December&#160;31, 2021, respectively. Aggregate contractual principal amounts due under our debt obligations were $22,056 million and $22,870 million as of June&#160;30, 2022 and December&#160;31, 2021, respectively, a decrease of $814 million. The decrease is attributable to the debt repayments as previously discussed under, under &#8220;&#8212; Liquidity and Capital Resources &#8212; Cash Flows &#8212; Financing Activities&#8221; during the six months ended June 30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the 2018 Restated Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the &#8220;Senior Secured Credit Facilities&#8221; under the Company&#8217;s Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018 (the &#8220;2018 Restated Credit Agreement&#8221;) with a syndicate of financial institutions and investors as lenders. Prior to the 2022 Amended Credit Agreement (as defined below), the 2018 Restated Credit Agreement provided for a revolving credit facility of $1,225 million, maturing on the earlier of June 1, 2023 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and Bausch Health Americas, Inc. (&#8220;BHA&#8221;) in an aggregate principal amount in excess of $1,000 million (the &#8220;2023 Revolving Credit Facility&#8221;) and term loan facilities of original principal amounts of $4,565 million and $1,500 million, maturing in June 2025 (the &#8220;June 2025 Term Loan B Facility&#8221;) and November 2025 (the &#8220;November 2025 Term Loan B Facility&#8221;), respectively.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the 2022 Amended Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, the Company and certain of its subsidiaries as guarantors entered into a Second Amendment (the &#8220;Second Amendment&#8221;) to the Fourth Amended and Restated Credit and Guaranty Agreement (as amended by the Second Amendment, the &#8220;2022 Amended Credit Agreement&#8221;). The 2022 Amended Credit Agreement provides for a new term loan facility with an aggregate principal amount of $2,500&#160;million (the &#8220;2027 Term Loan B Facility&#8221;) maturing on February 1, 2027 and a new revolving credit facility of $975&#160;million (the &#8220;2027 Revolving Credit Facility&#8221;) that will mature on the earlier of February 1, 2027 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and BHA in an aggregate principal amount in excess of $1,000&#160;million. Borrowings under the 2027 Revolving Credit Facility can be made in U.S. dollars, Canadian dollars or Euros. After giving effect to the Second Amendment, the 2023 Revolving Credit Facility, June 2025 Term Loan B Facility and November 2025 Term Loan B Facility were refinanced (such refinancing, the &#8220;Credit Agreement Refinancing&#8221;), along with certain of the Company&#8217;s existing senior notes, using net proceeds from the borrowings under the 2027 Term Loan B Facility, the B+L IPO and the B+L Debt Financing (as defined below) and available cash on hand. As of June 30, 2022, the Company had drawn $425&#160;million on the 2027 Revolving Credit Facility. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2027 Term Loan B Facility bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) a forward-looking term rate determined by reference to the financing rate for borrowing U.S. dollars overnight collateralized by U.S. Treasury securities (&#8220;term SOFR rate&#8221;) for the interest period relevant to such borrowing</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or (b) a base rate determined by reference to the highest of: (i) the prime rate (as defined in the 2022 Amended Credit Agreement), (ii) the federal funds effective rate plus 1/2 of 1.00% and (iii) the term SOFR rate for a period of one month plus 1.00% (or if such rate shall not be ascertainable, 1.50%) (provided, however, that the term SOFR rate with respect to the 2027 Term Loan B Facility shall at no time be less than 0.50% per annum), in each case, plus an applicable margin. Borrowings under the 2027 Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) the term SOFR rate (provided, however, that the term SOFR rate with respect to the 2027 Revolving Credit Facility shall at no time be less than 0.00% per annum) or (b) a base rate determined by reference to the highest of: (x) the prime rate (as defined in the 2022 Amended Credit Agreement), (y) the federal funds effective rate plus 1/2 of 1.00% or (z) the term SOFR rate for a period of one month plus 1.00%, (ii) Canadian dollars bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) the bankers&#8217; acceptance rate for Canadian dollar deposits in the Toronto interbank market (the &#8220;BA rate&#8221;) for the interest period relevant to such borrowing (provided, however, that the BA rate shall at no time be less than 0.00% per annum) or (b) a prime rate determined by reference to the higher of: (x) the rate of interest last quoted by The Wall Street Journal as the &#8220;Canadian Prime Rate&#8221; or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (y) the one month BA rate calculated daily plus 1.00% (provided, however, that the prime rate shall at no time be less than 0.00% per annum) and (iii) euros bear interest at a rate per annum equal to a term benchmark rate determined by reference to the cost of funds for euro deposits (&#8220;EURIBOR&#8221;) for the interest period relevant to such borrowing (provided, however, that such rate, shall at no time be less than 0.00% per annum in each case, plus an applicable margin). Term SOFR rate loans are subject to a credit spread adjustment ranging from 0.10%-0.25%.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margin for borrowings under the 2027 Term Loan B Facility is 5.25% for term SOFR rate loans and 4.25% for U.S. dollar base rate loans. The applicable interest rate margin for borrowings under the 2027 Revolving Credit Facility ranges from 4.75% to 5.25% for term SOFR rate loans, BA rate loans and EURIBOR loans and 3.75% to 4.25% for U.S. dollar base rate loans and Canadian prime rate loans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is required to pay commitment fees of 0.25%-0.50% per annum with respect to the unutilized commitments under the 2027 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on term SOFR rate borrowings under the 2027 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency fees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the 2022 Amended Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, and net proceeds thresholds), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the 2022 Amended Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the 2022 Amended Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights, and net proceeds thresholds). These mandatory prepayments may be used to satisfy future amortization. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for the 2027 Term Loan B Facility is 5.00% per annum, or $125&#160;million, payable in quarterly installments beginning on September 30, 2022. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of June 30, 2022, the remaining mandatory quarterly amortization payments for the 2027 Term Loan B Facility were $563&#160;million through December 2026.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Amended Credit Agreement permits the incurrence of incremental credit facility borrowings up to the greater of $1,000&#160;million and 40% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the 2022 Amended Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than 3.50:1.00, and, in the case of unsecured debt, either a total leverage ratio of not greater than 6.50:1.00 or an interest coverage ratio of not less than 2.00:1.00.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Amended Credit Agreement provides that Bausch + Lomb shall initially be a &#8220;restricted&#8221; subsidiary subject to the terms of the 2022 Amended Credit Agreement covenants, but does not require Bausch + Lomb to guarantee the obligations under the 2022 Amended Credit Agreement. The 2022 Amended Credit Agreement permits the Company to designate Bausch + Lomb as an &#8220;unrestricted&#8221; subsidiary under the 2022 Amended Credit Agreement and no longer subject to the terms of the covenants thereunder provided that no event of default is continuing or will result from such designation and the total leverage ratio of Remainco (as defined in the 2022 Amended Credit Agreement) will not be greater than 7.60:1.00 on a pro forma basis. The Credit Agreement Refinancing contains provisions designed to facilitate the B+L Separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the B+L Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, Bausch + Lomb entered into a credit agreement (the &#8220;B+L Credit Agreement&#8221;, and the credit facilities thereunder, the &#8220;B+L Credit Facilities&#8221;) providing for term loans of $2,500&#160;million with a five-year term to maturity (the &#8220;B+L Term Facility&#8221;) and a five-year revolving credit facility of $500&#160;million (the &#8220;B+L Revolving Credit Facility&#8221; and such financing, the &#8220;B+L Debt Financing&#8221;). The B+L Credit Facilities are secured by substantially all of the assets of Bausch + Lomb and its material, wholly-owned Canadian, U.S., Dutch and Irish subsidiaries, subject to certain exceptions. The term loans are denominated in U.S. dollars, and borrowings under the revolving credit facility will be made available in U.S. dollars, euros, pounds sterling and Canadian dollars. As of June 30, 2022, the B+L Revolving Credit Facility remains undrawn.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the B+L Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either: (a) the term SOFR rate for the interest period relevant to such borrowing or (b) a base rate, determined by reference to the highest of: (i) the prime rate (as defined in the B+L Credit Agreement), (ii) the federal funds effective rate plus 1/2 of 1.00% and (iii) the term SOFR rate for a period of one month plus 1.00% (or if such rate shall not be ascertainable, 1.00%) (provided, however, that the term SOFR rate with respect to the B+L Revolving Credit Facility shall at no time be less than 0.00% per annum), (ii) Canadian dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either: (a) the BA rate for the interest period relevant to such borrowing (provided, however, that the BA rate shall at no time be less than 0.00% per annum) or (b) prime rate determined by reference to the higher of: (x) the rate of interest last quoted by The Wall Street Journal as the &#8220;Canadian Prime Rate&#8221; or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (y) the one month BA rate calculated </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">daily plus 1.00% (provided, however, that the prime rate shall at no time be less than 0.00% per annum), (iii) euros bear interest at a rate per annum equal to EURIBOR for the interest period relevant to such borrowing (provided, however, that such rate shall at no time be less than 0.00% per annum) and (iv) pounds sterling bear interest at a rate per annum equal to the effective overnight interest rate for unsecured transaction in the Sterling Overnight Index Average (&#8220;SONIA&#8221;) (provided, however, that such rate, shall at no time be no less than 0.00% per annum, in each case, plus an applicable margin. Term SOFR rate loans are subject to a credit spread adjustment of 0.10% and sterling loans are subject to a credit spread adjustment of 0.0326%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for borrowings under the B+L Revolving Credit Facility are: (i) between 0.75% to 1.75% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between 1.75% to 2.75% with respect to term SOFR rate, EURIBOR, SONIA or BA rate borrowings based on Bausch + Lomb&#8217;s total net leverage ratio and (ii) after: (x) Bausch + Lomb&#8217;s senior unsecured non-credit-enhanced long term indebtedness for borrowed money receives an investment grade rating from at least two of S&amp;P, Moody&#8217;s and Fitch and (y) the B+L Term Loan Facility has been repaid in full in cash (the &#8220;IG Trigger&#8221;), between 0.015% to 0.475% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between 1.015% to 1.475% with respect to term SOFR rate, EURIBOR, SONIA or BA rate borrowings based on Bausch + Lomb&#8217;s debt rating. In addition, Bausch + Lomb is required to pay commitment fees of 0.25% per annum in respect of the unutilized commitments under the B+L Revolving Credit Facility, payable quarterly in arrears until the IG Trigger and a facility fee between 0.110% to 0.275% of the total revolving commitments, whether used or unused, based on Bausch + Lomb&#8217;s debt rating and payable quarterly in arrears. Bausch + Lomb is also required to pay letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on term SOFR rate borrowings under the B+L Revolving Credit Facility on a per annum basis, payable quarterly in arrears, as well as customary fronting fees for the issuance of letters of credit and agency fees. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the B+L Term Facility bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either (i) the term SOFR rate for the interest period relevant to such borrowing (provided, however, that the term SOFR rate with respect to the B+L Term Facility shall at no time be less than 0.50% per annum), plus an applicable margin of 3.25% or (ii) a base rate determined by reference to the highest of (x) the prime rate (as defined in the B+L Credit Agreement), (y) the federal funds effective rate plus 1/2 of 1.00% and (z) the term SOFR rate for a period of one month plus 1.00% (or if such rate shall not be ascertainable, 2.25% (provided, however, that the base rate with respect to the B+L Term Facility shall at no time be less than 0.50% per annum), plus an applicable margin of 2.25%. Term SOFR rate loans are subject to a credit spread adjustment of 0.10%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the B+L Credit Agreement, Bausch + Lomb is required to make mandatory prepayments of the loans under the B+L Term Facility under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the B+L Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the B+L Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for the B+L Term Facility is 1.00% per annum, or $25&#160;million, payable in quarterly installments beginning on September 30, 2022. Bausch + Lomb may direct that prepayments be applied to such amortization payments in order of maturity. As of June 30, 2022, the remaining mandatory quarterly amortization payments for the B+L Term Facility were $119&#160;million through March 2027.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes are guaranteed by each of the Company&#8217;s subsidiaries that is a guarantor under the 2022 Amended Credit Agreement and existing Senior Unsecured Notes (together, the &#8220;Note Guarantors&#8221;). The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#8217;s obligations under the 2022 Amended Credit Agreement under the terms of the indentures governing the Senior Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#8217;s and Note Guarantors&#8217; respective existing and future unsubordinated indebtedness and senior to the Company&#8217;s and Note Guarantors&#8217; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pari passu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">structurally subordinated to: (i) all liabilities of any of the Company&#8217;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#8217;s debt that is secured by assets that are not collateral.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#8217;s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate principal amount of our Senior Secured Notes as of June 30, 2022 and December&#160;31, 2021 was $4,850&#160;million and $3,850&#160;million, respectively, an increase of $1,000&#160;million representing the issuance of February 2027 Secured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Unsecured Notes issued by the Company are the Company&#8217;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the 2022 Amended Credit Agreement. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the 2022 Amended Credit Agreement. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes. In connection with the closing of the B+L IPO, the discharge of the April 2025 Unsecured Notes Indenture and the related release under the 2022 Amended Credit Agreement described above, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released. On a non-consolidated basis, the non-guarantor subsidiaries (which, for the avoidance of doubt, does not give effect to the release of the guarantees in connection with closing of the B+L IPO) had total assets of $6,343 million and total liabilities of $7,106 million as of June&#160;30, 2022, and revenues of $755 million and operating income of $50 million for the six months ended June 30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate principal amount of our Senior Unsecured Notes as of June 30, 2022 and December&#160;31, 2021 was $11,769&#160;million and $14,900&#160;million, respectively, a decrease of $3,131 million, attributable to: (i) the redemption in full of the April 2025 Senior Unsecured Notes and (ii) the repurchase and retirement of certain outstanding Senior Secured Notes in the open market with an aggregate par value of approximately $481 million for $300 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Availability Under Revolving Credit Facilities </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this filing, August 9, 2022, there were $550 million of outstanding borrowings, $40 million of issued and outstanding letters of credit and approximately $385 million of remaining availability under the 2027 Revolving Credit Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this filing, August 9, 2022, the B+L Revolving Credit Facility remains undrawn and has availability of approximately $500 million. Absent the making of a dividend, which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to Bausch + Lomb&#8217;s shareholders, proceeds from the B+L Revolving Credit Facility are not available to fund the operations, investing and financing activities of Bausch Health.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Covenant Compliance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any inability to comply with the covenants under the terms of our 2022 Amended Credit Agreement, B+L Credit Agreement, Senior Secured Notes indentures or Senior Unsecured Notes indentures could lead to a default or an event of default for which we may need to seek relief from our lenders and noteholders in order to waive the associated default or event of default and avoid a potential acceleration of the related indebtedness or cross-default or cross-acceleration to other debt. There can be no assurance that we would be able to obtain such relief on commercially reasonable terms or otherwise and we may be required to incur significant additional costs. In addition, the lenders under our 2022 Amended Credit Agreement and B+L Credit Agreement, holders of our Senior Secured Notes and holders of our Senior Unsecured Notes may impose additional operating and financial restrictions on us as a condition to granting any such waiver.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the Company was in compliance with its financial maintenance covenant related to its outstanding debt. The Company, based on its current forecast, expects to remain in compliance with the financial maintenance covenant and meet its debt service obligations for at least the twelve months following the date of issuance of this Form 10-Q. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to take steps to seek to improve its operating results to ensure continual compliance with its financial maintenance covenant and take other actions to reduce its debt levels to align with the Company&#8217;s long-term </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">strategy. The Company may consider taking other actions, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities including secondary offerings of the common shares of Bausch + Lomb, as deemed appropriate, to provide additional coverage in complying with the financial maintenance covenant and meeting its debt service obligations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Weighted Average Interest Rate</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average stated rate of interest of the Company&#8217;s outstanding debt as of June&#160;30, 2022 and December&#160;31, 2021 was 6.34% and 5.88%, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Consolidated Financial Statements for further details.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Focus on Capitalization of the Post-separation Entities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the B+L Separation, we have emphasized that it is important that the post-separation entities be well-capitalized, with appropriate leverage and with access to additional capital, if and when needed, to provide each entity with the ability to independently allocate capital to areas that will strengthen their own competitive positions in their respective lines of business and position each entity for sustainable growth. Therefore, we see the appropriate capitalization and leverage of these businesses post-separation as a key to bringing out the maximum value across our portfolio of assets and it is a primary objective of our plan of separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Ratings </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of August&#160;9, 2022, the credit ratings and outlook from Moody&#8217;s, Standard &amp; Poor&#8217;s (&#8220;S&amp;P&#8217;s&#8221;) and Fitch for certain outstanding obligations of the Company were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:16.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.316%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch Health Companies Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rating Agency</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate Rating</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Rating&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Rating</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outlook</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate Rating</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Rating</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outlook</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Moody&#8217;s&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Caa1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Caa2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Negative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Negative</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standard &amp; Poor&#8217;s</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CCC+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CCC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Negative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CCC+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CCC+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Developing</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fitch</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B-</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BB-</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B-</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Negative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BB+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rating Watch Evolving</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch Health Companies Inc. -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On May 10, 2022, in connection with the B+L IPO and related Credit Agreement Refinancing, Moody&#8217;s assigned our senior secured notes a Ba3 rating, consistent with the Ba3 rating assigned to the $2,500 million of term B loans and the $975 million revolving credit facility and to the newly issued February 2027 Secured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 31, 2022, S&amp;P&#8217;s downgraded all of its credit ratings 1-notch and affirmed its negative outlook.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2022, Moody&#8217;s lowered its credit ratings two notches to: a corporate rating of Caa1, a senior secured rating of B2 and a senior unsecured rating of Caa2. On August 1, 2022, S&amp;P&#8217;s lowered its credit ratings two notches to: a corporate rating to CCC+, a senior secured rating of B and a senior unsecured rating of CCC. On August 3, 2022, Fitch lowered its credit ratings one notch to: a corporate rating of B-, a senior secured rating of BB- and a senior unsecured rating of B-. These downgrades were a result of the Norwich Legal Decision (see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 18, &#8220;LEGAL PROCEEDINGS&#8221; to our unaudited interim Consolidated Financial Statements).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb Corporation - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch + Lomb is a restricted subsidiary under the 2022 Amended Credit Agreement and related indentures and will remain a restricted subsidiary until Bausch Health designates Bausch + Lomb as &#8220;unrestricted&#8221;, which is expected to occur at or prior to the distribution anticipated under the proposed B+L Separation. We expect Bausch + Lomb&#8217;s credit ratings could be capped to that of the Company, until we designate Bausch + Lomb as &#8220;unrestricted&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, S&amp;P lowered its credit ratings for Bausch + Lomb two notches to: a corporate rating of CCC+ and a senior secured rating of CCC+. Moody&#8217;s lowered its senior secured rating for Bausch + Lomb two notches to B1. Fitch lowered its corporate rating for Bausch + Lomb one notch to B+ and maintained its senior secured rating for Bausch + Lomb of BB+. These downgrades were made simultaneously with the downgrades to the credit ratings of Bausch Health, Bausch + Lomb&#8217;s parent company.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any downgrade in our corporate credit ratings or other credit ratings may increase our cost of borrowing and may negatively impact our ability to raise additional debt capital.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="i762fba229369426294c4424c2015a01a_202"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFF-BALANCE SHEET ARRANGEMENTS AND CONTRACTUAL OBLIGATIONS </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no off-balance sheet arrangements that have a material current effect or that are reasonably likely to have a material effect on our results of operations, financial condition, capital expenditures, liquidity, or capital resources. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our cash requirements for the remainder of 2022 are for debt service. Our other future cash requirements relate to working capital, capital expenditures, business development transactions (contingent consideration), restructuring, integration and separation costs, benefit obligations and litigation settlements. In addition, we may use cash to enter into licensing arrangements and/or to make strategic acquisitions. We regularly consider licensing and acquisition opportunities within our core therapeutic areas, some of which could be sizable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our working capital requirements, as of June&#160;30, 2022, we expect our primary cash requirements during the remainder of 2022 to include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Debt repayments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Based on our debt portfolio as of August 3, 2022, we anticipate making mandatory amortization payments of approximately $75 million and interest payments of approximately $730&#160;million during the period July 1, 2022 through December 31, 2022. As discussed below, we have and in the future may also elect to make additional principal payments under certain circumstances. Further, in the ordinary course of business, we may borrow and repay additional amounts under our credit facilities using cash on hand, cash from operations and cash provided from the sale of common stock and additional debt financings in connection with the B+L Separation;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">IT Infrastructure Investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make payments of approximately $20&#160;million for licensing, maintenance and capitalizable costs associated with our IT infrastructure improvement projects during the remainder of 2022;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Capital expenditures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make payments of approximately $180 million for property, plant and equipment during the remainder of 2022;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Contingent consideration payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make contingent consideration and other development/approval/sales-based milestone payments of approximately $25&#160;million during the remainder of 2022;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Restructuring and integration payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make payments of $20&#160;million during the remainder of 2022 for employee separation costs and lease termination obligations associated with restructuring and integration actions we have taken through June&#160;30, 2022;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Benefit obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make aggregate payments under our pension and postretirement obligations of $6&#160;million during the remainder of 2022; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Litigation Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In the ordinary course of business, the Company is involved in litigation, claims, government inquiries, investigations, charges and proceedings. As of June 30, 2022, the Company&#8217;s Consolidated Balance Sheet includes accrued current loss contingencies of $1,536 million related to matters which are both probable and reasonably estimable, of which $1,210 million is expected to be payable during the period July 1, 2022 through December 31, 2022; however, a reliable estimate of the period in which the remaining loss contingencies will be payable, if&#160;ever, cannot be made. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation for $1,210&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- The amounts which can be expected to be payable during the period July 1, 2022 through December 31, 2022 include inter alia the agreement to resolve the U.S. Securities litigation for $1,210 million. Final court approval of this settlement was granted in January 2021 but is subject to an objector&#8217;s appeal of the Court&#8217;s final approval order. The settlement resolves and discharges all claims against the Company in the class action. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against them and deny all allegations of wrongdoing. This settlement resolves the most significant of the Company&#8217;s remaining legacy legal matters and eliminates a material uncertainty regarding our Company. As of June 30, 2022, Restricted cash and other settlement deposits includes $1,210&#160;million of payments into an escrow fund under the terms of a settlement agreement regarding the U.S. Securities Litigation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 18, &#8220;LEGAL PROCEEDINGS&#8221; to our unaudited interim Consolidated Financial Statements for further details on this and other matters. Our ability to successfully defend the Company against pending and future litigation may impact future cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Costs of B+L Separation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred costs associated with activities to complete the B+L Separation and the suspended, Solta IPO, and will continue to incur costs associated with the B+L separation. These activities include the costs of: (i) separating Bausch + Lomb and the Solta Medical businesses from the remainder of the Company and (ii) registering Bausch + Lomb as an independent publicly traded entity. Separation and IPO costs are incremental costs directly related to the B+L Separation </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing new boards of directors and related board committees for Bausch + Lomb. The Company has also incurred, and will incur, Separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation. These costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. The extent and timing of future charges for these costs cannot be reasonably estimated at this time and could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Cost Savings Programs </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate opportunities to improve our operating results and may initiate additional cost savings programs to streamline our operations and eliminate&#160;redundant processes and expenses. These cost savings programs may include, but are not limited to: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The expenses associated with the implementation of these cost savings programs could be material and may impact our cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Licensing Payments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products primarily in the U.S. and Canada. In connection with these agreements, the Company may pay an upfront fee to secure the agreement. See Note 4, &#8220;LICENSING AGREEMENTS AND DIVESTITURE&#8221; to our unaudited interim Consolidated Financial Statements. Payments associated with the upfront fee for these agreements cannot be reasonably estimated at this time and could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the Company had unrecognized tax benefits totaling $840 million, of which, $14&#160;million is expected to be realized during the remainder of 2022, however a reliable estimate of the period in which the remaining uncertain tax positions will be payable, if&#160;ever, cannot be made. </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Repurchases of Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly evaluates market conditions, its liquidity profile, and various financing alternatives for opportunities to enhance its capital structure. If opportunities are favorable, we may, from time to time, purchase outstanding debt for cash in open market purchases or privately negotiated transactions. Such repurchases or exchanges, if any, will depend on prevailing market conditions, future liquidity requirements, contractual restrictions and other factors. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes to the contractual obligations disclosed in Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Off-Balance Sheet Arrangements and Contractual Obligations&#8221; included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC and the CSA on February&#160;23, 2022.</span></div><div id="i762fba229369426294c4424c2015a01a_205"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUTSTANDING SHARE DATA</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common shares trade on the New&#160;York Stock Exchange and the Toronto Stock Exchange under the symbol &#8220;BHC&#8221;. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At August 4, 2022, we had 361,728,490 issued and outstanding common shares. In addition, as of August 4, 2022, we had outstanding 10,932,203 stock options and 5,824,121 time-based restricted share units that each represent the right of a holder to receive one of the Company&#8217;s common shares, and 1,518,449 performance-based restricted share units that represent the right of a holder to receive a number of the Company&#8217;s common shares up to a specified maximum. A maximum of 1,129,202 common shares could be issued upon vesting of the performance-based restricted share units outstanding.</span></div><div id="i762fba229369426294c4424c2015a01a_208"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND ESTIMATES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical accounting policies and estimates are those policies and estimates that are most important and material to the preparation of our Consolidated Financial Statements, and which require management&#8217;s most subjective and complex judgment due to the need to select policies from among alternatives available, and to make estimates about matters that are inherently uncertain. Management has reassessed the critical accounting policies and estimates as disclosed in Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Critical Accounting Policies and Estimates&#8221; included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC and the CSA on February&#160;23, 2022, and determined that there were no significant changes in our critical accounting policies and estimates during the six months ended June 30, 2022, except for: (i) estimates and assumptions regarding the nature, timing and extent that the COVID-19 pandemic had on the Company&#8217;s operations and cash flows as discussed in Note 2, </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;SIGNIFICANT ACCOUNTING POLICIES&#8221; to our unaudited interim Consolidated Financial Statements, (ii) the impact that the current year segment and reporting unit realignments had on the Company&#8217;s allocation of goodwill as discussed in Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our unaudited interim Consolidated Financial Statements and (iii) the estimates associated with the fair value of Ortho Dermatologics reporting unit in testing goodwill for impairment as discussed in Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our unaudited interim Consolidated Financial Statements.</span></div><div id="i762fba229369426294c4424c2015a01a_211"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEW ACCOUNTING STANDARDS </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i762fba229369426294c4424c2015a01a_214"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caution regarding forward-looking information and statements and &#8220;Safe-Harbor&#8221; statements under the U.S.&#160;Private Securities Litigation Reform Act of&#160;1995 and applicable Canadian securities laws:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent any statements made in this Form&#160;10-Q contain information that is not historical, these statements are forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information within the meaning defined under applicable Canadian securities laws (collectively, &#8220;forward-looking statements&#8221;).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements relate to, among other things: our business strategy, business plans and prospects and forecasts and changes thereto; product pipeline, prospective products and product approvals, expected launches of new products, product development and future performance and results of current and anticipated products; anticipated revenues for our products; expected research and development (&#8220;R&amp;D&#8221;) and marketing spend; our expected primary cash and working capital requirements for 2022 and beyond; the Company&#8217;s plans for continued improvement in operational efficiency and the anticipated impact of such plans; our liquidity and our ability to satisfy our debt maturities as they become due; our ability to reduce debt levels; our ability to comply with the financial and other covenants contained in our Fourth Amended and Restated Credit and Guaranty Agreement dated as of June 1, 2018 (the &#8220;Restated Credit Agreement&#8221;), as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018 (the &#8220;2018 Restated Credit Agreement&#8221;) and the Second Amendment (the &#8220;Second Amendment&#8221;) to the 2018 Restated Credit Agreement, dated as of May 10, 2022 (as so amended, and as may be further amended, supplemented or otherwise modified from time to time in accordance with the terms thereof, the &#8220;2022 Amended Credit Agreement&#8221;), and senior notes indentures; the ability of our subsidiary, Bausch + Lomb Corporation (&#8220;Bausch + Lomb&#8221;), to comply with the financial and other covenants contained in its Credit and Guaranty Agreement (the &#8220;B+L Credit Agreement&#8221;, and the credit facilities thereunder, the &#8220;B+L Credit Facilities&#8221;), dated as of May 10, 2022; the impact of our distribution, fulfillment and other third-party arrangements; proposed pricing actions; exposure to foreign currency exchange rate changes and interest rate changes; the outcome of contingencies, such as litigation, subpoenas, investigations, reviews, audits and regulatory proceedings; the anticipated impact of the adoption of new accounting standards; general market conditions; our expectations regarding our financial performance, including revenues, expenses, gross margins and income&#160;taxes; our impairment assessments, including the assumptions used therein and the results thereof; the anticipated impact of the evolving COVID-19 pandemic and related responses from governments and private sector participants on the Company, its supply chain, third-party suppliers, project development timelines, costs, revenues, margins, liquidity and financial condition, the anticipated timing, speed and magnitude of recovery from these COVID-19 pandemic related impacts and the Company&#8217;s planned actions and responses to this pandemic; the anticipated impact from the ongoing conflict between Russia and Ukraine; and the Company&#8217;s plan to separate its eye health business, including the structure and timing of completing such separation transaction.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements can generally be identified by the use of words such as &#8220;believe&#8221;, &#8220;anticipate&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;estimate&#8221;, &#8220;plan&#8221;, &#8220;continue&#8221;, &#8220;will&#8221;, &#8220;may&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;should&#8221;, &#8220;target&#8221;, &#8220;potential&#8221;, &#8220;opportunity&#8221;, &#8220;designed&#8221;, &#8220;create&#8221;, &#8220;predict&#8221;, &#8220;project&#8221;, &#8220;forecast&#8221;, &#8220;seek&#8221;, &#8220;strive&#8221;, &#8220;ongoing&#8221;, &#8220;decrease&#8221; or &#8220;increase&#8221; and variations or other similar expressions. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements may not be appropriate for other purposes. All of the statements in this Form&#160;10-Q that contain forward-looking statements are qualified by these cautionary statements. These statements are based upon the current expectations and beliefs of management. Although we believe that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making such forward-looking statements, including, but not limited to, factors and assumptions regarding the items previously outlined, those factors, risks and uncertainties outlined below and the assumption that none of these factors, risks and uncertainties will cause actual results or events to differ materially from those described in such forward-looking statements. Actual results may differ materially from those expressed or implied in such statements. Important factors, risks and uncertainties that could cause actual results to differ materially from these expectations include, among other things, the&#160;following:</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, the fear of that pandemic, the availability and effectiveness of vaccines for COVID-19 (including with respect to current or future variants and subvariants), COVID-19 vaccine immunization rates, the emergence of variant and subvariant strains of COVID-19, the resurgence of the COVID-19 virus and variant and subvariant strains thereof (including, but not limited to, the recent resurgence of COVID-19 cases) and any resulting reinstitution of lockdowns and other restrictions, the evolving reaction of governments, private sector participants and the public to that pandemic, and the potential effects and economic impact of the pandemic and the reaction to it, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a significant adverse impact on the Company, including, but not limited to, its supply chain, third-party suppliers, project development timelines, employee base, liquidity, stock price, financial condition, costs (which may increase) and revenue and margins (both of which may decrease);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the challenges the Company faces as a result of the closing of the initial public offering (&#8220;IPO&#8221;) of Bausch + Lomb (the &#8220;B+L IPO&#8221;), including the transitional services being provided by and to Bausch + Lomb, any potential, actual or perceived conflict of interest of some of our directors and officers because of their equity ownership in Bausch + Lomb and/or because they also serve as directors or officers of Bausch + Lomb and our ability to timely consolidate the financial results of the Bausch + Lomb business; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">with respect to the Company's proposed plan to spinoff Bausch + Lomb, the risks and uncertainties include, but are not limited to, the expected benefits and costs of the spinoff, the expected timing of completion of the spinoff and its terms (including the Company&#8217;s expectation that the spinoff will be completed following the expiry of customary lock-ups related to the B+L IPO and achievement of targeted debt leverage ratios, subject to receipt of applicable shareholder and other necessary approvals), the Company&#8217;s ability to complete the spinoff considering the various conditions to the completion of the spinoff (some of which are outside the Company&#8217;s control, including conditions related to regulatory matters and applicable shareholder and stock exchange approvals), that market or other conditions are no longer favorable to completing the spinoff, that the previously announced planned IPO of the Company&#8217;s aesthetics medical device business, Global Solta (the &#8220;Solta IPO&#8221;) has been suspended, that the Norwich Legal Decision (see &#8220;Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Paragraph IV Proceedings&#8221; of Note 18, &#8220;LEGAL PROCEEDINGS&#8221; to our unaudited interim Consolidated Financial Statements) may affect the timing of, or our ability to complete the B+L Separation, that applicable shareholder, stock exchange, regulatory or other approvals is not obtained on the terms or timelines anticipated or at all, business disruption during the pendency of, or following, the spinoff, diversion of management time on separation transaction-related issues, retention of existing management team members, the reaction of customers and other parties to the separation transaction, the qualification of the separation transaction as a tax-free transaction for Canadian and/or U.S. federal income tax purposes (including whether or not an advance ruling from the Canada Revenue Agency and/or the Internal Revenue Service will be sought or obtained), the ability of the Company and the separated entity to satisfy the conditions required to maintain the tax-free status of the spinoff (some of which are beyond their control), other potential tax or other liabilities that may arise as a result of the spinoff, the potential dissynergy costs resulting from the spinoff, the impact of the spinoff on relationships with customers, suppliers, employees and other business counterparties, general economic conditions, conditions in the markets the Company is engaged in, behavior of customers, suppliers and competitors, technological developments, as well as legal and regulatory rules affecting the Company&#8217;s business. In particular, the Company can offer no assurance that any spinoff will occur at all, or that any such transaction will occur on the timelines anticipated by the Company; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ongoing litigation and potential additional litigation, claims, challenges and/or regulatory investigations challenging or otherwise relating to the B+L IPO and the spinoff and the costs, expenses, use of resources, diversion of management time and efforts, liability and damages that may result therefrom;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expense, timing and outcome of legal and governmental proceedings, investigations and information requests relating to, among other matters, our past distribution, marketing, pricing, disclosure and accounting practices (including with respect to our former relationship with Philidor Rx Services, LLC (&#8220;Philidor&#8221;)), including a number of pending non-class securities litigations (including certain pending opt-out actions in the U.S. related to the previously settled securities class action (which remains subject to an objector&#8217;s petition for rehearing of its appeal of the Court&#8217;s final approval order) and certain opt-out actions in Canada relating to the recently settled class action in Canada), certain pending lawsuits and other claims, investigations or proceedings that may be initiated or that may be asserted;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential additional litigation and regulatory investigations (and any costs, expenses, use of resources, diversion of management time and efforts, liability and damages that may result therefrom), negative publicity and reputational harm on our Company, products and business that may result from the past and ongoing public scrutiny of our past distribution, marketing, pricing, disclosure and accounting practices and from our former relationship with Philidor;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the past and ongoing scrutiny of our legacy business practices, including with respect to pricing, and any pricing controls or price adjustments that may be sought or imposed on our products as a result thereof; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing decisions that we have implemented, or may in the future elect to implement, such as the Patient Access and Pricing Committee&#8217;s historic practice of limiting the average annual price increase for our branded prescription pharmaceutical products to single digits, or any future pricing actions we may take in 2022 or beyond following review by our Patient Access and Pricing Committee (which is responsible for the pricing of our drugs);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">legislative or policy efforts, including those that may be introduced and passed by the U.S. Congress, designed to reduce patient out-of-pocket costs for medicines, which could result in new mandatory rebates and discounts or other pricing restrictions, controls or regulations (including mandatory price reductions);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ongoing oversight and review of our products and facilities by regulatory and governmental agencies, including periodic audits by the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) and equivalent agencies outside of the U.S. and the results thereof;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actions by the FDA or other regulatory authorities with respect to our products or facilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with the legal and regulatory requirements of our marketed products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our substantial debt (and potential additional future indebtedness) and current and future debt service obligations, our ability to reduce our outstanding debt levels and the resulting impact on our financial condition, cash flows and results of operations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with the financial and other covenants contained in our senior notes indentures, the 2027 Revolving Credit Facility (as defined below), the 2022 Amended Credit Agreement, the B+L Credit Agreement and other current or future credit and/or debt agreements, including the ability of Bausch + Lomb to comply with its covenants and obligations under the B+L Credit Agreement, restrictions and prohibitions such covenants impose or may impose on the way we conduct our business, including prohibitions on incurring additional debt if certain financial covenants are not met, limitations on the amount of additional obligations we are able to incur pursuant to other covenants, our ability to draw under our 2027 Revolving Credit Facility, Bausch + Lomb&#8217;s ability to draw down under the revolving credit facility under the B+L Credit Agreement and restrictions on our ability to make certain investments and other restricted payments;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any default under the terms of our senior notes indentures or the 2022 Amended Credit Agreement (and other current or future credit and/or debt agreements) and our ability, if any, to cure or obtain waivers of such default;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any downgrade by rating agencies in our credit ratings, which may impact, among other things, our ability to raise debt and the cost of capital for additional debt issuances;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any reductions in, or changes in the assumptions used in, our forecasts for fiscal year 2022 or beyond, including as a result of the impacts of the COVID-19 pandemic on our business and operations, which could lead to, among other things: (i) a failure to meet the financial and/or other covenants contained in the 2022 Amended Credit Agreement, senior notes indentures and/or the B+L Credit Agreement (and other current or future credit and/or debt agreements) and/or (ii) impairment in the goodwill associated with certain of our reporting units or impairment charges related to certain of our products or other intangible assets, which impairments could be material;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the assumptions used in connection with our impairment analyses or assessments, which would lead to a change in such impairment analyses and assessments and which could result in an impairment in the goodwill associated with any of our reporting units or impairment charges related to certain of our products or other intangible assets;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the uncertainties associated with the acquisition and launch of new products, assets and businesses, including, but not limited to, our ability to provide the time, resources, expertise and funds required for the commercial launch of new products, the acceptance and demand for new products, and the impact of competitive products and&#160;pricing, which could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability or inability to extend the profitable life of our products, including through line extensions and other life-cycle programs;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to retain, motivate and recruit directors, executives and other key&#160;employees;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to implement effective succession planning for our executives and key employees;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to stabilize and reposition our Ortho Dermatologics business to generate additional value, including the success of recently launched products and the approval of pipeline products (and the timing of such approvals);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to achieve anticipated revenues for our products, including changes in anticipated marketing spend on such products and launch of competing products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to achieve anticipated market acceptance for our products, including acceptance of the pricing, effectiveness of promotional efforts, reputation of our products and launch of competing products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the challenges and difficulties associated with managing a large complex business, which has, in the past, grown rapidly;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to compete against companies that are larger and have greater financial, technical and human resources than we do, as well as other competitive factors, such as technological advances achieved, patents obtained and new products introduced by our competitors;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively operate and grow our businesses in light of the challenges that the Company has faced and market conditions, including with respect to its substantial debt, pending investigations and legal proceedings, scrutiny of our past pricing and other practices, limitations on the way we conduct business imposed by the covenants contained in our 2022 Amended Credit Agreement, the B+L Credit Agreement, our senior notes indentures and the agreements governing our other indebtedness, and the impacts of the COVID-19 pandemic;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our products are reimbursed by government authorities, pharmacy benefit managers (&#8220;PBMs&#8221;) and other third-party payors; the impact our distribution, pricing and other practices may have on the decisions of such government authorities, PBMs and other third-party payors to reimburse our products; the impact of obtaining or maintaining such reimbursement on the price and sales of our products; and the launch and implementation of any new pharma-care or dental-care program or related spending by the Canadian federal government;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inclusion of our products on formularies or our ability to achieve favorable formulary status, as well as the impact on the price and sales of our products in connection therewith;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the consolidation of wholesalers, retail drug chains and other customer groups and the impact of such industry consolidation on our business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain strong relationships with physicians and other healthcare professionals;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our eligibility for benefits under tax treaties and the availability of low effective tax rates for the business profits of certain of our subsidiaries;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the implementation of the Organisation for Economic Co-operation and Development Inclusive Framework on Base Erosion and Profit Shifting, including the global minimum corporate tax rate, by the countries in which we operate; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of any audits by taxation authorities, which outcomes may differ from the estimates and assumptions that we may use in determining our consolidated tax provisions and accruals;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the actions of our third-party partners or service providers of research, development, manufacturing, marketing, distribution or other services, including their compliance with applicable laws and contracts, which actions may be beyond our control or influence, and the impact of such actions on our Company;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risks associated with the international scope of our operations, including our presence in emerging markets and the challenges we face when entering and operating in new and different geographic markets (including the challenges created by new and different regulatory regimes in such countries and the need to comply with applicable anti-bribery and economic sanctions laws and regulations);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse global economic conditions, including rates of inflation, and credit markets and foreign currency exchange uncertainty and volatility in certain of the countries in which we do&#160;business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the trade conflict between the U.S. and China;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the ongoing conflict between Russia and Ukraine and the export controls, sanctions and other restrictive actions that have been or may be imposed by the U.S., Canada and other countries against governmental and other entities in Russia, Belarus and parts of Ukraine;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the United States-Mexico-Canada Agreement (&#8220;USMCA&#8221;) and any potential changes to other trade agreements;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, maintain and license sufficient intellectual property rights over our products and enforce and defend against challenges to such intellectual property (such as in connection with the filing by Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;) of its Abbreviated New Drug Application (&#8220;ANDA&#8221;) for Xifaxan&#174; (rifaximin) 550 mg tablets and the Company&#8217;s related lawsuit filed against Norwich in connection therewith) and the impact of the Norwich matter on, among other things, our business results, financial results, and the proposed separation of B+L;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully appeal the decision of the U.S. District Court for the District of Delaware in the Company&#8217;s lawsuit against Norwich in connection with Norwich&#8217;s ANDA and challenge Norwich&#8217;s ability to achieve a modified ANDA that avoids an injunction [expected to be issued] by the District Court and omits the Xifaxan&#174; hepatic encephalopathy (&#8220;HE&#8221;) indication and HE safety data;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the fact that a substantial amount of our revenues are derived from the Xifaxan&#174; product line, and that we may be materially impacted by the entry of a generic rifaximin product earlier than January 2028;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the introduction of generic, biosimilar or other competitors of our branded products and other products, including the introduction of products that compete against our products that do not have patent or data exclusivity rights;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify, finance, acquire, close and integrate acquisition targets successfully and on a timely basis and the difficulties, challenges, time and resources associated with the integration of acquired companies, businesses and products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any divestitures of our assets or businesses and our ability to successfully complete any such divestitures on commercially reasonable terms and on a timely basis, or at all, and the impact of any such divestitures on our Company, including the reduction in the size or scope of our business or market share, loss of revenue, any loss on sale, including any resultant impairments of goodwill or other assets, or any adverse tax consequences suffered as a result of any such divestitures;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expense, timing and outcome of pending or future legal and governmental proceedings, arbitrations, investigations, subpoenas, tax and other regulatory audits, examinations, reviews and regulatory proceedings against us or relating to us and settlements thereof;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to negotiate the terms of or obtain court approval for the settlement of certain legal and regulatory proceedings;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain components, raw materials or finished products supplied by third&#160;parties (some of which may be single-sourced) and other manufacturing and related supply difficulties, interruptions and delays;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the disruption of delivery of our products and the routine flow of manufactured goods;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic factors over which the Company has no control, including changes in inflation, interest rates, foreign currency rates, and the potential effect of such factors on revenues, expenses and resulting margins;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interest rate risks associated with our floating rate debt borrowings;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively distribute our products and the effectiveness and success of our distribution arrangements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively promote our own products and those of our co-promotion partners;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our fulfillment arrangements with Walgreen Co., including market acceptance of, or market reaction to, such arrangements (including by customers, doctors, patients, PBMs, third-party payors and governmental agencies), and the continued compliance of such arrangements with applicable laws;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to secure and maintain third-party research, development, manufacturing, licensing, marketing or distribution arrangements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that our products could cause, or be alleged to cause, personal injury and adverse effects, leading to potential lawsuits, product liability claims and damages and/or recalls or withdrawals of products from the&#160;market;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the mandatory or voluntary recall or withdrawal of our products from the market and the costs associated therewith;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of, and our ability to obtain and maintain, adequate insurance coverage and/or our ability to cover or insure against the total amount of the claims and liabilities we face, whether through third-party insurance or self-insurance;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our indemnity agreements, which may result in an obligation to indemnify or reimburse the relevant counterparty, which amounts may be material;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the difficulty in predicting the expense, timing and outcome within our legal and regulatory environment, including with respect to approvals by the FDA, Health Canada, European Medicines Agency (&#8220;EMA&#8221;) and similar agencies in other countries, legal and regulatory proceedings and settlements thereof, the protection afforded by our patents and other intellectual and proprietary property, successful generic challenges to our products and infringement or alleged infringement of the intellectual property of&#160;others;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of continuing safety and efficacy studies by industry and government agencies;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of preclinical and clinical trials for our drug development pipeline or delays in clinical trials that adversely impact the timely commercialization of our pipeline products, as well as other factors impacting the commercial success of our products, which could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties around the successful improvement and modification of our existing products and development of new products, which may require significant expenditures and efforts;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of management reviews of our research and development portfolio (including following the receipt of clinical results or feedback from the FDA or other regulatory authorities), which could result in terminations of specific projects which, in turn, could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the seasonality of sales of certain of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">declines in the pricing and sales volume of certain of our products that are distributed or marketed by third parties, over which we have no or limited control;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance by the Company or our third-party partners and service providers (over whom we may have limited influence), or the failure of our Company or these third parties to comply, with health care &#8220;fraud and abuse&#8221; laws and other extensive regulation of our marketing, promotional and business practices (including with respect to pricing), worldwide anti-bribery laws (including the U.S. Foreign Corrupt Practices Act and the Canadian Corruption of Foreign Public Officials Act), worldwide economic sanctions and/or export laws, worldwide environmental laws and regulation and privacy and security regulations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impacts of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 and potential amendment thereof and other legislative and regulatory health care reforms in the countries in which we operate, including with respect to recent government inquiries on pricing;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of any changes in or reforms to the legislation, laws, rules, regulation and guidance that apply to the Company and its businesses and products or the enactment of any new or proposed legislation, laws, rules, regulations or guidance that will impact or apply to the Company or its businesses or products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of changes in federal laws and policy that may be undertaken under the current administration;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">illegal distribution or sale of counterfeit versions of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any plans for the Company's aesthetic medical business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruptions, breakdowns or breaches in our information technology systems; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks in Item 1A. &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed on February 23, 2022, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">risks under Item 1A. &#8220;Risk Factors&#8221; of Part II of this Form 10-Q </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and risks detailed from time to time in our other filings with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and the Canadian Securities Administrators (the&#160;&#8220;CSA&#8221;), as well as our ability to anticipate and manage the risks associated with the&#160;foregoing.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed on February 23, 2022, under Item&#160;1A. &#8220;Risk Factors&#8221;, under Item 1A. &#8220;Risk Factors&#8221; of Part II of this Form 10-Q and in the Company&#8217;s other filings with the SEC and the CSA. When relying on our forward-looking statements to make decisions with respect to the Company, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. These forward-looking statements speak only as of the date made. We undertake no obligation to update or revise any of these forward-looking statements to reflect events or circumstances after the date of this Form&#160;10-Q or&#160;to reflect actual outcomes, except as required by law. We caution that, as it is not possible to predict or identify all relevant factors that may impact forward-looking statements, the foregoing list of important factors that may affect future results is not exhaustive and should not be considered a complete statement of all potential risks and uncertainties.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="i762fba229369426294c4424c2015a01a_217"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;Quantitative and&#160;Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as indicated below under &#8220;&#8212; Interest Rate Risk&#8221; and &#8220;&#8212; Inflation Risk&#8221;, there have been no material changes to our exposures to market risks as disclosed in Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Quantitative and Qualitative Disclosures About Market Risks&#8221; included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC and the CSA on February&#160;23, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, we had $16,631&#160;million and $5,425&#160;million principal amount of issued fixed rate debt and variable rate debt, respectively. The estimated fair value of our issued fixed rate debt as of June&#160;30, 2022 was $11,266&#160;million. If interest rates were to increase by 100 basis-points, the fair value of our issued fixed rate debt would decrease by approximately $428&#160;million. If interest rates were to decrease by 100 basis-points, the fair value of our issued fixed rate debt would increase by approximately $451&#160;million. We are subject to interest rate risk on our variable rate debt as changes in interest rates could adversely affect earnings and cash flows. A 100 basis-points increase in interest rates would have an annualized pre-tax effect of approximately $54&#160;million in our Consolidated Statements of Operations and Cash Flows, based on current outstanding borrowings and effective interest rates on our variable rate debt. While our variable-rate debt may impact earnings and cash flows as interest rates change, it is not subject to changes in fair value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inflation Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to price control restrictions on our pharmaceutical products in a number of countries in which we operate. As a result, our ability to raise prices in a timely fashion in anticipation of inflation may be limited in some markets.</span></div><div id="i762fba229369426294c4424c2015a01a_220"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;Controls and&#160;Procedures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer (&#8220;CEO&#8221;) and Chief Financial Officer (&#8220;CFO&#8221;), has evaluated the effectiveness of our disclosure controls and procedures as of June&#160;30, 2022. Based on this evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective as of June&#160;30, 2022. </span></div><div id="i762fba229369426294c4424c2015a01a_223"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in the Company&#8217;s internal controls over financial reporting that occurred during the three months ended June 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><div id="i762fba229369426294c4424c2015a01a_226"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i762fba229369426294c4424c2015a01a_229"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;Legal Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information concerning legal proceedings, reference is made to Note 18, &#8220;LEGAL PROCEEDINGS&#8221; of notes to&#160;the unaudited interim Consolidated Financial Statements included elsewhere in this Form&#160;10-Q.</span></div><div id="i762fba229369426294c4424c2015a01a_232"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;Risk Factors</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Except as set forth below, there have been no material changes to the risk factors as disclosed in Item 1A. &#8220;Risk Factors&#8221; included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC and the CSA on February&#160;23, 2022. The following additional and amended and restated</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">risk factors set forth additional and/or amended risks affecting the Company from those originally presented in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">As a result of the current conflict between Russia and Ukraine, including the recent invasion of Ukraine by Russia, the current and any future responses by the global community to such conflict and any counter responses by the Russian government or other entities or individuals, and the potential expansion of the conflict to other countries, we have begun to experience and may continue to experience an adverse impact on our business and operations in this region, as well as on our business and operations generally, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 24, 2022, Russia launched a military invasion of Ukraine. The ongoing military conflict between Ukraine and Russia has provoked strong reactions from the United States, the UK, the EU, Canada and various other countries around the world, including the imposition of export controls and broad financial and economic sanctions against Russia, Belarus and specific areas of Ukraine. Additional sanctions or other measures may be imposed by the global community, and counteractive measures may be taken by the Russian government, other entities in Russia or governments or other entities outside of Russia.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the full year ended December 31, 2021 and the six months ended June 30, 2022, we derived approximately 2% of our revenues from sales of our products in Russia, less than 1% of our revenues from sales of our products in Ukraine, and less than 1% of our revenues from sales of our products in Belarus. As of the date of this filing, the conflict between Ukraine and Russia has begun to impact our business in the region, and we are continuously monitoring developments to assess any potential future impact that may arise. Given the nature of our products, we do not believe that the current sanctions and other measures imposed by the United States and other countries preclude us from conducting business in the region. However, we anticipate that the ongoing conflict in this region and the sanctions and other actions by the global community in response may continue to hinder our ability to conduct business with customers and vendors in this region. For example, we have experienced and may in the future experience disruption and delays in the supply of our products to our customers in Russia, Belarus and Ukraine. We have experienced and may in the future also experience decreased demand for our products in these countries as a result of the conflict and invasion. In addition, we may experience difficulties in collecting receivables from such customers. If we are hampered in our ability to conduct business with new or existing customers and vendors in this region, our business, and operations, including our revenues, profitability and cash flows, could be adversely impacted. Furthermore, if the sanctions and other retaliatory measures imposed by the global community change, we may be required to cease or suspend our operations in the region or, should the conflict worsen, we may voluntarily elect to do so. We cannot provide assurance that current sanctions or potential future changes in these sanctions or other measures will not have a material impact on our operations in Russia, Belarus and Ukraine. The disruption to, or suspension of, our business and operations in Russia, Belarus and Ukraine would adversely impact our business, financial condition, cash flows and results of operations in this region which may, in turn, materially adversely impact our overall business, financial condition, cash flows and results of operations, which impact could be material, and could cause the market value of our common shares to decline. Finally, we are also subject to risks if exchange controls were to be imposed that would limit the repatriation of profits from our operations in Russia. While we do not rely on profits or dividends from our Russian operations to fund our debt repayment or other business activities generally, as our operations from Russia primarily involve the sale of products purchased from our affiliates located outside of Russia, any exchange controls that would limit the purchase of or payment for products or goods from outside of Russia may have an adverse impact on our operations in Russia or the way we conduct business in Russia.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the precise effects of the ongoing military conflict and sanctions on the Russian and global economies remain uncertain, they have already resulted in significant volatility in financial markets and depreciation of the Russian ruble and the Ukrainian hryvnia against the U.S. dollar, as well as in an increase in energy and commodity prices globally. Should the conflict continue or escalate, there may be various economic and security consequences including, but not limited to, supply shortages of different kinds, further increases in prices of commodities, including piped gas, oil and agricultural goods, reduced consumer purchasing power, significant disruptions in logistics infrastructure, telecommunications services and risks relating to the unavailability of information technology systems and infrastructure. The resulting impacts to the global </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">economy, financial markets, inflation, interest rates and unemployment, among others, could adversely impact economic and financial conditions, and may disrupt the global economy&#8217;s ongoing recovery following the COVID-19 pandemic. Other potential consequences include, but are not limited to, growth in the number of popular uprisings in the region, increased political discontent, especially in the regions most affected by the conflict or economic sanctions, increase in cyberterrorism activities and attacks, displacement of persons to regions close to the areas of conflict and an increase in the number of refugees fleeing across Europe, among other unforeseen social and humanitarian effects.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a result of the ongoing conflict between Russia and Ukraine, we may experience other risks, difficulties and challenges in the way we conduct our business and operations generally. For example, there may be an increased risk of cybersecurity attacks due to the current conflict between Russia and Ukraine, including cyber security attacks perpetrated by Russia or others at its direction in response to economic sanctions and other actions taken against Russia as a result of its invasion of Ukraine. Any increase in such attacks on us or our third-party providers or other systems could adversely affect our network systems or other operations. In order to address the risks associated with cybersecurity attacks from the region (including state-sponsored cybersecurity attacks), we have taken action to consolidate network traffic from Russia and Belarus through a single point, which is designed to allow us to more closely inspect that traffic. In addition, if required, this consolidation provides a single point to quickly and efficiently disconnect the region from our corporate network. At this time, to the best of our knowledge, we do not believe we have experienced any cyberattacks that are related to the conflict between Russia and Ukraine. Although we have taken steps to enhance our protections against such attacks, we may not be able to address these cybersecurity threats proactively or implement adequate preventative measures and there can be no assurance that we will promptly detect and address any such disruption or security breach, if at all. In addition, as a result of the risk of collectability of receivables from our customers in Russia, Belarus and Ukraine, we may be required to adjust our accounting practices relating to revenue recognition in this region, with the result that we may not be able to recognize revenue from these customers until collected. We may also suffer reputational harm as a result of our continued operations in Russia, which may adversely impact our sales and other businesses in other countries. Finally, we have one global clinical trial involving Russia, Ukraine and Belarus with patients enrolled. We continue to support the existing patients, but have no plans to enroll new patients at this time. Plans for any additional trials involving Russia, Ukraine and Belarus have been postponed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A protracted conflict between Ukraine and Russia, any escalation of that conflict, and the financial and economic sanctions and import and/or export controls imposed on Russia by the U.S., the UK, the EU, Canada and others, and the above-mentioned adverse effect on our operations (both in this region and generally) and on the wider global economy and market conditions could, in turn, have a material adverse impact on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The B+L Separation, including the Distribution, is subject to challenge and could be subject to further challenges in the future, any of which could delay or prevent the consummation of such transactions or cause them to occur on worse terms than we currently expect.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The B+L Separation, including a distribution of all or a portion of our remaining equity interest in Bausch + Lomb to our shareholders, is subject to challenge, which could delay or prevent the consummation of such transactions or cause them to occur on worse terms than we currently expect. For example, in March 2022, the Company and Bausch + Lomb were named in a declaratory judgment action in the Superior Court of New Jersey, Somerset County, Chancery Division (which was subsequently removed to the U.S. District Court for the District of New Jersey), brought by certain individual investors in the Company&#8217;s common shares and debt securities who are also maintaining individual securities fraud claims against the Company and certain of its current or former officers and directors. This newly filed action seeks a declaratory judgment that the transfer of assets from the Company to Bausch + Lomb would constitute a voidable transfer under New Jersey&#8217;s Uniform Voidable Transactions Act and that Bausch + Lomb would become liable for damages awarded against the Company in the individual opt-out actions. In addition, the Company could, in the future, face additional legal proceedings and investigations and inquiries by governmental agencies relating to these or similar matters. For more information regarding legal proceedings, see Note 18, &#8220;LEGAL PROCEEDINGS&#8221; to our unaudited interim Consolidated Financial Statements elsewhere in this Form 10-Q. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict the outcome of any such proceedings, investigations and inquiries, but we may incur significant costs and diversion of management attention as a result of these matters, regardless of the outcome. Some or all of these proceedings, investigations and inquiries may lead to damages, settlement payments, fines, penalties, consent orders or other administrative sanctions against us. Furthermore, publicity surrounding these proceedings, investigations and inquiries or any enforcement action as a result thereof, even if ultimately resolved favorably for us could result in additional investigations and legal proceedings. As a result, these proceedings, investigations and inquiries could have a material adverse effect on our reputation, business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We recently announced that we are suspending our plan to pursue an IPO of our Solta medical device aesthetics business. Accordingly, the Solta IPO will not be completed in accordance with the previously-anticipated timeline, and may not be completed at all, and if resumed will involve significant time, expense, and distraction, any of which could disrupt or have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 3, 2021, we announced that we intended to pursue an IPO of Solta Medical. The proposed Solta IPO would establish Solta Medical as a separate publicly traded company that consists of our medical aesthetics business, subject to regulatory approvals and certain conditions, including final approval by our Board of Directors and compliance with (including completion of all necessary filings required by) U.S. securities laws and stock exchange rules. On June 16, 2022, as a result of challenging market conditions and other factors, we announced that we were suspending our plans for the Solta IPO, and that we will revisit alternative paths for Solta in the future. Such suspension could delay the completion of the Solta IPO for a significant period of time or prevent it from occurring at all.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our decision to suspend our plans for the Solta IPO could cause us not to realize some or all of the expected benefits, or realize them on a different timeline than expected. No assurance can be given as to whether and when the Solta IPO will occur or whether the Solta IPO, if pursued, will achieve the benefits we expect. As a result, there can be no assurance as to the timing of the completion of the Solta IPO or its terms. Any changes with respect to the timing of the Solta IPO or the terms and conditions on which the Solta IPO occurs could also delay the B+L Separation or cause the B+L Separation to occur on terms or conditions that are different or less favorable than expected. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we determine to proceed with the Solta IPO, unanticipated developments, including disruptions to business and commerce induced by the COVID-19 pandemic, unfavorable market conditions, possible delays in obtaining any necessary stock exchange, regulatory or other approvals or the failure to obtain any such approvals, negotiating challenges, the uncertainty of the financial markets, changes in the laws and regulations (both in the U.S. and in other jurisdictions, including China), reactions of customers and other parties, industry or economic conditions outside of the Company&#8217;s control, and other challenges in executing the Solta IPO, could further delay or prevent the completion of the Solta IPO, or cause the Solta IPO to occur on terms or conditions that are different or less favorable than expected. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the Solta IPO is completed, we may not be able to achieve the full strategic and financial benefits expected to result from the Solta IPO. The Solta IPO is expected to unlock value by creating an independent business and distinct investment identity with enhanced strategic and management focus that allows more efficient allocation of resources and capital. In addition, proceeds from the Solta IPO are expected to facilitate further reductions in the aggregate amount of our outstanding indebtedness. We may not achieve these and other anticipated benefits for a variety of reasons, including, among others: (i) following the Solta IPO, Solta may prove to be less valuable on an independent basis than we anticipate, including because it is more susceptible to economic downturns and other adverse events than if it were still a part of the Company and because its business will be less diversified than the Company&#8217;s business prior to the Solta IPO and (ii) other actions required to separate the respective businesses could disrupt our operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we determine to proceed with the Solta IPO, executing the Solta IPO will require significant resources, time and attention from our senior management and employees, which senior management and employees are already expending significant resources, time and attention on the B+L Separation. The Solta IPO could cause further distractions and further divert attention and resources away from other projects and the day-to-day operation of our business. Both we and Solta may also experience increased difficulties in attracting, retaining, and motivating management and employees during the pendency of the Solta IPO and following its completion. For more information on these and other related risks, see Item 1A. &#8220;Risk Factors&#8212;Employment-related Risks&#8221; of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. The Solta IPO, whether or not completed, may also have an adverse impact on our relationships with our customers, suppliers and other business counterparties. The price of our common shares could also fluctuate significantly in response to developments or market speculation related to the proposed Solta IPO. The Solta IPO, if completed, may also have the effect of exacerbating other risk factors disclosed in this Quarterly Report and in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have already incurred expenses in connection with the Solta IPO, and if we determine to proceed with the Solta IPO we expect that the process of completing the Solta IPO will be time-consuming and involve significant additional costs and expenses, which may not yield a discernible benefit if the Solta IPO is not completed or is not completed on the timeline or terms anticipated. In addition, regardless of whether the Solta IPO is completed, we have been and will be required to pay certain costs and expenses incurred in connection therewith, such as legal, accounting, and other professional and advisory fees. Furthermore, the Solta IPO, if completed, is expected to result in dyssynergy costs, which may be greater than we anticipate and/or may be significant. In addition, we could be subject to legal proceedings or other claims challenging the Solta IPO, which could result in substantial costs and liability and also divert management&#8217;s attention and resources, any of which could harm our business.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the above factors could cause the Solta IPO (or the failure to consummate the Solta IPO) to have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div id="i762fba229369426294c4424c2015a01a_235"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no sales of equity securities by the Company during the three months ended June 30, 2022.</span></div><div id="i762fba229369426294c4424c2015a01a_238"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Defaults Upon Senior Securities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i762fba229369426294c4424c2015a01a_241"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;Mine Safety Disclosures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i762fba229369426294c4424c2015a01a_244"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;Other Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i762fba229369426294c4424c2015a01a_247"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:2pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;Exhibits </span></div><div style="margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:8.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.126%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522125782/d283951dex992.htm">10.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522125782/d283951dex992.htm">Amendment to Master Separation Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of April 28, 2022, originally filed as Exhibit 99.2 to the Company&#8217;s Current Report on Form 8-K filed on April 28, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000885590/000119312522125782/d283951dex993.htm">10.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522125782/d283951dex993.htm">Amendment to Tax Matters Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of April 28, 2022, originally filed as Exhibit 99.3 to the Company&#8217;s Current Report on Form 8-K filed on April 28, 2022, which is incorporated by reference herein</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522125782/d283951dex991.htm">10.3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522125782/d283951dex991.htm">Arrangement Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation and the other parties thereto, dated as of April 28, 2022, originally filed as Exhibit 99.1 to the Company&#8217;s Current Report on Form 8-K filed on April 28, 2022, which is incorporated by reference herein.&#8224;#</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522146413/d298928dex101.htm">10.4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522146413/d298928dex101.htm">Second Amendment, dated as of May 10, 2022, among Bausch Health Companies Inc., Bausch Health Americas, Inc., certain other subsidiaries of the Company as subsidiary guarantors, each of the financial institutions named therein as lenders and issuing banks and Barclays Bank PLC, as Administrative Agent, originally filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on May 10, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522146413/d298928dex102.htm">10.5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522146413/d298928dex102.htm">Credit Agreement, dated as of May 10, 2022, among Bausch + Lomb Corporation, certain subsidiaries of the Company as subsidiary guarantors, each of the financial institutions named therein as lenders and issuing banks, Citibank, N.A., as Revolving Facility Administrative Agent and Goldman Sachs Bank USA, as Term Facility Administrative Agent, originally filed as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on May 10, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522136867/d296110ddef14a.htm#tx296110_38">10.6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522136867/d296110ddef14a.htm#tx296110_38">Bausch Health Companies Inc. Further Amended and Restated 2014 Omnibus Incentive Plan, effective as of June 21, 2022, originally filed as Exhibit B to the Company&#8217;s definitive proxy statement (File No. 001-14956) filed on May 2, 2022, which is incorporated by reference herein, &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit107bauschpharmacfoe.htm">10.7*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit107bauschpharmacfoe.htm">Employment Agreement, dated as of October 20, 2021, by and between Bausch Health Companies Inc. and Tom Vadaketh. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit108bauschpharmagcem.htm">10.8*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit108bauschpharmagcem.htm">Employment Agreement, dated as of December 3, 2021, by and between Bausch Health Companies Inc. and Seana Carson. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit109spurremploymenta.htm">10.9*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit109spurremploymenta.htm">Employment Agreement, dated as of May 28, 2020, by and between Bausch Health Companies Inc. and Robert Spurr. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1010spurremployment.htm">10.10*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1010spurremployment.htm">Amendment to Employment Agreement dated September 1, 2021 by and between Bausch Health Companies Inc. and Robert Spurr. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1011spurremployment.htm">10.11*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit1011spurremployment.htm">Separation Agreement, dated as of June 1, 2022, by and between Bausch Health Companies Inc. and Robert Spurr. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311q22022.htm">31.1*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311q22022.htm">Certification of the Chief Executive Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312q22022.htm">31.2*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312q22022.htm">Certification of the Chief Financial Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321q22022.htm">32.1*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321q22022.htm">Certificate of the Chief Executive Officer of Bausch Health Companies&#160;Inc. pursuant to 18&#160;U.S.C. &#167;&#160;1350 as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322q22022.htm">32.2*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322q22022.htm">Certificate of the Chief Financial Officer of Bausch Health Companies Inc. pursuant to 18&#160;U.S.C. &#167;&#160;1350 as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:174%">____________________________________</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*     Filed herewith.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplementally a copy of any omitted exhibit or schedule upon request by the Securities and Exchange Commission.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#    Portions of this exhibit have been omitted because they are both (i) not material and (ii) would likely cause competitive harm to Bausch Health Companies Inc. if publicly disclosed.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8224;&#8224;   Management contract or compensatory plan arrangement.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><div id="i762fba229369426294c4424c2015a01a_250"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.240%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Bausch Health Companies&#160;Inc.</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ THOMAS J. APPIO</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas J. Appio<br/>Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ TOM VADAKETH</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tom Vadaketh<br/>Executive Vice President, <br/>Chief Financial Officer <br/>(Principal Financial Officer)</span></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><div id="i762fba229369426294c4424c2015a01a_253"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="-sec-extract:summary;margin-bottom:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO EXHIBITS </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:8.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.126%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522125782/d283951dex992.htm">10.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522125782/d283951dex992.htm">Amendment to Master Separation Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of April 28, 2022, originally filed as Exhibit 99.2 to the Company&#8217;s Current Report on Form 8-K filed on April 28, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000885590/000119312522125782/d283951dex993.htm">10.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522125782/d283951dex993.htm">Amendment to Tax Matters Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation, dated as of April 28, 2022, originally filed as Exhibit 99.3 to the Company&#8217;s Current Report on Form 8-K filed on April 28, 2022, which is incorporated by reference herein</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522125782/d283951dex991.htm">10.3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522125782/d283951dex991.htm">Arrangement Agreement by and between Bausch Health Companies Inc. and Bausch + Lomb Corporation and the other parties thereto, dated as of April 28, 2022, originally filed as Exhibit 99.1 to the Company&#8217;s Current Report on Form 8-K filed on April 28, 2022, which is incorporated by reference herein.&#8224;#</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522146413/d298928dex101.htm">10.4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522146413/d298928dex101.htm">Second Amendment, dated as of May 10, 2022, among Bausch Health Companies Inc., Bausch Health Americas, Inc., certain other subsidiaries of the Company as subsidiary guarantors, each of the financial institutions named therein as lenders and issuing banks and Barclays Bank PLC, as Administrative Agent, originally filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on May 10, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522146413/d298928dex102.htm">10.5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522146413/d298928dex102.htm">Credit Agreement, dated as of May 10, 2022, among Bausch + Lomb Corporation, certain subsidiaries of the Company as subsidiary guarantors, each of the financial institutions named therein as lenders and issuing banks, Citibank, N.A., as Revolving Facility Administrative Agent and Goldman Sachs Bank USA, as Term Facility Administrative Agent, originally filed as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on May 10, 2022, which is incorporated by reference herein.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522136867/d296110ddef14a.htm#tx296110_38">10.6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522136867/d296110ddef14a.htm#tx296110_38">Bausch Health Companies Inc. Further Amended and Restated 2014 Omnibus Incentive Plan, effective as of June 21, 2022, originally filed as Exhibit B to the Company&#8217;s definitive proxy statement (File No. 001-14956) filed on May 2, 2022, which is incorporated by reference herein, &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522136867/d296110ddef14a.htm#tx296110_38">10.6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000885590/000119312522136867/d296110ddef14a.htm#tx296110_38">Bausch Health Companies Inc. Further Amended and Restated 2014 Omnibus Incentive Plan, effective as of June 21, 2022, originally filed as Exhibit B to the Company&#8217;s definitive proxy statement (File No. 001-14956) filed on May 2, 2022, which is incorporated by reference herein, &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit107bauschpharmacfoe.htm">10.7*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit107bauschpharmacfoe.htm">Employment Agreement, dated as of October 20, 2021, by and between Bausch Health Companies Inc. and Tom Vadaketh. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit108bauschpharmagcem.htm">10.8*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit108bauschpharmagcem.htm">Employment Agreement, dated as of December 3, 2021, by and between Bausch Health Companies Inc. and Seana Carson. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit109spurremploymenta.htm">10.9*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit109spurremploymenta.htm">Employment Agreement, dated as of May 28, 2020, by and between Bausch Health Companies Inc. and Robert Spurr. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1010spurremployment.htm">10.10*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1010spurremployment.htm">Amendment to Employment Agreement dated September 1, 2021 by and between Bausch Health Companies Inc. and Robert Spurr. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1011spurremployment.htm">10.11*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit1011spurremployment.htm">Separation Agreement, dated as of June 1, 2022, by and between Bausch Health Companies Inc. and Robert Spurr. &#8224;&#8224;</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311q22022.htm">31.1*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311q22022.htm">Certification of the Chief Executive Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312q22022.htm">31.2*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312q22022.htm">Certification of the Chief Financial Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321q22022.htm">32.1*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321q22022.htm">Certificate of the Chief Executive Officer of Bausch Health Companies&#160;Inc. pursuant to 18&#160;U.S.C. &#167;&#160;1350 as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322q22022.htm">32.2*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322q22022.htm">Certificate of the Chief Financial Officer of Bausch Health Companies Inc. pursuant to 18&#160;U.S.C. &#167;&#160;1350 as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:174%">____________________________________</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">*     Filed herewith.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8224;&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8224;&#8224;   Management contract or compensatory plan arrangement.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>2
<FILENAME>exhibit107bauschpharmacfoe.htm
<DESCRIPTION>EX-10.7
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iccd9e614a29444cd8ce125a7e204efe2_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.7</font></div></div><div style="margin-top:4.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BAUSCH HEALTH COMPANIES INC.</font></div><div style="margin-top:8.7pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EMPLOYMENT AGREEMENT</font></div><div style="margin-top:8.7pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THIS EMPLOYMENT AGREEMENT (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">reement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is hereby entered into as of October 20, 2021, by and between Bausch Health Companies Inc., a British Columbia corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Bausch Health</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and Tom Vadaketh, an individual (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) (hereinafter collectively referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">the parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Where the context requires, references to the Company shall include the Company&#8217;s subsidiaries and affiliates and any successors in interest thereto, which shall include Bausch Pharma at the time of the separation of the Bausch + Lomb business.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) has determined that it is in the best interests of Bausch Health and its stockholders to separate the eyecare business (such business, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Bausch + Lomb</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) into an independent publicly traded entity from the remainder of Bausch Health by providing for an initial public offering of Bausch + Lomb&#8217;s stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">IPO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and subsequently separating the Bausch + Lomb business from the Company (such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Separation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, in connection with the IPO, the Company desires to employ Executive on the terms set forth in this Agreement, for the period provided below, and Executive desires to accept such employment with the Company, subject to the terms and conditions set forth herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the respective agreements of the parties contained herein, it is agreed as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Commencement Date&#59; Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The term (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Employment Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of Executive&#8217;s employment under this Agreement shall be for the period commencing on January 3, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and ending on the third (3rd) anniversary of the Initial Commencement Date.  Thereafter, the Employment Term shall extend automatically for consecutive periods of one year unless either party provides notice of non-renewal not less than ninety (90) days prior to the end of the Employment Term as then in effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  During the Employment Term&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Executive shall be employed as the Chief Financial Officer of the pharmaceutical business of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Pharma Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) as of the Initial Commencement Date, at which time Executive shall report directly to the Chief Executive Officer of the Pharma Business. Contingent and effective upon the closing of the IPO, Executive shall be employed as the Chief Financial Officer of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Bausch Pharma Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), at which time Executive shall report directly to the Chief Executive Officer.  Executive shall perform the duties, undertake the responsibilities and exercise the authority customarily performed, undertaken and exercised by persons situated in similar executive capacities.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Excluding periods of vacation and sick leave to which Executive is entitled and other service outside of the Company contemplated in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Executive shall devote his full professional time and attention to the business and affairs of the Company to discharge the responsibilities of Executive hereunder.  Prior to joining or agreeing to serve on corporate, civil or charitable boards or committees, Executive shall obtain approval of the Chief Executive Officer. Executive may manage personal and family investments, participate in industry organizations and deliver lectures at educational institutions, so long as such activities do not interfere with the performance of Executive&#8217;s responsibilities hereunder. It is understood that, during Executive&#8217;s employment by the Company, Executive shall not engage in any activities that constitute a conflict of interest with the interests of the Company or its direct and indirect subsidiaries, as outlined in the Company&#8217;s conflict of interest policies for employees and executives in effect from time to time.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">#95012652v7&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Executive shall be subject to and shall abide by each of the personnel policies applicable to senior executives and which have been made generally available to Company executives, including any policy restricting pledging and hedging investments in Company equity by Company executives, any policy the Company adopts regarding the recovery of incentive compensation (sometimes referred to as &#8220;clawback&#8221;) and any additional clawback provisions as required by law and applicable listing rules.  This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall survive the termination of the Employment Term.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof, Executive&#8217;s employment with the Company is &#8220;at will,&#8221; such that each of Executive or the Company has the option to terminate Executive&#8217;s employment at any time, with or without advance notice, and with or without Cause or with or without Good Reason.  This Agreement does not constitute an express or implied agreement of continuing or long-term employment.  The at-will nature of Executive&#8217;s employment can be altered only by a written agreement specifying the altered status of Executive&#8217;s employment.  Such written agreement must be signed by both Executive and the Chief Executive Officer of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Annual Compensation.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Base Salar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">y.  Effective on the Initial Commencement Date, during the Employment Term, Executive shall be paid an annual base salary of $600,000 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  The Base Salary shall be payable in accordance with the Company&#8217;s regular payroll practices as then in effect.  During the Employment Term, the Base Salary will be reviewed annually and is subject to adjustment at the discretion of the Chief Executive Officer of the Company and the Talent and Compensation Committee of the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Performance Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Effective on the Initial Commencement Date, Executive will be eligible to participate in the Company&#8217;s annual incentive cash bonus program applicable to similarly situated senior executives in accordance with its terms as in effect from time to time and the terms of this Agreement, for each fiscal year of the Company ending during the Employment Term, Executive shall be eligible to receive a target annual cash bonus of 60% of Base Salary (such target bonus, as may hereafter be increased, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Target Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) with the opportunity to receive a maximum annual cash bonus of 200% of the Target Bonus&#59; provided that, for fiscal year 2021, Executive&#8217;s annual bonus shall be pro-rated for the number of days Executive is actively employed by the Company during such fiscal year. Annual bonuses, if any, will be payable in the Company&#8217;s discretion and in accordance with the Company&#8217;s customary practices applicable to bonuses paid to similarly situated executives of the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Additional Compensation.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">One-Time Sign-On Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Effective as of the Initial Commencement Date, Executive will be eligible to receive a one-time sign-on bonus of $500,000 (the &#8220;Sign-On Bonus&#8221;), less any required tax withholdings, payable within thirty (30) days following the Initial Commencement Date. If Executive voluntarily resigns without Good Reason (as such term is defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of this Agreement), or is terminated for &#8220;Cause&#8221; (as such term is defined in Section 7(c) of this Agreement), at any time within the first two (2) years of the Initial Commencement Date, Executive will be required to promptly repay the amount of the Sign-On Bonus received by Executive following the payment of all applicable withholdings and payment of taxes.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">One-Time Initial Equity Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Effective as of the Initial Commencement Date, Executive will receive a grant under the Bausch Health Companies Inc. Amended and Restated 2014 Omnibus Incentive Plan (as amended and restated from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of (i) a number of stock options with a target grant-date fair value of approximately $1,500,000 and (ii) a number of restricted stock units (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) with a grant-date fair value of approximately $1,500,000 (such stock options and RSUs, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).&#160;The stock </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">#95012652v7&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">options and RSUs will be subject to the terms and conditions of the Plan and applicable award agreement to be provided to Executive. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Existing Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. On and following the closing of the IPO, the outstanding and unvested portion of the Initial Award held by Executive, if any, shall remain outstanding in accordance with, and subject to the terms of the Plan and the applicable award agreement thereunder and shall remain an equity award in respect of Bausch Health&#8217;s successor stock (Bausch Pharma) on and following the Separation.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">On</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">oing Grants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive will be eligible for consideration for future equity grants during the Employment Term in the sole discretion of the Committee.</font></div><div style="margin-bottom:12.5pt;margin-top:3.45pt;padding-left:5.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.8pt;text-decoration:underline">Share Ownership Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive agrees to comply with any share ownership requirements adopted by the Company applicable to Executive, which shall be on the same terms as similarly situated executives of the Company.</font></div><div style="margin-bottom:12.5pt;margin-top:3.45pt;padding-left:5.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.8pt;text-decoration:underline">Other Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  During the Employment Term&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Employee Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive shall be entitled to participate in the employee benefit plans, practices and programs maintained by the Company, and made available to employees of the Company generally, including, without limitation, all pension, retirement, profit sharing, savings, medical, hospitalization, disability, dental, life or travel accident insurance benefit plans in accordance with the terms of the plans as in effect from time to time.  Executive&#8217;s participation in such plans, practices and programs shall be on the same basis and terms as are applicable to such employees.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Business Ex</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">p</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">enses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Upon submission of proper invoices in accordance with, and subject to, the Company&#8217;s normal policies and procedures, Executive shall be entitled to receive prompt reimbursement of all reasonable out-of-pocket business, entertainment and travel expenses incurred by him in connection with the performance of his duties hereunder.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Vacation and Sick Leave</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive shall be entitled, without loss of pay, to absent himself voluntarily from the performance of Executive&#8217;s employment under this Agreement, pursuant to the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Executive shall be entitled to annual vacation in accordance with and subject to the policies as periodically established for similarly situated executives of the Company&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Executive shall be entitled to sick leave (without loss of pay) in accordance with the Company&#8217;s policies as in effect from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive&#8217;s employment with the Company hereunder may be terminated under the circumstances set forth below&#59; p</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">rovided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that notwithstanding anything contained herein to the contrary, to the extent required by Section 409A (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), Executive shall not be considered to have terminated employment with the Company for purposes of this Agreement until he would be considered to have incurred a &#8220;separation from service&#8221; from the Company within the meaning of Section 409A.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive&#8217;s employment shall be terminated as of the date of Executive&#8217;s death and Executive&#8217;s beneficiaries shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">hereof.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Disabilit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">y.  The Company may terminate Executive&#8217;s employment, on written notice to Executive after having established Executive&#8217;s Disability and while Executive remains Disabled, and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">#95012652v7&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Disabilit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">y&#8221; shall have the meaning assigned to such term in the Plan.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company may terminate Executive&#8217;s employment for Cause effective as of the date of the Notice of Termination (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof) and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.  &#8220;Cause&#8221; shall  mean, for purposes of this Agreement&#58; (1) conviction of any felony (other than one related to a vehicular offense) or other criminal act involving fraud&#59; (2) willful misconduct that results in a material economic detriment to the Company&#59; (3) material violation of Company policies and directives, which is not cured after written notice and an opportunity for cure&#59; (4) continued refusal by Executive to perform his duties after written notice identifying the deficiencies and an opportunity for cure&#59; and (5) a material violation by Executive of any of the covenants to the Company, including those set forth in Sections 12, 13, 15 and 16 hereof.  No action or inaction shall be deemed willful if (x) not demonstrably willful and (y) taken, or not taken, by Executive in good faith and with the understanding that such action, or inaction, was not adverse to the best interests of the Company.  References in this paragraph to the Company shall also include direct and indirect subsidiaries of the Company, and materiality shall be measured based on the action or inaction and the impact upon the Company taken as a whole.  Without limiting the other rights of the Company under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> the Company may suspend Executive, without pay, upon Executive&#8217;s indictment for the commission of a felony as described under clause (1) above.  Such suspension may remain effective until such time as the indictment is either dismissed or a verdict of not guilty has been entered.  If such indictment does not result in a conviction, as soon as practicable following such dismissal or verdict, the Company will pay Executive the base salary and target bonus amount that Executive would have received for the period during which Executive was suspended without pay (with interest from the date such amounts would otherwise have been paid at the short-term applicable federal rate, compounded semi-annually, as determined under Section 1274 of the Code for the month in which payment would have been made but for the delay) and Executive will receive vesting credit for purposes of Executive&#8217;s outstanding equity awards.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Without Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company may terminate Executive&#8217;s employment without Cause.  The Company shall deliver to Executive a Notice of Termination (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof) not less than thirty (30) days prior to the termination of Executive&#8217;s employment without Cause and the Company shall have the option of terminating Executive&#8217;s duties and responsibilities prior to the expiration of such thirty-day notice period, and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive may terminate his employment for Good Reason (as defined below) by delivering to the Company a Notice of Termination not less than thirty (30) days prior to the termination of Executive&#8217;s employment for Good Reason and no more than one hundred fifty (150) days following the initial existence of the event or condition constituting Good Reason.  The Company shall have the option of terminating Executive&#8217;s duties and responsibilities prior to the expiration of such thirty (30) day notice period, and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean the occurrence of any  of the events  or conditions described in clauses (1) through (4) below during the Employment Term, without Executive&#8217;s prior written consent, which are not cured by the  Company (if susceptible to cure by the Company) within thirty (30) days after the Company has received written notice from Executive within ninety (90) days of the initial existence of the event or condition constituting Good Reason specifying the particular events or conditions which constitute Good Reason and the specific cure requested by Executive. </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Diminution of Res</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">p</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">onsibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  (A) Any material reduction in Executive&#8217;s duties or responsibilities as (i) Chief Financial Officer of the Pharma Business between the Initial Commencement Date and the Bausch Pharma Commencement Date or (ii) Chief Financial Officer of the Company following the Bausch Pharma Commencement Date, in each case as in effect immediately prior thereto (other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">#95012652v7&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">than a reduction where Executive is provided with other duties or responsibilities substantially comparable to Executive&#8217;s overall duties and responsibilities prior to such reduction) or (B) removal of Executive from the position of (i) Chief Financial Officer of the Pharma Business between the Initial Commencement Date and the Bausch Pharma Commencement Date or (ii) Chief Financial Officer of the Company following the Bausch Pharma Commencement Date (or, following a Change in Control or a corporate restructuring, removal from the position of Chief Financial Officer of the ultimate parent company of the resulting entity), except, in each of (A) and (B), in connection with (1) the termination of Executive&#8217;s employment for Disability, Cause, as a result of Executive&#8217;s death or by Executive other than for Good Reason, or (2) for the avoidance of doubt, the changes in the Executive&#8217;s position and reporting relationship contemplated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">p</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ensation Reduction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any reduction in Executive&#8217;s Base Salary or Target Bonus opportunity which is not comparable to reductions in the base salary or target bonus opportunity of other similarly situated executives of the Company&#59; </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Relocation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any relocation of Executive&#8217;s primary place of business that results in an increase of Executive&#8217;s one-way commute by fifty (50) miles or more&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that the Company&#8217;s request that Executive travel from time to time on behalf of the Company shall not constitute Good Reason&#59; or </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">p</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">any Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any other material breach by the Company of any material provision of this Agreement, including, but not limited to, the failure of the Company to consummate the closing of the IPO by the first anniversary of the Initial Commencement Date as contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Without Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive may voluntarily terminate his employment without Good Reason by delivering to the Company a Notice of Termination not less than thirty (30) days prior to the termination of Executive&#8217;s employment and the Company shall have the option of terminating Executive&#8217;s duties and responsibilities prior to the expiration of such thirty (30) day notice period, and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof through the last day of such notice period.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Notice of Non-Renewal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive&#8217;s employment shall terminate upon expiration of the Employment Term as then in effect following timely provision by either party of notice of non-renewal in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof, and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Notice of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any purported termination by the Company or by Executive shall be communicated by written Notice of Termination to the other party hereto.  For purposes of this Agreement, a &#8220;Notice of Termination&#8221; shall mean a notice which indicates a termination date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the specific termination provision in this Agreement relied upon and sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive&#8217;s employment under the provision so indicated.  For purposes of this Agreement, no such purported termination of Executive&#8217;s employment hereunder shall be effective without such Notice of Termination (unless waived by the party entitled to receive such notice).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Compensation Upon Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Upon termination of Executive&#8217;s employment during the Employment Term, Executive shall be entitled to the following benefits&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that any such benefits to which Executive is hereunder entitled shall be offset by those benefits that Executive receives, if any, under applicable law or otherwise&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Termination by the Company for Cause or by Executive Without Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If Executive&#8217;s employment is terminated by the Company for Cause or by Executive without Good Reason, the Company shall pay Executive all amounts earned or accrued hereunder through the Termination Date, including&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">#95012652v7&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">reimbursement for reasonable and necessary expenses incurred by Executive on behalf of the Company for the period ending on the Termination Date&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">any previous compensation which Executive has previously deferred (including any interest earned or credited thereon), in accordance with the terms and conditions of the applicable deferred compensation plans or arrangements then in effect&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">equity and incentive awards, to the extent previously vested, shall be paid or delivered to Executive in accordance with the terms of such awards&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">any amount or benefit as provided under any benefit plan or program (the foregoing items in clauses (1) through (4) being collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Accrued Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:0.12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Termination by the Company for Disability or Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If Executive&#8217;s employment is terminated by the Company for Disability or by reason of Executive&#8217;s death, then, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof, Executive shall be entitled to the benefits provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company shall pay Executive (or his beneficiaries, as applicable) the Accrued Compensation&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company shall pay to Executive (or his beneficiaries, as applicable) within sixty (60) days following the Termination Date, any bonus earned but unpaid in respect of any fiscal year preceding the Termination Date&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company shall pay to Executive a bonus or incentive award in respect of the fiscal year in which Executive&#8217;s Termination Date occurs in an amount equal to the product of (A) Executive&#8217;s Target Bonus and (B) a fraction (x) the numerator of which is the number of days in such fiscal year through the Termination Date and (y) the denominator of which is 365. Any bonus or incentive award payable to Executive under this clause (3) shall be paid in a lump sum payment by March 15 of the year following the fiscal year in which Executive&#8217;s Termination Date occurs</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Each unvested equity award held by Executive at the time of termination shall be governed by the terms of the applicable award agreement.</font></div><div style="margin-bottom:0.12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Termination by the Company Without Cause or by Executive for Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If Executive&#8217;s employment by the Company shall be terminated by the Company without Cause or by Executive for Good Reason, then, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof, Executive shall be entitled to the benefits provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company shall pay to Executive any Accrued Compensation&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company shall pay to Executive any bonus earned but unpaid in respect of any fiscal year preceding the Termination Date within sixty (60) days following the Termination Date&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company shall pay to Executive a bonus or incentive award in respect of the fiscal year in which Executive&#8217;s Termination Date occurs in an amount equal to the product of (A) the lesser of (x) the bonus or incentive award that Executive would have been entitled to receive based on actual achievement against the stated performance objectives and (y) Executive&#8217;s Target Bonus and (B) a fraction (x) the numerator of which is the number of days in such fiscal year through the Termination Date and (y) the denominator of which is 365 (provided that if such termination occurs in contemplation of a Change in Control (as defined in the Plan) or within twelve months following a Change in Control, then in the forgoing calculation, the amount under (A) above shall be equal to Executive&#8217;s Target Bonus).  Any bonus or incentive award payable to Executive under this clause (3) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">#95012652v7&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall be paid in a lump sum payment by March 15 of the year following the fiscal year in which Executive&#8217;s Termination Date occurs&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company shall pay Executive as severance pay, in lieu of any further compensation for the periods subsequent to the Termination Date, an amount in cash, which amount shall be payable in a lump sum payment within sixty (60) days following such termination (subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof), equal to one (1) times (or, if the Termination Date occurs either (x) on or before December 31, 2023, one and a half (1-1&#47;2) times) or (y) in contemplation of a Change in Control or within twelve months following a Change in Control, two (2) times) the sum of Executive&#8217;s Base Salary and Target Bonus, in each case, as in effect immediately prior to termination and without regard to any reduction thereto which constitutes Good Reason&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Each unvested equity award held by Executive at the time of termination shall be governed by the terms of the applicable award agreement&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company shall provide Executive with continued coverage through the first anniversary  of Executive&#8217;s Termination Date under any health, medical, dental or vision program or policy in which Executive (and his dependents, as applicable) participated in as of the time of the Termination Date on terms no less favorable to Executive and his dependents than those applicable to actively employed similarly situated executives of the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that Executive shall be solely responsible for any taxes incurred in respect of such coverage&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the Company may modify the continuation coverage contemplated by this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(c)(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (including by providing a lump-sum cash payment equal to the value for Executive of the continuation coverage provided herein) to the extent reasonably necessary to avoid the imposition of any excise taxes on the Company for failure to comply with the nondiscrimination requirements of the Patient Protection and Affordable Care Act of 2010, as amended, and&#47;or the Health Care and Education Reconciliation Act of 2010, as amended (to the extent applicable).</font></div><div style="margin-bottom:0.12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Ex</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">p</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">iration of Employment Term Upon Notice of Non-Renewal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If Executive&#8217;s employment  terminates  upon  expiration of the Employment Term as in effect following timely provision of a notice of non-renewal in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof, then, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof&#58;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">If such notice is submitted by Executive, then Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">If such notice is submitted by the Company, then Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.</font></div><div style="margin-bottom:0.12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Executive shall not be required to mitigate the amount of any payment provided for under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> by seeking other employment or otherwise and no such payment shall be offset or reduced by the amount of any compensation or benefits provided to Executive in any subsequent employment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The parties intend for the payments and benefits under this Agreement to be exempt from Section 409A or, if not so exempt, to be paid or provided in a manner which complies with the requirements of such section, and intend that this Agreement shall be construed and administered in accordance with such intention.  If any payments or benefits due to Executive hereunder would cause the application of an accelerated or additional tax under Section 409A, such payments or benefits shall be restructured in a mutually agreed upon manner that to the extent possible preserves the economic benefit and original intent thereof but does not cause such an accelerated or additional tax.  For purposes of the limitations on nonqualified deferred compensation under Section 409A, each payment of compensation under this Agreement shall be treated as a separate payment of compensation.  Without limiting the foregoing and notwithstanding anything contained herein to the contrary, to the extent required in order to avoid accelerated taxation and&#47;or tax penalties under Section 409A amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to this Agreement during the six-month period immediately following Executive&#8217;s separation from service shall instead be paid on the first business </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">#95012652v7&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">day after the date that is six months following Executive&#8217;s Termination Date (or death, if earlier).  Notwithstanding anything to the contrary in this Agreement, all (A) reimbursements and (B) in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A, including, where applicable, the requirement that (x) the amount of expenses eligible for reimbursement, or in kind benefits provided, during a calendar year may not affect the expenses eligible for reimbursement, or in kind benefits to be provided, in any other calendar year&#59; (y) the reimbursement of an eligible expense will be made no later than the last day of the calendar year following the year in which the expense is incurred&#59; and (z) the right to reimbursement or in kind benefits is not subject to liquidation or exchange for another benefit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Employee Protection</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Nothing in this Agreement or otherwise limits Executive&#8217;s ability to communicate directly with and provide information, including documents, not otherwise protected from disclosure by any applicable law or privilege to the Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) or any other federal, state or local governmental agency or commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Government Agency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) regarding possible legal violations, without disclosure to the Company.  The Company may not retaliate against Executive for any of these activities, and nothing in this Agreement or otherwise requires Executive to waive any monetary award or other payment that Executive might become entitled to from the SEC or any other Government Agency.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Records and Confidential Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Executive acknowledges that in connection with the performance of his duties during the Employment Term, the Company will make available to Executive, or Executive will have access to, certain Confidential Information (as defined below) of the Company and its affiliates.  Executive acknowledges and agrees that any and all Confidential Information disclosed to, or learned or obtained by, Executive during the course of his employment by the Company or otherwise, whether developed by Executive alone or in conjunction with others or otherwise, shall be and is the sole and exclusive property of the Company or the affiliate of the Company, as applicable, that is Executive&#8217;s employer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  No license or other right to any Confidential Information is granted to Executive under this Agreement.  To the extent that Executive acquires any right, title or interest in or to any Confidential Information, Executive hereby irrevocably assigns, transfers, conveys and delivers to the Employer all such right, title and interest in and to such Confidential Information.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof, the Confidential Information will be kept confidential by Executive, will not be used in any manner which is detrimental to the Company, will not be used other than in connection with Executive&#8217;s discharge of his duties hereunder, and will be safeguarded by Executive from unauthorized disclosure.  Executive acknowledges and agrees that the confidentiality restrictions set forth herein shall apply to any and all Confidential Information disclosed to, or learned or obtained by, Executive, whether before, on or after the date hereof.  For the avoidance of doubt, nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall prevent Executive from complying with a valid legal requirement (whether by oral questions, interrogatories, requests for information or documents, subpoena, civil investigative demand or similar process) to disclose any Confidential Information&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Executive shall first give notice to the Employer and reasonably cooperate with the Employer to obtain a protective order or other measures preserving the confidential treatment of such Confidential Information and requiring that the information or documents so disclosed be used only for the purposes for which the order was issued or is otherwise required by applicable law.  For the avoidance of doubt, nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall prevent Executive from exercising any legally protected whistleblower rights (including under Rule 21F under the Securities Exchange Act of 1934, as amended) as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Following the termination of Executive&#8217;s employment hereunder or upon the Company&#8217;s request, and subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof, as soon as possible after the Company&#8217;s written request, Executive will return to the Company all written Confidential Information which has been provided to Executive and Executive will return or destroy all copies of any analyses, compilations, studies or other documents prepared by Executive or for Executive&#8217;s use containing or reflecting any Confidential Information.  Within five (5) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">#95012652v7&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">business days of the receipt of such request by Executive, he shall, upon written request of the Company, deliver to each of the Company a document certifying that such written Confidential Information has been returned or destroyed in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">For the purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean any and all non-public, proprietary or other confidential information of the Company or its affiliates disclosed to Executive, to which Executive has access, or of which Executive otherwise becomes aware, in each case whether in oral, written, graphic or machine readable form, including, without limitation, (A) know-how, trade secrets, inventions, discoveries, concepts, information, works, materials, processes, methods, data, software, programs, apparatus, designs and the like, and any other intellectual property the value of which is contingent upon maintaining the confidentiality thereof, (B) information regarding the business of the Company or its affiliates, including its products, services, budgets, contracts, reports, investigations, experiments, research, work in progress, drawings, designs, plans, proposals, codes, marketing and sales programs, client lists, client mailing lists, supplier lists, financial projections, cost summaries, pricing formulae, marketing studies relating to prospective business opportunities, and all other concepts, ideas, materials, or information prepared or performed for or by the Company or its affiliates, (C) information regarding the skills and compensation of the employees, contractors, and any other service providers of the Company or its affiliates, (D) the existence of any business discussions, negotiations, or agreements between the Company or its affiliates and any third party, (E) all documents and other work product generated by you which contain, comment upon, or relate in any way to any information disclosed by the Company or its affiliates, (F) all third-party information held in confidence by the Company or its affiliates, and (G) the terms and conditions of this Agreement.  For purposes of this Agreement, the Confidential Information shall not include, and Executive&#8217;s obligation shall not extend to (A) information which is generally available to the public and (B) information obtained by Executive other than pursuant to or in connection with Executive&#8217;s employment.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Pursuant to Section 7 of the Defend Trade Secrets Act of 2016 (which added 18 U.S.C. &#167; 1833(b)), the Company and Executive acknowledge and agree that Executive shall not have criminal or civil liability under any federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney and (ii) solely for the purpose of reporting or investigating a suspected violation of law&#59; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.  In addition and without limiting the preceding sentence, if Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose the trade secret to Executive&#8217;s attorney and may use the trade secret information in the court proceeding, if Executive (X) files any document containing the trade secret under seal and (Y) does not disclose the trade secret, except pursuant to court order.  Nothing in this Agreement or otherwise is intended to conflict with 18 U.S.C. &#167; 1833(b) or create liability for disclosures of trade secrets that are expressly allowed by such Section.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">In connection with Executive&#8217;s employment with the Company, Executive will not use any confidential or proprietary information Executive may have obtained in connection with employment with any prior employer.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Executive&#8217;s obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall survive the termination of the Employment Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">Covenant Not to Solicit and Not to Compete&#59; Non-Disparagement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Covenants Not to Solicit or to Interfere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  To protect the Confidential Information, Company Intellectual Property (as defined below) and other trade secrets of the Company and its affiliates, Executive agrees, during the Employment Term and for a period of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">#95012652v7&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">twelve (12) months after Executive&#8217;s cessation of employment with the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Restricted Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), not to solicit, hire or participate in or assist in any way in the solicitation or hire of any employees of the Company or any of its subsidiaries (or any person who was an employee of the Company or any of its subsidiaries during the six-month period preceding such action).  For purposes of this covenant, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">solicit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means directly or indirectly influencing or attempting to influence employees of the Company or any of its subsidiaries to become employed with any other person, partnership, firm, corporation or other entity.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, to protect the Confidential Information, Company Intellectual Property and other trade secrets of the Company and its affiliates, Executive agrees, during the Employment Term and the Restricted Period, not to (x) solicit any client or customer to receive services or to purchase any good or services in competition with those provided by the Company or any of its subsidiaries or (y) interfere or attempt to interfere in any material respect with the relationship between the Company or any of its subsidiaries on one hand and any client, customer, supplier, investor, financing source or capital market intermediary on the other hand.  For purposes of this covenant, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">solicit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means directly or indirectly influencing or attempting to influence clients or customers of the Company or any of its affiliates to accept the services or goods of any other person, partnership, firm, corporation or other entity in competition with those provided by the Company or any of its affiliates.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive agrees that the covenants contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> are reasonable and desirable to protect the Confidential Information and Company Intellectual Property of the Company and its affiliates&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that solicitation through general advertising or the provision of references shall not constitute a breach of such obligations.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Covenant Not to Compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  To protect the Confidential Information, Company Intellectual Property and other trade secrets of the Company, the Company and its affiliates, Executive agrees (i) during the period beginning on the Initial Commencement Date and ending on the date that is 12 months after the Separation Date (but in no event later than the last day of the Restricted Period) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">First Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), not to engage in Prohibited Activities (as defined below) in any country in which the Company or any of its affiliates and, following the Separation Date, Bausch &#38; Lomb, conducts business, or plans to conduct business, and (ii) following the expiration of the First Period, during the Employment Term and the Restricted Period (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Second Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), not to engage in Prohibited Activities in any country in which the Company or any of its affiliates conducts business, or plans to conduct business.  For the purposes of this Agreement, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Prohibited Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means directly or indirectly engaging as an owner, employee, partner, member, consultant or agent of any entity that derives more than 10% of its consolidated revenue from the development, manufacturing, marketing and&#47;or distribution (directly or indirectly) of (x) during the First Period, branded or generic prescription or non-prescription pharmaceuticals or medical devices for treatments in the fields of neurology, dermatology, gastroenterology, ophthalmology or dentistry (y) during the Second Period, branded or generic prescription or non-prescription pharmaceuticals or medical devices for treatment in the same fields as clause (x), other than ophthalmology&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that Prohibited Activities shall not mean Executive&#8217;s investment in securities of a publicly-traded company equal to less than five (5%) percent of such company&#8217;s outstanding voting securities&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that, for the avoidance of doubt, Executive complies with the obligations set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 12,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">13(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">13(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.  Executive agrees that the covenants contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> are reasonable and desirable to protect the Confidential Information and Company Intellectual Property of the Company and its affiliates.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Non-Disparagement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive agrees not to make written or oral statements about the Company, its subsidiaries or affiliates, or its directors, executive officers or non-executive officer employees that are negative or disparaging, except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.  The Company shall instruct its directors and executive officers to not make written or oral </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">#95012652v7&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">statements about Executive that are negative or disparaging. Notwithstanding the foregoing, nothing in this Agreement or otherwise shall preclude Executive, the Company, its subsidiaries and affiliates, and the Company&#8217;s directors and executive officers from communicating or testifying truthfully to the extent required by law to any federal, state, provincial or local governmental agency or in response to a subpoena to testify issued by a court of competent jurisdiction.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">It is the intent and desire of Executive and the Company that the restrictive provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> be enforced to the fullest extent permissible under the laws and public policies as applied in each jurisdiction in which enforcement is sought.  If any particular provision of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall be determined to be invalid or unenforceable, such covenant shall be amended, without any action on the part of either party hereto, to delete there from the portion so determined to be invalid or unenforceable, such deletion to apply only with respect to the operation of such covenant in the particular jurisdiction in which such adjudication is made.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Executive&#8217;s obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall survive the termination of the Employment Term.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Remedies for Breach of Obligations under Sections 12 or 13 hereof</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive acknowledges that the Company will suffer irreparable injury, not readily susceptible of valuation in monetary damages, if Executive breaches his obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.  Accordingly, Executive agrees that the Company will be entitled, in addition to any other available remedies, to obtain injunctive relief against any breach or prospective breach by Executive of his obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.  Executive agrees that process in any or all of those actions or proceedings may be served by overnight courier, addressed to the last address provided by Executive to the Company, or in any other manner authorized by law (including personal service).  This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 14 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall survive the termination of the Employment Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Cooperation.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Following Executive&#8217;s termination of employment for any reason, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">hereof, Executive agrees to make himself reasonably available to cooperate with the Company and its affiliates in matters that materially concern&#58; (i) requests for information about the services Executive provided to the Company and its affiliates during his  employment with the Company and its affiliates, (ii) the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company and its affiliates which relate to events or occurrences that transpired while Executive was employed the Company and its affiliates and as to which Executive has, or would reasonably be expected to have, personal experience, knowledge or information or (iii) any investigation or review by any federal, state or local regulatory, quasi-regulatory or self-governing authority (including, without limitation, the US Department of Justice, the US Federal Trade Commission or the SEC) as any such investigation or review relates to events or occurrences that transpired while Executive was employed by the Company and its affiliates.  Executive&#8217;s cooperation shall include&#58; (A) making himself reasonably available to meet and speak with officers or employees of the Company, the Company&#8217;s counsel or any third-parties at the request of the Company at times and locations to be determined by the Company reasonably and in good faith, taking  into  account  the  Company&#8217;s  business  and  personal  needs  (the  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and (B) giving accurate and truthful information at any interviews and accurate  and  truthful  testimony in any legal proceedings or actions (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Witness Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall be construed to limit in any way any rights Executive may have at applicable law not to provide testimony with regard to specific matters.  Unless required by law or legal process, Executive will not knowingly or intentionally furnish information to or cooperate with any non-governmental entity (other than the Company) in connection with any potential or pending proceeding or legal action involving matters arising during Executive&#8217;s employment with the Company and its affiliates.  In addition, at the request of the Company, Executive shall be required to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">#95012652v7&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">complete a directors&#8217; and officers&#8217; questionnaire to facilitate the Company&#8217;s preparation and filing of its proxy statement and periodic reports with the SEC.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Executive shall not be entitled to any payments in addition to those otherwise set forth in this Agreement in respect of any Company Cooperation or Witness Cooperation, regardless of when provided.  The Company will reimburse Executive for any reasonable, out-of-pocket travel, hotel and meal expenses incurred in connection with Executive&#8217;s performance of obligations pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> for which Executive has obtained prior approval from the Company.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Nothing in this Agreement or any other agreement by and between the Parties is intended to or shall preclude or in any way limit or restrict Executive from providing accurate and truthful testimony or information to any governmental agency.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall survive the termination of the Employment Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Inventions and Intellectual Property.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  As used in this Agreement&#58;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all patents, invention disclosures, invention registrations, trademarks, service marks, trade names, trade dress, logos, domain names, copyrights, mask works, trade secrets, know-how and all other intellectual property and proprietary rights recognized by any applicable law of any jurisdiction, and all registrations and applications for registration of, and all goodwill associated with, the foregoing.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all inventions, discoveries, concepts, information, works, materials, processes, methods, data, software, programs, apparatus, designs and  the like.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive will disclose promptly in writing to the Company any and all Inventions and Intellectual Property, in each case that Executive conceives, develops, creates or reduces to practice, either alone or jointly with others, during the period of Executive&#8217;s employment that (1) are conceived, created or developed using any equipment, supplies, facilities, trade secrets, know-how or other Confidential Information of the Company or any of its affiliates, (2) result from any work performed by Executive for the Company or any of its affiliates and&#47;or (3) otherwise relate to the Company&#8217;s or any of its affiliates&#8217; business or actual or demonstrably anticipated research or development (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Ownership and Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive acknowledges and agrees that the Company will have exclusive title and ownership rights in and to all Company Intellectual Property.  To the extent that exclusive title and&#47;or ownership rights may not originally vest in the Company as contemplated herein, Executive hereby irrevocably assigns, transfers, conveys and delivers to the Company all right, title and interest in and to all Company Intellectual Property.  Executive acknowledges and agrees that, with respect to any Company Intellectual Property that may qualify as a Work Made For Hire as defined in 17 U.S.C. &#167; 101 or other applicable law, such Company Intellectual Property is and will be deemed a Work Made for Hire and the Company will have the sole and exclusive right to the copyright (or, in the event that any such Company Intellectual Property does not qualify as a Work Made for Hire, the copyright and all other rights thereto are automatically assigned to the Company as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">above).</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Prior Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (Prior Inventions) attached hereto is a complete list of all Inventions that Executive has, alone or jointly with others, conceived, developed created or reduced to practice prior to the commencement of Executive&#8217;s employment with the Company, that are Executive&#8217;s property, and that the Company acknowledges and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">#95012652v7&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">agrees are excluded from the scope of this Agreement (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Prior Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  If disclosure of any such Prior Invention would cause Executive to violate any prior confidentiality agreement, Executive understands that he is not to list such Prior Inventions in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> but is only to disclose where indicated a cursory name for each such Prior Invention, a listing of each person or entity to whom it belongs, and the fact that full disclosure as to such Prior Inventions has not been made for that reason (it being understood that, if no Invention or disclosure is provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Executive hereby represents and warrants that there are no Prior Inventions).  If, in the course of Executive&#8217;s employment with the Company, Executive incorporates any Prior Invention into any Company product, process or machine or otherwise uses any Prior Invention, Executive hereby grants to the Company and its affiliates a worldwide, non-exclusive, irrevocable, perpetual, fully paid-up and royalty-free license (with rights to sublicense through multiple tiers of sublicensees) to use, reproduce, modify, make derivative works of, publicly perform, publicly display, make, have made, sell, offer for sale, import and otherwise exploit such Prior Invention for any purpose.</font></div><div style="margin-bottom:8pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Assi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">nable Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If Executive is an employee whose principal work location is in California, Illinois, Kansas, Minnesota or Washington State, the provisions regarding Executive&#8217;s  assignment of Company Intellectual Property to  the  Company in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 16(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof do not apply to certain Inventions (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Assi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">nable Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) as specified in the statutory code of the applicable state.  Executive acknowledges having received and reviewed notification regarding such Non-Assignable Inventions pursuant to such states&#8217; codes.</font></div><div style="margin-bottom:8pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver of Moral Ri</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">hts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  To the extent that Executive may do so under applicable law, Executive hereby irrevocably waives and agrees never to assert any Moral Rights that Executive may have in or with respect to any Company Intellectual Property, even after termination of any work on behalf of the Company or its affiliates.  As used in this Agreement, &#8220;Moral Rig</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">hts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any rights to claim authorship of a work, to object to or prevent the modification or destruction of a work, or to withdraw from circulation or control the publication or distribution of a work, and any similar right, existing under any applicable law of any jurisdiction, regardless of whether or not such right is denominated or generally referred to as a &#8220;moral right.&#8221;</font></div><div style="margin-bottom:8pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive shall give the Company and its affiliates all reasonable assistance and execute all documents necessary to assist with enabling the Company and its affiliates to prosecute, perfect, register, record, enforce and defend any of their rights in any Company Intellectual Property and Confidential Information.</font></div><div style="margin-bottom:8pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall survive the termination of the Employment Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Miscellaneous.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Successors and Assigns.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">This Agreement shall be binding upon and shall inure to the benefit of the Company, its successors and permitted assigns.  The Company may not assign or delegate any rights or obligations hereunder except to a successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and&#47;or assets of the Company, as applicable.  Except for purposes of determining the occurrence of a Change in Control, the term &#8220;the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; as used herein shall mean a corporation or other entity acquiring all or substantially all the assets and business of the Company, as the case may be, (including this Agreement) whether by operation of law or otherwise.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Neither this Agreement nor any right or interest hereunder shall be assignable or transferable by Executive, Executive&#8217;s beneficiaries or legal representatives, except by will or by the, laws of descent and distribution.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">#95012652v7&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">This Agreement shall inure to the benefit of and be enforceable by Executive&#8217;s legal personal representatives.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For the purposes of this Agreement, notices and all other communications provided for in the Agreement (including the Notice of Termination) shall be in writing and shall be deemed to have been duly given when personally delivered or sent by overnight courier, addressed to the respective addresses last given by each party to each other party&#59; p</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">rovided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that all notices to the Company shall be directed to the attention of the General Counsel of the Company.  All notices and communications shall be deemed to have been received on the date of delivery thereof or on the third business day after the mailing thereof, except that notice of change of address shall be effective only upon receipt.</font></div><div style="margin-bottom:8pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnity Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company agrees to indemnify and hold Executive harmless to the fullest extent permitted by applicable law for actions taken as a director or officer of the Company, as in effect at the time of the subject act or omission.  In connection therewith, Executive shall be entitled to the protection of any insurance policies which the Company elects to maintain generally for the benefit of the Company&#8217;s directors and officers, against all costs, charges and expenses whatsoever incurred or sustained by Executive in connection with any action, suit or proceeding to which he may be made a party by reason of his being or having been a director, officer or employee of the Company.  This provision shall survive any termination of the Employment Term.</font></div><div style="margin-bottom:8pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Withholdin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">g.  The Company shall be entitled to withhold the amount, if any, of all taxes of any applicable jurisdiction required to be withheld by an employer with respect to any amount paid to Executive hereunder.  The Company, in its sole and absolute discretion, shall make all determinations as to whether it is obligated to withhold any taxes hereunder and the amount hereof.</font></div><div style="margin-bottom:12.35pt;margin-top:2.7pt;padding-left:108pt;padding-right:5.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Release of Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The termination benefits described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 9(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">9(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">9(d)(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof shall be conditioned on Executive delivering to the Company, and failing to revoke, a signed release of claims acceptable to the Company within twenty-one (21) days following Executive&#8217;s Termination Date&#59; provided, however, that Executive shall not be required to release any rights Executive may have to be indemnified by the Company under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.  Notwithstanding any provision of this Agreement to the contrary, in no event shall the timing of Executive&#8217;s execution of the release, directly or indirectly, result in Executive designating the calendar year of payment, and, to the extent required by Section 409A, if a payment that is subject to execution of the release could be made in more than one taxable year, payment shall be made in the later taxable year.  Where applicable, references to Executive in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall refer to Executive&#8217;s representative or estate.</font></div><div style="margin-bottom:12.35pt;margin-top:2.7pt;padding-left:108pt;padding-right:5.9pt;text-align:justify;text-indent:-30.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.07pt;text-decoration:underline">Modification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  No provision of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing and signed by Executive and the Company.  No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or provision of this Agreement to be performed by the other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time.  No agreement or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by any party which are not expressly set forth in this Agreement.</font></div><div style="margin-bottom:12.35pt;margin-top:2.7pt;padding-left:108pt;padding-right:5.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If any legally actionable dispute arises under this Agreement or otherwise which cannot be resolved by mutual discussion between the parties, then the Company and Executive each agree to resolve that dispute by binding arbitration before an arbitrator experienced in employment law.  Said arbitration will be conducted in accordance with the rules applicable to employment disputes of the Judicial Arbitration and Mediation Services (&#8220;JAMS&#8221;) and the law applicable to the claim.  The parties shall have 30 calendar days after notice of such arbitration has been given to attempt to agree </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">#95012652v7&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12.35pt;margin-top:2.7pt;padding-left:108pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">on the selection of an arbitrator from JAMS.  In the event the parties are unable to agree in such time, JAMS will provide a list of five (5) available arbitrators and an arbitrator will be selected from such five-member panel provided by JAMS by the parties alternately striking out one name of a potential arbitrator until only one name remains.  The party entitled to strike an arbitrator first shall be selected by a toss of a coin.  The parties agree that this agreement to arbitrate includes any such disputes that the Company may have against Executive, or Executive may have against the Company and&#47;or its related entities and&#47;or employees, arising out of or relating to this Agreement, or Executive&#8217;s employment or Executive&#8217;s termination, including any claims of discrimination or harassment in violation of applicable law and any other aspect of Executive&#8217;s compensation, employment, or Executive&#8217;s termination.  The parties further agree that arbitration as provided for in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> is the exclusive and binding remedy for any such dispute and will be used instead of any court action, which is hereby expressly waived, except for any request by any party for temporary, preliminary or permanent injunctive relief pending arbitration in accordance with applicable law or for breaches by either party of such party&#8217;s obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 12,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">16 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">hereof, as applicable, or an administrative claim with an administrative agency.  The parties agree that the arbitration provided herein shall be conducted in or around Morristown, New Jersey, unless otherwise mutually agreed.  The Company shall pay the cost of any arbitration brought pursuant to this paragraph, excluding, however, the cost of representation of Executive unless such cost is awarded in accordance with law or otherwise awarded by the arbitrators.  Except as otherwise provided above, the arbitrator may award legal fees to the prevailing party in his sole discretion, provided that the percentage of fees so awarded shall not exceed 1% of the net worth of the paying party (i.e., the Company or Executive).  Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof, except as may be required by law, neither party nor an arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written consent of both parties.</font></div><div style="margin-bottom:12.35pt;margin-top:2.7pt;padding-left:108pt;padding-right:5.9pt;text-align:justify;text-indent:-30.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.23pt;text-decoration:underline">Effect of Other Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Anything herein to the contrary notwithstanding, the terms of this Agreement shall be modified to the extent required to meet the provisions of the Sarbanes-Oxley Act of 2002, Section 409A, the Dodd-Frank Wall Street Reform and Consumer Protection Act or other federal law applicable to the employment arrangements between Executive and the Company.  Any delay in providing benefits or payments or any failure to provide a benefit or payment shall not in and of itself constitute a breach of this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the Company shall provide economically equivalent payments or benefits to Executive to the extent permitted by law.  Any request or requirement that Executive repay compensation that is required under the first sentence shall not in and of itself constitute a breach of this Agreement.</font></div><div style="margin-bottom:12.35pt;margin-top:2.7pt;padding-left:108pt;padding-right:5.9pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt;text-decoration:underline">Governin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New Jersey applicable to contracts executed in and to be performed entirely within such State, without giving effect to the conflict of law principles thereof.</font></div><div style="margin-bottom:12.35pt;margin-top:2.7pt;padding-left:108pt;padding-right:5.9pt;text-align:justify;text-indent:-30.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.68pt;text-decoration:underline">No Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  As a condition to the effectiveness of this Agreement, Executive represents and warrants to the Company that he is not a party to or otherwise bound by any agreement or arrangement (including, without limitation, any license, covenant, or commitment of any nature), or subject to any judgment, decree, or order of any court or administrative agency, that would conflict with or will be in conflict with or in any way preclude, limit or inhibit Executive&#8217;s ability to execute this Agreement or to carry out his duties and responsibilities hereunder.  In the event that the Company determines that Executive&#8217;s duties hereunder may conflict with an agreement or arrangement to which Executive is bound, Executive shall be required to cease engaging in any such activities, duties or responsibilities (including providing supervisory services over certain subsets of the Company&#8217;s business operations) and the Company will take steps to restrict Executive&#8217;s access to, and participation in, any such activities.  Any actions taken by the Company under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> to restrict or limit Executive&#8217;s access to information or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">#95012652v7&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12.35pt;margin-top:2.7pt;padding-left:108pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">provision of services shall not constitute Good Reason for purposes of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7(e) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">hereof.</font></div><div style="margin-bottom:12.35pt;margin-top:2.7pt;padding-left:108pt;padding-right:5.9pt;text-align:justify;text-indent:-30.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.23pt;text-decoration:underline">Severabilit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">y.  The provisions of this Agreement shall be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement constitutes the entire agreement between the parties hereto and supersedes all prior agreements, if any, understandings and arrangements, oral or written, between the parties hereto with respect to the subject matter hereof, including, without limitation, any term sheets or other similar presentations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement.  Signatures transmitted via facsimile or PDF will be deemed the equivalent of originals.</font></div><div style="margin-bottom:24.2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Remainder of page left intentionally blank</font></div><div style="margin-bottom:24pt;padding-left:5.95pt;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">#95012652v7&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have executed this Employment Agreement as of the day and year first above written, to be effective as of the Initial Commencement Date.</font></div><div style="margin-bottom:24pt;margin-top:30pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BAUSCH HEALTH COMPANIES INC.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Joseph C. Papa</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">                                                      </font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Joseph C. Papa</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Chairman of the Board and Chief Executive Officer</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:24pt;margin-top:30pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTIVE</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">s&#47; Tom Vadaketh</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">                                                     </font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;   Tom Vadaketh&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">#95012652v7&#160;&#160;&#160;&#160;</font></div></div></div><div id="iccd9e614a29444cd8ce125a7e204efe2_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT A<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PRIOR INVENTIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;The following is a complete list of all Prior Inventions (as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 16(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the attached Employment Agreement)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;Due to a prior confidentiality agreement, Executive cannot complete the disclosure under Section 1 above with respect to the Prior Inventions generally listed below, the duty of confidentiality with respect to which Executive owes to the following party(ies)&#58;</font></div><div><font><br></font></div><div style="padding-left:7.45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.731%"><tr><td style="width:1.0%"></td><td style="width:32.080%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.387%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Prior Invention</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Party(ies)</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Relationship</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">#95012652v7&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>3
<FILENAME>exhibit108bauschpharmagcem.htm
<DESCRIPTION>EX-10.8
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i74304cca20b5459b9f39f34f3b1036bc_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.8</font></div></div><div style="margin-top:4.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BAUSCH HEALTH COMPANIES INC.</font></div><div style="margin-top:8.7pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">EMPLOYMENT AGREEMENT</font></div><div style="margin-top:8.7pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THIS EMPLOYMENT AGREEMENT (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">reement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is hereby entered into as of December 3, 2021, by and between Bausch Health Companies Inc., a company incorporated in the Province of British Columbia, Canada (together with any successor thereto, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Bausch Health</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and Seana Carson, an individual (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) (hereinafter collectively referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">the parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Where the context requires, references to the Company shall include the Company&#8217;s subsidiaries and affiliates and any successors in interest thereto, which shall include Bausch Pharma at the time of the separation of the Bausch + Lomb business.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) has determined that it is in the best interests of Bausch Health and its stockholders to separate the global eye health business (such business, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Bausch + Lomb</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) from the remainder of Bausch Health by providing for an initial public offering of Bausch + Lomb&#8217;s stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">IPO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and subsequently separating the Bausch + Lomb business from the Company (such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Separation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, in connection with the IPO, the Company desires to employ Executive on the terms set forth in this Agreement, for the period provided below, and Executive desires to accept such employment with the Company, subject to the terms and conditions set forth herein&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, the Company and the Executive entered into a letter agreement dated as of November 2, 2020 setting forth certain payments payable to the Executive (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Separation Bonus Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;WHEREAS, the Company and the Executive desire that the Separation Bonus Letter shall remain in full force in effect with its terms and shall not be amended by this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the respective agreements of the parties contained herein, it is agreed as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Commencement Date&#59; Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The term (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Employment Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of Executive&#8217;s employment under this Agreement shall be for the period commencing on December 1, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and shall continue until it is terminated as provided herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  During the Employment Term&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Contingent and effective upon the closing of the IPO (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Bausch Pharma Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Executive shall be employed as the General Counsel of the Company, at which time Executive shall report directly to the Chief Executive Officer of the Company.  Executive shall perform the duties, undertake the responsibilities and exercise the authority customarily performed, undertaken and exercised by persons situated in similar executive capacities.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Excluding periods of vacation and sick leave to which Executive is entitled and other service outside of the Company contemplated in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Executive shall devote her full professional time and attention to the business and affairs of the Company to discharge the responsibilities of Executive hereunder.  Prior to joining or agreeing to serve on corporate, civil or charitable boards or committees, Executive shall obtain approval of the Chief Executive Officer. Executive may manage personal and family investments, participate in industry organizations and deliver lectures at educational institutions, so long as such activities do not interfere with the performance of Executive&#8217;s responsibilities hereunder. It is understood that, during Executive&#8217;s employment by the Company, Executive shall not engage in any activities that constitute a conflict of interest with the interests of the Company or its direct and indirect subsidiaries, as outlined in the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Company&#8217;s conflict of interest policies for employees and executives in effect from time to time.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Executive shall be subject to and shall abide by each of the personnel policies applicable to senior executives, including any policy restricting pledging and hedging investments in Company equity by Company executives, any policy the Company adopts regarding the recovery of incentive compensation (sometimes referred to as &#8220;clawback&#8221;) and any additional clawback provisions as required by law and applicable listing rules.  This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall survive the termination of the Employment Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Annual Compensation.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Base Salar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">y.  Effective on the Initial Commencement Date, during the Employment Term, Executive shall be paid an annual base salary of 665,000 CAD (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  The Base Salary shall be payable in accordance with the Company&#8217;s regular payroll practices as then in effect.  During the Employment Term, the Base Salary will be reviewed annually and is subject to adjustment at the discretion of the Chief Executive Officer of the Company and the Talent and Compensation Committee of the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Performance Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For the 2021 performance year, Executive will continue to be eligible to participate in Bausch Health&#8217;s annual incentive cash bonus program, in accordance with, and subject to the terms and conditions of, such plan. Effective as of the 2022 performance year, subject to the terms of the Company&#8217;s annual incentive cash bonus program as in effect from time to time and the provisions hereof, for each fiscal year of the Company ending during the Employment Term, Executive shall be eligible to receive a target annual cash bonus of 60% of Base Salary (such target bonus, as may hereafter be increased, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Target Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) with the opportunity to receive a maximum annual cash bonus of 200% of the Target Bonus. Annual bonuses, if any, will be payable in the Company&#8217;s discretion and in accordance with the Company&#8217;s customary practices applicable to bonuses paid to similarly situated executives of the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Additional Compensation.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt;text-decoration:underline">One-Time Initial Equity Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. As soon as administratively practicable following the Initial Commencement Date, and at such time when the Company is not restricted from making equity grants pursuant to applicable securities laws, Executive will receive a grant under the Bausch Health Companies Inc. Amended and Restated 2014 Omnibus Incentive Plan (as amended and restated from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of a number of restricted stock units (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) with a grant-date fair value of approximately $250,000 (such RSUs, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).&#160;The RSUs will be subject to the terms and conditions of the Plan and applicable award agreement to be provided to Executive and subject to continued employment with the Company through the applicable grant date. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">On</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">oing Grants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive will be eligible for consideration for future equity grants during the Employment Term in the sole discretion of the Committee.</font></div><div style="margin-bottom:12.5pt;margin-top:3.45pt;padding-left:5.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.8pt;text-decoration:underline">Share Ownership Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive agrees to comply with any share ownership requirements adopted by the Company applicable to Executive, which shall be on the same terms as similarly situated executives of the Company.</font></div><div style="margin-bottom:12.5pt;margin-top:3.45pt;padding-left:5.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21.8pt;text-decoration:underline">Other Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  During the Employment Term&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Employee Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive shall be entitled to participate in the employee benefit plans, practices and programs maintained by the Company, and made available to employees of the Company generally, including, without limitation, all pension, retirement, profit sharing, savings, medical, hospitalization, disability, dental, life or travel accident insurance benefit plans in accordance with the terms of the plans as in effect from time to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">time.  Executive&#8217;s participation in such plans, practices and programs shall be on the same basis and terms as are applicable to such employees.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt;text-decoration:underline">Business Ex</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">p</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">enses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Upon submission of proper invoices in accordance with, and subject to, the Company&#8217;s normal policies and procedures, Executive shall be entitled to receive prompt reimbursement of all reasonable out-of-pocket business, entertainment and travel expenses incurred by her in connection with the performance of her duties hereunder.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt;text-decoration:underline">Vacation and Sick Leave</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive shall be entitled, without loss of pay, to absent herself voluntarily from the performance of Executive&#8217;s employment under this Agreement, pursuant to the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Executive shall be entitled to annual vacation in accordance with and subject to the policies as periodically established for similarly situated executives of the Company&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Executive shall be entitled to sick leave (without loss of pay) in accordance with the Company&#8217;s policies as in effect from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive&#8217;s employment with the Company hereunder may be terminated under the circumstances set forth below&#59; p</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">rovided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that notwithstanding anything contained herein to the contrary, to the extent required by Section 409A (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Executive shall not be considered to have terminated employment with the Company for purposes of this Agreement until she would be considered to have incurred a &#8220;separation from service&#8221; from the Company within the meaning of Section 409A.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive&#8217;s employment shall be terminated as of the date of Executive&#8217;s death and Executive&#8217;s beneficiaries shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">hereof.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Disabilit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">y.  The Company may terminate Executive&#8217;s employment, on written notice to Executive after having established Executive&#8217;s Disability and while Executive remains Disabled, and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Disabilit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">y&#8221; shall have the meaning assigned to such term in the Plan.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company may terminate Executive&#8217;s employment for Cause effective as of the date of the Notice of Termination (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof) and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean, for purposes of this Agreement&#58; (1) conviction of any indictable offence (other than one related to a vehicular offense) or other criminal act involving fraud&#59; (2) willful misconduct that results in a material economic detriment to the Company&#59; (3) material violation of Company policies and directives, which is not cured after written notice and an opportunity for cure&#59; (4) continued refusal by Executive to perform her duties after written notice identifying the deficiencies and an opportunity for cure&#59; and (5) a material violation by Executive of any of the covenants to the Company, including those set forth in Sections 12, 13, 15 and 16 hereof.  No action or inaction shall be deemed willful if (x) not demonstrably willful and (y) taken, or not taken, by Executive in good faith and with the understanding that such action, or inaction, was not adverse to the best interests of the Company.  References in this paragraph to the Company shall also include direct and indirect subsidiaries of the Company, and materiality shall be measured based on the action or inaction and the impact upon the Company taken as a whole.  Without limiting the other rights of the Company under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> the Company may suspend Executive, without pay, upon Executive being charged for an offence as described under clause (1) above.  Such suspension may remain effective until such time as the indictment is either dismissed or a verdict of not guilty has been entered.  If such indictment does not result in a conviction, as soon as practicable following such dismissal or verdict, the Company will pay Executive the base salary and target bonus amount that Executive would have received for the period during </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">which Executive was suspended without pay (with interest from the date such amounts would otherwise have been paid at the short-term applicable federal rate, compounded semi-annually, as determined under Section 1274 of the Code for the month in which payment would have been made but for the delay) and Executive will receive vesting credit for purposes of Executive&#8217;s outstanding equity awards.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Without Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company may terminate Executive&#8217;s employment without Cause.  The Company shall deliver to Executive a Notice of Termination (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof) not less than thirty (30) days prior to the termination of Executive&#8217;s employment without Cause and the Company shall have the option of terminating Executive&#8217;s duties and responsibilities prior to the expiration of such thirty-day notice period, and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive may terminate her employment for Good Reason (as defined below) by delivering to the Company a Notice of Termination not less than thirty (30) days prior to the termination of Executive&#8217;s employment for Good Reason and no more than one hundred fifty (150) days following the initial existence of the event or condition constituting Good Reason.  The Company shall have the option of terminating Executive&#8217;s duties and responsibilities prior to the expiration of such thirty (30) day notice period, and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean the occurrence of any of the events or conditions described in clauses (1) through (4) below during the Employment Term, without Executive&#8217;s prior written consent, which are not cured by the Company (if susceptible to cure by the Company) within thirty (30) days after the Company has received written notice from Executive within ninety (90) days of the initial existence of the event or condition constituting Good Reason specifying the particular events or conditions which constitute Good Reason and the specific cure requested by Executive. </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Diminution of Res</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">p</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">onsibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  (A) Any material reduction in Executive&#8217;s duties or responsibilities as General Counsel of the Company following the Bausch Pharma Commencement Date, in each case as in effect immediately prior thereto (other than a reduction where Executive is provided with other duties or responsibilities substantially comparable to Executive&#8217;s overall duties and responsibilities prior to such reduction) or (B) removal of Executive from the position of General Counsel of the Company following the Bausch Pharma Commencement Date (or, following a Change in Control or a corporate restructuring, removal from the position of General Counsel of the ultimate parent company of the resulting entity), except, in each of (A) and (B), in connection with (1) the termination of Executive&#8217;s employment for Disability, Cause, as a result of Executive&#8217;s death or by Executive other than for Good Reason, or (2) for the avoidance of doubt, the changes in the Executive&#8217;s position and reporting relationship contemplated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">p</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ensation Reduction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any reduction in Executive&#8217;s Base Salary or Target Bonus opportunity which is not comparable to reductions in the base salary or target bonus opportunity of other similarly situated executives of the Company&#59; </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Relocation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any relocation of Executive&#8217;s primary place of business that results in an increase of Executive&#8217;s one-way commute by fifty (50) miles or more&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that Executive&#8217;s relocation, if any, in connection with Executive&#8217;s commencement of employment as General Counsel of the Company shall not constitute Good Reason&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that the Company&#8217;s request that Executive travel from time to time on behalf of the Company shall not constitute Good Reason&#59; or </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">p</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">any Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any other material breach by the Company of any material provision of this Agreement as contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Without Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive may voluntarily terminate her employment without Good Reason by delivering to the Company a Notice of Termination not less than thirty </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(30) days prior to the termination of Executive&#8217;s employment and the Company shall have the option of terminating Executive&#8217;s duties and responsibilities prior to the expiration of such thirty (30) day notice period, and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof through the last day of such notice period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Notice of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any purported termination by the Company or by Executive shall be communicated by written Notice of Termination to the other party hereto.  For purposes of this Agreement, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean a notice which indicates a termination date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the specific termination provision in this Agreement relied upon and sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive&#8217;s employment under the provision so indicated.  For purposes of this Agreement, no such purported termination of Executive&#8217;s employment hereunder shall be effective without such Notice of Termination (unless waived by the party entitled to receive such notice).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Compensation Upon Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Upon termination of Executive&#8217;s employment during the Employment Term, Executive shall be entitled to the following benefits&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that any such benefits to which Executive is hereunder entitled shall be offset by those benefits that Executive receives, if any, under applicable law (including, without limitation, under the applicable employment standards legislation, including the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Employment Standards Act 2000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, as may be amended or replaced (all such legislation, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ESA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)) or otherwise&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Termination by the Company for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If Executive&#8217;s employment is terminated by the Company for Cause, the Company shall provide Executive with only&#58;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Executive&#8217;s applicable minimum entitlements under the ESA in respect of the termination of Executive&#8217;s employment (including, without limitation, all ESA requirements in respect of notice, termination and severance pay, wages, benefits and vacation pay)&#59; </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">reimbursement for reasonable and necessary expenses incurred by Executive on behalf of the Company for the period ending on the Termination Date&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">any previous compensation which Executive has previously deferred (including any interest earned or credited thereon), in accordance with the terms and conditions of the applicable deferred compensation plans or arrangements then in effect&#59; </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">equity and incentive awards, whether vested or unvested, shall be immediately terminate in accordance with the terms of such awards&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">benefits continuation for only the minimum period required by the ESA.</font></div><div style="margin-bottom:0.12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Termination by Executive Without Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If Executive&#8217;s employment is terminated by Executive without Good Reason, the Company shall pay Executive all amounts earned or accrued hereunder through the Termination Date, including&#58;</font></div><div style="margin-bottom:12pt;margin-top:8pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">reimbursement for reasonable and necessary expenses incurred by Executive on behalf of the Company for the period ending on the Termination Date&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">any previous compensation which Executive has previously deferred (including any interest earned or credited thereon), in accordance with the terms and conditions of the applicable deferred compensation plans or arrangements then in effect&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">equity and incentive awards, to the extent previously vested, shall be paid or delivered to Executive in accordance with the terms of such awards&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">any amount or benefit as provided under any benefit plan or program (the foregoing items in clauses (1) through (4) being collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Accrued Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></div><div style="margin-bottom:0.12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Termination by the Company for Disability or Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If Executive&#8217;s employment is terminated by the Company for Disability or by reason of Executive&#8217;s death, then, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof, Executive shall be entitled to the benefits provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company shall pay Executive (or her beneficiaries, as applicable) the Accrued Compensation&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company shall pay to Executive (or her beneficiaries, as applicable) within sixty (60) days following the Termination Date, any bonus earned but unpaid in respect of any fiscal year preceding the Termination Date&#59; </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Each unvested equity award held by Executive at the time of termination shall be governed by the terms of the applicable award agreement&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">In the case of termination of Executive&#8217;s employment due to Disability, Executive&#8217;s applicable minimum entitlements under the ESA in respect of the termination of Executive&#8217;s employment (including, without limitation, all ESA requirements in respect of notice, termination and severance pay, wages, benefits and vacation pay). In such circumstances, benefits continuation for only the minimum period required by the ESA.</font></div><div style="margin-bottom:0.12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Termination by the Company Without Cause or by Executive for Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If Executive&#8217;s employment by the Company shall be terminated by the Company without Cause or by Executive for Good Reason, then, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof, Executive shall be entitled to the benefits provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;margin-top:8pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company shall pay to Executive any Accrued Compensation&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company shall pay to Executive any bonus earned but unpaid in respect of any fiscal year preceding the Termination Date within sixty (60) days following the Termination Date&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company shall pay to Executive a bonus or incentive award in respect of the fiscal year in which Executive&#8217;s Termination Date occurs in an amount equal to the product of (A) the lesser of (x) the bonus or incentive award that Executive would have been entitled to receive based on actual achievement against the stated performance objectives and (y) Executive&#8217;s Target Bonus and (B) a fraction (x) the numerator of which is the number of days in such fiscal year through the Termination Date and (y) the denominator of which is 365 (provided that if such termination occurs in contemplation of a Change in Control (as defined in the Plan) or within twelve months following a Change in Control, then in the forgoing calculation, the amount under (A) above shall be equal to Executive&#8217;s Target Bonus).  Any bonus or incentive award payable to Executive under this clause (3) shall be paid in a lump sum payment by March 15 of the year following the fiscal year in which Executive&#8217;s Termination Date occurs&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company shall pay Executive as severance pay, in lieu of any further compensation for the periods subsequent to the Termination Date, an amount in cash, which amount shall be payable in a lump sum payment within sixty (60) days following such termination (subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof), equal to one (1) times (or, if the Termination Date occurs either (x) on or before December 31, 2023, one and a half (1-1&#47;2) times) or (y) in contemplation of a Change in Control or within twelve months following a Change in Control, two (2) times) the sum of Executive&#8217;s Base Salary and Target Bonus, in each case, as in effect immediately prior to termination and without regard to any reduction thereto which constitutes Good Reason&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Each unvested equity award held by Executive at the time of termination shall be governed by the terms of the applicable award agreement&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company shall provide Executive with continued coverage through the first anniversary of Executive&#8217;s Termination Date under any health, medical, dental or vision program or policy in which Executive (and her dependents, as applicable) participated in as of the time of the Termination Date on terms no less favorable to Executive and her dependents than those applicable to actively employed similarly situated executives of the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that Executive shall be solely responsible for any taxes incurred in respect of such coverage.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Executive shall not be required to mitigate the amount of any payment provided for under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> by seeking other employment or otherwise and no such payment shall be offset or reduced by the amount of any compensation or benefits provided to Executive in any subsequent employment.</font></div><div style="margin-bottom:8pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;The termination arrangements set out in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> fully satisfy the Company&#8217;s and all affiliates&#8217; obligations to Executive in respect of the termination of Executive&#8217;s employment and Executive will not be entitled to further notice of termination, severance pay, incentive compensation, damages or other compensatory payments under common law or contract&#59; </font></div><div style="margin-bottom:8pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;Notwithstanding the foregoing, the parties agree that, if Executive&#8217;s entitlements upon termination of her employment pursuant to applicable law would result in the executive Executive&#8217;s entitlements upon termination of her employment being greater than her entitlements determined pursuant to Section 9, then applicable law shall apply and Executive shall not receive the payments or benefits set forth under Section 9.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The parties intend for the payments and benefits under this Agreement to be exempt from Section 409A or, if not so exempt, to be paid or provided in a manner which complies with the requirements of such section, and intend that this Agreement shall be construed and administered in accordance with such intention.  If any payments or benefits due to Executive hereunder would cause the application of an accelerated or additional tax under Section 409A, such payments or benefits shall be restructured in a mutually agreed upon manner that to the extent possible preserves the economic benefit and original intent thereof but does not cause such an accelerated or additional tax.  For purposes of the limitations on nonqualified deferred compensation under Section 409A, each payment of compensation under this Agreement shall be treated as a separate payment of compensation.  Without limiting the foregoing and notwithstanding anything contained herein to the contrary, to the extent required in order to avoid accelerated taxation and&#47;or tax penalties under Section 409A amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to this Agreement during the six-month period immediately following Executive&#8217;s separation from service shall instead be paid on the first business day after the date that is six months following Executive&#8217;s Termination Date (or death, if earlier).  Notwithstanding anything to the contrary in this Agreement, all (A) reimbursements and (B) in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A, including, where applicable, the requirement that (x) the amount of expenses eligible for reimbursement, or in kind benefits provided, during a calendar year may not affect the expenses eligible for reimbursement, or in kind benefits to be provided, in any other calendar year&#59; (y) the reimbursement of an eligible expense will be made no later than the last day of the calendar year following the year in which the expense is incurred&#59; and (z) the right to reimbursement or in kind benefits is not subject to liquidation or exchange for another benefit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Employee Protection</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Nothing in this Agreement or otherwise limits Executive&#8217;s ability to communicate directly with and provide information, including documents, not otherwise protected from disclosure by any applicable law or privilege to the Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) or any other federal, provincial, state or local governmental agency or commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Government Agency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) regarding possible legal violations, without disclosure to the Company.  The Company may not retaliate against Executive for any of these activities, and nothing in this Agreement or otherwise requires Executive to waive any monetary award or other payment that Executive might become entitled to from the SEC or any other Government Agency.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Records and Confidential Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Executive acknowledges that in connection with the performance of her duties during the Employment Term, the Company will make available to Executive, or Executive will have access to, certain Confidential Information (as defined below) of the Company and its affiliates.  Executive acknowledges and agrees that any and all Confidential Information disclosed to, or learned or obtained by, Executive during the course of her employment by the Company or otherwise, whether developed by Executive alone or in conjunction with others or otherwise, shall be and is the sole and exclusive property of the Company or the affiliate of the Company, as applicable, that is Executive&#8217;s employer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  No license or other right to any Confidential Information is granted to Executive under this Agreement.  To the extent that Executive acquires any right, title or interest in or to any Confidential Information, Executive hereby irrevocably assigns, transfers, conveys and delivers to the Employer all such right, title and interest in and to such Confidential Information.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof, the Confidential Information will be kept confidential by Executive, will not be used in any manner which is detrimental to the Company or any of its subsidiaries or affiliates (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), will not be used other than in connection with Executive&#8217;s discharge of her duties hereunder, and will be safeguarded by Executive from unauthorized disclosure.  Executive acknowledges and agrees that the confidentiality restrictions set forth herein shall apply to any and all Confidential Information disclosed to, or learned or obtained by, Executive, whether before, on or after the date hereof.  For the avoidance of doubt, nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall prevent Executive from complying with a valid legal requirement (whether by oral questions, interrogatories, requests for information or documents, subpoena, civil investigative demand or similar process) to disclose any Confidential Information&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Executive shall first give notice to the Employer and reasonably cooperate with the Employer to obtain a protective order or other measures preserving the confidential treatment of such Confidential Information and requiring that the information or documents so disclosed be used only for the purposes for which the order was issued or is otherwise required by applicable law.  For the avoidance of doubt, nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall prevent Executive from exercising any legally protected whistleblower rights (including under Rule 21F under the Securities Exchange Act of 1934, as amended and pursuant to the Ontario Securities Act) as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Following the termination of Executive&#8217;s employment hereunder or upon the applicable member of the Company Group&#8217;s request, and subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof, as soon as possible after such written request, Executive will return to the applicable member of the Company Group all written Confidential Information which has been provided to Executive and Executive will return or destroy all copies of any analyses, compilations, studies or other documents prepared by Executive or for Executive&#8217;s use containing or reflecting any Confidential Information.  Within five (5) business days of the receipt of such request by Executive, she shall, upon written request of the applicable member of the Company Group, deliver to such Company Group member a document certifying that such written Confidential Information has been returned or destroyed in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">For the purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean any and all non-public, proprietary or other confidential information of the Company Group disclosed to Executive, to which Executive has access, or of which Executive otherwise becomes aware, in each case whether in oral, written, graphic or machine readable form, including, without limitation, (A) know-how, trade secrets, inventions, discoveries, concepts, information, works, materials, processes, methods, data, software, programs, apparatus, designs and the like, and any other intellectual property the value of which is contingent upon maintaining the confidentiality thereof, (B) information regarding the business of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Company Group, including its products, services, budgets, contracts, reports, investigations, experiments, research, work in progress, drawings, designs, plans, proposals, codes, marketing and sales programs, client lists, client mailing lists, supplier lists, financial projections, cost summaries, pricing formulae, marketing studies relating to prospective business opportunities, and all other concepts, ideas, materials, or information prepared or performed for or by any member of the Company Group, (C) information regarding the skills and compensation of the employees, contractors, and any other service providers of the Company Group, (D) the existence of any business discussions, negotiations, or agreements between any member of the Company Group and any third party, (E) all documents and other work product generated by you which contain, comment upon, or relate in any way to any information disclosed by any member of the Company Group, (F) all third-party information held in confidence by the Company Group, and (G) the terms and conditions of this Agreement.  For purposes of this Agreement, the Confidential Information shall not include, and Executive&#8217;s obligation shall not extend to (A) information which is generally available to the public and (B) information obtained by Executive other than pursuant to or in connection with Executive&#8217;s employment.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Pursuant to Section 7 of the Defend Trade Secrets Act of 2016 (which added 18 U.S.C. &#167; 1833(b)), the Company Group and Executive acknowledge and agree that Executive shall not have criminal or civil liability under any federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney and (ii) solely for the purpose of reporting or investigating a suspected violation of law&#59; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.  In addition and without limiting the preceding sentence, if Executive files a lawsuit for retaliation by any member of the Company Group for reporting a suspected violation of law, Executive may disclose the trade secret to Executive&#8217;s attorney and may use the trade secret information in the court proceeding, if Executive (X) files any document containing the trade secret under seal and (Y) does not disclose the trade secret, except pursuant to court order.  Nothing in this Agreement or otherwise is intended to conflict with 18 U.S.C. &#167; 1833(b) or create liability for disclosures of trade secrets that are expressly allowed by such Section.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">In connection with Executive&#8217;s employment with the Company, Executive will not use any confidential or proprietary information Executive may have obtained in connection with employment with any prior employer.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Executive&#8217;s obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall survive the termination of the Employment Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Covenant Not to Solicit and Not to Compete&#59; Non-Disparagement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt;text-decoration:underline">Covenants Not to Solicit or to Interfere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  To protect the Confidential Information, Company Intellectual Property (as defined below) and other trade secrets of the Company Group, Executive agrees, during the Employment Term and for a period of twelve (12) months after Executive&#8217;s cessation of employment with the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Restricted Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), not to solicit, hire or participate in or assist in any way in the solicitation or hire of any person who is, to Executive&#8217;s knowledge, an employee of any member of the Company Group (or any person who was, to Executive&#8217;s knowledge, an employee of any member of the Company Group during the six-month period preceding such action).  For purposes of this covenant, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">solicit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means directly or indirectly contacting an individual for the purpose of influencing or attempting to influence employees of the Company Group to become employed with any other person, partnership, firm, corporation or other entity.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, to protect the Confidential Information, Company Intellectual Property and other trade secrets of the Company and its affiliates, Executive agrees, during the Employment Term and the Restricted Period, not to (x) solicit any client or customer to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">receive services or to purchase any good or services in competition with those provided by any member of the Company Group or (y) interfere or attempt to interfere in any material respect with the relationship between any member of the Company Group on one hand and any client, customer, supplier, investor, financing source or capital market intermediary on the other hand.  For purposes of this covenant, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">solicit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means directly or indirectly contacting clients or customers for the purpose of influencing or attempting to influence clients or customers of the Company Group to accept the services or goods of any other person, partnership, firm, corporation or other entity in competition with those provided by any member of the Company Group&#59; and references to &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">clients</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">customers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means those clients and customers, respectively, that Executive had direct and personal contact with in the course of performing her duties to the Company.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive agrees that the covenants contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> are reasonable and desirable to protect the Confidential Information and Company Intellectual Property of the Company and its affiliates&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that solicitation through general advertising or the provision of references shall not constitute a breach of such obligations.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Covenant Not to Compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  To protect the Confidential Information, Company Intellectual Property and other trade secrets of the Company, the Company and its affiliates, Executive agrees (i) during the period beginning on the Initial Commencement Date and ending on the date that is 12 months after the Separation Date (but in no event later than the last day of the Restricted Period) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">First Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), not to engage in Prohibited Activities (as defined below) in any country in which the Company or any of its affiliates and, following the Separation Date, Bausch &#38; Lomb, conducts business, or, to Executive&#8217;s knowledge, plans to conduct business, and (ii) following the expiration of the First Period, during the Employment Term and the Restricted Period (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Second Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), not to engage in Prohibited Activities in any country in which the Company or any of its affiliates conducts business, or, to Executive&#8217;s knowledge, plans to conduct business.  For the purposes of this Agreement, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Prohibited Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means directly or indirectly engaging as an owner, employee, partner, member, consultant or agent of any entity that derives more than 10% of its consolidated revenue from the development, manufacturing, marketing and&#47;or distribution (directly or indirectly) of (x) during the First Period, branded or generic prescription or non-prescription pharmaceuticals or medical devices for treatments in the fields of neurology, dermatology, gastroenterology, ophthalmology or dentistry (including, for the avoidance of doubt, the global eye health business and the global aesthetics medical device business) (y) during the Second Period, branded or generic prescription or non-prescription pharmaceuticals or medical devices for treatment in the same fields as clause (x), other than ophthalmology (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Competitive Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that Prohibited Activities shall not mean Executive&#8217;s investment in securities of a publicly-traded company equal to less than five (5%) percent of such company&#8217;s outstanding voting securities&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that, for the avoidance of doubt, Executive complies with the obligations set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 12,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">13(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">13(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.  Executive agrees that the covenants contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> are reasonable and desirable to protect the Confidential Information and Company Intellectual Property of the Company and its affiliates. Executive shall not be in breach of this covenant by being employed or engaged to provide services to a Competitive Business if such employment or engagement is not in a same or similar capacity. For purposes of this covenant, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">same or similar capacity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (i) employment or engagement in the same or similar capacity or function in which Executive worked for the Company Group at any time during the previous 12 months, which, for the avoidance of doubt, shall include any role or position as a senior executive (including in a non-legal capacity or function) of a Competitive Business, regardless of whether such role or position differs from Executive&#8217;s position hereunder&#59; and&#47;or (ii) employment or engagement in any other capacity where Executive&#8217;s knowledge of confidential information of the Company Group could provide a competitive advantage to any Competitive Business. For the purposes of this Section 13(b) only, the parties agree that Executive&#8217;s position shall be deemed to be equivalent to Chief Legal Officer.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Non-Disparagement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive agrees not to make written or oral statements about the Company Group, or any of their directors, executive officers or non-executive officer employees that are negative or disparaging, except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.  The Company shall instruct its directors and executive officers to not make written or oral statements about Executive that are negative or disparaging. Notwithstanding the foregoing, nothing in this Agreement or otherwise shall preclude Executive, the Company, its subsidiaries and affiliates, and the Company&#8217;s directors and executive officers from communicating or testifying truthfully to the extent required by law to any federal, state, provincial or local governmental agency or in response to a subpoena to testify issued by a court of competent jurisdiction. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">It is the intent and desire of Executive and the Company that the restrictive provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> be enforced to the fullest extent permissible under the laws and public policies as applied in each jurisdiction in which enforcement is sought.  If any particular provision of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall be determined to be invalid or unenforceable, such covenant shall be amended, without any action on the part of either party hereto, to delete there from the portion so determined to be invalid or unenforceable, such deletion to apply only with respect to the operation of such covenant in the particular jurisdiction in which such adjudication is made.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">Executive&#8217;s obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall survive the termination of the Employment Term.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Remedies for Breach of Obligations under Sections 12 or 13 hereof</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive acknowledges that the Company Group will suffer irreparable injury, not readily susceptible of valuation in monetary damages, if Executive breaches her obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.  Accordingly, Executive agrees that the applicable member of the Company Group will be entitled, in addition to any other available remedies, to obtain injunctive relief against any breach or prospective breach by Executive of her obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.  Executive agrees that process in any or all of those actions or proceedings may be served by overnight courier, addressed to the last address provided by Executive to the Company, or in any other manner authorized by law (including personal service).  This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 14 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall survive the termination of the Employment Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Cooperation.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Following Executive&#8217;s termination of employment for any reason, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">hereof, Executive agrees to make herself reasonably available to cooperate with the Company and its affiliates in matters that materially concern&#58; (i) requests for information about the services Executive provided to the Company and its affiliates during her employment with the Company and its affiliates, (ii) the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company and its affiliates which relate to events or occurrences that transpired while Executive was employed the Company and its affiliates and as to which Executive has, or would reasonably be expected to have, personal experience, knowledge or information or (iii) any investigation or review by any federal, provincial, state or local regulatory, quasi-regulatory or self-governing authority (including, without limitation, the US Department of Justice, the US Federal Trade Commission or the SEC or other securities commission) as any such investigation or review relates to events or occurrences that transpired while Executive was employed by the Company and its affiliates.  Executive&#8217;s cooperation shall include&#58; (A) making herself reasonably available to meet and speak with officers or employees of the Company, the Company&#8217;s counsel or any third-parties at the request of the Company at times and locations to be determined by the Company reasonably and in good faith, taking into account the Company&#8217;s business and personal needs  (the  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and (B) giving accurate and truthful information at any interviews and accurate and truthful testimony in any legal proceedings or actions (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Witness Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall be construed to limit in any way any rights Executive may have at applicable law not to provide testimony </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">with regard to specific matters.  Unless required by law or legal process, Executive will not knowingly or intentionally furnish information to or cooperate with any non-governmental entity (other than the Company) in connection with any potential or pending proceeding or legal action involving matters arising during Executive&#8217;s employment with the Company and its affiliates.  In addition, at the request of the Company, Executive shall be required to complete a directors&#8217; and officers&#8217; questionnaire to facilitate the Company&#8217;s preparation and filing of its proxy statement and periodic reports with the SEC.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">Executive shall not be entitled to any payments in addition to those otherwise set forth in this Agreement in respect of any Company Cooperation or Witness Cooperation, regardless of when provided.  The Company will reimburse Executive for any reasonable, out-of-pocket travel, hotel and meal expenses incurred in connection with Executive&#8217;s performance of obligations pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> for which Executive has obtained prior approval from the Company.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">Nothing in this Agreement or any other agreement by and between the Parties is intended to or shall preclude or in any way limit or restrict Executive from providing accurate and truthful testimony or information to any governmental agency.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall survive the termination of the Employment Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Inventions and Intellectual Property.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  As used in this Agreement&#58;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all patents, invention disclosures, invention registrations, trademarks, service marks, trade names, trade dress, logos, domain names, copyrights, mask works, trade secrets, know-how and all other intellectual property and proprietary rights recognized by any applicable law of any jurisdiction, and all registrations and applications for registration of, and all goodwill associated with, the foregoing.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all inventions, discoveries, concepts, information, works, materials, processes, methods, data, software, programs, apparatus, designs and the like.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive will disclose promptly in writing to the Company any and all Inventions and Intellectual Property, in each case that Executive conceives, develops, creates or reduces to practice, either alone or jointly with others, during the period of Executive&#8217;s employment that (1) are conceived, created or developed using any equipment, supplies, facilities, trade secrets, know-how or other Confidential Information of the Company or any of its affiliates, (2) result from any work performed by Executive for the Company or any of its affiliates and&#47;or (3) otherwise relate to the Company&#8217;s or any of its affiliates&#8217; business or actual or demonstrably anticipated research or development (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:0.12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Ownership and Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive acknowledges and agrees that the Company will have exclusive title and ownership rights in and to all Company Intellectual Property.  To the extent that exclusive title and&#47;or ownership rights may not originally vest in the Company as contemplated herein, Executive hereby irrevocably assigns, transfers, conveys and delivers to the Company all right, title and interest in and to all Company Intellectual Property.  Executive acknowledges and agrees that, with respect to any Company Intellectual Property that may qualify as a Work Made For Hire as defined in 17 U.S.C. &#167; 101 or other applicable law, such Company Intellectual Property is and will be deemed a Work Made for Hire and the Company will have the sole and exclusive right to the copyright (or, in the event that any such Company Intellectual Property does not qualify as a Work Made for Hire, the copyright and all other rights thereto are automatically assigned to the Company as above).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></div><div style="margin-bottom:0.12pt;margin-top:8pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Prior Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (Prior Inventions) attached hereto is a complete list of all Inventions that Executive has, alone or jointly with others, conceived, developed created or reduced to practice prior to the commencement of Executive&#8217;s employment with the Company, that are Executive&#8217;s property, and that the Company acknowledges and agrees are excluded from the scope of this Agreement (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Prior Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  If disclosure of any such Prior Invention would cause Executive to violate any prior confidentiality agreement, Executive understands that she is not to list such Prior Inventions in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> but is only to disclose where indicated a cursory name for each such Prior Invention, a listing of each person or entity to whom it belongs, and the fact that full disclosure as to such Prior Inventions has not been made for that reason (it being understood that, if no Invention or disclosure is provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Executive hereby represents and warrants that there are no Prior Inventions).  If, in the course of Executive&#8217;s employment with the Company, Executive incorporates any Prior Invention into any Company product, process or machine or otherwise uses any Prior Invention, Executive hereby grants to the Company and its affiliates a worldwide, non-exclusive, irrevocable, perpetual, fully paid-up and royalty-free license (with rights to sublicense through multiple tiers of sublicensees) to use, reproduce, modify, make derivative works of, publicly perform, publicly display, make, have made, sell, offer for sale, import and otherwise exploit such Prior Invention for any purpose.</font></div><div style="margin-bottom:0.12pt;margin-top:8pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Assi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">nable Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If Executive is an employee whose principal work location is in California, Illinois, Kansas, Minnesota or Washington State, the provisions regarding Executive&#8217;s assignment of Company Intellectual Property to the Company in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 16(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof do not apply to certain Inventions (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Assi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">nable Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) as specified in the statutory code of the applicable state.  Executive acknowledges having received and reviewed notification regarding such Non-Assignable Inventions pursuant to such states&#8217; codes.</font></div><div style="margin-bottom:0.12pt;margin-top:8pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver of Moral Ri</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">hts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  To the extent that Executive may do so under applicable law, Executive hereby irrevocably waives and agrees never to assert any Moral Rights that Executive may have in or with respect to any Company Intellectual Property, even after termination of any work on behalf of the Company or its affiliates.  As used in this Agreement, &#8220;Moral Rig</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">hts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any rights to claim authorship of a work, to object to or prevent the modification or destruction of a work, or to withdraw from circulation or control the publication or distribution of a work, and any similar right, existing under any applicable law of any jurisdiction, regardless of whether or not such right is denominated or generally referred to as a &#8220;moral right.&#8221;</font></div><div style="margin-bottom:0.12pt;margin-top:8pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Executive shall give the Company and its affiliates all reasonable assistance and execute all documents necessary to assist with enabling the Company and its affiliates to prosecute, perfect, register, record, enforce and defend any of their rights in any Company Intellectual Property and Confidential Information.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall survive the termination of the Employment Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Miscellaneous.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">This Agreement shall be binding upon and shall inure to the benefit of the Company, its successors and permitted assigns.  The Company may not assign or delegate any rights or obligations hereunder except to a successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and&#47;or assets of the Company, as applicable.  Except for purposes of determining the occurrence of a Change in Control, the term &#8220;the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; as used herein shall mean a corporation or other entity acquiring all or substantially all the assets and business of the Company, as the case may be, (including this Agreement) whether by operation of law or otherwise.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Neither this Agreement nor any right or interest hereunder shall be assignable or transferable by Executive, Executive&#8217;s beneficiaries or legal representatives, except by will or by the, laws of descent and distribution.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">This Agreement shall inure to the benefit of and be enforceable by Executive&#8217;s legal personal representatives.</font></div><div style="margin-bottom:8pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For the purposes of this Agreement, notices and all other communications provided for in the Agreement (including the Notice of Termination) shall be in writing and shall be deemed to have been duly given when personally delivered or sent by overnight courier, addressed to the respective addresses last given by each party to each other party&#59; p</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">rovided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that all notices to the Company shall be directed to the attention of the General Counsel of the Company.  All notices and communications shall be deemed to have been received on the date of delivery thereof or on the third business day after the mailing thereof, except that notice of change of address shall be effective only upon receipt.</font></div><div style="margin-bottom:8pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnity Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company agrees to indemnify and hold Executive harmless to the fullest extent permitted by applicable law for actions taken as a director or officer of the Company, as in effect at the time of the subject act or omission.  In connection therewith, Executive shall be entitled to the protection of any insurance policies which the Company elects to maintain generally for the benefit of the Company&#8217;s directors and officers, against all costs, charges and expenses whatsoever incurred or sustained by Executive in connection with any action, suit or proceeding to which she may be made a party by reason of her being or having been a director, officer or employee of the Company.  This provision shall survive any termination of the Employment Term.</font></div><div style="margin-bottom:8pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Withholdin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">g.  The Company shall be entitled to withhold the amount, if any, of all taxes of any applicable jurisdiction required to be withheld by an employer with respect to any amount paid to Executive hereunder.  The Company, in its sole and absolute discretion, shall make all determinations as to whether it is obligated to withhold any taxes hereunder and the amount hereof.</font></div><div style="margin-bottom:8pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Release of Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The termination benefits described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, which exceed Executive&#8217;s minimum applicable entitlements pursuant to the ESA shall be conditioned on Executive delivering to the Company a signed release of claims acceptable to the Company within seven (7) days following Executive&#8217;s Termination Date&#59; provided, however, that Executive shall not be required to release any rights Executive may have to be indemnified by the Company under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof.  Notwithstanding any provision of this Agreement to the contrary, in no event shall the timing of Executive&#8217;s execution of the release, directly or indirectly, result in Executive designating the calendar year of payment, and, to the extent required by Section 409A, if a payment that is subject to execution of the release could be made in more than one taxable year, payment shall be made in the later taxable year.  Where applicable, references to Executive in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall refer to Executive&#8217;s representative or estate.</font></div><div style="margin-bottom:8pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Modification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  No provision of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing and signed by Executive and the Company.  No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or provision of this Agreement to be performed by the other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time.  No agreement or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by any party which are not expressly set forth in this Agreement.</font></div><div style="margin-bottom:8pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If any legally actionable dispute arises under this Agreement or otherwise which cannot be resolved by mutual discussion between the parties, then the Company and Executive each agree to resolve that dispute by binding arbitration before an arbitrator experienced in employment law.  Said arbitration will be conducted in accordance with the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></div><div style="margin-bottom:8pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">rules applicable to employment disputes of the Judicial Arbitration and Mediation Services (&#8220;JAMS&#8221;) and the law applicable to the claim.  The parties shall have 30 calendar days after notice of such arbitration has been given to attempt to agree on the selection of an arbitrator from JAMS.  In the event the parties are unable to agree in such time, JAMS will provide a list of five (5) available arbitrators and an arbitrator will be selected from such five member panel provided by JAMS by the parties alternately striking out one name of a potential arbitrator until only one name remains.  The party entitled to strike an arbitrator first shall be selected by a toss of a coin.  The parties agree that this agreement to arbitrate includes any such disputes that the Company may have against Executive, or Executive may have against the Company and&#47;or its related entities and&#47;or employees, arising out of or relating to this Agreement, or Executive&#8217;s employment or Executive&#8217;s termination, including any claims of discrimination or harassment in violation of applicable law and any other aspect of Executive&#8217;s compensation, employment, or Executive&#8217;s termination.  The parties further agree that arbitration as provided for in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> is the exclusive and binding remedy for any such dispute and will be used instead of any court action, which is hereby expressly waived, except for any request by any party for temporary, preliminary or permanent injunctive relief pending arbitration in accordance with applicable law or for breaches by either party of such party&#8217;s obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 12,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">16 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">hereof, as applicable, or an administrative claim with an administrative agency&#59; and (ii) any dispute where the subject matter of such dispute is not capable of being the subject of arbitration under applicable law. Without limiting the generality of the forgoing clause (ii), nothing in this section prevents you from making a report to or filing a claim, application or charge with the applicable governmental or administrative agency or tribunal, including, as applicable, the applicable Ministry of Labour, human rights commission or tribunal, and labour relations board (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Administrative Agencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) if the terms of applicable legislation entitles Executive to do so and precludes exclusive pre-dispute recourse to arbitration. For the avoidance of any doubt, Administrative Agencies do not include provincial or federal courts. This section also does not prevent Administrative Agencies from adjudicating claims and awarding remedies based on those claims, even if the claims would otherwise be covered by this section. The Company will not retaliate against Executive for filing a claim with an administrative agency or for exercising rights in respect of any matter before any Administrative Agency. The parties agree that the arbitration provided herein shall be conducted in or around Toronto, Ontario, unless otherwise mutually agreed.  The Company shall pay the cost of any arbitration brought pursuant to this paragraph, excluding, however, the cost of representation of Executive unless such cost is awarded in accordance with law or otherwise awarded by the arbitrators.  Except as otherwise provided above, the arbitrator may award legal fees to the prevailing party in her sole discretion, provided that the percentage of fees so awarded shall not exceed 1% of the net worth of the paying party (i.e., the Company or Executive).  Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> hereof, except as may be required by law, neither party nor an arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written consent of both parties.</font></div><div style="margin-bottom:8pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Effect of Other Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Anything herein to the contrary notwithstanding, the terms of this Agreement shall be modified to the extent required to meet the provisions of the Sarbanes-Oxley Act of 2002, Section 409A, the Dodd-Frank Wall Street Reform and Consumer Protection Act or other federal law applicable to the employment arrangements between Executive and the Company.  Any delay in providing benefits or payments or any failure to provide a benefit or payment shall not in and of itself constitute a breach of this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the Company shall provide economically equivalent payments or benefits to Executive to the extent permitted by law.  Any request or requirement that Executive repay compensation that is required under the first sentence shall not in and of itself constitute a breach of this Agreement.</font></div><div style="margin-bottom:8pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Interpretation &#38; ESA Failsafe</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">It is the intention of Executive and the Company to comply with the ESA. Accordingly, this Agreement shall&#58; (i) not be interpreted as in any way waiving or contracting out of the ESA&#59; and (ii) be interpreted to achieve compliance with the ESA. This Agreement contains Executive and the Company&#8217;s mutual understanding and there shall be no presumption of strict interpretation against either party.  It is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></div><div style="margin-bottom:8pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">understood and agreed that all provisions of this Agreement are subject to all applicable minimum requirements under the ESA.  In the event that the ESA provides for superior entitlements upon termination of employment or otherwise (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Statutory Entitlements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) than provided for under this Agreement, the Company shall provide Executive with her Statutory Entitlements in substitution for her rights under this Agreement.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Governin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"> Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by and construed and enforced in accordance with the laws of the Province of Ontario and the federal laws of Canada applicable therein.</font></div><div style="margin-bottom:8pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">No Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  As a condition to the effectiveness of this Agreement, Executive represents and warrants to the Company that she is not a party to or otherwise bound by any agreement or arrangement (including, without limitation, any license, covenant, or commitment of any nature), or subject to any judgment, decree, or order of any court or administrative agency, that would conflict with or will be in conflict with or in any way preclude, limit or inhibit Executive&#8217;s ability to execute this Agreement or to carry out her duties and responsibilities hereunder.  In the event that the Company determines that Executive&#8217;s duties hereunder may conflict with an agreement or arrangement to which Executive is bound, Executive shall be required to cease engaging in any such activities, duties or responsibilities (including providing supervisory services over certain subsets of the Company&#8217;s business operations) and the Company will take steps to restrict Executive&#8217;s access to, and participation in, any such activities.  Any actions taken by the Company under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> to restrict or limit Executive&#8217;s access to information or provision of services shall not constitute Good Reason for purposes of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7(e) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">hereof.</font></div><div style="margin-bottom:8pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(l)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Severabilit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">y.  The provisions of this Agreement shall be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement constitutes the entire agreement between the parties hereto and supersedes all prior agreements, if any, understandings and arrangements, oral or written, between the parties hereto with respect to the subject matter hereof, including, without limitation, any term sheets or other similar presentations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement.  Signatures transmitted via facsimile or PDF will be deemed the equivalent of originals.</font></div><div style="margin-bottom:24.2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Remainder of page left intentionally blank</font></div><div style="margin-bottom:24pt;padding-left:5.95pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have executed this Employment Agreement as of the day and year first above written, to be effective as of the Initial Commencement Date.</font></div><div style="margin-bottom:24pt;margin-top:30pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BAUSCH HEALTH COMPANIES INC.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Joseph C. Papa  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">                                                     </font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Joseph C. Papa</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Chairman of the Board and Chief Executive Officer </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></div><div style="margin-bottom:24pt;margin-top:30pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXECUTIVE</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Seana Carson                                                         &#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;  Seana Carson</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="i74304cca20b5459b9f39f34f3b1036bc_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT A<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PRIOR INVENTIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;The following is a complete list of all Prior Inventions (as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 16(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> of the attached Employment Agreement)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;Due to a prior confidentiality agreement, Executive cannot complete the disclosure under Section 1 above with respect to the Prior Inventions generally listed below, the duty of confidentiality with respect to which Executive owes to the following party(ies)&#58;</font></div><div><font><br></font></div><div style="padding-left:7.45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Prior Invention</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Party(ies)</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Relationship</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>4
<FILENAME>exhibit109spurremploymenta.htm
<DESCRIPTION>EX-10.9
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id398c95c8bbf4a44a9c5307c4910246f_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.9</font></div></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:232%">BAUSCH HEALTH COMPANIES INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EMPLOYMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THIS EMPLOYMENT AGREEMENT (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is hereby entered into as of May 28, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), retroactive to May 27, 2020, by and between Bausch Health Companies Inc., a Canadian corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and Robert Spurr, an individual (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (hereinafter collectively referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">the parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Where the context requires, references to the Company shall include the Company&#8217;s subsidiaries and affiliates. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Company desires to employ Executive for the period provided in this Agreement, and Executive desires to accept such employment with the Company, subject to the terms and conditions set forth herein&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the respective agreements of the parties contained herein, it is agreed as follows&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Commencement Date&#59; Term&#59; Effect on Other Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The employment term (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of Executive&#8217;s employment under this Agreement shall be for the period commencing on May 27, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and ending on the third (3rd) anniversary of the Commencement Date.  Thereafter, the Employment Term shall extend automatically for consecutive periods of one year unless either party provides notice of non-renewal not less than ninety (90) days prior to the end of the Employment Term as then in effect. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Employment Term&#58;  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Executive shall be employed as President, Salix of the Company.  Executive shall report directly to the Chief Executive Officer of the Company.  Executive shall perform the duties, undertake the responsibilities and exercise the authority customarily performed, undertaken and exercised by persons situated in similar executive capacities. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Excluding periods of vacation and sick leave to which Executive is entitled and other service outside of the Company contemplated in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Executive shall devote Executive&#8217;s full professional time and attention to the business and affairs of the Company to discharge the responsibilities of Executive hereunder.  Prior to joining or agreeing to serve on corporate, civil or charitable boards or committees, Executive shall obtain approval of the Chief Executive Officer. Executive may manage personal and family investments, participate in industry organizations and deliver lectures at educational institutions, so long as such activities do not interfere with the performance of Executive&#8217;s responsibilities hereunder.  It is understood that, during Executive&#8217;s employment by the Company, Executive shall not engage in any activities that constitute a conflict of interest with the interests of the Company or its direct and indirect subsidiaries, as outlined in the Company&#8217;s conflict of interest policies for employees and executives in effect from time to time.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> Page B-1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Executive shall be subject to and shall abide by each of the personnel policies applicable to senior executives, including but not limited to any policy restricting pledging and hedging investments in Company equity by Company executives, any policy the Company adopts regarding the recovery of incentive compensation (sometimes referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clawback</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and any additional clawback provisions as required by law and applicable listing rules.  This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall survive the termination of the Employment Term.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof, Executive&#8217;s employment with the Company is &#8220;at will,&#8221; such that each of Executive or the Company has the option to terminate Executive&#8217;s employment at any time, with or without advance notice, and with or without Cause or with or without Good Reason.  This Agreement does not constitute an express or implied agreement of continuing or long term employment.  The at-will nature of Executive&#8217;s employment can be altered only by a written agreement specifying the altered status of Executive&#8217;s employment.  Such written agreement must be signed by both Executive and the Chief Executive Officer of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Annual Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Employment Term, Executive shall be paid an annual base salary of $600,000 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Base Salary shall be payable in accordance with the Company&#8217;s regular payroll practices as then in effect.  During the Employment Term, the Base Salary will be reviewed annually and is subject to adjustment at the discretion of the Talent and Compensation Committee of the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Performance Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Subject to the terms of the Company&#8217;s annual incentive cash bonus program as in effect from time to time and the provisions hereof, for each fiscal year of the Company ending during the Employment Term (commencing with the 2020 fiscal year), Executive shall be eligible to receive a target annual cash bonus of 80% of Base Salary (such target bonus, as may hereafter be increased, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Target Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) with the opportunity to receive a maximum annual cash bonus of 200% of the Target Bonus. Annual bonuses, if any, will be payable in the Company&#8217;s discretion and in accordance with the Company&#8217;s customary practices applicable to bonuses paid to similarly situated executives of the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Additional Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Ongoing Grants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive will be eligible for consideration for future equity grants during the Employment Term in the sole discretion of the Chief Executive Officer of the Company and the Committee. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Share Ownership Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive agrees to comply with any share ownership requirements adopted by the Company applicable to Executive, which shall be on the same terms as similarly situated executives of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Other Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Employment Term&#58; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Employee Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive shall be entitled to participate in all employee benefit plans, practices and programs maintained by the Company, and made available to employees generally (taking into account jurisdictional differences), including, without limitation, all pension, retirement, profit sharing, savings, medical, hospitalization, disability, dental, life or travel accident insurance benefit plans in accordance with the terms of the plans as in effect from time to time.  Executive&#8217;s participation in such plans, practices and programs shall be on the same basis and terms as are applicable to similarly situated executives of the Company.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Business Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon submission of proper invoices in accordance with, and subject to, the Company&#8217;s normal policies and procedures, Executive shall be entitled to receive prompt reimbursement of all reasonable out-of-pocket business, entertainment and travel expenses incurred by him in connection with the performance of Executive&#8217;s duties hereunder.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Vacation and Sick Leave</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive shall be entitled, without loss of pay, to absent himself voluntarily from the performance of Executive&#8217;s employment under this Agreement, pursuant to the following&#58; </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Executive shall be entitled to annual vacation in accordance with and subject to the policies as periodically established for similarly situated executives of the Company&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Executive shall be entitled to sick leave (without loss of pay) in accordance with the Company&#8217;s policies as in effect from time to time.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive&#8217;s employment with the Company hereunder may be terminated under the circumstances set forth below&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that notwithstanding anything contained herein to the contrary, to the extent required by Section 409A (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Executive shall not be considered to have terminated employment with the Company for purposes of this Agreement until he would be considered to have incurred a &#8220;separation from service&#8221; from the Company within the meaning of Section 409A.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive&#8217;s employment shall be terminated as of the date of Executive&#8217;s death and Executive&#8217;s beneficiaries shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may terminate Executive&#8217;s employment, on written notice to Executive after having established Executive&#8217;s Disability and while Executive remains disabled, and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning assigned to such term in the Plan.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may terminate Executive&#8217;s employment for Cause effective as of the date of the Notice of Termination (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof) and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, for purposes of this Agreement&#58; (1) conviction of any felony (other than one related to a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">vehicular offense) or other criminal act involving fraud&#59; (2) willful misconduct that results in a material economic detriment to the Company&#59; (3) material violation of Company policies and directives, which is not cured after written notice and an opportunity for cure&#59; (4) continued refusal by Executive to perform Executive&#8217;s duties after written notice identifying the deficiencies and an opportunity for cure&#59; and (5) a material violation by Executive of any of the covenants to the Company set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof.  No action or inaction shall be deemed willful if (x) not demonstrably willful and (y) taken, or not taken, by Executive in good faith and with the understanding that such action, or inaction, was not adverse to the best interests of the Company.  References in this paragraph to the Company shall also include direct and indirect subsidiaries of the Company, and materiality shall be measured based on the action or inaction and the impact upon the Company taken as a whole.  Without limiting the other rights of the Company under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Company may suspend Executive, without pay, upon Executive&#8217;s indictment for the commission of a felony as described under clause (1) above.  Such suspension may remain effective until such time as the indictment is either dismissed or a verdict of not guilty has been entered.  If such indictment does not result in a conviction, as soon as practicable following such dismissal or verdict, the Company shall pay Executive the base salary and target bonus amount that Executive would have received for the period during which Executive was suspended without pay (with interest from the date such amounts would otherwise have been paid at the short-term applicable federal rate, compounded semi-annually, as determined under Section 1274 of the Code for the month in which payment would have been made but for the delay) and Executive will receive vesting credit for purposes of Executive&#8217;s outstanding equity awards.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Without Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may terminate Executive&#8217;s employment without Cause.  The Company shall deliver to Executive a Notice of Termination (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof) not less than thirty (30) days prior to the termination of Executive&#8217;s employment without Cause and the Company shall have the option of terminating Executive&#8217;s duties and responsibilities prior to the expiration of such thirty-day notice period, and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive may terminate Executive&#8217;s employment for Good Reason (as defined below) by delivering to the Company a Notice of Termination not less than thirty (30) days prior to the termination of Executive&#8217;s employment for Good Reason and no more than one hundred fifty (150) days following the initial existence of the event or condition constituting Good Reason.  The Company shall have the option of terminating Executive&#8217;s duties and responsibilities prior to the expiration of such thirty (30) day notice, and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the occurrence of any of the events or conditions described in clauses (1) through (4) below which are not cured by the Company (if susceptible to cure by the Company) within thirty (30) days after the Company has received written notice from Executive within ninety (90) days of the initial existence of the event or condition constituting Good Reason specifying the particular events or conditions </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which constitute Good Reason and the specific cure requested by Executive.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Diminution of Responsibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  (A) Any material reduction in Executive&#8217;s duties or responsibilities as President, Salix, as in effect immediately prior thereto (other than a reduction where Executive is provided with other duties or responsibilities substantially comparable to Executive&#8217;s overall duties and responsibilities prior to such reduction) or (B) removal of Executive from the position of President, Salix  of the Company, except, in each case, in connection with the termination of Executive&#8217;s employment for Disability, Cause, as a result of Executive&#8217;s death or by Executive other than for Good Reason&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Compensation Reduction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any reduction in Executive&#8217;s Base Salary or Target Bonus opportunity which is not comparable to reductions in the base salary or target bonus opportunity of other similarly situated executives of the Company&#59; </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Relocation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any relocation of Executive&#8217;s primary place of business that results in an increase of Executive&#8217;s one-way commute by fifty (50) miles or more&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the Company&#8217;s request that Executive travel from time to time on behalf of the Company shall not constitute Good Reason&#59; or </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Company Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any other material breach by the Company of any material provision of this Agreement.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Without Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive may voluntarily terminate Executive&#8217;s employment without Good Reason by delivering to the Company a Notice of Termination not less than thirty (30) days prior to the termination of Executive&#8217;s employment and the Company shall have the option of terminating Executive&#8217;s duties and responsibilities prior to the expiration of such thirty (30) day notice period, and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof through the last day of such notice period.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Notice of Non-Renewal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive&#8217;s employment shall terminate upon expiration of the Employment Term as then in effect following timely provision by either party of notice of non-renewal in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof, and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Notice of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any purported termination by the Company or by Executive shall be communicated by written Notice of Termination to the other party hereto.  For purposes of this Agreement, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a notice which indicates a date of termination (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the specific termination provision in this Agreement relied upon and sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive&#8217;s employment under the provision so indicated.  For purposes of this Agreement, no such purported termination of Executive&#8217;s employment hereunder shall be effective without such Notice of Termination (unless waived by the party entitled to receive such notice).  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Compensation Upon Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon termination of Executive&#8217;s employment during the Employment Term, Executive shall be entitled to the following benefits&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that any such benefits to which Executive is hereunder entitled shall be offset by those benefits that Executive receives, if any, under applicable law or otherwise&#58; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination by the Company for Cause or by Executive Without Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Executive&#8217;s employment is terminated by the Company for Cause or by Executive without Good Reason, the Company shall pay Executive all amounts earned or accrued hereunder through the Termination Date, including&#58; </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">reimbursement for reasonable and necessary expenses incurred by Executive on behalf of the Company for the period ending on the Termination Date&#59; </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">any previous compensation which Executive has previously deferred (including any interest earned or credited thereon), in accordance with the terms and conditions of the applicable deferred compensation plans or arrangements then in effect&#59; </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">equity and incentive awards, to the extent previously vested, shall be paid or delivered to Executive in accordance with the terms of such awards&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">any amount or benefit as provided under any benefit plan or program (the foregoing items in clauses (1) through (4) being collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Accrued Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Termination by the Company for Disability or Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Executive&#8217;s employment is terminated by the Company for Disability or by reason of Executive&#8217;s death, then, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof, Executive shall be entitled to the benefits provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Company shall pay Executive (or Executive&#8217;s beneficiaries, as applicable) the Accrued Compensation&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Company shall pay to Executive (or Executive&#8217;s beneficiaries, as applicable) within sixty (60) days following the Termination Date, any bonus earned but unpaid in respect of any fiscal year preceding the Termination Date&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Each unvested equity award held by Executive at the time of termination shall be governed by the terms of the applicable award agreement. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination by the Company Without Cause or by Executive for Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Executive&#8217;s employment by the Company shall be terminated by the Company without Cause or by Executive for Good Reason, then, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof, Executive shall be entitled to the benefits provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Company shall pay to Executive any Accrued Compensation&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Company shall pay to Executive any bonus earned but unpaid in respect of any fiscal year preceding the Termination Date within sixty (60) days following the Termination Date&#59; </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Company shall pay to Executive a bonus or incentive award in respect of the fiscal year in which Executive&#8217;s Termination Date occurs in an amount equal to the product of (A) the lesser of (x) the bonus or incentive award that Executive would have been entitled to receive based on actual achievement against the stated performance objectives and (y) Executive&#8217;s Target Bonus and (B) a fraction (x) the numerator of which is the number of days in such fiscal year through the Termination Date and (y) the denominator of which is 365 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that if such termination occurs in contemplation of a Change in Control (as defined in the Plan) or within twelve months following a Change in Control, then in the forgoing calculation, the amount under (A) above shall be equal to Executive&#8217;s Target Bonus).  Any bonus or incentive award payable to Executive under this clause (3) shall be paid in a lump sum payment by March 15 of the year following the fiscal year in which Executive&#8217;s Termination Date occurs&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Company shall pay Executive as severance pay, in lieu of any further compensation (except as provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) for the periods subsequent to the Termination Date, an amount in cash, which amount shall be payable in a lump sum payment within sixty (60) days following such termination (subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof), equal to one (1) times (or, if such termination occurs in contemplation of a Change in Control or within twelve months following a Change in Control, two (2) times) the sum of Executive&#8217;s Base Salary and Target Bonus, in each case, as in effect immediately prior to termination and without regard to any reduction thereto which constitutes Good Reason&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Each unvested equity award held by Executive at the time of termination shall be governed by the terms of the applicable award agreement&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Company shall provide Executive with continued coverage through the first anniversary of the Termination Date under any health, medical, dental or vision program or policy in which Executive (and Executive&#8217;s dependents, as applicable) participated in as of the time of the Termination Date on terms no less favorable to Executive and Executive&#8217;s dependents than those applicable to actively employed senior executives of the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that Executive shall be solely responsible for any taxes incurred in respect of such coverage&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the Company may modify the continuation coverage contemplated by this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(c)(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (including by providing a lump-sum cash payment equal to the value for Executive of the continuation coverage provided herein) to the extent reasonably necessary to avoid the imposition of any excise taxes on the Company for failure to comply with the nondiscrimination requirements of the Patient Protection and Affordable Care Act of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2010, as amended, and&#47;or the Health Care and Education Reconciliation Act of 2010, as amended (to the extent applicable).</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Expiration of Employment Term Upon Notice of Non-Renewal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Executive&#8217;s employment terminates upon expiration of the Employment Term as then in effect following timely provision by either party of notice of non-renewal in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof, then, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof, Executive shall be entitled to the benefits provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Company shall pay to Executive any Accrued Compensation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Each unvested equity award held by Executive at the time of termination shall be governed by the terms of the applicable award agreement.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Executive shall not be required to mitigate the amount of any payment provided for under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> by seeking other employment or otherwise and no such payment shall be offset or reduced by the amount of any compensation or benefits provided to Executive in any subsequent employment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The parties intend for the payments and benefits under this Agreement to be exempt from Section 409A or, if not so exempt, to be paid or provided in a manner which complies with the requirements of such section, and intend that this Agreement shall be construed and administered in accordance with such intention.  If any payments or benefits due to Executive hereunder would cause the application of an accelerated or additional tax under Section 409A, such payments or benefits shall be restructured in a mutually agreed upon manner that to the extent possible preserves the economic benefit and original intent thereof but does not cause such an accelerated or additional tax.  For purposes of the limitations on nonqualified deferred compensation under Section 409A, each payment of compensation under this Agreement shall be treated as a separate payment of compensation.  Without limiting the foregoing and notwithstanding anything contained herein to the contrary, to the extent required in order to avoid accelerated taxation and&#47;or tax penalties under Section 409A, amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to this Agreement during the six-month period immediately following Executive&#8217;s separation from service shall instead be paid on the first business day after the date that is six months following Executive&#8217;s Termination Date (or death, if earlier).  Notwithstanding anything to the contrary in this Agreement, all (A) reimbursements and (B) in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A, including, where applicable, the requirement that (x) the amount of expenses eligible for reimbursement, or in kind benefits provided, during a calendar year may not affect the expenses eligible for reimbursement, or in kind benefits to be provided, in any other calendar year&#59; (y) the reimbursement of an eligible expense will be made no later than the last day of the calendar year following the year in which the expense is incurred&#59; and (z) the right to reimbursement or in kind benefits is not subject to liquidation or exchange for another benefit.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Employee Protection</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Nothing in this Agreement or otherwise limits Executive&#8217;s ability to communicate directly with and provide information, including documents, not otherwise protected from disclosure by any applicable law or privilege to the Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or any other federal, state or local governmental agency or commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Government Agency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) regarding possible legal violations, without disclosure to the Company.  The Company may not retaliate against Executive for any of these activities, and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nothing in this Agreement or otherwise requires Executive to waive any monetary award or other payment that Executive might become entitled to from the SEC or any other Government Agency. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Records and Confidential Data.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Ownership&#59; Recognition of Company&#8217;s Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive acknowledges that in connection with the performance of Executive&#8217;s duties during the Employment Term, the Company will make available to Executive, or Executive will have access to, certain Confidential Information (as defined below) of the Company and its affiliates. Executive acknowledges and agrees that any and all Confidential Information disclosed to, or learned or obtained by, Executive during the course of Executive&#8217;s employment by the Company or any of its affiliates or otherwise, whether developed by Executive alone or in conjunction with others or otherwise, shall be and is the sole and exclusive property of the Company or the affiliate of the Company, as applicable, that is Executive&#8217;s employer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). No license or other right to any Confidential Information is granted to Executive under this Agreement.  To the extent that Executive acquires any right, title or interest in or to any Confidential Information, Executive hereby assigns, transfers, conveys and delivers to the Employer all such right, title and interest in and to such Confidential Information.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive (A)&#160;will keep all Confidential Information strictly confidential, (B) will not use Confidential Information in any manner which is detrimental to the Company or its affiliates, (C) will not use Confidential Information other than in connection with the discharge of Executive&#8217;s duties to the Company and its affiliates, (D) will safeguard any and all Confidential Information from unauthorized disclosure, and (E)&#160;will not disclose, publish, use, transfer or otherwise disseminate any Confidential Information to any person or entity without the Employer&#8217;s express prior written consent, except as may be necessary to perform Executive&#8217;s duties as an employee of the Company or its affiliates for the benefit of the Company or its affiliates. Executive may, however, disclose Confidential Information to the extent it is in response to a valid order of a court or other governmental authority or to otherwise comply with applicable law&#59; provided that, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Executive shall first give notice to the Employer and reasonably cooperate with the Employer to obtain a protective order or other measures preserving the confidential treatment of such Confidential Information and requiring that the information or documents so disclosed be used only for the purposes for which the order was issued or is otherwise required by applicable law. For the avoidance of doubt, nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall prevent Executive from exercising any legally protected whistleblower rights (including under Rule 21F under the Exchange Act) as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Disposition of Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Following the termination of Executive&#8217;s employment or upon the Company&#8217;s request, Executive will return to the Company all copies of any and all Confidential Information in Executive&#8217;s custody, possession or control (including all copies of any analyses, compilations, studies or other documents prepared by Executive or for Executive&#8217;s use containing or reflecting any Confidential Information). Alternatively, with the Company&#8217;s prior written consent, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive may destroy such Confidential Information. Within five (5) business days of the termination of Executive&#8217;s employment or such request by the Company, Executive shall deliver to the Company a document certifying that such written Confidential Information has been returned or destroyed in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For the purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all non-public, proprietary or other confidential information of the Company or its affiliates disclosed to Executive, to which Executive has access, or of which Executive otherwise becomes aware, in each case whether in oral, written, graphic or machine readable form, including, without limitation, (A) know-how, trade secrets, inventions, discoveries, concepts, information, works, materials, processes, methods, data, software, programs, apparatus, designs and the like, and any other intellectual property the value of which is contingent upon maintaining the confidentiality thereof, (B) information regarding the business of the Company or its affiliates, including its products, services, budgets, contracts, reports, investigations, experiments, research, work in progress, drawings, designs, plans, proposals, codes, marketing and sales programs, client lists, client mailing lists, supplier lists, financial projections, cost summaries, pricing formulae, marketing studies relating to prospective business opportunities, and all other concepts, ideas, materials, or information prepared or performed for or by the Company or its affiliates, (C) information regarding the skills and compensation of the employees, contractors, and any other service providers of the Company or its affiliates, (D) the existence of any business discussions, negotiations, or agreements between the Company or its affiliates and any third party, (E) all documents and other work product generated by you which contain, comment upon, or relate in any way to any information disclosed by the Company or its affiliates, (F) all third-party information held in confidence by the Company or its affiliates, and (G) the terms and conditions of this Agreement. For purposes of this Agreement, the Confidential Information shall not include and Executive&#8217;s obligation shall not extend to (A) information which is generally available to the public and (B) information obtained by Executive other than pursuant to or in connection with Executive&#8217;s employment</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Defend Trade Secrets Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Pursuant to Section&#160;7 of the Defend Trade Secrets Act of 2016 (which added 18 U.S.C.  &#167; 1833(b)), the Company and Executive acknowledge and agree that Executive shall not have criminal or civil liability under any federal or state trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney and (ii) solely for the purpose of reporting or investigating a suspected violation of law&#59; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.  In addition and without limiting the preceding sentence, if Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose the trade secret to Executive&#8217;s attorney and may use the trade secret information in the court proceeding, if Executive (X) files any document containing the trade secret under seal and (Y) does not disclose the trade secret, except pursuant to court order.  Nothing in this Agreement is intended to conflict </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with 18 U.S.C. &#167; 1833(b) or create liability for disclosures of trade secrets that are expressly allowed by such Section.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">Executive&#8217;s obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall survive the termination of the Employment Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Covenant Not to Solicit and Not to Compete&#59; Non-Disparagement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Covenants Not to Solicit or to Interfere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To protect the Confidential Information, Company Intellectual Property (as defined below) and other trade secrets of the Company and its affiliates, Executive agrees, during the Employment Term and for a period of twelve (12) months after Executive&#8217;s cessation of employment with the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restricted Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), not to solicit, hire or participate in or assist in any way in the solicitation or hire of any employees of the Company or any of its subsidiaries (or any person who was an employee of the Company or any of its subsidiaries during the six-month period preceding such action).  For purposes of this covenant, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">solicit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means directly or indirectly influencing or attempting to influence employees of the Company or any of its subsidiaries to become employed with any other person, partnership, firm, corporation or other entity.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, to protect the Confidential Information, Company Intellectual Property and other trade secrets of the Company and its affiliates, Executive agrees, during the Employment Term and the Restricted Period, not to (x) solicit any client or customer to receive services or to purchase any good or services in competition with those provided by the Company or any of its subsidiaries or (y) interfere or attempt to interfere in any material respect with the relationship between the Company or any of its subsidiaries on one hand and any client, customer, supplier, investor, financing source or capital market intermediary on the other hand.  For purposes of this covenant, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">solicit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means directly or indirectly influencing or attempting to influence clients or customers of the Company or any of its affiliates to accept the services or goods of any other person, partnership, firm, corporation or other entity in competition with those provided by the Company or any of its affiliates.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive agrees that the covenants contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> are reasonable and desirable to protect the Confidential Information and Company Intellectual Property of the Company and its affiliates&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that solicitation through general advertising or the provision of references shall not constitute a breach of such obligations.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Covenant Not to Compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To protect the Confidential Information, Company Intellectual Property and other trade secrets of the Company and its affiliates, Executive agrees, during the Employment Term and the Restricted Period, not to engage in Prohibited Activities (as defined below) in any country in which the Company or any of its affiliates conducts business, or plans to conduct business, during the Employment Term.  For the purposes of this Agreement, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Prohibited Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means directly or indirectly engaging as an owner, employee, partner, member, consultant or agent of any entity that derives more than 10% of its consolidated revenue from the development, manufacturing, marketing and&#47;or distribution (directly or indirectly) of branded or generic </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prescription or non-prescription pharmaceuticals or medical devices for treatments in the fields of neurology, dermatology, gastroenterology, ophthalmology or dentistry&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that Prohibited Activities shall not mean Executive&#8217;s investment in securities of a publicly-traded company equal to less than five (5%) percent of such company&#8217;s outstanding voting securities&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that, for the avoidance of doubt, Executive complies with the obligations set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 12, 13(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof.  Executive agrees that the covenants contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> are reasonable and desirable to protect the Confidential Information and Company Intellectual Property of the Company and its affiliates.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Non-Disparagement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive agrees not to make written or oral statements about the Company, its subsidiaries or affiliates, or its directors, executive officers or non-executive officer employees that are negative or disparaging, except as provided in Section 11 hereof.  The Company shall instruct its directors and executive officers to not make written or oral statements about Executive that are negative or disparaging.  Notwithstanding the foregoing, nothing in this Agreement or otherwise shall preclude Executive, the Company, its subsidiaries and affiliates, and the Company&#8217;s directors and executive officers from communicating or testifying truthfully to the extent required by law to any federal, state, provincial or local governmental agency or in response to a subpoena to testify issued by a court of competent jurisdiction.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">It is the intent and desire of Executive and the Company that the restrictive provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> be enforced to the fullest extent permissible under the laws and public policies as applied in each jurisdiction in which enforcement is sought.  If any particular provision of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be determined to be invalid or unenforceable, such covenant shall be amended, without any action on the part of either party hereto, to delete there from the portion so determined to be invalid or unenforceable, such deletion to apply only with respect to the operation of such covenant in the particular jurisdiction in which such adjudication is made.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Executive&#8217;s obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall survive the termination of the Employment Term.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Remedies for Breach of Obligations under Sections 12 or 13 hereof</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive acknowledges that the Company will suffer irreparable injury, not readily susceptible of valuation in monetary damages, if Executive breaches Executive&#8217;s obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or 13 hereof.  Accordingly, Executive agrees that the Company will be entitled, in addition to any other available remedies, to obtain injunctive relief against any breach or prospective breach by Executive of Executive&#8217;s obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or 13 hereof.  Executive agrees that process in any or all of those actions or proceedings may be served by registered mail, addressed to the last address provided by Executive to the Company, or in any other manner authorized by law.  This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall survive the termination of the Employment Term. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Following Executive&#8217;s termination of employment for any reason, except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof, Executive agrees to make himself reasonably available to cooperate with the Company and its affiliates in matters that materially concern&#58; (i) requests for information about the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">services Executive provided to the Company and its affiliates during Executive&#8217;s employment with the Company and its affiliates, (ii) the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company and its affiliates which relate to events or occurrences that transpired while Executive was employed the Company and its affiliates and as to which Executive has, or would reasonably be expected to have, personal experience, knowledge or information or (iii) any investigation or review by any federal, state or local regulatory, quasi-regulatory or self-governing authority (including, without limitation, the US Department of Justice, the U.S. Federal Trade Commission or the SEC) as any such investigation or review relates to events or occurrences that transpired while Executive was employed by the Company and its affiliates.  Executive&#8217;s cooperation shall include&#58; (A) making himself reasonably available to meet and speak with officers or employees of the Company, the Company&#8217;s counsel or any third-parties at the request of the Company at times and locations to be determined by the Company reasonably and in good faith, taking into account the Company&#8217;s business and Executive&#8217;s business and personal needs (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and (B) giving accurate and truthful information at any interviews and accurate and truthful testimony in any legal proceedings or actions (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Witness Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be construed to limit in any way any rights Executive may have at applicable law not to provide testimony with regard to specific matters.  Unless required by law or legal process, Executive will not knowingly or intentionally furnish information to or cooperate with any non-governmental entity (other than the Company) in connection with any potential or pending proceeding or legal action involving matters arising during Executive&#8217;s employment with the Company and its affiliates, except as provided in Section 11.  In addition, at the request of the Company, Executive shall be required to complete a directors&#8217; and officers&#8217; questionnaire to facilitate the Company&#8217;s preparation and filing of its proxy statement and periodic reports with the SEC.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Executive shall not be entitled to any payments in addition to those otherwise set forth in this Agreement in respect of any Company Cooperation or Witness Cooperation, regardless of when provided.  The Company will reimburse Executive for any reasonable, out-of-pocket travel, hotel and meal expenses incurred in connection with Executive&#8217;s performance of obligations pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for which Executive has obtained prior approval from the Company.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Nothing in this Agreement or any other agreement by and between the Parties is intended to or shall preclude or in any way limit or restrict Executive from providing accurate and truthful testimony or information to any governmental agency.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall survive the termination of the Employment Term.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Disclosure and Ownership of Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Company Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive acknowledges and agrees that any intellectual property, including, without limitation, works, materials, inventions, invention disclosures, invention registrations, patent rights, trademarks, service marks, trade names, trade dress, logos, domain names, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">copyrights, design rights, mask works, software, apparatus, technology, data, trade secrets, know-how and all other intellectual property and proprietary rights recognized by any applicable law of any jurisdiction, that Executive creates, discovers, conceives, reduces to practice, develops or acquires during the course of Executive&#8217;s employment, either alone or jointly with others, (A) using any equipment, supplies, facilities, trade secrets, know-how or other Confidential Information of the Company or any of its affiliates, (B) that results from any work performed for the Company or any of its affiliates and&#47;or (B) that otherwise relates to the Company&#8217;s or any of its affiliates&#8217; business or actual or demonstrably anticipated research or development (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is and shall remain the exclusive property of the <br>Employer whether registered or otherwise exploited or not.  In furtherance of the foregoing, Executive hereby assigns, transfers, conveys and delivers to the Employer Executive&#8217;s entire right, title and interest in and to any and all such Company Intellectual Property.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Work Made for Hire</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive acknowledges and agrees that, with respect to any Company Intellectual Property that may qualify as a Work Made For Hire as defined in 17 U.S.C. &#167; 101 or other applicable law, such Company Intellectual Property is and will be deemed a Work Made for Hire and the Employer will have the sole and exclusive right to the copyright (or, in the event that any such Company Intellectual Property does not qualify as a Work Made for Hire, the copyright and all other rights thereto are hereby automatically assigned to the Employer as above).</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive agrees to record all activities undertaken in the course of Executive&#8217;s employment and to disclose promptly in writing to the Employer any and all Company Intellectual Property.  Executive agrees that Executive will give the Company or any of its affiliates all reasonable assistance and execute all documents necessary to assist with enabling the Company or any of its affiliates to prosecute, perfect, register, record, enforce and defend any and all of their rights in and to any Company Intellectual Property and Confidential Information.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Non-Assignable Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Executive&#8217;s principal work location is in California, Illinois, Kansas, Minnesota or Washington State, the provisions regarding Executive&#8217;s assignment of Company Intellectual Property to the Employer in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 16(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">16(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Agreement may not apply to certain inventions (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Assignable Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) as specified in the statutory code of the applicable state.  Executive acknowledges having received notification regarding such Non-Assignable Inventions pursuant to such states&#8217; codes.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Prior Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If, in the course of Executive&#8217;s employment with the Employer, Executive uses any intellectual property that is solely or jointly owned by Executive or licensed to Executive, with the right to sub-license (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Prior Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Executive hereby grants to the Company and its affiliates a worldwide, non-exclusive, irrevocable, perpetual, fully paid-up and royalty-free license (with rights to sublicense through multiple tiers of sublicensees) to use, reproduce, modify, make derivative works of, publicly perform, publicly display, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">make, have made, sell, offer for sale, import and otherwise exploit such Prior Intellectual Property for any purpose.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Waiver of Moral Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the extent Executive may do so under applicable law, Executive hereby waives and agrees never to assert any Moral Rights that Executive may have in or with respect to any Company Intellectual Property, even after termination of any work on behalf of the Company or its affiliates. As used in this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Moral Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any rights to claim authorship of a work, to object to or prevent the modification or destruction of a work, or to withdraw from circulation or control the publication or distribution of a work, and any similar right, existing under any applicable law of any jurisdiction, regardless of whether or not such right is denominated or generally referred to as a &#8220;moral right.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall survive the termination of the Employment Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">This Agreement shall be binding upon and shall inure to the benefit of the Company, its successors and permitted assigns.  The Company may not assign or delegate any rights or obligations hereunder except to a successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and&#47;or assets of the Company, as applicable.  Except for purposes of determining the occurrence of a Change in Control, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; as used herein shall mean a corporation or other entity acquiring all or substantially all the assets and business of the Company, as the case may be, (including this Agreement) whether by operation of law or otherwise.  </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Neither this Agreement nor any right or interest hereunder shall be assignable or transferable by Executive, Executive&#8217;s beneficiaries or legal representatives, except by will or by the, laws of descent and distribution.  </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">This Agreement shall inure to the benefit of and be enforceable by Executive&#8217;s legal personal representatives.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For the purposes of this Agreement, notices and all other communications provided for in the Agreement (including the Notice of Termination) shall be in writing and shall be deemed to have been duly given when personally delivered or sent by Certified mail, return receipt requested, postage prepaid, addressed to the respective addresses last given by each party to each other party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that all notices to the Company shall be directed to the attention of the General Counsel of the Company.  All notices and communications shall be deemed to have been received on the date of delivery thereof or on the third business day after the mailing thereof, except that notice of change of address shall be effective only upon receipt.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Indemnity Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company agrees to indemnify and hold Executive harmless to the fullest extent permitted by applicable law for actions taken as a director or officer of the Company, as in effect at the time of the subject act or omission.  In connection therewith, Executive shall be entitled to the protection of any insurance policies which the Company elects to maintain generally for the benefit of the Company&#8217;s directors and officers, against all costs, charges and expenses whatsoever incurred or sustained by Executive in connection with any action, suit or proceeding to which he may be made a party by reason of Executive&#8217;s being or having been a director, officer or employee of the Company.  This provision shall survive any termination of the Employment Term.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall be entitled to withhold the amount, if any, of all taxes of any applicable jurisdiction required to be withheld by an employer with respect to any amount paid to Executive hereunder.  The Company, in its sole and absolute discretion, shall make all determinations as to whether it is obligated to withhold any taxes hereunder and the amount hereof.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Release of Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The termination benefits described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 9(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">9(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">9(d)(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof shall be conditioned on Executive delivering to the Company, and failing to revoke, a signed release of claims acceptable to the Company within fifty-five (55) days following Executive&#8217;s Termination Date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that Executive shall not be required to release any rights Executive has to be indemnified by the Company under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof.  Notwithstanding any provision of this Agreement to the contrary, in no event shall the timing of Executive&#8217;s execution of the release, directly or indirectly, result in Executive designating the calendar year of payment, and, to the extent required by Section 409A, if a payment that is subject to execution of the release could be made in more than one taxable year, payment shall be made in the later taxable year.  Where applicable, references to Executive in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall refer to Executive&#8217;s representative or estate.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Modification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No provision of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing and signed by Executive and the Company.  No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or provision of this Agreement to be performed by the other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time.  No agreement or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by any party which are not expressly set forth in this Agreement.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any legally actionable dispute arises under this Agreement or otherwise which cannot be resolved by mutual discussion between the parties, then the Company and Executive each agree to resolve that dispute by binding arbitration before an arbitrator experienced in employment law.  Any arbitration hereunder shall be conducted in accordance with the Judicial Arbitration and Mediation Services (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">JAMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) Employment Arbitration Rules in effect at the time of the arbitration (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">JAMS Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and the law applicable to the claim(s) asserted therein.  The parties shall have fifteen (15) calendar days after JAMS issues a Commencement </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Letter (as defined in the JAMS Rules) to attempt to agree on the selection of an arbitrator from the JAMS roster.  In the event the parties are unable to agree in such time, JAMS will provide a list of five (5) qualified and available arbitrators, and an arbitrator will be selected from that list by the parties alternately striking out one name of a potential arbitrator until only one name remains.  The party entitled to strike an arbitrator first shall be selected by a coin toss.  The parties agree that this agreement to arbitrate includes any claims that the Company may have against Executive, or that Executive may have against the Company and&#47;or its related entities and&#47;or employees, arising out of or relating to this Agreement, Executive&#8217;s employment, or Executive&#8217;s termination, including but not limited to any claims of discrimination or harassment in violation of applicable law and any other aspect of Executive&#8217;s compensation, employment, or termination.  The parties further agree that arbitration as provided for in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is the exclusive and binding remedy for any such dispute and will be used instead of any court action, and the parties hereby expressly waive any rights to litigate claims covered by this agreement to arbitrate in a court or other venue, except for (i)&#160;a request by any party for temporary, preliminary or permanent injunctive relief pending arbitration in accordance with applicable law&#59; (ii)&#160;breaches by Executive of Executive&#8217;s obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof&#59; or (iii)&#160;an administrative claim with an administrative agency.  The parties agree that the arbitrator shall have the authority to and shall determine all gateway issues related to any dispute submitted to arbitration hereunder, including but not limited to the jurisdiction of the arbitrator, the arbitrability of any dispute (including the scope, validity, or enforceability of this agreement to arbitrate), and the proper or permissible parties to any such arbitration.  The parties further agree that the arbitrator shall be empowered to award damages and&#47;or equitable relief, as appropriate.  Any arbitration provided for herein shall be conducted in or around Morristown, New Jersey, unless otherwise mutually agreed.  The Company shall pay the cost of any arbitration brought pursuant to this paragraph, excluding, however, the costs of Executive&#8217;s representation in the arbitration (including but not limited to the fees and costs of Executive&#8217;s attorneys, advisors, experts, and other service providers), unless such cost is awarded in accordance with law or otherwise awarded by the arbitrator.  Except as otherwise provided above, the arbitrator may award legal fees to the prevailing party in the arbitrator&#8217;s sole discretion&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the percentage of fees so awarded shall not exceed 1% of the net worth of the paying party (i.e., the Company or Executive).  Judgment upon any resulting arbitration award may be entered in any federal or state court of competent jurisdiction.  Neither a party nor the arbitrator may disclose the existence, content, or outcome of any arbitration hereunder without the prior written consent of all parties to the arbitration, except (1)&#160;as provided by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof&#59; and (2) as may be required by law, including for purposes of entering judgment upon or enforcing the arbitrator&#8217;s award.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Effect of Other Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Anything herein to the contrary notwithstanding, the terms of this Agreement shall be modified to the extent required to meet the provisions of the Sarbanes-Oxley Act of 2002, Section 409A, the Dodd-Frank Wall Street Reform and Consumer Protection Act or other law applicable to the employment arrangements between Executive and the Company.  Any delay in providing benefits or payments or any failure to provide a benefit or payment shall not in and of itself constitute a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-17</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">breach of this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the Company shall provide economically equivalent payments or benefits to Executive to the extent permitted by law as soon as practicable after such benefits or payments are due.  Any request or requirement that Executive repay compensation that is required under the first sentence of this Section 17(h), or pursuant to a Company policy that is applicable to other executive officers of the Company and that is designed to advance the legitimate corporate governance objectives of the Company, shall not in and of itself constitute a breach of this Agreement.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New Jersey applicable to contracts executed in and to be performed entirely within such State, without giving effect to the conflict of law principles thereof.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">No Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As a condition to the effectiveness of this Agreement, Executive represents and warrants to the Company that he is not a party to or otherwise bound by any agreement or arrangement (including, without limitation, any license, covenant, or commitment of any nature), or subject to any judgment, decree, or order of any court or administrative agency, that would conflict with or will be in conflict with or in any way preclude, limit or inhibit Executive&#8217;s ability to execute this Agreement or to carry out Executive&#8217;s duties and responsibilities hereunder.  In the event that the Company determines that Executive&#8217;s duties hereunder may conflict with an agreement or arrangement to which Executive is bound, Executive shall be required to cease engaging in any such activities, duties or responsibilities (including providing supervisory services over certain subsets of the Company&#8217;s business operations) and the Company will take steps to restrict Executive&#8217;s access to, and participation in, any such activities.  Any actions taken by the Company under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to restrict or limit Executive&#8217;s access to information or provision of services shall not constitute Good Reason for purposes of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The provisions of this Agreement shall be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement constitutes the entire agreement between the parties hereto and supersedes all prior agreements, if any, understandings and arrangements, oral or written, between the parties hereto with respect to the subject matter hereof, including without limitation any term sheets or other similar presentations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement.  Signatures transmitted via facsimile or PDF will be deemed the equivalent of originals.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Remainder of page left intentionally blank</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-18</font></div><div><font><br></font></div></div></div><div id="id398c95c8bbf4a44a9c5307c4910246f_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have executed this Employment Agreement as of the day and year first above written, to be effective as of the Effective Date. </font></div><div style="margin-bottom:24pt;margin-top:30pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BAUSCH HEALTH COMPANIES INC.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Joseph C. Papa</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Joseph C. Papa</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Chairman of the Board and CEO</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:24pt;margin-top:30pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXECUTIVE</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> &#47;s&#47; Robert Spurr&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Robert Spurr</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>5
<FILENAME>exhibit1010spurremployment.htm
<DESCRIPTION>EX-10.10
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="icc7e8beb52c7425d95e099e15889d88e_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.10</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BAUSCH HEALTH COMPANIES INC.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDMENT TO EMPLOYMENT AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;This AMENDMENT TO EMPLOYMENT AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is made as of September 1, 2021 by and between Bausch Health Companies Inc., a Canadian corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and Robert Spurr, an individual (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Where the context requires, references to the Company in the Agreement (as defined below) and this Amendment shall include the Company&#8217;s subsidiaries and affiliates and any successors in interest thereto, which shall include Bausch Pharma at the time of the separation of the Bausch + Lomb business.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Company and the Executive entered into that certain Employment Agreement dated as of May 27, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and wish to amend the Agreement through this Amendment, effective as of the date hereof. Capitalized terms used herein but not defined shall have the respective meanings ascribed to such terms in the Agreement&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;WHEREAS, the Company and the Executive entered into a letter agreement dated as of November 2, 2020 setting forth certain payments and benefits payable to the Executive (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Separation Bonus Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;WHEREAS, the Company and the Executive desire that the Separation Bonus Letter shall remain in full force in effect with its terms and shall not be amended by this Amendment&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;WHEREAS, the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) has determined that it is in the best interests of the Company and its stockholders to separate the eyecare business (such business &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Bausch + Lomb</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) into an independent publicly traded entity from the remainder of the Company by first providing for an initial public offering of Bausch + Lomb&#8217;s stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">IPO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and subsequently separating the Bausch + Lomb business from the Company (such date, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Separation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;WHEREAS, on August 3, 2021, the Company announced that, in connection with the separation of the Bausch + Lomb business, the Executive will be appointed to the position of U.S. President of the pharmaceutical business of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Pharma Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), effective September 1, 2021, and, contingent and effective upon the closing of the IPO, the Executive shall cease to serve as the U.S. President of the Pharma Business and will be appointed as the U.S. President of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by each of the Parties, the Company and Executive hereby agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">AMENDMENTS</font></div><div style="padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:4.7pt">The first sentence of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Section 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> of the Agreement is hereby deleted and replaced in its entirety with the following</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Commencement Date&#59; Term&#59; Effect on Other Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The employment term (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of Executive&#8217;s employment under this Agreement shall be for the period commencing on September 1, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and shall continue through the third (3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) anniversary of the Initial Commencement Date. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:4.02pt">The first sentence of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Section 2(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> is hereby deleted and replaced in its entirety with the following</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="height:80.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive shall be employed as U.S. President of the Pharma Business effective as of the Initial Commencement Date, at which time the Executive shall report directly to the Chief Executive Officer of the Pharma Business. Contingent and effective upon the closing of the IPO, Executive shall cease to serve as the U.S. President of the Pharma Business and will be appointed as the U.S. President of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Bausch Pharma Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), at which time the Executive shall report directly to the Chief Executive Officer of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:4.7pt">The first sentence of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Section 3(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> is hereby deleted and replaced in its entirety with the following</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Compensation.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Base Salary.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> During the Employment Term, Executive shall be paid an annual base salary of $700,000 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:4.02pt">A new </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Section 4(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> is hereby added.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">One-Time Promotion Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Effective as of the Commencement Date, Executive will receive a grant under the Plan of (i) a number of restricted stock units with a grant-date fair value equal to $250,000 and (ii) a number of stock options with a grant-date fair value equal to $250,000.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:4.7pt;text-decoration:underline">Section 7(e)(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> is hereby deleted and replaced in its entirety with the following</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> Good Reason. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive may terminate his employment for Good Reason (as defined below) by delivering to the Company a Notice of Termination not less than thirty (30) days prior to the termination of Executive&#8217;s employment for Good Reason and no more than one hundred fifty (150) days following the initial existence of the event or condition constituting Good Reason.  The Company shall have the option of terminating Executive&#8217;s duties and responsibilities prior to the expiration of such thirty (30) day notice period, and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the occurrence of any of the events or conditions described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clauses (1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> through </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> below during the Employment Term, without Executive&#8217;s prior written consent, which are not cured by the Company (if susceptible to cure by the Company) within thirty (30) days after the Company has received written notice from Executive within ninety (90) days of the initial existence of the event or condition constituting Good Reason specifying the particular events or conditions which constitute Good Reason and the specific cure requested by Executive.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Diminution of Responsibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. (A) Any material reduction in Executive&#8217;s duties or responsibilities as (i) U.S. President of the Pharma Business between the Initial Commencement Date and the Bausch Pharma Commencement Date or (ii) U.S. President of the Company following the Bausch Pharma Commencement Date, in each case as in effect immediately prior thereto (other than a reduction where Executive is provided with other duties or responsibilities substantially comparable to Executive&#8217;s overall duties and responsibilities prior to such </font></div><div style="height:80.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reduction) or (B) removal of Executive from the position of (i) U.S. President of the Pharma Business between the Initial Commencement Date and the Bausch Pharma Commencement Date or (ii) U.S. President of the Company following the Bausch Pharma Commencement Date, except, in each of clauses (A) and (B), in connection with (1) the termination of Executive&#8217;s employment for Disability, Cause, as a result of Executive&#8217;s death or by Executive other than for Good Reason, or (2) for the avoidance of doubt, the changes in the Executive&#8217;s position and reporting relationship contemplated by Section 2(a)&#59;</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:6.03pt;text-decoration:underline">Section 13(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> is hereby deleted and replaced in its entirety with the following</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">(b) Covenant Not to Compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To protect the Confidential Information, Company Intellectual Property and other trade secrets of the Company, the Company and its affiliates, Executive agrees (i) during the period beginning on the Initial Commencement Date and ending on the date that is 12 months after the Separation Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">First Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), not to engage in Prohibited Activities (as defined below) in any country in which the Company or any of its affiliates and, following the Separation Date, Bausch &#38; Lomb, conducts business, or plans to conduct business, and (ii) following the expiration of the First Period, during the Employment Term and the Restricted Period (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Second Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Executive agrees not to engage in Prohibited Activities in any country in which the Company or any of its affiliates conducts business, or plans to conduct business.  For the purposes of this Agreement, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Prohibited Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means directly or indirectly engaging as an owner, employee, partner, member, consultant or agent of any entity that derives more than 10% of its consolidated revenue from the development, manufacturing, marketing and&#47;or distribution (directly or indirectly) of (x) during the First Period, branded or generic prescription or non-prescription pharmaceuticals or medical devices for treatments in the fields of neurology, dermatology, gastroenterology, ophthalmology or dentistry (y) during the Second Period, branded or generic prescription or non-prescription pharmaceuticals or medical devices for treatment in the same fields as clause (x), other than ophthalmology&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that Prohibited Activities shall not mean Executive&#8217;s investment in securities of a publicly-traded company equal to less than five (5%) percent of such company&#8217;s outstanding voting securities&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that, for the avoidance of doubt, Executive complies with the obligations set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 12, 13(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof.  Executive agrees that the covenants contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> are reasonable and desirable to protect the Confidential Information and Company Intellectual Property of the Company and its affiliates.</font></div><div style="margin-bottom:0.12pt;padding-left:72pt"><font><br></font></div><div style="height:80.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.12pt;padding-left:72pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt">EFFECTIVENESS OF AMENDMENT&#59; COUNTERPARTS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Amendment shall become effective on the date hereof.  Except as amended by the terms of this Amendment, the Agreement shall remain in full force and effect in accordance with its terms. For the avoidance of doubt, the Separation Bonus Letter shall remain in full force and effect in accordance with its terms and shall not be amended by this amendment. This Amendment may be executed by electronic transmission (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, facsimile or electronically transmitted portable document (PDF) or DocuSign or similar electronic signature) and in counterparts any one of which need not contain the signature of more than one Party, but all such counterparts taken together will constitute one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">***********</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Remainder of Page Left Intentionally Blank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div><div style="height:80.64pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><div id="icc7e8beb52c7425d95e099e15889d88e_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment as of the date first written above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:216pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:216pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THE COMPANY&#58;</font></div><div style="margin-bottom:30pt;text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BAUSCH HEALTH COMPANIES INC.</font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> &#47;s&#47; Joseph C. Papa                        </font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;  Joseph C. Papa</font></div><div style="margin-bottom:24pt;padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;    Chairman of the Board and CEO</font></div><div style="margin-bottom:24pt;text-align:justify;text-indent:225pt"><font><br></font></div><div style="margin-bottom:30pt;text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXECUTIVE&#58;</font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Robert Spurr</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Robert Spurr</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:216pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>6
<FILENAME>exhibit1011spurremployment.htm
<DESCRIPTION>EX-10.11
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i38da065826884bf2a1954b0494941abf_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.11</font></div></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:232%">BAUSCH HEALTH COMPANIES INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EMPLOYMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">THIS EMPLOYMENT AGREEMENT (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is hereby entered into as of May 28, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), retroactive to May 27, 2020, by and between Bausch Health Companies Inc., a Canadian corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and Robert Spurr, an individual (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (hereinafter collectively referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">the parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Where the context requires, references to the Company shall include the Company&#8217;s subsidiaries and affiliates. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Company desires to employ Executive for the period provided in this Agreement, and Executive desires to accept such employment with the Company, subject to the terms and conditions set forth herein&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the respective agreements of the parties contained herein, it is agreed as follows&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Commencement Date&#59; Term&#59; Effect on Other Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The employment term (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of Executive&#8217;s employment under this Agreement shall be for the period commencing on May 27, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and ending on the third (3rd) anniversary of the Commencement Date.  Thereafter, the Employment Term shall extend automatically for consecutive periods of one year unless either party provides notice of non-renewal not less than ninety (90) days prior to the end of the Employment Term as then in effect. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Employment Term&#58;  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Executive shall be employed as President, Salix of the Company.  Executive shall report directly to the Chief Executive Officer of the Company.  Executive shall perform the duties, undertake the responsibilities and exercise the authority customarily performed, undertaken and exercised by persons situated in similar executive capacities. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Excluding periods of vacation and sick leave to which Executive is entitled and other service outside of the Company contemplated in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Executive shall devote Executive&#8217;s full professional time and attention to the business and affairs of the Company to discharge the responsibilities of Executive hereunder.  Prior to joining or agreeing to serve on corporate, civil or charitable boards or committees, Executive shall obtain approval of the Chief Executive Officer. Executive may manage personal and family investments, participate in industry organizations and deliver lectures at educational institutions, so long as such activities do not interfere with the performance of Executive&#8217;s responsibilities hereunder.  It is understood that, during Executive&#8217;s employment by the Company, Executive shall not engage in any activities that constitute a conflict of interest with the interests of the Company or its direct and indirect subsidiaries, as outlined in the Company&#8217;s conflict of interest policies for employees and executives in effect from time to time.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> Page B-1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Executive shall be subject to and shall abide by each of the personnel policies applicable to senior executives, including but not limited to any policy restricting pledging and hedging investments in Company equity by Company executives, any policy the Company adopts regarding the recovery of incentive compensation (sometimes referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">clawback</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and any additional clawback provisions as required by law and applicable listing rules.  This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall survive the termination of the Employment Term.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof, Executive&#8217;s employment with the Company is &#8220;at will,&#8221; such that each of Executive or the Company has the option to terminate Executive&#8217;s employment at any time, with or without advance notice, and with or without Cause or with or without Good Reason.  This Agreement does not constitute an express or implied agreement of continuing or long term employment.  The at-will nature of Executive&#8217;s employment can be altered only by a written agreement specifying the altered status of Executive&#8217;s employment.  Such written agreement must be signed by both Executive and the Chief Executive Officer of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Annual Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Employment Term, Executive shall be paid an annual base salary of $600,000 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Base Salary shall be payable in accordance with the Company&#8217;s regular payroll practices as then in effect.  During the Employment Term, the Base Salary will be reviewed annually and is subject to adjustment at the discretion of the Talent and Compensation Committee of the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Performance Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Subject to the terms of the Company&#8217;s annual incentive cash bonus program as in effect from time to time and the provisions hereof, for each fiscal year of the Company ending during the Employment Term (commencing with the 2020 fiscal year), Executive shall be eligible to receive a target annual cash bonus of 80% of Base Salary (such target bonus, as may hereafter be increased, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Target Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) with the opportunity to receive a maximum annual cash bonus of 200% of the Target Bonus. Annual bonuses, if any, will be payable in the Company&#8217;s discretion and in accordance with the Company&#8217;s customary practices applicable to bonuses paid to similarly situated executives of the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Additional Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Ongoing Grants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive will be eligible for consideration for future equity grants during the Employment Term in the sole discretion of the Chief Executive Officer of the Company and the Committee. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Share Ownership Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive agrees to comply with any share ownership requirements adopted by the Company applicable to Executive, which shall be on the same terms as similarly situated executives of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Other Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Employment Term&#58; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Employee Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive shall be entitled to participate in all employee benefit plans, practices and programs maintained by the Company, and made available to employees generally (taking into account jurisdictional differences), including, without limitation, all pension, retirement, profit sharing, savings, medical, hospitalization, disability, dental, life or travel accident insurance benefit plans in accordance with the terms of the plans as in effect from time to time.  Executive&#8217;s participation in such plans, practices and programs shall be on the same basis and terms as are applicable to similarly situated executives of the Company.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Business Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon submission of proper invoices in accordance with, and subject to, the Company&#8217;s normal policies and procedures, Executive shall be entitled to receive prompt reimbursement of all reasonable out-of-pocket business, entertainment and travel expenses incurred by him in connection with the performance of Executive&#8217;s duties hereunder.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Vacation and Sick Leave</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive shall be entitled, without loss of pay, to absent himself voluntarily from the performance of Executive&#8217;s employment under this Agreement, pursuant to the following&#58; </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Executive shall be entitled to annual vacation in accordance with and subject to the policies as periodically established for similarly situated executives of the Company&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Executive shall be entitled to sick leave (without loss of pay) in accordance with the Company&#8217;s policies as in effect from time to time.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive&#8217;s employment with the Company hereunder may be terminated under the circumstances set forth below&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that notwithstanding anything contained herein to the contrary, to the extent required by Section 409A (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Executive shall not be considered to have terminated employment with the Company for purposes of this Agreement until he would be considered to have incurred a &#8220;separation from service&#8221; from the Company within the meaning of Section 409A.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive&#8217;s employment shall be terminated as of the date of Executive&#8217;s death and Executive&#8217;s beneficiaries shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may terminate Executive&#8217;s employment, on written notice to Executive after having established Executive&#8217;s Disability and while Executive remains disabled, and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning assigned to such term in the Plan.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may terminate Executive&#8217;s employment for Cause effective as of the date of the Notice of Termination (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof) and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, for purposes of this Agreement&#58; (1) conviction of any felony (other than one related to a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">vehicular offense) or other criminal act involving fraud&#59; (2) willful misconduct that results in a material economic detriment to the Company&#59; (3) material violation of Company policies and directives, which is not cured after written notice and an opportunity for cure&#59; (4) continued refusal by Executive to perform Executive&#8217;s duties after written notice identifying the deficiencies and an opportunity for cure&#59; and (5) a material violation by Executive of any of the covenants to the Company set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof.  No action or inaction shall be deemed willful if (x) not demonstrably willful and (y) taken, or not taken, by Executive in good faith and with the understanding that such action, or inaction, was not adverse to the best interests of the Company.  References in this paragraph to the Company shall also include direct and indirect subsidiaries of the Company, and materiality shall be measured based on the action or inaction and the impact upon the Company taken as a whole.  Without limiting the other rights of the Company under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Company may suspend Executive, without pay, upon Executive&#8217;s indictment for the commission of a felony as described under clause (1) above.  Such suspension may remain effective until such time as the indictment is either dismissed or a verdict of not guilty has been entered.  If such indictment does not result in a conviction, as soon as practicable following such dismissal or verdict, the Company shall pay Executive the base salary and target bonus amount that Executive would have received for the period during which Executive was suspended without pay (with interest from the date such amounts would otherwise have been paid at the short-term applicable federal rate, compounded semi-annually, as determined under Section 1274 of the Code for the month in which payment would have been made but for the delay) and Executive will receive vesting credit for purposes of Executive&#8217;s outstanding equity awards.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Without Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may terminate Executive&#8217;s employment without Cause.  The Company shall deliver to Executive a Notice of Termination (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof) not less than thirty (30) days prior to the termination of Executive&#8217;s employment without Cause and the Company shall have the option of terminating Executive&#8217;s duties and responsibilities prior to the expiration of such thirty-day notice period, and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive may terminate Executive&#8217;s employment for Good Reason (as defined below) by delivering to the Company a Notice of Termination not less than thirty (30) days prior to the termination of Executive&#8217;s employment for Good Reason and no more than one hundred fifty (150) days following the initial existence of the event or condition constituting Good Reason.  The Company shall have the option of terminating Executive&#8217;s duties and responsibilities prior to the expiration of such thirty (30) day notice, and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the occurrence of any of the events or conditions described in clauses (1) through (4) below which are not cured by the Company (if susceptible to cure by the Company) within thirty (30) days after the Company has received written notice from Executive within ninety (90) days of the initial existence of the event or condition constituting Good Reason specifying the particular events or conditions </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which constitute Good Reason and the specific cure requested by Executive.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Diminution of Responsibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  (A) Any material reduction in Executive&#8217;s duties or responsibilities as President, Salix, as in effect immediately prior thereto (other than a reduction where Executive is provided with other duties or responsibilities substantially comparable to Executive&#8217;s overall duties and responsibilities prior to such reduction) or (B) removal of Executive from the position of President, Salix  of the Company, except, in each case, in connection with the termination of Executive&#8217;s employment for Disability, Cause, as a result of Executive&#8217;s death or by Executive other than for Good Reason&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Compensation Reduction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any reduction in Executive&#8217;s Base Salary or Target Bonus opportunity which is not comparable to reductions in the base salary or target bonus opportunity of other similarly situated executives of the Company&#59; </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Relocation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any relocation of Executive&#8217;s primary place of business that results in an increase of Executive&#8217;s one-way commute by fifty (50) miles or more&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the Company&#8217;s request that Executive travel from time to time on behalf of the Company shall not constitute Good Reason&#59; or </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Company Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any other material breach by the Company of any material provision of this Agreement.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Without Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive may voluntarily terminate Executive&#8217;s employment without Good Reason by delivering to the Company a Notice of Termination not less than thirty (30) days prior to the termination of Executive&#8217;s employment and the Company shall have the option of terminating Executive&#8217;s duties and responsibilities prior to the expiration of such thirty (30) day notice period, and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof through the last day of such notice period.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Notice of Non-Renewal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive&#8217;s employment shall terminate upon expiration of the Employment Term as then in effect following timely provision by either party of notice of non-renewal in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof, and Executive shall be entitled to the benefits provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Notice of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any purported termination by the Company or by Executive shall be communicated by written Notice of Termination to the other party hereto.  For purposes of this Agreement, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a notice which indicates a date of termination (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the specific termination provision in this Agreement relied upon and sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive&#8217;s employment under the provision so indicated.  For purposes of this Agreement, no such purported termination of Executive&#8217;s employment hereunder shall be effective without such Notice of Termination (unless waived by the party entitled to receive such notice).  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Compensation Upon Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon termination of Executive&#8217;s employment during the Employment Term, Executive shall be entitled to the following benefits&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that any such benefits to which Executive is hereunder entitled shall be offset by those benefits that Executive receives, if any, under applicable law or otherwise&#58; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination by the Company for Cause or by Executive Without Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Executive&#8217;s employment is terminated by the Company for Cause or by Executive without Good Reason, the Company shall pay Executive all amounts earned or accrued hereunder through the Termination Date, including&#58; </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">reimbursement for reasonable and necessary expenses incurred by Executive on behalf of the Company for the period ending on the Termination Date&#59; </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">any previous compensation which Executive has previously deferred (including any interest earned or credited thereon), in accordance with the terms and conditions of the applicable deferred compensation plans or arrangements then in effect&#59; </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">equity and incentive awards, to the extent previously vested, shall be paid or delivered to Executive in accordance with the terms of such awards&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">any amount or benefit as provided under any benefit plan or program (the foregoing items in clauses (1) through (4) being collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Accrued Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Termination by the Company for Disability or Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Executive&#8217;s employment is terminated by the Company for Disability or by reason of Executive&#8217;s death, then, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof, Executive shall be entitled to the benefits provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Company shall pay Executive (or Executive&#8217;s beneficiaries, as applicable) the Accrued Compensation&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Company shall pay to Executive (or Executive&#8217;s beneficiaries, as applicable) within sixty (60) days following the Termination Date, any bonus earned but unpaid in respect of any fiscal year preceding the Termination Date&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Each unvested equity award held by Executive at the time of termination shall be governed by the terms of the applicable award agreement. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination by the Company Without Cause or by Executive for Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Executive&#8217;s employment by the Company shall be terminated by the Company without Cause or by Executive for Good Reason, then, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof, Executive shall be entitled to the benefits provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Company shall pay to Executive any Accrued Compensation&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Company shall pay to Executive any bonus earned but unpaid in respect of any fiscal year preceding the Termination Date within sixty (60) days following the Termination Date&#59; </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Company shall pay to Executive a bonus or incentive award in respect of the fiscal year in which Executive&#8217;s Termination Date occurs in an amount equal to the product of (A) the lesser of (x) the bonus or incentive award that Executive would have been entitled to receive based on actual achievement against the stated performance objectives and (y) Executive&#8217;s Target Bonus and (B) a fraction (x) the numerator of which is the number of days in such fiscal year through the Termination Date and (y) the denominator of which is 365 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that if such termination occurs in contemplation of a Change in Control (as defined in the Plan) or within twelve months following a Change in Control, then in the forgoing calculation, the amount under (A) above shall be equal to Executive&#8217;s Target Bonus).  Any bonus or incentive award payable to Executive under this clause (3) shall be paid in a lump sum payment by March 15 of the year following the fiscal year in which Executive&#8217;s Termination Date occurs&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Company shall pay Executive as severance pay, in lieu of any further compensation (except as provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) for the periods subsequent to the Termination Date, an amount in cash, which amount shall be payable in a lump sum payment within sixty (60) days following such termination (subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof), equal to one (1) times (or, if such termination occurs in contemplation of a Change in Control or within twelve months following a Change in Control, two (2) times) the sum of Executive&#8217;s Base Salary and Target Bonus, in each case, as in effect immediately prior to termination and without regard to any reduction thereto which constitutes Good Reason&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Each unvested equity award held by Executive at the time of termination shall be governed by the terms of the applicable award agreement&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Company shall provide Executive with continued coverage through the first anniversary of the Termination Date under any health, medical, dental or vision program or policy in which Executive (and Executive&#8217;s dependents, as applicable) participated in as of the time of the Termination Date on terms no less favorable to Executive and Executive&#8217;s dependents than those applicable to actively employed senior executives of the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that Executive shall be solely responsible for any taxes incurred in respect of such coverage&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the Company may modify the continuation coverage contemplated by this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(c)(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (including by providing a lump-sum cash payment equal to the value for Executive of the continuation coverage provided herein) to the extent reasonably necessary to avoid the imposition of any excise taxes on the Company for failure to comply with the nondiscrimination requirements of the Patient Protection and Affordable Care Act of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2010, as amended, and&#47;or the Health Care and Education Reconciliation Act of 2010, as amended (to the extent applicable).</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Expiration of Employment Term Upon Notice of Non-Renewal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Executive&#8217;s employment terminates upon expiration of the Employment Term as then in effect following timely provision by either party of notice of non-renewal in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof, then, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof, Executive shall be entitled to the benefits provided in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Company shall pay to Executive any Accrued Compensation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Each unvested equity award held by Executive at the time of termination shall be governed by the terms of the applicable award agreement.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Executive shall not be required to mitigate the amount of any payment provided for under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> by seeking other employment or otherwise and no such payment shall be offset or reduced by the amount of any compensation or benefits provided to Executive in any subsequent employment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The parties intend for the payments and benefits under this Agreement to be exempt from Section 409A or, if not so exempt, to be paid or provided in a manner which complies with the requirements of such section, and intend that this Agreement shall be construed and administered in accordance with such intention.  If any payments or benefits due to Executive hereunder would cause the application of an accelerated or additional tax under Section 409A, such payments or benefits shall be restructured in a mutually agreed upon manner that to the extent possible preserves the economic benefit and original intent thereof but does not cause such an accelerated or additional tax.  For purposes of the limitations on nonqualified deferred compensation under Section 409A, each payment of compensation under this Agreement shall be treated as a separate payment of compensation.  Without limiting the foregoing and notwithstanding anything contained herein to the contrary, to the extent required in order to avoid accelerated taxation and&#47;or tax penalties under Section 409A, amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to this Agreement during the six-month period immediately following Executive&#8217;s separation from service shall instead be paid on the first business day after the date that is six months following Executive&#8217;s Termination Date (or death, if earlier).  Notwithstanding anything to the contrary in this Agreement, all (A) reimbursements and (B) in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A, including, where applicable, the requirement that (x) the amount of expenses eligible for reimbursement, or in kind benefits provided, during a calendar year may not affect the expenses eligible for reimbursement, or in kind benefits to be provided, in any other calendar year&#59; (y) the reimbursement of an eligible expense will be made no later than the last day of the calendar year following the year in which the expense is incurred&#59; and (z) the right to reimbursement or in kind benefits is not subject to liquidation or exchange for another benefit.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Employee Protection</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Nothing in this Agreement or otherwise limits Executive&#8217;s ability to communicate directly with and provide information, including documents, not otherwise protected from disclosure by any applicable law or privilege to the Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or any other federal, state or local governmental agency or commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Government Agency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) regarding possible legal violations, without disclosure to the Company.  The Company may not retaliate against Executive for any of these activities, and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">nothing in this Agreement or otherwise requires Executive to waive any monetary award or other payment that Executive might become entitled to from the SEC or any other Government Agency. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Records and Confidential Data.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Ownership&#59; Recognition of Company&#8217;s Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive acknowledges that in connection with the performance of Executive&#8217;s duties during the Employment Term, the Company will make available to Executive, or Executive will have access to, certain Confidential Information (as defined below) of the Company and its affiliates. Executive acknowledges and agrees that any and all Confidential Information disclosed to, or learned or obtained by, Executive during the course of Executive&#8217;s employment by the Company or any of its affiliates or otherwise, whether developed by Executive alone or in conjunction with others or otherwise, shall be and is the sole and exclusive property of the Company or the affiliate of the Company, as applicable, that is Executive&#8217;s employer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). No license or other right to any Confidential Information is granted to Executive under this Agreement.  To the extent that Executive acquires any right, title or interest in or to any Confidential Information, Executive hereby assigns, transfers, conveys and delivers to the Employer all such right, title and interest in and to such Confidential Information.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive (A)&#160;will keep all Confidential Information strictly confidential, (B) will not use Confidential Information in any manner which is detrimental to the Company or its affiliates, (C) will not use Confidential Information other than in connection with the discharge of Executive&#8217;s duties to the Company and its affiliates, (D) will safeguard any and all Confidential Information from unauthorized disclosure, and (E)&#160;will not disclose, publish, use, transfer or otherwise disseminate any Confidential Information to any person or entity without the Employer&#8217;s express prior written consent, except as may be necessary to perform Executive&#8217;s duties as an employee of the Company or its affiliates for the benefit of the Company or its affiliates. Executive may, however, disclose Confidential Information to the extent it is in response to a valid order of a court or other governmental authority or to otherwise comply with applicable law&#59; provided that, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Executive shall first give notice to the Employer and reasonably cooperate with the Employer to obtain a protective order or other measures preserving the confidential treatment of such Confidential Information and requiring that the information or documents so disclosed be used only for the purposes for which the order was issued or is otherwise required by applicable law. For the avoidance of doubt, nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall prevent Executive from exercising any legally protected whistleblower rights (including under Rule 21F under the Exchange Act) as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Disposition of Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Following the termination of Executive&#8217;s employment or upon the Company&#8217;s request, Executive will return to the Company all copies of any and all Confidential Information in Executive&#8217;s custody, possession or control (including all copies of any analyses, compilations, studies or other documents prepared by Executive or for Executive&#8217;s use containing or reflecting any Confidential Information). Alternatively, with the Company&#8217;s prior written consent, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive may destroy such Confidential Information. Within five (5) business days of the termination of Executive&#8217;s employment or such request by the Company, Executive shall deliver to the Company a document certifying that such written Confidential Information has been returned or destroyed in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For the purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any and all non-public, proprietary or other confidential information of the Company or its affiliates disclosed to Executive, to which Executive has access, or of which Executive otherwise becomes aware, in each case whether in oral, written, graphic or machine readable form, including, without limitation, (A) know-how, trade secrets, inventions, discoveries, concepts, information, works, materials, processes, methods, data, software, programs, apparatus, designs and the like, and any other intellectual property the value of which is contingent upon maintaining the confidentiality thereof, (B) information regarding the business of the Company or its affiliates, including its products, services, budgets, contracts, reports, investigations, experiments, research, work in progress, drawings, designs, plans, proposals, codes, marketing and sales programs, client lists, client mailing lists, supplier lists, financial projections, cost summaries, pricing formulae, marketing studies relating to prospective business opportunities, and all other concepts, ideas, materials, or information prepared or performed for or by the Company or its affiliates, (C) information regarding the skills and compensation of the employees, contractors, and any other service providers of the Company or its affiliates, (D) the existence of any business discussions, negotiations, or agreements between the Company or its affiliates and any third party, (E) all documents and other work product generated by you which contain, comment upon, or relate in any way to any information disclosed by the Company or its affiliates, (F) all third-party information held in confidence by the Company or its affiliates, and (G) the terms and conditions of this Agreement. For purposes of this Agreement, the Confidential Information shall not include and Executive&#8217;s obligation shall not extend to (A) information which is generally available to the public and (B) information obtained by Executive other than pursuant to or in connection with Executive&#8217;s employment</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Defend Trade Secrets Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Pursuant to Section&#160;7 of the Defend Trade Secrets Act of 2016 (which added 18 U.S.C.  &#167; 1833(b)), the Company and Executive acknowledge and agree that Executive shall not have criminal or civil liability under any federal or state trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney and (ii) solely for the purpose of reporting or investigating a suspected violation of law&#59; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.  In addition and without limiting the preceding sentence, if Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose the trade secret to Executive&#8217;s attorney and may use the trade secret information in the court proceeding, if Executive (X) files any document containing the trade secret under seal and (Y) does not disclose the trade secret, except pursuant to court order.  Nothing in this Agreement is intended to conflict </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with 18 U.S.C. &#167; 1833(b) or create liability for disclosures of trade secrets that are expressly allowed by such Section.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">Executive&#8217;s obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall survive the termination of the Employment Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Covenant Not to Solicit and Not to Compete&#59; Non-Disparagement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Covenants Not to Solicit or to Interfere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To protect the Confidential Information, Company Intellectual Property (as defined below) and other trade secrets of the Company and its affiliates, Executive agrees, during the Employment Term and for a period of twelve (12) months after Executive&#8217;s cessation of employment with the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restricted Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), not to solicit, hire or participate in or assist in any way in the solicitation or hire of any employees of the Company or any of its subsidiaries (or any person who was an employee of the Company or any of its subsidiaries during the six-month period preceding such action).  For purposes of this covenant, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">solicit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means directly or indirectly influencing or attempting to influence employees of the Company or any of its subsidiaries to become employed with any other person, partnership, firm, corporation or other entity.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, to protect the Confidential Information, Company Intellectual Property and other trade secrets of the Company and its affiliates, Executive agrees, during the Employment Term and the Restricted Period, not to (x) solicit any client or customer to receive services or to purchase any good or services in competition with those provided by the Company or any of its subsidiaries or (y) interfere or attempt to interfere in any material respect with the relationship between the Company or any of its subsidiaries on one hand and any client, customer, supplier, investor, financing source or capital market intermediary on the other hand.  For purposes of this covenant, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">solicit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means directly or indirectly influencing or attempting to influence clients or customers of the Company or any of its affiliates to accept the services or goods of any other person, partnership, firm, corporation or other entity in competition with those provided by the Company or any of its affiliates.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive agrees that the covenants contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> are reasonable and desirable to protect the Confidential Information and Company Intellectual Property of the Company and its affiliates&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that solicitation through general advertising or the provision of references shall not constitute a breach of such obligations.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Covenant Not to Compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To protect the Confidential Information, Company Intellectual Property and other trade secrets of the Company and its affiliates, Executive agrees, during the Employment Term and the Restricted Period, not to engage in Prohibited Activities (as defined below) in any country in which the Company or any of its affiliates conducts business, or plans to conduct business, during the Employment Term.  For the purposes of this Agreement, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Prohibited Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means directly or indirectly engaging as an owner, employee, partner, member, consultant or agent of any entity that derives more than 10% of its consolidated revenue from the development, manufacturing, marketing and&#47;or distribution (directly or indirectly) of branded or generic </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prescription or non-prescription pharmaceuticals or medical devices for treatments in the fields of neurology, dermatology, gastroenterology, ophthalmology or dentistry&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that Prohibited Activities shall not mean Executive&#8217;s investment in securities of a publicly-traded company equal to less than five (5%) percent of such company&#8217;s outstanding voting securities&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that, for the avoidance of doubt, Executive complies with the obligations set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 12, 13(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof.  Executive agrees that the covenants contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> are reasonable and desirable to protect the Confidential Information and Company Intellectual Property of the Company and its affiliates.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Non-Disparagement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive agrees not to make written or oral statements about the Company, its subsidiaries or affiliates, or its directors, executive officers or non-executive officer employees that are negative or disparaging, except as provided in Section 11 hereof.  The Company shall instruct its directors and executive officers to not make written or oral statements about Executive that are negative or disparaging.  Notwithstanding the foregoing, nothing in this Agreement or otherwise shall preclude Executive, the Company, its subsidiaries and affiliates, and the Company&#8217;s directors and executive officers from communicating or testifying truthfully to the extent required by law to any federal, state, provincial or local governmental agency or in response to a subpoena to testify issued by a court of competent jurisdiction.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">It is the intent and desire of Executive and the Company that the restrictive provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> be enforced to the fullest extent permissible under the laws and public policies as applied in each jurisdiction in which enforcement is sought.  If any particular provision of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be determined to be invalid or unenforceable, such covenant shall be amended, without any action on the part of either party hereto, to delete there from the portion so determined to be invalid or unenforceable, such deletion to apply only with respect to the operation of such covenant in the particular jurisdiction in which such adjudication is made.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Executive&#8217;s obligations under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall survive the termination of the Employment Term.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Remedies for Breach of Obligations under Sections 12 or 13 hereof</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive acknowledges that the Company will suffer irreparable injury, not readily susceptible of valuation in monetary damages, if Executive breaches Executive&#8217;s obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or 13 hereof.  Accordingly, Executive agrees that the Company will be entitled, in addition to any other available remedies, to obtain injunctive relief against any breach or prospective breach by Executive of Executive&#8217;s obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or 13 hereof.  Executive agrees that process in any or all of those actions or proceedings may be served by registered mail, addressed to the last address provided by Executive to the Company, or in any other manner authorized by law.  This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall survive the termination of the Employment Term. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Following Executive&#8217;s termination of employment for any reason, except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof, Executive agrees to make himself reasonably available to cooperate with the Company and its affiliates in matters that materially concern&#58; (i) requests for information about the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">services Executive provided to the Company and its affiliates during Executive&#8217;s employment with the Company and its affiliates, (ii) the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company and its affiliates which relate to events or occurrences that transpired while Executive was employed the Company and its affiliates and as to which Executive has, or would reasonably be expected to have, personal experience, knowledge or information or (iii) any investigation or review by any federal, state or local regulatory, quasi-regulatory or self-governing authority (including, without limitation, the US Department of Justice, the U.S. Federal Trade Commission or the SEC) as any such investigation or review relates to events or occurrences that transpired while Executive was employed by the Company and its affiliates.  Executive&#8217;s cooperation shall include&#58; (A) making himself reasonably available to meet and speak with officers or employees of the Company, the Company&#8217;s counsel or any third-parties at the request of the Company at times and locations to be determined by the Company reasonably and in good faith, taking into account the Company&#8217;s business and Executive&#8217;s business and personal needs (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and (B) giving accurate and truthful information at any interviews and accurate and truthful testimony in any legal proceedings or actions (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Witness Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Nothing in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be construed to limit in any way any rights Executive may have at applicable law not to provide testimony with regard to specific matters.  Unless required by law or legal process, Executive will not knowingly or intentionally furnish information to or cooperate with any non-governmental entity (other than the Company) in connection with any potential or pending proceeding or legal action involving matters arising during Executive&#8217;s employment with the Company and its affiliates, except as provided in Section 11.  In addition, at the request of the Company, Executive shall be required to complete a directors&#8217; and officers&#8217; questionnaire to facilitate the Company&#8217;s preparation and filing of its proxy statement and periodic reports with the SEC.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Executive shall not be entitled to any payments in addition to those otherwise set forth in this Agreement in respect of any Company Cooperation or Witness Cooperation, regardless of when provided.  The Company will reimburse Executive for any reasonable, out-of-pocket travel, hotel and meal expenses incurred in connection with Executive&#8217;s performance of obligations pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for which Executive has obtained prior approval from the Company.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Nothing in this Agreement or any other agreement by and between the Parties is intended to or shall preclude or in any way limit or restrict Executive from providing accurate and truthful testimony or information to any governmental agency.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall survive the termination of the Employment Term.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Disclosure and Ownership of Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Company Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive acknowledges and agrees that any intellectual property, including, without limitation, works, materials, inventions, invention disclosures, invention registrations, patent rights, trademarks, service marks, trade names, trade dress, logos, domain names, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">copyrights, design rights, mask works, software, apparatus, technology, data, trade secrets, know-how and all other intellectual property and proprietary rights recognized by any applicable law of any jurisdiction, that Executive creates, discovers, conceives, reduces to practice, develops or acquires during the course of Executive&#8217;s employment, either alone or jointly with others, (A) using any equipment, supplies, facilities, trade secrets, know-how or other Confidential Information of the Company or any of its affiliates, (B) that results from any work performed for the Company or any of its affiliates and&#47;or (B) that otherwise relates to the Company&#8217;s or any of its affiliates&#8217; business or actual or demonstrably anticipated research or development (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is and shall remain the exclusive property of the <br>Employer whether registered or otherwise exploited or not.  In furtherance of the foregoing, Executive hereby assigns, transfers, conveys and delivers to the Employer Executive&#8217;s entire right, title and interest in and to any and all such Company Intellectual Property.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Work Made for Hire</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive acknowledges and agrees that, with respect to any Company Intellectual Property that may qualify as a Work Made For Hire as defined in 17 U.S.C. &#167; 101 or other applicable law, such Company Intellectual Property is and will be deemed a Work Made for Hire and the Employer will have the sole and exclusive right to the copyright (or, in the event that any such Company Intellectual Property does not qualify as a Work Made for Hire, the copyright and all other rights thereto are hereby automatically assigned to the Employer as above).</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive agrees to record all activities undertaken in the course of Executive&#8217;s employment and to disclose promptly in writing to the Employer any and all Company Intellectual Property.  Executive agrees that Executive will give the Company or any of its affiliates all reasonable assistance and execute all documents necessary to assist with enabling the Company or any of its affiliates to prosecute, perfect, register, record, enforce and defend any and all of their rights in and to any Company Intellectual Property and Confidential Information.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Non-Assignable Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If Executive&#8217;s principal work location is in California, Illinois, Kansas, Minnesota or Washington State, the provisions regarding Executive&#8217;s assignment of Company Intellectual Property to the Employer in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 16(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">16(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of this Agreement may not apply to certain inventions (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Assignable Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) as specified in the statutory code of the applicable state.  Executive acknowledges having received notification regarding such Non-Assignable Inventions pursuant to such states&#8217; codes.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Prior Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If, in the course of Executive&#8217;s employment with the Employer, Executive uses any intellectual property that is solely or jointly owned by Executive or licensed to Executive, with the right to sub-license (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Prior Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Executive hereby grants to the Company and its affiliates a worldwide, non-exclusive, irrevocable, perpetual, fully paid-up and royalty-free license (with rights to sublicense through multiple tiers of sublicensees) to use, reproduce, modify, make derivative works of, publicly perform, publicly display, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">make, have made, sell, offer for sale, import and otherwise exploit such Prior Intellectual Property for any purpose.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Waiver of Moral Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the extent Executive may do so under applicable law, Executive hereby waives and agrees never to assert any Moral Rights that Executive may have in or with respect to any Company Intellectual Property, even after termination of any work on behalf of the Company or its affiliates. As used in this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Moral Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any rights to claim authorship of a work, to object to or prevent the modification or destruction of a work, or to withdraw from circulation or control the publication or distribution of a work, and any similar right, existing under any applicable law of any jurisdiction, regardless of whether or not such right is denominated or generally referred to as a &#8220;moral right.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall survive the termination of the Employment Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">This Agreement shall be binding upon and shall inure to the benefit of the Company, its successors and permitted assigns.  The Company may not assign or delegate any rights or obligations hereunder except to a successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and&#47;or assets of the Company, as applicable.  Except for purposes of determining the occurrence of a Change in Control, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; as used herein shall mean a corporation or other entity acquiring all or substantially all the assets and business of the Company, as the case may be, (including this Agreement) whether by operation of law or otherwise.  </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Neither this Agreement nor any right or interest hereunder shall be assignable or transferable by Executive, Executive&#8217;s beneficiaries or legal representatives, except by will or by the, laws of descent and distribution.  </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">This Agreement shall inure to the benefit of and be enforceable by Executive&#8217;s legal personal representatives.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For the purposes of this Agreement, notices and all other communications provided for in the Agreement (including the Notice of Termination) shall be in writing and shall be deemed to have been duly given when personally delivered or sent by Certified mail, return receipt requested, postage prepaid, addressed to the respective addresses last given by each party to each other party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that all notices to the Company shall be directed to the attention of the General Counsel of the Company.  All notices and communications shall be deemed to have been received on the date of delivery thereof or on the third business day after the mailing thereof, except that notice of change of address shall be effective only upon receipt.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Indemnity Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company agrees to indemnify and hold Executive harmless to the fullest extent permitted by applicable law for actions taken as a director or officer of the Company, as in effect at the time of the subject act or omission.  In connection therewith, Executive shall be entitled to the protection of any insurance policies which the Company elects to maintain generally for the benefit of the Company&#8217;s directors and officers, against all costs, charges and expenses whatsoever incurred or sustained by Executive in connection with any action, suit or proceeding to which he may be made a party by reason of Executive&#8217;s being or having been a director, officer or employee of the Company.  This provision shall survive any termination of the Employment Term.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall be entitled to withhold the amount, if any, of all taxes of any applicable jurisdiction required to be withheld by an employer with respect to any amount paid to Executive hereunder.  The Company, in its sole and absolute discretion, shall make all determinations as to whether it is obligated to withhold any taxes hereunder and the amount hereof.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Release of Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The termination benefits described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 9(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">9(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">9(d)(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof shall be conditioned on Executive delivering to the Company, and failing to revoke, a signed release of claims acceptable to the Company within fifty-five (55) days following Executive&#8217;s Termination Date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that Executive shall not be required to release any rights Executive has to be indemnified by the Company under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 15(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof.  Notwithstanding any provision of this Agreement to the contrary, in no event shall the timing of Executive&#8217;s execution of the release, directly or indirectly, result in Executive designating the calendar year of payment, and, to the extent required by Section 409A, if a payment that is subject to execution of the release could be made in more than one taxable year, payment shall be made in the later taxable year.  Where applicable, references to Executive in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall refer to Executive&#8217;s representative or estate.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Modification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No provision of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing and signed by Executive and the Company.  No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or provision of this Agreement to be performed by the other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time.  No agreement or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by any party which are not expressly set forth in this Agreement.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any legally actionable dispute arises under this Agreement or otherwise which cannot be resolved by mutual discussion between the parties, then the Company and Executive each agree to resolve that dispute by binding arbitration before an arbitrator experienced in employment law.  Any arbitration hereunder shall be conducted in accordance with the Judicial Arbitration and Mediation Services (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">JAMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) Employment Arbitration Rules in effect at the time of the arbitration (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">JAMS Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and the law applicable to the claim(s) asserted therein.  The parties shall have fifteen (15) calendar days after JAMS issues a Commencement </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Letter (as defined in the JAMS Rules) to attempt to agree on the selection of an arbitrator from the JAMS roster.  In the event the parties are unable to agree in such time, JAMS will provide a list of five (5) qualified and available arbitrators, and an arbitrator will be selected from that list by the parties alternately striking out one name of a potential arbitrator until only one name remains.  The party entitled to strike an arbitrator first shall be selected by a coin toss.  The parties agree that this agreement to arbitrate includes any claims that the Company may have against Executive, or that Executive may have against the Company and&#47;or its related entities and&#47;or employees, arising out of or relating to this Agreement, Executive&#8217;s employment, or Executive&#8217;s termination, including but not limited to any claims of discrimination or harassment in violation of applicable law and any other aspect of Executive&#8217;s compensation, employment, or termination.  The parties further agree that arbitration as provided for in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is the exclusive and binding remedy for any such dispute and will be used instead of any court action, and the parties hereby expressly waive any rights to litigate claims covered by this agreement to arbitrate in a court or other venue, except for (i)&#160;a request by any party for temporary, preliminary or permanent injunctive relief pending arbitration in accordance with applicable law&#59; (ii)&#160;breaches by Executive of Executive&#8217;s obligations under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sections 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof&#59; or (iii)&#160;an administrative claim with an administrative agency.  The parties agree that the arbitrator shall have the authority to and shall determine all gateway issues related to any dispute submitted to arbitration hereunder, including but not limited to the jurisdiction of the arbitrator, the arbitrability of any dispute (including the scope, validity, or enforceability of this agreement to arbitrate), and the proper or permissible parties to any such arbitration.  The parties further agree that the arbitrator shall be empowered to award damages and&#47;or equitable relief, as appropriate.  Any arbitration provided for herein shall be conducted in or around Morristown, New Jersey, unless otherwise mutually agreed.  The Company shall pay the cost of any arbitration brought pursuant to this paragraph, excluding, however, the costs of Executive&#8217;s representation in the arbitration (including but not limited to the fees and costs of Executive&#8217;s attorneys, advisors, experts, and other service providers), unless such cost is awarded in accordance with law or otherwise awarded by the arbitrator.  Except as otherwise provided above, the arbitrator may award legal fees to the prevailing party in the arbitrator&#8217;s sole discretion&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the percentage of fees so awarded shall not exceed 1% of the net worth of the paying party (i.e., the Company or Executive).  Judgment upon any resulting arbitration award may be entered in any federal or state court of competent jurisdiction.  Neither a party nor the arbitrator may disclose the existence, content, or outcome of any arbitration hereunder without the prior written consent of all parties to the arbitration, except (1)&#160;as provided by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof&#59; and (2) as may be required by law, including for purposes of entering judgment upon or enforcing the arbitrator&#8217;s award.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Effect of Other Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Anything herein to the contrary notwithstanding, the terms of this Agreement shall be modified to the extent required to meet the provisions of the Sarbanes-Oxley Act of 2002, Section 409A, the Dodd-Frank Wall Street Reform and Consumer Protection Act or other law applicable to the employment arrangements between Executive and the Company.  Any delay in providing benefits or payments or any failure to provide a benefit or payment shall not in and of itself constitute a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-17</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">breach of this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the Company shall provide economically equivalent payments or benefits to Executive to the extent permitted by law as soon as practicable after such benefits or payments are due.  Any request or requirement that Executive repay compensation that is required under the first sentence of this Section 17(h), or pursuant to a Company policy that is applicable to other executive officers of the Company and that is designed to advance the legitimate corporate governance objectives of the Company, shall not in and of itself constitute a breach of this Agreement.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New Jersey applicable to contracts executed in and to be performed entirely within such State, without giving effect to the conflict of law principles thereof.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">No Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As a condition to the effectiveness of this Agreement, Executive represents and warrants to the Company that he is not a party to or otherwise bound by any agreement or arrangement (including, without limitation, any license, covenant, or commitment of any nature), or subject to any judgment, decree, or order of any court or administrative agency, that would conflict with or will be in conflict with or in any way preclude, limit or inhibit Executive&#8217;s ability to execute this Agreement or to carry out Executive&#8217;s duties and responsibilities hereunder.  In the event that the Company determines that Executive&#8217;s duties hereunder may conflict with an agreement or arrangement to which Executive is bound, Executive shall be required to cease engaging in any such activities, duties or responsibilities (including providing supervisory services over certain subsets of the Company&#8217;s business operations) and the Company will take steps to restrict Executive&#8217;s access to, and participation in, any such activities.  Any actions taken by the Company under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 17(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to restrict or limit Executive&#8217;s access to information or provision of services shall not constitute Good Reason for purposes of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The provisions of this Agreement shall be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement constitutes the entire agreement between the parties hereto and supersedes all prior agreements, if any, understandings and arrangements, oral or written, between the parties hereto with respect to the subject matter hereof, including without limitation any term sheets or other similar presentations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement.  Signatures transmitted via facsimile or PDF will be deemed the equivalent of originals.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Remainder of page left intentionally blank</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Page B-18</font></div><div><font><br></font></div></div></div><div id="i38da065826884bf2a1954b0494941abf_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have executed this Employment Agreement as of the day and year first above written, to be effective as of the Effective Date. </font></div><div style="margin-bottom:24pt;margin-top:30pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BAUSCH HEALTH COMPANIES INC.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Joseph C. Papa</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">                                              &#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Joseph C. Papa</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Chairman of the Board and CEO</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:24pt;margin-top:30pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXECUTIVE</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Robert Spurr  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">                                          &#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Robert Spurr</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>exhibit311q22022.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i80bb4dfb3cb543658a6e248ec671d201_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Thomas J. Appio, certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of Bausch Health Companies&#160;Inc. (the&#160;&#8220;Company&#8221;)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this&#160;report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this&#160;report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The Company's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as&#160;defined in Exchange Act Rules&#160;13a-15(e) and&#160;15d-15(e)) and internal control over financial reporting (as&#160;defined in Exchange Act Rules&#160;13a-15(f) and&#160;15d-15(f)) for the Company and&#160;have&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being&#160;prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;Evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;Disclosed in this report any change in the Company&#8217;s internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The Company's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit committee of the Company&#8217;s board of directors (or&#160;persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.454%"><tr><td style="width:1.0%"></td><td style="width:5.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.693%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; THOMAS J. APPIO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas J. Appio</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>exhibit312q22022.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if2c4f592b39b4df78584cda0af610363_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Tom Vadaketh, certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of Bausch Health Companies&#160;Inc. (the&#160;&#8220;Company&#8221;)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this&#160;report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this&#160;report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The Company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as&#160;defined in Exchange Act Rules&#160;13a-15(e) and&#160;15d-15(e)) and internal control over financial reporting (as&#160;defined in Exchange Act Rules&#160;13a-15(f) and&#160;15d-15(f)) for the Company and&#160;have&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being&#160;prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;Evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;Disclosed in this report any change in the Company&#8217;s internal control over financial reporting that occurred during the Company&#8217;s most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The Company&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit committee of the Company&#8217;s board of directors (or&#160;persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.727%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; TOM VADAKETH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Tom Vadaketh</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer<br>(Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>exhibit321q22022.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie196e573feaa4cf4bc748adbfe4b8d45_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18&#160;U.S.C. &#167;&#160;1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Thomas J. Appio, Chief Executive Officer of Bausch Health Companies&#160;Inc. (the&#160;&#8220;Company&#8221;), certify, pursuant to 18&#160;U.S.C. &#167;&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my&#160;knowledge&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;The Quarterly Report on Form&#160;10-Q of the Company for the quarter ended June&#160;30, 2022 (the&#160;&#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the&#160;Company.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.382%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; THOMAS J. APPIO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas J. Appio</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the&#160;&#8220;Exchange Act&#8221;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by&#160;reference.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the U.S.&#160;Securities and Exchange Commission or its staff upon&#160;request.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>exhibit322q22022.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i589c704da194438080f03497e963730a_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18&#160;U.S.C. &#167;&#160;1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Tom Vadaketh, Executive Vice-President, Chief Financial Officer of Bausch Health Companies&#160;Inc. (the&#160;&#8220;Company&#8221;), certify, pursuant to 18&#160;U.S.C. &#167;&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my&#160;knowledge&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;The Quarterly Report on Form&#160;10-Q of the Company for the quarter ended June&#160;30, 2022 (the&#160;&#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the&#160;Company.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.382%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; TOM VADAKETH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Tom Vadaketh</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer<br>(Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the&#160;&#8220;Exchange Act&#8221;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by&#160;reference.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the U.S.&#160;Securities and Exchange Commission or its staff upon&#160;request.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>bhc-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:08e728a9-955b-42e6-9f9e-75e33d236c1d,g:6cf439ae-5822-43c6-a8ac-f8ebfd7ee7fe-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bhc="http://www.bauschhealth.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.bauschhealth.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.bauschhealth.com/role/DocumentandEntityInformation">
        <link:definition>0001001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESS" roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS">
        <link:definition>2101101 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails">
        <link:definition>2402401 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2103102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2204201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
        <link:definition>2405402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITION" roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITION">
        <link:definition>2106103 - Disclosure - REVENUE RECOGNITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONTables" roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONTables">
        <link:definition>2307301 - Disclosure - REVENUE RECOGNITION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONNarrativeDetails" roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails">
        <link:definition>2408403 - Disclosure - REVENUE RECOGNITION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONVariableConsiderationProvisionsDetails" roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails">
        <link:definition>2409404 - Disclosure - REVENUE RECOGNITION - Variable Consideration Provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails" roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails">
        <link:definition>2410405 - Disclosure - REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSINGAGREEMENTSANDDIVESTITURE" roleURI="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURE">
        <link:definition>2111104 - Disclosure - LICENSING AGREEMENTS AND DIVESTITURE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" roleURI="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails">
        <link:definition>2412406 - Disclosure - LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS" roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS">
        <link:definition>2113105 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails">
        <link:definition>2414407 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS">
        <link:definition>2115106 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables">
        <link:definition>2316302 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>2417408 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails">
        <link:definition>2418409 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails">
        <link:definition>2419410 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails">
        <link:definition>2420411 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails">
        <link:definition>2421412 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails">
        <link:definition>2422413 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails">
        <link:definition>2423414 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails">
        <link:definition>2424415 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails">
        <link:definition>2425416 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails">
        <link:definition>2426417 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIES" roleURI="http://www.bauschhealth.com/role/INVENTORIES">
        <link:definition>2127107 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESTables" roleURI="http://www.bauschhealth.com/role/INVENTORIESTables">
        <link:definition>2328303 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESComponentsofInventoriesDetails" roleURI="http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails">
        <link:definition>2429418 - Disclosure - INVENTORIES - Components of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILL" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL">
        <link:definition>2130108 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLTables" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables">
        <link:definition>2331304 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails">
        <link:definition>2432419 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLNarrativeDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails">
        <link:definition>2433420 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails">
        <link:definition>2434421 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails">
        <link:definition>2435422 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDANDOTHERCURRENTLIABILITIES" roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES">
        <link:definition>2136109 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDANDOTHERCURRENTLIABILITIESTables" roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables">
        <link:definition>2337305 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails" roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails">
        <link:definition>2438423 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTS" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS">
        <link:definition>2139110 - Disclosure - FINANCING ARRANGEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSTables" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables">
        <link:definition>2340306 - Disclosure - FINANCING ARRANGEMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails">
        <link:definition>2441424 - Disclosure - FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSCovenantComplianceDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails">
        <link:definition>2442425 - Disclosure - FINANCING ARRANGEMENTS - Covenant Compliance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails">
        <link:definition>2443426 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails">
        <link:definition>2444427 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails">
        <link:definition>2445428 - Disclosure - FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails">
        <link:definition>2446429 - Disclosure - FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails">
        <link:definition>2447430 - Disclosure - FINANCING ARRANGEMENTS - Gain (Loss) on Extinguishment of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails">
        <link:definition>2448431 - Disclosure - FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS">
        <link:definition>2149111 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables">
        <link:definition>2350307 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails">
        <link:definition>2451432 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATION" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION">
        <link:definition>2152112 - Disclosure - SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONTables" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables">
        <link:definition>2353308 - Disclosure - SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>2454433 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails">
        <link:definition>2455434 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails">
        <link:definition>2456435 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSS" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS">
        <link:definition>2157113 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables">
        <link:definition>2358309 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails">
        <link:definition>2459436 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails">
        <link:definition>2460437 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESEARCHANDDEVELOPMENT" roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT">
        <link:definition>2161114 - Disclosure - RESEARCH AND DEVELOPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESEARCHANDDEVELOPMENTTables" roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables">
        <link:definition>2362310 - Disclosure - RESEARCH AND DEVELOPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails" roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails">
        <link:definition>2463438 - Disclosure - RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSENET" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENET">
        <link:definition>2164115 - Disclosure - OTHER EXPENSE, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSENETTables" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETTables">
        <link:definition>2365311 - Disclosure - OTHER EXPENSE, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSENETSummaryofOtherExpenseNetDetails" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails">
        <link:definition>2466439 - Disclosure - OTHER EXPENSE, NET - Summary of Other Expense, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSENETNarrativeDetails" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails">
        <link:definition>2467440 - Disclosure - OTHER EXPENSE, NET - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.bauschhealth.com/role/INCOMETAXES">
        <link:definition>2168116 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>2469441 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSPERSHARE" roleURI="http://www.bauschhealth.com/role/LOSSPERSHARE">
        <link:definition>2170117 - Disclosure - LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSPERSHARETables" roleURI="http://www.bauschhealth.com/role/LOSSPERSHARETables">
        <link:definition>2371312 - Disclosure - LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails" roleURI="http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails">
        <link:definition>2472442 - Disclosure - LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSPERSHARENarrativeDetails" roleURI="http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails">
        <link:definition>2473443 - Disclosure - LOSS PER SHARE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGS" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGS">
        <link:definition>2174118 - Disclosure - LEGAL PROCEEDINGS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails">
        <link:definition>2475444 - Disclosure - LEGAL PROCEEDINGS - Legal Proceeds and Governmental and Regulatory Inquiries (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails">
        <link:definition>2476445 - Disclosure - LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSAntitrustDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails">
        <link:definition>2477446 - Disclosure - LEGAL PROCEEDINGS - Antitrust (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSIntellectualPropertyDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails">
        <link:definition>2478447 - Disclosure - LEGAL PROCEEDINGS - Intellectual Property (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSProductLiabilityDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails">
        <link:definition>2479448 - Disclosure - LEGAL PROCEEDINGS - Product Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSGeneralCivilActionsDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails">
        <link:definition>2480449 - Disclosure - LEGAL PROCEEDINGS - General Civil Actions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATION" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATION">
        <link:definition>2181119 - Disclosure - SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONTables" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables">
        <link:definition>2382313 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails">
        <link:definition>2483450 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails">
        <link:definition>2484451 - Disclosure - SEGMENT INFORMATION - Segment Revenues and Profit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONDisaggregationofRevenueDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails">
        <link:definition>2485452 - Disclosure - SEGMENT INFORMATION - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONNarrativeDetails_1" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1">
        <link:definition>2486453 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONRevenuebyGeographicAreaDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails">
        <link:definition>2487454 - Disclosure - SEGMENT INFORMATION - Revenue by Geographic Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONMajorCustomersDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails">
        <link:definition>2488455 - Disclosure - SEGMENT INFORMATION - Major Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENT" roleURI="http://www.bauschhealth.com/role/SUBSEQUENTEVENT">
        <link:definition>2189120 - Disclosure - SUBSEQUENT EVENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SUBSEQUENTEVENTNarrativeDetails">
        <link:definition>2490456 - Disclosure - SUBSEQUENT EVENT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bhc_DerivativeGainExcludedComponent" abstract="false" name="DerivativeGainExcludedComponent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" abstract="false" name="LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" abstract="false" name="GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeniorSecuredCreditFacilityMember" abstract="true" name="SeniorSecuredCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes500DueFebruary2029Member" abstract="true" name="SeniorNotes500DueFebruary2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReserveForDistributionFeesMember" abstract="true" name="ReserveForDistributionFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" abstract="false" name="ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DeferredIncomeTaxNoncashExpenseBenefit" abstract="false" name="DeferredIncomeTaxNoncashExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ApotexIncLitigationMember" abstract="true" name="ApotexIncLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReportingUnitImpairmentTestLongTermGrowthRate" abstract="false" name="ReportingUnitImpairmentTestLongTermGrowthRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_SeniorNotes900DueDecember2025Member" abstract="true" name="SeniorNotes900DueDecember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" abstract="true" name="ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bhc_PriceAppreciationCreditMember" abstract="true" name="PriceAppreciationCreditMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" abstract="true" name="ViolationofCanadianProvincialSecuritiesLegislationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" abstract="true" name="GlumetzaAntitrustLitigationNonClassComplaintsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_MeasurementInputWeightedAverageDiscountRateMember" abstract="true" name="MeasurementInputWeightedAverageDiscountRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentAnnualAmortizationRatePercentage" abstract="false" name="DebtInstrumentAnnualAmortizationRatePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_CanadianBankersAcceptanceRateMember" abstract="true" name="CanadianBankersAcceptanceRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReserveForChargebacksMember" abstract="true" name="ReserveForChargebacksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance" abstract="false" name="SaleOfStockNumberOfAdditionalSharesAvailableForIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bhc_NonExecutiveEligibleRecipientsMember" abstract="true" name="NonExecutiveEligibleRecipientsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SOFRCDOREURIBORAndSONIARatesMember" abstract="true" name="SOFRCDOREURIBORAndSONIARatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TermLoanBFacilityDueNovember2025Member" abstract="true" name="TermLoanBFacilityDueNovember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes525DueFebruary2031Member" abstract="true" name="SeniorNotes525DueFebruary2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ScheduleOfOtherIncomeAndExpensesLineItems" abstract="true" name="ScheduleOfOtherIncomeAndExpensesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_OrthoDermatologicsSegmentMember" abstract="true" name="OrthoDermatologicsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes700DueMarch2024Member" abstract="true" name="SeniorNotes700DueMarch2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TaroPharmaceuticalsIncLitigationMember" abstract="true" name="TaroPharmaceuticalsIncLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_GlumetzaAntitrustLitigationMember" abstract="true" name="GlumetzaAntitrustLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes850DueJanuary2027Member" abstract="true" name="SeniorNotes850DueJanuary2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencySettlementAgreementsNumberOfInsurers" abstract="false" name="LossContingencySettlementAgreementsNumberOfInsurers" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_SaleOfStockOverAllotmentTerm" abstract="false" name="SaleOfStockOverAllotmentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_ShowerToShowerProductLiabilityLitigationMember" abstract="true" name="ShowerToShowerProductLiabilityLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PartnerRelationshipsMember" abstract="true" name="PartnerRelationshipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" abstract="false" name="DebtInstrumentCovenantComplianceSecuredLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" abstract="false" name="LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_LitigationwithFormerSalixCEOMember" abstract="true" name="LitigationwithFormerSalixCEOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_InternationalRxMember" abstract="true" name="InternationalRxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" abstract="false" name="DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_NewRestatedCreditAgreementMember" abstract="true" name="NewRestatedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AccruedAndOtherCurrentLiabilitiesMember" abstract="true" name="AccruedAndOtherCurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_CardinalHealthIncMember" abstract="true" name="CardinalHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReserveForDiscountsAndAllowancesMember" abstract="true" name="ReserveForDiscountsAndAllowancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" abstract="false" name="DebtInstrumentCovenantTermsFixedChargeCoverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_SOFRCDORAndEURIBORRatesMember" abstract="true" name="SOFRCDORAndEURIBORRatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" abstract="false" name="LossContingencyStayOfApprovalMotionToExtendPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_GainContingencyStayOfApprovalPeriod" abstract="false" name="GainContingencyStayOfApprovalPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" abstract="false" name="AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_IPOAndOverAllotmentOptionMember" abstract="true" name="IPOAndOverAllotmentOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" abstract="false" name="PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ConcentrationRiskNumberOfProducts" abstract="false" name="ConcentrationRiskNumberOfProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_ProductBrandsMember" abstract="true" name="ProductBrandsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_UnitedStatesandPuertoRicoMember" abstract="true" name="UnitedStatesandPuertoRicoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RestructuringChargesAndInitialPublicOfferingCosts" abstract="false" name="RestructuringChargesAndInitialPublicOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeniorNotes625DueFebruary2029Member" abstract="true" name="SeniorNotes625DueFebruary2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BauschLombInternationalMember" abstract="true" name="BauschLombInternationalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AnnualAmortizationOfIntangibleAssets" abstract="false" name="AnnualAmortizationOfIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_NorwichPharmaceuticalsIncLitigationMember" abstract="true" name="NorwichPharmaceuticalsIncLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencyNumberOfInsurancePolicyPeriods" abstract="false" name="LossContingencyNumberOfInsurancePolicyPeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_DiscontinuedProductLinesMember" abstract="true" name="DiscontinuedProductLinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes6125DueApril2025Member" abstract="true" name="SeniorNotes6125DueApril2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_HighlyLiquidInvestmentsMaturityPeriod" abstract="false" name="HighlyLiquidInvestmentsMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_PadagisLitigationMember" abstract="true" name="PadagisLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AmounPharmaceuticalCompanySAEMember" abstract="true" name="AmounPharmaceuticalCompanySAEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" abstract="false" name="LossContingencyPlaintiffsNumberofGroupsofInvestors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" abstract="true" name="USDollarBaseRateAndCanadianDollarPrimeRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_MSNLaboratoriesPrivateLtdLitigationMember" abstract="true" name="MSNLaboratoriesPrivateLtdLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes500DueJanuary2028Member" abstract="true" name="SeniorNotes500DueJanuary2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SalixSegmentMember" abstract="true" name="SalixSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" abstract="false" name="BusinessAcquisitionContingentConsiderationFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_OmnibusIncentivePlan2014Member" abstract="true" name="OmnibusIncentivePlan2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OtherRevenuesMember" abstract="true" name="OtherRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecured5.50NotesDueNovember2025Member" abstract="true" name="SeniorSecured5.50NotesDueNovember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BLCreditAgreementMember" abstract="true" name="BLCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RevolvingCreditFacilityDueMay2027Member" abstract="true" name="RevolvingCreditFacilityDueMay2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TermLoanBFacilityDueJune2025Member" abstract="true" name="TermLoanBFacilityDueJune2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_MilestonePaymentRelatedToCertainProductMember" abstract="true" name="MilestonePaymentRelatedToCertainProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" abstract="false" name="LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" abstract="true" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_AmerisourceBergenCorporationMember" abstract="true" name="AmerisourceBergenCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" abstract="false" name="UnrecognizedTaxBenefitsIncludingInterestAndPenalties" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_BauschLombToBeDistributedToOtherLegalEntitiesMember" abstract="true" name="BauschLombToBeDistributedToOtherLegalEntitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" abstract="false" name="DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_LossContingencyStayOfApprovalPeriod" abstract="false" name="LossContingencyStayOfApprovalPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_SeniorSecured6125NotesDueFebruary2027Member" abstract="true" name="SeniorSecured6125NotesDueFebruary2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_Legalsettlementsandrelatedfees" abstract="false" name="Legalsettlementsandrelatedfees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_TermLoanBFacilityDueFebruary2027Member" abstract="true" name="TermLoanBFacilityDueFebruary2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RICOClassActionsMember" abstract="true" name="RICOClassActionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" abstract="true" name="BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" abstract="false" name="DebtInstrumentCovenantAmountAvailableForRestrictedPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_AccruedProductRebateCurrent" abstract="false" name="AccruedProductRebateCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_OrthoDermatologicsReportingUnitMember" abstract="true" name="OrthoDermatologicsReportingUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_CustomerTopTenProductsMember" abstract="true" name="CustomerTopTenProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" abstract="false" name="DebtInstrumentCreditSpreadAdjustmentOnVariableRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_SeniorSecured5.75NotesDueAugust2027Member" abstract="true" name="SeniorSecured5.75NotesDueAugust2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BrandedandOtherGenericProductsMember" abstract="true" name="BrandedandOtherGenericProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LitigationSettlementNumberOfObjectorsAppeals" abstract="false" name="LitigationSettlementNumberOfObjectorsAppeals" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_DiversifiedProductsSegmentMember" abstract="true" name="DiversifiedProductsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" abstract="false" name="BusinessCombinationContingentConsiderationNoncurrentLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" abstract="false" name="AccountsReceivableAllowanceForForeignExchangeAndOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_PatentInfringementLitigationMember" abstract="true" name="PatentInfringementLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes525DueJanuary2030Member" abstract="true" name="SeniorNotes525DueJanuary2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RestructuringAndIntegrationCostsMember" abstract="true" name="RestructuringAndIntegrationCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTotalLeverageRatio" abstract="false" name="DebtInstrumentCovenantTotalLeverageRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_RevenuesNetMember" abstract="true" name="RevenuesNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" abstract="false" name="LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" abstract="false" name="ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember" abstract="true" name="VisionCareSurgicalAndOphthalmicReportingUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_IPOFoundersGrantsMember" abstract="true" name="IPOFoundersGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RevolvingCreditFacilityDueFebruary2027Member" abstract="true" name="RevolvingCreditFacilityDueFebruary2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" abstract="false" name="LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_DeclaratoryJudgementActionLitigationMember" abstract="true" name="DeclaratoryJudgementActionLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" abstract="false" name="LineOfCreditFacilityThresholdForIncrementalBorrowings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SONIARateMember" abstract="true" name="SONIARateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AllowancesForLossesOnAccountsReceivableAndInventories" abstract="false" name="AllowancesForLossesOnAccountsReceivableAndInventories" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ReserveForCustomerReturnsMember" abstract="true" name="ReserveForCustomerReturnsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_GainContingencyNumberOfDefendants" abstract="false" name="GainContingencyNumberOfDefendants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_OutLicensedTechnologyMember" abstract="true" name="OutLicensedTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PreserVisionAREDSPatentLitigationMember" abstract="true" name="PreserVisionAREDSPatentLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" abstract="false" name="AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_AssetImpairmentChargesMember" abstract="true" name="AssetImpairmentChargesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" abstract="false" name="RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_RestrictedCashAndOtherSettlementDepositsCurrent" abstract="false" name="RestrictedCashAndOtherSettlementDepositsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" abstract="true" name="FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes700DueJanuary2028Member" abstract="true" name="SeniorNotes700DueJanuary2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" abstract="true" name="ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReportingUnitsExcludingOrthoDermatologicsMember" abstract="true" name="ReportingUnitsExcludingOrthoDermatologicsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" abstract="false" name="ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="ROTCPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OtherIncomeExpenseNet" abstract="false" name="OtherIncomeExpenseNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_RevolvingCreditFacilityDueJune2023Member" abstract="true" name="RevolvingCreditFacilityDueJune2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ResearchAndDevelopmentExpenseQualityAssurance" abstract="false" name="ResearchAndDevelopmentExpenseQualityAssurance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" abstract="false" name="DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" abstract="false" name="DebtInstrumentCovenantTotalLeverageRatioMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_OtherLongTermDebtMember" abstract="true" name="OtherLongTermDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DoctorsAllergyFormulaLLCLitigationMember" abstract="true" name="DoctorsAllergyFormulaLLCLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" abstract="false" name="SummaryOfResearchAndDevelopmentExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_DefaultJudgementMember" abstract="true" name="DefaultJudgementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_GainLossRelatedToLitigationSettlementGross" abstract="false" name="GainLossRelatedToLitigationSettlementGross" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ResearchAndDevelopmentExpenseProductRelated" abstract="false" name="ResearchAndDevelopmentExpenseProductRelated" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember" abstract="true" name="LumifyParagraphIVProceedingsLupinANDALitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TermFacilityDueMay2027Member" abstract="true" name="TermFacilityDueMay2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PlaintiffsDirectPurchasersMember" abstract="true" name="PlaintiffsDirectPurchasersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_InsuranceCoverageLawsuitMember" abstract="true" name="InsuranceCoverageLawsuitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_CanadianSecuritiesLitigationMember" abstract="true" name="CanadianSecuritiesLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_A9.00SeniorNotesdueDecember2025Member" abstract="true" name="A9.00SeniorNotesdueDecember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DeviceProductsMember" abstract="true" name="DeviceProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes925DueApril2026Member" abstract="true" name="SeniorNotes925DueApril2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantInterestCoverageRatioMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" abstract="false" name="RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" abstract="false" name="DebtInstrumentRedemptionPricePercentageChangeinControl" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_PharmaceuticalProductsMember" abstract="true" name="PharmaceuticalProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" abstract="false" name="DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_EuropeInterbankOfferedRateEURIBORMember" abstract="true" name="EuropeInterbankOfferedRateEURIBORMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" abstract="false" name="DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_McKessonCorporationMember" abstract="true" name="McKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" abstract="false" name="DebtInstrumentCovenantTermsSecuredLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_SeniorSecured4875NotesDueJune2028Member" abstract="true" name="SeniorSecured4875NotesDueJune2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" abstract="false" name="LossContingencyNewClaimsFiledButNotYetServedNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember" abstract="true" name="AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecuredCreditFacilitiesMember" abstract="true" name="SeniorSecuredCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" abstract="true" name="ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OvertheCounterProductsMember" abstract="true" name="OvertheCounterProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ScheduleOfOtherIncomeAndExpensesTable" abstract="true" name="ScheduleOfOtherIncomeAndExpensesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" abstract="true" name="PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" abstract="false" name="LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_SeparationPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="SeparationPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_TSRPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="TSRPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AccretionForTimeValueOfMoneyMember" abstract="true" name="AccretionForTimeValueOfMoneyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TimeBasedRSUMember" abstract="true" name="TimeBasedRSUMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReserveForRebatesAdvertisingCreditsPortionMember" abstract="true" name="ReserveForRebatesAdvertisingCreditsPortionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OtherCountriesMember" abstract="true" name="OtherCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember" abstract="true" name="RestrictedCashAndOtherSettlementDepositsCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember" abstract="true" name="PerrigoIsraelPharmaceuticalsLtdLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" abstract="false" name="SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" abstract="false" name="LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_PerformanceBasedRestrictedStockUnitsMember" abstract="true" name="PerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BauschLombMember" abstract="true" name="BauschLombMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeparationAndInitialPublicOfferingCostsMember" abstract="true" name="SeparationAndInitialPublicOfferingCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ValeantUSSecuritiesLitigationMember" abstract="true" name="ValeantUSSecuritiesLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" abstract="false" name="SummaryOfValuationAndQualifyingAccountsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_SeniorNotes725DueMay2029Member" abstract="true" name="SeniorNotes725DueMay2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReserveForRebatesMember" abstract="true" name="ReserveForRebatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AccruedProductReturnCurrent" abstract="false" name="AccruedProductReturnCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_InterestSettlementOnCrossCurrencySwaps" abstract="false" name="InterestSettlementOnCrossCurrencySwaps" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_XifaxanBrandedProductsMember" abstract="true" name="XifaxanBrandedProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SoltaMedicalSegmentMember" abstract="true" name="SoltaMedicalSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember" abstract="true" name="LumifyParagraphIVProceedingsSlaybackANDALitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>bhc-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:08e728a9-955b-42e6-9f9e-75e33d236c1d,g:6cf439ae-5822-43c6-a8ac-f8ebfd7ee7fe-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bhc-20220630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9d26e0ec-6968-4417-b21e-786957bd7e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a0f5b130-9571-4a9e-a797-e4eaade17cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9d26e0ec-6968-4417-b21e-786957bd7e60" xlink:to="loc_us-gaap_StockholdersEquity_a0f5b130-9571-4a9e-a797-e4eaade17cf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_bf5eb4f7-b264-456b-a81a-4de1eb491905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9d26e0ec-6968-4417-b21e-786957bd7e60" xlink:to="loc_us-gaap_MinorityInterest_bf5eb4f7-b264-456b-a81a-4de1eb491905" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_11101912-2efd-4879-ac18-9529eb2cdf25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2302029d-c8e9-43ab-ac08-5b49a9c33e76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_11101912-2efd-4879-ac18-9529eb2cdf25" xlink:to="loc_us-gaap_Liabilities_2302029d-c8e9-43ab-ac08-5b49a9c33e76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e1a854d1-e8cc-414f-af4d-a13ad645e597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_11101912-2efd-4879-ac18-9529eb2cdf25" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e1a854d1-e8cc-414f-af4d-a13ad645e597" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_9bed1d4d-c4da-4808-a0cd-b9c81d693d12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_11101912-2efd-4879-ac18-9529eb2cdf25" xlink:to="loc_us-gaap_CommitmentsAndContingencies_9bed1d4d-c4da-4808-a0cd-b9c81d693d12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_62bf5104-1f10-4925-85ca-d0b1e4ef9833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1d09dda0-0956-4738-ae5e-42bdf7202bca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_62bf5104-1f10-4925-85ca-d0b1e4ef9833" xlink:to="loc_us-gaap_LiabilitiesCurrent_1d09dda0-0956-4738-ae5e-42bdf7202bca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_e743cd07-e3dc-42ff-bcd1-fe291163b2df" xlink:href="bhc-20220630.xsd#bhc_BusinessCombinationContingentConsiderationNoncurrentLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_62bf5104-1f10-4925-85ca-d0b1e4ef9833" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_e743cd07-e3dc-42ff-bcd1-fe291163b2df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_edda3dc2-2966-4731-abbb-d7a2b6de3d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_62bf5104-1f10-4925-85ca-d0b1e4ef9833" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_edda3dc2-2966-4731-abbb-d7a2b6de3d7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b684e3b5-e5b5-42b7-9d85-8a6f10f5e8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_62bf5104-1f10-4925-85ca-d0b1e4ef9833" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b684e3b5-e5b5-42b7-9d85-8a6f10f5e8f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_53b3245f-f159-4333-a277-ee64fd93bb47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_62bf5104-1f10-4925-85ca-d0b1e4ef9833" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_53b3245f-f159-4333-a277-ee64fd93bb47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ff38c986-c0dc-455e-b550-9483953e7f38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_db8bba6d-79ae-440c-bf16-8dd1ba96b9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff38c986-c0dc-455e-b550-9483953e7f38" xlink:to="loc_us-gaap_CommonStockValue_db8bba6d-79ae-440c-bf16-8dd1ba96b9fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8d0ff280-dd33-455e-9043-7a7f1834e76e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff38c986-c0dc-455e-b550-9483953e7f38" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8d0ff280-dd33-455e-9043-7a7f1834e76e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b6399949-c310-43df-a15d-46a9b52e0927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff38c986-c0dc-455e-b550-9483953e7f38" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b6399949-c310-43df-a15d-46a9b52e0927" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cd41fa0e-035f-43ed-8f97-3f9ac849c26a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff38c986-c0dc-455e-b550-9483953e7f38" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cd41fa0e-035f-43ed-8f97-3f9ac849c26a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9f5a406f-fca4-447a-8bb4-83e83035f1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_691b20e2-a127-4ab8-8afc-a3f70c64756f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9f5a406f-fca4-447a-8bb4-83e83035f1fa" xlink:to="loc_us-gaap_AccountsPayableCurrent_691b20e2-a127-4ab8-8afc-a3f70c64756f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7a6eb2f8-64f2-4be9-84b2-43a464892c84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9f5a406f-fca4-447a-8bb4-83e83035f1fa" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7a6eb2f8-64f2-4be9-84b2-43a464892c84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_dddd154c-e8f0-4fea-8b23-5b8023c6a785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9f5a406f-fca4-447a-8bb4-83e83035f1fa" xlink:to="loc_us-gaap_LongTermDebtCurrent_dddd154c-e8f0-4fea-8b23-5b8023c6a785" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3c1f08ab-b85b-407a-a636-abe7964c6064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_614fff75-b1e7-4c21-b037-2ffeae2ff861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3c1f08ab-b85b-407a-a636-abe7964c6064" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_614fff75-b1e7-4c21-b037-2ffeae2ff861" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_a674fa84-76fd-47ae-b6be-e65be6a844f7" xlink:href="bhc-20220630.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3c1f08ab-b85b-407a-a636-abe7964c6064" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_a674fa84-76fd-47ae-b6be-e65be6a844f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_ae1ecc3c-98be-4679-8c39-e79f54c699c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3c1f08ab-b85b-407a-a636-abe7964c6064" xlink:to="loc_us-gaap_ReceivablesNetCurrent_ae1ecc3c-98be-4679-8c39-e79f54c699c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7009fb2e-b018-4e6b-a0a7-8c13963921b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3c1f08ab-b85b-407a-a636-abe7964c6064" xlink:to="loc_us-gaap_InventoryNet_7009fb2e-b018-4e6b-a0a7-8c13963921b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_26236495-e7d2-4d09-9bb9-e6ca997654d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3c1f08ab-b85b-407a-a636-abe7964c6064" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_26236495-e7d2-4d09-9bb9-e6ca997654d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_fd3313bb-2397-40a2-a833-84a3fa762d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_131e1a5a-c3d3-42a6-b179-174d923898b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fd3313bb-2397-40a2-a833-84a3fa762d7e" xlink:to="loc_us-gaap_AssetsCurrent_131e1a5a-c3d3-42a6-b179-174d923898b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d1cfe1ee-174d-4280-b382-1a025b1b05dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fd3313bb-2397-40a2-a833-84a3fa762d7e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d1cfe1ee-174d-4280-b382-1a025b1b05dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4f4fbc05-f143-436c-9255-caf9caea929d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fd3313bb-2397-40a2-a833-84a3fa762d7e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4f4fbc05-f143-436c-9255-caf9caea929d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3eea35be-4cfc-417a-bf1e-d5910d813bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fd3313bb-2397-40a2-a833-84a3fa762d7e" xlink:to="loc_us-gaap_Goodwill_3eea35be-4cfc-417a-bf1e-d5910d813bb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_5d1cb91b-759a-4262-b861-cddc276bf33a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fd3313bb-2397-40a2-a833-84a3fa762d7e" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_5d1cb91b-759a-4262-b861-cddc276bf33a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_641b1d6b-5b78-4b27-aaab-6f96ed3b6bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fd3313bb-2397-40a2-a833-84a3fa762d7e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_641b1d6b-5b78-4b27-aaab-6f96ed3b6bf2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bhc-20220630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c4ec4e02-308e-4bae-a165-54bf7e467d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c03b1b62-4442-4866-b44a-a95b21149d42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c4ec4e02-308e-4bae-a165-54bf7e467d92" xlink:to="loc_us-gaap_ProfitLoss_c03b1b62-4442-4866-b44a-a95b21149d42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2eb772a8-7de7-4e1e-ba9f-05e4fd06d157" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c4ec4e02-308e-4bae-a165-54bf7e467d92" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2eb772a8-7de7-4e1e-ba9f-05e4fd06d157" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5367af3c-f7d9-4ca1-842b-343ef864f3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6f20f938-2bc1-4e2a-a27a-06cc8f4ffdeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5367af3c-f7d9-4ca1-842b-343ef864f3b2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6f20f938-2bc1-4e2a-a27a-06cc8f4ffdeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_945621bc-b5e0-4210-a049-015c32a72d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5367af3c-f7d9-4ca1-842b-343ef864f3b2" xlink:to="loc_us-gaap_CostsAndExpenses_945621bc-b5e0-4210-a049-015c32a72d2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_42d286a4-9875-4fa5-a379-ae0cae76d95b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bc3b23bd-9ac5-4918-bc65-d8b1d481ea4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_42d286a4-9875-4fa5-a379-ae0cae76d95b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bc3b23bd-9ac5-4918-bc65-d8b1d481ea4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_040cb915-4faf-406d-847b-7efaa907e9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_42d286a4-9875-4fa5-a379-ae0cae76d95b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_040cb915-4faf-406d-847b-7efaa907e9c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_09721486-d000-49cc-b79f-9c2f3c5dc992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ea755180-5660-468d-9d58-90223dd89f55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_09721486-d000-49cc-b79f-9c2f3c5dc992" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ea755180-5660-468d-9d58-90223dd89f55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ab632364-1798-4ff5-985d-92f91b301763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_09721486-d000-49cc-b79f-9c2f3c5dc992" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ab632364-1798-4ff5-985d-92f91b301763" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_269192ef-5a17-4ab6-b914-9d36e55d70c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_09721486-d000-49cc-b79f-9c2f3c5dc992" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_269192ef-5a17-4ab6-b914-9d36e55d70c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_0aee09f0-e8e7-4c2d-abed-723676554017" xlink:href="bhc-20220630.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_09721486-d000-49cc-b79f-9c2f3c5dc992" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_0aee09f0-e8e7-4c2d-abed-723676554017" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_c03ae25a-0598-4621-8e70-3fbb6c4daef7" xlink:href="bhc-20220630.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_09721486-d000-49cc-b79f-9c2f3c5dc992" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_c03ae25a-0598-4621-8e70-3fbb6c4daef7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_4e4e4420-cfea-416a-a887-4f5661425058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_09721486-d000-49cc-b79f-9c2f3c5dc992" xlink:to="loc_us-gaap_AssetImpairmentCharges_4e4e4420-cfea-416a-a887-4f5661425058" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_bd9cee43-dfbf-4db8-89a6-933b2f0f3f32" xlink:href="bhc-20220630.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_09721486-d000-49cc-b79f-9c2f3c5dc992" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_bd9cee43-dfbf-4db8-89a6-933b2f0f3f32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_944fb674-b481-470a-87fa-e7d465c74eab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_09721486-d000-49cc-b79f-9c2f3c5dc992" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_944fb674-b481-470a-87fa-e7d465c74eab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c9c1a5b1-eb2c-4212-8980-75d08458df9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2765ecfd-0946-4e53-8343-b4b5c73c2e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c9c1a5b1-eb2c-4212-8980-75d08458df9e" xlink:to="loc_us-gaap_OperatingIncomeLoss_2765ecfd-0946-4e53-8343-b4b5c73c2e53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_0565aeef-786a-4655-942a-2c6e24a2527f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c9c1a5b1-eb2c-4212-8980-75d08458df9e" xlink:to="loc_us-gaap_InvestmentIncomeInterest_0565aeef-786a-4655-942a-2c6e24a2527f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_366fc820-f1b1-4922-b682-701a1052e89c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c9c1a5b1-eb2c-4212-8980-75d08458df9e" xlink:to="loc_us-gaap_InterestExpenseDebt_366fc820-f1b1-4922-b682-701a1052e89c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_96aa536a-0ad1-458f-b7df-331b95c086e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c9c1a5b1-eb2c-4212-8980-75d08458df9e" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_96aa536a-0ad1-458f-b7df-331b95c086e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_66d4922f-c2e0-4d07-b655-dedabe044ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c9c1a5b1-eb2c-4212-8980-75d08458df9e" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_66d4922f-c2e0-4d07-b655-dedabe044ab1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bhc-20220630.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6c503b0b-cafa-4dab-b363-3a65f632c2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_bb728f3b-a6f7-47cc-ac98-d011adbd36d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6c503b0b-cafa-4dab-b363-3a65f632c2d7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_bb728f3b-a6f7-47cc-ac98-d011adbd36d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_b6257779-4350-4b76-b319-271fb0c3ace4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6c503b0b-cafa-4dab-b363-3a65f632c2d7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_b6257779-4350-4b76-b319-271fb0c3ace4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_56a93dbb-eefd-45a3-affe-58bd6ec09fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_32dd3041-87cd-4c47-afb9-8b7380b89534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_56a93dbb-eefd-45a3-affe-58bd6ec09fdf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_32dd3041-87cd-4c47-afb9-8b7380b89534" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_9b3ae595-2d8c-4b50-8683-bfa780e6224f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_56a93dbb-eefd-45a3-affe-58bd6ec09fdf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_9b3ae595-2d8c-4b50-8683-bfa780e6224f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_bf6246c6-5f7b-4e40-b737-d8c24ceb8c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c83623fd-48ea-4b3f-9ae9-2ec596907559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_bf6246c6-5f7b-4e40-b737-d8c24ceb8c2f" xlink:to="loc_us-gaap_ProfitLoss_c83623fd-48ea-4b3f-9ae9-2ec596907559" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_26170ad2-d18a-4987-8f37-d061e363d6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_bf6246c6-5f7b-4e40-b737-d8c24ceb8c2f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_26170ad2-d18a-4987-8f37-d061e363d6fd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bhc-20220630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d3362d4-c1bb-4887-9836-cb5474eb2c80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_adaf6670-ea8c-4bdb-a845-2d22bfe98518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d3362d4-c1bb-4887-9836-cb5474eb2c80" xlink:to="loc_us-gaap_ProfitLoss_adaf6670-ea8c-4bdb-a845-2d22bfe98518" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_483dcd2e-9618-4195-858e-48f77f3c0e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d3362d4-c1bb-4887-9836-cb5474eb2c80" xlink:to="loc_us-gaap_DepreciationAndAmortization_483dcd2e-9618-4195-858e-48f77f3c0e0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_06d8bd3a-8b72-4a6d-9438-de3da625a364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d3362d4-c1bb-4887-9836-cb5474eb2c80" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_06d8bd3a-8b72-4a6d-9438-de3da625a364" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_072da3f2-498d-4d33-85f7-5d1628d1ee2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d3362d4-c1bb-4887-9836-cb5474eb2c80" xlink:to="loc_us-gaap_AssetImpairmentCharges_072da3f2-498d-4d33-85f7-5d1628d1ee2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_bf820ff3-f8b8-4232-a0fe-a832c47e8e9e" xlink:href="bhc-20220630.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d3362d4-c1bb-4887-9836-cb5474eb2c80" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_bf820ff3-f8b8-4232-a0fe-a832c47e8e9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_ebafb6d2-f1a1-4041-9a9e-16c9381289e3" xlink:href="bhc-20220630.xsd#bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d3362d4-c1bb-4887-9836-cb5474eb2c80" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_ebafb6d2-f1a1-4041-9a9e-16c9381289e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_fe164d51-10f3-46ec-9cbd-2090549b6d17" xlink:href="bhc-20220630.xsd#bhc_AllowancesForLossesOnAccountsReceivableAndInventories"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d3362d4-c1bb-4887-9836-cb5474eb2c80" xlink:to="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_fe164d51-10f3-46ec-9cbd-2090549b6d17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_c8e30e12-3518-4d2c-b08e-c23a152190c7" xlink:href="bhc-20220630.xsd#bhc_DeferredIncomeTaxNoncashExpenseBenefit"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d3362d4-c1bb-4887-9836-cb5474eb2c80" xlink:to="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_c8e30e12-3518-4d2c-b08e-c23a152190c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_f52218f5-540d-4159-89b1-cb28cfa75e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d3362d4-c1bb-4887-9836-cb5474eb2c80" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_f52218f5-540d-4159-89b1-cb28cfa75e6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainLossRelatedToLitigationSettlementGross_30b68a03-5ee6-452f-b0cb-c2af97fc7ccc" xlink:href="bhc-20220630.xsd#bhc_GainLossRelatedToLitigationSettlementGross"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d3362d4-c1bb-4887-9836-cb5474eb2c80" xlink:to="loc_bhc_GainLossRelatedToLitigationSettlementGross_30b68a03-5ee6-452f-b0cb-c2af97fc7ccc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_00740e75-0981-4892-9d70-28a80464b4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d3362d4-c1bb-4887-9836-cb5474eb2c80" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_00740e75-0981-4892-9d70-28a80464b4c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a1a0ace8-6a87-4596-8f4b-3ef8b8c2f957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d3362d4-c1bb-4887-9836-cb5474eb2c80" xlink:to="loc_us-gaap_ShareBasedCompensation_a1a0ace8-6a87-4596-8f4b-3ef8b8c2f957" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_071b5549-617a-4308-b497-31f2c13f532b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d3362d4-c1bb-4887-9836-cb5474eb2c80" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_071b5549-617a-4308-b497-31f2c13f532b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeGainExcludedComponent_23c40024-ffca-4e9d-8687-b872a950a086" xlink:href="bhc-20220630.xsd#bhc_DerivativeGainExcludedComponent"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d3362d4-c1bb-4887-9836-cb5474eb2c80" xlink:to="loc_bhc_DerivativeGainExcludedComponent_23c40024-ffca-4e9d-8687-b872a950a086" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e8f396b7-1367-4cbc-86d7-a515267a12e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d3362d4-c1bb-4887-9836-cb5474eb2c80" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e8f396b7-1367-4cbc-86d7-a515267a12e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_8abcd631-4d30-4685-b038-04e4cecd338a" xlink:href="bhc-20220630.xsd#bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d3362d4-c1bb-4887-9836-cb5474eb2c80" xlink:to="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_8abcd631-4d30-4685-b038-04e4cecd338a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_5c892520-fed6-48b8-aa62-1f2bb60dca3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d3362d4-c1bb-4887-9836-cb5474eb2c80" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_5c892520-fed6-48b8-aa62-1f2bb60dca3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f7c97ebf-fdd7-407b-b652-9c1665018ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d3362d4-c1bb-4887-9836-cb5474eb2c80" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f7c97ebf-fdd7-407b-b652-9c1665018ec7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_fa079fb8-5070-4173-a7bc-01aa6a133919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d3362d4-c1bb-4887-9836-cb5474eb2c80" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_fa079fb8-5070-4173-a7bc-01aa6a133919" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9ce0c2ff-23cb-46c3-a04f-2abbc810d78c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="20" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d3362d4-c1bb-4887-9836-cb5474eb2c80" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9ce0c2ff-23cb-46c3-a04f-2abbc810d78c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_96ace15f-d28e-433d-8cc9-2cf3f6bc25c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="21" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d3362d4-c1bb-4887-9836-cb5474eb2c80" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_96ace15f-d28e-433d-8cc9-2cf3f6bc25c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_52e10635-3cca-411a-ae78-35a92119c191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e78ad18a-5f4e-438c-b469-4f19bda7c44e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_52e10635-3cca-411a-ae78-35a92119c191" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e78ad18a-5f4e-438c-b469-4f19bda7c44e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_ed43ef57-85d8-433f-886c-b320f0e310d1" xlink:href="bhc-20220630.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_52e10635-3cca-411a-ae78-35a92119c191" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_ed43ef57-85d8-433f-886c-b320f0e310d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_8e867c4a-0584-418b-8739-06a6f3f5a912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_52e10635-3cca-411a-ae78-35a92119c191" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_8e867c4a-0584-418b-8739-06a6f3f5a912" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_431f6012-69b0-4202-a727-4f5b2cc9bc96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8f9ba79d-2cfd-4744-89c5-c01546841c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_431f6012-69b0-4202-a727-4f5b2cc9bc96" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_8f9ba79d-2cfd-4744-89c5-c01546841c9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_10219917-11b1-4383-be68-17475e4e08d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_431f6012-69b0-4202-a727-4f5b2cc9bc96" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_10219917-11b1-4383-be68-17475e4e08d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty_48395d0b-9996-4db2-b57a-b0b7c0572801" xlink:href="bhc-20220630.xsd#bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_431f6012-69b0-4202-a727-4f5b2cc9bc96" xlink:to="loc_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty_48395d0b-9996-4db2-b57a-b0b7c0572801" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_5f9c7ac5-d58d-455e-94f3-fcd7c0c67486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_431f6012-69b0-4202-a727-4f5b2cc9bc96" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_5f9c7ac5-d58d-455e-94f3-fcd7c0c67486" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_dde4d779-d539-4124-9404-31711a18cd0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_431f6012-69b0-4202-a727-4f5b2cc9bc96" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_dde4d779-d539-4124-9404-31711a18cd0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_f2f8bfae-30ff-4c99-8827-183b0c3a4f28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_431f6012-69b0-4202-a727-4f5b2cc9bc96" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_f2f8bfae-30ff-4c99-8827-183b0c3a4f28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_bb8dc4eb-7fff-4abc-879c-0bcc2d7674ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_431f6012-69b0-4202-a727-4f5b2cc9bc96" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_bb8dc4eb-7fff-4abc-879c-0bcc2d7674ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a13cfa24-9b71-4a66-9709-68d5c48da1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_567a1132-aac6-4536-92bf-1cea23c79175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a13cfa24-9b71-4a66-9709-68d5c48da1a0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_567a1132-aac6-4536-92bf-1cea23c79175" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_78126097-293e-40a4-85bf-20b6ce32f3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a13cfa24-9b71-4a66-9709-68d5c48da1a0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_78126097-293e-40a4-85bf-20b6ce32f3d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_13bdc9d4-f294-4972-a0ca-21dce7a5d175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a13cfa24-9b71-4a66-9709-68d5c48da1a0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_13bdc9d4-f294-4972-a0ca-21dce7a5d175" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0f01439f-f90a-4634-864a-33c453819c84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a13cfa24-9b71-4a66-9709-68d5c48da1a0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0f01439f-f90a-4634-864a-33c453819c84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a8a2673a-af9e-4732-a85c-5ac2f9a639bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6a7a276c-84ed-44c8-a9d2-9221738f00c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a8a2673a-af9e-4732-a85c-5ac2f9a639bb" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6a7a276c-84ed-44c8-a9d2-9221738f00c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_10e7dc13-34c6-4f86-a637-be78f061984f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a8a2673a-af9e-4732-a85c-5ac2f9a639bb" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_10e7dc13-34c6-4f86-a637-be78f061984f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_42ce3be9-7453-4c9e-b6a6-4d38db6b59fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a8a2673a-af9e-4732-a85c-5ac2f9a639bb" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_42ce3be9-7453-4c9e-b6a6-4d38db6b59fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_8bbcd3f9-3bb6-4b61-b000-7c8141677d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a8a2673a-af9e-4732-a85c-5ac2f9a639bb" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_8bbcd3f9-3bb6-4b61-b000-7c8141677d79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_0e3c2f4c-092f-44f5-9c74-83d0b7cbd891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a8a2673a-af9e-4732-a85c-5ac2f9a639bb" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_0e3c2f4c-092f-44f5-9c74-83d0b7cbd891" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InterestSettlementOnCrossCurrencySwaps_4ab93688-7a32-4bfe-b7d2-43bf8df14eaf" xlink:href="bhc-20220630.xsd#bhc_InterestSettlementOnCrossCurrencySwaps"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a8a2673a-af9e-4732-a85c-5ac2f9a639bb" xlink:to="loc_bhc_InterestSettlementOnCrossCurrencySwaps_4ab93688-7a32-4bfe-b7d2-43bf8df14eaf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ac77f668-07c0-46f6-b1a0-a96c8dedc53e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_ef844ad3-c19a-44f9-992c-46e4dec8e901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ac77f668-07c0-46f6-b1a0-a96c8dedc53e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_ef844ad3-c19a-44f9-992c-46e4dec8e901" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_0f8dcd04-9580-4d34-8689-07f1e8598a63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ac77f668-07c0-46f6-b1a0-a96c8dedc53e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_0f8dcd04-9580-4d34-8689-07f1e8598a63" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#INVENTORIESComponentsofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_0f6e0c04-baf8-4496-b261-9582cf3b356c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_2be38907-3400-41f0-adb9-f0830d4b5085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_0f6e0c04-baf8-4496-b261-9582cf3b356c" xlink:to="loc_us-gaap_InventoryRawMaterials_2be38907-3400-41f0-adb9-f0830d4b5085" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_ee51c34a-a457-46c8-94ac-0176b97d3c49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_0f6e0c04-baf8-4496-b261-9582cf3b356c" xlink:to="loc_us-gaap_InventoryWorkInProcess_ee51c34a-a457-46c8-94ac-0176b97d3c49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_8c793cc9-0de3-49a7-a9a0-7be4abcc2d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_0f6e0c04-baf8-4496-b261-9582cf3b356c" xlink:to="loc_us-gaap_InventoryFinishedGoods_8c793cc9-0de3-49a7-a9a0-7be4abcc2d14" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7ea32802-c874-4087-9b19-6af443dfbf9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3ba7ace4-8a8c-4a24-ac6b-2cae8c1f7581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7ea32802-c874-4087-9b19-6af443dfbf9b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3ba7ace4-8a8c-4a24-ac6b-2cae8c1f7581" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_297e75f5-6d34-4079-af2f-a6e22e9fb063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7ea32802-c874-4087-9b19-6af443dfbf9b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_297e75f5-6d34-4079-af2f-a6e22e9fb063" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aea7435b-db05-4cc7-9f3e-4ab56e83592a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_220603e9-1a37-400a-bc46-5fe9f4e58eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aea7435b-db05-4cc7-9f3e-4ab56e83592a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_220603e9-1a37-400a-bc46-5fe9f4e58eca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ae08315d-8871-4d7f-b169-4318406553e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_aea7435b-db05-4cc7-9f3e-4ab56e83592a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ae08315d-8871-4d7f-b169-4318406553e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_513a7bc6-1eeb-4671-aa63-2d366cc125fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_19fbae13-fd15-4417-a564-1dd1cf0fff0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_513a7bc6-1eeb-4671-aa63-2d366cc125fe" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_19fbae13-fd15-4417-a564-1dd1cf0fff0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f127dbbb-90a9-4076-aa22-cfa0a811f24a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_513a7bc6-1eeb-4671-aa63-2d366cc125fe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f127dbbb-90a9-4076-aa22-cfa0a811f24a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_582b85b0-b1c0-438b-ae4b-a79578f32159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_cc8ccd25-2b49-4a01-a97d-a44e9422e3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_582b85b0-b1c0-438b-ae4b-a79578f32159" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_cc8ccd25-2b49-4a01-a97d-a44e9422e3a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_afc66911-d935-49ad-ad40-c2491f097cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_582b85b0-b1c0-438b-ae4b-a79578f32159" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_afc66911-d935-49ad-ad40-c2491f097cfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_08f3f1b6-728f-4230-bf05-072579517414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_582b85b0-b1c0-438b-ae4b-a79578f32159" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_08f3f1b6-728f-4230-bf05-072579517414" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_8dc64196-a287-42eb-b076-573b6a2b6c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_582b85b0-b1c0-438b-ae4b-a79578f32159" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_8dc64196-a287-42eb-b076-573b6a2b6c45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_00584f68-cc2c-4dbb-afa6-7339ecd9fa3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_582b85b0-b1c0-438b-ae4b-a79578f32159" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_00584f68-cc2c-4dbb-afa6-7339ecd9fa3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_a8aea26f-a16b-496f-9d93-38f0bb3852c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_582b85b0-b1c0-438b-ae4b-a79578f32159" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_a8aea26f-a16b-496f-9d93-38f0bb3852c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_5dd62194-1887-4df3-b072-5af82d726244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_582b85b0-b1c0-438b-ae4b-a79578f32159" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_5dd62194-1887-4df3-b072-5af82d726244" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5604e1c2-669c-4ed6-a4ab-06f9a57734b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_Legalsettlementsandrelatedfees_b53b0b96-5b8e-4379-8e54-76019c4b32cb" xlink:href="bhc-20220630.xsd#bhc_Legalsettlementsandrelatedfees"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5604e1c2-669c-4ed6-a4ab-06f9a57734b8" xlink:to="loc_bhc_Legalsettlementsandrelatedfees_b53b0b96-5b8e-4379-8e54-76019c4b32cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductRebateCurrent_d744286b-dfb9-4b39-8f8f-b6e008a8859b" xlink:href="bhc-20220630.xsd#bhc_AccruedProductRebateCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5604e1c2-669c-4ed6-a4ab-06f9a57734b8" xlink:to="loc_bhc_AccruedProductRebateCurrent_d744286b-dfb9-4b39-8f8f-b6e008a8859b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductReturnCurrent_4c9db5dd-a486-4863-b9af-7b76fb997292" xlink:href="bhc-20220630.xsd#bhc_AccruedProductReturnCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5604e1c2-669c-4ed6-a4ab-06f9a57734b8" xlink:to="loc_bhc_AccruedProductReturnCurrent_4c9db5dd-a486-4863-b9af-7b76fb997292" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_d979cbe4-46ec-4440-ba6e-e30855474862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5604e1c2-669c-4ed6-a4ab-06f9a57734b8" xlink:to="loc_us-gaap_InterestPayableCurrent_d979cbe4-46ec-4440-ba6e-e30855474862" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_384246ce-99b2-4eb7-8d40-fb6e610d3535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5604e1c2-669c-4ed6-a4ab-06f9a57734b8" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_384246ce-99b2-4eb7-8d40-fb6e610d3535" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_a00f4e00-d428-407d-a79c-7c1d06f8836a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5604e1c2-669c-4ed6-a4ab-06f9a57734b8" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_a00f4e00-d428-407d-a79c-7c1d06f8836a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4bae566e-457d-43d3-a49b-d170f41d8696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5604e1c2-669c-4ed6-a4ab-06f9a57734b8" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4bae566e-457d-43d3-a49b-d170f41d8696" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4a882104-d395-4b62-a5e3-f4a8c9261288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_bce3a35d-4fbd-41ab-ba52-38e9602b7ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_4a882104-d395-4b62-a5e3-f4a8c9261288" xlink:to="loc_us-gaap_LongTermDebtCurrent_bce3a35d-4fbd-41ab-ba52-38e9602b7ae7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_5d14cf89-5974-4b3e-9dba-95b41a9b73cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_4a882104-d395-4b62-a5e3-f4a8c9261288" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_5d14cf89-5974-4b3e-9dba-95b41a9b73cf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_58947bb9-37d4-4c29-aab2-e22193c51160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_2011cf60-17f0-41fa-a35e-6de3196c2e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_58947bb9-37d4-4c29-aab2-e22193c51160" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_2011cf60-17f0-41fa-a35e-6de3196c2e58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_863dc2de-76ca-4d69-9ac5-1b44c6058bad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_58947bb9-37d4-4c29-aab2-e22193c51160" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_863dc2de-76ca-4d69-9ac5-1b44c6058bad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1b3eedc8-f294-499b-8806-9d650429b4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_58947bb9-37d4-4c29-aab2-e22193c51160" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1b3eedc8-f294-499b-8806-9d650429b4f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_e95a6fda-0365-4df3-8d28-3420cf1c2ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_58947bb9-37d4-4c29-aab2-e22193c51160" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_e95a6fda-0365-4df3-8d28-3420cf1c2ac9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_d34e86bc-1a52-414f-8fb1-f04eb073be95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_58947bb9-37d4-4c29-aab2-e22193c51160" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_d34e86bc-1a52-414f-8fb1-f04eb073be95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2b55e754-d715-46f1-9874-019bc7d2e3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_58947bb9-37d4-4c29-aab2-e22193c51160" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2b55e754-d715-46f1-9874-019bc7d2e3bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_6f48488d-00e3-4db7-aca1-23bc97f97abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_58947bb9-37d4-4c29-aab2-e22193c51160" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_6f48488d-00e3-4db7-aca1-23bc97f97abc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_71e58c73-0d22-4f0d-97c8-193a6b3704c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_96d6282f-1030-4a5d-abbd-c832c8cf8ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_71e58c73-0d22-4f0d-97c8-193a6b3704c9" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_96d6282f-1030-4a5d-abbd-c832c8cf8ca3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_3473ca3a-6126-44ca-885a-5e0b004a7738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_71e58c73-0d22-4f0d-97c8-193a6b3704c9" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_3473ca3a-6126-44ca-885a-5e0b004a7738" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_87694b0d-43e1-44bb-b8dd-a517ea098d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_aab2d326-667f-40c5-bbe3-637f15bc6f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_87694b0d-43e1-44bb-b8dd-a517ea098d1d" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_aab2d326-667f-40c5-bbe3-637f15bc6f6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_07bc190f-0afa-42a3-b8ed-5edadef17657" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_87694b0d-43e1-44bb-b8dd-a517ea098d1d" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_07bc190f-0afa-42a3-b8ed-5edadef17657" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_b9e313e0-a817-4aa1-80fa-ee25c50108a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_87694b0d-43e1-44bb-b8dd-a517ea098d1d" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_b9e313e0-a817-4aa1-80fa-ee25c50108a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_242bbfef-7eef-4d7e-a0c2-82e1e1539f99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_87694b0d-43e1-44bb-b8dd-a517ea098d1d" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_242bbfef-7eef-4d7e-a0c2-82e1e1539f99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_1cda0a09-9b3a-4f04-af66-5471520823cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_87694b0d-43e1-44bb-b8dd-a517ea098d1d" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_1cda0a09-9b3a-4f04-af66-5471520823cf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_320147f0-0bb7-4d47-8ef6-890959290507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_13a97fa8-677b-4d30-954b-59b80b34afe0" xlink:href="bhc-20220630.xsd#bhc_ResearchAndDevelopmentExpenseProductRelated"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_320147f0-0bb7-4d47-8ef6-890959290507" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_13a97fa8-677b-4d30-954b-59b80b34afe0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_ce116db8-23fa-451f-9e2f-fe1c693423bf" xlink:href="bhc-20220630.xsd#bhc_ResearchAndDevelopmentExpenseQualityAssurance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_320147f0-0bb7-4d47-8ef6-890959290507" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_ce116db8-23fa-451f-9e2f-fe1c693423bf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#OTHEREXPENSENETSummaryofOtherExpenseNetDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c93a50da-e523-4e4c-b21d-f0fc661aed12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_1411fb2e-29a3-40a2-8af8-8d3d3c7a87ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_c93a50da-e523-4e4c-b21d-f0fc661aed12" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_1411fb2e-29a3-40a2-8af8-8d3d3c7a87ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1c3553a1-7eff-4235-94e6-d8dbf1511143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_c93a50da-e523-4e4c-b21d-f0fc661aed12" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1c3553a1-7eff-4235-94e6-d8dbf1511143" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_a71c7919-3218-48f4-8a38-65be1d873861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_c93a50da-e523-4e4c-b21d-f0fc661aed12" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_a71c7919-3218-48f4-8a38-65be1d873861" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_873be63e-61de-4464-a7f9-a660f6b4f61e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_c93a50da-e523-4e4c-b21d-f0fc661aed12" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_873be63e-61de-4464-a7f9-a660f6b4f61e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherIncomeExpenseNet_dab03094-f461-4603-8891-4ce999f7583c" xlink:href="bhc-20220630.xsd#bhc_OtherIncomeExpenseNet"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_c93a50da-e523-4e4c-b21d-f0fc661aed12" xlink:to="loc_bhc_OtherIncomeExpenseNet_dab03094-f461-4603-8891-4ce999f7583c" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>bhc-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:08e728a9-955b-42e6-9f9e-75e33d236c1d,g:6cf439ae-5822-43c6-a8ac-f8ebfd7ee7fe-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bhc-20220630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="ie305b28697be4ad1b4c5399ff3a25a2e_CONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_ed36541b-ab5e-49fd-9268-5fe44a9437e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_RevenuesAbstract_ed36541b-ab5e-49fd-9268-5fe44a9437e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9f628dda-858f-445c-a4f0-297791785445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_ed36541b-ab5e-49fd-9268-5fe44a9437e9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9f628dda-858f-445c-a4f0-297791785445" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_0344d775-d641-4098-b750-810cf061dad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_0344d775-d641-4098-b750-810cf061dad8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d08b6721-a069-4903-96ca-9cd63c880e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0344d775-d641-4098-b750-810cf061dad8" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d08b6721-a069-4903-96ca-9cd63c880e60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7da73ac8-fbca-44e6-8ec0-efed5225149f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0344d775-d641-4098-b750-810cf061dad8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7da73ac8-fbca-44e6-8ec0-efed5225149f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4e9ef837-c072-4b97-8b42-24176add9d03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0344d775-d641-4098-b750-810cf061dad8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4e9ef837-c072-4b97-8b42-24176add9d03" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_1d819cc8-79d0-461b-8790-018bd055f0ca" xlink:href="bhc-20220630.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0344d775-d641-4098-b750-810cf061dad8" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_1d819cc8-79d0-461b-8790-018bd055f0ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_4778e4f0-f1d2-4977-bbf1-7f48cbb1d370" xlink:href="bhc-20220630.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0344d775-d641-4098-b750-810cf061dad8" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_4778e4f0-f1d2-4977-bbf1-7f48cbb1d370" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_4aee2aba-6b9b-4a42-8cdd-2a535936f6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0344d775-d641-4098-b750-810cf061dad8" xlink:to="loc_us-gaap_AssetImpairmentCharges_4aee2aba-6b9b-4a42-8cdd-2a535936f6f0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_7872f56d-940a-4e8a-ade5-4f7077a4513b" xlink:href="bhc-20220630.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0344d775-d641-4098-b750-810cf061dad8" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_7872f56d-940a-4e8a-ade5-4f7077a4513b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_3b795495-fa92-4487-bc62-5053f3e7e2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0344d775-d641-4098-b750-810cf061dad8" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_3b795495-fa92-4487-bc62-5053f3e7e2f4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_111fae42-11a2-485d-bbf8-18312fb1adff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0344d775-d641-4098-b750-810cf061dad8" xlink:to="loc_us-gaap_CostsAndExpenses_111fae42-11a2-485d-bbf8-18312fb1adff" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6a38ef55-476c-40a9-902c-b615cc36aa86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_OperatingIncomeLoss_6a38ef55-476c-40a9-902c-b615cc36aa86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_0c1716ab-4ddb-4ceb-882c-41eb87ee3306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_InvestmentIncomeInterest_0c1716ab-4ddb-4ceb-882c-41eb87ee3306" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_e4f53e8c-000b-49eb-abe9-21da0989642a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_InterestExpenseDebt_e4f53e8c-000b-49eb-abe9-21da0989642a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_92ff57e0-ddf8-4f05-a1f0-22137ceaa6be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_92ff57e0-ddf8-4f05-a1f0-22137ceaa6be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_a3d6b891-0dff-49ab-a1c1-6cc62914b249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_a3d6b891-0dff-49ab-a1c1-6cc62914b249" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e10648f2-d686-4418-a39e-a5f033d64fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e10648f2-d686-4418-a39e-a5f033d64fbf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_92872358-bf02-4f90-b7a4-88bd6ef2fc03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_92872358-bf02-4f90-b7a4-88bd6ef2fc03" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c1ce6b26-8f72-4f10-a263-98a0316429f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_ProfitLoss_c1ce6b26-8f72-4f10-a263-98a0316429f9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5be641ee-3377-4e12-b176-cf4b88bf1444" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5be641ee-3377-4e12-b176-cf4b88bf1444" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a9ba92ac-bf01-4312-9fef-1ee35d0a901f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_NetIncomeLoss_a9ba92ac-bf01-4312-9fef-1ee35d0a901f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_64d82cd3-a427-4e83-8ddb-8de66e258dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_EarningsPerShareBasic_64d82cd3-a427-4e83-8ddb-8de66e258dbe" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_78c7fbec-1e93-4783-867f-e667f17ad119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_EarningsPerShareDiluted_78c7fbec-1e93-4783-867f-e667f17ad119" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8bfa85fe-b018-4095-abd4-e8383e9c58e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8bfa85fe-b018-4095-abd4-e8383e9c58e1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_54fe581e-9afa-4dd7-8049-eaece1f0a98d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_54fe581e-9afa-4dd7-8049-eaece1f0a98d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_33993ae0-bb20-4a30-9495-666246e094d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_StatementTable_33993ae0-bb20-4a30-9495-666246e094d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f73bc642-0b5d-4443-97ed-6b9a832bda98" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_33993ae0-bb20-4a30-9495-666246e094d9" xlink:to="loc_srt_ProductOrServiceAxis_f73bc642-0b5d-4443-97ed-6b9a832bda98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f73bc642-0b5d-4443-97ed-6b9a832bda98_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f73bc642-0b5d-4443-97ed-6b9a832bda98" xlink:to="loc_srt_ProductsAndServicesDomain_f73bc642-0b5d-4443-97ed-6b9a832bda98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c5ed4a1c-5943-4e94-badf-6a297da066a1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f73bc642-0b5d-4443-97ed-6b9a832bda98" xlink:to="loc_srt_ProductsAndServicesDomain_c5ed4a1c-5943-4e94-badf-6a297da066a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_91c0298b-c88d-4c32-b462-062b37f4bc12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5ed4a1c-5943-4e94-badf-6a297da066a1" xlink:to="loc_us-gaap_ProductMember_91c0298b-c88d-4c32-b462-062b37f4bc12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_da5b202d-3167-4416-888a-5736606ac258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c5ed4a1c-5943-4e94-badf-6a297da066a1" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_da5b202d-3167-4416-888a-5736606ac258" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="bhc-20220630.xsd#CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" xlink:type="extended" id="i8ff5f399443f466e974d7c96707d289e_CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_506077bf-7c75-4c96-b930-e51fb3527657" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ba2b31d6-dc79-4335-b721-3044b803ac34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_506077bf-7c75-4c96-b930-e51fb3527657" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ba2b31d6-dc79-4335-b721-3044b803ac34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4678f3c0-15ab-41b4-9f87-cd53a40d1252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ba2b31d6-dc79-4335-b721-3044b803ac34" xlink:to="loc_us-gaap_CommonStockSharesIssued_4678f3c0-15ab-41b4-9f87-cd53a40d1252" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8895574b-794d-4325-af37-63f1716bd491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ba2b31d6-dc79-4335-b721-3044b803ac34" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8895574b-794d-4325-af37-63f1716bd491" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8b168354-4a24-4c87-a41b-720d2edddd75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ba2b31d6-dc79-4335-b721-3044b803ac34" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8b168354-4a24-4c87-a41b-720d2edddd75" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7909477f-af30-4712-8779-1c81c29ba1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ba2b31d6-dc79-4335-b721-3044b803ac34" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7909477f-af30-4712-8779-1c81c29ba1e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_321dc4cf-5ea4-4301-bc7d-a35baa055858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ba2b31d6-dc79-4335-b721-3044b803ac34" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_321dc4cf-5ea4-4301-bc7d-a35baa055858" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1d9bb6d1-71a3-403c-b328-165b6c01ff2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ba2b31d6-dc79-4335-b721-3044b803ac34" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1d9bb6d1-71a3-403c-b328-165b6c01ff2b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_b62f3c1d-0ef8-4863-a015-fc5767925e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ba2b31d6-dc79-4335-b721-3044b803ac34" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_b62f3c1d-0ef8-4863-a015-fc5767925e4d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7f928b2d-32c8-4b69-a005-5412f4666f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ba2b31d6-dc79-4335-b721-3044b803ac34" xlink:to="loc_us-gaap_ProfitLoss_7f928b2d-32c8-4b69-a005-5412f4666f4b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f4317d39-5389-4e39-b5be-db063d9157ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ba2b31d6-dc79-4335-b721-3044b803ac34" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f4317d39-5389-4e39-b5be-db063d9157ee" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4b21f513-8d3d-474f-b4b7-50f8277263ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ac13a273-db07-4e8d-8706-ae4944bdfdc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0245ddaf-4b70-4cba-9879-2ec01a71e2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_506077bf-7c75-4c96-b930-e51fb3527657" xlink:to="loc_us-gaap_StatementTable_0245ddaf-4b70-4cba-9879-2ec01a71e2c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4c49ef5b-88e0-4c9c-8adc-2819196db738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0245ddaf-4b70-4cba-9879-2ec01a71e2c9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4c49ef5b-88e0-4c9c-8adc-2819196db738" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4c49ef5b-88e0-4c9c-8adc-2819196db738_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4c49ef5b-88e0-4c9c-8adc-2819196db738" xlink:to="loc_us-gaap_EquityComponentDomain_4c49ef5b-88e0-4c9c-8adc-2819196db738_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b8f9282d-d952-456c-bbec-32ab39e4bd49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4c49ef5b-88e0-4c9c-8adc-2819196db738" xlink:to="loc_us-gaap_EquityComponentDomain_b8f9282d-d952-456c-bbec-32ab39e4bd49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_dba81a2b-8f36-4dbd-a300-2a3a65d267da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8f9282d-d952-456c-bbec-32ab39e4bd49" xlink:to="loc_us-gaap_ParentMember_dba81a2b-8f36-4dbd-a300-2a3a65d267da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ea644766-10e3-48f1-aea9-db65dbeec4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_dba81a2b-8f36-4dbd-a300-2a3a65d267da" xlink:to="loc_us-gaap_CommonStockMember_ea644766-10e3-48f1-aea9-db65dbeec4b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_be180383-4020-469e-8310-fa4ceeb995a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_dba81a2b-8f36-4dbd-a300-2a3a65d267da" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_be180383-4020-469e-8310-fa4ceeb995a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_02e8f100-28b5-4255-b330-a48b27b08db2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_dba81a2b-8f36-4dbd-a300-2a3a65d267da" xlink:to="loc_us-gaap_RetainedEarningsMember_02e8f100-28b5-4255-b330-a48b27b08db2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fa5672ec-0d45-43c1-a595-6b24986a9954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_dba81a2b-8f36-4dbd-a300-2a3a65d267da" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fa5672ec-0d45-43c1-a595-6b24986a9954" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_33087ee1-6481-41cf-a1a8-a0727fa2a82c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8f9282d-d952-456c-bbec-32ab39e4bd49" xlink:to="loc_us-gaap_NoncontrollingInterestMember_33087ee1-6481-41cf-a1a8-a0727fa2a82c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#DESCRIPTIONOFBUSINESSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" xlink:type="extended" id="ic383751ac92645298ddadfb8e26ad087_DESCRIPTIONOFBUSINESSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d5693bf2-c9ad-4253-bd90-24cdd9f8202a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_dc8d286b-2fb9-4a88-92dc-3eb544719047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d5693bf2-c9ad-4253-bd90-24cdd9f8202a" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_dc8d286b-2fb9-4a88-92dc-3eb544719047" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_7ee6991f-82f8-4b4a-922d-302ddd5bcd67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d5693bf2-c9ad-4253-bd90-24cdd9f8202a" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_7ee6991f-82f8-4b4a-922d-302ddd5bcd67" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_b38b67f6-9838-436e-bb27-e664b8795967" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_7ee6991f-82f8-4b4a-922d-302ddd5bcd67" xlink:to="loc_srt_OwnershipAxis_b38b67f6-9838-436e-bb27-e664b8795967" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_b38b67f6-9838-436e-bb27-e664b8795967_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_b38b67f6-9838-436e-bb27-e664b8795967" xlink:to="loc_srt_OwnershipDomain_b38b67f6-9838-436e-bb27-e664b8795967_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_5eb2f128-402e-4b8b-b5d1-2914b0aad1db" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_b38b67f6-9838-436e-bb27-e664b8795967" xlink:to="loc_srt_OwnershipDomain_5eb2f128-402e-4b8b-b5d1-2914b0aad1db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_92affc08-bf8a-4f03-b7b1-8e6c96793989" xlink:href="bhc-20220630.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_5eb2f128-402e-4b8b-b5d1-2914b0aad1db" xlink:to="loc_bhc_BauschLombMember_92affc08-bf8a-4f03-b7b1-8e6c96793989" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended" id="i35985003b0d04d2eac65da2e0c8851c1_SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_e693906f-284c-466f-8bdb-20655c51c63b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3f368fb7-b651-47f1-b16a-47af1a1a559e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e693906f-284c-466f-8bdb-20655c51c63b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3f368fb7-b651-47f1-b16a-47af1a1a559e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_52787568-7527-48cc-87f4-8766c085d572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e693906f-284c-466f-8bdb-20655c51c63b" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_52787568-7527-48cc-87f4-8766c085d572" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SaleOfStockOverAllotmentTerm_e9cea870-0420-4ace-b5b0-bfaadaf38d8b" xlink:href="bhc-20220630.xsd#bhc_SaleOfStockOverAllotmentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e693906f-284c-466f-8bdb-20655c51c63b" xlink:to="loc_bhc_SaleOfStockOverAllotmentTerm_e9cea870-0420-4ace-b5b0-bfaadaf38d8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance_bea4354f-d8ed-4c50-9a89-3bff29f54036" xlink:href="bhc-20220630.xsd#bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e693906f-284c-466f-8bdb-20655c51c63b" xlink:to="loc_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance_bea4354f-d8ed-4c50-9a89-3bff29f54036" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d7c5a8cd-437c-450d-9af2-1fd92a945750" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e693906f-284c-466f-8bdb-20655c51c63b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d7c5a8cd-437c-450d-9af2-1fd92a945750" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_b723fe01-5b1c-4f21-96fc-6122048dc562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e693906f-284c-466f-8bdb-20655c51c63b" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_b723fe01-5b1c-4f21-96fc-6122048dc562" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f019f735-5e3f-4176-9af7-a5eae9cb9791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e693906f-284c-466f-8bdb-20655c51c63b" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f019f735-5e3f-4176-9af7-a5eae9cb9791" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_dfb2cf22-e539-46e1-8993-7eb44e6d8cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e693906f-284c-466f-8bdb-20655c51c63b" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_dfb2cf22-e539-46e1-8993-7eb44e6d8cdc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c508d48d-d6c9-4a92-af6d-9a3b0d42e0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_dfb2cf22-e539-46e1-8993-7eb44e6d8cdc" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c508d48d-d6c9-4a92-af6d-9a3b0d42e0ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c508d48d-d6c9-4a92-af6d-9a3b0d42e0ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c508d48d-d6c9-4a92-af6d-9a3b0d42e0ba" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c508d48d-d6c9-4a92-af6d-9a3b0d42e0ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_102c98fd-2c8d-43e9-89f7-470f612cc6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c508d48d-d6c9-4a92-af6d-9a3b0d42e0ba" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_102c98fd-2c8d-43e9-89f7-470f612cc6ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IPOAndOverAllotmentOptionMember_c6f103e4-d835-46db-9073-fbedb0b78e7c" xlink:href="bhc-20220630.xsd#bhc_IPOAndOverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_102c98fd-2c8d-43e9-89f7-470f612cc6ae" xlink:to="loc_bhc_IPOAndOverAllotmentOptionMember_c6f103e4-d835-46db-9073-fbedb0b78e7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_13b05fbe-7697-4f2e-8b9e-bfdda730ca5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IPOAndOverAllotmentOptionMember_c6f103e4-d835-46db-9073-fbedb0b78e7c" xlink:to="loc_us-gaap_IPOMember_13b05fbe-7697-4f2e-8b9e-bfdda730ca5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_262adb7e-f6f9-4d06-a21e-b0b4c0144371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IPOAndOverAllotmentOptionMember_c6f103e4-d835-46db-9073-fbedb0b78e7c" xlink:to="loc_us-gaap_OverAllotmentOptionMember_262adb7e-f6f9-4d06-a21e-b0b4c0144371" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_bb4cb9af-6a1e-4e83-a119-ad69780f1d25" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_dfb2cf22-e539-46e1-8993-7eb44e6d8cdc" xlink:to="loc_srt_OwnershipAxis_bb4cb9af-6a1e-4e83-a119-ad69780f1d25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_bb4cb9af-6a1e-4e83-a119-ad69780f1d25_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_bb4cb9af-6a1e-4e83-a119-ad69780f1d25" xlink:to="loc_srt_OwnershipDomain_bb4cb9af-6a1e-4e83-a119-ad69780f1d25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_95d57de2-b49b-4b8b-8f93-0cd6502813ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_bb4cb9af-6a1e-4e83-a119-ad69780f1d25" xlink:to="loc_srt_OwnershipDomain_95d57de2-b49b-4b8b-8f93-0cd6502813ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_8bb3fb55-3383-4d6d-8051-bbb61ebbbb3b" xlink:href="bhc-20220630.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_95d57de2-b49b-4b8b-8f93-0cd6502813ba" xlink:to="loc_bhc_BauschLombMember_8bb3fb55-3383-4d6d-8051-bbb61ebbbb3b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#REVENUERECOGNITIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails" xlink:type="extended" id="i35e7c2f78d9a4fb7bccc961a8622bd93_REVENUERECOGNITIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_742da137-f521-4801-8706-9366e6021163" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_5383913e-0c3d-42ee-96b0-9d7803c08077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_742da137-f521-4801-8706-9366e6021163" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_5383913e-0c3d-42ee-96b0-9d7803c08077" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_01b84b81-61e8-425b-881b-08ecd7d49153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_742da137-f521-4801-8706-9366e6021163" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_01b84b81-61e8-425b-881b-08ecd7d49153" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2298b9e9-63fc-4350-8e39-cb2809570cba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_742da137-f521-4801-8706-9366e6021163" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2298b9e9-63fc-4350-8e39-cb2809570cba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_9ea26615-9d28-4187-b7e7-87aa636e1599" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_742da137-f521-4801-8706-9366e6021163" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_9ea26615-9d28-4187-b7e7-87aa636e1599" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_30ab0748-8eed-4255-83a5-05cb427cf638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_9ea26615-9d28-4187-b7e7-87aa636e1599" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_30ab0748-8eed-4255-83a5-05cb427cf638" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_30ab0748-8eed-4255-83a5-05cb427cf638_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_30ab0748-8eed-4255-83a5-05cb427cf638" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_30ab0748-8eed-4255-83a5-05cb427cf638_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_e00c971a-7303-4137-8f50-b54ee44243e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_30ab0748-8eed-4255-83a5-05cb427cf638" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_e00c971a-7303-4137-8f50-b54ee44243e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_9c9c45dd-e743-4cc1-84b5-88f82f4354d5" xlink:href="bhc-20220630.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e00c971a-7303-4137-8f50-b54ee44243e6" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_9c9c45dd-e743-4cc1-84b5-88f82f4354d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_7214ccc0-ce28-4819-8f73-1af4bbe03097" xlink:href="bhc-20220630.xsd#bhc_ReserveForRebatesAdvertisingCreditsPortionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e00c971a-7303-4137-8f50-b54ee44243e6" xlink:to="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_7214ccc0-ce28-4819-8f73-1af4bbe03097" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_abc1579c-649b-4003-b5c2-ee1b54a706da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_9ea26615-9d28-4187-b7e7-87aa636e1599" xlink:to="loc_srt_ProductOrServiceAxis_abc1579c-649b-4003-b5c2-ee1b54a706da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_abc1579c-649b-4003-b5c2-ee1b54a706da_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_abc1579c-649b-4003-b5c2-ee1b54a706da" xlink:to="loc_srt_ProductsAndServicesDomain_abc1579c-649b-4003-b5c2-ee1b54a706da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1659437c-be13-4b06-b877-b237aff8cbf2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_abc1579c-649b-4003-b5c2-ee1b54a706da" xlink:to="loc_srt_ProductsAndServicesDomain_1659437c-be13-4b06-b877-b237aff8cbf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PriceAppreciationCreditMember_36080ac3-3c47-4918-88a2-d178c6c01712" xlink:href="bhc-20220630.xsd#bhc_PriceAppreciationCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1659437c-be13-4b06-b877-b237aff8cbf2" xlink:to="loc_bhc_PriceAppreciationCreditMember_36080ac3-3c47-4918-88a2-d178c6c01712" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#REVENUERECOGNITIONVariableConsiderationProvisionsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails" xlink:type="extended" id="i57af0a923e7e4bf98a443e7ad0a7fc17_REVENUERECOGNITIONVariableConsiderationProvisionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4faf3713-8a45-424e-8681-cf2d3324010c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_56fb1c54-c73b-4869-810d-5c61669d763b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4faf3713-8a45-424e-8681-cf2d3324010c" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_56fb1c54-c73b-4869-810d-5c61669d763b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_d1920731-be75-47f0-99fe-5d5a920e57e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_56fb1c54-c73b-4869-810d-5c61669d763b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_d1920731-be75-47f0-99fe-5d5a920e57e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_fa662251-ed15-4b59-a2bf-47a611bf863a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_56fb1c54-c73b-4869-810d-5c61669d763b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_fa662251-ed15-4b59-a2bf-47a611bf863a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_38783672-aeb9-4953-b1f4-f1d310314216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_56fb1c54-c73b-4869-810d-5c61669d763b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_38783672-aeb9-4953-b1f4-f1d310314216" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_a7da7f22-6a12-4285-ba50-94c76897c5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a07370ae-e923-4c5d-a8a1-e169f216f440" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4faf3713-8a45-424e-8681-cf2d3324010c" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a07370ae-e923-4c5d-a8a1-e169f216f440" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1552dadb-9d5d-4d74-b43c-cc6056699055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a07370ae-e923-4c5d-a8a1-e169f216f440" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1552dadb-9d5d-4d74-b43c-cc6056699055" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_1552dadb-9d5d-4d74-b43c-cc6056699055_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1552dadb-9d5d-4d74-b43c-cc6056699055" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_1552dadb-9d5d-4d74-b43c-cc6056699055_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_1da73fad-d41f-4d45-89cb-c94a5cde1115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1552dadb-9d5d-4d74-b43c-cc6056699055" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_1da73fad-d41f-4d45-89cb-c94a5cde1115" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDiscountsAndAllowancesMember_3cdb02f5-9a99-4be9-aa65-efe1ae99ebc2" xlink:href="bhc-20220630.xsd#bhc_ReserveForDiscountsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1da73fad-d41f-4d45-89cb-c94a5cde1115" xlink:to="loc_bhc_ReserveForDiscountsAndAllowancesMember_3cdb02f5-9a99-4be9-aa65-efe1ae99ebc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_a0ae52a7-1957-486b-b3b4-1a6c08fe6240" xlink:href="bhc-20220630.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1da73fad-d41f-4d45-89cb-c94a5cde1115" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_a0ae52a7-1957-486b-b3b4-1a6c08fe6240" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesMember_178afff2-e312-4a66-811e-a01bee66f0a2" xlink:href="bhc-20220630.xsd#bhc_ReserveForRebatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1da73fad-d41f-4d45-89cb-c94a5cde1115" xlink:to="loc_bhc_ReserveForRebatesMember_178afff2-e312-4a66-811e-a01bee66f0a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForChargebacksMember_7465dc85-0b39-4ed1-a30d-62da29c78d19" xlink:href="bhc-20220630.xsd#bhc_ReserveForChargebacksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1da73fad-d41f-4d45-89cb-c94a5cde1115" xlink:to="loc_bhc_ReserveForChargebacksMember_7465dc85-0b39-4ed1-a30d-62da29c78d19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDistributionFeesMember_5ea84e92-1108-4239-b223-8da8eed15e07" xlink:href="bhc-20220630.xsd#bhc_ReserveForDistributionFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1da73fad-d41f-4d45-89cb-c94a5cde1115" xlink:to="loc_bhc_ReserveForDistributionFeesMember_5ea84e92-1108-4239-b223-8da8eed15e07" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" xlink:type="extended" id="id133ba5e84a34a45abcdc1a51fe21337_LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7bae42ae-15f7-4f47-8a82-238bfbc78da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_0fde6c05-0c50-4b8c-9276-111375cc4468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7bae42ae-15f7-4f47-8a82-238bfbc78da6" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_0fde6c05-0c50-4b8c-9276-111375cc4468" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_a70f21a2-5395-4476-9e61-65b7676692ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7bae42ae-15f7-4f47-8a82-238bfbc78da6" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_a70f21a2-5395-4476-9e61-65b7676692ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_049b7cb9-6743-4e81-9b1f-ac92ddbc71c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7bae42ae-15f7-4f47-8a82-238bfbc78da6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_049b7cb9-6743-4e81-9b1f-ac92ddbc71c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d09c0c7f-335d-4b66-9d4d-3b9a847d3226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7bae42ae-15f7-4f47-8a82-238bfbc78da6" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d09c0c7f-335d-4b66-9d4d-3b9a847d3226" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_bffdd80d-88ef-4297-9060-789b447d9c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d09c0c7f-335d-4b66-9d4d-3b9a847d3226" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_bffdd80d-88ef-4297-9060-789b447d9c0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_bffdd80d-88ef-4297-9060-789b447d9c0d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_bffdd80d-88ef-4297-9060-789b447d9c0d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_bffdd80d-88ef-4297-9060-789b447d9c0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6fe68551-7926-4dca-a9b9-7ec76f2c0c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_bffdd80d-88ef-4297-9060-789b447d9c0d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6fe68551-7926-4dca-a9b9-7ec76f2c0c7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_b97bcb6c-bbba-492d-b02e-8b2cc1f004bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_6fe68551-7926-4dca-a9b9-7ec76f2c0c7f" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_b97bcb6c-bbba-492d-b02e-8b2cc1f004bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2ace9aee-f566-4d54-a7a1-ff416b19eab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d09c0c7f-335d-4b66-9d4d-3b9a847d3226" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2ace9aee-f566-4d54-a7a1-ff416b19eab3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2ace9aee-f566-4d54-a7a1-ff416b19eab3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2ace9aee-f566-4d54-a7a1-ff416b19eab3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2ace9aee-f566-4d54-a7a1-ff416b19eab3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_316531da-f5bb-4c15-b5ef-5ca46900a87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2ace9aee-f566-4d54-a7a1-ff416b19eab3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_316531da-f5bb-4c15-b5ef-5ca46900a87d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember_741672ee-d525-4f25-8047-67be12246da2" xlink:href="bhc-20220630.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_316531da-f5bb-4c15-b5ef-5ca46900a87d" xlink:to="loc_bhc_AmounPharmaceuticalCompanySAEMember_741672ee-d525-4f25-8047-67be12246da2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1a2399da-06ba-4736-bc94-ad250fbcc2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d09c0c7f-335d-4b66-9d4d-3b9a847d3226" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1a2399da-06ba-4736-bc94-ad250fbcc2a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1a2399da-06ba-4736-bc94-ad250fbcc2a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1a2399da-06ba-4736-bc94-ad250fbcc2a0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1a2399da-06ba-4736-bc94-ad250fbcc2a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dfe9c67a-7542-4484-8baf-a2c2be8b384b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1a2399da-06ba-4736-bc94-ad250fbcc2a0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dfe9c67a-7542-4484-8baf-a2c2be8b384b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetImpairmentChargesMember_be2cb816-7d34-46e6-85fd-9918e87d0d32" xlink:href="bhc-20220630.xsd#bhc_AssetImpairmentChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_dfe9c67a-7542-4484-8baf-a2c2be8b384b" xlink:to="loc_bhc_AssetImpairmentChargesMember_be2cb816-7d34-46e6-85fd-9918e87d0d32" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" xlink:type="extended" id="i654fbbe995a94eedb5c97e6a6e16e538_RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_935a0fb6-1346-41fe-a62a-a9ec6908e995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_86ea01a4-55c0-4f6f-89dd-512edb948f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_935a0fb6-1346-41fe-a62a-a9ec6908e995" xlink:to="loc_us-gaap_RestructuringReserve_86ea01a4-55c0-4f6f-89dd-512edb948f21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_a1a0d020-cafc-46bd-b83d-ac36fc765b91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_935a0fb6-1346-41fe-a62a-a9ec6908e995" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_a1a0d020-cafc-46bd-b83d-ac36fc765b91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_ac8acddc-565b-4c40-af07-01391a95901f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_935a0fb6-1346-41fe-a62a-a9ec6908e995" xlink:to="loc_us-gaap_PaymentsForRestructuring_ac8acddc-565b-4c40-af07-01391a95901f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_16905064-abb1-4edd-8d93-cc1f2cf90a88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_935a0fb6-1346-41fe-a62a-a9ec6908e995" xlink:to="loc_us-gaap_RestructuringCharges_16905064-abb1-4edd-8d93-cc1f2cf90a88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e5ff4df1-6927-4f17-a4f2-1dfa0336b598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_935a0fb6-1346-41fe-a62a-a9ec6908e995" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e5ff4df1-6927-4f17-a4f2-1dfa0336b598" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8f893fbd-3524-4619-a8a9-b0182078a736" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_935a0fb6-1346-41fe-a62a-a9ec6908e995" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8f893fbd-3524-4619-a8a9-b0182078a736" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_8b1c2348-b477-4092-8ed0-29d724400ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8f893fbd-3524-4619-a8a9-b0182078a736" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_8b1c2348-b477-4092-8ed0-29d724400ea6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_8b1c2348-b477-4092-8ed0-29d724400ea6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_8b1c2348-b477-4092-8ed0-29d724400ea6" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_8b1c2348-b477-4092-8ed0-29d724400ea6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_878bb80f-a905-4cc0-b708-62aba770d8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_8b1c2348-b477-4092-8ed0-29d724400ea6" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_878bb80f-a905-4cc0-b708-62aba770d8f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndIntegrationCostsMember_46ad1218-6d14-4875-a3e4-507951dbe557" xlink:href="bhc-20220630.xsd#bhc_RestructuringAndIntegrationCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_878bb80f-a905-4cc0-b708-62aba770d8f5" xlink:to="loc_bhc_RestructuringAndIntegrationCostsMember_46ad1218-6d14-4875-a3e4-507951dbe557" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationAndInitialPublicOfferingCostsMember_57f88a7c-a2b0-4974-9163-0fce2a26bdbc" xlink:href="bhc-20220630.xsd#bhc_SeparationAndInitialPublicOfferingCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_878bb80f-a905-4cc0-b708-62aba770d8f5" xlink:to="loc_bhc_SeparationAndInitialPublicOfferingCostsMember_57f88a7c-a2b0-4974-9163-0fce2a26bdbc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="i476b1436ffe247efb83206190f7fd4a3_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_66911e27-6310-483c-a68c-7d8bf5366502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_a341b01c-a872-4687-b96d-f271c6a5d459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_66911e27-6310-483c-a68c-7d8bf5366502" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_a341b01c-a872-4687-b96d-f271c6a5d459" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_befb9f91-a7ca-4ff1-bdce-801838a6b344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a341b01c-a872-4687-b96d-f271c6a5d459" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_befb9f91-a7ca-4ff1-bdce-801838a6b344" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_d7d90eb2-e63a-425e-9609-0b1a92649f75" xlink:href="bhc-20220630.xsd#bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a341b01c-a872-4687-b96d-f271c6a5d459" xlink:to="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_d7d90eb2-e63a-425e-9609-0b1a92649f75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_c75a0987-76cd-498f-ab72-65950e39c335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a341b01c-a872-4687-b96d-f271c6a5d459" xlink:to="loc_us-gaap_DerivativeAssets_c75a0987-76cd-498f-ab72-65950e39c335" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_a7dd021f-467e-4e49-9422-06fb240cb87a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_66911e27-6310-483c-a68c-7d8bf5366502" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_a7dd021f-467e-4e49-9422-06fb240cb87a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_7aebf2f6-e7c7-4e89-93c3-fe903a70e8a1" xlink:href="bhc-20220630.xsd#bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_a7dd021f-467e-4e49-9422-06fb240cb87a" xlink:to="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_7aebf2f6-e7c7-4e89-93c3-fe903a70e8a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_5d1c7fe8-5aa8-4792-b181-0ba3d9d9f772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_a7dd021f-467e-4e49-9422-06fb240cb87a" xlink:to="loc_us-gaap_DerivativeLiabilities_5d1c7fe8-5aa8-4792-b181-0ba3d9d9f772" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9fb0527f-2691-46ea-8aa0-7cef3b92d12f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_66911e27-6310-483c-a68c-7d8bf5366502" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9fb0527f-2691-46ea-8aa0-7cef3b92d12f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_74979b69-0a8b-4aa0-a8d1-9ec848b73b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9fb0527f-2691-46ea-8aa0-7cef3b92d12f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_74979b69-0a8b-4aa0-a8d1-9ec848b73b6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_74979b69-0a8b-4aa0-a8d1-9ec848b73b6b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_74979b69-0a8b-4aa0-a8d1-9ec848b73b6b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_74979b69-0a8b-4aa0-a8d1-9ec848b73b6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e88e5bf8-126d-4d3e-8675-de56a098a17e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_74979b69-0a8b-4aa0-a8d1-9ec848b73b6b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e88e5bf8-126d-4d3e-8675-de56a098a17e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f6eb0ea5-00f3-4cff-b373-88ed61c82c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e88e5bf8-126d-4d3e-8675-de56a098a17e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f6eb0ea5-00f3-4cff-b373-88ed61c82c14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_304bb639-980d-4aba-9577-ab314c0ff8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9fb0527f-2691-46ea-8aa0-7cef3b92d12f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_304bb639-980d-4aba-9577-ab314c0ff8b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_304bb639-980d-4aba-9577-ab314c0ff8b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_304bb639-980d-4aba-9577-ab314c0ff8b1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_304bb639-980d-4aba-9577-ab314c0ff8b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_88cdcd45-d92b-4227-ad61-2d1b8f797840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_304bb639-980d-4aba-9577-ab314c0ff8b1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_88cdcd45-d92b-4227-ad61-2d1b8f797840" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d79b1a2d-97e3-48e4-8ccd-81dfbdc329f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_88cdcd45-d92b-4227-ad61-2d1b8f797840" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d79b1a2d-97e3-48e4-8ccd-81dfbdc329f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6d92b1e0-122d-4cec-b368-af6b995c90e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_88cdcd45-d92b-4227-ad61-2d1b8f797840" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6d92b1e0-122d-4cec-b368-af6b995c90e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ef506ca4-da9b-470f-a93e-80435866f586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_88cdcd45-d92b-4227-ad61-2d1b8f797840" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ef506ca4-da9b-470f-a93e-80435866f586" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_35bd2c61-20b3-4507-8568-7b575fee06e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9fb0527f-2691-46ea-8aa0-7cef3b92d12f" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_35bd2c61-20b3-4507-8568-7b575fee06e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_35bd2c61-20b3-4507-8568-7b575fee06e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_35bd2c61-20b3-4507-8568-7b575fee06e6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_35bd2c61-20b3-4507-8568-7b575fee06e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1b9d4253-b300-4d32-bee8-d292e56bf509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_35bd2c61-20b3-4507-8568-7b575fee06e6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1b9d4253-b300-4d32-bee8-d292e56bf509" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_e8c329ff-c25e-427c-810e-cc5c9a587009" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1b9d4253-b300-4d32-bee8-d292e56bf509" xlink:to="loc_us-gaap_ForeignExchangeContractMember_e8c329ff-c25e-427c-810e-cc5c9a587009" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_60d64cf9-4331-4d10-8e0c-4be795df6f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9fb0527f-2691-46ea-8aa0-7cef3b92d12f" xlink:to="loc_us-gaap_HedgingDesignationAxis_60d64cf9-4331-4d10-8e0c-4be795df6f9d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_60d64cf9-4331-4d10-8e0c-4be795df6f9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_60d64cf9-4331-4d10-8e0c-4be795df6f9d" xlink:to="loc_us-gaap_HedgingDesignationDomain_60d64cf9-4331-4d10-8e0c-4be795df6f9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_fd2a508c-0584-420a-bf8b-2e8c7d8923c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_60d64cf9-4331-4d10-8e0c-4be795df6f9d" xlink:to="loc_us-gaap_HedgingDesignationDomain_fd2a508c-0584-420a-bf8b-2e8c7d8923c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_8a12d33a-ce97-42e8-a80d-44534bf8374d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_fd2a508c-0584-420a-bf8b-2e8c7d8923c2" xlink:to="loc_us-gaap_NondesignatedMember_8a12d33a-ce97-42e8-a80d-44534bf8374d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" xlink:type="extended" id="i9afbcb019cea41e4885a13af440f85d1_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41a72bca-8ea5-4a42-9bda-fe6275492cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_7aafa8dc-84c9-4b8c-80e5-ebb265da1a76" xlink:href="bhc-20220630.xsd#bhc_HighlyLiquidInvestmentsMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41a72bca-8ea5-4a42-9bda-fe6275492cb7" xlink:to="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_7aafa8dc-84c9-4b8c-80e5-ebb265da1a76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d9e583cc-15ee-4cbe-987c-b1f7662572e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41a72bca-8ea5-4a42-9bda-fe6275492cb7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d9e583cc-15ee-4cbe-987c-b1f7662572e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_9ad6fe58-4808-4cff-b410-aaa87c90ec89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41a72bca-8ea5-4a42-9bda-fe6275492cb7" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_9ad6fe58-4808-4cff-b410-aaa87c90ec89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationSettlementNumberOfObjectorsAppeals_8466a6da-10a2-4050-9097-580d60e79e51" xlink:href="bhc-20220630.xsd#bhc_LitigationSettlementNumberOfObjectorsAppeals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41a72bca-8ea5-4a42-9bda-fe6275492cb7" xlink:to="loc_bhc_LitigationSettlementNumberOfObjectorsAppeals_8466a6da-10a2-4050-9097-580d60e79e51" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58fdf8e9-cbfb-4fb2-8689-d786da1c7d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41a72bca-8ea5-4a42-9bda-fe6275492cb7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58fdf8e9-cbfb-4fb2-8689-d786da1c7d43" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_7c5a275e-c854-4436-84cb-6cce9b4f2fe3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58fdf8e9-cbfb-4fb2-8689-d786da1c7d43" xlink:to="loc_srt_LitigationCaseAxis_7c5a275e-c854-4436-84cb-6cce9b4f2fe3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_7c5a275e-c854-4436-84cb-6cce9b4f2fe3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_7c5a275e-c854-4436-84cb-6cce9b4f2fe3" xlink:to="loc_srt_LitigationCaseTypeDomain_7c5a275e-c854-4436-84cb-6cce9b4f2fe3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_67234b7b-9ac4-4bd5-bb88-ddcc846f40b4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_7c5a275e-c854-4436-84cb-6cce9b4f2fe3" xlink:to="loc_srt_LitigationCaseTypeDomain_67234b7b-9ac4-4bd5-bb88-ddcc846f40b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_7a870614-491f-4dbf-9e92-c99ef51cfc31" xlink:href="bhc-20220630.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_67234b7b-9ac4-4bd5-bb88-ddcc846f40b4" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_7a870614-491f-4dbf-9e92-c99ef51cfc31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_c447a455-7df4-49b8-bc8c-b0a39c6645ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58fdf8e9-cbfb-4fb2-8689-d786da1c7d43" xlink:to="loc_us-gaap_LitigationStatusAxis_c447a455-7df4-49b8-bc8c-b0a39c6645ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_c447a455-7df4-49b8-bc8c-b0a39c6645ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_c447a455-7df4-49b8-bc8c-b0a39c6645ee" xlink:to="loc_us-gaap_LitigationStatusDomain_c447a455-7df4-49b8-bc8c-b0a39c6645ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_b2455b20-137c-44f5-b5a0-034f2f57e865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_c447a455-7df4-49b8-bc8c-b0a39c6645ee" xlink:to="loc_us-gaap_LitigationStatusDomain_b2455b20-137c-44f5-b5a0-034f2f57e865" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_7721d174-6b6e-44ff-81ee-66cd54c61514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_b2455b20-137c-44f5-b5a0-034f2f57e865" xlink:to="loc_us-gaap_SettledLitigationMember_7721d174-6b6e-44ff-81ee-66cd54c61514" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8a900ce0-218b-4cf0-a5ad-854d0c9d19dc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58fdf8e9-cbfb-4fb2-8689-d786da1c7d43" xlink:to="loc_srt_StatementGeographicalAxis_8a900ce0-218b-4cf0-a5ad-854d0c9d19dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8a900ce0-218b-4cf0-a5ad-854d0c9d19dc_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_8a900ce0-218b-4cf0-a5ad-854d0c9d19dc" xlink:to="loc_srt_SegmentGeographicalDomain_8a900ce0-218b-4cf0-a5ad-854d0c9d19dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3eaf1572-8744-4b3c-9a45-638bafc63373" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_8a900ce0-218b-4cf0-a5ad-854d0c9d19dc" xlink:to="loc_srt_SegmentGeographicalDomain_3eaf1572-8744-4b3c-9a45-638bafc63373" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_6ab8150c-c01d-42f3-97fb-fa653111ede1" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3eaf1572-8744-4b3c-9a45-638bafc63373" xlink:to="loc_stpr_NJ_6ab8150c-c01d-42f3-97fb-fa653111ede1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d8a6dc2c-ddc7-411d-a531-8da9314a8bad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58fdf8e9-cbfb-4fb2-8689-d786da1c7d43" xlink:to="loc_dei_LegalEntityAxis_d8a6dc2c-ddc7-411d-a531-8da9314a8bad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d8a6dc2c-ddc7-411d-a531-8da9314a8bad_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_d8a6dc2c-ddc7-411d-a531-8da9314a8bad" xlink:to="loc_dei_EntityDomain_d8a6dc2c-ddc7-411d-a531-8da9314a8bad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a6bfac9b-d549-443e-ace3-5e8c55f9b8f8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_d8a6dc2c-ddc7-411d-a531-8da9314a8bad" xlink:to="loc_dei_EntityDomain_a6bfac9b-d549-443e-ace3-5e8c55f9b8f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_f10ebaba-c904-4ac3-b7b5-9c581ff40343" xlink:href="bhc-20220630.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a6bfac9b-d549-443e-ace3-5e8c55f9b8f8" xlink:to="loc_bhc_BauschLombMember_f10ebaba-c904-4ac3-b7b5-9c581ff40343" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombToBeDistributedToOtherLegalEntitiesMember_dfa13134-34f5-4e09-b472-d520ecdb1f4a" xlink:href="bhc-20220630.xsd#bhc_BauschLombToBeDistributedToOtherLegalEntitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_BauschLombMember_f10ebaba-c904-4ac3-b7b5-9c581ff40343" xlink:to="loc_bhc_BauschLombToBeDistributedToOtherLegalEntitiesMember_dfa13134-34f5-4e09-b472-d520ecdb1f4a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="extended" id="iaa71a0dc7320446c9eef3163261fedb3_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_95ce7fd5-976d-4584-ad55-922d1efbdc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_cfd33b2e-bf91-4f70-9646-3c28bcf06344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_95ce7fd5-976d-4584-ad55-922d1efbdc3b" xlink:to="loc_us-gaap_DerivativeNotionalAmount_cfd33b2e-bf91-4f70-9646-3c28bcf06344" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_cdb1ef71-60f5-4529-9399-fb222cf1ad1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_95ce7fd5-976d-4584-ad55-922d1efbdc3b" xlink:to="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_cdb1ef71-60f5-4529-9399-fb222cf1ad1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_194e8427-9b0b-4cdb-ac17-56b917e85d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_95ce7fd5-976d-4584-ad55-922d1efbdc3b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_194e8427-9b0b-4cdb-ac17-56b917e85d3d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_20963df0-b41b-474f-a3a4-269f8ba5f276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_194e8427-9b0b-4cdb-ac17-56b917e85d3d" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_20963df0-b41b-474f-a3a4-269f8ba5f276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_20963df0-b41b-474f-a3a4-269f8ba5f276_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_20963df0-b41b-474f-a3a4-269f8ba5f276" xlink:to="loc_us-gaap_HedgingRelationshipDomain_20963df0-b41b-474f-a3a4-269f8ba5f276_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_24628cd5-3fd2-4cf0-a23a-2e51a1de1d71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_20963df0-b41b-474f-a3a4-269f8ba5f276" xlink:to="loc_us-gaap_HedgingRelationshipDomain_24628cd5-3fd2-4cf0-a23a-2e51a1de1d71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_6af35738-3e8b-4ef3-8292-b6f57c56ff77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_24628cd5-3fd2-4cf0-a23a-2e51a1de1d71" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_6af35738-3e8b-4ef3-8292-b6f57c56ff77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5ab33470-11bf-4c3f-af70-956ac94914c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_194e8427-9b0b-4cdb-ac17-56b917e85d3d" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5ab33470-11bf-4c3f-af70-956ac94914c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5ab33470-11bf-4c3f-af70-956ac94914c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5ab33470-11bf-4c3f-af70-956ac94914c5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5ab33470-11bf-4c3f-af70-956ac94914c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_27a089ad-5d3d-4240-a41c-f968e8fb7e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5ab33470-11bf-4c3f-af70-956ac94914c5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_27a089ad-5d3d-4240-a41c-f968e8fb7e00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_605f14ce-bc86-4050-be66-26e54573e059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_27a089ad-5d3d-4240-a41c-f968e8fb7e00" xlink:to="loc_us-gaap_CurrencySwapMember_605f14ce-bc86-4050-be66-26e54573e059" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_f2066bb3-d840-4539-a6fb-ae6cccfb3efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_194e8427-9b0b-4cdb-ac17-56b917e85d3d" xlink:to="loc_us-gaap_HedgingDesignationAxis_f2066bb3-d840-4539-a6fb-ae6cccfb3efb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_f2066bb3-d840-4539-a6fb-ae6cccfb3efb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_f2066bb3-d840-4539-a6fb-ae6cccfb3efb" xlink:to="loc_us-gaap_HedgingDesignationDomain_f2066bb3-d840-4539-a6fb-ae6cccfb3efb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_a49a04fb-4253-4332-a256-6a23ad7b7962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_f2066bb3-d840-4539-a6fb-ae6cccfb3efb" xlink:to="loc_us-gaap_HedgingDesignationDomain_a49a04fb-4253-4332-a256-6a23ad7b7962" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_8370f60d-ae3a-4b54-843e-5e072d4bce07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_a49a04fb-4253-4332-a256-6a23ad7b7962" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_8370f60d-ae3a-4b54-843e-5e072d4bce07" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="extended" id="i9edaf9686560435ebf66d442697a0a82_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2b0140cb-0330-4e4a-ac96-5337652cee6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_4fdf245d-b43c-4984-84ae-4d2c992f5062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2b0140cb-0330-4e4a-ac96-5337652cee6b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_4fdf245d-b43c-4984-84ae-4d2c992f5062" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_b41ef5e6-a062-44e4-89c6-a6f6e572ab53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2b0140cb-0330-4e4a-ac96-5337652cee6b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_b41ef5e6-a062-44e4-89c6-a6f6e572ab53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1c999711-406b-4fe1-9675-70fac88e92c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2b0140cb-0330-4e4a-ac96-5337652cee6b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1c999711-406b-4fe1-9675-70fac88e92c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a458a421-ffe1-43db-b714-6e8eea48fd68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1c999711-406b-4fe1-9675-70fac88e92c0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a458a421-ffe1-43db-b714-6e8eea48fd68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_a458a421-ffe1-43db-b714-6e8eea48fd68_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a458a421-ffe1-43db-b714-6e8eea48fd68" xlink:to="loc_us-gaap_HedgingRelationshipDomain_a458a421-ffe1-43db-b714-6e8eea48fd68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_d563b737-f3dc-4cc2-8e92-6feb7f26be67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a458a421-ffe1-43db-b714-6e8eea48fd68" xlink:to="loc_us-gaap_HedgingRelationshipDomain_d563b737-f3dc-4cc2-8e92-6feb7f26be67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_b3db0494-6e3d-465c-9803-f0b58ef81904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_d563b737-f3dc-4cc2-8e92-6feb7f26be67" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_b3db0494-6e3d-465c-9803-f0b58ef81904" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ced9a02c-4400-4a31-a667-a41367d50818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1c999711-406b-4fe1-9675-70fac88e92c0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ced9a02c-4400-4a31-a667-a41367d50818" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ced9a02c-4400-4a31-a667-a41367d50818_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ced9a02c-4400-4a31-a667-a41367d50818" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ced9a02c-4400-4a31-a667-a41367d50818_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_78321653-fdf0-4fe2-aa8c-e8aa51e1c811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ced9a02c-4400-4a31-a667-a41367d50818" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_78321653-fdf0-4fe2-aa8c-e8aa51e1c811" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_f93ac061-cb24-40f7-86a9-15c094edfed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_78321653-fdf0-4fe2-aa8c-e8aa51e1c811" xlink:to="loc_us-gaap_CurrencySwapMember_f93ac061-cb24-40f7-86a9-15c094edfed6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_bb0457d1-0420-4d40-9027-1f89dad0dbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1c999711-406b-4fe1-9675-70fac88e92c0" xlink:to="loc_us-gaap_HedgingDesignationAxis_bb0457d1-0420-4d40-9027-1f89dad0dbbd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_bb0457d1-0420-4d40-9027-1f89dad0dbbd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_bb0457d1-0420-4d40-9027-1f89dad0dbbd" xlink:to="loc_us-gaap_HedgingDesignationDomain_bb0457d1-0420-4d40-9027-1f89dad0dbbd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_6db2ccde-4cf1-4677-a8bd-f8af0ec93434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_bb0457d1-0420-4d40-9027-1f89dad0dbbd" xlink:to="loc_us-gaap_HedgingDesignationDomain_6db2ccde-4cf1-4677-a8bd-f8af0ec93434" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_7912dd06-8a0d-4f82-a302-d7b872c27526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_6db2ccde-4cf1-4677-a8bd-f8af0ec93434" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_7912dd06-8a0d-4f82-a302-d7b872c27526" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_69d21dec-930b-4a96-a70c-3e298a27e462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1c999711-406b-4fe1-9675-70fac88e92c0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_69d21dec-930b-4a96-a70c-3e298a27e462" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_69d21dec-930b-4a96-a70c-3e298a27e462_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_69d21dec-930b-4a96-a70c-3e298a27e462" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_69d21dec-930b-4a96-a70c-3e298a27e462_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_587984ed-7760-4f44-af38-42dd0baabf04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_69d21dec-930b-4a96-a70c-3e298a27e462" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_587984ed-7760-4f44-af38-42dd0baabf04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_55190683-2965-49e0-8359-146d365c5688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_587984ed-7760-4f44-af38-42dd0baabf04" xlink:to="loc_us-gaap_InterestExpenseMember_55190683-2965-49e0-8359-146d365c5688" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="extended" id="i242957a428964304836b1c7ea7c4d9a8_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c0794bbd-b1c0-43dc-8034-c0b944174736" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_a2df10c8-7abe-4cac-9603-62de30dfe0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c0794bbd-b1c0-43dc-8034-c0b944174736" xlink:to="loc_us-gaap_DerivativeNotionalAmount_a2df10c8-7abe-4cac-9603-62de30dfe0b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1b5d2e74-7646-4320-8e3d-999d6517ceb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c0794bbd-b1c0-43dc-8034-c0b944174736" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1b5d2e74-7646-4320-8e3d-999d6517ceb2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_1f2de3a6-d549-4076-80c3-db0cc2441202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1b5d2e74-7646-4320-8e3d-999d6517ceb2" xlink:to="loc_us-gaap_HedgingDesignationAxis_1f2de3a6-d549-4076-80c3-db0cc2441202" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_1f2de3a6-d549-4076-80c3-db0cc2441202_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_1f2de3a6-d549-4076-80c3-db0cc2441202" xlink:to="loc_us-gaap_HedgingDesignationDomain_1f2de3a6-d549-4076-80c3-db0cc2441202_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_f8773359-9961-435c-a083-bbc12c3f0b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_1f2de3a6-d549-4076-80c3-db0cc2441202" xlink:to="loc_us-gaap_HedgingDesignationDomain_f8773359-9961-435c-a083-bbc12c3f0b9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_25bd7807-b15a-4389-8266-b8b9848670ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_f8773359-9961-435c-a083-bbc12c3f0b9f" xlink:to="loc_us-gaap_NondesignatedMember_25bd7807-b15a-4389-8266-b8b9848670ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_432a8509-6631-4bed-a4db-e36244705b15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1b5d2e74-7646-4320-8e3d-999d6517ceb2" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_432a8509-6631-4bed-a4db-e36244705b15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_432a8509-6631-4bed-a4db-e36244705b15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_432a8509-6631-4bed-a4db-e36244705b15" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_432a8509-6631-4bed-a4db-e36244705b15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_99beceb2-f2e6-4947-b852-c24356c11dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_432a8509-6631-4bed-a4db-e36244705b15" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_99beceb2-f2e6-4947-b852-c24356c11dcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_51981c3c-201c-4951-834c-10e2bc6853a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_99beceb2-f2e6-4947-b852-c24356c11dcd" xlink:to="loc_us-gaap_ForeignExchangeContractMember_51981c3c-201c-4951-834c-10e2bc6853a2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="extended" id="ida62334b4c404564a9b67b224dd65950_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c4f91b6e-ce8e-4c66-9e6b-87e075673545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_3059a510-245e-49df-94c8-8c3da0fa6526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c4f91b6e-ce8e-4c66-9e6b-87e075673545" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_3059a510-245e-49df-94c8-8c3da0fa6526" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_af28da57-20a8-492d-b531-50be1b9034f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c4f91b6e-ce8e-4c66-9e6b-87e075673545" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_af28da57-20a8-492d-b531-50be1b9034f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e14756d2-1d2d-4333-b2ce-aa9b7f6d0d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_af28da57-20a8-492d-b531-50be1b9034f4" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e14756d2-1d2d-4333-b2ce-aa9b7f6d0d1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e14756d2-1d2d-4333-b2ce-aa9b7f6d0d1a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e14756d2-1d2d-4333-b2ce-aa9b7f6d0d1a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e14756d2-1d2d-4333-b2ce-aa9b7f6d0d1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e15d8486-1cf6-42ce-bb59-538d4d304396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e14756d2-1d2d-4333-b2ce-aa9b7f6d0d1a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e15d8486-1cf6-42ce-bb59-538d4d304396" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember_a2b59c23-34f3-4e64-9a06-d8ead3d82ac0" xlink:href="bhc-20220630.xsd#bhc_AccruedAndOtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e15d8486-1cf6-42ce-bb59-538d4d304396" xlink:to="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember_a2b59c23-34f3-4e64-9a06-d8ead3d82ac0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_a7ad5d07-8f6d-4194-ac87-dd696c745fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e15d8486-1cf6-42ce-bb59-538d4d304396" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_a7ad5d07-8f6d-4194-ac87-dd696c745fdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_f296969d-a55e-4378-935f-a6eafefaeb5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_af28da57-20a8-492d-b531-50be1b9034f4" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_f296969d-a55e-4378-935f-a6eafefaeb5c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f296969d-a55e-4378-935f-a6eafefaeb5c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f296969d-a55e-4378-935f-a6eafefaeb5c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f296969d-a55e-4378-935f-a6eafefaeb5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_48a3a9c0-6312-447d-a780-7cf2b884666f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f296969d-a55e-4378-935f-a6eafefaeb5c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_48a3a9c0-6312-447d-a780-7cf2b884666f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_858dd550-3c00-4101-8f4f-1133f0e4e956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_48a3a9c0-6312-447d-a780-7cf2b884666f" xlink:to="loc_us-gaap_ForeignExchangeContractMember_858dd550-3c00-4101-8f4f-1133f0e4e956" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_7db9522a-c444-4362-a4d4-7ad71101ff4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_af28da57-20a8-492d-b531-50be1b9034f4" xlink:to="loc_us-gaap_HedgingDesignationAxis_7db9522a-c444-4362-a4d4-7ad71101ff4b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7db9522a-c444-4362-a4d4-7ad71101ff4b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_7db9522a-c444-4362-a4d4-7ad71101ff4b" xlink:to="loc_us-gaap_HedgingDesignationDomain_7db9522a-c444-4362-a4d4-7ad71101ff4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_873caad0-d6f6-442a-8635-38b0d3110ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_7db9522a-c444-4362-a4d4-7ad71101ff4b" xlink:to="loc_us-gaap_HedgingDesignationDomain_873caad0-d6f6-442a-8635-38b0d3110ac1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_98ba621f-5cb6-46d7-b254-c7c278290fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_873caad0-d6f6-442a-8635-38b0d3110ac1" xlink:to="loc_us-gaap_NondesignatedMember_98ba621f-5cb6-46d7-b254-c7c278290fdd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" xlink:type="extended" id="ia9ff899704cb4cf38f686686554a7231_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dd74ce2b-e35a-4d60-afb8-5fe8a041c5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_8df266b7-ca12-414a-8879-31354a3e8d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dd74ce2b-e35a-4d60-afb8-5fe8a041c5b5" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_8df266b7-ca12-414a-8879-31354a3e8d8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain_1212a88f-a37d-4429-b257-b8c0133bb47d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dd74ce2b-e35a-4d60-afb8-5fe8a041c5b5" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain_1212a88f-a37d-4429-b257-b8c0133bb47d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_3b8952b8-db79-465f-ad3c-893b05d4cc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dd74ce2b-e35a-4d60-afb8-5fe8a041c5b5" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_3b8952b8-db79-465f-ad3c-893b05d4cc1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e4fd77d3-2155-4242-bbb4-4ad97a3110c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dd74ce2b-e35a-4d60-afb8-5fe8a041c5b5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e4fd77d3-2155-4242-bbb4-4ad97a3110c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_f39e21b4-f873-4f8e-af9c-75860f0a9bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e4fd77d3-2155-4242-bbb4-4ad97a3110c7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_f39e21b4-f873-4f8e-af9c-75860f0a9bfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f39e21b4-f873-4f8e-af9c-75860f0a9bfc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f39e21b4-f873-4f8e-af9c-75860f0a9bfc" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f39e21b4-f873-4f8e-af9c-75860f0a9bfc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a819122b-300b-4221-9a37-7b7953b840f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f39e21b4-f873-4f8e-af9c-75860f0a9bfc" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a819122b-300b-4221-9a37-7b7953b840f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ab8fcdc5-e979-4da9-8d09-0e66e7511ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a819122b-300b-4221-9a37-7b7953b840f8" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ab8fcdc5-e979-4da9-8d09-0e66e7511ed8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_ae5dfc23-5662-4990-b36d-66b202a81d94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e4fd77d3-2155-4242-bbb4-4ad97a3110c7" xlink:to="loc_us-gaap_HedgingDesignationAxis_ae5dfc23-5662-4990-b36d-66b202a81d94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ae5dfc23-5662-4990-b36d-66b202a81d94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_ae5dfc23-5662-4990-b36d-66b202a81d94" xlink:to="loc_us-gaap_HedgingDesignationDomain_ae5dfc23-5662-4990-b36d-66b202a81d94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_845e3b2a-73cd-4775-b1cc-5ad672198bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_ae5dfc23-5662-4990-b36d-66b202a81d94" xlink:to="loc_us-gaap_HedgingDesignationDomain_845e3b2a-73cd-4775-b1cc-5ad672198bd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_23b5302d-870f-4322-8cdd-9c3a09d020a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_845e3b2a-73cd-4775-b1cc-5ad672198bd0" xlink:to="loc_us-gaap_NondesignatedMember_23b5302d-870f-4322-8cdd-9c3a09d020a1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" xlink:type="extended" id="ib12e28db0a924f49b269a35b8ff1165b_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4a924dea-706d-4b76-8dc0-eb38a420a813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_4db11514-7d74-4a5c-afbf-1a99c7d80c31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4a924dea-706d-4b76-8dc0-eb38a420a813" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_4db11514-7d74-4a5c-afbf-1a99c7d80c31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6fb3c67f-3de4-4d91-a0da-01b68af6a312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4a924dea-706d-4b76-8dc0-eb38a420a813" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6fb3c67f-3de4-4d91-a0da-01b68af6a312" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_772a803d-4208-4832-8f14-8cca9f0ed112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6fb3c67f-3de4-4d91-a0da-01b68af6a312" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_772a803d-4208-4832-8f14-8cca9f0ed112" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_772a803d-4208-4832-8f14-8cca9f0ed112_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_772a803d-4208-4832-8f14-8cca9f0ed112" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_772a803d-4208-4832-8f14-8cca9f0ed112_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9eeeafc3-9c44-4c5f-a32d-4146776af306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_772a803d-4208-4832-8f14-8cca9f0ed112" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9eeeafc3-9c44-4c5f-a32d-4146776af306" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b678dc63-bce3-419e-b97d-3c36ce581abb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9eeeafc3-9c44-4c5f-a32d-4146776af306" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b678dc63-bce3-419e-b97d-3c36ce581abb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_79e6e221-d32e-45ae-be30-810a028f65f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6fb3c67f-3de4-4d91-a0da-01b68af6a312" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_79e6e221-d32e-45ae-be30-810a028f65f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_79e6e221-d32e-45ae-be30-810a028f65f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_79e6e221-d32e-45ae-be30-810a028f65f5" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_79e6e221-d32e-45ae-be30-810a028f65f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d017a5a2-e24a-49c9-8cd8-86da992277b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_79e6e221-d32e-45ae-be30-810a028f65f5" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d017a5a2-e24a-49c9-8cd8-86da992277b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_4a733e48-4a3d-4ef8-9e89-5f8ab16ea43d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d017a5a2-e24a-49c9-8cd8-86da992277b1" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_4a733e48-4a3d-4ef8-9e89-5f8ab16ea43d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_2cd74a5f-ff10-4996-a88e-ec9f79b3a4f9" xlink:href="bhc-20220630.xsd#bhc_MeasurementInputWeightedAverageDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d017a5a2-e24a-49c9-8cd8-86da992277b1" xlink:to="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_2cd74a5f-ff10-4996-a88e-ec9f79b3a4f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b36478c5-f6b1-49fb-88a1-41d0d3e6a590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6fb3c67f-3de4-4d91-a0da-01b68af6a312" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b36478c5-f6b1-49fb-88a1-41d0d3e6a590" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b36478c5-f6b1-49fb-88a1-41d0d3e6a590_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b36478c5-f6b1-49fb-88a1-41d0d3e6a590" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b36478c5-f6b1-49fb-88a1-41d0d3e6a590_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc9df23b-c03d-4776-bd91-ba79351d6397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b36478c5-f6b1-49fb-88a1-41d0d3e6a590" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc9df23b-c03d-4776-bd91-ba79351d6397" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f1693475-d847-4328-a1fb-1a025f5a8a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc9df23b-c03d-4776-bd91-ba79351d6397" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f1693475-d847-4328-a1fb-1a025f5a8a78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d910d26d-e48c-4266-bf05-c4cc5e38f654" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6fb3c67f-3de4-4d91-a0da-01b68af6a312" xlink:to="loc_srt_RangeAxis_d910d26d-e48c-4266-bf05-c4cc5e38f654" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d910d26d-e48c-4266-bf05-c4cc5e38f654_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d910d26d-e48c-4266-bf05-c4cc5e38f654" xlink:to="loc_srt_RangeMember_d910d26d-e48c-4266-bf05-c4cc5e38f654_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7a909ff1-03f0-494f-8f6e-51a9edc06086" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d910d26d-e48c-4266-bf05-c4cc5e38f654" xlink:to="loc_srt_RangeMember_7a909ff1-03f0-494f-8f6e-51a9edc06086" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bad6ab75-2530-4b6b-a3b5-1f46eb92bf81" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7a909ff1-03f0-494f-8f6e-51a9edc06086" xlink:to="loc_srt_MinimumMember_bad6ab75-2530-4b6b-a3b5-1f46eb92bf81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1d9a6bd4-00f7-448e-991b-b4846c5408e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7a909ff1-03f0-494f-8f6e-51a9edc06086" xlink:to="loc_srt_MaximumMember_1d9a6bd4-00f7-448e-991b-b4846c5408e6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="extended" id="i8eba706083e14efa892c88b05b5e244c_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_54192029-3569-4161-b82c-98e69633c995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_84228a9e-7c29-4b76-bf92-5007cb3a25a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_54192029-3569-4161-b82c-98e69633c995" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_84228a9e-7c29-4b76-bf92-5007cb3a25a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b603033a-f342-49af-a05c-b1fa1ea834aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_84228a9e-7c29-4b76-bf92-5007cb3a25a8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b603033a-f342-49af-a05c-b1fa1ea834aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_ea652c61-b293-470a-bbc5-a071eac1272b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_84228a9e-7c29-4b76-bf92-5007cb3a25a8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_ea652c61-b293-470a-bbc5-a071eac1272b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_736aeec8-cf4b-4726-85d5-3a83d6c783cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_84228a9e-7c29-4b76-bf92-5007cb3a25a8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_736aeec8-cf4b-4726-85d5-3a83d6c783cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_dbeefbb5-e3b8-474b-a347-d2e761b88ded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_84228a9e-7c29-4b76-bf92-5007cb3a25a8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_dbeefbb5-e3b8-474b-a347-d2e761b88ded" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_63629515-644b-4a19-823c-4de0dd7e57b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_207740e5-509b-4a5a-bed2-e2e008d2d4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_84228a9e-7c29-4b76-bf92-5007cb3a25a8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_207740e5-509b-4a5a-bed2-e2e008d2d4fa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_eb1ae609-21ac-4d91-ac2e-e04753d47694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_84228a9e-7c29-4b76-bf92-5007cb3a25a8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_eb1ae609-21ac-4d91-ac2e-e04753d47694" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5959d0a0-b58c-4ac0-beef-1ea484278389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_54192029-3569-4161-b82c-98e69633c995" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5959d0a0-b58c-4ac0-beef-1ea484278389" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_b6169d41-b1a2-4fc9-b9d2-a77d1ed61c99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5959d0a0-b58c-4ac0-beef-1ea484278389" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_b6169d41-b1a2-4fc9-b9d2-a77d1ed61c99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_b6169d41-b1a2-4fc9-b9d2-a77d1ed61c99_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_b6169d41-b1a2-4fc9-b9d2-a77d1ed61c99" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_b6169d41-b1a2-4fc9-b9d2-a77d1ed61c99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_2181b532-00e9-419e-be4e-dfca66770d53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_b6169d41-b1a2-4fc9-b9d2-a77d1ed61c99" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_2181b532-00e9-419e-be4e-dfca66770d53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccretionForTimeValueOfMoneyMember_8521c1ea-d157-4617-bd58-00389f340f76" xlink:href="bhc-20220630.xsd#bhc_AccretionForTimeValueOfMoneyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2181b532-00e9-419e-be4e-dfca66770d53" xlink:to="loc_bhc_AccretionForTimeValueOfMoneyMember_8521c1ea-d157-4617-bd58-00389f340f76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_da22367e-9a1c-4321-9737-60165c190fc8" xlink:href="bhc-20220630.xsd#bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2181b532-00e9-419e-be4e-dfca66770d53" xlink:to="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_da22367e-9a1c-4321-9737-60165c190fc8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails" xlink:type="extended" id="i0d1e541763fb4f7bbf9ec866a4a9fff1_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7bd67713-a36e-4502-a8e5-f337a262c702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_4ba2e9f3-68f6-4c65-8312-6983398c1b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7bd67713-a36e-4502-a8e5-f337a262c702" xlink:to="loc_us-gaap_DebtInstrumentFairValue_4ba2e9f3-68f6-4c65-8312-6983398c1b89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_751564cd-c326-497e-b438-498db8e2084e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7bd67713-a36e-4502-a8e5-f337a262c702" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_751564cd-c326-497e-b438-498db8e2084e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d35a56c3-f7e7-4be9-b155-f0b0127f4bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_751564cd-c326-497e-b438-498db8e2084e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d35a56c3-f7e7-4be9-b155-f0b0127f4bb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d35a56c3-f7e7-4be9-b155-f0b0127f4bb9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d35a56c3-f7e7-4be9-b155-f0b0127f4bb9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d35a56c3-f7e7-4be9-b155-f0b0127f4bb9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7a14e874-f2d2-48e2-ad1a-053412d9dc55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d35a56c3-f7e7-4be9-b155-f0b0127f4bb9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7a14e874-f2d2-48e2-ad1a-053412d9dc55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_1ead5c8f-15f9-43dc-898a-a66885fc646f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7a14e874-f2d2-48e2-ad1a-053412d9dc55" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_1ead5c8f-15f9-43dc-898a-a66885fc646f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_95f423a2-8c2a-4581-9bbb-04cdf81716c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_751564cd-c326-497e-b438-498db8e2084e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_95f423a2-8c2a-4581-9bbb-04cdf81716c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95f423a2-8c2a-4581-9bbb-04cdf81716c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_95f423a2-8c2a-4581-9bbb-04cdf81716c9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95f423a2-8c2a-4581-9bbb-04cdf81716c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11ee3884-2f4e-4b84-8489-ee948109a821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_95f423a2-8c2a-4581-9bbb-04cdf81716c9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11ee3884-2f4e-4b84-8489-ee948109a821" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6c8fd575-f9b0-46fa-9e54-8e0ba954374e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11ee3884-2f4e-4b84-8489-ee948109a821" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6c8fd575-f9b0-46fa-9e54-8e0ba954374e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="extended" id="i4732fdc2467d42c4a496cc900cdb32b5_INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_a78343f2-630e-4bf5-8966-491c289026b1" xlink:href="bhc-20220630.xsd#bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_89042acc-6595-4959-a1f0-b01d23132285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_a78343f2-630e-4bf5-8966-491c289026b1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_89042acc-6595-4959-a1f0-b01d23132285" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_430bd9b1-cf45-41c0-b80c-c1687b867a97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_89042acc-6595-4959-a1f0-b01d23132285" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_430bd9b1-cf45-41c0-b80c-c1687b867a97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4c38bdd1-16e4-40f6-8c96-ff690d200499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_89042acc-6595-4959-a1f0-b01d23132285" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4c38bdd1-16e4-40f6-8c96-ff690d200499" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a759fc3f-f387-4c74-8860-7014809bdaf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_89042acc-6595-4959-a1f0-b01d23132285" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a759fc3f-f387-4c74-8860-7014809bdaf3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_6dd5f489-7e48-4ad2-9d1a-8b94135993bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_a78343f2-630e-4bf5-8966-491c289026b1" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_6dd5f489-7e48-4ad2-9d1a-8b94135993bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5a408cf3-5074-4243-97ad-34ef1f52b1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_6dd5f489-7e48-4ad2-9d1a-8b94135993bc" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5a408cf3-5074-4243-97ad-34ef1f52b1f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0acce920-3021-4ed3-b692-9bd04f894c36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_a78343f2-630e-4bf5-8966-491c289026b1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0acce920-3021-4ed3-b692-9bd04f894c36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_99f0c534-0bd8-4f27-8076-78a5af4a1bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0acce920-3021-4ed3-b692-9bd04f894c36" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_99f0c534-0bd8-4f27-8076-78a5af4a1bd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_62d9ce12-7a2b-4780-b9eb-f239fd459806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0acce920-3021-4ed3-b692-9bd04f894c36" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_62d9ce12-7a2b-4780-b9eb-f239fd459806" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_0cc08a8b-9b77-4233-a515-2b0a0a471a9e" xlink:href="bhc-20220630.xsd#bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_a78343f2-630e-4bf5-8966-491c289026b1" xlink:to="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_0cc08a8b-9b77-4233-a515-2b0a0a471a9e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_de25b488-aa20-4180-b48f-77098f1044dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_0cc08a8b-9b77-4233-a515-2b0a0a471a9e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_de25b488-aa20-4180-b48f-77098f1044dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_de25b488-aa20-4180-b48f-77098f1044dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_de25b488-aa20-4180-b48f-77098f1044dd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_de25b488-aa20-4180-b48f-77098f1044dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2f8a00e-7594-4289-a3ae-2794ef9bc3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_de25b488-aa20-4180-b48f-77098f1044dd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2f8a00e-7594-4289-a3ae-2794ef9bc3f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_8201b732-3303-44c3-87f1-31ca5b7e085b" xlink:href="bhc-20220630.xsd#bhc_ProductBrandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2f8a00e-7594-4289-a3ae-2794ef9bc3f5" xlink:to="loc_bhc_ProductBrandsMember_8201b732-3303-44c3-87f1-31ca5b7e085b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_a3a77192-9225-458c-85a3-1f4ebf166d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2f8a00e-7594-4289-a3ae-2794ef9bc3f5" xlink:to="loc_us-gaap_TradeNamesMember_a3a77192-9225-458c-85a3-1f4ebf166d77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_79173ba8-8814-4e09-a7e8-605f4cbdde96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2f8a00e-7594-4289-a3ae-2794ef9bc3f5" xlink:to="loc_us-gaap_ContractualRightsMember_79173ba8-8814-4e09-a7e8-605f4cbdde96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember_0c4dfd7b-f8bb-4f25-adfc-17b11bbec9ee" xlink:href="bhc-20220630.xsd#bhc_PartnerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2f8a00e-7594-4289-a3ae-2794ef9bc3f5" xlink:to="loc_bhc_PartnerRelationshipsMember_0c4dfd7b-f8bb-4f25-adfc-17b11bbec9ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember_84c49b67-db8d-4a28-a503-ee39ac79bee0" xlink:href="bhc-20220630.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2f8a00e-7594-4289-a3ae-2794ef9bc3f5" xlink:to="loc_bhc_OutLicensedTechnologyMember_84c49b67-db8d-4a28-a503-ee39ac79bee0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c7f75f6f-35c5-487a-af1b-d5dc6f498e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_0cc08a8b-9b77-4233-a515-2b0a0a471a9e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c7f75f6f-35c5-487a-af1b-d5dc6f498e4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c7f75f6f-35c5-487a-af1b-d5dc6f498e4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c7f75f6f-35c5-487a-af1b-d5dc6f498e4e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c7f75f6f-35c5-487a-af1b-d5dc6f498e4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_41ac5007-82b2-4c96-b73b-477d4e296969" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c7f75f6f-35c5-487a-af1b-d5dc6f498e4e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_41ac5007-82b2-4c96-b73b-477d4e296969" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_8288a366-a387-45c0-8dd0-7475c6432b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_41ac5007-82b2-4c96-b73b-477d4e296969" xlink:to="loc_us-gaap_TrademarksMember_8288a366-a387-45c0-8dd0-7475c6432b06" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#INTANGIBLEASSETSANDGOODWILLNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="extended" id="i347b29e3973a46ddb8f6a53217342f21_INTANGIBLEASSETSANDGOODWILLNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_bfbc80a5-4cb1-4c8d-81f0-866b7d958eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_bfbc80a5-4cb1-4c8d-81f0-866b7d958eb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d66b382e-466b-4d4c-a5ee-9ec69957debb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d66b382e-466b-4d4c-a5ee-9ec69957debb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0a5a3a4a-6915-4683-bc37-dd28cd4a629b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0a5a3a4a-6915-4683-bc37-dd28cd4a629b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AnnualAmortizationOfIntangibleAssets_1fd73b2f-7c3e-468d-b72b-891068b297e0" xlink:href="bhc-20220630.xsd#bhc_AnnualAmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:to="loc_bhc_AnnualAmortizationOfIntangibleAssets_1fd73b2f-7c3e-468d-b72b-891068b297e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_96b36aee-1691-4249-8227-0f43397d8496" xlink:href="bhc-20220630.xsd#bhc_ReportingUnitImpairmentTestLongTermGrowthRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:to="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_96b36aee-1691-4249-8227-0f43397d8496" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_3b2a8bd1-0147-4f41-a44a-41e941f778ea" xlink:href="bhc-20220630.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:to="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_3b2a8bd1-0147-4f41-a44a-41e941f778ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate_4de401db-9897-4983-b70b-15fa7b6f4e5e" xlink:href="bhc-20220630.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:to="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate_4de401db-9897-4983-b70b-15fa7b6f4e5e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_d3deeba2-68bc-4461-8403-358864337280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_d3deeba2-68bc-4461-8403-358864337280" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_311c9766-15df-40d3-80c3-9e071cfd7ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_311c9766-15df-40d3-80c3-9e071cfd7ff9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_258b7af5-1adc-4d58-9e93-bb285e67985c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:to="loc_us-gaap_NumberOfReportingUnits_258b7af5-1adc-4d58-9e93-bb285e67985c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_93deffee-0531-4fa6-9d79-b309ec391e48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_93deffee-0531-4fa6-9d79-b309ec391e48" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ad13aeca-4998-4572-886f-998c0b712a52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ad13aeca-4998-4572-886f-998c0b712a52" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cf4ece78-edce-4848-9e74-c2d282310f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cf4ece78-edce-4848-9e74-c2d282310f9a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_3fdd620d-8551-4df3-a5b1-e9bbd38ee478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_3fdd620d-8551-4df3-a5b1-e9bbd38ee478" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e79551e3-4428-4816-83d3-c1d477660142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_3fdd620d-8551-4df3-a5b1-e9bbd38ee478" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e79551e3-4428-4816-83d3-c1d477660142" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e79551e3-4428-4816-83d3-c1d477660142_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e79551e3-4428-4816-83d3-c1d477660142" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e79551e3-4428-4816-83d3-c1d477660142_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c64be1b9-2f02-412a-8482-7acdbb512e72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e79551e3-4428-4816-83d3-c1d477660142" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c64be1b9-2f02-412a-8482-7acdbb512e72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_1241c999-9c51-4e59-a0f5-ff0e1bf89526" xlink:href="bhc-20220630.xsd#bhc_ProductBrandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c64be1b9-2f02-412a-8482-7acdbb512e72" xlink:to="loc_bhc_ProductBrandsMember_1241c999-9c51-4e59-a0f5-ff0e1bf89526" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiscontinuedProductLinesMember_30b021c3-f1d6-4370-b79a-e97d0292bc72" xlink:href="bhc-20220630.xsd#bhc_DiscontinuedProductLinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c64be1b9-2f02-412a-8482-7acdbb512e72" xlink:to="loc_bhc_DiscontinuedProductLinesMember_30b021c3-f1d6-4370-b79a-e97d0292bc72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_e7d0c99e-c4a8-418e-96b5-8bfae6a18563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_3fdd620d-8551-4df3-a5b1-e9bbd38ee478" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_e7d0c99e-c4a8-418e-96b5-8bfae6a18563" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e7d0c99e-c4a8-418e-96b5-8bfae6a18563_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e7d0c99e-c4a8-418e-96b5-8bfae6a18563" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e7d0c99e-c4a8-418e-96b5-8bfae6a18563_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6e812518-a599-4c1f-86b9-47a4a68931a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e7d0c99e-c4a8-418e-96b5-8bfae6a18563" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6e812518-a599-4c1f-86b9-47a4a68931a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_7fa30d05-1235-45a6-888e-0710504ef39c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_6e812518-a599-4c1f-86b9-47a4a68931a4" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_7fa30d05-1235-45a6-888e-0710504ef39c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7a7ae0fc-29c4-4e55-a868-3638253771ce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_3fdd620d-8551-4df3-a5b1-e9bbd38ee478" xlink:to="loc_srt_RangeAxis_7a7ae0fc-29c4-4e55-a868-3638253771ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7a7ae0fc-29c4-4e55-a868-3638253771ce_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7a7ae0fc-29c4-4e55-a868-3638253771ce" xlink:to="loc_srt_RangeMember_7a7ae0fc-29c4-4e55-a868-3638253771ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_19b3eaee-d3e7-4691-ba6a-ede0c06d1b97" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7a7ae0fc-29c4-4e55-a868-3638253771ce" xlink:to="loc_srt_RangeMember_19b3eaee-d3e7-4691-ba6a-ede0c06d1b97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_45d69756-2000-4f0c-a6d9-73871a006dbe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_19b3eaee-d3e7-4691-ba6a-ede0c06d1b97" xlink:to="loc_srt_MinimumMember_45d69756-2000-4f0c-a6d9-73871a006dbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_eb93d269-10d0-43a8-aa76-17daa5df0fe6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_19b3eaee-d3e7-4691-ba6a-ede0c06d1b97" xlink:to="loc_srt_MaximumMember_eb93d269-10d0-43a8-aa76-17daa5df0fe6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_114101ba-63d9-4798-942b-55a47a2d3f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_3fdd620d-8551-4df3-a5b1-e9bbd38ee478" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_114101ba-63d9-4798-942b-55a47a2d3f9d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_114101ba-63d9-4798-942b-55a47a2d3f9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_114101ba-63d9-4798-942b-55a47a2d3f9d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_114101ba-63d9-4798-942b-55a47a2d3f9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0a9c703c-0464-4ae5-81b8-387af3da33b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_114101ba-63d9-4798-942b-55a47a2d3f9d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0a9c703c-0464-4ae5-81b8-387af3da33b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember_815bbdff-3864-4937-9396-1a9281a1bf09" xlink:href="bhc-20220630.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0a9c703c-0464-4ae5-81b8-387af3da33b1" xlink:to="loc_bhc_AmounPharmaceuticalCompanySAEMember_815bbdff-3864-4937-9396-1a9281a1bf09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_ed38881e-df3e-45ef-adb9-96dfe8fbd47b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_3fdd620d-8551-4df3-a5b1-e9bbd38ee478" xlink:to="loc_us-gaap_ReportingUnitAxis_ed38881e-df3e-45ef-adb9-96dfe8fbd47b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_ed38881e-df3e-45ef-adb9-96dfe8fbd47b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_ed38881e-df3e-45ef-adb9-96dfe8fbd47b" xlink:to="loc_us-gaap_ReportingUnitDomain_ed38881e-df3e-45ef-adb9-96dfe8fbd47b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_f3055656-4121-48f4-8e3d-e5301a3e89cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_ed38881e-df3e-45ef-adb9-96dfe8fbd47b" xlink:to="loc_us-gaap_ReportingUnitDomain_f3055656-4121-48f4-8e3d-e5301a3e89cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_61178fea-97b3-49ba-91e5-504b2395ca5b" xlink:href="bhc-20220630.xsd#bhc_ReportingUnitsExcludingOrthoDermatologicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_f3055656-4121-48f4-8e3d-e5301a3e89cd" xlink:to="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_61178fea-97b3-49ba-91e5-504b2395ca5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsReportingUnitMember_12634b31-39ad-4def-a914-30bbb2e8aba7" xlink:href="bhc-20220630.xsd#bhc_OrthoDermatologicsReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_f3055656-4121-48f4-8e3d-e5301a3e89cd" xlink:to="loc_bhc_OrthoDermatologicsReportingUnitMember_12634b31-39ad-4def-a914-30bbb2e8aba7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember_a709f24b-8d04-4b27-9fe2-912a623d9d5e" xlink:href="bhc-20220630.xsd#bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_f3055656-4121-48f4-8e3d-e5301a3e89cd" xlink:to="loc_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember_a709f24b-8d04-4b27-9fe2-912a623d9d5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember_9626d247-ea6b-4b44-8478-1559aac32dcd" xlink:href="bhc-20220630.xsd#bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_f3055656-4121-48f4-8e3d-e5301a3e89cd" xlink:to="loc_bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember_9626d247-ea6b-4b44-8478-1559aac32dcd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f45317bd-7c25-4934-bf8f-afbc2b528793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_3fdd620d-8551-4df3-a5b1-e9bbd38ee478" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f45317bd-7c25-4934-bf8f-afbc2b528793" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f45317bd-7c25-4934-bf8f-afbc2b528793_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f45317bd-7c25-4934-bf8f-afbc2b528793" xlink:to="loc_us-gaap_SegmentDomain_f45317bd-7c25-4934-bf8f-afbc2b528793_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4d365e41-f4b5-4386-8620-10c98fa333c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f45317bd-7c25-4934-bf8f-afbc2b528793" xlink:to="loc_us-gaap_SegmentDomain_4d365e41-f4b5-4386-8620-10c98fa333c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_19b596d6-50cf-4abc-ab2a-0aeeb25dfee5" xlink:href="bhc-20220630.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4d365e41-f4b5-4386-8620-10c98fa333c9" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_19b596d6-50cf-4abc-ab2a-0aeeb25dfee5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_7dd9384a-547b-48cd-b558-8a12560b8d11" xlink:href="bhc-20220630.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4d365e41-f4b5-4386-8620-10c98fa333c9" xlink:to="loc_bhc_SalixSegmentMember_7dd9384a-547b-48cd-b558-8a12560b8d11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2c0e5864-554d-49c9-9011-904ad687396f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_3fdd620d-8551-4df3-a5b1-e9bbd38ee478" xlink:to="loc_dei_LegalEntityAxis_2c0e5864-554d-49c9-9011-904ad687396f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2c0e5864-554d-49c9-9011-904ad687396f_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2c0e5864-554d-49c9-9011-904ad687396f" xlink:to="loc_dei_EntityDomain_2c0e5864-554d-49c9-9011-904ad687396f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_43f149fb-35ca-4afd-b55b-f5b0f254ae76" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2c0e5864-554d-49c9-9011-904ad687396f" xlink:to="loc_dei_EntityDomain_43f149fb-35ca-4afd-b55b-f5b0f254ae76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_3c172cc3-b324-4e05-959f-319033ecf7fd" xlink:href="bhc-20220630.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_43f149fb-35ca-4afd-b55b-f5b0f254ae76" xlink:to="loc_bhc_BauschLombMember_3c172cc3-b324-4e05-959f-319033ecf7fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9da0c344-6ae8-4384-bde6-c131757167f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_3fdd620d-8551-4df3-a5b1-e9bbd38ee478" xlink:to="loc_srt_ProductOrServiceAxis_9da0c344-6ae8-4384-bde6-c131757167f7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9da0c344-6ae8-4384-bde6-c131757167f7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9da0c344-6ae8-4384-bde6-c131757167f7" xlink:to="loc_srt_ProductsAndServicesDomain_9da0c344-6ae8-4384-bde6-c131757167f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_23a11ebf-9cd8-4dd1-8faa-c94dd0cdd455" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9da0c344-6ae8-4384-bde6-c131757167f7" xlink:to="loc_srt_ProductsAndServicesDomain_23a11ebf-9cd8-4dd1-8faa-c94dd0cdd455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_XifaxanBrandedProductsMember_4e645e11-1776-4424-9491-59da4be47a23" xlink:href="bhc-20220630.xsd#bhc_XifaxanBrandedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_23a11ebf-9cd8-4dd1-8faa-c94dd0cdd455" xlink:to="loc_bhc_XifaxanBrandedProductsMember_4e645e11-1776-4424-9491-59da4be47a23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_352afd39-0b61-4dd7-b895-f462c29744e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_3fdd620d-8551-4df3-a5b1-e9bbd38ee478" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_352afd39-0b61-4dd7-b895-f462c29744e9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_352afd39-0b61-4dd7-b895-f462c29744e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_352afd39-0b61-4dd7-b895-f462c29744e9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_352afd39-0b61-4dd7-b895-f462c29744e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_26ab84ab-2841-4e05-8fc2-65ac11103766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_352afd39-0b61-4dd7-b895-f462c29744e9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_26ab84ab-2841-4e05-8fc2-65ac11103766" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_9ff11752-5ad8-4762-86df-f838f4626d03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_26ab84ab-2841-4e05-8fc2-65ac11103766" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_9ff11752-5ad8-4762-86df-f838f4626d03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_700eced1-930d-4510-8367-1b3c1ca8e4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_3fdd620d-8551-4df3-a5b1-e9bbd38ee478" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_700eced1-930d-4510-8367-1b3c1ca8e4c7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_700eced1-930d-4510-8367-1b3c1ca8e4c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_700eced1-930d-4510-8367-1b3c1ca8e4c7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_700eced1-930d-4510-8367-1b3c1ca8e4c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_286ef1d4-8b1b-4602-a22b-c25e2719808c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_700eced1-930d-4510-8367-1b3c1ca8e4c7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_286ef1d4-8b1b-4602-a22b-c25e2719808c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_3f208181-8132-42f1-8ba9-8ad9944d7cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_286ef1d4-8b1b-4602-a22b-c25e2719808c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_3f208181-8132-42f1-8ba9-8ad9944d7cff" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails" xlink:type="extended" id="i26599868344b4f9fb104e7282a99f5af_INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_f730dc52-b995-448c-9027-497851d7b44d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_5522da64-f8a2-4084-8205-0555edc0463f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_f730dc52-b995-448c-9027-497851d7b44d" xlink:to="loc_us-gaap_GoodwillRollForward_5522da64-f8a2-4084-8205-0555edc0463f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8bfb7ca6-63bc-4728-93fb-9ebc07f0f8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_5522da64-f8a2-4084-8205-0555edc0463f" xlink:to="loc_us-gaap_Goodwill_8bfb7ca6-63bc-4728-93fb-9ebc07f0f8e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_1494020b-4251-44e3-ba44-03173653d69f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_5522da64-f8a2-4084-8205-0555edc0463f" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_1494020b-4251-44e3-ba44-03173653d69f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_635cc1f5-63b0-46f1-a1b3-809724e93d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_5522da64-f8a2-4084-8205-0555edc0463f" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_635cc1f5-63b0-46f1-a1b3-809724e93d8c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_6850c3d6-20f7-4a11-b866-a230321dec58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_5522da64-f8a2-4084-8205-0555edc0463f" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_6850c3d6-20f7-4a11-b866-a230321dec58" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4e7ee489-5db8-40d5-9611-a8a92575b001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_da59e6a9-9276-4163-8f2a-d1d0683062ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_f730dc52-b995-448c-9027-497851d7b44d" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_da59e6a9-9276-4163-8f2a-d1d0683062ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6a67065e-8aae-4b88-8683-2f334f933bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_da59e6a9-9276-4163-8f2a-d1d0683062ac" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6a67065e-8aae-4b88-8683-2f334f933bf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6a67065e-8aae-4b88-8683-2f334f933bf4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6a67065e-8aae-4b88-8683-2f334f933bf4" xlink:to="loc_us-gaap_SegmentDomain_6a67065e-8aae-4b88-8683-2f334f933bf4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bc32cd02-f739-4f8c-972b-ece8cc20576e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6a67065e-8aae-4b88-8683-2f334f933bf4" xlink:to="loc_us-gaap_SegmentDomain_bc32cd02-f739-4f8c-972b-ece8cc20576e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombInternationalMember_2392762c-3783-4e82-b359-5531cb895997" xlink:href="bhc-20220630.xsd#bhc_BauschLombInternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bc32cd02-f739-4f8c-972b-ece8cc20576e" xlink:to="loc_bhc_BauschLombInternationalMember_2392762c-3783-4e82-b359-5531cb895997" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_5ab28e3d-68b1-42b3-afc1-f96e74ab6bad" xlink:href="bhc-20220630.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bc32cd02-f739-4f8c-972b-ece8cc20576e" xlink:to="loc_bhc_BauschLombMember_5ab28e3d-68b1-42b3-afc1-f96e74ab6bad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_b7f9e337-23af-48ca-8406-ea299fdd438b" xlink:href="bhc-20220630.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bc32cd02-f739-4f8c-972b-ece8cc20576e" xlink:to="loc_bhc_SalixSegmentMember_b7f9e337-23af-48ca-8406-ea299fdd438b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_7551215e-906f-4abf-a949-4d0830fd3b47" xlink:href="bhc-20220630.xsd#bhc_InternationalRxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bc32cd02-f739-4f8c-972b-ece8cc20576e" xlink:to="loc_bhc_InternationalRxMember_7551215e-906f-4abf-a949-4d0830fd3b47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_4df4ea86-8b04-4d1d-8268-c5c0c1480f55" xlink:href="bhc-20220630.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bc32cd02-f739-4f8c-972b-ece8cc20576e" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_4df4ea86-8b04-4d1d-8268-c5c0c1480f55" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_832e189a-eb2d-4980-bff9-ba859cf4b05a" xlink:href="bhc-20220630.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bc32cd02-f739-4f8c-972b-ece8cc20576e" xlink:to="loc_bhc_SoltaMedicalSegmentMember_832e189a-eb2d-4980-bff9-ba859cf4b05a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_2f25c2da-bb7e-44fb-8d59-d8259daa9774" xlink:href="bhc-20220630.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bc32cd02-f739-4f8c-972b-ece8cc20576e" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_2f25c2da-bb7e-44fb-8d59-d8259daa9774" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="extended" id="i8681fe293f154ef6a15b7c1d448d9837_FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0aa5a5c9-2e6a-44a2-afae-7763a7c64865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_537d9eef-95d7-41b8-be2c-b733c97e5293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0aa5a5c9-2e6a-44a2-afae-7763a7c64865" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_537d9eef-95d7-41b8-be2c-b733c97e5293" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_90a7f8a3-b0b0-4188-8370-2dd74d4f34ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0aa5a5c9-2e6a-44a2-afae-7763a7c64865" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_90a7f8a3-b0b0-4188-8370-2dd74d4f34ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5ef7c655-dd34-42f3-bce3-9405c910cf46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0aa5a5c9-2e6a-44a2-afae-7763a7c64865" xlink:to="loc_us-gaap_LongTermDebt_5ef7c655-dd34-42f3-bce3-9405c910cf46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_04ecf859-dca2-4f64-baaa-8630c229d1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0aa5a5c9-2e6a-44a2-afae-7763a7c64865" xlink:to="loc_us-gaap_LongTermDebtCurrent_04ecf859-dca2-4f64-baaa-8630c229d1a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_bbc16e19-d01f-4137-bee2-f15b2b0451f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0aa5a5c9-2e6a-44a2-afae-7763a7c64865" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_bbc16e19-d01f-4137-bee2-f15b2b0451f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_80cefb0a-7242-4373-bf60-15080674dab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0aa5a5c9-2e6a-44a2-afae-7763a7c64865" xlink:to="loc_us-gaap_DebtInstrumentTable_80cefb0a-7242-4373-bf60-15080674dab2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_67b209d6-e6ad-4c9e-aee8-af6fd20f3595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_80cefb0a-7242-4373-bf60-15080674dab2" xlink:to="loc_us-gaap_CreditFacilityAxis_67b209d6-e6ad-4c9e-aee8-af6fd20f3595" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_67b209d6-e6ad-4c9e-aee8-af6fd20f3595_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_67b209d6-e6ad-4c9e-aee8-af6fd20f3595" xlink:to="loc_us-gaap_CreditFacilityDomain_67b209d6-e6ad-4c9e-aee8-af6fd20f3595_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ac3732f7-9fb0-498e-9978-a713a458faa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_67b209d6-e6ad-4c9e-aee8-af6fd20f3595" xlink:to="loc_us-gaap_CreditFacilityDomain_ac3732f7-9fb0-498e-9978-a713a458faa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_aa968220-549d-4c62-966f-a4b09375c784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_ac3732f7-9fb0-498e-9978-a713a458faa8" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_aa968220-549d-4c62-966f-a4b09375c784" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5528d2e8-561f-46fa-814f-2d9832ad4e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_80cefb0a-7242-4373-bf60-15080674dab2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5528d2e8-561f-46fa-814f-2d9832ad4e19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5528d2e8-561f-46fa-814f-2d9832ad4e19_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5528d2e8-561f-46fa-814f-2d9832ad4e19" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5528d2e8-561f-46fa-814f-2d9832ad4e19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6bff6894-dc54-483c-b2c8-b42d0050f120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5528d2e8-561f-46fa-814f-2d9832ad4e19" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6bff6894-dc54-483c-b2c8-b42d0050f120" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_b0682e9a-4e1a-4d00-9b41-f052a05b6d58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6bff6894-dc54-483c-b2c8-b42d0050f120" xlink:to="loc_us-gaap_SecuredDebtMember_b0682e9a-4e1a-4d00-9b41-f052a05b6d58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_eec20a56-447d-4eef-8a49-99a2afc6148e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6bff6894-dc54-483c-b2c8-b42d0050f120" xlink:to="loc_us-gaap_UnsecuredDebtMember_eec20a56-447d-4eef-8a49-99a2afc6148e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_827237ba-c342-4b8f-a608-aeb68855de22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_80cefb0a-7242-4373-bf60-15080674dab2" xlink:to="loc_us-gaap_DebtInstrumentAxis_827237ba-c342-4b8f-a608-aeb68855de22" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_827237ba-c342-4b8f-a608-aeb68855de22_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_827237ba-c342-4b8f-a608-aeb68855de22" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_827237ba-c342-4b8f-a608-aeb68855de22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_827237ba-c342-4b8f-a608-aeb68855de22" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_7412991f-6379-4d7b-bae6-8fd218834778" xlink:href="bhc-20220630.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_7412991f-6379-4d7b-bae6-8fd218834778" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_419060a9-7a8d-4ff3-afba-218ca235f294" xlink:href="bhc-20220630.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_419060a9-7a8d-4ff3-afba-218ca235f294" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_5413978e-68ee-4202-a992-a5b07e928128" xlink:href="bhc-20220630.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_5413978e-68ee-4202-a992-a5b07e928128" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_2f41eab1-20d6-4720-aac8-9d0b0a8a4799" xlink:href="bhc-20220630.xsd#bhc_RevolvingCreditFacilityDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_2f41eab1-20d6-4720-aac8-9d0b0a8a4799" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueFebruary2027Member_1a9b6394-9f8d-4cb2-950a-ca8960e48fd9" xlink:href="bhc-20220630.xsd#bhc_TermLoanBFacilityDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_TermLoanBFacilityDueFebruary2027Member_1a9b6394-9f8d-4cb2-950a-ca8960e48fd9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueMay2027Member_44e85fbc-c5b8-4d3a-9f50-94d926134bd4" xlink:href="bhc-20220630.xsd#bhc_RevolvingCreditFacilityDueMay2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_RevolvingCreditFacilityDueMay2027Member_44e85fbc-c5b8-4d3a-9f50-94d926134bd4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermFacilityDueMay2027Member_bbfbcb15-3c32-4d68-b984-d27f1ae49d01" xlink:href="bhc-20220630.xsd#bhc_TermFacilityDueMay2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_TermFacilityDueMay2027Member_bbfbcb15-3c32-4d68-b984-d27f1ae49d01" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_b043d2d3-c13d-4829-a51e-ba8113b75d91" xlink:href="bhc-20220630.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_b043d2d3-c13d-4829-a51e-ba8113b75d91" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_eed6a61f-4ae3-4084-895a-7fe5fbaaddf8" xlink:href="bhc-20220630.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_eed6a61f-4ae3-4084-895a-7fe5fbaaddf8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_9ad2e185-f780-426f-af5d-fac2edfd676b" xlink:href="bhc-20220630.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_9ad2e185-f780-426f-af5d-fac2edfd676b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member_b19f74a0-d4c7-4647-8f33-44750ce66f9a" xlink:href="bhc-20220630.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorSecured4875NotesDueJune2028Member_b19f74a0-d4c7-4647-8f33-44750ce66f9a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_b891f1a9-fe29-4078-811a-a95b43be315c" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_b891f1a9-fe29-4078-811a-a95b43be315c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes900DueDecember2025Member_da41fbef-4e46-4149-8bf8-1f817903ef15" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes900DueDecember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorNotes900DueDecember2025Member_da41fbef-4e46-4149-8bf8-1f817903ef15" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member_23d5792c-8d1e-47b0-b17d-a40516ccbcd2" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorNotes925DueApril2026Member_23d5792c-8d1e-47b0-b17d-a40516ccbcd2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member_a7534258-4474-44e9-83b4-89f3f72d2702" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorNotes850DueJanuary2027Member_a7534258-4474-44e9-83b4-89f3f72d2702" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member_1b396cf4-6952-4f5c-a297-b3b64bba19b1" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorNotes700DueJanuary2028Member_1b396cf4-6952-4f5c-a297-b3b64bba19b1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member_f7fa0641-2d82-411f-b86c-1aa372b8a191" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorNotes500DueJanuary2028Member_f7fa0641-2d82-411f-b86c-1aa372b8a191" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member_82185426-5177-4e27-a5da-6be955bec7f4" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorNotes625DueFebruary2029Member_82185426-5177-4e27-a5da-6be955bec7f4" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member_d44ff3ca-6974-4960-a0e1-779491b0aa5b" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorNotes500DueFebruary2029Member_d44ff3ca-6974-4960-a0e1-779491b0aa5b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member_ddebf70e-902d-44d6-8ee9-3a7ec978d310" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorNotes725DueMay2029Member_ddebf70e-902d-44d6-8ee9-3a7ec978d310" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member_e1bf2d09-950f-4720-bf54-dc05dda0a67e" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorNotes525DueJanuary2030Member_e1bf2d09-950f-4720-bf54-dc05dda0a67e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member_03c82c0e-8b9d-4dfe-8186-613bb1ae9635" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorNotes525DueFebruary2031Member_03c82c0e-8b9d-4dfe-8186-613bb1ae9635" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherLongTermDebtMember_977da6b2-35ab-4cec-a7c5-7bbd85de63be" xlink:href="bhc-20220630.xsd#bhc_OtherLongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_OtherLongTermDebtMember_977da6b2-35ab-4cec-a7c5-7bbd85de63be" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_cd2c62a8-4632-455e-99c0-0237930df0ad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_80cefb0a-7242-4373-bf60-15080674dab2" xlink:to="loc_dei_LegalEntityAxis_cd2c62a8-4632-455e-99c0-0237930df0ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_cd2c62a8-4632-455e-99c0-0237930df0ad_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_cd2c62a8-4632-455e-99c0-0237930df0ad" xlink:to="loc_dei_EntityDomain_cd2c62a8-4632-455e-99c0-0237930df0ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4cf02bf3-e523-45e1-a75a-f77fe24384e1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_cd2c62a8-4632-455e-99c0-0237930df0ad" xlink:to="loc_dei_EntityDomain_4cf02bf3-e523-45e1-a75a-f77fe24384e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_89ca5025-c514-4763-bec5-4166b69c225a" xlink:href="bhc-20220630.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4cf02bf3-e523-45e1-a75a-f77fe24384e1" xlink:to="loc_bhc_BauschLombMember_89ca5025-c514-4763-bec5-4166b69c225a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FINANCINGARRANGEMENTSCovenantComplianceDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="extended" id="iecca870ef2ce44efaaa65fc21add79e8_FINANCINGARRANGEMENTSCovenantComplianceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a543db37-fac0-41fa-a4ad-d29411ce0cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_e2aabfcf-84a6-4fc4-b701-ecb7304d7792" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a543db37-fac0-41fa-a4ad-d29411ce0cf4" xlink:to="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_e2aabfcf-84a6-4fc4-b701-ecb7304d7792" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_5234081f-16c3-45b2-856f-15d6ce1a103b" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a543db37-fac0-41fa-a4ad-d29411ce0cf4" xlink:to="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_5234081f-16c3-45b2-856f-15d6ce1a103b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_1b796ae7-b26c-4336-8931-d74c5ceed198" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a543db37-fac0-41fa-a4ad-d29411ce0cf4" xlink:to="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_1b796ae7-b26c-4336-8931-d74c5ceed198" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_55287028-f5fc-443c-9ead-83d3a1e00f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a543db37-fac0-41fa-a4ad-d29411ce0cf4" xlink:to="loc_us-gaap_DebtInstrumentTable_55287028-f5fc-443c-9ead-83d3a1e00f4a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_30d4e70a-bc93-4132-9be4-b8978e1458cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_55287028-f5fc-443c-9ead-83d3a1e00f4a" xlink:to="loc_us-gaap_CreditFacilityAxis_30d4e70a-bc93-4132-9be4-b8978e1458cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_30d4e70a-bc93-4132-9be4-b8978e1458cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_30d4e70a-bc93-4132-9be4-b8978e1458cd" xlink:to="loc_us-gaap_CreditFacilityDomain_30d4e70a-bc93-4132-9be4-b8978e1458cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_873a29ad-3b71-4f00-9f33-1fb350cef581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_30d4e70a-bc93-4132-9be4-b8978e1458cd" xlink:to="loc_us-gaap_CreditFacilityDomain_873a29ad-3b71-4f00-9f33-1fb350cef581" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilityMember_376be3d6-26d2-4f4e-9c3a-2460bdee0a49" xlink:href="bhc-20220630.xsd#bhc_SeniorSecuredCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_873a29ad-3b71-4f00-9f33-1fb350cef581" xlink:to="loc_bhc_SeniorSecuredCreditFacilityMember_376be3d6-26d2-4f4e-9c3a-2460bdee0a49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_167d4d21-f205-4dfe-abf5-f396b41dfa4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_873a29ad-3b71-4f00-9f33-1fb350cef581" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_167d4d21-f205-4dfe-abf5-f396b41dfa4b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="extended" id="ifdf362ac85a648e3a996fc6f6ea53343_FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ee457483-e1d4-4dec-a361-837913f1e979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ee457483-e1d4-4dec-a361-837913f1e979" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_b2898f7b-b88e-41fd-aa87-bbf431243259" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_b2898f7b-b88e-41fd-aa87-bbf431243259" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_7eff8a32-7870-432f-a6d9-eee698eaf177" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_7eff8a32-7870-432f-a6d9-eee698eaf177" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_11f3181b-34ee-4de8-b535-824c93e822ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_11f3181b-34ee-4de8-b535-824c93e822ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c5eb7b31-3a53-40fd-aaae-116bbaf4b3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_us-gaap_LongTermDebt_c5eb7b31-3a53-40fd-aaae-116bbaf4b3bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_312dfc3e-25e6-4d98-86d1-b97650b2a4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_312dfc3e-25e6-4d98-86d1-b97650b2a4b6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable_fd7d2cae-2c47-438d-bb11-1d8d28ad3eda" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable_fd7d2cae-2c47-438d-bb11-1d8d28ad3eda" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_512872ad-8459-49de-8514-85483a5e5495" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_512872ad-8459-49de-8514-85483a5e5495" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_fba3b353-741e-4df5-9a13-f726e8ad4ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_fba3b353-741e-4df5-9a13-f726e8ad4ddd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_236405bd-2baf-4472-b3d1-aed42f9328e8" xlink:href="bhc-20220630.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_236405bd-2baf-4472-b3d1-aed42f9328e8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_f68fe18c-954e-402e-abbe-9a8b66ac8198" xlink:href="bhc-20220630.xsd#bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_f68fe18c-954e-402e-abbe-9a8b66ac8198" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_2ff9c81c-806c-4658-bee5-6e58460e26b7" xlink:href="bhc-20220630.xsd#bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_2ff9c81c-806c-4658-bee5-6e58460e26b7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_ca0fa0b9-c48e-45b0-a2bc-ca7fa0f00ae4" xlink:href="bhc-20220630.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_ca0fa0b9-c48e-45b0-a2bc-ca7fa0f00ae4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_4091e3fa-13ed-4bc3-8b28-a2a843c7e714" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentAnnualAmortizationRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_4091e3fa-13ed-4bc3-8b28-a2a843c7e714" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_b7f887c2-b9fe-4bb1-b821-4cb73dcf638c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_b7f887c2-b9fe-4bb1-b821-4cb73dcf638c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization_250edc68-20b5-48ed-bf99-115d49fe3148" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization_250edc68-20b5-48ed-bf99-115d49fe3148" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_14a5bd67-c624-47cb-a152-a1e246b6fdad" xlink:href="bhc-20220630.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_14a5bd67-c624-47cb-a152-a1e246b6fdad" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage_bb8a043c-8dd1-43fd-996d-752a0bd0c3c8" xlink:href="bhc-20220630.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage_bb8a043c-8dd1-43fd-996d-752a0bd0c3c8" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_291ad786-2617-4c1a-8059-0c05c1381eee" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_291ad786-2617-4c1a-8059-0c05c1381eee" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_99afd73f-dc05-4535-9838-12f91b5e039d" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_99afd73f-dc05-4535-9838-12f91b5e039d" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_87aa481c-f837-4b11-8ede-7eb874b7b35e" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_87aa481c-f837-4b11-8ede-7eb874b7b35e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio_cf984646-f726-4c0b-ba89-543755921ffb" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio_cf984646-f726-4c0b-ba89-543755921ffb" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_98a5a690-8bc7-450d-8a0c-fd5436f89be2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_us-gaap_DebtInstrumentTerm_98a5a690-8bc7-450d-8a0c-fd5436f89be2" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_5710a306-2c25-44c0-b0ac-3dd8c57a80d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_5710a306-2c25-44c0-b0ac-3dd8c57a80d8" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_25de9279-0336-4d37-9d24-a0722350724d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_us-gaap_DebtInstrumentTable_25de9279-0336-4d37-9d24-a0722350724d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2de460b5-34bc-4510-b792-10c226649a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_25de9279-0336-4d37-9d24-a0722350724d" xlink:to="loc_us-gaap_CreditFacilityAxis_2de460b5-34bc-4510-b792-10c226649a3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2de460b5-34bc-4510-b792-10c226649a3c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_2de460b5-34bc-4510-b792-10c226649a3c" xlink:to="loc_us-gaap_CreditFacilityDomain_2de460b5-34bc-4510-b792-10c226649a3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_73b9bf85-93d9-4bc1-8b18-61234a2d514f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_2de460b5-34bc-4510-b792-10c226649a3c" xlink:to="loc_us-gaap_CreditFacilityDomain_73b9bf85-93d9-4bc1-8b18-61234a2d514f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_de77ca83-63a7-467b-a9f3-af2349f0ccda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_73b9bf85-93d9-4bc1-8b18-61234a2d514f" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_de77ca83-63a7-467b-a9f3-af2349f0ccda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2f18c9bc-bcfc-42b4-9736-8470c3d62976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_25de9279-0336-4d37-9d24-a0722350724d" xlink:to="loc_us-gaap_DebtInstrumentAxis_2f18c9bc-bcfc-42b4-9736-8470c3d62976" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2f18c9bc-bcfc-42b4-9736-8470c3d62976_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2f18c9bc-bcfc-42b4-9736-8470c3d62976" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2f18c9bc-bcfc-42b4-9736-8470c3d62976_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a259b098-8e5f-4934-b9c4-ae727098b4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2f18c9bc-bcfc-42b4-9736-8470c3d62976" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a259b098-8e5f-4934-b9c4-ae727098b4e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_1c8d3739-d3a6-4320-893b-9db1e998075e" xlink:href="bhc-20220630.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a259b098-8e5f-4934-b9c4-ae727098b4e3" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_1c8d3739-d3a6-4320-893b-9db1e998075e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_c9267542-7ffa-4cb4-84ef-6ebfb786b413" xlink:href="bhc-20220630.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a259b098-8e5f-4934-b9c4-ae727098b4e3" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_c9267542-7ffa-4cb4-84ef-6ebfb786b413" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_0aa20e2f-5d4e-4c6d-806e-104dbee3f82a" xlink:href="bhc-20220630.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a259b098-8e5f-4934-b9c4-ae727098b4e3" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_0aa20e2f-5d4e-4c6d-806e-104dbee3f82a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueFebruary2027Member_866afe10-64f8-476f-bfbd-e7eeb7200a6e" xlink:href="bhc-20220630.xsd#bhc_TermLoanBFacilityDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a259b098-8e5f-4934-b9c4-ae727098b4e3" xlink:to="loc_bhc_TermLoanBFacilityDueFebruary2027Member_866afe10-64f8-476f-bfbd-e7eeb7200a6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_b3c62ad8-1290-49a4-9717-967d165e0254" xlink:href="bhc-20220630.xsd#bhc_RevolvingCreditFacilityDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a259b098-8e5f-4934-b9c4-ae727098b4e3" xlink:to="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_b3c62ad8-1290-49a4-9717-967d165e0254" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilitiesMember_f886e8fb-3445-4000-8929-3c4ac4eeb67a" xlink:href="bhc-20220630.xsd#bhc_SeniorSecuredCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a259b098-8e5f-4934-b9c4-ae727098b4e3" xlink:to="loc_bhc_SeniorSecuredCreditFacilitiesMember_f886e8fb-3445-4000-8929-3c4ac4eeb67a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NewRestatedCreditAgreementMember_a813efc4-3de4-4cd3-ae6d-ff1009b04af8" xlink:href="bhc-20220630.xsd#bhc_NewRestatedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a259b098-8e5f-4934-b9c4-ae727098b4e3" xlink:to="loc_bhc_NewRestatedCreditAgreementMember_a813efc4-3de4-4cd3-ae6d-ff1009b04af8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermFacilityDueMay2027Member_c4b94cb2-e3fd-4213-aa5b-d024253de6a1" xlink:href="bhc-20220630.xsd#bhc_TermFacilityDueMay2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a259b098-8e5f-4934-b9c4-ae727098b4e3" xlink:to="loc_bhc_TermFacilityDueMay2027Member_c4b94cb2-e3fd-4213-aa5b-d024253de6a1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueMay2027Member_ab93c2d6-61f0-4b33-a6d5-50a79b157f0e" xlink:href="bhc-20220630.xsd#bhc_RevolvingCreditFacilityDueMay2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a259b098-8e5f-4934-b9c4-ae727098b4e3" xlink:to="loc_bhc_RevolvingCreditFacilityDueMay2027Member_ab93c2d6-61f0-4b33-a6d5-50a79b157f0e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BLCreditAgreementMember_f7e310fd-132c-4046-9b88-38b44ba9c72e" xlink:href="bhc-20220630.xsd#bhc_BLCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a259b098-8e5f-4934-b9c4-ae727098b4e3" xlink:to="loc_bhc_BLCreditAgreementMember_f7e310fd-132c-4046-9b88-38b44ba9c72e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_2a334cdf-49da-463b-9730-36d44f13ed0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_25de9279-0336-4d37-9d24-a0722350724d" xlink:to="loc_us-gaap_VariableRateAxis_2a334cdf-49da-463b-9730-36d44f13ed0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_2a334cdf-49da-463b-9730-36d44f13ed0b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_2a334cdf-49da-463b-9730-36d44f13ed0b" xlink:to="loc_us-gaap_VariableRateDomain_2a334cdf-49da-463b-9730-36d44f13ed0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_a69ef02d-35e1-4096-8c38-e0f4ded21bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_2a334cdf-49da-463b-9730-36d44f13ed0b" xlink:to="loc_us-gaap_VariableRateDomain_a69ef02d-35e1-4096-8c38-e0f4ded21bb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_7b9caf32-dbc3-4a2c-86b2-3eb7c90d14b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_a69ef02d-35e1-4096-8c38-e0f4ded21bb3" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_7b9caf32-dbc3-4a2c-86b2-3eb7c90d14b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember_37d3b303-40e4-4242-82f8-d119af0f913b" xlink:href="bhc-20220630.xsd#bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_a69ef02d-35e1-4096-8c38-e0f4ded21bb3" xlink:to="loc_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember_37d3b303-40e4-4242-82f8-d119af0f913b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_93feb061-56f2-4416-ab61-8db5d486fc6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_a69ef02d-35e1-4096-8c38-e0f4ded21bb3" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_93feb061-56f2-4416-ab61-8db5d486fc6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadianBankersAcceptanceRateMember_031ad950-ad8a-4e4f-a9c9-3fcb74cea3aa" xlink:href="bhc-20220630.xsd#bhc_CanadianBankersAcceptanceRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_a69ef02d-35e1-4096-8c38-e0f4ded21bb3" xlink:to="loc_bhc_CanadianBankersAcceptanceRateMember_031ad950-ad8a-4e4f-a9c9-3fcb74cea3aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EuropeInterbankOfferedRateEURIBORMember_68c92bb3-aa4f-4656-bb36-e0f02a61474b" xlink:href="bhc-20220630.xsd#bhc_EuropeInterbankOfferedRateEURIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_a69ef02d-35e1-4096-8c38-e0f4ded21bb3" xlink:to="loc_bhc_EuropeInterbankOfferedRateEURIBORMember_68c92bb3-aa4f-4656-bb36-e0f02a61474b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_1f850990-ce52-4757-8769-9cc0f44b25a7" xlink:href="bhc-20220630.xsd#bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_a69ef02d-35e1-4096-8c38-e0f4ded21bb3" xlink:to="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_1f850990-ce52-4757-8769-9cc0f44b25a7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_c361fe2a-0db3-432a-88e5-0dad75499150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_a69ef02d-35e1-4096-8c38-e0f4ded21bb3" xlink:to="loc_us-gaap_BaseRateMember_c361fe2a-0db3-432a-88e5-0dad75499150" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDORAndEURIBORRatesMember_8b88156f-9624-4815-82ca-22774b7f4385" xlink:href="bhc-20220630.xsd#bhc_SOFRCDORAndEURIBORRatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_a69ef02d-35e1-4096-8c38-e0f4ded21bb3" xlink:to="loc_bhc_SOFRCDORAndEURIBORRatesMember_8b88156f-9624-4815-82ca-22774b7f4385" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SONIARateMember_5175bb5b-9bd0-4d27-9587-6468d7f666b4" xlink:href="bhc-20220630.xsd#bhc_SONIARateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_a69ef02d-35e1-4096-8c38-e0f4ded21bb3" xlink:to="loc_bhc_SONIARateMember_5175bb5b-9bd0-4d27-9587-6468d7f666b4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember_2409045e-40b1-4ec2-826d-75115796cb91" xlink:href="bhc-20220630.xsd#bhc_SOFRCDOREURIBORAndSONIARatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_a69ef02d-35e1-4096-8c38-e0f4ded21bb3" xlink:to="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember_2409045e-40b1-4ec2-826d-75115796cb91" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c087ad34-1e69-45e5-8bb6-88a64a9c5ed7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_25de9279-0336-4d37-9d24-a0722350724d" xlink:to="loc_srt_RangeAxis_c087ad34-1e69-45e5-8bb6-88a64a9c5ed7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c087ad34-1e69-45e5-8bb6-88a64a9c5ed7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c087ad34-1e69-45e5-8bb6-88a64a9c5ed7" xlink:to="loc_srt_RangeMember_c087ad34-1e69-45e5-8bb6-88a64a9c5ed7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b5f96d83-fb7f-4033-8ddc-f2bee3a5d5f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c087ad34-1e69-45e5-8bb6-88a64a9c5ed7" xlink:to="loc_srt_RangeMember_b5f96d83-fb7f-4033-8ddc-f2bee3a5d5f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_83f574cf-a9e2-425d-b5f9-61464b66bbaa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b5f96d83-fb7f-4033-8ddc-f2bee3a5d5f7" xlink:to="loc_srt_MinimumMember_83f574cf-a9e2-425d-b5f9-61464b66bbaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7e7c65e5-640b-4da9-9044-58915ff77a58" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b5f96d83-fb7f-4033-8ddc-f2bee3a5d5f7" xlink:to="loc_srt_MaximumMember_7e7c65e5-640b-4da9-9044-58915ff77a58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3f8030b3-c218-4687-80cd-012dd376f171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_25de9279-0336-4d37-9d24-a0722350724d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3f8030b3-c218-4687-80cd-012dd376f171" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3f8030b3-c218-4687-80cd-012dd376f171_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3f8030b3-c218-4687-80cd-012dd376f171" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3f8030b3-c218-4687-80cd-012dd376f171_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_81ac0528-c535-4e02-af74-09339e592340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3f8030b3-c218-4687-80cd-012dd376f171" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_81ac0528-c535-4e02-af74-09339e592340" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_28e83031-17c5-4156-91eb-9fd12d717b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_81ac0528-c535-4e02-af74-09339e592340" xlink:to="loc_us-gaap_SecuredDebtMember_28e83031-17c5-4156-91eb-9fd12d717b0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_8951e676-22e5-4671-a373-b1b65f060926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_81ac0528-c535-4e02-af74-09339e592340" xlink:to="loc_us-gaap_UnsecuredDebtMember_8951e676-22e5-4671-a373-b1b65f060926" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c2bd4cf7-15f2-41b7-aeef-e9c3aee50bc0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_25de9279-0336-4d37-9d24-a0722350724d" xlink:to="loc_dei_LegalEntityAxis_c2bd4cf7-15f2-41b7-aeef-e9c3aee50bc0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c2bd4cf7-15f2-41b7-aeef-e9c3aee50bc0_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_c2bd4cf7-15f2-41b7-aeef-e9c3aee50bc0" xlink:to="loc_dei_EntityDomain_c2bd4cf7-15f2-41b7-aeef-e9c3aee50bc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e78f332c-3aa0-42ae-9aea-c1d5e8e5c8f3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_c2bd4cf7-15f2-41b7-aeef-e9c3aee50bc0" xlink:to="loc_dei_EntityDomain_e78f332c-3aa0-42ae-9aea-c1d5e8e5c8f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_8e6a41af-a08c-422f-9577-208f8aafdecd" xlink:href="bhc-20220630.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e78f332c-3aa0-42ae-9aea-c1d5e8e5c8f3" xlink:to="loc_bhc_BauschLombMember_8e6a41af-a08c-422f-9577-208f8aafdecd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="extended" id="i3d381748850b407cbc3cc2841f370439_FINANCINGARRANGEMENTSSeniorSecuredNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6ac8794c-0c09-4706-b147-6af303ff6fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f0ceb864-8157-48fc-8395-553a58d152cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ac8794c-0c09-4706-b147-6af303ff6fe2" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f0ceb864-8157-48fc-8395-553a58d152cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_68dbb3f0-6179-442d-9cd6-16129cc3c541" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ac8794c-0c09-4706-b147-6af303ff6fe2" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_68dbb3f0-6179-442d-9cd6-16129cc3c541" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_5f21df0d-5443-47fc-8a78-d638769ffa2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ac8794c-0c09-4706-b147-6af303ff6fe2" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_5f21df0d-5443-47fc-8a78-d638769ffa2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_a317a840-963a-468a-8da4-91cf882ee154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ac8794c-0c09-4706-b147-6af303ff6fe2" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_a317a840-963a-468a-8da4-91cf882ee154" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d2b5a9c0-8370-4dad-b8fa-450031929d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ac8794c-0c09-4706-b147-6af303ff6fe2" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d2b5a9c0-8370-4dad-b8fa-450031929d5e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_17baa3bd-195c-4832-af13-49b4d5b2f7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ac8794c-0c09-4706-b147-6af303ff6fe2" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_17baa3bd-195c-4832-af13-49b4d5b2f7e6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_e014fa6c-df75-42e3-b8c5-2fd1d8873733" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ac8794c-0c09-4706-b147-6af303ff6fe2" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_e014fa6c-df75-42e3-b8c5-2fd1d8873733" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a1c90d7b-1549-4df9-8aa5-de179136fc59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ac8794c-0c09-4706-b147-6af303ff6fe2" xlink:to="loc_us-gaap_DebtInstrumentTable_a1c90d7b-1549-4df9-8aa5-de179136fc59" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1a35d39c-aa7b-415d-a728-e757d2fc370d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a1c90d7b-1549-4df9-8aa5-de179136fc59" xlink:to="loc_us-gaap_DebtInstrumentAxis_1a35d39c-aa7b-415d-a728-e757d2fc370d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1a35d39c-aa7b-415d-a728-e757d2fc370d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1a35d39c-aa7b-415d-a728-e757d2fc370d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1a35d39c-aa7b-415d-a728-e757d2fc370d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_55643340-2c14-47ac-9fdc-f36bf8d3c59d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1a35d39c-aa7b-415d-a728-e757d2fc370d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_55643340-2c14-47ac-9fdc-f36bf8d3c59d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_df5d9e3a-183b-4e3c-ad3b-5439b6a8da0d" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_55643340-2c14-47ac-9fdc-f36bf8d3c59d" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_df5d9e3a-183b-4e3c-ad3b-5439b6a8da0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member_f3332b35-2612-4de7-9a93-8afd2098178c" xlink:href="bhc-20220630.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_55643340-2c14-47ac-9fdc-f36bf8d3c59d" xlink:to="loc_bhc_SeniorSecured4875NotesDueJune2028Member_f3332b35-2612-4de7-9a93-8afd2098178c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueMarch2024Member_18bf2e0a-6fb4-4889-8210-8570274195e1" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes700DueMarch2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_55643340-2c14-47ac-9fdc-f36bf8d3c59d" xlink:to="loc_bhc_SeniorNotes700DueMarch2024Member_18bf2e0a-6fb4-4889-8210-8570274195e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_6ad9ca11-62cb-410d-b07d-808333150e32" xlink:href="bhc-20220630.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_55643340-2c14-47ac-9fdc-f36bf8d3c59d" xlink:to="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_6ad9ca11-62cb-410d-b07d-808333150e32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d45be0e5-4fca-4c20-b11a-c2fd9e0a3246" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a1c90d7b-1549-4df9-8aa5-de179136fc59" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d45be0e5-4fca-4c20-b11a-c2fd9e0a3246" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d45be0e5-4fca-4c20-b11a-c2fd9e0a3246_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d45be0e5-4fca-4c20-b11a-c2fd9e0a3246" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d45be0e5-4fca-4c20-b11a-c2fd9e0a3246_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2309be8f-0419-4720-a0d2-cb2503306293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d45be0e5-4fca-4c20-b11a-c2fd9e0a3246" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2309be8f-0419-4720-a0d2-cb2503306293" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_7cc1fa12-ed0c-4e7d-b4a9-962dc03166ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2309be8f-0419-4720-a0d2-cb2503306293" xlink:to="loc_us-gaap_UnsecuredDebtMember_7cc1fa12-ed0c-4e7d-b4a9-962dc03166ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_3283a16d-8e5a-4aa5-87b6-f1115bebd2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2309be8f-0419-4720-a0d2-cb2503306293" xlink:to="loc_us-gaap_SecuredDebtMember_3283a16d-8e5a-4aa5-87b6-f1115bebd2e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_9a55fdec-47ce-455d-9eb0-890372e8d3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a1c90d7b-1549-4df9-8aa5-de179136fc59" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_9a55fdec-47ce-455d-9eb0-890372e8d3d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_9a55fdec-47ce-455d-9eb0-890372e8d3d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_9a55fdec-47ce-455d-9eb0-890372e8d3d6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_9a55fdec-47ce-455d-9eb0-890372e8d3d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_48e09131-9fac-4aa8-9628-e047d2cc8e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_9a55fdec-47ce-455d-9eb0-890372e8d3d6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_48e09131-9fac-4aa8-9628-e047d2cc8e92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_46deb7e4-2564-4798-bdac-933c45db3df3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_48e09131-9fac-4aa8-9628-e047d2cc8e92" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_46deb7e4-2564-4798-bdac-933c45db3df3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_eff32cb7-4e75-4196-ab93-adab610a4bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_48e09131-9fac-4aa8-9628-e047d2cc8e92" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_eff32cb7-4e75-4196-ab93-adab610a4bb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1d56b964-03ae-403d-8a8d-a275395457df" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a1c90d7b-1549-4df9-8aa5-de179136fc59" xlink:to="loc_srt_RangeAxis_1d56b964-03ae-403d-8a8d-a275395457df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1d56b964-03ae-403d-8a8d-a275395457df_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1d56b964-03ae-403d-8a8d-a275395457df" xlink:to="loc_srt_RangeMember_1d56b964-03ae-403d-8a8d-a275395457df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fdc8f87c-f7e1-4f2d-8488-57b43da2c631" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1d56b964-03ae-403d-8a8d-a275395457df" xlink:to="loc_srt_RangeMember_fdc8f87c-f7e1-4f2d-8488-57b43da2c631" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ced653bf-e13d-44bd-b65c-deb9d790cacb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fdc8f87c-f7e1-4f2d-8488-57b43da2c631" xlink:to="loc_srt_MaximumMember_ced653bf-e13d-44bd-b65c-deb9d790cacb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="extended" id="i17d3ce9e7f4f4a709a5b9dcb4d2cb1a4_FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_33e6d2f1-627a-41d0-80cc-71c3f4020e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_38dc055c-db71-40f4-97c1-601dca07cfd4" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33e6d2f1-627a-41d0-80cc-71c3f4020e42" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_38dc055c-db71-40f4-97c1-601dca07cfd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_ff225cc4-56a8-4e4b-a14f-9d6411e84df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33e6d2f1-627a-41d0-80cc-71c3f4020e42" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_ff225cc4-56a8-4e4b-a14f-9d6411e84df8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_68151922-82a2-4fcf-9896-176545e8dae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33e6d2f1-627a-41d0-80cc-71c3f4020e42" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_68151922-82a2-4fcf-9896-176545e8dae7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_542653ac-06bf-4af5-abf2-dc31f2bf1279" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33e6d2f1-627a-41d0-80cc-71c3f4020e42" xlink:to="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_542653ac-06bf-4af5-abf2-dc31f2bf1279" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_8bf875be-bf86-4d65-9532-8900bd917af2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33e6d2f1-627a-41d0-80cc-71c3f4020e42" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_8bf875be-bf86-4d65-9532-8900bd917af2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e04216fc-643e-45d3-b53b-c0b1f0e16640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33e6d2f1-627a-41d0-80cc-71c3f4020e42" xlink:to="loc_us-gaap_DebtInstrumentTable_e04216fc-643e-45d3-b53b-c0b1f0e16640" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e6dc286b-aadb-4350-822f-75399a86a679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e04216fc-643e-45d3-b53b-c0b1f0e16640" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e6dc286b-aadb-4350-822f-75399a86a679" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e6dc286b-aadb-4350-822f-75399a86a679_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e6dc286b-aadb-4350-822f-75399a86a679" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e6dc286b-aadb-4350-822f-75399a86a679_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ff4bc4e5-82e8-4b3e-b949-47f44d8207b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e6dc286b-aadb-4350-822f-75399a86a679" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ff4bc4e5-82e8-4b3e-b949-47f44d8207b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_c55a7292-e29c-4ae4-b15a-c6c59e55eced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ff4bc4e5-82e8-4b3e-b949-47f44d8207b0" xlink:to="loc_us-gaap_UnsecuredDebtMember_c55a7292-e29c-4ae4-b15a-c6c59e55eced" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_41afbfa3-bfdd-47e9-89c9-f2098124e62a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e04216fc-643e-45d3-b53b-c0b1f0e16640" xlink:to="loc_us-gaap_DebtInstrumentAxis_41afbfa3-bfdd-47e9-89c9-f2098124e62a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_41afbfa3-bfdd-47e9-89c9-f2098124e62a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_41afbfa3-bfdd-47e9-89c9-f2098124e62a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_41afbfa3-bfdd-47e9-89c9-f2098124e62a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ef92f3a1-27d9-45ac-a9c3-6d6af9d33069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_41afbfa3-bfdd-47e9-89c9-f2098124e62a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ef92f3a1-27d9-45ac-a9c3-6d6af9d33069" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.00SeniorNotesdueDecember2025Member_a3a29dfd-cdf4-4712-aab6-ca582c97c5f8" xlink:href="bhc-20220630.xsd#bhc_A9.00SeniorNotesdueDecember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ef92f3a1-27d9-45ac-a9c3-6d6af9d33069" xlink:to="loc_bhc_A9.00SeniorNotesdueDecember2025Member_a3a29dfd-cdf4-4712-aab6-ca582c97c5f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_11270db7-10ca-439a-97bb-2059961d9389" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ef92f3a1-27d9-45ac-a9c3-6d6af9d33069" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_11270db7-10ca-439a-97bb-2059961d9389" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails" xlink:type="extended" id="i3b68c6668cfc4204a219c51c813529f1_FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e414ac5c-4d51-4ace-9d64-a1d713d09e25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_40f1b8d7-4e81-45a6-b884-d4cc257e5af7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e414ac5c-4d51-4ace-9d64-a1d713d09e25" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_40f1b8d7-4e81-45a6-b884-d4cc257e5af7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_a671e86b-a52f-4d17-9df0-173696391d59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e414ac5c-4d51-4ace-9d64-a1d713d09e25" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_a671e86b-a52f-4d17-9df0-173696391d59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_90f47040-85b2-4a98-9250-88a75869a6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e414ac5c-4d51-4ace-9d64-a1d713d09e25" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_90f47040-85b2-4a98-9250-88a75869a6e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_20229212-3ac5-4b02-8bd1-a679ec1731a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e414ac5c-4d51-4ace-9d64-a1d713d09e25" xlink:to="loc_us-gaap_DebtInstrumentTable_20229212-3ac5-4b02-8bd1-a679ec1731a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_94126238-0990-454c-8984-176d3a76f9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_20229212-3ac5-4b02-8bd1-a679ec1731a5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_94126238-0990-454c-8984-176d3a76f9d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_94126238-0990-454c-8984-176d3a76f9d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_94126238-0990-454c-8984-176d3a76f9d3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_94126238-0990-454c-8984-176d3a76f9d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_47a13b88-53d8-4de8-a2ac-84abae31d8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_94126238-0990-454c-8984-176d3a76f9d3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_47a13b88-53d8-4de8-a2ac-84abae31d8b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_90efdf73-5851-439e-a020-85110f97cc54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_47a13b88-53d8-4de8-a2ac-84abae31d8b0" xlink:to="loc_us-gaap_UnsecuredDebtMember_90efdf73-5851-439e-a020-85110f97cc54" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended" id="i8839a61f98f246b5bb58d455dabeb580_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f1fe7b47-53a3-446d-a3c1-d0f4ed8119c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_bac60f94-e52c-4dcf-b888-94e6d4d8b545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f1fe7b47-53a3-446d-a3c1-d0f4ed8119c3" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_bac60f94-e52c-4dcf-b888-94e6d4d8b545" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_6b2e56f0-e6f5-40ac-9824-e899d2d53926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f1fe7b47-53a3-446d-a3c1-d0f4ed8119c3" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_6b2e56f0-e6f5-40ac-9824-e899d2d53926" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_cbb1ae1d-b8b8-4a2d-9d71-899a8700daea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f1fe7b47-53a3-446d-a3c1-d0f4ed8119c3" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_cbb1ae1d-b8b8-4a2d-9d71-899a8700daea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_500ac639-410e-43b1-8445-fdc313879f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f1fe7b47-53a3-446d-a3c1-d0f4ed8119c3" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_500ac639-410e-43b1-8445-fdc313879f0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_0f7aaf43-af90-4d30-b4bb-51f0ebffe55e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f1fe7b47-53a3-446d-a3c1-d0f4ed8119c3" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_0f7aaf43-af90-4d30-b4bb-51f0ebffe55e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_08871fe6-3ca2-4f04-a322-1a699ddc252a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f1fe7b47-53a3-446d-a3c1-d0f4ed8119c3" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_08871fe6-3ca2-4f04-a322-1a699ddc252a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c2a8fff5-4120-4c19-9fe1-da4d65b08334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f1fe7b47-53a3-446d-a3c1-d0f4ed8119c3" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c2a8fff5-4120-4c19-9fe1-da4d65b08334" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_4fcc0339-a75b-4ca0-8e6b-d2e584f2798c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c2a8fff5-4120-4c19-9fe1-da4d65b08334" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_4fcc0339-a75b-4ca0-8e6b-d2e584f2798c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_4fcc0339-a75b-4ca0-8e6b-d2e584f2798c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_4fcc0339-a75b-4ca0-8e6b-d2e584f2798c" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_4fcc0339-a75b-4ca0-8e6b-d2e584f2798c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_65bdae4b-ea24-486c-a3f3-13b21f9c0a60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_4fcc0339-a75b-4ca0-8e6b-d2e584f2798c" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_65bdae4b-ea24-486c-a3f3-13b21f9c0a60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_010d4e6d-1a5f-4fb8-a9b1-bd2031f47b62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_65bdae4b-ea24-486c-a3f3-13b21f9c0a60" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_010d4e6d-1a5f-4fb8-a9b1-bd2031f47b62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_88c1354f-aedf-4d9b-83ef-db45ae47ede5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_65bdae4b-ea24-486c-a3f3-13b21f9c0a60" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_88c1354f-aedf-4d9b-83ef-db45ae47ede5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_35a4d77d-6a03-47c8-8e23-1b5d61948744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c2a8fff5-4120-4c19-9fe1-da4d65b08334" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_35a4d77d-6a03-47c8-8e23-1b5d61948744" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_35a4d77d-6a03-47c8-8e23-1b5d61948744_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_35a4d77d-6a03-47c8-8e23-1b5d61948744" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_35a4d77d-6a03-47c8-8e23-1b5d61948744_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_f128741a-0b85-4929-a1a2-90e76f7fec45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_35a4d77d-6a03-47c8-8e23-1b5d61948744" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_f128741a-0b85-4929-a1a2-90e76f7fec45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_2024267b-82b2-4359-aac0-b2e272d31ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_f128741a-0b85-4929-a1a2-90e76f7fec45" xlink:to="loc_us-gaap_DomesticPlanMember_2024267b-82b2-4359-aac0-b2e272d31ed6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_d26343cf-39cf-4289-8efc-0d9212eec221" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_2024267b-82b2-4359-aac0-b2e272d31ed6" xlink:to="loc_country_US_d26343cf-39cf-4289-8efc-0d9212eec221" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_82a21ec8-fda8-49b3-9f8e-b536f8b0364a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_f128741a-0b85-4929-a1a2-90e76f7fec45" xlink:to="loc_us-gaap_ForeignPlanMember_82a21ec8-fda8-49b3-9f8e-b536f8b0364a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended" id="i3d6fc02b4f6a4c30a2c8c4b054fd9de8_SHAREBASEDCOMPENSATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b4f8395-0555-4b96-af55-c8b12c598a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_47596a3a-d9a6-4319-83ab-b609dc0f501b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b4f8395-0555-4b96-af55-c8b12c598a26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_47596a3a-d9a6-4319-83ab-b609dc0f501b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0c9582fd-be59-4b63-a29e-e3e79a0d2e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b4f8395-0555-4b96-af55-c8b12c598a26" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0c9582fd-be59-4b63-a29e-e3e79a0d2e2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c2fad6f7-5890-4467-9329-3ac3389f3d11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b4f8395-0555-4b96-af55-c8b12c598a26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c2fad6f7-5890-4467-9329-3ac3389f3d11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_428270cc-de46-4841-b7c7-b4b3affe44dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b4f8395-0555-4b96-af55-c8b12c598a26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_428270cc-de46-4841-b7c7-b4b3affe44dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_79291c06-5264-46fb-b2d0-4192312b0cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b4f8395-0555-4b96-af55-c8b12c598a26" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_79291c06-5264-46fb-b2d0-4192312b0cbf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_74229185-f25e-4645-a264-8da632bf8e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b4f8395-0555-4b96-af55-c8b12c598a26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_74229185-f25e-4645-a264-8da632bf8e9c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_47bcbb5e-48ac-48ec-97ff-ad613b50b772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b4f8395-0555-4b96-af55-c8b12c598a26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_47bcbb5e-48ac-48ec-97ff-ad613b50b772" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent_5c473cb8-ee65-4a96-bb72-7028aaf97d05" xlink:href="bhc-20220630.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b4f8395-0555-4b96-af55-c8b12c598a26" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent_5c473cb8-ee65-4a96-bb72-7028aaf97d05" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross_bd0b7600-22c9-4e59-b60a-7c71a774aabb" xlink:href="bhc-20220630.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b4f8395-0555-4b96-af55-c8b12c598a26" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross_bd0b7600-22c9-4e59-b60a-7c71a774aabb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e0c73717-9877-4baa-9584-78c737e8b090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b4f8395-0555-4b96-af55-c8b12c598a26" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e0c73717-9877-4baa-9584-78c737e8b090" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2d5a51cc-0155-456f-a7e4-6fa3bcdd0f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b4f8395-0555-4b96-af55-c8b12c598a26" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2d5a51cc-0155-456f-a7e4-6fa3bcdd0f0e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_56103315-594e-4967-9ac1-1951a04f4e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b4f8395-0555-4b96-af55-c8b12c598a26" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_56103315-594e-4967-9ac1-1951a04f4e19" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d635739-00fb-4ece-acef-2baea7fe0630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b4f8395-0555-4b96-af55-c8b12c598a26" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d635739-00fb-4ece-acef-2baea7fe0630" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_8a630756-3cd3-48b4-af19-204a90ec4f12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d635739-00fb-4ece-acef-2baea7fe0630" xlink:to="loc_us-gaap_PlanNameAxis_8a630756-3cd3-48b4-af19-204a90ec4f12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8a630756-3cd3-48b4-af19-204a90ec4f12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_8a630756-3cd3-48b4-af19-204a90ec4f12" xlink:to="loc_us-gaap_PlanNameDomain_8a630756-3cd3-48b4-af19-204a90ec4f12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9bfe0e9a-19d5-42a3-923a-5afd8d506196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_8a630756-3cd3-48b4-af19-204a90ec4f12" xlink:to="loc_us-gaap_PlanNameDomain_9bfe0e9a-19d5-42a3-923a-5afd8d506196" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014Member_22a4715b-46d5-42cf-ba32-10250c0cc12e" xlink:href="bhc-20220630.xsd#bhc_OmnibusIncentivePlan2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9bfe0e9a-19d5-42a3-923a-5afd8d506196" xlink:to="loc_bhc_OmnibusIncentivePlan2014Member_22a4715b-46d5-42cf-ba32-10250c0cc12e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IPOFoundersGrantsMember_5088f3a5-b891-4eb9-a200-1a8d5aad6d45" xlink:href="bhc-20220630.xsd#bhc_IPOFoundersGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9bfe0e9a-19d5-42a3-923a-5afd8d506196" xlink:to="loc_bhc_IPOFoundersGrantsMember_5088f3a5-b891-4eb9-a200-1a8d5aad6d45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_e0e24bc4-47a4-4c51-aa5b-94d24d4adf3f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d635739-00fb-4ece-acef-2baea7fe0630" xlink:to="loc_srt_TitleOfIndividualAxis_e0e24bc4-47a4-4c51-aa5b-94d24d4adf3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e0e24bc4-47a4-4c51-aa5b-94d24d4adf3f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_e0e24bc4-47a4-4c51-aa5b-94d24d4adf3f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e0e24bc4-47a4-4c51-aa5b-94d24d4adf3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_57bbfc88-fb50-4ed3-93eb-bcf9dcfe825b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_e0e24bc4-47a4-4c51-aa5b-94d24d4adf3f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_57bbfc88-fb50-4ed3-93eb-bcf9dcfe825b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_76f53c2a-3cf7-4155-8e5e-6cd3bd1bb1ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_57bbfc88-fb50-4ed3-93eb-bcf9dcfe825b" xlink:to="loc_srt_ExecutiveOfficerMember_76f53c2a-3cf7-4155-8e5e-6cd3bd1bb1ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonExecutiveEligibleRecipientsMember_9629daed-0f7c-428b-853d-e20c7a10a5e3" xlink:href="bhc-20220630.xsd#bhc_NonExecutiveEligibleRecipientsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_57bbfc88-fb50-4ed3-93eb-bcf9dcfe825b" xlink:to="loc_bhc_NonExecutiveEligibleRecipientsMember_9629daed-0f7c-428b-853d-e20c7a10a5e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ab8bd1d6-135e-4341-96c4-94c379313448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d635739-00fb-4ece-acef-2baea7fe0630" xlink:to="loc_us-gaap_AwardTypeAxis_ab8bd1d6-135e-4341-96c4-94c379313448" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab8bd1d6-135e-4341-96c4-94c379313448_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ab8bd1d6-135e-4341-96c4-94c379313448" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab8bd1d6-135e-4341-96c4-94c379313448_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2a4e7150-8b46-4ff6-9439-12559e411c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ab8bd1d6-135e-4341-96c4-94c379313448" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2a4e7150-8b46-4ff6-9439-12559e411c82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_be19b3fb-01bd-4a77-98cc-81a1080f3663" xlink:href="bhc-20220630.xsd#bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2a4e7150-8b46-4ff6-9439-12559e411c82" xlink:to="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_be19b3fb-01bd-4a77-98cc-81a1080f3663" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d304a01b-2d2c-4908-8bb9-ea4bc821cf03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_be19b3fb-01bd-4a77-98cc-81a1080f3663" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d304a01b-2d2c-4908-8bb9-ea4bc821cf03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_eef63862-c8ce-4eab-9d5a-9cd0d9ca456e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_be19b3fb-01bd-4a77-98cc-81a1080f3663" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_eef63862-c8ce-4eab-9d5a-9cd0d9ca456e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_0d30811a-386c-40c7-9934-325cb57821a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d635739-00fb-4ece-acef-2baea7fe0630" xlink:to="loc_dei_LegalEntityAxis_0d30811a-386c-40c7-9934-325cb57821a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0d30811a-386c-40c7-9934-325cb57821a9_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_0d30811a-386c-40c7-9934-325cb57821a9" xlink:to="loc_dei_EntityDomain_0d30811a-386c-40c7-9934-325cb57821a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7a34f7bc-bbae-44ab-a37c-2eac2f1d3e33" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_0d30811a-386c-40c7-9934-325cb57821a9" xlink:to="loc_dei_EntityDomain_7a34f7bc-bbae-44ab-a37c-2eac2f1d3e33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_9f50d469-2092-4c05-872b-9c8286a99c39" xlink:href="bhc-20220630.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_7a34f7bc-bbae-44ab-a37c-2eac2f1d3e33" xlink:to="loc_bhc_BauschLombMember_9f50d469-2092-4c05-872b-9c8286a99c39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_620b3406-f1e8-42c2-8a3a-ab44756648d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d635739-00fb-4ece-acef-2baea7fe0630" xlink:to="loc_us-gaap_VestingAxis_620b3406-f1e8-42c2-8a3a-ab44756648d3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_620b3406-f1e8-42c2-8a3a-ab44756648d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_620b3406-f1e8-42c2-8a3a-ab44756648d3" xlink:to="loc_us-gaap_VestingDomain_620b3406-f1e8-42c2-8a3a-ab44756648d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_7c114f0e-0811-4433-a1ec-67e95da707e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_620b3406-f1e8-42c2-8a3a-ab44756648d3" xlink:to="loc_us-gaap_VestingDomain_7c114f0e-0811-4433-a1ec-67e95da707e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_56f0ef39-12c2-43b3-a29a-55088ba4fc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_7c114f0e-0811-4433-a1ec-67e95da707e3" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_56f0ef39-12c2-43b3-a29a-55088ba4fc7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0265df68-a832-473c-a53e-e1aa0ca6d0da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_7c114f0e-0811-4433-a1ec-67e95da707e3" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0265df68-a832-473c-a53e-e1aa0ca6d0da" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="extended" id="i71b03604bcb04866ae9370adfde673c1_SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1bd1ff55-ecc2-4edc-a811-f5876ac6b5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_fd2fcf53-8119-4122-9b9a-a26ca2f5f708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1bd1ff55-ecc2-4edc-a811-f5876ac6b5b5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_fd2fcf53-8119-4122-9b9a-a26ca2f5f708" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9e9e60d2-819d-4c84-b4da-c84bdd9f9770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1bd1ff55-ecc2-4edc-a811-f5876ac6b5b5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9e9e60d2-819d-4c84-b4da-c84bdd9f9770" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_77930fa3-0780-4041-a20b-ebebeb339461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9e9e60d2-819d-4c84-b4da-c84bdd9f9770" xlink:to="loc_us-gaap_AwardTypeAxis_77930fa3-0780-4041-a20b-ebebeb339461" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77930fa3-0780-4041-a20b-ebebeb339461_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_77930fa3-0780-4041-a20b-ebebeb339461" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77930fa3-0780-4041-a20b-ebebeb339461_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a859eef-532a-4b43-bc3e-339f9f392ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_77930fa3-0780-4041-a20b-ebebeb339461" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a859eef-532a-4b43-bc3e-339f9f392ce4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e074a93e-cd84-46d5-b083-623eec37138a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a859eef-532a-4b43-bc3e-339f9f392ce4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e074a93e-cd84-46d5-b083-623eec37138a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_274827a2-24ad-412e-a7de-245f2ef2e582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a859eef-532a-4b43-bc3e-339f9f392ce4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_274827a2-24ad-412e-a7de-245f2ef2e582" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fbd9f428-75c1-42bb-96df-8f7b141b0cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9e9e60d2-819d-4c84-b4da-c84bdd9f9770" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fbd9f428-75c1-42bb-96df-8f7b141b0cb6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fbd9f428-75c1-42bb-96df-8f7b141b0cb6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fbd9f428-75c1-42bb-96df-8f7b141b0cb6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fbd9f428-75c1-42bb-96df-8f7b141b0cb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_da2e88da-e596-43de-afed-93f2f435b2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fbd9f428-75c1-42bb-96df-8f7b141b0cb6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_da2e88da-e596-43de-afed-93f2f435b2b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_af19a836-5e57-4f97-b325-6453a078f07b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_da2e88da-e596-43de-afed-93f2f435b2b0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_af19a836-5e57-4f97-b325-6453a078f07b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_94260544-5987-42b5-8adb-e859bd05df8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_da2e88da-e596-43de-afed-93f2f435b2b0" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_94260544-5987-42b5-8adb-e859bd05df8a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails" xlink:type="extended" id="i593daf415d2d447ea45c1baca6167ed8_SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c29a844-2f75-4316-90a2-736f2e6c3cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_f2407023-e922-45e0-9525-9ba395df3c35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c29a844-2f75-4316-90a2-736f2e6c3cbf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_f2407023-e922-45e0-9525-9ba395df3c35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d3105019-bcfe-4e6c-8df5-28719cefe8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_f2407023-e922-45e0-9525-9ba395df3c35" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d3105019-bcfe-4e6c-8df5-28719cefe8a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_82009888-2be4-4046-9a94-4dbcabcdd1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_f2407023-e922-45e0-9525-9ba395df3c35" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_82009888-2be4-4046-9a94-4dbcabcdd1c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bbfae3d0-1484-4db7-a26e-41498297cfc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_f2407023-e922-45e0-9525-9ba395df3c35" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bbfae3d0-1484-4db7-a26e-41498297cfc9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_3ef31472-d854-4b51-a680-88ef7c9078dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c29a844-2f75-4316-90a2-736f2e6c3cbf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_3ef31472-d854-4b51-a680-88ef7c9078dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8648c11d-aa44-4547-bf53-a491391345b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_3ef31472-d854-4b51-a680-88ef7c9078dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8648c11d-aa44-4547-bf53-a491391345b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_aa087956-147c-4ef2-ab59-2a0461cb8f74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_3ef31472-d854-4b51-a680-88ef7c9078dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_aa087956-147c-4ef2-ab59-2a0461cb8f74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82f8ebd9-546a-466c-a294-062a23e934d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c29a844-2f75-4316-90a2-736f2e6c3cbf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82f8ebd9-546a-466c-a294-062a23e934d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7ff15b7e-1a84-41d6-a205-77d48756d829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82f8ebd9-546a-466c-a294-062a23e934d3" xlink:to="loc_us-gaap_AwardTypeAxis_7ff15b7e-1a84-41d6-a205-77d48756d829" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ff15b7e-1a84-41d6-a205-77d48756d829_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7ff15b7e-1a84-41d6-a205-77d48756d829" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ff15b7e-1a84-41d6-a205-77d48756d829_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94309650-dafa-4144-8508-6fbab31bee20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7ff15b7e-1a84-41d6-a205-77d48756d829" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94309650-dafa-4144-8508-6fbab31bee20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8edabcfd-f294-4dd3-98bf-87f805bec639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94309650-dafa-4144-8508-6fbab31bee20" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8edabcfd-f294-4dd3-98bf-87f805bec639" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TimeBasedRSUMember_0ea0b765-f2ed-4503-9d3f-fb62ed4194e6" xlink:href="bhc-20220630.xsd#bhc_TimeBasedRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94309650-dafa-4144-8508-6fbab31bee20" xlink:to="loc_bhc_TimeBasedRSUMember_0ea0b765-f2ed-4503-9d3f-fb62ed4194e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_5177a80e-3010-46b1-bd51-93cc574fb2c2" xlink:href="bhc-20220630.xsd#bhc_TSRPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94309650-dafa-4144-8508-6fbab31bee20" xlink:to="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_5177a80e-3010-46b1-bd51-93cc574fb2c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_1954ddae-d41e-4de9-91cf-be99a42521e9" xlink:href="bhc-20220630.xsd#bhc_ROTCPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94309650-dafa-4144-8508-6fbab31bee20" xlink:to="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_1954ddae-d41e-4de9-91cf-be99a42521e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember_71fdda56-8951-490b-87b5-464f5ce08396" xlink:href="bhc-20220630.xsd#bhc_SeparationPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94309650-dafa-4144-8508-6fbab31bee20" xlink:to="loc_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember_71fdda56-8951-490b-87b5-464f5ce08396" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f17cd310-7aeb-43ff-aef1-0d2b98f805bb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82f8ebd9-546a-466c-a294-062a23e934d3" xlink:to="loc_dei_LegalEntityAxis_f17cd310-7aeb-43ff-aef1-0d2b98f805bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f17cd310-7aeb-43ff-aef1-0d2b98f805bb_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_f17cd310-7aeb-43ff-aef1-0d2b98f805bb" xlink:to="loc_dei_EntityDomain_f17cd310-7aeb-43ff-aef1-0d2b98f805bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f5819f89-c90c-4cee-9f0e-f755077491dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_f17cd310-7aeb-43ff-aef1-0d2b98f805bb" xlink:to="loc_dei_EntityDomain_f5819f89-c90c-4cee-9f0e-f755077491dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_5932fc82-c944-477d-8eb5-e7bd389509eb" xlink:href="bhc-20220630.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_f5819f89-c90c-4cee-9f0e-f755077491dc" xlink:to="loc_bhc_BauschLombMember_5932fc82-c944-477d-8eb5-e7bd389509eb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails" xlink:type="extended" id="ia9d16340a76d421d91bbb4a883bdbbcb_ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_304c9f8f-f70c-4744-9f41-63d68c231397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1285c793-78d0-46c6-9da6-130ebfbc33e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_304c9f8f-f70c-4744-9f41-63d68c231397" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1285c793-78d0-46c6-9da6-130ebfbc33e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3667222a-35de-4692-90b7-7ef02a1b7485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_304c9f8f-f70c-4744-9f41-63d68c231397" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3667222a-35de-4692-90b7-7ef02a1b7485" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_af36667c-5fb8-48b2-8847-0ee880886a25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3667222a-35de-4692-90b7-7ef02a1b7485" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_af36667c-5fb8-48b2-8847-0ee880886a25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_af36667c-5fb8-48b2-8847-0ee880886a25_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_af36667c-5fb8-48b2-8847-0ee880886a25" xlink:to="loc_us-gaap_EquityComponentDomain_af36667c-5fb8-48b2-8847-0ee880886a25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b8977883-6f9e-485c-91ad-0eb6dc86f47a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_af36667c-5fb8-48b2-8847-0ee880886a25" xlink:to="loc_us-gaap_EquityComponentDomain_b8977883-6f9e-485c-91ad-0eb6dc86f47a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_ceddd88c-6310-4885-8319-daeb8f882739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8977883-6f9e-485c-91ad-0eb6dc86f47a" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_ceddd88c-6310-4885-8319-daeb8f882739" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_f54e0fe7-3a65-420e-a1bf-c1f78031f737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8977883-6f9e-485c-91ad-0eb6dc86f47a" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_f54e0fe7-3a65-420e-a1bf-c1f78031f737" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c98a2396-5a66-42a5-97c0-cd5d19d7d726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b8977883-6f9e-485c-91ad-0eb6dc86f47a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c98a2396-5a66-42a5-97c0-cd5d19d7d726" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails" xlink:type="extended" id="i47d935e5bd20474084abd3e9b322d743_ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_fbe4dc57-c096-4d2a-9a88-b54dce098e71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d7c83065-cacf-4ec9-afd1-1a3aff4d72c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_fbe4dc57-c096-4d2a-9a88-b54dce098e71" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d7c83065-cacf-4ec9-afd1-1a3aff4d72c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_592f3071-ac2b-4b31-9a4c-519733543162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_fbe4dc57-c096-4d2a-9a88-b54dce098e71" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_592f3071-ac2b-4b31-9a4c-519733543162" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6ebe4ffb-306d-417e-b90e-4cddcd8457db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_592f3071-ac2b-4b31-9a4c-519733543162" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6ebe4ffb-306d-417e-b90e-4cddcd8457db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6ebe4ffb-306d-417e-b90e-4cddcd8457db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6ebe4ffb-306d-417e-b90e-4cddcd8457db" xlink:to="loc_us-gaap_EquityComponentDomain_6ebe4ffb-306d-417e-b90e-4cddcd8457db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d499a667-8b2b-4e08-9549-110b1098779d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6ebe4ffb-306d-417e-b90e-4cddcd8457db" xlink:to="loc_us-gaap_EquityComponentDomain_d499a667-8b2b-4e08-9549-110b1098779d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0f1bbade-9544-47c9-ae22-6a60e625ed1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d499a667-8b2b-4e08-9549-110b1098779d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0f1bbade-9544-47c9-ae22-6a60e625ed1e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#OTHEREXPENSENETNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails" xlink:type="extended" id="i648febb4ac674b0b9b504c0f18f19106_OTHEREXPENSENETNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_663de3bf-3c60-40a8-9319-8fe4c509fbb3" xlink:href="bhc-20220630.xsd#bhc_ScheduleOfOtherIncomeAndExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_4009d5f9-79ad-4003-9b27-309296311ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_663de3bf-3c60-40a8-9319-8fe4c509fbb3" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_4009d5f9-79ad-4003-9b27-309296311ebf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_6b85d400-4530-4e39-8617-7b023e8432a5" xlink:href="bhc-20220630.xsd#bhc_ScheduleOfOtherIncomeAndExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_663de3bf-3c60-40a8-9319-8fe4c509fbb3" xlink:to="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_6b85d400-4530-4e39-8617-7b023e8432a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c4c063c4-f193-4b15-832d-94b76975f943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_6b85d400-4530-4e39-8617-7b023e8432a5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c4c063c4-f193-4b15-832d-94b76975f943" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c4c063c4-f193-4b15-832d-94b76975f943_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c4c063c4-f193-4b15-832d-94b76975f943" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c4c063c4-f193-4b15-832d-94b76975f943_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d1dea199-5839-4740-87a2-4cea46583328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c4c063c4-f193-4b15-832d-94b76975f943" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d1dea199-5839-4740-87a2-4cea46583328" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MilestonePaymentRelatedToCertainProductMember_ce829c48-a050-4d07-a6ea-2abf9c1728b2" xlink:href="bhc-20220630.xsd#bhc_MilestonePaymentRelatedToCertainProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d1dea199-5839-4740-87a2-4cea46583328" xlink:to="loc_bhc_MilestonePaymentRelatedToCertainProductMember_ce829c48-a050-4d07-a6ea-2abf9c1728b2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#LOSSPERSHARENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails" xlink:type="extended" id="i259a5df7d15d4890a9515a6f937f526d_LOSSPERSHARENarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_08180b56-928e-4b25-9432-4d3cb91165a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5a82ba06-69db-485d-853e-f4b7f49da28e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_08180b56-928e-4b25-9432-4d3cb91165a1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5a82ba06-69db-485d-853e-f4b7f49da28e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount_644d9eb7-8b94-48be-8e9f-98213452a322" xlink:href="bhc-20220630.xsd#bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_08180b56-928e-4b25-9432-4d3cb91165a1" xlink:to="loc_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount_644d9eb7-8b94-48be-8e9f-98213452a322" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2a7349e4-c1bb-4d9e-9839-fa15fee104ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_08180b56-928e-4b25-9432-4d3cb91165a1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2a7349e4-c1bb-4d9e-9839-fa15fee104ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_da770f34-5290-4650-ab81-1402292efe65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2a7349e4-c1bb-4d9e-9839-fa15fee104ab" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_da770f34-5290-4650-ab81-1402292efe65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_da770f34-5290-4650-ab81-1402292efe65_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_da770f34-5290-4650-ab81-1402292efe65" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_da770f34-5290-4650-ab81-1402292efe65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_40a49387-20c9-4a8a-b3bc-13c7beb8596b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_da770f34-5290-4650-ab81-1402292efe65" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_40a49387-20c9-4a8a-b3bc-13c7beb8596b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_7205210c-5410-42c7-8f28-fc214bbcdb11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_40a49387-20c9-4a8a-b3bc-13c7beb8596b" xlink:to="loc_us-gaap_StockCompensationPlanMember_7205210c-5410-42c7-8f28-fc214bbcdb11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_7850f116-d859-4641-a923-001b02028262" xlink:href="bhc-20220630.xsd#bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_40a49387-20c9-4a8a-b3bc-13c7beb8596b" xlink:to="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_7850f116-d859-4641-a923-001b02028262" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_cf64d783-e9f7-4c11-ac31-7bb1ad8ec2c1" xlink:href="bhc-20220630.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_40a49387-20c9-4a8a-b3bc-13c7beb8596b" xlink:to="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_cf64d783-e9f7-4c11-ac31-7bb1ad8ec2c1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails" xlink:type="extended" id="ia533ffbc1f1d41e0a670330ec3ffd7fe_LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_5e12085c-c8ac-48ec-8e64-bff354fe2347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_0912a5d4-211e-4b68-9804-a540bfa9af7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5e12085c-c8ac-48ec-8e64-bff354fe2347" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_0912a5d4-211e-4b68-9804-a540bfa9af7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_c661fc12-2328-41dc-b1dc-c00e93594f76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5e12085c-c8ac-48ec-8e64-bff354fe2347" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_c661fc12-2328-41dc-b1dc-c00e93594f76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_5a394541-71f6-44da-8859-d6ef46d2e949" xlink:href="bhc-20220630.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5e12085c-c8ac-48ec-8e64-bff354fe2347" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_5a394541-71f6-44da-8859-d6ef46d2e949" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_db5a11a5-8c42-40e5-800d-0fc1acb4f3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5e12085c-c8ac-48ec-8e64-bff354fe2347" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_db5a11a5-8c42-40e5-800d-0fc1acb4f3e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_51f7cf91-94c5-4c31-8804-0239cd188d7d" xlink:href="bhc-20220630.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5e12085c-c8ac-48ec-8e64-bff354fe2347" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_51f7cf91-94c5-4c31-8804-0239cd188d7d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_6a0492cf-373d-4627-8ba8-568ca4bd4ea8" xlink:href="bhc-20220630.xsd#bhc_LossContingencyNewClaimsFiledButNotYetServedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5e12085c-c8ac-48ec-8e64-bff354fe2347" xlink:to="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_6a0492cf-373d-4627-8ba8-568ca4bd4ea8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_04a5aec0-7ef1-4c72-bc10-1c0aa71d851a" xlink:href="bhc-20220630.xsd#bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5e12085c-c8ac-48ec-8e64-bff354fe2347" xlink:to="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_04a5aec0-7ef1-4c72-bc10-1c0aa71d851a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_d4316c02-6cd5-4ac0-a065-ada675ef88b0" xlink:href="bhc-20220630.xsd#bhc_LossContingencyNumberOfInsurancePolicyPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5e12085c-c8ac-48ec-8e64-bff354fe2347" xlink:to="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_d4316c02-6cd5-4ac0-a065-ada675ef88b0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers_dfbad18a-ecd0-4be7-ab63-d8737ea25c4c" xlink:href="bhc-20220630.xsd#bhc_LossContingencySettlementAgreementsNumberOfInsurers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5e12085c-c8ac-48ec-8e64-bff354fe2347" xlink:to="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers_dfbad18a-ecd0-4be7-ab63-d8737ea25c4c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_3aca16c5-6451-4b9c-99ca-e91ac70e83b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5e12085c-c8ac-48ec-8e64-bff354fe2347" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_3aca16c5-6451-4b9c-99ca-e91ac70e83b2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_999deaf4-4fca-475e-b989-d7ed5e3fdbe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_5e12085c-c8ac-48ec-8e64-bff354fe2347" xlink:to="loc_us-gaap_LossContingenciesTable_999deaf4-4fca-475e-b989-d7ed5e3fdbe3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_046d17fb-c76e-405d-9697-91b2b0eacd5a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_999deaf4-4fca-475e-b989-d7ed5e3fdbe3" xlink:to="loc_srt_LitigationCaseAxis_046d17fb-c76e-405d-9697-91b2b0eacd5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_046d17fb-c76e-405d-9697-91b2b0eacd5a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_046d17fb-c76e-405d-9697-91b2b0eacd5a" xlink:to="loc_srt_LitigationCaseTypeDomain_046d17fb-c76e-405d-9697-91b2b0eacd5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ea536eaf-de38-4d11-b69d-332c0777cdf0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_046d17fb-c76e-405d-9697-91b2b0eacd5a" xlink:to="loc_srt_LitigationCaseTypeDomain_ea536eaf-de38-4d11-b69d-332c0777cdf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_8ab441fb-e4af-4661-8e47-e4dfd983971a" xlink:href="bhc-20220630.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ea536eaf-de38-4d11-b69d-332c0777cdf0" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_8ab441fb-e4af-4661-8e47-e4dfd983971a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadianSecuritiesLitigationMember_0411f2ba-b4ca-4d4c-bc79-895404cb6a8a" xlink:href="bhc-20220630.xsd#bhc_CanadianSecuritiesLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ea536eaf-de38-4d11-b69d-332c0777cdf0" xlink:to="loc_bhc_CanadianSecuritiesLitigationMember_0411f2ba-b4ca-4d4c-bc79-895404cb6a8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RICOClassActionsMember_f0a821cd-5133-4d32-bd68-9cf44ad56585" xlink:href="bhc-20220630.xsd#bhc_RICOClassActionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ea536eaf-de38-4d11-b69d-332c0777cdf0" xlink:to="loc_bhc_RICOClassActionsMember_f0a821cd-5133-4d32-bd68-9cf44ad56585" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InsuranceCoverageLawsuitMember_a299b671-98a9-422f-9656-b649c964aa44" xlink:href="bhc-20220630.xsd#bhc_InsuranceCoverageLawsuitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ea536eaf-de38-4d11-b69d-332c0777cdf0" xlink:to="loc_bhc_InsuranceCoverageLawsuitMember_a299b671-98a9-422f-9656-b649c964aa44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_151f962c-2fd2-4ef5-aee3-9c59f6014567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_999deaf4-4fca-475e-b989-d7ed5e3fdbe3" xlink:to="loc_us-gaap_LitigationStatusAxis_151f962c-2fd2-4ef5-aee3-9c59f6014567" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_151f962c-2fd2-4ef5-aee3-9c59f6014567_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_151f962c-2fd2-4ef5-aee3-9c59f6014567" xlink:to="loc_us-gaap_LitigationStatusDomain_151f962c-2fd2-4ef5-aee3-9c59f6014567_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_b8492d02-3617-436b-9e0f-bbc0861a9c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_151f962c-2fd2-4ef5-aee3-9c59f6014567" xlink:to="loc_us-gaap_LitigationStatusDomain_b8492d02-3617-436b-9e0f-bbc0861a9c1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_d3732d72-835b-4d97-b454-418e5a75d370" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_b8492d02-3617-436b-9e0f-bbc0861a9c1c" xlink:to="loc_us-gaap_SettledLitigationMember_d3732d72-835b-4d97-b454-418e5a75d370" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e6865260-cbeb-41f6-85a1-a9b27f9ab16c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_999deaf4-4fca-475e-b989-d7ed5e3fdbe3" xlink:to="loc_srt_StatementGeographicalAxis_e6865260-cbeb-41f6-85a1-a9b27f9ab16c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e6865260-cbeb-41f6-85a1-a9b27f9ab16c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_e6865260-cbeb-41f6-85a1-a9b27f9ab16c" xlink:to="loc_srt_SegmentGeographicalDomain_e6865260-cbeb-41f6-85a1-a9b27f9ab16c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_bc002e6b-8821-48d6-bb37-f0c92d811d14" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_e6865260-cbeb-41f6-85a1-a9b27f9ab16c" xlink:to="loc_srt_SegmentGeographicalDomain_bc002e6b-8821-48d6-bb37-f0c92d811d14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_38de8bfc-7afb-48af-9797-6df20aca084b" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_bc002e6b-8821-48d6-bb37-f0c92d811d14" xlink:to="loc_stpr_NJ_38de8bfc-7afb-48af-9797-6df20aca084b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_7a19cc53-6053-4e90-8cba-aa4c6f46dba8" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_bc002e6b-8821-48d6-bb37-f0c92d811d14" xlink:to="loc_country_CA_7a19cc53-6053-4e90-8cba-aa4c6f46dba8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_aa411856-3cfe-4b46-a763-0ab8e552dab8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_999deaf4-4fca-475e-b989-d7ed5e3fdbe3" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_aa411856-3cfe-4b46-a763-0ab8e552dab8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_aa411856-3cfe-4b46-a763-0ab8e552dab8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_aa411856-3cfe-4b46-a763-0ab8e552dab8" xlink:to="loc_us-gaap_LossContingencyNatureDomain_aa411856-3cfe-4b46-a763-0ab8e552dab8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_315bb7ae-36a6-4c0f-b89b-44f39410ceb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_aa411856-3cfe-4b46-a763-0ab8e552dab8" xlink:to="loc_us-gaap_LossContingencyNatureDomain_315bb7ae-36a6-4c0f-b89b-44f39410ceb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_70f639c4-d848-43fe-8064-a721d02996c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_315bb7ae-36a6-4c0f-b89b-44f39410ceb2" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_70f639c4-d848-43fe-8064-a721d02996c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_c17b469c-ef12-4f97-be5b-be1178dc4842" xlink:href="bhc-20220630.xsd#bhc_ViolationofCanadianProvincialSecuritiesLegislationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_315bb7ae-36a6-4c0f-b89b-44f39410ceb2" xlink:to="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_c17b469c-ef12-4f97-be5b-be1178dc4842" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8d87c4a7-f0b6-4859-8bc5-f4027936e9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_999deaf4-4fca-475e-b989-d7ed5e3fdbe3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8d87c4a7-f0b6-4859-8bc5-f4027936e9e5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8d87c4a7-f0b6-4859-8bc5-f4027936e9e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8d87c4a7-f0b6-4859-8bc5-f4027936e9e5" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8d87c4a7-f0b6-4859-8bc5-f4027936e9e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_be64a4f0-76f3-42dd-8ea8-78f382b006c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8d87c4a7-f0b6-4859-8bc5-f4027936e9e5" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_be64a4f0-76f3-42dd-8ea8-78f382b006c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember_adc38407-1c79-4c04-bf0d-557ff673060d" xlink:href="bhc-20220630.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_be64a4f0-76f3-42dd-8ea8-78f382b006c6" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember_adc38407-1c79-4c04-bf0d-557ff673060d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#LEGALPROCEEDINGSAntitrustDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails" xlink:type="extended" id="i17101ba60ee44adc9fce78ba82e73a60_LEGALPROCEEDINGSAntitrustDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_e7e2f12f-f360-4549-bb35-5bb56ec37851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_b022b3bd-d216-4946-ba2d-79f2d294b2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e7e2f12f-f360-4549-bb35-5bb56ec37851" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_b022b3bd-d216-4946-ba2d-79f2d294b2b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e25f4d52-d62f-4cb7-a69d-5d00c61c25f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e7e2f12f-f360-4549-bb35-5bb56ec37851" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e25f4d52-d62f-4cb7-a69d-5d00c61c25f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_e2087a49-df29-44ee-881b-1ea667a5c999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_e7e2f12f-f360-4549-bb35-5bb56ec37851" xlink:to="loc_us-gaap_LossContingenciesTable_e2087a49-df29-44ee-881b-1ea667a5c999" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_849d646b-c1d4-4448-ab3c-42ca31e1ce4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e2087a49-df29-44ee-881b-1ea667a5c999" xlink:to="loc_srt_LitigationCaseAxis_849d646b-c1d4-4448-ab3c-42ca31e1ce4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_849d646b-c1d4-4448-ab3c-42ca31e1ce4e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_849d646b-c1d4-4448-ab3c-42ca31e1ce4e" xlink:to="loc_srt_LitigationCaseTypeDomain_849d646b-c1d4-4448-ab3c-42ca31e1ce4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_5aa478d1-d976-437b-880f-8545c3338e23" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_849d646b-c1d4-4448-ab3c-42ca31e1ce4e" xlink:to="loc_srt_LitigationCaseTypeDomain_5aa478d1-d976-437b-880f-8545c3338e23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationMember_66d4eac6-f20c-4532-b3f0-72504a3290c6" xlink:href="bhc-20220630.xsd#bhc_GlumetzaAntitrustLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_5aa478d1-d976-437b-880f-8545c3338e23" xlink:to="loc_bhc_GlumetzaAntitrustLitigationMember_66d4eac6-f20c-4532-b3f0-72504a3290c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_306b660f-193f-4b62-9bdf-3c11be023778" xlink:href="bhc-20220630.xsd#bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_5aa478d1-d976-437b-880f-8545c3338e23" xlink:to="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_306b660f-193f-4b62-9bdf-3c11be023778" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c32e95c8-0853-4dd7-8b0d-7e452686fa10" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e2087a49-df29-44ee-881b-1ea667a5c999" xlink:to="loc_srt_CounterpartyNameAxis_c32e95c8-0853-4dd7-8b0d-7e452686fa10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c32e95c8-0853-4dd7-8b0d-7e452686fa10_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c32e95c8-0853-4dd7-8b0d-7e452686fa10" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c32e95c8-0853-4dd7-8b0d-7e452686fa10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_47dc0d40-cf38-4390-9940-72b2032dc3aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c32e95c8-0853-4dd7-8b0d-7e452686fa10" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_47dc0d40-cf38-4390-9940-72b2032dc3aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PlaintiffsDirectPurchasersMember_6c28762b-26fc-43bf-9c1a-17f87689a7fe" xlink:href="bhc-20220630.xsd#bhc_PlaintiffsDirectPurchasersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_47dc0d40-cf38-4390-9940-72b2032dc3aa" xlink:to="loc_bhc_PlaintiffsDirectPurchasersMember_6c28762b-26fc-43bf-9c1a-17f87689a7fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_ad8fd8fc-496f-4b83-a636-838c0a062e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e2087a49-df29-44ee-881b-1ea667a5c999" xlink:to="loc_us-gaap_LitigationStatusAxis_ad8fd8fc-496f-4b83-a636-838c0a062e19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_ad8fd8fc-496f-4b83-a636-838c0a062e19_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_ad8fd8fc-496f-4b83-a636-838c0a062e19" xlink:to="loc_us-gaap_LitigationStatusDomain_ad8fd8fc-496f-4b83-a636-838c0a062e19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_444308f8-ac13-4cfe-979a-3a208a448fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_ad8fd8fc-496f-4b83-a636-838c0a062e19" xlink:to="loc_us-gaap_LitigationStatusDomain_444308f8-ac13-4cfe-979a-3a208a448fbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_eb2f801f-fe48-473c-90e3-837167425206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_444308f8-ac13-4cfe-979a-3a208a448fbf" xlink:to="loc_us-gaap_PendingLitigationMember_eb2f801f-fe48-473c-90e3-837167425206" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#LEGALPROCEEDINGSIntellectualPropertyDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails" xlink:type="extended" id="i32e7f92b95d74deab75bf82831d6cd1d_LEGALPROCEEDINGSIntellectualPropertyDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_53f9b185-e7f8-40b8-8383-8b513dc75db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyStayOfApprovalPeriod_c147eaad-c84a-4a15-90fe-a60dca240f7b" xlink:href="bhc-20220630.xsd#bhc_GainContingencyStayOfApprovalPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_53f9b185-e7f8-40b8-8383-8b513dc75db8" xlink:to="loc_bhc_GainContingencyStayOfApprovalPeriod_c147eaad-c84a-4a15-90fe-a60dca240f7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyNumberOfDefendants_d1557eff-f20e-4ac4-8c78-4ac15060508e" xlink:href="bhc-20220630.xsd#bhc_GainContingencyNumberOfDefendants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_53f9b185-e7f8-40b8-8383-8b513dc75db8" xlink:to="loc_bhc_GainContingencyNumberOfDefendants_d1557eff-f20e-4ac4-8c78-4ac15060508e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_bbf233cc-7f35-4ade-b2c4-3857a6e0e5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_53f9b185-e7f8-40b8-8383-8b513dc75db8" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_bbf233cc-7f35-4ade-b2c4-3857a6e0e5f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_1c027782-b16a-435a-ab8f-2d4590dc8470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_53f9b185-e7f8-40b8-8383-8b513dc75db8" xlink:to="loc_us-gaap_LossContingenciesTable_1c027782-b16a-435a-ab8f-2d4590dc8470" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_2970cf7e-e3fb-4bc8-b544-891754cb138d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1c027782-b16a-435a-ab8f-2d4590dc8470" xlink:to="loc_srt_LitigationCaseAxis_2970cf7e-e3fb-4bc8-b544-891754cb138d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_2970cf7e-e3fb-4bc8-b544-891754cb138d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_2970cf7e-e3fb-4bc8-b544-891754cb138d" xlink:to="loc_srt_LitigationCaseTypeDomain_2970cf7e-e3fb-4bc8-b544-891754cb138d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_489a6c43-3228-4654-a6dc-229ae2cacfaa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_2970cf7e-e3fb-4bc8-b544-891754cb138d" xlink:to="loc_srt_LitigationCaseTypeDomain_489a6c43-3228-4654-a6dc-229ae2cacfaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NorwichPharmaceuticalsIncLitigationMember_f277de3e-4374-4f4c-b339-292201e04c5b" xlink:href="bhc-20220630.xsd#bhc_NorwichPharmaceuticalsIncLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_489a6c43-3228-4654-a6dc-229ae2cacfaa" xlink:to="loc_bhc_NorwichPharmaceuticalsIncLitigationMember_f277de3e-4374-4f4c-b339-292201e04c5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_b40fac16-24c2-4270-a1d0-a00a267e6dd1" xlink:href="bhc-20220630.xsd#bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_489a6c43-3228-4654-a6dc-229ae2cacfaa" xlink:to="loc_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_b40fac16-24c2-4270-a1d0-a00a267e6dd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaroPharmaceuticalsIncLitigationMember_a2006153-d4bb-4ba2-b00e-993d2b4121ce" xlink:href="bhc-20220630.xsd#bhc_TaroPharmaceuticalsIncLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_489a6c43-3228-4654-a6dc-229ae2cacfaa" xlink:to="loc_bhc_TaroPharmaceuticalsIncLitigationMember_a2006153-d4bb-4ba2-b00e-993d2b4121ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PadagisLitigationMember_5e8994e3-9ae4-4c33-8cdb-07e43f5c0fba" xlink:href="bhc-20220630.xsd#bhc_PadagisLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_489a6c43-3228-4654-a6dc-229ae2cacfaa" xlink:to="loc_bhc_PadagisLitigationMember_5e8994e3-9ae4-4c33-8cdb-07e43f5c0fba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_4606314e-8cfb-4df9-9377-96addca3f633" xlink:href="bhc-20220630.xsd#bhc_MSNLaboratoriesPrivateLtdLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_489a6c43-3228-4654-a6dc-229ae2cacfaa" xlink:to="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_4606314e-8cfb-4df9-9377-96addca3f633" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PreserVisionAREDSPatentLitigationMember_e473e4b3-1811-4bf1-ae43-6cbfb255d384" xlink:href="bhc-20220630.xsd#bhc_PreserVisionAREDSPatentLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_489a6c43-3228-4654-a6dc-229ae2cacfaa" xlink:to="loc_bhc_PreserVisionAREDSPatentLitigationMember_e473e4b3-1811-4bf1-ae43-6cbfb255d384" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember_6e5ef747-87f5-42e3-af58-419f5712ebf2" xlink:href="bhc-20220630.xsd#bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_489a6c43-3228-4654-a6dc-229ae2cacfaa" xlink:to="loc_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember_6e5ef747-87f5-42e3-af58-419f5712ebf2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember_6a04d2b9-9877-4637-afd4-804d983e34bd" xlink:href="bhc-20220630.xsd#bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_489a6c43-3228-4654-a6dc-229ae2cacfaa" xlink:to="loc_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember_6a04d2b9-9877-4637-afd4-804d983e34bd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PatentInfringementLitigationMember_8e713620-d9b1-4ebf-bcec-505baafe8791" xlink:href="bhc-20220630.xsd#bhc_PatentInfringementLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_489a6c43-3228-4654-a6dc-229ae2cacfaa" xlink:to="loc_bhc_PatentInfringementLitigationMember_8e713620-d9b1-4ebf-bcec-505baafe8791" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ApotexIncLitigationMember_f52afa83-04cf-4fd2-82d3-eb25438ad56b" xlink:href="bhc-20220630.xsd#bhc_ApotexIncLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_489a6c43-3228-4654-a6dc-229ae2cacfaa" xlink:to="loc_bhc_ApotexIncLitigationMember_f52afa83-04cf-4fd2-82d3-eb25438ad56b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b20767ed-1f6b-44ec-ae90-2441f954eacb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1c027782-b16a-435a-ab8f-2d4590dc8470" xlink:to="loc_srt_StatementGeographicalAxis_b20767ed-1f6b-44ec-ae90-2441f954eacb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b20767ed-1f6b-44ec-ae90-2441f954eacb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_b20767ed-1f6b-44ec-ae90-2441f954eacb" xlink:to="loc_srt_SegmentGeographicalDomain_b20767ed-1f6b-44ec-ae90-2441f954eacb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8f68de9e-1e0a-4091-be34-3d5928a877ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_b20767ed-1f6b-44ec-ae90-2441f954eacb" xlink:to="loc_srt_SegmentGeographicalDomain_8f68de9e-1e0a-4091-be34-3d5928a877ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_8824ab0f-9954-4a40-a4a2-337d0a07a5a8" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8f68de9e-1e0a-4091-be34-3d5928a877ee" xlink:to="loc_country_CA_8824ab0f-9954-4a40-a4a2-337d0a07a5a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_d2dd43d3-f664-49f6-acf8-a1f124b26a91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1c027782-b16a-435a-ab8f-2d4590dc8470" xlink:to="loc_us-gaap_LitigationStatusAxis_d2dd43d3-f664-49f6-acf8-a1f124b26a91" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_d2dd43d3-f664-49f6-acf8-a1f124b26a91_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_d2dd43d3-f664-49f6-acf8-a1f124b26a91" xlink:to="loc_us-gaap_LitigationStatusDomain_d2dd43d3-f664-49f6-acf8-a1f124b26a91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_fed42bb5-1f30-4ea5-bbe0-19da270a9b18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_d2dd43d3-f664-49f6-acf8-a1f124b26a91" xlink:to="loc_us-gaap_LitigationStatusDomain_fed42bb5-1f30-4ea5-bbe0-19da270a9b18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_db4e9ce7-a5be-4dc6-b7f6-049b17b0e64a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_fed42bb5-1f30-4ea5-bbe0-19da270a9b18" xlink:to="loc_us-gaap_PendingLitigationMember_db4e9ce7-a5be-4dc6-b7f6-049b17b0e64a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_0fdef64f-d5a6-471d-a56a-520fa5fd1b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_fed42bb5-1f30-4ea5-bbe0-19da270a9b18" xlink:to="loc_us-gaap_SettledLitigationMember_0fdef64f-d5a6-471d-a56a-520fa5fd1b6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefaultJudgementMember_e09a1867-fdae-4ff9-bb23-9818beeaac7a" xlink:href="bhc-20220630.xsd#bhc_DefaultJudgementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_fed42bb5-1f30-4ea5-bbe0-19da270a9b18" xlink:to="loc_bhc_DefaultJudgementMember_e09a1867-fdae-4ff9-bb23-9818beeaac7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeclaratoryJudgementActionLitigationMember_6bd0a34c-81cd-4043-b2ef-81ae3282c4f8" xlink:href="bhc-20220630.xsd#bhc_DeclaratoryJudgementActionLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_fed42bb5-1f30-4ea5-bbe0-19da270a9b18" xlink:to="loc_bhc_DeclaratoryJudgementActionLitigationMember_6bd0a34c-81cd-4043-b2ef-81ae3282c4f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d0bfe24d-916a-4576-879b-492b071bd7f1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1c027782-b16a-435a-ab8f-2d4590dc8470" xlink:to="loc_dei_LegalEntityAxis_d0bfe24d-916a-4576-879b-492b071bd7f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d0bfe24d-916a-4576-879b-492b071bd7f1_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_d0bfe24d-916a-4576-879b-492b071bd7f1" xlink:to="loc_dei_EntityDomain_d0bfe24d-916a-4576-879b-492b071bd7f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_779627bd-c063-436d-b4fe-3a16e60f1fdb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_d0bfe24d-916a-4576-879b-492b071bd7f1" xlink:to="loc_dei_EntityDomain_779627bd-c063-436d-b4fe-3a16e60f1fdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_d4ea0dab-5d18-46ef-9aa7-d12048ee45c1" xlink:href="bhc-20220630.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_779627bd-c063-436d-b4fe-3a16e60f1fdb" xlink:to="loc_bhc_BauschLombMember_d4ea0dab-5d18-46ef-9aa7-d12048ee45c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4d244cbb-fb5e-4a89-9781-819b006d4f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1c027782-b16a-435a-ab8f-2d4590dc8470" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4d244cbb-fb5e-4a89-9781-819b006d4f6e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4d244cbb-fb5e-4a89-9781-819b006d4f6e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4d244cbb-fb5e-4a89-9781-819b006d4f6e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4d244cbb-fb5e-4a89-9781-819b006d4f6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3f61e6dc-56fc-4836-b190-fe45d8846013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4d244cbb-fb5e-4a89-9781-819b006d4f6e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3f61e6dc-56fc-4836-b190-fe45d8846013" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ebaa132b-bc48-40fc-8bab-9dc03eb3b062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3f61e6dc-56fc-4836-b190-fe45d8846013" xlink:to="loc_us-gaap_SubsequentEventMember_ebaa132b-bc48-40fc-8bab-9dc03eb3b062" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#LEGALPROCEEDINGSProductLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails" xlink:type="extended" id="ic55331a39d284e6b9f96d65f0c8c2ff3_LEGALPROCEEDINGSProductLiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_b4c92d30-7342-4efe-93cb-c8a2da119913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_ff37092f-48eb-4cb1-8775-1383ef745264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b4c92d30-7342-4efe-93cb-c8a2da119913" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_ff37092f-48eb-4cb1-8775-1383ef745264" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalPeriod_8f066306-1346-41a8-a22a-8c6ec61053f3" xlink:href="bhc-20220630.xsd#bhc_LossContingencyStayOfApprovalPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b4c92d30-7342-4efe-93cb-c8a2da119913" xlink:to="loc_bhc_LossContingencyStayOfApprovalPeriod_8f066306-1346-41a8-a22a-8c6ec61053f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_5970ec7f-41df-4f19-8d93-2367540600a6" xlink:href="bhc-20220630.xsd#bhc_LossContingencyStayOfApprovalMotionToExtendPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b4c92d30-7342-4efe-93cb-c8a2da119913" xlink:to="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_5970ec7f-41df-4f19-8d93-2367540600a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_8a427a65-09e0-4732-b987-0a56421ee2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_b4c92d30-7342-4efe-93cb-c8a2da119913" xlink:to="loc_us-gaap_LossContingenciesTable_8a427a65-09e0-4732-b987-0a56421ee2a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_ad814173-15ac-4e56-8e00-80dc5f0dbdab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8a427a65-09e0-4732-b987-0a56421ee2a4" xlink:to="loc_srt_LitigationCaseAxis_ad814173-15ac-4e56-8e00-80dc5f0dbdab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ad814173-15ac-4e56-8e00-80dc5f0dbdab_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_ad814173-15ac-4e56-8e00-80dc5f0dbdab" xlink:to="loc_srt_LitigationCaseTypeDomain_ad814173-15ac-4e56-8e00-80dc5f0dbdab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_4c6a388c-bf47-4cc6-acc9-d7de29fb9488" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_ad814173-15ac-4e56-8e00-80dc5f0dbdab" xlink:to="loc_srt_LitigationCaseTypeDomain_4c6a388c-bf47-4cc6-acc9-d7de29fb9488" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_2eff6010-7b1a-467c-a536-a764a99229ea" xlink:href="bhc-20220630.xsd#bhc_ShowerToShowerProductLiabilityLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_4c6a388c-bf47-4cc6-acc9-d7de29fb9488" xlink:to="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_2eff6010-7b1a-467c-a536-a764a99229ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_08dcf918-31e6-4a52-85ff-3192817de659" xlink:href="bhc-20220630.xsd#bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_2eff6010-7b1a-467c-a536-a764a99229ea" xlink:to="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_08dcf918-31e6-4a52-85ff-3192817de659" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_aa705dd7-93a6-45e4-a900-6be44f66dfba" xlink:href="bhc-20220630.xsd#bhc_MSNLaboratoriesPrivateLtdLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_4c6a388c-bf47-4cc6-acc9-d7de29fb9488" xlink:to="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_aa705dd7-93a6-45e4-a900-6be44f66dfba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_10f4bfa7-d47f-49b7-b354-40ef5d9432aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8a427a65-09e0-4732-b987-0a56421ee2a4" xlink:to="loc_us-gaap_LitigationStatusAxis_10f4bfa7-d47f-49b7-b354-40ef5d9432aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_10f4bfa7-d47f-49b7-b354-40ef5d9432aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_10f4bfa7-d47f-49b7-b354-40ef5d9432aa" xlink:to="loc_us-gaap_LitigationStatusDomain_10f4bfa7-d47f-49b7-b354-40ef5d9432aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_6bc837a6-2a5c-4a8c-b172-ef8b3ecb5b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_10f4bfa7-d47f-49b7-b354-40ef5d9432aa" xlink:to="loc_us-gaap_LitigationStatusDomain_6bc837a6-2a5c-4a8c-b172-ef8b3ecb5b3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_d5496ea1-ea03-46a9-b96e-c646e255e5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_6bc837a6-2a5c-4a8c-b172-ef8b3ecb5b3b" xlink:to="loc_us-gaap_PendingLitigationMember_d5496ea1-ea03-46a9-b96e-c646e255e5b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember_4bc3ed9d-10ce-4384-a794-170af20eccb5" xlink:href="bhc-20220630.xsd#bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PendingLitigationMember_d5496ea1-ea03-46a9-b96e-c646e255e5b4" xlink:to="loc_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember_4bc3ed9d-10ce-4384-a794-170af20eccb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_421b1018-1924-4467-b5f2-08e05d33e41c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8a427a65-09e0-4732-b987-0a56421ee2a4" xlink:to="loc_srt_StatementGeographicalAxis_421b1018-1924-4467-b5f2-08e05d33e41c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_421b1018-1924-4467-b5f2-08e05d33e41c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_421b1018-1924-4467-b5f2-08e05d33e41c" xlink:to="loc_srt_SegmentGeographicalDomain_421b1018-1924-4467-b5f2-08e05d33e41c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b6aee091-06dd-40e9-9735-741bddade6c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_421b1018-1924-4467-b5f2-08e05d33e41c" xlink:to="loc_srt_SegmentGeographicalDomain_b6aee091-06dd-40e9-9735-741bddade6c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_37ace2bf-d014-4509-9b29-b54f0aeee49e" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b6aee091-06dd-40e9-9735-741bddade6c7" xlink:to="loc_country_CA_37ace2bf-d014-4509-9b29-b54f0aeee49e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-BC_c57024aa-42af-489b-b3c9-5b5ce41e3bb0" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA-BC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b6aee091-06dd-40e9-9735-741bddade6c7" xlink:to="loc_stpr_CA-BC_c57024aa-42af-489b-b3c9-5b5ce41e3bb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-QC_1e59ebba-1712-47c1-816e-a227b7c5382c" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA-QC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b6aee091-06dd-40e9-9735-741bddade6c7" xlink:to="loc_stpr_CA-QC_1e59ebba-1712-47c1-816e-a227b7c5382c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#LEGALPROCEEDINGSGeneralCivilActionsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails" xlink:type="extended" id="i8444ff0cbd064857a9f5ab4ee44c3187_LEGALPROCEEDINGSGeneralCivilActionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_6e129fe6-252b-4bc4-adac-7aaf9b5b65ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_2095b38e-316f-45a5-803a-dfa86266a3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_6e129fe6-252b-4bc4-adac-7aaf9b5b65ac" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_2095b38e-316f-45a5-803a-dfa86266a3d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_b201b153-4655-4de9-bccd-3756dd8f361e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_6e129fe6-252b-4bc4-adac-7aaf9b5b65ac" xlink:to="loc_us-gaap_LossContingenciesTable_b201b153-4655-4de9-bccd-3756dd8f361e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_b22f3d12-c461-48c9-9858-fd1bf59699ce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b201b153-4655-4de9-bccd-3756dd8f361e" xlink:to="loc_srt_LitigationCaseAxis_b22f3d12-c461-48c9-9858-fd1bf59699ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_b22f3d12-c461-48c9-9858-fd1bf59699ce_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_b22f3d12-c461-48c9-9858-fd1bf59699ce" xlink:to="loc_srt_LitigationCaseTypeDomain_b22f3d12-c461-48c9-9858-fd1bf59699ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e0349262-abe2-4888-822d-eea0765bf9c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_b22f3d12-c461-48c9-9858-fd1bf59699ce" xlink:to="loc_srt_LitigationCaseTypeDomain_e0349262-abe2-4888-822d-eea0765bf9c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_61dae81f-abe4-45c6-bf5c-3723af4a507e" xlink:href="bhc-20220630.xsd#bhc_DoctorsAllergyFormulaLLCLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e0349262-abe2-4888-822d-eea0765bf9c7" xlink:to="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_61dae81f-abe4-45c6-bf5c-3723af4a507e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationwithFormerSalixCEOMember_6430d625-aaa0-40be-9f92-21571415e9e0" xlink:href="bhc-20220630.xsd#bhc_LitigationwithFormerSalixCEOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e0349262-abe2-4888-822d-eea0765bf9c7" xlink:to="loc_bhc_LitigationwithFormerSalixCEOMember_6430d625-aaa0-40be-9f92-21571415e9e0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended" id="ia367299e7fe84d8696adf1671e88edcc_SEGMENTINFORMATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_0d563833-abc7-4e20-bcac-2d9661a6f333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_d522deb7-7c73-42b4-b5e9-da2eb7ad6a36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0d563833-abc7-4e20-bcac-2d9661a6f333" xlink:to="loc_us-gaap_NumberOfReportingUnits_d522deb7-7c73-42b4-b5e9-da2eb7ad6a36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a36b9e8d-3091-4ba1-ada1-9f5ee00a5c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0d563833-abc7-4e20-bcac-2d9661a6f333" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a36b9e8d-3091-4ba1-ada1-9f5ee00a5c3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d922c65e-ec28-4a8e-9ad5-3d9ea823dea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0d563833-abc7-4e20-bcac-2d9661a6f333" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d922c65e-ec28-4a8e-9ad5-3d9ea823dea5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1774eb09-3288-4fc4-9821-5aed5e0ee7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d922c65e-ec28-4a8e-9ad5-3d9ea823dea5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1774eb09-3288-4fc4-9821-5aed5e0ee7d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1774eb09-3288-4fc4-9821-5aed5e0ee7d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1774eb09-3288-4fc4-9821-5aed5e0ee7d3" xlink:to="loc_us-gaap_SegmentDomain_1774eb09-3288-4fc4-9821-5aed5e0ee7d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8483dde1-a651-47f2-bde9-9f6ab5eb3e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1774eb09-3288-4fc4-9821-5aed5e0ee7d3" xlink:to="loc_us-gaap_SegmentDomain_8483dde1-a651-47f2-bde9-9f6ab5eb3e8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_3765ce63-f256-4af9-8f19-e904eee00440" xlink:href="bhc-20220630.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8483dde1-a651-47f2-bde9-9f6ab5eb3e8f" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_3765ce63-f256-4af9-8f19-e904eee00440" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_e1f31b23-6cc1-4f15-820a-d2ea6c665eba" xlink:href="bhc-20220630.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8483dde1-a651-47f2-bde9-9f6ab5eb3e8f" xlink:to="loc_bhc_SalixSegmentMember_e1f31b23-6cc1-4f15-820a-d2ea6c665eba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_71961223-e869-435f-84ef-335b37523a7d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d922c65e-ec28-4a8e-9ad5-3d9ea823dea5" xlink:to="loc_srt_ProductOrServiceAxis_71961223-e869-435f-84ef-335b37523a7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_71961223-e869-435f-84ef-335b37523a7d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_71961223-e869-435f-84ef-335b37523a7d" xlink:to="loc_srt_ProductsAndServicesDomain_71961223-e869-435f-84ef-335b37523a7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8e527cc1-d5c0-4dd8-a629-687898e9b2fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_71961223-e869-435f-84ef-335b37523a7d" xlink:to="loc_srt_ProductsAndServicesDomain_8e527cc1-d5c0-4dd8-a629-687898e9b2fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_XifaxanBrandedProductsMember_de88b188-7b7f-4ce9-bbf1-150dade0f6be" xlink:href="bhc-20220630.xsd#bhc_XifaxanBrandedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8e527cc1-d5c0-4dd8-a629-687898e9b2fd" xlink:to="loc_bhc_XifaxanBrandedProductsMember_de88b188-7b7f-4ce9-bbf1-150dade0f6be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_294cdd3e-49d6-4be4-8511-8e0227920eb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d922c65e-ec28-4a8e-9ad5-3d9ea823dea5" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_294cdd3e-49d6-4be4-8511-8e0227920eb6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_294cdd3e-49d6-4be4-8511-8e0227920eb6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_294cdd3e-49d6-4be4-8511-8e0227920eb6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_294cdd3e-49d6-4be4-8511-8e0227920eb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8c10f20a-dbd0-401c-96f6-30c85f4ca8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_294cdd3e-49d6-4be4-8511-8e0227920eb6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8c10f20a-dbd0-401c-96f6-30c85f4ca8cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_9dd2cb1a-18a0-406c-8b7d-7c4cb050bb11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8c10f20a-dbd0-401c-96f6-30c85f4ca8cb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_9dd2cb1a-18a0-406c-8b7d-7c4cb050bb11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_926e8399-5c8b-48a7-9677-da97c18f12df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d922c65e-ec28-4a8e-9ad5-3d9ea823dea5" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_926e8399-5c8b-48a7-9677-da97c18f12df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_926e8399-5c8b-48a7-9677-da97c18f12df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_926e8399-5c8b-48a7-9677-da97c18f12df" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_926e8399-5c8b-48a7-9677-da97c18f12df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1c759b7d-0941-4374-af51-5e9a281485a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_926e8399-5c8b-48a7-9677-da97c18f12df" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1c759b7d-0941-4374-af51-5e9a281485a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_b83a9ec9-5109-4835-a4a3-104d261cb8e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1c759b7d-0941-4374-af51-5e9a281485a3" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_b83a9ec9-5109-4835-a4a3-104d261cb8e2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" xlink:type="extended" id="i9ac4755868da42d594bca20e9e52b9e6_SEGMENTINFORMATIONSegmentRevenuesandProfitDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_e756200a-2f86-4de7-a08a-7281bff3363d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93e0aa5f-dff9-4749-bc75-5b79edb99509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e756200a-2f86-4de7-a08a-7281bff3363d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93e0aa5f-dff9-4749-bc75-5b79edb99509" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2585d8e6-8897-4af4-b67a-c63b29330cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e756200a-2f86-4de7-a08a-7281bff3363d" xlink:to="loc_us-gaap_OperatingIncomeLoss_2585d8e6-8897-4af4-b67a-c63b29330cc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_f52bb712-62c7-49ec-bc96-9a0b61bdc89d" xlink:href="bhc-20220630.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e756200a-2f86-4de7-a08a-7281bff3363d" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_f52bb712-62c7-49ec-bc96-9a0b61bdc89d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_6cfecb5f-0bcb-4a49-8fbd-7a27bfb15b5a" xlink:href="bhc-20220630.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e756200a-2f86-4de7-a08a-7281bff3363d" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_6cfecb5f-0bcb-4a49-8fbd-7a27bfb15b5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_b337a278-9513-4cec-9ee2-3fb576b3b480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e756200a-2f86-4de7-a08a-7281bff3363d" xlink:to="loc_us-gaap_AssetImpairmentCharges_b337a278-9513-4cec-9ee2-3fb576b3b480" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_ab24614e-ae08-4cc8-8483-91e20faca5dc" xlink:href="bhc-20220630.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e756200a-2f86-4de7-a08a-7281bff3363d" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_ab24614e-ae08-4cc8-8483-91e20faca5dc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_764f2f6b-c331-465d-ad65-b77feec928d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e756200a-2f86-4de7-a08a-7281bff3363d" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_764f2f6b-c331-465d-ad65-b77feec928d2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_74962c3e-9801-442c-81bd-0eca510ff2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e756200a-2f86-4de7-a08a-7281bff3363d" xlink:to="loc_us-gaap_InvestmentIncomeInterest_74962c3e-9801-442c-81bd-0eca510ff2ca" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_1ad2adfa-bd34-4058-a2fc-492444e45c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e756200a-2f86-4de7-a08a-7281bff3363d" xlink:to="loc_us-gaap_InterestExpenseDebt_1ad2adfa-bd34-4058-a2fc-492444e45c01" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_563d5fec-f630-47b2-8d67-72ffc1d7220b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e756200a-2f86-4de7-a08a-7281bff3363d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_563d5fec-f630-47b2-8d67-72ffc1d7220b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_d4f6f0d9-56a3-452c-b57b-9f2169b0e84c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e756200a-2f86-4de7-a08a-7281bff3363d" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_d4f6f0d9-56a3-452c-b57b-9f2169b0e84c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1e489961-2fe2-49ac-9dee-51c550b28f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e756200a-2f86-4de7-a08a-7281bff3363d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1e489961-2fe2-49ac-9dee-51c550b28f78" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_71a25989-f4e8-4c09-974f-16aebca7ea45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e756200a-2f86-4de7-a08a-7281bff3363d" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_71a25989-f4e8-4c09-974f-16aebca7ea45" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_a93ef358-cabf-4cbe-8fe9-58ecbfecaec9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_71a25989-f4e8-4c09-974f-16aebca7ea45" xlink:to="loc_srt_ConsolidationItemsAxis_a93ef358-cabf-4cbe-8fe9-58ecbfecaec9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a93ef358-cabf-4cbe-8fe9-58ecbfecaec9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_a93ef358-cabf-4cbe-8fe9-58ecbfecaec9" xlink:to="loc_srt_ConsolidationItemsDomain_a93ef358-cabf-4cbe-8fe9-58ecbfecaec9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_00fb934a-2c78-4443-b07e-bc241203e0d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_a93ef358-cabf-4cbe-8fe9-58ecbfecaec9" xlink:to="loc_srt_ConsolidationItemsDomain_00fb934a-2c78-4443-b07e-bc241203e0d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_50a110af-6102-4587-a57b-b7c9f5bfa784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_00fb934a-2c78-4443-b07e-bc241203e0d0" xlink:to="loc_us-gaap_OperatingSegmentsMember_50a110af-6102-4587-a57b-b7c9f5bfa784" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_b97a504b-6925-4638-bf54-16165f7aafe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_00fb934a-2c78-4443-b07e-bc241203e0d0" xlink:to="loc_us-gaap_CorporateNonSegmentMember_b97a504b-6925-4638-bf54-16165f7aafe4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_03e95e31-a030-4206-a4da-19b6d59a4ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_71a25989-f4e8-4c09-974f-16aebca7ea45" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_03e95e31-a030-4206-a4da-19b6d59a4ca9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_03e95e31-a030-4206-a4da-19b6d59a4ca9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_03e95e31-a030-4206-a4da-19b6d59a4ca9" xlink:to="loc_us-gaap_SegmentDomain_03e95e31-a030-4206-a4da-19b6d59a4ca9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_eaeac100-78bc-4cc2-af6b-6db0811cfa0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_03e95e31-a030-4206-a4da-19b6d59a4ca9" xlink:to="loc_us-gaap_SegmentDomain_eaeac100-78bc-4cc2-af6b-6db0811cfa0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_24d222d8-4b12-4cea-9fe5-e07eeb477996" xlink:href="bhc-20220630.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_eaeac100-78bc-4cc2-af6b-6db0811cfa0d" xlink:to="loc_bhc_SalixSegmentMember_24d222d8-4b12-4cea-9fe5-e07eeb477996" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_740b7f66-04d2-4e90-b773-923f23e1a357" xlink:href="bhc-20220630.xsd#bhc_InternationalRxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_eaeac100-78bc-4cc2-af6b-6db0811cfa0d" xlink:to="loc_bhc_InternationalRxMember_740b7f66-04d2-4e90-b773-923f23e1a357" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_b24cd15a-d4b1-42e8-98cb-e99e5d33cd45" xlink:href="bhc-20220630.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_eaeac100-78bc-4cc2-af6b-6db0811cfa0d" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_b24cd15a-d4b1-42e8-98cb-e99e5d33cd45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_f9add56b-382f-49a3-9323-f156d6377ec7" xlink:href="bhc-20220630.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_eaeac100-78bc-4cc2-af6b-6db0811cfa0d" xlink:to="loc_bhc_SoltaMedicalSegmentMember_f9add56b-382f-49a3-9323-f156d6377ec7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_6afa26aa-69ae-4a84-9281-1d25b3451848" xlink:href="bhc-20220630.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_eaeac100-78bc-4cc2-af6b-6db0811cfa0d" xlink:to="loc_bhc_BauschLombMember_6afa26aa-69ae-4a84-9281-1d25b3451848" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#SEGMENTINFORMATIONDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails" xlink:type="extended" id="idb3bdfe041a143418caac4f115d9b3db_SEGMENTINFORMATIONDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_eaf70b20-a8d4-42bf-9cb2-d2db96e721a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_87302516-0399-419d-9bf3-bb98bc374682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_eaf70b20-a8d4-42bf-9cb2-d2db96e721a3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_87302516-0399-419d-9bf3-bb98bc374682" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_30663a82-6623-4bd8-a5b3-590631d29dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_eaf70b20-a8d4-42bf-9cb2-d2db96e721a3" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_30663a82-6623-4bd8-a5b3-590631d29dc3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_adbce4d9-f37c-4295-a66a-072cd8d1866a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_30663a82-6623-4bd8-a5b3-590631d29dc3" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_adbce4d9-f37c-4295-a66a-072cd8d1866a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_adbce4d9-f37c-4295-a66a-072cd8d1866a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_adbce4d9-f37c-4295-a66a-072cd8d1866a" xlink:to="loc_us-gaap_SegmentDomain_adbce4d9-f37c-4295-a66a-072cd8d1866a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_443d198f-c9d0-4ef1-a667-2b7949fa8ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_adbce4d9-f37c-4295-a66a-072cd8d1866a" xlink:to="loc_us-gaap_SegmentDomain_443d198f-c9d0-4ef1-a667-2b7949fa8ca3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_fbd98aa9-74e1-4edd-9a64-b6d203c80ef7" xlink:href="bhc-20220630.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_443d198f-c9d0-4ef1-a667-2b7949fa8ca3" xlink:to="loc_bhc_SalixSegmentMember_fbd98aa9-74e1-4edd-9a64-b6d203c80ef7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_0f3b5efe-d353-48bb-931a-ed72a6016064" xlink:href="bhc-20220630.xsd#bhc_InternationalRxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_443d198f-c9d0-4ef1-a667-2b7949fa8ca3" xlink:to="loc_bhc_InternationalRxMember_0f3b5efe-d353-48bb-931a-ed72a6016064" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_a6d906c4-6efc-41c2-8565-a4afa528a78d" xlink:href="bhc-20220630.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_443d198f-c9d0-4ef1-a667-2b7949fa8ca3" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_a6d906c4-6efc-41c2-8565-a4afa528a78d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_a9d74a75-ed52-4dec-b468-cb3330f3891f" xlink:href="bhc-20220630.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_443d198f-c9d0-4ef1-a667-2b7949fa8ca3" xlink:to="loc_bhc_SoltaMedicalSegmentMember_a9d74a75-ed52-4dec-b468-cb3330f3891f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_c0cfe1ee-5830-429b-8e97-bfa1d02aa3df" xlink:href="bhc-20220630.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_443d198f-c9d0-4ef1-a667-2b7949fa8ca3" xlink:to="loc_bhc_BauschLombMember_c0cfe1ee-5830-429b-8e97-bfa1d02aa3df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cf37df1a-97dc-4898-841e-24eb0a22321b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_30663a82-6623-4bd8-a5b3-590631d29dc3" xlink:to="loc_srt_ProductOrServiceAxis_cf37df1a-97dc-4898-841e-24eb0a22321b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cf37df1a-97dc-4898-841e-24eb0a22321b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_cf37df1a-97dc-4898-841e-24eb0a22321b" xlink:to="loc_srt_ProductsAndServicesDomain_cf37df1a-97dc-4898-841e-24eb0a22321b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b1d7f155-e3af-44f6-9727-685e0081c595" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_cf37df1a-97dc-4898-841e-24eb0a22321b" xlink:to="loc_srt_ProductsAndServicesDomain_b1d7f155-e3af-44f6-9727-685e0081c595" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PharmaceuticalProductsMember_0a82272a-0065-4a12-be14-41275d9c23f8" xlink:href="bhc-20220630.xsd#bhc_PharmaceuticalProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b1d7f155-e3af-44f6-9727-685e0081c595" xlink:to="loc_bhc_PharmaceuticalProductsMember_0a82272a-0065-4a12-be14-41275d9c23f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeviceProductsMember_181438a1-e12e-4243-8e1a-cadc4dff0082" xlink:href="bhc-20220630.xsd#bhc_DeviceProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b1d7f155-e3af-44f6-9727-685e0081c595" xlink:to="loc_bhc_DeviceProductsMember_181438a1-e12e-4243-8e1a-cadc4dff0082" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OvertheCounterProductsMember_4c5a1681-6aac-4068-8247-1026bb03c0b9" xlink:href="bhc-20220630.xsd#bhc_OvertheCounterProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b1d7f155-e3af-44f6-9727-685e0081c595" xlink:to="loc_bhc_OvertheCounterProductsMember_4c5a1681-6aac-4068-8247-1026bb03c0b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BrandedandOtherGenericProductsMember_9614a326-c634-47a1-9da6-38900a8fc1d8" xlink:href="bhc-20220630.xsd#bhc_BrandedandOtherGenericProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b1d7f155-e3af-44f6-9727-685e0081c595" xlink:to="loc_bhc_BrandedandOtherGenericProductsMember_9614a326-c634-47a1-9da6-38900a8fc1d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherRevenuesMember_3624392a-181c-4bd1-8af7-a6414debf801" xlink:href="bhc-20220630.xsd#bhc_OtherRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b1d7f155-e3af-44f6-9727-685e0081c595" xlink:to="loc_bhc_OtherRevenuesMember_3624392a-181c-4bd1-8af7-a6414debf801" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1" xlink:type="simple" xlink:href="bhc-20220630.xsd#SEGMENTINFORMATIONNarrativeDetails_1"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1" xlink:type="extended" id="i7dbe0bdf91cf492ca72bf0d4ebcc2639_SEGMENTINFORMATIONNarrativeDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_453bc6a2-e01e-4c8f-9ad1-5de47c8b76a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskNumberOfProducts_f10ca7b5-0cd0-4a37-9352-f6f3c68e67f8" xlink:href="bhc-20220630.xsd#bhc_ConcentrationRiskNumberOfProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_453bc6a2-e01e-4c8f-9ad1-5de47c8b76a3" xlink:to="loc_bhc_ConcentrationRiskNumberOfProducts_f10ca7b5-0cd0-4a37-9352-f6f3c68e67f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_73e386d4-1bdd-4224-8e86-41be6a8a23f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_453bc6a2-e01e-4c8f-9ad1-5de47c8b76a3" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_73e386d4-1bdd-4224-8e86-41be6a8a23f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_696a5bcf-9984-4fa2-ba1f-0f6a10aac2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_453bc6a2-e01e-4c8f-9ad1-5de47c8b76a3" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_696a5bcf-9984-4fa2-ba1f-0f6a10aac2a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5a01d38e-5ed8-4795-a66e-1c3feb7bc754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_696a5bcf-9984-4fa2-ba1f-0f6a10aac2a5" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5a01d38e-5ed8-4795-a66e-1c3feb7bc754" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5a01d38e-5ed8-4795-a66e-1c3feb7bc754_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5a01d38e-5ed8-4795-a66e-1c3feb7bc754" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5a01d38e-5ed8-4795-a66e-1c3feb7bc754_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_034755d2-5a9e-4fdb-a8bf-8a97ca1a9f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5a01d38e-5ed8-4795-a66e-1c3feb7bc754" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_034755d2-5a9e-4fdb-a8bf-8a97ca1a9f8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_f579c4e8-92e9-4430-bb66-712d2cfb3fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_034755d2-5a9e-4fdb-a8bf-8a97ca1a9f8f" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_f579c4e8-92e9-4430-bb66-712d2cfb3fe7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b36a6c87-61e6-45e8-aa19-74b4fcf8cb73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_696a5bcf-9984-4fa2-ba1f-0f6a10aac2a5" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b36a6c87-61e6-45e8-aa19-74b4fcf8cb73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b36a6c87-61e6-45e8-aa19-74b4fcf8cb73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b36a6c87-61e6-45e8-aa19-74b4fcf8cb73" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b36a6c87-61e6-45e8-aa19-74b4fcf8cb73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_928cabb3-a00f-408e-8dfb-9ded3527f277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b36a6c87-61e6-45e8-aa19-74b4fcf8cb73" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_928cabb3-a00f-408e-8dfb-9ded3527f277" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_8d826e2e-8641-4afe-9afc-d54151f08dbd" xlink:href="bhc-20220630.xsd#bhc_RevenuesNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_928cabb3-a00f-408e-8dfb-9ded3527f277" xlink:to="loc_bhc_RevenuesNetMember_8d826e2e-8641-4afe-9afc-d54151f08dbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f68c0e06-f89f-47a9-b084-28646f5176c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_696a5bcf-9984-4fa2-ba1f-0f6a10aac2a5" xlink:to="loc_srt_MajorCustomersAxis_f68c0e06-f89f-47a9-b084-28646f5176c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f68c0e06-f89f-47a9-b084-28646f5176c5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_f68c0e06-f89f-47a9-b084-28646f5176c5" xlink:to="loc_srt_NameOfMajorCustomerDomain_f68c0e06-f89f-47a9-b084-28646f5176c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f31be6df-6adf-4618-9532-f456768c99f3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_f68c0e06-f89f-47a9-b084-28646f5176c5" xlink:to="loc_srt_NameOfMajorCustomerDomain_f31be6df-6adf-4618-9532-f456768c99f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CustomerTopTenProductsMember_bd351ba4-4c7a-437c-abab-ff50b7753d78" xlink:href="bhc-20220630.xsd#bhc_CustomerTopTenProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f31be6df-6adf-4618-9532-f456768c99f3" xlink:to="loc_bhc_CustomerTopTenProductsMember_bd351ba4-4c7a-437c-abab-ff50b7753d78" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails" xlink:type="extended" id="i6330e8f429ca4274969a4d9ed2db354e_SEGMENTINFORMATIONRevenuebyGeographicAreaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_131045c0-24ea-4a96-abf6-499964465fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aadda5d4-0325-400e-8b02-54e77e45f883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_131045c0-24ea-4a96-abf6-499964465fe0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aadda5d4-0325-400e-8b02-54e77e45f883" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_7b8d5fe6-b6cf-4bbf-84cc-f3783e1568e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_131045c0-24ea-4a96-abf6-499964465fe0" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_7b8d5fe6-b6cf-4bbf-84cc-f3783e1568e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7823b416-70ea-4179-8508-98279a8956f6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_7b8d5fe6-b6cf-4bbf-84cc-f3783e1568e3" xlink:to="loc_srt_StatementGeographicalAxis_7823b416-70ea-4179-8508-98279a8956f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7823b416-70ea-4179-8508-98279a8956f6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_7823b416-70ea-4179-8508-98279a8956f6" xlink:to="loc_srt_SegmentGeographicalDomain_7823b416-70ea-4179-8508-98279a8956f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_7823b416-70ea-4179-8508-98279a8956f6" xlink:to="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember_908cae90-eacf-4360-982f-6fe16bc0b4c4" xlink:href="bhc-20220630.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:to="loc_bhc_UnitedStatesandPuertoRicoMember_908cae90-eacf-4360-982f-6fe16bc0b4c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_8c5359ee-f919-4f8e-a053-5a0a3ef7dccb" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:to="loc_country_CN_8c5359ee-f919-4f8e-a053-5a0a3ef7dccb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_134184fa-61c5-4b1c-836c-30a1aadbaae1" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:to="loc_country_CA_134184fa-61c5-4b1c-836c-30a1aadbaae1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL_c3e05c48-51ba-40bb-87cf-1952c674a434" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_PL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:to="loc_country_PL_c3e05c48-51ba-40bb-87cf-1952c674a434" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX_eb4f0d26-0156-4886-ab7a-20d003d24b9f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:to="loc_country_MX_eb4f0d26-0156-4886-ab7a-20d003d24b9f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_2bf61a84-1b26-4f64-8f50-755a8f5d1910" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:to="loc_country_FR_2bf61a84-1b26-4f64-8f50-755a8f5d1910" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_4ebcb8ff-4a6c-41e2-a2ea-55102339e5d5" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:to="loc_country_JP_4ebcb8ff-4a6c-41e2-a2ea-55102339e5d5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_6f6fe378-8ce8-42f7-9cdf-0e72978cedca" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:to="loc_country_DE_6f6fe378-8ce8-42f7-9cdf-0e72978cedca" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_c6e54d5d-f31b-4819-933d-cec6549ba5f9" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:to="loc_country_GB_c6e54d5d-f31b-4819-933d-cec6549ba5f9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_RU_c229a457-c923-4b3f-908f-6b9eea4b93e9" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_RU"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:to="loc_country_RU_c229a457-c923-4b3f-908f-6b9eea4b93e9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES_6cb73c33-7d92-43a8-8103-558fee3b4597" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_ES"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:to="loc_country_ES_6cb73c33-7d92-43a8-8103-558fee3b4597" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT_fe7a699b-7de7-4609-ab20-31ac0d66a0d9" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:to="loc_country_IT_fe7a699b-7de7-4609-ab20-31ac0d66a0d9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_KR_fdc4032a-5623-4aa0-98a8-d63cbd5c6d3c" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:to="loc_country_KR_fdc4032a-5623-4aa0-98a8-d63cbd5c6d3c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember_2806806e-3822-4518-abc9-7a439d7156ef" xlink:href="bhc-20220630.xsd#bhc_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:to="loc_bhc_OtherCountriesMember_2806806e-3822-4518-abc9-7a439d7156ef" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#SEGMENTINFORMATIONMajorCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="extended" id="i7ff687f4053b4224910af0612251cee9_SEGMENTINFORMATIONMajorCustomersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_8d830ed3-88d2-492d-b135-ca8c0fd067c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_6913a029-9126-4242-97cd-cce5957e6961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_8d830ed3-88d2-492d-b135-ca8c0fd067c8" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_6913a029-9126-4242-97cd-cce5957e6961" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f276ce53-1a98-4f14-9f20-7a6a639c3507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_8d830ed3-88d2-492d-b135-ca8c0fd067c8" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f276ce53-1a98-4f14-9f20-7a6a639c3507" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c7ca86c6-a1eb-4937-9613-f7b89eca1448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f276ce53-1a98-4f14-9f20-7a6a639c3507" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c7ca86c6-a1eb-4937-9613-f7b89eca1448" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c7ca86c6-a1eb-4937-9613-f7b89eca1448_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c7ca86c6-a1eb-4937-9613-f7b89eca1448" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c7ca86c6-a1eb-4937-9613-f7b89eca1448_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d9f51ca9-8672-4369-8d1b-9a08632e8d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c7ca86c6-a1eb-4937-9613-f7b89eca1448" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d9f51ca9-8672-4369-8d1b-9a08632e8d9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_62efd871-6fe2-4b8a-8d38-addaa312dae7" xlink:href="bhc-20220630.xsd#bhc_RevenuesNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d9f51ca9-8672-4369-8d1b-9a08632e8d9b" xlink:to="loc_bhc_RevenuesNetMember_62efd871-6fe2-4b8a-8d38-addaa312dae7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_6a15256f-20ca-4907-b848-c7523b55156a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f276ce53-1a98-4f14-9f20-7a6a639c3507" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_6a15256f-20ca-4907-b848-c7523b55156a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6a15256f-20ca-4907-b848-c7523b55156a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_6a15256f-20ca-4907-b848-c7523b55156a" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6a15256f-20ca-4907-b848-c7523b55156a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_77b2f8ce-3f2d-4be6-8eee-b72aa906d63c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_6a15256f-20ca-4907-b848-c7523b55156a" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_77b2f8ce-3f2d-4be6-8eee-b72aa906d63c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_d38c1922-be4d-4ca9-bdb5-e3ac9aaa0654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_77b2f8ce-3f2d-4be6-8eee-b72aa906d63c" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_d38c1922-be4d-4ca9-bdb5-e3ac9aaa0654" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_6759a8c7-2cdd-400a-a357-171385b2e78d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f276ce53-1a98-4f14-9f20-7a6a639c3507" xlink:to="loc_srt_MajorCustomersAxis_6759a8c7-2cdd-400a-a357-171385b2e78d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_6759a8c7-2cdd-400a-a357-171385b2e78d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_6759a8c7-2cdd-400a-a357-171385b2e78d" xlink:to="loc_srt_NameOfMajorCustomerDomain_6759a8c7-2cdd-400a-a357-171385b2e78d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_fbeb7c46-c578-4634-8ce4-c7ab6bfeee54" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_6759a8c7-2cdd-400a-a357-171385b2e78d" xlink:to="loc_srt_NameOfMajorCustomerDomain_fbeb7c46-c578-4634-8ce4-c7ab6bfeee54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmerisourceBergenCorporationMember_2c738609-e0c1-405f-834c-854e8b124dbf" xlink:href="bhc-20220630.xsd#bhc_AmerisourceBergenCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_fbeb7c46-c578-4634-8ce4-c7ab6bfeee54" xlink:to="loc_bhc_AmerisourceBergenCorporationMember_2c738609-e0c1-405f-834c-854e8b124dbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_McKessonCorporationMember_cbdc6648-dc07-4e6f-be47-5dc8269ba800" xlink:href="bhc-20220630.xsd#bhc_McKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_fbeb7c46-c578-4634-8ce4-c7ab6bfeee54" xlink:to="loc_bhc_McKessonCorporationMember_cbdc6648-dc07-4e6f-be47-5dc8269ba800" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CardinalHealthIncMember_25af02f0-3712-4bc5-8e24-6ac13f2a8081" xlink:href="bhc-20220630.xsd#bhc_CardinalHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_fbeb7c46-c578-4634-8ce4-c7ab6bfeee54" xlink:to="loc_bhc_CardinalHealthIncMember_25af02f0-3712-4bc5-8e24-6ac13f2a8081" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SUBSEQUENTEVENTNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#SUBSEQUENTEVENTNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SUBSEQUENTEVENTNarrativeDetails" xlink:type="extended" id="i7aa98faec90644a7aefe7af481950abf_SUBSEQUENTEVENTNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_4c2150f0-6978-428a-beb6-a00da0c40f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_44918adb-fefb-436e-a207-99f580aedeb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4c2150f0-6978-428a-beb6-a00da0c40f1e" xlink:to="loc_us-gaap_DerivativeNotionalAmount_44918adb-fefb-436e-a207-99f580aedeb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_8c9b99a4-4956-43f7-ad67-8c8167eb3596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_4c2150f0-6978-428a-beb6-a00da0c40f1e" xlink:to="loc_us-gaap_SubsequentEventTable_8c9b99a4-4956-43f7-ad67-8c8167eb3596" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c7c9045b-8554-4378-a25b-8ab164b4a79a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_8c9b99a4-4956-43f7-ad67-8c8167eb3596" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c7c9045b-8554-4378-a25b-8ab164b4a79a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c7c9045b-8554-4378-a25b-8ab164b4a79a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c7c9045b-8554-4378-a25b-8ab164b4a79a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c7c9045b-8554-4378-a25b-8ab164b4a79a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e0cbbadc-08b2-4c45-9929-96a41985c2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c7c9045b-8554-4378-a25b-8ab164b4a79a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e0cbbadc-08b2-4c45-9929-96a41985c2c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6da56783-598b-483b-8776-4e3f62fb6c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e0cbbadc-08b2-4c45-9929-96a41985c2c7" xlink:to="loc_us-gaap_SubsequentEventMember_6da56783-598b-483b-8776-4e3f62fb6c38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_915fcd9e-8a2b-4cfb-863b-1de44569ff83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_8c9b99a4-4956-43f7-ad67-8c8167eb3596" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_915fcd9e-8a2b-4cfb-863b-1de44569ff83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_915fcd9e-8a2b-4cfb-863b-1de44569ff83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_915fcd9e-8a2b-4cfb-863b-1de44569ff83" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_915fcd9e-8a2b-4cfb-863b-1de44569ff83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e9889f71-0d49-4c8b-a09b-151e03d29650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_915fcd9e-8a2b-4cfb-863b-1de44569ff83" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e9889f71-0d49-4c8b-a09b-151e03d29650" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_d5767c6b-080c-46c2-888a-1f6b90910f79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e9889f71-0d49-4c8b-a09b-151e03d29650" xlink:to="loc_us-gaap_CurrencySwapMember_d5767c6b-080c-46c2-888a-1f6b90910f79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_89896ad7-9f3d-4473-a9df-d0e1fb9d929a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_8c9b99a4-4956-43f7-ad67-8c8167eb3596" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_89896ad7-9f3d-4473-a9df-d0e1fb9d929a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_89896ad7-9f3d-4473-a9df-d0e1fb9d929a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_89896ad7-9f3d-4473-a9df-d0e1fb9d929a" xlink:to="loc_us-gaap_HedgingRelationshipDomain_89896ad7-9f3d-4473-a9df-d0e1fb9d929a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_a463d337-c090-4cbd-afc2-08aaa8ade532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_89896ad7-9f3d-4473-a9df-d0e1fb9d929a" xlink:to="loc_us-gaap_HedgingRelationshipDomain_a463d337-c090-4cbd-afc2-08aaa8ade532" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_d644e51d-ac3c-4b19-b35e-de55ad8da95c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_a463d337-c090-4cbd-afc2-08aaa8ade532" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_d644e51d-ac3c-4b19-b35e-de55ad8da95c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_b57125b7-2667-4343-bb35-1e2468f108dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_8c9b99a4-4956-43f7-ad67-8c8167eb3596" xlink:to="loc_us-gaap_HedgingDesignationAxis_b57125b7-2667-4343-bb35-1e2468f108dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_b57125b7-2667-4343-bb35-1e2468f108dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_b57125b7-2667-4343-bb35-1e2468f108dc" xlink:to="loc_us-gaap_HedgingDesignationDomain_b57125b7-2667-4343-bb35-1e2468f108dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_429cdb1a-bc5b-4037-8e56-de74773717ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_b57125b7-2667-4343-bb35-1e2468f108dc" xlink:to="loc_us-gaap_HedgingDesignationDomain_429cdb1a-bc5b-4037-8e56-de74773717ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6980156e-18d8-40b6-b852-ca57d4e76386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_429cdb1a-bc5b-4037-8e56-de74773717ae" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6980156e-18d8-40b6-b852-ca57d4e76386" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_3d09c12a-a8da-4bd1-a4b8-28717e121b3d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_8c9b99a4-4956-43f7-ad67-8c8167eb3596" xlink:to="loc_dei_LegalEntityAxis_3d09c12a-a8da-4bd1-a4b8-28717e121b3d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3d09c12a-a8da-4bd1-a4b8-28717e121b3d_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_3d09c12a-a8da-4bd1-a4b8-28717e121b3d" xlink:to="loc_dei_EntityDomain_3d09c12a-a8da-4bd1-a4b8-28717e121b3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_238d1499-bd3c-457e-82d2-2cdcabf93b98" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_3d09c12a-a8da-4bd1-a4b8-28717e121b3d" xlink:to="loc_dei_EntityDomain_238d1499-bd3c-457e-82d2-2cdcabf93b98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_1a0cef57-03c4-44a2-b663-d871313c4da8" xlink:href="bhc-20220630.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_238d1499-bd3c-457e-82d2-2cdcabf93b98" xlink:to="loc_bhc_BauschLombMember_1a0cef57-03c4-44a2-b663-d871313c4da8" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>bhc-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:08e728a9-955b-42e6-9f9e-75e33d236c1d,g:6cf439ae-5822-43c6-a8ac-f8ebfd7ee7fe-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bfc8cb88-ea49-476d-97b8-3c7f8c886461_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_c0d2e652-c419-4e93-8bd4-58be08c47ecd_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_f7c64186-1f03-4f0f-b8f8-870383f03e87_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_7e32ddf1-5727-4f4f-8e0e-97644c465e6a_netLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_02f83c7e-5701-423b-90d7-7015908cd230_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_3449dbf8-5d9b-4cce-befe-c568150667e3_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lawsuits pending</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_aa2c0ae4-23ab-4950-ad45-f1a2b465c6ed_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_59f1a990-559f-411e-bd77-2395eb162272_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_237a0cf0-a5c9-470b-a3cc-7d632cb2e859_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_ca6e6a31-cac8-4c13-b0b6-8ea7519d772e_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt obligations</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount_7aeca7a4-e365-4544-9884-e9fdfa5a8eae_terseLabel_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax provision (benefit) for discrete items</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount_label_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Discrete Items, Amount</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount_documentation_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Discrete Items, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:href="bhc-20220630.xsd#bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:to="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5c5abc87-33af-4a66-9a49-d011aea2fa25_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LitigationSettlementNumberOfObjectorsAppeals_4aed2fb3-91c9-48b6-b325-03d128c66f9a_terseLabel_en-US" xlink:label="lab_bhc_LitigationSettlementNumberOfObjectorsAppeals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement, escrow fund included in restricted cash, number of objectors' appeals</link:label>
    <link:label id="lab_bhc_LitigationSettlementNumberOfObjectorsAppeals_label_en-US" xlink:label="lab_bhc_LitigationSettlementNumberOfObjectorsAppeals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Number of Objectors' Appeals</link:label>
    <link:label id="lab_bhc_LitigationSettlementNumberOfObjectorsAppeals_documentation_en-US" xlink:label="lab_bhc_LitigationSettlementNumberOfObjectorsAppeals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Number of Objectors' Appeals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationSettlementNumberOfObjectorsAppeals" xlink:href="bhc-20220630.xsd#bhc_LitigationSettlementNumberOfObjectorsAppeals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LitigationSettlementNumberOfObjectorsAppeals" xlink:to="lab_bhc_LitigationSettlementNumberOfObjectorsAppeals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_c915047f-492f-4cfd-84ff-0b74486e5fd1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_cf28f2cd-3884-4a3a-9c68-58471376209c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_0494e308-37fe-437d-92d3-67b4178be86b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CanadianSecuritiesLitigationMember_290bef4c-f169-4fb4-a882-ea8ef34e18b7_terseLabel_en-US" xlink:label="lab_bhc_CanadianSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Securities Litigation</link:label>
    <link:label id="lab_bhc_CanadianSecuritiesLitigationMember_label_en-US" xlink:label="lab_bhc_CanadianSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Securities Litigation [Member]</link:label>
    <link:label id="lab_bhc_CanadianSecuritiesLitigationMember_documentation_en-US" xlink:label="lab_bhc_CanadianSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Securities Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadianSecuritiesLitigationMember" xlink:href="bhc-20220630.xsd#bhc_CanadianSecuritiesLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CanadianSecuritiesLitigationMember" xlink:to="lab_bhc_CanadianSecuritiesLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_25bd79aa-a371-4023-9708-09213a3755b5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d8f65c4e-496e-4093-a266-06176535312d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_8dbf8059-c38e-4bd2-b6dc-c00dad6112fc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA-QC_e60ad4f6-e55b-423b-88ee-900d5cc323e3_terseLabel_en-US" xlink:label="lab_stpr_CA-QC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">QUEBEC</link:label>
    <link:label id="lab_stpr_CA-QC_label_en-US" xlink:label="lab_stpr_CA-QC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">QUEBEC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-QC" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA-QC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA-QC" xlink:to="lab_stpr_CA-QC" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_c39bee52-b010-4aec-b1e6-72abc5fcea90_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities associated with restructuring, integration and separation costs</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_43d7e6bf-ea8f-4167-826d-6aa315716288_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and credits</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_219f4eb4-46bc-421b-bb1c-32c95a1d5d85_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_3f468b3a-58d7-4f05-9437-8a283ea50aef_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and benefit costs</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_61d06bcc-69c8-436e-9c61-09e5d76ff9a4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_eed45bb1-2873-4c22-9522-5f9a3f1ff133_terseLabel_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_label_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Noncurrent Liability</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_documentation_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Noncurrent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:href="bhc-20220630.xsd#bhc_BusinessCombinationContingentConsiderationNoncurrentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:to="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_241ba3ea-6996-4c57-9880-d0abde34a7ab_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue associated with products for disposal</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_c8a8dd5d-28b7-4963-aa96-5deb9123f0a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of other expense, net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_daff8967-84d3-4bd2-afc1-c45663a8d015_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_6ce9b207-7ce2-43b2-987f-810a18c6273f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_5ab01f58-3ab4-46f4-bb70-b40d8580ab5e_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_085ab3b1-5171-47fb-908a-6706b788dbc8_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_a92a1ee8-0c7f-43f0-8479-e0577b8691bc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of revenue attributed to a geographic region</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_b5f6c7d0-9cce-41cd-8035-a45d273aa81f_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate on debt (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_82e0bd7a-2fac-42ce-9f5c-bd0045761268_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_de66f259-14f8-4aa1-a479-d3113095f79c_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_213fd662-665c-4821-8a4f-3b4f07b42e73_terseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEGAL PROCEEDINGS</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember_62c15b0c-e0f0-4bb5-b4f0-5373446ad1be_terseLabel_en-US" xlink:label="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Doctors Allergy Formula, LLC Litigation</link:label>
    <link:label id="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember_label_en-US" xlink:label="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Doctors Allergy Formula, LLC Litigation [Member]</link:label>
    <link:label id="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember_documentation_en-US" xlink:label="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Doctors Allergy Formula, LLC Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:href="bhc-20220630.xsd#bhc_DoctorsAllergyFormulaLLCLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:to="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0af0ed25-a45d-43d4-803f-25ff2a47f565_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_bf07a49e-be00-4b13-8c27-4efe62ebe6ae_negatedLabel_en-US" xlink:label="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of contingent consideration adjustments, including accretion</link:label>
    <link:label id="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_label_en-US" xlink:label="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Contingent Consideration Liability, Including Accretion, Operating Activities</link:label>
    <link:label id="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_documentation_en-US" xlink:label="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Contingent Consideration Liability, Including Accretion, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:href="bhc-20220630.xsd#bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:to="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_5ba4e1d3-b2d0-4cfd-a5ff-91d2fc282bd2_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic (benefit) cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermLoanBFacilityDueNovember2025Member_90d7475a-ff4b-4e87-a1ac-17092814070b_terseLabel_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due November 2025</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueNovember2025Member_label_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due November 2025 [Member]</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueNovember2025Member_documentation_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due November 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member" xlink:href="bhc-20220630.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermLoanBFacilityDueNovember2025Member" xlink:to="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_a8b6eabb-5c14-46a7-8922-42977b0947cd_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AmerisourceBergenCorporationMember_2bb2d06b-40d0-4e31-9aac-fba2db9b38ab_terseLabel_en-US" xlink:label="lab_bhc_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corporation</link:label>
    <link:label id="lab_bhc_AmerisourceBergenCorporationMember_label_en-US" xlink:label="lab_bhc_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amerisource Bergen Corporation [Member]</link:label>
    <link:label id="lab_bhc_AmerisourceBergenCorporationMember_documentation_en-US" xlink:label="lab_bhc_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the major customer of the entity, AmerisourceBergen Corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmerisourceBergenCorporationMember" xlink:href="bhc-20220630.xsd#bhc_AmerisourceBergenCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AmerisourceBergenCorporationMember" xlink:to="lab_bhc_AmerisourceBergenCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_8ac5f16e-087e-4a4d-8424-1a77a1f484a9_terseLabel_en-US" xlink:label="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Units Excluding Ortho Dermatologics</link:label>
    <link:label id="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_label_en-US" xlink:label="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Units Excluding Ortho Dermatologics [Member]</link:label>
    <link:label id="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_documentation_en-US" xlink:label="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Units Excluding Ortho Dermatologics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:href="bhc-20220630.xsd#bhc_ReportingUnitsExcludingOrthoDermatologicsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:to="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers_731a20ef-43ef-48e9-a447-3e3beccc3e6e_terseLabel_en-US" xlink:label="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement agreements, number of insurers</link:label>
    <link:label id="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers_label_en-US" xlink:label="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Settlement Agreements, Number Of Insurers</link:label>
    <link:label id="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers_documentation_en-US" xlink:label="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Settlement Agreements, Number Of Insurers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:href="bhc-20220630.xsd#bhc_LossContingencySettlementAgreementsNumberOfInsurers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:to="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_3d14d12b-7562-48d6-81f6-efc34ac07b61_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a2ca6092-cd37-4a54-9508-dbce66433985_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_9cb92930-ad35-42c2-af90-db31d5074240_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_40d041b7-25ee-416d-baaf-b06dfee8bffb_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive shares not included in the computation of diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_2fbc33b5-5f27-422d-934e-c97b51245120_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2c2ce56e-c2c4-4a24-8cee-f426f802e75d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of potential common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_69304ecc-6f3d-41cf-89c0-570d540c2e3e_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ecec0dbf-378f-4347-a0c2-e3435f76731f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of long-term debt maturities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_b516fa21-6429-40e2-bf74-fa6edea97b2f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_748e46c1-d577-49e2-ab19-d949978f33fa_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service credit and other</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_8d3cadde-8d25-4395-8b5a-2f70f83f53bf_terseLabel_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_410960a6-8130-4c35-9333-5340603efe44_negatedLabel_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_label_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets Excluding Amortization Allocated to Revenues Cost of Good Sold</link:label>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_documentation_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:href="bhc-20220630.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:to="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_a47269a2-6503-4a89-9365-68d7da430f42_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Funds</link:label>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_c7121377-c134-4395-a35f-ad2be7f4f4b1_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_6723bbfb-510c-4834-a2a1-1b931a54c64d_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_94cc0654-bdf6-49cc-ad4f-2d2decbbb63b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_48944a9c-2b99-4df3-a1d3-d0b373d1f257_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrecurring adjustment</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_fa9c8dea-c85e-4eeb-9312-3f3aba608617_terseLabel_en-US" xlink:label="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Dollar Base Rate and Canadian Dollar Prime Rate</link:label>
    <link:label id="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_label_en-US" xlink:label="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Dollar Base Rate and Canadian Dollar Prime Rate [Member]</link:label>
    <link:label id="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_documentation_en-US" xlink:label="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Dollar Base Rate and Canadian Dollar Prime Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:href="bhc-20220630.xsd#bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:to="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_cbe02325-6f31-4c6b-9214-bce583ae413d_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_35168891-c940-41f4-b036-8065eeb49cc3_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_cae0d653-9738-44e3-9b45-87ca44d03bcf_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_aba00b3a-ed6c-4e74-b63f-269d4f2fd824_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_d7dd3a2c-f0a5-4f6b-9712-add59cd840d1_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_8e6c7574-2cb4-44e5-911a-202215f393a5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting rights, percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance_bedb2bda-5266-4af8-9bdd-38629546b105_terseLabel_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quality assurance</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance_label_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Quality Assurance</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance_documentation_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Quality Assurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:href="bhc-20220630.xsd#bhc_ResearchAndDevelopmentExpenseQualityAssurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:to="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_b655dfa8-40b3-4ed4-8ddd-e6b829d50da8_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_f0df3265-e664-4cf4-ac4c-7c9c41264331_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock_2d5b9c50-096e-46b9-842c-b92f34bda301_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of foreign exchange contracts on the Consolidated Statements of Operations and Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments Included in Trading Activities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_89da2edb-8fbb-4510-a856-1b447fdf1ac5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ExecutiveOfficerMember_e4c371cd-5a39-4094-83fe-22ac6a73de48_terseLabel_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer</link:label>
    <link:label id="lab_srt_ExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ExecutiveOfficerMember" xlink:to="lab_srt_ExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_d2c8fb41-ae3c-46ad-abf5-d883144046b7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes725DueMay2029Member_dac102f9-2c30-44c9-a720-b01d55a8f3f1_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes725DueMay2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.25 % Senior Notes Due May 2029</link:label>
    <link:label id="lab_bhc_SeniorNotes725DueMay2029Member_label_en-US" xlink:label="lab_bhc_SeniorNotes725DueMay2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.25%, Due May 2029 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes725DueMay2029Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes725DueMay2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes 7.25 Percent Due May 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes725DueMay2029Member" xlink:to="lab_bhc_SeniorNotes725DueMay2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_9b7a825f-d686-4e97-8b07-f4b71f0280f7_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherIncomeExpenseNet_8ec8a39a-4f67-454c-8d32-c75184f04d6d_terseLabel_en-US" xlink:label="lab_bhc_OtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, Net</link:label>
    <link:label id="lab_bhc_OtherIncomeExpenseNet_label_en-US" xlink:label="lab_bhc_OtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:label id="lab_bhc_OtherIncomeExpenseNet_documentation_en-US" xlink:label="lab_bhc_OtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherIncomeExpenseNet" xlink:href="bhc-20220630.xsd#bhc_OtherIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherIncomeExpenseNet" xlink:to="lab_bhc_OtherIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_5096efa9-3fee-4b47-87ff-46ac7f1fd935_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember_bf482f22-965f-43a2-b29a-e85176384266_terseLabel_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Other Settlement Deposits, Current</link:label>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember_label_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Other Settlement Deposits, Current [Member]</link:label>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember_documentation_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Other Settlement Deposits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember" xlink:href="bhc-20220630.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember" xlink:to="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_89a341d9-6c08-42c2-85a7-d23c09bbb0e0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_201426b4-3c91-4951-a021-e1e46584c8c7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_95ebb2be-ff7f-46ab-bc4f-e65d3ba55b19_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_35ca0f8d-ad1b-40a2-ba47-832d1cdab73d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_bdd22b53-b26e-42df-8833-4514721439f3_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_770f3528-34d4-4c93-862b-f81b9cbee0f3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_bcfdd58a-a8ea-4b03-8702-22e5b772fe5f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_67411c1e-2a88-40a1-9c32-0e901aa0cd4a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_f4bdc961-820d-4ced-82d2-f60a3e3653bc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Segment Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Segment Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_9806c1a1-9b03-445a-ae7c-6665431f037b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_5e3c03d7-8cda-4538-96b4-8170d3e1d34f_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_d44ac906-756c-4f89-a7ce-78087d7e4965_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash proceeds from divestiture</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7bb30269-18f2-4df0-9b26-7b6dd3e06c3e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_0a8024d3-4a30-40fb-9fff-8d8f1636222b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit related to changes in uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_e0d1347e-4fc2-4810-ac62-efa49aa7cba6_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_ee2b40db-8e70-4e77-a2e1-61acd0b41c0e_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stay of approval, motion to extend, period</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_label_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Motion To Extend, Period</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_documentation_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Motion To Extend, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:href="bhc-20220630.xsd#bhc_LossContingencyStayOfApprovalMotionToExtendPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:to="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit_fd5892f7-3f31-4539-86b2-db73ffcd66e3_terseLabel_en-US" xlink:label="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit_label_en-US" xlink:label="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Noncash Expense (Benefit)</link:label>
    <link:label id="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit_documentation_en-US" xlink:label="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:href="bhc-20220630.xsd#bhc_DeferredIncomeTaxNoncashExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:to="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_6d72cada-f26c-4dca-9ba2-f65b047849c2_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recoveries</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Recovery</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_4a0891b7-58c7-4a80-8424-be4884e23f84_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SOFRCDORAndEURIBORRatesMember_9f58be47-4219-4c1f-a38b-58015a10e5ac_terseLabel_en-US" xlink:label="lab_bhc_SOFRCDORAndEURIBORRatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR and EURIBOR Rates</link:label>
    <link:label id="lab_bhc_SOFRCDORAndEURIBORRatesMember_label_en-US" xlink:label="lab_bhc_SOFRCDORAndEURIBORRatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR and EURIBOR Rates [Member]</link:label>
    <link:label id="lab_bhc_SOFRCDORAndEURIBORRatesMember_documentation_en-US" xlink:label="lab_bhc_SOFRCDORAndEURIBORRatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR and EURIBOR Rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDORAndEURIBORRatesMember" xlink:href="bhc-20220630.xsd#bhc_SOFRCDORAndEURIBORRatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SOFRCDORAndEURIBORRatesMember" xlink:to="lab_bhc_SOFRCDORAndEURIBORRatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_e5659954-5516-4dba-9298-b0b45847a938_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_bed8712d-b811-4b30-b1aa-5d0b2c7b120c_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member_d954108c-9fe0-42da-bfb3-e28bf1f285aa_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Notes Due February 2027</link:label>
    <link:label id="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member_label_en-US" xlink:label="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 6.125% Notes Due February 2027 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 6.125% Notes Due February 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:href="bhc-20220630.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:to="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_65859c29-853b-453a-8c7b-5c0baa356895_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForChargebacksMember_4c130abd-5bb3-4dc2-abe6-ce27256e2866_terseLabel_en-US" xlink:label="lab_bhc_ReserveForChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks</link:label>
    <link:label id="lab_bhc_ReserveForChargebacksMember_label_en-US" xlink:label="lab_bhc_ReserveForChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Chargebacks [Member]</link:label>
    <link:label id="lab_bhc_ReserveForChargebacksMember_documentation_en-US" xlink:label="lab_bhc_ReserveForChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Chargebacks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForChargebacksMember" xlink:href="bhc-20220630.xsd#bhc_ReserveForChargebacksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForChargebacksMember" xlink:to="lab_bhc_ReserveForChargebacksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_616e6a7e-d1a4-42f9-a95f-dce8a7264706_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_17e91fa6-84b9-456d-bf52-a41ec0ebc2ac_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cb17b9df-63aa-4a01-92ec-b50cff2af452_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_8b146bc9-6caf-4b8a-9e4e-76043357cebc_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from B+L initial public offering, net of costs (Note 2)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_fafc1968-81dc-4a26-acd9-45b643ad7451_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to reflect change in ownership interest in Bausch + Lomb</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_a531616a-026a-4acd-a031-b3d1d75d3921_terseLabel_en-US" xlink:label="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustments due to changes in estimates of other future payments</link:label>
    <link:label id="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_label_en-US" xlink:label="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustments, Changes In Estimates Of Other Future Payments [Member]</link:label>
    <link:label id="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_documentation_en-US" xlink:label="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustments, Changes In Estimates Of Other Future Payments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:href="bhc-20220630.xsd#bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:to="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember_5c16bd23-4ab0-4307-ad7d-0522c10e0cbf_terseLabel_en-US" xlink:label="lab_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumify Paragraph I V Proceedings Lupin ANDA Litigation</link:label>
    <link:label id="lab_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember_label_en-US" xlink:label="lab_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumify Paragraph I V Proceedings Lupin ANDA Litigation [Member]</link:label>
    <link:label id="lab_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember_documentation_en-US" xlink:label="lab_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumify Paragraph I V Proceedings Lupin ANDA Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember" xlink:href="bhc-20220630.xsd#bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember" xlink:to="lab_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_4b623eac-5cc7-4c6b-b4bf-b345eb8233a3_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_525caff7-8052-401b-ae58-f0efd569875f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherLongTermDebtMember_910d8b6c-cd4d-40b9-bb0d-bdf3f7bc9ab3_terseLabel_en-US" xlink:label="lab_bhc_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_bhc_OtherLongTermDebtMember_label_en-US" xlink:label="lab_bhc_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Debt [Member]</link:label>
    <link:label id="lab_bhc_OtherLongTermDebtMember_documentation_en-US" xlink:label="lab_bhc_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents long-term debt obligations not elsewhere enumerated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherLongTermDebtMember" xlink:href="bhc-20220630.xsd#bhc_OtherLongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherLongTermDebtMember" xlink:to="lab_bhc_OtherLongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_f2ff3784-531f-4983-b38d-7ee1aee03d68_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_b7d46d61-6d3c-490f-9eb4-4f74d942e6bd_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BauschLombMember_9ba2a004-cdf2-41c9-88c0-499b1909c61d_terseLabel_en-US" xlink:label="lab_bhc_BauschLombMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb</link:label>
    <link:label id="lab_bhc_BauschLombMember_label_en-US" xlink:label="lab_bhc_BauschLombMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb [Member]</link:label>
    <link:label id="lab_bhc_BauschLombMember_documentation_en-US" xlink:label="lab_bhc_BauschLombMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember" xlink:href="bhc-20220630.xsd#bhc_BauschLombMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BauschLombMember" xlink:to="lab_bhc_BauschLombMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_7e7e213a-7987-48e3-ac4d-dc0cc118c690_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_b5e96abd-cd5f-4534-beb5-529c8162676a_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR Rate</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_6529c094-ddee-4db9-83c2-f76ae0b9f869_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization_010b6e50-d06f-4345-847f-8300b00ea2fc_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining quarterly amortization payments</link:label>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization_label_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Remaining Quarterly Amortization</link:label>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Remaining Quarterly Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" xlink:to="lab_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_26a25562-8a7a-4ada-a527-6df2bfad8b8f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_InternationalRxMember_1ebdc670-7d85-4e28-a515-5e725477aa26_terseLabel_en-US" xlink:label="lab_bhc_InternationalRxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_bhc_InternationalRxMember_44f01c55-28d2-4f79-8be7-00f92ce6ea2d_verboseLabel_en-US" xlink:label="lab_bhc_InternationalRxMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_bhc_InternationalRxMember_label_en-US" xlink:label="lab_bhc_InternationalRxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Rx [Member]</link:label>
    <link:label id="lab_bhc_InternationalRxMember_documentation_en-US" xlink:label="lab_bhc_InternationalRxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Rx</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember" xlink:href="bhc-20220630.xsd#bhc_InternationalRxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_InternationalRxMember" xlink:to="lab_bhc_InternationalRxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8ef620f5-cc48-41bb-9199-9b4be96318e1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_0cd5ab72-e47c-480d-9ba8-0b1c81f9f1ad_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_3853c6d8-5e10-4ed1-a116-7b726f4fe244_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FINANCING ARRANGEMENTS</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_1863f777-3b14-47bb-8f78-5f9d2718a7ff_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseProductRelated_659220b9-43eb-4e87-8332-2318f8936fa9_terseLabel_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product related research and development</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseProductRelated_label_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Product Related</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseProductRelated_documentation_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Product Related</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:href="bhc-20220630.xsd#bhc_ResearchAndDevelopmentExpenseProductRelated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:to="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilitiesMember_a0f74244-09f6-4935-bf70-fa95380ad467_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities</link:label>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilitiesMember_label_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilitiesMember_documentation_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilitiesMember" xlink:href="bhc-20220630.xsd#bhc_SeniorSecuredCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecuredCreditFacilitiesMember" xlink:to="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_a0a9267d-0a2c-4c9e-b4e3-698e83f08f02_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_c1f212ac-7e2b-477c-abae-abb6fdc30bad_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember_18b50cbd-2b44-496d-ad5a-ea577d2691b2_terseLabel_en-US" xlink:label="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued And Other Current Liabilities [Member]</link:label>
    <link:label id="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued And Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:href="bhc-20220630.xsd#bhc_AccruedAndOtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:to="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember_7ddd0b45-61f6-47fe-b99a-54513c7a471e_terseLabel_en-US" xlink:label="lab_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumify Paragraph I V Proceedings Slayback ANDA Litigation</link:label>
    <link:label id="lab_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember_label_en-US" xlink:label="lab_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumify Paragraph I V Proceedings Slayback ANDA Litigation [Member]</link:label>
    <link:label id="lab_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember_documentation_en-US" xlink:label="lab_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumify Paragraph I V Proceedings Slayback ANDA Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember" xlink:href="bhc-20220630.xsd#bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember" xlink:to="lab_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross_13c7050c-838f-46ba-b5e6-3e0c616a5e19_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock plan, grants in period (in shares)</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Grants In Period, Gross</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Grants In Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" xlink:href="bhc-20220630.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_a42952cc-dc0c-48ce-bdaa-e9f3551672cf_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_f70f00e5-f3f4-4842-8afe-db852e074111_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_c524a578-2c0d-4751-9abd-6ce3545d9e8d_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lawsuits pending</link:label>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_label_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed upon, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:to="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage_afc12cb7-db9b-4c83-98fc-9317d98d3575_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental borrowings interest rate</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Threshold For Incremental Borrowings, Percentage</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Threshold For Incremental Borrowings, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" xlink:href="bhc-20220630.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" xlink:to="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_a3af347f-72e2-4ba1-b791-baee97fa0cb9_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_6ecba28e-8acc-41ef-b17c-6a1cd48b0256_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a399fa84-f1f2-4803-bfbb-b7b0eff8887d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_67e9ce32-8d78-48d4-ab09-9aab1032f27a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period, Second Year after Grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_4f52c066-9570-4242-ab61-463fe6833656_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit spread adjustment (as a percent)</link:label>
    <link:label id="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_label_en-US" xlink:label="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Credit Spread Adjustment on Variable Rate</link:label>
    <link:label id="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Credit Spread Adjustment on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:to="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_6fc1b42b-38a8-4775-b8ea-0420f19776ad_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of groups of investors filing action, remain pending</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_label_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_documentation_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:href="bhc-20220630.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:to="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_ff36df57-d4ca-435a-b340-4f3fb8dcb8ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the components of Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_ac2f6036-084a-459d-b047-c5f03abc147b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_de8c5414-d00b-408a-9b6a-b96a7aada6bc_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CustomerTopTenProductsMember_39d28cd4-6af1-4d4a-9cfe-d6eb50a2f376_terseLabel_en-US" xlink:label="lab_bhc_CustomerTopTenProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer, Top Ten Products</link:label>
    <link:label id="lab_bhc_CustomerTopTenProductsMember_label_en-US" xlink:label="lab_bhc_CustomerTopTenProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer, Top Ten Products [Member]</link:label>
    <link:label id="lab_bhc_CustomerTopTenProductsMember_documentation_en-US" xlink:label="lab_bhc_CustomerTopTenProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer, Top Ten Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CustomerTopTenProductsMember" xlink:href="bhc-20220630.xsd#bhc_CustomerTopTenProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CustomerTopTenProductsMember" xlink:to="lab_bhc_CustomerTopTenProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_fda82bfb-1f83-4a8a-b56f-cd40dbf53904_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-offs</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_adbf4ab6-eae8-4871-83f1-b39df6a902ca_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_7e7f58f0-d23c-4cf8-ab87-694450ab5fdb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_e0672f01-9afa-4680-b57d-6f3f83c13af2_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amount to be received</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded from Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_af228cd0-034f-4f5c-b93b-a28c172d818b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_a1afcbf7-a606-4e20-a873-cbf6a0311975_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments or receipts in settlement of cross-currency swaps</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Hedge, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bc95fbc0-c43d-4460-bc4c-939ebd0c82dc_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TaroPharmaceuticalsIncLitigationMember_c61662f2-99d8-4cc6-a5f7-0b94b38b9615_terseLabel_en-US" xlink:label="lab_bhc_TaroPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taro Pharmaceuticals Inc. Litigation</link:label>
    <link:label id="lab_bhc_TaroPharmaceuticalsIncLitigationMember_label_en-US" xlink:label="lab_bhc_TaroPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taro Pharmaceuticals Inc. Litigation [Member]</link:label>
    <link:label id="lab_bhc_TaroPharmaceuticalsIncLitigationMember_documentation_en-US" xlink:label="lab_bhc_TaroPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taro Pharmaceuticals Inc. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaroPharmaceuticalsIncLitigationMember" xlink:href="bhc-20220630.xsd#bhc_TaroPharmaceuticalsIncLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TaroPharmaceuticalsIncLitigationMember" xlink:to="lab_bhc_TaroPharmaceuticalsIncLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_a1977c9f-ba81-436e-8bac-e5f22fec7532_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_f1db96e5-6878-491d-b212-31c024924e7f_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_cc75a968-fe53-42ec-b8ab-f506121b6020_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_90545935-365d-48c8-b24a-25766686c543_verboseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4d4fbf75-8244-45c0-a1d7-9fa6bcef874e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_25240e97-5242-4abb-8a7c-1d8825577d72_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_0c2c66b3-3563-4255-99fe-dfe33a6e41c3_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_360fd2f9-c5eb-44fe-9a57-115bb46aebe3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_770980f6-6735-4e03-bcf6-9189fe788562_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_ea64b112-2cce-4b70-b7d8-77c4626d8819_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_05cde04a-28c0-4376-83fd-169d48b09d9a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f8c15f02-e2c4-4003-a048-249a19c384c9_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_e20d3fda-0897-4514-a036-df85725a3bd3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_43bc19dd-b1eb-4e6f-8bef-f88d9e766efe_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_d57f3da5-1652-4d11-b1c5-9936265fed92_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_a3a6ab50-b76a-4a56-9e28-d92c4018b867_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_3e9b6fbf-0397-4166-b9b1-c6396c52e656_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and write-off of debt premiums, discounts and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_f59a0fa1-5a95-497b-bd51-5045bd21be43_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LOSS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_89fded88-4be1-4684-95fa-cb4d89de01ee_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_93e58b7e-7fa9-426e-80f4-b1ae6c3a313f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IPOAndOverAllotmentOptionMember_c48ab629-ed70-4d25-a9ca-19b364683a3e_terseLabel_en-US" xlink:label="lab_bhc_IPOAndOverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO and Over-Allotment Option</link:label>
    <link:label id="lab_bhc_IPOAndOverAllotmentOptionMember_label_en-US" xlink:label="lab_bhc_IPOAndOverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO And Over-Allotment Option [Member]</link:label>
    <link:label id="lab_bhc_IPOAndOverAllotmentOptionMember_documentation_en-US" xlink:label="lab_bhc_IPOAndOverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO And Over-Allotment Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IPOAndOverAllotmentOptionMember" xlink:href="bhc-20220630.xsd#bhc_IPOAndOverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IPOAndOverAllotmentOptionMember" xlink:to="lab_bhc_IPOAndOverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_cc42fb06-1426-470a-bcc8-d6989673b793_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash proceeds from incurrence of debt</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Percentage of Net Proceeds from Incurrence of Debt Payable as Mandatory Pre-payments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of net cash proceeds from the incurrence of debt payable as mandatory prepayments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:href="bhc-20220630.xsd#bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:to="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_32eede7d-f8f2-4064-a58a-bb3afddfcce4_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5d5ea9f4-76b7-42bd-8900-272e38b57f72_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_d5bae66b-1851-44b1-a154-3ed2474f42a6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) recognized in Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_a90c4038-f8ec-4343-8631-7760ac628076_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assets and liabilities associated with derivatives, included in the Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf03bce1-d831-478b-9aa7-74b18e01ffd6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_940ce419-119b-4158-b111-b6b6df19c0b0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average service period over which compensation cost is expected to be recognized (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_93da8cb8-3690-4be6-9f5d-1e4985ad2efe_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_d4f55132-655d-42e0-8cef-fa1a13aa9ca6_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_3fd0dedd-9796-4bc0-8cc8-7e3e9ea0b7fd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_daa9d917-7ca8-4e3b-a2fd-37d16a6b74dd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e8f2d388-03b3-4b05-8ae5-db9837ed6775_terseLabel_en-US" xlink:label="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived and Indefinite Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:href="bhc-20220630.xsd#bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_f893311d-c899-42e4-adcb-d779b7590ac8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_47a8ab69-f8cd-4e16-a6ad-9b705aa203ce_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes625DueFebruary2029Member_16b59d15-4fe6-4ce6-825b-aa71a3ebedaf_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.25% Senior Notes Due February 2029</link:label>
    <link:label id="lab_bhc_SeniorNotes625DueFebruary2029Member_label_en-US" xlink:label="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.25%, Due February 2029 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes625DueFebruary2029Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.25%, Due February 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes625DueFebruary2029Member" xlink:to="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_57416ffc-a888-4279-bf09-ea6f9a4dbbb9_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_4e95f270-e8aa-41a7-8d52-6d8b73c4bf7a_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options and RSUs</link:label>
    <link:label id="lab_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_label_en-US" xlink:label="lab_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option And Restricted Stock Units RSUs [Member]</link:label>
    <link:label id="lab_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_documentation_en-US" xlink:label="lab_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option And Restricted Stock Units RSUs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" xlink:href="bhc-20220630.xsd#bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" xlink:to="lab_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_290d010e-a389-49af-9f47-e3054850a996_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_619a8ca6-7c55-4173-9a8a-578ae9f4068d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchased principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts_ee17df25-a818-4aec-98b7-07abfae2d4de_terseLabel_en-US" xlink:label="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, integration, separation and IPO costs</link:label>
    <link:label id="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts_7da190fe-cc19-41ae-abf1-8490e724ba8a_negatedTerseLabel_en-US" xlink:label="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, integration, separation and IPO costs</link:label>
    <link:label id="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts_label_en-US" xlink:label="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges And Initial Public Offering Costs</link:label>
    <link:label id="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts_documentation_en-US" xlink:label="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges And Initial Public Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:href="bhc-20220630.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:to="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_017ad2f9-5918-4805-8318-3db4dc285441_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_7786d3f2-6544-41ac-900e-b60f5f036a06_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENT</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DerivativeGainExcludedComponent_ea2dbb13-f2f0-481c-aeaf-87caddd5e5ec_negatedTerseLabel_en-US" xlink:label="lab_bhc_DerivativeGainExcludedComponent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain excluded from hedge effectiveness</link:label>
    <link:label id="lab_bhc_DerivativeGainExcludedComponent_label_en-US" xlink:label="lab_bhc_DerivativeGainExcludedComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain, Excluded Component</link:label>
    <link:label id="lab_bhc_DerivativeGainExcludedComponent_documentation_en-US" xlink:label="lab_bhc_DerivativeGainExcludedComponent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain, Excluded Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeGainExcludedComponent" xlink:href="bhc-20220630.xsd#bhc_DerivativeGainExcludedComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DerivativeGainExcludedComponent" xlink:to="lab_bhc_DerivativeGainExcludedComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GainContingencyStayOfApprovalPeriod_d1d34a9e-e9f3-4f14-ba6e-6fa2cebf60d1_terseLabel_en-US" xlink:label="lab_bhc_GainContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stay of approval, period</link:label>
    <link:label id="lab_bhc_GainContingencyStayOfApprovalPeriod_label_en-US" xlink:label="lab_bhc_GainContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Stay Of Approval, Period</link:label>
    <link:label id="lab_bhc_GainContingencyStayOfApprovalPeriod_documentation_en-US" xlink:label="lab_bhc_GainContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Stay Of Approval, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyStayOfApprovalPeriod" xlink:href="bhc-20220630.xsd#bhc_GainContingencyStayOfApprovalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GainContingencyStayOfApprovalPeriod" xlink:to="lab_bhc_GainContingencyStayOfApprovalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccruedProductReturnCurrent_42b3990e-7481-4b58-9379-ff2aca63a385_terseLabel_en-US" xlink:label="lab_bhc_AccruedProductReturnCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product returns</link:label>
    <link:label id="lab_bhc_AccruedProductReturnCurrent_label_en-US" xlink:label="lab_bhc_AccruedProductReturnCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Product Return Current</link:label>
    <link:label id="lab_bhc_AccruedProductReturnCurrent_documentation_en-US" xlink:label="lab_bhc_AccruedProductReturnCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductReturnCurrent" xlink:href="bhc-20220630.xsd#bhc_AccruedProductReturnCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccruedProductReturnCurrent" xlink:to="lab_bhc_AccruedProductReturnCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_c51c341f-f556-47b5-ae46-5ba6379f83e2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_787331dc-00eb-46bb-aa50-7fc472e7f1f2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermFacilityDueMay2027Member_9419c73f-2b66-4640-8cda-f7a376a311cd_terseLabel_en-US" xlink:label="lab_bhc_TermFacilityDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Facility Due May 2027</link:label>
    <link:label id="lab_bhc_TermFacilityDueMay2027Member_label_en-US" xlink:label="lab_bhc_TermFacilityDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Facility Due May 2027 [Member]</link:label>
    <link:label id="lab_bhc_TermFacilityDueMay2027Member_documentation_en-US" xlink:label="lab_bhc_TermFacilityDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Facility Due May 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermFacilityDueMay2027Member" xlink:href="bhc-20220630.xsd#bhc_TermFacilityDueMay2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermFacilityDueMay2027Member" xlink:to="lab_bhc_TermFacilityDueMay2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_90c32911-dd57-4923-9789-be82083591aa_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment included in other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_522be828-8d2f-4543-ade7-b0efa65f7039_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_60ea279e-3e53-4c59-ba17-acc35a6ac9bd_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of suits filed but not yet served</link:label>
    <link:label id="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_label_en-US" xlink:label="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency New Claims Filed But Not Yet Served Number</link:label>
    <link:label id="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_documentation_en-US" xlink:label="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency New Claims Filed But Not Yet Served Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:href="bhc-20220630.xsd#bhc_LossContingencyNewClaimsFiledButNotYetServedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:to="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_5bb0ab39-fd74-4ab5-8881-e530f347fbbf_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_f9b91f06-6a21-4c70-bb75-ae928feb1480_terseLabel_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting unit, impairment test, long-term growth rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_label_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Long-Term Growth Rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_documentation_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Long-Term Growth Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:href="bhc-20220630.xsd#bhc_ReportingUnitImpairmentTestLongTermGrowthRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:to="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7589c77b-d247-427b-ba2d-8137769180aa_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a2278523-7f68-4e0f-9f1c-a06a56cd996e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_19418113-decf-4151-a4ae-323bef65b650_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3e0f24a1-08a8-424b-b318-6b5f1c2f8a22_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_8371d7b0-8d0a-4f69-8b6b-93ea2bd39267_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_country_DE_24dd325d-6ef0-4dd9-b9f6-a874bbcf4bf0_terseLabel_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Germany</link:label>
    <link:label id="lab_country_DE_label_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GERMANY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE" xlink:to="lab_country_DE" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_1c92eef6-60d7-43be-8306-2e5f17486726_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Percentage of Net Cash Proceeds of Insurance and Condemnation Proceeds from Property or Asset Losses Payable as Mandatory Prepayments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of net cash proceeds of insurance and condemnation proceeds for property or asset (losses) which is payable as mandatory prepayment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:href="bhc-20220630.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:to="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_7bede76a-4a1d-4150-a89e-e7f814b35f65_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForDistributionFeesMember_90c95071-a63b-4ed8-9ea1-33688e986475_terseLabel_en-US" xlink:label="lab_bhc_ReserveForDistributionFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution Fees</link:label>
    <link:label id="lab_bhc_ReserveForDistributionFeesMember_label_en-US" xlink:label="lab_bhc_ReserveForDistributionFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Distribution Fees [Member]</link:label>
    <link:label id="lab_bhc_ReserveForDistributionFeesMember_documentation_en-US" xlink:label="lab_bhc_ReserveForDistributionFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Distribution Fees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDistributionFeesMember" xlink:href="bhc-20220630.xsd#bhc_ReserveForDistributionFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForDistributionFeesMember" xlink:to="lab_bhc_ReserveForDistributionFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SaleOfStockOverAllotmentTerm_adbdbd3f-e4d4-4a47-b21c-f0d7652119ea_terseLabel_en-US" xlink:label="lab_bhc_SaleOfStockOverAllotmentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters option to purchase additional shares, term</link:label>
    <link:label id="lab_bhc_SaleOfStockOverAllotmentTerm_label_en-US" xlink:label="lab_bhc_SaleOfStockOverAllotmentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Over-Allotment, Term</link:label>
    <link:label id="lab_bhc_SaleOfStockOverAllotmentTerm_documentation_en-US" xlink:label="lab_bhc_SaleOfStockOverAllotmentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Over-Allotment, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SaleOfStockOverAllotmentTerm" xlink:href="bhc-20220630.xsd#bhc_SaleOfStockOverAllotmentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SaleOfStockOverAllotmentTerm" xlink:to="lab_bhc_SaleOfStockOverAllotmentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_abe408a2-c1bb-4dd9-8e9f-d83371688831_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_6c09c508-f840-4fdd-bbf1-0fb9fa24c341_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7aacda6b-8816-444c-b894-349be46f45db_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_675476ac-8119-40b4-a175-14cb71558e2d_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured leverage ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Secured Leverage Ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Secured Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:to="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_96ad18a0-9542-48cb-84be-90e155509dab_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_6bba12a5-f165-48ae-9b0d-d6ee3b9dd7eb_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b399bf2b-2626-4043-8567-fe70bf886adb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_b5f7195b-aebd-41ca-bb01-c4d29fd0ed71_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_cd54469f-df84-4403-accb-6daeb45fc037_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_4d6b4a06-0cc7-4fb7-8aaa-c24f0955b8a9_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_56069eeb-fe71-4390-828f-32618c313777_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OvertheCounterProductsMember_5c545e34-05e7-467a-b920-7cfc6296a94f_terseLabel_en-US" xlink:label="lab_bhc_OvertheCounterProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC</link:label>
    <link:label id="lab_bhc_OvertheCounterProductsMember_label_en-US" xlink:label="lab_bhc_OvertheCounterProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over the Counter Products [Member]</link:label>
    <link:label id="lab_bhc_OvertheCounterProductsMember_documentation_en-US" xlink:label="lab_bhc_OvertheCounterProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over the Counter Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OvertheCounterProductsMember" xlink:href="bhc-20220630.xsd#bhc_OvertheCounterProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OvertheCounterProductsMember" xlink:to="lab_bhc_OvertheCounterProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_77569f92-0769-4bd7-beca-fd7cbc8e8e09_terseLabel_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits including interest and penalties</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_label_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Including Interest and Penalties</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_documentation_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The gross amount of unrecognized tax benefits including interest and penalties pertaining to uncertain tax positions taken in tax returns as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:href="bhc-20220630.xsd#bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:to="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_0346145b-5c28-4fd5-aea3-0fcc401f0ed8_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Line Items]</link:label>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_label_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Line Items]</link:label>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_documentation_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Schedule Of Other Income And Expenses [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:href="bhc-20220630.xsd#bhc_ScheduleOfOtherIncomeAndExpensesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:to="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_b0423cef-9bb8-4317-98af-7bc1bf043250_terseLabel_en-US" xlink:label="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR Performance-Based Restricted Stock Units</link:label>
    <link:label id="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR Performance-Based Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20220630.xsd#bhc_TSRPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5865cf82-7a14-4336-82f7-3820ad494537_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e7ef1dbc-6b51-42ab-9d45-95da9f6bf2f6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_ea656b08-e7a3-4cf7-bc96-1e3bed1c9397_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CA_689efe4d-8362-45ee-a4dc-47d488b92c2a_terseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada</link:label>
    <link:label id="lab_country_CA_label_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AmounPharmaceuticalCompanySAEMember_eeb7a3e0-a6f8-45ce-a1d4-3276a600d4d2_terseLabel_en-US" xlink:label="lab_bhc_AmounPharmaceuticalCompanySAEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amoun</link:label>
    <link:label id="lab_bhc_AmounPharmaceuticalCompanySAEMember_label_en-US" xlink:label="lab_bhc_AmounPharmaceuticalCompanySAEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amoun Pharmaceutical Company S.A.E [Member]</link:label>
    <link:label id="lab_bhc_AmounPharmaceuticalCompanySAEMember_documentation_en-US" xlink:label="lab_bhc_AmounPharmaceuticalCompanySAEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amoun Pharmaceutical Company S.A.E</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember" xlink:href="bhc-20220630.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AmounPharmaceuticalCompanySAEMember" xlink:to="lab_bhc_AmounPharmaceuticalCompanySAEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_3782188c-e087-4341-9320-5fa1a91c08ad_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of shares held</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Percentage of Ownership after Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_4461df46-f34e-453e-a795-5f055914c672_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance_b0cbba93-3e3f-401e-af58-2f96e0b51caf_terseLabel_en-US" xlink:label="lab_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares available for issuance (in shares)</link:label>
    <link:label id="lab_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance_label_en-US" xlink:label="lab_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Number Of Additional Shares Available For Issuance</link:label>
    <link:label id="lab_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance_documentation_en-US" xlink:label="lab_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Number Of Additional Shares Available For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance" xlink:href="bhc-20220630.xsd#bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance" xlink:to="lab_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermLoanBFacilityDueFebruary2027Member_363eeebf-dd1c-4308-8b13-460925c8d7a8_terseLabel_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due February 2027</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueFebruary2027Member_label_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due February 2027 [Member]</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueFebruary2027Member_documentation_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due February 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueFebruary2027Member" xlink:href="bhc-20220630.xsd#bhc_TermLoanBFacilityDueFebruary2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermLoanBFacilityDueFebruary2027Member" xlink:to="lab_bhc_TermLoanBFacilityDueFebruary2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NonExecutiveEligibleRecipientsMember_76a69ad3-da1d-4752-81a6-7f250731b260_terseLabel_en-US" xlink:label="lab_bhc_NonExecutiveEligibleRecipientsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Executive Eligible Recipients</link:label>
    <link:label id="lab_bhc_NonExecutiveEligibleRecipientsMember_label_en-US" xlink:label="lab_bhc_NonExecutiveEligibleRecipientsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Executive Eligible Recipients [Member]</link:label>
    <link:label id="lab_bhc_NonExecutiveEligibleRecipientsMember_documentation_en-US" xlink:label="lab_bhc_NonExecutiveEligibleRecipientsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Executive Eligible Recipients</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonExecutiveEligibleRecipientsMember" xlink:href="bhc-20220630.xsd#bhc_NonExecutiveEligibleRecipientsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NonExecutiveEligibleRecipientsMember" xlink:to="lab_bhc_NonExecutiveEligibleRecipientsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_4a11b99b-3504-4a8c-8453-7b2130c52efa_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_75ecc747-ac5d-41fc-90cc-e2546438ef6f_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_102b8249-84b1-4059-bc4e-69faeeec497d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_51099e15-378c-4292-99d1-f89235c6589e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_Legalsettlementsandrelatedfees_0df3371c-73c2-42da-9a91-864845467b50_terseLabel_en-US" xlink:label="lab_bhc_Legalsettlementsandrelatedfees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal matters and related fees</link:label>
    <link:label id="lab_bhc_Legalsettlementsandrelatedfees_label_en-US" xlink:label="lab_bhc_Legalsettlementsandrelatedfees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal settlements and related fees</link:label>
    <link:label id="lab_bhc_Legalsettlementsandrelatedfees_documentation_en-US" xlink:label="lab_bhc_Legalsettlementsandrelatedfees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal settlements and related fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_Legalsettlementsandrelatedfees" xlink:href="bhc-20220630.xsd#bhc_Legalsettlementsandrelatedfees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_Legalsettlementsandrelatedfees" xlink:to="lab_bhc_Legalsettlementsandrelatedfees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_25cbdc1d-235b-4da5-bd75-49fc8bdf7004_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_685e34b6-717a-4848-9efd-7dd8620eb698_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_label_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:to="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_19832b04-836e-4808-990d-0b21422db635_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f38a8527-91fd-49e3-ba7b-d3685a3d1994_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_dacfc8e8-286a-46cd-a2c0-a05c2af40f00_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_79c4e8f9-abf4-4e66-b824-c960b5aaf943_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_881eb75f-4a7d-4474-89cb-f54bf43d23bc_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b42000ca-93b7-4c45-903c-4a9406bb627e_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_57e7e4f8-5ffb-44a9-bb09-7a2b3ed2582e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_8d98890d-a504-4c53-a3ed-77a5f018e9ae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4b9fb8cd-6d6d-4447-ba9c-580093f3f3b0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_5db516bc-b8bf-46a9-ba77-d03acabf902e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_a28bfbe2-f5b3-4dc6-a758-1840b062a12a_terseLabel_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting unit, impairment test, estimated cash flows, discount rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_label_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_documentation_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:href="bhc-20220630.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:to="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_76616b06-ea4a-4038-8b88-fcb0d84f0267_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPayment_aaf95a1f-6aef-4352-a31f-60a6f489f1a4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly installment payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPayment_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPayment" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_6ba2367a-861b-4023-b804-36942a7dbfa0_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod_731e2707-e185-471a-9588-ce4f1600a6b0_terseLabel_en-US" xlink:label="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Highly liquid investments, maturity period (or less)</link:label>
    <link:label id="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod_label_en-US" xlink:label="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Highly Liquid Investments, Maturity Period</link:label>
    <link:label id="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod_documentation_en-US" xlink:label="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Highly Liquid Investments, Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:href="bhc-20220630.xsd#bhc_HighlyLiquidInvestmentsMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:to="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent_acbca18b-ae45-49d4-afe3-b6c9f09d71d1_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock plan, award type, percent</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Award Type, Percent</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Award Type, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" xlink:href="bhc-20220630.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7342c1f1-55d6-4ea3-956f-18e159b7168d_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_ea3477a0-a3f1-457b-a186-3aa80f7084c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of changes in the carrying amount of goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_022954f7-7f1a-43cf-ad61-c5c1e391a674_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic loss per share attributable to Bausch Health Companies Inc. (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_e9604081-bcd3-4d33-b56c-4b0c857c459a_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of annual excess cash flow</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Percentage of Consolidated Excess Cash Flow Payable as Mandatory Prepayments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of annual excess cash flow with any excess amounts after the prepayment of the loans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:href="bhc-20220630.xsd#bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:to="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember_30dfdfdd-8958-45d6-a12b-26cd7dd80009_terseLabel_en-US" xlink:label="lab_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation, Agreed Stipulations of Dismissal Submitted</link:label>
    <link:label id="lab_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember_label_en-US" xlink:label="lab_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation, Agreed Stipulations Of Dismissal Submitted [Member]</link:label>
    <link:label id="lab_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember_documentation_en-US" xlink:label="lab_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation, Agreed Stipulations Of Dismissal Submitted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" xlink:href="bhc-20220630.xsd#bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" xlink:to="lab_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RICOClassActionsMember_e54ef4e1-acc1-4e9c-8dfc-8c3594851c7b_terseLabel_en-US" xlink:label="lab_bhc_RICOClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RICO Class Actions</link:label>
    <link:label id="lab_bhc_RICOClassActionsMember_label_en-US" xlink:label="lab_bhc_RICOClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RICO Class Actions [Member]</link:label>
    <link:label id="lab_bhc_RICOClassActionsMember_documentation_en-US" xlink:label="lab_bhc_RICOClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RICO Class Actions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RICOClassActionsMember" xlink:href="bhc-20220630.xsd#bhc_RICOClassActionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RICOClassActionsMember" xlink:to="lab_bhc_RICOClassActionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_6a0fb811-fe61-438e-8933-965ce8ece107_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CanadianBankersAcceptanceRateMember_f64a562d-08e9-4969-9f39-9619d96512a4_terseLabel_en-US" xlink:label="lab_bhc_CanadianBankersAcceptanceRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BA Rate</link:label>
    <link:label id="lab_bhc_CanadianBankersAcceptanceRateMember_label_en-US" xlink:label="lab_bhc_CanadianBankersAcceptanceRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Bankers Acceptance Rate [Member]</link:label>
    <link:label id="lab_bhc_CanadianBankersAcceptanceRateMember_documentation_en-US" xlink:label="lab_bhc_CanadianBankersAcceptanceRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Bankers Acceptance Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadianBankersAcceptanceRateMember" xlink:href="bhc-20220630.xsd#bhc_CanadianBankersAcceptanceRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CanadianBankersAcceptanceRateMember" xlink:to="lab_bhc_CanadianBankersAcceptanceRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_fe31913e-19b5-4282-a3ce-1192a48670ad_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_0449275f-ecc8-4fb6-8030-c66e35c5fbd3_terseLabel_en-US" xlink:label="lab_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Perrigo Israel Pharmaceuticals, Ltd. Litigation</link:label>
    <link:label id="lab_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_label_en-US" xlink:label="lab_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Perrigo Israel Pharmaceuticals, Ltd. Litigation [Member]</link:label>
    <link:label id="lab_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_documentation_en-US" xlink:label="lab_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Perrigo Israel Pharmaceuticals, Ltd. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember" xlink:href="bhc-20220630.xsd#bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember" xlink:to="lab_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_f0f3f65b-4c90-46ac-a109-741b9797319c_negatedTerseLabel_en-US" xlink:label="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_label_en-US" xlink:label="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance For Foreign Exchange And Other</link:label>
    <link:label id="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_documentation_en-US" xlink:label="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance For Foreign Exchange And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:href="bhc-20220630.xsd#bhc_AccountsReceivableAllowanceForForeignExchangeAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:to="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_70de45ec-4a74-44cb-b6e6-66c09ebef4de_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_f523a9dd-0d11-4d0c-a373-af2c034182eb_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and postretirement benefit plan adjustments, net of income taxes</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_69799ec0-d4ec-45af-a1a2-740d691767d0_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured leverage ratio (not greater than)</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Secured Leverage Ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Secured Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:to="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_af1406c5-33b3-4da2-b5d4-8149e14af496_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_c0024807-ddce-463f-88c5-f2927f3dafb7_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_6e0e0200-3c86-4134-94f8-c19026c369c7_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages sought</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_b859131c-846a-4b3c-a26f-1e82a4f7b816_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_ba9b45c5-1db2-4d65-ae38-fad85fd379ba_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Bausch Health Companies Inc. shareholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_f101bd8f-7ab6-4022-98a5-4f54db289f17_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForCustomerReturnsMember_5ceae397-817e-4390-ba86-1ff3240f98e1_terseLabel_en-US" xlink:label="lab_bhc_ReserveForCustomerReturnsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_bhc_ReserveForCustomerReturnsMember_label_en-US" xlink:label="lab_bhc_ReserveForCustomerReturnsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Customer Returns [Member]</link:label>
    <link:label id="lab_bhc_ReserveForCustomerReturnsMember_documentation_en-US" xlink:label="lab_bhc_ReserveForCustomerReturnsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Customer Returns [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember" xlink:href="bhc-20220630.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForCustomerReturnsMember" xlink:to="lab_bhc_ReserveForCustomerReturnsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_ff57f384-be70-4714-920e-f89bcf03085f_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount_4b6e527e-eeb6-41e8-b6f7-865671ac34f4_terseLabel_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision related to filing certain tax returns</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount_label_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Expense Filing Tax Returns, Amount</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount_documentation_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Expense Filing Tax Returns, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:href="bhc-20220630.xsd#bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:to="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_3c491a02-080e-46b2-b11c-b11919bca0aa_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_08862ad5-7c37-43ed-8dfc-2842c38f3c67_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GainContingencyNumberOfDefendants_981bbfe7-4457-4418-891a-cbbcb9472cd4_terseLabel_en-US" xlink:label="lab_bhc_GainContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of defendants</link:label>
    <link:label id="lab_bhc_GainContingencyNumberOfDefendants_label_en-US" xlink:label="lab_bhc_GainContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number Of Defendants</link:label>
    <link:label id="lab_bhc_GainContingencyNumberOfDefendants_documentation_en-US" xlink:label="lab_bhc_GainContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number Of Defendants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyNumberOfDefendants" xlink:href="bhc-20220630.xsd#bhc_GainContingencyNumberOfDefendants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GainContingencyNumberOfDefendants" xlink:to="lab_bhc_GainContingencyNumberOfDefendants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f3c428e7-7ca8-4205-9c58-61e5d51ce420_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8fb985c2-01db-41ea-a3d5-4415a3194acc_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization and Impairments</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_420d3f4c-d234-46b2-b27d-9d4b025dc089_terseLabel_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation, Non-Class Complaints</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_label_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation, Non-Class Complaints [Member]</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_documentation_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation, Non-Class Complaints [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:href="bhc-20220630.xsd#bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:to="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BrandedandOtherGenericProductsMember_2f264d85-f03f-4fbc-ad30-5c4ad4a06fc4_terseLabel_en-US" xlink:label="lab_bhc_BrandedandOtherGenericProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded and Other Generics</link:label>
    <link:label id="lab_bhc_BrandedandOtherGenericProductsMember_label_en-US" xlink:label="lab_bhc_BrandedandOtherGenericProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded and Other Generic Products [Member]</link:label>
    <link:label id="lab_bhc_BrandedandOtherGenericProductsMember_documentation_en-US" xlink:label="lab_bhc_BrandedandOtherGenericProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded and Other Generic Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BrandedandOtherGenericProductsMember" xlink:href="bhc-20220630.xsd#bhc_BrandedandOtherGenericProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BrandedandOtherGenericProductsMember" xlink:to="lab_bhc_BrandedandOtherGenericProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_4dd78ad3-4ce4-4f36-965f-b2850d822a09_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_09b624cc-4557-4d50-96fb-553f12fdfa7f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_73e7edbb-40cc-45dd-b26a-359a4676de88_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_5709d85e-48b9-4f99-9c6d-e1164a168039_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_952da5c4-0642-471e-9417-3d2afd4d7123_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_93c7b2ec-2988-4148-8bf1-a74a0d2c3bcc_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_b51a9a16-0fa1-4706-adc4-5e849fc55ffc_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment reporting information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MilestonePaymentRelatedToCertainProductMember_b364e896-aea5-4cb6-b834-100ad5a459bd_terseLabel_en-US" xlink:label="lab_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Related To Certain Product</link:label>
    <link:label id="lab_bhc_MilestonePaymentRelatedToCertainProductMember_label_en-US" xlink:label="lab_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Related To Certain Product [Member]</link:label>
    <link:label id="lab_bhc_MilestonePaymentRelatedToCertainProductMember_documentation_en-US" xlink:label="lab_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Related To Certain Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:href="bhc-20220630.xsd#bhc_MilestonePaymentRelatedToCertainProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:to="lab_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_05a0802b-b888-42ab-8654-06073643826b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation and other matters</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_fbce0a2d-0f2c-4b4e-8985-c46a75f385ed_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_97dc99ba-6eff-4df8-bb94-5914509ed826_terseLabel_en-US" xlink:label="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROTC performance-based RSUs</link:label>
    <link:label id="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROTC Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROTC Performance-Based Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20220630.xsd#bhc_ROTCPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_df99d2ba-5486-4eff-86d9-7eb4d3887080_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes525DueJanuary2030Member_fa2f6d60-dcfe-424d-a74c-a1d593e2f554_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Notes Due January 2030</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueJanuary2030Member_label_en-US" xlink:label="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.25%, Due January 2030 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueJanuary2030Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Notes Due January 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes525DueJanuary2030Member" xlink:to="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f375d741-e25a-4714-a11f-8e3b9310ac18_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issued under share-based compensation plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AnnualAmortizationOfIntangibleAssets_06a0dbdd-4f83-4baa-b595-9819a1deb192_terseLabel_en-US" xlink:label="lab_bhc_AnnualAmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite lived intangible assets, annual amortization expense</link:label>
    <link:label id="lab_bhc_AnnualAmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_bhc_AnnualAmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Amortization Of Intangible Assets</link:label>
    <link:label id="lab_bhc_AnnualAmortizationOfIntangibleAssets_documentation_en-US" xlink:label="lab_bhc_AnnualAmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Amortization Of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AnnualAmortizationOfIntangibleAssets" xlink:href="bhc-20220630.xsd#bhc_AnnualAmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AnnualAmortizationOfIntangibleAssets" xlink:to="lab_bhc_AnnualAmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6e9a77a0-719f-4135-a08f-1c6ef535a540_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for future grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes700DueMarch2024Member_81368e6d-117f-4426-a7e5-c1db76ca8ce4_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes700DueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.00% Senior Notes, Due March 2024</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueMarch2024Member_label_en-US" xlink:label="lab_bhc_SeniorNotes700DueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.00%, Due March 2024 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueMarch2024Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes700DueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.00%, Due March 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueMarch2024Member" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes700DueMarch2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes700DueMarch2024Member" xlink:to="lab_bhc_SeniorNotes700DueMarch2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_3afb61e7-c8e7-49b8-a1a4-2da42374fc04_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestructuringAndIntegrationCostsMember_8f4b7928-8241-48b1-9edc-b94d40ceb1e1_terseLabel_en-US" xlink:label="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Integration Costs</link:label>
    <link:label id="lab_bhc_RestructuringAndIntegrationCostsMember_label_en-US" xlink:label="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Integration Costs [Member]</link:label>
    <link:label id="lab_bhc_RestructuringAndIntegrationCostsMember_documentation_en-US" xlink:label="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Integration Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndIntegrationCostsMember" xlink:href="bhc-20220630.xsd#bhc_RestructuringAndIntegrationCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestructuringAndIntegrationCostsMember" xlink:to="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_4eb15c32-0931-47ff-a161-cf2779c148b4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_ed98f681-1675-4193-a9a1-dbeb067523d5_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_9f4d0861-cc3c-4503-816c-f9a3ffcfa587_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of principal amount that can be redeemed</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_9bb1ac37-6241-4620-9aa0-23fba9f55293_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_62b1e3c2-9257-49ef-acc1-222df8f0273c_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_50e2df59-4f8b-489a-acb3-df24e75e0768_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_958eb231-5781-4965-9702-6f743b43ef8e_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount available for restricted payments</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Amount Available For Restricted Payments</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Amount Available For Restricted Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:to="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_5e3b124a-844b-4e42-b96e-1dce64533593_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and postretirement benefit plan adjustments, net of income taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PerformanceBasedRestrictedStockUnitsMember_3320bcab-baf2-425d-bd1d-35d5b02dffa5_terseLabel_en-US" xlink:label="lab_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units</link:label>
    <link:label id="lab_bhc_PerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_PerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20220630.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_a5e56951-f4a9-4670-a80f-00875a8dd465_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_dda2c3e8-aa63-4811-a598-26e5496c0a05_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain excluded from assessment of hedge effectiveness</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_InterestSettlementOnCrossCurrencySwaps_b41b6a2b-8e5d-45f1-a7dd-c70c25756fec_terseLabel_en-US" xlink:label="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest settlements from cross-currency swaps</link:label>
    <link:label id="lab_bhc_InterestSettlementOnCrossCurrencySwaps_label_en-US" xlink:label="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Settlement On Cross-Currency Swaps</link:label>
    <link:label id="lab_bhc_InterestSettlementOnCrossCurrencySwaps_documentation_en-US" xlink:label="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Settlement On Cross-Currency Swaps</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:href="bhc-20220630.xsd#bhc_InterestSettlementOnCrossCurrencySwaps"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:to="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_d6d6c79d-5746-4ee6-8472-71420526f2b2_terseLabel_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_label_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements Change in Amount of Contingent Consideration Asset Cash</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_documentation_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:href="bhc-20220630.xsd#bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:to="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_865d9871-2687-43ce-8e5a-fe44da264838_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PharmaceuticalProductsMember_47a5094f-d446-4cd2-8e9b-7b9eb61bfbba_terseLabel_en-US" xlink:label="lab_bhc_PharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceuticals</link:label>
    <link:label id="lab_bhc_PharmaceuticalProductsMember_label_en-US" xlink:label="lab_bhc_PharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Products [Member]</link:label>
    <link:label id="lab_bhc_PharmaceuticalProductsMember_documentation_en-US" xlink:label="lab_bhc_PharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PharmaceuticalProductsMember" xlink:href="bhc-20220630.xsd#bhc_PharmaceuticalProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PharmaceuticalProductsMember" xlink:to="lab_bhc_PharmaceuticalProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_14cf141a-0b6f-4fff-adcc-5b1d13d40de9_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured4875NotesDueJune2028Member_e95d3208-1fb4-4421-8c5f-d102d0e8bcc3_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.875% Senior Notes Due June 2028</link:label>
    <link:label id="lab_bhc_SeniorSecured4875NotesDueJune2028Member_label_en-US" xlink:label="lab_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 4.875% Notes Due June 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured4875NotesDueJune2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 4.875% Notes Due June 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:href="bhc-20220630.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:to="lab_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueJune2023Member_27595165-440a-4fff-8883-96dcf934d0f5_terseLabel_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due June 2023</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueJune2023Member_label_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due June 2023 [Member]</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueJune2023Member_documentation_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due June 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:href="bhc-20220630.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:to="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6added47-c177-483f-a302-e3d4d60da7ee_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_country_FR_deb37e6b-9b24-4ec2-a0eb-4f2a5a021585_terseLabel_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">France</link:label>
    <link:label id="lab_country_FR_label_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FRANCE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_FR" xlink:to="lab_country_FR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_82578828-940b-4541-9a29-213f21e02705_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PartnerRelationshipsMember_bee1de9e-7e23-4c8f-82cc-859c25d31f00_terseLabel_en-US" xlink:label="lab_bhc_PartnerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner relationships</link:label>
    <link:label id="lab_bhc_PartnerRelationshipsMember_label_en-US" xlink:label="lab_bhc_PartnerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner Relationships [Member]</link:label>
    <link:label id="lab_bhc_PartnerRelationshipsMember_documentation_en-US" xlink:label="lab_bhc_PartnerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to existing arrangements with various other entities, for which the entity provides regulatory, compliance, sales, marketing and distribution functions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember" xlink:href="bhc-20220630.xsd#bhc_PartnerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PartnerRelationshipsMember" xlink:to="lab_bhc_PartnerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_b08f39f8-aa6d-4ab7-ab7e-c2355b2bbe89_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_ac917015-87e5-46c8-b560-a8027c43a48a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_bf1f3d26-9bd9-4e51-b63a-d31f095f6545_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_0ded52a7-1d57-459d-8756-95d057bc196c_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb Trademark</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_b1d90e24-8d6d-4ed4-b909-ac6ae063d1c7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_8a9cc061-d5f4-44c0-a2d4-d4f4576a198f_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NorwichPharmaceuticalsIncLitigationMember_e8ae5397-c99a-4a43-9aad-6f7c60dc4f68_terseLabel_en-US" xlink:label="lab_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norwich Pharmaceuticals Inc. Litigation</link:label>
    <link:label id="lab_bhc_NorwichPharmaceuticalsIncLitigationMember_label_en-US" xlink:label="lab_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norwich Pharmaceuticals Inc. Litigation [Member]</link:label>
    <link:label id="lab_bhc_NorwichPharmaceuticalsIncLitigationMember_documentation_en-US" xlink:label="lab_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norwich Pharmaceuticals Inc. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:href="bhc-20220630.xsd#bhc_NorwichPharmaceuticalsIncLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:to="lab_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member_612a51f5-a5ac-4ab9-adfd-d86b85141edc_verboseLabel_en-US" xlink:label="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.75% Senior Notes Due August 2027</link:label>
    <link:label id="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member_label_en-US" xlink:label="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.75% Notes Due August 2027 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.75% Notes Due August 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:href="bhc-20220630.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:to="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_1712e5da-8259-4c7e-b5cf-ac9f518bc26f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_25d74383-0029-4293-be0e-b6796ad1d06d_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. Plans</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PlaintiffsDirectPurchasersMember_46fc75c6-b336-4739-8ebf-7e682be4b217_terseLabel_en-US" xlink:label="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiffs, Direct Purchasers</link:label>
    <link:label id="lab_bhc_PlaintiffsDirectPurchasersMember_label_en-US" xlink:label="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiffs, Direct Purchasers [Member]</link:label>
    <link:label id="lab_bhc_PlaintiffsDirectPurchasersMember_documentation_en-US" xlink:label="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiffs, Direct Purchasers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PlaintiffsDirectPurchasersMember" xlink:href="bhc-20220630.xsd#bhc_PlaintiffsDirectPurchasersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PlaintiffsDirectPurchasersMember" xlink:to="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_GB_cac662e1-6936-45ef-9c9a-09971e44342e_terseLabel_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom</link:label>
    <link:label id="lab_country_GB_label_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED KINGDOM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB" xlink:to="lab_country_GB" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_749ccff3-0948-4fd9-b788-cf7e863003d1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_b143c0e8-0746-41a7-bdd3-ddf4369365f2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_32785513-7873-47d7-85aa-06ba9b222fb8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion included in Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherRevenuesMember_c4fd3475-79df-4c12-a02f-34d055da7c25_terseLabel_en-US" xlink:label="lab_bhc_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_bhc_OtherRevenuesMember_label_en-US" xlink:label="lab_bhc_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues [Member]</link:label>
    <link:label id="lab_bhc_OtherRevenuesMember_documentation_en-US" xlink:label="lab_bhc_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherRevenuesMember" xlink:href="bhc-20220630.xsd#bhc_OtherRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherRevenuesMember" xlink:to="lab_bhc_OtherRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes850DueJanuary2027Member_f8c452c4-81ac-41d3-851b-32b83c030ba6_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.50% Senior Notes Due January 2027</link:label>
    <link:label id="lab_bhc_SeniorNotes850DueJanuary2027Member_label_en-US" xlink:label="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 8.50%, Due January 2027 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes850DueJanuary2027Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.50% Senior Notes Due January 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes850DueJanuary2027Member" xlink:to="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_06d91b2d-f045-41b8-ad83-b773c4cf6f4d_terseLabel_en-US" xlink:label="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LICENSING AGREEMENTS AND DIVESTITURE</link:label>
    <link:label id="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_label_en-US" xlink:label="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]</link:label>
    <link:label id="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_documentation_en-US" xlink:label="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:href="bhc-20220630.xsd#bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:to="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_0907adf1-5e8c-48a2-a79f-f65eade699f5_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_d86bfaba-1593-4d44-9679-3e068e5a4a61_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d510dea-82be-4ce8-8b32-4465eed59eb4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_eb5d9c5a-7521-4d34-ad98-c633aa4a4ee1_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_55b0c289-ee40-474f-8dca-96f9da0ad564_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation and IPO-related costs included in selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_0fc6ad15-c488-4e90-af6e-dcfb6a0b7759_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9695154a-80f2-45ec-a9c2-42806879e558_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OrthoDermatologicsReportingUnitMember_3d7c699c-4988-47c5-95c3-76a61028a30c_terseLabel_en-US" xlink:label="lab_bhc_OrthoDermatologicsReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Reporting Unit</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsReportingUnitMember_label_en-US" xlink:label="lab_bhc_OrthoDermatologicsReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Reporting Unit [Member]</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsReportingUnitMember_documentation_en-US" xlink:label="lab_bhc_OrthoDermatologicsReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Reporting Unit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsReportingUnitMember" xlink:href="bhc-20220630.xsd#bhc_OrthoDermatologicsReportingUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OrthoDermatologicsReportingUnitMember" xlink:to="lab_bhc_OrthoDermatologicsReportingUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_9d7f7990-f418-478d-8580-24f516f261ec_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1e49b1f0-e933-4cb9-97a4-d8fa1eacde0f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_ES_0055d413-678e-49ef-a443-6e679f7aa55b_terseLabel_en-US" xlink:label="lab_country_ES" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spain</link:label>
    <link:label id="lab_country_ES_label_en-US" xlink:label="lab_country_ES" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPAIN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_ES"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_ES" xlink:to="lab_country_ES" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_f8d5fe46-d608-4883-9f38-70e9ca4e5684_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCUMULATED OTHER COMPREHENSIVE LOSS</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage_6ed65a3b-0bb1-4d03-9970-f64c08f1562e_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual amortization rate (as a percent)</link:label>
    <link:label id="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage_label_en-US" xlink:label="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Annual Amortization Rate, Percentage</link:label>
    <link:label id="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Annual Amortization Rate, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentAnnualAmortizationRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:to="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_505f7892-b619-4307-a3a9-3e076cc6b8f8_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_8456ca6c-7184-4b7f-ad2c-656c90e3472b_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_7871a61a-043c-48cb-a24a-af9ae2807ecb_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_a0a4ee0d-e22e-4d2d-8317-e9a1733ede58_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_d4b6b50e-9797-470e-9c1a-a8869d2f8de7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_9054d9aa-9abf-4980-ba46-d1dc0000cd8a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share-based awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_f394d77e-a11f-4444-8a9d-5930f8219b54_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeNet_7cc689ad-46b1-4bee-aa5d-f99603334eeb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Fair Value, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A9.00SeniorNotesdueDecember2025Member_f8bd0848-03dd-4498-92f4-b120887f7215_terseLabel_en-US" xlink:label="lab_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes due December 2025</link:label>
    <link:label id="lab_bhc_A9.00SeniorNotesdueDecember2025Member_label_en-US" xlink:label="lab_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes due December 2025 [Member]</link:label>
    <link:label id="lab_bhc_A9.00SeniorNotesdueDecember2025Member_documentation_en-US" xlink:label="lab_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes due December 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:href="bhc-20220630.xsd#bhc_A9.00SeniorNotesdueDecember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:to="lab_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_4ae71494-ced5-4e84-a473-5342f7bce5db_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes500DueJanuary2028Member_241e5baa-5642-4d5f-81a6-136c446309a8_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Notes Due January 2028</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueJanuary2028Member_label_en-US" xlink:label="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.00%, Due January 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueJanuary2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Notes Due January 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes500DueJanuary2028Member" xlink:to="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_47a007f7-f2ff-49fa-9364-a1e243354a7f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PriceAppreciationCreditMember_4224bb05-35a0-4c0f-b1bf-d0ee02fa4c93_terseLabel_en-US" xlink:label="lab_bhc_PriceAppreciationCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Appreciation Credit</link:label>
    <link:label id="lab_bhc_PriceAppreciationCreditMember_label_en-US" xlink:label="lab_bhc_PriceAppreciationCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Appreciation Credit [Member]</link:label>
    <link:label id="lab_bhc_PriceAppreciationCreditMember_documentation_en-US" xlink:label="lab_bhc_PriceAppreciationCreditMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Appreciation Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PriceAppreciationCreditMember" xlink:href="bhc-20220630.xsd#bhc_PriceAppreciationCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PriceAppreciationCreditMember" xlink:to="lab_bhc_PriceAppreciationCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_825f210a-3bff-4aa2-922e-7c4a22b4dca8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_3a9fcf77-fcc2-4732-adc1-5dac48ee6535_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_3e7d9f9c-3061-4a45-b443-19a8d6a541a2_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_edcf421f-5bb1-4614-a2ba-6e3386307567_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_Goodwill_909c71b0-d8ab-464f-a52e-26b2849619f3_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_eb969245-8761-432b-ab3e-d04c9369b0fb_terseLabel_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and other settlement deposits</link:label>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_818bfd2f-1e75-4395-9a72-ca3518dcbd4c_verboseLabel_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and other settlement deposits</link:label>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_label_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Other Settlement Deposits, Current</link:label>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_documentation_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Other Settlement Deposits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:href="bhc-20220630.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:to="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationMember_73cfe882-ef3e-4711-9495-3b9ee5460588_terseLabel_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower to Shower Product Liability Litigation</link:label>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationMember_label_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower To Shower Product Liability Litigation [Member]</link:label>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationMember_documentation_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower to Shower Product Liability Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:href="bhc-20220630.xsd#bhc_ShowerToShowerProductLiabilityLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:to="lab_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8a6f3bb5-abff-4261-ac40-bcbff78b434a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_889eba3a-6cbf-4f89-a080-d61f76898268_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of contingent payment obligations measured on a recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c26f2df2-8751-41c1-ba7c-dcef2383ad93_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0de6d2dd-a3f4-46ea-bd62-d26be758ee21_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INTANGIBLE ASSETS AND GOODWILL</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock_62d6dc68-3ed8-4e52-b57b-37e422a74621_terseLabel_en-US" xlink:label="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</link:label>
    <link:label id="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock_label_en-US" xlink:label="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Activities And Initial Public Offering Costs Disclosure [Text Block]</link:label>
    <link:label id="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock_documentation_en-US" xlink:label="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Activities And Initial Public Offering Costs Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:href="bhc-20220630.xsd#bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:to="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5ef688cb-0ab6-429f-84de-f16fd8d9b99e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Provision for) benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_a356e546-9e57-4ecf-9f40-c907ddaa333b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember_4cbb8571-f7b0-48af-b70d-aa6c4ed1afb6_terseLabel_en-US" xlink:label="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighted Average Risk-Adjusted Discount Rate</link:label>
    <link:label id="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember_label_en-US" xlink:label="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighted-Average Discount Rate [Member]</link:label>
    <link:label id="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember_documentation_en-US" xlink:label="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighted-Average Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:href="bhc-20220630.xsd#bhc_MeasurementInputWeightedAverageDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:to="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_602d2919-e688-4a5e-8483-61e3af758786_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_dd62080e-e3ff-4145-8527-038232d14dd8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance against deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_23039d60-32f7-4fc5-9441-d579b04a98d9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_f0c9ac8b-44ee-4064-9175-59791e0bfbad_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_642edc8d-8d18-469e-a731-3fe783a1bdb7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_e6b4b560-56cb-4cdd-8823-585c4d69a2f1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_3b0d51ea-4e80-4046-b42d-81e3d7e1c07f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_961ff5e6-3b0f-4e17-9681-f28367bc07c6_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IPOFoundersGrantsMember_4218ea19-886b-4cb2-b353-0c9646823278_terseLabel_en-US" xlink:label="lab_bhc_IPOFoundersGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO Founders Grants</link:label>
    <link:label id="lab_bhc_IPOFoundersGrantsMember_label_en-US" xlink:label="lab_bhc_IPOFoundersGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO Founders Grants [Member]</link:label>
    <link:label id="lab_bhc_IPOFoundersGrantsMember_documentation_en-US" xlink:label="lab_bhc_IPOFoundersGrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO Founders Grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IPOFoundersGrantsMember" xlink:href="bhc-20220630.xsd#bhc_IPOFoundersGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IPOFoundersGrantsMember" xlink:to="lab_bhc_IPOFoundersGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_e49ed8ee-9fe6-42d6-9d93-ae34947b57ba_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_4d2fdcc4-b512-4432-bc32-7b7b9ce2ce1b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable_f04eb175-848a-47e4-95a2-458c2a24a00b_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Table]</link:label>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable_label_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Table]</link:label>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable_documentation_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:href="bhc-20220630.xsd#bhc_ScheduleOfOtherIncomeAndExpensesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:to="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_d51ac4d0-184e-47f6-914a-a81d5c7f7aee_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, redemption and discharge condition, amount, if circumstances met</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:to="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ConcentrationRiskNumberOfProducts_52521bcd-db1d-4b70-b78a-9d23b312aeec_terseLabel_en-US" xlink:label="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products represented of total revenue</link:label>
    <link:label id="lab_bhc_ConcentrationRiskNumberOfProducts_label_en-US" xlink:label="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number Of Products</link:label>
    <link:label id="lab_bhc_ConcentrationRiskNumberOfProducts_documentation_en-US" xlink:label="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number Of Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskNumberOfProducts" xlink:href="bhc-20220630.xsd#bhc_ConcentrationRiskNumberOfProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ConcentrationRiskNumberOfProducts" xlink:to="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_0341b1c8-6183-4925-a32b-1a58ff8b3f8d_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_d53a7339-6238-4062-b98e-52763342e9aa_terseLabel_en-US" xlink:label="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of research and development</link:label>
    <link:label id="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_label_en-US" xlink:label="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Research And Development Expense [Table Text Block]</link:label>
    <link:label id="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_documentation_en-US" xlink:label="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Research And Development Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:href="bhc-20220630.xsd#bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:to="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_58e75f40-4c71-4a12-bd12-9c78372983ab_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted-average common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_53814ea8-540e-4b9e-b0af-0ea2c62d4340_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted-average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_9a42b498-53ef-42de-8936-743ab0c4ef8a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_d01c16ad-e7cf-4abb-aa48-a6b798030078_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_XifaxanBrandedProductsMember_5188321c-87a7-4af0-898f-5aeae7be135e_terseLabel_en-US" xlink:label="lab_bhc_XifaxanBrandedProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xifaxan Branded Products</link:label>
    <link:label id="lab_bhc_XifaxanBrandedProductsMember_label_en-US" xlink:label="lab_bhc_XifaxanBrandedProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xifaxan Branded Products [Member]</link:label>
    <link:label id="lab_bhc_XifaxanBrandedProductsMember_documentation_en-US" xlink:label="lab_bhc_XifaxanBrandedProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xifaxan Branded Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_XifaxanBrandedProductsMember" xlink:href="bhc-20220630.xsd#bhc_XifaxanBrandedProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_XifaxanBrandedProductsMember" xlink:to="lab_bhc_XifaxanBrandedProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_57ffae54-f387-4d38-9ff2-e2b9df7b27e4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the components of inventories, net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_c14dc359-1a02-4993-9b35-7baa2e2ec6a2_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8890cfa1-fc46-4e75-ab58-a33f42f4dcd1_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_f18d8d08-bffc-4478-97bf-b175706df3fd_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_69f8eaea-688f-4213-8a08-666a4837d4e5_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_c3342a93-a112-4ba5-9f88-02748cf5605a_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of groups of investors filing action</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_label_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_documentation_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:href="bhc-20220630.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:to="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_5bbebf23-eb32-4294-a99e-ce942529552e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of countries in which entity operates</link:label>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Countries in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes925DueApril2026Member_d657d5a7-98e1-4372-bebe-087acf1af1ba_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes925DueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.25% Senior Notes Due April 2026</link:label>
    <link:label id="lab_bhc_SeniorNotes925DueApril2026Member_label_en-US" xlink:label="lab_bhc_SeniorNotes925DueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 9.25%, Due April 2026 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes925DueApril2026Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes925DueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.25% Senior Notes Due April 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes925DueApril2026Member" xlink:to="lab_bhc_SeniorNotes925DueApril2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember_90e447a0-62e7-48a7-b686-15b978af3e73_terseLabel_en-US" xlink:label="lab_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision Care, Surgical And Ophthalmic Reporting Units</link:label>
    <link:label id="lab_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember_label_en-US" xlink:label="lab_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision Care, Surgical And Ophthalmic Reporting Units [Member]</link:label>
    <link:label id="lab_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember_documentation_en-US" xlink:label="lab_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision Care, Surgical And Ophthalmic Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember" xlink:href="bhc-20220630.xsd#bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember" xlink:to="lab_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_340965b6-a7f4-44c6-a811-236db8d068f3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, no par value, unlimited shares authorized, 361,571,921 and 359,405,748 issued and outstanding at June 30, 2022 and December&#160;31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_08d4ccdb-f1c7-4d81-87d1-788bccedc75f_terseLabel_en-US" xlink:label="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_label_en-US" xlink:label="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration Fair Value Disclosure</link:label>
    <link:label id="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_documentation_en-US" xlink:label="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement which may include cash and shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:href="bhc-20220630.xsd#bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:to="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_eab3483b-028d-4b03-ba3c-30ea6ac1ce03_terseLabel_en-US" xlink:label="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-based RSUs, Performance-based RSUs and Stock Options</link:label>
    <link:label id="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20220630.xsd#bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_6e5791f8-0b14-4bbe-a7d4-edc7b50f4dbc_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed charge coverage ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:to="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_5c927a7b-9a7a-44bf-993f-8242028fd1d5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_InsuranceCoverageLawsuitMember_b87e887d-e31c-4818-9869-df87dcf4dee8_terseLabel_en-US" xlink:label="lab_bhc_InsuranceCoverageLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Lawsuit</link:label>
    <link:label id="lab_bhc_InsuranceCoverageLawsuitMember_label_en-US" xlink:label="lab_bhc_InsuranceCoverageLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Lawsuit [Member]</link:label>
    <link:label id="lab_bhc_InsuranceCoverageLawsuitMember_documentation_en-US" xlink:label="lab_bhc_InsuranceCoverageLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Lawsuit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InsuranceCoverageLawsuitMember" xlink:href="bhc-20220630.xsd#bhc_InsuranceCoverageLawsuitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_InsuranceCoverageLawsuitMember" xlink:to="lab_bhc_InsuranceCoverageLawsuitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9dbc7208-160e-41c2-bdb6-a0cb07594234_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_2af9d477-8196-46db-84eb-7d50f4d28c42_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales return provisions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_f62a0e48-a57c-4536-812d-1059ac948970_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period provisions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_2ad07f6a-17f3-4420-a2d4-85ad61213064_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_57cd5118-f645-4a6b-8c0b-4a4e6ae67226_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_99e4f725-11fd-441f-a2f0-6e54c44b503b_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price percentage to change in control (as a percent)</link:label>
    <link:label id="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_label_en-US" xlink:label="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage, Change in Control</link:label>
    <link:label id="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage, Change in Control</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:to="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate_bfcd2fa4-e008-427c-9400-829f8bb0d286_terseLabel_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting unit, impairment test, estimated cash flows, change in discount rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate_label_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Estimated Cash Flows, Increase (Decrease) In Discount Rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate_documentation_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Estimated Cash Flows, Increase (Decrease) In Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" xlink:href="bhc-20220630.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" xlink:to="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_f3c61a29-f46c-4658-95b6-ae7a4088da48_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components and classification of financial assets and liabilities measured at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_edd3a3ed-0198-4d74-9692-779c00c22a04_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segment</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_dcd5096a-67fe-4457-b85a-68a4db229d38_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_d2e42e3c-284b-4297-a556-189edba3d363_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss related to settlements</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_45ccb4eb-656b-44e2-90d2-70ee262de20a_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_ddd79ebb-db27-465d-902d-13750d34b97e_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_cd82bac3-34a2-4a8e-bb3e-8c695deca461_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefit, amount possible to decrease in next twelve months</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SalixSegmentMember_4bb32abf-be19-4b00-9e81-13348fba55ac_terseLabel_en-US" xlink:label="lab_bhc_SalixSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix</link:label>
    <link:label id="lab_bhc_SalixSegmentMember_label_en-US" xlink:label="lab_bhc_SalixSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix Segment [Member]</link:label>
    <link:label id="lab_bhc_SalixSegmentMember_documentation_en-US" xlink:label="lab_bhc_SalixSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember" xlink:href="bhc-20220630.xsd#bhc_SalixSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SalixSegmentMember" xlink:to="lab_bhc_SalixSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AssetImpairmentChargesMember_819c95bc-c5ba-42fd-bf89-63b755f9c9a9_terseLabel_en-US" xlink:label="lab_bhc_AssetImpairmentChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments, including loss on assets held for sale</link:label>
    <link:label id="lab_bhc_AssetImpairmentChargesMember_label_en-US" xlink:label="lab_bhc_AssetImpairmentChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges [Member]</link:label>
    <link:label id="lab_bhc_AssetImpairmentChargesMember_documentation_en-US" xlink:label="lab_bhc_AssetImpairmentChargesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetImpairmentChargesMember" xlink:href="bhc-20220630.xsd#bhc_AssetImpairmentChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AssetImpairmentChargesMember" xlink:to="lab_bhc_AssetImpairmentChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5322cdd1-5466-44ce-97a3-5a4f893f979b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash and other settlement deposits, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_72519371-0bbf-47e6-8a44-8f67ffddca4e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash and other settlement deposits, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0c424d4b-9590-40d6-91e0-f5d68abe53e4_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash and other settlement deposits, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes525DueFebruary2031Member_1622a77e-230f-4241-ac21-3cbb83d8ba24_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Notes Due February 2031</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueFebruary2031Member_label_en-US" xlink:label="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.25%, Due February 2031 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueFebruary2031Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.25%, Due February 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes525DueFebruary2031Member" xlink:to="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_38152cfe-8e09-4bed-a592-0f0bef32ef22_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilityMember_e21cc312-aaff-43ae-8202-8789aba164da_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facility</link:label>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilityMember_label_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facility [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilityMember_documentation_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilityMember" xlink:href="bhc-20220630.xsd#bhc_SeniorSecuredCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecuredCreditFacilityMember" xlink:to="lab_bhc_SeniorSecuredCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_de3d4a37-e6e6-4955-8a0b-0f672f80f26d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_3d0ee16f-7722-4d06-9c07-f106c3e6c757_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated goodwill impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_717658d9-9601-419a-87f1-86b16b150479_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_0a244205-ef51-4090-915d-4bb157aad06b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of long-term debt, net of discounts</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_11ce1164-3444-46f2-bbbc-bd15b2e3b557_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d2ac0718-2239-4995-9944-4f3f63ac4530_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_91ddc289-f558-4d29-a48d-1929b140f164_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PreserVisionAREDSPatentLitigationMember_0884a3be-d883-42d0-aecb-796d3594e1d2_terseLabel_en-US" xlink:label="lab_bhc_PreserVisionAREDSPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PreserVision&#174; AREDS Patent Litigation</link:label>
    <link:label id="lab_bhc_PreserVisionAREDSPatentLitigationMember_label_en-US" xlink:label="lab_bhc_PreserVisionAREDSPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PreserVision&#174; AREDS Patent Litigation [Member]</link:label>
    <link:label id="lab_bhc_PreserVisionAREDSPatentLitigationMember_documentation_en-US" xlink:label="lab_bhc_PreserVisionAREDSPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PreserVision&#174; AREDS Patent Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PreserVisionAREDSPatentLitigationMember" xlink:href="bhc-20220630.xsd#bhc_PreserVisionAREDSPatentLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PreserVisionAREDSPatentLitigationMember" xlink:to="lab_bhc_PreserVisionAREDSPatentLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_36ed8431-042b-4423-9ee4-ba1a5158a171_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest coverage ratio (not less than)</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:to="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_3e5d997a-5f09-4071-a5fe-2f09fc373200_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch Health Companies&#160;Inc. Shareholders&#8217; Deficit</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_13faa960-d2cf-4e72-9ebd-534cc4eaa5b5_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_15f1846e-5638-45aa-b367-14ae97ecbaf7_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_5b8de698-e8c5-4ee2-8b98-49f90983be12_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_edbd22e8-7cbb-442b-bfab-bd2d37176966_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a34c30ed-d4a9-480a-98b4-0afe3ac07c88_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalPeriod_80ff4c23-afa8-499c-8cb5-45cea011120e_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stay of approval, period</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalPeriod_label_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Period</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalPeriod_documentation_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalPeriod" xlink:href="bhc-20220630.xsd#bhc_LossContingencyStayOfApprovalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyStayOfApprovalPeriod" xlink:to="lab_bhc_LossContingencyStayOfApprovalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable_b2274a3c-f8a9-41e8-8a75-259e108868e4_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate, if rate not ascertainable (as a percent)</link:label>
    <link:label id="lab_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable_label_en-US" xlink:label="lab_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread On Variable Rate, If Rate Not Ascertainable</link:label>
    <link:label id="lab_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread On Variable Rate, If Rate Not Ascertainable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" xlink:to="lab_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain_9ef078c6-4417-4a8f-b8f4-6b9be152f680_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain related to settlements</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_89ee50fb-e134-4a3c-8828-861419afef2f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0fab2d50-255f-4c36-9e26-a3e32015cb14_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite lived intangible assets, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_68d09692-51e3-4193-a3d0-a462e1e25dbf_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_81b0e30f-56a7-4efc-a9c5-10fd05818ed8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_country_KR_6c90733b-79bc-4865-83bc-bd9f6a3fe286_terseLabel_en-US" xlink:label="lab_country_KR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">South Korea</link:label>
    <link:label id="lab_country_KR_label_en-US" xlink:label="lab_country_KR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KOREA, REPUBLIC OF</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_KR" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_KR" xlink:to="lab_country_KR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_9fc50f03-e98c-4792-9792-3b3000a8a1ca_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of suits filed</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_39307032-43b6-4d27-a407-f71c46add89b_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of putative antitrust class actions filed</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c5aa5fdf-9901-4ab3-9409-7396a668e1c7_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7f1dbb47-861b-42d6-b02a-586c547c4823_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_35e23830-80e6-4ca1-b7cd-9ad9ead1c265_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IT_0cea2ae5-4b60-4e86-a4c4-368f674def2e_terseLabel_en-US" xlink:label="lab_country_IT" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Italy</link:label>
    <link:label id="lab_country_IT_label_en-US" xlink:label="lab_country_IT" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ITALY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IT"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IT" xlink:to="lab_country_IT" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025Member_165aed7f-fe2c-4897-8291-925070c7e5eb_verboseLabel_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025Member_label_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025 [Member]</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025Member_documentation_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member" xlink:href="bhc-20220630.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermLoanBFacilityDueJune2025Member" xlink:to="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_3c66a386-8f40-4dcd-9e4e-5459baf294b9_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_973ca075-8810-4590-981f-34bfff4debae_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite Lived and Indefinite Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_label_en-US" xlink:label="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite Lived and Indefinite Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_documentation_en-US" xlink:label="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of the carrying value of amortizable and nonamortizable intangibles assets, in total and by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:href="bhc-20220630.xsd#bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:to="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio_23bb495b-ccf2-440e-8b5c-035f5cb1f530_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total leverage ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Total Leverage Ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Total Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:to="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_9d342044-fdd1-4ac6-b977-f7224e21b5f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of segment revenues and profit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_c20ec884-d8a7-4983-9969-56bce94a541f_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_599506de-74e0-4d89-b17d-ae816d856ac5_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_be1b50ce-7fb9-452e-ba7c-3601168cd366_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_10b0a66d-9695-477f-b92c-9ba9603439b3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TimeBasedRSUMember_1d14c5c8-9ceb-46d2-8db1-051037c9bdaa_terseLabel_en-US" xlink:label="lab_bhc_TimeBasedRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-based RSUs</link:label>
    <link:label id="lab_bhc_TimeBasedRSUMember_label_en-US" xlink:label="lab_bhc_TimeBasedRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based RSU [Member]</link:label>
    <link:label id="lab_bhc_TimeBasedRSUMember_documentation_en-US" xlink:label="lab_bhc_TimeBasedRSUMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents stock awards in the form of time-based restricted stock units (RSUs) to certain directors, officers and other eligible employees pursuant to the company's incentive compensation plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TimeBasedRSUMember" xlink:href="bhc-20220630.xsd#bhc_TimeBasedRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TimeBasedRSUMember" xlink:to="lab_bhc_TimeBasedRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_527748a7-d4ac-402f-a5e5-38a7457e01e0_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GainLossRelatedToLitigationSettlementGross_9ca07fc6-2a3b-4223-9751-cc8032f924ae_negatedLabel_en-US" xlink:label="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to accrued legal settlements</link:label>
    <link:label id="lab_bhc_GainLossRelatedToLitigationSettlementGross_label_en-US" xlink:label="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related To Litigation Settlement, Gross</link:label>
    <link:label id="lab_bhc_GainLossRelatedToLitigationSettlementGross_documentation_en-US" xlink:label="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement, Gross payments not offset by insurance proceeds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainLossRelatedToLitigationSettlementGross" xlink:href="bhc-20220630.xsd#bhc_GainLossRelatedToLitigationSettlementGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GainLossRelatedToLitigationSettlementGross" xlink:to="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA-BC_6f37021d-85dd-4191-82db-23cb8162a70f_terseLabel_en-US" xlink:label="lab_stpr_CA-BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BRITISH COLUMBIA</link:label>
    <link:label id="lab_stpr_CA-BC_label_en-US" xlink:label="lab_stpr_CA-BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BRITISH COLUMBIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-BC" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA-BC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA-BC" xlink:to="lab_stpr_CA-BC" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_45c7485a-8b34-4261-bb31-8ce67a84729c_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BauschLombToBeDistributedToOtherLegalEntitiesMember_9881690e-cdb5-4c4f-861f-05f25d62956f_terseLabel_en-US" xlink:label="lab_bhc_BauschLombToBeDistributedToOtherLegalEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb. To Be Distributed To Other Legal Entities</link:label>
    <link:label id="lab_bhc_BauschLombToBeDistributedToOtherLegalEntitiesMember_label_en-US" xlink:label="lab_bhc_BauschLombToBeDistributedToOtherLegalEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb. To Be Distributed To Other Legal Entities [Member]</link:label>
    <link:label id="lab_bhc_BauschLombToBeDistributedToOtherLegalEntitiesMember_documentation_en-US" xlink:label="lab_bhc_BauschLombToBeDistributedToOtherLegalEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb. To Be Distributed To Other Legal Entities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombToBeDistributedToOtherLegalEntitiesMember" xlink:href="bhc-20220630.xsd#bhc_BauschLombToBeDistributedToOtherLegalEntitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BauschLombToBeDistributedToOtherLegalEntitiesMember" xlink:to="lab_bhc_BauschLombToBeDistributedToOtherLegalEntitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_51ecc09a-b307-4f58-a68d-f27ad9b5b2d8_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee (as a percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_30fb95c3-4d7f-48b7-8cf7-bbdd35e39ec6_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_f2173a39-df59-4c1c-8d0b-d02b30aa32c4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DefaultJudgementMember_d66ff53c-32c2-407e-8c19-2fae3cbac637_terseLabel_en-US" xlink:label="lab_bhc_DefaultJudgementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Default Judgement</link:label>
    <link:label id="lab_bhc_DefaultJudgementMember_label_en-US" xlink:label="lab_bhc_DefaultJudgementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Default Judgement [Member]</link:label>
    <link:label id="lab_bhc_DefaultJudgementMember_documentation_en-US" xlink:label="lab_bhc_DefaultJudgementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Default Judgement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefaultJudgementMember" xlink:href="bhc-20220630.xsd#bhc_DefaultJudgementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DefaultJudgementMember" xlink:to="lab_bhc_DefaultJudgementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForDiscountsAndAllowancesMember_c630e250-344d-4548-bfef-ede37cf71956_terseLabel_en-US" xlink:label="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts and Allowances</link:label>
    <link:label id="lab_bhc_ReserveForDiscountsAndAllowancesMember_label_en-US" xlink:label="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Discounts And Allowances [Member]</link:label>
    <link:label id="lab_bhc_ReserveForDiscountsAndAllowancesMember_documentation_en-US" xlink:label="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Discounts And Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDiscountsAndAllowancesMember" xlink:href="bhc-20220630.xsd#bhc_ReserveForDiscountsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForDiscountsAndAllowancesMember" xlink:to="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_449b3d97-461d-4390-8f78-d5909fdde3c3_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember_23472172-faae-4b44-adbb-9decbad3d58e_terseLabel_en-US" xlink:label="lab_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">B+L Separation performance-based RSUs</link:label>
    <link:label id="lab_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation Performance-Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20220630.xsd#bhc_SeparationPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_5fe2e15b-dab8-476a-83e9-1975723541a3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of possible loss, income tax examination (up to)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:to="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_508f3798-e5f1-4a69-a81c-083174a3528d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income Loss [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0696779f-b52d-4a08-9cf8-f47c48c717c2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized premiums, discounts and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods_cf188149-4f1b-4ff9-abc7-7449bcea21e6_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distinct insurance policy periods</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods_label_en-US" xlink:label="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Insurance Policy Periods</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods_documentation_en-US" xlink:label="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Insurance Policy Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:href="bhc-20220630.xsd#bhc_LossContingencyNumberOfInsurancePolicyPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:to="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_97fe2799-1dde-4fd6-95b9-6c67384cdaa2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED AND OTHER CURRENT LIABILITIES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes500DueFebruary2029Member_3b653630-79f0-42a6-9294-2090a2aaad59_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Notes Due February 2029</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueFebruary2029Member_label_en-US" xlink:label="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.00%, Due February 2029 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueFebruary2029Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.00%, Due February 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes500DueFebruary2029Member" xlink:to="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_fe3f98e8-5486-43c7-86e3-28f1c74ee300_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current accrued loss contingencies</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_69ad3c4c-b7d0-4d95-87bc-efe21e782398_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">B+L IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_25f067cc-1982-48e2-8eab-d7ae4341eea6_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_24356b7e-235f-4557-9411-792124598d81_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f39e72d0-06cc-43e4-9c18-6e4c01cf7417_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and other</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_35d8e852-2c4d-41b5-bd7d-c4c017975a44_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_58720458-fb65-4f75-9db4-4a02065ef781_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount_77e5ecd3-2170-4602-ae6f-10816d581459_terseLabel_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision related to withholding tax, intercompany dividends</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount_label_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Withholding Tax, Intercompany Dividends, Amount</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount_documentation_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Withholding Tax, Intercompany Dividends, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount" xlink:href="bhc-20220630.xsd#bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount" xlink:to="lab_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_415172a0-797e-487f-8f7e-39b7b149a6e3_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_1aec6068-e1b2-42f5-a6f8-69f3798a52d6_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_9e47bd34-b849-4cce-9500-c1c50bb1ea23_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of estimated aggregate amortization expense for each of the five succeeding years</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3275bb65-3fd7-410b-9143-87d5cc44cfb4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_e13f6922-eef1-49ef-880e-db95c2726e25_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_35e2bf2e-581b-42fa-ab33-a7b1de1e06e9_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_719c78e2-88fd-46bd-a216-5dfa855cd110_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_a783d9bd-8a4c-4f78-94e4-74104e1f0434_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER EXPENSE, NET</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes700DueJanuary2028Member_ec1fab6b-4b86-49c9-862d-cef3a0a621a7_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.00 % Senior Notes Due January 2028</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueJanuary2028Member_label_en-US" xlink:label="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.00%, Due January 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueJanuary2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes 7.00 Percent Due January 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes700DueJanuary2028Member" xlink:to="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_a5e8ec50-87ce-428c-ab35-0754268668ac_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_e62a13ae-cfe3-4c90-bba7-0cd4207c6a50_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense (income), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_d486e152-ad4a-40f0-b441-ab3c65e0ce55_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_8f5cb0b1-97e0-4527-985c-e666ea7beb97_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount drawn under credit facility</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_46463486-62f8-47dd-96cb-7af2cd7c92a9_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b6322690-200f-4aa4-a6c7-d191a1fdc76f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_53fbc9bc-25d1-48f0-b379-798a90de472d_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price of shares sold (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_d2597c69-89f0-46f6-992a-b43a76671e14_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) related to changes in fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_3a6c0045-2f5c-465d-b5dc-413d5965a939_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e682e4b5-d10a-462d-995d-0c913189b9c9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_9316a789-857b-45c5-bad1-ab4ae3b486a2_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_11991708-2da1-4d2c-bbc1-6d4c6b0217f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of revenues by segment and product category</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_208b71f5-ca3a-4bd6-ba62-ee8189ce0bc5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_country_PL_cf77afc1-86a5-4441-8398-2742ac050e63_terseLabel_en-US" xlink:label="lab_country_PL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Poland</link:label>
    <link:label id="lab_country_PL_label_en-US" xlink:label="lab_country_PL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">POLAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_PL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_PL" xlink:to="lab_country_PL" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeviceProductsMember_5c68186b-c316-49f0-9007-e529a88aa06a_terseLabel_en-US" xlink:label="lab_bhc_DeviceProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Devices</link:label>
    <link:label id="lab_bhc_DeviceProductsMember_label_en-US" xlink:label="lab_bhc_DeviceProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Products [Member]</link:label>
    <link:label id="lab_bhc_DeviceProductsMember_documentation_en-US" xlink:label="lab_bhc_DeviceProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeviceProductsMember" xlink:href="bhc-20220630.xsd#bhc_DeviceProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeviceProductsMember" xlink:to="lab_bhc_DeviceProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_945174e0-9e8f-469e-8374-adc417077fa1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_2b6157e2-df16-40bf-b593-79a4c8bd7aba_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options and RSUs</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d1207bb6-7712-48b9-8cad-266952063396_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_1a747b59-72ab-4a9a-b52c-f797ee01b9c5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_01c16ded-0bce-4b31-b60a-7084052d03b2_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_f247a8e8-3beb-453b-bb67-c2d80bb4e5d2_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b04d7397-29ce-4d45-8066-f39da71d4e59_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_f47509e4-7783-4311-9378-b34a93a694ba_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_1c51095b-3fee-4099-a2d6-07bdbbfebd26_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of accrued legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_518c77e4-1294-496b-be6c-e264b5fd8131_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realignment of segment goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_b0b9a33e-5421-4f56-8de1-9ac0b196c354_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_7558f827-735d-4491-bd2e-ae019b256209_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Smaller Reporting Company</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_83b7d58c-4fbf-4e88-9e4e-372f407a4168_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_af333020-4a01-4bec-86a4-96f6055fb745_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_b8c9b0c4-1b78-4bc6-9092-ace1f41490fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NJ_354f5b5c-d85b-4aad-96a2-b9cab8d17ea1_terseLabel_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW JERSEY</link:label>
    <link:label id="lab_stpr_NJ_4b7aa8e7-342c-485b-8a52-eda31c51493a_verboseLabel_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey</link:label>
    <link:label id="lab_stpr_NJ_label_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW JERSEY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NJ" xlink:to="lab_stpr_NJ" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_764a5a1d-f5fc-4066-9fd2-c18f84d0a66d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_f03b1bbe-2a19-49e6-8993-a0951d443623_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_67c620a6-6b5e-4512-acb2-8b52313d31fc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnitedStatesandPuertoRicoMember_79ced248-daa0-4fec-a0a7-a6a225d3f096_terseLabel_en-US" xlink:label="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. and Puerto Rico</link:label>
    <link:label id="lab_bhc_UnitedStatesandPuertoRicoMember_label_en-US" xlink:label="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States and Puerto Rico [Member]</link:label>
    <link:label id="lab_bhc_UnitedStatesandPuertoRicoMember_documentation_en-US" xlink:label="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States and Puerto Rico [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember" xlink:href="bhc-20220630.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnitedStatesandPuertoRicoMember" xlink:to="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0787ebc7-ce00-4aa2-b64d-9fa7d94c3078_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bc5b4aee-f8ed-4233-ae3e-8746bacccaae_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining unrecognized compensation expense related to non-vested awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DiversifiedProductsSegmentMember_40263c30-a0f8-467e-b5d6-eead030e6159_terseLabel_en-US" xlink:label="lab_bhc_DiversifiedProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diversified Products</link:label>
    <link:label id="lab_bhc_DiversifiedProductsSegmentMember_label_en-US" xlink:label="lab_bhc_DiversifiedProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diversified Products Segment [Member]</link:label>
    <link:label id="lab_bhc_DiversifiedProductsSegmentMember_documentation_en-US" xlink:label="lab_bhc_DiversifiedProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diversified Products Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember" xlink:href="bhc-20220630.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DiversifiedProductsSegmentMember" xlink:to="lab_bhc_DiversifiedProductsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueFebruary2027Member_b4a4832f-c33c-4034-9dfb-80659ecd153e_terseLabel_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due February 2027</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueFebruary2027Member_label_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due February 2027 [Member]</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueFebruary2027Member_documentation_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due February 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member" xlink:href="bhc-20220630.xsd#bhc_RevolvingCreditFacilityDueFebruary2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member" xlink:to="lab_bhc_RevolvingCreditFacilityDueFebruary2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_f90949da-fda8-4803-80bc-fcb518c48459_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternate term, principal amount maturity threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_label_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Principal Amount Maturity Threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Principal Amount Maturity Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:to="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccruedProductRebateCurrent_541f6507-128d-46c7-9626-05d60177a974_terseLabel_en-US" xlink:label="lab_bhc_AccruedProductRebateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product rebates</link:label>
    <link:label id="lab_bhc_AccruedProductRebateCurrent_label_en-US" xlink:label="lab_bhc_AccruedProductRebateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Product Rebate Current</link:label>
    <link:label id="lab_bhc_AccruedProductRebateCurrent_documentation_en-US" xlink:label="lab_bhc_AccruedProductRebateCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the current portion of accrued product rebates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductRebateCurrent" xlink:href="bhc-20220630.xsd#bhc_AccruedProductRebateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccruedProductRebateCurrent" xlink:to="lab_bhc_AccruedProductRebateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember_0a5586e3-5371-4af3-b465-9c830081004c_terseLabel_en-US" xlink:label="lab_bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Reporting Units, Excluding Ortho Dermatologics, Vision Care, Surgical and Ophthalmic</link:label>
    <link:label id="lab_bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember_label_en-US" xlink:label="lab_bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Reporting Units, Excluding Ortho Dermatologics, Vision Care, Surgical And Ophthalmic [Member]</link:label>
    <link:label id="lab_bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember_documentation_en-US" xlink:label="lab_bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Reporting Units, Excluding Ortho Dermatologics, Vision Care, Surgical And Ophthalmic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember" xlink:href="bhc-20220630.xsd#bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember" xlink:to="lab_bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ec267294-f0b0-447d-84ac-a144652ff576_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6a6d5b39-f310-4c4e-871f-1e3233a39c8e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_1889a3b0-9f5e-4894-98d9-bca540600091_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5f5f5854-547c-451b-95b7-35670c72cc21_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_1ae5a5a2-c38f-4214-8a4e-824e8b25d03a_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_f96a425d-2d83-44aa-b3fa-4c85a562c48e_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_b4028d39-4a6e-4fcf-9ffa-122b20860d06_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_MX_da538bd4-4992-4d63-ae28-17aa3059787d_terseLabel_en-US" xlink:label="lab_country_MX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mexico</link:label>
    <link:label id="lab_country_MX_label_en-US" xlink:label="lab_country_MX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MEXICO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_MX" xlink:to="lab_country_MX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_d8809d6a-855d-42df-877e-bf34cc242d95_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_65ead3ba-d9eb-42be-86d2-7db51cb05092_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_10ffaab8-130e-4788-a76f-fe7f94b08640_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_416b3b01-5c25-419f-91dd-080964d5b33a_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of unamortized debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_fd8f4273-3f84-41b8-a98b-10581e5d7663_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_55823853-0e76-4a79-9e69-19e9f786397c_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2f3a58d1-d712-4a47-b502-540b0f5faa30_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issued under share-based compensation plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_52f02e35-7b12-48f8-ad51-34fc90117283_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_McKessonCorporationMember_6f52a5a8-4135-4f18-805e-5b3d6a0f74ba_terseLabel_en-US" xlink:label="lab_bhc_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation (including McKesson Specialty)</link:label>
    <link:label id="lab_bhc_McKessonCorporationMember_label_en-US" xlink:label="lab_bhc_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mc Kesson Corporation [Member]</link:label>
    <link:label id="lab_bhc_McKessonCorporationMember_documentation_en-US" xlink:label="lab_bhc_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the major customer of the entity, McKesson Corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_McKessonCorporationMember" xlink:href="bhc-20220630.xsd#bhc_McKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_McKessonCorporationMember" xlink:to="lab_bhc_McKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_1c1680db-697c-407d-ae6a-f6d4c7ee8a2b_terseLabel_en-US" xlink:label="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of variable consideration provisions</link:label>
    <link:label id="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_label_en-US" xlink:label="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Valuation And Qualifying Accounts [Table Text Block]</link:label>
    <link:label id="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_documentation_en-US" xlink:label="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Valuation And Qualifying Accounts [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:href="bhc-20220630.xsd#bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:to="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_0350ac05-17ce-425b-ac32-67e7689d4320_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount_2c2d676f-3edb-4934-b445-1ebabc42e886_negatedTerseLabel_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit for legal settlements</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount_label_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Legal Settlements, Amount</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount_documentation_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Legal Settlements, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount" xlink:href="bhc-20220630.xsd#bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount" xlink:to="lab_bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_b120f922-ea7b-4d82-82be-9532813ae375_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cooperative advertising credits included in rebates</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_41563d55-c5e6-4214-af08-0fa54676e78e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve beginning balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_55c17c00-5fba-494d-853e-040774e34baa_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve ending balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d8a31e0c-89e5-4931-84af-351200e0cf68_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_06cbf3a0-f07f-4aa2-a6e2-d55c0b459b12_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_3905439f-5ae8-4a8d-b613-79859bc1d730_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit related to stock compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_70d16cb9-6def-4800-afb8-7191af4ea02e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_b40ddac7-ff4a-42c2-ac19-b61448a2427b_terseLabel_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairments</link:label>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_17175b6e-ba8e-4dbf-a042-029f2714a8e5_verboseLabel_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairments</link:label>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_3435b765-0229-47fd-aad3-b6e5bf57a4c8_negatedTerseLabel_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairments</link:label>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_label_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</link:label>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_documentation_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:href="bhc-20220630.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:to="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_02f9f1d0-0ceb-41e4-b659-ccb9d6551154_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cce0015b-311e-49fc-949d-6251d13d0e02_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_9267bb37-ec6f-46fb-822e-3616d1378df6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for intangible and other assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_8b29153f-b654-47cd-af67-b294c69dc40d_verboseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement, escrow fund included in restricted cash and other settlement deposits</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ab4aadb6-7a25-447e-983a-569ec944d246_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement, agreed to pay</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_af37f533-61bb-4d9e-b8fd-a13f08cbc2b5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualRightsMember_4890e67e-ee7c-41b4-89c6-25d514b61775_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product rights/patents</link:label>
    <link:label id="lab_us-gaap_ContractualRightsMember_label_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualRightsMember" xlink:to="lab_us-gaap_ContractualRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccretionForTimeValueOfMoneyMember_982b581d-d05b-4d89-82c9-90e290ff3105_terseLabel_en-US" xlink:label="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion for the time value of money</link:label>
    <link:label id="lab_bhc_AccretionForTimeValueOfMoneyMember_label_en-US" xlink:label="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion For Time Value Of Money [Member]</link:label>
    <link:label id="lab_bhc_AccretionForTimeValueOfMoneyMember_documentation_en-US" xlink:label="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion For Time Value Of Money [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccretionForTimeValueOfMoneyMember" xlink:href="bhc-20220630.xsd#bhc_AccretionForTimeValueOfMoneyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccretionForTimeValueOfMoneyMember" xlink:to="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8921cb7b-6c5f-4b47-9089-1b22f30af66b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold, net proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_7cfd1840-a43b-4f1c-b2c3-b5361d3c55a2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_e142dccb-a4a5-4c90-a36a-17e3a0541127_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_5f26da32-017c-4752-bda2-8989e3b19899_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes6125DueApril2025Member_825311e0-3721-46f8-a81b-362f1bdc9125_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Notes Due April 2025</link:label>
    <link:label id="lab_bhc_SeniorNotes6125DueApril2025Member_label_en-US" xlink:label="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.125%, Due April 2025 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes6125DueApril2025Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Notes due April 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes6125DueApril2025Member" xlink:to="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_fc666cdc-ff09-4976-9b4b-b3bae65a22de_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, integration, separation, and IPO costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_e8b34979-ff15-400e-be65-41a29fbbcaba_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_97db6530-62bc-4b5a-90a5-ddc0075532b6_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_1fcbd8e6-74b5-44f4-84cb-2b580e8f3292_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_5e1d7865-d365-4db9-8bcb-cf6f9b167a54_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_e23d0827-41f0-453c-b296-da2884452a34_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SoltaMedicalSegmentMember_d34fb2cf-0e3c-40cd-b7f0-347a2edd15e6_terseLabel_en-US" xlink:label="lab_bhc_SoltaMedicalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solta Medical</link:label>
    <link:label id="lab_bhc_SoltaMedicalSegmentMember_label_en-US" xlink:label="lab_bhc_SoltaMedicalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solta Medical Segment [Member]</link:label>
    <link:label id="lab_bhc_SoltaMedicalSegmentMember_documentation_en-US" xlink:label="lab_bhc_SoltaMedicalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solta Medical Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember" xlink:href="bhc-20220630.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SoltaMedicalSegmentMember" xlink:to="lab_bhc_SoltaMedicalSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9be9a361-3985-4bb8-aecc-99e2577215cf_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted-average common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_84fa6095-4f48-4152-82b2-d039235ccda5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted-average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_cbd22800-a205-42fe-997d-5c72cf739389_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of reporting value, greater than its carrying value</link:label>
    <link:label id="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_label_en-US" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:to="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_df9df1f3-3903-44d1-939c-814526855a63_terseLabel_en-US" xlink:label="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates, Advertising Credits Portion</link:label>
    <link:label id="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_label_en-US" xlink:label="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates, Advertising Credits Portion [Member]</link:label>
    <link:label id="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_documentation_en-US" xlink:label="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates, Advertising Credits Portion [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:href="bhc-20220630.xsd#bhc_ReserveForRebatesAdvertisingCreditsPortionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:to="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_fca7d82c-9f81-42fa-9ffc-5af03bc5d532_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Plan</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_ac66b4ea-5261-4ee5-9215-0ac2216e8b2f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_413f8f01-97b5-402e-9229-f4e5e8056a54_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_af804d80-485e-4b12-a09c-a2a79049b765_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 18)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c5b76a65-1f49-4f11-9c0e-ce81f654c08d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_69f42ccd-cd68-4087-88a0-ea67b75949b2_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_7031f532-7422-4ee3-8ffe-ed709abb0de2_terseLabel_en-US" xlink:label="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and other settlement deposits</link:label>
    <link:label id="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_label_en-US" xlink:label="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure</link:label>
    <link:label id="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_documentation_en-US" xlink:label="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:href="bhc-20220630.xsd#bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:to="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty_c18ae28d-aa70-4c00-b9a2-286b0e6c7bf6_terseLabel_en-US" xlink:label="lab_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from B+L initial public offering, net of costs</link:label>
    <link:label id="lab_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty_label_en-US" xlink:label="lab_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering, Net Of Costs, Related Party</link:label>
    <link:label id="lab_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty_documentation_en-US" xlink:label="lab_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering, Net Of Costs, Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" xlink:href="bhc-20220630.xsd#bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" xlink:to="lab_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BauschLombInternationalMember_387d9f63-8221-4a9c-9594-ca1836f09638_terseLabel_en-US" xlink:label="lab_bhc_BauschLombInternationalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb/ International</link:label>
    <link:label id="lab_bhc_BauschLombInternationalMember_label_en-US" xlink:label="lab_bhc_BauschLombInternationalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb/International [Member]</link:label>
    <link:label id="lab_bhc_BauschLombInternationalMember_documentation_en-US" xlink:label="lab_bhc_BauschLombInternationalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch Lomb/International [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombInternationalMember" xlink:href="bhc-20220630.xsd#bhc_BauschLombInternationalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BauschLombInternationalMember" xlink:to="lab_bhc_BauschLombInternationalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_99bae95a-9068-4c33-ba4b-8ea6fb516681_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain on sale of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_8b082932-f919-4b84-8d4e-71598cbe9011_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of assets, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_331e3813-a90c-4992-b74f-40d291513fcd_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone achievement, included in net (loss) gain on sale of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_271d9331-991e-4a89-92b2-785c163010a4_terseLabel_en-US" xlink:label="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Violation of Canadian Provincial Securities Legislation</link:label>
    <link:label id="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_label_en-US" xlink:label="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Violation of Canadian Provincial Securities Legislation [Member]</link:label>
    <link:label id="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_documentation_en-US" xlink:label="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Violation of Canadian Provincial Securities Legislation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:href="bhc-20220630.xsd#bhc_ViolationofCanadianProvincialSecuritiesLegislationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:to="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ProductBrandsMember_d27c1f38-0106-431c-9a0f-eceeb06c8ddd_terseLabel_en-US" xlink:label="lab_bhc_ProductBrandsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product brands</link:label>
    <link:label id="lab_bhc_ProductBrandsMember_label_en-US" xlink:label="lab_bhc_ProductBrandsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Brands [Member]</link:label>
    <link:label id="lab_bhc_ProductBrandsMember_documentation_en-US" xlink:label="lab_bhc_ProductBrandsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the rights to non-patented product brands.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember" xlink:href="bhc-20220630.xsd#bhc_ProductBrandsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ProductBrandsMember" xlink:to="lab_bhc_ProductBrandsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_b15eb87d-d26e-41de-8af8-266ac1a141f7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate notional amounts</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_90b6e65e-5537-4e1f-9f7b-7f0ee50e65a6_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of entities, exercised opt-out right, pursuing action</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_label_en-US" xlink:label="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_documentation_en-US" xlink:label="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:href="bhc-20220630.xsd#bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:to="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_c3756f0f-93d3-45cd-907c-9ef6e7ebd9f2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of long-term debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_776ac1d9-4624-4581-a0c9-29d3551bdd6c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7ce5b9b5-1420-4905-85dc-84135cebdcca_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price appreciation credits</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_aaea78c9-5300-4fd8-8e9b-23a269bf67ff_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BLCreditAgreementMember_36486586-8047-4649-9c2b-89b267cfad84_terseLabel_en-US" xlink:label="lab_bhc_BLCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">B+L Credit Agreement</link:label>
    <link:label id="lab_bhc_BLCreditAgreementMember_label_en-US" xlink:label="lab_bhc_BLCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">B+L Credit Agreement [Member]</link:label>
    <link:label id="lab_bhc_BLCreditAgreementMember_documentation_en-US" xlink:label="lab_bhc_BLCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">B+L Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BLCreditAgreementMember" xlink:href="bhc-20220630.xsd#bhc_BLCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BLCreditAgreementMember" xlink:to="lab_bhc_BLCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_8c1fc88f-bf47-4f13-8814-a4c2d63d6371_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold for incremental borrowings</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Threshold For Incremental Borrowings</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Threshold For Incremental Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:href="bhc-20220630.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:to="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OutLicensedTechnologyMember_f4050da5-b3a5-4e45-a8b3-11c866ea66b6_terseLabel_en-US" xlink:label="lab_bhc_OutLicensedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology and other</link:label>
    <link:label id="lab_bhc_OutLicensedTechnologyMember_label_en-US" xlink:label="lab_bhc_OutLicensedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out Licensed Technology [Member]</link:label>
    <link:label id="lab_bhc_OutLicensedTechnologyMember_documentation_en-US" xlink:label="lab_bhc_OutLicensedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the rights to receive cash flows under an out-license arrangement (for example, license fees, milestone payments and royalties).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember" xlink:href="bhc-20220630.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OutLicensedTechnologyMember" xlink:to="lab_bhc_OutLicensedTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e524e75b-aec0-4899-b10b-93cad22ada94_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_71834039-26cd-4897-b7b8-942b6aa6c81c_terseLabel_en-US" xlink:label="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for losses on trade receivable and inventories</link:label>
    <link:label id="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_label_en-US" xlink:label="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for Losses on Accounts Receivable and Inventories</link:label>
    <link:label id="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_documentation_en-US" xlink:label="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:href="bhc-20220630.xsd#bhc_AllowancesForLossesOnAccountsReceivableAndInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:to="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_37d9b059-9756-4eb7-90c5-5f3e04a8a324_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_55cfb769-6aac-40fd-84ab-f0307c81dff7_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_b95b3dd3-758d-4479-954f-5ff7cd2e1266_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_b5c23fe5-5536-4a50-8ae8-d238f343f9b1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_81244673-425e-4d87-b441-9730dd2a820d_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_811ad0a9-fec4-4919-9d91-297c69d745f2_negatedLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_b024cc4a-db16-43cf-b033-02b8077acca8_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_852f195d-d611-4807-b422-f158eea3adf7_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHARE-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_580ede3a-d416-47aa-9fce-132e73321761_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueMay2027Member_e6e4de8f-44b9-4d07-b53c-84ade673c112_terseLabel_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due May 2027</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueMay2027Member_label_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due May 2027 [Member]</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueMay2027Member_documentation_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due May 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:href="bhc-20220630.xsd#bhc_RevolvingCreditFacilityDueMay2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:to="lab_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_7a22739d-be42-4597-9fb2-5048da7c13b5_periodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_aa4d1123-d146-435e-9d5b-3e4ea537a9d6_periodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_9532a7db-320e-4f16-8d3c-fb7d2e770b3c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the components and classification of share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_54426ca1-ef34-4066-9489-f90e7b075a04_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUE RECOGNITION</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_46fb3e6e-b03c-41c9-9989-2abbed43a902_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_ca457df6-ca95-47a9-98d5-144d5af7b47c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_927603f2-c19d-4770-a405-16a1b20539d2_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_c7f72b38-6fb3-465b-bd99-bea40e9130c1_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs incurred</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_71cf6776-9c9e-45ce-b21a-3ae60007bb17_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of net loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_caadfb37-41a2-43d7-955f-fc74cf638c15_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of employee withholding taxes related to share-based awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_7af78563-2949-408c-8ece-2934494ea15f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_b1ccf42e-0f8f-4c81-9869-ea4b570842ca_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_25576878-17d2-46c7-baa1-94eb4a066d1c_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_73032116-67ab-478c-9877-69ea4df752f9_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_34d85317-ea35-46ff-9f21-ef556336a53e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_91888435-0cdd-40dc-9b47-aa291f0d41c9_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in the carrying amount of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_081b93c0-b593-4275-ad4f-817933f933e3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effect of hedging instruments on financial statements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_24bedb10-21a6-437b-ab0c-a2c2f088f5d3_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total leverage ratio (not greater than)</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Total Leverage Ratio, Maximum</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Total Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:to="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_3f0efc1f-677c-40e1-b019-29e5a7258759_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_77b77a67-a09a-42a6-a230-0c1194851a4b_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_b97212a9-d6c7-4122-bb4b-8c850f6a168a_terseLabel_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower to Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma or Breast Cancer</link:label>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_label_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower To Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma Or Breast Cancer [Member]</link:label>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_documentation_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower To Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma Or Breast Cancer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:href="bhc-20220630.xsd#bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:to="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes900DueDecember2025Member_f1234feb-b462-4b85-b379-3f5aad340b4c_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes Due December 2025</link:label>
    <link:label id="lab_bhc_SeniorNotes900DueDecember2025Member_label_en-US" xlink:label="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 9.00%, Due December 2025 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes900DueDecember2025Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes due December 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes900DueDecember2025Member" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes900DueDecember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes900DueDecember2025Member" xlink:to="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_8d4b76a1-0270-46da-86f8-548782dc1703_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_928f91b7-c166-48cd-8805-7c2a1b4d8b2f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bd8cb132-eec5-4488-904a-b00931e1dfee_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components and classification of share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_342335d6-0471-4b4e-b683-4c151bfb7491_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_def3b3b1-221c-405a-880e-613b61299318_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_c721494f-78fc-4111-a0c6-c8b087fbbf9b_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_4ebdda32-26b2-4ac1-a367-c073c1f35705_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits related to interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_f56ff931-1107-4abc-b524-f924ef6559b7_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_7da4c973-4fc9-4f40-b6f0-daa7339fbde4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted loss per share attributable to Bausch Health Companies Inc. (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_db510c85-7e8b-40c1-8836-d96beafc6ec4_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_4dcb6681-06dd-4d32-88c1-53473f3f887b_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_53ee0621-76dd-41cf-9923-4fbc3a53501b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c838e08a-6cad-44fc-9b31-63d4c34a38c4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period, Third Year after Grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b4dc02bb-588d-4881-b86e-9575596b769b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock plan, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_aacc68d7-fa98-46f6-a035-c3e516ffa643_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage by parent</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6121266f-88eb-4bb4-8bc4-c0ddac42d1ba_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_ca713162-9a89-4748-a032-7fdd97723e17_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_b325b5a6-9e1c-4731-8562-b44ff4b1cb7f_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_e4456a50-d898-41de-a1be-3c475e9593fd_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_bca9e5ce-f566-463e-9710-441def762676_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_032c9443-1a6c-4c80-a16e-0cc6b5cb8404_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_bc16ab78-0c7e-4eb3-ae16-a1f65c64c9cd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of activity in allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NewRestatedCreditAgreementMember_d6a2c8fd-b1b2-44f7-a2ec-a3bee0a23ec5_terseLabel_en-US" xlink:label="lab_bhc_NewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Restated Credit Agreement</link:label>
    <link:label id="lab_bhc_NewRestatedCreditAgreementMember_label_en-US" xlink:label="lab_bhc_NewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Restated Credit Agreement [Member]</link:label>
    <link:label id="lab_bhc_NewRestatedCreditAgreementMember_documentation_en-US" xlink:label="lab_bhc_NewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Restated Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NewRestatedCreditAgreementMember" xlink:href="bhc-20220630.xsd#bhc_NewRestatedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NewRestatedCreditAgreementMember" xlink:to="lab_bhc_NewRestatedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CardinalHealthIncMember_2acdd049-f38e-4266-9603-a066adb33a0f_terseLabel_en-US" xlink:label="lab_bhc_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health,&#160;Inc.</link:label>
    <link:label id="lab_bhc_CardinalHealthIncMember_label_en-US" xlink:label="lab_bhc_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health Inc [Member]</link:label>
    <link:label id="lab_bhc_CardinalHealthIncMember_documentation_en-US" xlink:label="lab_bhc_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the major customer of the entity, Cardinal Health, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CardinalHealthIncMember" xlink:href="bhc-20220630.xsd#bhc_CardinalHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CardinalHealthIncMember" xlink:to="lab_bhc_CardinalHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_1755a7dc-b89c-45be-93f4-ec81f9b13f1b_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DiscontinuedProductLinesMember_7bca5a32-2d9b-47b3-99fa-7d44996fe8d5_terseLabel_en-US" xlink:label="lab_bhc_DiscontinuedProductLinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Product Lines</link:label>
    <link:label id="lab_bhc_DiscontinuedProductLinesMember_label_en-US" xlink:label="lab_bhc_DiscontinuedProductLinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Product Lines [Member]</link:label>
    <link:label id="lab_bhc_DiscontinuedProductLinesMember_documentation_en-US" xlink:label="lab_bhc_DiscontinuedProductLinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Product Lines</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiscontinuedProductLinesMember" xlink:href="bhc-20220630.xsd#bhc_DiscontinuedProductLinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DiscontinuedProductLinesMember" xlink:to="lab_bhc_DiscontinuedProductLinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_795bea18-e92b-4558-9d22-788db34bd126_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost-rationalization and integration initiatives</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_country_RU_7c80e68c-381d-4fe3-9f7d-a5b5681837d6_terseLabel_en-US" xlink:label="lab_country_RU" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Russia</link:label>
    <link:label id="lab_country_RU_label_en-US" xlink:label="lab_country_RU" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RUSSIAN FEDERATION</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_RU" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_RU"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_RU" xlink:to="lab_country_RU" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_bbccf9ec-5bf5-48af-b9be-baa53337b6f9_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of unrecognized tax benefits, if recognized, would reduce the Company's effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PatentInfringementLitigationMember_d1103f78-e3d2-40fd-964c-3a035dc2aecd_terseLabel_en-US" xlink:label="lab_bhc_PatentInfringementLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement Litigation</link:label>
    <link:label id="lab_bhc_PatentInfringementLitigationMember_label_en-US" xlink:label="lab_bhc_PatentInfringementLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement Litigation [Member]</link:label>
    <link:label id="lab_bhc_PatentInfringementLitigationMember_documentation_en-US" xlink:label="lab_bhc_PatentInfringementLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PatentInfringementLitigationMember" xlink:href="bhc-20220630.xsd#bhc_PatentInfringementLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PatentInfringementLitigationMember" xlink:to="lab_bhc_PatentInfringementLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8c7c1af2-1861-4892-b597-5310f75795de_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock plan, term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_207228fc-6403-4239-846a-03e8f12d9f66_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility fee (as a percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EuropeInterbankOfferedRateEURIBORMember_6779a3e1-6b9d-4e8a-9851-e592bf0c5be6_terseLabel_en-US" xlink:label="lab_bhc_EuropeInterbankOfferedRateEURIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EURIBOR</link:label>
    <link:label id="lab_bhc_EuropeInterbankOfferedRateEURIBORMember_label_en-US" xlink:label="lab_bhc_EuropeInterbankOfferedRateEURIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe Interbank Offered Rate (EURIBOR) [Member]</link:label>
    <link:label id="lab_bhc_EuropeInterbankOfferedRateEURIBORMember_documentation_en-US" xlink:label="lab_bhc_EuropeInterbankOfferedRateEURIBORMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe Interbank Offered Rate (EURIBOR)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EuropeInterbankOfferedRateEURIBORMember" xlink:href="bhc-20220630.xsd#bhc_EuropeInterbankOfferedRateEURIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EuropeInterbankOfferedRateEURIBORMember" xlink:to="lab_bhc_EuropeInterbankOfferedRateEURIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OrthoDermatologicsSegmentMember_28aaa3ed-aca8-4d7c-9e82-6e0d9d7c2ccf_verboseLabel_en-US" xlink:label="lab_bhc_OrthoDermatologicsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsSegmentMember_label_en-US" xlink:label="lab_bhc_OrthoDermatologicsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Segment [Member]</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsSegmentMember_documentation_en-US" xlink:label="lab_bhc_OrthoDermatologicsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember" xlink:href="bhc-20220630.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OrthoDermatologicsSegmentMember" xlink:to="lab_bhc_OrthoDermatologicsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_08e3e31d-3b6c-4044-b7be-ab9a0613cfe6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of customers that accounted for 10% or more of total revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_652f02d8-966a-4da3-b240-dce28180beb3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_5a61ce8f-3dfd-431b-8990-e6e3cca4811e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationMember_243c6c55-73c2-44bf-ba5a-9f891bd3c66f_terseLabel_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationMember_label_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation [Member]</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationMember_documentation_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Class Actions Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationMember" xlink:href="bhc-20220630.xsd#bhc_GlumetzaAntitrustLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GlumetzaAntitrustLitigationMember" xlink:to="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_c9470a34-66d5-43f5-8673-adb1e4451794_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_1dcf5bfd-b4af-446b-a0f8-51eb7c810940_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_9b69ec82-b338-4ef3-92c6-b4adb2758924_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims dismissed</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Dismissed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:to="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_f149e177-ce25-44c9-aeb4-910c9480f5fc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_c04eb13f-384e-4457-ac62-3a1c9204838a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_1e0e9a9f-75f6-4fa9-bfa7-421fa88493e1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_233675a9-535d-4ba1-8adb-29e3c486366b_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate brands</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeparationAndInitialPublicOfferingCostsMember_53899eb4-a4e7-4576-a8d1-1ccb3c012a38_terseLabel_en-US" xlink:label="lab_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation and IPO Costs</link:label>
    <link:label id="lab_bhc_SeparationAndInitialPublicOfferingCostsMember_label_en-US" xlink:label="lab_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation And Initial Public Offering Costs [Member]</link:label>
    <link:label id="lab_bhc_SeparationAndInitialPublicOfferingCostsMember_documentation_en-US" xlink:label="lab_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation And Initial Public Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:href="bhc-20220630.xsd#bhc_SeparationAndInitialPublicOfferingCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:to="lab_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_6f12e53b-9f4a-437e-84aa-a8c7aac2c2ed_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_8b879e3c-3c28-4912-ba2d-6f8dc57c2348_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_daadcb51-cfbd-4650-bbee-516abae60821_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_c4db88ad-23b8-4496-bfbb-29c82efa8f0a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014Member_98f06d5e-93c1-4b85-a66e-91aa73a5ec8e_terseLabel_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Plan</link:label>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014Member_label_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Incentive Plan 2014 [Member]</link:label>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014Member_documentation_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Incentive Plan 2014 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014Member" xlink:href="bhc-20220630.xsd#bhc_OmnibusIncentivePlan2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OmnibusIncentivePlan2014Member" xlink:to="lab_bhc_OmnibusIncentivePlan2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherCountriesMember_aefd05df-55e9-42eb-b165-5d15853ad740_terseLabel_en-US" xlink:label="lab_bhc_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_bhc_OtherCountriesMember_label_en-US" xlink:label="lab_bhc_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:label id="lab_bhc_OtherCountriesMember_documentation_en-US" xlink:label="lab_bhc_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember" xlink:href="bhc-20220630.xsd#bhc_OtherCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherCountriesMember" xlink:to="lab_bhc_OtherCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_e9fd2957-cbe2-4e40-a799-047972c78fc3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember_a7440044-e5ca-4fe2-badd-d204212982ea_terseLabel_en-US" xlink:label="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR, EURIBOR and SONIA Rates</link:label>
    <link:label id="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember_label_en-US" xlink:label="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR, EURIBOR and SONIA Rates [Member]</link:label>
    <link:label id="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember_documentation_en-US" xlink:label="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR, EURIBOR and SONIA Rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:href="bhc-20220630.xsd#bhc_SOFRCDOREURIBORAndSONIARatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:to="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_6117f08d-aaa6-4815-9c53-a5539edc5218_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2d181e66-7384-43f7-969a-8770cbb66e85_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_b8ca352a-090b-4fc5-b82b-9226d1576599_terseLabel_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable Regulatory Action</link:label>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_label_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable Regulatory Action [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnfavorableRegulatoryActionMember" xlink:to="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_335a1101-cfc2-4eb0-9591-9ee133878b0e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_8e72cc5f-471d-413e-8673-866105fa0959_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_2b547565-fbce-401b-a6d5-63078e8ebe76_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member_5ecbffe2-40e8-4baf-b9f4-523cda19600f_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Senior Notes Due November 2025</link:label>
    <link:label id="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member_label_en-US" xlink:label="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.50% Notes Due November 2025 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.50% Notes Due November 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:href="bhc-20220630.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:to="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_6faef61d-ed89-46f9-8e10-d2245c1f9bf2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LitigationwithFormerSalixCEOMember_719322c2-2b90-4fd6-b0c0-28ad25f21c03_terseLabel_en-US" xlink:label="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation with Former Salix CEO</link:label>
    <link:label id="lab_bhc_LitigationwithFormerSalixCEOMember_label_en-US" xlink:label="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation with Former Salix CEO [Member]</link:label>
    <link:label id="lab_bhc_LitigationwithFormerSalixCEOMember_documentation_en-US" xlink:label="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation with Former Salix CEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationwithFormerSalixCEOMember" xlink:href="bhc-20220630.xsd#bhc_LitigationwithFormerSalixCEOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LitigationwithFormerSalixCEOMember" xlink:to="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_faf12966-4e4b-420a-a103-972d384b992a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ca1d7c41-5a84-4edb-ac64-36aac769e9a1_totalLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_45b815bb-22d5-4532-b843-c59d7378382b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrencySwapMember_b427dde1-748c-49e6-b6a8-7f0cf60d82b8_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_label_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencySwapMember" xlink:to="lab_us-gaap_CurrencySwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e55fbc47-ab94-4acf-9f69-349de0c92b4d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents, restricted cash and other settlement deposits</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForRebatesMember_91cad0d5-a07b-45a8-89ec-7a5ca7f02efa_terseLabel_en-US" xlink:label="lab_bhc_ReserveForRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates</link:label>
    <link:label id="lab_bhc_ReserveForRebatesMember_label_en-US" xlink:label="lab_bhc_ReserveForRebatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates [Member]</link:label>
    <link:label id="lab_bhc_ReserveForRebatesMember_documentation_en-US" xlink:label="lab_bhc_ReserveForRebatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesMember" xlink:href="bhc-20220630.xsd#bhc_ReserveForRebatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForRebatesMember" xlink:to="lab_bhc_ReserveForRebatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_039a62e5-ef90-4d98-baf2-3b90e8dbdc19_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, contingent consideration obligations, discount rate</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_c401d7d5-77ec-493f-a9d3-f17d40d70a70_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_ac36b4ca-8ddf-47a3-8dec-45ed4a004818_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_2a183aa3-ab1e-4fca-a9cd-3ef7e353c4f6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_b075d05e-ba4c-44f7-a8bc-01e889db882e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_bcd31243-07b9-480b-8378-5a283f8cf5fd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ApotexIncLitigationMember_d2bb29ca-5530-4bdc-9794-9865e5221b9f_terseLabel_en-US" xlink:label="lab_bhc_ApotexIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apotex Inc. Litigation</link:label>
    <link:label id="lab_bhc_ApotexIncLitigationMember_label_en-US" xlink:label="lab_bhc_ApotexIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apotex Inc. Litigation [Member]</link:label>
    <link:label id="lab_bhc_ApotexIncLitigationMember_documentation_en-US" xlink:label="lab_bhc_ApotexIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apotex Inc. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ApotexIncLitigationMember" xlink:href="bhc-20220630.xsd#bhc_ApotexIncLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ApotexIncLitigationMember" xlink:to="lab_bhc_ApotexIncLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember_da44ab73-4cf3-4754-bb7c-230865c0dbaa_terseLabel_en-US" xlink:label="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSN Laboratories Private Ltd. Litigation</link:label>
    <link:label id="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember_label_en-US" xlink:label="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSN Laboratories Private Ltd. Litigation [Member]</link:label>
    <link:label id="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember_documentation_en-US" xlink:label="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSN Laboratories Private Ltd. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:href="bhc-20220630.xsd#bhc_MSNLaboratoriesPrivateLtdLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:to="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8e847a9d-66f3-4e24-af79-2fac34b17d8c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_de713a1f-c07d-435e-9dba-630724e94cdb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee withholding taxes related to share-based awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_684ebf1c-0b55-464f-ba2f-971da7199219_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_6dbf9376-01a2-49c0-af26-4f0a958c6e46_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_4f6e8602-3b8c-46dd-83fa-57774b932ee6_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_8bdbc877-c69b-49d7-957a-e8cb58c1d787_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_d1b76ed1-3ecd-4d83-893d-4700184b300c_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_5aebada8-de9d-4601-aad6-93ef9104a53f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_a829d683-6db4-44a3-bfdf-5e17ef61e204_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount_dbd39deb-2716-4e92-9a2a-8692c22d184a_terseLabel_en-US" xlink:label="lab_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excluded from computation of earnings per share, performance conditions not met (in shares)</link:label>
    <link:label id="lab_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount_label_en-US" xlink:label="lab_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Excluded From Computation Of Earnings Per Share, Performance Conditions Not Met, Amount</link:label>
    <link:label id="lab_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount_documentation_en-US" xlink:label="lab_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Excluded From Computation Of Earnings Per Share, Performance Conditions Not Met, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" xlink:href="bhc-20220630.xsd#bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" xlink:to="lab_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_ccfb6044-1317-4c08-b4b3-13cc3fdee0e7_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_5c9a585f-7f2b-461b-8c12-6b74df828fe1_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_e7d33812-badb-4c50-b607-fa244237f195_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ValeantUSSecuritiesLitigationMember_afaf23b9-8829-4ad9-aa82-b1695d58e38b_terseLabel_en-US" xlink:label="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Securities Litigation</link:label>
    <link:label id="lab_bhc_ValeantUSSecuritiesLitigationMember_label_en-US" xlink:label="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valeant US Securities Litigation [Member]</link:label>
    <link:label id="lab_bhc_ValeantUSSecuritiesLitigationMember_documentation_en-US" xlink:label="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valeant US Securities Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember" xlink:href="bhc-20220630.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ValeantUSSecuritiesLitigationMember" xlink:to="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_040f1ebd-29af-4315-afee-7c066b4f2a3d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_353ea858-7f05-4678-8a38-bbb6e9edfbcc_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5edfca27-5202-4091-b980-15dd9be18e9b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit) on ordinary loss</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_21a8251a-4ff3-4aff-8844-f20b4963c345_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_72b8d41c-c51a-46a1-8e75-66f70f3c7c81_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_871fe674-f6d2-4924-9482-c4598c51b3da_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SONIARateMember_b6f84197-5e20-4aa2-a628-d23f8d5f36fc_terseLabel_en-US" xlink:label="lab_bhc_SONIARateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SONIA Rate</link:label>
    <link:label id="lab_bhc_SONIARateMember_label_en-US" xlink:label="lab_bhc_SONIARateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SONIA Rate [Member]</link:label>
    <link:label id="lab_bhc_SONIARateMember_documentation_en-US" xlink:label="lab_bhc_SONIARateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SONIA Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SONIARateMember" xlink:href="bhc-20220630.xsd#bhc_SONIARateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SONIARateMember" xlink:to="lab_bhc_SONIARateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d7d04812-0d22-49b3-9f0c-8b341718d043_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_0ad8941f-34d6-4ac1-8b8f-271c3187554c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f457becb-4b70-488b-aadf-79de05a7fb8a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_f7c2062c-407a-4c93-9c76-9a5c1651c126_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_c6ef8bdc-d5a0-42f0-9d1c-74725c14fd56_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_f5097b17-5ef1-4558-8906-d4efd55498ca_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Percentage of Net Cash Proceeds from Asset Sales Outside Ordinary Course of Business Payable as Mandatory Prepayments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of net cash proceeds from asset sales outside ordinary course of business payable as mandatory prepayments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:href="bhc-20220630.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:to="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_db37f18f-3c29-409e-9ecf-977f05a0daff_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5c4f8980-6381-4e9e-839c-3bab6868d397_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_48b31a7b-70d6-4de9-a421-72a736515675_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments, including loss on assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_cc6f8941-f540-435d-add2-d56bd9bb20bc_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments, including loss on assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_485f4c04-2ce3-477c-9a07-b75353b08706_negatedLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments, including loss on assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_d8d96381-30d8-4bca-9741-967e979744e3_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_44922de4-a04e-429f-923b-462bb8838b0f_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember_f9fc4f56-7df2-4074-bcd1-a282e7abfff1_terseLabel_en-US" xlink:label="lab_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate Factor, SOFR</link:label>
    <link:label id="lab_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember_label_en-US" xlink:label="lab_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate Factor, Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
    <link:label id="lab_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember_documentation_en-US" xlink:label="lab_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate Factor, Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" xlink:href="bhc-20220630.xsd#bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" xlink:to="lab_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PadagisLitigationMember_ecc8e206-0320-475e-8986-9c48c7653146_terseLabel_en-US" xlink:label="lab_bhc_PadagisLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Padagis Litigation</link:label>
    <link:label id="lab_bhc_PadagisLitigationMember_label_en-US" xlink:label="lab_bhc_PadagisLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Padagis Litigation [Member]</link:label>
    <link:label id="lab_bhc_PadagisLitigationMember_documentation_en-US" xlink:label="lab_bhc_PadagisLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Padagis Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PadagisLitigationMember" xlink:href="bhc-20220630.xsd#bhc_PadagisLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PadagisLitigationMember" xlink:to="lab_bhc_PadagisLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1337f80a-97f3-48c0-b753-2ede9f638e92_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_c94c3c81-bcf5-498c-a25c-af7c89a60e96_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of assets and businesses, net of costs to sell</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses, Net of Cash Divested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a3913a0e-a38e-4b1c-95b5-e060076a6747_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of calculation of net loss per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevenuesNetMember_2241ebae-567d-4907-a211-739ba6987157_terseLabel_en-US" xlink:label="lab_bhc_RevenuesNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_bhc_RevenuesNetMember_label_en-US" xlink:label="lab_bhc_RevenuesNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues Net [Member]</link:label>
    <link:label id="lab_bhc_RevenuesNetMember_documentation_en-US" xlink:label="lab_bhc_RevenuesNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate net revenues during the period in the normal course of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember" xlink:href="bhc-20220630.xsd#bhc_RevenuesNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevenuesNetMember" xlink:to="lab_bhc_RevenuesNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeclaratoryJudgementActionLitigationMember_d9ad6526-bc65-4850-861a-764d93945c6b_terseLabel_en-US" xlink:label="lab_bhc_DeclaratoryJudgementActionLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Declaratory Judgement Action Litigation</link:label>
    <link:label id="lab_bhc_DeclaratoryJudgementActionLitigationMember_label_en-US" xlink:label="lab_bhc_DeclaratoryJudgementActionLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Declaratory Judgement Action Litigation [Member]</link:label>
    <link:label id="lab_bhc_DeclaratoryJudgementActionLitigationMember_documentation_en-US" xlink:label="lab_bhc_DeclaratoryJudgementActionLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Declaratory Judgement Action Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeclaratoryJudgementActionLitigationMember" xlink:href="bhc-20220630.xsd#bhc_DeclaratoryJudgementActionLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeclaratoryJudgementActionLitigationMember" xlink:to="lab_bhc_DeclaratoryJudgementActionLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_02c695d9-336c-438e-95e8-f9935c894958_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RESEARCH AND DEVELOPMENT</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_0a27b55b-c940-4f68-8e15-e49cb414e42d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_a40d3fa3-e60a-4b28-98ef-d431375205a1_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_414ed707-55bd-45da-84db-32d426a5f286_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postretirement Benefit Plan</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>bhc-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:08e728a9-955b-42e6-9f9e-75e33d236c1d,g:6cf439ae-5822-43c6-a8ac-f8ebfd7ee7fe-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="bhc-20220630.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_389d0f6b-12e7-41d7-b699-14a11d71bf4d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_DocumentType_389d0f6b-12e7-41d7-b699-14a11d71bf4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_5036dd2c-f10a-4c37-a744-d0211a713594" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_DocumentQuarterlyReport_5036dd2c-f10a-4c37-a744-d0211a713594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9ef34f11-9cd5-40bf-9f0d-0c20e3c28405" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_DocumentPeriodEndDate_9ef34f11-9cd5-40bf-9f0d-0c20e3c28405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_aad97cf5-c7b5-46b4-bad0-a6b1f93176fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_DocumentTransitionReport_aad97cf5-c7b5-46b4-bad0-a6b1f93176fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_740df33a-2697-44fc-98b1-2abcb2b1c19e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_EntityFileNumber_740df33a-2697-44fc-98b1-2abcb2b1c19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b46c903f-6d18-45d1-bab7-b201d680f11b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_EntityRegistrantName_b46c903f-6d18-45d1-bab7-b201d680f11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_302d9c30-f4e6-4140-8927-db9f44660a04" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_302d9c30-f4e6-4140-8927-db9f44660a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_1e0192f5-92d8-4ed4-bcad-ab9a97b4bbb2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_EntityAddressCountry_1e0192f5-92d8-4ed4-bcad-ab9a97b4bbb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_86cc277f-bd00-4818-9b58-b6e43a48dc7c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_EntityTaxIdentificationNumber_86cc277f-bd00-4818-9b58-b6e43a48dc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_fb217361-0875-4b1d-a8b0-417c9f62413b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_EntityAddressAddressLine1_fb217361-0875-4b1d-a8b0-417c9f62413b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_fb02cc7a-b3a4-486f-ae9a-968fd3834ecd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_EntityAddressCityOrTown_fb02cc7a-b3a4-486f-ae9a-968fd3834ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_48c82097-09dd-4250-8677-69e73b620422" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_EntityAddressStateOrProvince_48c82097-09dd-4250-8677-69e73b620422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d7b56005-263b-437c-ab17-73d3b49da05b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_EntityAddressPostalZipCode_d7b56005-263b-437c-ab17-73d3b49da05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_234d60fb-d0dd-4e19-a83f-145034430c94" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_CityAreaCode_234d60fb-d0dd-4e19-a83f-145034430c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_8a883cbf-fb32-4509-bb55-434c9689c7ef" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_LocalPhoneNumber_8a883cbf-fb32-4509-bb55-434c9689c7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ba41dcab-44de-43b1-b307-b3e6269055e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_Security12bTitle_ba41dcab-44de-43b1-b307-b3e6269055e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_6f83872b-9972-451c-b279-a5b32c21d876" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_TradingSymbol_6f83872b-9972-451c-b279-a5b32c21d876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_712c72c8-62f7-4d8e-833a-c570689cb8fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_SecurityExchangeName_712c72c8-62f7-4d8e-833a-c570689cb8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_bbd4756d-0bde-41c1-8641-c767052297d3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_EntityCurrentReportingStatus_bbd4756d-0bde-41c1-8641-c767052297d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_b995a20a-a935-47d0-8f21-64722bfb98ae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_EntityInteractiveDataCurrent_b995a20a-a935-47d0-8f21-64722bfb98ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_eab9b841-6f8c-4932-b9a7-ae85d2a10787" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_EntityFilerCategory_eab9b841-6f8c-4932-b9a7-ae85d2a10787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_9fa7fa5b-951a-429c-8cae-7874a19e59dd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_EntitySmallBusiness_9fa7fa5b-951a-429c-8cae-7874a19e59dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2c8a463a-dcba-4d9e-9783-0b8b02544ca7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_EntityEmergingGrowthCompany_2c8a463a-dcba-4d9e-9783-0b8b02544ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_ee873668-14ef-46c1-863f-42e52106d038" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_EntityShellCompany_ee873668-14ef-46c1-863f-42e52106d038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_c6377903-442e-4e54-9117-6a6f6d3d418a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_c6377903-442e-4e54-9117-6a6f6d3d418a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5eab5fe8-fb59-4a7a-8199-5511dba8f943" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_EntityCentralIndexKey_5eab5fe8-fb59-4a7a-8199-5511dba8f943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_388ed499-25b7-4293-9875-8f42ef7457f4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_CurrentFiscalYearEndDate_388ed499-25b7-4293-9875-8f42ef7457f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_74701c80-cca1-4b74-9a5e-0a5fe7f272a8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_DocumentFiscalYearFocus_74701c80-cca1-4b74-9a5e-0a5fe7f272a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_4cce1437-eed4-46ba-bb3d-890530cd56f7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_DocumentFiscalPeriodFocus_4cce1437-eed4-46ba-bb3d-890530cd56f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_198b4ca1-c0a1-4260-8ae0-bed99962e446" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6c258442-552e-4eea-90ef-102c7aa4c42e" xlink:to="loc_dei_AmendmentFlag_198b4ca1-c0a1-4260-8ae0-bed99962e446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bhc-20220630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_80c74d6e-5d9d-4053-b860-0598d43a9bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_2ada0e9b-ba78-4f1f-96d2-4c5f22bc82eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_80c74d6e-5d9d-4053-b860-0598d43a9bfd" xlink:to="loc_us-gaap_AssetsAbstract_2ada0e9b-ba78-4f1f-96d2-4c5f22bc82eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d6cd94af-71f3-4b34-9ced-8e47a808b709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2ada0e9b-ba78-4f1f-96d2-4c5f22bc82eb" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d6cd94af-71f3-4b34-9ced-8e47a808b709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_04e3db8d-d00f-4c7d-b1b1-2070728f7b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d6cd94af-71f3-4b34-9ced-8e47a808b709" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_04e3db8d-d00f-4c7d-b1b1-2070728f7b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_37b19522-b5bf-49cc-837a-c3b416eb1fd9" xlink:href="bhc-20220630.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d6cd94af-71f3-4b34-9ced-8e47a808b709" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_37b19522-b5bf-49cc-837a-c3b416eb1fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_2b4a5b1d-3d77-4827-b45d-8005c5eb3096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d6cd94af-71f3-4b34-9ced-8e47a808b709" xlink:to="loc_us-gaap_ReceivablesNetCurrent_2b4a5b1d-3d77-4827-b45d-8005c5eb3096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_06772f77-0ee3-4f59-82f7-7382413f945e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d6cd94af-71f3-4b34-9ced-8e47a808b709" xlink:to="loc_us-gaap_InventoryNet_06772f77-0ee3-4f59-82f7-7382413f945e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0a9d8270-3c42-4861-b838-d89420563537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d6cd94af-71f3-4b34-9ced-8e47a808b709" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0a9d8270-3c42-4861-b838-d89420563537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f297b25a-4e4c-4a1c-8c29-6a9bdf2e49da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d6cd94af-71f3-4b34-9ced-8e47a808b709" xlink:to="loc_us-gaap_AssetsCurrent_f297b25a-4e4c-4a1c-8c29-6a9bdf2e49da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ae1d2f52-90b7-4cfc-a867-cee82801dc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2ada0e9b-ba78-4f1f-96d2-4c5f22bc82eb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ae1d2f52-90b7-4cfc-a867-cee82801dc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a580ef2c-83f1-47e2-97b1-a8723bdd9772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2ada0e9b-ba78-4f1f-96d2-4c5f22bc82eb" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a580ef2c-83f1-47e2-97b1-a8723bdd9772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_89547342-8741-4a6e-90a5-27119840345d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2ada0e9b-ba78-4f1f-96d2-4c5f22bc82eb" xlink:to="loc_us-gaap_Goodwill_89547342-8741-4a6e-90a5-27119840345d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_001fbc87-e262-462f-8ed6-8d6b77755003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2ada0e9b-ba78-4f1f-96d2-4c5f22bc82eb" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_001fbc87-e262-462f-8ed6-8d6b77755003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a04755c4-3331-4a31-9710-42c913c02962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2ada0e9b-ba78-4f1f-96d2-4c5f22bc82eb" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a04755c4-3331-4a31-9710-42c913c02962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a89cd6c0-ca87-4659-a7c1-18eb27178a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2ada0e9b-ba78-4f1f-96d2-4c5f22bc82eb" xlink:to="loc_us-gaap_Assets_a89cd6c0-ca87-4659-a7c1-18eb27178a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_7eea66bd-83ae-4b74-8837-70089c630fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_80c74d6e-5d9d-4053-b860-0598d43a9bfd" xlink:to="loc_us-gaap_LiabilitiesAbstract_7eea66bd-83ae-4b74-8837-70089c630fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_15dc20c7-fc39-427b-a1ec-431fa420cb0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_7eea66bd-83ae-4b74-8837-70089c630fe1" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_15dc20c7-fc39-427b-a1ec-431fa420cb0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_834f348a-3e3e-4f8a-9a3a-6728fa44db0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15dc20c7-fc39-427b-a1ec-431fa420cb0d" xlink:to="loc_us-gaap_AccountsPayableCurrent_834f348a-3e3e-4f8a-9a3a-6728fa44db0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3c0f4a9c-aea6-48de-b692-bf740329adfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15dc20c7-fc39-427b-a1ec-431fa420cb0d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3c0f4a9c-aea6-48de-b692-bf740329adfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_e1b4cefe-f46d-401c-a814-cd87157be8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15dc20c7-fc39-427b-a1ec-431fa420cb0d" xlink:to="loc_us-gaap_LongTermDebtCurrent_e1b4cefe-f46d-401c-a814-cd87157be8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_006b35f7-5c5a-4f63-ac89-57bd180bfd53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15dc20c7-fc39-427b-a1ec-431fa420cb0d" xlink:to="loc_us-gaap_LiabilitiesCurrent_006b35f7-5c5a-4f63-ac89-57bd180bfd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_8ce07af6-6fc8-4be0-9e79-595385e4e4b1" xlink:href="bhc-20220630.xsd#bhc_BusinessCombinationContingentConsiderationNoncurrentLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_7eea66bd-83ae-4b74-8837-70089c630fe1" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_8ce07af6-6fc8-4be0-9e79-595385e4e4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_8a9873dc-f5d8-4792-b516-471c263bf483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_7eea66bd-83ae-4b74-8837-70089c630fe1" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_8a9873dc-f5d8-4792-b516-471c263bf483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8935572e-65ee-42bf-bee8-013e0133b003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_7eea66bd-83ae-4b74-8837-70089c630fe1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8935572e-65ee-42bf-bee8-013e0133b003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6c6c78a6-71ba-4eb8-b42f-75ae0bb21d07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_7eea66bd-83ae-4b74-8837-70089c630fe1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6c6c78a6-71ba-4eb8-b42f-75ae0bb21d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9ea8c916-ba29-42bf-9c95-4f8fe583b166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_7eea66bd-83ae-4b74-8837-70089c630fe1" xlink:to="loc_us-gaap_Liabilities_9ea8c916-ba29-42bf-9c95-4f8fe583b166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3a01d001-c8a6-424d-8446-8ed339bb8c15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_80c74d6e-5d9d-4053-b860-0598d43a9bfd" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3a01d001-c8a6-424d-8446-8ed339bb8c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_784b43b4-edff-42fe-9fb3-a39136b6d0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_80c74d6e-5d9d-4053-b860-0598d43a9bfd" xlink:to="loc_us-gaap_StockholdersEquityAbstract_784b43b4-edff-42fe-9fb3-a39136b6d0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ef88773f-3f26-418a-a043-44d1c0ad333c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_784b43b4-edff-42fe-9fb3-a39136b6d0aa" xlink:to="loc_us-gaap_CommonStockValue_ef88773f-3f26-418a-a043-44d1c0ad333c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8bf30629-5db6-4429-86d0-9130431a8ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_784b43b4-edff-42fe-9fb3-a39136b6d0aa" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8bf30629-5db6-4429-86d0-9130431a8ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_280c7031-a19c-419c-87f7-47730885fa57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_784b43b4-edff-42fe-9fb3-a39136b6d0aa" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_280c7031-a19c-419c-87f7-47730885fa57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7bc338ac-794a-49aa-9cbb-be496d94c415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_784b43b4-edff-42fe-9fb3-a39136b6d0aa" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7bc338ac-794a-49aa-9cbb-be496d94c415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8402d8fb-878a-4ea7-93ee-299c69a54cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_784b43b4-edff-42fe-9fb3-a39136b6d0aa" xlink:to="loc_us-gaap_StockholdersEquity_8402d8fb-878a-4ea7-93ee-299c69a54cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_3359c952-e4c3-4190-81a0-be888815aca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_784b43b4-edff-42fe-9fb3-a39136b6d0aa" xlink:to="loc_us-gaap_MinorityInterest_3359c952-e4c3-4190-81a0-be888815aca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d4fafd3a-619c-4942-95cd-0590ab20b3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_784b43b4-edff-42fe-9fb3-a39136b6d0aa" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d4fafd3a-619c-4942-95cd-0590ab20b3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_21973300-00fc-446e-9aaf-0af8f4ccdcca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_80c74d6e-5d9d-4053-b860-0598d43a9bfd" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_21973300-00fc-446e-9aaf-0af8f4ccdcca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="bhc-20220630.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b7157f5e-52db-48de-a150-dfa8a4ee4a25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_fe284bfe-c8e6-4524-8086-e9e0fdfab39a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b7157f5e-52db-48de-a150-dfa8a4ee4a25" xlink:to="loc_us-gaap_CommonStockSharesIssued_fe284bfe-c8e6-4524-8086-e9e0fdfab39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ac7389f6-c651-4bcf-b9f3-d20a43604918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b7157f5e-52db-48de-a150-dfa8a4ee4a25" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ac7389f6-c651-4bcf-b9f3-d20a43604918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bhc-20220630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_e43d9035-0a3a-4a74-aaae-9d1e477a4c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_33993ae0-bb20-4a30-9495-666246e094d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e43d9035-0a3a-4a74-aaae-9d1e477a4c29" xlink:to="loc_us-gaap_StatementTable_33993ae0-bb20-4a30-9495-666246e094d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f73bc642-0b5d-4443-97ed-6b9a832bda98" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_33993ae0-bb20-4a30-9495-666246e094d9" xlink:to="loc_srt_ProductOrServiceAxis_f73bc642-0b5d-4443-97ed-6b9a832bda98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c5ed4a1c-5943-4e94-badf-6a297da066a1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f73bc642-0b5d-4443-97ed-6b9a832bda98" xlink:to="loc_srt_ProductsAndServicesDomain_c5ed4a1c-5943-4e94-badf-6a297da066a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_91c0298b-c88d-4c32-b462-062b37f4bc12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5ed4a1c-5943-4e94-badf-6a297da066a1" xlink:to="loc_us-gaap_ProductMember_91c0298b-c88d-4c32-b462-062b37f4bc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_da5b202d-3167-4416-888a-5736606ac258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c5ed4a1c-5943-4e94-badf-6a297da066a1" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_da5b202d-3167-4416-888a-5736606ac258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_33993ae0-bb20-4a30-9495-666246e094d9" xlink:to="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_ed36541b-ab5e-49fd-9268-5fe44a9437e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_RevenuesAbstract_ed36541b-ab5e-49fd-9268-5fe44a9437e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9f628dda-858f-445c-a4f0-297791785445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_ed36541b-ab5e-49fd-9268-5fe44a9437e9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9f628dda-858f-445c-a4f0-297791785445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_0344d775-d641-4098-b750-810cf061dad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_0344d775-d641-4098-b750-810cf061dad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d08b6721-a069-4903-96ca-9cd63c880e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0344d775-d641-4098-b750-810cf061dad8" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d08b6721-a069-4903-96ca-9cd63c880e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7da73ac8-fbca-44e6-8ec0-efed5225149f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0344d775-d641-4098-b750-810cf061dad8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7da73ac8-fbca-44e6-8ec0-efed5225149f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4e9ef837-c072-4b97-8b42-24176add9d03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0344d775-d641-4098-b750-810cf061dad8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4e9ef837-c072-4b97-8b42-24176add9d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_1d819cc8-79d0-461b-8790-018bd055f0ca" xlink:href="bhc-20220630.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0344d775-d641-4098-b750-810cf061dad8" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_1d819cc8-79d0-461b-8790-018bd055f0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_4778e4f0-f1d2-4977-bbf1-7f48cbb1d370" xlink:href="bhc-20220630.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0344d775-d641-4098-b750-810cf061dad8" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_4778e4f0-f1d2-4977-bbf1-7f48cbb1d370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_4aee2aba-6b9b-4a42-8cdd-2a535936f6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0344d775-d641-4098-b750-810cf061dad8" xlink:to="loc_us-gaap_AssetImpairmentCharges_4aee2aba-6b9b-4a42-8cdd-2a535936f6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_7872f56d-940a-4e8a-ade5-4f7077a4513b" xlink:href="bhc-20220630.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0344d775-d641-4098-b750-810cf061dad8" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_7872f56d-940a-4e8a-ade5-4f7077a4513b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_3b795495-fa92-4487-bc62-5053f3e7e2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0344d775-d641-4098-b750-810cf061dad8" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_3b795495-fa92-4487-bc62-5053f3e7e2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_111fae42-11a2-485d-bbf8-18312fb1adff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_0344d775-d641-4098-b750-810cf061dad8" xlink:to="loc_us-gaap_CostsAndExpenses_111fae42-11a2-485d-bbf8-18312fb1adff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6a38ef55-476c-40a9-902c-b615cc36aa86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_OperatingIncomeLoss_6a38ef55-476c-40a9-902c-b615cc36aa86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_0c1716ab-4ddb-4ceb-882c-41eb87ee3306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_InvestmentIncomeInterest_0c1716ab-4ddb-4ceb-882c-41eb87ee3306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_e4f53e8c-000b-49eb-abe9-21da0989642a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_InterestExpenseDebt_e4f53e8c-000b-49eb-abe9-21da0989642a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_92ff57e0-ddf8-4f05-a1f0-22137ceaa6be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_92ff57e0-ddf8-4f05-a1f0-22137ceaa6be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_a3d6b891-0dff-49ab-a1c1-6cc62914b249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_a3d6b891-0dff-49ab-a1c1-6cc62914b249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e10648f2-d686-4418-a39e-a5f033d64fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e10648f2-d686-4418-a39e-a5f033d64fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_92872358-bf02-4f90-b7a4-88bd6ef2fc03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_92872358-bf02-4f90-b7a4-88bd6ef2fc03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c1ce6b26-8f72-4f10-a263-98a0316429f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_ProfitLoss_c1ce6b26-8f72-4f10-a263-98a0316429f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5be641ee-3377-4e12-b176-cf4b88bf1444" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5be641ee-3377-4e12-b176-cf4b88bf1444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a9ba92ac-bf01-4312-9fef-1ee35d0a901f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_NetIncomeLoss_a9ba92ac-bf01-4312-9fef-1ee35d0a901f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_64d82cd3-a427-4e83-8ddb-8de66e258dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_EarningsPerShareBasic_64d82cd3-a427-4e83-8ddb-8de66e258dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_78c7fbec-1e93-4783-867f-e667f17ad119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_EarningsPerShareDiluted_78c7fbec-1e93-4783-867f-e667f17ad119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8bfa85fe-b018-4095-abd4-e8383e9c58e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8bfa85fe-b018-4095-abd4-e8383e9c58e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_54fe581e-9afa-4dd7-8049-eaece1f0a98d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e65da170-6811-4118-b9bf-3f0183cc1d33" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_54fe581e-9afa-4dd7-8049-eaece1f0a98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bhc-20220630.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d8360901-0891-4667-9be6-29f081ee1eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_44acaffa-9486-404c-8cc6-1417c17d0a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d8360901-0891-4667-9be6-29f081ee1eb1" xlink:to="loc_us-gaap_ProfitLoss_44acaffa-9486-404c-8cc6-1417c17d0a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_77c9c83b-83c5-4610-a841-307d870b8f99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d8360901-0891-4667-9be6-29f081ee1eb1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_77c9c83b-83c5-4610-a841-307d870b8f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_33b23a5a-93e2-4159-85c9-769de79f4a41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_77c9c83b-83c5-4610-a841-307d870b8f99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_33b23a5a-93e2-4159-85c9-769de79f4a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_84b6fe5c-31ae-4dd8-8f35-3eabff417fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_77c9c83b-83c5-4610-a841-307d870b8f99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_84b6fe5c-31ae-4dd8-8f35-3eabff417fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3c030778-73d5-4c43-af32-7138e2a24b62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_77c9c83b-83c5-4610-a841-307d870b8f99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3c030778-73d5-4c43-af32-7138e2a24b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_444bac47-9709-4da6-b8b8-34c050b9626e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d8360901-0891-4667-9be6-29f081ee1eb1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_444bac47-9709-4da6-b8b8-34c050b9626e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_36c2ab13-cabd-4d53-bb58-ce3774ee2f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d8360901-0891-4667-9be6-29f081ee1eb1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_36c2ab13-cabd-4d53-bb58-ce3774ee2f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_63ff8a30-e006-4a41-a0ab-84e5bf0c8fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d8360901-0891-4667-9be6-29f081ee1eb1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_63ff8a30-e006-4a41-a0ab-84e5bf0c8fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="bhc-20220630.xsd#CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d500c259-c70c-4719-a3d9-160c0753402f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0245ddaf-4b70-4cba-9879-2ec01a71e2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d500c259-c70c-4719-a3d9-160c0753402f" xlink:to="loc_us-gaap_StatementTable_0245ddaf-4b70-4cba-9879-2ec01a71e2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4c49ef5b-88e0-4c9c-8adc-2819196db738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0245ddaf-4b70-4cba-9879-2ec01a71e2c9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4c49ef5b-88e0-4c9c-8adc-2819196db738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b8f9282d-d952-456c-bbec-32ab39e4bd49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4c49ef5b-88e0-4c9c-8adc-2819196db738" xlink:to="loc_us-gaap_EquityComponentDomain_b8f9282d-d952-456c-bbec-32ab39e4bd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_dba81a2b-8f36-4dbd-a300-2a3a65d267da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8f9282d-d952-456c-bbec-32ab39e4bd49" xlink:to="loc_us-gaap_ParentMember_dba81a2b-8f36-4dbd-a300-2a3a65d267da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ea644766-10e3-48f1-aea9-db65dbeec4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_dba81a2b-8f36-4dbd-a300-2a3a65d267da" xlink:to="loc_us-gaap_CommonStockMember_ea644766-10e3-48f1-aea9-db65dbeec4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_be180383-4020-469e-8310-fa4ceeb995a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_dba81a2b-8f36-4dbd-a300-2a3a65d267da" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_be180383-4020-469e-8310-fa4ceeb995a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_02e8f100-28b5-4255-b330-a48b27b08db2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_dba81a2b-8f36-4dbd-a300-2a3a65d267da" xlink:to="loc_us-gaap_RetainedEarningsMember_02e8f100-28b5-4255-b330-a48b27b08db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fa5672ec-0d45-43c1-a595-6b24986a9954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_dba81a2b-8f36-4dbd-a300-2a3a65d267da" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fa5672ec-0d45-43c1-a595-6b24986a9954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_33087ee1-6481-41cf-a1a8-a0727fa2a82c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8f9282d-d952-456c-bbec-32ab39e4bd49" xlink:to="loc_us-gaap_NoncontrollingInterestMember_33087ee1-6481-41cf-a1a8-a0727fa2a82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_506077bf-7c75-4c96-b930-e51fb3527657" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0245ddaf-4b70-4cba-9879-2ec01a71e2c9" xlink:to="loc_us-gaap_StatementLineItems_506077bf-7c75-4c96-b930-e51fb3527657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ba2b31d6-dc79-4335-b721-3044b803ac34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_506077bf-7c75-4c96-b930-e51fb3527657" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ba2b31d6-dc79-4335-b721-3044b803ac34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4678f3c0-15ab-41b4-9f87-cd53a40d1252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ba2b31d6-dc79-4335-b721-3044b803ac34" xlink:to="loc_us-gaap_CommonStockSharesIssued_4678f3c0-15ab-41b4-9f87-cd53a40d1252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8895574b-794d-4325-af37-63f1716bd491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ba2b31d6-dc79-4335-b721-3044b803ac34" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8895574b-794d-4325-af37-63f1716bd491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8b168354-4a24-4c87-a41b-720d2edddd75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ba2b31d6-dc79-4335-b721-3044b803ac34" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8b168354-4a24-4c87-a41b-720d2edddd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7909477f-af30-4712-8779-1c81c29ba1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ba2b31d6-dc79-4335-b721-3044b803ac34" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7909477f-af30-4712-8779-1c81c29ba1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_321dc4cf-5ea4-4301-bc7d-a35baa055858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ba2b31d6-dc79-4335-b721-3044b803ac34" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_321dc4cf-5ea4-4301-bc7d-a35baa055858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1d9bb6d1-71a3-403c-b328-165b6c01ff2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ba2b31d6-dc79-4335-b721-3044b803ac34" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1d9bb6d1-71a3-403c-b328-165b6c01ff2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_b62f3c1d-0ef8-4863-a015-fc5767925e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ba2b31d6-dc79-4335-b721-3044b803ac34" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_b62f3c1d-0ef8-4863-a015-fc5767925e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7f928b2d-32c8-4b69-a005-5412f4666f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ba2b31d6-dc79-4335-b721-3044b803ac34" xlink:to="loc_us-gaap_ProfitLoss_7f928b2d-32c8-4b69-a005-5412f4666f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f4317d39-5389-4e39-b5be-db063d9157ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ba2b31d6-dc79-4335-b721-3044b803ac34" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f4317d39-5389-4e39-b5be-db063d9157ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4b21f513-8d3d-474f-b4b7-50f8277263ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ba2b31d6-dc79-4335-b721-3044b803ac34" xlink:to="loc_us-gaap_CommonStockSharesIssued_4b21f513-8d3d-474f-b4b7-50f8277263ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ac13a273-db07-4e8d-8706-ae4944bdfdc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ba2b31d6-dc79-4335-b721-3044b803ac34" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ac13a273-db07-4e8d-8706-ae4944bdfdc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bhc-20220630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_898b01c2-0a06-4c34-aeec-358c43644735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f0da37fc-abde-4447-9f4c-1d9c34901688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_898b01c2-0a06-4c34-aeec-358c43644735" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f0da37fc-abde-4447-9f4c-1d9c34901688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6a593822-63bc-409e-b75c-7f03d1edc0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f0da37fc-abde-4447-9f4c-1d9c34901688" xlink:to="loc_us-gaap_ProfitLoss_6a593822-63bc-409e-b75c-7f03d1edc0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55577e28-2ec3-43f8-b9f3-e34b966b6500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f0da37fc-abde-4447-9f4c-1d9c34901688" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55577e28-2ec3-43f8-b9f3-e34b966b6500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_a747cd4f-6a2b-49a2-985c-ce45990bdb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55577e28-2ec3-43f8-b9f3-e34b966b6500" xlink:to="loc_us-gaap_DepreciationAndAmortization_a747cd4f-6a2b-49a2-985c-ce45990bdb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_8c4ef74f-9cba-46de-833a-b6ac67d1d950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55577e28-2ec3-43f8-b9f3-e34b966b6500" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_8c4ef74f-9cba-46de-833a-b6ac67d1d950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_6685ce32-cb4f-4a5e-b972-05443d92308f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55577e28-2ec3-43f8-b9f3-e34b966b6500" xlink:to="loc_us-gaap_AssetImpairmentCharges_6685ce32-cb4f-4a5e-b972-05443d92308f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_cf5de7e2-8421-438b-beab-10569f1c8773" xlink:href="bhc-20220630.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55577e28-2ec3-43f8-b9f3-e34b966b6500" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_cf5de7e2-8421-438b-beab-10569f1c8773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_e9f844c5-23be-452a-98a4-f75eb1a3e49d" xlink:href="bhc-20220630.xsd#bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55577e28-2ec3-43f8-b9f3-e34b966b6500" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_e9f844c5-23be-452a-98a4-f75eb1a3e49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_c13aad62-c1d9-4176-b150-35420598d73d" xlink:href="bhc-20220630.xsd#bhc_AllowancesForLossesOnAccountsReceivableAndInventories"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55577e28-2ec3-43f8-b9f3-e34b966b6500" xlink:to="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_c13aad62-c1d9-4176-b150-35420598d73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_e7b27cd3-389c-4780-9647-9cc6a1188f41" xlink:href="bhc-20220630.xsd#bhc_DeferredIncomeTaxNoncashExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55577e28-2ec3-43f8-b9f3-e34b966b6500" xlink:to="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_e7b27cd3-389c-4780-9647-9cc6a1188f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_55c6b3aa-0e22-44d7-b096-b7ab2925a95c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55577e28-2ec3-43f8-b9f3-e34b966b6500" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_55c6b3aa-0e22-44d7-b096-b7ab2925a95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainLossRelatedToLitigationSettlementGross_bdf4d270-0513-4e75-91d6-7c4eabdce54c" xlink:href="bhc-20220630.xsd#bhc_GainLossRelatedToLitigationSettlementGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55577e28-2ec3-43f8-b9f3-e34b966b6500" xlink:to="loc_bhc_GainLossRelatedToLitigationSettlementGross_bdf4d270-0513-4e75-91d6-7c4eabdce54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_88bf50ea-a339-4ee7-9ea8-d2fb792ee9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55577e28-2ec3-43f8-b9f3-e34b966b6500" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_88bf50ea-a339-4ee7-9ea8-d2fb792ee9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b382f0c9-a372-4be5-b630-f7c81ee0c97d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55577e28-2ec3-43f8-b9f3-e34b966b6500" xlink:to="loc_us-gaap_ShareBasedCompensation_b382f0c9-a372-4be5-b630-f7c81ee0c97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_5267a928-debb-4c4b-800c-4edd5114210b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55577e28-2ec3-43f8-b9f3-e34b966b6500" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_5267a928-debb-4c4b-800c-4edd5114210b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeGainExcludedComponent_fb320534-2a13-4c9e-873b-6d12126e29a1" xlink:href="bhc-20220630.xsd#bhc_DerivativeGainExcludedComponent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55577e28-2ec3-43f8-b9f3-e34b966b6500" xlink:to="loc_bhc_DerivativeGainExcludedComponent_fb320534-2a13-4c9e-873b-6d12126e29a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8bbf5197-364d-4e66-8d0f-2469746d1e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55577e28-2ec3-43f8-b9f3-e34b966b6500" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_8bbf5197-364d-4e66-8d0f-2469746d1e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_58f2cfd0-f749-48d4-bce4-4ea190c8bcf2" xlink:href="bhc-20220630.xsd#bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55577e28-2ec3-43f8-b9f3-e34b966b6500" xlink:to="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_58f2cfd0-f749-48d4-bce4-4ea190c8bcf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_7119fa31-abe5-4547-abe1-15cc8b1625ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55577e28-2ec3-43f8-b9f3-e34b966b6500" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_7119fa31-abe5-4547-abe1-15cc8b1625ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a2e74ba3-9e31-4fdf-81f0-37af12a4c68a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_55577e28-2ec3-43f8-b9f3-e34b966b6500" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a2e74ba3-9e31-4fdf-81f0-37af12a4c68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a698c96a-bbc7-48a5-8120-07f8a7506094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a2e74ba3-9e31-4fdf-81f0-37af12a4c68a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a698c96a-bbc7-48a5-8120-07f8a7506094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_a5c97968-b5b5-4c1d-a035-39f9088f416f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a2e74ba3-9e31-4fdf-81f0-37af12a4c68a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_a5c97968-b5b5-4c1d-a035-39f9088f416f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3874322a-d024-481c-b541-0cc81a30f1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a2e74ba3-9e31-4fdf-81f0-37af12a4c68a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3874322a-d024-481c-b541-0cc81a30f1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4142230b-0dec-473a-82df-84313df42b54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a2e74ba3-9e31-4fdf-81f0-37af12a4c68a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4142230b-0dec-473a-82df-84313df42b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a7430793-2a34-47f3-a5ca-dbf5129541d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f0da37fc-abde-4447-9f4c-1d9c34901688" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a7430793-2a34-47f3-a5ca-dbf5129541d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0baed10c-adca-4326-87ac-895ccfb6cf04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_898b01c2-0a06-4c34-aeec-358c43644735" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0baed10c-adca-4326-87ac-895ccfb6cf04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1419ab8f-5d48-4917-b6b6-cec2558ef50c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0baed10c-adca-4326-87ac-895ccfb6cf04" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1419ab8f-5d48-4917-b6b6-cec2558ef50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_3443d798-0ec4-42f1-b1fc-f9ce52e7367f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0baed10c-adca-4326-87ac-895ccfb6cf04" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_3443d798-0ec4-42f1-b1fc-f9ce52e7367f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_2e6e4173-7cda-4c81-8f5c-a3f4fd8074d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0baed10c-adca-4326-87ac-895ccfb6cf04" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_2e6e4173-7cda-4c81-8f5c-a3f4fd8074d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_00f8375e-03a5-41c0-81c7-3a11e022a9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0baed10c-adca-4326-87ac-895ccfb6cf04" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_00f8375e-03a5-41c0-81c7-3a11e022a9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_fbe4c939-f470-46a9-9e63-8a86cea43028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0baed10c-adca-4326-87ac-895ccfb6cf04" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_fbe4c939-f470-46a9-9e63-8a86cea43028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InterestSettlementOnCrossCurrencySwaps_121fa647-2aea-4dfe-876e-637b2b66c445" xlink:href="bhc-20220630.xsd#bhc_InterestSettlementOnCrossCurrencySwaps"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0baed10c-adca-4326-87ac-895ccfb6cf04" xlink:to="loc_bhc_InterestSettlementOnCrossCurrencySwaps_121fa647-2aea-4dfe-876e-637b2b66c445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_411067c8-a923-4043-aa59-665dd8bbd228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0baed10c-adca-4326-87ac-895ccfb6cf04" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_411067c8-a923-4043-aa59-665dd8bbd228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4b61fef1-aed7-45f1-afe5-2d00e0d41f63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_898b01c2-0a06-4c34-aeec-358c43644735" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4b61fef1-aed7-45f1-afe5-2d00e0d41f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9419f2d4-c173-495e-b15e-df736ae1e91a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4b61fef1-aed7-45f1-afe5-2d00e0d41f63" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9419f2d4-c173-495e-b15e-df736ae1e91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_368165fe-d601-4a68-9307-6d243805516b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4b61fef1-aed7-45f1-afe5-2d00e0d41f63" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_368165fe-d601-4a68-9307-6d243805516b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty_22e6cdad-9ec4-4718-a00a-22e75d3889b0" xlink:href="bhc-20220630.xsd#bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4b61fef1-aed7-45f1-afe5-2d00e0d41f63" xlink:to="loc_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty_22e6cdad-9ec4-4718-a00a-22e75d3889b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_47930fce-461d-4ecc-894e-6876ff4d10a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4b61fef1-aed7-45f1-afe5-2d00e0d41f63" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_47930fce-461d-4ecc-894e-6876ff4d10a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_783f6f05-8bdd-4ff5-8679-49faf9789663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4b61fef1-aed7-45f1-afe5-2d00e0d41f63" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_783f6f05-8bdd-4ff5-8679-49faf9789663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_741a552b-05d2-4abf-9ef2-a24757797235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4b61fef1-aed7-45f1-afe5-2d00e0d41f63" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_741a552b-05d2-4abf-9ef2-a24757797235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_ec766216-e67d-4667-a204-a362abe763dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4b61fef1-aed7-45f1-afe5-2d00e0d41f63" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_ec766216-e67d-4667-a204-a362abe763dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d7f92287-9d3c-426e-b31e-abad9f218f60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4b61fef1-aed7-45f1-afe5-2d00e0d41f63" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d7f92287-9d3c-426e-b31e-abad9f218f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ee83183d-efd7-45bb-a316-b848c0a12eed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_898b01c2-0a06-4c34-aeec-358c43644735" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ee83183d-efd7-45bb-a316-b848c0a12eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cc3f6e9b-1c25-4f83-ad0a-aaa604b66778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_898b01c2-0a06-4c34-aeec-358c43644735" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cc3f6e9b-1c25-4f83-ad0a-aaa604b66778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4e0115d0-4e63-4f1d-bf26-db5491f5deb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_898b01c2-0a06-4c34-aeec-358c43644735" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4e0115d0-4e63-4f1d-bf26-db5491f5deb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b2e9bcdf-9a8d-4073-9ecb-a690dfc39d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_898b01c2-0a06-4c34-aeec-358c43644735" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b2e9bcdf-9a8d-4073-9ecb-a690dfc39d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a808c548-5d16-41e7-88fd-b24d515f88ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_898b01c2-0a06-4c34-aeec-358c43644735" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a808c548-5d16-41e7-88fd-b24d515f88ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_d088e9f3-afe8-4173-b8e5-63157ece4f3b" xlink:href="bhc-20220630.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_898b01c2-0a06-4c34-aeec-358c43644735" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_d088e9f3-afe8-4173-b8e5-63157ece4f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_ca54a69a-bcba-4884-ae32-3c2b194481b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_898b01c2-0a06-4c34-aeec-358c43644735" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_ca54a69a-bcba-4884-ae32-3c2b194481b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aa549a5d-51f7-4c96-a03f-eb1ca4547ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_898b01c2-0a06-4c34-aeec-358c43644735" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aa549a5d-51f7-4c96-a03f-eb1ca4547ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="bhc-20220630.xsd#DESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_934d537a-910e-480e-b06f-ae5fefbaeb88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_4cf15290-f227-49da-a4c8-34e2ed703f82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_934d537a-910e-480e-b06f-ae5fefbaeb88" xlink:to="loc_us-gaap_NatureOfOperations_4cf15290-f227-49da-a4c8-34e2ed703f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#DESCRIPTIONOFBUSINESSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e9520729-de11-4114-8b33-e1044def67f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_08fdaa49-12d0-4742-b9ae-ed863772f3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e9520729-de11-4114-8b33-e1044def67f2" xlink:to="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_08fdaa49-12d0-4742-b9ae-ed863772f3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_7ee6991f-82f8-4b4a-922d-302ddd5bcd67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e9520729-de11-4114-8b33-e1044def67f2" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_7ee6991f-82f8-4b4a-922d-302ddd5bcd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_b38b67f6-9838-436e-bb27-e664b8795967" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_7ee6991f-82f8-4b4a-922d-302ddd5bcd67" xlink:to="loc_srt_OwnershipAxis_b38b67f6-9838-436e-bb27-e664b8795967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_5eb2f128-402e-4b8b-b5d1-2914b0aad1db" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_b38b67f6-9838-436e-bb27-e664b8795967" xlink:to="loc_srt_OwnershipDomain_5eb2f128-402e-4b8b-b5d1-2914b0aad1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_92affc08-bf8a-4f03-b7b1-8e6c96793989" xlink:href="bhc-20220630.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_5eb2f128-402e-4b8b-b5d1-2914b0aad1db" xlink:to="loc_bhc_BauschLombMember_92affc08-bf8a-4f03-b7b1-8e6c96793989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d5693bf2-c9ad-4253-bd90-24cdd9f8202a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_7ee6991f-82f8-4b4a-922d-302ddd5bcd67" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d5693bf2-c9ad-4253-bd90-24cdd9f8202a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_dc8d286b-2fb9-4a88-92dc-3eb544719047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_d5693bf2-c9ad-4253-bd90-24cdd9f8202a" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_dc8d286b-2fb9-4a88-92dc-3eb544719047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="bhc-20220630.xsd#SIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fccd8a82-459c-4f60-9ca4-0e9f0f0c6336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_772a0fdb-27f3-404c-b295-e3e24466d32e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fccd8a82-459c-4f60-9ca4-0e9f0f0c6336" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_772a0fdb-27f3-404c-b295-e3e24466d32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="bhc-20220630.xsd#SIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_18e00bbf-98a3-43f4-b9e8-b6b248de3cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_074c786e-a193-4c71-bc39-120e327ac501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_18e00bbf-98a3-43f4-b9e8-b6b248de3cfe" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_074c786e-a193-4c71-bc39-120e327ac501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_c40fdb5d-e292-423f-8b5a-88534b91182e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_18e00bbf-98a3-43f4-b9e8-b6b248de3cfe" xlink:to="loc_us-gaap_UseOfEstimates_c40fdb5d-e292-423f-8b5a-88534b91182e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_0b16e579-0410-435e-8547-ee0c05e73924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_18e00bbf-98a3-43f4-b9e8-b6b248de3cfe" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_0b16e579-0410-435e-8547-ee0c05e73924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_0af2c6d1-d786-4808-8246-25df251f81d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_18e00bbf-98a3-43f4-b9e8-b6b248de3cfe" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_0af2c6d1-d786-4808-8246-25df251f81d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_ef235ebf-b659-4534-aa40-6a86977b1138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_18e00bbf-98a3-43f4-b9e8-b6b248de3cfe" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_ef235ebf-b659-4534-aa40-6a86977b1138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_29f2188e-8c30-45a5-b03c-7f5aac1ac440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_dfb2cf22-e539-46e1-8993-7eb44e6d8cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_29f2188e-8c30-45a5-b03c-7f5aac1ac440" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_dfb2cf22-e539-46e1-8993-7eb44e6d8cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c508d48d-d6c9-4a92-af6d-9a3b0d42e0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_dfb2cf22-e539-46e1-8993-7eb44e6d8cdc" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c508d48d-d6c9-4a92-af6d-9a3b0d42e0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_102c98fd-2c8d-43e9-89f7-470f612cc6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c508d48d-d6c9-4a92-af6d-9a3b0d42e0ba" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_102c98fd-2c8d-43e9-89f7-470f612cc6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IPOAndOverAllotmentOptionMember_c6f103e4-d835-46db-9073-fbedb0b78e7c" xlink:href="bhc-20220630.xsd#bhc_IPOAndOverAllotmentOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_102c98fd-2c8d-43e9-89f7-470f612cc6ae" xlink:to="loc_bhc_IPOAndOverAllotmentOptionMember_c6f103e4-d835-46db-9073-fbedb0b78e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_13b05fbe-7697-4f2e-8b9e-bfdda730ca5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IPOAndOverAllotmentOptionMember_c6f103e4-d835-46db-9073-fbedb0b78e7c" xlink:to="loc_us-gaap_IPOMember_13b05fbe-7697-4f2e-8b9e-bfdda730ca5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_262adb7e-f6f9-4d06-a21e-b0b4c0144371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IPOAndOverAllotmentOptionMember_c6f103e4-d835-46db-9073-fbedb0b78e7c" xlink:to="loc_us-gaap_OverAllotmentOptionMember_262adb7e-f6f9-4d06-a21e-b0b4c0144371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_bb4cb9af-6a1e-4e83-a119-ad69780f1d25" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_dfb2cf22-e539-46e1-8993-7eb44e6d8cdc" xlink:to="loc_srt_OwnershipAxis_bb4cb9af-6a1e-4e83-a119-ad69780f1d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_95d57de2-b49b-4b8b-8f93-0cd6502813ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_bb4cb9af-6a1e-4e83-a119-ad69780f1d25" xlink:to="loc_srt_OwnershipDomain_95d57de2-b49b-4b8b-8f93-0cd6502813ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_8bb3fb55-3383-4d6d-8051-bbb61ebbbb3b" xlink:href="bhc-20220630.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_95d57de2-b49b-4b8b-8f93-0cd6502813ba" xlink:to="loc_bhc_BauschLombMember_8bb3fb55-3383-4d6d-8051-bbb61ebbbb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_e693906f-284c-466f-8bdb-20655c51c63b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_dfb2cf22-e539-46e1-8993-7eb44e6d8cdc" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_e693906f-284c-466f-8bdb-20655c51c63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3f368fb7-b651-47f1-b16a-47af1a1a559e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e693906f-284c-466f-8bdb-20655c51c63b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3f368fb7-b651-47f1-b16a-47af1a1a559e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_52787568-7527-48cc-87f4-8766c085d572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e693906f-284c-466f-8bdb-20655c51c63b" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_52787568-7527-48cc-87f4-8766c085d572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SaleOfStockOverAllotmentTerm_e9cea870-0420-4ace-b5b0-bfaadaf38d8b" xlink:href="bhc-20220630.xsd#bhc_SaleOfStockOverAllotmentTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e693906f-284c-466f-8bdb-20655c51c63b" xlink:to="loc_bhc_SaleOfStockOverAllotmentTerm_e9cea870-0420-4ace-b5b0-bfaadaf38d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance_bea4354f-d8ed-4c50-9a89-3bff29f54036" xlink:href="bhc-20220630.xsd#bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e693906f-284c-466f-8bdb-20655c51c63b" xlink:to="loc_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance_bea4354f-d8ed-4c50-9a89-3bff29f54036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d7c5a8cd-437c-450d-9af2-1fd92a945750" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e693906f-284c-466f-8bdb-20655c51c63b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d7c5a8cd-437c-450d-9af2-1fd92a945750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_b723fe01-5b1c-4f21-96fc-6122048dc562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e693906f-284c-466f-8bdb-20655c51c63b" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_b723fe01-5b1c-4f21-96fc-6122048dc562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f019f735-5e3f-4176-9af7-a5eae9cb9791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e693906f-284c-466f-8bdb-20655c51c63b" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f019f735-5e3f-4176-9af7-a5eae9cb9791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITION" xlink:type="simple" xlink:href="bhc-20220630.xsd#REVENUERECOGNITION"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cde67ee2-d5a8-4f91-9d5c-897119097da9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_fa44997a-0999-494c-b2c2-bdc96eee677f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_cde67ee2-d5a8-4f91-9d5c-897119097da9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_fa44997a-0999-494c-b2c2-bdc96eee677f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONTables" xlink:type="simple" xlink:href="bhc-20220630.xsd#REVENUERECOGNITIONTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_169f3ab7-e96d-4a59-8555-df4010917abd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_f97d9b29-6319-4d82-a444-5d6b70994e79" xlink:href="bhc-20220630.xsd#bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_169f3ab7-e96d-4a59-8555-df4010917abd" xlink:to="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_f97d9b29-6319-4d82-a444-5d6b70994e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_6d1e06f8-a550-4aba-8e53-cabab281954d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_169f3ab7-e96d-4a59-8555-df4010917abd" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_6d1e06f8-a550-4aba-8e53-cabab281954d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#REVENUERECOGNITIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_81ea5b60-9870-4814-9e1e-ea2b95976ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_9ea26615-9d28-4187-b7e7-87aa636e1599" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_81ea5b60-9870-4814-9e1e-ea2b95976ab4" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_9ea26615-9d28-4187-b7e7-87aa636e1599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_30ab0748-8eed-4255-83a5-05cb427cf638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_9ea26615-9d28-4187-b7e7-87aa636e1599" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_30ab0748-8eed-4255-83a5-05cb427cf638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_e00c971a-7303-4137-8f50-b54ee44243e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_30ab0748-8eed-4255-83a5-05cb427cf638" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_e00c971a-7303-4137-8f50-b54ee44243e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_9c9c45dd-e743-4cc1-84b5-88f82f4354d5" xlink:href="bhc-20220630.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e00c971a-7303-4137-8f50-b54ee44243e6" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_9c9c45dd-e743-4cc1-84b5-88f82f4354d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_7214ccc0-ce28-4819-8f73-1af4bbe03097" xlink:href="bhc-20220630.xsd#bhc_ReserveForRebatesAdvertisingCreditsPortionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e00c971a-7303-4137-8f50-b54ee44243e6" xlink:to="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_7214ccc0-ce28-4819-8f73-1af4bbe03097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_abc1579c-649b-4003-b5c2-ee1b54a706da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_9ea26615-9d28-4187-b7e7-87aa636e1599" xlink:to="loc_srt_ProductOrServiceAxis_abc1579c-649b-4003-b5c2-ee1b54a706da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1659437c-be13-4b06-b877-b237aff8cbf2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_abc1579c-649b-4003-b5c2-ee1b54a706da" xlink:to="loc_srt_ProductsAndServicesDomain_1659437c-be13-4b06-b877-b237aff8cbf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PriceAppreciationCreditMember_36080ac3-3c47-4918-88a2-d178c6c01712" xlink:href="bhc-20220630.xsd#bhc_PriceAppreciationCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1659437c-be13-4b06-b877-b237aff8cbf2" xlink:to="loc_bhc_PriceAppreciationCreditMember_36080ac3-3c47-4918-88a2-d178c6c01712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_742da137-f521-4801-8706-9366e6021163" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_9ea26615-9d28-4187-b7e7-87aa636e1599" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_742da137-f521-4801-8706-9366e6021163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_5383913e-0c3d-42ee-96b0-9d7803c08077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_742da137-f521-4801-8706-9366e6021163" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_5383913e-0c3d-42ee-96b0-9d7803c08077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_01b84b81-61e8-425b-881b-08ecd7d49153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_742da137-f521-4801-8706-9366e6021163" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_01b84b81-61e8-425b-881b-08ecd7d49153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2298b9e9-63fc-4350-8e39-cb2809570cba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_742da137-f521-4801-8706-9366e6021163" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2298b9e9-63fc-4350-8e39-cb2809570cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#REVENUERECOGNITIONVariableConsiderationProvisionsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a94bbb62-a34b-4f55-ae9b-3a8d374c2ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a07370ae-e923-4c5d-a8a1-e169f216f440" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a94bbb62-a34b-4f55-ae9b-3a8d374c2ff5" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a07370ae-e923-4c5d-a8a1-e169f216f440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1552dadb-9d5d-4d74-b43c-cc6056699055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a07370ae-e923-4c5d-a8a1-e169f216f440" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1552dadb-9d5d-4d74-b43c-cc6056699055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_1da73fad-d41f-4d45-89cb-c94a5cde1115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1552dadb-9d5d-4d74-b43c-cc6056699055" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_1da73fad-d41f-4d45-89cb-c94a5cde1115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDiscountsAndAllowancesMember_3cdb02f5-9a99-4be9-aa65-efe1ae99ebc2" xlink:href="bhc-20220630.xsd#bhc_ReserveForDiscountsAndAllowancesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1da73fad-d41f-4d45-89cb-c94a5cde1115" xlink:to="loc_bhc_ReserveForDiscountsAndAllowancesMember_3cdb02f5-9a99-4be9-aa65-efe1ae99ebc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_a0ae52a7-1957-486b-b3b4-1a6c08fe6240" xlink:href="bhc-20220630.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1da73fad-d41f-4d45-89cb-c94a5cde1115" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_a0ae52a7-1957-486b-b3b4-1a6c08fe6240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesMember_178afff2-e312-4a66-811e-a01bee66f0a2" xlink:href="bhc-20220630.xsd#bhc_ReserveForRebatesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1da73fad-d41f-4d45-89cb-c94a5cde1115" xlink:to="loc_bhc_ReserveForRebatesMember_178afff2-e312-4a66-811e-a01bee66f0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForChargebacksMember_7465dc85-0b39-4ed1-a30d-62da29c78d19" xlink:href="bhc-20220630.xsd#bhc_ReserveForChargebacksMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1da73fad-d41f-4d45-89cb-c94a5cde1115" xlink:to="loc_bhc_ReserveForChargebacksMember_7465dc85-0b39-4ed1-a30d-62da29c78d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDistributionFeesMember_5ea84e92-1108-4239-b223-8da8eed15e07" xlink:href="bhc-20220630.xsd#bhc_ReserveForDistributionFeesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_1da73fad-d41f-4d45-89cb-c94a5cde1115" xlink:to="loc_bhc_ReserveForDistributionFeesMember_5ea84e92-1108-4239-b223-8da8eed15e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4faf3713-8a45-424e-8681-cf2d3324010c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_a07370ae-e923-4c5d-a8a1-e169f216f440" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4faf3713-8a45-424e-8681-cf2d3324010c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_56fb1c54-c73b-4869-810d-5c61669d763b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4faf3713-8a45-424e-8681-cf2d3324010c" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_56fb1c54-c73b-4869-810d-5c61669d763b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_d1920731-be75-47f0-99fe-5d5a920e57e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_56fb1c54-c73b-4869-810d-5c61669d763b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_d1920731-be75-47f0-99fe-5d5a920e57e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_fa662251-ed15-4b59-a2bf-47a611bf863a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_56fb1c54-c73b-4869-810d-5c61669d763b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_fa662251-ed15-4b59-a2bf-47a611bf863a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_38783672-aeb9-4953-b1f4-f1d310314216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_56fb1c54-c73b-4869-810d-5c61669d763b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_38783672-aeb9-4953-b1f4-f1d310314216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_a7da7f22-6a12-4285-ba50-94c76897c5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_56fb1c54-c73b-4869-810d-5c61669d763b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_a7da7f22-6a12-4285-ba50-94c76897c5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_58c064f6-8b4d-47d7-948f-5f8d91d9130e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_283e8e3f-68b2-4e39-8c4a-f434ee2ecc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_58c064f6-8b4d-47d7-948f-5f8d91d9130e" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_283e8e3f-68b2-4e39-8c4a-f434ee2ecc8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_9bb40271-252d-4711-873d-1910501685c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_283e8e3f-68b2-4e39-8c4a-f434ee2ecc8f" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_9bb40271-252d-4711-873d-1910501685c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_fc74e73a-25dc-4e80-91fb-3bce7f506abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_283e8e3f-68b2-4e39-8c4a-f434ee2ecc8f" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_fc74e73a-25dc-4e80-91fb-3bce7f506abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_13cca955-1ba1-4955-8afd-43e622b8a9be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_283e8e3f-68b2-4e39-8c4a-f434ee2ecc8f" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_13cca955-1ba1-4955-8afd-43e622b8a9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_aebd8e48-9a4c-47fa-b9f7-1ea06ae2f4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_283e8e3f-68b2-4e39-8c4a-f434ee2ecc8f" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_aebd8e48-9a4c-47fa-b9f7-1ea06ae2f4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_5c0df9c6-3957-43b4-8a52-7f6f97cc93d8" xlink:href="bhc-20220630.xsd#bhc_AccountsReceivableAllowanceForForeignExchangeAndOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_283e8e3f-68b2-4e39-8c4a-f434ee2ecc8f" xlink:to="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_5c0df9c6-3957-43b4-8a52-7f6f97cc93d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_71fd0829-8733-4694-bb75-86849fdb07f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_283e8e3f-68b2-4e39-8c4a-f434ee2ecc8f" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_71fd0829-8733-4694-bb75-86849fdb07f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURE" xlink:type="simple" xlink:href="bhc-20220630.xsd#LICENSINGAGREEMENTSANDDIVESTITURE"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ab452e3c-a0e6-4c81-b6f6-4490cf4cb2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_7a39c1ce-c9d7-4d00-b5a3-2c9c35979a9a" xlink:href="bhc-20220630.xsd#bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ab452e3c-a0e6-4c81-b6f6-4490cf4cb2b2" xlink:to="loc_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_7a39c1ce-c9d7-4d00-b5a3-2c9c35979a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_85e41806-30e8-47ab-b9a9-5ae948d431fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d09c0c7f-335d-4b66-9d4d-3b9a847d3226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_85e41806-30e8-47ab-b9a9-5ae948d431fb" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d09c0c7f-335d-4b66-9d4d-3b9a847d3226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_bffdd80d-88ef-4297-9060-789b447d9c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d09c0c7f-335d-4b66-9d4d-3b9a847d3226" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_bffdd80d-88ef-4297-9060-789b447d9c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6fe68551-7926-4dca-a9b9-7ec76f2c0c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_bffdd80d-88ef-4297-9060-789b447d9c0d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6fe68551-7926-4dca-a9b9-7ec76f2c0c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_b97bcb6c-bbba-492d-b02e-8b2cc1f004bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_6fe68551-7926-4dca-a9b9-7ec76f2c0c7f" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_b97bcb6c-bbba-492d-b02e-8b2cc1f004bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2ace9aee-f566-4d54-a7a1-ff416b19eab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d09c0c7f-335d-4b66-9d4d-3b9a847d3226" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2ace9aee-f566-4d54-a7a1-ff416b19eab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_316531da-f5bb-4c15-b5ef-5ca46900a87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2ace9aee-f566-4d54-a7a1-ff416b19eab3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_316531da-f5bb-4c15-b5ef-5ca46900a87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember_741672ee-d525-4f25-8047-67be12246da2" xlink:href="bhc-20220630.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_316531da-f5bb-4c15-b5ef-5ca46900a87d" xlink:to="loc_bhc_AmounPharmaceuticalCompanySAEMember_741672ee-d525-4f25-8047-67be12246da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1a2399da-06ba-4736-bc94-ad250fbcc2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d09c0c7f-335d-4b66-9d4d-3b9a847d3226" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1a2399da-06ba-4736-bc94-ad250fbcc2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dfe9c67a-7542-4484-8baf-a2c2be8b384b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1a2399da-06ba-4736-bc94-ad250fbcc2a0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dfe9c67a-7542-4484-8baf-a2c2be8b384b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetImpairmentChargesMember_be2cb816-7d34-46e6-85fd-9918e87d0d32" xlink:href="bhc-20220630.xsd#bhc_AssetImpairmentChargesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_dfe9c67a-7542-4484-8baf-a2c2be8b384b" xlink:to="loc_bhc_AssetImpairmentChargesMember_be2cb816-7d34-46e6-85fd-9918e87d0d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7bae42ae-15f7-4f47-8a82-238bfbc78da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d09c0c7f-335d-4b66-9d4d-3b9a847d3226" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_7bae42ae-15f7-4f47-8a82-238bfbc78da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_0fde6c05-0c50-4b8c-9276-111375cc4468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7bae42ae-15f7-4f47-8a82-238bfbc78da6" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_0fde6c05-0c50-4b8c-9276-111375cc4468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_a70f21a2-5395-4476-9e61-65b7676692ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7bae42ae-15f7-4f47-8a82-238bfbc78da6" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_a70f21a2-5395-4476-9e61-65b7676692ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_049b7cb9-6743-4e81-9b1f-ac92ddbc71c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7bae42ae-15f7-4f47-8a82-238bfbc78da6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_049b7cb9-6743-4e81-9b1f-ac92ddbc71c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS" xlink:type="simple" xlink:href="bhc-20220630.xsd#RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_17bdf0e5-126e-4d5e-85a7-ce74831de7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock_c91e60eb-de4e-4908-940c-34d815565fd0" xlink:href="bhc-20220630.xsd#bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_17bdf0e5-126e-4d5e-85a7-ce74831de7ae" xlink:to="loc_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock_c91e60eb-de4e-4908-940c-34d815565fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0928180c-00d8-4a82-a554-39b2a2298bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8f893fbd-3524-4619-a8a9-b0182078a736" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0928180c-00d8-4a82-a554-39b2a2298bf7" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8f893fbd-3524-4619-a8a9-b0182078a736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_8b1c2348-b477-4092-8ed0-29d724400ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8f893fbd-3524-4619-a8a9-b0182078a736" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_8b1c2348-b477-4092-8ed0-29d724400ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_878bb80f-a905-4cc0-b708-62aba770d8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_8b1c2348-b477-4092-8ed0-29d724400ea6" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_878bb80f-a905-4cc0-b708-62aba770d8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndIntegrationCostsMember_46ad1218-6d14-4875-a3e4-507951dbe557" xlink:href="bhc-20220630.xsd#bhc_RestructuringAndIntegrationCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_878bb80f-a905-4cc0-b708-62aba770d8f5" xlink:to="loc_bhc_RestructuringAndIntegrationCostsMember_46ad1218-6d14-4875-a3e4-507951dbe557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationAndInitialPublicOfferingCostsMember_57f88a7c-a2b0-4974-9163-0fce2a26bdbc" xlink:href="bhc-20220630.xsd#bhc_SeparationAndInitialPublicOfferingCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_878bb80f-a905-4cc0-b708-62aba770d8f5" xlink:to="loc_bhc_SeparationAndInitialPublicOfferingCostsMember_57f88a7c-a2b0-4974-9163-0fce2a26bdbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_935a0fb6-1346-41fe-a62a-a9ec6908e995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8f893fbd-3524-4619-a8a9-b0182078a736" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_935a0fb6-1346-41fe-a62a-a9ec6908e995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_86ea01a4-55c0-4f6f-89dd-512edb948f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_935a0fb6-1346-41fe-a62a-a9ec6908e995" xlink:to="loc_us-gaap_RestructuringReserve_86ea01a4-55c0-4f6f-89dd-512edb948f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_a1a0d020-cafc-46bd-b83d-ac36fc765b91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_935a0fb6-1346-41fe-a62a-a9ec6908e995" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_a1a0d020-cafc-46bd-b83d-ac36fc765b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_ac8acddc-565b-4c40-af07-01391a95901f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_935a0fb6-1346-41fe-a62a-a9ec6908e995" xlink:to="loc_us-gaap_PaymentsForRestructuring_ac8acddc-565b-4c40-af07-01391a95901f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_16905064-abb1-4edd-8d93-cc1f2cf90a88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_935a0fb6-1346-41fe-a62a-a9ec6908e995" xlink:to="loc_us-gaap_RestructuringCharges_16905064-abb1-4edd-8d93-cc1f2cf90a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e5ff4df1-6927-4f17-a4f2-1dfa0336b598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_935a0fb6-1346-41fe-a62a-a9ec6908e995" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e5ff4df1-6927-4f17-a4f2-1dfa0336b598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="bhc-20220630.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d0327446-2d43-4351-9301-75ffb9379a02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_937d7fbc-e153-48e2-9c96-5e161d1407e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d0327446-2d43-4351-9301-75ffb9379a02" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_937d7fbc-e153-48e2-9c96-5e161d1407e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="bhc-20220630.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_844c5e0a-cc03-464a-a9d9-60393026d6af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_5b48fab3-4a98-4707-a5ea-f1f353fffe90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_844c5e0a-cc03-464a-a9d9-60393026d6af" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_5b48fab3-4a98-4707-a5ea-f1f353fffe90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_5c807cf3-01f2-417e-a3aa-ecab13c6b55e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_844c5e0a-cc03-464a-a9d9-60393026d6af" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_5c807cf3-01f2-417e-a3aa-ecab13c6b55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_e3d72b25-4d3c-4641-bf59-32b695e70dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_844c5e0a-cc03-464a-a9d9-60393026d6af" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_e3d72b25-4d3c-4641-bf59-32b695e70dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock_cbcbf4d2-9b86-436f-b281-2c95a68b4ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_844c5e0a-cc03-464a-a9d9-60393026d6af" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock_cbcbf4d2-9b86-436f-b281-2c95a68b4ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_973a1f4b-b9b1-4eae-afd8-53055e9af6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_844c5e0a-cc03-464a-a9d9-60393026d6af" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_973a1f4b-b9b1-4eae-afd8-53055e9af6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a06560c4-ab9a-4022-b03f-b546662fc7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9fb0527f-2691-46ea-8aa0-7cef3b92d12f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a06560c4-ab9a-4022-b03f-b546662fc7e5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9fb0527f-2691-46ea-8aa0-7cef3b92d12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_74979b69-0a8b-4aa0-a8d1-9ec848b73b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9fb0527f-2691-46ea-8aa0-7cef3b92d12f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_74979b69-0a8b-4aa0-a8d1-9ec848b73b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e88e5bf8-126d-4d3e-8675-de56a098a17e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_74979b69-0a8b-4aa0-a8d1-9ec848b73b6b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e88e5bf8-126d-4d3e-8675-de56a098a17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f6eb0ea5-00f3-4cff-b373-88ed61c82c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e88e5bf8-126d-4d3e-8675-de56a098a17e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f6eb0ea5-00f3-4cff-b373-88ed61c82c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_304bb639-980d-4aba-9577-ab314c0ff8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9fb0527f-2691-46ea-8aa0-7cef3b92d12f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_304bb639-980d-4aba-9577-ab314c0ff8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_88cdcd45-d92b-4227-ad61-2d1b8f797840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_304bb639-980d-4aba-9577-ab314c0ff8b1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_88cdcd45-d92b-4227-ad61-2d1b8f797840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d79b1a2d-97e3-48e4-8ccd-81dfbdc329f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_88cdcd45-d92b-4227-ad61-2d1b8f797840" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d79b1a2d-97e3-48e4-8ccd-81dfbdc329f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6d92b1e0-122d-4cec-b368-af6b995c90e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_88cdcd45-d92b-4227-ad61-2d1b8f797840" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6d92b1e0-122d-4cec-b368-af6b995c90e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ef506ca4-da9b-470f-a93e-80435866f586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_88cdcd45-d92b-4227-ad61-2d1b8f797840" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ef506ca4-da9b-470f-a93e-80435866f586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_35bd2c61-20b3-4507-8568-7b575fee06e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9fb0527f-2691-46ea-8aa0-7cef3b92d12f" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_35bd2c61-20b3-4507-8568-7b575fee06e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1b9d4253-b300-4d32-bee8-d292e56bf509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_35bd2c61-20b3-4507-8568-7b575fee06e6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1b9d4253-b300-4d32-bee8-d292e56bf509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_e8c329ff-c25e-427c-810e-cc5c9a587009" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1b9d4253-b300-4d32-bee8-d292e56bf509" xlink:to="loc_us-gaap_ForeignExchangeContractMember_e8c329ff-c25e-427c-810e-cc5c9a587009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_60d64cf9-4331-4d10-8e0c-4be795df6f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9fb0527f-2691-46ea-8aa0-7cef3b92d12f" xlink:to="loc_us-gaap_HedgingDesignationAxis_60d64cf9-4331-4d10-8e0c-4be795df6f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_fd2a508c-0584-420a-bf8b-2e8c7d8923c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_60d64cf9-4331-4d10-8e0c-4be795df6f9d" xlink:to="loc_us-gaap_HedgingDesignationDomain_fd2a508c-0584-420a-bf8b-2e8c7d8923c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_8a12d33a-ce97-42e8-a80d-44534bf8374d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_fd2a508c-0584-420a-bf8b-2e8c7d8923c2" xlink:to="loc_us-gaap_NondesignatedMember_8a12d33a-ce97-42e8-a80d-44534bf8374d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_66911e27-6310-483c-a68c-7d8bf5366502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9fb0527f-2691-46ea-8aa0-7cef3b92d12f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_66911e27-6310-483c-a68c-7d8bf5366502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_a341b01c-a872-4687-b96d-f271c6a5d459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_66911e27-6310-483c-a68c-7d8bf5366502" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_a341b01c-a872-4687-b96d-f271c6a5d459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_befb9f91-a7ca-4ff1-bdce-801838a6b344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a341b01c-a872-4687-b96d-f271c6a5d459" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_befb9f91-a7ca-4ff1-bdce-801838a6b344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_d7d90eb2-e63a-425e-9609-0b1a92649f75" xlink:href="bhc-20220630.xsd#bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a341b01c-a872-4687-b96d-f271c6a5d459" xlink:to="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_d7d90eb2-e63a-425e-9609-0b1a92649f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_c75a0987-76cd-498f-ab72-65950e39c335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a341b01c-a872-4687-b96d-f271c6a5d459" xlink:to="loc_us-gaap_DerivativeAssets_c75a0987-76cd-498f-ab72-65950e39c335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_a7dd021f-467e-4e49-9422-06fb240cb87a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_66911e27-6310-483c-a68c-7d8bf5366502" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_a7dd021f-467e-4e49-9422-06fb240cb87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_7aebf2f6-e7c7-4e89-93c3-fe903a70e8a1" xlink:href="bhc-20220630.xsd#bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_a7dd021f-467e-4e49-9422-06fb240cb87a" xlink:to="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_7aebf2f6-e7c7-4e89-93c3-fe903a70e8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_5d1c7fe8-5aa8-4792-b181-0ba3d9d9f772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_a7dd021f-467e-4e49-9422-06fb240cb87a" xlink:to="loc_us-gaap_DerivativeLiabilities_5d1c7fe8-5aa8-4792-b181-0ba3d9d9f772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3087840c-36df-4fbf-95a0-624569426df5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58fdf8e9-cbfb-4fb2-8689-d786da1c7d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3087840c-36df-4fbf-95a0-624569426df5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58fdf8e9-cbfb-4fb2-8689-d786da1c7d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_7c5a275e-c854-4436-84cb-6cce9b4f2fe3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58fdf8e9-cbfb-4fb2-8689-d786da1c7d43" xlink:to="loc_srt_LitigationCaseAxis_7c5a275e-c854-4436-84cb-6cce9b4f2fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_67234b7b-9ac4-4bd5-bb88-ddcc846f40b4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_7c5a275e-c854-4436-84cb-6cce9b4f2fe3" xlink:to="loc_srt_LitigationCaseTypeDomain_67234b7b-9ac4-4bd5-bb88-ddcc846f40b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_7a870614-491f-4dbf-9e92-c99ef51cfc31" xlink:href="bhc-20220630.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_67234b7b-9ac4-4bd5-bb88-ddcc846f40b4" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_7a870614-491f-4dbf-9e92-c99ef51cfc31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_c447a455-7df4-49b8-bc8c-b0a39c6645ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58fdf8e9-cbfb-4fb2-8689-d786da1c7d43" xlink:to="loc_us-gaap_LitigationStatusAxis_c447a455-7df4-49b8-bc8c-b0a39c6645ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_b2455b20-137c-44f5-b5a0-034f2f57e865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_c447a455-7df4-49b8-bc8c-b0a39c6645ee" xlink:to="loc_us-gaap_LitigationStatusDomain_b2455b20-137c-44f5-b5a0-034f2f57e865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_7721d174-6b6e-44ff-81ee-66cd54c61514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_b2455b20-137c-44f5-b5a0-034f2f57e865" xlink:to="loc_us-gaap_SettledLitigationMember_7721d174-6b6e-44ff-81ee-66cd54c61514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8a900ce0-218b-4cf0-a5ad-854d0c9d19dc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58fdf8e9-cbfb-4fb2-8689-d786da1c7d43" xlink:to="loc_srt_StatementGeographicalAxis_8a900ce0-218b-4cf0-a5ad-854d0c9d19dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3eaf1572-8744-4b3c-9a45-638bafc63373" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_8a900ce0-218b-4cf0-a5ad-854d0c9d19dc" xlink:to="loc_srt_SegmentGeographicalDomain_3eaf1572-8744-4b3c-9a45-638bafc63373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_6ab8150c-c01d-42f3-97fb-fa653111ede1" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3eaf1572-8744-4b3c-9a45-638bafc63373" xlink:to="loc_stpr_NJ_6ab8150c-c01d-42f3-97fb-fa653111ede1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d8a6dc2c-ddc7-411d-a531-8da9314a8bad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58fdf8e9-cbfb-4fb2-8689-d786da1c7d43" xlink:to="loc_dei_LegalEntityAxis_d8a6dc2c-ddc7-411d-a531-8da9314a8bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a6bfac9b-d549-443e-ace3-5e8c55f9b8f8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_d8a6dc2c-ddc7-411d-a531-8da9314a8bad" xlink:to="loc_dei_EntityDomain_a6bfac9b-d549-443e-ace3-5e8c55f9b8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_f10ebaba-c904-4ac3-b7b5-9c581ff40343" xlink:href="bhc-20220630.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a6bfac9b-d549-443e-ace3-5e8c55f9b8f8" xlink:to="loc_bhc_BauschLombMember_f10ebaba-c904-4ac3-b7b5-9c581ff40343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombToBeDistributedToOtherLegalEntitiesMember_dfa13134-34f5-4e09-b472-d520ecdb1f4a" xlink:href="bhc-20220630.xsd#bhc_BauschLombToBeDistributedToOtherLegalEntitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_BauschLombMember_f10ebaba-c904-4ac3-b7b5-9c581ff40343" xlink:to="loc_bhc_BauschLombToBeDistributedToOtherLegalEntitiesMember_dfa13134-34f5-4e09-b472-d520ecdb1f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41a72bca-8ea5-4a42-9bda-fe6275492cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58fdf8e9-cbfb-4fb2-8689-d786da1c7d43" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41a72bca-8ea5-4a42-9bda-fe6275492cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_7aafa8dc-84c9-4b8c-80e5-ebb265da1a76" xlink:href="bhc-20220630.xsd#bhc_HighlyLiquidInvestmentsMaturityPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41a72bca-8ea5-4a42-9bda-fe6275492cb7" xlink:to="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_7aafa8dc-84c9-4b8c-80e5-ebb265da1a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d9e583cc-15ee-4cbe-987c-b1f7662572e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41a72bca-8ea5-4a42-9bda-fe6275492cb7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d9e583cc-15ee-4cbe-987c-b1f7662572e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_9ad6fe58-4808-4cff-b410-aaa87c90ec89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41a72bca-8ea5-4a42-9bda-fe6275492cb7" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_9ad6fe58-4808-4cff-b410-aaa87c90ec89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationSettlementNumberOfObjectorsAppeals_8466a6da-10a2-4050-9097-580d60e79e51" xlink:href="bhc-20220630.xsd#bhc_LitigationSettlementNumberOfObjectorsAppeals"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41a72bca-8ea5-4a42-9bda-fe6275492cb7" xlink:to="loc_bhc_LitigationSettlementNumberOfObjectorsAppeals_8466a6da-10a2-4050-9097-580d60e79e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ed9016e2-5f10-4b00-b30d-7ec6741d09a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_194e8427-9b0b-4cdb-ac17-56b917e85d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ed9016e2-5f10-4b00-b30d-7ec6741d09a4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_194e8427-9b0b-4cdb-ac17-56b917e85d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_20963df0-b41b-474f-a3a4-269f8ba5f276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_194e8427-9b0b-4cdb-ac17-56b917e85d3d" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_20963df0-b41b-474f-a3a4-269f8ba5f276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_24628cd5-3fd2-4cf0-a23a-2e51a1de1d71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_20963df0-b41b-474f-a3a4-269f8ba5f276" xlink:to="loc_us-gaap_HedgingRelationshipDomain_24628cd5-3fd2-4cf0-a23a-2e51a1de1d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_6af35738-3e8b-4ef3-8292-b6f57c56ff77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_24628cd5-3fd2-4cf0-a23a-2e51a1de1d71" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_6af35738-3e8b-4ef3-8292-b6f57c56ff77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5ab33470-11bf-4c3f-af70-956ac94914c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_194e8427-9b0b-4cdb-ac17-56b917e85d3d" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5ab33470-11bf-4c3f-af70-956ac94914c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_27a089ad-5d3d-4240-a41c-f968e8fb7e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5ab33470-11bf-4c3f-af70-956ac94914c5" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_27a089ad-5d3d-4240-a41c-f968e8fb7e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_605f14ce-bc86-4050-be66-26e54573e059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_27a089ad-5d3d-4240-a41c-f968e8fb7e00" xlink:to="loc_us-gaap_CurrencySwapMember_605f14ce-bc86-4050-be66-26e54573e059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_f2066bb3-d840-4539-a6fb-ae6cccfb3efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_194e8427-9b0b-4cdb-ac17-56b917e85d3d" xlink:to="loc_us-gaap_HedgingDesignationAxis_f2066bb3-d840-4539-a6fb-ae6cccfb3efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_a49a04fb-4253-4332-a256-6a23ad7b7962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_f2066bb3-d840-4539-a6fb-ae6cccfb3efb" xlink:to="loc_us-gaap_HedgingDesignationDomain_a49a04fb-4253-4332-a256-6a23ad7b7962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_8370f60d-ae3a-4b54-843e-5e072d4bce07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_a49a04fb-4253-4332-a256-6a23ad7b7962" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_8370f60d-ae3a-4b54-843e-5e072d4bce07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_95ce7fd5-976d-4584-ad55-922d1efbdc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_194e8427-9b0b-4cdb-ac17-56b917e85d3d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_95ce7fd5-976d-4584-ad55-922d1efbdc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_cfd33b2e-bf91-4f70-9646-3c28bcf06344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_95ce7fd5-976d-4584-ad55-922d1efbdc3b" xlink:to="loc_us-gaap_DerivativeNotionalAmount_cfd33b2e-bf91-4f70-9646-3c28bcf06344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_cdb1ef71-60f5-4529-9399-fb222cf1ad1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_95ce7fd5-976d-4584-ad55-922d1efbdc3b" xlink:to="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_cdb1ef71-60f5-4529-9399-fb222cf1ad1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c1670d84-3505-441e-9ec2-32fe38a11b45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1c999711-406b-4fe1-9675-70fac88e92c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c1670d84-3505-441e-9ec2-32fe38a11b45" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1c999711-406b-4fe1-9675-70fac88e92c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a458a421-ffe1-43db-b714-6e8eea48fd68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1c999711-406b-4fe1-9675-70fac88e92c0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a458a421-ffe1-43db-b714-6e8eea48fd68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_d563b737-f3dc-4cc2-8e92-6feb7f26be67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_a458a421-ffe1-43db-b714-6e8eea48fd68" xlink:to="loc_us-gaap_HedgingRelationshipDomain_d563b737-f3dc-4cc2-8e92-6feb7f26be67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_b3db0494-6e3d-465c-9803-f0b58ef81904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_d563b737-f3dc-4cc2-8e92-6feb7f26be67" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_b3db0494-6e3d-465c-9803-f0b58ef81904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ced9a02c-4400-4a31-a667-a41367d50818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1c999711-406b-4fe1-9675-70fac88e92c0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ced9a02c-4400-4a31-a667-a41367d50818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_78321653-fdf0-4fe2-aa8c-e8aa51e1c811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ced9a02c-4400-4a31-a667-a41367d50818" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_78321653-fdf0-4fe2-aa8c-e8aa51e1c811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_f93ac061-cb24-40f7-86a9-15c094edfed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_78321653-fdf0-4fe2-aa8c-e8aa51e1c811" xlink:to="loc_us-gaap_CurrencySwapMember_f93ac061-cb24-40f7-86a9-15c094edfed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_bb0457d1-0420-4d40-9027-1f89dad0dbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1c999711-406b-4fe1-9675-70fac88e92c0" xlink:to="loc_us-gaap_HedgingDesignationAxis_bb0457d1-0420-4d40-9027-1f89dad0dbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_6db2ccde-4cf1-4677-a8bd-f8af0ec93434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_bb0457d1-0420-4d40-9027-1f89dad0dbbd" xlink:to="loc_us-gaap_HedgingDesignationDomain_6db2ccde-4cf1-4677-a8bd-f8af0ec93434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_7912dd06-8a0d-4f82-a302-d7b872c27526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_6db2ccde-4cf1-4677-a8bd-f8af0ec93434" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_7912dd06-8a0d-4f82-a302-d7b872c27526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_69d21dec-930b-4a96-a70c-3e298a27e462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1c999711-406b-4fe1-9675-70fac88e92c0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_69d21dec-930b-4a96-a70c-3e298a27e462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_587984ed-7760-4f44-af38-42dd0baabf04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_69d21dec-930b-4a96-a70c-3e298a27e462" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_587984ed-7760-4f44-af38-42dd0baabf04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_55190683-2965-49e0-8359-146d365c5688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_587984ed-7760-4f44-af38-42dd0baabf04" xlink:to="loc_us-gaap_InterestExpenseMember_55190683-2965-49e0-8359-146d365c5688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2b0140cb-0330-4e4a-ac96-5337652cee6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1c999711-406b-4fe1-9675-70fac88e92c0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2b0140cb-0330-4e4a-ac96-5337652cee6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_4fdf245d-b43c-4984-84ae-4d2c992f5062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2b0140cb-0330-4e4a-ac96-5337652cee6b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_4fdf245d-b43c-4984-84ae-4d2c992f5062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_b41ef5e6-a062-44e4-89c6-a6f6e572ab53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2b0140cb-0330-4e4a-ac96-5337652cee6b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_b41ef5e6-a062-44e4-89c6-a6f6e572ab53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_63e92722-efb9-4b0a-895b-4844c36ee541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1b5d2e74-7646-4320-8e3d-999d6517ceb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_63e92722-efb9-4b0a-895b-4844c36ee541" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1b5d2e74-7646-4320-8e3d-999d6517ceb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_1f2de3a6-d549-4076-80c3-db0cc2441202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1b5d2e74-7646-4320-8e3d-999d6517ceb2" xlink:to="loc_us-gaap_HedgingDesignationAxis_1f2de3a6-d549-4076-80c3-db0cc2441202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_f8773359-9961-435c-a083-bbc12c3f0b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_1f2de3a6-d549-4076-80c3-db0cc2441202" xlink:to="loc_us-gaap_HedgingDesignationDomain_f8773359-9961-435c-a083-bbc12c3f0b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_25bd7807-b15a-4389-8266-b8b9848670ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_f8773359-9961-435c-a083-bbc12c3f0b9f" xlink:to="loc_us-gaap_NondesignatedMember_25bd7807-b15a-4389-8266-b8b9848670ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_432a8509-6631-4bed-a4db-e36244705b15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1b5d2e74-7646-4320-8e3d-999d6517ceb2" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_432a8509-6631-4bed-a4db-e36244705b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_99beceb2-f2e6-4947-b852-c24356c11dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_432a8509-6631-4bed-a4db-e36244705b15" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_99beceb2-f2e6-4947-b852-c24356c11dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_51981c3c-201c-4951-834c-10e2bc6853a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_99beceb2-f2e6-4947-b852-c24356c11dcd" xlink:to="loc_us-gaap_ForeignExchangeContractMember_51981c3c-201c-4951-834c-10e2bc6853a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c0794bbd-b1c0-43dc-8034-c0b944174736" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1b5d2e74-7646-4320-8e3d-999d6517ceb2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c0794bbd-b1c0-43dc-8034-c0b944174736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_a2df10c8-7abe-4cac-9603-62de30dfe0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c0794bbd-b1c0-43dc-8034-c0b944174736" xlink:to="loc_us-gaap_DerivativeNotionalAmount_a2df10c8-7abe-4cac-9603-62de30dfe0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_655209dd-f728-4eb9-9700-44bf3d9eb04d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_af28da57-20a8-492d-b531-50be1b9034f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_655209dd-f728-4eb9-9700-44bf3d9eb04d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_af28da57-20a8-492d-b531-50be1b9034f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e14756d2-1d2d-4333-b2ce-aa9b7f6d0d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_af28da57-20a8-492d-b531-50be1b9034f4" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e14756d2-1d2d-4333-b2ce-aa9b7f6d0d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e15d8486-1cf6-42ce-bb59-538d4d304396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e14756d2-1d2d-4333-b2ce-aa9b7f6d0d1a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e15d8486-1cf6-42ce-bb59-538d4d304396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember_a2b59c23-34f3-4e64-9a06-d8ead3d82ac0" xlink:href="bhc-20220630.xsd#bhc_AccruedAndOtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e15d8486-1cf6-42ce-bb59-538d4d304396" xlink:to="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember_a2b59c23-34f3-4e64-9a06-d8ead3d82ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_a7ad5d07-8f6d-4194-ac87-dd696c745fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e15d8486-1cf6-42ce-bb59-538d4d304396" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_a7ad5d07-8f6d-4194-ac87-dd696c745fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_f296969d-a55e-4378-935f-a6eafefaeb5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_af28da57-20a8-492d-b531-50be1b9034f4" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_f296969d-a55e-4378-935f-a6eafefaeb5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_48a3a9c0-6312-447d-a780-7cf2b884666f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f296969d-a55e-4378-935f-a6eafefaeb5c" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_48a3a9c0-6312-447d-a780-7cf2b884666f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_858dd550-3c00-4101-8f4f-1133f0e4e956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_48a3a9c0-6312-447d-a780-7cf2b884666f" xlink:to="loc_us-gaap_ForeignExchangeContractMember_858dd550-3c00-4101-8f4f-1133f0e4e956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_7db9522a-c444-4362-a4d4-7ad71101ff4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_af28da57-20a8-492d-b531-50be1b9034f4" xlink:to="loc_us-gaap_HedgingDesignationAxis_7db9522a-c444-4362-a4d4-7ad71101ff4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_873caad0-d6f6-442a-8635-38b0d3110ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_7db9522a-c444-4362-a4d4-7ad71101ff4b" xlink:to="loc_us-gaap_HedgingDesignationDomain_873caad0-d6f6-442a-8635-38b0d3110ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_98ba621f-5cb6-46d7-b254-c7c278290fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_873caad0-d6f6-442a-8635-38b0d3110ac1" xlink:to="loc_us-gaap_NondesignatedMember_98ba621f-5cb6-46d7-b254-c7c278290fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c4f91b6e-ce8e-4c66-9e6b-87e075673545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_af28da57-20a8-492d-b531-50be1b9034f4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c4f91b6e-ce8e-4c66-9e6b-87e075673545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_3059a510-245e-49df-94c8-8c3da0fa6526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c4f91b6e-ce8e-4c66-9e6b-87e075673545" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_3059a510-245e-49df-94c8-8c3da0fa6526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_30291e66-6f53-4874-8e74-a37a4ae3cce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e4fd77d3-2155-4242-bbb4-4ad97a3110c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_30291e66-6f53-4874-8e74-a37a4ae3cce7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e4fd77d3-2155-4242-bbb4-4ad97a3110c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_f39e21b4-f873-4f8e-af9c-75860f0a9bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e4fd77d3-2155-4242-bbb4-4ad97a3110c7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_f39e21b4-f873-4f8e-af9c-75860f0a9bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a819122b-300b-4221-9a37-7b7953b840f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f39e21b4-f873-4f8e-af9c-75860f0a9bfc" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a819122b-300b-4221-9a37-7b7953b840f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ab8fcdc5-e979-4da9-8d09-0e66e7511ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a819122b-300b-4221-9a37-7b7953b840f8" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ab8fcdc5-e979-4da9-8d09-0e66e7511ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_ae5dfc23-5662-4990-b36d-66b202a81d94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e4fd77d3-2155-4242-bbb4-4ad97a3110c7" xlink:to="loc_us-gaap_HedgingDesignationAxis_ae5dfc23-5662-4990-b36d-66b202a81d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_845e3b2a-73cd-4775-b1cc-5ad672198bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_ae5dfc23-5662-4990-b36d-66b202a81d94" xlink:to="loc_us-gaap_HedgingDesignationDomain_845e3b2a-73cd-4775-b1cc-5ad672198bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_23b5302d-870f-4322-8cdd-9c3a09d020a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_845e3b2a-73cd-4775-b1cc-5ad672198bd0" xlink:to="loc_us-gaap_NondesignatedMember_23b5302d-870f-4322-8cdd-9c3a09d020a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dd74ce2b-e35a-4d60-afb8-5fe8a041c5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e4fd77d3-2155-4242-bbb4-4ad97a3110c7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dd74ce2b-e35a-4d60-afb8-5fe8a041c5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_8df266b7-ca12-414a-8879-31354a3e8d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dd74ce2b-e35a-4d60-afb8-5fe8a041c5b5" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_8df266b7-ca12-414a-8879-31354a3e8d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain_1212a88f-a37d-4429-b257-b8c0133bb47d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dd74ce2b-e35a-4d60-afb8-5fe8a041c5b5" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain_1212a88f-a37d-4429-b257-b8c0133bb47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_3b8952b8-db79-465f-ad3c-893b05d4cc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dd74ce2b-e35a-4d60-afb8-5fe8a041c5b5" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_3b8952b8-db79-465f-ad3c-893b05d4cc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_470fe955-1b72-4b83-8a11-ce70a5f15ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6fb3c67f-3de4-4d91-a0da-01b68af6a312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_470fe955-1b72-4b83-8a11-ce70a5f15ebd" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6fb3c67f-3de4-4d91-a0da-01b68af6a312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_772a803d-4208-4832-8f14-8cca9f0ed112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6fb3c67f-3de4-4d91-a0da-01b68af6a312" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_772a803d-4208-4832-8f14-8cca9f0ed112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9eeeafc3-9c44-4c5f-a32d-4146776af306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_772a803d-4208-4832-8f14-8cca9f0ed112" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9eeeafc3-9c44-4c5f-a32d-4146776af306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b678dc63-bce3-419e-b97d-3c36ce581abb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9eeeafc3-9c44-4c5f-a32d-4146776af306" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b678dc63-bce3-419e-b97d-3c36ce581abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_79e6e221-d32e-45ae-be30-810a028f65f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6fb3c67f-3de4-4d91-a0da-01b68af6a312" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_79e6e221-d32e-45ae-be30-810a028f65f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d017a5a2-e24a-49c9-8cd8-86da992277b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_79e6e221-d32e-45ae-be30-810a028f65f5" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d017a5a2-e24a-49c9-8cd8-86da992277b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_4a733e48-4a3d-4ef8-9e89-5f8ab16ea43d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d017a5a2-e24a-49c9-8cd8-86da992277b1" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_4a733e48-4a3d-4ef8-9e89-5f8ab16ea43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_2cd74a5f-ff10-4996-a88e-ec9f79b3a4f9" xlink:href="bhc-20220630.xsd#bhc_MeasurementInputWeightedAverageDiscountRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d017a5a2-e24a-49c9-8cd8-86da992277b1" xlink:to="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_2cd74a5f-ff10-4996-a88e-ec9f79b3a4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b36478c5-f6b1-49fb-88a1-41d0d3e6a590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6fb3c67f-3de4-4d91-a0da-01b68af6a312" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b36478c5-f6b1-49fb-88a1-41d0d3e6a590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc9df23b-c03d-4776-bd91-ba79351d6397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b36478c5-f6b1-49fb-88a1-41d0d3e6a590" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc9df23b-c03d-4776-bd91-ba79351d6397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f1693475-d847-4328-a1fb-1a025f5a8a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc9df23b-c03d-4776-bd91-ba79351d6397" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f1693475-d847-4328-a1fb-1a025f5a8a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d910d26d-e48c-4266-bf05-c4cc5e38f654" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6fb3c67f-3de4-4d91-a0da-01b68af6a312" xlink:to="loc_srt_RangeAxis_d910d26d-e48c-4266-bf05-c4cc5e38f654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7a909ff1-03f0-494f-8f6e-51a9edc06086" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d910d26d-e48c-4266-bf05-c4cc5e38f654" xlink:to="loc_srt_RangeMember_7a909ff1-03f0-494f-8f6e-51a9edc06086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bad6ab75-2530-4b6b-a3b5-1f46eb92bf81" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7a909ff1-03f0-494f-8f6e-51a9edc06086" xlink:to="loc_srt_MinimumMember_bad6ab75-2530-4b6b-a3b5-1f46eb92bf81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1d9a6bd4-00f7-448e-991b-b4846c5408e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7a909ff1-03f0-494f-8f6e-51a9edc06086" xlink:to="loc_srt_MaximumMember_1d9a6bd4-00f7-448e-991b-b4846c5408e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4a924dea-706d-4b76-8dc0-eb38a420a813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_6fb3c67f-3de4-4d91-a0da-01b68af6a312" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4a924dea-706d-4b76-8dc0-eb38a420a813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_4db11514-7d74-4a5c-afbf-1a99c7d80c31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_4a924dea-706d-4b76-8dc0-eb38a420a813" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_4db11514-7d74-4a5c-afbf-1a99c7d80c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_539c4f12-ff6d-4807-a70f-53e00fc6b898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5959d0a0-b58c-4ac0-beef-1ea484278389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_539c4f12-ff6d-4807-a70f-53e00fc6b898" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5959d0a0-b58c-4ac0-beef-1ea484278389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_b6169d41-b1a2-4fc9-b9d2-a77d1ed61c99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5959d0a0-b58c-4ac0-beef-1ea484278389" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_b6169d41-b1a2-4fc9-b9d2-a77d1ed61c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_2181b532-00e9-419e-be4e-dfca66770d53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_b6169d41-b1a2-4fc9-b9d2-a77d1ed61c99" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_2181b532-00e9-419e-be4e-dfca66770d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccretionForTimeValueOfMoneyMember_8521c1ea-d157-4617-bd58-00389f340f76" xlink:href="bhc-20220630.xsd#bhc_AccretionForTimeValueOfMoneyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2181b532-00e9-419e-be4e-dfca66770d53" xlink:to="loc_bhc_AccretionForTimeValueOfMoneyMember_8521c1ea-d157-4617-bd58-00389f340f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_da22367e-9a1c-4321-9737-60165c190fc8" xlink:href="bhc-20220630.xsd#bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2181b532-00e9-419e-be4e-dfca66770d53" xlink:to="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_da22367e-9a1c-4321-9737-60165c190fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_54192029-3569-4161-b82c-98e69633c995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5959d0a0-b58c-4ac0-beef-1ea484278389" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_54192029-3569-4161-b82c-98e69633c995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_84228a9e-7c29-4b76-bf92-5007cb3a25a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_54192029-3569-4161-b82c-98e69633c995" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_84228a9e-7c29-4b76-bf92-5007cb3a25a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b603033a-f342-49af-a05c-b1fa1ea834aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_84228a9e-7c29-4b76-bf92-5007cb3a25a8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b603033a-f342-49af-a05c-b1fa1ea834aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_ea652c61-b293-470a-bbc5-a071eac1272b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_84228a9e-7c29-4b76-bf92-5007cb3a25a8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_ea652c61-b293-470a-bbc5-a071eac1272b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_736aeec8-cf4b-4726-85d5-3a83d6c783cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_84228a9e-7c29-4b76-bf92-5007cb3a25a8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_736aeec8-cf4b-4726-85d5-3a83d6c783cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_dbeefbb5-e3b8-474b-a347-d2e761b88ded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_84228a9e-7c29-4b76-bf92-5007cb3a25a8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_dbeefbb5-e3b8-474b-a347-d2e761b88ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_63629515-644b-4a19-823c-4de0dd7e57b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_84228a9e-7c29-4b76-bf92-5007cb3a25a8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_63629515-644b-4a19-823c-4de0dd7e57b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_207740e5-509b-4a5a-bed2-e2e008d2d4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_84228a9e-7c29-4b76-bf92-5007cb3a25a8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_207740e5-509b-4a5a-bed2-e2e008d2d4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_eb1ae609-21ac-4d91-ac2e-e04753d47694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_84228a9e-7c29-4b76-bf92-5007cb3a25a8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_eb1ae609-21ac-4d91-ac2e-e04753d47694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5720680d-0606-4b23-9123-3c4fc86e8f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_751564cd-c326-497e-b438-498db8e2084e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5720680d-0606-4b23-9123-3c4fc86e8f6c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_751564cd-c326-497e-b438-498db8e2084e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d35a56c3-f7e7-4be9-b155-f0b0127f4bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_751564cd-c326-497e-b438-498db8e2084e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d35a56c3-f7e7-4be9-b155-f0b0127f4bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7a14e874-f2d2-48e2-ad1a-053412d9dc55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d35a56c3-f7e7-4be9-b155-f0b0127f4bb9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7a14e874-f2d2-48e2-ad1a-053412d9dc55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_1ead5c8f-15f9-43dc-898a-a66885fc646f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7a14e874-f2d2-48e2-ad1a-053412d9dc55" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_1ead5c8f-15f9-43dc-898a-a66885fc646f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_95f423a2-8c2a-4581-9bbb-04cdf81716c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_751564cd-c326-497e-b438-498db8e2084e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_95f423a2-8c2a-4581-9bbb-04cdf81716c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11ee3884-2f4e-4b84-8489-ee948109a821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_95f423a2-8c2a-4581-9bbb-04cdf81716c9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11ee3884-2f4e-4b84-8489-ee948109a821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6c8fd575-f9b0-46fa-9e54-8e0ba954374e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11ee3884-2f4e-4b84-8489-ee948109a821" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6c8fd575-f9b0-46fa-9e54-8e0ba954374e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7bd67713-a36e-4502-a8e5-f337a262c702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_751564cd-c326-497e-b438-498db8e2084e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7bd67713-a36e-4502-a8e5-f337a262c702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_4ba2e9f3-68f6-4c65-8312-6983398c1b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7bd67713-a36e-4502-a8e5-f337a262c702" xlink:to="loc_us-gaap_DebtInstrumentFairValue_4ba2e9f3-68f6-4c65-8312-6983398c1b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIES" xlink:type="simple" xlink:href="bhc-20220630.xsd#INVENTORIES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_f69220da-bc56-46ee-bcad-081f5acdbde9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_675e727c-6ef2-4723-b854-9e4b3fedea37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_f69220da-bc56-46ee-bcad-081f5acdbde9" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_675e727c-6ef2-4723-b854-9e4b3fedea37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIESTables" xlink:type="simple" xlink:href="bhc-20220630.xsd#INVENTORIESTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_bec89b35-3812-4be5-8f19-1fb21fd252db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_39df2c59-ff7e-4e90-8dd9-b715e3325e38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_bec89b35-3812-4be5-8f19-1fb21fd252db" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_39df2c59-ff7e-4e90-8dd9-b715e3325e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#INVENTORIESComponentsofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_3a56e2db-e1d2-4948-b072-7c23e6665ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_69b53492-5b58-4ab7-80f7-b25f6e65066e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3a56e2db-e1d2-4948-b072-7c23e6665ef2" xlink:to="loc_us-gaap_InventoryRawMaterials_69b53492-5b58-4ab7-80f7-b25f6e65066e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_8ab945ee-7473-4fdd-baf1-0f877fe7a689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3a56e2db-e1d2-4948-b072-7c23e6665ef2" xlink:to="loc_us-gaap_InventoryWorkInProcess_8ab945ee-7473-4fdd-baf1-0f877fe7a689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_3aaa7b5b-834e-49d9-a149-526a765a0761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3a56e2db-e1d2-4948-b072-7c23e6665ef2" xlink:to="loc_us-gaap_InventoryFinishedGoods_3aaa7b5b-834e-49d9-a149-526a765a0761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_7e4f9f35-0994-41e6-9d2c-bba62770a296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3a56e2db-e1d2-4948-b072-7c23e6665ef2" xlink:to="loc_us-gaap_InventoryGross_7e4f9f35-0994-41e6-9d2c-bba62770a296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL" xlink:type="simple" xlink:href="bhc-20220630.xsd#INTANGIBLEASSETSANDGOODWILL"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3fe104a1-b6a8-4b10-9807-f118f0c27c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_052d6068-5eb4-44ec-bba1-f0a461adcde4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3fe104a1-b6a8-4b10-9807-f118f0c27c8d" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_052d6068-5eb4-44ec-bba1-f0a461adcde4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables" xlink:type="simple" xlink:href="bhc-20220630.xsd#INTANGIBLEASSETSANDGOODWILLTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6c613e88-ca4e-4f45-a063-1776219c9028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_db969dca-1f27-4021-ae15-90de2ba406fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6c613e88-ca4e-4f45-a063-1776219c9028" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_db969dca-1f27-4021-ae15-90de2ba406fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_bf0a23ed-5905-4eae-90ab-cb7734a056d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6c613e88-ca4e-4f45-a063-1776219c9028" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_bf0a23ed-5905-4eae-90ab-cb7734a056d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_a05fbc53-b1bd-4bbe-80e1-d689423a0843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6c613e88-ca4e-4f45-a063-1776219c9028" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_a05fbc53-b1bd-4bbe-80e1-d689423a0843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_44993647-8182-4162-955b-8753f6ebf05b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6c613e88-ca4e-4f45-a063-1776219c9028" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_44993647-8182-4162-955b-8753f6ebf05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6f187754-e7b1-4748-82e0-0e6c0fcd7aec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_0cc08a8b-9b77-4233-a515-2b0a0a471a9e" xlink:href="bhc-20220630.xsd#bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6f187754-e7b1-4748-82e0-0e6c0fcd7aec" xlink:to="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_0cc08a8b-9b77-4233-a515-2b0a0a471a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_de25b488-aa20-4180-b48f-77098f1044dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_0cc08a8b-9b77-4233-a515-2b0a0a471a9e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_de25b488-aa20-4180-b48f-77098f1044dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2f8a00e-7594-4289-a3ae-2794ef9bc3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_de25b488-aa20-4180-b48f-77098f1044dd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2f8a00e-7594-4289-a3ae-2794ef9bc3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_8201b732-3303-44c3-87f1-31ca5b7e085b" xlink:href="bhc-20220630.xsd#bhc_ProductBrandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2f8a00e-7594-4289-a3ae-2794ef9bc3f5" xlink:to="loc_bhc_ProductBrandsMember_8201b732-3303-44c3-87f1-31ca5b7e085b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_a3a77192-9225-458c-85a3-1f4ebf166d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2f8a00e-7594-4289-a3ae-2794ef9bc3f5" xlink:to="loc_us-gaap_TradeNamesMember_a3a77192-9225-458c-85a3-1f4ebf166d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_79173ba8-8814-4e09-a7e8-605f4cbdde96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2f8a00e-7594-4289-a3ae-2794ef9bc3f5" xlink:to="loc_us-gaap_ContractualRightsMember_79173ba8-8814-4e09-a7e8-605f4cbdde96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember_0c4dfd7b-f8bb-4f25-adfc-17b11bbec9ee" xlink:href="bhc-20220630.xsd#bhc_PartnerRelationshipsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2f8a00e-7594-4289-a3ae-2794ef9bc3f5" xlink:to="loc_bhc_PartnerRelationshipsMember_0c4dfd7b-f8bb-4f25-adfc-17b11bbec9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember_84c49b67-db8d-4a28-a503-ee39ac79bee0" xlink:href="bhc-20220630.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2f8a00e-7594-4289-a3ae-2794ef9bc3f5" xlink:to="loc_bhc_OutLicensedTechnologyMember_84c49b67-db8d-4a28-a503-ee39ac79bee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c7f75f6f-35c5-487a-af1b-d5dc6f498e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_0cc08a8b-9b77-4233-a515-2b0a0a471a9e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c7f75f6f-35c5-487a-af1b-d5dc6f498e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_41ac5007-82b2-4c96-b73b-477d4e296969" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c7f75f6f-35c5-487a-af1b-d5dc6f498e4e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_41ac5007-82b2-4c96-b73b-477d4e296969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_8288a366-a387-45c0-8dd0-7475c6432b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_41ac5007-82b2-4c96-b73b-477d4e296969" xlink:to="loc_us-gaap_TrademarksMember_8288a366-a387-45c0-8dd0-7475c6432b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_a78343f2-630e-4bf5-8966-491c289026b1" xlink:href="bhc-20220630.xsd#bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_0cc08a8b-9b77-4233-a515-2b0a0a471a9e" xlink:to="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_a78343f2-630e-4bf5-8966-491c289026b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_89042acc-6595-4959-a1f0-b01d23132285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_a78343f2-630e-4bf5-8966-491c289026b1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_89042acc-6595-4959-a1f0-b01d23132285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_430bd9b1-cf45-41c0-b80c-c1687b867a97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_89042acc-6595-4959-a1f0-b01d23132285" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_430bd9b1-cf45-41c0-b80c-c1687b867a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4c38bdd1-16e4-40f6-8c96-ff690d200499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_89042acc-6595-4959-a1f0-b01d23132285" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4c38bdd1-16e4-40f6-8c96-ff690d200499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a759fc3f-f387-4c74-8860-7014809bdaf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_89042acc-6595-4959-a1f0-b01d23132285" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a759fc3f-f387-4c74-8860-7014809bdaf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_6dd5f489-7e48-4ad2-9d1a-8b94135993bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_a78343f2-630e-4bf5-8966-491c289026b1" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_6dd5f489-7e48-4ad2-9d1a-8b94135993bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5a408cf3-5074-4243-97ad-34ef1f52b1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_6dd5f489-7e48-4ad2-9d1a-8b94135993bc" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5a408cf3-5074-4243-97ad-34ef1f52b1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0acce920-3021-4ed3-b692-9bd04f894c36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_a78343f2-630e-4bf5-8966-491c289026b1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0acce920-3021-4ed3-b692-9bd04f894c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_99f0c534-0bd8-4f27-8076-78a5af4a1bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0acce920-3021-4ed3-b692-9bd04f894c36" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_99f0c534-0bd8-4f27-8076-78a5af4a1bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_62d9ce12-7a2b-4780-b9eb-f239fd459806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0acce920-3021-4ed3-b692-9bd04f894c36" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_62d9ce12-7a2b-4780-b9eb-f239fd459806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#INTANGIBLEASSETSANDGOODWILLNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bd2e8ed3-3028-4ec3-b202-2934727911ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_3fdd620d-8551-4df3-a5b1-e9bbd38ee478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bd2e8ed3-3028-4ec3-b202-2934727911ac" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_3fdd620d-8551-4df3-a5b1-e9bbd38ee478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e79551e3-4428-4816-83d3-c1d477660142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_3fdd620d-8551-4df3-a5b1-e9bbd38ee478" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e79551e3-4428-4816-83d3-c1d477660142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c64be1b9-2f02-412a-8482-7acdbb512e72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e79551e3-4428-4816-83d3-c1d477660142" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c64be1b9-2f02-412a-8482-7acdbb512e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_1241c999-9c51-4e59-a0f5-ff0e1bf89526" xlink:href="bhc-20220630.xsd#bhc_ProductBrandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c64be1b9-2f02-412a-8482-7acdbb512e72" xlink:to="loc_bhc_ProductBrandsMember_1241c999-9c51-4e59-a0f5-ff0e1bf89526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiscontinuedProductLinesMember_30b021c3-f1d6-4370-b79a-e97d0292bc72" xlink:href="bhc-20220630.xsd#bhc_DiscontinuedProductLinesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c64be1b9-2f02-412a-8482-7acdbb512e72" xlink:to="loc_bhc_DiscontinuedProductLinesMember_30b021c3-f1d6-4370-b79a-e97d0292bc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_e7d0c99e-c4a8-418e-96b5-8bfae6a18563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_3fdd620d-8551-4df3-a5b1-e9bbd38ee478" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_e7d0c99e-c4a8-418e-96b5-8bfae6a18563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6e812518-a599-4c1f-86b9-47a4a68931a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e7d0c99e-c4a8-418e-96b5-8bfae6a18563" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6e812518-a599-4c1f-86b9-47a4a68931a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_7fa30d05-1235-45a6-888e-0710504ef39c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_6e812518-a599-4c1f-86b9-47a4a68931a4" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_7fa30d05-1235-45a6-888e-0710504ef39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7a7ae0fc-29c4-4e55-a868-3638253771ce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_3fdd620d-8551-4df3-a5b1-e9bbd38ee478" xlink:to="loc_srt_RangeAxis_7a7ae0fc-29c4-4e55-a868-3638253771ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_19b3eaee-d3e7-4691-ba6a-ede0c06d1b97" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7a7ae0fc-29c4-4e55-a868-3638253771ce" xlink:to="loc_srt_RangeMember_19b3eaee-d3e7-4691-ba6a-ede0c06d1b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_45d69756-2000-4f0c-a6d9-73871a006dbe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_19b3eaee-d3e7-4691-ba6a-ede0c06d1b97" xlink:to="loc_srt_MinimumMember_45d69756-2000-4f0c-a6d9-73871a006dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_eb93d269-10d0-43a8-aa76-17daa5df0fe6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_19b3eaee-d3e7-4691-ba6a-ede0c06d1b97" xlink:to="loc_srt_MaximumMember_eb93d269-10d0-43a8-aa76-17daa5df0fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_114101ba-63d9-4798-942b-55a47a2d3f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_3fdd620d-8551-4df3-a5b1-e9bbd38ee478" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_114101ba-63d9-4798-942b-55a47a2d3f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0a9c703c-0464-4ae5-81b8-387af3da33b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_114101ba-63d9-4798-942b-55a47a2d3f9d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0a9c703c-0464-4ae5-81b8-387af3da33b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember_815bbdff-3864-4937-9396-1a9281a1bf09" xlink:href="bhc-20220630.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0a9c703c-0464-4ae5-81b8-387af3da33b1" xlink:to="loc_bhc_AmounPharmaceuticalCompanySAEMember_815bbdff-3864-4937-9396-1a9281a1bf09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_ed38881e-df3e-45ef-adb9-96dfe8fbd47b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_3fdd620d-8551-4df3-a5b1-e9bbd38ee478" xlink:to="loc_us-gaap_ReportingUnitAxis_ed38881e-df3e-45ef-adb9-96dfe8fbd47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_f3055656-4121-48f4-8e3d-e5301a3e89cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_ed38881e-df3e-45ef-adb9-96dfe8fbd47b" xlink:to="loc_us-gaap_ReportingUnitDomain_f3055656-4121-48f4-8e3d-e5301a3e89cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_61178fea-97b3-49ba-91e5-504b2395ca5b" xlink:href="bhc-20220630.xsd#bhc_ReportingUnitsExcludingOrthoDermatologicsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_f3055656-4121-48f4-8e3d-e5301a3e89cd" xlink:to="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_61178fea-97b3-49ba-91e5-504b2395ca5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsReportingUnitMember_12634b31-39ad-4def-a914-30bbb2e8aba7" xlink:href="bhc-20220630.xsd#bhc_OrthoDermatologicsReportingUnitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_f3055656-4121-48f4-8e3d-e5301a3e89cd" xlink:to="loc_bhc_OrthoDermatologicsReportingUnitMember_12634b31-39ad-4def-a914-30bbb2e8aba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember_a709f24b-8d04-4b27-9fe2-912a623d9d5e" xlink:href="bhc-20220630.xsd#bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_f3055656-4121-48f4-8e3d-e5301a3e89cd" xlink:to="loc_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember_a709f24b-8d04-4b27-9fe2-912a623d9d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember_9626d247-ea6b-4b44-8478-1559aac32dcd" xlink:href="bhc-20220630.xsd#bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_f3055656-4121-48f4-8e3d-e5301a3e89cd" xlink:to="loc_bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember_9626d247-ea6b-4b44-8478-1559aac32dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f45317bd-7c25-4934-bf8f-afbc2b528793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_3fdd620d-8551-4df3-a5b1-e9bbd38ee478" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f45317bd-7c25-4934-bf8f-afbc2b528793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4d365e41-f4b5-4386-8620-10c98fa333c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f45317bd-7c25-4934-bf8f-afbc2b528793" xlink:to="loc_us-gaap_SegmentDomain_4d365e41-f4b5-4386-8620-10c98fa333c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_19b596d6-50cf-4abc-ab2a-0aeeb25dfee5" xlink:href="bhc-20220630.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4d365e41-f4b5-4386-8620-10c98fa333c9" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_19b596d6-50cf-4abc-ab2a-0aeeb25dfee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_7dd9384a-547b-48cd-b558-8a12560b8d11" xlink:href="bhc-20220630.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4d365e41-f4b5-4386-8620-10c98fa333c9" xlink:to="loc_bhc_SalixSegmentMember_7dd9384a-547b-48cd-b558-8a12560b8d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2c0e5864-554d-49c9-9011-904ad687396f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_3fdd620d-8551-4df3-a5b1-e9bbd38ee478" xlink:to="loc_dei_LegalEntityAxis_2c0e5864-554d-49c9-9011-904ad687396f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_43f149fb-35ca-4afd-b55b-f5b0f254ae76" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2c0e5864-554d-49c9-9011-904ad687396f" xlink:to="loc_dei_EntityDomain_43f149fb-35ca-4afd-b55b-f5b0f254ae76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_3c172cc3-b324-4e05-959f-319033ecf7fd" xlink:href="bhc-20220630.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_43f149fb-35ca-4afd-b55b-f5b0f254ae76" xlink:to="loc_bhc_BauschLombMember_3c172cc3-b324-4e05-959f-319033ecf7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9da0c344-6ae8-4384-bde6-c131757167f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_3fdd620d-8551-4df3-a5b1-e9bbd38ee478" xlink:to="loc_srt_ProductOrServiceAxis_9da0c344-6ae8-4384-bde6-c131757167f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_23a11ebf-9cd8-4dd1-8faa-c94dd0cdd455" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9da0c344-6ae8-4384-bde6-c131757167f7" xlink:to="loc_srt_ProductsAndServicesDomain_23a11ebf-9cd8-4dd1-8faa-c94dd0cdd455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_XifaxanBrandedProductsMember_4e645e11-1776-4424-9491-59da4be47a23" xlink:href="bhc-20220630.xsd#bhc_XifaxanBrandedProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_23a11ebf-9cd8-4dd1-8faa-c94dd0cdd455" xlink:to="loc_bhc_XifaxanBrandedProductsMember_4e645e11-1776-4424-9491-59da4be47a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_352afd39-0b61-4dd7-b895-f462c29744e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_3fdd620d-8551-4df3-a5b1-e9bbd38ee478" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_352afd39-0b61-4dd7-b895-f462c29744e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_26ab84ab-2841-4e05-8fc2-65ac11103766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_352afd39-0b61-4dd7-b895-f462c29744e9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_26ab84ab-2841-4e05-8fc2-65ac11103766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_9ff11752-5ad8-4762-86df-f838f4626d03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_26ab84ab-2841-4e05-8fc2-65ac11103766" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_9ff11752-5ad8-4762-86df-f838f4626d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_700eced1-930d-4510-8367-1b3c1ca8e4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_3fdd620d-8551-4df3-a5b1-e9bbd38ee478" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_700eced1-930d-4510-8367-1b3c1ca8e4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_286ef1d4-8b1b-4602-a22b-c25e2719808c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_700eced1-930d-4510-8367-1b3c1ca8e4c7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_286ef1d4-8b1b-4602-a22b-c25e2719808c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_3f208181-8132-42f1-8ba9-8ad9944d7cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_286ef1d4-8b1b-4602-a22b-c25e2719808c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_3f208181-8132-42f1-8ba9-8ad9944d7cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_3fdd620d-8551-4df3-a5b1-e9bbd38ee478" xlink:to="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_bfbc80a5-4cb1-4c8d-81f0-866b7d958eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_bfbc80a5-4cb1-4c8d-81f0-866b7d958eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d66b382e-466b-4d4c-a5ee-9ec69957debb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d66b382e-466b-4d4c-a5ee-9ec69957debb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0a5a3a4a-6915-4683-bc37-dd28cd4a629b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0a5a3a4a-6915-4683-bc37-dd28cd4a629b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AnnualAmortizationOfIntangibleAssets_1fd73b2f-7c3e-468d-b72b-891068b297e0" xlink:href="bhc-20220630.xsd#bhc_AnnualAmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:to="loc_bhc_AnnualAmortizationOfIntangibleAssets_1fd73b2f-7c3e-468d-b72b-891068b297e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_96b36aee-1691-4249-8227-0f43397d8496" xlink:href="bhc-20220630.xsd#bhc_ReportingUnitImpairmentTestLongTermGrowthRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:to="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_96b36aee-1691-4249-8227-0f43397d8496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_3b2a8bd1-0147-4f41-a44a-41e941f778ea" xlink:href="bhc-20220630.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:to="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_3b2a8bd1-0147-4f41-a44a-41e941f778ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate_4de401db-9897-4983-b70b-15fa7b6f4e5e" xlink:href="bhc-20220630.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:to="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate_4de401db-9897-4983-b70b-15fa7b6f4e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_d3deeba2-68bc-4461-8403-358864337280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_d3deeba2-68bc-4461-8403-358864337280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_311c9766-15df-40d3-80c3-9e071cfd7ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_311c9766-15df-40d3-80c3-9e071cfd7ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_258b7af5-1adc-4d58-9e93-bb285e67985c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:to="loc_us-gaap_NumberOfReportingUnits_258b7af5-1adc-4d58-9e93-bb285e67985c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_93deffee-0531-4fa6-9d79-b309ec391e48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_93deffee-0531-4fa6-9d79-b309ec391e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ad13aeca-4998-4572-886f-998c0b712a52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ad13aeca-4998-4572-886f-998c0b712a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cf4ece78-edce-4848-9e74-c2d282310f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_41951bb9-5b9e-46e3-a263-67e11122f055" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cf4ece78-edce-4848-9e74-c2d282310f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5c23f453-7d69-4763-a949-c268d210b1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_a7384f8e-06bf-4116-a6b2-c5ae76623345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5c23f453-7d69-4763-a949-c268d210b1d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_a7384f8e-06bf-4116-a6b2-c5ae76623345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b6147e3c-55f9-46a5-8609-bab0a0fc1b36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5c23f453-7d69-4763-a949-c268d210b1d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b6147e3c-55f9-46a5-8609-bab0a0fc1b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c389ceff-0c72-42b2-85af-939668ca5118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5c23f453-7d69-4763-a949-c268d210b1d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c389ceff-0c72-42b2-85af-939668ca5118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_de2b3a3c-867c-4a88-b093-395b4d819dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5c23f453-7d69-4763-a949-c268d210b1d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_de2b3a3c-867c-4a88-b093-395b4d819dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_42d2f245-d904-4f18-9c00-40266bf94d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5c23f453-7d69-4763-a949-c268d210b1d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_42d2f245-d904-4f18-9c00-40266bf94d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_bf8dc488-ca2a-4975-a86a-f92fcb2f6d68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5c23f453-7d69-4763-a949-c268d210b1d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_bf8dc488-ca2a-4975-a86a-f92fcb2f6d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_b869708e-3e42-4cc0-af42-6382101d5369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5c23f453-7d69-4763-a949-c268d210b1d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_b869708e-3e42-4cc0-af42-6382101d5369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_393a53cb-e6b0-49ac-9e00-4860bf3f1ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5c23f453-7d69-4763-a949-c268d210b1d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_393a53cb-e6b0-49ac-9e00-4860bf3f1ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_875f9208-a188-468e-b8aa-3c62eadb29c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_da59e6a9-9276-4163-8f2a-d1d0683062ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_875f9208-a188-468e-b8aa-3c62eadb29c8" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_da59e6a9-9276-4163-8f2a-d1d0683062ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6a67065e-8aae-4b88-8683-2f334f933bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_da59e6a9-9276-4163-8f2a-d1d0683062ac" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6a67065e-8aae-4b88-8683-2f334f933bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bc32cd02-f739-4f8c-972b-ece8cc20576e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6a67065e-8aae-4b88-8683-2f334f933bf4" xlink:to="loc_us-gaap_SegmentDomain_bc32cd02-f739-4f8c-972b-ece8cc20576e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombInternationalMember_2392762c-3783-4e82-b359-5531cb895997" xlink:href="bhc-20220630.xsd#bhc_BauschLombInternationalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bc32cd02-f739-4f8c-972b-ece8cc20576e" xlink:to="loc_bhc_BauschLombInternationalMember_2392762c-3783-4e82-b359-5531cb895997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_5ab28e3d-68b1-42b3-afc1-f96e74ab6bad" xlink:href="bhc-20220630.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bc32cd02-f739-4f8c-972b-ece8cc20576e" xlink:to="loc_bhc_BauschLombMember_5ab28e3d-68b1-42b3-afc1-f96e74ab6bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_b7f9e337-23af-48ca-8406-ea299fdd438b" xlink:href="bhc-20220630.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bc32cd02-f739-4f8c-972b-ece8cc20576e" xlink:to="loc_bhc_SalixSegmentMember_b7f9e337-23af-48ca-8406-ea299fdd438b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_7551215e-906f-4abf-a949-4d0830fd3b47" xlink:href="bhc-20220630.xsd#bhc_InternationalRxMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bc32cd02-f739-4f8c-972b-ece8cc20576e" xlink:to="loc_bhc_InternationalRxMember_7551215e-906f-4abf-a949-4d0830fd3b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_4df4ea86-8b04-4d1d-8268-c5c0c1480f55" xlink:href="bhc-20220630.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bc32cd02-f739-4f8c-972b-ece8cc20576e" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_4df4ea86-8b04-4d1d-8268-c5c0c1480f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_832e189a-eb2d-4980-bff9-ba859cf4b05a" xlink:href="bhc-20220630.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bc32cd02-f739-4f8c-972b-ece8cc20576e" xlink:to="loc_bhc_SoltaMedicalSegmentMember_832e189a-eb2d-4980-bff9-ba859cf4b05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_2f25c2da-bb7e-44fb-8d59-d8259daa9774" xlink:href="bhc-20220630.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bc32cd02-f739-4f8c-972b-ece8cc20576e" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_2f25c2da-bb7e-44fb-8d59-d8259daa9774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_f730dc52-b995-448c-9027-497851d7b44d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_da59e6a9-9276-4163-8f2a-d1d0683062ac" xlink:to="loc_us-gaap_GoodwillLineItems_f730dc52-b995-448c-9027-497851d7b44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_5522da64-f8a2-4084-8205-0555edc0463f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_f730dc52-b995-448c-9027-497851d7b44d" xlink:to="loc_us-gaap_GoodwillRollForward_5522da64-f8a2-4084-8205-0555edc0463f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8bfb7ca6-63bc-4728-93fb-9ebc07f0f8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_5522da64-f8a2-4084-8205-0555edc0463f" xlink:to="loc_us-gaap_Goodwill_8bfb7ca6-63bc-4728-93fb-9ebc07f0f8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_1494020b-4251-44e3-ba44-03173653d69f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_5522da64-f8a2-4084-8205-0555edc0463f" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_1494020b-4251-44e3-ba44-03173653d69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_635cc1f5-63b0-46f1-a1b3-809724e93d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_5522da64-f8a2-4084-8205-0555edc0463f" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_635cc1f5-63b0-46f1-a1b3-809724e93d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_6850c3d6-20f7-4a11-b866-a230321dec58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_5522da64-f8a2-4084-8205-0555edc0463f" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_6850c3d6-20f7-4a11-b866-a230321dec58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4e7ee489-5db8-40d5-9611-a8a92575b001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_5522da64-f8a2-4084-8205-0555edc0463f" xlink:to="loc_us-gaap_Goodwill_4e7ee489-5db8-40d5-9611-a8a92575b001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES" xlink:type="simple" xlink:href="bhc-20220630.xsd#ACCRUEDANDOTHERCURRENTLIABILITIES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_ebc63f3a-e8ab-44e3-81e0-58939d15306d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_39ef7899-88ca-4d9d-b750-4515cfd543b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ebc63f3a-e8ab-44e3-81e0-58939d15306d" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_39ef7899-88ca-4d9d-b750-4515cfd543b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables" xlink:type="simple" xlink:href="bhc-20220630.xsd#ACCRUEDANDOTHERCURRENTLIABILITIESTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_50915042-c7a8-441a-a40e-3575bbfd7731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4e510760-2053-42be-8dd1-6362528340e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_50915042-c7a8-441a-a40e-3575bbfd7731" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4e510760-2053-42be-8dd1-6362528340e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_f9b53004-41e3-4112-9312-4aaf2d575784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_Legalsettlementsandrelatedfees_1fef116a-befd-4a93-b607-563ec0d3a95a" xlink:href="bhc-20220630.xsd#bhc_Legalsettlementsandrelatedfees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f9b53004-41e3-4112-9312-4aaf2d575784" xlink:to="loc_bhc_Legalsettlementsandrelatedfees_1fef116a-befd-4a93-b607-563ec0d3a95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductRebateCurrent_a9b06041-5036-4415-adca-c844f23c5215" xlink:href="bhc-20220630.xsd#bhc_AccruedProductRebateCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f9b53004-41e3-4112-9312-4aaf2d575784" xlink:to="loc_bhc_AccruedProductRebateCurrent_a9b06041-5036-4415-adca-c844f23c5215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductReturnCurrent_42b610ba-d9ed-416b-aabc-c5d3985e0628" xlink:href="bhc-20220630.xsd#bhc_AccruedProductReturnCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f9b53004-41e3-4112-9312-4aaf2d575784" xlink:to="loc_bhc_AccruedProductReturnCurrent_42b610ba-d9ed-416b-aabc-c5d3985e0628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_2af16c18-b88b-47fb-8ffb-036f3d4f690e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f9b53004-41e3-4112-9312-4aaf2d575784" xlink:to="loc_us-gaap_InterestPayableCurrent_2af16c18-b88b-47fb-8ffb-036f3d4f690e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_8de6cb2f-c308-4961-bc52-277110e7746f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f9b53004-41e3-4112-9312-4aaf2d575784" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_8de6cb2f-c308-4961-bc52-277110e7746f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_945bc60d-72d6-4b8b-8238-21708e15165c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f9b53004-41e3-4112-9312-4aaf2d575784" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_945bc60d-72d6-4b8b-8238-21708e15165c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_46265dfa-4841-43ec-b9ec-f397a5dc18df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f9b53004-41e3-4112-9312-4aaf2d575784" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_46265dfa-4841-43ec-b9ec-f397a5dc18df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_cd82a148-ad8c-4194-af22-730152c75cee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f9b53004-41e3-4112-9312-4aaf2d575784" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_cd82a148-ad8c-4194-af22-730152c75cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS" xlink:type="simple" xlink:href="bhc-20220630.xsd#FINANCINGARRANGEMENTS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c616ce26-8e61-42d1-bfc2-d4b220191e15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_9a6f0f76-4815-4715-8e03-6103e1e3d1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c616ce26-8e61-42d1-bfc2-d4b220191e15" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_9a6f0f76-4815-4715-8e03-6103e1e3d1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables" xlink:type="simple" xlink:href="bhc-20220630.xsd#FINANCINGARRANGEMENTSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6506a7ff-ce3c-4755-999c-3c28a56567dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_03f07858-caba-4456-847e-ba50810d5e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6506a7ff-ce3c-4755-999c-3c28a56567dc" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_03f07858-caba-4456-847e-ba50810d5e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1349cea0-87aa-4ab4-8d72-9516e75f8981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6506a7ff-ce3c-4755-999c-3c28a56567dc" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1349cea0-87aa-4ab4-8d72-9516e75f8981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_881525ed-d8ae-4a11-93a3-ee0ed1214e05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_80cefb0a-7242-4373-bf60-15080674dab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_881525ed-d8ae-4a11-93a3-ee0ed1214e05" xlink:to="loc_us-gaap_DebtInstrumentTable_80cefb0a-7242-4373-bf60-15080674dab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_67b209d6-e6ad-4c9e-aee8-af6fd20f3595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_80cefb0a-7242-4373-bf60-15080674dab2" xlink:to="loc_us-gaap_CreditFacilityAxis_67b209d6-e6ad-4c9e-aee8-af6fd20f3595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ac3732f7-9fb0-498e-9978-a713a458faa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_67b209d6-e6ad-4c9e-aee8-af6fd20f3595" xlink:to="loc_us-gaap_CreditFacilityDomain_ac3732f7-9fb0-498e-9978-a713a458faa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_aa968220-549d-4c62-966f-a4b09375c784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_ac3732f7-9fb0-498e-9978-a713a458faa8" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_aa968220-549d-4c62-966f-a4b09375c784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5528d2e8-561f-46fa-814f-2d9832ad4e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_80cefb0a-7242-4373-bf60-15080674dab2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5528d2e8-561f-46fa-814f-2d9832ad4e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6bff6894-dc54-483c-b2c8-b42d0050f120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5528d2e8-561f-46fa-814f-2d9832ad4e19" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6bff6894-dc54-483c-b2c8-b42d0050f120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_b0682e9a-4e1a-4d00-9b41-f052a05b6d58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6bff6894-dc54-483c-b2c8-b42d0050f120" xlink:to="loc_us-gaap_SecuredDebtMember_b0682e9a-4e1a-4d00-9b41-f052a05b6d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_eec20a56-447d-4eef-8a49-99a2afc6148e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6bff6894-dc54-483c-b2c8-b42d0050f120" xlink:to="loc_us-gaap_UnsecuredDebtMember_eec20a56-447d-4eef-8a49-99a2afc6148e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_827237ba-c342-4b8f-a608-aeb68855de22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_80cefb0a-7242-4373-bf60-15080674dab2" xlink:to="loc_us-gaap_DebtInstrumentAxis_827237ba-c342-4b8f-a608-aeb68855de22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_827237ba-c342-4b8f-a608-aeb68855de22" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_7412991f-6379-4d7b-bae6-8fd218834778" xlink:href="bhc-20220630.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_7412991f-6379-4d7b-bae6-8fd218834778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_419060a9-7a8d-4ff3-afba-218ca235f294" xlink:href="bhc-20220630.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_419060a9-7a8d-4ff3-afba-218ca235f294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_5413978e-68ee-4202-a992-a5b07e928128" xlink:href="bhc-20220630.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_5413978e-68ee-4202-a992-a5b07e928128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_2f41eab1-20d6-4720-aac8-9d0b0a8a4799" xlink:href="bhc-20220630.xsd#bhc_RevolvingCreditFacilityDueFebruary2027Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_2f41eab1-20d6-4720-aac8-9d0b0a8a4799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueFebruary2027Member_1a9b6394-9f8d-4cb2-950a-ca8960e48fd9" xlink:href="bhc-20220630.xsd#bhc_TermLoanBFacilityDueFebruary2027Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_TermLoanBFacilityDueFebruary2027Member_1a9b6394-9f8d-4cb2-950a-ca8960e48fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueMay2027Member_44e85fbc-c5b8-4d3a-9f50-94d926134bd4" xlink:href="bhc-20220630.xsd#bhc_RevolvingCreditFacilityDueMay2027Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_RevolvingCreditFacilityDueMay2027Member_44e85fbc-c5b8-4d3a-9f50-94d926134bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermFacilityDueMay2027Member_bbfbcb15-3c32-4d68-b984-d27f1ae49d01" xlink:href="bhc-20220630.xsd#bhc_TermFacilityDueMay2027Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_TermFacilityDueMay2027Member_bbfbcb15-3c32-4d68-b984-d27f1ae49d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_b043d2d3-c13d-4829-a51e-ba8113b75d91" xlink:href="bhc-20220630.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_b043d2d3-c13d-4829-a51e-ba8113b75d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_eed6a61f-4ae3-4084-895a-7fe5fbaaddf8" xlink:href="bhc-20220630.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_eed6a61f-4ae3-4084-895a-7fe5fbaaddf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_9ad2e185-f780-426f-af5d-fac2edfd676b" xlink:href="bhc-20220630.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_9ad2e185-f780-426f-af5d-fac2edfd676b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member_b19f74a0-d4c7-4647-8f33-44750ce66f9a" xlink:href="bhc-20220630.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorSecured4875NotesDueJune2028Member_b19f74a0-d4c7-4647-8f33-44750ce66f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_b891f1a9-fe29-4078-811a-a95b43be315c" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_b891f1a9-fe29-4078-811a-a95b43be315c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes900DueDecember2025Member_da41fbef-4e46-4149-8bf8-1f817903ef15" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes900DueDecember2025Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorNotes900DueDecember2025Member_da41fbef-4e46-4149-8bf8-1f817903ef15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member_23d5792c-8d1e-47b0-b17d-a40516ccbcd2" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorNotes925DueApril2026Member_23d5792c-8d1e-47b0-b17d-a40516ccbcd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member_a7534258-4474-44e9-83b4-89f3f72d2702" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorNotes850DueJanuary2027Member_a7534258-4474-44e9-83b4-89f3f72d2702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member_1b396cf4-6952-4f5c-a297-b3b64bba19b1" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorNotes700DueJanuary2028Member_1b396cf4-6952-4f5c-a297-b3b64bba19b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member_f7fa0641-2d82-411f-b86c-1aa372b8a191" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorNotes500DueJanuary2028Member_f7fa0641-2d82-411f-b86c-1aa372b8a191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member_82185426-5177-4e27-a5da-6be955bec7f4" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorNotes625DueFebruary2029Member_82185426-5177-4e27-a5da-6be955bec7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member_d44ff3ca-6974-4960-a0e1-779491b0aa5b" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorNotes500DueFebruary2029Member_d44ff3ca-6974-4960-a0e1-779491b0aa5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member_ddebf70e-902d-44d6-8ee9-3a7ec978d310" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorNotes725DueMay2029Member_ddebf70e-902d-44d6-8ee9-3a7ec978d310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member_e1bf2d09-950f-4720-bf54-dc05dda0a67e" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorNotes525DueJanuary2030Member_e1bf2d09-950f-4720-bf54-dc05dda0a67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member_03c82c0e-8b9d-4dfe-8186-613bb1ae9635" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_SeniorNotes525DueFebruary2031Member_03c82c0e-8b9d-4dfe-8186-613bb1ae9635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherLongTermDebtMember_977da6b2-35ab-4cec-a7c5-7bbd85de63be" xlink:href="bhc-20220630.xsd#bhc_OtherLongTermDebtMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2de40c7a-ae18-4420-a307-61a82136ff3e" xlink:to="loc_bhc_OtherLongTermDebtMember_977da6b2-35ab-4cec-a7c5-7bbd85de63be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_cd2c62a8-4632-455e-99c0-0237930df0ad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_80cefb0a-7242-4373-bf60-15080674dab2" xlink:to="loc_dei_LegalEntityAxis_cd2c62a8-4632-455e-99c0-0237930df0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4cf02bf3-e523-45e1-a75a-f77fe24384e1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_cd2c62a8-4632-455e-99c0-0237930df0ad" xlink:to="loc_dei_EntityDomain_4cf02bf3-e523-45e1-a75a-f77fe24384e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_89ca5025-c514-4763-bec5-4166b69c225a" xlink:href="bhc-20220630.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4cf02bf3-e523-45e1-a75a-f77fe24384e1" xlink:to="loc_bhc_BauschLombMember_89ca5025-c514-4763-bec5-4166b69c225a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0aa5a5c9-2e6a-44a2-afae-7763a7c64865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_80cefb0a-7242-4373-bf60-15080674dab2" xlink:to="loc_us-gaap_DebtInstrumentLineItems_0aa5a5c9-2e6a-44a2-afae-7763a7c64865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_537d9eef-95d7-41b8-be2c-b733c97e5293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0aa5a5c9-2e6a-44a2-afae-7763a7c64865" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_537d9eef-95d7-41b8-be2c-b733c97e5293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_90a7f8a3-b0b0-4188-8370-2dd74d4f34ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0aa5a5c9-2e6a-44a2-afae-7763a7c64865" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_90a7f8a3-b0b0-4188-8370-2dd74d4f34ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5ef7c655-dd34-42f3-bce3-9405c910cf46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0aa5a5c9-2e6a-44a2-afae-7763a7c64865" xlink:to="loc_us-gaap_LongTermDebt_5ef7c655-dd34-42f3-bce3-9405c910cf46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_04ecf859-dca2-4f64-baaa-8630c229d1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0aa5a5c9-2e6a-44a2-afae-7763a7c64865" xlink:to="loc_us-gaap_LongTermDebtCurrent_04ecf859-dca2-4f64-baaa-8630c229d1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_bbc16e19-d01f-4137-bee2-f15b2b0451f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0aa5a5c9-2e6a-44a2-afae-7763a7c64865" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_bbc16e19-d01f-4137-bee2-f15b2b0451f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FINANCINGARRANGEMENTSCovenantComplianceDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_bc16bf74-57e5-4c01-bbc3-b8d5c638a760" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_55287028-f5fc-443c-9ead-83d3a1e00f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bc16bf74-57e5-4c01-bbc3-b8d5c638a760" xlink:to="loc_us-gaap_DebtInstrumentTable_55287028-f5fc-443c-9ead-83d3a1e00f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_30d4e70a-bc93-4132-9be4-b8978e1458cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_55287028-f5fc-443c-9ead-83d3a1e00f4a" xlink:to="loc_us-gaap_CreditFacilityAxis_30d4e70a-bc93-4132-9be4-b8978e1458cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_873a29ad-3b71-4f00-9f33-1fb350cef581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_30d4e70a-bc93-4132-9be4-b8978e1458cd" xlink:to="loc_us-gaap_CreditFacilityDomain_873a29ad-3b71-4f00-9f33-1fb350cef581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilityMember_376be3d6-26d2-4f4e-9c3a-2460bdee0a49" xlink:href="bhc-20220630.xsd#bhc_SeniorSecuredCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_873a29ad-3b71-4f00-9f33-1fb350cef581" xlink:to="loc_bhc_SeniorSecuredCreditFacilityMember_376be3d6-26d2-4f4e-9c3a-2460bdee0a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_167d4d21-f205-4dfe-abf5-f396b41dfa4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_873a29ad-3b71-4f00-9f33-1fb350cef581" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_167d4d21-f205-4dfe-abf5-f396b41dfa4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a543db37-fac0-41fa-a4ad-d29411ce0cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_55287028-f5fc-443c-9ead-83d3a1e00f4a" xlink:to="loc_us-gaap_DebtInstrumentLineItems_a543db37-fac0-41fa-a4ad-d29411ce0cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_e2aabfcf-84a6-4fc4-b701-ecb7304d7792" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a543db37-fac0-41fa-a4ad-d29411ce0cf4" xlink:to="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_e2aabfcf-84a6-4fc4-b701-ecb7304d7792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_5234081f-16c3-45b2-856f-15d6ce1a103b" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a543db37-fac0-41fa-a4ad-d29411ce0cf4" xlink:to="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_5234081f-16c3-45b2-856f-15d6ce1a103b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_1b796ae7-b26c-4336-8931-d74c5ceed198" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a543db37-fac0-41fa-a4ad-d29411ce0cf4" xlink:to="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_1b796ae7-b26c-4336-8931-d74c5ceed198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_bcd83fe2-fb8c-4741-8b6f-bf263313e6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_25de9279-0336-4d37-9d24-a0722350724d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bcd83fe2-fb8c-4741-8b6f-bf263313e6cf" xlink:to="loc_us-gaap_DebtInstrumentTable_25de9279-0336-4d37-9d24-a0722350724d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2de460b5-34bc-4510-b792-10c226649a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_25de9279-0336-4d37-9d24-a0722350724d" xlink:to="loc_us-gaap_CreditFacilityAxis_2de460b5-34bc-4510-b792-10c226649a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_73b9bf85-93d9-4bc1-8b18-61234a2d514f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_2de460b5-34bc-4510-b792-10c226649a3c" xlink:to="loc_us-gaap_CreditFacilityDomain_73b9bf85-93d9-4bc1-8b18-61234a2d514f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_de77ca83-63a7-467b-a9f3-af2349f0ccda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_73b9bf85-93d9-4bc1-8b18-61234a2d514f" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_de77ca83-63a7-467b-a9f3-af2349f0ccda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2f18c9bc-bcfc-42b4-9736-8470c3d62976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_25de9279-0336-4d37-9d24-a0722350724d" xlink:to="loc_us-gaap_DebtInstrumentAxis_2f18c9bc-bcfc-42b4-9736-8470c3d62976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a259b098-8e5f-4934-b9c4-ae727098b4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2f18c9bc-bcfc-42b4-9736-8470c3d62976" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a259b098-8e5f-4934-b9c4-ae727098b4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_1c8d3739-d3a6-4320-893b-9db1e998075e" xlink:href="bhc-20220630.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a259b098-8e5f-4934-b9c4-ae727098b4e3" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_1c8d3739-d3a6-4320-893b-9db1e998075e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_c9267542-7ffa-4cb4-84ef-6ebfb786b413" xlink:href="bhc-20220630.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a259b098-8e5f-4934-b9c4-ae727098b4e3" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_c9267542-7ffa-4cb4-84ef-6ebfb786b413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_0aa20e2f-5d4e-4c6d-806e-104dbee3f82a" xlink:href="bhc-20220630.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a259b098-8e5f-4934-b9c4-ae727098b4e3" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_0aa20e2f-5d4e-4c6d-806e-104dbee3f82a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueFebruary2027Member_866afe10-64f8-476f-bfbd-e7eeb7200a6e" xlink:href="bhc-20220630.xsd#bhc_TermLoanBFacilityDueFebruary2027Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a259b098-8e5f-4934-b9c4-ae727098b4e3" xlink:to="loc_bhc_TermLoanBFacilityDueFebruary2027Member_866afe10-64f8-476f-bfbd-e7eeb7200a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_b3c62ad8-1290-49a4-9717-967d165e0254" xlink:href="bhc-20220630.xsd#bhc_RevolvingCreditFacilityDueFebruary2027Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a259b098-8e5f-4934-b9c4-ae727098b4e3" xlink:to="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_b3c62ad8-1290-49a4-9717-967d165e0254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilitiesMember_f886e8fb-3445-4000-8929-3c4ac4eeb67a" xlink:href="bhc-20220630.xsd#bhc_SeniorSecuredCreditFacilitiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a259b098-8e5f-4934-b9c4-ae727098b4e3" xlink:to="loc_bhc_SeniorSecuredCreditFacilitiesMember_f886e8fb-3445-4000-8929-3c4ac4eeb67a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NewRestatedCreditAgreementMember_a813efc4-3de4-4cd3-ae6d-ff1009b04af8" xlink:href="bhc-20220630.xsd#bhc_NewRestatedCreditAgreementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a259b098-8e5f-4934-b9c4-ae727098b4e3" xlink:to="loc_bhc_NewRestatedCreditAgreementMember_a813efc4-3de4-4cd3-ae6d-ff1009b04af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermFacilityDueMay2027Member_c4b94cb2-e3fd-4213-aa5b-d024253de6a1" xlink:href="bhc-20220630.xsd#bhc_TermFacilityDueMay2027Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a259b098-8e5f-4934-b9c4-ae727098b4e3" xlink:to="loc_bhc_TermFacilityDueMay2027Member_c4b94cb2-e3fd-4213-aa5b-d024253de6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueMay2027Member_ab93c2d6-61f0-4b33-a6d5-50a79b157f0e" xlink:href="bhc-20220630.xsd#bhc_RevolvingCreditFacilityDueMay2027Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a259b098-8e5f-4934-b9c4-ae727098b4e3" xlink:to="loc_bhc_RevolvingCreditFacilityDueMay2027Member_ab93c2d6-61f0-4b33-a6d5-50a79b157f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BLCreditAgreementMember_f7e310fd-132c-4046-9b88-38b44ba9c72e" xlink:href="bhc-20220630.xsd#bhc_BLCreditAgreementMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a259b098-8e5f-4934-b9c4-ae727098b4e3" xlink:to="loc_bhc_BLCreditAgreementMember_f7e310fd-132c-4046-9b88-38b44ba9c72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_2a334cdf-49da-463b-9730-36d44f13ed0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_25de9279-0336-4d37-9d24-a0722350724d" xlink:to="loc_us-gaap_VariableRateAxis_2a334cdf-49da-463b-9730-36d44f13ed0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_a69ef02d-35e1-4096-8c38-e0f4ded21bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_2a334cdf-49da-463b-9730-36d44f13ed0b" xlink:to="loc_us-gaap_VariableRateDomain_a69ef02d-35e1-4096-8c38-e0f4ded21bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_7b9caf32-dbc3-4a2c-86b2-3eb7c90d14b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_a69ef02d-35e1-4096-8c38-e0f4ded21bb3" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_7b9caf32-dbc3-4a2c-86b2-3eb7c90d14b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember_37d3b303-40e4-4242-82f8-d119af0f913b" xlink:href="bhc-20220630.xsd#bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_a69ef02d-35e1-4096-8c38-e0f4ded21bb3" xlink:to="loc_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember_37d3b303-40e4-4242-82f8-d119af0f913b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_93feb061-56f2-4416-ab61-8db5d486fc6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_a69ef02d-35e1-4096-8c38-e0f4ded21bb3" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_93feb061-56f2-4416-ab61-8db5d486fc6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadianBankersAcceptanceRateMember_031ad950-ad8a-4e4f-a9c9-3fcb74cea3aa" xlink:href="bhc-20220630.xsd#bhc_CanadianBankersAcceptanceRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_a69ef02d-35e1-4096-8c38-e0f4ded21bb3" xlink:to="loc_bhc_CanadianBankersAcceptanceRateMember_031ad950-ad8a-4e4f-a9c9-3fcb74cea3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EuropeInterbankOfferedRateEURIBORMember_68c92bb3-aa4f-4656-bb36-e0f02a61474b" xlink:href="bhc-20220630.xsd#bhc_EuropeInterbankOfferedRateEURIBORMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_a69ef02d-35e1-4096-8c38-e0f4ded21bb3" xlink:to="loc_bhc_EuropeInterbankOfferedRateEURIBORMember_68c92bb3-aa4f-4656-bb36-e0f02a61474b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_1f850990-ce52-4757-8769-9cc0f44b25a7" xlink:href="bhc-20220630.xsd#bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_a69ef02d-35e1-4096-8c38-e0f4ded21bb3" xlink:to="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_1f850990-ce52-4757-8769-9cc0f44b25a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_c361fe2a-0db3-432a-88e5-0dad75499150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_a69ef02d-35e1-4096-8c38-e0f4ded21bb3" xlink:to="loc_us-gaap_BaseRateMember_c361fe2a-0db3-432a-88e5-0dad75499150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDORAndEURIBORRatesMember_8b88156f-9624-4815-82ca-22774b7f4385" xlink:href="bhc-20220630.xsd#bhc_SOFRCDORAndEURIBORRatesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_a69ef02d-35e1-4096-8c38-e0f4ded21bb3" xlink:to="loc_bhc_SOFRCDORAndEURIBORRatesMember_8b88156f-9624-4815-82ca-22774b7f4385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SONIARateMember_5175bb5b-9bd0-4d27-9587-6468d7f666b4" xlink:href="bhc-20220630.xsd#bhc_SONIARateMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_a69ef02d-35e1-4096-8c38-e0f4ded21bb3" xlink:to="loc_bhc_SONIARateMember_5175bb5b-9bd0-4d27-9587-6468d7f666b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember_2409045e-40b1-4ec2-826d-75115796cb91" xlink:href="bhc-20220630.xsd#bhc_SOFRCDOREURIBORAndSONIARatesMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_a69ef02d-35e1-4096-8c38-e0f4ded21bb3" xlink:to="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember_2409045e-40b1-4ec2-826d-75115796cb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c087ad34-1e69-45e5-8bb6-88a64a9c5ed7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_25de9279-0336-4d37-9d24-a0722350724d" xlink:to="loc_srt_RangeAxis_c087ad34-1e69-45e5-8bb6-88a64a9c5ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b5f96d83-fb7f-4033-8ddc-f2bee3a5d5f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c087ad34-1e69-45e5-8bb6-88a64a9c5ed7" xlink:to="loc_srt_RangeMember_b5f96d83-fb7f-4033-8ddc-f2bee3a5d5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_83f574cf-a9e2-425d-b5f9-61464b66bbaa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b5f96d83-fb7f-4033-8ddc-f2bee3a5d5f7" xlink:to="loc_srt_MinimumMember_83f574cf-a9e2-425d-b5f9-61464b66bbaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7e7c65e5-640b-4da9-9044-58915ff77a58" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b5f96d83-fb7f-4033-8ddc-f2bee3a5d5f7" xlink:to="loc_srt_MaximumMember_7e7c65e5-640b-4da9-9044-58915ff77a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3f8030b3-c218-4687-80cd-012dd376f171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_25de9279-0336-4d37-9d24-a0722350724d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3f8030b3-c218-4687-80cd-012dd376f171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_81ac0528-c535-4e02-af74-09339e592340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3f8030b3-c218-4687-80cd-012dd376f171" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_81ac0528-c535-4e02-af74-09339e592340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_28e83031-17c5-4156-91eb-9fd12d717b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_81ac0528-c535-4e02-af74-09339e592340" xlink:to="loc_us-gaap_SecuredDebtMember_28e83031-17c5-4156-91eb-9fd12d717b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_8951e676-22e5-4671-a373-b1b65f060926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_81ac0528-c535-4e02-af74-09339e592340" xlink:to="loc_us-gaap_UnsecuredDebtMember_8951e676-22e5-4671-a373-b1b65f060926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c2bd4cf7-15f2-41b7-aeef-e9c3aee50bc0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_25de9279-0336-4d37-9d24-a0722350724d" xlink:to="loc_dei_LegalEntityAxis_c2bd4cf7-15f2-41b7-aeef-e9c3aee50bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e78f332c-3aa0-42ae-9aea-c1d5e8e5c8f3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_c2bd4cf7-15f2-41b7-aeef-e9c3aee50bc0" xlink:to="loc_dei_EntityDomain_e78f332c-3aa0-42ae-9aea-c1d5e8e5c8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_8e6a41af-a08c-422f-9577-208f8aafdecd" xlink:href="bhc-20220630.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e78f332c-3aa0-42ae-9aea-c1d5e8e5c8f3" xlink:to="loc_bhc_BauschLombMember_8e6a41af-a08c-422f-9577-208f8aafdecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_25de9279-0336-4d37-9d24-a0722350724d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ee457483-e1d4-4dec-a361-837913f1e979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ee457483-e1d4-4dec-a361-837913f1e979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_b2898f7b-b88e-41fd-aa87-bbf431243259" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_b2898f7b-b88e-41fd-aa87-bbf431243259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_7eff8a32-7870-432f-a6d9-eee698eaf177" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_7eff8a32-7870-432f-a6d9-eee698eaf177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_11f3181b-34ee-4de8-b535-824c93e822ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_11f3181b-34ee-4de8-b535-824c93e822ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c5eb7b31-3a53-40fd-aaae-116bbaf4b3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_us-gaap_LongTermDebt_c5eb7b31-3a53-40fd-aaae-116bbaf4b3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_312dfc3e-25e6-4d98-86d1-b97650b2a4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_312dfc3e-25e6-4d98-86d1-b97650b2a4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable_fd7d2cae-2c47-438d-bb11-1d8d28ad3eda" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable_fd7d2cae-2c47-438d-bb11-1d8d28ad3eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_512872ad-8459-49de-8514-85483a5e5495" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_512872ad-8459-49de-8514-85483a5e5495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_fba3b353-741e-4df5-9a13-f726e8ad4ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_fba3b353-741e-4df5-9a13-f726e8ad4ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_236405bd-2baf-4472-b3d1-aed42f9328e8" xlink:href="bhc-20220630.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_236405bd-2baf-4472-b3d1-aed42f9328e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_f68fe18c-954e-402e-abbe-9a8b66ac8198" xlink:href="bhc-20220630.xsd#bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_f68fe18c-954e-402e-abbe-9a8b66ac8198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_2ff9c81c-806c-4658-bee5-6e58460e26b7" xlink:href="bhc-20220630.xsd#bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_2ff9c81c-806c-4658-bee5-6e58460e26b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_ca0fa0b9-c48e-45b0-a2bc-ca7fa0f00ae4" xlink:href="bhc-20220630.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_ca0fa0b9-c48e-45b0-a2bc-ca7fa0f00ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_4091e3fa-13ed-4bc3-8b28-a2a843c7e714" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentAnnualAmortizationRatePercentage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_4091e3fa-13ed-4bc3-8b28-a2a843c7e714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_b7f887c2-b9fe-4bb1-b821-4cb73dcf638c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_b7f887c2-b9fe-4bb1-b821-4cb73dcf638c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization_250edc68-20b5-48ed-bf99-115d49fe3148" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization_250edc68-20b5-48ed-bf99-115d49fe3148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_14a5bd67-c624-47cb-a152-a1e246b6fdad" xlink:href="bhc-20220630.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_14a5bd67-c624-47cb-a152-a1e246b6fdad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage_bb8a043c-8dd1-43fd-996d-752a0bd0c3c8" xlink:href="bhc-20220630.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage_bb8a043c-8dd1-43fd-996d-752a0bd0c3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_291ad786-2617-4c1a-8059-0c05c1381eee" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_291ad786-2617-4c1a-8059-0c05c1381eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_99afd73f-dc05-4535-9838-12f91b5e039d" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_99afd73f-dc05-4535-9838-12f91b5e039d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_87aa481c-f837-4b11-8ede-7eb874b7b35e" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_87aa481c-f837-4b11-8ede-7eb874b7b35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio_cf984646-f726-4c0b-ba89-543755921ffb" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatio"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio_cf984646-f726-4c0b-ba89-543755921ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_98a5a690-8bc7-450d-8a0c-fd5436f89be2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_us-gaap_DebtInstrumentTerm_98a5a690-8bc7-450d-8a0c-fd5436f89be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_5710a306-2c25-44c0-b0ac-3dd8c57a80d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9a322ef3-de6c-4c47-a03a-35b3bba97b53" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_5710a306-2c25-44c0-b0ac-3dd8c57a80d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_27a3efe9-9e37-4be8-b093-bcd6f5c0de99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a1c90d7b-1549-4df9-8aa5-de179136fc59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_27a3efe9-9e37-4be8-b093-bcd6f5c0de99" xlink:to="loc_us-gaap_DebtInstrumentTable_a1c90d7b-1549-4df9-8aa5-de179136fc59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1a35d39c-aa7b-415d-a728-e757d2fc370d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a1c90d7b-1549-4df9-8aa5-de179136fc59" xlink:to="loc_us-gaap_DebtInstrumentAxis_1a35d39c-aa7b-415d-a728-e757d2fc370d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_55643340-2c14-47ac-9fdc-f36bf8d3c59d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1a35d39c-aa7b-415d-a728-e757d2fc370d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_55643340-2c14-47ac-9fdc-f36bf8d3c59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_df5d9e3a-183b-4e3c-ad3b-5439b6a8da0d" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_55643340-2c14-47ac-9fdc-f36bf8d3c59d" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_df5d9e3a-183b-4e3c-ad3b-5439b6a8da0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member_f3332b35-2612-4de7-9a93-8afd2098178c" xlink:href="bhc-20220630.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_55643340-2c14-47ac-9fdc-f36bf8d3c59d" xlink:to="loc_bhc_SeniorSecured4875NotesDueJune2028Member_f3332b35-2612-4de7-9a93-8afd2098178c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueMarch2024Member_18bf2e0a-6fb4-4889-8210-8570274195e1" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes700DueMarch2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_55643340-2c14-47ac-9fdc-f36bf8d3c59d" xlink:to="loc_bhc_SeniorNotes700DueMarch2024Member_18bf2e0a-6fb4-4889-8210-8570274195e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_6ad9ca11-62cb-410d-b07d-808333150e32" xlink:href="bhc-20220630.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_55643340-2c14-47ac-9fdc-f36bf8d3c59d" xlink:to="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_6ad9ca11-62cb-410d-b07d-808333150e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d45be0e5-4fca-4c20-b11a-c2fd9e0a3246" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a1c90d7b-1549-4df9-8aa5-de179136fc59" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d45be0e5-4fca-4c20-b11a-c2fd9e0a3246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2309be8f-0419-4720-a0d2-cb2503306293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d45be0e5-4fca-4c20-b11a-c2fd9e0a3246" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2309be8f-0419-4720-a0d2-cb2503306293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_7cc1fa12-ed0c-4e7d-b4a9-962dc03166ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2309be8f-0419-4720-a0d2-cb2503306293" xlink:to="loc_us-gaap_UnsecuredDebtMember_7cc1fa12-ed0c-4e7d-b4a9-962dc03166ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_3283a16d-8e5a-4aa5-87b6-f1115bebd2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2309be8f-0419-4720-a0d2-cb2503306293" xlink:to="loc_us-gaap_SecuredDebtMember_3283a16d-8e5a-4aa5-87b6-f1115bebd2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_9a55fdec-47ce-455d-9eb0-890372e8d3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a1c90d7b-1549-4df9-8aa5-de179136fc59" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_9a55fdec-47ce-455d-9eb0-890372e8d3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_48e09131-9fac-4aa8-9628-e047d2cc8e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_9a55fdec-47ce-455d-9eb0-890372e8d3d6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_48e09131-9fac-4aa8-9628-e047d2cc8e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_46deb7e4-2564-4798-bdac-933c45db3df3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_48e09131-9fac-4aa8-9628-e047d2cc8e92" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_46deb7e4-2564-4798-bdac-933c45db3df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_eff32cb7-4e75-4196-ab93-adab610a4bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_48e09131-9fac-4aa8-9628-e047d2cc8e92" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_eff32cb7-4e75-4196-ab93-adab610a4bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1d56b964-03ae-403d-8a8d-a275395457df" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a1c90d7b-1549-4df9-8aa5-de179136fc59" xlink:to="loc_srt_RangeAxis_1d56b964-03ae-403d-8a8d-a275395457df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fdc8f87c-f7e1-4f2d-8488-57b43da2c631" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1d56b964-03ae-403d-8a8d-a275395457df" xlink:to="loc_srt_RangeMember_fdc8f87c-f7e1-4f2d-8488-57b43da2c631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ced653bf-e13d-44bd-b65c-deb9d790cacb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fdc8f87c-f7e1-4f2d-8488-57b43da2c631" xlink:to="loc_srt_MaximumMember_ced653bf-e13d-44bd-b65c-deb9d790cacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6ac8794c-0c09-4706-b147-6af303ff6fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a1c90d7b-1549-4df9-8aa5-de179136fc59" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6ac8794c-0c09-4706-b147-6af303ff6fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f0ceb864-8157-48fc-8395-553a58d152cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ac8794c-0c09-4706-b147-6af303ff6fe2" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f0ceb864-8157-48fc-8395-553a58d152cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_68dbb3f0-6179-442d-9cd6-16129cc3c541" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ac8794c-0c09-4706-b147-6af303ff6fe2" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_68dbb3f0-6179-442d-9cd6-16129cc3c541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_5f21df0d-5443-47fc-8a78-d638769ffa2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ac8794c-0c09-4706-b147-6af303ff6fe2" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_5f21df0d-5443-47fc-8a78-d638769ffa2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_a317a840-963a-468a-8da4-91cf882ee154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ac8794c-0c09-4706-b147-6af303ff6fe2" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_a317a840-963a-468a-8da4-91cf882ee154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d2b5a9c0-8370-4dad-b8fa-450031929d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ac8794c-0c09-4706-b147-6af303ff6fe2" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d2b5a9c0-8370-4dad-b8fa-450031929d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_17baa3bd-195c-4832-af13-49b4d5b2f7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ac8794c-0c09-4706-b147-6af303ff6fe2" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_17baa3bd-195c-4832-af13-49b4d5b2f7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_e014fa6c-df75-42e3-b8c5-2fd1d8873733" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ac8794c-0c09-4706-b147-6af303ff6fe2" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_e014fa6c-df75-42e3-b8c5-2fd1d8873733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_56b78a9a-1db6-4be8-a275-c295f498e8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e04216fc-643e-45d3-b53b-c0b1f0e16640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_56b78a9a-1db6-4be8-a275-c295f498e8cd" xlink:to="loc_us-gaap_DebtInstrumentTable_e04216fc-643e-45d3-b53b-c0b1f0e16640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e6dc286b-aadb-4350-822f-75399a86a679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e04216fc-643e-45d3-b53b-c0b1f0e16640" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e6dc286b-aadb-4350-822f-75399a86a679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ff4bc4e5-82e8-4b3e-b949-47f44d8207b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e6dc286b-aadb-4350-822f-75399a86a679" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ff4bc4e5-82e8-4b3e-b949-47f44d8207b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_c55a7292-e29c-4ae4-b15a-c6c59e55eced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ff4bc4e5-82e8-4b3e-b949-47f44d8207b0" xlink:to="loc_us-gaap_UnsecuredDebtMember_c55a7292-e29c-4ae4-b15a-c6c59e55eced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_41afbfa3-bfdd-47e9-89c9-f2098124e62a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e04216fc-643e-45d3-b53b-c0b1f0e16640" xlink:to="loc_us-gaap_DebtInstrumentAxis_41afbfa3-bfdd-47e9-89c9-f2098124e62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ef92f3a1-27d9-45ac-a9c3-6d6af9d33069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_41afbfa3-bfdd-47e9-89c9-f2098124e62a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ef92f3a1-27d9-45ac-a9c3-6d6af9d33069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.00SeniorNotesdueDecember2025Member_a3a29dfd-cdf4-4712-aab6-ca582c97c5f8" xlink:href="bhc-20220630.xsd#bhc_A9.00SeniorNotesdueDecember2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ef92f3a1-27d9-45ac-a9c3-6d6af9d33069" xlink:to="loc_bhc_A9.00SeniorNotesdueDecember2025Member_a3a29dfd-cdf4-4712-aab6-ca582c97c5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_11270db7-10ca-439a-97bb-2059961d9389" xlink:href="bhc-20220630.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ef92f3a1-27d9-45ac-a9c3-6d6af9d33069" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_11270db7-10ca-439a-97bb-2059961d9389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_33e6d2f1-627a-41d0-80cc-71c3f4020e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e04216fc-643e-45d3-b53b-c0b1f0e16640" xlink:to="loc_us-gaap_DebtInstrumentLineItems_33e6d2f1-627a-41d0-80cc-71c3f4020e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_38dc055c-db71-40f4-97c1-601dca07cfd4" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33e6d2f1-627a-41d0-80cc-71c3f4020e42" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_38dc055c-db71-40f4-97c1-601dca07cfd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_ff225cc4-56a8-4e4b-a14f-9d6411e84df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33e6d2f1-627a-41d0-80cc-71c3f4020e42" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_ff225cc4-56a8-4e4b-a14f-9d6411e84df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_68151922-82a2-4fcf-9896-176545e8dae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33e6d2f1-627a-41d0-80cc-71c3f4020e42" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_68151922-82a2-4fcf-9896-176545e8dae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_542653ac-06bf-4af5-abf2-dc31f2bf1279" xlink:href="bhc-20220630.xsd#bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33e6d2f1-627a-41d0-80cc-71c3f4020e42" xlink:to="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_542653ac-06bf-4af5-abf2-dc31f2bf1279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_8bf875be-bf86-4d65-9532-8900bd917af2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_33e6d2f1-627a-41d0-80cc-71c3f4020e42" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_8bf875be-bf86-4d65-9532-8900bd917af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4fd4714f-b5b3-44a2-ae61-54edef31de20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_72b312db-9f6d-40e3-a10b-2fadd4a6fa92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4fd4714f-b5b3-44a2-ae61-54edef31de20" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_72b312db-9f6d-40e3-a10b-2fadd4a6fa92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d44f1605-f544-4398-b4e9-b3135d51e110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_20229212-3ac5-4b02-8bd1-a679ec1731a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d44f1605-f544-4398-b4e9-b3135d51e110" xlink:to="loc_us-gaap_DebtInstrumentTable_20229212-3ac5-4b02-8bd1-a679ec1731a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_94126238-0990-454c-8984-176d3a76f9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_20229212-3ac5-4b02-8bd1-a679ec1731a5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_94126238-0990-454c-8984-176d3a76f9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_47a13b88-53d8-4de8-a2ac-84abae31d8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_94126238-0990-454c-8984-176d3a76f9d3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_47a13b88-53d8-4de8-a2ac-84abae31d8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_90efdf73-5851-439e-a020-85110f97cc54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_47a13b88-53d8-4de8-a2ac-84abae31d8b0" xlink:to="loc_us-gaap_UnsecuredDebtMember_90efdf73-5851-439e-a020-85110f97cc54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e414ac5c-4d51-4ace-9d64-a1d713d09e25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_20229212-3ac5-4b02-8bd1-a679ec1731a5" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e414ac5c-4d51-4ace-9d64-a1d713d09e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_40f1b8d7-4e81-45a6-b884-d4cc257e5af7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e414ac5c-4d51-4ace-9d64-a1d713d09e25" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_40f1b8d7-4e81-45a6-b884-d4cc257e5af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_a671e86b-a52f-4d17-9df0-173696391d59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e414ac5c-4d51-4ace-9d64-a1d713d09e25" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_a671e86b-a52f-4d17-9df0-173696391d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_90f47040-85b2-4a98-9250-88a75869a6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e414ac5c-4d51-4ace-9d64-a1d713d09e25" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_90f47040-85b2-4a98-9250-88a75869a6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_253cf16b-7d86-4edf-bcc5-de40aec0d99b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_717df13d-3b7a-47be-be8a-1352355fecb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_253cf16b-7d86-4edf-bcc5-de40aec0d99b" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_717df13d-3b7a-47be-be8a-1352355fecb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_cfd4539d-9807-446d-87ed-7160b8f3c024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_253cf16b-7d86-4edf-bcc5-de40aec0d99b" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_cfd4539d-9807-446d-87ed-7160b8f3c024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1b0b9f7c-357d-40a4-83bf-e2c213956c26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_253cf16b-7d86-4edf-bcc5-de40aec0d99b" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1b0b9f7c-357d-40a4-83bf-e2c213956c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2f2bbff7-a234-4750-9b57-e3123044aa43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_253cf16b-7d86-4edf-bcc5-de40aec0d99b" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2f2bbff7-a234-4750-9b57-e3123044aa43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_2a3bb22c-1191-48ef-aaf1-34f3cc7faf22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_253cf16b-7d86-4edf-bcc5-de40aec0d99b" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_2a3bb22c-1191-48ef-aaf1-34f3cc7faf22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_529d1d4c-fd5c-4379-b1d4-10427bf7fa4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_253cf16b-7d86-4edf-bcc5-de40aec0d99b" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_529d1d4c-fd5c-4379-b1d4-10427bf7fa4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_473ef707-a18a-4637-a2b1-eaa5f65e52ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_253cf16b-7d86-4edf-bcc5-de40aec0d99b" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_473ef707-a18a-4637-a2b1-eaa5f65e52ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_11a2c3e4-4553-415e-a7c4-eb445bb8f7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_253cf16b-7d86-4edf-bcc5-de40aec0d99b" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_11a2c3e4-4553-415e-a7c4-eb445bb8f7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_389a7a04-0a4e-4d4b-ae4a-187394ecaca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_253cf16b-7d86-4edf-bcc5-de40aec0d99b" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_389a7a04-0a4e-4d4b-ae4a-187394ecaca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f3428e30-e28f-4ab5-9215-81594ef79c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_253cf16b-7d86-4edf-bcc5-de40aec0d99b" xlink:to="loc_us-gaap_LongTermDebt_f3428e30-e28f-4ab5-9215-81594ef79c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS" xlink:type="simple" xlink:href="bhc-20220630.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d66f6c99-873b-4768-b1a7-200aba6691f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_a568962b-c875-4364-b3de-6a87880cafec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d66f6c99-873b-4768-b1a7-200aba6691f4" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_a568962b-c875-4364-b3de-6a87880cafec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" xlink:type="simple" xlink:href="bhc-20220630.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_84bd3569-5771-401c-889e-1fc521cd3565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_7d5cafd0-cbb6-43f4-a493-0a84a94e7607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_84bd3569-5771-401c-889e-1fc521cd3565" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_7d5cafd0-cbb6-43f4-a493-0a84a94e7607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f2049a95-fcbc-4cdd-a835-7cd32978ee4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c2a8fff5-4120-4c19-9fe1-da4d65b08334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f2049a95-fcbc-4cdd-a835-7cd32978ee4c" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c2a8fff5-4120-4c19-9fe1-da4d65b08334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_4fcc0339-a75b-4ca0-8e6b-d2e584f2798c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c2a8fff5-4120-4c19-9fe1-da4d65b08334" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_4fcc0339-a75b-4ca0-8e6b-d2e584f2798c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_65bdae4b-ea24-486c-a3f3-13b21f9c0a60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_4fcc0339-a75b-4ca0-8e6b-d2e584f2798c" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_65bdae4b-ea24-486c-a3f3-13b21f9c0a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_010d4e6d-1a5f-4fb8-a9b1-bd2031f47b62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_65bdae4b-ea24-486c-a3f3-13b21f9c0a60" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_010d4e6d-1a5f-4fb8-a9b1-bd2031f47b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_88c1354f-aedf-4d9b-83ef-db45ae47ede5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_65bdae4b-ea24-486c-a3f3-13b21f9c0a60" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_88c1354f-aedf-4d9b-83ef-db45ae47ede5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_35a4d77d-6a03-47c8-8e23-1b5d61948744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c2a8fff5-4120-4c19-9fe1-da4d65b08334" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_35a4d77d-6a03-47c8-8e23-1b5d61948744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_f128741a-0b85-4929-a1a2-90e76f7fec45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_35a4d77d-6a03-47c8-8e23-1b5d61948744" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_f128741a-0b85-4929-a1a2-90e76f7fec45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_2024267b-82b2-4359-aac0-b2e272d31ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_f128741a-0b85-4929-a1a2-90e76f7fec45" xlink:to="loc_us-gaap_DomesticPlanMember_2024267b-82b2-4359-aac0-b2e272d31ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_d26343cf-39cf-4289-8efc-0d9212eec221" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_2024267b-82b2-4359-aac0-b2e272d31ed6" xlink:to="loc_country_US_d26343cf-39cf-4289-8efc-0d9212eec221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_82a21ec8-fda8-49b3-9f8e-b536f8b0364a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_f128741a-0b85-4929-a1a2-90e76f7fec45" xlink:to="loc_us-gaap_ForeignPlanMember_82a21ec8-fda8-49b3-9f8e-b536f8b0364a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f1fe7b47-53a3-446d-a3c1-d0f4ed8119c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c2a8fff5-4120-4c19-9fe1-da4d65b08334" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f1fe7b47-53a3-446d-a3c1-d0f4ed8119c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_bac60f94-e52c-4dcf-b888-94e6d4d8b545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f1fe7b47-53a3-446d-a3c1-d0f4ed8119c3" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_bac60f94-e52c-4dcf-b888-94e6d4d8b545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_6b2e56f0-e6f5-40ac-9824-e899d2d53926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f1fe7b47-53a3-446d-a3c1-d0f4ed8119c3" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_6b2e56f0-e6f5-40ac-9824-e899d2d53926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_cbb1ae1d-b8b8-4a2d-9d71-899a8700daea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f1fe7b47-53a3-446d-a3c1-d0f4ed8119c3" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_cbb1ae1d-b8b8-4a2d-9d71-899a8700daea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_500ac639-410e-43b1-8445-fdc313879f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f1fe7b47-53a3-446d-a3c1-d0f4ed8119c3" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_500ac639-410e-43b1-8445-fdc313879f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_0f7aaf43-af90-4d30-b4bb-51f0ebffe55e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f1fe7b47-53a3-446d-a3c1-d0f4ed8119c3" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_0f7aaf43-af90-4d30-b4bb-51f0ebffe55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_08871fe6-3ca2-4f04-a322-1a699ddc252a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f1fe7b47-53a3-446d-a3c1-d0f4ed8119c3" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_08871fe6-3ca2-4f04-a322-1a699ddc252a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="bhc-20220630.xsd#SHAREBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a7880e2c-06cb-4628-9034-def77cb45092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_dff29edc-702b-4b4b-a8b8-f11b05644e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a7880e2c-06cb-4628-9034-def77cb45092" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_dff29edc-702b-4b4b-a8b8-f11b05644e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="bhc-20220630.xsd#SHAREBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c397a17f-9723-4ca9-89a8-9ed68fdf566b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_24760abf-3eb3-41b0-955a-b04ea6fa3523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c397a17f-9723-4ca9-89a8-9ed68fdf566b" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_24760abf-3eb3-41b0-955a-b04ea6fa3523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_6460f7bb-f8b2-4cd3-aed6-064885374aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c397a17f-9723-4ca9-89a8-9ed68fdf566b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_6460f7bb-f8b2-4cd3-aed6-064885374aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3c9514e2-238e-44c4-a7f6-b87c1865ebde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d635739-00fb-4ece-acef-2baea7fe0630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3c9514e2-238e-44c4-a7f6-b87c1865ebde" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d635739-00fb-4ece-acef-2baea7fe0630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_8a630756-3cd3-48b4-af19-204a90ec4f12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d635739-00fb-4ece-acef-2baea7fe0630" xlink:to="loc_us-gaap_PlanNameAxis_8a630756-3cd3-48b4-af19-204a90ec4f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9bfe0e9a-19d5-42a3-923a-5afd8d506196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_8a630756-3cd3-48b4-af19-204a90ec4f12" xlink:to="loc_us-gaap_PlanNameDomain_9bfe0e9a-19d5-42a3-923a-5afd8d506196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014Member_22a4715b-46d5-42cf-ba32-10250c0cc12e" xlink:href="bhc-20220630.xsd#bhc_OmnibusIncentivePlan2014Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9bfe0e9a-19d5-42a3-923a-5afd8d506196" xlink:to="loc_bhc_OmnibusIncentivePlan2014Member_22a4715b-46d5-42cf-ba32-10250c0cc12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IPOFoundersGrantsMember_5088f3a5-b891-4eb9-a200-1a8d5aad6d45" xlink:href="bhc-20220630.xsd#bhc_IPOFoundersGrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9bfe0e9a-19d5-42a3-923a-5afd8d506196" xlink:to="loc_bhc_IPOFoundersGrantsMember_5088f3a5-b891-4eb9-a200-1a8d5aad6d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_e0e24bc4-47a4-4c51-aa5b-94d24d4adf3f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d635739-00fb-4ece-acef-2baea7fe0630" xlink:to="loc_srt_TitleOfIndividualAxis_e0e24bc4-47a4-4c51-aa5b-94d24d4adf3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_57bbfc88-fb50-4ed3-93eb-bcf9dcfe825b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_e0e24bc4-47a4-4c51-aa5b-94d24d4adf3f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_57bbfc88-fb50-4ed3-93eb-bcf9dcfe825b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_76f53c2a-3cf7-4155-8e5e-6cd3bd1bb1ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_57bbfc88-fb50-4ed3-93eb-bcf9dcfe825b" xlink:to="loc_srt_ExecutiveOfficerMember_76f53c2a-3cf7-4155-8e5e-6cd3bd1bb1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonExecutiveEligibleRecipientsMember_9629daed-0f7c-428b-853d-e20c7a10a5e3" xlink:href="bhc-20220630.xsd#bhc_NonExecutiveEligibleRecipientsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_57bbfc88-fb50-4ed3-93eb-bcf9dcfe825b" xlink:to="loc_bhc_NonExecutiveEligibleRecipientsMember_9629daed-0f7c-428b-853d-e20c7a10a5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ab8bd1d6-135e-4341-96c4-94c379313448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d635739-00fb-4ece-acef-2baea7fe0630" xlink:to="loc_us-gaap_AwardTypeAxis_ab8bd1d6-135e-4341-96c4-94c379313448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2a4e7150-8b46-4ff6-9439-12559e411c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ab8bd1d6-135e-4341-96c4-94c379313448" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2a4e7150-8b46-4ff6-9439-12559e411c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_be19b3fb-01bd-4a77-98cc-81a1080f3663" xlink:href="bhc-20220630.xsd#bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2a4e7150-8b46-4ff6-9439-12559e411c82" xlink:to="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_be19b3fb-01bd-4a77-98cc-81a1080f3663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d304a01b-2d2c-4908-8bb9-ea4bc821cf03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_be19b3fb-01bd-4a77-98cc-81a1080f3663" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d304a01b-2d2c-4908-8bb9-ea4bc821cf03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_eef63862-c8ce-4eab-9d5a-9cd0d9ca456e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember_be19b3fb-01bd-4a77-98cc-81a1080f3663" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_eef63862-c8ce-4eab-9d5a-9cd0d9ca456e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_0d30811a-386c-40c7-9934-325cb57821a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d635739-00fb-4ece-acef-2baea7fe0630" xlink:to="loc_dei_LegalEntityAxis_0d30811a-386c-40c7-9934-325cb57821a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7a34f7bc-bbae-44ab-a37c-2eac2f1d3e33" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_0d30811a-386c-40c7-9934-325cb57821a9" xlink:to="loc_dei_EntityDomain_7a34f7bc-bbae-44ab-a37c-2eac2f1d3e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_9f50d469-2092-4c05-872b-9c8286a99c39" xlink:href="bhc-20220630.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_7a34f7bc-bbae-44ab-a37c-2eac2f1d3e33" xlink:to="loc_bhc_BauschLombMember_9f50d469-2092-4c05-872b-9c8286a99c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_620b3406-f1e8-42c2-8a3a-ab44756648d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d635739-00fb-4ece-acef-2baea7fe0630" xlink:to="loc_us-gaap_VestingAxis_620b3406-f1e8-42c2-8a3a-ab44756648d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_7c114f0e-0811-4433-a1ec-67e95da707e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_620b3406-f1e8-42c2-8a3a-ab44756648d3" xlink:to="loc_us-gaap_VestingDomain_7c114f0e-0811-4433-a1ec-67e95da707e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_56f0ef39-12c2-43b3-a29a-55088ba4fc7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_7c114f0e-0811-4433-a1ec-67e95da707e3" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_56f0ef39-12c2-43b3-a29a-55088ba4fc7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0265df68-a832-473c-a53e-e1aa0ca6d0da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_7c114f0e-0811-4433-a1ec-67e95da707e3" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0265df68-a832-473c-a53e-e1aa0ca6d0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b4f8395-0555-4b96-af55-c8b12c598a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2d635739-00fb-4ece-acef-2baea7fe0630" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b4f8395-0555-4b96-af55-c8b12c598a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_47596a3a-d9a6-4319-83ab-b609dc0f501b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b4f8395-0555-4b96-af55-c8b12c598a26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_47596a3a-d9a6-4319-83ab-b609dc0f501b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0c9582fd-be59-4b63-a29e-e3e79a0d2e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b4f8395-0555-4b96-af55-c8b12c598a26" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0c9582fd-be59-4b63-a29e-e3e79a0d2e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c2fad6f7-5890-4467-9329-3ac3389f3d11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b4f8395-0555-4b96-af55-c8b12c598a26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c2fad6f7-5890-4467-9329-3ac3389f3d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_428270cc-de46-4841-b7c7-b4b3affe44dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b4f8395-0555-4b96-af55-c8b12c598a26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_428270cc-de46-4841-b7c7-b4b3affe44dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_79291c06-5264-46fb-b2d0-4192312b0cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b4f8395-0555-4b96-af55-c8b12c598a26" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_79291c06-5264-46fb-b2d0-4192312b0cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_74229185-f25e-4645-a264-8da632bf8e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b4f8395-0555-4b96-af55-c8b12c598a26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_74229185-f25e-4645-a264-8da632bf8e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_47bcbb5e-48ac-48ec-97ff-ad613b50b772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b4f8395-0555-4b96-af55-c8b12c598a26" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_47bcbb5e-48ac-48ec-97ff-ad613b50b772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent_5c473cb8-ee65-4a96-bb72-7028aaf97d05" xlink:href="bhc-20220630.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b4f8395-0555-4b96-af55-c8b12c598a26" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent_5c473cb8-ee65-4a96-bb72-7028aaf97d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross_bd0b7600-22c9-4e59-b60a-7c71a774aabb" xlink:href="bhc-20220630.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b4f8395-0555-4b96-af55-c8b12c598a26" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross_bd0b7600-22c9-4e59-b60a-7c71a774aabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e0c73717-9877-4baa-9584-78c737e8b090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b4f8395-0555-4b96-af55-c8b12c598a26" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e0c73717-9877-4baa-9584-78c737e8b090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2d5a51cc-0155-456f-a7e4-6fa3bcdd0f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b4f8395-0555-4b96-af55-c8b12c598a26" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2d5a51cc-0155-456f-a7e4-6fa3bcdd0f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_56103315-594e-4967-9ac1-1951a04f4e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0b4f8395-0555-4b96-af55-c8b12c598a26" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_56103315-594e-4967-9ac1-1951a04f4e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_72c14348-1ab3-4fdc-81b1-7e835a30e215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9e9e60d2-819d-4c84-b4da-c84bdd9f9770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_72c14348-1ab3-4fdc-81b1-7e835a30e215" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9e9e60d2-819d-4c84-b4da-c84bdd9f9770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_77930fa3-0780-4041-a20b-ebebeb339461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9e9e60d2-819d-4c84-b4da-c84bdd9f9770" xlink:to="loc_us-gaap_AwardTypeAxis_77930fa3-0780-4041-a20b-ebebeb339461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a859eef-532a-4b43-bc3e-339f9f392ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_77930fa3-0780-4041-a20b-ebebeb339461" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a859eef-532a-4b43-bc3e-339f9f392ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e074a93e-cd84-46d5-b083-623eec37138a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a859eef-532a-4b43-bc3e-339f9f392ce4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e074a93e-cd84-46d5-b083-623eec37138a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_274827a2-24ad-412e-a7de-245f2ef2e582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a859eef-532a-4b43-bc3e-339f9f392ce4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_274827a2-24ad-412e-a7de-245f2ef2e582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fbd9f428-75c1-42bb-96df-8f7b141b0cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9e9e60d2-819d-4c84-b4da-c84bdd9f9770" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fbd9f428-75c1-42bb-96df-8f7b141b0cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_da2e88da-e596-43de-afed-93f2f435b2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fbd9f428-75c1-42bb-96df-8f7b141b0cb6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_da2e88da-e596-43de-afed-93f2f435b2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_af19a836-5e57-4f97-b325-6453a078f07b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_da2e88da-e596-43de-afed-93f2f435b2b0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_af19a836-5e57-4f97-b325-6453a078f07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_94260544-5987-42b5-8adb-e859bd05df8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_da2e88da-e596-43de-afed-93f2f435b2b0" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_94260544-5987-42b5-8adb-e859bd05df8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1bd1ff55-ecc2-4edc-a811-f5876ac6b5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9e9e60d2-819d-4c84-b4da-c84bdd9f9770" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1bd1ff55-ecc2-4edc-a811-f5876ac6b5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_fd2fcf53-8119-4122-9b9a-a26ca2f5f708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1bd1ff55-ecc2-4edc-a811-f5876ac6b5b5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_fd2fcf53-8119-4122-9b9a-a26ca2f5f708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d22d54b-991a-4c2e-98ad-fd24d4257bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82f8ebd9-546a-466c-a294-062a23e934d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d22d54b-991a-4c2e-98ad-fd24d4257bd3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82f8ebd9-546a-466c-a294-062a23e934d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7ff15b7e-1a84-41d6-a205-77d48756d829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82f8ebd9-546a-466c-a294-062a23e934d3" xlink:to="loc_us-gaap_AwardTypeAxis_7ff15b7e-1a84-41d6-a205-77d48756d829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94309650-dafa-4144-8508-6fbab31bee20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7ff15b7e-1a84-41d6-a205-77d48756d829" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94309650-dafa-4144-8508-6fbab31bee20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8edabcfd-f294-4dd3-98bf-87f805bec639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94309650-dafa-4144-8508-6fbab31bee20" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8edabcfd-f294-4dd3-98bf-87f805bec639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TimeBasedRSUMember_0ea0b765-f2ed-4503-9d3f-fb62ed4194e6" xlink:href="bhc-20220630.xsd#bhc_TimeBasedRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94309650-dafa-4144-8508-6fbab31bee20" xlink:to="loc_bhc_TimeBasedRSUMember_0ea0b765-f2ed-4503-9d3f-fb62ed4194e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_5177a80e-3010-46b1-bd51-93cc574fb2c2" xlink:href="bhc-20220630.xsd#bhc_TSRPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94309650-dafa-4144-8508-6fbab31bee20" xlink:to="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_5177a80e-3010-46b1-bd51-93cc574fb2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_1954ddae-d41e-4de9-91cf-be99a42521e9" xlink:href="bhc-20220630.xsd#bhc_ROTCPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94309650-dafa-4144-8508-6fbab31bee20" xlink:to="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_1954ddae-d41e-4de9-91cf-be99a42521e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember_71fdda56-8951-490b-87b5-464f5ce08396" xlink:href="bhc-20220630.xsd#bhc_SeparationPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_94309650-dafa-4144-8508-6fbab31bee20" xlink:to="loc_bhc_SeparationPerformanceBasedRestrictedStockUnitsMember_71fdda56-8951-490b-87b5-464f5ce08396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f17cd310-7aeb-43ff-aef1-0d2b98f805bb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82f8ebd9-546a-466c-a294-062a23e934d3" xlink:to="loc_dei_LegalEntityAxis_f17cd310-7aeb-43ff-aef1-0d2b98f805bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f5819f89-c90c-4cee-9f0e-f755077491dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_f17cd310-7aeb-43ff-aef1-0d2b98f805bb" xlink:to="loc_dei_EntityDomain_f5819f89-c90c-4cee-9f0e-f755077491dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_5932fc82-c944-477d-8eb5-e7bd389509eb" xlink:href="bhc-20220630.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_f5819f89-c90c-4cee-9f0e-f755077491dc" xlink:to="loc_bhc_BauschLombMember_5932fc82-c944-477d-8eb5-e7bd389509eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c29a844-2f75-4316-90a2-736f2e6c3cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82f8ebd9-546a-466c-a294-062a23e934d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c29a844-2f75-4316-90a2-736f2e6c3cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_f2407023-e922-45e0-9525-9ba395df3c35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c29a844-2f75-4316-90a2-736f2e6c3cbf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_f2407023-e922-45e0-9525-9ba395df3c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d3105019-bcfe-4e6c-8df5-28719cefe8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_f2407023-e922-45e0-9525-9ba395df3c35" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d3105019-bcfe-4e6c-8df5-28719cefe8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_82009888-2be4-4046-9a94-4dbcabcdd1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_f2407023-e922-45e0-9525-9ba395df3c35" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_82009888-2be4-4046-9a94-4dbcabcdd1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bbfae3d0-1484-4db7-a26e-41498297cfc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_f2407023-e922-45e0-9525-9ba395df3c35" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bbfae3d0-1484-4db7-a26e-41498297cfc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_3ef31472-d854-4b51-a680-88ef7c9078dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c29a844-2f75-4316-90a2-736f2e6c3cbf" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_3ef31472-d854-4b51-a680-88ef7c9078dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8648c11d-aa44-4547-bf53-a491391345b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_3ef31472-d854-4b51-a680-88ef7c9078dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8648c11d-aa44-4547-bf53-a491391345b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_aa087956-147c-4ef2-ab59-2a0461cb8f74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_3ef31472-d854-4b51-a680-88ef7c9078dc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_aa087956-147c-4ef2-ab59-2a0461cb8f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bhc-20220630.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_5c0cb9ec-a2b1-4c7e-99f6-350f764dc114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_a783ec47-204e-4d68-83ad-1fb374063c94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_5c0cb9ec-a2b1-4c7e-99f6-350f764dc114" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_a783ec47-204e-4d68-83ad-1fb374063c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" xlink:type="simple" xlink:href="bhc-20220630.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_b96382a5-d920-485d-b41a-994c1ce9a430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_aa166a68-3aed-493a-b46c-e75ac61d560d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_b96382a5-d920-485d-b41a-994c1ce9a430" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_aa166a68-3aed-493a-b46c-e75ac61d560d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_85806a5a-e744-4f49-8452-f1a8f28c5146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3667222a-35de-4692-90b7-7ef02a1b7485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_85806a5a-e744-4f49-8452-f1a8f28c5146" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3667222a-35de-4692-90b7-7ef02a1b7485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_af36667c-5fb8-48b2-8847-0ee880886a25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3667222a-35de-4692-90b7-7ef02a1b7485" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_af36667c-5fb8-48b2-8847-0ee880886a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b8977883-6f9e-485c-91ad-0eb6dc86f47a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_af36667c-5fb8-48b2-8847-0ee880886a25" xlink:to="loc_us-gaap_EquityComponentDomain_b8977883-6f9e-485c-91ad-0eb6dc86f47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_ceddd88c-6310-4885-8319-daeb8f882739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8977883-6f9e-485c-91ad-0eb6dc86f47a" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_ceddd88c-6310-4885-8319-daeb8f882739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_f54e0fe7-3a65-420e-a1bf-c1f78031f737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8977883-6f9e-485c-91ad-0eb6dc86f47a" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_f54e0fe7-3a65-420e-a1bf-c1f78031f737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c98a2396-5a66-42a5-97c0-cd5d19d7d726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b8977883-6f9e-485c-91ad-0eb6dc86f47a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c98a2396-5a66-42a5-97c0-cd5d19d7d726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_304c9f8f-f70c-4744-9f41-63d68c231397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3667222a-35de-4692-90b7-7ef02a1b7485" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_304c9f8f-f70c-4744-9f41-63d68c231397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1285c793-78d0-46c6-9da6-130ebfbc33e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_304c9f8f-f70c-4744-9f41-63d68c231397" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1285c793-78d0-46c6-9da6-130ebfbc33e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ab0c2c1e-45b0-4d58-beba-fc3b5b2fafe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_592f3071-ac2b-4b31-9a4c-519733543162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ab0c2c1e-45b0-4d58-beba-fc3b5b2fafe2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_592f3071-ac2b-4b31-9a4c-519733543162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6ebe4ffb-306d-417e-b90e-4cddcd8457db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_592f3071-ac2b-4b31-9a4c-519733543162" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6ebe4ffb-306d-417e-b90e-4cddcd8457db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d499a667-8b2b-4e08-9549-110b1098779d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6ebe4ffb-306d-417e-b90e-4cddcd8457db" xlink:to="loc_us-gaap_EquityComponentDomain_d499a667-8b2b-4e08-9549-110b1098779d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0f1bbade-9544-47c9-ae22-6a60e625ed1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d499a667-8b2b-4e08-9549-110b1098779d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0f1bbade-9544-47c9-ae22-6a60e625ed1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_fbe4dc57-c096-4d2a-9a88-b54dce098e71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_592f3071-ac2b-4b31-9a4c-519733543162" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_fbe4dc57-c096-4d2a-9a88-b54dce098e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d7c83065-cacf-4ec9-afd1-1a3aff4d72c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_fbe4dc57-c096-4d2a-9a88-b54dce098e71" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d7c83065-cacf-4ec9-afd1-1a3aff4d72c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT" xlink:type="simple" xlink:href="bhc-20220630.xsd#RESEARCHANDDEVELOPMENT"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_7197f0f7-1c5c-43ea-a053-9f263a450952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_ec6f8d30-c28d-464e-8309-aaa2f498c93b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_7197f0f7-1c5c-43ea-a053-9f263a450952" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_ec6f8d30-c28d-464e-8309-aaa2f498c93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables" xlink:type="simple" xlink:href="bhc-20220630.xsd#RESEARCHANDDEVELOPMENTTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_fe3fcec3-2244-49f2-8dba-b974bbc9a239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_085269fe-fdb9-4af6-87d5-cbea4dcc15e6" xlink:href="bhc-20220630.xsd#bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_fe3fcec3-2244-49f2-8dba-b974bbc9a239" xlink:to="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_085269fe-fdb9-4af6-87d5-cbea4dcc15e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_e5e6dc6d-13c3-4d20-8a04-74e741eff42e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_0defaa08-d9d3-45fa-9667-05cf514d12ec" xlink:href="bhc-20220630.xsd#bhc_ResearchAndDevelopmentExpenseProductRelated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_e5e6dc6d-13c3-4d20-8a04-74e741eff42e" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_0defaa08-d9d3-45fa-9667-05cf514d12ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_72d17ede-b243-4b15-a3d9-e6b9f24bbcc6" xlink:href="bhc-20220630.xsd#bhc_ResearchAndDevelopmentExpenseQualityAssurance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_e5e6dc6d-13c3-4d20-8a04-74e741eff42e" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_72d17ede-b243-4b15-a3d9-e6b9f24bbcc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_a685c371-4947-4785-b70a-4e0ffee27b08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_e5e6dc6d-13c3-4d20-8a04-74e741eff42e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_a685c371-4947-4785-b70a-4e0ffee27b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENET" xlink:type="simple" xlink:href="bhc-20220630.xsd#OTHEREXPENSENET"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_19b0bf6a-0106-4eb7-a52e-785352c3d208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_15a2ca85-6c1b-4c3f-aa4b-ad23fbe135df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_19b0bf6a-0106-4eb7-a52e-785352c3d208" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_15a2ca85-6c1b-4c3f-aa4b-ad23fbe135df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETTables" xlink:type="simple" xlink:href="bhc-20220630.xsd#OTHEREXPENSENETTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_e997cc67-0aad-4a65-9a78-e7b8288072ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_c7b799e8-5b02-4f3c-833a-17f160501773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e997cc67-0aad-4a65-9a78-e7b8288072ad" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_c7b799e8-5b02-4f3c-833a-17f160501773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#OTHEREXPENSENETSummaryofOtherExpenseNetDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_8a843c58-d2f4-4d6c-aa0a-ba969cbdd8af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_af4bf723-e630-4bb0-b402-a01e1b361790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_8a843c58-d2f4-4d6c-aa0a-ba969cbdd8af" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_af4bf723-e630-4bb0-b402-a01e1b361790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_24bd8a00-def2-4d66-8d2f-4cd857f318d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_8a843c58-d2f4-4d6c-aa0a-ba969cbdd8af" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_24bd8a00-def2-4d66-8d2f-4cd857f318d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_5a988b6d-2cc6-4a2a-8367-e1188e04109b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_8a843c58-d2f4-4d6c-aa0a-ba969cbdd8af" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_5a988b6d-2cc6-4a2a-8367-e1188e04109b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_0662fedb-0b82-445c-9661-50325700c939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_8a843c58-d2f4-4d6c-aa0a-ba969cbdd8af" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_0662fedb-0b82-445c-9661-50325700c939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherIncomeExpenseNet_9a3d3055-f105-4286-abb9-5f12a7512514" xlink:href="bhc-20220630.xsd#bhc_OtherIncomeExpenseNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_8a843c58-d2f4-4d6c-aa0a-ba969cbdd8af" xlink:to="loc_bhc_OtherIncomeExpenseNet_9a3d3055-f105-4286-abb9-5f12a7512514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b56b9dc8-5288-44d0-9b63-906b299978bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_8a843c58-d2f4-4d6c-aa0a-ba969cbdd8af" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b56b9dc8-5288-44d0-9b63-906b299978bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#OTHEREXPENSENETNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_de00376b-1770-47ca-b3e0-1b3d300e6fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_6b85d400-4530-4e39-8617-7b023e8432a5" xlink:href="bhc-20220630.xsd#bhc_ScheduleOfOtherIncomeAndExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_de00376b-1770-47ca-b3e0-1b3d300e6fd5" xlink:to="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_6b85d400-4530-4e39-8617-7b023e8432a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c4c063c4-f193-4b15-832d-94b76975f943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_6b85d400-4530-4e39-8617-7b023e8432a5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c4c063c4-f193-4b15-832d-94b76975f943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d1dea199-5839-4740-87a2-4cea46583328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c4c063c4-f193-4b15-832d-94b76975f943" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d1dea199-5839-4740-87a2-4cea46583328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MilestonePaymentRelatedToCertainProductMember_ce829c48-a050-4d07-a6ea-2abf9c1728b2" xlink:href="bhc-20220630.xsd#bhc_MilestonePaymentRelatedToCertainProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d1dea199-5839-4740-87a2-4cea46583328" xlink:to="loc_bhc_MilestonePaymentRelatedToCertainProductMember_ce829c48-a050-4d07-a6ea-2abf9c1728b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_663de3bf-3c60-40a8-9319-8fe4c509fbb3" xlink:href="bhc-20220630.xsd#bhc_ScheduleOfOtherIncomeAndExpensesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_6b85d400-4530-4e39-8617-7b023e8432a5" xlink:to="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_663de3bf-3c60-40a8-9319-8fe4c509fbb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_4009d5f9-79ad-4003-9b27-309296311ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_663de3bf-3c60-40a8-9319-8fe4c509fbb3" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_4009d5f9-79ad-4003-9b27-309296311ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXES" xlink:type="simple" xlink:href="bhc-20220630.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_18f34a2c-a7f7-4676-92e2-98886855e042" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_01856cec-935f-4d08-9065-ccfe7f03caa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_18f34a2c-a7f7-4676-92e2-98886855e042" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_01856cec-935f-4d08-9065-ccfe7f03caa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_64ccf6c4-4043-49d7-a6ae-dc00dccf6505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_29e5cc13-5f2b-4227-875c-d6e86441e43f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64ccf6c4-4043-49d7-a6ae-dc00dccf6505" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_29e5cc13-5f2b-4227-875c-d6e86441e43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_661c2478-9af1-4c8a-82a6-2ff15d44523d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64ccf6c4-4043-49d7-a6ae-dc00dccf6505" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_661c2478-9af1-4c8a-82a6-2ff15d44523d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount_2c5c21f0-6efa-4a5a-8429-8bd44b0af3f8" xlink:href="bhc-20220630.xsd#bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64ccf6c4-4043-49d7-a6ae-dc00dccf6505" xlink:to="loc_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount_2c5c21f0-6efa-4a5a-8429-8bd44b0af3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_89a423b7-a0a3-483f-ae2a-d99f9544d318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64ccf6c4-4043-49d7-a6ae-dc00dccf6505" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_89a423b7-a0a3-483f-ae2a-d99f9544d318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount_3af02015-0e2b-46b3-9883-a0e270d706f1" xlink:href="bhc-20220630.xsd#bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64ccf6c4-4043-49d7-a6ae-dc00dccf6505" xlink:to="loc_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount_3af02015-0e2b-46b3-9883-a0e270d706f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount_9d913d17-de63-4a47-bbfb-d17d8ad61432" xlink:href="bhc-20220630.xsd#bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64ccf6c4-4043-49d7-a6ae-dc00dccf6505" xlink:to="loc_bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount_9d913d17-de63-4a47-bbfb-d17d8ad61432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount_c1611803-5227-4864-bd71-07d73fa3067d" xlink:href="bhc-20220630.xsd#bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64ccf6c4-4043-49d7-a6ae-dc00dccf6505" xlink:to="loc_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount_c1611803-5227-4864-bd71-07d73fa3067d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_46133539-9842-4dbc-9cb8-a32b3faba324" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64ccf6c4-4043-49d7-a6ae-dc00dccf6505" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_46133539-9842-4dbc-9cb8-a32b3faba324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c5c9815d-42f9-4c4d-903c-4678bc662989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64ccf6c4-4043-49d7-a6ae-dc00dccf6505" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c5c9815d-42f9-4c4d-903c-4678bc662989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_76cf2da1-3756-42fa-bd12-e2535e59374e" xlink:href="bhc-20220630.xsd#bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64ccf6c4-4043-49d7-a6ae-dc00dccf6505" xlink:to="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_76cf2da1-3756-42fa-bd12-e2535e59374e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_33bcd842-03c7-4e4b-b53d-4019fd4f1809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64ccf6c4-4043-49d7-a6ae-dc00dccf6505" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_33bcd842-03c7-4e4b-b53d-4019fd4f1809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_a3f34f65-f721-4a6a-993a-df78ed295558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64ccf6c4-4043-49d7-a6ae-dc00dccf6505" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_a3f34f65-f721-4a6a-993a-df78ed295558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_929aac5d-aa58-4cb6-ac3c-123c9e742a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64ccf6c4-4043-49d7-a6ae-dc00dccf6505" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_929aac5d-aa58-4cb6-ac3c-123c9e742a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_b4920855-2ed7-4647-b766-e54bd24ee42c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64ccf6c4-4043-49d7-a6ae-dc00dccf6505" xlink:to="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_b4920855-2ed7-4647-b766-e54bd24ee42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LOSSPERSHARE" xlink:type="simple" xlink:href="bhc-20220630.xsd#LOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5cc548cc-543c-43dd-bbeb-12cbec1324ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_c94a586f-3988-481f-b8f6-ffabb6adf85b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5cc548cc-543c-43dd-bbeb-12cbec1324ab" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_c94a586f-3988-481f-b8f6-ffabb6adf85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LOSSPERSHARETables" xlink:type="simple" xlink:href="bhc-20220630.xsd#LOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_83a88440-4a14-4ed6-ad7e-e9796345bc74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_db9c6f31-dfe6-45d2-bf97-7be72e59695e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_83a88440-4a14-4ed6-ad7e-e9796345bc74" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_db9c6f31-dfe6-45d2-bf97-7be72e59695e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d0c82b8f-fb62-4879-a9dd-c60b1e68c429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3bdfe92e-b65d-4bc1-bd9d-d64475d1f1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d0c82b8f-fb62-4879-a9dd-c60b1e68c429" xlink:to="loc_us-gaap_NetIncomeLoss_3bdfe92e-b65d-4bc1-bd9d-d64475d1f1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4448aa1a-bc2e-4c16-b9c9-ed64ef2031ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d0c82b8f-fb62-4879-a9dd-c60b1e68c429" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4448aa1a-bc2e-4c16-b9c9-ed64ef2031ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1fc975e0-9915-47ba-b9e9-c13f6500c7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d0c82b8f-fb62-4879-a9dd-c60b1e68c429" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1fc975e0-9915-47ba-b9e9-c13f6500c7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_dc11dd08-b82a-4b9b-ad09-2b1f9eca3405" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d0c82b8f-fb62-4879-a9dd-c60b1e68c429" xlink:to="loc_us-gaap_EarningsPerShareBasic_dc11dd08-b82a-4b9b-ad09-2b1f9eca3405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_dc5fc1c0-123f-43ff-a0c8-8a3444c7dedb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d0c82b8f-fb62-4879-a9dd-c60b1e68c429" xlink:to="loc_us-gaap_EarningsPerShareDiluted_dc5fc1c0-123f-43ff-a0c8-8a3444c7dedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#LOSSPERSHARENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_42c4a244-ae3b-4b36-916b-d865a0170445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2a7349e4-c1bb-4d9e-9839-fa15fee104ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_42c4a244-ae3b-4b36-916b-d865a0170445" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2a7349e4-c1bb-4d9e-9839-fa15fee104ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_da770f34-5290-4650-ab81-1402292efe65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2a7349e4-c1bb-4d9e-9839-fa15fee104ab" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_da770f34-5290-4650-ab81-1402292efe65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_40a49387-20c9-4a8a-b3bc-13c7beb8596b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_da770f34-5290-4650-ab81-1402292efe65" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_40a49387-20c9-4a8a-b3bc-13c7beb8596b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_7205210c-5410-42c7-8f28-fc214bbcdb11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_40a49387-20c9-4a8a-b3bc-13c7beb8596b" xlink:to="loc_us-gaap_StockCompensationPlanMember_7205210c-5410-42c7-8f28-fc214bbcdb11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_7850f116-d859-4641-a923-001b02028262" xlink:href="bhc-20220630.xsd#bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_40a49387-20c9-4a8a-b3bc-13c7beb8596b" xlink:to="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_7850f116-d859-4641-a923-001b02028262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_cf64d783-e9f7-4c11-ac31-7bb1ad8ec2c1" xlink:href="bhc-20220630.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_40a49387-20c9-4a8a-b3bc-13c7beb8596b" xlink:to="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_cf64d783-e9f7-4c11-ac31-7bb1ad8ec2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_08180b56-928e-4b25-9432-4d3cb91165a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2a7349e4-c1bb-4d9e-9839-fa15fee104ab" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_08180b56-928e-4b25-9432-4d3cb91165a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5a82ba06-69db-485d-853e-f4b7f49da28e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_08180b56-928e-4b25-9432-4d3cb91165a1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5a82ba06-69db-485d-853e-f4b7f49da28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount_644d9eb7-8b94-48be-8e9f-98213452a322" xlink:href="bhc-20220630.xsd#bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_08180b56-928e-4b25-9432-4d3cb91165a1" xlink:to="loc_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount_644d9eb7-8b94-48be-8e9f-98213452a322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGS" xlink:type="simple" xlink:href="bhc-20220630.xsd#LEGALPROCEEDINGS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5d8aed5a-5036-4c2d-a609-d8eee1df1581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_fe71c3cd-b8f0-4e4d-aa20-7c77f4318e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5d8aed5a-5036-4c2d-a609-d8eee1df1581" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_fe71c3cd-b8f0-4e4d-aa20-7c77f4318e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e512aee8-d615-4ece-aaa7-7d3970496429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_eeb4f0b0-78fb-440f-830a-3425ef6c1408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e512aee8-d615-4ece-aaa7-7d3970496429" xlink:to="loc_us-gaap_LitigationReserveCurrent_eeb4f0b0-78fb-440f-830a-3425ef6c1408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2ed2b392-9d69-4b1f-bcc9-777a6c95fccf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_999deaf4-4fca-475e-b989-d7ed5e3fdbe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2ed2b392-9d69-4b1f-bcc9-777a6c95fccf" xlink:to="loc_us-gaap_LossContingenciesTable_999deaf4-4fca-475e-b989-d7ed5e3fdbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_046d17fb-c76e-405d-9697-91b2b0eacd5a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_999deaf4-4fca-475e-b989-d7ed5e3fdbe3" xlink:to="loc_srt_LitigationCaseAxis_046d17fb-c76e-405d-9697-91b2b0eacd5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ea536eaf-de38-4d11-b69d-332c0777cdf0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_046d17fb-c76e-405d-9697-91b2b0eacd5a" xlink:to="loc_srt_LitigationCaseTypeDomain_ea536eaf-de38-4d11-b69d-332c0777cdf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_8ab441fb-e4af-4661-8e47-e4dfd983971a" xlink:href="bhc-20220630.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ea536eaf-de38-4d11-b69d-332c0777cdf0" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_8ab441fb-e4af-4661-8e47-e4dfd983971a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadianSecuritiesLitigationMember_0411f2ba-b4ca-4d4c-bc79-895404cb6a8a" xlink:href="bhc-20220630.xsd#bhc_CanadianSecuritiesLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ea536eaf-de38-4d11-b69d-332c0777cdf0" xlink:to="loc_bhc_CanadianSecuritiesLitigationMember_0411f2ba-b4ca-4d4c-bc79-895404cb6a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RICOClassActionsMember_f0a821cd-5133-4d32-bd68-9cf44ad56585" xlink:href="bhc-20220630.xsd#bhc_RICOClassActionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ea536eaf-de38-4d11-b69d-332c0777cdf0" xlink:to="loc_bhc_RICOClassActionsMember_f0a821cd-5133-4d32-bd68-9cf44ad56585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InsuranceCoverageLawsuitMember_a299b671-98a9-422f-9656-b649c964aa44" xlink:href="bhc-20220630.xsd#bhc_InsuranceCoverageLawsuitMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ea536eaf-de38-4d11-b69d-332c0777cdf0" xlink:to="loc_bhc_InsuranceCoverageLawsuitMember_a299b671-98a9-422f-9656-b649c964aa44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_151f962c-2fd2-4ef5-aee3-9c59f6014567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_999deaf4-4fca-475e-b989-d7ed5e3fdbe3" xlink:to="loc_us-gaap_LitigationStatusAxis_151f962c-2fd2-4ef5-aee3-9c59f6014567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_b8492d02-3617-436b-9e0f-bbc0861a9c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_151f962c-2fd2-4ef5-aee3-9c59f6014567" xlink:to="loc_us-gaap_LitigationStatusDomain_b8492d02-3617-436b-9e0f-bbc0861a9c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_d3732d72-835b-4d97-b454-418e5a75d370" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_b8492d02-3617-436b-9e0f-bbc0861a9c1c" xlink:to="loc_us-gaap_SettledLitigationMember_d3732d72-835b-4d97-b454-418e5a75d370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e6865260-cbeb-41f6-85a1-a9b27f9ab16c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_999deaf4-4fca-475e-b989-d7ed5e3fdbe3" xlink:to="loc_srt_StatementGeographicalAxis_e6865260-cbeb-41f6-85a1-a9b27f9ab16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_bc002e6b-8821-48d6-bb37-f0c92d811d14" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_e6865260-cbeb-41f6-85a1-a9b27f9ab16c" xlink:to="loc_srt_SegmentGeographicalDomain_bc002e6b-8821-48d6-bb37-f0c92d811d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_38de8bfc-7afb-48af-9797-6df20aca084b" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_bc002e6b-8821-48d6-bb37-f0c92d811d14" xlink:to="loc_stpr_NJ_38de8bfc-7afb-48af-9797-6df20aca084b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_7a19cc53-6053-4e90-8cba-aa4c6f46dba8" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_bc002e6b-8821-48d6-bb37-f0c92d811d14" xlink:to="loc_country_CA_7a19cc53-6053-4e90-8cba-aa4c6f46dba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_aa411856-3cfe-4b46-a763-0ab8e552dab8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_999deaf4-4fca-475e-b989-d7ed5e3fdbe3" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_aa411856-3cfe-4b46-a763-0ab8e552dab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_315bb7ae-36a6-4c0f-b89b-44f39410ceb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_aa411856-3cfe-4b46-a763-0ab8e552dab8" xlink:to="loc_us-gaap_LossContingencyNatureDomain_315bb7ae-36a6-4c0f-b89b-44f39410ceb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_70f639c4-d848-43fe-8064-a721d02996c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_315bb7ae-36a6-4c0f-b89b-44f39410ceb2" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_70f639c4-d848-43fe-8064-a721d02996c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_c17b469c-ef12-4f97-be5b-be1178dc4842" xlink:href="bhc-20220630.xsd#bhc_ViolationofCanadianProvincialSecuritiesLegislationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_315bb7ae-36a6-4c0f-b89b-44f39410ceb2" xlink:to="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_c17b469c-ef12-4f97-be5b-be1178dc4842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8d87c4a7-f0b6-4859-8bc5-f4027936e9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_999deaf4-4fca-475e-b989-d7ed5e3fdbe3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8d87c4a7-f0b6-4859-8bc5-f4027936e9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_be64a4f0-76f3-42dd-8ea8-78f382b006c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8d87c4a7-f0b6-4859-8bc5-f4027936e9e5" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_be64a4f0-76f3-42dd-8ea8-78f382b006c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember_adc38407-1c79-4c04-bf0d-557ff673060d" xlink:href="bhc-20220630.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_be64a4f0-76f3-42dd-8ea8-78f382b006c6" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember_adc38407-1c79-4c04-bf0d-557ff673060d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_5e12085c-c8ac-48ec-8e64-bff354fe2347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_999deaf4-4fca-475e-b989-d7ed5e3fdbe3" xlink:to="loc_us-gaap_LossContingenciesLineItems_5e12085c-c8ac-48ec-8e64-bff354fe2347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_0912a5d4-211e-4b68-9804-a540bfa9af7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5e12085c-c8ac-48ec-8e64-bff354fe2347" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_0912a5d4-211e-4b68-9804-a540bfa9af7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_c661fc12-2328-41dc-b1dc-c00e93594f76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5e12085c-c8ac-48ec-8e64-bff354fe2347" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_c661fc12-2328-41dc-b1dc-c00e93594f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_5a394541-71f6-44da-8859-d6ef46d2e949" xlink:href="bhc-20220630.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5e12085c-c8ac-48ec-8e64-bff354fe2347" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_5a394541-71f6-44da-8859-d6ef46d2e949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_db5a11a5-8c42-40e5-800d-0fc1acb4f3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5e12085c-c8ac-48ec-8e64-bff354fe2347" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_db5a11a5-8c42-40e5-800d-0fc1acb4f3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_51f7cf91-94c5-4c31-8804-0239cd188d7d" xlink:href="bhc-20220630.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5e12085c-c8ac-48ec-8e64-bff354fe2347" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_51f7cf91-94c5-4c31-8804-0239cd188d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_6a0492cf-373d-4627-8ba8-568ca4bd4ea8" xlink:href="bhc-20220630.xsd#bhc_LossContingencyNewClaimsFiledButNotYetServedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5e12085c-c8ac-48ec-8e64-bff354fe2347" xlink:to="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_6a0492cf-373d-4627-8ba8-568ca4bd4ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_04a5aec0-7ef1-4c72-bc10-1c0aa71d851a" xlink:href="bhc-20220630.xsd#bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5e12085c-c8ac-48ec-8e64-bff354fe2347" xlink:to="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_04a5aec0-7ef1-4c72-bc10-1c0aa71d851a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_d4316c02-6cd5-4ac0-a065-ada675ef88b0" xlink:href="bhc-20220630.xsd#bhc_LossContingencyNumberOfInsurancePolicyPeriods"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5e12085c-c8ac-48ec-8e64-bff354fe2347" xlink:to="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_d4316c02-6cd5-4ac0-a065-ada675ef88b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers_dfbad18a-ecd0-4be7-ab63-d8737ea25c4c" xlink:href="bhc-20220630.xsd#bhc_LossContingencySettlementAgreementsNumberOfInsurers"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5e12085c-c8ac-48ec-8e64-bff354fe2347" xlink:to="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers_dfbad18a-ecd0-4be7-ab63-d8737ea25c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_3aca16c5-6451-4b9c-99ca-e91ac70e83b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5e12085c-c8ac-48ec-8e64-bff354fe2347" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_3aca16c5-6451-4b9c-99ca-e91ac70e83b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#LEGALPROCEEDINGSAntitrustDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4eca3c24-ccac-41f5-b713-56d64ed4875f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_e2087a49-df29-44ee-881b-1ea667a5c999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4eca3c24-ccac-41f5-b713-56d64ed4875f" xlink:to="loc_us-gaap_LossContingenciesTable_e2087a49-df29-44ee-881b-1ea667a5c999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_849d646b-c1d4-4448-ab3c-42ca31e1ce4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e2087a49-df29-44ee-881b-1ea667a5c999" xlink:to="loc_srt_LitigationCaseAxis_849d646b-c1d4-4448-ab3c-42ca31e1ce4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_5aa478d1-d976-437b-880f-8545c3338e23" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_849d646b-c1d4-4448-ab3c-42ca31e1ce4e" xlink:to="loc_srt_LitigationCaseTypeDomain_5aa478d1-d976-437b-880f-8545c3338e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationMember_66d4eac6-f20c-4532-b3f0-72504a3290c6" xlink:href="bhc-20220630.xsd#bhc_GlumetzaAntitrustLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_5aa478d1-d976-437b-880f-8545c3338e23" xlink:to="loc_bhc_GlumetzaAntitrustLitigationMember_66d4eac6-f20c-4532-b3f0-72504a3290c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_306b660f-193f-4b62-9bdf-3c11be023778" xlink:href="bhc-20220630.xsd#bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_5aa478d1-d976-437b-880f-8545c3338e23" xlink:to="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_306b660f-193f-4b62-9bdf-3c11be023778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c32e95c8-0853-4dd7-8b0d-7e452686fa10" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e2087a49-df29-44ee-881b-1ea667a5c999" xlink:to="loc_srt_CounterpartyNameAxis_c32e95c8-0853-4dd7-8b0d-7e452686fa10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_47dc0d40-cf38-4390-9940-72b2032dc3aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c32e95c8-0853-4dd7-8b0d-7e452686fa10" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_47dc0d40-cf38-4390-9940-72b2032dc3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PlaintiffsDirectPurchasersMember_6c28762b-26fc-43bf-9c1a-17f87689a7fe" xlink:href="bhc-20220630.xsd#bhc_PlaintiffsDirectPurchasersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_47dc0d40-cf38-4390-9940-72b2032dc3aa" xlink:to="loc_bhc_PlaintiffsDirectPurchasersMember_6c28762b-26fc-43bf-9c1a-17f87689a7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_ad8fd8fc-496f-4b83-a636-838c0a062e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e2087a49-df29-44ee-881b-1ea667a5c999" xlink:to="loc_us-gaap_LitigationStatusAxis_ad8fd8fc-496f-4b83-a636-838c0a062e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_444308f8-ac13-4cfe-979a-3a208a448fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_ad8fd8fc-496f-4b83-a636-838c0a062e19" xlink:to="loc_us-gaap_LitigationStatusDomain_444308f8-ac13-4cfe-979a-3a208a448fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_eb2f801f-fe48-473c-90e3-837167425206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_444308f8-ac13-4cfe-979a-3a208a448fbf" xlink:to="loc_us-gaap_PendingLitigationMember_eb2f801f-fe48-473c-90e3-837167425206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_e7e2f12f-f360-4549-bb35-5bb56ec37851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e2087a49-df29-44ee-881b-1ea667a5c999" xlink:to="loc_us-gaap_LossContingenciesLineItems_e7e2f12f-f360-4549-bb35-5bb56ec37851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_b022b3bd-d216-4946-ba2d-79f2d294b2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e7e2f12f-f360-4549-bb35-5bb56ec37851" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_b022b3bd-d216-4946-ba2d-79f2d294b2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e25f4d52-d62f-4cb7-a69d-5d00c61c25f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e7e2f12f-f360-4549-bb35-5bb56ec37851" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e25f4d52-d62f-4cb7-a69d-5d00c61c25f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#LEGALPROCEEDINGSIntellectualPropertyDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6d54b1ec-3548-41a4-8335-6ff1206edc2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_1c027782-b16a-435a-ab8f-2d4590dc8470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6d54b1ec-3548-41a4-8335-6ff1206edc2f" xlink:to="loc_us-gaap_LossContingenciesTable_1c027782-b16a-435a-ab8f-2d4590dc8470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_2970cf7e-e3fb-4bc8-b544-891754cb138d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1c027782-b16a-435a-ab8f-2d4590dc8470" xlink:to="loc_srt_LitigationCaseAxis_2970cf7e-e3fb-4bc8-b544-891754cb138d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_489a6c43-3228-4654-a6dc-229ae2cacfaa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_2970cf7e-e3fb-4bc8-b544-891754cb138d" xlink:to="loc_srt_LitigationCaseTypeDomain_489a6c43-3228-4654-a6dc-229ae2cacfaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NorwichPharmaceuticalsIncLitigationMember_f277de3e-4374-4f4c-b339-292201e04c5b" xlink:href="bhc-20220630.xsd#bhc_NorwichPharmaceuticalsIncLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_489a6c43-3228-4654-a6dc-229ae2cacfaa" xlink:to="loc_bhc_NorwichPharmaceuticalsIncLitigationMember_f277de3e-4374-4f4c-b339-292201e04c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_b40fac16-24c2-4270-a1d0-a00a267e6dd1" xlink:href="bhc-20220630.xsd#bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_489a6c43-3228-4654-a6dc-229ae2cacfaa" xlink:to="loc_bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember_b40fac16-24c2-4270-a1d0-a00a267e6dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaroPharmaceuticalsIncLitigationMember_a2006153-d4bb-4ba2-b00e-993d2b4121ce" xlink:href="bhc-20220630.xsd#bhc_TaroPharmaceuticalsIncLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_489a6c43-3228-4654-a6dc-229ae2cacfaa" xlink:to="loc_bhc_TaroPharmaceuticalsIncLitigationMember_a2006153-d4bb-4ba2-b00e-993d2b4121ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PadagisLitigationMember_5e8994e3-9ae4-4c33-8cdb-07e43f5c0fba" xlink:href="bhc-20220630.xsd#bhc_PadagisLitigationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_489a6c43-3228-4654-a6dc-229ae2cacfaa" xlink:to="loc_bhc_PadagisLitigationMember_5e8994e3-9ae4-4c33-8cdb-07e43f5c0fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_4606314e-8cfb-4df9-9377-96addca3f633" xlink:href="bhc-20220630.xsd#bhc_MSNLaboratoriesPrivateLtdLitigationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_489a6c43-3228-4654-a6dc-229ae2cacfaa" xlink:to="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_4606314e-8cfb-4df9-9377-96addca3f633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PreserVisionAREDSPatentLitigationMember_e473e4b3-1811-4bf1-ae43-6cbfb255d384" xlink:href="bhc-20220630.xsd#bhc_PreserVisionAREDSPatentLitigationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_489a6c43-3228-4654-a6dc-229ae2cacfaa" xlink:to="loc_bhc_PreserVisionAREDSPatentLitigationMember_e473e4b3-1811-4bf1-ae43-6cbfb255d384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember_6e5ef747-87f5-42e3-af58-419f5712ebf2" xlink:href="bhc-20220630.xsd#bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_489a6c43-3228-4654-a6dc-229ae2cacfaa" xlink:to="loc_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember_6e5ef747-87f5-42e3-af58-419f5712ebf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember_6a04d2b9-9877-4637-afd4-804d983e34bd" xlink:href="bhc-20220630.xsd#bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_489a6c43-3228-4654-a6dc-229ae2cacfaa" xlink:to="loc_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember_6a04d2b9-9877-4637-afd4-804d983e34bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PatentInfringementLitigationMember_8e713620-d9b1-4ebf-bcec-505baafe8791" xlink:href="bhc-20220630.xsd#bhc_PatentInfringementLitigationMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_489a6c43-3228-4654-a6dc-229ae2cacfaa" xlink:to="loc_bhc_PatentInfringementLitigationMember_8e713620-d9b1-4ebf-bcec-505baafe8791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ApotexIncLitigationMember_f52afa83-04cf-4fd2-82d3-eb25438ad56b" xlink:href="bhc-20220630.xsd#bhc_ApotexIncLitigationMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_489a6c43-3228-4654-a6dc-229ae2cacfaa" xlink:to="loc_bhc_ApotexIncLitigationMember_f52afa83-04cf-4fd2-82d3-eb25438ad56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b20767ed-1f6b-44ec-ae90-2441f954eacb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1c027782-b16a-435a-ab8f-2d4590dc8470" xlink:to="loc_srt_StatementGeographicalAxis_b20767ed-1f6b-44ec-ae90-2441f954eacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8f68de9e-1e0a-4091-be34-3d5928a877ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_b20767ed-1f6b-44ec-ae90-2441f954eacb" xlink:to="loc_srt_SegmentGeographicalDomain_8f68de9e-1e0a-4091-be34-3d5928a877ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_8824ab0f-9954-4a40-a4a2-337d0a07a5a8" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8f68de9e-1e0a-4091-be34-3d5928a877ee" xlink:to="loc_country_CA_8824ab0f-9954-4a40-a4a2-337d0a07a5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_d2dd43d3-f664-49f6-acf8-a1f124b26a91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1c027782-b16a-435a-ab8f-2d4590dc8470" xlink:to="loc_us-gaap_LitigationStatusAxis_d2dd43d3-f664-49f6-acf8-a1f124b26a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_fed42bb5-1f30-4ea5-bbe0-19da270a9b18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_d2dd43d3-f664-49f6-acf8-a1f124b26a91" xlink:to="loc_us-gaap_LitigationStatusDomain_fed42bb5-1f30-4ea5-bbe0-19da270a9b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_db4e9ce7-a5be-4dc6-b7f6-049b17b0e64a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_fed42bb5-1f30-4ea5-bbe0-19da270a9b18" xlink:to="loc_us-gaap_PendingLitigationMember_db4e9ce7-a5be-4dc6-b7f6-049b17b0e64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_0fdef64f-d5a6-471d-a56a-520fa5fd1b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_fed42bb5-1f30-4ea5-bbe0-19da270a9b18" xlink:to="loc_us-gaap_SettledLitigationMember_0fdef64f-d5a6-471d-a56a-520fa5fd1b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefaultJudgementMember_e09a1867-fdae-4ff9-bb23-9818beeaac7a" xlink:href="bhc-20220630.xsd#bhc_DefaultJudgementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_fed42bb5-1f30-4ea5-bbe0-19da270a9b18" xlink:to="loc_bhc_DefaultJudgementMember_e09a1867-fdae-4ff9-bb23-9818beeaac7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeclaratoryJudgementActionLitigationMember_6bd0a34c-81cd-4043-b2ef-81ae3282c4f8" xlink:href="bhc-20220630.xsd#bhc_DeclaratoryJudgementActionLitigationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_fed42bb5-1f30-4ea5-bbe0-19da270a9b18" xlink:to="loc_bhc_DeclaratoryJudgementActionLitigationMember_6bd0a34c-81cd-4043-b2ef-81ae3282c4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d0bfe24d-916a-4576-879b-492b071bd7f1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1c027782-b16a-435a-ab8f-2d4590dc8470" xlink:to="loc_dei_LegalEntityAxis_d0bfe24d-916a-4576-879b-492b071bd7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_779627bd-c063-436d-b4fe-3a16e60f1fdb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_d0bfe24d-916a-4576-879b-492b071bd7f1" xlink:to="loc_dei_EntityDomain_779627bd-c063-436d-b4fe-3a16e60f1fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_d4ea0dab-5d18-46ef-9aa7-d12048ee45c1" xlink:href="bhc-20220630.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_779627bd-c063-436d-b4fe-3a16e60f1fdb" xlink:to="loc_bhc_BauschLombMember_d4ea0dab-5d18-46ef-9aa7-d12048ee45c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4d244cbb-fb5e-4a89-9781-819b006d4f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1c027782-b16a-435a-ab8f-2d4590dc8470" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4d244cbb-fb5e-4a89-9781-819b006d4f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3f61e6dc-56fc-4836-b190-fe45d8846013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4d244cbb-fb5e-4a89-9781-819b006d4f6e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3f61e6dc-56fc-4836-b190-fe45d8846013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ebaa132b-bc48-40fc-8bab-9dc03eb3b062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3f61e6dc-56fc-4836-b190-fe45d8846013" xlink:to="loc_us-gaap_SubsequentEventMember_ebaa132b-bc48-40fc-8bab-9dc03eb3b062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_53f9b185-e7f8-40b8-8383-8b513dc75db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1c027782-b16a-435a-ab8f-2d4590dc8470" xlink:to="loc_us-gaap_LossContingenciesLineItems_53f9b185-e7f8-40b8-8383-8b513dc75db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyStayOfApprovalPeriod_c147eaad-c84a-4a15-90fe-a60dca240f7b" xlink:href="bhc-20220630.xsd#bhc_GainContingencyStayOfApprovalPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_53f9b185-e7f8-40b8-8383-8b513dc75db8" xlink:to="loc_bhc_GainContingencyStayOfApprovalPeriod_c147eaad-c84a-4a15-90fe-a60dca240f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyNumberOfDefendants_d1557eff-f20e-4ac4-8c78-4ac15060508e" xlink:href="bhc-20220630.xsd#bhc_GainContingencyNumberOfDefendants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_53f9b185-e7f8-40b8-8383-8b513dc75db8" xlink:to="loc_bhc_GainContingencyNumberOfDefendants_d1557eff-f20e-4ac4-8c78-4ac15060508e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_bbf233cc-7f35-4ade-b2c4-3857a6e0e5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_53f9b185-e7f8-40b8-8383-8b513dc75db8" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_bbf233cc-7f35-4ade-b2c4-3857a6e0e5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#LEGALPROCEEDINGSProductLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5910be0b-13f3-43ee-91d7-f1affdf020b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_8a427a65-09e0-4732-b987-0a56421ee2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5910be0b-13f3-43ee-91d7-f1affdf020b2" xlink:to="loc_us-gaap_LossContingenciesTable_8a427a65-09e0-4732-b987-0a56421ee2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_ad814173-15ac-4e56-8e00-80dc5f0dbdab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8a427a65-09e0-4732-b987-0a56421ee2a4" xlink:to="loc_srt_LitigationCaseAxis_ad814173-15ac-4e56-8e00-80dc5f0dbdab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_4c6a388c-bf47-4cc6-acc9-d7de29fb9488" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_ad814173-15ac-4e56-8e00-80dc5f0dbdab" xlink:to="loc_srt_LitigationCaseTypeDomain_4c6a388c-bf47-4cc6-acc9-d7de29fb9488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_2eff6010-7b1a-467c-a536-a764a99229ea" xlink:href="bhc-20220630.xsd#bhc_ShowerToShowerProductLiabilityLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_4c6a388c-bf47-4cc6-acc9-d7de29fb9488" xlink:to="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_2eff6010-7b1a-467c-a536-a764a99229ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_08dcf918-31e6-4a52-85ff-3192817de659" xlink:href="bhc-20220630.xsd#bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_2eff6010-7b1a-467c-a536-a764a99229ea" xlink:to="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_08dcf918-31e6-4a52-85ff-3192817de659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_aa705dd7-93a6-45e4-a900-6be44f66dfba" xlink:href="bhc-20220630.xsd#bhc_MSNLaboratoriesPrivateLtdLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_4c6a388c-bf47-4cc6-acc9-d7de29fb9488" xlink:to="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_aa705dd7-93a6-45e4-a900-6be44f66dfba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_10f4bfa7-d47f-49b7-b354-40ef5d9432aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8a427a65-09e0-4732-b987-0a56421ee2a4" xlink:to="loc_us-gaap_LitigationStatusAxis_10f4bfa7-d47f-49b7-b354-40ef5d9432aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_6bc837a6-2a5c-4a8c-b172-ef8b3ecb5b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_10f4bfa7-d47f-49b7-b354-40ef5d9432aa" xlink:to="loc_us-gaap_LitigationStatusDomain_6bc837a6-2a5c-4a8c-b172-ef8b3ecb5b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_d5496ea1-ea03-46a9-b96e-c646e255e5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_6bc837a6-2a5c-4a8c-b172-ef8b3ecb5b3b" xlink:to="loc_us-gaap_PendingLitigationMember_d5496ea1-ea03-46a9-b96e-c646e255e5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember_4bc3ed9d-10ce-4384-a794-170af20eccb5" xlink:href="bhc-20220630.xsd#bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PendingLitigationMember_d5496ea1-ea03-46a9-b96e-c646e255e5b4" xlink:to="loc_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember_4bc3ed9d-10ce-4384-a794-170af20eccb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_421b1018-1924-4467-b5f2-08e05d33e41c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8a427a65-09e0-4732-b987-0a56421ee2a4" xlink:to="loc_srt_StatementGeographicalAxis_421b1018-1924-4467-b5f2-08e05d33e41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b6aee091-06dd-40e9-9735-741bddade6c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_421b1018-1924-4467-b5f2-08e05d33e41c" xlink:to="loc_srt_SegmentGeographicalDomain_b6aee091-06dd-40e9-9735-741bddade6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_37ace2bf-d014-4509-9b29-b54f0aeee49e" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b6aee091-06dd-40e9-9735-741bddade6c7" xlink:to="loc_country_CA_37ace2bf-d014-4509-9b29-b54f0aeee49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-BC_c57024aa-42af-489b-b3c9-5b5ce41e3bb0" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA-BC"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b6aee091-06dd-40e9-9735-741bddade6c7" xlink:to="loc_stpr_CA-BC_c57024aa-42af-489b-b3c9-5b5ce41e3bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-QC_1e59ebba-1712-47c1-816e-a227b7c5382c" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA-QC"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b6aee091-06dd-40e9-9735-741bddade6c7" xlink:to="loc_stpr_CA-QC_1e59ebba-1712-47c1-816e-a227b7c5382c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_b4c92d30-7342-4efe-93cb-c8a2da119913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8a427a65-09e0-4732-b987-0a56421ee2a4" xlink:to="loc_us-gaap_LossContingenciesLineItems_b4c92d30-7342-4efe-93cb-c8a2da119913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_ff37092f-48eb-4cb1-8775-1383ef745264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b4c92d30-7342-4efe-93cb-c8a2da119913" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_ff37092f-48eb-4cb1-8775-1383ef745264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalPeriod_8f066306-1346-41a8-a22a-8c6ec61053f3" xlink:href="bhc-20220630.xsd#bhc_LossContingencyStayOfApprovalPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b4c92d30-7342-4efe-93cb-c8a2da119913" xlink:to="loc_bhc_LossContingencyStayOfApprovalPeriod_8f066306-1346-41a8-a22a-8c6ec61053f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_5970ec7f-41df-4f19-8d93-2367540600a6" xlink:href="bhc-20220630.xsd#bhc_LossContingencyStayOfApprovalMotionToExtendPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b4c92d30-7342-4efe-93cb-c8a2da119913" xlink:to="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_5970ec7f-41df-4f19-8d93-2367540600a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#LEGALPROCEEDINGSGeneralCivilActionsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9229257f-7b52-43b2-8034-7c77caa40617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_b201b153-4655-4de9-bccd-3756dd8f361e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9229257f-7b52-43b2-8034-7c77caa40617" xlink:to="loc_us-gaap_LossContingenciesTable_b201b153-4655-4de9-bccd-3756dd8f361e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_b22f3d12-c461-48c9-9858-fd1bf59699ce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b201b153-4655-4de9-bccd-3756dd8f361e" xlink:to="loc_srt_LitigationCaseAxis_b22f3d12-c461-48c9-9858-fd1bf59699ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e0349262-abe2-4888-822d-eea0765bf9c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_b22f3d12-c461-48c9-9858-fd1bf59699ce" xlink:to="loc_srt_LitigationCaseTypeDomain_e0349262-abe2-4888-822d-eea0765bf9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_61dae81f-abe4-45c6-bf5c-3723af4a507e" xlink:href="bhc-20220630.xsd#bhc_DoctorsAllergyFormulaLLCLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e0349262-abe2-4888-822d-eea0765bf9c7" xlink:to="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_61dae81f-abe4-45c6-bf5c-3723af4a507e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationwithFormerSalixCEOMember_6430d625-aaa0-40be-9f92-21571415e9e0" xlink:href="bhc-20220630.xsd#bhc_LitigationwithFormerSalixCEOMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e0349262-abe2-4888-822d-eea0765bf9c7" xlink:to="loc_bhc_LitigationwithFormerSalixCEOMember_6430d625-aaa0-40be-9f92-21571415e9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_6e129fe6-252b-4bc4-adac-7aaf9b5b65ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b201b153-4655-4de9-bccd-3756dd8f361e" xlink:to="loc_us-gaap_LossContingenciesLineItems_6e129fe6-252b-4bc4-adac-7aaf9b5b65ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_2095b38e-316f-45a5-803a-dfa86266a3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_6e129fe6-252b-4bc4-adac-7aaf9b5b65ac" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_2095b38e-316f-45a5-803a-dfa86266a3d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATION" xlink:type="simple" xlink:href="bhc-20220630.xsd#SEGMENTINFORMATION"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_28852bc3-45fc-46cd-9bcd-2eac16494af5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_844728c9-a08a-4e12-9740-ebe5fec95a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_28852bc3-45fc-46cd-9bcd-2eac16494af5" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_844728c9-a08a-4e12-9740-ebe5fec95a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="bhc-20220630.xsd#SEGMENTINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_82251492-9b72-444f-8f68-87f7d0ca221e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_dbefe615-f9f1-4b7d-b8af-73e58780f54b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_82251492-9b72-444f-8f68-87f7d0ca221e" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_dbefe615-f9f1-4b7d-b8af-73e58780f54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_6a67f2ae-a70b-4f91-9bb0-9023da4acae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_82251492-9b72-444f-8f68-87f7d0ca221e" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_6a67f2ae-a70b-4f91-9bb0-9023da4acae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_542f27f7-699c-4717-9610-6e1642d5a5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_82251492-9b72-444f-8f68-87f7d0ca221e" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_542f27f7-699c-4717-9610-6e1642d5a5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_02aa85e8-a682-4ed4-b13a-852c81c6c963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_82251492-9b72-444f-8f68-87f7d0ca221e" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_02aa85e8-a682-4ed4-b13a-852c81c6c963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_3fb9c7b3-addd-4c97-842c-a1cdae4ecbff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d922c65e-ec28-4a8e-9ad5-3d9ea823dea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3fb9c7b3-addd-4c97-842c-a1cdae4ecbff" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d922c65e-ec28-4a8e-9ad5-3d9ea823dea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1774eb09-3288-4fc4-9821-5aed5e0ee7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d922c65e-ec28-4a8e-9ad5-3d9ea823dea5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1774eb09-3288-4fc4-9821-5aed5e0ee7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8483dde1-a651-47f2-bde9-9f6ab5eb3e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1774eb09-3288-4fc4-9821-5aed5e0ee7d3" xlink:to="loc_us-gaap_SegmentDomain_8483dde1-a651-47f2-bde9-9f6ab5eb3e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_3765ce63-f256-4af9-8f19-e904eee00440" xlink:href="bhc-20220630.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8483dde1-a651-47f2-bde9-9f6ab5eb3e8f" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_3765ce63-f256-4af9-8f19-e904eee00440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_e1f31b23-6cc1-4f15-820a-d2ea6c665eba" xlink:href="bhc-20220630.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8483dde1-a651-47f2-bde9-9f6ab5eb3e8f" xlink:to="loc_bhc_SalixSegmentMember_e1f31b23-6cc1-4f15-820a-d2ea6c665eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_71961223-e869-435f-84ef-335b37523a7d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d922c65e-ec28-4a8e-9ad5-3d9ea823dea5" xlink:to="loc_srt_ProductOrServiceAxis_71961223-e869-435f-84ef-335b37523a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8e527cc1-d5c0-4dd8-a629-687898e9b2fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_71961223-e869-435f-84ef-335b37523a7d" xlink:to="loc_srt_ProductsAndServicesDomain_8e527cc1-d5c0-4dd8-a629-687898e9b2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_XifaxanBrandedProductsMember_de88b188-7b7f-4ce9-bbf1-150dade0f6be" xlink:href="bhc-20220630.xsd#bhc_XifaxanBrandedProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8e527cc1-d5c0-4dd8-a629-687898e9b2fd" xlink:to="loc_bhc_XifaxanBrandedProductsMember_de88b188-7b7f-4ce9-bbf1-150dade0f6be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_294cdd3e-49d6-4be4-8511-8e0227920eb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d922c65e-ec28-4a8e-9ad5-3d9ea823dea5" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_294cdd3e-49d6-4be4-8511-8e0227920eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8c10f20a-dbd0-401c-96f6-30c85f4ca8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_294cdd3e-49d6-4be4-8511-8e0227920eb6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8c10f20a-dbd0-401c-96f6-30c85f4ca8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_9dd2cb1a-18a0-406c-8b7d-7c4cb050bb11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8c10f20a-dbd0-401c-96f6-30c85f4ca8cb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_9dd2cb1a-18a0-406c-8b7d-7c4cb050bb11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_926e8399-5c8b-48a7-9677-da97c18f12df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d922c65e-ec28-4a8e-9ad5-3d9ea823dea5" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_926e8399-5c8b-48a7-9677-da97c18f12df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1c759b7d-0941-4374-af51-5e9a281485a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_926e8399-5c8b-48a7-9677-da97c18f12df" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1c759b7d-0941-4374-af51-5e9a281485a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_b83a9ec9-5109-4835-a4a3-104d261cb8e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1c759b7d-0941-4374-af51-5e9a281485a3" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_b83a9ec9-5109-4835-a4a3-104d261cb8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_0d563833-abc7-4e20-bcac-2d9661a6f333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d922c65e-ec28-4a8e-9ad5-3d9ea823dea5" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_0d563833-abc7-4e20-bcac-2d9661a6f333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_d522deb7-7c73-42b4-b5e9-da2eb7ad6a36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0d563833-abc7-4e20-bcac-2d9661a6f333" xlink:to="loc_us-gaap_NumberOfReportingUnits_d522deb7-7c73-42b4-b5e9-da2eb7ad6a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a36b9e8d-3091-4ba1-ada1-9f5ee00a5c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0d563833-abc7-4e20-bcac-2d9661a6f333" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a36b9e8d-3091-4ba1-ada1-9f5ee00a5c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1f2f603f-4826-4a7f-b7be-7521eb85a355" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_71a25989-f4e8-4c09-974f-16aebca7ea45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1f2f603f-4826-4a7f-b7be-7521eb85a355" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_71a25989-f4e8-4c09-974f-16aebca7ea45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_a93ef358-cabf-4cbe-8fe9-58ecbfecaec9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_71a25989-f4e8-4c09-974f-16aebca7ea45" xlink:to="loc_srt_ConsolidationItemsAxis_a93ef358-cabf-4cbe-8fe9-58ecbfecaec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_00fb934a-2c78-4443-b07e-bc241203e0d0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_a93ef358-cabf-4cbe-8fe9-58ecbfecaec9" xlink:to="loc_srt_ConsolidationItemsDomain_00fb934a-2c78-4443-b07e-bc241203e0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_50a110af-6102-4587-a57b-b7c9f5bfa784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_00fb934a-2c78-4443-b07e-bc241203e0d0" xlink:to="loc_us-gaap_OperatingSegmentsMember_50a110af-6102-4587-a57b-b7c9f5bfa784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_b97a504b-6925-4638-bf54-16165f7aafe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_00fb934a-2c78-4443-b07e-bc241203e0d0" xlink:to="loc_us-gaap_CorporateNonSegmentMember_b97a504b-6925-4638-bf54-16165f7aafe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_03e95e31-a030-4206-a4da-19b6d59a4ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_71a25989-f4e8-4c09-974f-16aebca7ea45" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_03e95e31-a030-4206-a4da-19b6d59a4ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_eaeac100-78bc-4cc2-af6b-6db0811cfa0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_03e95e31-a030-4206-a4da-19b6d59a4ca9" xlink:to="loc_us-gaap_SegmentDomain_eaeac100-78bc-4cc2-af6b-6db0811cfa0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_24d222d8-4b12-4cea-9fe5-e07eeb477996" xlink:href="bhc-20220630.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_eaeac100-78bc-4cc2-af6b-6db0811cfa0d" xlink:to="loc_bhc_SalixSegmentMember_24d222d8-4b12-4cea-9fe5-e07eeb477996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_740b7f66-04d2-4e90-b773-923f23e1a357" xlink:href="bhc-20220630.xsd#bhc_InternationalRxMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_eaeac100-78bc-4cc2-af6b-6db0811cfa0d" xlink:to="loc_bhc_InternationalRxMember_740b7f66-04d2-4e90-b773-923f23e1a357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_b24cd15a-d4b1-42e8-98cb-e99e5d33cd45" xlink:href="bhc-20220630.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_eaeac100-78bc-4cc2-af6b-6db0811cfa0d" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_b24cd15a-d4b1-42e8-98cb-e99e5d33cd45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_f9add56b-382f-49a3-9323-f156d6377ec7" xlink:href="bhc-20220630.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_eaeac100-78bc-4cc2-af6b-6db0811cfa0d" xlink:to="loc_bhc_SoltaMedicalSegmentMember_f9add56b-382f-49a3-9323-f156d6377ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_6afa26aa-69ae-4a84-9281-1d25b3451848" xlink:href="bhc-20220630.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_eaeac100-78bc-4cc2-af6b-6db0811cfa0d" xlink:to="loc_bhc_BauschLombMember_6afa26aa-69ae-4a84-9281-1d25b3451848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_e756200a-2f86-4de7-a08a-7281bff3363d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_71a25989-f4e8-4c09-974f-16aebca7ea45" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_e756200a-2f86-4de7-a08a-7281bff3363d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93e0aa5f-dff9-4749-bc75-5b79edb99509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e756200a-2f86-4de7-a08a-7281bff3363d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93e0aa5f-dff9-4749-bc75-5b79edb99509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2585d8e6-8897-4af4-b67a-c63b29330cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e756200a-2f86-4de7-a08a-7281bff3363d" xlink:to="loc_us-gaap_OperatingIncomeLoss_2585d8e6-8897-4af4-b67a-c63b29330cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_f52bb712-62c7-49ec-bc96-9a0b61bdc89d" xlink:href="bhc-20220630.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e756200a-2f86-4de7-a08a-7281bff3363d" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_f52bb712-62c7-49ec-bc96-9a0b61bdc89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_6cfecb5f-0bcb-4a49-8fbd-7a27bfb15b5a" xlink:href="bhc-20220630.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e756200a-2f86-4de7-a08a-7281bff3363d" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_6cfecb5f-0bcb-4a49-8fbd-7a27bfb15b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_b337a278-9513-4cec-9ee2-3fb576b3b480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e756200a-2f86-4de7-a08a-7281bff3363d" xlink:to="loc_us-gaap_AssetImpairmentCharges_b337a278-9513-4cec-9ee2-3fb576b3b480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_ab24614e-ae08-4cc8-8483-91e20faca5dc" xlink:href="bhc-20220630.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e756200a-2f86-4de7-a08a-7281bff3363d" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_ab24614e-ae08-4cc8-8483-91e20faca5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_764f2f6b-c331-465d-ad65-b77feec928d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e756200a-2f86-4de7-a08a-7281bff3363d" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_764f2f6b-c331-465d-ad65-b77feec928d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_74962c3e-9801-442c-81bd-0eca510ff2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e756200a-2f86-4de7-a08a-7281bff3363d" xlink:to="loc_us-gaap_InvestmentIncomeInterest_74962c3e-9801-442c-81bd-0eca510ff2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_1ad2adfa-bd34-4058-a2fc-492444e45c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e756200a-2f86-4de7-a08a-7281bff3363d" xlink:to="loc_us-gaap_InterestExpenseDebt_1ad2adfa-bd34-4058-a2fc-492444e45c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_563d5fec-f630-47b2-8d67-72ffc1d7220b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e756200a-2f86-4de7-a08a-7281bff3363d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_563d5fec-f630-47b2-8d67-72ffc1d7220b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_d4f6f0d9-56a3-452c-b57b-9f2169b0e84c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e756200a-2f86-4de7-a08a-7281bff3363d" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_d4f6f0d9-56a3-452c-b57b-9f2169b0e84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1e489961-2fe2-49ac-9dee-51c550b28f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_e756200a-2f86-4de7-a08a-7281bff3363d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1e489961-2fe2-49ac-9dee-51c550b28f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#SEGMENTINFORMATIONDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_15359a23-a797-4644-b8fe-62a1947fb12d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_30663a82-6623-4bd8-a5b3-590631d29dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_15359a23-a797-4644-b8fe-62a1947fb12d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_30663a82-6623-4bd8-a5b3-590631d29dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_adbce4d9-f37c-4295-a66a-072cd8d1866a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_30663a82-6623-4bd8-a5b3-590631d29dc3" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_adbce4d9-f37c-4295-a66a-072cd8d1866a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_443d198f-c9d0-4ef1-a667-2b7949fa8ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_adbce4d9-f37c-4295-a66a-072cd8d1866a" xlink:to="loc_us-gaap_SegmentDomain_443d198f-c9d0-4ef1-a667-2b7949fa8ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_fbd98aa9-74e1-4edd-9a64-b6d203c80ef7" xlink:href="bhc-20220630.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_443d198f-c9d0-4ef1-a667-2b7949fa8ca3" xlink:to="loc_bhc_SalixSegmentMember_fbd98aa9-74e1-4edd-9a64-b6d203c80ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_0f3b5efe-d353-48bb-931a-ed72a6016064" xlink:href="bhc-20220630.xsd#bhc_InternationalRxMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_443d198f-c9d0-4ef1-a667-2b7949fa8ca3" xlink:to="loc_bhc_InternationalRxMember_0f3b5efe-d353-48bb-931a-ed72a6016064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_a6d906c4-6efc-41c2-8565-a4afa528a78d" xlink:href="bhc-20220630.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_443d198f-c9d0-4ef1-a667-2b7949fa8ca3" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_a6d906c4-6efc-41c2-8565-a4afa528a78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_a9d74a75-ed52-4dec-b468-cb3330f3891f" xlink:href="bhc-20220630.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_443d198f-c9d0-4ef1-a667-2b7949fa8ca3" xlink:to="loc_bhc_SoltaMedicalSegmentMember_a9d74a75-ed52-4dec-b468-cb3330f3891f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_c0cfe1ee-5830-429b-8e97-bfa1d02aa3df" xlink:href="bhc-20220630.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_443d198f-c9d0-4ef1-a667-2b7949fa8ca3" xlink:to="loc_bhc_BauschLombMember_c0cfe1ee-5830-429b-8e97-bfa1d02aa3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cf37df1a-97dc-4898-841e-24eb0a22321b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_30663a82-6623-4bd8-a5b3-590631d29dc3" xlink:to="loc_srt_ProductOrServiceAxis_cf37df1a-97dc-4898-841e-24eb0a22321b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b1d7f155-e3af-44f6-9727-685e0081c595" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_cf37df1a-97dc-4898-841e-24eb0a22321b" xlink:to="loc_srt_ProductsAndServicesDomain_b1d7f155-e3af-44f6-9727-685e0081c595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PharmaceuticalProductsMember_0a82272a-0065-4a12-be14-41275d9c23f8" xlink:href="bhc-20220630.xsd#bhc_PharmaceuticalProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b1d7f155-e3af-44f6-9727-685e0081c595" xlink:to="loc_bhc_PharmaceuticalProductsMember_0a82272a-0065-4a12-be14-41275d9c23f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeviceProductsMember_181438a1-e12e-4243-8e1a-cadc4dff0082" xlink:href="bhc-20220630.xsd#bhc_DeviceProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b1d7f155-e3af-44f6-9727-685e0081c595" xlink:to="loc_bhc_DeviceProductsMember_181438a1-e12e-4243-8e1a-cadc4dff0082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OvertheCounterProductsMember_4c5a1681-6aac-4068-8247-1026bb03c0b9" xlink:href="bhc-20220630.xsd#bhc_OvertheCounterProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b1d7f155-e3af-44f6-9727-685e0081c595" xlink:to="loc_bhc_OvertheCounterProductsMember_4c5a1681-6aac-4068-8247-1026bb03c0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BrandedandOtherGenericProductsMember_9614a326-c634-47a1-9da6-38900a8fc1d8" xlink:href="bhc-20220630.xsd#bhc_BrandedandOtherGenericProductsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b1d7f155-e3af-44f6-9727-685e0081c595" xlink:to="loc_bhc_BrandedandOtherGenericProductsMember_9614a326-c634-47a1-9da6-38900a8fc1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherRevenuesMember_3624392a-181c-4bd1-8af7-a6414debf801" xlink:href="bhc-20220630.xsd#bhc_OtherRevenuesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b1d7f155-e3af-44f6-9727-685e0081c595" xlink:to="loc_bhc_OtherRevenuesMember_3624392a-181c-4bd1-8af7-a6414debf801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_eaf70b20-a8d4-42bf-9cb2-d2db96e721a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_30663a82-6623-4bd8-a5b3-590631d29dc3" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_eaf70b20-a8d4-42bf-9cb2-d2db96e721a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_87302516-0399-419d-9bf3-bb98bc374682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_eaf70b20-a8d4-42bf-9cb2-d2db96e721a3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_87302516-0399-419d-9bf3-bb98bc374682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1" xlink:type="simple" xlink:href="bhc-20220630.xsd#SEGMENTINFORMATIONNarrativeDetails_1"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_41e90375-2851-48c0-8da5-2f1719cb26e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_696a5bcf-9984-4fa2-ba1f-0f6a10aac2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_41e90375-2851-48c0-8da5-2f1719cb26e0" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_696a5bcf-9984-4fa2-ba1f-0f6a10aac2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5a01d38e-5ed8-4795-a66e-1c3feb7bc754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_696a5bcf-9984-4fa2-ba1f-0f6a10aac2a5" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5a01d38e-5ed8-4795-a66e-1c3feb7bc754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_034755d2-5a9e-4fdb-a8bf-8a97ca1a9f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5a01d38e-5ed8-4795-a66e-1c3feb7bc754" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_034755d2-5a9e-4fdb-a8bf-8a97ca1a9f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_f579c4e8-92e9-4430-bb66-712d2cfb3fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_034755d2-5a9e-4fdb-a8bf-8a97ca1a9f8f" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_f579c4e8-92e9-4430-bb66-712d2cfb3fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b36a6c87-61e6-45e8-aa19-74b4fcf8cb73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_696a5bcf-9984-4fa2-ba1f-0f6a10aac2a5" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b36a6c87-61e6-45e8-aa19-74b4fcf8cb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_928cabb3-a00f-408e-8dfb-9ded3527f277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b36a6c87-61e6-45e8-aa19-74b4fcf8cb73" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_928cabb3-a00f-408e-8dfb-9ded3527f277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_8d826e2e-8641-4afe-9afc-d54151f08dbd" xlink:href="bhc-20220630.xsd#bhc_RevenuesNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_928cabb3-a00f-408e-8dfb-9ded3527f277" xlink:to="loc_bhc_RevenuesNetMember_8d826e2e-8641-4afe-9afc-d54151f08dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f68c0e06-f89f-47a9-b084-28646f5176c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_696a5bcf-9984-4fa2-ba1f-0f6a10aac2a5" xlink:to="loc_srt_MajorCustomersAxis_f68c0e06-f89f-47a9-b084-28646f5176c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f31be6df-6adf-4618-9532-f456768c99f3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_f68c0e06-f89f-47a9-b084-28646f5176c5" xlink:to="loc_srt_NameOfMajorCustomerDomain_f31be6df-6adf-4618-9532-f456768c99f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CustomerTopTenProductsMember_bd351ba4-4c7a-437c-abab-ff50b7753d78" xlink:href="bhc-20220630.xsd#bhc_CustomerTopTenProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f31be6df-6adf-4618-9532-f456768c99f3" xlink:to="loc_bhc_CustomerTopTenProductsMember_bd351ba4-4c7a-437c-abab-ff50b7753d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_453bc6a2-e01e-4c8f-9ad1-5de47c8b76a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_696a5bcf-9984-4fa2-ba1f-0f6a10aac2a5" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_453bc6a2-e01e-4c8f-9ad1-5de47c8b76a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskNumberOfProducts_f10ca7b5-0cd0-4a37-9352-f6f3c68e67f8" xlink:href="bhc-20220630.xsd#bhc_ConcentrationRiskNumberOfProducts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_453bc6a2-e01e-4c8f-9ad1-5de47c8b76a3" xlink:to="loc_bhc_ConcentrationRiskNumberOfProducts_f10ca7b5-0cd0-4a37-9352-f6f3c68e67f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_73e386d4-1bdd-4224-8e86-41be6a8a23f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_453bc6a2-e01e-4c8f-9ad1-5de47c8b76a3" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_73e386d4-1bdd-4224-8e86-41be6a8a23f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_8480bac5-0d89-4ab2-b856-6bc45f7133eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_7b8d5fe6-b6cf-4bbf-84cc-f3783e1568e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_8480bac5-0d89-4ab2-b856-6bc45f7133eb" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_7b8d5fe6-b6cf-4bbf-84cc-f3783e1568e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7823b416-70ea-4179-8508-98279a8956f6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_7b8d5fe6-b6cf-4bbf-84cc-f3783e1568e3" xlink:to="loc_srt_StatementGeographicalAxis_7823b416-70ea-4179-8508-98279a8956f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_7823b416-70ea-4179-8508-98279a8956f6" xlink:to="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember_908cae90-eacf-4360-982f-6fe16bc0b4c4" xlink:href="bhc-20220630.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:to="loc_bhc_UnitedStatesandPuertoRicoMember_908cae90-eacf-4360-982f-6fe16bc0b4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_8c5359ee-f919-4f8e-a053-5a0a3ef7dccb" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:to="loc_country_CN_8c5359ee-f919-4f8e-a053-5a0a3ef7dccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_134184fa-61c5-4b1c-836c-30a1aadbaae1" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:to="loc_country_CA_134184fa-61c5-4b1c-836c-30a1aadbaae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL_c3e05c48-51ba-40bb-87cf-1952c674a434" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_PL"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:to="loc_country_PL_c3e05c48-51ba-40bb-87cf-1952c674a434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX_eb4f0d26-0156-4886-ab7a-20d003d24b9f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MX"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:to="loc_country_MX_eb4f0d26-0156-4886-ab7a-20d003d24b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_2bf61a84-1b26-4f64-8f50-755a8f5d1910" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:to="loc_country_FR_2bf61a84-1b26-4f64-8f50-755a8f5d1910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_4ebcb8ff-4a6c-41e2-a2ea-55102339e5d5" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:to="loc_country_JP_4ebcb8ff-4a6c-41e2-a2ea-55102339e5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_6f6fe378-8ce8-42f7-9cdf-0e72978cedca" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:to="loc_country_DE_6f6fe378-8ce8-42f7-9cdf-0e72978cedca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_c6e54d5d-f31b-4819-933d-cec6549ba5f9" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:to="loc_country_GB_c6e54d5d-f31b-4819-933d-cec6549ba5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_RU_c229a457-c923-4b3f-908f-6b9eea4b93e9" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_RU"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:to="loc_country_RU_c229a457-c923-4b3f-908f-6b9eea4b93e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES_6cb73c33-7d92-43a8-8103-558fee3b4597" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_ES"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:to="loc_country_ES_6cb73c33-7d92-43a8-8103-558fee3b4597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT_fe7a699b-7de7-4609-ab20-31ac0d66a0d9" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IT"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:to="loc_country_IT_fe7a699b-7de7-4609-ab20-31ac0d66a0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_KR_fdc4032a-5623-4aa0-98a8-d63cbd5c6d3c" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:to="loc_country_KR_fdc4032a-5623-4aa0-98a8-d63cbd5c6d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember_2806806e-3822-4518-abc9-7a439d7156ef" xlink:href="bhc-20220630.xsd#bhc_OtherCountriesMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_eb352f6a-d1a1-4860-8375-6cc228661f1f" xlink:to="loc_bhc_OtherCountriesMember_2806806e-3822-4518-abc9-7a439d7156ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_131045c0-24ea-4a96-abf6-499964465fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_7b8d5fe6-b6cf-4bbf-84cc-f3783e1568e3" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_131045c0-24ea-4a96-abf6-499964465fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aadda5d4-0325-400e-8b02-54e77e45f883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_131045c0-24ea-4a96-abf6-499964465fe0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aadda5d4-0325-400e-8b02-54e77e45f883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#SEGMENTINFORMATIONMajorCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ca9d72a1-ddd7-487b-a15d-097988f60262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f276ce53-1a98-4f14-9f20-7a6a639c3507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ca9d72a1-ddd7-487b-a15d-097988f60262" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f276ce53-1a98-4f14-9f20-7a6a639c3507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c7ca86c6-a1eb-4937-9613-f7b89eca1448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f276ce53-1a98-4f14-9f20-7a6a639c3507" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c7ca86c6-a1eb-4937-9613-f7b89eca1448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d9f51ca9-8672-4369-8d1b-9a08632e8d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c7ca86c6-a1eb-4937-9613-f7b89eca1448" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d9f51ca9-8672-4369-8d1b-9a08632e8d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_62efd871-6fe2-4b8a-8d38-addaa312dae7" xlink:href="bhc-20220630.xsd#bhc_RevenuesNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d9f51ca9-8672-4369-8d1b-9a08632e8d9b" xlink:to="loc_bhc_RevenuesNetMember_62efd871-6fe2-4b8a-8d38-addaa312dae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_6a15256f-20ca-4907-b848-c7523b55156a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f276ce53-1a98-4f14-9f20-7a6a639c3507" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_6a15256f-20ca-4907-b848-c7523b55156a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_77b2f8ce-3f2d-4be6-8eee-b72aa906d63c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_6a15256f-20ca-4907-b848-c7523b55156a" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_77b2f8ce-3f2d-4be6-8eee-b72aa906d63c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_d38c1922-be4d-4ca9-bdb5-e3ac9aaa0654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_77b2f8ce-3f2d-4be6-8eee-b72aa906d63c" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_d38c1922-be4d-4ca9-bdb5-e3ac9aaa0654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_6759a8c7-2cdd-400a-a357-171385b2e78d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f276ce53-1a98-4f14-9f20-7a6a639c3507" xlink:to="loc_srt_MajorCustomersAxis_6759a8c7-2cdd-400a-a357-171385b2e78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_fbeb7c46-c578-4634-8ce4-c7ab6bfeee54" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_6759a8c7-2cdd-400a-a357-171385b2e78d" xlink:to="loc_srt_NameOfMajorCustomerDomain_fbeb7c46-c578-4634-8ce4-c7ab6bfeee54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmerisourceBergenCorporationMember_2c738609-e0c1-405f-834c-854e8b124dbf" xlink:href="bhc-20220630.xsd#bhc_AmerisourceBergenCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_fbeb7c46-c578-4634-8ce4-c7ab6bfeee54" xlink:to="loc_bhc_AmerisourceBergenCorporationMember_2c738609-e0c1-405f-834c-854e8b124dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_McKessonCorporationMember_cbdc6648-dc07-4e6f-be47-5dc8269ba800" xlink:href="bhc-20220630.xsd#bhc_McKessonCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_fbeb7c46-c578-4634-8ce4-c7ab6bfeee54" xlink:to="loc_bhc_McKessonCorporationMember_cbdc6648-dc07-4e6f-be47-5dc8269ba800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CardinalHealthIncMember_25af02f0-3712-4bc5-8e24-6ac13f2a8081" xlink:href="bhc-20220630.xsd#bhc_CardinalHealthIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_fbeb7c46-c578-4634-8ce4-c7ab6bfeee54" xlink:to="loc_bhc_CardinalHealthIncMember_25af02f0-3712-4bc5-8e24-6ac13f2a8081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_8d830ed3-88d2-492d-b135-ca8c0fd067c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_f276ce53-1a98-4f14-9f20-7a6a639c3507" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_8d830ed3-88d2-492d-b135-ca8c0fd067c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_6913a029-9126-4242-97cd-cce5957e6961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_8d830ed3-88d2-492d-b135-ca8c0fd067c8" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_6913a029-9126-4242-97cd-cce5957e6961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SUBSEQUENTEVENT" xlink:type="simple" xlink:href="bhc-20220630.xsd#SUBSEQUENTEVENT"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SUBSEQUENTEVENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_11e99bf8-b5b7-413b-b4d1-9625284b10bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_adc7ba8c-acac-414f-9000-6ae8eeea953f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_11e99bf8-b5b7-413b-b4d1-9625284b10bb" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_adc7ba8c-acac-414f-9000-6ae8eeea953f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SUBSEQUENTEVENTNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220630.xsd#SUBSEQUENTEVENTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SUBSEQUENTEVENTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_ec83b4fc-62b2-48ad-a6ca-b7614bcf283b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_8c9b99a4-4956-43f7-ad67-8c8167eb3596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_ec83b4fc-62b2-48ad-a6ca-b7614bcf283b" xlink:to="loc_us-gaap_SubsequentEventTable_8c9b99a4-4956-43f7-ad67-8c8167eb3596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c7c9045b-8554-4378-a25b-8ab164b4a79a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8c9b99a4-4956-43f7-ad67-8c8167eb3596" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c7c9045b-8554-4378-a25b-8ab164b4a79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e0cbbadc-08b2-4c45-9929-96a41985c2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c7c9045b-8554-4378-a25b-8ab164b4a79a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e0cbbadc-08b2-4c45-9929-96a41985c2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6da56783-598b-483b-8776-4e3f62fb6c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e0cbbadc-08b2-4c45-9929-96a41985c2c7" xlink:to="loc_us-gaap_SubsequentEventMember_6da56783-598b-483b-8776-4e3f62fb6c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_915fcd9e-8a2b-4cfb-863b-1de44569ff83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8c9b99a4-4956-43f7-ad67-8c8167eb3596" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_915fcd9e-8a2b-4cfb-863b-1de44569ff83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e9889f71-0d49-4c8b-a09b-151e03d29650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_915fcd9e-8a2b-4cfb-863b-1de44569ff83" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e9889f71-0d49-4c8b-a09b-151e03d29650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_d5767c6b-080c-46c2-888a-1f6b90910f79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e9889f71-0d49-4c8b-a09b-151e03d29650" xlink:to="loc_us-gaap_CurrencySwapMember_d5767c6b-080c-46c2-888a-1f6b90910f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_89896ad7-9f3d-4473-a9df-d0e1fb9d929a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8c9b99a4-4956-43f7-ad67-8c8167eb3596" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_89896ad7-9f3d-4473-a9df-d0e1fb9d929a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_a463d337-c090-4cbd-afc2-08aaa8ade532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_89896ad7-9f3d-4473-a9df-d0e1fb9d929a" xlink:to="loc_us-gaap_HedgingRelationshipDomain_a463d337-c090-4cbd-afc2-08aaa8ade532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_d644e51d-ac3c-4b19-b35e-de55ad8da95c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_a463d337-c090-4cbd-afc2-08aaa8ade532" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_d644e51d-ac3c-4b19-b35e-de55ad8da95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_b57125b7-2667-4343-bb35-1e2468f108dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8c9b99a4-4956-43f7-ad67-8c8167eb3596" xlink:to="loc_us-gaap_HedgingDesignationAxis_b57125b7-2667-4343-bb35-1e2468f108dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_429cdb1a-bc5b-4037-8e56-de74773717ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_b57125b7-2667-4343-bb35-1e2468f108dc" xlink:to="loc_us-gaap_HedgingDesignationDomain_429cdb1a-bc5b-4037-8e56-de74773717ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6980156e-18d8-40b6-b852-ca57d4e76386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_429cdb1a-bc5b-4037-8e56-de74773717ae" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_6980156e-18d8-40b6-b852-ca57d4e76386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_3d09c12a-a8da-4bd1-a4b8-28717e121b3d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8c9b99a4-4956-43f7-ad67-8c8167eb3596" xlink:to="loc_dei_LegalEntityAxis_3d09c12a-a8da-4bd1-a4b8-28717e121b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_238d1499-bd3c-457e-82d2-2cdcabf93b98" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_3d09c12a-a8da-4bd1-a4b8-28717e121b3d" xlink:to="loc_dei_EntityDomain_238d1499-bd3c-457e-82d2-2cdcabf93b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_1a0cef57-03c4-44a2-b663-d871313c4da8" xlink:href="bhc-20220630.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_238d1499-bd3c-457e-82d2-2cdcabf93b98" xlink:to="loc_bhc_BauschLombMember_1a0cef57-03c4-44a2-b663-d871313c4da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_4c2150f0-6978-428a-beb6-a00da0c40f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_8c9b99a4-4956-43f7-ad67-8c8167eb3596" xlink:to="loc_us-gaap_SubsequentEventLineItems_4c2150f0-6978-428a-beb6-a00da0c40f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_44918adb-fefb-436e-a207-99f580aedeb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4c2150f0-6978-428a-beb6-a00da0c40f1e" xlink:to="loc_us-gaap_DerivativeNotionalAmount_44918adb-fefb-436e-a207-99f580aedeb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012040337408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Aug. 04, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Bausch Health Companies Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0448205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2150 St. Elz&#233;ar Blvd. West<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Laval<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">QC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">H7L 4A8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">744-6792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, No Par Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BHC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Smaller Reporting Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,728,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000885590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012037104032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 659<span></span>
</td>
<td class="nump">$ 582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestrictedCashAndOtherSettlementDepositsCurrent', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">1,220<span></span>
</td>
<td class="nump">1,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">1,645<span></span>
</td>
<td class="nump">1,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">1,073<span></span>
</td>
<td class="nump">993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">820<span></span>
</td>
<td class="nump">720<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">5,417<span></span>
</td>
<td class="nump">5,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">1,545<span></span>
</td>
<td class="nump">1,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">6,322<span></span>
</td>
<td class="nump">6,948<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">12,266<span></span>
</td>
<td class="nump">12,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">2,283<span></span>
</td>
<td class="nump">2,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">338<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">28,171<span></span>
</td>
<td class="nump">29,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">536<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">4,311<span></span>
</td>
<td class="nump">4,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,997<span></span>
</td>
<td class="nump">5,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of long-term debt</a></td>
<td class="nump">21,664<span></span>
</td>
<td class="nump">22,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities, net</a></td>
<td class="nump">545<span></span>
</td>
<td class="nump">529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">524<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">27,918<span></span>
</td>
<td class="nump">29,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 18)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares, no par value, unlimited shares authorized, 361,571,921 and 359,405,748 issued and outstanding at June 30, 2022 and December&#160;31, 2021, respectively</a></td>
<td class="nump">10,380<span></span>
</td>
<td class="nump">10,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(9,175)<span></span>
</td>
<td class="num">(8,961)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(2,002)<span></span>
</td>
<td class="num">(1,924)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Bausch Health Companies Inc. shareholders&#8217; deficit</a></td>
<td class="num">(693)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">946<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity (deficit)</a></td>
<td class="nump">253<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity (deficit)</a></td>
<td class="nump">$ 28,171<span></span>
</td>
<td class="nump">$ 29,202<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Noncurrent Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessCombinationContingentConsiderationNoncurrentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestrictedCashAndOtherSettlementDepositsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash And Other Settlement Deposits, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestrictedCashAndOtherSettlementDepositsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012040336256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued (in shares)</a></td>
<td class="nump">361,571,921<span></span>
</td>
<td class="nump">359,405,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding (in shares)</a></td>
<td class="nump">361,571,921<span></span>
</td>
<td class="nump">359,405,748<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012038619120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 1,967<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">$ 3,885<span></span>
</td>
<td class="nump">$ 4,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">676<span></span>
</td>
<td class="nump">685<span></span>
</td>
<td class="nump">1,298<span></span>
</td>
<td class="nump">1,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold', window );">Amortization of intangible assets</a></td>
<td class="nump">302<span></span>
</td>
<td class="nump">360<span></span>
</td>
<td class="nump">612<span></span>
</td>
<td class="nump">717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges', window );">Goodwill impairments</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments, including loss on assets held for sale</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestructuringChargesAndInitialPublicOfferingCosts', window );">Restructuring, integration, separation and IPO costs</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other expense, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">542<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">512<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">1,806<span></span>
</td>
<td class="nump">2,370<span></span>
</td>
<td class="nump">3,439<span></span>
</td>
<td class="nump">4,618<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">161<span></span>
</td>
<td class="num">(270)<span></span>
</td>
<td class="nump">446<span></span>
</td>
<td class="num">(491)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="num">(410)<span></span>
</td>
<td class="num">(364)<span></span>
</td>
<td class="num">(772)<span></span>
</td>
<td class="num">(732)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="nump">113<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange and other</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(129)<span></span>
</td>
<td class="num">(670)<span></span>
</td>
<td class="num">(211)<span></span>
</td>
<td class="num">(1,261)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Provision for) benefit from income taxes</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(139)<span></span>
</td>
<td class="num">(593)<span></span>
</td>
<td class="num">(205)<span></span>
</td>
<td class="num">(1,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interest</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Bausch Health Companies Inc.</a></td>
<td class="num">$ (145)<span></span>
</td>
<td class="num">$ (595)<span></span>
</td>
<td class="num">$ (214)<span></span>
</td>
<td class="num">$ (1,205)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share attributable to Bausch Health Companies Inc. (in usd per share)</a></td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (1.66)<span></span>
</td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (3.37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share attributable to Bausch Health Companies Inc. (in usd per share)</a></td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (1.66)<span></span>
</td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (3.37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average common shares (in shares)</a></td>
<td class="nump">362.2<span></span>
</td>
<td class="nump">359.1<span></span>
</td>
<td class="nump">361.5<span></span>
</td>
<td class="nump">358.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average common shares (in shares)</a></td>
<td class="nump">362.2<span></span>
</td>
<td class="nump">359.1<span></span>
</td>
<td class="nump">361.5<span></span>
</td>
<td class="nump">358.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 1,947<span></span>
</td>
<td class="nump">$ 2,076<span></span>
</td>
<td class="nump">$ 3,845<span></span>
</td>
<td class="nump">$ 4,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues</a></td>
<td class="nump">570<span></span>
</td>
<td class="nump">604<span></span>
</td>
<td class="nump">1,113<span></span>
</td>
<td class="nump">1,168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestructuringChargesAndInitialPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges And Initial Public Offering Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestructuringChargesAndInitialPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012032532896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (139)<span></span>
</td>
<td class="num">$ (593)<span></span>
</td>
<td class="num">$ (205)<span></span>
</td>
<td class="num">$ (1,200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive (loss) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(166)<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="num">(222)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent', window );">Pension and postretirement benefit plan adjustments, net of income taxes</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="num">(165)<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="num">(215)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(304)<span></span>
</td>
<td class="num">(518)<span></span>
</td>
<td class="num">(420)<span></span>
</td>
<td class="num">(1,248)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income attributable to noncontrolling interest</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Bausch Health Companies Inc.</a></td>
<td class="num">$ (310)<span></span>
</td>
<td class="num">$ (521)<span></span>
</td>
<td class="num">$ (429)<span></span>
</td>
<td class="num">$ (1,254)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012034387200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Bausch Health Companies&#160;Inc. Shareholders&#8217; Deficit</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Non- controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 605<span></span>
</td>
<td class="nump">$ 535<span></span>
</td>
<td class="nump">$ 10,227<span></span>
</td>
<td class="nump">$ 454<span></span>
</td>
<td class="num">$ (8,013)<span></span>
</td>
<td class="num">$ (2,133)<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common shares issued under share-based compensation plans</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Employee withholding taxes related to share-based awards</a></td>
<td class="num">(45)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(1,200)<span></span>
</td>
<td class="num">(1,205)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,205)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Jun. 30, 2021</a></td>
<td class="num">(611)<span></span>
</td>
<td class="num">(687)<span></span>
</td>
<td class="nump">$ 10,300<span></span>
</td>
<td class="nump">413<span></span>
</td>
<td class="num">(9,218)<span></span>
</td>
<td class="num">(2,182)<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Mar. 31, 2021</a></td>
<td class="num">(124)<span></span>
</td>
<td class="num">(197)<span></span>
</td>
<td class="nump">$ 10,289<span></span>
</td>
<td class="nump">393<span></span>
</td>
<td class="num">(8,623)<span></span>
</td>
<td class="num">(2,256)<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common shares issued under share-based compensation plans</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Employee withholding taxes related to share-based awards</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(593)<span></span>
</td>
<td class="num">(595)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(595)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Jun. 30, 2021</a></td>
<td class="num">$ (611)<span></span>
</td>
<td class="num">(687)<span></span>
</td>
<td class="nump">$ 10,300<span></span>
</td>
<td class="nump">413<span></span>
</td>
<td class="num">(9,218)<span></span>
</td>
<td class="num">(2,182)<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">359,405,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2021</a></td>
<td class="num">$ (34)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="nump">$ 10,317<span></span>
</td>
<td class="nump">462<span></span>
</td>
<td class="num">(8,961)<span></span>
</td>
<td class="num">(1,924)<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from B+L initial public offering, net of costs (Note 2)</a></td>
<td class="nump">675<span></span>
</td>
<td class="num">(190)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(327)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="nump">865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common shares issued under share-based compensation plans</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Employee withholding taxes related to share-based awards</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(205)<span></span>
</td>
<td class="num">(214)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(214)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="num">$ (215)<span></span>
</td>
<td class="num">(215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">361,571,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Jun. 30, 2022</a></td>
<td class="nump">$ 253<span></span>
</td>
<td class="num">(693)<span></span>
</td>
<td class="nump">$ 10,380<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="num">(9,175)<span></span>
</td>
<td class="num">(2,002)<span></span>
</td>
<td class="nump">946<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Mar. 31, 2022</a></td>
<td class="num">(141)<span></span>
</td>
<td class="num">(216)<span></span>
</td>
<td class="nump">$ 10,373<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="num">(9,030)<span></span>
</td>
<td class="num">(1,974)<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from B+L initial public offering, net of costs (Note 2)</a></td>
<td class="nump">675<span></span>
</td>
<td class="num">(190)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(327)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="nump">865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common shares issued under share-based compensation plans</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Employee withholding taxes related to share-based awards</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(139)<span></span>
</td>
<td class="num">(145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="num">$ (165)<span></span>
</td>
<td class="num">(165)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(165)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">361,571,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Jun. 30, 2022</a></td>
<td class="nump">$ 253<span></span>
</td>
<td class="num">$ (693)<span></span>
</td>
<td class="nump">$ 10,380<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
<td class="num">$ (9,175)<span></span>
</td>
<td class="num">$ (2,002)<span></span>
</td>
<td class="nump">$ 946<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012033083168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (205)<span></span>
</td>
<td class="num">$ (1,200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization of intangible assets</a></td>
<td class="nump">699<span></span>
</td>
<td class="nump">807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization and write-off of debt premiums, discounts and issuance costs</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments, including loss on assets held for sale</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges', window );">Goodwill impairments</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash', window );">Acquisition-related contingent consideration</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AllowancesForLossesOnAccountsReceivableAndInventories', window );">Allowances for losses on trade receivable and inventories</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DeferredIncomeTaxNoncashExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(99)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Net gain on sale of assets</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GainLossRelatedToLitigationSettlementGross', window );">Adjustments to accrued legal settlements</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments of accrued legal settlements</a></td>
<td class="num">(360)<span></span>
</td>
<td class="num">(129)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Foreign exchange loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DerivativeGainExcludedComponent', window );">Gain excluded from hedge effectiveness</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">(Gain) loss on extinguishment of debt</a></td>
<td class="num">(113)<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities', window );">Payments of contingent consideration adjustments, including accretion</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables</a></td>
<td class="nump">107<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(138)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(48)<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued and other liabilities</a></td>
<td class="num">(26)<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(98)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payments for intangible and other assets</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale of marketable securities</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested', window );">Proceeds from sale of assets and businesses, net of costs to sell</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_InterestSettlementOnCrossCurrencySwaps', window );">Interest settlements from cross-currency swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(114)<span></span>
</td>
<td class="num">(99)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Issuance of long-term debt, net of discounts</a></td>
<td class="nump">6,320<span></span>
</td>
<td class="nump">1,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="num">(7,083)<span></span>
</td>
<td class="num">(2,100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty', window );">Net proceeds from B+L initial public offering, net of costs</a></td>
<td class="nump">675<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments of employee withholding taxes related to share-based awards</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments of acquisition-related contingent consideration</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of financing costs</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(162)<span></span>
</td>
<td class="num">(631)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and other</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents, restricted cash and other settlement deposits</a></td>
<td class="num">(240)<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash and other settlement deposits, beginning of period</a></td>
<td class="nump">2,119<span></span>
</td>
<td class="nump">1,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash and other settlement deposits, end of period</a></td>
<td class="nump">1,879<span></span>
</td>
<td class="nump">1,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">659<span></span>
</td>
<td class="nump">642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestrictedCashAndOtherSettlementDepositsCurrent', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">1,220<span></span>
</td>
<td class="nump">1,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash and cash equivalents, held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash and other settlement deposits, end of period</a></td>
<td class="nump">$ 1,879<span></span>
</td>
<td class="nump">$ 1,918<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AllowancesForLossesOnAccountsReceivableAndInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AllowancesForLossesOnAccountsReceivableAndInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DeferredIncomeTaxNoncashExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DeferredIncomeTaxNoncashExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DerivativeGainExcludedComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative, Gain, Excluded Component</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DerivativeGainExcludedComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GainLossRelatedToLitigationSettlementGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) Related to Litigation Settlement, Gross payments not offset by insurance proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GainLossRelatedToLitigationSettlementGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_InterestSettlementOnCrossCurrencySwaps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Settlement On Cross-Currency Swaps</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_InterestSettlementOnCrossCurrencySwaps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment For Contingent Consideration Liability, Including Accretion, Operating Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance Initial Public Offering, Net Of Costs, Related Party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestrictedCashAndOtherSettlementDepositsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash And Other Settlement Deposits, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestrictedCashAndOtherSettlementDepositsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the cash inflow during the period from the sale of a component of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012040321872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text">DESCRIPTION OF BUSINESS Bausch Health Companies Inc. (the&#160;&#8220;Company&#8221; or &#8220;Bausch Health&#8221;) is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (&#8220;GI&#8221;) and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (&#8220;OTC&#8221;) products and medical aesthetic devices and, through its approximately 90% ownership of Bausch + Lomb Corporation (&#8220;Bausch + Lomb&#8221;), branded, and branded generic pharmaceuticals, OTC products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment) in the therapeutic area of eye health. The Company's products are marketed directly or indirectly in approximately 100 countries.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012042496496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SIGNIFICANT ACCOUNTING POLICIES <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared by the Company in U.S. dollars and in accordance with&#160;U.S. generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;) for interim financial reporting, which do not conform in all respects to the requirements of U.S.&#160;GAAP for annual financial statements. Accordingly, these notes to the unaudited Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements prepared in accordance with U.S.&#160;GAAP that are contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the U.S. Securities and Exchange Commission (the&#160;&#8220;SEC&#8221;) and the Canadian Securities Administrators (the&#160;&#8220;CSA&#8221;) on February&#160;23, 2022. The unaudited Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#8217;s audited Consolidated Financial Statements for the year ended December&#160;31, 2021. The unaudited Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statement of the Company&#8217;s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full&#160;year.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation of the Bausch + Lomb Eye Health Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, the Company announced its intentions to separate its eye health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc. (the &#8220;B+L Separation&#8221;). In January 2022, the Company completed the internal organizational design and structure of the new eye health entity, Bausch + Lomb, as previously announced. The registration statement related to the initial public offering (&#8220;IPO&#8221;) of Bausch + Lomb (the &#8220;B+L IPO&#8221;) was declared effective on May 5, 2022, and Bausch + Lomb&#8217;s common stock began trading on the New York Stock Exchange and the Toronto Stock Exchange, in each case under the ticker symbol &#8220;BLCO&#8221; on May 6, 2022. Prior to the effectiveness of the registration statement, Bausch + Lomb was an indirect wholly-owned subsidiary of the Company. On May 10, 2022, a wholly owned subsidiary of the Company (the &#8220;Selling Shareholder&#8221;) sold 35,000,000 common shares of Bausch + Lomb, at an offering price of $18.00 per share, pursuant to the B+L IPO. In addition, the Selling Shareholder granted the underwriters an option for a period of 30 days from the date of the B+L IPO to purchase up to an additional 5,250,000 common shares to cover over-allotments at the IPO price less underwriting commissions. On May 31, 2022, the underwriters partially exercised the over-allotment option granted by the Selling Shareholder and, on June 1, 2022, the Selling Shareholder sold an additional 4,550,357 common shares of Bausch + Lomb at an offering price of $18.00 per share (less applicable underwriting discount). The remainder of the over-allotment option granted to the underwriters expired.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the closing of the B+L IPO and after giving effect to the partial exercise of the over-allotment option, Bausch Health directly or indirectly holds 310,449,643 Bausch + Lomb common shares, which represent approximately 88.7% of Bausch + Lomb&#8217;s outstanding common shares. The aggregate net proceeds from the B+L IPO and the partial exercise of the over-allotment option by the underwriters, after deducting underwriting commissions were approximately $675&#160;million. The Company remains committed to completing the B+L Separation and believes the separation makes strategic sense. The completion of the B+L Separation is subject to the expiry of customary lockups related to the B+L IPO, the achievement of targeted debt leverage ratios and the receipt of applicable shareholder and other necessary approvals. The Company continues to evaluate the factors and considerations related to completing the B+L Separation and effect of the Norwich Legal Decision (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 18, &#8220;LEGAL PROCEEDINGS&#8221;) on the B+L Separation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The B+L IPO established two separate companies that include: (i) a fully integrated eye health company which consists of the Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals businesses and (ii) a diversified pharmaceutical company which includes the Company&#8217;s Salix, International (formerly International Rx), Diversified (dentistry, neurology, medical dermatology and generics pharmaceutical) products, and Solta aesthetic medical device businesses. Other than the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effects of the B+L IPO described above, these unaudited Consolidated Financial Statements do not include any adjustments to give effect to the B+L Separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impacts of COVID-19 Pandemic </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unprecedented nature of the COVID-19 pandemic has, and continues to, adversely impact the global economy. The COVID-19 pandemic and the reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which these events may continue to impact the Company&#8217;s business, financial condition, cash flows and results of operations, in particular, will depend on future developments which are highly uncertain and many of which are outside the Company&#8217;s control. Such developments include the availability and effectiveness of vaccines for the COVID-19 virus, the ultimate geographic spread and duration of the pandemic, COVID-19 vaccine immunization rates, the extent and duration of a resurgence of the COVID-19 virus and variant strains thereof, such as the delta and omicron variants, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus and the economic impact of the pandemic and the reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company&#8217;s business, financial condition, cash flows and results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing. Although it is difficult to predict the broad macroeconomic effects that the COVID-19 pandemic will have on industries or individual companies, the Company has assessed the possible effects and outcomes of the pandemic on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand and currently believes that its estimates are reasonable. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Initial Public Offering of Solta Medical Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2021, the Company announced its intentions to conduct an IPO of its aesthetic medical device business, Solta Medical (formerly Global Solta) (the &#8220;Solta IPO&#8221;). In January 2022, the Company completed the internal organizational design and structure of the new Solta Medical entity, Solta Medical Corporation (&#8220;Solta&#8221;). On June 16, 2022, as a result of challenging market conditions and other factors, the Company announced it was suspending its plans for the Solta IPO. Solta will remain part of Bausch Health, as the Company plans to revisit alternate paths for its Solta medical aesthetic devices business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the unaudited Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Consolidated Financial Statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the differences could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#8217;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#8217;s results of operations and financial position could be materially impacted.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Reportable Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2022, the Company operates in the following reportable segments: (i) Salix, (ii) International (formerly International Rx), (iii) Diversified Products, (iv) Solta Medical, and (v) Bausch + Lomb. Prior to the first quarter of 2022, the Company operated in the following reportable segments: (i) Salix, (ii) International Rx, (iii) Ortho </span></div>Dermatologics, (iv) Diversified Products and (v) Bausch + Lomb. Prior period presentations have been recast to conform to the current segment reporting structure. See Note 19, &#8220;SEGMENT INFORMATION&#8221; for additional information.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012041130240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE RECOGNITION</a></td>
<td class="text">REVENUE RECOGNITION <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, principally in the therapeutic areas of GI, dermatology, and eye health, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics medical devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 19, &#8220;SEGMENT INFORMATION&#8221; for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160;The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company&#8217;s products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#8217;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the activity and ending balances of the Company&#8217;s variable consideration provisions for the six months ended June 30, 2022 and 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.616%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(976)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,602)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,971&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $48 million and $36&#160;million as of June 30, 2022 and January 1, 2022, respectively, which are reflected as a reduction of Trade receivables, net in the Consolidated Balance Sheets. There were no price appreciation credits during the six months ended June 30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.616%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(296)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,025)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,012)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,546)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">981&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $41 million and $32&#160;million as of June 30, 2021 and January 1, 2021, respectively. Included as a reduction of Distribution fees in the table above are price appreciation credits of approximately $1&#160;million during the six months ended June 30, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Contract Liabilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allowance for Credit Losses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collateral (if any), and any relevant current and reasonably supportable future economic factors.&#160;Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses. The activity in the allowance for credit losses for trade receivables for the six months ended June 30, 2022 and 2021 is as follows.</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.447%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.830%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012043149440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSING AGREEMENTS AND DIVESTITURE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock', window );">LICENSING AGREEMENTS AND DIVESTITURE</a></td>
<td class="text">LICENSING AGREEMENTS AND DIVESTITURE<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early stage development that target unique conditions. The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by regulatory agencies, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain. The commitment periods under these agreements vary and include customary termination provisions. Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred. Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture of Amoun Pharmaceutical Company S.A.E. (&#8220;Amoun&#8221;)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, the Company announced that it and certain of its affiliates had entered into a definitive agreement to sell all of its equity interests in Amoun for total gross consideration of approximately $740&#160;million (including the assignment to the purchasing entity of an intercompany loan granted by the Company to Amoun), subject to certain adjustments (the &#8220;Amoun Sale&#8221;). The Amoun Sale closed on July 26, 2021. As part of the Amoun Sale, cash generated by Amoun during the period from the locked-box date of January 1, 2021 through closing was for the benefit of the purchasing entity, subject to working capital during such period. Amoun manufactures, markets and distributes branded generics of human and animal health products. The Amoun business was part of the International segment (previously included within the former Bausch + Lomb/International Rx segment) and was reclassified as held for sale as of December 31, 2020. As a result of meeting the criteria for held for sale classification, the carrying value of the Amoun business, was adjusted to its estimated fair value, less </span></div>costs to sell, and the Company recognized impairment losses of $20&#160;million and $88&#160;million during the three and six months ended June 30, 2021, respectively, included within Asset impairments, including loss on assets held for sale in the Consolidated Statements of Operations. Revenues associated with Amoun were $70&#160;million and $137&#160;million for the three and six months ended June 30, 2021, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012032894640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock', window );">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</a></td>
<td class="text">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and Integration Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates opportunities to improve its operating results and implement cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The liability associated with restructuring and integration costs as of June 30, 2022 was $30 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $25 million and $6&#160;million of restructuring and integration costs and made payments of $15&#160;million and $9&#160;million during the six months ended June 30, 2022 and 2021, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation Costs, Separation-related Costs, IPO Costs and IPO-related Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred, and expects to continue to incur costs associated with activities to effectuate the B+L Separation. The Company also incurred costs associated with activities to effectuate the Solta IPO, which was suspended in June 2022. These B+L Separation and Solta IPO activities include: (i) separating the Bausch + Lomb and Solta Medical businesses from the remainder of the Company, (ii) completing the B+L IPO and preparing for the suspended Solta IPO and (iii) completing the actions necessary for Bausch + Lomb to become an independent publicly traded entity. Separation and IPO costs are incremental costs directly related to the ongoing B+L Separation and the suspended Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing a new board of directors and related board committees for the Bausch + Lomb and Solta Medical entities. Included in Restructuring, integration, separation and IPO costs for the six months ended June 30, 2022 and 2021 are Separation and IPO costs of $23&#160;million and $15&#160;million, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also incurred Separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation and the suspended Solta IPO and will continue to incur incremental costs indirectly related with the B+L Separation. Separation-related and IPO-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. Included in Selling, general and administrative for the six months ended June 30, 2022 and 2021 are Separation-related and IPO-related costs of $64&#160;million and $55&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent and timing of future charges of these costs to complete the B+L Separation cannot be reasonably estimated at this time and could be material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring And Related Activities And Initial Public Offering Costs Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012032894640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are estimated based on valuation techniques and inputs categorized as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1&#160;&#8212;&#160;Quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2&#160;&#8212;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;&#160;and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or&#160;estimation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the&#160;instrument.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.196%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of three months or less when&#160;purchased, and are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature. Cash, cash equivalents and restricted cash and other settlements as presented in the Consolidated Balance Sheet as of June 30, 2022 includes $446&#160;million of cash, cash equivalents and restricted cash held by legal entities of Bausch + Lomb, of which approximately $92&#160;million was due to be distributed to other legal entities owned by the Company in connection with the separation of Bausch +Lomb. Cash otherwise held by Bausch + Lomb legal entities and any future cash from the operations, investing and financing activities of Bausch + Lomb, is expected to be retained by Bausch + Lomb entities and are generally not available to support the operations, investing and financing activities of other legal entities, including Bausch + Lomb&#8217;s parent company unless paid as a dividend which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to  Bausch + Lomb&#8217;s shareholders. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, Restricted cash and other settlement deposits includes $1,210&#160;million of payments into an escrow fund under the terms of a settlement agreement regarding certain U.S. securities litigation (which settlement agreement is subject to one objector&#8217;s appeal of the final court approval of the agreement), and is reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to its short-term nature. These payments will remain in escrow until resolution of the appeal of the final court approval of the settlement agreement, as discussed in Note 18, &#8220;LEGAL PROCEEDINGS&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers into or out of Level 3 during the six months ended June 30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cross-currency Swaps</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into cross-currency swaps, with aggregate notional amounts of $1,250 million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its Consolidated Financial Statements from fluctuation in exchange rates. The euro-denominated net investment being hedged was the Company&#8217;s investment in certain euro-denominated subsidiaries. The Company unwound these cross-currency swaps during November 2021. As a result, there were no assets or liabilities related to the cross-currency swaps included in the Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of hedging instruments on the Consolidated Statements of Comprehensive Loss and the Consolidated Statements of Operations for the three and six months ended June 30, 2022 and 2021:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain excluded from assessment of hedge effectiveness</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of gain of excluded component</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No portion of the cross-currency swaps was ineffective for the six months ended June 30, 2021. During the six months ended June 30, 2022 and 2021, the Company received $0 and $11&#160;million, respectively, in interest settlements which are reported as investing activities in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Contracts</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2020, the Company has been entering into foreign currency exchange contracts. As of June 30, 2022, these contracts had an aggregate outstanding notional amount of $332&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. The Company&#8217;s foreign currency exchange contracts are economically hedging the foreign exchange exposure on certain of the Company&#8217;s intercompany balances. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other. Settlements of the Company&#8217;s foreign currency exchange contracts are reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other and reported as operating activities in the Consolidated Statements of Cash Flows. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company&#8217;s foreign exchange contracts as included in the Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.443%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of the Company&#8217;s foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for the three and six months ended June 30, 2022 and 2021:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.982%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.366%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) related to changes in fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) related to settlements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related Contingent Consideration Obligations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level&#160;3) inputs. These inputs may include: (i)&#160;the estimated amount and timing of projected cash flows, (ii)&#160;the probability of the achievement of the factor(s) on which the contingency is based and (iii)&#160;the risk-adjusted discount rate used to present value the probability-weighted cash&#160;flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At June&#160;30, 2022, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from 6% to 18%, and a weighted average risk-adjusted discount rate of 7%. The weighted average risk-adjusted discount rate was calculated by weighting each contract&#8217;s relative fair value at June&#160;30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the six months ended June 30, 2022 and 2021: </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.534%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to Acquisition-related contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion for the time value of money</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments due to changes in estimates of other future payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment included in other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Long-term Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of long-term debt as of June&#160;30, 2022 and December&#160;31, 2021 was $16,141 million and $22,689 million, respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012038318064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consist of:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012041325200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS AND GOODWILL</a></td>
<td class="text">INTANGIBLE ASSETS AND GOODWILL<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets consist of: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,695)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(506)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,364&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,740)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bausch + Lomb Trademark</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,062&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,740)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,322&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,948&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments in the Consolidated Statement of Operations. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale, for the six months ended June 30, 2022 were $14&#160;million and include: (i) impairments of $10&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines and (ii) impairments of $4&#160;million, in aggregate, related to the discontinuance of certain product lines.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale, for the six months ended June 30, 2021 were $195&#160;million and include: (i) $96&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines, (ii) an adjustment of $88&#160;million due to the loss on assets held for sale in connection with the Amoun Sale and (iii) impairments of $11&#160;million, in aggregate, related to the discontinuance of certain product lines. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense of finite-lived intangible assets for the remainder of 2022 and each of the five succeeding years ending December&#160;31 and thereafter is as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.833%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net includes finite-lived intangible assets related to the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> branded products with a carrying value of approximately $2,963&#160;million as of June 30, 2022, and a remaining estimated life of 66 months. Amortization expense related to these intangible assets amounts to approximately $539&#160;million annually. While the Company intends to appeal the Norwich Legal Decision (see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 18, &#8220;LEGAL PROCEEDINGS&#8221;), it is possible that this and other potential future developments: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">may adversely impact the estimated future cash flows associated with these brands, which could result in an impairment of the value of these intangible assets in one or more future periods. Any such impairment could be material to the Company&#8217;s results of operations in the period in which it occurs; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">may result in shortened useful lives of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets, which would increase amortization expense in future periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill during the six months ended June 30, 2022 and the year ended December&#160;31, 2021 were as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.298%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.447%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.494%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bausch + Lomb/ International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,704)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(578)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,232&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,987&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,266&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit (Step 1).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair value of a reporting unit using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The quantitative fair value test is performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit&#8217;s terminal value. </span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To forecast a reporting unit&#8217;s cash flows the Company takes into consideration economic conditions and trends, estimated future operating results, management&#8217;s and a market participant&#8217;s view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts are based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected loss of exclusivity to the Company&#8217;s product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company&#8217;s control could have a positive or negative impact on achieving its targets. Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and such change could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Quarter 2021 - Realignment of Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2021, the Company began operating in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International, (iv) Ortho Dermatologics and (v) Diversified Products. The Bausch + Lomb segment consisted of the: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. The Salix segment consisted of the Salix reporting unit. The International segment consisted of the International (formerly International Rx) reporting unit. The Ortho Dermatologics segment consisted of the: (i) Ortho Dermatologics and (ii) Global Solta reporting units. The Diversified Products segment consisted of the: (i) Neurology and Other, (ii) Generics and (iii) Dentistry reporting units. This realignment in segment structure resulted in a change in the Company&#8217;s former International reporting unit, which was divided between the International Bausch + Lomb reporting unit and International reporting unit. In addition, as part of the realignment of segment structure, certain products historically included in the Generics reporting unit were included in the U.S. Bausch + Lomb reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of this realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. Goodwill previously reported in the former International reporting unit was reassigned to the International Bausch + Lomb and International reporting units, and a portion of goodwill previously reported in the former Generics reporting unit was reassigned to the U.S. Bausch + Lomb reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the change in reporting units, the Company performed a qualitative fair value assessment for its former: (i) International and (ii) Generics reporting units. Based on the qualitative fair value assessment performed, Management believed that it was more likely than not that the carrying values of its former: (i) International and (ii) Generics reporting units were less than their respective fair values and therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately following the change in reporting units, as a result of the change in composition of the net assets for its: (i) International Bausch + Lomb, (ii) International and (iii) Generics reporting units, the Company performed a quantitative fair value test. The quantitative fair value test utilized a range of long-term growth rates of 1.0% to 3.0% and a range of discount rates between 11.0% and 12.25%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than 40%, and, therefore, there was no impairment to goodwill. In addition, as the U.S. Bausch + Lomb reporting unit had a change in composition of its net assets related to certain products historically included in the Generics reporting unit now being included in the U.S. Bausch + Lomb reporting unit, the Company performed a qualitative assessment of this reporting unit. Based on the qualitative fair value assessment performed, Management believed that it was more likely than not that the carrying value of its current U.S. Bausch + Lomb reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Interim Goodwill Impairment Testing</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the interim periods of 2021, with the exception of the Ortho Dermatologics reporting unit, no events occurred, or circumstances changed that would indicate that the fair value of any other reporting unit might be below its carrying value and therefore, no impairments were recorded.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, management identified launches of certain Ortho Dermatologics products which were not going to achieve their trajectories as forecasted once the social restrictions associated with the COVID-19 pandemic began to ease in the U.S. and offices of health care professionals could reopen. In addition, insurance coverage pressures within the U.S. continued to persist limiting patient access to topical acne and psoriasis products. In light of these developments, during the first quarter of 2021, the Company began taking steps to: (i) redirect its R&amp;D spend to eliminate projects it had identified as high cost and high risk, (ii) redirect a portion of its marketing and product development outside the U.S. to geographies where there is better patient access and (iii) reduce its cost structure to be more competitive. As a result, during the three months ended March 31, 2021, the Company revised its long-term forecasts for the Ortho Dermatologics reporting unit. Management believed that these events were indicators that there was less headroom as of March 31, 2021 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2020). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed. The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the first quarter of 2021 to reflect the </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business changes previously discussed, including a range of potential outcomes, along with a long-term growth rate of 1.0% and a range of discount rates between 9.0% and 10.0%. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at March 31, 2021, and the Company recognized a goodwill impairment of $469&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Quarter 2021 - Realignment of Bausch + Lomb Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the second quarter of 2021, the Company changed the way it reviews the financial information of its Bausch + Lomb segment. Beginning in the second quarter of 2021, management no longer reviews the financial information of its Bausch + Lomb segment on a geographic basis, but instead reviews this financial information on a business line basis. This change created a change in the reporting units of the Bausch + Lomb segment. After the change, under its business line view, the Bausch + Lomb segment consisted of the global: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. Prior to the second quarter of 2021, under the geographic view, the Bausch + Lomb segment consisted of the former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. As a result of the realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. The change in Bausch + Lomb reporting units did not impact the reported revenues and segment profits of the Bausch + Lomb segment for any prior periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the change in its Bausch + Lomb reporting units, the Company performed a qualitative fair value assessment for its former reporting units. Based on the qualitative fair value assessment, management believed that it was more likely than not that the carrying values of its former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units were less than their respective fair values and, therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the change in composition of net assets, the Company performed a quantitative fair value test of its new: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units immediately following the change in the Bausch + Lomb segment. The quantitative fair value test utilized long-term growth rates of 2.0% and 3.0% and a range of discount rates between 7.0% and 10.0%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than 45%, and, therefore, there was no impairment to goodwill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Annual Goodwill Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2021 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2021, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2021, the Company considered, among other matters, the limited headroom as a result of the impairment to the goodwill of the Ortho Dermatologics reporting unit when last tested (March 31, 2021) and macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The Company believed that these facts and circumstances may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2021, utilizing a long-term growth rate of 1.0% and a discount rate of 9.0%, in estimation of the fair value of this reporting unit. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately 10% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Quarter 2022 - Realignment of Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2022, the Company began operating in the following reportable segments: (i) Salix, (ii) International, (iii) Diversified Products, (iv) Solta Medical and (v) Bausch + Lomb. The Salix segment consists of the Salix reporting unit. The International segment consists of the International reporting unit. The Diversified Products segment consists of the: (i) Neurology and Other, (ii) Generics, (iii) Ortho Dermatologics and (iv) Dentistry reporting units. The Solta Medical segment consists of the Solta reporting unit. The Bausch + Lomb segment consists of the: (i) Vision Care (formerly Vision Care / Consumer Products), (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. As such, the new segment structure does not impact the Company&#8217;s reporting units but realigns the two reporting units of the former Ortho Dermatologics segment whereby the Ortho Dermatologics reporting unit is now part of the current Diversified Products segment and the Solta reporting unit is now its own operating and reportable segment, and therefore management concluded that a quantitative fair value test was not required. See Note 19, &#8220;SEGMENT INFORMATION&#8221; for additional information.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">March 31, 2022 Interim Assessment of Goodwill</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, macroeconomic factors had impacted interest rates and the U.S. inflation rate was higher than previously expected. Given the limited headroom of the Ortho Dermatologics reporting unit as calculated on October 1, 2021, the Company believed that these facts and circumstances suggest the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the first quarter of 2022 and utilized a long-term growth rate of 1% and a discount rate of 9%. The discount rate contemplates changes in the current macroeconomic conditions noting certain inputs such as the risk free rate increased over the three months ended March 31, 2022, and was offset by decreases in other reporting unit specific risks during the same period. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was less than 2% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">June 30, 2022 Interim Assessment of Goodwill </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ortho Dermatologics</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to monitor the market conditions impacting the Ortho Dermatologics reporting unit. During the three months ended June 30, 2022, increases in interest rates and, to a lesser extent, higher than expected inflation in the U.S. and other macroeconomic factors impacted key assumptions used to value the Ortho Dermatologics reporting unit at March 31, 2022 (the last time goodwill of the Ortho Dermatologics reporting unit was tested). Given the limited headroom of the Ortho Dermatologics reporting unit as calculated on March 31, 2022, the Company believed that these facts and circumstances suggest the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the second quarter of 2022 which reflect current market conditions and current trends in business performance. The Company&#8217;s latest discounted cash flow model for the Ortho Dermatologics reporting unit includes a range of potential outcomes for, among other matters, macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The quantitative fair value test utilized a long-term growth rate of 1% and a discount rate of 10%. The discount rate has increased 1% since the assessment performed at March 31, 2022, as a result of changes in current macroeconomic conditions, including an increase in the risk free rate during the three months ended June 30, 2022. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at June 30, 2022, and the Company recognized a goodwill impairment of $83&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch + Lomb Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period May 6, 2022 (the time Bausch + Lomb&#8217;s stock began trading publicly) through June 30, 2022, equity and bond markets were negatively impacted by various macroeconomic and geopolitical factors including, but not limited to: rising inflation rates in the U.S. and abroad, uncertainties created by the Russia/Ukraine conflict, interest rate volatility, COVID-19 related lockdowns and supply issues. The decline in the equity markets negatively impacted the market price for Bausch + Lomb&#8217;s common stock which at June 30, 2022 was trading below its IPO offering price. The Company believed that these facts and circumstances suggest the fair value of the three reporting units of the Bausch + Lomb segment could be less than their respective carrying amounts. Therefore, separate quantitative fair value tests were performed for the Vision Care, Surgical and Ophthalmic reporting units of the Bausch + Lomb segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value tests utilized Bausch + Lomb&#8217;s most recent cash flow projections for each of the reporting units and utilized long-term growth rates of 2% and 3% and discount rates of 9.0% and 11.5%. After completing the testing, the fair value of each of these reporting units exceeded their respective carrying values by more than 25%, and, therefore, there was no impairment to goodwill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the interim periods of 2022, with the exception of the Ortho Dermatologics reporting unit and the reporting units of the Bausch + Lomb segment, no events occurred, or circumstances changed that would indicate that the fair value of any other reporting unit might be below its carrying value and therefore, no impairment to those reporting units was recorded. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated goodwill impairment charges through June&#160;30, 2022 were $4,263 million.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other events occurred or circumstances changed during the period October 1, 2021 (the last time goodwill was tested for all other reporting units) through June 30, 2022 that would indicate that the fair value of any reporting unit, other than the Ortho Dermatologics reporting unit, might be below its carrying value.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 80% of Salix segment&#8217;s revenue for the six months ended June 30, 2022, or $775&#160;million was derived from the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line. While the Company intends to appeal the Norwich Legal Decision (see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 18, &#8220;LEGAL PROCEEDINGS&#8221;), it is possible that this and other potential future developments, may adversely impact the estimated fair value of the Salix segment, in one or more future periods. Any such impairment could be material to the Company&#8217;s results of operations in the period in which it occurs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012038456208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED AND OTHER CURRENT LIABILITIES</a></td>
<td class="text">ACCRUED AND OTHER CURRENT LIABILITIES<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matters and related fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefit costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,311&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,791&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012042019872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">FINANCING ARRANGEMENTS</a></td>
<td class="text">FINANCING ARRANGEMENTS<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs consist of the following: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2018 Restated Credit Agreement</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2022 Amended Credit Agreement</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">B+L Credit Facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B+L Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B+L Term Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.125% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.75% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.875% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.125%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.00%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.50%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.00%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.25%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,056&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,814&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,870&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,664&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Covenant Compliance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities (as defined below), the B+L Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes (as defined and described in the table above) and Senior Unsecured Notes (as defined and described in the table above) contain customary affirmative and negative covenants and specified events of default. These affirmative and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company&#8217;s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. As of June&#160;30, 2022, the amount available for restricted payments under the &#8220;builder basket&#8221; in the Company&#8217;s most restrictive indentures (as defined by those indentures) was approximately $14,100&#160;million (although such availability is subject to the Company&#8217;s compliance with a 2.00:1.00 fixed charge coverage ratio). The 2027 Revolving Credit Facility (as defined below) also contains a financial </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">maintenance covenant that, requires the Company to maintain a first lien net leverage ratio of not greater than 4.00:1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast for the next twelve months from the date of issuance of these financial statements, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations over that same period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to take steps to improve its operating results to seek to ensure continual compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company&#8217;s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the 2018 Restated Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the &#8220;Senior Secured Credit Facilities&#8221; under the Company&#8217;s Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018 (the &#8220;2018 Restated Credit Agreement&#8221;) with a syndicate of financial institutions and investors as lenders. Prior to the 2022 Amended Credit Agreement (as defined below), the 2018 Restated Credit Agreement provided for a revolving credit facility of $1,225 million, maturing on the earlier of June 1, 2023 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and Bausch Health Americas, Inc. (&#8220;BHA&#8221;) in an aggregate principal amount in excess of $1,000 million (the &#8220;2023 Revolving Credit Facility&#8221;) and term loan facilities of original principal amounts of $4,565 million and $1,500 million, maturing in June 2025 (the &#8220;June 2025 Term Loan B Facility&#8221;) and November 2025 (the &#8220;November 2025 Term Loan B Facility&#8221;), respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the 2022 Amended Credit Agreement</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, the Company and certain of its subsidiaries as guarantors entered into a Second Amendment (the &#8220;Second Amendment&#8221;) to the Fourth Amended and Restated Credit and Guaranty Agreement (as amended by the Second Amendment, the &#8220;2022 Amended Credit Agreement&#8221;). The 2022 Amended Credit Agreement provides for a new term loan facility with an aggregate principal amount of $2,500&#160;million (the &#8220;2027 Term Loan B Facility&#8221;) maturing on February 1, 2027 and a new revolving credit facility of $975&#160;million (the &#8220;2027 Revolving Credit Facility&#8221;) that will mature on the earlier of February 1, 2027 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and BHA in an aggregate principal amount in excess of $1,000&#160;million. Borrowings under the 2027 Revolving Credit Facility can be made in U.S. dollars, Canadian dollars or Euros. After giving effect to the Second Amendment, the 2023 Revolving Credit Facility, June 2025 Term Loan B Facility and November 2025 Term Loan B Facility were refinanced (such refinancing, the &#8220;Credit Agreement Refinancing&#8221;), along with certain of the Company&#8217;s existing senior notes, using net proceeds from the borrowings under the 2027 Term Loan B Facility, the B+L IPO and the B+L Debt Financing (as defined below) and available cash on hand. As of June 30, 2022, the Company had drawn $425&#160;million on the 2027 Revolving Credit Facility. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2027 Term Loan B Facility bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) a forward-looking term rate determined by reference to the financing rate for borrowing U.S. dollars overnight collateralized by U.S. Treasury securities (&#8220;term SOFR rate&#8221;) for the interest period relevant to such borrowing</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or (b) a base rate determined by reference to the highest of: (i) the prime rate (as defined in the 2022 Amended Credit Agreement), (ii) the federal funds effective rate plus 1/2 of 1.00% and (iii) the term SOFR rate for a period of one month plus 1.00% (or if such rate shall not be ascertainable, 1.50%) (provided, however, that the term SOFR rate with respect to the 2027 Term Loan B Facility shall at no time be less than 0.50% per annum), in each case, plus an applicable margin. Borrowings under the 2027 Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) the term SOFR rate (provided, however, that the term SOFR rate with respect to the 2027 Revolving Credit Facility shall at no time be less than 0.00% per annum) or (b) a base rate determined by reference to the highest of: (x) the prime rate (as defined in the 2022 Amended Credit Agreement), (y) the federal funds effective rate plus 1/2 of 1.00% or (z) the term SOFR rate for a period of one month plus 1.00%, (ii) Canadian dollars bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) the bankers&#8217; acceptance rate for Canadian dollar deposits in the Toronto interbank market (the &#8220;BA rate&#8221;) for the interest period relevant to such borrowing (provided, however, that the BA rate shall at no time be less than 0.00% per annum) or (b) a prime rate determined by reference to the higher of: (x) the rate of interest last quoted by The Wall Street Journal as the &#8220;Canadian Prime Rate&#8221; or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (y) the one month BA rate calculated daily plus 1.00% (provided, however, that the prime rate shall at no time be less than 0.00% per annum) and (iii) euros bear interest at a rate per annum </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equal to a term benchmark rate determined by reference to the cost of funds for euro deposits (&#8220;EURIBOR&#8221;) for the interest period relevant to such borrowing (provided, however, that such rate, shall at no time be less than 0.00% per annum in each case, plus an applicable margin). Term SOFR rate loans are subject to a credit spread adjustment ranging from 0.10%-0.25%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margin for borrowings under the 2027 Term Loan B Facility is 5.25% for term SOFR rate loans and 4.25% for U.S. dollar base rate loans. The applicable interest rate margin for borrowings under the 2027 Revolving Credit Facility ranges from 4.75% to 5.25% for term SOFR rate loans, BA rate loans and EURIBOR loans and</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.75% to 4.25% for U.S. dollar base rate loans and Canadian prime rate loans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is required to pay commitment fees of 0.25%-0.50% per annum with respect to the unutilized commitments under the 2027 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on term SOFR rate borrowings under the 2027 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency fees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the 2022 Amended Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, and net proceeds thresholds), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the 2022 Amended Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the 2022 Amended Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights, and net proceeds thresholds). These mandatory prepayments may be used to satisfy future amortization. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for the 2027 Term Loan B Facility is 5.00% per annum, or $125&#160;million, payable in quarterly installments beginning on September 30, 2022. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of June 30, 2022, the remaining mandatory quarterly amortization payments for the 2027 Term Loan B Facility were $563&#160;million through December 2026.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Amended Credit Agreement permits the incurrence of incremental credit facility borrowings up to the greater of $1,000&#160;million and 40% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the 2022 Amended Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than 3.50:1.00, and, in the case of unsecured debt, either a total leverage ratio of not greater than 6.50:1.00 or an interest coverage ratio of not less than 2.00:1.00.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Amended Credit Agreement provides that Bausch + Lomb shall initially be a &#8220;restricted&#8221; subsidiary subject to the terms of the 2022 Amended Credit Agreement covenants, but does not require Bausch + Lomb to guarantee the obligations under the 2022 Amended Credit Agreement. The 2022 Amended Credit Agreement permits the Company to designate Bausch + Lomb as an &#8220;unrestricted&#8221; subsidiary under the 2022 Amended Credit Agreement and no longer subject to the terms of the covenants thereunder provided that no event of default is continuing or will result from such designation and the total leverage ratio of Remainco (as defined in the 2022 Amended Credit Agreement) will not be greater than 7.60:1.00 on a pro forma basis. The Credit Agreement Refinancing contains provisions designed to facilitate the B+L Separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the B+L Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, Bausch + Lomb entered into a credit agreement (the &#8220;B+L Credit Agreement&#8221;, and the credit facilities thereunder, the &#8220;B+L Credit Facilities&#8221;) providing for term loans of $2,500&#160;million with a five-year term to maturity (the &#8220;B+L Term Facility&#8221;) and a five-year revolving credit facility of $500&#160;million (the &#8220;B+L Revolving Credit Facility&#8221; and such financing, the &#8220;B+L Debt Financing&#8221;). The B+L Credit Facilities are secured by substantially all of the assets of Bausch + Lomb and its material, wholly-owned Canadian, U.S., Dutch and Irish subsidiaries, subject to certain exceptions. The term loans are denominated in U.S. dollars, and borrowings under the revolving credit facility will be made available in U.S. dollars, euros, pounds sterling and Canadian dollars. As of June 30, 2022, the B+L Revolving Credit Facility remains undrawn.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The B+L Revolving Credit Facility is a source of funding for Bausch + Lomb and its subsidiaries only. Absent the making of a dividend, which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to Bausch + Lomb&#8217;s shareholders, proceeds from the B+L Revolving Credit Facility are not available to fund the operations, investing and financing activities of Bausch Health.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Borrowings under the B+L Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either: (a) the term SOFR rate for the interest period relevant to such borrowing or (b) a base rate, determined by reference to the highest of: (i) the prime rate (as defined in the B+L Credit Agreement), (ii) the federal funds </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">effective rate plus 1/2 of 1.00% and (iii) the term SOFR rate for a period of one month plus 1.00% (or if such rate shall not be ascertainable, 1.00%) (provided, however, that the term SOFR rate with respect to the B+L Revolving Credit Facility shall at no time be less than 0.00% per annum), (ii) Canadian dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either: (a) the BA rate for the interest period relevant to such borrowing (provided, however, that the BA rate shall at no time be less than 0.00% per annum) or (b) prime rate determined by reference to the higher of: (x) the rate of interest last quoted by The Wall Street Journal as the &#8220;Canadian Prime Rate&#8221; or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (y) the one month BA rate calculated daily plus 1.00% (provided, however, that the prime rate shall at no time be less than 0.00% per annum), (iii) euros bear interest at a rate per annum equal to EURIBOR for the interest period relevant to such borrowing (provided, however, that such rate shall at no time be less than 0.00% per annum) and (iv) pounds sterling bear interest at a rate per annum equal to the effective overnight interest rate for unsecured transaction in the Sterling Overnight Index Average (&#8220;SONIA&#8221;) (provided, however, that such rate, shall at no time be no less than 0.00% per annum, in each case, plus an applicable margin. Term SOFR rate loans are subject to a credit spread adjustment of 0.10% and sterling loans are subject to a credit spread adjustment of 0.0326%.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for borrowings under the B+L Revolving Credit Facility are: (i) between 0.75% to 1.75% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between 1.75% to 2.75% with respect to term SOFR rate, EURIBOR, SONIA or BA rate borrowings based on Bausch + Lomb&#8217;s total net leverage ratio and (ii) after: (x) Bausch + Lomb&#8217;s senior unsecured non-credit-enhanced long term indebtedness for borrowed money receives an investment grade rating from at least two of S&amp;P, Moody&#8217;s and Fitch and (y) the B+L Term Loan Facility has been repaid in full in cash (the &#8220;IG Trigger&#8221;), between 0.015% to 0.475% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between 1.015% to 1.475% with respect to term SOFR rate, EURIBOR, SONIA or BA rate borrowings based on Bausch + Lomb&#8217;s debt rating. In addition, Bausch + Lomb is required to pay commitment fees of 0.25% per annum in respect of the unutilized commitments under the B+L Revolving Credit Facility, payable quarterly in arrears until the IG Trigger and a facility fee between 0.110% to 0.275% of the total revolving commitments, whether used or unused, based on Bausch + Lomb&#8217;s debt rating and payable quarterly in arrears. Bausch + Lomb is also required to pay letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on term SOFR rate borrowings under the B+L Revolving Credit Facility on a per annum basis, payable quarterly in arrears, as well as customary fronting fees for the issuance of letters of credit and agency fees. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the B+L Term Facility bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either (i) the term SOFR rate for the interest period relevant to such borrowing (provided, however, that the term SOFR rate with respect to the B+L Term Facility shall at no time be less than 0.50% per annum), plus an applicable margin of 3.25% or (ii) a base rate determined by reference to the highest of (x) the prime rate (as defined in the B+L Credit Agreement), (y) the federal funds effective rate plus 1/2 of 1.00% and (z) the term SOFR rate for a period of one month plus 1.00% (or if such rate shall not be ascertainable, 2.25%) (provided, however, that the base rate with respect to the B+L Term Facility shall at no time be less than 0.50% per annum), plus an applicable margin of 2.25%. Term SOFR rate loans are subject to a credit spread adjustment of 0.10%.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the B+L Credit Agreement, Bausch + Lomb is required to make mandatory prepayments of the loans under the B+L Term Facility under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the B+L Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the B+L Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for the B+L Term Facility is 1.00% per annum, or $25&#160;million, payable in quarterly installments beginning on September 30, 2022. Bausch + Lomb may direct that prepayments be applied to such amortization payments in order of maturity. As of June 30, 2022, the remaining mandatory quarterly amortization payments for the B+L Term Facility were $119&#160;million through March 2027. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Notes</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes are guaranteed by each of the Company&#8217;s subsidiaries that is a guarantor under the 2022 Amended Credit Agreement and existing Senior Unsecured Notes (together, the &#8220;Note Guarantors&#8221;). In connection with the closing of the B+L IPO, the redemption of the Company&#8217;s 6.125% Senior Unsecured Notes due 2025 (the &#8220;April 2025 Unsecured Notes&#8221; and the related indenture, the &#8220;April 2025 Unsecured Notes Indenture&#8221;) (as discussed below) and the related release in respect of the 2018 Restated Credit Agreement, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#8217;s obligations under the 2022 Amended Credit Agreement under the terms of the indentures governing the Senior Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#8217;s and Note Guarantors&#8217; respective existing and future unsubordinated indebtedness and senior to the Company&#8217;s and Note Guarantors&#8217; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pari passu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#8217;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#8217;s debt that is secured by assets that are not collateral.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#8217;s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">4.875% Senior Secured Notes due 2028 - June 2021 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, the Company issued $1,600&#160;million aggregate principal amount of 4.875% Senior Secured Notes due June 2028 (the &#8220;June 2028 Secured Notes&#8221;) in a private placement. The proceeds and cash on hand were used to: (i) repurchase a portion and redeem the remainder of $1,600&#160;million of 7.00% Senior Secured Notes due 2024 (the &#8220;March 2024 Secured Notes&#8221;), representing the remaining outstanding principal balance of the March 2024 Secured Notes and (ii) pay all fees and expenses associated with these transactions (collectively, the &#8220;June 2021 Refinancing Transactions&#8221;). The June 2021 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $38&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value. Interest on the June 2028 Secured Notes is payable semi-annually in arrears on each June 1 and December 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2028 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after June 1, 2024, at the redemption prices set forth in the June 2028 Secured Notes indenture. The Company may redeem some or all of the June 2028 Secured Notes prior to June 1, 2024 at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of the redemption plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to June 1, 2024, the Company may redeem up to 40% of the aggregate principal amount of the June 2028 Secured Notes using the net proceeds of certain equity offerings at the redemption price set forth in the June 2028 Secured Notes indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">6.125% Senior Secured Notes due 2027 - February 2022 Financing</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2022, the Company issued $1,000&#160;million aggregate principal amount of 6.125% Senior Secured Notes due February 2027 (the &#8220;February 2027 Secured Notes&#8221;). The proceeds from the February 2027 Secured Notes, along with proceeds from the B+L IPO, the 2027 Term Loans and the B+L Debt Financing and cash on hand, were used to redeem the April 2025 Unsecured Notes and the Credit Agreement Refinancing as discussed below. The February 2027 Secured Notes accrue interest at a rate of 6.125% per year, payable semi-annually in arrears on each February and August. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The February 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after February 2024, at the redemption prices set forth in the indenture. The Company may redeem some or all of the February 2027 Secured Notes prior to February 2024 at a price equal to 100% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. Prior to February 2024, the Company may redeem up to 40% of the aggregate principal amount of the February 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Unsecured Notes issued by the Company are the Company&#8217;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the 2022 Amended Credit Agreement. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the 2022 Amended Credit Agreement. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes. In connection with the closing of the B+L IPO, the discharge of the April 2025 Unsecured Notes Indenture and the related release in respect of the 2018 Restated Credit Agreement, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Redemption of April 2025 Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, the Company issued conditional notices of redemption to redeem: (i) all of the April 2025 Unsecured Notes conditioned upon the completion of the Credit Agreement Refinancing and (ii) $370&#160;million in aggregate principal amount of the Company&#8217;s outstanding 9.000% Senior Unsecured Notes due 2025 (the &#8220;December 2025 Unsecured Notes&#8221;) conditioned upon the receipt of aggregate proceeds of at least $7,000&#160;million from: (a) the B+L IPO, (b) the B+L Debt Financing, (c) the Credit Agreement Refinancing and (d) the issuance of the February 2027 Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of the B+L IPO, the conditions of the redemption of its April 2025 Unsecured Notes were satisfied and the Company discharged the April 2025 Unsecured Notes Indenture using: (i) the net proceeds from the issuance of the February 2027 Secured Notes, (ii) the net proceeds from the B+L IPO, (iii) the net proceeds from the borrowings under the B+L Debt Financing and (iv) cash on hand. On May 10, 2022, the Company caused sufficient funds for the redemption in full of its April 2025 Unsecured Notes at a redemption price of 101.021% of the principal amount then outstanding to be irrevocably deposited with the Bank of New York Mellon, N.A., as trustee under the April 2025 Unsecured Notes Indenture, and the April 2025 Unsecured Notes Indenture was discharged. The April 2025 Unsecured Notes were redeemed on May 16, 2022. The redemption was accounted for as an extinguishment of debt. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, the Company notified the Trustee and holders of its outstanding December 2025 Unsecured Notes that the conditions to its previously announced redemption would not be satisfied, and the conditional redemption was cancelled.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of the B+L IPO, the discharge of the April 2025 Unsecured Notes Indenture and the related release in respect of the 2018 Restated Credit Agreement as described above, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Stated Rate of Interest</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average stated rate of interest for the Company&#8217;s outstanding debt obligations as of June&#160;30, 2022 and December&#160;31, 2021 was 6.34% and 5.88%, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gain (Loss) on Extinguishment of Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022, the Company repurchased and retired, outstanding Senior Unsecured Notes with an aggregate par value of $481&#160;million in the open market, for an aggregate cost of $300&#160;million. In connection with these repurchases, the Company recognized a gain of $176&#160;million on extinguishment of debt which represents the differences between the amounts paid to settle the extinguished debt and its carrying value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the repayment of: (i) June 2025 Term Loan B Facility, (ii) November 2025 Term Loan B Facility, (iii) 2023 Revolving Credit Facility and (iv) redemption of April 2025 Unsecured Notes the Company incurred a loss on extinguishment of debt of $63&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may, from time to time, purchase outstanding debt for cash in open market purchases or privately negotiated transactions. Such repurchases or exchanges, if any, will depend on prevailing market conditions, future liquidity requirements, contractual restrictions and other factors. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of debt obligations for the remainder of 2022, the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.383%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,056&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized premiums, discounts and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(242)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,814&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012038318064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</a></td>
<td class="text">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which covers certain U.S. employees and employees in certain other countries. Net periodic (benefit) cost for the Company&#8217;s defined benefit pension plans and postretirement benefit plan for the six months ended June 30, 2022 and 2021 consists of: </span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.971%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.980%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Postretirement<br/>Benefit<br/>Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012122434064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text">SHARE-BASED COMPENSATION<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bausch Health&#8217;s Long-Term Incentive Plan</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2014, shareholders approved the Company&#8217;s 2014 Omnibus Incentive Plan (the &#8220;2014 Plan&#8221;) which replaced the Company&#8217;s 2011 Omnibus Incentive Plan (the &#8220;2011 Plan&#8221;) for future equity awards granted by the Company. The Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan was equal to 18,000,000 common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or surrendered under the 2011 Plan and the Company&#8217;s 2007 Equity Compensation Plan. The Company registered 20,000,000 common shares for issuance under the 2014 Plan. The 2014 Plan was amended and restated effective April 30, 2018 and April 28, 2020 to, among other things, increase the number of common shares authorized for issuance under the 2014 Plan. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective June 21, 2022, the Company further amended and restated the 2014 Plan, as subsequently amended and restated (the &#8220;Amended and Restated 2014 Plan&#8221;). Such amendment and restatement increased the number of common shares authorized for issuance under the Amended and Restated 2014 Plan by an additional 11,500,000 common shares, among other things.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 21,627,000 common shares were available for future grants under the Amended and Restated 2014 Plan as of June&#160;30, 2022. The Company uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with the Company&#8217;s focus on improving its tangible capital usage and allocation while maintaining focus on improving total shareholder return over the long-term. The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based restricted share units (&#8220;RSUs&#8221;) and performance-based RSUs. Performance-based RSUs are comprised of awards that: (i) vest upon achievement of certain share price appreciation conditions that are based on total shareholder return (&#8220;TSR&#8221;), (ii) vest upon attainment of certain performance targets that are based on the Company&#8217;s return on tangible capital (&#8220;ROTC&#8221;) and (iii) vest fully or partially upon attainment of certain goals that are linked to the B+L Separation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bausch + Lomb Long-Term Incentive Plan</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb participated in Bausch Health&#8217;s long-term incentive program prior to the establishment of the Bausch + Lomb Incentive Plan. Effective May 5, 2022, Bausch + Lomb established the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the &#8220;B+L Plan&#8221;). A total of 28,000,000 common shares of Bausch + Lomb are authorized under the B+L Plan. The B+L Plan provides for the grant of various types of awards including RSUs, stock appreciation rights, stock options, performance-based awards and cash awards. Under the Plan, the exercise price of awards, if any, is set on the grant date and may not be less than the fair market value per share on that date. Generally, stock options have a term of ten years and a three-year vesting period, subject to limited exceptions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2022, in connection with the B+L IPO, </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb granted certain awards to certain eligible recipients (the &#8220;IPO Founder Grants&#8221;). Eligible recipients are individuals employed by Bausch + Lomb or employed by an affiliate of Bausch + Lomb. Approximately 3,900,000 IPO Founder Grants were issued to </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb executive officers and were awarded 50% in the form of stock options and 50% in the form of RSUs. Additionally, </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb granted approximately 5,700,000 stock options and RSUs to non-executive eligible recipients, of which approximately 4,300,000 were IPO Founder Grants. The options have a three-year graded vesting period and the RSUs vest 50% in the second year and 50% in the third year after the grant. Vesting of the IPO Founder Grants are contingent on the completion of the B+L Separation and expense recognition will begin near the time of the B+L Separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 18,400,000 Bausch + Lomb common shares were available for future grants as of June&#160;30, 2022 under the B+L Plan. Bausch + Lomb uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components and classification of Bausch Health share-based compensation expenses related to stock options and RSUs for the three and six months ended June 30, 2022 and 2021: </span></div><div style="margin-bottom:6pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.447%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based awards granted for the six months ended June 30, 2022 and 2021 consist of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch Health Share-Based Awards</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,570,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,466,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time-based RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,680,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,861,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TSR performance-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROTC performance-based RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B+L Separation performance-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch+ Lomb Share-Based Awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,455,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,207,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the remaining unrecognized compensation expenses related to all outstanding non-vested stock options, time-based RSUs and performance-based RSUs under the Amended and Restated 2014 Plan amounted to $139 million, which will be amortized over a weighted-average period of 1.74 years.</span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the remaining unrecognized compensation expenses related to all outstanding non-vested stock options, time-based RSUs and performance-based RSUs under the B+L Plan amounted to $59&#160;million, which will be amortized over a weighted-average period of 1.77 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012122353040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">ACCUMULATED OTHER COMPREHENSIVE LOSS</a></td>
<td class="text">ACCUMULATED OTHER COMPREHENSIVE LOSS<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss consists of: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:69.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,990)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,905)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and postretirement benefit plan adjustments, net of income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,002)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,924)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company&#8217;s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company&#8217;s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the change in the Company&#8217;s ownership interest in Bausch + Lomb, the carrying amount of accumulated other comprehensive income was adjusted to reflect the change in the ownership interest in Bausch + Lomb through a corresponding credit of $137&#160;million to equity attributable to the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI https://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012038235936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">RESEARCH AND DEVELOPMENT</a></td>
<td class="text">RESEARCH AND DEVELOPMENT<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. Research and development costs consist of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product related research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI https://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012038113536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE, NET<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">OTHER EXPENSE, NET</a></td>
<td class="text">OTHER EXPENSE, NET<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net consists of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.340%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, Net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of assets, net for the six months ended June 30, 2021, includes $25&#160;million related to the achievement of a milestone related to a certain product.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI https://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI https://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012038180960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For interim financial statement purposes, U.S. GAAP income tax expense/benefit related to ordinary income is determined by applying an estimated annual effective income tax rate against a company&#8217;s ordinary income. Income tax expense/benefit related to items not characterized as ordinary income is recognized as a discrete item when incurred. The estimation of the Company&#8217;s income tax provision requires the use of management forecasts and other estimates, application of statutory income tax rates, and an evaluation of valuation allowances. The Company&#8217;s estimated annual effective income tax rate may be revised, if necessary, in each interim period.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Benefit from income taxes for the six months ended June 30, 2022 was $6 million and included: (i) $16&#160;million of income tax expense for the Company&#8217;s ordinary loss for the six months ended June 30, 2022 and (ii) $22 million of net income tax benefit for discrete items, which includes: (a) $39&#160;million of net income tax benefit recognized for changes in uncertain tax positions and (b) a $16&#160;million tax provision associated with filing certain tax returns.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefit from income taxes for the six months ended June 30, 2021 was $61 million and included: (i) $50 million of income tax benefit for the Company&#8217;s ordinary loss for the six months ended June 30, 2021 and (ii) $11&#160;million of net income tax provision for discrete items, which includes: (a) a $54&#160;million of net income tax benefit associated with certain legal settlements, (b) a $46&#160;million tax provision related to potential and recognized withholding tax on intercompany dividends, (c) a $7&#160;million tax benefit related to a deduction for stock compensation and (d) a $4&#160;million tax provision associated with the filing of certain tax returns. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made. The valuation allowance against deferred tax assets was $2,277 million and $2,222 million as of June&#160;30, 2022 and December&#160;31, 2021, respectively. The increase was primarily due to losses in Canada. The Company will continue to assess the need for a valuation allowance on an ongoing basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8, 2021, the Organisation for Economic Co-operation and Development (&#8220;OECD&#8221;)/G20 inclusive framework on Base Erosion and Profit Shifting (the &#8220;Inclusive Framework&#8221;) published a statement updating and finalizing the key </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">components of a two-pillar plan on global tax reform originally agreed on July 1, 2021, and a timetable for implementation by 2023. The timetable for implementation has since been extended to 2024. The Inclusive Framework plan has now been agreed to by 141 OECD members, including several countries which did not agree to the initial plan. Under pillar one, taxing rights over multinational businesses with global turnover above &#8364;20 billion and a profit margin above 10% will generally be re-allocated to market jurisdictions. Under pillar two, the Inclusive Framework has agreed on a global minimum corporate tax rate of 15% for companies with revenue above &#8364;750 million, calculated on a country-by-country basis. On October 30, 2021, the G20 formally endorsed the new global minimum corporate tax rate rules. The Inclusive Framework agreement must now be implemented by the OECD Members who have agreed to the plan, effective in 2023. On December 20, 2021, the OECD published model rules to implement the pillar two rules, which are generally consistent with agreements reached by the Inclusive Framework in October 2021. Some further guidance on the plan and rules has been published, with additional guidance expected to be published in 2023. The Company will continue to monitor the implementation of the Inclusive Framework agreement by the countries in which we operate. While the Company is unable to predict when and how the Inclusive Framework agreement will be enacted into law in these countries, it is possible that the implementation of the Inclusive Framework agreement, including the global minimum corporate tax rate could have a material effect on the Company&#8217;s liability for corporate taxes and the Company&#8217;s consolidated effective tax rate. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December&#160;31, 2021, the Company had $840 million and $927 million of unrecognized tax benefits, which included $44 million and $41 million of interest and penalties, respectively. Of the total unrecognized tax benefits as of June&#160;30, 2022, $179 million would reduce the Company&#8217;s effective tax rate, if recognized. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits at June&#160;30, 2022 could decrease by approximately $14 million in the next 12 months as a result of the resolution of certain tax audits and other events.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to be under examination by the Canada Revenue Agency. The Company&#8217;s position as of June&#160;30, 2022 with regard to proposed audit adjustments was updated to reflect an updated assessment received for 2015 which would primarily result in a loss of tax attributes that are subject to a full valuation allowance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Company undertook an internal restructuring in the form of what is commonly known as a Granite Trust transaction, which resulted in a recorded capital loss (the &#8220;2017 capital loss&#8221;). In the U.S., the 2014 tax year remains open to the extent of the portion of the 2017 capital loss carried back to that year. The Internal Revenue Service (&#8220;IRS&#8221;) is continuing its examination of the Company&#8217;s annual tax filings for 2015 and 2016 and the Company&#8217;s short period tax return for the period ended September 8, 2017, which was filed as a result of the Company&#8217;s internal restructuring efforts during 2017. In 2021, the Company received a notice of proposed adjustment from the IRS that would disallow the 2017 capital loss. The Company intends to contest any proposed tax deficiency through the IRS administrative appeals process, and if necessary, appropriate litigation. If the Company were ultimately unsuccessful in defending its position, and all or a substantial portion of the 2017 capital loss deduction were disallowed, the Company estimates, in a worst-case scenario, that it could be liable for additional income taxes (excluding penalties and interest) of up to $2,100&#160;million, which could have an adverse effect on the Company&#8217;s financial condition and results of operations. The Company intends to vigorously defend its position, including through appropriate litigation, if necessary, and ultimately believes it will sustain its deduction of the 2017 capital loss, and, accordingly, no income tax provision has been recorded. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2015 through 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries in Germany are under audit for tax years 2014 through 2016. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#8217;s Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company settled its audit with the Australian Taxation Office for various years beginning in 2011 through 2017 with no material adjustments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain affiliates of the Company in regions outside of Canada, the U.S., Germany and Australia are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#8217;s Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012038235936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSS PER SHARE</a></td>
<td class="text">LOSS PER SHARE<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share attributable to Bausch Health Companies Inc. were calculated as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.977%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.575%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(595)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,205)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362.2&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359.1&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.0&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to Bausch Health</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Companies Inc.</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.66)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.59)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.37)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2022 and 2021, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately 1,184,000 and 4,558,000 common shares for the three months ended June 30, 2022 and 2021, respectively, and approximately 2,392,000 and 5,608,000 common shares for the six months ended June 30, 2022 and 2021, respectively.</span></div>During the three and six months ended June 30, 2022, time-based RSUs, performance-based RSUs and stock options to purchase approximately 15,372,000 and 13,771,000 common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During the three and six months ended June 30, 2021, time-based RSUs, performance-based RSUs and stock options to purchase approximately 3,929,000 and 4,110,000 common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During the three months ended June 30, 2022, an additional 156,000 performance-based RSUs were not included in the computation of diluted earnings per share as the required performance conditions had not been met.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012038219968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">LEGAL PROCEEDINGS</a></td>
<td class="text">LEGAL PROCEEDINGS<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC and the CSA on February 23, 2022. Except as described below, there have been no material updates or developments with respect to any such proceedings or actions during the six months ended June 30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued. As of June 30, 2022, the Company&#8217;s Consolidated Balance Sheets includes accrued current loss contingencies of $1,536 million related to matters which are both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company&#8217;s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental and Regulatory Inquiries</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above, during the three months ended June 30, 2022, there have been no material updates or developments with respect to certain other proceedings or actions as described under &#8220;Governmental and Regulatory Inquiries&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC and the CSA on February 23, 2022. These matters include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation by the U.S. Attorney&#8217;s Office for the District of Massachusetts - re OraPharma</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company received a subpoena from the U.S. Attorney&#8217;s Office for the District of Massachusetts, requesting materials including documents concerning the sales, marketing, coverage and reimbursement of Arestin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including related support services, and other matters. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is cooperating with this investigation. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities and RICO Class Actions and Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation - Opt-Out Litigation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658). On January 31, 2021, the District Court issued an order granting final approval of this settlement. On February 4, 2021, Timber Hill LLC (&#8220;Timber Hill&#8221;) filed a notice of appeal of the Court&#8217;s final approval order, which overruled its objections to the allocation of settlement proceeds as between common stock and options. On March 1, 2021, Cathy Lochridge filed a notice of appeal of the Court&#8217;s final approval order, which overruled her objections as to the attorneys&#8217; fees awarded to class counsel. On October 14, 2021, Timber Hill dismissed its appeal of the final approval order. On December 20, 2021, the Third Circuit denied Lochridge&#8217;s appeal. On January 3, 2022, Lochridge filed a petition for rehearing of the appeal en banc. On May 12, 2022, the Third Circuit denied Lochridge&#8217;s petition for rehearing en banc. The deadline for Lochridge to file a petition for a writ of certiorari with the U.S. Supreme Court is August 10, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2015, four putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#8217;s business and prospects, including relating to drug pricing, the Company&#8217;s use of specialty pharmacies, and the Company&#8217;s relationship with Philidor Rx Services, LLC (&#8220;Philidor&#8221;). On May 31, 2016, the court entered an order consolidating the four actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658. On December 16, 2019, the Company, the current or former officers and directors, ValueAct, and the underwriters announced that they agreed to resolve the securities action for $1,210 million, subject to final court approval. This settlement received final approval from the court on January 31, 2021 and will resolve and discharge all claims against the Company in the class action. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. The settlement remains subject to appeal of the final court approval (as such appeal is further described above). In order to qualify for a settlement payment all persons and entities that purchased or otherwise acquired the Company securities during the class period must have submitted a proof of claim and release form by May 6, 2020. The settlement payments have been paid into an escrow account in accordance with the payment schedule outlined in the settlement agreement. These payments, less certain settlement expenses and attorneys&#8217; fees, will remain in escrow until resolution of the appeal of the final court approval of the settlement agreement. The opt-out litigations discussed below remain ongoing. As of June 30, 2022, Restricted cash and other settlement deposits includes an aggregate $1,210&#160;million of: (i) payments in the escrow fund and (ii) certain disbursements for settlement expenses and attorney&#8217;s fees. Disbursements for attorney&#8217;s fees remain refundable until resolution of the appeal of the final court approval of the settlement agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 18-cv-10246), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company&#8217;s common stock during the period January 4, 2013 through August 11, 2016. On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 15-cv-07658). On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the consolidated putative class action, thirty-seven groups of individual investors in the Company&#8217;s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. These actions were captioned previously in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on February 23, 2022. Sixteen of the thirty-seven opt-out actions have been dismissed; and the total number of remaining opt-out actions pending in the District of New Jersey is twenty-one actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These individual shareholder actions assert claims under Sections 10(b), and 20(a) of the Exchange Act. Certain of these individual actions assert additional claims, including claims under Section 18 of the Exchange Act, Sections 11, 12(a)(2), and 15 of the Securities Act, common law fraud, negligent misrepresentation, and claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act. These claims are based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss were filed in many of these individual actions and the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud, and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) opt-out action, closing the case. On September 10, 2019, the Court granted defendants&#8217; motion to dismiss all claims in the Bahaa Aly v. Valeant Pharmaceuticals International, Inc. (&#8220;Aly&#8221;) (Case No. 18-cv-17393) opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. On June 16, 2021, the Court of Appeals granted plaintiffs&#8217; appeal in the Aly action. This action has been remanded to the District Court. On June 19, 2020, the Court entered stipulations of voluntary dismissal in the Catalyst, Mississippi, Connecticut, and Delaware actions. On July 13, 2020, the Court entered a stipulation of voluntary dismissal in the NYCERS action. On December 30, 2020, the Court entered a stipulation of voluntary dismissal in the BlueMountain action. On February 18, 2021, and March 10, 2021, the Court entered stipulations of voluntary dismissal in the T. Rowe, BloombergSen, Principal Funds, Pentwater, Lord Abbett, Equity Trustees, and UC Regents actions. On April 30, 2021, the Court entered a stipulation of voluntary dismissal in the Florida SBA action. On July 20, 2021, the Court entered a stipulation of voluntary dismissal in the Janus action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery in the opt-out actions has concluded. Motions for summary judgment were filed on August 1, 2022 but have not yet been fully briefed. Trial dates have not been set in any of the opt-out actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it in the remaining individual opt-out complaints and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canadian Securities Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, six putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec. The Company is also aware of two additional putative class actions that were filed with the applicable court but which have not been served on the Company and the factual allegations made in these actions are substantially similar to those outlined herein. These actions were captioned previously in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on February 23, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these putative class actions, other than the Catucci action in the Quebec Superior Court, was discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec Securities Act and authorized the class proceeding. On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a hearing on November 11, 2019, the court approved a settlement in the Catucci action between the class members and the Company&#8217;s auditors and the action was dismissed as against them. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2020, the Company entered into a settlement agreement with the plaintiffs in Catucci, on behalf of the class, pursuant to which it agreed to resolve the Catucci action for the amount of CAD 94,000,000 plus payment of an additional amount to cover notice and settlement administration costs and disbursements. As part of the settlement, the Company and the other defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. Court approval of the settlement was granted after a hearing on November 16, 2020. The Catucci action has now been dismissed against the Company, its current and former directors and officers, its underwriters and its insurers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action. On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, one of the entities which exercised its opt-out rights, the California State Teachers&#8217; Retirement System (&#8220;CalSTRS&#8221;), served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers&#8217; Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt-out proceedings. On that same date, CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2020, the Quebec Superior Court granted the applications of CalSTRS and BlackRock for leave to pursue their respective actions asserting claims under the Quebec Securities Act. On June 16, 2020, the Quebec Court of Appeal granted the defendants leave to appeal that decision. The appeal was heard on September 29, 2021 and, by judgment dated October 29, 2021, the appeals were dismissed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8 and 9, 2020, respectively, CalSTRS amended its proceedings to, among other things, include a new alleged misrepresentation concerning the accounting treatment of &#8220;price appreciation credits&#8221; in respect of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the period covered by the claims. A hearing was held on February 17, 2021 with respect to whether CalSTRS would be permitted to file the proposed amended proceedings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2021, the Quebec Superior Court granted the Company&#8217;s application to strike the new allegations from its Quebec Securities Act claim, but permitted the amendments to its claim under the Quebec Civil Code. On December 8, 2021, CalSTRS delivered its amended pleadings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2021, four additional opt-outs from the Catucci class issued a Statement of Claim in the Ontario Superior Court of Justice. That proceeding is captioned The Bank of Korea et al. v. Valeant Pharmaceuticals International Inc. et al. (Court File No. 21-006589666-0000). In addition, these plaintiffs also served and filed a motion for leave to pursue claims under the Ontario Securities Act. The allegations in this proceeding are similar to those made by the plaintiffs in the Catucci class action and the plaintiffs in the opt-out actions described above. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Securities and RICO Class Actions and Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above, during the three months ended June 30, 2022, there have been no material updates or developments with respect to certain other proceedings or actions as described under &#8220;Securities and RICO Class Actions and Related Matters&#8221; in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC and the CSA on February 23, 2022. Such matters include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RICO Class Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between May 27, 2016 and September 16, 2016, three actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties (these actions were subsequently consolidated), alleging claims under the federal Racketeer Influenced Corrupt Organizations Act (&#8220;RICO&#8221;) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company-branded drugs between January 2, 2013 and November 9, 2015.&#160;The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding: (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured&#8217;s consent to renew the prescription.&#160;The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute.&#160;On August 4, 2021, the Company executed a stipulation of settlement for this action and, on August 17, 2021, the Court preliminarily approved the settlement. On December 6, 2021 the Special Master overseeing this litigation issued a report and recommendation recommending final approval of the settlement, and on February 22, 2022 the settlement was approved by the district court. The time to appeal the district court&#8217;s final approval order expired on March 24, 2022, and the settlement has resolved and discharged all claims against the Company in this action. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Coverage Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during two distinct policy periods, (i) 2013-14 and (ii) 2015-16. The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; Case No. 3:18-CV-00493). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the lawsuit, the Company seeks coverage for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (the &#8220;Allergan Securities Litigation&#8221;) (under the 2013-2014 coverage period) and (ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and the SEC Investigation and certain of the other investigations described under &#8220;Complete or Inactive Matters&#8221; in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021 and under &#8220;Governmental and Regulatory Inquiries&#8221; and &#8220;Complete or Inactive Matters&#8221; in Note 21, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC and the CSA on February 19, 2020 (under the 2015-2016 coverage period).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021, the Company entered into settlement agreements with the insurers in the 2015-2016 coverage period in which the Company agreed to resolve its claims for insurance coverage in connection with the U.S. Securities Litigation and the Canadian Securities Litigation and related opt-out litigation and related investigations matters described above. On that same day, the Company entered into settlement agreements with two of its insurers in the 2013-2014 coverage period in which the Company agreed to resolve its claims against those two insurers only for insurance coverage in connection with the Allergan Securities Litigation. As a result of all of the settlement agreements entered into with the insurers on July 20, 2021, the Company has received an aggregate sum of $213&#160;million. The Company&#8217;s insurance claims with respect to the Allergan Securities Litigation against the remaining insurers in the 2013-2014 coverage period remain pending.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Hound Partners Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP, and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County that asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. The Company disputes the claims and intends to vigorously defend this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between August 2019 and July 2020, eight (8) putative antitrust class actions and four (4) non-class complaints naming the Company, Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., and Santarus, Inc. (for purposes of this subsection, collectively, the &#8220;Company&#8221;), among other defendants, were filed or transferred to the Northern District of California. Three (3) of the class actions were filed by plaintiffs seeking to represent a class of direct purchasers. The purported classes of direct purchasers filed a consolidated first amended complaint and a motion for class certification in April 2020. The court certified a direct purchaser class in August 2020. The putative class action complaints filed by end payer purchasers have all been voluntarily dismissed. Three (3) of the non-class complaints were filed by direct purchasers. The fourth non-class complaint, asserting claims based on both direct and indirect purchases, was filed by an insurer plaintiff in July 2020 and subsequently amended in September 2020. In December 2020, the court denied the Company&#8217;s motion to dismiss as to the insurer plaintiff&#8217;s direct claims but dismissed the insurer plaintiff&#8217;s indirect claims. On February 2, 2021, the insurer plaintiff&#8217;s motion for leave to amend its complaint was denied.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These actions were consolidated and coordinated in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822-WHA (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The lawsuits alleged that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or grant any other company a license to do so. The complaints alleged that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. Both the class and non-class plaintiffs sought damages under federal antitrust laws for claims based on direct purchases.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2021, the insurer plaintiff filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#8220;State Court Action&#8221;) (discussed in further detail below, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see Glumetza State-Law Insurer Litigations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Defendants&#8217; demurrer in the State Court Action was heard on September 22, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 26, 2021, the Company reached an agreement in principle and, thereafter, on September 14, 2021, executed a final settlement agreement to resolve the class plaintiffs&#8217; claims for $300&#160;million, subject to court approval. On August 1, 2021, the Company also reached an agreement in principle to resolve the non-class direct purchaser plaintiffs&#8217; claims, described above, for additional consideration. A final settlement agreement with the non-class direct purchaser plaintiffs was executed on August 6, 2021. As part of the settlements, the Company admitted no liability as to the claims against it and denied all allegations of wrongdoing. On September 20, 2021, the insurer plaintiff voluntarily dismissed its claims in the consolidated </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">federal action. By stipulation, the insurer plaintiff has asserted its direct opt-out claims in the State Court Action, resulting in the consolidation of all of its opt-out claims in the State Court Action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 22, 2021, the court granted preliminary approval of the class settlement agreement and vacated the October 2021 trial date and all other pre-trial deadlines in the consolidated actions. On February 3, 2022, the court granted final approval of the class settlement and ordered dismissal of the class plaintiffs&#8217; claims. The deadline to appeal the final approval of the class settlement has now passed, and the settlements have resolved and discharged all asserted class and direct purchaser non-class claims against the Company in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pricing Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries, Oceanside Pharmaceuticals, Inc. (&#8220;Oceanside&#8221;), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (&#8220;Bausch Health US&#8221;), and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (&#8220;Bausch Health Americas&#8221;) (for the purposes of this paragraph, collectively, the &#8220;Company&#8221;), are defendants in multidistrict antitrust litigation (&#8220;MDL&#8221;) entitled In re: Generic Pharmaceuticals Pricing Antitrust Litigation, pending in the United States District Court for the Eastern District of Pennsylvania (MDL 2724, 16- MD-2724). The lawsuits seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company&#8217;s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals. The lawsuits, which have been brought as putative class actions by direct purchasers, end payers, and indirect resellers, and as direct actions by direct purchasers, end payers, insurers, States, and various Counties, Cities, and Towns, have been consolidated into the MDL. There are also additional, separate complaints which have been consolidated in the same MDL that do not name the Company or any of its subsidiaries as a defendant. There are cases pending in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed in the cases. The cases have been placed in deferred status. The Company disputes the claims against it and continues to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Bausch Health Companies Inc. and certain U.S. and Canadian subsidiaries (for the purposes of this paragraph, collectively the &#8220;Company&#8221;) have been named as defendants in a proposed class proceeding entitled Kathryn Eaton v. Teva Canada Limited, et al. in the Federal Court in Toronto, Ontario, Canada (Court File No. T-607-20). The plaintiff seeks to certify a proposed class action on behalf of persons in Canada who purchased generic drugs in the private sector, alleging that the Company and other defendants violated the Competition Act by conspiring to allocate the market, fix prices, and maintain the supply of generic drugs, and seeking damages under federal law. The proposed class action contains similar allegations to the In re: Generic Pharmaceuticals Pricing Antitrust Litigation pending in the United States Court for the Eastern District of Pennsylvania. The Company disputes the claims against it and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These lawsuits cover products of both Bausch + Lomb and the Company&#8217;s businesses. It is anticipated that Bausch + Lomb and the Company will split the fees and expenses associated with defending these claims, as well as any potential damages or other liabilities awarded in or otherwise arising from these claims, in the manner set forth in the Master Separation Agreement between Bausch Health and Bausch + Lomb.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza State-Law Insurer Litigations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2021, the insurer plaintiff from the federal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822- WHA (N.D. Cal.) (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) (discussed in further detail above) filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#8220;State Court Action&#8221;). The State Court Action alleges that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or grant any other company a license to do so. The State Court Action alleges that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. On September 20, 2021, the parties stipulated that the insurer plaintiff&#8217;s direct opt-out claims from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, discussed above, were deemed asserted in the State Court Action. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defendants&#8217; demurrer in the State Court Action was heard on September 22, 2021. On November 29, 2021, the court denied the motion in part and granted it in part as to certain state law claims, with leave to amend. The insurer plaintiff did not amend the complaint. Defendants&#8217; answers were filed on February 3, 2022. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 5, 2022, Health Care Service Corporation filed an action with similar substantive allegations and similar indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others. Defendants&#8217; answers were filed on June 17, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims and intends to vigorously defend these matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation/Paragraph IV Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company (and/or certain of its affiliates) is also party to certain patent infringement proceedings in the United States and Canada, including as arising from claims filed by the Company (or that the Company anticipates filing within the required time periods) in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers respecting their pending applications for generic versions of certain products sold by or on behalf of the Company, including Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 550mg, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Injection, Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Nuvessa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Canada, or other similar suits.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2020, the Company and Alfasigma S.p.A. (&#8220;Alfasigma&#8221;) received a Notice of Paragraph IV Certification from Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;), in which Norwich asserted that the U.S. patents listed in the FDA&#8217;s Orange Book for the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Norwich&#8217;s generic rifaximin tablets, 550 mg, for which an Abbreviated New Drug Application (&#8220;ANDA&#8221;) has been filed by Norwich. The Company, through its subsidiaries Salix Pharmaceuticals, Inc. and Bausch Health Ireland Limited, holds the New Drug Application for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and owns or exclusively licenses (from Alfasigma) these patents.&#160;On March 26, 2020, certain of the Company&#8217;s subsidiaries and Alfasigma filed suit against Norwich in the U.S. District Court for the District of Delaware (Case No. 20-cv-00430) pursuant to the Hatch-Waxman Act, alleging infringement by Norwich of one or more claims of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of Norwich&#8217;s ANDA for rifaximin tablets, 550 mg. Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is protected by 26 patents covering the composition of matter and the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange&#160;Book. Trial in this matter was held in March 2022. The court issued an Oral Order on July 28, 2022 indicating that the court will find certain U.S. Patents protecting the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets for the reduction in risk of hepatic encephalopathy (&#8220;HE&#8221;) recurrence valid and infringed and U.S. Patents protecting the composition, and use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for treating inflammatory bowel syndrome with diarrhea (&#8220;IBS-D&#8221;) invalid (the &#8220;Norwich Legal Decision&#8221;). The Company remains confident in the strength of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to appeal the court&#8217;s decision and vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (now Padagis LLC) (&#8220;Padagis&#8221;), in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotene) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#8217; generic lotion, for which an ANDA has been filed by Padagis. On August 28, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described below, regarding Padagis&#8217; ANDA for generic Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion. The court scheduled a trial to begin on October 4, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company received a Notice of Paragraph IV Certification from Taro Pharmaceuticals Inc. (&#8220;Taro&#8221;), in which Taro asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotene) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use, sale, offer for sale, or importation of Taro&#8217;s generic lotion, for which an ANDA has been filed by Taro. On July 21, 2022, the Company filed suit against Taro pursuant to the Hatch-Waxman Act, alleging infringement by Taro of one or more claims of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents and triggering a 30-month stay of the approval of the Taro ANDA. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains confident in the strength of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Padagis, in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#8217; generic halobetasol propionate lotion, for which an ANDA has been filed by Padagis. On May 1, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA for halobetasol propionate lotion. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described above, regarding Padagis&#8217; ANDA for generic Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotene) lotion. The court scheduled a trial to </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">begin on October 4, 2022. The Company remains confident in the strength of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company commenced litigation against MSN Laboratories Private Ltd. (&#8220;MSN&#8221;) and Mylan Pharmaceuticals Inc., (&#8220;Mylan&#8221;) alleging patent infringement by MSN&#8217;s and Mylan&#8217;s filing of their ANDA for generic Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) 3mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from each of MSN and Mylan, in which they had each asserted that the U.S. patents listed in the FDA&#8217;s Orange Book for the Company&#8217;s Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 3 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of their respective generic plecanatide tablets, 3 mg. The filing of these suits triggered a 30-month stay of the approval of the MSN and Mylan ANDAs for plecanatide tablets. The Company remains confident in the strength of the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> AREDS Patent Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AREDS and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AREDS 2 are over the counter eye vitamin formulas for those with moderate-to-advanced age-related degeneration (&#8220;AMD&#8221;). The PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> U.S. formulation patent expired in March 2021, but a patent covering methods of using the formulation remains in force into 2026. Bausch + Lomb Incorporated (&#8220;B&amp;L Inc.&#8221;) has filed patent infringement proceedings against 16 defendants claiming infringement of these patents and, in certain circumstances, related unfair competition and false advertising causes of action. Twelve of these proceedings were subsequently settled; two resulted in a default. One defendant filed a declaratory judgment action after B&amp;L Inc. filed its suit, seeking declaratory judgment related to patent claims as well as false advertising and unfair competition claims. As of the date of this filing, there are two ongoing actions: (1) Bausch &amp; Lomb Inc. &amp; PF Consumer Healthcare 1 LLC v. ZeaVision LLC, C.A. No. 6:20-cv-06452-CJS (W.D.N.Y.); and (2) Bausch &amp; Lomb Inc. &amp; PF Consumer Healthcare 1 LLC v. SBH Holdings LLC, C.A. No. 20-cv-01463-VAC-CJB (D. Del.). Bausch + Lomb remains confident in the strength of these patents and B&amp;L Inc. intends to continue to vigorously pursue these matters and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation against Certain Ocuvite and PreserVision </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2021, ZeaVision, LLC (&#8220;ZeaVision&#8221;) filed a complaint for patent infringement against certain of the Ocuvite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products in the Eastern District of Missouri (Case No. 4:21-cv-00739-RWS). On June 29, 2021, ZeaVision amended its complaint to assert a second patent against certain of the Ocuvite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products. On November 16, 2021, ZeaVision filed an additional complaint for patent infringement to assert a third patent against certain of the PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products (Case No. 4:21-cv-01352-RWS). On March 1, 2022, the cases were consolidated. On March 10, 2022, the court granted Bausch + Lomb&#8217;s motion to stay all proceedings pending inter partes review. On July 1, 2022, ZeaVision filed a motion to partially lift the stay to allow Case No. 4:21-cv-01352-RWS to proceed, and Bausch + Lomb opposed the motion. The Company disputes the claims and intends to vigorously defend this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2021, B&amp;L Inc. received a Notice of Paragraph IV Certification from Slayback Pharma LLC (&#8220;Slayback&#8221;), in which Slayback asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brimonidine tartrate solution) drops (the &#8220;Lumify Patents&#8221;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Slayback&#8217;s generic drops, for which an ANDA has been filed by Slayback. B&amp;L Inc., through its affiliate Bausch + Lomb Ireland Limited, exclusively licenses the Lumify Patents from Eye Therapies, LLC (&#8220;Eye Therapies&#8221;). On September 10, 2021, B&amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Slayback pursuant to the Hatch-Waxman Act, alleging infringement by Slayback of one or more claims of the Lumify Patents, thereby triggering a 30-month stay of the approval of the Slayback ANDA.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2022, B&amp;L Inc. received a Notice of Paragraph IV Certification from Lupin Ltd. (&#8220;Lupin&#8221;), in which Lupin asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brimonidine tartrate solution) drops (the &#8220;Lumify Patents&#8221;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Lupin&#8217;s generic brimonidine tartrate solution, for which its ANDA No. 216716 has been filed by Lupin. On February 2, 2022, B&amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Lupin pursuant to the Hatch-Waxman Act, alleging patent infringement by Lupin of one or more claims of the Lumify Patents, thereby triggering a 30-month stay of the approval of the Lupin ANDA.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B&amp;L Inc. remains confident in the strength of the Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related patents and B&amp;L Inc. intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Parties Review Proceedings at the U.S. Patent and Trademark Office</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patents covering the Company&#8217;s branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review (&#8220;IPR&#8221;) at the U.S. Patent &amp; Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution. IPR challenges have been brought against patents covering the Company&#8217;s branded pharmaceutical products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following Acrux DDS&#8217;s IPR petition, the U.S. Patent and Trial Appeal Board (&#8220;PTAB&#8221;), in May 2017, instituted inter partes review for an Orange Book-listed patent covering Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (U.S. Patent No. 7,214,506 (the &#8220;&#8216;506 Patent&#8221;)) and, on June 6, 2018, issued a written determination invalidating such patent. An appeal of this decision was filed on August 7, 2018. On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings. As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion. The &#8216;506 Patent, therefore, remains valid and enforceable and expires in 2026. Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is covered by sixteen Orange Book-listed patents owned by the Company or its licensor, which expire in the years 2028 through 2035. In August and September 2018, the Company received notices of the filing of a number of ANDAs with paragraph IV certification, and has timely filed patent infringement suits against these ANDA filers, and, in addition, the Company has also commenced certain patent infringement proceedings in Canada against four separate defendants. All cases in U.S. regarding Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been settled. In Canada, two lawsuits remain pending against Apotex Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mylan has filed IPR petitions for certain U.S. patents listed in the FDA Orange Book for Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide). On March 21, 2022, Mylan filed a petition for IPR of U.S. Patent No. 7,041,786. On June 10, 2022, Mylan filed petitions for IPR of U.S. Patent Nos. 9,610,321, 9,616,097, 9,919,024, and 9,925,231. The Company remains confident in the strength of these patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Products Liability Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2016, the Company has been named in a number of product liability lawsuits involving the Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> body powder product acquired in September 2012 from Johnson &amp; Johnson; due to dismissals, twenty-nine (29) of such product liability suits currently remain pending. In three (3) cases pending in the Atlantic County, New Jersey Multi-County Litigation, agreed stipulations of dismissal have been entered by the Court, thus dismissing the Company from those cases. Potential liability (including its attorneys&#8217; fees and costs) arising out of these remaining suits is subject to full indemnification obligations of Johnson &amp; Johnson owed to the Company and its affiliates, and legal fees and costs will be paid by Johnson &amp; Johnson. Twenty-eight (28) of these lawsuits filed by individual plaintiffs allege that the use of Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> caused the plaintiffs to develop ovarian cancer, mesothelioma or breast cancer. The allegations in these cases include failure to warn, design defect, manufacturing defect, negligence, gross negligence, breach of express and implied warranties, civil conspiracy concert in action, negligent misrepresentation, wrongful death, loss of consortium and/or punitive damages. The damages sought include compensatory damages, including medical expenses, lost wages or earning capacity, loss of consortium and/or compensation for pain and suffering, mental anguish anxiety and discomfort, physical impairment and loss of enjoyment of life. Plaintiffs also seek pre- and post-judgment interest, exemplary and punitive damages, and attorneys&#8217; fees. Additionally, two proposed class actions have been filed in Canada against the Company and various Johnson &amp; Johnson entities (one in the Supreme Court of British Columbia and one in the Superior Court of Quebec), on behalf of persons who have purchased or used Johnson &amp; Johnson&#8217;s Baby Powder or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The class actions allege the use of the product increases certain health risks (British Columbia) or negligence in failing to properly test, failing to warn of health risks, and failing to remove the products from the market in a timely manner (Quebec). The plaintiffs in these actions are seeking awards of general, special, compensatory and punitive damages. On November 17, 2020, the British Columbia court issued a judgment declining to certify a class as to the Company or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and at this time no appeal of that judgment has been filed. </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2021, the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plaintiff in the British Columbia class action filed a Second Amended Notice of Civil Claim and Application</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for Certification, removing the Company as a defendant; as a result, the British Columbia class action is concluded</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as to the Company.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson, through one or more subsidiaries, has purported to have completed a Texas divisional merger with respect to any talc liabilities at Johnson &amp; Johnson Consumer, Inc. (&#8220;JJCI&#8221;). LTL Management, LLC (&#8220;LTL&#8221;), the resulting entity of the divisional merger, assumed JJCI&#8217;s talc liabilities and thereafter filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the Western District of North Carolina. Pursuant to court orders entered in November 2021, the case was transferred to the United States District Court for the District of New Jersey (the &#8220;Bankruptcy Court&#8221;), and substantially all cases related to Johnson &amp; Johnson&#8217;s talc liability were stayed for a period of sixty (60) days pursuant to a preliminary injunction. Notwithstanding the divisional merger and LTL&#8217;s bankruptcy case, the Company and its affiliates continue to have indemnification claims and rights against Johnson &amp; Johnson and LTL pursuant to the terms of the indemnification agreement entered into between JJCI and its affiliates and the Company and its affiliates, which indemnification agreement remains in effect. As a result, it is the Company&#8217;s current expectation that it will not incur any material impairments with respect to its indemnification claims as a result of the divisional merger or the bankruptcy. In </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 2021, certain talc claimants filed motions to dismiss the bankruptcy case. Shortly thereafter, LTL filed a motion in the Bankruptcy Court to extend the 60-day preliminary injunction. On February 25, 2022, the Bankruptcy Court entered orders denying the motions to dismiss and extending the preliminary injunction staying substantially all cases subject to the indemnification agreement related to Johnson &amp; Johnson&#8217;s talc liability through at least June 29, 2022. The order denying the motions to dismiss and the order extending the preliminary injunction are subject to appeal and the bankruptcy court certified their appeals directly to the United States Court of Appeals for the Third Circuit. On May 11, 2022, the Third Circuit granted authorization for the parties to proceed with their direct appeals and on June 24, 2022, set an expedited briefing schedule to conclude on September 6, 2022. Further, pursuant to a court order dated March 18, 2022, the Bankruptcy Court directed certain talc claimants and LTL to mediate the issues related to the case in the hopes of achieving a global resolution. The Bankruptcy Court has also ordered separate mediation with respect to certain consumer protection claims against LTL by various state attorneys general. On May 4, 2022, the Bankruptcy Court extended LTL&#8217;s exclusive period to file a chapter 11 plan until September 9, 2022, which the talc claimants have challenged by filing a motion to terminate the exclusivity period and requesting a hearing on such motion for September 14, 2022. On July 26, 2022, the Bankruptcy Court held a hearing to consider alternative paths to case resolution, and on July 28, 2022, authorized an abbreviated estimation process designed to determine the extent of the debtor&#8217;s aggregate liability. Additionally, the Bankruptcy Court identified its proposed independent expert who will issue a report forecasting and estimating the volume and value of claims. Thereafter, the Bankruptcy Court will direct the parties to reconvene for mediation. On July 28, 2022, the Bankruptcy Court also ruled that it would leave in place the stay and injunction enjoining talc product liability cases from proceeding until at least the completion of the estimation process. Following the Bankruptcy Court&#8217;s July 28 ruling, on August 2, 2022, LTL filed a motion to extend its exclusivity period until 30 days after the issuance of the independent expert&#8217;s report, with a hearing on such motion requested for August 23, 2022. To the extent that any cases proceed during the pendency of the bankruptcy case, it is the Company&#8217;s expectation that Johnson &amp; Johnson, in accordance with the indemnification agreement, will continue to vigorously defend the Company in each of the remaining actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation - New Jersey Declaratory Judgment Lawsu</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">it</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 24, 2022, the Company and Bausch + Lomb were named in a declaratory judgment action in the Superior </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Court of New Jersey, Somerset County, Chancery Division, brought by certain individual investors in the Company&#8217;s common shares and debt securities who are also maintaining individual securities fraud claims against the Company and certain current or former officers and directors as part of the U.S. Securities Litigation. This newly filed action seeks a declaratory judgment that the transfer of the Company assets to Bausch + Lomb would constitute a voidable transfer under New Jersey&#8217;s Uniform Voidable Transactions Act and that Bausch + Lomb would become liable for damages awarded against the Company in the individual opt-out actions. The declaratory judgment action alleges that a transfer of assets from the Company to Bausch + Lomb would leave the Company with inadequate financial resources to satisfy these plaintiffs&#8217; alleged securities fraud damages in the underlying individual opt-out actions. None of the plaintiffs in this declaratory judgment action have obtained a judgment against the Company in the underlying individual opt-out actions and the Company disputes the claims against it in those underlying actions. The underlying individual opt-out actions assert claims under Sections 10(b) and 20(a) of the Exchange Act, and certain actions assert claims under Section 18 of the Exchange Act. The allegations in those underlying individual opt out actions are made against the Company and several of its former officers and directors only and relate to, among other things, allegedly false and misleading statements made during the 2013-2016 time period by the Company and/or failures to disclose information about the Company&#8217;s business and prospects including relating to drug pricing and the use of specialty pharmacies. On March 31, 2022, the Company and Bausch + Lomb removed the action to the U.S. District Court for the District of New Jersey. As a result, the New Jersey Superior Court action is closed and the case is now pending in the District of New Jersey (Case No. 22-cv-01823). On April 29, 2022, Plaintiffs filed a motion to remand. That motion is fully briefed and pending as of June 30, 2022. Other proceedings are in abeyance pending resolution of Plaintiffs&#8217; remand motion. Both the Company and Bausch + Lomb dispute the claims in this declaratory judgment action and intend to vigorously defend this matter. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Proposition 65 Related Matter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson &amp; Johnson (Gutierrez, et al. v. Johnson &amp; Johnson, et al., Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the California Safe Cosmetics Act. This lawsuit was served on Bausch Health US in June 2019 and was subsequently removed to the United States District Court for the Southern District of California, where it is currently pending. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. Bausch Health US filed a motion to dismiss Plaintiffs&#8217; claims, which was granted in April 2020 without prejudice. In May 2020, Plaintiffs filed an amended complaint and in June 2020, filed a motion for leave to amend the complaint further, which was granted. In August 2020, Plaintiffs filed </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Fifth Amended Complaint. On January 22, 2021, the Court granted the motion to dismiss with prejudice. On February 19, 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit Court of Appeals. On July 1, 2021, Appellants (Plaintiffs) filed their opening brief; Appellees&#8217; response briefs were filed on October 8, 2021. This matter was stayed by the Ninth Circuit on December 7, 2021, due to the preliminary injunction entered by the Bankruptcy Court in the LTL bankruptcy proceeding. This stay included Appellants&#8217; reply brief deadline, which was previously due to be filed on or before December 2, 2021. On March 9, 2022, the Ninth Circuit issued an order extending the stay through July 29, 2022. On July 29, 2022, Johnson &amp; Johnson filed a status report in the Gutierrez appeal, outlining the developments since the last status report and the imposition of the current stay. Johnson &amp; Johnson noted that following a July 26, 2022, hearing, the Bankruptcy Court left the preliminary injunction in place, and accordingly, asked the Ninth Circuit if Johnson &amp; Johnson could have until December 19, 2022, to provide the next status report while the stay remains in place in this action. They also indicated they will inform the court if the status of the bankruptcy stay changes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Mexico Attorney General Consumer Protection Action</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US were named in an action brought by State of New Mexico ex rel. Hector H. Balderas, Attorney General of New Mexico, in the County of Santa Fe New Mexico First Judicial District Court (New Mexico ex rel. Balderas v. Johnson &amp; Johnson, et al., Civil Action No. D-101-CV-2020-00013, filed on January 2, 2020), alleging consumer protection claims against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer, Inc., the Company and Bausch Health US related to Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its alleged causal link to mesothelioma and other cancers. In April 2020, Bausch Health US filed a motion to dismiss, which in September 2020, the Court granted in part as to the New Mexico Medicaid Fraud Act and New Mexico Fraud Against Taxpayers Act claims and denied as to all other claims. The State of New Mexico brings claims against all defendants under the New Mexico Unfair Practices Act and other common law and equitable causes of action, alleging defendants engaged in wrongful marketing, sale and promotion of talcum powder products. The lawsuit seeks to recover the cost of the talcum powder products as well as the cost of treating asbestos-related cancers allegedly caused by those products. Bausch Health US filed its answer on November 16, 2020. On December 30, 2020 Johnson &amp; Johnson filed a Motion for Partial Judgment on the Pleadings and on January 4, 2021, Bausch Health US filed a joinder to that motion, which was denied on March 8, 2021. Trial is scheduled to begin on March 6, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 14, 2022, LTL filed an adversary proceeding in the Bankruptcy Court (Case No. 21-30589, Adv. Pro. No. 22-01231) against the State of New Mexico ex rel. Hector H. Balderas, Attorney General, and a motion seeking an injunction barring the State of New Mexico from continuing to prosecute the action while the bankruptcy case is pending. On July 20, 2022, the Bankruptcy Court entered a consent order pursuant to which, among other things, a hearing on the injunction is scheduled for August 23, 2022, and the action is stayed pending further order on the injunction motion. The one exception is that the parties in the New Mexico case may continue to litigate the scheduling order extension in that case which has been scheduled for hearing August 24, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above, during the three months ended June 30, 2022, there have been no material updates or developments with respect to certain proceedings or actions as described under &#8220;General Civil Actions&#8221; in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021. These matters include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Doctors Allergy Formula Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, Doctors Allergy Formula, LLC (&#8220;Doctors Allergy&#8221;), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, asserting breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas.&#160;Doctors Allergy claims its damages are not less than $23 million. Bausch Health Americas has asserted counterclaims against Doctors Allergy. Bausch Health Americas filed a motion seeking an order granting Bausch Health Americas summary judgment on its counterclaims against Plaintiff and dismissing Plaintiff&#8217;s claims against it. The motion was fully briefed as of May 2021. The Court held a hearing on the motion on January 25, 2022. The motion remains pending. Bausch Health Americas disputes the claims against it and intends to continue to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation with Former Salix CEO</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, asserting claims for breach of contract and declaratory relief. On November 19, 2021, Logan amended her complaint to add a claim for breach of the implied covenant of good faith and fair dealing. The lawsuit arises out of the contractual termination </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of approximately $30 million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd. Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification. On June 20, 2019, the Court entered an order staying the claim for declaratory relief pending the final resolution of the breach of contract claim. Trial is scheduled to commence on April 10, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it in each of these matters and intends to vigorously defend the matters.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012038155296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text">SEGMENT INFORMATION<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company&#8217;s previously announced plan to separate its Solta business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., the Company had begun managing its operations in a manner which was consistent with the organizational structure of the two separate entities as proposed by the Solta IPO. As a result, during the first quarter of 2022, the Company&#8217;s Chief Executive Officer (&#8220;CEO&#8221;), who is the Company&#8217;s Chief Operating Decision Maker, commenced managing the business differently through changes in its operating and reportable segments, which necessitated a realignment of the Company&#8217;s historical segment structure. This realignment is consistent with how the Company&#8217;s CEO currently: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports. Pursuant to these changes, effective in the first quarter of 2022, the Company operates in the following reportable segments: (i) Salix, (ii) International (formerly International Rx), (iii) Diversified Products, (iv) Solta Medical and (v) Bausch + Lomb. The new segment structure does not impact the Company&#8217;s reporting units but realigns the two reporting units of the former Ortho Dermatologics segment whereby its medical dermatology reporting unit (Ortho Dermatologics) is now part of the current Diversified Products segment and the Solta reporting unit is now the sole reporting unit of the new Solta Medical segment. Prior period presentation of segment revenues and segment profits has been recast to conform to the current segment reporting structure.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2022, the Company announced it was suspending plans for the Solta IPO; however, the Company is continuing to manage and operate the business in its current reportable segment structure. See Note 2, &#8220;SIGNIFICANT ACCOUNTING POLICIES&#8221; for additional information.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief description of the Company&#8217;s segments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales in the U.S. of GI products. Sales of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line represented 81% and 80% of the Salix segment&#8217;s revenues for the three and six months ended June 30, 2022, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified Products segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological) products and (iv) dentistry products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Solta Medical segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Solta aesthetic medical devices. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Bausch + Lomb segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment profit is based on operating income after the elimination of intercompany transactions, including between Bausch + Lomb and other segments. Certain costs, such as Amortization of intangible assets, Asset impairments, Goodwill impairments, Restructuring, integration, separation and IPO costs and Other (income) expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#8217;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Revenues and Profits</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenues and profits were as&#160;follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,885&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,601&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,803&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(380)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(360)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(717)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(542)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(512)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(270)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(491)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(772)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(732)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(670)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,261)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues by Segment and Product Category </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by segment and product category were as&#160;follows:</span></div><div style="margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.108%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,885&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The top ten products for the six months ended June 30, 2022 and 2021 represented 48% and 43% of total revenues for the six months ended June 30, 2022 and 2021, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are attributed to a geographic region based on the location of the customer and were as&#160;follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,190&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,305&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,378&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,885&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made and are reflected in the table above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that accounted for 10% or more of total revenues were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation (including McKesson Specialty)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health,&#160;Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012038184192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENT</a></td>
<td class="text">SUBSEQUENT EVENT Cross-Currency SwapsDuring July 2022, the Company entered into cross-currency swaps, with aggregate notional amounts of $1,000&#160;million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its Consolidated Financial Statements from adverse movements in exchange rates. The euro-denominated net investment being hedged is the Company&#8217;s investment in certain Bausch + Lomb euro-denominated subsidiaries.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012040259008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared by the Company in U.S. dollars and in accordance with&#160;U.S. generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;) for interim financial reporting, which do not conform in all respects to the requirements of U.S.&#160;GAAP for annual financial statements. Accordingly, these notes to the unaudited Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements prepared in accordance with U.S.&#160;GAAP that are contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the U.S. Securities and Exchange Commission (the&#160;&#8220;SEC&#8221;) and the Canadian Securities Administrators (the&#160;&#8220;CSA&#8221;) on February&#160;23, 2022. The unaudited Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#8217;s audited Consolidated Financial Statements for the year ended December&#160;31, 2021. The unaudited Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statement of the Company&#8217;s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full&#160;year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the unaudited Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Consolidated Financial Statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the differences could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#8217;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#8217;s results of operations and financial position could be materially impacted.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">REVENUE RECOGNITION <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, principally in the therapeutic areas of GI, dermatology, and eye health, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics medical devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 19, &#8220;SEGMENT INFORMATION&#8221; for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160;The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company&#8217;s products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#8217;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012040302720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock', window );">Summary of variable consideration provisions</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the activity and ending balances of the Company&#8217;s variable consideration provisions for the six months ended June 30, 2022 and 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.616%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(976)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,602)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,971&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $48 million and $36&#160;million as of June 30, 2022 and January 1, 2022, respectively, which are reflected as a reduction of Trade receivables, net in the Consolidated Balance Sheets. There were no price appreciation credits during the six months ended June 30, 2022.</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.616%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(296)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,025)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,012)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,546)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">981&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Summary of activity in allowance for credit losses</a></td>
<td class="text">The activity in the allowance for credit losses for trade receivables for the six months ended June 30, 2022 and 2021 is as follows.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.447%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.830%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Valuation And Qualifying Accounts [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012040135696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of components and classification of financial assets and liabilities measured at fair value</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.196%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of effect of hedging instruments on financial statements</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of hedging instruments on the Consolidated Statements of Comprehensive Loss and the Consolidated Statements of Operations for the three and six months ended June 30, 2022 and 2021:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain excluded from assessment of hedge effectiveness</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of gain of excluded component</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Schedule of assets and liabilities associated with derivatives, included in the Consolidated Balance Sheets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company&#8217;s foreign exchange contracts as included in the Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.443%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock', window );">Schedule of foreign exchange contracts on the Consolidated Statements of Operations and Consolidated Statements of Cash Flows</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of the Company&#8217;s foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for the three and six months ended June 30, 2022 and 2021:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.982%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.366%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) related to changes in fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) related to settlements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3)</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the six months ended June 30, 2022 and 2021: </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.534%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to Acquisition-related contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion for the time value of money</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments due to changes in estimates of other future payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment included in other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of gains and losses on derivative instruments included in an entity's trading activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4F<br> -Subparagraph (a),(b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624186-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 55<br> -Paragraph 184<br> -URI https://asc.fasb.org/extlink&amp;oid=127000641&amp;loc=SL5634876-113961<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for net investment hedges of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012038295520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of the components of inventories, net</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consist of:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,073&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012131124496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of indefinite-lived intangible assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets consist of: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,695)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(506)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,364&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,740)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bausch + Lomb Trademark</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,062&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,740)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,322&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,948&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of finite-lived intangible assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets consist of: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,695)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(506)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,364&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,740)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bausch + Lomb Trademark</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,062&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,740)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,322&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,948&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of estimated aggregate amortization expense for each of the five succeeding years</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense of finite-lived intangible assets for the remainder of 2022 and each of the five succeeding years ending December&#160;31 and thereafter is as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.833%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remainder of 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of changes in the carrying amount of goodwill</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill during the six months ended June 30, 2022 and the year ended December&#160;31, 2021 were as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.298%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.447%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.494%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bausch + Lomb/ International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,704)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(578)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, June 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,232&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,987&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,266&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012038240416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued and other current liabilities</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matters and related fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefit costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,311&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,791&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012040279344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of long-term debt</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs consist of the following: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2018 Restated Credit Agreement</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2022 Amended Credit Agreement</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">B+L Credit Facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B+L Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B+L Term Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.125% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.75% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.875% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.125%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.00%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.50%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.00%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.25%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,056&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,814&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,870&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,664&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of long-term debt maturities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of debt obligations for the remainder of 2022, the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.383%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,056&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized premiums, discounts and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(242)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,814&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012038155296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Components of net periodic benefit cost</a></td>
<td class="text">Net periodic (benefit) cost for the Company&#8217;s defined benefit pension plans and postretirement benefit plan for the six months ended June 30, 2022 and 2021 consists of: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.971%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.980%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Postretirement<br/>Benefit<br/>Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012040175872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of the components and classification of share-based compensation expense</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components and classification of Bausch Health share-based compensation expenses related to stock options and RSUs for the three and six months ended June 30, 2022 and 2021: </span></div><div style="margin-bottom:6pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.447%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of share-based awards</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based awards granted for the six months ended June 30, 2022 and 2021 consist of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch Health Share-Based Awards</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,570,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,466,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time-based RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,680,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,861,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TSR performance-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROTC performance-based RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B+L Separation performance-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch+ Lomb Share-Based Awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,455,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,207,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012038375664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of the components of Accumulated other comprehensive loss</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss consists of: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:69.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,990)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,905)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and postretirement benefit plan adjustments, net of income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,002)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,924)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012038200592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock', window );">Summary of research and development</a></td>
<td class="text">Research and development costs consist of:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product related research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Research And Development Expense [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012038375664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of other expense, net</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net consists of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.340%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, Net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012038240416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of calculation of net loss per share</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share attributable to Bausch Health Companies Inc. were calculated as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.977%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.575%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(595)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,205)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362.2&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359.1&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.0&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to Bausch Health</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Companies Inc.</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.40)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.66)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.59)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.37)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012036723312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of segment revenues and profit</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenues and profits were as&#160;follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,885&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,601&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,803&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(380)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(360)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(717)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(542)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(512)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(270)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(491)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(772)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(732)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(670)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,261)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of revenues by segment and product category</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by segment and product category were as&#160;follows:</span></div><div style="margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.108%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">965&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,830&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,885&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of revenue attributed to a geographic region</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are attributed to a geographic region based on the location of the customer and were as&#160;follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,190&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,305&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,378&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,885&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of customers that accounted for 10% or more of total revenue</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that accounted for 10% or more of total revenues were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation (including McKesson Specialty)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health,&#160;Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012033066816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>country</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfCountriesInWhichEntityOperates', window );">Number of countries in which entity operates</a></td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage by parent</a></td>
<td class="nump">90.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfCountriesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of countries in which the entity operates as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfCountriesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012033101168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Jun. 01, 2022</div></th>
<th class="th"><div>May 10, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,571,921<span></span>
</td>
<td class="nump">359,405,748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding (in shares)</a></td>
<td class="nump">310,449,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Percentage of shares held</a></td>
<td class="nump">88.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bhc_IPOAndOverAllotmentOptionMember', window );">IPO and Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Shares sold, net proceeds</a></td>
<td class="nump">$ 675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">B+L IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price of shares sold (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="nump">4,550,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price of shares sold (in usd per share)</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_SaleOfStockOverAllotmentTerm', window );">Underwriters option to purchase additional shares, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance', window );">Number of additional shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Number Of Additional Shares Available For Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SaleOfStockOverAllotmentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Over-Allotment, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SaleOfStockOverAllotmentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bhc_IPOAndOverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bhc_IPOAndOverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012033291344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Sales return provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,710,000,000<span></span>
</td>
<td class="nump">$ 2,713,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Cooperative advertising credits included in rebates</a></td>
<td class="nump">$ 1,971,000,000<span></span>
</td>
<td class="nump">$ 1,980,000,000<span></span>
</td>
<td class="nump">1,971,000,000<span></span>
</td>
<td class="nump">1,980,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,863,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,813,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Price appreciation credits</a></td>
<td class="nump">1,967,000,000<span></span>
</td>
<td class="nump">2,100,000,000<span></span>
</td>
<td class="nump">3,885,000,000<span></span>
</td>
<td class="nump">4,127,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_PriceAppreciationCreditMember', window );">Price Appreciation Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Price appreciation credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Sales return provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">77,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Cooperative advertising credits included in rebates</a></td>
<td class="nump">435,000,000<span></span>
</td>
<td class="nump">533,000,000<span></span>
</td>
<td class="nump">435,000,000<span></span>
</td>
<td class="nump">533,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 482,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesAdvertisingCreditsPortionMember', window );">Rebates, Advertising Credits Portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Cooperative advertising credits included in rebates</a></td>
<td class="nump">$ 48,000,000<span></span>
</td>
<td class="nump">$ 41,000,000<span></span>
</td>
<td class="nump">$ 48,000,000<span></span>
</td>
<td class="nump">$ 41,000,000<span></span>
</td>
<td class="nump">$ 36,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_PriceAppreciationCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_PriceAppreciationCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesAdvertisingCreditsPortionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesAdvertisingCreditsPortionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012032742224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION - Variable Consideration Provisions (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">$ 1,863<span></span>
</td>
<td class="nump">$ 1,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">2,710<span></span>
</td>
<td class="nump">2,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(2,602)<span></span>
</td>
<td class="num">(2,546)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">1,971<span></span>
</td>
<td class="nump">1,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDiscountsAndAllowancesMember', window );">Discounts and Allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">222<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">278<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(303)<span></span>
</td>
<td class="num">(296)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">482<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(107)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">435<span></span>
</td>
<td class="nump">533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">944<span></span>
</td>
<td class="nump">779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">1,236<span></span>
</td>
<td class="nump">1,227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(1,170)<span></span>
</td>
<td class="num">(1,025)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">1,010<span></span>
</td>
<td class="nump">981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForChargebacksMember', window );">Chargebacks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">1,028<span></span>
</td>
<td class="nump">993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(976)<span></span>
</td>
<td class="num">(1,012)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">222<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDistributionFeesMember', window );">Distribution Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">$ 107<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDiscountsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDiscountsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForChargebacksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForChargebacksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDistributionFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDistributionFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012036787808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Beginning balance</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write-offs</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries', window );">Recoveries</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther', window );">Foreign exchange and other</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance For Foreign Exchange And Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccountsReceivableAllowanceForForeignExchangeAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in allowance for credit loss on accounts receivable, from recovery.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012033092880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details) - Disposal Group, Disposed of by Sale, Not Discontinued Operations - Amoun - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Cash proceeds from divestiture</a></td>
<td class="nump">$ 740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue associated with products for disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Asset impairments, including loss on assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 88<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=bhc_AssetImpairmentChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=bhc_AssetImpairmentChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012034095920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Cost-rationalization and integration initiatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Separation and IPO-related costs included in selling, general and administrative expenses</a></td>
<td class="nump">$ 676<span></span>
</td>
<td class="nump">$ 685<span></span>
</td>
<td class="nump">$ 1,298<span></span>
</td>
<td class="nump">$ 1,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=bhc_RestructuringAndIntegrationCostsMember', window );">Restructuring and Integration Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Cost-rationalization and integration initiatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Liabilities associated with restructuring, integration and separation costs</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Restructuring payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=bhc_SeparationAndInitialPublicOfferingCostsMember', window );">Separation and IPO Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Cost-rationalization and integration initiatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring, integration, separation, and IPO costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Separation and IPO-related costs included in selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=bhc_RestructuringAndIntegrationCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=bhc_RestructuringAndIntegrationCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=bhc_SeparationAndInitialPublicOfferingCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=bhc_SeparationAndInitialPublicOfferingCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012032617600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Recurring basis - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">1,220<span></span>
</td>
<td class="nump">1,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Foreign currency exchange contracts</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Foreign currency exchange contracts</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">1,220<span></span>
</td>
<td class="nump">1,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Foreign currency exchange contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Foreign currency exchange contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;2 | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Foreign currency exchange contracts</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Foreign currency exchange contracts</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3 | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Foreign currency exchange contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Foreign currency exchange contracts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement which may include cash and shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012037064656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 16, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>appeal</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_HighlyLiquidInvestmentsMaturityPeriod', window );">Highly liquid investments, maturity period (or less)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 659<span></span>
</td>
<td class="nump">$ 582<span></span>
</td>
<td class="nump">$ 642<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bhc_BauschLombToBeDistributedToOtherLegalEntitiesMember', window );">Bausch + Lomb. To Be Distributed To Other Legal Entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">US Securities Litigation | Settled Litigation | NEW JERSEY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement, escrow fund included in restricted cash and other settlement deposits</a></td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LitigationSettlementNumberOfObjectorsAppeals', window );">Settlement, escrow fund included in restricted cash, number of objectors' appeals | appeal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_HighlyLiquidInvestmentsMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Highly Liquid Investments, Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_HighlyLiquidInvestmentsMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LitigationSettlementNumberOfObjectorsAppeals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Number of Objectors' Appeals</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LitigationSettlementNumberOfObjectorsAppeals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombToBeDistributedToOtherLegalEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombToBeDistributedToOtherLegalEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012037051296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details) - Currency Swap - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities', window );">Payments or receipts in settlement of cross-currency swaps</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Aggregate notional amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromHedgeInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012037211456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details) - Net Investment Hedging - Currency Swap - Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Gain (loss) recognized in Other comprehensive loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Gain excluded from assessment of hedge effectiveness</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012041141632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Foreign currency exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Aggregate notional amounts</a></td>
<td class="nump">$ 332,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012033190096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details) - Foreign currency exchange contracts - Not Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Net fair value</a></td>
<td class="num">$ (10)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=bhc_AccruedAndOtherCurrentLiabilitiesMember', window );">Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Net fair value</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Net fair value</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the assets less the liabilities of a derivative or group of derivatives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=bhc_AccruedAndOtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=bhc_AccruedAndOtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012032778224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details) - Foreign currency exchange contracts - Not Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Gain (loss) related to changes in fair value</a></td>
<td class="num">$ (3)<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="num">$ (10)<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain', window );">Gain related to settlements</a></td>
<td class="num">$ (10)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss', window );">Loss related to settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized loss of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012033237968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details) - Recurring basis - Level&#160;3<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>rate</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measurement Input, Discount Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value, contingent consideration obligations, discount rate</a></td>
<td class="nump">0.06<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measurement Input, Discount Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value, contingent consideration obligations, discount rate</a></td>
<td class="nump">0.18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measurement Input, Weighted Average Risk-Adjusted Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value, contingent consideration obligations, discount rate</a></td>
<td class="nump">0.07<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=bhc_MeasurementInputWeightedAverageDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=bhc_MeasurementInputWeightedAverageDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012034114432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, beginning of period</a></td>
<td class="nump">$ 241<span></span>
</td>
<td class="nump">$ 328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Acquisition-related contingent consideration</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments/Settlements</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome', window );">Foreign currency translation adjustment included in other comprehensive loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, end of period</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion included in Accrued and other current liabilities</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Non-current portion</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_AccretionForTimeValueOfMoneyMember', window );">Accretion for the time value of money</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember', window );">Fair value adjustments due to changes in estimates of other future payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Acquisition-related contingent consideration</a></td>
<td class="num">$ (10)<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_AccretionForTimeValueOfMoneyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bhc_AccretionForTimeValueOfMoneyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012038131296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring adjustment | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of long-term debt</a></td>
<td class="nump">$ 16,141<span></span>
</td>
<td class="nump">$ 22,689<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012032884416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES - Components of Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 301<span></span>
</td>
<td class="nump">$ 279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">648<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total Inventories</a></td>
<td class="nump">$ 1,073<span></span>
</td>
<td class="nump">$ 993<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012034277840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 25,364<span></span>
</td>
<td class="nump">$ 25,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(20,740)<span></span>
</td>
<td class="num">(20,180)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">4,624<span></span>
</td>
<td class="nump">5,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Total intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">27,062<span></span>
</td>
<td class="nump">27,128<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">6,322<span></span>
</td>
<td class="nump">6,948<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Bausch + Lomb Trademark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">1,698<span></span>
</td>
<td class="nump">1,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember', window );">Product brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">20,807<span></span>
</td>
<td class="nump">20,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(16,695)<span></span>
</td>
<td class="num">(16,169)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">4,112<span></span>
</td>
<td class="nump">4,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">897<span></span>
</td>
<td class="nump">902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(506)<span></span>
</td>
<td class="num">(473)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">391<span></span>
</td>
<td class="nump">429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember', window );">Product rights/patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">3,318<span></span>
</td>
<td class="nump">3,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(3,197)<span></span>
</td>
<td class="num">(3,174)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember', window );">Partner relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(158)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember', window );">Technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(196)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012029640880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>reporting_unit</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>reporting_unit</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>reporting_unit</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="nump">$ 195,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,624,000,000<span></span>
</td>
<td class="nump">$ 4,624,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,624,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Fair value of reporting value, greater than its carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated goodwill impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,263,000,000<span></span>
</td>
<td class="nump">4,263,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,263,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,967,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000,000<span></span>
</td>
<td class="nump">3,885,000,000<span></span>
</td>
<td class="nump">$ 4,127,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_XifaxanBrandedProductsMember', window );">Xifaxan Branded Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,963,000,000<span></span>
</td>
<td class="nump">2,963,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,963,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite lived intangible assets, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">66 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AnnualAmortizationOfIntangibleAssets', window );">Finite lived intangible assets, annual amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 539,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | reporting_unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | reporting_unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 501,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 516,000,000<span></span>
</td>
<td class="nump">965,000,000<span></span>
</td>
<td class="nump">$ 988,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Xifaxan Branded Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 775,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Xifaxan Branded Products | Product Concentration Risk | Revenue from Contract with Customer, Segment Benchmark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=bhc_ReportingUnitsExcludingOrthoDermatologicsMember', window );">Reporting Units Excluding Ortho Dermatologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=bhc_OrthoDermatologicsReportingUnitMember', window );">Ortho Dermatologics Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, change in discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Fair value of reporting value, greater than its carrying value</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 469,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember', window );">Vision Care, Surgical And Ophthalmic Reporting Units | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Fair value of reporting value, greater than its carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember', window );">All Reporting Units, Excluding Ortho Dermatologics, Vision Care, Surgical and Ophthalmic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Ortho Dermatologics Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Vision Care, Surgical And Ophthalmic Reporting Units | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">12.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Ortho Dermatologics Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Vision Care, Surgical And Ophthalmic Reporting Units | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Amoun</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember', window );">Product brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">96,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,112,000,000<span></span>
</td>
<td class="nump">$ 4,112,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,112,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,673,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_DiscontinuedProductLinesMember', window );">Discontinued Product Lines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AnnualAmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Amortization Of Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AnnualAmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reporting Unit, Impairment Test, Estimated Cash Flows, Increase (Decrease) In Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reporting Unit, Impairment Test, Long-Term Growth Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ReportingUnitImpairmentTestLongTermGrowthRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of fair value of reporting unit in excess of carrying amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_XifaxanBrandedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_XifaxanBrandedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=bhc_ReportingUnitsExcludingOrthoDermatologicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=bhc_ReportingUnitsExcludingOrthoDermatologicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=bhc_OrthoDermatologicsReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=bhc_OrthoDermatologicsReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_DiscontinuedProductLinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_DiscontinuedProductLinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012033192944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remainder of 2022</a></td>
<td class="nump">$ 565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">1,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 4,624<span></span>
</td>
<td class="nump">$ 5,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012038627648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,457,000,000<span></span>
</td>
<td class="nump">$ 13,044,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(83,000,000)<span></span>
</td>
<td class="num">(469,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(108,000,000)<span></span>
</td>
<td class="num">(118,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,266,000,000<span></span>
</td>
<td class="nump">12,457,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombInternationalMember', window );">Bausch + Lomb/ International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,704,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,704,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,318,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,395,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86,000,000)<span></span>
</td>
<td class="num">(77,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,232,000,000<span></span>
</td>
<td class="nump">5,318,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">887,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,000,000)<span></span>
</td>
<td class="num">(62,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">773,000,000<span></span>
</td>
<td class="nump">825,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">798,000,000<span></span>
</td>
<td class="nump">1,267,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(798,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(469,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">798,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,357,000,000<span></span>
</td>
<td class="nump">2,914,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">683,000,000<span></span>
</td>
<td class="num">(578,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">21,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,987,000,000<span></span>
</td>
<td class="nump">$ 2,357,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombInternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombInternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012034123280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_Legalsettlementsandrelatedfees', window );">Legal matters and related fees</a></td>
<td class="nump">$ 1,536<span></span>
</td>
<td class="nump">$ 1,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AccruedProductRebateCurrent', window );">Product rebates</a></td>
<td class="nump">962<span></span>
</td>
<td class="nump">908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AccruedProductReturnCurrent', window );">Product returns</a></td>
<td class="nump">435<span></span>
</td>
<td class="nump">482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest</a></td>
<td class="nump">326<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee compensation and benefit costs</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">716<span></span>
</td>
<td class="nump">749<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">$ 4,311<span></span>
</td>
<td class="nump">$ 4,791<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccruedProductRebateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the current portion of accrued product rebates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccruedProductRebateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccruedProductReturnCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccruedProductReturnCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_Legalsettlementsandrelatedfees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Legal settlements and related fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_Legalsettlementsandrelatedfees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012029884976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Feb. 10, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 08, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 22,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">21,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of long-term debt</a></td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of long-term debt</a></td>
<td class="nump">21,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member', window );">Term Loan B Facility Due June 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member', window );">Term Loan B Facility Due November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member', window );">Term Loan B Facility Due February 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">2,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 2,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 5.50% Senior Notes Due November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 1,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 6.125% Senior Notes Due February 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.125%<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 5.75% Senior Notes Due August 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 4.875% Senior Notes Due June 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 1,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 6.125% Senior Notes Due April 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 9.00% Senior Notes Due December 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 1,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 9.25% Senior Notes Due April 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 1,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 8.50% Senior Notes Due January 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 1,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 7.00 % Senior Notes Due January 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.00% Senior Notes Due January 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 1,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 6.25% Senior Notes Due February 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 1,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.00% Senior Notes Due February 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 7.25 % Senior Notes Due May 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.25% Senior Notes Due January 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 1,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.25% Senior Notes Due February 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due May 2027 | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.50NotesDueNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.50NotesDueNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.75NotesDueAugust2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.75NotesDueAugust2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes900DueDecember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes900DueDecember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes925DueApril2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes925DueApril2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueJanuary2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueJanuary2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueFebruary2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueFebruary2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_OtherLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_OtherLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueMay2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueMay2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012034401456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Covenant Compliance (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=bhc_SeniorSecuredCreditFacilityMember', window );">Senior Secured Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments', window );">Amount available for restricted payments</a></td>
<td class="nump">$ 14,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio', window );">Fixed charge coverage ratio</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio', window );">Secured leverage ratio</a></td>
<td class="nump">4.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Amount Available For Restricted Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Secured Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bhc_SeniorSecuredCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bhc_SeniorSecuredCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012027965056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>May 10, 2022</div></th>
<th class="th"><div>Jun. 01, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="nump">$ 21,814,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,654,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member', window );">Term Loan B Facility Due June 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,565,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,772,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member', window );">Term Loan B Facility Due November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">984,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member', window );">Term Loan B Facility Due February 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="nump">2,448,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentAnnualAmortizationRatePercentage', window );">Annual amortization rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Quarterly installment payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization', window );">Remaining quarterly amortization payments</a></td>
<td class="nump">563,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member', window );">Term Loan B Facility Due February 2027 | Federal Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member', window );">Term Loan B Facility Due February 2027 | Base Rate Factor, SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member', window );">Term Loan B Facility Due February 2027 | SOFR Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable', window );">Variable rate, if rate not ascertainable (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member', window );">Term Loan B Facility Due February 2027 | SOFR Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member', window );">Term Loan B Facility Due February 2027 | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember', window );">Senior Secured Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments', window );">Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments', window );">Percentage of cash proceeds from incurrence of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments', window );">Percentage of annual excess cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments', window );">Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_NewRestatedCreditAgreementMember', window );">New Restated Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTotalLeverageRatio', window );">Total leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization', window );">Remaining quarterly amortization payments</a></td>
<td class="nump">119,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="nump">2,446,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentAnnualAmortizationRatePercentage', window );">Annual amortization rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Quarterly installment payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | Federal Funds | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | Base Rate Factor, SOFR | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable', window );">Variable rate, if rate not ascertainable (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | SOFR Rate | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate', window );">Credit spread adjustment (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | SOFR Rate | Minimum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Minimum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.015%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Maximum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.475%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | Base Rate | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | Base Rate | Minimum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | SOFR, CDOR, EURIBOR and SONIA Rates | Minimum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.015%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | SOFR, CDOR, EURIBOR and SONIA Rates | Maximum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.475%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_BLCreditAgreementMember', window );">B+L Credit Agreement | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments', window );">Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments', window );">Percentage of cash proceeds from incurrence of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments', window );">Percentage of annual excess cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments', window );">Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold', window );">Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">91 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold', window );">Alternate term, principal amount maturity threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 975,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold', window );">Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">91 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold', window );">Alternate term, principal amount maturity threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="nump">425,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings', window );">Threshold for incremental borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage', window );">Incremental borrowings interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum', window );">Interest coverage ratio (not less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio', window );">Secured leverage ratio (not greater than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027 | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum', window );">Total leverage ratio (not greater than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027 | Federal Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027 | SOFR Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027 | SOFR Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate', window );">Credit spread adjustment (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027 | SOFR Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate', window );">Credit spread adjustment (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027 | BA Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027 | BA Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027 | EURIBOR | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027 | U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027 | U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027 | SOFR, CDOR and EURIBOR Rates | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027 | SOFR, CDOR and EURIBOR Rates | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due May 2027 | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Facility fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due May 2027 | Minimum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.11%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due May 2027 | Maximum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.275%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due May 2027 | Federal Funds | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due May 2027 | SOFR Rate | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable', window );">Variable rate, if rate not ascertainable (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate', window );">Credit spread adjustment (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due May 2027 | SOFR Rate | Minimum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due May 2027 | BA Rate | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due May 2027 | BA Rate | Minimum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due May 2027 | EURIBOR | Minimum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due May 2027 | U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Minimum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due May 2027 | U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Maximum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due May 2027 | SONIA Rate | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate', window );">Credit spread adjustment (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0326%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due May 2027 | SONIA Rate | Minimum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due May 2027 | SOFR, CDOR, EURIBOR and SONIA Rates | Minimum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due May 2027 | SOFR, CDOR, EURIBOR and SONIA Rates | Maximum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Alternate Term, Principal Amount Maturity Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAnnualAmortizationRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Annual Amortization Rate, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAnnualAmortizationRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Basis Spread On Variable Rate, If Rate Not Ascertainable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Secured Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTotalLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Total Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTotalLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Total Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Credit Spread Adjustment on Variable Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment, Remaining Quarterly Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of annual excess cash flow with any excess amounts after the prepayment of the loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of net cash proceeds from asset sales outside ordinary course of business payable as mandatory prepayments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of net cash proceeds of insurance and condemnation proceeds for property or asset (losses) which is payable as mandatory prepayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of net cash proceeds from the incurrence of debt payable as mandatory prepayments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Threshold For Incremental Borrowings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility Threshold For Incremental Borrowings, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_NewRestatedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_NewRestatedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_SOFRCDOREURIBORAndSONIARatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_SOFRCDOREURIBORAndSONIARatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_BLCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_BLCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_CanadianBankersAcceptanceRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_CanadianBankersAcceptanceRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_EuropeInterbankOfferedRateEURIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_EuropeInterbankOfferedRateEURIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_SOFRCDORAndEURIBORRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_SOFRCDORAndEURIBORRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueMay2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueMay2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_SONIARateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_SONIARateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012032399440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Senior Secured Notes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 10, 2022</div></th>
<th class="th"><div>Feb. 10, 2022</div></th>
<th class="th"><div>Jun. 08, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,083,000,000<span></span>
</td>
<td class="nump">$ 2,100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">$ 63,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,000,000<span></span>
</td>
<td class="num">$ (113,000,000)<span></span>
</td>
<td class="nump">$ 45,000,000<span></span>
</td>
<td class="num">$ (113,000,000)<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (176,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member', window );">6.125% Senior Notes Due April 2025 | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price (as a percent)</a></td>
<td class="nump">101.021%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member', window );">4.875% Senior Notes Due June 2028 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member', window );">4.875% Senior Notes Due June 2028 | Senior Secured Notes | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member', window );">4.875% Senior Notes Due June 2028 | Senior Secured Notes | Debt Instrument, Redemption, Period Two | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Maximum percentage of principal amount that can be redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueMarch2024Member', window );">7.00% Senior Notes, Due March 2024 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member', window );">6.125% Senior Notes Due February 2027 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member', window );">6.125% Senior Notes Due February 2027 | Senior Secured Notes | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member', window );">6.125% Senior Notes Due February 2027 | Senior Secured Notes | Debt Instrument, Redemption, Period Two | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Maximum percentage of principal amount that can be redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Percentage, Change in Control</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentRedemptionPricePercentageChangeinControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueMarch2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueMarch2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012033546848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 10, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jan. 18, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 481,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 9.00% Senior Notes due December 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 370,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet', window );">Debt covenant, redemption and discharge condition, amount, if circumstances met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 6.125% Senior Notes Due April 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price (as a percent)</a></td>
<td class="nump">101.021%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Percentage, Change in Control</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentRedemptionPricePercentageChangeinControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012038240416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="nump">6.34%<span></span>
</td>
<td class="nump">5.88%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012040156992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Gain (Loss) on Extinguishment of Debt (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 10, 2022</div></th>
<th class="th"><div>Jun. 08, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,083,000,000<span></span>
</td>
<td class="nump">$ 2,100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="num">$ (63,000,000)<span></span>
</td>
<td class="num">$ (38,000,000)<span></span>
</td>
<td class="nump">$ 113,000,000<span></span>
</td>
<td class="num">$ (45,000,000)<span></span>
</td>
<td class="nump">113,000,000<span></span>
</td>
<td class="num">$ (50,000,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 481,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012033433376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Remainder of 2022</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">1,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">8,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt obligations</a></td>
<td class="nump">22,056<span></span>
</td>
<td class="nump">$ 22,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized premiums, discounts and issuance costs</a></td>
<td class="num">(242)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 21,814<span></span>
</td>
<td class="nump">$ 22,654<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012033444352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | U.S. Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credit and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credit and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of net loss</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Benefit Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credit and other</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012029530528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 05, 2022</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>May 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Remaining unrecognized compensation expense related to non-vested awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average service period over which compensation cost is expected to be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum shares authorized (in shares)</a></td>
<td class="nump">28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Remaining unrecognized compensation expense related to non-vested awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average service period over which compensation cost is expected to be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Incentive stock plan, term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Incentive stock plan, vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bhc_NonExecutiveEligibleRecipientsMember', window );">Non-Executive Eligible Recipients | Options and RSUs | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross', window );">Incentive stock plan, grants in period (in shares)</a></td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bhc_NonExecutiveEligibleRecipientsMember', window );">Non-Executive Eligible Recipients | Stock options | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Incentive stock plan, vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bhc_NonExecutiveEligibleRecipientsMember', window );">Non-Executive Eligible Recipients | RSUs | Bausch + Lomb | Vesting Period, Second Year after Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bhc_NonExecutiveEligibleRecipientsMember', window );">Non-Executive Eligible Recipients | RSUs | Bausch + Lomb | Vesting Period, Third Year after Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014Member', window );">2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,627,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember', window );">IPO Founders Grants | Executive Officer | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember', window );">IPO Founders Grants | Executive Officer | Stock options | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent', window );">Incentive stock plan, award type, percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember', window );">IPO Founders Grants | Executive Officer | RSUs | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent', window );">Incentive stock plan, award type, percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember', window );">IPO Founders Grants | Non-Executive Eligible Recipients | Options and RSUs | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross', window );">Incentive stock plan, grants in period (in shares)</a></td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Award Type, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Grants In Period, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bhc_NonExecutiveEligibleRecipientsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bhc_NonExecutiveEligibleRecipientsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bhc_IPOFoundersGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012032770560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012027937024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract', window );"><strong>Stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">2,570<span></span>
</td>
<td class="nump">1,466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price (in usd per share)</a></td>
<td class="nump">$ 23.95<span></span>
</td>
<td class="nump">$ 32.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 6.60<span></span>
</td>
<td class="nump">$ 11.18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract', window );"><strong>Stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">6,455<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price (in usd per share)</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 4.55<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember', window );">Time-based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">2,680<span></span>
</td>
<td class="nump">2,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 18.49<span></span>
</td>
<td class="nump">$ 32.26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember', window );">Time-based RSUs | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">3,207<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 17.92<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_TSRPerformanceBasedRestrictedStockUnitsMember', window );">TSR Performance-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 56.04<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_ROTCPerformanceBasedRestrictedStockUnitsMember', window );">ROTC performance-based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">369<span></span>
</td>
<td class="nump">413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 9.40<span></span>
</td>
<td class="nump">$ 31.72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_SeparationPerformanceBasedRestrictedStockUnitsMember', window );">B+L Separation performance-based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 32.56<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_TSRPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_TSRPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_ROTCPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_ROTCPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_SeparationPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_SeparationPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012031175232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of Accumulated Other Comprehensive Loss (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">$ 253<span></span>
</td>
<td class="num">$ (141)<span></span>
</td>
<td class="num">$ (34)<span></span>
</td>
<td class="num">$ (611)<span></span>
</td>
<td class="num">$ (124)<span></span>
</td>
<td class="nump">$ 605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,990)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,905)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Pension and postretirement benefit plan adjustments, net of income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="num">$ (2,002)<span></span>
</td>
<td class="num">$ (1,974)<span></span>
</td>
<td class="num">$ (1,924)<span></span>
</td>
<td class="num">$ (2,182)<span></span>
</td>
<td class="num">$ (2,256)<span></span>
</td>
<td class="num">$ (2,133)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012034256928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Adjustment to reflect change in ownership interest in Bausch + Lomb</a></td>
<td class="nump">$ 675<span></span>
</td>
<td class="nump">$ 675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Adjustment to reflect change in ownership interest in Bausch + Lomb</a></td>
<td class="nump">$ 137<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012032912144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ResearchAndDevelopmentExpenseProductRelated', window );">Product related research and development</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
<td class="nump">$ 241<span></span>
</td>
<td class="nump">$ 214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ResearchAndDevelopmentExpenseQualityAssurance', window );">Quality assurance</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development costs</a></td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">$ 254<span></span>
</td>
<td class="nump">$ 227<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ResearchAndDevelopmentExpenseProductRelated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Product Related</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ResearchAndDevelopmentExpenseProductRelated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ResearchAndDevelopmentExpenseQualityAssurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Quality Assurance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ResearchAndDevelopmentExpenseQualityAssurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012036825328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE, NET - Summary of Other Expense, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation and other matters</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 532<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Acquisition-related contingent consideration</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain on sale of assets, net</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development costs</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_OtherIncomeExpenseNet', window );">Other, Net</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense (income), net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 542<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 512<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_OtherIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Income (Expense), Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_OtherIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012040152800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE, NET - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ScheduleOfOtherIncomeAndExpensesLineItems', window );"><strong>Schedule Of Other Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Milestone achievement, included in net (loss) gain on sale of assets</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bhc_MilestonePaymentRelatedToCertainProductMember', window );">Milestone Payment Related To Certain Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ScheduleOfOtherIncomeAndExpensesLineItems', window );"><strong>Schedule Of Other Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Milestone achievement, included in net (loss) gain on sale of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ScheduleOfOtherIncomeAndExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Schedule Of Other Income And Expenses [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ScheduleOfOtherIncomeAndExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bhc_MilestonePaymentRelatedToCertainProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bhc_MilestonePaymentRelatedToCertainProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012033125488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="num">$ (10)<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax expense (benefit) on ordinary loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount', window );">Income tax provision (benefit) for discrete items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Tax benefit related to changes in uncertain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount', window );">Provision related to filing certain tax returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount', window );">Income tax benefit for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount', window );">Provision related to withholding tax, intercompany dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Tax benefit related to stock compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance against deferred tax assets</a></td>
<td class="nump">2,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties', window );">Unrecognized tax benefits including interest and penalties</a></td>
<td class="nump">840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits related to interest and penalties</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Portion of unrecognized tax benefits, if recognized, would reduce the Company's effective tax rate</a></td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Unrecognized tax benefit, amount possible to decrease in next twelve months</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss', window );">Estimate of possible loss, income tax examination (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Discrete Items, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Expense Filing Tax Returns, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Legal Settlements, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Withholding Tax, Intercompany Dividends, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross amount of unrecognized tax benefits including interest and penalties pertaining to uncertain tax positions taken in tax returns as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970579&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated amount of loss resulting from an adverse tax position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012042227024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Bausch Health Companies Inc.</a></td>
<td class="num">$ (145)<span></span>
</td>
<td class="num">$ (595)<span></span>
</td>
<td class="num">$ (214)<span></span>
</td>
<td class="num">$ (1,205)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">362.2<span></span>
</td>
<td class="nump">359.1<span></span>
</td>
<td class="nump">361.5<span></span>
</td>
<td class="nump">358.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">362.2<span></span>
</td>
<td class="nump">359.1<span></span>
</td>
<td class="nump">361.5<span></span>
</td>
<td class="nump">358.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share attributable to Bausch Health Companies Inc. (in usd per share)</a></td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (1.66)<span></span>
</td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (3.37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share attributable to Bausch Health Companies Inc. (in usd per share)</a></td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (1.66)<span></span>
</td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (3.37)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012033544128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE - Narrative (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Stock Options and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive shares not included in the computation of diluted earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive effect of potential common shares (in shares)</a></td>
<td class="nump">1,184<span></span>
</td>
<td class="nump">4,558<span></span>
</td>
<td class="nump">2,392<span></span>
</td>
<td class="nump">5,608<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember', window );">Time-based RSUs, Performance-based RSUs and Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive shares not included in the computation of diluted earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive effect of potential common shares (in shares)</a></td>
<td class="nump">15,372<span></span>
</td>
<td class="nump">3,929<span></span>
</td>
<td class="nump">13,771<span></span>
</td>
<td class="nump">4,110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive shares not included in the computation of diluted earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount', window );">Excluded from computation of earnings per share, performance conditions not met (in shares)</a></td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities Excluded From Computation Of Earnings Per Share, Performance Conditions Not Met, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012122360880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - Legal Proceeds and Governmental and Regulatory Inquiries (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Current accrued loss contingencies</a></td>
<td class="nump">$ 1,536<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012038733600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)<br> $ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 20, 2021 </div>
<div>USD ($) </div>
<div>insured</div>
</th>
<th class="th">
<div>Aug. 04, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 16, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 07, 2017 </div>
<div>insurance_policy_period</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>case</div>
</th>
<th class="th">
<div>Sep. 16, 2016 </div>
<div>action</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>group </div>
<div>action </div>
<div>case</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>case</div>
</th>
<th class="th">
<div>Mar. 17, 2021 </div>
<div>entity</div>
</th>
<th class="th">
<div>Feb. 15, 2019 </div>
<div>entity</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">US Securities Litigation | New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors', window );">Number of groups of investors filing action | group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsDismissedNumber', window );">Number of claims dismissed | case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending', window );">Number of groups of investors filing action, remain pending | group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">US Securities Litigation | New Jersey | Unfavorable Regulatory Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of suits filed | case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">US Securities Litigation | Settled Litigation | New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement, agreed to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">US Securities Litigation | Settled Litigation | New Jersey | Restricted Cash And Other Settlement Deposits, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement, agreed to pay</a></td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember', window );">Canadian Securities Litigation | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of suits filed | case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember', window );">Canadian Securities Litigation | Canada | Violation of Canadian Provincial Securities Legislation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber', window );">Number of suits filed but not yet served | action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction', window );">Number of entities, exercised opt-out right, pursuing action | entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember', window );">Canadian Securities Litigation | Settled Litigation | Canada | Violation of Canadian Provincial Securities Legislation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement, agreed to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_RICOClassActionsMember', window );">RICO Class Actions | New Jersey | Unfavorable Regulatory Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of suits filed | action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember', window );">Insurance Coverage Lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyNumberOfInsurancePolicyPeriods', window );">Number of distinct insurance policy periods | insurance_policy_period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember', window );">Insurance Coverage Lawsuit | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencySettlementAgreementsNumberOfInsurers', window );">Settlement agreements, number of insurers | insured</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Aggregate amount to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency New Claims Filed But Not Yet Served Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNewClaimsFiledButNotYetServedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNumberOfInsurancePolicyPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Insurance Policy Periods</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNumberOfInsurancePolicyPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Plaintiffs, Number of Groups of Investors</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencySettlementAgreementsNumberOfInsurers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Settlement Agreements, Number Of Insurers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencySettlementAgreementsNumberOfInsurers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsDismissedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims dismissed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsDismissedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=bhc_ViolationofCanadianProvincialSecuritiesLegislationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=bhc_ViolationofCanadianProvincialSecuritiesLegislationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_RICOClassActionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_RICOClassActionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012040163632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - Antitrust (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 26, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 30, 2020 </div>
<div>case</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember', window );">Glumetza Antitrust Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of putative antitrust class actions filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember', window );">Glumetza Antitrust Litigation | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement, agreed to pay | $</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember', window );">Glumetza Antitrust Litigation | Plaintiffs, Direct Purchasers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of putative antitrust class actions filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember', window );">Glumetza Antitrust Litigation, Non-Class Complaints</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of putative antitrust class actions filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember', window );">Glumetza Antitrust Litigation, Non-Class Complaints | Plaintiffs, Direct Purchasers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of putative antitrust class actions filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bhc_PlaintiffsDirectPurchasersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bhc_PlaintiffsDirectPurchasersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012028208960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - Intellectual Property (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 09, 2022 </div>
<div>defendant</div>
</th>
<th class="th"><div>Jul. 21, 2022</div></th>
<th class="th"><div>Feb. 02, 2022</div></th>
<th class="th"><div>Aug. 28, 2020</div></th>
<th class="th"><div>May 01, 2020</div></th>
<th class="th"><div>Mar. 26, 2020</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>defendant</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>defendant</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>lawsuit </div>
<div>defendant</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_NorwichPharmaceuticalsIncLitigationMember', window );">Norwich Pharmaceuticals Inc. Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GainContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember', window );">Perrigo Israel Pharmaceuticals, Ltd. Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GainContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_TaroPharmaceuticalsIncLitigationMember', window );">Taro Pharmaceuticals Inc. Litigation | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GainContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PadagisLitigationMember', window );">Padagis Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GainContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_MSNLaboratoriesPrivateLtdLitigationMember', window );">MSN Laboratories Private Ltd. Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GainContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PreserVisionAREDSPatentLitigationMember', window );">PreserVision&#174; AREDS Patent Litigation | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GainContingencyNumberOfDefendants', window );">Number of defendants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PreserVisionAREDSPatentLitigationMember', window );">PreserVision&#174; AREDS Patent Litigation | Pending Litigation | Bausch + Lomb | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GainContingencyNumberOfDefendants', window );">Number of defendants</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PreserVisionAREDSPatentLitigationMember', window );">PreserVision&#174; AREDS Patent Litigation | Settled Litigation | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GainContingencyNumberOfDefendants', window );">Number of defendants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PreserVisionAREDSPatentLitigationMember', window );">PreserVision&#174; AREDS Patent Litigation | Default Judgement | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GainContingencyNumberOfDefendants', window );">Number of defendants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PreserVisionAREDSPatentLitigationMember', window );">PreserVision&#174; AREDS Patent Litigation | Declaratory Judgement Action Litigation | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GainContingencyNumberOfDefendants', window );">Number of defendants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember', window );">Lumify Paragraph I V Proceedings Slayback ANDA Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GainContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember', window );">Lumify Paragraph I V Proceedings Lupin ANDA Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GainContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PatentInfringementLitigationMember', window );">Patent Infringement Litigation | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GainContingencyNumberOfDefendants', window );">Number of defendants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ApotexIncLitigationMember', window );">Apotex Inc. Litigation | Canada | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of lawsuits pending | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GainContingencyNumberOfDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Number Of Defendants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GainContingencyNumberOfDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GainContingencyStayOfApprovalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Stay Of Approval, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GainContingencyStayOfApprovalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of entity's patents that another entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_NorwichPharmaceuticalsIncLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_NorwichPharmaceuticalsIncLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_TaroPharmaceuticalsIncLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_TaroPharmaceuticalsIncLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_PadagisLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_PadagisLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_MSNLaboratoriesPrivateLtdLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_MSNLaboratoriesPrivateLtdLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_PreserVisionAREDSPatentLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_PreserVisionAREDSPatentLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=bhc_DefaultJudgementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=bhc_DefaultJudgementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=bhc_DeclaratoryJudgementActionLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=bhc_DeclaratoryJudgementActionLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_PatentInfringementLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_PatentInfringementLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ApotexIncLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ApotexIncLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012029621776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - Product Liability (Details) - case<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod', window );">Stay of approval, motion to extend, period</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | BRITISH COLUMBIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | QUEBEC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | Pending Litigation, Agreed Stipulations of Dismissal Submitted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember', window );">Shower to Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma or Breast Cancer | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Stay Of Approval, Motion To Extend, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyStayOfApprovalMotionToExtendPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyStayOfApprovalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Stay Of Approval, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyStayOfApprovalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA-BC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA-BC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA-QC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA-QC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012034257184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - General Civil Actions (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 28, 2019</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_DoctorsAllergyFormulaLLCLitigationMember', window );">Doctors Allergy Formula, LLC Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_LitigationwithFormerSalixCEOMember', window );">Litigation with Former Salix CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_DoctorsAllergyFormulaLLCLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_DoctorsAllergyFormulaLLCLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_LitigationwithFormerSalixCEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_LitigationwithFormerSalixCEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012040552960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Narrative (Details) - reporting_unit<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Xifaxan Branded Products | Revenue from Contract with Customer, Segment Benchmark | Product Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">81.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_XifaxanBrandedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_XifaxanBrandedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012026421008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Segment Revenues and Profit (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 10, 2022</div></th>
<th class="th"><div>Jun. 08, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,967<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">$ 3,885<span></span>
</td>
<td class="nump">$ 4,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="num">(270)<span></span>
</td>
<td class="nump">446<span></span>
</td>
<td class="num">(491)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(302)<span></span>
</td>
<td class="num">(360)<span></span>
</td>
<td class="num">(612)<span></span>
</td>
<td class="num">(717)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges', window );">Goodwill impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(83)<span></span>
</td>
<td class="num">(469)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments, including loss on assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestructuringChargesAndInitialPublicOfferingCosts', window );">Restructuring, integration, separation and IPO costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (expense), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(542)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(512)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(410)<span></span>
</td>
<td class="num">(364)<span></span>
</td>
<td class="num">(772)<span></span>
</td>
<td class="num">(732)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="num">$ (63)<span></span>
</td>
<td class="num">$ (38)<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(129)<span></span>
</td>
<td class="num">(670)<span></span>
</td>
<td class="num">(211)<span></span>
</td>
<td class="num">(1,261)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">501<span></span>
</td>
<td class="nump">516<span></span>
</td>
<td class="nump">965<span></span>
</td>
<td class="nump">988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="nump">477<span></span>
</td>
<td class="nump">619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="nump">484<span></span>
</td>
<td class="nump">560<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">941<span></span>
</td>
<td class="nump">934<span></span>
</td>
<td class="nump">1,830<span></span>
</td>
<td class="nump">1,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,967<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">3,885<span></span>
</td>
<td class="nump">4,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">789<span></span>
</td>
<td class="nump">887<span></span>
</td>
<td class="nump">1,601<span></span>
</td>
<td class="nump">1,803<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment | Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">501<span></span>
</td>
<td class="nump">516<span></span>
</td>
<td class="nump">965<span></span>
</td>
<td class="nump">988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="nump">676<span></span>
</td>
<td class="nump">697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="nump">477<span></span>
</td>
<td class="nump">619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment | Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="nump">484<span></span>
</td>
<td class="nump">560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="nump">299<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment | Solta Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">941<span></span>
</td>
<td class="nump">934<span></span>
</td>
<td class="nump">1,830<span></span>
</td>
<td class="nump">1,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="nump">414<span></span>
</td>
<td class="nump">452<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (202)<span></span>
</td>
<td class="num">$ (199)<span></span>
</td>
<td class="num">$ (396)<span></span>
</td>
<td class="num">$ (380)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestructuringChargesAndInitialPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges And Initial Public Offering Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestructuringChargesAndInitialPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012030984352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Disaggregation of Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 1,967<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">$ 3,885<span></span>
</td>
<td class="nump">$ 4,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember', window );">Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">884<span></span>
</td>
<td class="nump">942<span></span>
</td>
<td class="nump">1,728<span></span>
</td>
<td class="nump">1,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_DeviceProductsMember', window );">Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">449<span></span>
</td>
<td class="nump">470<span></span>
</td>
<td class="nump">907<span></span>
</td>
<td class="nump">924<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember', window );">OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">359<span></span>
</td>
<td class="nump">775<span></span>
</td>
<td class="nump">706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember', window );">Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">305<span></span>
</td>
<td class="nump">435<span></span>
</td>
<td class="nump">615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_OtherRevenuesMember', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">501<span></span>
</td>
<td class="nump">516<span></span>
</td>
<td class="nump">965<span></span>
</td>
<td class="nump">988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">501<span></span>
</td>
<td class="nump">514<span></span>
</td>
<td class="nump">965<span></span>
</td>
<td class="nump">984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="nump">477<span></span>
</td>
<td class="nump">619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="nump">418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="nump">484<span></span>
</td>
<td class="nump">560<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">223<span></span>
</td>
<td class="nump">402<span></span>
</td>
<td class="nump">465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">941<span></span>
</td>
<td class="nump">934<span></span>
</td>
<td class="nump">1,830<span></span>
</td>
<td class="nump">1,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">397<span></span>
</td>
<td class="nump">778<span></span>
</td>
<td class="nump">779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">364<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="nump">699<span></span>
</td>
<td class="nump">645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_DeviceProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_DeviceProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_OtherRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_OtherRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012033536448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Narrative (Details) - product<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ConcentrationRiskNumberOfProducts', window );">Number of products represented of total revenue</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Product Concentration Risk | Revenues | Customer, Top Ten Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">48.00%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ConcentrationRiskNumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Number Of Products</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ConcentrationRiskNumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_CustomerTopTenProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_CustomerTopTenProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012034229888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Revenue by Geographic Area (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 1,967<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">$ 3,885<span></span>
</td>
<td class="nump">$ 4,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember', window );">U.S. and Puerto Rico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,190<span></span>
</td>
<td class="nump">1,216<span></span>
</td>
<td class="nump">2,305<span></span>
</td>
<td class="nump">2,378<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_PL', window );">Poland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MX', window );">Mexico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_FR', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_RU', window );">Russia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_ES', window );">Spain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IT', window );">Italy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KR', window );">South Korea</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bhc_OtherCountriesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 207<span></span>
</td>
<td class="nump">$ 288<span></span>
</td>
<td class="nump">$ 426<span></span>
</td>
<td class="nump">$ 568<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_PL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_PL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_RU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_RU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_ES">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_ES</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bhc_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bhc_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012033515920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Major Customers (Details) - Revenues - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember', window );">AmerisourceBergen Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember', window );">McKesson Corporation (including McKesson Specialty)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember', window );">Cardinal Health,&#160;Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_AmerisourceBergenCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_AmerisourceBergenCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_McKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_McKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_CardinalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_CardinalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140012040414752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENT - Narrative (Details) - Currency Swap - Net Investment Hedging - Designated as Hedging Instrument - USD ($)<br></strong></div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Aggregate notional amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Aggregate notional amounts</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>bhc-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bhc="http://www.bauschhealth.com/20220630"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bhc-20220630.xsd" xlink:type="simple"/>
    <context id="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9e1813544ece4aedbf13459cd893081d_I20220804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2022-08-04</instant>
        </period>
    </context>
    <context id="ifa4f1d340e184a83a769da723d5d1bdf_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i318a5014ae1e41d09bf1de7db3ca0828_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5375b8e373564a36aaf52188e7d12cf6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic162a3439c8c430c97c3765d64ade238_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie4dcf9828b6146d280f1c8faa0decc1b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2aeffa8d800d40419ffca17d6354a930_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i77051dd59400460d84de895305bdc503_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ice79c5989bb147d780b5ce3edbaaa033_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id8b6d4b376e54c96b6861f58b066f558_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia4e2c9d81976431390f8ae34842a6dec_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1e13e115ca834d5c8178e3e30589f645_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iecf0a43ebd03491a8cd2f55d19444acd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i95b6dd1dfae14edfa03b4da8db2e5244_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibd553c3824724691bb7773ce70306e33_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifd7c9074c6584fea8bf7d00e43ce6c43_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5c3a44068c7b46ba80b46ad12a02d69c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4391dfc5122a436f9abd2091fc12ec77_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib3b6d9e41bb6491cbf140d6d7a14372b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if4c2ca217eb1474a9e4606fb8ac62dc8_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0faf02d0dab04ba2a12aed2a72ddb539_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie6ef01f8c2d44283b8c7b657548358e5_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3678a5f161a2409b8cb49dac580a2b3e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i07f07a50d8c848a5b09b20937a317971_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i87b5d05e9653487da8ca7e66ab3fba48_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8730ee88d2bc423b9151cc9c2820d19d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i36716f0b028846cb85d4eb4230d3d560_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2dc7cc39fb2243a28ac5a77266758826_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6b5d37c24d0e41cb994b6d343566c79e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i916cf2185b2841f8a9e4fd0d5fec5a62_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i43b9c3f038194349830beac9c871e79d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6dfaea77d3414998bbda1fdaa74c3687_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i58298d9eca31468d856c6a8af9ac695d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i737ae3f3c29c44eda0e06a604ac5d478_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id66ae7f7283b4cb5b860cc7e725569c3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4373a86e3f3641b1b628310fe43e6cc4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibc5bc84b42294f459a348f63c3726c9c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6daf46a421eb422cab6a685d448b4571_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i06d85523749f4a83b2b4c231d9c4dcda_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i57be2e142e074165b286ea861bf03454_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie3059ef14d774d44a01059d4de19473d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i030001e1f73a4abcb80a144774c1d968_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i76f8e88b904b44a792fab696eda910bf_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i774f5c7dc8fe4f20874a5a05070d8148_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i167c3eb2b5a24484aae6de79b43072b9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i22ce8f1c4aba43659ab73d3c120bd01f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5f0bb2a47484474cbd31c19016dce90b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iadf2cdcdd456462bb8b4d9279093e8ad_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2238c74c755346c79d5d762dfe2cd6aa_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0f2ab9065125401bb73c3a17f98f4c57_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i94793ac34eb24e699f57a3960e391e71_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic6618ebcc4884ef78540a8090e1935b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i87abd59869d7404c8d073f59e57b3927_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb17c62b32e2446fbb119cdb52d7cf3f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a5f744b0e03413c9fa836c080e97ee8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i989da2ed6f4b41c18402f75e75411454_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i16963925dad9481f931247cb3748b170_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4677f0249548444e9357645b49193bd4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i29d13958e0ae471a9601cbcfbee2a354_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1f62a1dbada6412d9a70817c07d9551c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic4af951a869647b7a15353420cc9a86f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iba4b227c13d94a3c8b88f5359bdef6ad_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2226daa2ed09422d853e54bab742c402_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1ca51f98774641caa2fa73733729ac9b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6241ec65cd5841d28d2b1250bb5b5996_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i12c22386ccd746679fcffe88ce0ac211_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i628fbe5e0c6641f0821414b9534fdfbc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8f53aee8e3d54f4c9d733db6eaab6639_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i83ec1ba0169043a5b8ee5935b00c293f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic5e21899f1044f7fa7cb214f91d5655c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i168fd2ab08394dc88509e23e01fe1f09_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i54f5ce0b0a044bc88c6f3917442a0aee_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic8ecdccc3b9849ea91d1b8d126581ab7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia4bd722a099c434c96732e1638d0eef9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if281e8e8aeee4142a78388f4196a2cb4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic9b445a9016e474ea5b82e795dd9171f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iab6dfe2f976644e99955a0681d7c0c9c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1508df3b43b1420ea4df39c0ed271596_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i1419e3c9d7064ed0ae3e2c5034298ca9_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="ifdd2e805422643dfb113cf804f616871_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i0d34ce2c08d1460f808a069165908113_D20220601-20220601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="i929d5ea1c5624f61b981d629befc7a9d_I20220601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="i1441c284542b4be69c98952b98de6886_I20220601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="ifd3c0b53338441d68bc503e5527d1220_D20220601-20220601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="id112e4cb690043fba76b75855a318fed_D20220601-20220601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bhc:IPOAndOverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="i5351c87dd28040558ca2b56602428e56_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i41079230ec4f4c298b2e78b68dbf4675_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a1cc3e19bb5406f9f7bb16e324efb73_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4154c578f14243c9b9bf1af4b506141a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5c45771f0e2f47988c015be717b2f0b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i41e06bd172a5482eaf50c7db24abc26a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iaa9af24c349540cc966f28ac5d9956ed_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i53c5043ff3cf49cd84342b026a1ccd23_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icc6e7bacd9e74e10ab66ecc0b3c66513_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib43f03b9a4c24364af00b0bee48970f3_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib720c993198b4897b6de065be0d2db71_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0903c200bb4544e59a69d3d41e660f9c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4c259ae988c6479faf350e58d008e78c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i635febccfe0048d18fbd37689e3cd69d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i415e68faef7f4ba28dd9ac453dcd2665_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id1bf4e809b854d01bce396823e6d1480_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3635e4095c1b4cbf852ec17575d58b30_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i4f09824df81c4936b5ccd49a133e7471_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4ca0942470cf47b0a264c45f0187b74c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9595e765516542c0911edc919a2de08e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9607524bf3464d7c9cddb1ba970385e3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i340db29595784ee08b18b8bab8b169b8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie2c856c4b2614789b5fd854b8955fd6d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i60bf28905a394c1890a5d2e6ceb0cfcf_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6269a678f67b4ecf9db4720dcce9ef03_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4887e1b949fa47e0995174f52a3c62f4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6cc2ce2251ff4d70a86c4ce36ba413dd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i38ce7e9873ed48928d8f66267a5181b9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1c8105ccfc3c4797a29a70cd4dd59ad9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2c02e9fd592b472e98bf4f6aa3087550_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i543391a7e8714bbfafcedd3cb1ad5539_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6e5553f78cf642b4a35f59e0c0a41f82_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5e4b08ae397c4999b5a89bd9886028e8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i946fa40358f2484eb2b268a38b324c08_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i88092f2a3121475ea6f4d62c541f5263_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ic3691b4d8ff64742b92e7f95b3ab5725_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic98d97b553c347bba74a30a630426fa0_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i60aea4fd35f0463c9e764ebeb3fc9833_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:AssetImpairmentChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4b7ebf59aac94b30b7f7b423b41e117c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:AssetImpairmentChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i52c2c4c1d1a5416b9c90de8eeb79bb48_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8c73de91dfce436faf9fe431bbdc6487_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1ee589a448d54140b1753817a06b38e6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i73006e60a9e74841887814ddcaca7dc1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i99ee9e6ccc2443c0b6ca3d2b22341738_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3945140cd4d9458eafb0336b8c0878ac_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationAndInitialPublicOfferingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i571cafc77df6419e8f7ad8e88a7f5d22_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationAndInitialPublicOfferingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib1d5ed0948004c6da2b0030b9c2d5c61_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1cce3ab850c54369b71be99818c2eadc_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifd4d5e497f284e3bb6f031694e5e632b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i20f3c15d038f4d9a95a41ec1632623ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id78b9bd044e04128813ea5234fe8bbef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic88bcecca27f4caf845d3357626418ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb74f1a8f9f947d5b4d8a76565d7e64a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i61bd5fedea3e409b8e2fc3fcc1946608_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if25b6bb0d9734b1da12ac4c00dfb2152_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic835863b5091449ea80b36560fc1e6a3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8379b2caaf1244258cefe506e215e56c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9145c463e6ca4724adb2d0d6582fec23_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if1b5f54af20f4de8bfeeea70bfb7ff42_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9c974af31735487dabbddfa5989251cd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie63c790d802547cea65c40ded8c158fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a344934b62143ffb69252e4cddaf7f0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iaabfd7c03ce9402ea41cfcee705244c4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombToBeDistributedToOtherLegalEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i189afe61ed934a13beac41e9a8e72d03_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia3cc2ca14e8e4aa5b2cdb9d9edc76003_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i80db1e595e9640d1885c3342cd690c01_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i54705085633648acb51a31a97ced439a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iece67921157f4e1a974430192b9d3bb2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i74f9e7451c5d4e35be2c1947c78de1e3_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iea270cf4c54447e083b7f756deb2b619_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id174b5ac9dab4a9795348c9cab5bd884_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id5970569842e447ca7e924e7d2d9c57b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iadd5508489ab4388a28166622ded71ec_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2748f8a48f1c4077a65379baa42188c9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9e40ec51c8e14dcf8242bf19258f7e98_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i56a275573f694076bcb43a832f0ec8ed_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5073339adb074151bb1c3f96161a4030_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4b891f480d594aed8e806f205699bb48_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i29a580e8bc224076a70259444452e1ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i79fc8f975e3d4b62a88faa67e904f40e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i96796514e5f543db98cc98707c804220_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1483a64c418348fa85a7a2e2d92d9a71_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0beb279eb94a4ed9a49020c90d93ed68_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i518e98f1651849d6aa762c450415511f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8726b33a91484a12951301843f01bde5_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1a487257cff84ebb8f7de444b4ebbe8e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id76bfb01eac947359aab3481b8c4cc1a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8a317605867040149a9dee38efc52b70_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i85f23aaeb4ab4696888e25b5585acb6d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bhc:MeasurementInputWeightedAverageDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ieac99a0231e043b7a6cf8a6875d75f4a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5ed8d150a9e04ca1951e0567580a1c34_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i605f016464d646fabfb72ea00b5aa146_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i26184bc3f87e42b8af77e4f35e46cdae_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6085cb4d390c424680c3eafd241edadf_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5faaf2aaa33e43408f0747441c0e1404_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i61fbe90e93374904b5398ecb0a93c67f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2a23787efe874f5c8d650b7fef441ddb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icdab7f29e78845a9b4b14d6cdf3e20d7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7b1968cf2be247feb9dd0cc924d8f8c8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic83fa38af9914b0993c6039b714e49b9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i19b47b5930ac4a57b58e47cb7fb6bc97_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0408adaddad474dbeeab55bfaf37b13_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i43736d02e7b34234a0989ae49e2de7e9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0c83dd8e105e4a4692fb8791ce3bd76a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idda5195bfad44f2d9f625be80dcbf677_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4ead88a7e4a8400f82d1ed2f6fed1364_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic81756cf7add4054878a13b141b160aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ida1c327408524e2b9da48b8046b1596c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iddcfbc0128c04d5d9a4a4a24b7c58559_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6b3901031b674c118620c5be45160bef_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i30cfd27625d04204b5b2e2739311e5d9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6cc006d888334261a3b145852eb7937f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9ff241de36bb4d838d517bfa74e1000c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idda6bfc9237c4952a9c07b6cd1fb8aa6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8f2123e8bcd8437b81c7aee9a2cf5046_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i86923f0a7d294df0951a3efb41cfb120_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb4539c0cd93410f8877606829a28dbd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6b9c8e4e54e14c11a2541b80edd0ce79_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i70c6f0d3c53c4ae0b8bac9c750c52401_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ife7ba88747a44275adc038a9f0579315_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib0e2720588804bb59fc95044cb42a692_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i88df2b54d58543dd9380c146b625dca4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i382fa2f0b4d84cefb5705374b83054c8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ife45351a90c740ae923457acb3f6c195_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib5108829d89c48d8b0cb4fec084de93a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia6009ca6df304f4ab8d03e57a2f270b8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0a80fbad02df47ffb3f0b027e0c7052a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iafb5fd0adbea424d95cb70b136e7d1c2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0d31c842cea74aa198d8cb6778701a57_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i754ebf26cb214d2a9e08dde9805eca10_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff73055417e147b7bd096e9578313bc1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if2b016ed329f478591978619289e8da6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4dc4af5c709c464682b201a4d8b84132_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i92e5ef7f7dc14944b76087572c2ba682_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief312576a3114c0aaed496cc8a87eb3b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e70d8f7f02147b4a2ff2c867e6566d2_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i86bd562069224eb1a2aa48a2a7c117a3_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9c7b76190d5140fd9da04108a1ed24e5_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i430a37ccee354cf9b59987d97e781a8f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i86a04889bcf044b38603f4f4ca1d8de4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i864ee40a0f6549cab4f16fffdd93c3fd_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iecd0285b18fe41da9fc167864657bccb_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3b0f083a6d9044aaa355608d9d198fb8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie7f5bfb1314341ee926c9b0fc40e54e2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0f643780bb9448ef9016e16f6b89c2c1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3f56f31b09064a848920713fa0661b76_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i647555e6b2b54c909b5caeb1da998334_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5607e58e61534749aa9df1f4280fb05a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4284138a323449c291086d55ad27a489_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifcb19cddd3134b4d8f4ea965f330d69a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i31f42e923b084ff0a4f4fbc812d7be7f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie53716daef0b4224954a5c9de0faef7a_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if80b04373ab14c578c53ef3c8014d242_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:ReportingUnitsExcludingOrthoDermatologicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9e3ff28c3d904d4bb50e1f6b60dc5774_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i128de9e46d854032ac8fdb6fcc689f05_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie76f7d931cfe4a698fa9381288d5e165_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iefe6bc2fdd6b4faa87a273eecb773668_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i448fd15a1c2c4081960f6912ee1d7df8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i48edc6c592494439969797a031f0a38a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ifede6e1372dd4ddb9ca2270e1f8b8a13_D20210630-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-06-30</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i495d40d3ed894092a5e407185421dded_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="ie0b5d00c327249b888e21da2766eda53_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="ib56d8698081a436cb05434bb225f22eb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i15ce718b5f734e61a6ad0bdd28c54691_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5a8c0ca7ff6d40f5a4b99dd032ce969d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i56c650b8e02f446bbdb4b9a650860424_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i161c125a316c41338df59b517707ec98_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id6fc6e77709e4c859b776fc4a4a569d6_D20220506-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-06</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i09575f835d044c72a01f338fc66e8824_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9fd9c089632f4f5f8b22cfa9e437b633_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1a6c26cc64df4c86826a5f9b2862ceec_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ied74a18a6e8c464cbf9706fc4935c4ab_D20220506-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-06</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i08e5c94f206e49029306d4605cb23f7b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icc599dddc6874659a5df85bf6a360251_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie564ee44d1b6403eb498a73450791f9f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icc66dfaa572849969745a0c5f0b68d37_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i793328a205eb4096950273313b00bd65_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6fa6b74354994e99b127ae89877febc7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0edf0a7a93de4224aba9d200f79ca4dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic2335f26e5e14e98a36115419811c130_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6c45bbfd4f504c27b6226cc0c73a33f9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieadee1866a824ef498fe7b558d0181c4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i40aff33e8b24488a834a063a1529422b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iafc837c840c1423691e83ffca1191fb0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6cbc2b4901924769a731d568c6814714_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f38d4ca2bf94b95844417747e708aa1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia7c9cb43c0384e9db889a190dda21497_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b1a4f289c1e48948d7f02b9bee8c3b7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idf103131598445f68811c80a255e6f67_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i52543bc3134e4d3ab18b8abb808ab987_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibfe50f19787342d2a1eba96ea86a16dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d8d5f877595471594e7cd0d8a9a9bb3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id0abb0ba205745ee88868776020e8f2c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i833d75561bf74683841f8a1a38848570_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8cea3fe80b2940b89f52022162775e03_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i28a10e63f05e408188f20f7b9cdcf496_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia55753b63d414228b384e230c86e775f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a25c3e0cf7640eb931b7c3c9e6872cd_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iee049418c13b4e299a8c83e2be11bc55_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic8a3b188d15b4912ba75bc9ee39e79b0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2a975e0e21154064a6bcc406c36b62b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee91cc92408044d795d6bcf969858eb1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6f324ee7a47e4543b63557fd35984d09_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if9165a4c4fa4438b9df24cf0a0792346_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if803056461c6486db832367a43895632_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i398c1b11a4d14d1a9a22642a4366b4f3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i13687ae43098477691509c97baced059_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7141189be3804bae89bd5a07b8eed649_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic76bf6c1d1e74dbdac6341facf5d2281_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2065ef23dc6d4584b71fd6c1feee2ce9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia157a13c8e7444d9a15b0ef900f499ac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i55d39b6dbdc64a07aafafbab0a66b4cf_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4db4028fafd541e2adcdd0f2a8acb446_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i14f52e507b3c4725b4e1096cc5b3092f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7b92a3adf20a4c61a5df00eff00b36d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c2ba2913e7c4009a057680b01952716_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iaa56bff66e564adaa6394ca261106b7c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifeef119d45684adb8aeab24feb20d75c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id8fbf55e1f7641c9a02ee367f63c49ea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic5eee7cc73d847faac3aa9d22d79a2c3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0c1392391ca546758b079e1238c10a9f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie97aa1338630440fa931939603c3afa8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bhc:SeniorSecuredCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9a193ea233134644af3474c6d58858b2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i70293a619f5141b8baf60127b5cdb2d3_I20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-01</instant>
        </period>
    </context>
    <context id="i3dee274036df4695a83fc9e2f921cd2a_D20180601-20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-01</endDate>
        </period>
    </context>
    <context id="ia3f9fb93db3f4b06852f02dd6bfe37ae_I20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-01</instant>
        </period>
    </context>
    <context id="icd3b61934fa0481cb903c6cad1023951_I20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-01</instant>
        </period>
    </context>
    <context id="id684a5f342be4a9dacf6da92dfbae334_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="ie870cb7bef5c4e1f80f119d7291d6694_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="i6da3d0cbf2d147fc8ed6d47a33114b1b_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="if697bdbf4b2341c28c62cc63991814b1_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ic821cb350682455fb80a7cf379859436_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="id3317da9d69b44a5a0f5530521c43d9a_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ib41ea84450c549cdbd5dd7eb01cb3125_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i1b5b14287deb4a36811e3567b40c972b_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i3e01c970675a436bbf061ef17c476e22_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:CanadianBankersAcceptanceRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="id1101765767e40daa36e42e2d05de9aa_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:CanadianBankersAcceptanceRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ifdc5cac429d2406fad6f5db1a981f8e5_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:EuropeInterbankOfferedRateEURIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ia8243ac81d9d44639387960613fa815a_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i6e609a7fc5194c08831552ad31cb3326_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i084c2ea2f89c4a93a0688cf9fa993c87_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDORAndEURIBORRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i3357e0f78c5d4623aa4578bb9c5bfb71_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDORAndEURIBORRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i8e66748d2095465691388b65def844ec_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i84a6900222c6444eaa2f43c56b21657f_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i8ce4074fb09e40f88a53999eaedb2071_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ia63076c25e4a4832b2cbf2122f93d974_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i31d884d227e045f3b2a89fc5ec26f5bf_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i88238e27384b4699bca91ad69cb37063_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i6b587afb6b2449d6abebb3e8259edaf4_D20220630-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i317f673a636e4cfbbe6308e053f9a1b1_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="i222693060eda48fcb8a8ff27a64972c7_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="i1be7401b40834ec4b9897f7ca08a3bcc_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:NewRestatedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="if65afec1ca9042d88f04d82fb68476c8_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="i0459e2e91fe04b5099b8551dc212bb5b_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i025e4c51c5f2476eaa7e7b81b3dd925e_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="iaf0a3be8d6bd4202945aa5df250dec6c_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="i13fb480b68044eeba4d131527e8279e9_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i5197b5b99efa4eb8bf8f5a69128f60d6_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="id57f7f9d4d2d4e3e9eb4720166ca7a73_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:CanadianBankersAcceptanceRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i37e23f9713ba4df0a3897cb703b32626_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:CanadianBankersAcceptanceRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i9b4a82c59de848fd933f25769865c682_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:EuropeInterbankOfferedRateEURIBORMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ic57a642f15b64fba9bd4ead705bdcd69_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SONIARateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i745d6bb83b7948309a5bca9ce9967c7f_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SONIARateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i794772c7b0a94cb4ae0831e44b12025a_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="if00b75865db04bb2a36148fc758260df_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i9fa8451ab2b24a2f9856257a3e56525b_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i97fcf2fb2a11462b97034820ecfbea20_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i89435b8df34c4e929c8786a5809ae39d_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i6eb7b9d116404dcbb45abb5c29aab3db_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ia79343ddb46b49649e9595a3a81569bf_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i7f27835a65de4739ba485d7737c8fcf1_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i4503aad9ff7046f7b027b10d33ee0a67_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i62be326ed1094f42a72cf8f28f3824e9_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i3bcd09daf6ff45d1be1768c23751ced6_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i586f734bb9414bcab81efe9583058179_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i54647254f8ae45e6b7709b92695601f7_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i86c83d00da024414839c7b0495b95f61_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ife48262157f54a9f9411801fa38bef33_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i31491c26d42f4c55a76225f7c3e1437b_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:BLCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ib72d5c0c9cae4427a65ac12763613c50_D20220630-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i22e56e38486147d28bc2898f73182eef_I20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-08</instant>
        </period>
    </context>
    <context id="if19b6a01b94c43baac9f6b2e2576cb33_D20210608-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueMarch2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="ib2801d5faaff4cff805188a7408a18d9_I20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueMarch2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-08</instant>
        </period>
    </context>
    <context id="id15e04f207ca454ab4b3869196ecb3aa_D20210608-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="i7ba95d1a1d8a4e50be9c80b6091f5c9f_D20210608-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="i670946275ba0478c9fa99c66c759a07f_D20210608-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="i88c94d8d653b41e2bece3ba32629f570_I20220210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-10</instant>
        </period>
    </context>
    <context id="iaaa9e9d10abf4341b32b2669fa6bd9c5_D20220210-20220210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-10</startDate>
            <endDate>2022-02-10</endDate>
        </period>
    </context>
    <context id="ib171e1f6ad134f1e8a838ae91f96bdc6_D20220210-20220210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-10</startDate>
            <endDate>2022-02-10</endDate>
        </period>
    </context>
    <context id="icacf3f32142f4f7793bba94c9b3e3ebe_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib86afa84ce1b41d5b48258b10accd8f9_I20220118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.00SeniorNotesdueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-18</instant>
        </period>
    </context>
    <context id="i00eb5a1c1bb64566b2473aca50a87f8b_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ib99e0e69c7014f3db279170c3e995c4c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i79deb0713cde44578625b28d0e656766_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0acce2b828944f6db85708f4bd37bcd0_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i1b39d2ccabe247cca573ab8370a379ba_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ia07ca095cb3c4d2989e3bb13b2aa76e4_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ib6f49645538a4fd882535c15503691a1_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i8b237fbee2f7460db22b0481466222cf_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i4cd8cb835ea2462f98e5d1fadf8a2bf3_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia0860bb9611a474495df2c84fca443ea_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iba8a2efe71f24a6fa3f18d4fe8dc0568_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i666ce213d28248b1853cff9f08dadf3c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia9f1c1de00ee4efcb8697ec7c3c5c449_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5ffeb2497315442bb679da042122c643_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1b4bf4e8fe81409981be4a7ea9e8c8b8_I20140531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-05-31</instant>
        </period>
    </context>
    <context id="i8fcb725d105e49e7b841b1a1b6ea5845_D20180430-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-30</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="ib6c3216122874ca2a63bc8576f858181_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9ddb299f73684060bea0bc507f71ef99_I20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="i5d0bb60ae16b4974b67f6d117230127a_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i1d3dfe74f4714b7a933c87137684aa03_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="id6202db2af2b4bafa11ccccaaf34418a_I20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="i9090a13c2aa6459eaac11b6d545fcbe2_I20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="i9f3765198c384eddb84bb962d8f1d47c_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i224371ec19ea4a1fab4ab9edec1c44b2_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:IPOFoundersGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i82c8f4dd25114f83975b0eb530968e3c_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i6be3a30d81ad44bdaad72c4d270fd4a4_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i515efea05dbc4414985b6f9579a6bbce_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonExecutiveEligibleRecipientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i33dd60c60854413ab4b719ac057cf817_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibc3fb9c24a1a42d6a1abed1c7e372f2a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id4690e57d623418889d484725bb730c7_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i41c4ed7db4b34d4bbdc90c34f51f1caa_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie919cd08314e401e805d15dfd8c4b7f9_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id624e9058a214f69b2edf512f1e9c531_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i79b44039ced246f8b01d5c45ecee92be_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id7f366437a554f0881430dd47c95e590_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8324a3a87b5b4431a240a863bcd109e7_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i162c7abaff6441bcaafdcb7c3786380f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia50d9a9309cc4eeabfd8a0b7ec06cbb9_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idd76194575be490ba80170f4fdd8bdeb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8c788daa389d46c7ab261260e329fa06_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id2a52a76022341358c404e2fb242b953_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibd6d0843d657451284d1138fc8962e1a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia4c50767d19044e08e9feb4b807a2916_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifc74e57032d14542b4caf11d925a446c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie6dc26b569a743babd2022197af82304_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i451c05ed9bb34dfd81236d9bd495bdd4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i697b06c7bfab4c66b24bd5ee7d182aff_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icac063b2f1aa4b21b334538c17b2df50_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ROTCPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i557729c1fe0b4b1480972c1737bd0a7f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ROTCPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie92ec71133c44dfc990b249053e5e02b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:SeparationPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iadcde18252cb48d884cbe14183aa9c67_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:SeparationPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i68d73c7e5e384257812c2170febe4778_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5f24f78b6a854ff5ad91cc5ccdd5b4af_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iab029c733228479b92d1b8a6e2205965_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idd8a8752f1f749c88cde59232457ef50_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idd08efb021e240aebc5ee605feba929f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i720ba0ebf9c2430f814fa6947f648cee_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i25c764472afe40a994fbab76db8f8203_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i488260ae8425453ebec7df5c26c9c934_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibdc7a899aaa242abbfc3fb10b5125784_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib81ba7780e6c4af981ed3d93789a7a30_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bhc:MilestonePaymentRelatedToCertainProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib67e20cff1f34666a7bda60fe85e0092_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icb9c38f8768a42babfa04ab70b2ba49b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7c6c606001c0400cac53065471f71ff1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib34295b40b53420292196a9f2aa2100a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib34421622cb84c04846df6c8e22ebbed_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3b78053555ef422d9b068388d75f6068_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5d86e8e57d7e44a4bdcd3c9f0a800e7d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if9065eee32f34d6fa02a0d1a52cb32c9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie62c44e3a5424b748e2e6a9534f2057c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i30507c6e944f444ebabb56848a53aea3_D20151001-20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="ie30ec1de778c473aa24992db460e51ab_D20191216-20191216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-16</startDate>
            <endDate>2019-12-16</endDate>
        </period>
    </context>
    <context id="i74040cd3e59640bf9752be2e23b0ac69_D20220630-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:RestrictedCashAndOtherSettlementDepositsCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4102d9065afe4932a90e498521bfa3cb_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib9028ff993434533b2b5623750bbd556_D20150101-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="i5274caaee15944b38fc2385088096f35_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icb691d8ec4ac4d71aee1342723827741_D20200804-20200804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-04</startDate>
            <endDate>2020-08-04</endDate>
        </period>
    </context>
    <context id="i757e35cf9f3d40a4b5c93f8ca62f5f21_I20190215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-15</instant>
        </period>
    </context>
    <context id="iaf7e31cd823147eabf32516dee47b2d9_I20210317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-17</instant>
        </period>
    </context>
    <context id="i5d58819753a6484caa4ffdf910353903_D20160527-20160916">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:RICOClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-05-27</startDate>
            <endDate>2016-09-16</endDate>
        </period>
    </context>
    <context id="i4305560891084775b5a8f280c90557dd_D20171207-20171207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-07</startDate>
            <endDate>2017-12-07</endDate>
        </period>
    </context>
    <context id="i74c5348c904e49149ebdc8edaa5089a9_I20210720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-20</instant>
        </period>
    </context>
    <context id="iddba8dcdaa5c416aba241e33eece7d94_D20210720-20210720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-20</startDate>
            <endDate>2021-07-20</endDate>
        </period>
    </context>
    <context id="i59952c7ec62348a0bf0304c3e9c4aa1f_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i26aebd3fd2cf4b1b9c6310ad6e35e2e8_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i9b5eea4e2b054fe9b33f5a1c2468e6be_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i2bacfb7cad21454aa0b7847ed301e366_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="ib1b9c6e509b24bc380ee524ca05ae442_D20210726-20210726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-26</startDate>
            <endDate>2021-07-26</endDate>
        </period>
    </context>
    <context id="i6a2d38205ea946e095aed8012d8b17c2_D20200326-20200326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:NorwichPharmaceuticalsIncLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-26</startDate>
            <endDate>2020-03-26</endDate>
        </period>
    </context>
    <context id="i0ccb1877ab504b0da10aae4fbd2023a4_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PerrigoIsraelPharmaceuticalsLtdLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="ie0c3cf86c7f3419099a730b07b8db1b8_D20220721-20220721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:TaroPharmaceuticalsIncLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-21</startDate>
            <endDate>2022-07-21</endDate>
        </period>
    </context>
    <context id="i3ada237c7e9e4db3b48af8ba931e7f96_D20200501-20200501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PadagisLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-01</endDate>
        </period>
    </context>
    <context id="i19fa8a54dc9d4942b1269451e77f4405_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:MSNLaboratoriesPrivateLtdLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i163c3bd2391743dca52453bf7bb54c2d_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic0fbaa5244774f8785a4c3159850c238_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9fa2cc2f25c840c8aa8cd8f821e0e024_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">bhc:DefaultJudgementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i535a21de35094309b7dde211b4cc6c75_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">bhc:DeclaratoryJudgementActionLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5e13b85e78034bd58a4c8e9b49e1b7f8_D20220809-20220809">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-09</startDate>
            <endDate>2022-08-09</endDate>
        </period>
    </context>
    <context id="i699127da9e51419abf9760aca1b136de_D20220202-20220202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LumifyParagraphIVProceedingsSlaybackANDALitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-02</startDate>
            <endDate>2022-02-02</endDate>
        </period>
    </context>
    <context id="i9baba49f62e74a14aed75dbbd081c3b4_D20220202-20220202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LumifyParagraphIVProceedingsLupinANDALitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-02</startDate>
            <endDate>2022-02-02</endDate>
        </period>
    </context>
    <context id="ifac3480ee2d142bf905b63b471677601_D20180801-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PatentInfringementLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ic187ba4416b64839ad042a51d60bfdd1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ApotexIncLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibf92d71d956242d2ae34c263d78aac0a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ife18e9be510b4194a3a4277ad67e7250_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">bhc:PendingLitigationAgreedStipulationsOfDismissalSubmittedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8381d2aef44c4cb6bbf760cd8d3e40b8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i768a63ca14b44cf0a9b21c5ad06e8cea_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic0c00ea3613744deacee586a7d91e4c2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-BC</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibed3ef3f1abe40969ae83f8df49eaddc_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i256a9238c6d447949e96e0113ba7913c_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="ie1614b745c4246e89dd4a1987611b15c_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3da2b3029b9e49809af6f64595c73392_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:DoctorsAllergyFormulaLLCLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i521280a2735e43e2bc975a7b850cdd00_D20190128-20190128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LitigationwithFormerSalixCEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-28</startDate>
            <endDate>2019-01-28</endDate>
        </period>
    </context>
    <context id="i99a74cae63104c7b82e2b04e1ad12241_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i135087334a5d4c22bfa9b973191edec2_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i33f1397d8a6c4970be8e3744fa05b614_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iaa70c909ebed4960ac5793fab0872d29_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia1fd4b8f2dca420587be152cd56a71f1_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6165a9798c56425cb4efb5a5f6723bfc_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8bd4de5a193d4a029240767ca5a07233_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ife570419c7bf420eb1abf7c964aaca40_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3029344c603341c39ead09035d7dfa4d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0dd827b38d174dab9b133e198c4a8961_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i58ecd7a903984152b7f6c2ae9bec8334_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib91d44ce63944098b3420f5c3736b8a9_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifc157eb51cba40e89c5c61507c69e6e5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i66c6b838e58742c0aec7f7e50a13b045_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0ffd9a91d95843f5b57ffc1c00e8f083_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3dba412bc4484690b009184d4ba468c6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i52b7ac6f51a042f3af9aea0cd5d38c09_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i641af432b0f64dcb834dccbe69309abd_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if41baecc67df46e3909a38e74cfc03c7_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id4ade95eb6964658bc80338e46f307dc_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie7050fd087c144698ee6de6deb8f7b08_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i56f9693a8c8e416f9524496f13d18f13_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i457d6b1c8dad41d797d6f3caa45e3c46_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3c0e69d16e47492cba77b50588ee0475_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8193e2fcad6a491c9c98e5dadc6de63a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iabd877b8ef23452c8e9fb08b70c21536_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic7fcbc8743ff4d28a9642d1d245a31c3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia26aedc76fcf44ae81e064729f28caf3_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i341826d4665e4f9691c35f15ba5167d5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i120c5c3448804817954acd3db4e441ce_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9f6e559fe09a4393a2f7b2d796409368_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1917cf604f114f61a3027f48b8e509ba_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i304de3dee0ca46afbd4d773d5b73caeb_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia5bdd34908934731b3f7ed30e692ca37_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib94cfde72d4a4cceaa45cabf3b8613fe_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i697b4e937dcf4444a2da425da4f9da4a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8bf870b296aa434ba035c90e0472f7b5_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i37722f9f64464a7789b7776cda56802e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i68e196aa912c4a06b50fe1a7ff07c9c3_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1535a26028ca41d681e4eb89f1cab0ef_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4ac012d36aa744d285111dd5bfa0f49b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1532aea43eb6489e973b019623e7468c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i40ac48836f7b4475b5d15a50602624db_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie3591c7e9bf84e3b97a9bfacbd8fc4c0_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9945eced06dd4de19098303f4b0695b2_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic6fdf97ea30640ada7e3f06ac163c2d4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i363714d873034daabe033fe4530323c5_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i18def26b9d7f4f769191fbb1b702e4e8_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9dde17363f0241f99f397e9fc622e2dd_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4e6d327e99e94ae6ac9c9222edaffe89_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia2c6d5fc0df14fdd8c5d865fdd5a471f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5244d54181f2446bb8ba651b7b0fbad7_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id527f274d97e461ab64689a5373f4d81_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7b3c647fe76d46f0bc12c314d43c29b1_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib4daa40222c247d590b95cd5d1197454_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i00857c1731c645e18fc5b267ac5193c4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id70a3d87ffc848f3a702d8181bb0aac1_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9098718d68eb4191b04c1220647b46ac_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i98252b07170a475c86a2d0a8454ebb3e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4d0cc468650a4f8eb079db9c1f1d724f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icb0c495400cf41aaabcb4ebdf8cc8c54_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i52b3e89147934577b98cf490c2dc6e6d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iad533e12c8984d1aabaf4ca2ea7f295f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic8a84b3f2b824ca7bb450377f0288abe_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id997cc25c0184d418316a9c77c4792d5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i175f3c9ffed049e683076ff08bfebbbd_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia439123672ce49b5b793b5103844ab11_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie3a10c843c354c3eb832c610df7c4cec_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i094e2621cd8646149b22d5835913eff4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id8d1a68df38d4361a9ac80a5d0b7650d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7f1a30d7d1d8412cb4ef23629b723985_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i55e9e9d493b84ce3b937b48d26431696_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia453e822304242f5817dad90b1b13517_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iaf81fc999e7d4614a4ac10b31038913c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie523d947f1fa44f2a62fe53506efc11d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i45ab7ba925334c48973d75b0c877af73_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic38842b1d031468aaa7b2c3123e44ef8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i636acc71a6ad4a25a53a6db7c8380b4c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i71427b5dcdf84da295d3722e33c25b53_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ieda5739af68749139a002f6bbc8b7968_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8cc095d5494b464eba663d1927c92206_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6ff22abce45548b7ae5bae24b04a665a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if6117b7192764a0b83f96ffa1cb7174b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i66e4cb2eef1c497aba28c323a09b369d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7885ad991d8747f994509e41120e1156_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i033175b733ff4d76ac19b4af757b2c72_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2a94cf1fdbb647919430b66b2c3f4818_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iaa1d61d59efe430d99d872a21dbbb93f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i58fa049f1be9491d86f8e95d6a2c5777_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie753b580b8874261b8650c0a68ba8d70_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id5c02cb63e5b4aa3a0984f648ed39900_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iecf369ea76514f31b38a239710bbca0f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8530b669e5514873aea052a84f77f1e8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i13a41399fcd14f7c86e4befc31b9bed4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i96c50519eebe43e28fe0e6f1d4c9fcf4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i96c60e82572346049ef163998e5a970d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0da421ef8e5c446692c399776ebed030_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0702da316be6440e840ce3f2f1780427_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iddbe6a4096ff457cb62338fc9c69d310_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie25fd17d002a4da395da4369a027c307_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia4ef1ddaae604d258905581fe15e36d0_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia5239df425024a3e9d3b04b6422f8d1c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i425a979e48b04f06b178c9b31d745920_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if1b2fa78c45a42dd8e6d9fc4f37b7f8f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icd114af7b13347929658a839ced9cb43_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2c7ae506423648cf912c0b4dafc6bb92_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4fa22ed31f5d47d78586f590cb5b2296_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if81393d129bb4f80a2217b7c9d4c8957_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i08b72bf14f6c499fbdab27dad66f293c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if2e2aafd1b5e4899a9552e3dacb16fce_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iffba9783b7fe44a6935ad5a994bbbee4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id62f002563a345a4b90b427b6746a4ba_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iff8125862d7c4fa8b63656e4caef3fea_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1843b2170f054dfda4d14d6b65d9e07e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i875a6c5886a44cbe9f224b9739a1d650_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ife0400651f12423ea171a23fe5b7b728_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9906ce0703774a55b40a2d2cbed1fa6f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5ba7a99462cd4381a45f105bbdc6d784_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i39805184860940d5bd360342cd8f0cf6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idf03874e602d4ffa881dc7e9af5ec89f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic07dceb99d094428b0107fdfd7ea2ded_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0b8d25aa564b48688828b7b52a248072_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iaa7024726e6548129771c398104f4234_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i09631ce9f39243a38774112d96ca119c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i36c7f7595c284373909f23141e52949e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4105a97cccf946db9ca58a8b45433ea7_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i57f06f60daf14282b059eb9c693125a2_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i05e092a9ec4e49c6a71e8efa4a8d7087_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4002b0e7cb584f409ca3835643a996ce_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1ecff54947c94ec5a731ac192a3eac6f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie837436aa8784d168ff0c0b936ad7cbe_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if5f965033d67432c81edaee2da1a1977_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0bde276d18e442d082198091776c5340_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i406023bd6e5f421284bd2cc748d58de8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i86081bcd6aa54f46bf54174fe6157caf_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6d9741cc605c4351b5b3308c245d8cae_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8bfae50f3756423ca86237fa9b199c6f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie00839f31b7c419293449f6db9edd59a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i64314cb261074ff9adb800d48da61982_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i895071e19f56442e8979c066881d9317_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia36c07693d1f4df588ce2d80fa89ff6e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib42a147c0c7b4941bae23485591fe3e2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7c9e5781756f4250be2a94d03142b737_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i98b834d54e804d5ea61ab8adaffb5153_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3fbc6006e021429bb57b14e5be7faea9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3a5341f0ece54bcca5e06f9dbc2c5aa7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4be2243ad7b746ff8509e04bcc66e578_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i28cd923a4f904a5da05278a0549bb209_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1a79025dcf9b4067a64a869b30e5d82f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i85da69a1931c49e8b2e5ce17cb63defa_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8c72a40331c64039b9c3787b46aac39c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icf5411fb6d544cfd8fd5bf410f862cbc_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id5a9a936aaad4510ab5bf3d9d20d705c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i73af0e3646d5483ab230a7ecb7d39952_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia56d626754214d8bb30c6d8a7af45bde_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i18484995d42c4a828a942edcda3b3121_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i13c03a791f84448bb0b7d082960d3002_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3ed7a35687114a9980b0c5849d0ae283_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id15af34d73934993bcabdfba417f3137_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id018321b208247d78d77fe559ea5026b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i04f8b4bf53f849b2a0c2101807367a6e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i99757cb9fe65492481f94c5710ab5f19_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib382d5d0d22742d48bc99e77c138c9e1_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i20309133d4fc442aa35447c20bd22671_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2cfaca18cad64ba8b05f366fe634d9ef_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4deb7698e4954a5b8d104244e7a7dc24_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9362d500d1bd48e4b930877c7401396e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i456aa1b7ef8e4440b7cb8b6579de00b4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5171d1e65dcd4cbdb5cc14e47de1aa9b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie9ff5741a13c41598bd951eb6df22a49_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id9c0f8ff2e5749af9aff83169945c02a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i43c8fbd8ff914b6ca19f0386f21d064b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i14ff28c4ec8a4de49643e94dca541c07_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia381cdacc8be46eca693495fb7945846_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibe893c791888473889bea0f1c91bcd39_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia641b1adcc574ee0ab038b7fa110e50a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7834297d0db94dfe9f7141a9f3078f4d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i591e4832b4f54fbb9d7adb9df692f736_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1ed4f56387c146ce93bc623b05db992f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8f1990f6b2cd456e92b332bb89de592f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i60c79a94ccae45868e7311a72fb1d515_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i884265fef55745918deccdac9bcfa489_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i069927ecb29c4fe080759394b3c8dc0c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3ced9f4e29364491b1408b971112bc7c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibdc9dc66188149c59e6c7ce0524d38b6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6bf2b6a85341450abb18712f9efb5eda_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7053004fc5084f679e0978de05d595ea_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i31517ff0a8fc467a97fb7a044c926728_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i70de35ed376b493a9c17e9a01ab991c0_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib63abbc4e400433b9f6ec4a807834bce_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i60d3cf48dd964670a527396a7fe4eb90_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i73244b3c309e4530819a1d26aa067e4b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie300b629f5f74f4a92f1b3212fe0f30e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6948cd6efdde4ea5884d6a6035885001_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idce9b5dcada741cfa3553faf07a2ab29_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i17e0e178db084c9caca62884ab5d8e93_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0e2d85cd6a68443cb41d6924d9e95324_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i42b0806f1ff343be83a859afbca2a621_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i443d6ce9e17f413aa131fd871f9a563c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i084806bf6a674211835a0bd79f97abba_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1a390cca570a48afb39f787bcd7cada6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i869eb22b61c947cda0c17505c748ba31_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i99dbbb9db6434a699d016c9c43e9044f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icce4f70058be4e0b99727594cbdf1550_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1e85ab61967049ef95c26fe225814698_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i007fd7d6bf5e4f9e867874fad1935ed7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5eb5ee1718564d8b976f1851830b7dbd_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i059deee3380c481ca365b22d8012a26f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibcc32b6fa5394db2a95a6046a14c34da_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibb02cd70b47347f8b7ffdf5647ef00c0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id7079eca37c44de7aacc67bf6c5a6511_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1b1368ef6dc84e9b8b1bacbf9cd7dd96_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib74d8519f3d64c62a7f44ecee5857716_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iefa92bbaed9340e4a7f6b8cfcdecb6ef_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i70e4a3d5230a4ff8b71fd4c1597f8ffe_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4b528c8c45d94928a7607bd144197d86_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if74073e3926d4398abab160d9cbb64e6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3c750ce60d174c2d8ea17243fca49290_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i420e7b1dee5c49dbb3ab84d5bf60a017_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id551f20a7c294526a90193e44a7d481b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6e57a428831244d0addaf1c93da509e0_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7f42c8f52d064fceaa8822b15b9cebc7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0cf345d189714dc1bec54dec30d5fe8a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i648582730a944818a8954c08f4676c96_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i227c1b875ad04673a4bb23d3cb69932a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i640e2ab4eb224f69a463e994c0e65ae1_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7ba3dd5c6bf14d8ea672f7543ae52430_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i555a31f9bb61484a89ccf486fcac5905_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i83b432d29b6b47c8a7c436116ed24dae_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="country">
        <measure>bhc:country</measure>
    </unit>
    <unit id="appeal">
        <measure>bhc:appeal</measure>
    </unit>
    <unit id="rate">
        <measure>bhc:rate</measure>
    </unit>
    <unit id="reporting_unit">
        <measure>bhc:reporting_unit</measure>
    </unit>
    <unit id="case">
        <measure>bhc:case</measure>
    </unit>
    <unit id="group">
        <measure>bhc:group</measure>
    </unit>
    <unit id="action">
        <measure>bhc:action</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="entity">
        <measure>bhc:entity</measure>
    </unit>
    <unit id="insurance_policy_period">
        <measure>bhc:insurance_policy_period</measure>
    </unit>
    <unit id="insured">
        <measure>bhc:insured</measure>
    </unit>
    <unit id="defendant">
        <measure>bhc:defendant</measure>
    </unit>
    <unit id="lawsuit">
        <measure>bhc:lawsuit</measure>
    </unit>
    <unit id="product">
        <measure>bhc:product</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80L2ZyYWc6MWVlZGJkODU2ZWY3NGFhYTgyYTBkNTJkY2UwMmU4NjUvdGFibGU6MDNiMGIxYmZmZTk3NDA1NWJkZDQzM2U5OTRhNTZjMWIvdGFibGVyYW5nZTowM2IwYjFiZmZlOTc0MDU1YmRkNDMzZTk5NGE1NmMxYl8zLTEtMS0xLTExNjc3MQ_d69b7289-8e80-43bd-a97f-35fc29539696">0000885590</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80L2ZyYWc6MWVlZGJkODU2ZWY3NGFhYTgyYTBkNTJkY2UwMmU4NjUvdGFibGU6MDNiMGIxYmZmZTk3NDA1NWJkZDQzM2U5OTRhNTZjMWIvdGFibGVyYW5nZTowM2IwYjFiZmZlOTc0MDU1YmRkNDMzZTk5NGE1NmMxYl80LTEtMS0xLTExNjc3MQ_b6e379ce-4e41-4598-9193-cce44af6e39f">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80L2ZyYWc6MWVlZGJkODU2ZWY3NGFhYTgyYTBkNTJkY2UwMmU4NjUvdGFibGU6MDNiMGIxYmZmZTk3NDA1NWJkZDQzM2U5OTRhNTZjMWIvdGFibGVyYW5nZTowM2IwYjFiZmZlOTc0MDU1YmRkNDMzZTk5NGE1NmMxYl81LTEtMS0xLTExNjc3MQ_d97853aa-7076-4374-aebb-c4e49112b963">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80L2ZyYWc6MWVlZGJkODU2ZWY3NGFhYTgyYTBkNTJkY2UwMmU4NjUvdGFibGU6MDNiMGIxYmZmZTk3NDA1NWJkZDQzM2U5OTRhNTZjMWIvdGFibGVyYW5nZTowM2IwYjFiZmZlOTc0MDU1YmRkNDMzZTk5NGE1NmMxYl82LTEtMS0xLTExNjc3MQ_821d3229-1618-4c07-ae1e-f7b80e265b9b">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80L2ZyYWc6MWVlZGJkODU2ZWY3NGFhYTgyYTBkNTJkY2UwMmU4NjUvdGFibGU6MDNiMGIxYmZmZTk3NDA1NWJkZDQzM2U5OTRhNTZjMWIvdGFibGVyYW5nZTowM2IwYjFiZmZlOTc0MDU1YmRkNDMzZTk5NGE1NmMxYl83LTEtMS0xLTExNjc3MQ_a933cb89-c2a3-4458-9e61-cb3045dacf36">false</dei:AmendmentFlag>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i1b39d2ccabe247cca573ab8370a379ba_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xOTQwL2ZyYWc6YzY0MDA0ODM4ZWE3NGUwMTkxMmRlMTY2NTJiNzllYzkvdGFibGU6NzNkNWQ0Mzk4ZGM1NDQ1N2JhN2M0MjZhYWY1Yjg5NmYvdGFibGVyYW5nZTo3M2Q1ZDQzOThkYzU0NDU3YmE3YzQyNmFhZjViODk2Zl8wLTEtMS0xLTEyODA2MA_b8f2dbc5-bf30-4ef7-9ebc-064c38ef7ef6"
      unitRef="number">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia07ca095cb3c4d2989e3bb13b2aa76e4_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xOTQwL2ZyYWc6YzY0MDA0ODM4ZWE3NGUwMTkxMmRlMTY2NTJiNzllYzkvdGFibGU6ZDI1YzNkYjFlMmQ5NDVmMDgxMjZkYmUwMjk3MzVlMDgvdGFibGVyYW5nZTpkMjVjM2RiMWUyZDk0NWYwODEyNmRiZTAyOTczNWUwOF8wLTEtMS0xLTEyODEwOQ_d879cf74-18ce-44b2-989e-f074ee14afb9"
      unitRef="number">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ib6f49645538a4fd882535c15503691a1_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xOTQwL2ZyYWc6YzY0MDA0ODM4ZWE3NGUwMTkxMmRlMTY2NTJiNzllYzkvdGFibGU6ZTA5ZTYwMDdkOTY3NDRkNWFhMGMwMjQ4NGQxYzNkZTIvdGFibGVyYW5nZTplMDllNjAwN2Q5Njc0NGQ1YWEwYzAyNDg0ZDFjM2RlMl8wLTEtMS0xLTEyODE5Nw_375bdfc6-2be1-4880-aa65-2f13cf8cb6b4"
      unitRef="number">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i8b237fbee2f7460db22b0481466222cf_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xOTQwL2ZyYWc6YzY0MDA0ODM4ZWE3NGUwMTkxMmRlMTY2NTJiNzllYzkvdGFibGU6YThkYzcwNjcxMzUyNDEzM2FjZGU1ZmVlMWE3MWE5NWIvdGFibGVyYW5nZTphOGRjNzA2NzEzNTI0MTMzYWNkZTVmZWUxYTcxYTk1Yl8wLTEtMS0xLTEyODI4Mg_eb5c6b8d-2128-4d43-8c4e-923d0e69dc80"
      unitRef="number">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <dei:DocumentType
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGV4dHJlZ2lvbjozNThjNTVjZWE3NDI0MDU2OWJmODA0NDAzN2FhZTNjNl8xOTgx_c0d716aa-0942-4eee-bbf5-68a5bcbe17b1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGFibGU6ODhjYzg5Y2VlZDJiNGI5YzkyMmQ5ZWZhMWNmZjVjOTQvdGFibGVyYW5nZTo4OGNjODljZWVkMmI0YjljOTIyZDllZmExY2ZmNWM5NF8wLTAtMS0xLTExNjc3MQ_d1847283-c435-482c-93b9-b8402c2b3d44">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGFibGU6ODhjYzg5Y2VlZDJiNGI5YzkyMmQ5ZWZhMWNmZjVjOTQvdGFibGVyYW5nZTo4OGNjODljZWVkMmI0YjljOTIyZDllZmExY2ZmNWM5NF8xLTItMS0xLTExNjc3MQ_639f6896-eb93-456b-9643-fbf57d770174">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGFibGU6ODhjYzg5Y2VlZDJiNGI5YzkyMmQ5ZWZhMWNmZjVjOTQvdGFibGVyYW5nZTo4OGNjODljZWVkMmI0YjljOTIyZDllZmExY2ZmNWM5NF8zLTAtMS0xLTExNjc3MQ_8a9e695c-b9ba-4406-963c-9a1c631a37b8">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGV4dHJlZ2lvbjozNThjNTVjZWE3NDI0MDU2OWJmODA0NDAzN2FhZTNjNl8xOTc0_44129916-4470-42c6-b2ce-20d4aa4e0a09">001-14956</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGV4dHJlZ2lvbjozNThjNTVjZWE3NDI0MDU2OWJmODA0NDAzN2FhZTNjNl8xOTc3_7b4614ba-3825-43e7-aac1-2be282949561">Bausch Health Companies Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGFibGU6MzY3YmU0M2FlOTUzNDhkMTgzYTg0NWEwYzM5OTQ2OGYvdGFibGVyYW5nZTozNjdiZTQzYWU5NTM0OGQxODNhODQ1YTBjMzk5NDY4Zl8wLTAtMS0xLTExNjc3MQ_fde2cbb2-227a-4b13-8c02-654174d102d7">A1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressCountry
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGFibGU6MzY3YmU0M2FlOTUzNDhkMTgzYTg0NWEwYzM5OTQ2OGYvdGFibGVyYW5nZTozNjdiZTQzYWU5NTM0OGQxODNhODQ1YTBjMzk5NDY4Zl8wLTQtMS0xLTExNjc3MQ_602185dc-4b13-4e16-bda4-0db9807f16cd">CA</dei:EntityAddressCountry>
    <dei:EntityTaxIdentificationNumber
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGFibGU6MzY3YmU0M2FlOTUzNDhkMTgzYTg0NWEwYzM5OTQ2OGYvdGFibGVyYW5nZTozNjdiZTQzYWU5NTM0OGQxODNhODQ1YTBjMzk5NDY4Zl8wLTctMS0xLTExNjc3MQ_74582c99-b736-495f-aae7-37e7e65af777">98-0448205</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGV4dHJlZ2lvbjozNThjNTVjZWE3NDI0MDU2OWJmODA0NDAzN2FhZTNjNl8xOTcw_326bd7ed-bb14-40bc-aa61-88735af69f99">2150 St. Elz&#xe9;ar Blvd. West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGV4dHJlZ2lvbjozNThjNTVjZWE3NDI0MDU2OWJmODA0NDAzN2FhZTNjNl8xOTgy_64d825b3-c761-4eec-81d1-228a0a97b724">Laval</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGV4dHJlZ2lvbjozNThjNTVjZWE3NDI0MDU2OWJmODA0NDAzN2FhZTNjNl8xOTc4_b29b1b26-1b8e-445e-8360-e56bac138d50">QC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGV4dHJlZ2lvbjozNThjNTVjZWE3NDI0MDU2OWJmODA0NDAzN2FhZTNjNl8xOTc1_9cf39bbb-2073-4a65-836b-a0cb7a88e166">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGV4dHJlZ2lvbjozNThjNTVjZWE3NDI0MDU2OWJmODA0NDAzN2FhZTNjNl8xOTc2_62eb6f1f-d0cf-4502-9a28-48586566fe66">H7L 4A8</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGV4dHJlZ2lvbjozNThjNTVjZWE3NDI0MDU2OWJmODA0NDAzN2FhZTNjNl8xOTgz_786a22af-5b2c-4963-8929-cb14d831cca2">514</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGV4dHJlZ2lvbjozNThjNTVjZWE3NDI0MDU2OWJmODA0NDAzN2FhZTNjNl8xOTc5_002944d5-e602-46b5-9fbf-aa37277cc0e9">744-6792</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGFibGU6NWIzYTZiMGVmMzliNDNhMmE5NTUyMDZlNzU4NTQ2OWMvdGFibGVyYW5nZTo1YjNhNmIwZWYzOWI0M2EyYTk1NTIwNmU3NTg1NDY5Y18xLTAtMS0xLTExNjc3MQ_5b9d0be1-9a17-409a-8e53-84b33bbcab66">Common Shares, No Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGFibGU6NWIzYTZiMGVmMzliNDNhMmE5NTUyMDZlNzU4NTQ2OWMvdGFibGVyYW5nZTo1YjNhNmIwZWYzOWI0M2EyYTk1NTIwNmU3NTg1NDY5Y18xLTEtMS0xLTExNjc3MQ_3bac0764-9892-4791-850d-ca917ea7bed9">BHC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGFibGU6NWIzYTZiMGVmMzliNDNhMmE5NTUyMDZlNzU4NTQ2OWMvdGFibGVyYW5nZTo1YjNhNmIwZWYzOWI0M2EyYTk1NTIwNmU3NTg1NDY5Y18xLTItMS0xLTExNjc3MQ_5723fd09-c43f-4597-bd9a-b4846d9ae4be">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGV4dHJlZ2lvbjozNThjNTVjZWE3NDI0MDU2OWJmODA0NDAzN2FhZTNjNl8xOTcx_adb177cf-67c4-4974-a10f-d836a1ce2586">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGV4dHJlZ2lvbjozNThjNTVjZWE3NDI0MDU2OWJmODA0NDAzN2FhZTNjNl8xOTcy_255be64d-0743-4677-8a18-3734be2e202b">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGFibGU6YzM4ODk0MTk2YmIzNGJiYzlmNjAzMGQ2MzAwYTg2MDMvdGFibGVyYW5nZTpjMzg4OTQxOTZiYjM0YmJjOWY2MDMwZDYzMDBhODYwM18wLTAtMS0xLTExNjc3MQ_741dffe8-bf4d-4c78-a1a1-83ab6013b05d">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGFibGU6YzM4ODk0MTk2YmIzNGJiYzlmNjAzMGQ2MzAwYTg2MDMvdGFibGVyYW5nZTpjMzg4OTQxOTZiYjM0YmJjOWY2MDMwZDYzMDBhODYwM18wLTctMS0xLTExNjc3MQ_b7e0c557-3ebf-40a3-b348-01b5bbad17b9">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGFibGU6YzM4ODk0MTk2YmIzNGJiYzlmNjAzMGQ2MzAwYTg2MDMvdGFibGVyYW5nZTpjMzg4OTQxOTZiYjM0YmJjOWY2MDMwZDYzMDBhODYwM18wLTktMS0xLTExNjc3MQ_9ba2c89d-314f-44e4-b268-682072026e90">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGV4dHJlZ2lvbjozNThjNTVjZWE3NDI0MDU2OWJmODA0NDAzN2FhZTNjNl8xOTgw_864582ec-f50b-4eca-af5e-c7798369f97c">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i9e1813544ece4aedbf13459cd893081d_I20220804"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xL2ZyYWc6MzU4YzU1Y2VhNzQyNDA1NjliZjgwNDQwMzdhYWUzYzYvdGV4dHJlZ2lvbjozNThjNTVjZWE3NDI0MDU2OWJmODA0NDAzN2FhZTNjNl8xOTI5_89f966e2-c4df-416c-aa1c-4863f3510bb4"
      unitRef="shares">361728490</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMy0xLTEtMS0xMTY3NzE_997ae05b-ef98-4f53-a96c-09bc01c4fac9"
      unitRef="usd">659000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMy0zLTEtMS0xMTY3NzE_fc8841ed-f51a-4550-8ca7-f9c50e3b837f"
      unitRef="usd">582000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <bhc:RestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfNC0xLTEtMS0xMTY3NzE_8d75d951-9aa3-4b49-8a64-fbb61e8dd119"
      unitRef="usd">1220000000</bhc:RestrictedCashAndOtherSettlementDepositsCurrent>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="i5375b8e373564a36aaf52188e7d12cf6_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfNC0xLTEtMS0xMTY3NzE_981787f7-d593-4a2a-80bf-09aa335c6bc1"
      unitRef="usd">1220000000</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfNC0zLTEtMS0xMTY3NzE_53b4ae8a-19aa-47c6-9a53-cdae7ffbddda"
      unitRef="usd">1537000000</bhc:RestrictedCashAndOtherSettlementDepositsCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfNS0xLTEtMS0xMTY3NzE_18a1f447-e364-487c-89f1-4a488785e6a8"
      unitRef="usd">1645000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfNS0zLTEtMS0xMTY3NzE_8d9b3d5f-5b13-48cf-864f-c7eddafdc67e"
      unitRef="usd">1775000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfNi0xLTEtMS0xMTY3NzE_47fd1d95-8c92-4d7b-8baa-6b41cdfe3bd9"
      unitRef="usd">1073000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfNi0zLTEtMS0xMTY3NzE_08b1b8a2-dfda-49f2-b8f3-fe0599e7e9b0"
      unitRef="usd">993000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfNy0xLTEtMS0xMTY3NzE_6f50fe9d-cdd6-4543-9541-b3d19c837848"
      unitRef="usd">820000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfNy0zLTEtMS0xMTY3NzE_ed64b646-70d4-450a-b5f7-77835715a9cc"
      unitRef="usd">720000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfOC0xLTEtMS0xMTY3NzE_e62739b1-3188-4a08-a4dd-1a69503ddf5a"
      unitRef="usd">5417000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfOC0zLTEtMS0xMTY3NzE_a325b64d-887d-496c-a7c6-4ac3487ea170"
      unitRef="usd">5607000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfOS0xLTEtMS0xMTY3NzE_464d13ee-c7fb-4a48-9c6a-03ca30036a46"
      unitRef="usd">1545000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfOS0zLTEtMS0xMTY3NzE_3cb3b855-bc8e-4801-8f56-9dd35ba73ea7"
      unitRef="usd">1598000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTAtMS0xLTEtMTE2Nzcx_de58aca2-c80f-41ac-885d-7f156fdddbad"
      unitRef="usd">6322000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTAtMy0xLTEtMTE2Nzcx_606c3d57-4f49-47e0-8814-cb3e8f4d3dd0"
      unitRef="usd">6948000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTEtMS0xLTEtMTE2Nzcx_f34825b3-d8df-4889-99e4-b69c9ffe7985"
      unitRef="usd">12266000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTEtMy0xLTEtMTE2Nzcx_9a3d3849-3ccc-4175-bc3d-96cee3acb58e"
      unitRef="usd">12457000000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTItMS0xLTEtMTE2Nzcx_c42010a4-36b7-40a2-9490-81c0f3e7fbe9"
      unitRef="usd">2283000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTItMy0xLTEtMTE2Nzcx_394dd9df-89dd-4318-a471-d62710aa6ff2"
      unitRef="usd">2252000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTMtMS0xLTEtMTE2Nzcx_63173ba3-631d-4b4b-a2c3-0b2dd5fcb3d7"
      unitRef="usd">338000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTMtMy0xLTEtMTE2Nzcx_1d12c085-b786-449e-9155-c39132cc89c6"
      unitRef="usd">340000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTQtMS0xLTEtMTE2Nzcx_0cf35d5d-ef69-43d8-9b02-da16b8ed2942"
      unitRef="usd">28171000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTQtMy0xLTEtMTE2Nzcx_2ef6c77f-a71b-4cd8-bfa6-fd0ae347753b"
      unitRef="usd">29202000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTctMS0xLTEtMTE2Nzcx_51c20494-2228-4b97-af94-da9920a6ab99"
      unitRef="usd">536000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTctMy0xLTEtMTE2Nzcx_eb4410d6-ada5-49cd-9914-fd7e9048682f"
      unitRef="usd">407000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTgtMS0xLTEtMTE2Nzcx_239d40d3-97f9-4ecf-97af-b817ff36c6e0"
      unitRef="usd">4311000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTgtMy0xLTEtMTE2Nzcx_0a43202c-93a9-4b55-b55e-0ba951c3377a"
      unitRef="usd">4791000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTktMS0xLTEtMTE2Nzcx_8a3823f4-c321-48d6-bbd4-bd859fd0c74f"
      unitRef="usd">150000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMTktMy0xLTEtMTE2Nzcx_880002bb-0e34-4b08-87fc-16d21a4091bd"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjAtMS0xLTEtMTE2Nzcx_e5da6758-3877-4cdf-b7fd-c2873c77ef21"
      unitRef="usd">4997000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjAtMy0xLTEtMTE2Nzcx_7a128c27-9855-4a80-a490-06c8e00f11f4"
      unitRef="usd">5198000000</us-gaap:LiabilitiesCurrent>
    <bhc:BusinessCombinationContingentConsiderationNoncurrentLiability
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjEtMS0xLTEtMTE2Nzcx_ef2232ca-ff5e-47e2-a22d-833e0b832e51"
      unitRef="usd">188000000</bhc:BusinessCombinationContingentConsiderationNoncurrentLiability>
    <bhc:BusinessCombinationContingentConsiderationNoncurrentLiability
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjEtMy0xLTEtMTE2Nzcx_78c5e3c2-b8df-4a8b-ad0e-c34dfd872d28"
      unitRef="usd">202000000</bhc:BusinessCombinationContingentConsiderationNoncurrentLiability>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjItMS0xLTEtMTE2Nzcx_57a23c32-977b-4f74-9d77-3da783492712"
      unitRef="usd">21664000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjItMy0xLTEtMTE2Nzcx_8224d1c3-6ef4-4eba-99a0-d9ff368f4455"
      unitRef="usd">22654000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjMtMS0xLTEtMTE2Nzcx_a4fafc25-6b77-40a7-b3e4-75bf8b881e87"
      unitRef="usd">545000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjMtMy0xLTEtMTE2Nzcx_1aab534c-613a-4d43-820a-56b67ef0a72e"
      unitRef="usd">529000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjQtMS0xLTEtMTE2Nzcx_fdc86dc9-a94a-48fb-a443-75c9f74812ac"
      unitRef="usd">524000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjQtMy0xLTEtMTE2Nzcx_3787d279-feab-431f-8aab-827b92d0a0db"
      unitRef="usd">653000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjUtMS0xLTEtMTE2Nzcx_c5380731-604d-4bc8-93e7-fa79ca611bf6"
      unitRef="usd">27918000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjUtMy0xLTEtMTE2Nzcx_c2665d52-dd23-45d4-adaf-68b7b2eaa0de"
      unitRef="usd">29236000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjYtMS0xLTEtMTE2Nzcx_83c1f003-7967-469e-bbbb-4d36a568f0d8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjYtMy0xLTEtMTE2Nzcx_8888a4d0-bff2-403e-a230-a32fb84da00b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesIssued
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjgtMC0xLTEtMTE2NzcxL3RleHRyZWdpb246NmY4ZGZiZTRlZTgxNDE5M2EwZmExN2UxZDUzOTI3MjlfNjI_3064d1ee-8594-422e-9564-108449f285ef"
      unitRef="shares">361571921</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjgtMC0xLTEtMTE2NzcxL3RleHRyZWdpb246NmY4ZGZiZTRlZTgxNDE5M2EwZmExN2UxZDUzOTI3MjlfNjI_9e190418-35af-4f9a-8be6-a466cc084ecf"
      unitRef="shares">361571921</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjgtMC0xLTEtMTE2NzcxL3RleHRyZWdpb246NmY4ZGZiZTRlZTgxNDE5M2EwZmExN2UxZDUzOTI3MjlfNjk_12888894-2992-41c9-81e0-1d5804f28f57"
      unitRef="shares">359405748</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjgtMC0xLTEtMTE2NzcxL3RleHRyZWdpb246NmY4ZGZiZTRlZTgxNDE5M2EwZmExN2UxZDUzOTI3MjlfNjk_14f7c61d-66ac-407b-800d-e244445ef48c"
      unitRef="shares">359405748</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjgtMS0xLTEtMTE2Nzcx_af534d1c-47fd-4c8b-a981-8dfcf7726896"
      unitRef="usd">10380000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjgtMy0xLTEtMTE2Nzcx_1656e81c-895b-4fa5-a72f-75af0aa49eb8"
      unitRef="usd">10317000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjktMS0xLTEtMTE2Nzcx_fba1293b-929e-468a-935e-4b63acbfc1c1"
      unitRef="usd">104000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMjktMy0xLTEtMTE2Nzcx_356e2087-82fb-4b3d-80d9-c0becd61a026"
      unitRef="usd">462000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMzAtMS0xLTEtMTE2Nzcx_bdce2dd6-7219-4d1a-95f2-3a4e0a290544"
      unitRef="usd">-9175000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMzAtMy0xLTEtMTE2Nzcx_54b9a009-3093-4ef7-98dc-46754f40ab40"
      unitRef="usd">-8961000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMzEtMS0xLTEtMTE2Nzcx_0f83a48b-0a7f-43c1-bd9b-c9c2af396721"
      unitRef="usd">-2002000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMzEtMy0xLTEtMTE2Nzcx_b0bcc346-9005-4af5-9007-4486b65c26ea"
      unitRef="usd">-1924000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMzItMS0xLTEtMTE2Nzcx_c55ec8be-106e-4e18-9e88-ba105372ecf7"
      unitRef="usd">-693000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMzItMy0xLTEtMTE2Nzcx_8b1693ce-1767-4256-8e55-a344c41a8e41"
      unitRef="usd">-106000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMzMtMS0xLTEtMTE2Nzcx_31ad8aa1-8025-491f-9e5c-ad36dc045568"
      unitRef="usd">946000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMzMtMy0xLTEtMTE2Nzcx_199136d7-cb2b-43e9-ad62-feae61344e5a"
      unitRef="usd">72000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMzQtMS0xLTEtMTE2Nzcx_8d5c0988-4b03-421d-b467-0d83d27083ee"
      unitRef="usd">253000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMzQtMy0xLTEtMTE2Nzcx_5a51434b-a89c-43b3-9e4a-2f53cc0fb595"
      unitRef="usd">-34000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMzUtMS0xLTEtMTE2Nzcx_75e1dbd8-33c6-4d58-b1a4-a688ab0aefa2"
      unitRef="usd">28171000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yMi9mcmFnOjlhMzUyNzhmM2YzYTQ4Yjc5MjEyZjkxMzQyMzIyZjE0L3RhYmxlOmI4NmIxN2MwYjIxODQ4N2JiZjcyYWJhN2E4NGI4MzdlL3RhYmxlcmFuZ2U6Yjg2YjE3YzBiMjE4NDg3YmJmNzJhYmE3YTg0YjgzN2VfMzUtMy0xLTEtMTE2Nzcx_42dd55d6-8ac5-4fab-a85b-0b9630419866"
      unitRef="usd">29202000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic162a3439c8c430c97c3765d64ade238_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMy0xLTEtMS0xMTY3NzE_ef9583e0-8b70-4609-876a-23d1b57cad09"
      unitRef="usd">1947000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4dcf9828b6146d280f1c8faa0decc1b_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMy0zLTEtMS0xMTY3NzE_ac2c2309-ef74-4366-90ed-91bddef6b9ff"
      unitRef="usd">2076000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2aeffa8d800d40419ffca17d6354a930_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMy01LTEtMS0xMTY3NzE_013c921e-8819-4b69-b87e-4c64de76f7f7"
      unitRef="usd">3845000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77051dd59400460d84de895305bdc503_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMy03LTEtMS0xMTY3NzE_04800d87-2ff6-47ed-802f-95c0ec503c3e"
      unitRef="usd">4079000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice79c5989bb147d780b5ce3edbaaa033_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfNC0xLTEtMS0xMTY3NzE_5df293fe-7527-4608-beea-a70838fc6bce"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8b6d4b376e54c96b6861f58b066f558_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfNC0zLTEtMS0xMTY3NzE_ef4a4487-0857-4723-a032-3aeea06f705a"
      unitRef="usd">24000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4e2c9d81976431390f8ae34842a6dec_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfNC01LTEtMS0xMTY3NzE_f2ad2392-771f-406c-939d-4e0e4568784a"
      unitRef="usd">40000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e13e115ca834d5c8178e3e30589f645_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfNC03LTEtMS0xMTY3NzE_984c8dd4-8fec-4cfc-9edf-cc46b3c88fb3"
      unitRef="usd">48000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfNS0xLTEtMS0xMTY3NzE_5ea575e0-17e3-401c-8847-badaf2328bb8"
      unitRef="usd">1967000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfNS0zLTEtMS0xMTY3NzE_c93dbbfb-760b-4c78-977f-2c4558618707"
      unitRef="usd">2100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfNS01LTEtMS0xMTY3NzE_494706b9-6291-4811-8235-74d9af6e3b82"
      unitRef="usd">3885000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfNS03LTEtMS0xMTY3NzE_58838485-b147-4496-b150-d8b521ab3d5f"
      unitRef="usd">4127000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic162a3439c8c430c97c3765d64ade238_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfNy0xLTEtMS0xMTY3NzE_39be0924-dee5-4386-bb5b-481a1363cd25"
      unitRef="usd">570000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie4dcf9828b6146d280f1c8faa0decc1b_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfNy0zLTEtMS0xMTY3NzE_4e67dfde-6f6c-40ff-a297-67621747233c"
      unitRef="usd">604000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2aeffa8d800d40419ffca17d6354a930_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfNy01LTEtMS0xMTY3NzE_60c51fa6-0bc7-4313-8779-a90796dece1a"
      unitRef="usd">1113000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i77051dd59400460d84de895305bdc503_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfNy03LTEtMS0xMTY3NzE_d75a8b24-adba-4954-89d0-fb03ac808851"
      unitRef="usd">1168000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ice79c5989bb147d780b5ce3edbaaa033_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfOC0xLTEtMS0xMTY3NzE_1601d5ad-1154-4734-af8c-d196f9938b62"
      unitRef="usd">7000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id8b6d4b376e54c96b6861f58b066f558_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfOC0zLTEtMS0xMTY3NzE_c875298f-1691-4505-affe-f5cf536b88eb"
      unitRef="usd">8000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia4e2c9d81976431390f8ae34842a6dec_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfOC01LTEtMS0xMTY3NzE_79d8000a-2507-465b-9cad-9e43d6308140"
      unitRef="usd">15000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1e13e115ca834d5c8178e3e30589f645_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfOC03LTEtMS0xMTY3NzE_0bd65f30-a4bb-4e66-9e5d-4fab736436ff"
      unitRef="usd">18000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfOS0xLTEtMS0xMTY3NzE_64a9ec71-583d-4416-bedd-1457e44b09de"
      unitRef="usd">676000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfOS0zLTEtMS0xMTY3NzE_0c848359-d598-451b-b6a0-9bc81359f819"
      unitRef="usd">685000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfOS01LTEtMS0xMTY3NzE_0908b017-3ef3-4422-a67f-b1a2d45d851c"
      unitRef="usd">1298000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfOS03LTEtMS0xMTY3NzE_ba1d1e58-757a-47d8-97f6-65acfda3c362"
      unitRef="usd">1291000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTAtMS0xLTEtMTE2Nzcx_afb73e69-bd1f-4f39-94b1-a6adf1192da8"
      unitRef="usd">127000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTAtMy0xLTEtMTE2Nzcx_f0e16aa0-945c-46f6-9261-c9a62970eccd"
      unitRef="usd">115000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTAtNS0xLTEtMTE2Nzcx_7584b161-7cea-489e-96f8-0a6c21a00d3f"
      unitRef="usd">254000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTAtNy0xLTEtMTE2Nzcx_915e24c7-8607-403c-b393-60e01a94414a"
      unitRef="usd">227000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTEtMS0xLTEtMTE2Nzcx_484599de-de9e-4f9a-8339-d638ee7ac137"
      unitRef="usd">302000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTEtMy0xLTEtMTE2Nzcx_8d4f913b-bb97-4614-8024-4c261b1dd3db"
      unitRef="usd">360000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTEtNS0xLTEtMTE2Nzcx_64d4c39f-3499-4b75-bd58-50ed61038efe"
      unitRef="usd">612000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTEtNy0xLTEtMTE2Nzcx_da9d57c5-33e3-4781-9c7a-38963472bb13"
      unitRef="usd">717000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTItMS0xLTEtMTE2Nzcx_32c4e933-017f-472f-a765-6022739c7cea"
      unitRef="usd">83000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTItMy0xLTEtMTE2Nzcx_279427eb-841d-4632-a91a-014071c61913"
      unitRef="usd">0</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTItNS0xLTEtMTE2Nzcx_a9fa993d-831a-407e-817e-8fd13a6b2db0"
      unitRef="usd">83000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTItNy0xLTEtMTE2Nzcx_131b6c2c-0816-4843-aa9b-ef03a3e40028"
      unitRef="usd">469000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTMtMS0xLTEtMTE2Nzcx_f662062c-bd60-41ce-ae6b-d8aead6a5bb9"
      unitRef="usd">6000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTMtMy0xLTEtMTE2Nzcx_ce722cc3-fc29-46ef-8bb0-1b515dba99f4"
      unitRef="usd">47000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTMtNS0xLTEtMTE2Nzcx_162d5a32-4c7c-455c-9ec3-f600333f2e71"
      unitRef="usd">14000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTMtNy0xLTEtMTE2Nzcx_5feeb2b0-2520-4880-8323-c2a99cfc9e7a"
      unitRef="usd">195000000</us-gaap:AssetImpairmentCharges>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTQtMS0xLTEtMTE2Nzcx_16546a82-44af-4381-a4fd-27c894d440f8"
      unitRef="usd">35000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTQtMy0xLTEtMTE2Nzcx_a25573f5-135f-4b31-858e-76cd053e4e4d"
      unitRef="usd">9000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTQtNS0xLTEtMTE2Nzcx_902dde1f-df34-4c6a-9b56-4a78098afdf1"
      unitRef="usd">48000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTQtNy0xLTEtMTE2Nzcx_d8768424-beee-44f1-a9ea-a449c152d4fb"
      unitRef="usd">21000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTUtMS0xLTEtMTE2Nzcx_0d55e3f5-eb29-4ee4-b424-d7faaf9a0606"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTUtMy0xLTEtMTE2Nzcx_e3c5a001-8a65-4470-97fd-ddd971c9b37a"
      unitRef="usd">-542000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTUtNS0xLTEtMTE2Nzcx_7e56f0b8-8cf5-4d8e-8b5b-40a4b19e1dc5"
      unitRef="usd">-2000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTUtNy0xLTEtMTE2Nzcx_71507c22-d235-4061-8042-e2f12a3470cf"
      unitRef="usd">-512000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostsAndExpenses
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTYtMS0xLTEtMTE2Nzcx_4fc57d15-b083-4291-a791-da6d66ea773b"
      unitRef="usd">1806000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTYtMy0xLTEtMTE2Nzcx_c93f3268-51f7-41f5-929b-a22aa20dcba2"
      unitRef="usd">2370000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTYtNS0xLTEtMTE2Nzcx_a4eefa07-8462-47da-9e1b-9e88ce8547d2"
      unitRef="usd">3439000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTYtNy0xLTEtMTE2Nzcx_0e8f1976-16da-438e-8e77-0d51ac41206b"
      unitRef="usd">4618000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTctMS0xLTEtMTE2Nzcx_793a794c-68c4-417c-b1be-76d01cafde98"
      unitRef="usd">161000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTctMy0xLTEtMTE2Nzcx_49489d5e-a3c9-4ec8-a5b1-6cae807f95fe"
      unitRef="usd">-270000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTctNS0xLTEtMTE2Nzcx_a3d5bc30-1eb6-4560-a37d-ed509167042b"
      unitRef="usd">446000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTctNy0xLTEtMTE2Nzcx_cb30c889-df79-43f5-9705-84733a99df47"
      unitRef="usd">-491000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTgtMS0xLTEtMTE2Nzcx_e9afe573-ebc8-41a7-bc19-0584ed2e3650"
      unitRef="usd">3000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTgtMy0xLTEtMTE2Nzcx_4b32d011-b10c-46dd-8253-4b61228ee10c"
      unitRef="usd">2000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTgtNS0xLTEtMTE2Nzcx_d9949348-6437-46b3-a756-54cda4a8835d"
      unitRef="usd">5000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTgtNy0xLTEtMTE2Nzcx_7a8be7ac-9955-495f-a4a6-874d590ae828"
      unitRef="usd">4000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseDebt
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTktMS0xLTEtMTE2Nzcx_8d851b2b-8c6d-45e3-9747-24f900f80fa8"
      unitRef="usd">410000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTktMy0xLTEtMTE2Nzcx_80ffcc72-c5f5-4206-bbbe-06953e60f68f"
      unitRef="usd">364000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTktNS0xLTEtMTE2Nzcx_dce77335-5e0d-479a-acf5-72d045d7cdb1"
      unitRef="usd">772000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMTktNy0xLTEtMTE2Nzcx_e628eb2b-7e73-43eb-ac88-70985a06a0a3"
      unitRef="usd">732000000</us-gaap:InterestExpenseDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjAtMS0xLTEtMTE2Nzcx_baf9ec75-9902-436b-be76-7688e0cc7172"
      unitRef="usd">113000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjAtMy0xLTEtMTE2Nzcx_e3b78bfe-1a5c-4c5a-bb03-8e7c9fb78a2c"
      unitRef="usd">-45000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjAtNS0xLTEtMTE2Nzcx_9b1ef3f8-fd9b-4a6d-9b85-50dc9cf4ff45"
      unitRef="usd">113000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjAtNy0xLTEtMTE2Nzcx_14988bbb-6588-4d2c-90d3-b74f5595800a"
      unitRef="usd">-50000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjEtMS0xLTEtMTE2Nzcx_a0f56511-c13b-4ae3-8543-75005f248c9f"
      unitRef="usd">4000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjEtMy0xLTEtMTE2Nzcx_ff8c8198-cf8f-4119-b532-0c462337e5b3"
      unitRef="usd">7000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjEtNS0xLTEtMTE2Nzcx_6c8255fd-17cc-4649-98dc-ff8a02f3c314"
      unitRef="usd">-3000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjEtNy0xLTEtMTE2Nzcx_b93d9763-f184-46e4-a844-cb00c027c63d"
      unitRef="usd">8000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjItMS0xLTEtMTE2Nzcx_3cefb2c9-0381-4cee-bfe2-7f08b4721abe"
      unitRef="usd">-129000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjItMy0xLTEtMTE2Nzcx_3e04ccba-951d-431a-aa41-4f689123db04"
      unitRef="usd">-670000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjItNS0xLTEtMTE2Nzcx_e68f6c51-cc5e-4a56-b7dd-b6a0e512e6ed"
      unitRef="usd">-211000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjItNy0xLTEtMTE2Nzcx_e8fefd88-91c4-48a9-bdfb-cf9e49f7ed71"
      unitRef="usd">-1261000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjMtMS0xLTEtMTE2Nzcx_4637021d-c524-40dd-a168-9576c9048232"
      unitRef="usd">10000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjMtMy0xLTEtMTE2Nzcx_42ef07c9-1a84-43e4-9863-a0170c872091"
      unitRef="usd">-77000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjMtNS0xLTEtMTE2Nzcx_416f30b3-9a64-4644-a285-a8b8bba4ace0"
      unitRef="usd">-6000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjMtNy0xLTEtMTE2Nzcx_13d3a34e-9e11-4829-83ec-d9a6b17f2c12"
      unitRef="usd">-61000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjQtMS0xLTEtMTE2Nzcx_b68eb744-63f6-43f6-961a-201aeb01d4e6"
      unitRef="usd">-139000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjQtMy0xLTEtMTE2Nzcx_ee37169c-eeaf-4efe-8ef1-3b209ae9df30"
      unitRef="usd">-593000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjQtNS0xLTEtMTE2Nzcx_06a52c19-f9ad-41f6-b950-462b277b14c1"
      unitRef="usd">-205000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjQtNy0xLTEtMTE2Nzcx_6c7a05a8-bd5b-484c-838b-da9d46099cce"
      unitRef="usd">-1200000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjUtMS0xLTEtMTE2Nzcx_a892606f-1229-4e7a-983c-04b8a2727ac3"
      unitRef="usd">6000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjUtMy0xLTEtMTE2Nzcx_cfba24e2-5f0d-4045-95f2-00b9e218865e"
      unitRef="usd">2000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjUtNS0xLTEtMTE2Nzcx_3d5b8969-bc2c-42e7-bdea-0635ae3de0bf"
      unitRef="usd">9000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjUtNy0xLTEtMTE2Nzcx_82662cbc-2eaa-4799-8a46-393e9783cca9"
      unitRef="usd">5000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjYtMS0xLTEtMTE2Nzcx_57dd0348-335f-4a1b-a8d7-e869af4321f7"
      unitRef="usd">-145000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjYtMy0xLTEtMTE2Nzcx_fe833a24-cb57-4846-b159-9c93f8a02bfb"
      unitRef="usd">-595000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjYtNS0xLTEtMTE2Nzcx_626b24fb-a5f3-449f-91fd-533d99be2982"
      unitRef="usd">-214000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjYtNy0xLTEtMTE2Nzcx_11d3e26c-18ea-41a6-b270-6d88cd86215c"
      unitRef="usd">-1205000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjktMS0xLTEtMTE2Nzcx_265ff4c3-528e-46a9-825e-7224c3c45718"
      unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjktMS0xLTEtMTE2Nzcx_9cb90fc5-b0ab-44c2-bd7a-caeeb5a4b82f"
      unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjktMy0xLTEtMTE2Nzcx_2cdeda4b-46b6-4bef-a17a-7faac1a766ff"
      unitRef="usdPerShare">-1.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjktMy0xLTEtMTE2Nzcx_4f6e992a-5796-469f-8860-200a94372aa2"
      unitRef="usdPerShare">-1.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjktNS0xLTEtMTE2Nzcx_04b936c4-5ce7-4780-aae9-48ca049ea687"
      unitRef="usdPerShare">-0.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjktNS0xLTEtMTE2Nzcx_ec2ad1d5-0e9f-4569-a10e-d11f55843f6c"
      unitRef="usdPerShare">-0.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjktNy0xLTEtMTE2Nzcx_0365dda3-80f9-4b69-9099-b0f4ad685600"
      unitRef="usdPerShare">-3.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMjktNy0xLTEtMTE2Nzcx_53ac96a1-7d4f-4861-99f2-521b57f21ebc"
      unitRef="usdPerShare">-3.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMzMtMS0xLTEtMTE2Nzcx_3d856aa6-170a-4ffe-b302-9769db5dfec9"
      unitRef="shares">362200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMzMtMS0xLTEtMTE2Nzcx_9641a01e-051d-4ebe-86b5-6c7e5d9b8a5e"
      unitRef="shares">362200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMzMtMy0xLTEtMTE2Nzcx_0e735f3f-38c7-4f88-982d-c539356f7eeb"
      unitRef="shares">359100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMzMtMy0xLTEtMTE2Nzcx_55194c8f-ea06-4c98-9298-a7f78d9f03c4"
      unitRef="shares">359100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMzMtNS0xLTEtMTE2Nzcx_1189b2fe-8ce8-4805-83e9-4426af4badf4"
      unitRef="shares">361500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMzMtNS0xLTEtMTE2Nzcx_50c56646-02e7-4ac0-a842-c089656bec94"
      unitRef="shares">361500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMzMtNy0xLTEtMTE2Nzcx_7bad3fef-e6f1-4b42-945d-48da57025ff2"
      unitRef="shares">358000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yNS9mcmFnOmE0N2IwYzJjNTJkMTRkZmRiZTk0MmFkNjMwNDU5MWVhL3RhYmxlOmMwNzJjYjBiYTA3MTQyZmI4OWQ0YjRhODdhZDQxYTc4L3RhYmxlcmFuZ2U6YzA3MmNiMGJhMDcxNDJmYjg5ZDRiNGE4N2FkNDFhNzhfMzMtNy0xLTEtMTE2Nzcx_d87b09cc-e1da-4796-9cc5-866df4e19191"
      unitRef="shares">358000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfMi0xLTEtMS0xMTY3NzE_492095ad-84cb-4d8a-bf5b-6af693218ed4"
      unitRef="usd">-139000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfMi0zLTEtMS0xMTY3NzE_f4d0d311-17f6-4627-a7d7-a5a41fe568ac"
      unitRef="usd">-593000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfMi01LTEtMS0xMTY3NzE_a3ae049e-5a90-4a73-a135-b1afacb81399"
      unitRef="usd">-205000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfMi03LTEtMS0xMTY3NzE_24bf3689-6530-4c62-a691-799e2b0d2651"
      unitRef="usd">-1200000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNC0xLTEtMS0xMTY3NzE_0ffa44ad-bc91-4ccd-87fc-6de00ee53e91"
      unitRef="usd">-166000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNC0zLTEtMS0xMTY3NzE_9ea14d5b-616d-4412-a297-defbc4eeb047"
      unitRef="usd">76000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNC01LTEtMS0xMTY3NzE_0375685b-0110-4f17-b7bb-7ebbf08cd344"
      unitRef="usd">-222000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNC03LTEtMS0xMTY3NzE_6ccc4f26-7d24-4261-9ae3-35f61790ebe9"
      unitRef="usd">-48000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNS0xLTEtMS0xMTY3NzE_792454dd-0c43-498f-a831-09b7e86a8055"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNS0zLTEtMS0xMTY3NzE_1bf7d769-ae8b-43cd-be2d-205cdb90e155"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNS01LTEtMS0xMTY3NzE_c5d42ad7-2391-42a1-8361-9950251e2e71"
      unitRef="usd">-7000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNS03LTEtMS0xMTY3NzE_08df6fc7-ffff-4bc1-8dc6-6395f14d5ff5"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNi0xLTEtMS0xMTY3NzE_8ede0585-f362-4bbd-98fe-99891289d1b5"
      unitRef="usd">-165000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNi0zLTEtMS0xMTY3NzE_5750c630-857c-40f9-9634-f21f4e663b3c"
      unitRef="usd">75000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNi01LTEtMS0xMTY3NzE_9ae2dcca-d712-4cd5-9338-335e68501187"
      unitRef="usd">-215000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNi03LTEtMS0xMTY3NzE_84836560-765d-4699-bba9-293754a82b36"
      unitRef="usd">-48000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNy0xLTEtMS0xMTY3NzE_6d56be83-9101-4f6b-8c76-2d46d13fcbd2"
      unitRef="usd">-304000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNy0zLTEtMS0xMTY3NzE_23fa0e48-17c6-444b-a930-3b6fb7addf53"
      unitRef="usd">-518000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNy01LTEtMS0xMTY3NzE_2c1ce1f7-6d88-4a25-8fdb-066ea5a943f8"
      unitRef="usd">-420000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfNy03LTEtMS0xMTY3NzE_7336cefb-7ce2-4a1e-941c-67830c2248f5"
      unitRef="usd">-1248000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfOC0xLTEtMS0xMTY3NzE_87e76db1-c06c-45b4-bb4e-0bd59c894481"
      unitRef="usd">6000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfOC0zLTEtMS0xMTY3NzE_8a881a41-e02b-4d3d-a52b-c43f6d72a0c2"
      unitRef="usd">3000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfOC01LTEtMS0xMTY3NzE_d1c7dfa7-dc30-4118-b95c-ff9f91c9a14b"
      unitRef="usd">9000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfOC03LTEtMS0xMTY3NzE_da7aecb7-5bca-4ab2-b263-bb8f122aed20"
      unitRef="usd">6000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfOS0xLTEtMS0xMTY3NzE_fcd8db59-1777-4270-8299-cad33295fc22"
      unitRef="usd">-310000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfOS0zLTEtMS0xMTY3NzE_9503c9ad-a4a0-4cf4-adc1-8e8b78eb2f28"
      unitRef="usd">-521000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfOS01LTEtMS0xMTY3NzE_f32ba1ab-c428-4f8c-a740-4914949905e6"
      unitRef="usd">-429000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8yOC9mcmFnOjA2MDBjNTU2NzcyMjRhOTk4OGNjMzhjOWMzZGM4M2I5L3RhYmxlOjlkZGVmMDc1MDhhMDQ4ODViZTM3MzMwNzEzYWIxYzcwL3RhYmxlcmFuZ2U6OWRkZWYwNzUwOGEwNDg4NWJlMzczMzA3MTNhYjFjNzBfOS03LTEtMS0xMTY3NzE_ca85afe6-42cc-4ff7-8a9d-eecd7ca8c2bb"
      unitRef="usd">-1254000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="iecf0a43ebd03491a8cd2f55d19444acd_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNC0yLTEtMS0xMTY3NzE_c8c5b255-4228-4e3d-8e76-47f018ac6e5d"
      unitRef="shares">361300000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iecf0a43ebd03491a8cd2f55d19444acd_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNC00LTEtMS0xMTY3NzE_7e34bce2-4d5f-4a4b-b8c7-49bcf458b919"
      unitRef="usd">10373000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i95b6dd1dfae14edfa03b4da8db2e5244_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNC02LTEtMS0xMTY3NzE_9d045c3e-c67b-4740-bc52-10b318a1af9b"
      unitRef="usd">415000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibd553c3824724691bb7773ce70306e33_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNC04LTEtMS0xMTY3NzE_659124e5-769b-40d5-a73a-0fd5ef00a995"
      unitRef="usd">-9030000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifd7c9074c6584fea8bf7d00e43ce6c43_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNC0xMC0xLTEtMTE2Nzcx_be9b8ddf-c6bc-4ee4-a034-1c714df428f1"
      unitRef="usd">-1974000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5c3a44068c7b46ba80b46ad12a02d69c_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNC0xMi0xLTEtMTE2Nzcx_0700bc7c-ed06-4a80-a2fa-efae232454e3"
      unitRef="usd">-216000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4391dfc5122a436f9abd2091fc12ec77_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNC0xNC0xLTEtMTE2Nzcx_eb2d16a4-8306-4eb8-81b2-4af43574035a"
      unitRef="usd">75000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib3b6d9e41bb6491cbf140d6d7a14372b_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNC0xNi0xLTEtMTE2Nzcx_3b89533f-469d-446f-812c-d2a3d82279b7"
      unitRef="usd">-141000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if4c2ca217eb1474a9e4606fb8ac62dc8_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNS02LTEtMS0xMzQ0MzM_c42ffd46-5fb1-4143-98f6-4e46b5a3a23c"
      unitRef="usd">-327000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0faf02d0dab04ba2a12aed2a72ddb539_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNS0xMC0xLTEtMTM0NDMz_71a341ee-a083-4e91-849d-973311cb04a0"
      unitRef="usd">137000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie6ef01f8c2d44283b8c7b657548358e5_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNS0xMi0xLTEtMTM0NDMz_ece42765-5d8a-40ca-8b6d-391aa57e1e9c"
      unitRef="usd">-190000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3678a5f161a2409b8cb49dac580a2b3e_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNS0xNC0xLTEtMTM0NDMz_e0905762-4f39-40cd-ad73-aa8884abd91b"
      unitRef="usd">865000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNS0xNi0xLTEtMTM0NDMz_aa7a2203-5ccd-4545-973e-98b1879c670e"
      unitRef="usd">675000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i07f07a50d8c848a5b09b20937a317971_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNS0yLTEtMS0xMTY3NzE_aea2d7c2-5f5e-4198-ae3b-53d91a86b0a1"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i07f07a50d8c848a5b09b20937a317971_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNS00LTEtMS0xMTY3NzE_17f8d124-f8df-4f3e-8b2a-d589f350a5f5"
      unitRef="usd">7000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if4c2ca217eb1474a9e4606fb8ac62dc8_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNS02LTEtMS0xMTY3NzE_754fdf85-a4a8-4e0b-bcb2-36402927af15"
      unitRef="usd">-6000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie6ef01f8c2d44283b8c7b657548358e5_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNS0xMi0xLTEtMTE2Nzcx_83311d63-e425-45d8-aec8-d6395b9042b8"
      unitRef="usd">1000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNS0xNi0xLTEtMTE2Nzcx_a7ea9ead-326c-4c4c-8ef5-e0d1810d1060"
      unitRef="usd">1000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if4c2ca217eb1474a9e4606fb8ac62dc8_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNi02LTEtMS0xMTY3NzE_789c6aef-b358-4077-a381-1f750cbd705c"
      unitRef="usd">26000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie6ef01f8c2d44283b8c7b657548358e5_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNi0xMi0xLTEtMTE2Nzcx_1489f350-8afb-4f8e-b4b0-91947b0538ea"
      unitRef="usd">26000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNi0xNi0xLTEtMTE2Nzcx_cc063f31-2170-4458-8e0c-497504456013"
      unitRef="usd">26000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if4c2ca217eb1474a9e4606fb8ac62dc8_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNy02LTEtMS0xMTY3NzE_89aca76f-d5db-4d48-a426-515e89143be5"
      unitRef="usd">4000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie6ef01f8c2d44283b8c7b657548358e5_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNy0xMi0xLTEtMTE2Nzcx_6bbb263a-673a-40f6-8a1a-9aa4921e5145"
      unitRef="usd">4000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNy0xNi0xLTEtMTE2Nzcx_f03bc072-4dee-4199-b66b-4b68769ec8f2"
      unitRef="usd">4000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="i87b5d05e9653487da8ca7e66ab3fba48_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTAtOC0xLTEtMTE2Nzcx_54440090-11eb-4d40-acfd-60249cfb2145"
      unitRef="usd">-145000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie6ef01f8c2d44283b8c7b657548358e5_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTAtMTItMS0xLTExNjc3MQ_3678f9dc-f50b-4a29-a315-111699704a53"
      unitRef="usd">-145000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3678a5f161a2409b8cb49dac580a2b3e_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTAtMTQtMS0xLTExNjc3MQ_52410789-0b16-4580-b7dc-dddecb55748e"
      unitRef="usd">6000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTAtMTYtMS0xLTExNjc3MQ_67b7cb2c-32e1-461a-bf91-f95eb8cdabd5"
      unitRef="usd">-139000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0faf02d0dab04ba2a12aed2a72ddb539_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTEtMTAtMS0xLTExNjc3MQ_0eea0c62-b715-4f2b-9dc5-8c26e2cf657b"
      unitRef="usd">-165000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie6ef01f8c2d44283b8c7b657548358e5_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTEtMTItMS0xLTExNjc3MQ_1cde1689-5956-49bc-ae77-b4ba1ec101d2"
      unitRef="usd">-165000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTEtMTYtMS0xLTExNjc3MQ_d0ad01e3-b31f-424f-8610-f74a25e97218"
      unitRef="usd">-165000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8730ee88d2bc423b9151cc9c2820d19d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTItMi0xLTEtMTE2Nzcx_82e5ae47-dde7-43f6-91be-7c8bdccfe8f1"
      unitRef="shares">361600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8730ee88d2bc423b9151cc9c2820d19d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTItNC0xLTEtMTE2Nzcx_ed628313-2d35-4ef6-b0e8-3534b1dfde9e"
      unitRef="usd">10380000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i36716f0b028846cb85d4eb4230d3d560_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTItNi0xLTEtMTE2Nzcx_7e6d7c47-af7d-4f29-8cdf-579d7c726f26"
      unitRef="usd">104000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2dc7cc39fb2243a28ac5a77266758826_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTItOC0xLTEtMTE2Nzcx_05b54485-f38d-4070-bde0-f904af00ec12"
      unitRef="usd">-9175000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6b5d37c24d0e41cb994b6d343566c79e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTItMTAtMS0xLTExNjc3MQ_9f2c6ea3-9641-417f-b8be-b1f4b0d212ac"
      unitRef="usd">-2002000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i916cf2185b2841f8a9e4fd0d5fec5a62_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTItMTItMS0xLTExNjc3MQ_14301a9a-ca3d-45d6-aaee-3dff794db790"
      unitRef="usd">-693000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i43b9c3f038194349830beac9c871e79d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTItMTQtMS0xLTExNjc3MQ_cfa44828-c33b-4428-a0d1-cce197e5555a"
      unitRef="usd">946000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTItMTYtMS0xLTExNjc3MQ_64a5f283-7ac2-44d5-b2d0-d087912d6f6b"
      unitRef="usd">253000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6dfaea77d3414998bbda1fdaa74c3687_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTUtMi0xLTEtMTE2Nzcx_195c88ed-70c4-4f26-b557-d0c79b3eb6e1"
      unitRef="shares">358100000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6dfaea77d3414998bbda1fdaa74c3687_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTUtNC0xLTEtMTE2Nzcx_a3b1a2ec-834f-4811-abf2-2a43c12438df"
      unitRef="usd">10289000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i58298d9eca31468d856c6a8af9ac695d_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTUtNi0xLTEtMTE2Nzcx_bf67d10b-6622-41d8-8a2c-37267050cd65"
      unitRef="usd">393000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i737ae3f3c29c44eda0e06a604ac5d478_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTUtOC0xLTEtMTE2Nzcx_565f2a0d-8615-406b-a4db-2dce07502db0"
      unitRef="usd">-8623000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id66ae7f7283b4cb5b860cc7e725569c3_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTUtMTAtMS0xLTExNjc3MQ_6b85e22c-f6fb-4088-9ada-628bdf248985"
      unitRef="usd">-2256000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4373a86e3f3641b1b628310fe43e6cc4_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTUtMTItMS0xLTExNjc3MQ_64312a4d-c563-4692-88ce-a2b880e72095"
      unitRef="usd">-197000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibc5bc84b42294f459a348f63c3726c9c_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTUtMTQtMS0xLTExNjc3MQ_3973b2ac-7333-4e85-a20a-ed457db5d6bf"
      unitRef="usd">73000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6daf46a421eb422cab6a685d448b4571_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTUtMTYtMS0xLTExNjc3MQ_66e3c984-54e5-4eaa-9207-91fcccefc806"
      unitRef="usd">-124000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i06d85523749f4a83b2b4c231d9c4dcda_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTYtMi0xLTEtMTE2Nzcx_720c4dd4-0239-4a75-8d74-989807d8f3c0"
      unitRef="shares">600000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i06d85523749f4a83b2b4c231d9c4dcda_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTYtNC0xLTEtMTE2Nzcx_031bf44c-3210-446d-8b1a-77b869c6f2cc"
      unitRef="usd">11000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i57be2e142e074165b286ea861bf03454_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTYtNi0xLTEtMTE2Nzcx_484f2072-f518-425e-8f76-7eaaed186ad3"
      unitRef="usd">-7000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie3059ef14d774d44a01059d4de19473d_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTctMTItMS0xLTEyMTgyMg_c5c016a8-de04-4d66-9706-0d540a463443"
      unitRef="usd">4000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTYtMTYtMS0xLTExNjc3MQ_e8bedd62-dad4-427d-a77f-1a28232e401a"
      unitRef="usd">4000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i57be2e142e074165b286ea861bf03454_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTctNi0xLTEtMTE2Nzcx_19557708-ac2a-44f5-85b8-8e0aec6c193a"
      unitRef="usd">31000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie3059ef14d774d44a01059d4de19473d_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTctMTItMS0xLTExNjc3MQ_db598485-cfb6-481e-83e9-212d2b1cc024"
      unitRef="usd">31000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTctMTYtMS0xLTExNjc3MQ_e8ef9333-2a05-4286-b104-eb2df99f7e7c"
      unitRef="usd">31000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i57be2e142e074165b286ea861bf03454_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTgtNi0xLTEtMTE2Nzcx_2b11c421-5527-4eab-a70c-2c358a90e34b"
      unitRef="usd">4000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie3059ef14d774d44a01059d4de19473d_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTgtMTItMS0xLTExNjc3MQ_a727f27f-0534-489e-b14c-1f04d4a19760"
      unitRef="usd">4000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMTgtMTYtMS0xLTExNjc3MQ_5340191c-588e-4e14-b22b-2381c1046d43"
      unitRef="usd">4000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="i030001e1f73a4abcb80a144774c1d968_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjAtOC0xLTEtMTE2Nzcx_92827d7d-1095-4e1e-bc2b-bb3396216c9b"
      unitRef="usd">-595000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie3059ef14d774d44a01059d4de19473d_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjAtMTItMS0xLTExNjc3MQ_c5623cb2-385a-4059-a67f-5827cf0cd53b"
      unitRef="usd">-595000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i76f8e88b904b44a792fab696eda910bf_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjAtMTQtMS0xLTExNjc3MQ_7ca8f616-fb24-4ebf-a422-131724c93f41"
      unitRef="usd">2000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjAtMTYtMS0xLTExNjc3MQ_7ff7ed11-1af8-4952-b065-2024d8afaf8c"
      unitRef="usd">-593000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i774f5c7dc8fe4f20874a5a05070d8148_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjEtMTAtMS0xLTExNjc3MQ_89a16aa5-96fb-4312-80bc-58f20f06f263"
      unitRef="usd">74000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie3059ef14d774d44a01059d4de19473d_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjEtMTItMS0xLTExNjc3MQ_d038c152-0dbc-4915-bb5d-a74e8fcd6640"
      unitRef="usd">74000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i76f8e88b904b44a792fab696eda910bf_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjEtMTQtMS0xLTExNjc3MQ_680733d7-8614-4d70-8e18-6ecd57b1545a"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjEtMTYtMS0xLTExNjc3MQ_4ac305a4-05e5-4480-beb4-caaed2f21d9e"
      unitRef="usd">75000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i167c3eb2b5a24484aae6de79b43072b9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjItMi0xLTEtMTE2Nzcx_40ad60e4-be31-46ec-9510-ee016fdbee3b"
      unitRef="shares">358700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i167c3eb2b5a24484aae6de79b43072b9_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjItNC0xLTEtMTE2Nzcx_c80969bb-3152-4a0b-ab6c-76f58a4663f8"
      unitRef="usd">10300000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i22ce8f1c4aba43659ab73d3c120bd01f_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjItNi0xLTEtMTE2Nzcx_b7cefb00-342f-47e2-bb40-08e26763aee3"
      unitRef="usd">413000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5f0bb2a47484474cbd31c19016dce90b_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjItOC0xLTEtMTE2Nzcx_6d05eecb-2dbd-4150-ad6c-8d4f5eef4e35"
      unitRef="usd">-9218000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iadf2cdcdd456462bb8b4d9279093e8ad_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjItMTAtMS0xLTExNjc3MQ_bc9d0bee-c6fa-4abf-b3b8-b125e4c6d361"
      unitRef="usd">-2182000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2238c74c755346c79d5d762dfe2cd6aa_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjItMTItMS0xLTExNjc3MQ_942a843b-145b-4c5f-8914-5e107a51c0b1"
      unitRef="usd">-687000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0f2ab9065125401bb73c3a17f98f4c57_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjItMTQtMS0xLTExNjc3MQ_1f2cbda1-0a3f-4016-9362-6417ad35238c"
      unitRef="usd">76000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i94793ac34eb24e699f57a3960e391e71_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjItMTYtMS0xLTExNjc3MQ_88bc9716-fef9-4a02-9eda-f325f7805771"
      unitRef="usd">-611000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic6618ebcc4884ef78540a8090e1935b4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjUtMi0xLTEtMTE2Nzcx_96789b84-8501-4554-8ef2-4ee937de32f8"
      unitRef="shares">359400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic6618ebcc4884ef78540a8090e1935b4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjUtNC0xLTEtMTE2Nzcx_7d634a18-7636-4ea9-b703-e39eceeaebf1"
      unitRef="usd">10317000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i87abd59869d7404c8d073f59e57b3927_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjUtNi0xLTEtMTE2Nzcx_14d66a33-c724-42ff-875f-089317e5f3c7"
      unitRef="usd">462000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idb17c62b32e2446fbb119cdb52d7cf3f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjUtOC0xLTEtMTE2Nzcx_109ff350-fc08-4f5f-bd1b-beffdc4e1b53"
      unitRef="usd">-8961000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a5f744b0e03413c9fa836c080e97ee8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjUtMTAtMS0xLTExNjc3MQ_d6501eaa-d003-491e-bcad-b0ec6b387b10"
      unitRef="usd">-1924000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i989da2ed6f4b41c18402f75e75411454_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjUtMTItMS0xLTExNjc3MQ_4019286b-4444-4e7c-ae00-67bd1a54dea9"
      unitRef="usd">-106000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i16963925dad9481f931247cb3748b170_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjUtMTQtMS0xLTExNjc3MQ_6ea9d881-395d-4dd6-824b-35257faecb87"
      unitRef="usd">72000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjUtMTYtMS0xLTExNjc3MQ_31c0c217-0a9b-4e04-8f5f-d6827e05b657"
      unitRef="usd">-34000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4677f0249548444e9357645b49193bd4_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjgtNi0xLTEtMTM0NDM2_533f6bfe-44de-46f7-ac21-e419bbab1d1a"
      unitRef="usd">-327000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i29d13958e0ae471a9601cbcfbee2a354_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjgtMTAtMS0xLTEzNDQzNg_32b4dde8-8d86-4e63-b52c-2825981d34f8"
      unitRef="usd">137000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1f62a1dbada6412d9a70817c07d9551c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjgtMTItMS0xLTEzNDQzNg_e8d5d3dd-5316-4b30-866d-7e5a7fb11e5d"
      unitRef="usd">-190000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic4af951a869647b7a15353420cc9a86f_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjgtMTQtMS0xLTEzNDQzNg_230f93aa-b8cd-4414-9012-ecab6084c7d9"
      unitRef="usd">865000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjgtMTYtMS0xLTEzNDQzNg_aaec5848-c47e-4cc2-b414-c706892336eb"
      unitRef="usd">675000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="iba4b227c13d94a3c8b88f5359bdef6ad_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjYtMi0xLTEtMTE2Nzcx_e69e8269-e81d-4a69-8100-a69224a19480"
      unitRef="shares">2200000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iba4b227c13d94a3c8b88f5359bdef6ad_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjYtNC0xLTEtMTE2Nzcx_4a0715ac-5a06-4f19-b80f-ee26171a1796"
      unitRef="usd">63000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4677f0249548444e9357645b49193bd4_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjYtNi0xLTEtMTE2Nzcx_4962b567-a2d1-46d3-a9a8-8efc4dcedabe"
      unitRef="usd">-60000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1f62a1dbada6412d9a70817c07d9551c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjYtMTItMS0xLTExNjc3MQ_ad225cc4-b299-4b63-a75f-dcc53ac885b4"
      unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjYtMTYtMS0xLTExNjc3MQ_c8725f25-07e3-41a7-846c-48549cb91753"
      unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4677f0249548444e9357645b49193bd4_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjctNi0xLTEtMTE2Nzcx_8e1d1688-dd01-4ac2-b411-6db2b47dc0f9"
      unitRef="usd">58000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1f62a1dbada6412d9a70817c07d9551c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjctMTItMS0xLTExNjc3MQ_264bfd17-0d79-485e-b45c-881f8fe3888a"
      unitRef="usd">58000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjctMTYtMS0xLTExNjc3MQ_d181423c-a520-4b5c-ae27-0f2ea1ab5777"
      unitRef="usd">58000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i4677f0249548444e9357645b49193bd4_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjgtNi0xLTEtMTE2Nzcx_7804103e-e9b8-4925-b843-d5f8e5b67a33"
      unitRef="usd">29000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i1f62a1dbada6412d9a70817c07d9551c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjgtMTItMS0xLTExNjc3MQ_3781235b-6f92-4b37-8f3c-3136728192d6"
      unitRef="usd">29000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjgtMTYtMS0xLTExNjc3MQ_1a1bdbb3-0ea2-4eac-ac09-82229bf2e2e1"
      unitRef="usd">29000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="i2226daa2ed09422d853e54bab742c402_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjktOC0xLTEtMTE2Nzcx_e3395e58-a805-4979-8faa-432bd5946a88"
      unitRef="usd">-214000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1f62a1dbada6412d9a70817c07d9551c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjktMTItMS0xLTExNjc3MQ_d1f8c909-c772-4749-a6d0-3ad79b1901eb"
      unitRef="usd">-214000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic4af951a869647b7a15353420cc9a86f_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjktMTQtMS0xLTExNjc3MQ_99d3671a-9017-40ae-9e2d-a88d98fd1849"
      unitRef="usd">9000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMjktMTYtMS0xLTExNjc3MQ_e3da109c-9c8e-42e3-a9ce-d8fb5db72798"
      unitRef="usd">-205000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i29d13958e0ae471a9601cbcfbee2a354_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzAtMTAtMS0xLTExNjc3MQ_6f9afd4e-58f5-4db1-a32e-5fa8196d9c6c"
      unitRef="usd">-215000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1f62a1dbada6412d9a70817c07d9551c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzAtMTItMS0xLTExNjc3MQ_8a2922bf-79b4-427f-a07d-6ce4db63c5ee"
      unitRef="usd">-215000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzAtMTYtMS0xLTExNjc3MQ_74528bd1-e6f5-49c6-acd3-16b8945314ea"
      unitRef="usd">-215000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8730ee88d2bc423b9151cc9c2820d19d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzEtMi0xLTEtMTE2Nzcx_b27ffb71-ad4a-48bc-976f-aa33ced0d8da"
      unitRef="shares">361600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8730ee88d2bc423b9151cc9c2820d19d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzEtNC0xLTEtMTE2Nzcx_9befad24-6202-45c8-b9cc-d5eedda0b07f"
      unitRef="usd">10380000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i36716f0b028846cb85d4eb4230d3d560_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzEtNi0xLTEtMTE2Nzcx_a7232a3b-7745-4ddb-9875-083f9fb2a9d7"
      unitRef="usd">104000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2dc7cc39fb2243a28ac5a77266758826_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzEtOC0xLTEtMTE2Nzcx_3a14636f-0863-44e9-842a-8210788a064f"
      unitRef="usd">-9175000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6b5d37c24d0e41cb994b6d343566c79e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzEtMTAtMS0xLTExNjc3MQ_f2822713-b2a7-4ef4-a6a7-ba16a6eb79ae"
      unitRef="usd">-2002000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i916cf2185b2841f8a9e4fd0d5fec5a62_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzEtMTItMS0xLTExNjc3MQ_7c50225b-6edf-4294-85e4-915d5cd0189c"
      unitRef="usd">-693000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i43b9c3f038194349830beac9c871e79d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzEtMTQtMS0xLTExNjc3MQ_fd6d58a4-a488-4b47-a3e0-6d39db5689a8"
      unitRef="usd">946000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzEtMTYtMS0xLTExNjc3MQ_8a4c2ae4-50ba-4e68-a160-d2e2a3a9e986"
      unitRef="usd">253000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1ca51f98774641caa2fa73733729ac9b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzQtMi0xLTEtMTE2Nzcx_fd8c7fb2-18a2-4182-bcd0-edf5a4260cc7"
      unitRef="shares">355400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1ca51f98774641caa2fa73733729ac9b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzQtNC0xLTEtMTE2Nzcx_012a6036-ca0f-4eb7-9d27-f11993a47f4b"
      unitRef="usd">10227000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6241ec65cd5841d28d2b1250bb5b5996_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzQtNi0xLTEtMTE2Nzcx_74faa725-82cf-486b-aa0f-66ef92c04845"
      unitRef="usd">454000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i12c22386ccd746679fcffe88ce0ac211_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzQtOC0xLTEtMTE2Nzcx_64831593-65a8-45c9-a58b-448628492607"
      unitRef="usd">-8013000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i628fbe5e0c6641f0821414b9534fdfbc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzQtMTAtMS0xLTExNjc3MQ_364acc46-a88d-4e54-a119-bdd83664dd07"
      unitRef="usd">-2133000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f53aee8e3d54f4c9d733db6eaab6639_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzQtMTItMS0xLTExNjc3MQ_f5f352a0-6ded-47ce-a480-c3c9be026848"
      unitRef="usd">535000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i83ec1ba0169043a5b8ee5935b00c293f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzQtMTQtMS0xLTExNjc3MQ_755a9ea6-4f3b-4e93-8c2f-68868cd00020"
      unitRef="usd">70000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic5e21899f1044f7fa7cb214f91d5655c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzQtMTYtMS0xLTExNjc3MQ_a564f562-31e9-4e24-b861-e889b10ba697"
      unitRef="usd">605000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i168fd2ab08394dc88509e23e01fe1f09_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzUtMi0xLTEtMTE2Nzcx_2febf823-cb02-4618-9424-4a029f3d08dd"
      unitRef="shares">3300000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i168fd2ab08394dc88509e23e01fe1f09_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzUtNC0xLTEtMTE2Nzcx_b605c41d-8fbe-42aa-bf11-379113844127"
      unitRef="usd">73000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i54f5ce0b0a044bc88c6f3917442a0aee_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzUtNi0xLTEtMTE2Nzcx_45375620-1977-461e-9d63-36c28e540452"
      unitRef="usd">-58000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic8ecdccc3b9849ea91d1b8d126581ab7_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzUtMTItMS0xLTExNjc3MQ_ace75714-84c9-4f86-b435-500003f4905c"
      unitRef="usd">15000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzUtMTYtMS0xLTExNjc3MQ_a3a07d65-e5ae-4e68-857d-a3a717a310cf"
      unitRef="usd">15000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i54f5ce0b0a044bc88c6f3917442a0aee_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzYtNi0xLTEtMTE2Nzcx_5ca80fa2-0306-4753-b852-95481830b0f9"
      unitRef="usd">62000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic8ecdccc3b9849ea91d1b8d126581ab7_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzYtMTItMS0xLTExNjc3MQ_52ee561c-5b57-459b-b299-d5d283dabe49"
      unitRef="usd">62000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzYtMTYtMS0xLTExNjc3MQ_7c1d1618-b52c-4ca9-bffe-ed4f78ee86b0"
      unitRef="usd">62000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i54f5ce0b0a044bc88c6f3917442a0aee_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzctNi0xLTEtMTE2Nzcx_0410f434-0be1-472c-8d40-94a951d73a1f"
      unitRef="usd">45000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ic8ecdccc3b9849ea91d1b8d126581ab7_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzctMTItMS0xLTExNjc3MQ_94a1f390-9a74-441d-b97c-4017939df5fd"
      unitRef="usd">45000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzctMTYtMS0xLTExNjc3MQ_2a31a403-8cff-4203-a1d8-99f8d114ff45"
      unitRef="usd">45000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="ia4bd722a099c434c96732e1638d0eef9_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzgtOC0xLTEtMTE2Nzcx_39538422-44d3-4314-bf14-91c29e1af5ed"
      unitRef="usd">-1205000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzgtOC0xLTEtMTE2Nzcx_ce9cc730-46dc-4484-b836-fab046e2159f"
      unitRef="usd">-1205000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="ic8ecdccc3b9849ea91d1b8d126581ab7_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzgtMTItMS0xLTExNjc3MQ_3209d732-4da6-410b-a37e-5d9c2b9c57d5"
      unitRef="usd">-1205000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if281e8e8aeee4142a78388f4196a2cb4_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzgtMTQtMS0xLTExNjc3MQ_844c130f-5146-4abb-9097-bf34f8d98761"
      unitRef="usd">5000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzgtMTYtMS0xLTExNjc3MQ_729913d2-ac19-4799-90c1-a9ae567a3350"
      unitRef="usd">-1200000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic9b445a9016e474ea5b82e795dd9171f_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzktMTAtMS0xLTExNjc3MQ_7cd1ae0e-1cda-4d7e-b4de-7b0c06160ece"
      unitRef="usd">-49000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic8ecdccc3b9849ea91d1b8d126581ab7_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzktMTItMS0xLTExNjc3MQ_c81f84e1-c1e6-42dd-a17a-b02d71eb74ac"
      unitRef="usd">-49000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if281e8e8aeee4142a78388f4196a2cb4_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNDEtMTQtMS0xLTEyMTgzMQ_66bc15a0-484b-47a9-b08e-c8d53e1ffadc"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfMzktMTYtMS0xLTExNjc3MQ_34dd5dc6-507c-4184-b593-eef224df72eb"
      unitRef="usd">-48000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i167c3eb2b5a24484aae6de79b43072b9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNDAtMi0xLTEtMTE2Nzcx_f55dc603-5d6a-4c4a-a533-0f66a04bf8b2"
      unitRef="shares">358700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i167c3eb2b5a24484aae6de79b43072b9_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNDAtNC0xLTEtMTE2Nzcx_5bae49a5-5cd8-4d64-8754-1f84eacb65ea"
      unitRef="usd">10300000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i22ce8f1c4aba43659ab73d3c120bd01f_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNDAtNi0xLTEtMTE2Nzcx_76397726-bbb8-44db-a1ba-79219a397151"
      unitRef="usd">413000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5f0bb2a47484474cbd31c19016dce90b_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNDAtOC0xLTEtMTE2Nzcx_c4dbc7bd-be74-4242-8801-a91c90d79b56"
      unitRef="usd">-9218000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iadf2cdcdd456462bb8b4d9279093e8ad_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNDAtMTAtMS0xLTExNjc3MQ_82580eeb-3ced-434a-acb1-b061ef60d395"
      unitRef="usd">-2182000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2238c74c755346c79d5d762dfe2cd6aa_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNDAtMTItMS0xLTExNjc3MQ_728ebbdb-c08d-4193-a0be-6185a022dab4"
      unitRef="usd">-687000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0f2ab9065125401bb73c3a17f98f4c57_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNDAtMTQtMS0xLTExNjc3MQ_94cbc5e8-6656-43f2-a546-8c133e315fc5"
      unitRef="usd">76000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i94793ac34eb24e699f57a3960e391e71_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zMS9mcmFnOjQ2NTkxNTNhZGEzYTRlODM5MzZkZDcxYzVkYWZlMWVmL3RhYmxlOmY1ZGNlYmE2ZjBjYTRmMWM4YWIwNTg2NGU2ZTE0MjQxL3RhYmxlcmFuZ2U6ZjVkY2ViYTZmMGNhNGYxYzhhYjA1ODY0ZTZlMTQyNDFfNDAtMTYtMS0xLTExNjc3MQ_f9f867cb-86b4-4471-8e34-70fb9409e216"
      unitRef="usd">-611000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMy0xLTEtMS0xMTY3NzE_a3ae049e-5a90-4a73-a135-b1afacb81399"
      unitRef="usd">-205000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMy0zLTEtMS0xMTY3NzE_24bf3689-6530-4c62-a691-799e2b0d2651"
      unitRef="usd">-1200000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNS0xLTEtMS0xMTY3NzE_32cdbbba-0334-4963-9865-222528b15e64"
      unitRef="usd">699000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNS0zLTEtMS0xMTY3NzE_c47a37d0-8359-49d9-bda6-0c25bdc8c1ff"
      unitRef="usd">807000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNi0xLTEtMS0xMTY3NzE_0966aa06-10cd-45d4-a4e0-0c2814dd872d"
      unitRef="usd">64000000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNi0zLTEtMS0xMTY3NzE_9c62dbd2-6b02-4d06-8d94-2ea735480bf6"
      unitRef="usd">25000000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AssetImpairmentCharges
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNy0xLTEtMS0xMTY3NzE_162d5a32-4c7c-455c-9ec3-f600333f2e71"
      unitRef="usd">14000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNy0zLTEtMS0xMTY3NzE_5feeb2b0-2520-4880-8323-c2a99cfc9e7a"
      unitRef="usd">195000000</us-gaap:AssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfOC0xLTEtMS0xMTY3NzE_a9fa993d-831a-407e-817e-8fd13a6b2db0"
      unitRef="usd">83000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfOC0zLTEtMS0xMTY3NzE_131b6c2c-0816-4843-aa9b-ef03a3e40028"
      unitRef="usd">469000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfOS0xLTEtMS0xMTY3NzE_6b7dd1dc-1f3e-4585-a9c0-5c904398c100"
      unitRef="usd">-2000000</bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash>
    <bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfOS0zLTEtMS0xMTY3NzE_9372386c-84f1-4e8d-a89e-402db54ee3af"
      unitRef="usd">0</bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash>
    <bhc:AllowancesForLossesOnAccountsReceivableAndInventories
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTAtMS0xLTEtMTE2Nzcx_94bdf0fd-99b0-451b-b155-897628847786"
      unitRef="usd">19000000</bhc:AllowancesForLossesOnAccountsReceivableAndInventories>
    <bhc:AllowancesForLossesOnAccountsReceivableAndInventories
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTAtMy0xLTEtMTE2Nzcx_cf3b1bd5-6f26-415c-a7f2-cece70d6348c"
      unitRef="usd">35000000</bhc:AllowancesForLossesOnAccountsReceivableAndInventories>
    <bhc:DeferredIncomeTaxNoncashExpenseBenefit
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTEtMS0xLTEtMTE2Nzcx_46f185a2-ab02-45b5-a448-66991799a37f"
      unitRef="usd">-99000000</bhc:DeferredIncomeTaxNoncashExpenseBenefit>
    <bhc:DeferredIncomeTaxNoncashExpenseBenefit
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTEtMy0xLTEtMTE2Nzcx_801162d5-efaf-45e6-80ab-d18e9eb4fe56"
      unitRef="usd">-120000000</bhc:DeferredIncomeTaxNoncashExpenseBenefit>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTItMS0xLTEtMTE2Nzcx_d3f271b2-63da-4c26-ab85-4d2c67e5e228"
      unitRef="usd">3000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTItMy0xLTEtMTE2Nzcx_6d6e15f5-3405-4487-a774-3c849eca8d57"
      unitRef="usd">23000000</us-gaap:GainLossOnDispositionOfAssets1>
    <bhc:GainLossRelatedToLitigationSettlementGross
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTMtMS0xLTEtMTE2Nzcx_c67fbc03-eb32-4d24-a4e4-e600cf001f0e"
      unitRef="usd">-7000000</bhc:GainLossRelatedToLitigationSettlementGross>
    <bhc:GainLossRelatedToLitigationSettlementGross
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTMtMy0xLTEtMTE2Nzcx_590ceaae-0c5b-452d-b47d-79a51c26321c"
      unitRef="usd">-532000000</bhc:GainLossRelatedToLitigationSettlementGross>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTQtMS0xLTEtMTE2Nzcx_e840382a-52c3-4a02-bb3a-28d52bf83354"
      unitRef="usd">360000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTQtMy0xLTEtMTE2Nzcx_5b4defd1-2699-4b0a-b8a1-bac6cce041f6"
      unitRef="usd">129000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:ShareBasedCompensation
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTUtMS0xLTEtMTE2Nzcx_0666c920-edcf-4f10-9667-e7f317dd9176"
      unitRef="usd">58000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTUtMy0xLTEtMTE2Nzcx_027da782-d243-4ec8-ab94-8b2d35100e50"
      unitRef="usd">62000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTYtMS0xLTEtMTE2Nzcx_f3c471fc-fd51-4788-9e0f-b97a10090b7a"
      unitRef="usd">0</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTYtMy0xLTEtMTE2Nzcx_b0e835c2-21fd-454d-9eaa-fab368703ed4"
      unitRef="usd">-7000000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <bhc:DerivativeGainExcludedComponent
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTctMS0xLTEtMTE2Nzcx_9d153f0d-fd00-49e4-9d63-ad9e004445e2"
      unitRef="usd">0</bhc:DerivativeGainExcludedComponent>
    <bhc:DerivativeGainExcludedComponent
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTctMy0xLTEtMTE2Nzcx_40ae2e30-1579-4771-9a8f-c9e7fee229ab"
      unitRef="usd">11000000</bhc:DerivativeGainExcludedComponent>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTgtMS0xLTEtMTE2Nzcx_8a817854-8661-453b-893a-a17b889b9e82"
      unitRef="usd">113000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTgtMy0xLTEtMTE2Nzcx_d072985a-d3f1-43e3-bf0f-0a5b45692d9d"
      unitRef="usd">-50000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTktMS0xLTEtMTE2Nzcx_0f7320d0-4385-4e82-bda2-556511480d78"
      unitRef="usd">1000000</bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities>
    <bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMTktMy0xLTEtMTE2Nzcx_ca15da75-cefb-4281-b739-639183ade66e"
      unitRef="usd">8000000</bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjAtMS0xLTEtMTE2Nzcx_50c8095c-90ed-485e-a459-0107cb0d8e11"
      unitRef="usd">-4000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjAtMy0xLTEtMTE2Nzcx_ec651cc5-92db-4ff5-b1f9-53aa23acdc03"
      unitRef="usd">24000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjItMS0xLTEtMTE2Nzcx_b577d0dd-8756-4eb0-a822-65108f4d4a7f"
      unitRef="usd">-107000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjItMy0xLTEtMTE2Nzcx_2db211c8-b901-4492-8cf3-19d1cae5084e"
      unitRef="usd">48000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjMtMS0xLTEtMTE2Nzcx_21691c0c-3077-470d-8fa3-98f964c60d66"
      unitRef="usd">138000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjMtMy0xLTEtMTE2Nzcx_096a860d-5099-4149-8f03-41ee7f9cb107"
      unitRef="usd">47000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjQtMS0xLTEtMTE2Nzcx_fea8db59-5261-45fb-a3ef-ea8f4f112bbd"
      unitRef="usd">48000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjQtMy0xLTEtMTE2Nzcx_a1755a9b-7772-46b0-884b-6967fa58ba37"
      unitRef="usd">-21000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjUtMS0xLTEtMTE2Nzcx_4290c570-22e1-436c-a2d5-a854ba87e5c8"
      unitRef="usd">-26000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjUtMy0xLTEtMTE2Nzcx_7f0fd06e-e707-418e-a9ad-61aa2597018f"
      unitRef="usd">245000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjYtMS0xLTEtMTE2Nzcx_27b240c9-6600-4d48-b1a4-f5da0902b889"
      unitRef="usd">60000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjYtMy0xLTEtMTE2Nzcx_a2c1b9ef-e81f-4248-82ba-d0d4ada3005d"
      unitRef="usd">838000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjgtMS0xLTEtMTE2Nzcx_942dc476-0251-454f-a050-c7a7bb1b3c2d"
      unitRef="usd">98000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjgtMy0xLTEtMTE2Nzcx_c2aa58f7-7040-4d2c-8b11-481d45d0a9e6"
      unitRef="usd">128000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjktMS0xLTEtMTE2Nzcx_4b1879af-6735-4663-a289-721b60d65bc5"
      unitRef="usd">15000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMjktMy0xLTEtMTE2Nzcx_044298bd-ca4e-4582-84d3-bca8b7b4c1bb"
      unitRef="usd">4000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMzAtMS0xLTEtMTE2Nzcx_08ca6630-bd0b-43e6-8dc9-1648317089d9"
      unitRef="usd">14000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMzAtMy0xLTEtMTE2Nzcx_c866abf9-f8a3-482b-aa97-f4b8ca83aa14"
      unitRef="usd">11000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMzEtMS0xLTEtMTE2Nzcx_a3e3a905-d5ad-4c6d-af2f-1305a5ba2d84"
      unitRef="usd">13000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMzEtMy0xLTEtMTE2Nzcx_97647781-2e2a-47da-b2c9-42f04ef7cfea"
      unitRef="usd">8000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMzItMS0xLTEtMTE2Nzcx_83285002-36a2-476a-81d6-505ab1ce3fc0"
      unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMzItMy0xLTEtMTE2Nzcx_f28ef311-c93d-47b4-ac2f-bf819a9b8cac"
      unitRef="usd">25000000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <bhc:InterestSettlementOnCrossCurrencySwaps
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMzMtMS0xLTEtMTE2Nzcx_448a5338-962f-4f08-a1f9-2860243f5f8d"
      unitRef="usd">0</bhc:InterestSettlementOnCrossCurrencySwaps>
    <bhc:InterestSettlementOnCrossCurrencySwaps
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMzMtMy0xLTEtMTE2Nzcx_330d1eb6-d828-402d-8b4f-9f1676a40d3a"
      unitRef="usd">11000000</bhc:InterestSettlementOnCrossCurrencySwaps>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMzQtMS0xLTEtMTE2Nzcx_8fe607dc-51bd-4047-af8d-f9ce493c5614"
      unitRef="usd">-114000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMzQtMy0xLTEtMTE2Nzcx_0576911a-1ade-4291-9dfd-3f1b5e903407"
      unitRef="usd">-99000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMzYtMS0xLTEtMTE2Nzcx_50a53d3e-51d3-4ab4-afad-37dc0c905409"
      unitRef="usd">6320000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMzYtMy0xLTEtMTE2Nzcx_41010b66-7b07-4d33-98f6-fe03c4cc9c07"
      unitRef="usd">1579000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMzctMS0xLTEtMTE2Nzcx_109aa529-119a-4b23-9ad2-f8b0ff5aab28"
      unitRef="usd">7083000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfMzctMy0xLTEtMTE2Nzcx_38ad36b6-b1dd-41fa-be6d-ebcb25da4425"
      unitRef="usd">2100000000</us-gaap:RepaymentsOfLongTermDebt>
    <bhc:ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDAtMS0xLTEtMTIzMjE5_f6b8668a-f535-4c97-bec6-aaf860a38d55"
      unitRef="usd">675000000</bhc:ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty>
    <bhc:ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDAtMy0xLTEtMTIzMjE5_622174bd-b7ce-4aa9-9f66-cf8ce8022c38"
      unitRef="usd">0</bhc:ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDAtMS0xLTEtMTE2Nzcx_b05551f3-2b5a-4cb7-b01c-5b43ec8fa5a4"
      unitRef="usd">29000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDAtMy0xLTEtMTE2Nzcx_836ccb73-9cb8-4f29-93cc-f1b50874666b"
      unitRef="usd">45000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDEtMS0xLTEtMTE2Nzcx_b8cc507e-65e4-4ead-8872-b7353e0148bc"
      unitRef="usd">13000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDEtMy0xLTEtMTE2Nzcx_5140593c-80ae-4172-837c-9b90194469da"
      unitRef="usd">41000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDItMS0xLTEtMTE2Nzcx_f53ee2ac-93a5-4082-8664-470126697fef"
      unitRef="usd">34000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDItMy0xLTEtMTE2Nzcx_9463f43b-2cdc-4c3f-8f68-05de9ba3803e"
      unitRef="usd">38000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDMtMS0xLTEtMTE2Nzcx_0eb62768-52d6-4a07-8d5e-8b969351de24"
      unitRef="usd">2000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDMtMy0xLTEtMTE2Nzcx_3335a195-c6d7-4215-80a3-0891b639932d"
      unitRef="usd">14000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDQtMS0xLTEtMTE2Nzcx_5488b2db-fdbe-4e9a-8cf1-09685da7725d"
      unitRef="usd">-162000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDQtMy0xLTEtMTE2Nzcx_115d0136-a210-406d-ace7-487108f40fd6"
      unitRef="usd">-631000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDUtMS0xLTEtMTE2Nzcx_13cb9949-cd44-46f0-ba1a-3c5bcf25046e"
      unitRef="usd">-24000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDUtMy0xLTEtMTE2Nzcx_d4c6638f-e334-4757-a3de-a1eaf802ad20"
      unitRef="usd">-6000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDYtMS0xLTEtMTE2Nzcx_57476996-b6c4-42f0-9566-3ae435830f08"
      unitRef="usd">-240000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDYtMy0xLTEtMTE2Nzcx_281fd155-dca9-41b9-ac97-4de9c2a03887"
      unitRef="usd">102000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDctMS0xLTEtMTE2Nzcx_a612bf12-ec8d-40c2-b57f-5e9c0779a666"
      unitRef="usd">2119000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic5e21899f1044f7fa7cb214f91d5655c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDctMy0xLTEtMTE2Nzcx_5f94229b-e21c-47dc-9b11-4bd46ecc39bb"
      unitRef="usd">1816000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDgtMS0xLTEtMTE2Nzcx_ce107062-4a68-4144-926b-585087c73f0a"
      unitRef="usd">1879000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i94793ac34eb24e699f57a3960e391e71_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDgtMy0xLTEtMTE2Nzcx_c9465487-4375-4a30-b048-235ab646dd32"
      unitRef="usd">1918000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDktMS0xLTEtMTE2Nzcx_0840c291-597f-42c4-9a5e-783f46312794"
      unitRef="usd">659000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i94793ac34eb24e699f57a3960e391e71_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNDktMy0xLTEtMTE2Nzcx_b535cf7c-2c0b-43d1-a77d-e34932936151"
      unitRef="usd">642000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <bhc:RestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNTAtMS0xLTEtMTE2Nzcx_6ae4c475-c6b9-42fd-a8a9-26eff370c9e9"
      unitRef="usd">1220000000</bhc:RestrictedCashAndOtherSettlementDepositsCurrent>
    <bhc:RestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="i94793ac34eb24e699f57a3960e391e71_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNTAtMy0xLTEtMTE2Nzcx_f2bcd6a9-227a-4843-9d21-6d6225b53a2b"
      unitRef="usd">1214000000</bhc:RestrictedCashAndOtherSettlementDepositsCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNTEtMS0xLTEtMTE2Nzcx_7a332666-cc97-4f32-9d35-cd68b97eb32b"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="i94793ac34eb24e699f57a3960e391e71_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNTEtMy0xLTEtMTE2Nzcx_8fc8cef0-f5d4-44ca-a424-376a96bd2823"
      unitRef="usd">62000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNTItMS0xLTEtMTE2Nzcx_1d51e992-62a5-48c7-8eb7-45bdab115f38"
      unitRef="usd">1879000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i94793ac34eb24e699f57a3960e391e71_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8zNC9mcmFnOmI3ZGYzMjQ2ZjBjMjRlMDE4NjMxZmFkODhlMWFjZDJmL3RhYmxlOmZkZGQzMTkwYzYwZDRlYzg5MzI3MDdlNDhhOGQ4MzRjL3RhYmxlcmFuZ2U6ZmRkZDMxOTBjNjBkNGVjODkzMjcwN2U0OGE4ZDgzNGNfNTItMy0xLTEtMTE2Nzcx_98a7b717-cabe-4458-bc23-bc73b6c8ab40"
      unitRef="usd">1918000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80MC9mcmFnOjMzMmVjNTIzMWExMzQ0NTNiM2UzMzM3ZjE2MzY5NzYwL3RleHRyZWdpb246MzMyZWM1MjMxYTEzNDQ1M2IzZTMzMzdmMTYzNjk3NjBfNTg5_95088a49-85ed-4cb8-9669-26379f399ef6">DESCRIPTION OF BUSINESS Bausch Health Companies Inc. (the&#160;&#x201c;Company&#x201d; or &#x201c;Bausch Health&#x201d;) is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (&#x201c;GI&#x201d;) and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (&#x201c;OTC&#x201d;) products and medical aesthetic devices and, through its approximately 90% ownership of Bausch + Lomb Corporation (&#x201c;Bausch + Lomb&#x201d;), branded, and branded generic pharmaceuticals, OTC products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment) in the therapeutic area of eye health. The Company's products are marketed directly or indirectly in approximately 100 countries.</us-gaap:NatureOfOperations>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="iab6dfe2f976644e99955a0681d7c0c9c_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80MC9mcmFnOjMzMmVjNTIzMWExMzQ0NTNiM2UzMzM3ZjE2MzY5NzYwL3RleHRyZWdpb246MzMyZWM1MjMxYTEzNDQ1M2IzZTMzMzdmMTYzNjk3NjBfNDM5ODA0NjUxMjE5Ng_0df7e40a-91b9-4651-b416-a83e5e186cb7"
      unitRef="number">0.90</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:NumberOfCountriesInWhichEntityOperates
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80MC9mcmFnOjMzMmVjNTIzMWExMzQ0NTNiM2UzMzM3ZjE2MzY5NzYwL3RleHRyZWdpb246MzMyZWM1MjMxYTEzNDQ1M2IzZTMzMzdmMTYzNjk3NjBfNTc0_fb152f90-fbd2-4ead-8e81-75100d6abcd1"
      unitRef="country">100</us-gaap:NumberOfCountriesInWhichEntityOperates>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80My9mcmFnOjA5ZDllMmE3ZWIwZDQ3NWU5NTk4ZGI1ZGY4NzQ2MDZiL3RleHRyZWdpb246MDlkOWUyYTdlYjBkNDc1ZTk1OThkYjVkZjg3NDYwNmJfNzk3MQ_788d70e9-5f6b-4ad5-91c8-ad05053e2a40">SIGNIFICANT ACCOUNTING POLICIES &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation and Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Consolidated Financial Statements have been prepared by the Company in U.S. dollars and in accordance with&#160;U.S. generally accepted accounting principles (&#x201c;U.S.&#160;GAAP&#x201d;) for interim financial reporting, which do not conform in all respects to the requirements of U.S.&#160;GAAP for annual financial statements. Accordingly, these notes to the unaudited Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements prepared in accordance with U.S.&#160;GAAP that are contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the U.S. Securities and Exchange Commission (the&#160;&#x201c;SEC&#x201d;) and the Canadian Securities Administrators (the&#160;&#x201c;CSA&#x201d;) on February&#160;23, 2022. The unaudited Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#x2019;s audited Consolidated Financial Statements for the year ended December&#160;31, 2021. The unaudited Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statement of the Company&#x2019;s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full&#160;year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Separation of the Bausch + Lomb Eye Health Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 6, 2020, the Company announced its intentions to separate its eye health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc. (the &#x201c;B+L Separation&#x201d;). In January 2022, the Company completed the internal organizational design and structure of the new eye health entity, Bausch + Lomb, as previously announced. The registration statement related to the initial public offering (&#x201c;IPO&#x201d;) of Bausch + Lomb (the &#x201c;B+L IPO&#x201d;) was declared effective on May 5, 2022, and Bausch + Lomb&#x2019;s common stock began trading on the New York Stock Exchange and the Toronto Stock Exchange, in each case under the ticker symbol &#x201c;BLCO&#x201d; on May 6, 2022. Prior to the effectiveness of the registration statement, Bausch + Lomb was an indirect wholly-owned subsidiary of the Company. On May 10, 2022, a wholly owned subsidiary of the Company (the &#x201c;Selling Shareholder&#x201d;) sold 35,000,000 common shares of Bausch + Lomb, at an offering price of $18.00 per share, pursuant to the B+L IPO. In addition, the Selling Shareholder granted the underwriters an option for a period of 30 days from the date of the B+L IPO to purchase up to an additional 5,250,000 common shares to cover over-allotments at the IPO price less underwriting commissions. On May 31, 2022, the underwriters partially exercised the over-allotment option granted by the Selling Shareholder and, on June 1, 2022, the Selling Shareholder sold an additional 4,550,357 common shares of Bausch + Lomb at an offering price of $18.00 per share (less applicable underwriting discount). The remainder of the over-allotment option granted to the underwriters expired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the closing of the B+L IPO and after giving effect to the partial exercise of the over-allotment option, Bausch Health directly or indirectly holds 310,449,643 Bausch + Lomb common shares, which represent approximately 88.7% of Bausch + Lomb&#x2019;s outstanding common shares. The aggregate net proceeds from the B+L IPO and the partial exercise of the over-allotment option by the underwriters, after deducting underwriting commissions were approximately $675&#160;million. The Company remains committed to completing the B+L Separation and believes the separation makes strategic sense. The completion of the B+L Separation is subject to the expiry of customary lockups related to the B+L IPO, the achievement of targeted debt leverage ratios and the receipt of applicable shareholder and other necessary approvals. The Company continues to evaluate the factors and considerations related to completing the B+L Separation and effect of the Norwich Legal Decision (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; of Note 18, &#x201c;LEGAL PROCEEDINGS&#x201d;) on the B+L Separation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The B+L IPO established two separate companies that include: (i) a fully integrated eye health company which consists of the Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals businesses and (ii) a diversified pharmaceutical company which includes the Company&#x2019;s Salix, International (formerly International Rx), Diversified (dentistry, neurology, medical dermatology and generics pharmaceutical) products, and Solta aesthetic medical device businesses. Other than the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;effects of the B+L IPO described above, these unaudited Consolidated Financial Statements do not include any adjustments to give effect to the B+L Separation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impacts of COVID-19 Pandemic &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unprecedented nature of the COVID-19 pandemic has, and continues to, adversely impact the global economy. The COVID-19 pandemic and the reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent to which these events may continue to impact the Company&#x2019;s business, financial condition, cash flows and results of operations, in particular, will depend on future developments which are highly uncertain and many of which are outside the Company&#x2019;s control. Such developments include the availability and effectiveness of vaccines for the COVID-19 virus, the ultimate geographic spread and duration of the pandemic, COVID-19 vaccine immunization rates, the extent and duration of a resurgence of the COVID-19 virus and variant strains thereof, such as the delta and omicron variants, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus and the economic impact of the pandemic and the reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company&#x2019;s business, financial condition, cash flows and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing. Although it is difficult to predict the broad macroeconomic effects that the COVID-19 pandemic will have on industries or individual companies, the Company has assessed the possible effects and outcomes of the pandemic on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand and currently believes that its estimates are reasonable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Initial Public Offering of Solta Medical Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 3, 2021, the Company announced its intentions to conduct an IPO of its aesthetic medical device business, Solta Medical (formerly Global Solta) (the &#x201c;Solta IPO&#x201d;). In January 2022, the Company completed the internal organizational design and structure of the new Solta Medical entity, Solta Medical Corporation (&#x201c;Solta&#x201d;). On June 16, 2022, as a result of challenging market conditions and other factors, the Company announced it was suspending its plans for the Solta IPO. Solta will remain part of Bausch Health, as the Company plans to revisit alternate paths for its Solta medical aesthetic devices business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In preparing the unaudited Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Consolidated Financial Statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the differences could be material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#x2019;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#x2019;s results of operations and financial position could be materially impacted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior year amounts to conform to the current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Changes in Reportable Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commencing in the first quarter of 2022, the Company operates in the following reportable segments: (i) Salix, (ii) International (formerly International Rx), (iii) Diversified Products, (iv) Solta Medical, and (v) Bausch + Lomb. Prior to the first quarter of 2022, the Company operated in the following reportable segments: (i) Salix, (ii) International Rx, (iii) Ortho &lt;/span&gt;&lt;/div&gt;Dermatologics, (iv) Diversified Products and (v) Bausch + Lomb. Prior period presentations have been recast to conform to the current segment reporting structure. See Note 19, &#x201c;SEGMENT INFORMATION&#x201d; for additional information.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80My9mcmFnOjA5ZDllMmE3ZWIwZDQ3NWU5NTk4ZGI1ZGY4NzQ2MDZiL3RleHRyZWdpb246MDlkOWUyYTdlYjBkNDc1ZTk1OThkYjVkZjg3NDYwNmJfNzk3Mw_382df0ef-311f-403a-b3f2-a0d23ce5d96e">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation and Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Consolidated Financial Statements have been prepared by the Company in U.S. dollars and in accordance with&#160;U.S. generally accepted accounting principles (&#x201c;U.S.&#160;GAAP&#x201d;) for interim financial reporting, which do not conform in all respects to the requirements of U.S.&#160;GAAP for annual financial statements. Accordingly, these notes to the unaudited Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements prepared in accordance with U.S.&#160;GAAP that are contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the U.S. Securities and Exchange Commission (the&#160;&#x201c;SEC&#x201d;) and the Canadian Securities Administrators (the&#160;&#x201c;CSA&#x201d;) on February&#160;23, 2022. The unaudited Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#x2019;s audited Consolidated Financial Statements for the year ended December&#160;31, 2021. The unaudited Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statement of the Company&#x2019;s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full&#160;year.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i1508df3b43b1420ea4df39c0ed271596_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80My9mcmFnOjA5ZDllMmE3ZWIwZDQ3NWU5NTk4ZGI1ZGY4NzQ2MDZiL3RleHRyZWdpb246MDlkOWUyYTdlYjBkNDc1ZTk1OThkYjVkZjg3NDYwNmJfMjczMg_4b7676ee-6040-4ca6-b150-30103e9398da"
      unitRef="shares">35000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i1419e3c9d7064ed0ae3e2c5034298ca9_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80My9mcmFnOjA5ZDllMmE3ZWIwZDQ3NWU5NTk4ZGI1ZGY4NzQ2MDZiL3RleHRyZWdpb246MDlkOWUyYTdlYjBkNDc1ZTk1OThkYjVkZjg3NDYwNmJfMjc5MQ_93957a5d-69b7-4c7e-a1ea-c8ae03c076c8"
      unitRef="usdPerShare">18.00</us-gaap:SaleOfStockPricePerShare>
    <bhc:SaleOfStockOverAllotmentTerm
      contextRef="ifdd2e805422643dfb113cf804f616871_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80My9mcmFnOjA5ZDllMmE3ZWIwZDQ3NWU5NTk4ZGI1ZGY4NzQ2MDZiL3RleHRyZWdpb246MDlkOWUyYTdlYjBkNDc1ZTk1OThkYjVkZjg3NDYwNmJfMTI2NDQzODM3MzgyOTQ_ba661f57-6693-44ab-ab64-f38cdf4a3fdd">P30D</bhc:SaleOfStockOverAllotmentTerm>
    <bhc:SaleOfStockNumberOfAdditionalSharesAvailableForIssuance
      contextRef="ifdd2e805422643dfb113cf804f616871_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80My9mcmFnOjA5ZDllMmE3ZWIwZDQ3NWU5NTk4ZGI1ZGY4NzQ2MDZiL3RleHRyZWdpb246MDlkOWUyYTdlYjBkNDc1ZTk1OThkYjVkZjg3NDYwNmJfMTI2NDQzODM3MzgzMDg_227fd18d-adfd-45c5-995e-fe6bc15c829b"
      unitRef="shares">5250000</bhc:SaleOfStockNumberOfAdditionalSharesAvailableForIssuance>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i0d34ce2c08d1460f808a069165908113_D20220601-20220601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80My9mcmFnOjA5ZDllMmE3ZWIwZDQ3NWU5NTk4ZGI1ZGY4NzQ2MDZiL3RleHRyZWdpb246MDlkOWUyYTdlYjBkNDc1ZTk1OThkYjVkZjg3NDYwNmJfNDk0NzgwMjMzNDEwMQ_5ed7353a-5ac7-4351-b9c7-d48dde801532"
      unitRef="shares">4550357</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i929d5ea1c5624f61b981d629befc7a9d_I20220601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80My9mcmFnOjA5ZDllMmE3ZWIwZDQ3NWU5NTk4ZGI1ZGY4NzQ2MDZiL3RleHRyZWdpb246MDlkOWUyYTdlYjBkNDc1ZTk1OThkYjVkZjg3NDYwNmJfNDk0NzgwMjMzNDExMw_bec8c855-a7a4-4c38-a744-31c3c270e4fb"
      unitRef="usdPerShare">18.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1441c284542b4be69c98952b98de6886_I20220601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80My9mcmFnOjA5ZDllMmE3ZWIwZDQ3NWU5NTk4ZGI1ZGY4NzQ2MDZiL3RleHRyZWdpb246MDlkOWUyYTdlYjBkNDc1ZTk1OThkYjVkZjg3NDYwNmJfNDk0NzgwMjM0MzQzNQ_6c478be7-6c72-48e8-94ea-0b9690842de0"
      unitRef="shares">310449643</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="ifd3c0b53338441d68bc503e5527d1220_D20220601-20220601"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80My9mcmFnOjA5ZDllMmE3ZWIwZDQ3NWU5NTk4ZGI1ZGY4NzQ2MDZiL3RleHRyZWdpb246MDlkOWUyYTdlYjBkNDc1ZTk1OThkYjVkZjg3NDYwNmJfNDk0NzgwMjMzNDA5NA_6ac80cfa-da14-4ddf-8ed7-a6f1b749da3c"
      unitRef="number">0.887</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="id112e4cb690043fba76b75855a318fed_D20220601-20220601"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80My9mcmFnOjA5ZDllMmE3ZWIwZDQ3NWU5NTk4ZGI1ZGY4NzQ2MDZiL3RleHRyZWdpb246MDlkOWUyYTdlYjBkNDc1ZTk1OThkYjVkZjg3NDYwNmJfMTA5OTUxMTYyOTI1ODc_3db3e860-dbb2-4d34-b3ad-53aa729b4aaa"
      unitRef="usd">675000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:UseOfEstimates
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80My9mcmFnOjA5ZDllMmE3ZWIwZDQ3NWU5NTk4ZGI1ZGY4NzQ2MDZiL3RleHRyZWdpb246MDlkOWUyYTdlYjBkNDc1ZTk1OThkYjVkZjg3NDYwNmJfNzk2Nw_45cbe1a1-f149-431a-b815-de106ae3fff2">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In preparing the unaudited Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Consolidated Financial Statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the differences could be material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#x2019;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#x2019;s results of operations and financial position could be materially impacted.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80My9mcmFnOjA5ZDllMmE3ZWIwZDQ3NWU5NTk4ZGI1ZGY4NzQ2MDZiL3RleHRyZWdpb246MDlkOWUyYTdlYjBkNDc1ZTk1OThkYjVkZjg3NDYwNmJfNzk2Mw_5dd4e25d-6383-4102-b01d-c00c3dd0f7e4">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80My9mcmFnOjA5ZDllMmE3ZWIwZDQ3NWU5NTk4ZGI1ZGY4NzQ2MDZiL3RleHRyZWdpb246MDlkOWUyYTdlYjBkNDc1ZTk1OThkYjVkZjg3NDYwNmJfNzk3OA_f9ab2aea-ddae-473e-867f-a1ecb2a42ed5">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior year amounts to conform to the current year presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RleHRyZWdpb246NzgxZTk0MGE3OTBkNGRmMWFlMjA0NDg3ZGIwNWY4MTFfNTY3OA_69a94a54-16fc-47c1-917e-763f7f395bad">REVENUE RECOGNITION &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenues are primarily generated from product sales, principally in the therapeutic areas of GI, dermatology, and eye health, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics medical devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 19, &#x201c;SEGMENT INFORMATION&#x201d; for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Sales Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160;The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company&#x2019;s products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#x2019;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the activity and ending balances of the Company&#x2019;s variable consideration provisions for the six months ended June 30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(976)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $48 million and $36&#160;million as of June 30, 2022 and January 1, 2022, respectively, which are reflected as a reduction of Trade receivables, net in the Consolidated Balance Sheets. There were no price appreciation credits during the six months ended June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(296)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,025)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,546)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $41 million and $32&#160;million as of June 30, 2021 and January 1, 2021, respectively. Included as a reduction of Distribution fees in the table above are price appreciation credits of approximately $1&#160;million during the six months ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Assets and Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collateral (if any), and any relevant current and reasonably supportable future economic factors.&#160;Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses. The activity in the allowance for credit losses for trade receivables for the six months ended June 30, 2022 and 2021 is as follows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-offs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RleHRyZWdpb246NzgxZTk0MGE3OTBkNGRmMWFlMjA0NDg3ZGIwNWY4MTFfNTcxNQ_d5d02c40-9c6b-41fb-b03e-6acffd212561">REVENUE RECOGNITION &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenues are primarily generated from product sales, principally in the therapeutic areas of GI, dermatology, and eye health, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics medical devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 19, &#x201c;SEGMENT INFORMATION&#x201d; for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Sales Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160;The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company&#x2019;s products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#x2019;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RleHRyZWdpb246NzgxZTk0MGE3OTBkNGRmMWFlMjA0NDg3ZGIwNWY4MTFfNTcwMw_a75e584e-d008-42fa-b907-4f7adcaf1020">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the activity and ending balances of the Company&#x2019;s variable consideration provisions for the six months ended June 30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(976)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $48 million and $36&#160;million as of June 30, 2022 and January 1, 2022, respectively, which are reflected as a reduction of Trade receivables, net in the Consolidated Balance Sheets. There were no price appreciation credits during the six months ended June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(296)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,025)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,546)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i5351c87dd28040558ca2b56602428e56_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfMi0yLTEtMS0xMTY3NzE_5100fc6f-374b-4b42-ab5a-9f32e7ee0924"
      unitRef="usd">222000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i41079230ec4f4c298b2e78b68dbf4675_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfMi00LTEtMS0xMTY3NzE_41797b9e-06d9-41bb-9110-68cf199d7f0f"
      unitRef="usd">482000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i3a1cc3e19bb5406f9f7bb16e324efb73_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfMi02LTEtMS0xMTY3NzE_d64ac83a-1999-4b8d-ac58-2fe5b24df4b0"
      unitRef="usd">944000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i4154c578f14243c9b9bf1af4b506141a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfMi04LTEtMS0xMTY3NzE_a5b3ccf7-c398-4fb2-9da6-d779f6da91c3"
      unitRef="usd">170000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i5c45771f0e2f47988c015be717b2f0b1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfMi0xMC0xLTEtMTE2Nzcx_b03c87db-8d52-4287-ad7f-610205d8b479"
      unitRef="usd">45000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfMi0xMi0xLTEtMTE2Nzcx_af0c7f47-5740-4f34-b75c-adecd723d453"
      unitRef="usd">1863000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i41e06bd172a5482eaf50c7db24abc26a_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfMy0yLTEtMS0xMTY3NzE_4d094508-dc47-4070-85f0-70273959c341"
      unitRef="usd">278000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="iaa9af24c349540cc966f28ac5d9956ed_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfMy00LTEtMS0xMTY3NzE_7019e352-a324-475e-9557-e85f30e278b2"
      unitRef="usd">60000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i53c5043ff3cf49cd84342b026a1ccd23_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfMy02LTEtMS0xMTY3NzE_fe3cbe6c-480f-4d3c-9669-d9835e7f16b3"
      unitRef="usd">1236000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="icc6e7bacd9e74e10ab66ecc0b3c66513_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfMy04LTEtMS0xMTY3NzE_732d15e3-58e0-4e16-af7c-7aa63750f3ab"
      unitRef="usd">1028000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ib43f03b9a4c24364af00b0bee48970f3_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfMy0xMC0xLTEtMTE2Nzcx_5b4655bd-76fa-4dd9-b8b2-b3a964a985ac"
      unitRef="usd">108000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfMy0xMi0xLTEtMTE2Nzcx_68291ec4-72ac-489f-92bd-e0e933eb63f9"
      unitRef="usd">2710000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i41e06bd172a5482eaf50c7db24abc26a_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfNC0yLTEtMS0xMTY3NzE_c0230cc1-f48a-487a-8a6d-cd4e63f3ba60"
      unitRef="usd">303000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="iaa9af24c349540cc966f28ac5d9956ed_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfNC00LTEtMS0xMTY3NzE_79bf2fd5-51f9-4502-bc0f-543c3975d525"
      unitRef="usd">107000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i53c5043ff3cf49cd84342b026a1ccd23_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfNC02LTEtMS0xMTY3NzE_d75bee4c-9da3-4460-8994-2e33554200c5"
      unitRef="usd">1170000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="icc6e7bacd9e74e10ab66ecc0b3c66513_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfNC04LTEtMS0xMTY3NzE_48e11a6d-2398-4c56-8aa3-ddb998134441"
      unitRef="usd">976000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ib43f03b9a4c24364af00b0bee48970f3_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfNC0xMC0xLTEtMTE2Nzcx_25e1ed01-71d7-402e-be99-29196eb8e09a"
      unitRef="usd">46000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfNC0xMi0xLTEtMTE2Nzcx_b6b207cf-c524-40f4-b020-3f2f0476625f"
      unitRef="usd">2602000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ib720c993198b4897b6de065be0d2db71_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfNS0yLTEtMS0xMTY3NzE_acea96a5-e722-4774-8075-3f51f086aa53"
      unitRef="usd">197000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i0903c200bb4544e59a69d3d41e660f9c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfNS00LTEtMS0xMTY3NzE_f6bfe366-4d65-4d3e-b5ba-7ce7aed50b50"
      unitRef="usd">435000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i4c259ae988c6479faf350e58d008e78c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfNS02LTEtMS0xMTY3NzE_7ab23ba5-3c83-48ab-a900-f28ab9e41661"
      unitRef="usd">1010000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i635febccfe0048d18fbd37689e3cd69d_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfNS04LTEtMS0xMTY3NzE_a43d3b25-3876-4e3b-8a9a-9b4c1bbdfdb5"
      unitRef="usd">222000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i415e68faef7f4ba28dd9ac453dcd2665_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfNS0xMC0xLTEtMTE2Nzcx_94c4a97f-d272-44e4-b267-dc2f6f5f5705"
      unitRef="usd">107000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOmU5ZTAzOGU0MWYzODQxOGI5NGEzMWU3ZGExNDMxNTEyL3RhYmxlcmFuZ2U6ZTllMDM4ZTQxZjM4NDE4Yjk0YTMxZTdkYTE0MzE1MTJfNS0xMi0xLTEtMTE2Nzcx_992cee0b-8c61-484b-9941-237d0eaa4676"
      unitRef="usd">1971000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id1bf4e809b854d01bce396823e6d1480_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RleHRyZWdpb246NzgxZTk0MGE3OTBkNGRmMWFlMjA0NDg3ZGIwNWY4MTFfNDEwMA_aa9ef620-2b24-48e2-b592-9defb04040b0"
      unitRef="usd">48000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i3635e4095c1b4cbf852ec17575d58b30_I20220101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RleHRyZWdpb246NzgxZTk0MGE3OTBkNGRmMWFlMjA0NDg3ZGIwNWY4MTFfNDEwNw_a649caeb-6e57-4129-9a93-a606cf9039c8"
      unitRef="usd">36000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f09824df81c4936b5ccd49a133e7471_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RleHRyZWdpb246NzgxZTk0MGE3OTBkNGRmMWFlMjA0NDg3ZGIwNWY4MTFfNDI1Ng_6d721fb9-6da1-47ae-a661-b76249cb99e7"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i4ca0942470cf47b0a264c45f0187b74c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfMi0yLTEtMS0xMTY3NzE_f125d6c5-7427-4e92-aa7c-d770f257a2f1"
      unitRef="usd">190000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i9595e765516542c0911edc919a2de08e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfMi00LTEtMS0xMTY3NzE_e77f8fc3-e095-4de8-acf8-bf46e04c2519"
      unitRef="usd">575000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i9607524bf3464d7c9cddb1ba970385e3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfMi02LTEtMS0xMTY3NzE_041ac836-40d1-4ce3-8bbc-0f372b786de2"
      unitRef="usd">779000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i340db29595784ee08b18b8bab8b169b8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfMi04LTEtMS0xMTY3NzE_ed3c4a63-84fd-4102-bf0b-a4c80858b8ae"
      unitRef="usd">184000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ie2c856c4b2614789b5fd854b8955fd6d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfMi0xMC0xLTEtMTE2Nzcx_6c468e29-612d-43d8-99f4-f4c5c4f3efee"
      unitRef="usd">85000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ic5e21899f1044f7fa7cb214f91d5655c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfMi0xMi0xLTEtMTE2Nzcx_fe577601-29a8-4215-acaa-49fc124b0da7"
      unitRef="usd">1813000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i60bf28905a394c1890a5d2e6ceb0cfcf_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfMy0yLTEtMS0xMTY3NzE_81a9bb44-1a83-4ca0-81d8-5400b377c2f4"
      unitRef="usd">306000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i6269a678f67b4ecf9db4720dcce9ef03_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfMy00LTEtMS0xMTY3NzE_62a6202e-8c10-48d8-a7a1-79bcd232fc8a"
      unitRef="usd">77000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i4887e1b949fa47e0995174f52a3c62f4_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfMy02LTEtMS0xMTY3NzE_247b40d0-975a-4618-b256-dc9fcc4543c7"
      unitRef="usd">1227000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i6cc2ce2251ff4d70a86c4ce36ba413dd_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfMy04LTEtMS0xMTY3NzE_bf954a14-c7b3-4d51-92bc-1df568fb6eb8"
      unitRef="usd">993000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i38ce7e9873ed48928d8f66267a5181b9_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfMy0xMC0xLTEtMTE2Nzcx_f07439e7-1049-46b5-88cc-a94963f64bf3"
      unitRef="usd">110000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfMy0xMi0xLTEtMTE2Nzcx_a158a323-e0bb-4a03-a3b1-ea14eb72a886"
      unitRef="usd">2713000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i60bf28905a394c1890a5d2e6ceb0cfcf_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfNC0yLTEtMS0xMTY3NzE_d8f6453e-364a-4456-b974-dc6bc9bf6f67"
      unitRef="usd">296000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i6269a678f67b4ecf9db4720dcce9ef03_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfNC00LTEtMS0xMTY3NzE_4464eacc-b45b-407f-a1fd-313bc8af9c50"
      unitRef="usd">119000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i4887e1b949fa47e0995174f52a3c62f4_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfNC02LTEtMS0xMTY3NzE_0da2917d-7cfc-4c85-a858-9317f6fb1608"
      unitRef="usd">1025000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i6cc2ce2251ff4d70a86c4ce36ba413dd_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfNC04LTEtMS0xMTY3NzE_0b1fe9e6-4654-4b0d-bb48-a87a0e723ecf"
      unitRef="usd">1012000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i38ce7e9873ed48928d8f66267a5181b9_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfNC0xMC0xLTEtMTE2Nzcx_b06e81ff-4b12-4f9d-980b-a9fe54d6850c"
      unitRef="usd">94000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfNC0xMi0xLTEtMTE2Nzcx_c64dba04-a74b-43f7-b9d4-f7d638be3be5"
      unitRef="usd">2546000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i1c8105ccfc3c4797a29a70cd4dd59ad9_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfNS0yLTEtMS0xMTY3NzE_7576ca59-e279-45bb-b73e-7d91dd79d14e"
      unitRef="usd">200000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i2c02e9fd592b472e98bf4f6aa3087550_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfNS00LTEtMS0xMTY3NzE_406da637-fc6d-4716-8a89-dcdff63e8283"
      unitRef="usd">533000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i543391a7e8714bbfafcedd3cb1ad5539_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfNS02LTEtMS0xMTY3NzE_bc095620-b984-4e86-9be6-0f7571e01492"
      unitRef="usd">981000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i6e5553f78cf642b4a35f59e0c0a41f82_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfNS04LTEtMS0xMTY3NzE_db22b539-2272-4496-9915-473409b9e22e"
      unitRef="usd">165000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i5e4b08ae397c4999b5a89bd9886028e8_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfNS0xMC0xLTEtMTE2Nzcx_85b78dcf-04b8-4cc6-b2f6-08df988beefb"
      unitRef="usd">101000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i94793ac34eb24e699f57a3960e391e71_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjUyZGNiNDQzYzAwMDRiZWI5ZTI3MGQyMzNjYjVjNzllL3RhYmxlcmFuZ2U6NTJkY2I0NDNjMDAwNGJlYjllMjcwZDIzM2NiNWM3OWVfNS0xMi0xLTEtMTE2Nzcx_29d24dd4-570e-4212-b995-a301f7f68741"
      unitRef="usd">1980000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i946fa40358f2484eb2b268a38b324c08_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RleHRyZWdpb246NzgxZTk0MGE3OTBkNGRmMWFlMjA0NDg3ZGIwNWY4MTFfNDQxMg_b00917e9-4608-4dbb-8935-a2062e343d94"
      unitRef="usd">41000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i88092f2a3121475ea6f4d62c541f5263_I20210101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RleHRyZWdpb246NzgxZTk0MGE3OTBkNGRmMWFlMjA0NDg3ZGIwNWY4MTFfNDQxOQ_b325f12d-d0f7-48aa-a829-8864c212ce09"
      unitRef="usd">32000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3691b4d8ff64742b92e7f95b3ab5725_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RleHRyZWdpb246NzgxZTk0MGE3OTBkNGRmMWFlMjA0NDg3ZGIwNWY4MTFfNDU3Mg_3153c712-fb0e-422d-bccd-270640d225b1"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RleHRyZWdpb246NzgxZTk0MGE3OTBkNGRmMWFlMjA0NDg3ZGIwNWY4MTFfNTY4NA_1507d060-7749-4fdb-be77-28a701890b1b">The activity in the allowance for credit losses for trade receivables for the six months ended June 30, 2022 and 2021 is as follows.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-offs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjU5NTFiZDZlYTYzMTQ2ZTg4MzNmNWIyYmI1MzI1Y2NkL3RhYmxlcmFuZ2U6NTk1MWJkNmVhNjMxNDZlODgzM2Y1YjJiYjUzMjVjY2RfMS0xLTEtMS0xMTY3NzE_88543d5c-d1fd-471e-93c1-360c38b1606c"
      unitRef="usd">35000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ic5e21899f1044f7fa7cb214f91d5655c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjU5NTFiZDZlYTYzMTQ2ZTg4MzNmNWIyYmI1MzI1Y2NkL3RhYmxlcmFuZ2U6NTk1MWJkNmVhNjMxNDZlODgzM2Y1YjJiYjUzMjVjY2RfMS0zLTEtMS0xMTY3NzE_e5d99b51-ca0f-4a91-a675-efccf43d379b"
      unitRef="usd">39000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjU5NTFiZDZlYTYzMTQ2ZTg4MzNmNWIyYmI1MzI1Y2NkL3RhYmxlcmFuZ2U6NTk1MWJkNmVhNjMxNDZlODgzM2Y1YjJiYjUzMjVjY2RfMi0xLTEtMS0xMTY3NzE_498b35b2-b400-4c7e-b202-00831dfb4890"
      unitRef="usd">1000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjU5NTFiZDZlYTYzMTQ2ZTg4MzNmNWIyYmI1MzI1Y2NkL3RhYmxlcmFuZ2U6NTk1MWJkNmVhNjMxNDZlODgzM2Y1YjJiYjUzMjVjY2RfMi0zLTEtMS0xMTY3NzE_14d3d0d2-d1e9-4eb3-a28f-093b610cdbbb"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjU5NTFiZDZlYTYzMTQ2ZTg4MzNmNWIyYmI1MzI1Y2NkL3RhYmxlcmFuZ2U6NTk1MWJkNmVhNjMxNDZlODgzM2Y1YjJiYjUzMjVjY2RfMy0xLTEtMS0xMTY3NzE_5478e79f-3796-44a6-bd85-fcfb20e3ef13"
      unitRef="usd">1000000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjU5NTFiZDZlYTYzMTQ2ZTg4MzNmNWIyYmI1MzI1Y2NkL3RhYmxlcmFuZ2U6NTk1MWJkNmVhNjMxNDZlODgzM2Y1YjJiYjUzMjVjY2RfMy0zLTEtMS0xMTY3NzE_de2b3138-f57e-489d-ba32-ee50ae91810a"
      unitRef="usd">1000000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjU5NTFiZDZlYTYzMTQ2ZTg4MzNmNWIyYmI1MzI1Y2NkL3RhYmxlcmFuZ2U6NTk1MWJkNmVhNjMxNDZlODgzM2Y1YjJiYjUzMjVjY2RfNC0xLTEtMS0xMTY3NzE_996a67ff-25a4-4943-9628-3fe4cafa5265"
      unitRef="usd">3000000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjU5NTFiZDZlYTYzMTQ2ZTg4MzNmNWIyYmI1MzI1Y2NkL3RhYmxlcmFuZ2U6NTk1MWJkNmVhNjMxNDZlODgzM2Y1YjJiYjUzMjVjY2RfNC0zLTEtMS0xMTY3NzE_85940645-b95b-4cf9-ad63-2e525ad5f9c7"
      unitRef="usd">1000000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <bhc:AccountsReceivableAllowanceForForeignExchangeAndOther
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjU5NTFiZDZlYTYzMTQ2ZTg4MzNmNWIyYmI1MzI1Y2NkL3RhYmxlcmFuZ2U6NTk1MWJkNmVhNjMxNDZlODgzM2Y1YjJiYjUzMjVjY2RfNS0xLTEtMS0xMTY3NzE_99ae996a-2af9-4611-b8c4-740788c2bbe7"
      unitRef="usd">2000000</bhc:AccountsReceivableAllowanceForForeignExchangeAndOther>
    <bhc:AccountsReceivableAllowanceForForeignExchangeAndOther
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjU5NTFiZDZlYTYzMTQ2ZTg4MzNmNWIyYmI1MzI1Y2NkL3RhYmxlcmFuZ2U6NTk1MWJkNmVhNjMxNDZlODgzM2Y1YjJiYjUzMjVjY2RfNS0zLTEtMS0xMTY3NzE_160a3a87-c3de-485c-ad7a-28aa231ba732"
      unitRef="usd">0</bhc:AccountsReceivableAllowanceForForeignExchangeAndOther>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjU5NTFiZDZlYTYzMTQ2ZTg4MzNmNWIyYmI1MzI1Y2NkL3RhYmxlcmFuZ2U6NTk1MWJkNmVhNjMxNDZlODgzM2Y1YjJiYjUzMjVjY2RfNi0xLTEtMS0xMTY3NzE_098491e0-095d-4b98-8414-17380587dc11"
      unitRef="usd">36000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i94793ac34eb24e699f57a3960e391e71_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80Ni9mcmFnOjc4MWU5NDBhNzkwZDRkZjFhZTIwNDQ4N2RiMDVmODExL3RhYmxlOjU5NTFiZDZlYTYzMTQ2ZTg4MzNmNWIyYmI1MzI1Y2NkL3RhYmxlcmFuZ2U6NTk1MWJkNmVhNjMxNDZlODgzM2Y1YjJiYjUzMjVjY2RfNi0zLTEtMS0xMTY3NzE_f18c70a8-30e7-4a14-9188-30234ff6021e"
      unitRef="usd">39000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80OS9mcmFnOjdlMTM0ZjI4ZDdiYzRmNjE4MWJiYTI2MDMwMDU1ODMzL3RleHRyZWdpb246N2UxMzRmMjhkN2JjNGY2MTgxYmJhMjYwMzAwNTU4MzNfMjQ0Ng_ec5fc26b-a708-4f4f-b41e-4eaae65a2331">LICENSING AGREEMENTS AND DIVESTITURE&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Licensing Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early stage development that target unique conditions. The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by regulatory agencies, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain. The commitment periods under these agreements vary and include customary termination provisions. Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred. Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Divestiture of Amoun Pharmaceutical Company S.A.E. (&#x201c;Amoun&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 31, 2021, the Company announced that it and certain of its affiliates had entered into a definitive agreement to sell all of its equity interests in Amoun for total gross consideration of approximately $740&#160;million (including the assignment to the purchasing entity of an intercompany loan granted by the Company to Amoun), subject to certain adjustments (the &#x201c;Amoun Sale&#x201d;). The Amoun Sale closed on July 26, 2021. As part of the Amoun Sale, cash generated by Amoun during the period from the locked-box date of January 1, 2021 through closing was for the benefit of the purchasing entity, subject to working capital during such period. Amoun manufactures, markets and distributes branded generics of human and animal health products. The Amoun business was part of the International segment (previously included within the former Bausch + Lomb/International Rx segment) and was reclassified as held for sale as of December 31, 2020. As a result of meeting the criteria for held for sale classification, the carrying value of the Amoun business, was adjusted to its estimated fair value, less &lt;/span&gt;&lt;/div&gt;costs to sell, and the Company recognized impairment losses of $20&#160;million and $88&#160;million during the three and six months ended June 30, 2021, respectively, included within Asset impairments, including loss on assets held for sale in the Consolidated Statements of Operations. Revenues associated with Amoun were $70&#160;million and $137&#160;million for the three and six months ended June 30, 2021, respectively.</bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="ic98d97b553c347bba74a30a630426fa0_D20210331-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80OS9mcmFnOjdlMTM0ZjI4ZDdiYzRmNjE4MWJiYTI2MDMwMDU1ODMzL3RleHRyZWdpb246N2UxMzRmMjhkN2JjNGY2MTgxYmJhMjYwMzAwNTU4MzNfMTI1MQ_e6397307-9e20-43e5-a588-7c8bdbec12b3"
      unitRef="usd">740000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i60aea4fd35f0463c9e764ebeb3fc9833_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80OS9mcmFnOjdlMTM0ZjI4ZDdiYzRmNjE4MWJiYTI2MDMwMDU1ODMzL3RleHRyZWdpb246N2UxMzRmMjhkN2JjNGY2MTgxYmJhMjYwMzAwNTU4MzNfMjE5Mw_97aefc48-c09b-48f6-95ac-4c203ec96e57"
      unitRef="usd">20000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i4b7ebf59aac94b30b7f7b423b41e117c_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80OS9mcmFnOjdlMTM0ZjI4ZDdiYzRmNjE4MWJiYTI2MDMwMDU1ODMzL3RleHRyZWdpb246N2UxMzRmMjhkN2JjNGY2MTgxYmJhMjYwMzAwNTU4MzNfMjc0ODc3OTA3MTkxMA_60f46e5e-9369-4f85-b545-6cfbbfac4a3e"
      unitRef="usd">88000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i52c2c4c1d1a5416b9c90de8eeb79bb48_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80OS9mcmFnOjdlMTM0ZjI4ZDdiYzRmNjE4MWJiYTI2MDMwMDU1ODMzL3RleHRyZWdpb246N2UxMzRmMjhkN2JjNGY2MTgxYmJhMjYwMzAwNTU4MzNfMjM5OA_447ca86c-a47b-484f-833a-0d293240b419"
      unitRef="usd">70000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i8c73de91dfce436faf9fe431bbdc6487_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV80OS9mcmFnOjdlMTM0ZjI4ZDdiYzRmNjE4MWJiYTI2MDMwMDU1ODMzL3RleHRyZWdpb246N2UxMzRmMjhkN2JjNGY2MTgxYmJhMjYwMzAwNTU4MzNfNzE0NjgyNTU4MzI4OQ_3ac4c551-e89b-4daa-9575-423a1dc15b7e"
      unitRef="usd">137000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <bhc:RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81Mi9mcmFnOjg3MDgxMWIzZDgyZDRjM2I5YWQ4Nzg5ZmNkNmQ4ODhkL3RleHRyZWdpb246ODcwODExYjNkODJkNGMzYjlhZDg3ODlmY2Q2ZDg4OGRfMjM2Nw_22a8f82e-6661-4cfb-be56-16d494b4f7c7">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restructuring and Integration Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates opportunities to improve its operating results and implement cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The liability associated with restructuring and integration costs as of June 30, 2022 was $30 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred $25 million and $6&#160;million of restructuring and integration costs and made payments of $15&#160;million and $9&#160;million during the six months ended June 30, 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Separation Costs, Separation-related Costs, IPO Costs and IPO-related Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred, and expects to continue to incur costs associated with activities to effectuate the B+L Separation. The Company also incurred costs associated with activities to effectuate the Solta IPO, which was suspended in June 2022. These B+L Separation and Solta IPO activities include: (i) separating the Bausch + Lomb and Solta Medical businesses from the remainder of the Company, (ii) completing the B+L IPO and preparing for the suspended Solta IPO and (iii) completing the actions necessary for Bausch + Lomb to become an independent publicly traded entity. Separation and IPO costs are incremental costs directly related to the ongoing B+L Separation and the suspended Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing a new board of directors and related board committees for the Bausch + Lomb and Solta Medical entities. Included in Restructuring, integration, separation and IPO costs for the six months ended June 30, 2022 and 2021 are Separation and IPO costs of $23&#160;million and $15&#160;million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has also incurred Separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation and the suspended Solta IPO and will continue to incur incremental costs indirectly related with the B+L Separation. Separation-related and IPO-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. Included in Selling, general and administrative for the six months ended June 30, 2022 and 2021 are Separation-related and IPO-related costs of $64&#160;million and $55&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent and timing of future charges of these costs to complete the B+L Separation cannot be reasonably estimated at this time and could be material.&lt;/span&gt;&lt;/div&gt;</bhc:RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i1ee589a448d54140b1753817a06b38e6_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81Mi9mcmFnOjg3MDgxMWIzZDgyZDRjM2I5YWQ4Nzg5ZmNkNmQ4ODhkL3RleHRyZWdpb246ODcwODExYjNkODJkNGMzYjlhZDg3ODlmY2Q2ZDg4OGRfNzA5_b3864989-cf2d-49e1-851d-e7215891fb30"
      unitRef="usd">30000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i73006e60a9e74841887814ddcaca7dc1_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81Mi9mcmFnOjg3MDgxMWIzZDgyZDRjM2I5YWQ4Nzg5ZmNkNmQ4ODhkL3RleHRyZWdpb246ODcwODExYjNkODJkNGMzYjlhZDg3ODlmY2Q2ZDg4OGRfNzM0_ca3600d9-dd30-429d-a2ea-1033409d411d"
      unitRef="usd">25000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i99ee9e6ccc2443c0b6ca3d2b22341738_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81Mi9mcmFnOjg3MDgxMWIzZDgyZDRjM2I5YWQ4Nzg5ZmNkNmQ4ODhkL3RleHRyZWdpb246ODcwODExYjNkODJkNGMzYjlhZDg3ODlmY2Q2ZDg4OGRfNzQx_00ab6b20-ec29-49a3-a436-2891a9591ddf"
      unitRef="usd">6000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:PaymentsForRestructuring
      contextRef="i73006e60a9e74841887814ddcaca7dc1_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81Mi9mcmFnOjg3MDgxMWIzZDgyZDRjM2I5YWQ4Nzg5ZmNkNmQ4ODhkL3RleHRyZWdpb246ODcwODExYjNkODJkNGMzYjlhZDg3ODlmY2Q2ZDg4OGRfODA0_6a275d79-2abf-4e97-a326-a72ee8e2d770"
      unitRef="usd">15000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i99ee9e6ccc2443c0b6ca3d2b22341738_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81Mi9mcmFnOjg3MDgxMWIzZDgyZDRjM2I5YWQ4Nzg5ZmNkNmQ4ODhkL3RleHRyZWdpb246ODcwODExYjNkODJkNGMzYjlhZDg3ODlmY2Q2ZDg4OGRfODEx_b7d5fca7-748f-492e-a306-144fda0d0b93"
      unitRef="usd">9000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringCharges
      contextRef="i3945140cd4d9458eafb0336b8c0878ac_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81Mi9mcmFnOjg3MDgxMWIzZDgyZDRjM2I5YWQ4Nzg5ZmNkNmQ4ODhkL3RleHRyZWdpb246ODcwODExYjNkODJkNGMzYjlhZDg3ODlmY2Q2ZDg4OGRfMTY4OQ_118b35e5-a7c1-4987-8b76-ac5ccbdc7101"
      unitRef="usd">23000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i571cafc77df6419e8f7ad8e88a7f5d22_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81Mi9mcmFnOjg3MDgxMWIzZDgyZDRjM2I5YWQ4Nzg5ZmNkNmQ4ODhkL3RleHRyZWdpb246ODcwODExYjNkODJkNGMzYjlhZDg3ODlmY2Q2ZDg4OGRfMTY5Ng_5eb1a778-03b5-43c4-85ac-880b6345db00"
      unitRef="usd">15000000</us-gaap:RestructuringCharges>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i3945140cd4d9458eafb0336b8c0878ac_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81Mi9mcmFnOjg3MDgxMWIzZDgyZDRjM2I5YWQ4Nzg5ZmNkNmQ4ODhkL3RleHRyZWdpb246ODcwODExYjNkODJkNGMzYjlhZDg3ODlmY2Q2ZDg4OGRfMjIxNA_348848e2-3282-480a-a7bd-8083c75701b5"
      unitRef="usd">64000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i571cafc77df6419e8f7ad8e88a7f5d22_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81Mi9mcmFnOjg3MDgxMWIzZDgyZDRjM2I5YWQ4Nzg5ZmNkNmQ4ODhkL3RleHRyZWdpb246ODcwODExYjNkODJkNGMzYjlhZDg3ODlmY2Q2ZDg4OGRfMjIyMQ_b8bacb2e-2c10-457f-b2aa-decd50a99061"
      unitRef="usd">55000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfNjE5Mw_0f947b82-f7e1-428d-b4a4-72e98cffd1f2">FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value measurements are estimated based on valuation techniques and inputs categorized as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1&#160;&#x2014;&#160;Quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2&#160;&#x2014;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;&#160;and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3&#160;&#x2014;&#160;Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or&#160;estimation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the&#160;instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table presents the components and classification of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.196%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and other settlement deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of three months or less when&#160;purchased, and are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature. Cash, cash equivalents and restricted cash and other settlements as presented in the Consolidated Balance Sheet as of June 30, 2022 includes $446&#160;million of cash, cash equivalents and restricted cash held by legal entities of Bausch + Lomb, of which approximately $92&#160;million was due to be distributed to other legal entities owned by the Company in connection with the separation of Bausch +Lomb. Cash otherwise held by Bausch + Lomb legal entities and any future cash from the operations, investing and financing activities of Bausch + Lomb, is expected to be retained by Bausch + Lomb entities and are generally not available to support the operations, investing and financing activities of other legal entities, including Bausch + Lomb&#x2019;s parent company unless paid as a dividend which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to  Bausch + Lomb&#x2019;s shareholders. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, Restricted cash and other settlement deposits includes $1,210&#160;million of payments into an escrow fund under the terms of a settlement agreement regarding certain U.S. securities litigation (which settlement agreement is subject to one objector&#x2019;s appeal of the final court approval of the agreement), and is reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to its short-term nature. These payments will remain in escrow until resolution of the appeal of the final court approval of the settlement agreement, as discussed in Note 18, &#x201c;LEGAL PROCEEDINGS&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers into or out of Level 3 during the six months ended June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cross-currency Swaps&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, the Company entered into cross-currency swaps, with aggregate notional amounts of $1,250 million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its Consolidated Financial Statements from fluctuation in exchange rates. The euro-denominated net investment being hedged was the Company&#x2019;s investment in certain euro-denominated subsidiaries. The Company unwound these cross-currency swaps during November 2021. As a result, there were no assets or liabilities related to the cross-currency swaps included in the Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of hedging instruments on the Consolidated Statements of Comprehensive Loss and the Consolidated Statements of Operations for the three and six months ended June 30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized in Other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain excluded from assessment of hedge effectiveness&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Location of gain of excluded component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No portion of the cross-currency swaps was ineffective for the six months ended June 30, 2021. During the six months ended June 30, 2022 and 2021, the Company received $0 and $11&#160;million, respectively, in interest settlements which are reported as investing activities in the Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Exchange Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since 2020, the Company has been entering into foreign currency exchange contracts. As of June 30, 2022, these contracts had an aggregate outstanding notional amount of $332&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. The Company&#x2019;s foreign currency exchange contracts are economically hedging the foreign exchange exposure on certain of the Company&#x2019;s intercompany balances. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other. Settlements of the Company&#x2019;s foreign currency exchange contracts are reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other and reported as operating activities in the Consolidated Statements of Cash Flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities associated with the Company&#x2019;s foreign exchange contracts as included in the Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of the Company&#x2019;s foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for the three and six months ended June 30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.982%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.366%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) related to changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) related to settlements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisition-related Contingent Consideration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level&#160;3) inputs. These inputs may include: (i)&#160;the estimated amount and timing of projected cash flows, (ii)&#160;the probability of the achievement of the factor(s) on which the contingency is based and (iii)&#160;the risk-adjusted discount rate used to present value the probability-weighted cash&#160;flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At June&#160;30, 2022, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from 6% to 18%, and a weighted average risk-adjusted discount rate of 7%. The weighted average risk-adjusted discount rate was calculated by weighting each contract&#x2019;s relative fair value at June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the six months ended June 30, 2022 and 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to Acquisition-related contingent consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion for the time value of money&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments due to changes in estimates of other future payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments/Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment included in other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Long-term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of long-term debt as of June&#160;30, 2022 and December&#160;31, 2021 was $16,141 million and $22,689 million, respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfNjIwMw_31abf95c-0c30-4948-b80d-c081dbbf0840">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table presents the components and classification of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.196%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and other settlement deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib1d5ed0948004c6da2b0030b9c2d5c61_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfMy0yLTEtMS0xMTY3NzE_c1eddc22-d1e9-413c-8fea-faf801db5ae1"
      unitRef="usd">20000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5375b8e373564a36aaf52188e7d12cf6_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfMy00LTEtMS0xMTY3NzE_15e5b0da-fe12-427b-8e5e-6d5e7160a07d"
      unitRef="usd">7000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1cce3ab850c54369b71be99818c2eadc_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfMy02LTEtMS0xMTY3NzE_c14a94be-2181-4cba-bf45-c93f5cb1b04b"
      unitRef="usd">13000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifd4d5e497f284e3bb6f031694e5e632b_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfMy04LTEtMS0xMTY3NzE_b6d7c2a1-dedd-46e8-bf56-4472c7cfe014"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i20f3c15d038f4d9a95a41ec1632623ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfMy0xMC0xLTEtMTE2Nzcx_9c9e39f9-4062-4f65-9ee4-2bc0b56c3207"
      unitRef="usd">76000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id78b9bd044e04128813ea5234fe8bbef_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfMy0xMi0xLTEtMTE2Nzcx_23b72d1f-81ee-4bb4-8345-48ed6f0f8390"
      unitRef="usd">58000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic88bcecca27f4caf845d3357626418ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfMy0xNC0xLTEtMTE2Nzcx_347be691-543f-4e5d-bc7d-81a2953579f0"
      unitRef="usd">18000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="idb74f1a8f9f947d5b4d8a76565d7e64a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfMy0xNi0xLTEtMTE2Nzcx_64891a3b-c7eb-4cb4-8bba-b3806000bca9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="ib1d5ed0948004c6da2b0030b9c2d5c61_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNC0yLTEtMS0xMTY3NzE_fd030ee6-ac6e-4183-af44-f458c1a9273c"
      unitRef="usd">1220000000</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNC00LTEtMS0xMTY3NzE_8d75d951-9aa3-4b49-8a64-fbb61e8dd119"
      unitRef="usd">1220000000</bhc:RestrictedCashAndOtherSettlementDepositsCurrent>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="i5375b8e373564a36aaf52188e7d12cf6_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNC00LTEtMS0xMTY3NzE_981787f7-d593-4a2a-80bf-09aa335c6bc1"
      unitRef="usd">1220000000</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="i1cce3ab850c54369b71be99818c2eadc_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNC02LTEtMS0xMTY3NzE_4b9bcc46-fe96-4f58-a675-cbf6b8c388e4"
      unitRef="usd">0</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="ifd4d5e497f284e3bb6f031694e5e632b_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNC04LTEtMS0xMTY3NzE_55f444b0-a4a7-420b-bc90-792c6efd2c02"
      unitRef="usd">0</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="i20f3c15d038f4d9a95a41ec1632623ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNC0xMC0xLTEtMTE2Nzcx_996fa8f9-4313-4d78-8df4-a6b9b0557fd4"
      unitRef="usd">1537000000</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="id78b9bd044e04128813ea5234fe8bbef_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNC0xMi0xLTEtMTE2Nzcx_aff94ebe-1931-4fcd-a54b-d0058299e342"
      unitRef="usd">1537000000</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="ic88bcecca27f4caf845d3357626418ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNC0xNC0xLTEtMTE2Nzcx_81a9adb0-a240-4e51-87a4-907fd133a8c9"
      unitRef="usd">0</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="idb74f1a8f9f947d5b4d8a76565d7e64a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNC0xNi0xLTEtMTE2Nzcx_9eb29989-2578-4402-8a77-60fc23f2239f"
      unitRef="usd">0</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <us-gaap:DerivativeAssets
      contextRef="i61bd5fedea3e409b8e2fc3fcc1946608_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNS0yLTEtMS0xMTY3NzE_34c9bed8-3b3d-4d66-aa5a-74757cf4fd0a"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="if25b6bb0d9734b1da12ac4c00dfb2152_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNS00LTEtMS0xMTY3NzE_2494ee5f-e901-432d-970c-245e90a132d0"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ic835863b5091449ea80b36560fc1e6a3_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNS02LTEtMS0xMTY3NzE_4d104241-c35a-4bf1-b43e-373482fb647a"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i8379b2caaf1244258cefe506e215e56c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNS04LTEtMS0xMTY3NzE_f077c82a-0567-459b-9a5a-e20831758798"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i9145c463e6ca4724adb2d0d6582fec23_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNS0xMC0xLTEtMTE2Nzcx_75785c8b-2ffe-4b2a-bf93-ffbb965746fa"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="if1b5f54af20f4de8bfeeea70bfb7ff42_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNS0xMi0xLTEtMTE2Nzcx_911ac0e6-d0ff-4a8e-8b88-5595fa56b155"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i9c974af31735487dabbddfa5989251cd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNS0xNC0xLTEtMTE2Nzcx_cc3b8814-2cd0-45bb-8ddb-9346c188fa08"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ie63c790d802547cea65c40ded8c158fb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNS0xNi0xLTEtMTE2Nzcx_27a448e4-53b6-4508-a209-b843f530f358"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="ib1d5ed0948004c6da2b0030b9c2d5c61_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNy0yLTEtMS0xMTY3NzE_6621adc3-c675-4941-9e74-f5cdb69ecd3b"
      unitRef="usd">225000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i5375b8e373564a36aaf52188e7d12cf6_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNy00LTEtMS0xMTY3NzE_0dc6701e-2f88-4778-a5bd-ea0eaaf8820b"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i1cce3ab850c54369b71be99818c2eadc_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNy02LTEtMS0xMTY3NzE_751b6e7d-a545-46a5-919a-9a930a257275"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="ifd4d5e497f284e3bb6f031694e5e632b_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNy04LTEtMS0xMTY3NzE_daa99a7b-27dc-4686-9a00-ff653008b968"
      unitRef="usd">225000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i20f3c15d038f4d9a95a41ec1632623ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNy0xMC0xLTEtMTE2Nzcx_df572509-2d2c-4916-ae09-bffade871898"
      unitRef="usd">241000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="id78b9bd044e04128813ea5234fe8bbef_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNy0xMi0xLTEtMTE2Nzcx_606d7d96-acdf-4e2f-9cea-75faf6a66c60"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="ic88bcecca27f4caf845d3357626418ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNy0xNC0xLTEtMTE2Nzcx_ab87c328-83b3-4af8-b14e-cac97d9e84d3"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="idb74f1a8f9f947d5b4d8a76565d7e64a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfNy0xNi0xLTEtMTE2Nzcx_6fa7473f-1cdb-41ea-b51e-6facb1670c68"
      unitRef="usd">241000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i61bd5fedea3e409b8e2fc3fcc1946608_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfOC0yLTEtMS0xMTY3NzE_1dbf0ffb-7ebf-4e61-9d71-e26eb996f689"
      unitRef="usd">11000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="if25b6bb0d9734b1da12ac4c00dfb2152_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfOC00LTEtMS0xMTY3NzE_4a50a9bd-f8f1-46e5-a3c5-931e96e4b5a6"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ic835863b5091449ea80b36560fc1e6a3_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfOC02LTEtMS0xMTY3NzE_997385bd-b340-4c5d-b884-ad73e5aa29de"
      unitRef="usd">11000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i8379b2caaf1244258cefe506e215e56c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfOC04LTEtMS0xMTY3NzE_3f0e3a59-d3b2-44ac-8f45-388eba126246"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i9145c463e6ca4724adb2d0d6582fec23_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfOC0xMC0xLTEtMTE2Nzcx_4c7562db-a05c-4377-b3d8-8cf4011d1122"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="if1b5f54af20f4de8bfeeea70bfb7ff42_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfOC0xMi0xLTEtMTE2Nzcx_78b6f76f-60f0-40b8-8b2d-ae59c6693f20"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i9c974af31735487dabbddfa5989251cd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfOC0xNC0xLTEtMTE2Nzcx_a9894b89-a677-4545-b02a-70b942eec1b2"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ie63c790d802547cea65c40ded8c158fb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjFhMTc3Yjk3NDc3NDQ3MWY5MTU0MzYxMzMyM2ZlMTlkL3RhYmxlcmFuZ2U6MWExNzdiOTc0Nzc0NDcxZjkxNTQzNjEzMzIzZmUxOWRfOC0xNi0xLTEtMTE2Nzcx_bd8e2faa-9b3f-43ee-ad37-1ab0286686e2"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <bhc:HighlyLiquidInvestmentsMaturityPeriod
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfMTQyOA_57b142c2-e33a-46cc-ae85-cc0fc83d5fb2">P3M</bhc:HighlyLiquidInvestmentsMaturityPeriod>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2a344934b62143ffb69252e4cddaf7f0_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfNDM5ODA0NjUxODg1Ng_a8606383-961f-4f5a-8999-36fd2719f6a4"
      unitRef="usd">446000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iaabfd7c03ce9402ea41cfcee705244c4_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfNDM5ODA0NjUxOTI0OA_70496a95-2be4-4cda-95ba-00de6c54da1f"
      unitRef="usd">92000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i189afe61ed934a13beac41e9a8e72d03_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfMTY1NA_2c513c1c-498e-41e6-bfac-f9bb5d1fdfc1"
      unitRef="usd">1210000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bhc:LitigationSettlementNumberOfObjectorsAppeals
      contextRef="ia3cc2ca14e8e4aa5b2cdb9d9edc76003_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfMTgxOA_bf860801-834f-459a-9262-3cafd2f089ff"
      unitRef="appeal">1</bhc:LitigationSettlementNumberOfObjectorsAppeals>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i80db1e595e9640d1885c3342cd690c01_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfMjM0MA_97593055-8ef9-4e97-81b3-33a425117d2a"
      unitRef="usd">1250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfNjE4Mw_ee889a21-e09b-4f7c-96dc-cec67465be81">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of hedging instruments on the Consolidated Statements of Comprehensive Loss and the Consolidated Statements of Operations for the three and six months ended June 30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized in Other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain excluded from assessment of hedge effectiveness&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Location of gain of excluded component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i54705085633648acb51a31a97ced439a_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjQ4MTc1N2U0N2JhNDQ3NTg5MmViY2VkNmY1MzgzNDc3L3RhYmxlcmFuZ2U6NDgxNzU3ZTQ3YmE0NDc1ODkyZWJjZWQ2ZjUzODM0NzdfMi0yLTEtMS0xMjAyMjk_8f80ccf5-6e30-4372-ad40-2832ff0a946d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="iece67921157f4e1a974430192b9d3bb2_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjQ4MTc1N2U0N2JhNDQ3NTg5MmViY2VkNmY1MzgzNDc3L3RhYmxlcmFuZ2U6NDgxNzU3ZTQ3YmE0NDc1ODkyZWJjZWQ2ZjUzODM0NzdfMi00LTEtMS0xMjAyMzE_92f0d6f6-1677-49c9-815d-ccea9ac4a5a4"
      unitRef="usd">-12000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i74f9e7451c5d4e35be2c1947c78de1e3_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjQ4MTc1N2U0N2JhNDQ3NTg5MmViY2VkNmY1MzgzNDc3L3RhYmxlcmFuZ2U6NDgxNzU3ZTQ3YmE0NDc1ODkyZWJjZWQ2ZjUzODM0NzdfMi0yLTEtMS0xMTY3NzE_bcf0b58a-2f68-4306-b680-e6fdb514456e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="iea270cf4c54447e083b7f756deb2b619_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjQ4MTc1N2U0N2JhNDQ3NTg5MmViY2VkNmY1MzgzNDc3L3RhYmxlcmFuZ2U6NDgxNzU3ZTQ3YmE0NDc1ODkyZWJjZWQ2ZjUzODM0NzdfMi00LTEtMS0xMTY3NzE_0529a68b-529a-4093-a5d5-d2414c6dc601"
      unitRef="usd">29000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="id174b5ac9dab4a9795348c9cab5bd884_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjQ4MTc1N2U0N2JhNDQ3NTg5MmViY2VkNmY1MzgzNDc3L3RhYmxlcmFuZ2U6NDgxNzU3ZTQ3YmE0NDc1ODkyZWJjZWQ2ZjUzODM0NzdfMy0yLTEtMS0xMjAyMjk_364b73fb-4be0-4c7e-91e0-ac87256c205f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="id5970569842e447ca7e924e7d2d9c57b_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjQ4MTc1N2U0N2JhNDQ3NTg5MmViY2VkNmY1MzgzNDc3L3RhYmxlcmFuZ2U6NDgxNzU3ZTQ3YmE0NDc1ODkyZWJjZWQ2ZjUzODM0NzdfMy00LTEtMS0xMjAyMzE_f7fa0853-e344-4578-98b6-a389d6f01c7b"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="iadd5508489ab4388a28166622ded71ec_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjQ4MTc1N2U0N2JhNDQ3NTg5MmViY2VkNmY1MzgzNDc3L3RhYmxlcmFuZ2U6NDgxNzU3ZTQ3YmE0NDc1ODkyZWJjZWQ2ZjUzODM0NzdfMy0yLTEtMS0xMTY3NzE_02867c34-1162-43d6-87ec-19e144535c61"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i2748f8a48f1c4077a65379baa42188c9_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjQ4MTc1N2U0N2JhNDQ3NTg5MmViY2VkNmY1MzgzNDc3L3RhYmxlcmFuZ2U6NDgxNzU3ZTQ3YmE0NDc1ODkyZWJjZWQ2ZjUzODM0NzdfMy00LTEtMS0xMTY3NzE_9cbaaafa-dd35-44b1-a8f8-fff5155c4f42"
      unitRef="usd">11000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:PaymentsForProceedsFromHedgeInvestingActivities
      contextRef="i9e40ec51c8e14dcf8242bf19258f7e98_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfMzIyNw_941a4221-06ef-40d6-9e49-d96165870c21"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromHedgeInvestingActivities>
    <us-gaap:PaymentsForProceedsFromHedgeInvestingActivities
      contextRef="i56a275573f694076bcb43a832f0ec8ed_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfMzIzNA_65dbaadf-248b-4d9b-a4ca-1dd22455b45b"
      unitRef="usd">11000000</us-gaap:PaymentsForProceedsFromHedgeInvestingActivities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i5073339adb074151bb1c3f96161a4030_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfMzU1Mw_826d4972-d484-4f3c-b490-317512a1eef7"
      unitRef="usd">332000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfNjE4NA_0ccc5085-b551-417b-9b00-0e14312f94a8">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities associated with the Company&#x2019;s foreign exchange contracts as included in the Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="i4b891f480d594aed8e806f205699bb48_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjRmYmExYmNlYjk2NDQzZmZiMDk0NWRjMzY2ODYzMTRjL3RhYmxlcmFuZ2U6NGZiYTFiY2ViOTY0NDNmZmIwOTQ1ZGMzNjY4NjMxNGNfMS0xLTEtMS0xMTY3NzE_e6f6fbd5-03f2-4e87-85af-08b48b9f9a09"
      unitRef="usd">11000000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="i29a580e8bc224076a70259444452e1ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjRmYmExYmNlYjk2NDQzZmZiMDk0NWRjMzY2ODYzMTRjL3RhYmxlcmFuZ2U6NGZiYTFiY2ViOTY0NDNmZmIwOTQ1ZGMzNjY4NjMxNGNfMS0zLTEtMS0xMTY3NzE_0f5275ea-cdcc-4798-867f-52791e796a24"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="i79fc8f975e3d4b62a88faa67e904f40e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjRmYmExYmNlYjk2NDQzZmZiMDk0NWRjMzY2ODYzMTRjL3RhYmxlcmFuZ2U6NGZiYTFiY2ViOTY0NDNmZmIwOTQ1ZGMzNjY4NjMxNGNfMi0xLTEtMS0xMTY3NzE_ca1881a0-cd5c-469c-920a-7b81f088e4db"
      unitRef="usd">-1000000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="i96796514e5f543db98cc98707c804220_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjRmYmExYmNlYjk2NDQzZmZiMDk0NWRjMzY2ODYzMTRjL3RhYmxlcmFuZ2U6NGZiYTFiY2ViOTY0NDNmZmIwOTQ1ZGMzNjY4NjMxNGNfMi0zLTEtMS0xMTY3NzE_f58b27c9-75aa-4283-86e6-8c55c39812e1"
      unitRef="usd">-1000000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="i5073339adb074151bb1c3f96161a4030_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjRmYmExYmNlYjk2NDQzZmZiMDk0NWRjMzY2ODYzMTRjL3RhYmxlcmFuZ2U6NGZiYTFiY2ViOTY0NDNmZmIwOTQ1ZGMzNjY4NjMxNGNfMy0xLTEtMS0xMTY3NzE_7e18f023-b0d1-460f-80e1-152f6e532896"
      unitRef="usd">-10000000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="i1483a64c418348fa85a7a2e2d92d9a71_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjRmYmExYmNlYjk2NDQzZmZiMDk0NWRjMzY2ODYzMTRjL3RhYmxlcmFuZ2U6NGZiYTFiY2ViOTY0NDNmZmIwOTQ1ZGMzNjY4NjMxNGNfMy0zLTEtMS0xMTY3NzE_23a78e39-bf0e-4b2d-b92d-ed3db0fd5271"
      unitRef="usd">1000000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfNjE5OA_c2100729-df99-4a30-89c0-8bc29c0ec34b">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of the Company&#x2019;s foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for the three and six months ended June 30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.982%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.366%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) related to changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) related to settlements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i0beb279eb94a4ed9a49020c90d93ed68_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjM4ODBiMzU3YTk0OTQxNmI5NjYyYjg4MGYwYmEzNDg1L3RhYmxlcmFuZ2U6Mzg4MGIzNTdhOTQ5NDE2Yjk2NjJiODgwZjBiYTM0ODVfMi0xLTEtMS0xMjAyMzU_08fb83c6-4517-46c8-90aa-2fa0fcb9d7e5"
      unitRef="usd">-3000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i518e98f1651849d6aa762c450415511f_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjM4ODBiMzU3YTk0OTQxNmI5NjYyYjg4MGYwYmEzNDg1L3RhYmxlcmFuZ2U6Mzg4MGIzNTdhOTQ5NDE2Yjk2NjJiODgwZjBiYTM0ODVfMi0zLTEtMS0xMjAyMzc_54e2ea95-1ebd-4698-ba8c-47cc93b9dd8c"
      unitRef="usd">7000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i8726b33a91484a12951301843f01bde5_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjM4ODBiMzU3YTk0OTQxNmI5NjYyYjg4MGYwYmEzNDg1L3RhYmxlcmFuZ2U6Mzg4MGIzNTdhOTQ5NDE2Yjk2NjJiODgwZjBiYTM0ODVfMi0xLTEtMS0xMTY3NzE_1e411b3a-03cf-4733-84bb-fc1fe0495db0"
      unitRef="usd">-10000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i1a487257cff84ebb8f7de444b4ebbe8e_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjM4ODBiMzU3YTk0OTQxNmI5NjYyYjg4MGYwYmEzNDg1L3RhYmxlcmFuZ2U6Mzg4MGIzNTdhOTQ5NDE2Yjk2NjJiODgwZjBiYTM0ODVfMi0zLTEtMS0xMTY3NzE_c3936fe7-bea3-464a-a3c6-a04555a3433d"
      unitRef="usd">5000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain
      contextRef="i0beb279eb94a4ed9a49020c90d93ed68_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjM4ODBiMzU3YTk0OTQxNmI5NjYyYjg4MGYwYmEzNDg1L3RhYmxlcmFuZ2U6Mzg4MGIzNTdhOTQ5NDE2Yjk2NjJiODgwZjBiYTM0ODVfMy0xLTEtMS0xMjAyMzU_e8c1216c-2b58-47e9-a234-b8cb0a446cc6"
      unitRef="usd">10000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain
      contextRef="i518e98f1651849d6aa762c450415511f_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjM4ODBiMzU3YTk0OTQxNmI5NjYyYjg4MGYwYmEzNDg1L3RhYmxlcmFuZ2U6Mzg4MGIzNTdhOTQ5NDE2Yjk2NjJiODgwZjBiYTM0ODVfMy0zLTEtMS0xMjAyMzc_266efef8-5dcb-4334-acaa-d320a0a9f5aa"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss
      contextRef="i8726b33a91484a12951301843f01bde5_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjM4ODBiMzU3YTk0OTQxNmI5NjYyYjg4MGYwYmEzNDg1L3RhYmxlcmFuZ2U6Mzg4MGIzNTdhOTQ5NDE2Yjk2NjJiODgwZjBiYTM0ODVfMy0xLTEtMS0xMTY3NzE_e003e362-fd19-48b0-81ab-4cd73a5a7b06"
      unitRef="usd">3000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss
      contextRef="i1a487257cff84ebb8f7de444b4ebbe8e_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjM4ODBiMzU3YTk0OTQxNmI5NjYyYjg4MGYwYmEzNDg1L3RhYmxlcmFuZ2U6Mzg4MGIzNTdhOTQ5NDE2Yjk2NjJiODgwZjBiYTM0ODVfMy0zLTEtMS0xMTY3NzE_8c7b010b-f367-44f8-a454-20dcdd8d9ee9"
      unitRef="usd">9000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="id76bfb01eac947359aab3481b8c4cc1a_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfNTYxMQ_f72b8550-8921-45af-957c-9fc1a0a30ce3"
      unitRef="rate">0.06</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i8a317605867040149a9dee38efc52b70_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfNTYxNw_b0b5cada-120a-47da-a9ac-21efef4784b8"
      unitRef="rate">0.18</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i85f23aaeb4ab4696888e25b5585acb6d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfNTY3NQ_ed8fc8a7-9b3c-4298-904c-95d5daf91c5e"
      unitRef="rate">0.07</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfNjE4Ng_c0def7cd-7536-4484-a782-7e0bb35f690b">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the six months ended June 30, 2022 and 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to Acquisition-related contingent consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion for the time value of money&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments due to changes in estimates of other future payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments/Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment included in other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfMS00LTEtMS0xMTY3NzE_ab148daa-003d-4c64-a24d-a0da7be43c9f"
      unitRef="usd">241000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ic5e21899f1044f7fa7cb214f91d5655c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfMS04LTEtMS0xMTY3NzE_179b4c77-1828-4056-8e2e-66295d3ecd20"
      unitRef="usd">328000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ieac99a0231e043b7a6cf8a6875d75f4a_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfMy0yLTEtMS0xMTY3NzE_66306116-2c9d-4ab4-95bd-9339bc8c40f0"
      unitRef="usd">8000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i5ed8d150a9e04ca1951e0567580a1c34_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfMy02LTEtMS0xMTY3NzE_8b214d23-3b28-4dbf-918b-e12f83af097f"
      unitRef="usd">9000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i605f016464d646fabfb72ea00b5aa146_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfNC0yLTEtMS0xMTY3NzE_a172f46a-e23f-4df0-bd38-b8e69316b714"
      unitRef="usd">-10000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i26184bc3f87e42b8af77e4f35e46cdae_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfNC02LTEtMS0xMTY3NzE_4b50c1a6-e137-4ee4-af70-10dab4382b43"
      unitRef="usd">-9000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfNS00LTEtMS0xMTY3NzE_d5eb74e7-22ca-4d00-83bb-5b0597e9d3e4"
      unitRef="usd">-2000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfNS04LTEtMS0xMTY3NzE_8b19c1de-3115-42f7-ac05-743ceede3c3f"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfNi00LTEtMS0xMTY3NzE_2e895fe8-c2db-418a-a219-42a95fbc5311"
      unitRef="usd">14000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfNi04LTEtMS0xMTY3NzE_d7973bd8-c47c-4cbc-9660-ba31edde0a84"
      unitRef="usd">49000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfNy00LTEtMS0xMjIwODk_64277667-d0be-44a7-934e-2fb5f7fa5bb1"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfNy04LTEtMS0xMjIwOTE_3eb77943-3bcc-4368-babe-3c28f12b8728"
      unitRef="usd">1000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfOC00LTEtMS0xMTY3NzE_1c25086d-95f7-4abd-86c7-8d4afd5cb3e3"
      unitRef="usd">225000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i94793ac34eb24e699f57a3960e391e71_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfOC04LTEtMS0xMTY3NzE_4f10cd73-1c09-4161-a552-20cf4eb0a757"
      unitRef="usd">280000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfOS00LTEtMS0xMTY3NzE_b8959187-4e7b-4451-bc83-656e3891c4aa"
      unitRef="usd">37000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i94793ac34eb24e699f57a3960e391e71_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfOS04LTEtMS0xMTY3NzE_771877af-8b40-4884-a7c1-14ad462317be"
      unitRef="usd">74000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfMTAtNC0xLTEtMTE2Nzcx_c766bba0-52be-48d1-bc6c-b336b172e5ff"
      unitRef="usd">188000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i94793ac34eb24e699f57a3960e391e71_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RhYmxlOjBhOGQ3MTBkOWZkNjRiY2FhOWRmNGQyMzdmMDlkMTkxL3RhYmxlcmFuZ2U6MGE4ZDcxMGQ5ZmQ2NGJjYWE5ZGY0ZDIzN2YwOWQxOTFfMTAtOC0xLTEtMTE2Nzcx_5d33a300-d535-4c95-9a71-7a7a685b2d3e"
      unitRef="usd">206000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i6085cb4d390c424680c3eafd241edadf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfNjA2MA_5e0f4a48-3547-4f50-a1f6-a14fce693590"
      unitRef="usd">16141000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i5faaf2aaa33e43408f0747441c0e1404_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81NS9mcmFnOjQ4OTBkNDQxMDQ0NjRmOTBiNWNmNTZjY2NiZDE1MTJkL3RleHRyZWdpb246NDg5MGQ0NDEwNDQ2NGY5MGI1Y2Y1NmNjY2JkMTUxMmRfNjA2Nw_2ccdcdbc-35f9-4ef5-ae9f-a3eb97dbd81d"
      unitRef="usd">22689000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81OC9mcmFnOmE5ZjZjZDYyMzg3ZDRjNWFhNGIwZDRjNWQ0YTYxNjU1L3RleHRyZWdpb246YTlmNmNkNjIzODdkNGM1YWE0YjBkNGM1ZDRhNjE2NTVfNTQ_a2e7a75d-eeb5-4314-aa47-2ff5121bab82">INVENTORIES&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81OC9mcmFnOmE5ZjZjZDYyMzg3ZDRjNWFhNGIwZDRjNWQ0YTYxNjU1L3RleHRyZWdpb246YTlmNmNkNjIzODdkNGM1YWE0YjBkNGM1ZDRhNjE2NTVfNjA_0b01a7c7-ca5f-4ebc-ac9d-925f9c8dc601">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81OC9mcmFnOmE5ZjZjZDYyMzg3ZDRjNWFhNGIwZDRjNWQ0YTYxNjU1L3RhYmxlOjkyNjU0ZTZlZTQ1NDQyZTQ4MjNhNjRjOTQ2ZmU4OGQxL3RhYmxlcmFuZ2U6OTI2NTRlNmVlNDU0NDJlNDgyM2E2NGM5NDZmZTg4ZDFfMS0yLTEtMS0xMTY3NzE_634259c1-cc61-4526-89ba-6e21ff4e0755"
      unitRef="usd">301000000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81OC9mcmFnOmE5ZjZjZDYyMzg3ZDRjNWFhNGIwZDRjNWQ0YTYxNjU1L3RhYmxlOjkyNjU0ZTZlZTQ1NDQyZTQ4MjNhNjRjOTQ2ZmU4OGQxL3RhYmxlcmFuZ2U6OTI2NTRlNmVlNDU0NDJlNDgyM2E2NGM5NDZmZTg4ZDFfMS00LTEtMS0xMTY3NzE_da128153-bf8e-4031-ba5f-1e28fa2d9be9"
      unitRef="usd">279000000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81OC9mcmFnOmE5ZjZjZDYyMzg3ZDRjNWFhNGIwZDRjNWQ0YTYxNjU1L3RhYmxlOjkyNjU0ZTZlZTQ1NDQyZTQ4MjNhNjRjOTQ2ZmU4OGQxL3RhYmxlcmFuZ2U6OTI2NTRlNmVlNDU0NDJlNDgyM2E2NGM5NDZmZTg4ZDFfMi0yLTEtMS0xMTY3NzE_bd05fe95-6d75-4e46-b9c8-cedf8d45dd17"
      unitRef="usd">124000000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81OC9mcmFnOmE5ZjZjZDYyMzg3ZDRjNWFhNGIwZDRjNWQ0YTYxNjU1L3RhYmxlOjkyNjU0ZTZlZTQ1NDQyZTQ4MjNhNjRjOTQ2ZmU4OGQxL3RhYmxlcmFuZ2U6OTI2NTRlNmVlNDU0NDJlNDgyM2E2NGM5NDZmZTg4ZDFfMi00LTEtMS0xMTY3NzE_ad9d1f41-0c97-415a-8cf1-5e3e53d59f39"
      unitRef="usd">112000000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81OC9mcmFnOmE5ZjZjZDYyMzg3ZDRjNWFhNGIwZDRjNWQ0YTYxNjU1L3RhYmxlOjkyNjU0ZTZlZTQ1NDQyZTQ4MjNhNjRjOTQ2ZmU4OGQxL3RhYmxlcmFuZ2U6OTI2NTRlNmVlNDU0NDJlNDgyM2E2NGM5NDZmZTg4ZDFfMy0yLTEtMS0xMTY3NzE_2b84c980-8c33-4dc8-92e1-348feeefd461"
      unitRef="usd">648000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81OC9mcmFnOmE5ZjZjZDYyMzg3ZDRjNWFhNGIwZDRjNWQ0YTYxNjU1L3RhYmxlOjkyNjU0ZTZlZTQ1NDQyZTQ4MjNhNjRjOTQ2ZmU4OGQxL3RhYmxlcmFuZ2U6OTI2NTRlNmVlNDU0NDJlNDgyM2E2NGM5NDZmZTg4ZDFfMy00LTEtMS0xMTY3NzE_61b037f8-7462-40ce-87dc-71ccefa23d20"
      unitRef="usd">602000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81OC9mcmFnOmE5ZjZjZDYyMzg3ZDRjNWFhNGIwZDRjNWQ0YTYxNjU1L3RhYmxlOjkyNjU0ZTZlZTQ1NDQyZTQ4MjNhNjRjOTQ2ZmU4OGQxL3RhYmxlcmFuZ2U6OTI2NTRlNmVlNDU0NDJlNDgyM2E2NGM5NDZmZTg4ZDFfNC0yLTEtMS0xMTY3NzE_90402397-5019-46e1-8e7b-d47d41e8127c"
      unitRef="usd">1073000000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV81OC9mcmFnOmE5ZjZjZDYyMzg3ZDRjNWFhNGIwZDRjNWQ0YTYxNjU1L3RhYmxlOjkyNjU0ZTZlZTQ1NDQyZTQ4MjNhNjRjOTQ2ZmU4OGQxL3RhYmxlcmFuZ2U6OTI2NTRlNmVlNDU0NDJlNDgyM2E2NGM5NDZmZTg4ZDFfNC00LTEtMS0xMTY3NzE_1497570f-83dc-41ca-b07c-d3c139b0f91a"
      unitRef="usd">993000000</us-gaap:InventoryGross>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTczMTI_b8f44b8e-bf56-4aad-b698-9e6f65bbab50">INTANGIBLE ASSETS AND GOODWILL&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of intangible assets consist of: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,695)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb Trademark&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments in the Consolidated Statement of Operations. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset impairments, including loss on assets held for sale, for the six months ended June 30, 2022 were $14&#160;million and include: (i) impairments of $10&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines and (ii) impairments of $4&#160;million, in aggregate, related to the discontinuance of certain product lines.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset impairments, including loss on assets held for sale, for the six months ended June 30, 2021 were $195&#160;million and include: (i) $96&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines, (ii) an adjustment of $88&#160;million due to the loss on assets held for sale in connection with the Amoun Sale and (iii) impairments of $11&#160;million, in aggregate, related to the discontinuance of certain product lines. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated amortization expense of finite-lived intangible assets for the remainder of 2022 and each of the five succeeding years ending December&#160;31 and thereafter is as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net includes finite-lived intangible assets related to the Company&#x2019;s Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; branded products with a carrying value of approximately $2,963&#160;million as of June 30, 2022, and a remaining estimated life of 66 months. Amortization expense related to these intangible assets amounts to approximately $539&#160;million annually. While the Company intends to appeal the Norwich Legal Decision (see &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; of Note 18, &#x201c;LEGAL PROCEEDINGS&#x201d;), it is possible that this and other potential future developments: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;may adversely impact the estimated future cash flows associated with these brands, which could result in an impairment of the value of these intangible assets in one or more future periods. Any such impairment could be material to the Company&#x2019;s results of operations in the period in which it occurs; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt"&gt;may result in shortened useful lives of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; intangible assets, which would increase amortization expense in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying amounts of goodwill during the six months ended June 30, 2022 and the year ended December&#160;31, 2021 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb/ International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Realignment of segment goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Realignment of segment goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit (Step 1).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair value of a reporting unit using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The quantitative fair value test is performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit&#x2019;s terminal value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To forecast a reporting unit&#x2019;s cash flows the Company takes into consideration economic conditions and trends, estimated future operating results, management&#x2019;s and a market participant&#x2019;s view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts are based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected loss of exclusivity to the Company&#x2019;s product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company&#x2019;s control could have a positive or negative impact on achieving its targets. Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and such change could be material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;First Quarter 2021 - Realignment of Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commencing in the first quarter of 2021, the Company began operating in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International, (iv) Ortho Dermatologics and (v) Diversified Products. The Bausch + Lomb segment consisted of the: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. The Salix segment consisted of the Salix reporting unit. The International segment consisted of the International (formerly International Rx) reporting unit. The Ortho Dermatologics segment consisted of the: (i) Ortho Dermatologics and (ii) Global Solta reporting units. The Diversified Products segment consisted of the: (i) Neurology and Other, (ii) Generics and (iii) Dentistry reporting units. This realignment in segment structure resulted in a change in the Company&#x2019;s former International reporting unit, which was divided between the International Bausch + Lomb reporting unit and International reporting unit. In addition, as part of the realignment of segment structure, certain products historically included in the Generics reporting unit were included in the U.S. Bausch + Lomb reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of this realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. Goodwill previously reported in the former International reporting unit was reassigned to the International Bausch + Lomb and International reporting units, and a portion of goodwill previously reported in the former Generics reporting unit was reassigned to the U.S. Bausch + Lomb reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately prior to the change in reporting units, the Company performed a qualitative fair value assessment for its former: (i) International and (ii) Generics reporting units. Based on the qualitative fair value assessment performed, Management believed that it was more likely than not that the carrying values of its former: (i) International and (ii) Generics reporting units were less than their respective fair values and therefore, concluded a quantitative assessment was not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately following the change in reporting units, as a result of the change in composition of the net assets for its: (i) International Bausch + Lomb, (ii) International and (iii) Generics reporting units, the Company performed a quantitative fair value test. The quantitative fair value test utilized a range of long-term growth rates of 1.0% to 3.0% and a range of discount rates between 11.0% and 12.25%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than 40%, and, therefore, there was no impairment to goodwill. In addition, as the U.S. Bausch + Lomb reporting unit had a change in composition of its net assets related to certain products historically included in the Generics reporting unit now being included in the U.S. Bausch + Lomb reporting unit, the Company performed a qualitative assessment of this reporting unit. Based on the qualitative fair value assessment performed, Management believed that it was more likely than not that the carrying value of its current U.S. Bausch + Lomb reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Interim Goodwill Impairment Testing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the interim periods of 2021, with the exception of the Ortho Dermatologics reporting unit, no events occurred, or circumstances changed that would indicate that the fair value of any other reporting unit might be below its carrying value and therefore, no impairments were recorded.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2021, management identified launches of certain Ortho Dermatologics products which were not going to achieve their trajectories as forecasted once the social restrictions associated with the COVID-19 pandemic began to ease in the U.S. and offices of health care professionals could reopen. In addition, insurance coverage pressures within the U.S. continued to persist limiting patient access to topical acne and psoriasis products. In light of these developments, during the first quarter of 2021, the Company began taking steps to: (i) redirect its R&amp;amp;D spend to eliminate projects it had identified as high cost and high risk, (ii) redirect a portion of its marketing and product development outside the U.S. to geographies where there is better patient access and (iii) reduce its cost structure to be more competitive. As a result, during the three months ended March 31, 2021, the Company revised its long-term forecasts for the Ortho Dermatologics reporting unit. Management believed that these events were indicators that there was less headroom as of March 31, 2021 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2020). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed. The quantitative fair value test utilized the Company&#x2019;s most recent cash flow projections as revised in the first quarter of 2021 to reflect the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;business changes previously discussed, including a range of potential outcomes, along with a long-term growth rate of 1.0% and a range of discount rates between 9.0% and 10.0%. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at March 31, 2021, and the Company recognized a goodwill impairment of $469&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Second Quarter 2021 - Realignment of Bausch + Lomb Reporting Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commencing in the second quarter of 2021, the Company changed the way it reviews the financial information of its Bausch + Lomb segment. Beginning in the second quarter of 2021, management no longer reviews the financial information of its Bausch + Lomb segment on a geographic basis, but instead reviews this financial information on a business line basis. This change created a change in the reporting units of the Bausch + Lomb segment. After the change, under its business line view, the Bausch + Lomb segment consisted of the global: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. Prior to the second quarter of 2021, under the geographic view, the Bausch + Lomb segment consisted of the former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. As a result of the realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. The change in Bausch + Lomb reporting units did not impact the reported revenues and segment profits of the Bausch + Lomb segment for any prior periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately prior to the change in its Bausch + Lomb reporting units, the Company performed a qualitative fair value assessment for its former reporting units. Based on the qualitative fair value assessment, management believed that it was more likely than not that the carrying values of its former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units were less than their respective fair values and, therefore, concluded a quantitative assessment was not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the change in composition of net assets, the Company performed a quantitative fair value test of its new: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units immediately following the change in the Bausch + Lomb segment. The quantitative fair value test utilized long-term growth rates of 2.0% and 3.0% and a range of discount rates between 7.0% and 10.0%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than 45%, and, therefore, there was no impairment to goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Annual Goodwill Impairment Test&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company conducted its annual goodwill impairment test as of October 1, 2021 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2021, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2021, the Company considered, among other matters, the limited headroom as a result of the impairment to the goodwill of the Ortho Dermatologics reporting unit when last tested (March 31, 2021) and macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The Company believed that these facts and circumstances may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2021, utilizing a long-term growth rate of 1.0% and a discount rate of 9.0%, in estimation of the fair value of this reporting unit. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately 10% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;First Quarter 2022 - Realignment of Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commencing in the first quarter of 2022, the Company began operating in the following reportable segments: (i) Salix, (ii) International, (iii) Diversified Products, (iv) Solta Medical and (v) Bausch + Lomb. The Salix segment consists of the Salix reporting unit. The International segment consists of the International reporting unit. The Diversified Products segment consists of the: (i) Neurology and Other, (ii) Generics, (iii) Ortho Dermatologics and (iv) Dentistry reporting units. The Solta Medical segment consists of the Solta reporting unit. The Bausch + Lomb segment consists of the: (i) Vision Care (formerly Vision Care / Consumer Products), (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. As such, the new segment structure does not impact the Company&#x2019;s reporting units but realigns the two reporting units of the former Ortho Dermatologics segment whereby the Ortho Dermatologics reporting unit is now part of the current Diversified Products segment and the Solta reporting unit is now its own operating and reportable segment, and therefore management concluded that a quantitative fair value test was not required. See Note 19, &#x201c;SEGMENT INFORMATION&#x201d; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;March 31, 2022 Interim Assessment of Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, macroeconomic factors had impacted interest rates and the U.S. inflation rate was higher than previously expected. Given the limited headroom of the Ortho Dermatologics reporting unit as calculated on October 1, 2021, the Company believed that these facts and circumstances suggest the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The quantitative fair value test utilized the Company&#x2019;s most recent cash flow projections as revised in the first quarter of 2022 and utilized a long-term growth rate of 1% and a discount rate of 9%. The discount rate contemplates changes in the current macroeconomic conditions noting certain inputs such as the risk free rate increased over the three months ended March 31, 2022, and was offset by decreases in other reporting unit specific risks during the same period. Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was less than 2% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;June 30, 2022 Interim Assessment of Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to monitor the market conditions impacting the Ortho Dermatologics reporting unit. During the three months ended June 30, 2022, increases in interest rates and, to a lesser extent, higher than expected inflation in the U.S. and other macroeconomic factors impacted key assumptions used to value the Ortho Dermatologics reporting unit at March 31, 2022 (the last time goodwill of the Ortho Dermatologics reporting unit was tested). Given the limited headroom of the Ortho Dermatologics reporting unit as calculated on March 31, 2022, the Company believed that these facts and circumstances suggest the fair value of the Ortho Dermatologics reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The quantitative fair value test utilized the Company&#x2019;s most recent cash flow projections as revised in the second quarter of 2022 which reflect current market conditions and current trends in business performance. The Company&#x2019;s latest discounted cash flow model for the Ortho Dermatologics reporting unit includes a range of potential outcomes for, among other matters, macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The quantitative fair value test utilized a long-term growth rate of 1% and a discount rate of 10%. The discount rate has increased 1% since the assessment performed at March 31, 2022, as a result of changes in current macroeconomic conditions, including an increase in the risk free rate during the three months ended June 30, 2022. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at June 30, 2022, and the Company recognized a goodwill impairment of $83&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch + Lomb Reporting Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the period May 6, 2022 (the time Bausch + Lomb&#x2019;s stock began trading publicly) through June 30, 2022, equity and bond markets were negatively impacted by various macroeconomic and geopolitical factors including, but not limited to: rising inflation rates in the U.S. and abroad, uncertainties created by the Russia/Ukraine conflict, interest rate volatility, COVID-19 related lockdowns and supply issues. The decline in the equity markets negatively impacted the market price for Bausch + Lomb&#x2019;s common stock which at June 30, 2022 was trading below its IPO offering price. The Company believed that these facts and circumstances suggest the fair value of the three reporting units of the Bausch + Lomb segment could be less than their respective carrying amounts. Therefore, separate quantitative fair value tests were performed for the Vision Care, Surgical and Ophthalmic reporting units of the Bausch + Lomb segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The quantitative fair value tests utilized Bausch + Lomb&#x2019;s most recent cash flow projections for each of the reporting units and utilized long-term growth rates of 2% and 3% and discount rates of 9.0% and 11.5%. After completing the testing, the fair value of each of these reporting units exceeded their respective carrying values by more than 25%, and, therefore, there was no impairment to goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the interim periods of 2022, with the exception of the Ortho Dermatologics reporting unit and the reporting units of the Bausch + Lomb segment, no events occurred, or circumstances changed that would indicate that the fair value of any other reporting unit might be below its carrying value and therefore, no impairment to those reporting units was recorded. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated goodwill impairment charges through June&#160;30, 2022 were $4,263 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Reporting Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No other events occurred or circumstances changed during the period October 1, 2021 (the last time goodwill was tested for all other reporting units) through June 30, 2022 that would indicate that the fair value of any reporting unit, other than the Ortho Dermatologics reporting unit, might be below its carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximately 80% of Salix segment&#x2019;s revenue for the six months ended June 30, 2022, or $775&#160;million was derived from the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; product line. While the Company intends to appeal the Norwich Legal Decision (see &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; of Note 18, &#x201c;LEGAL PROCEEDINGS&#x201d;), it is possible that this and other potential future developments, may adversely impact the estimated fair value of the Salix segment, in one or more future periods. Any such impairment could be material to the Company&#x2019;s results of operations in the period in which it occurs.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTcyODg_c4d95367-0528-4f77-b0e8-2a2521ead687">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of intangible assets consist of: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,695)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb Trademark&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTczMTg_b0551f8f-de10-451d-8d66-146ba6baea1a">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of intangible assets consist of: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,695)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb Trademark&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i61fbe90e93374904b5398ecb0a93c67f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfMy0yLTEtMS0xMTY3NzE_24cfca27-f79c-49a4-84cd-569692ba714e"
      unitRef="usd">20807000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i61fbe90e93374904b5398ecb0a93c67f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfMy00LTEtMS0xMTY3NzE_ba2f6d03-6ddd-459c-988a-c023dc343890"
      unitRef="usd">16695000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i61fbe90e93374904b5398ecb0a93c67f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfMy02LTEtMS0xMTY3NzE_e44ed9ca-8f6a-436c-941e-60f7b4b106f9"
      unitRef="usd">4112000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2a23787efe874f5c8d650b7fef441ddb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfMy04LTEtMS0xMTY3NzE_9c14dbd1-092d-4e84-bcce-fa617500d1f7"
      unitRef="usd">20842000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2a23787efe874f5c8d650b7fef441ddb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfMy0xMC0xLTEtMTE2Nzcx_69c0efcd-194b-4aac-bdd3-fb65b5c272a9"
      unitRef="usd">16169000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2a23787efe874f5c8d650b7fef441ddb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfMy0xMi0xLTEtMTE2Nzcx_3f95178f-42eb-4f54-bdd6-2e940b13d060"
      unitRef="usd">4673000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="icdab7f29e78845a9b4b14d6cdf3e20d7_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNC0yLTEtMS0xMTY3NzE_46baf8af-a3d7-4aee-9bab-1ea4f540577d"
      unitRef="usd">897000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="icdab7f29e78845a9b4b14d6cdf3e20d7_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNC00LTEtMS0xMTY3NzE_5cdea3ac-2f88-41a7-8d62-77ceed74eb44"
      unitRef="usd">506000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="icdab7f29e78845a9b4b14d6cdf3e20d7_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNC02LTEtMS0xMTY3NzE_08f4c253-df85-4cbb-930c-fc9c000f5f78"
      unitRef="usd">391000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7b1968cf2be247feb9dd0cc924d8f8c8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNC04LTEtMS0xMTY3NzE_c066b21f-eb9a-4d9b-ba87-35cfb73ba126"
      unitRef="usd">902000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7b1968cf2be247feb9dd0cc924d8f8c8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNC0xMC0xLTEtMTE2Nzcx_9a4f61e6-28d1-4460-bbf9-52ec1cc6c93e"
      unitRef="usd">473000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7b1968cf2be247feb9dd0cc924d8f8c8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNC0xMi0xLTEtMTE2Nzcx_d089d04a-405c-4400-b53c-b2f35675e978"
      unitRef="usd">429000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic83fa38af9914b0993c6039b714e49b9_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNS0yLTEtMS0xMTY3NzE_1cc64a42-213e-4a27-92ca-4ed66acfc582"
      unitRef="usd">3318000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic83fa38af9914b0993c6039b714e49b9_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNS00LTEtMS0xMTY3NzE_e899a10d-6bab-4ef2-b76e-41a2c5b01fcf"
      unitRef="usd">3197000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic83fa38af9914b0993c6039b714e49b9_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNS02LTEtMS0xMTY3NzE_ba3f0c45-7bfb-4c4b-9bdd-cd101d85786c"
      unitRef="usd">121000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i19b47b5930ac4a57b58e47cb7fb6bc97_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNS04LTEtMS0xMTY3NzE_45fd140c-48e9-46b6-8a79-862cfa1e2180"
      unitRef="usd">3321000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i19b47b5930ac4a57b58e47cb7fb6bc97_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNS0xMC0xLTEtMTE2Nzcx_7b360540-e063-4738-b3a5-000a010d018c"
      unitRef="usd">3174000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i19b47b5930ac4a57b58e47cb7fb6bc97_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNS0xMi0xLTEtMTE2Nzcx_580e62b5-e9ca-46e8-97c2-17a1fb1ab67a"
      unitRef="usd">147000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib0408adaddad474dbeeab55bfaf37b13_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNi0yLTEtMS0xMTY3NzE_4f8233b0-9d03-423b-9930-3191dbb38471"
      unitRef="usd">146000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib0408adaddad474dbeeab55bfaf37b13_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNi00LTEtMS0xMTY3NzE_c15815a1-9a98-4daa-a6f5-d1cd339a2c42"
      unitRef="usd">146000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib0408adaddad474dbeeab55bfaf37b13_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNi02LTEtMS0xMTY3NzE_486f730a-965e-4ae1-8412-37db1929a972"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i43736d02e7b34234a0989ae49e2de7e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNi04LTEtMS0xMTY3NzE_1999232d-375a-461c-9cd3-25fd4c00be2e"
      unitRef="usd">158000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i43736d02e7b34234a0989ae49e2de7e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNi0xMC0xLTEtMTE2Nzcx_923a1a41-e0d6-4791-bcda-9f0901ad2793"
      unitRef="usd">158000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i43736d02e7b34234a0989ae49e2de7e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNi0xMi0xLTEtMTE2Nzcx_380a36ae-b393-45bd-b58a-4bac80f5c3d7"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0c83dd8e105e4a4692fb8791ce3bd76a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNy0yLTEtMS0xMTY3NzE_50ed7734-7cfb-4b17-96af-b430f62aff98"
      unitRef="usd">196000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0c83dd8e105e4a4692fb8791ce3bd76a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNy00LTEtMS0xMTY3NzE_4f73861e-75e3-42ed-a669-c8301beae220"
      unitRef="usd">196000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0c83dd8e105e4a4692fb8791ce3bd76a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNy02LTEtMS0xMTY3NzE_b4c42f5d-ac75-42d4-8c05-f8c62bad1b92"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="idda5195bfad44f2d9f625be80dcbf677_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNy04LTEtMS0xMTY3NzE_6c6ef65d-1ad1-4203-9bd3-b0401e6951f6"
      unitRef="usd">207000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idda5195bfad44f2d9f625be80dcbf677_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNy0xMC0xLTEtMTE2Nzcx_e1ab15af-3be6-4b15-8592-b0d442e3eb9e"
      unitRef="usd">206000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="idda5195bfad44f2d9f625be80dcbf677_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfNy0xMi0xLTEtMTE2Nzcx_ad2bf552-9b47-4a8c-9013-cb0b482eb017"
      unitRef="usd">1000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfOC0yLTEtMS0xMTY3NzE_1fee7e70-e23e-4ef7-be96-fede84fefc9b"
      unitRef="usd">25364000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfOC00LTEtMS0xMTY3NzE_721c2a36-a168-4861-a4bb-530749d8f6ac"
      unitRef="usd">20740000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfOC02LTEtMS0xMTY3NzE_bd527f6d-ff54-4ec1-ad25-28f2de086adb"
      unitRef="usd">4624000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfOC04LTEtMS0xMTY3NzE_8b2255d4-0ee1-4c91-acc6-ad4b1820ed47"
      unitRef="usd">25430000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfOC0xMC0xLTEtMTE2Nzcx_0173fc77-9544-4e12-b8f7-753587e9e4d5"
      unitRef="usd">20180000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfOC0xMi0xLTEtMTE2Nzcx_f7edb4f7-6cce-44ef-b476-0c682cd4d2f4"
      unitRef="usd">5250000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i4ead88a7e4a8400f82d1ed2f6fed1364_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfOS0yLTEtMS0xMTY3NzE_7abd519c-ee16-40d7-b8b7-153a9c2f326e"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i4ead88a7e4a8400f82d1ed2f6fed1364_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfOS02LTEtMS0xMTY3NzE_d5dfeb6b-cdab-4587-ae07-cef1dc3ca515"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic81756cf7add4054878a13b141b160aa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfOS04LTEtMS0xMTY3NzE_8d68d24f-3c37-4626-95c1-591e3dff1c73"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic81756cf7add4054878a13b141b160aa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfOS0xMi0xLTEtMTE2Nzcx_46b37554-776e-4ca4-92a5-8b5efda4c06b"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfMTAtMi0xLTEtMTE2Nzcx_955e1ed5-eb5d-48be-a808-e2d6bbd525c5"
      unitRef="usd">27062000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfMTAtNC0xLTEtMTE2Nzcx_595f76fb-e9bf-4231-a1aa-86f25eb73fca"
      unitRef="usd">20740000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfMTAtNi0xLTEtMTE2Nzcx_769e1663-5b38-4b0f-a523-0cdb31ddfe7f"
      unitRef="usd">6322000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfMTAtOC0xLTEtMTE2Nzcx_8be05b70-80c7-483a-a0cf-2d873fef0dfb"
      unitRef="usd">27128000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfMTAtMTAtMS0xLTExNjc3MQ_b6efcca7-9564-4a47-8839-4166b40cb4bd"
      unitRef="usd">20180000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFjNjJmYWU3ODlhNzQzMGFiZDIyN2Q1ZTQxMmEyNWY4L3RhYmxlcmFuZ2U6MWM2MmZhZTc4OWE3NDMwYWJkMjI3ZDVlNDEyYTI1ZjhfMTAtMTItMS0xLTExNjc3MQ_9d03ecee-81e0-437e-b14a-8a8956e41eea"
      unitRef="usd">6948000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNjY3_d8c3dbc5-749b-4e52-be43-f8bfba8029b2"
      unitRef="usd">14000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="ida1c327408524e2b9da48b8046b1596c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNzAy_92e568ba-1a02-4a9b-8a65-0455fed27edc"
      unitRef="usd">10000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="iddcfbc0128c04d5d9a4a4a24b7c58559_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfODA3_d8da742b-72f6-43b3-aab5-43c54368133f"
      unitRef="usd">4000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfOTU1_021b373a-2ff8-476b-b9ee-2d6361d947a0"
      unitRef="usd">195000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i6b3901031b674c118620c5be45160bef_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfOTc1_5b07dd81-91e8-4381-b44d-b341db753a0c"
      unitRef="usd">96000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i8c73de91dfce436faf9fe431bbdc6487_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTExNA_cd8d596a-d599-43e1-85a1-044d6abe93de"
      unitRef="usd">88000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i30cfd27625d04204b5b2e2739311e5d9_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTIxNg_841ccbd8-41ae-4fc9-8a1a-6fdc0189ad88"
      unitRef="usd">11000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTczMDk_794fef19-e4a0-4f98-a2e6-6855cdee4cba">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated amortization expense of finite-lived intangible assets for the remainder of 2022 and each of the five succeeding years ending December&#160;31 and thereafter is as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFlZWQ4ZjA0ZmE0MTRlOTU4ZDE5NTM1YTJkZGVmZWM0L3RhYmxlcmFuZ2U6MWVlZDhmMDRmYTQxNGU5NThkMTk1MzVhMmRkZWZlYzRfMS0yLTEtMS0xMTY3NzE_667abb0c-b7bc-49a6-8b4c-b7fc6577c22e"
      unitRef="usd">565000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFlZWQ4ZjA0ZmE0MTRlOTU4ZDE5NTM1YTJkZGVmZWM0L3RhYmxlcmFuZ2U6MWVlZDhmMDRmYTQxNGU5NThkMTk1MzVhMmRkZWZlYzRfMS00LTEtMS0xMTY3NzE_98394a78-da4a-4c3a-9b72-852c11fcc52b"
      unitRef="usd">1020000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFlZWQ4ZjA0ZmE0MTRlOTU4ZDE5NTM1YTJkZGVmZWM0L3RhYmxlcmFuZ2U6MWVlZDhmMDRmYTQxNGU5NThkMTk1MzVhMmRkZWZlYzRfMS02LTEtMS0xMTY3NzE_0e6894a4-d4cb-4010-9436-92671fb69c09"
      unitRef="usd">898000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFlZWQ4ZjA0ZmE0MTRlOTU4ZDE5NTM1YTJkZGVmZWM0L3RhYmxlcmFuZ2U6MWVlZDhmMDRmYTQxNGU5NThkMTk1MzVhMmRkZWZlYzRfMS04LTEtMS0xMTY3NzE_ff105633-3269-4505-bcbe-f740c5ea5fca"
      unitRef="usd">792000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFlZWQ4ZjA0ZmE0MTRlOTU4ZDE5NTM1YTJkZGVmZWM0L3RhYmxlcmFuZ2U6MWVlZDhmMDRmYTQxNGU5NThkMTk1MzVhMmRkZWZlYzRfMS0xMC0xLTEtMTE2Nzcx_fa443dfa-0c2e-48c0-9515-e6f66307ad2f"
      unitRef="usd">664000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFlZWQ4ZjA0ZmE0MTRlOTU4ZDE5NTM1YTJkZGVmZWM0L3RhYmxlcmFuZ2U6MWVlZDhmMDRmYTQxNGU5NThkMTk1MzVhMmRkZWZlYzRfMS0xMi0xLTEtMTE2Nzcx_12444ce1-9321-40f2-9c46-dca2d546b62a"
      unitRef="usd">627000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFlZWQ4ZjA0ZmE0MTRlOTU4ZDE5NTM1YTJkZGVmZWM0L3RhYmxlcmFuZ2U6MWVlZDhmMDRmYTQxNGU5NThkMTk1MzVhMmRkZWZlYzRfMS0xNC0xLTEtMTE2Nzcx_bae84cc4-0293-446b-a1a6-c8c304759a77"
      unitRef="usd">58000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjFlZWQ4ZjA0ZmE0MTRlOTU4ZDE5NTM1YTJkZGVmZWM0L3RhYmxlcmFuZ2U6MWVlZDhmMDRmYTQxNGU5NThkMTk1MzVhMmRkZWZlYzRfMS0xNi0xLTEtMTE2Nzcx_634cb060-5435-4b90-a563-1ed97c9c8d2b"
      unitRef="usd">4624000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6cc006d888334261a3b145852eb7937f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU2NjQ4OA_1ad3b102-3842-48c4-ab47-84f7fb989889"
      unitRef="usd">2963000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i9ff241de36bb4d838d517bfa74e1000c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU2NjUwNA_f913a7d7-6ead-4992-a4c8-b25da6e0dd34">P66M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <bhc:AnnualAmortizationOfIntangibleAssets
      contextRef="i9ff241de36bb4d838d517bfa74e1000c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU2NjUxMw_f014ef8e-dcc5-49d2-8070-0aec3b16875a"
      unitRef="usd">539000000</bhc:AnnualAmortizationOfIntangibleAssets>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTczMTU_0747c71b-1bed-4fc4-b3ba-0276fdb077d6">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying amounts of goodwill during the six months ended June 30, 2022 and the year ended December&#160;31, 2021 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb/ International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Realignment of segment goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Realignment of segment goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="idda6bfc9237c4952a9c07b6cd1fb8aa6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMS0yLTEtMS0xMTY3NzE_aceddf60-b3ee-44f2-851c-4ea6692276eb"
      unitRef="usd">5704000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i8f2123e8bcd8437b81c7aee9a2cf5046_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMS00LTEtMS0xMjEzMDk_827f8bc7-7f07-472d-98d7-fd9afe17d016"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i86923f0a7d294df0951a3efb41cfb120_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMS02LTEtMS0xMTY3NzE_4c0acf57-81a9-4f42-9186-d99ca4db27b0"
      unitRef="usd">3159000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ifb4539c0cd93410f8877606829a28dbd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMS04LTEtMS0xMjEzMDc_2e70a917-d5bc-44f3-bf43-1feec77c8de7"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6b9c8e4e54e14c11a2541b80edd0ce79_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMS0xMC0xLTEtMTE2Nzcx_c02a6546-3dad-42c7-8cb4-31acdb1f3bee"
      unitRef="usd">1267000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i70c6f0d3c53c4ae0b8bac9c750c52401_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMS0xMi0xLTEtMTIxMzA1_f127c3d2-0f0d-46aa-aafc-d98ba08d79f7"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ife7ba88747a44275adc038a9f0579315_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMS0xNC0xLTEtMTE2Nzcx_3b545c64-7eb5-4893-b9d2-98d8a99a5b63"
      unitRef="usd">2914000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ic5e21899f1044f7fa7cb214f91d5655c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMS0xNi0xLTEtMTE2Nzcx_af16a9ba-d30f-42d8-92d0-b6b1fe5f3431"
      unitRef="usd">13044000000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ib0e2720588804bb59fc95044cb42a692_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMi0yLTEtMS0xMTY3NzE_54daefcf-9005-4818-93af-85bf2d7301e0"
      unitRef="usd">-5704000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i88df2b54d58543dd9380c146b625dca4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMi00LTEtMS0xMTY3NzE_3729ef3f-5ed3-4dbb-bc33-a481e24a2513"
      unitRef="usd">5395000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i382fa2f0b4d84cefb5705374b83054c8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMi02LTEtMS0xMzQxNjA_aea95a18-7dff-4c2f-ab2e-411a2f5ffa87"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ife45351a90c740ae923457acb3f6c195_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMi04LTEtMS0xMTY3NzE_578aae25-b07a-4d71-8715-42d029024bbc"
      unitRef="usd">887000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ib5108829d89c48d8b0cb4fec084de93a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMi0xMC0xLTEtMTM0MTc2_d9164ead-f25f-43d0-a058-ebf8fa187b24"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ia6009ca6df304f4ab8d03e57a2f270b8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMi0xMi0xLTEtMTM0MTgw_30915294-7845-4d47-bcfe-de808c039112"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i0a80fbad02df47ffb3f0b027e0c7052a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMi0xNC0xLTEtMTE2Nzcx_1004a734-c142-4247-9095-364dfd836c14"
      unitRef="usd">-578000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="iafb5fd0adbea424d95cb70b136e7d1c2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMi0xNi0xLTEtMTE2Nzcx_50761b88-9c85-47bc-99a2-e1e4bf97a856"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ib0e2720588804bb59fc95044cb42a692_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMy0yLTEtMS0xMTY3NzE_c956b6bb-352b-4872-9f10-eb67a162a94c"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i88df2b54d58543dd9380c146b625dca4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMy00LTEtMS0xMzQxNTQ_7306bb4c-7bbe-4981-8580-957bd9c6ccab"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i382fa2f0b4d84cefb5705374b83054c8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMy02LTEtMS0xMzQxNjA_13ef198d-9db1-48b8-b8a4-29d461b71ddc"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ife45351a90c740ae923457acb3f6c195_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMy04LTEtMS0xMzQxNzA_5b65e24b-4004-46dd-8540-09b16c881cba"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ib5108829d89c48d8b0cb4fec084de93a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMy0xMC0xLTEtMTE2Nzcx_af80a5f4-dd35-4d80-bf97-c031d4ac6734"
      unitRef="usd">469000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ia6009ca6df304f4ab8d03e57a2f270b8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMy0xMi0xLTEtMTM0MTg0_c1cab5c5-2a4d-4a44-ae19-1649b9fc6225"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i0a80fbad02df47ffb3f0b027e0c7052a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMy0xNC0xLTEtMTM0MTg4_7376321e-b069-4ab4-a869-a51f0cf1a148"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="iafb5fd0adbea424d95cb70b136e7d1c2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfMy0xNi0xLTEtMTE2Nzcx_731be0c1-abee-40f1-b293-5b9c89a5ab74"
      unitRef="usd">469000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ib0e2720588804bb59fc95044cb42a692_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNC0yLTEtMS0xMTY3NzE_a37a30e0-41a9-45ad-acf5-23676a8e40e0"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i88df2b54d58543dd9380c146b625dca4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNC00LTEtMS0xMTY3NzE_ad69ca4e-cfb1-4a7b-acae-56dca647728f"
      unitRef="usd">77000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i382fa2f0b4d84cefb5705374b83054c8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNC02LTEtMS0xMzQxNjA_da0306a0-54fe-4837-bb9a-7893c4a40b76"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ife45351a90c740ae923457acb3f6c195_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNC04LTEtMS0xMTY3NzE_922ad61e-727d-4cf7-9e3c-53ce53644bf9"
      unitRef="usd">62000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ib5108829d89c48d8b0cb4fec084de93a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNC0xMC0xLTEtMTM0MTky_45107137-eb69-4bc4-a67d-a61e64197633"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ia6009ca6df304f4ab8d03e57a2f270b8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNC0xMi0xLTEtMTM0MTk1_b23a1ebf-4b21-4799-9f72-e3dc344db1b7"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i0a80fbad02df47ffb3f0b027e0c7052a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNC0xNC0xLTEtMTE2Nzcx_0b8b59ef-6757-4715-a3ee-5a1de8205916"
      unitRef="usd">-21000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="iafb5fd0adbea424d95cb70b136e7d1c2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNC0xNi0xLTEtMTE2Nzcx_5ddb33bf-cbad-4ff5-abcc-a0ffd5d947e0"
      unitRef="usd">118000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i0d31c842cea74aa198d8cb6778701a57_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNS0yLTEtMS0xMTY3NzE_a4743322-8b5e-457d-ba7d-e8ea0207bad9"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i754ebf26cb214d2a9e08dde9805eca10_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNS00LTEtMS0xMTY3NzE_1d666e3b-6cbb-4540-bdb3-4741707b3dc5"
      unitRef="usd">5318000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iff73055417e147b7bd096e9578313bc1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNS02LTEtMS0xMTY3NzE_e5d77127-ba07-4b6f-ad67-c047b35c06a3"
      unitRef="usd">3159000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if2b016ed329f478591978619289e8da6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNS04LTEtMS0xMTY3NzE_f085d6dd-1b09-45a2-a47b-c407be299a18"
      unitRef="usd">825000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i4dc4af5c709c464682b201a4d8b84132_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNS0xMC0xLTEtMTE2Nzcx_3f51a00a-d259-49a2-b60c-34489c786527"
      unitRef="usd">798000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i92e5ef7f7dc14944b76087572c2ba682_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNS0xMi0xLTEtMTE2Nzcx_8b05c06f-b902-4244-97fd-bd51e2d0ece9"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ief312576a3114c0aaed496cc8a87eb3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNS0xNC0xLTEtMTE2Nzcx_90446531-7b88-4d82-833e-179cf1275b4e"
      unitRef="usd">2357000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNS0xNi0xLTEtMTE2Nzcx_4b242745-09b9-4f6d-9e2a-d951673e9f2a"
      unitRef="usd">12457000000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i4e70d8f7f02147b4a2ff2c867e6566d2_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNi0yLTEtMS0xMTY3NzE_c90b8105-bc40-43cc-8596-b113ce6904b6"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i86bd562069224eb1a2aa48a2a7c117a3_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNi00LTEtMS0xMzQxNTY_f748d824-6526-406d-bbab-778e46cb8be3"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i9c7b76190d5140fd9da04108a1ed24e5_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNi02LTEtMS0xMzQxNjM_db2d8096-354a-4ef2-9d41-a585866ba258"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i430a37ccee354cf9b59987d97e781a8f_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNi04LTEtMS0xMzQxNzM_1c59658d-c667-4b8c-a08c-db40cf15beb3"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i86a04889bcf044b38603f4f4ca1d8de4_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNi0xMC0xLTEtMTE2Nzcx_c2d88dff-5fb6-422c-a452-032db00eef2b"
      unitRef="usd">-798000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i864ee40a0f6549cab4f16fffdd93c3fd_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNi0xMi0xLTEtMTE2Nzcx_4fb9e982-4273-4ad1-8427-42b498fa0e24"
      unitRef="usd">115000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="iecd0285b18fe41da9fc167864657bccb_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNi0xNC0xLTEtMTE2Nzcx_98135135-10ae-4260-87cf-40991eabfb74"
      unitRef="usd">683000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNi0xNi0xLTEtMTE2Nzcx_7c87dd22-1382-44f3-b86b-6a129bb45070"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i4e70d8f7f02147b4a2ff2c867e6566d2_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy0yLTEtMS0xMzg3NzU_713a9985-1ada-47e2-be51-b35987e7b796"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i86bd562069224eb1a2aa48a2a7c117a3_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy00LTEtMS0xMzg3NzU_963541d9-7fb6-471d-831b-aa5cdbd7594a"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i9c7b76190d5140fd9da04108a1ed24e5_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy02LTEtMS0xMzg3NzU_9b67fb4f-7e50-4dd4-8a08-d0a1612159ac"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i430a37ccee354cf9b59987d97e781a8f_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy04LTEtMS0xMzg3NzU_bb614671-94d3-4ec5-8271-64636bc60c65"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i86a04889bcf044b38603f4f4ca1d8de4_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy0xMC0xLTEtMTM4Nzc1_c641a328-6cce-4362-85de-0a9dbf086aeb"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i864ee40a0f6549cab4f16fffdd93c3fd_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy0xMi0xLTEtMTM4Nzc1_726f1a7d-95bd-44b2-8b44-c9d0f97f0877"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="iecd0285b18fe41da9fc167864657bccb_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy0xNC0xLTEtMTM4Mzgx_af17a4f6-742a-48f4-9b09-b217782856f2"
      unitRef="usd">83000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy0xNi0xLTEtMTM4Mzgz_91d8656d-c6f6-4a7c-8b8e-f450aa416830"
      unitRef="usd">83000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i4e70d8f7f02147b4a2ff2c867e6566d2_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy0yLTEtMS0xMTY3NzE_073dfc52-4932-45d6-bac1-96469e6d985f"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i86bd562069224eb1a2aa48a2a7c117a3_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy00LTEtMS0xMTY3NzE_6e37d92d-ecfd-4f52-b987-86de9285da3d"
      unitRef="usd">86000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i9c7b76190d5140fd9da04108a1ed24e5_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy02LTEtMS0xMzQxNjc_2e92d7b1-7bf5-4de1-bcbd-d1f03ef89a28"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i430a37ccee354cf9b59987d97e781a8f_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy04LTEtMS0xMTY3NzE_abff59fa-8656-41a9-b490-3c74a749a748"
      unitRef="usd">52000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i86a04889bcf044b38603f4f4ca1d8de4_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy0xMC0xLTEtMTM0MTk5_eb987980-e972-41cd-abcc-5b0f9b6a7ebb"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i864ee40a0f6549cab4f16fffdd93c3fd_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy0xMi0xLTEtMTM0MjAz_5fbcab4f-a8e5-450f-b1b2-bd5664668482"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="iecd0285b18fe41da9fc167864657bccb_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy0xNC0xLTEtMTE2Nzcx_a37c538e-0e88-42d9-8651-6c315c9246f6"
      unitRef="usd">-30000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfNy0xNi0xLTEtMTE2Nzcx_0add01c3-78fe-48a5-a801-4f556b32559b"
      unitRef="usd">108000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i3b0f083a6d9044aaa355608d9d198fb8_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfOC0yLTEtMS0xMTY3NzE_8ac784fb-a4f5-4abb-affe-4c788c9b466e"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie7f5bfb1314341ee926c9b0fc40e54e2_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfOC00LTEtMS0xMTY3NzE_42de14a4-c329-4775-8961-eea616dda11c"
      unitRef="usd">5232000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0f643780bb9448ef9016e16f6b89c2c1_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfOC02LTEtMS0xMTY3NzE_bc560474-bec0-47f2-ba76-170634ec2cfc"
      unitRef="usd">3159000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i3f56f31b09064a848920713fa0661b76_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfOC04LTEtMS0xMTY3NzE_8ab1820c-9f1a-4623-a54f-e219907f7870"
      unitRef="usd">773000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i647555e6b2b54c909b5caeb1da998334_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfOC0xMC0xLTEtMTE2Nzcx_af4f8838-3ad7-4b3f-94de-f2763a93e947"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5607e58e61534749aa9df1f4280fb05a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfOC0xMi0xLTEtMTE2Nzcx_d6f72512-55f4-4506-9f18-1e9b52ea70cc"
      unitRef="usd">115000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i4284138a323449c291086d55ad27a489_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfOC0xNC0xLTEtMTE2Nzcx_9db850e1-20f2-4c2a-81a1-12923796acfe"
      unitRef="usd">2987000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RhYmxlOjMzNTYxMDUxZGVjNTQ2NGFiNmEyMTgxYmQwMzE0ODkzL3RhYmxlcmFuZ2U6MzM1NjEwNTFkZWM1NDY0YWI2YTIxODFiZDAzMTQ4OTNfOC0xNi0xLTEtMTE2Nzcx_18aa0cae-cfe5-4c37-a7f4-ffc9a9999b32"
      unitRef="usd">12266000000</us-gaap:Goodwill>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="ifcb19cddd3134b4d8f4ea965f330d69a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNjkyMA_306f68e8-d981-4260-8277-4f8ea41ad9a3"
      unitRef="number">0.010</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i31f42e923b084ff0a4f4fbc812d7be7f_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNjkyNg_c66961ec-1ca5-4e7f-b9bf-e91021147c39"
      unitRef="number">0.030</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="ifcb19cddd3134b4d8f4ea965f330d69a_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNjk2Nw_c12f2c69-5406-46e6-93cf-d94d76deffd9"
      unitRef="number">0.110</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i31f42e923b084ff0a4f4fbc812d7be7f_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNjk3NA_a42bfe6c-8519-4eb3-bd04-f4b81aadf0cc"
      unitRef="number">0.1225</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i6daf46a421eb422cab6a685d448b4571_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNzE1Mw_6e68e2a0-3e03-4075-85f7-d3d2c933f23a"
      unitRef="number">0.40</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ie53716daef0b4224954a5c9de0faef7a_D20210331-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNzE4Mw_f9e6040e-2eb5-42de-ae3f-2b7cc3657cce"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="if80b04373ab14c578c53ef3c8014d242_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfODEwNg_813adfb0-6021-476c-8b3f-42803cda3fbc"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i9e3ff28c3d904d4bb50e1f6b60dc5774_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfOTcyNA_2c6a7d11-3dbd-49af-b866-dfae05941972"
      unitRef="number">0.010</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i128de9e46d854032ac8fdb6fcc689f05_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfOTc2NQ_b8d2e8d6-36b4-40a1-879b-1f4a5ceb059f"
      unitRef="number">0.090</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="ie76f7d931cfe4a698fa9381288d5e165_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfOTc3Mg_793941d8-9f3c-4fe8-a677-12103e427129"
      unitRef="number">0.100</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="iefe6bc2fdd6b4faa87a273eecb773668_D20210331-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfOTk3NQ_12e95d28-3dc1-4eb9-a347-5e8499008dd2"
      unitRef="usd">469000000</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i448fd15a1c2c4081960f6912ee1d7df8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTIwMjI_e16e65ed-94ac-4e23-8bdd-79907f5e0520"
      unitRef="number">0.020</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i48edc6c592494439969797a031f0a38a_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTIwMjk_b0a3c68b-75d6-43e3-b03f-a02e5aeb6d44"
      unitRef="number">0.030</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i448fd15a1c2c4081960f6912ee1d7df8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTIwNzA_1a9c1345-944c-4f1a-8822-c0d9177f327f"
      unitRef="number">0.070</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i448fd15a1c2c4081960f6912ee1d7df8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTIwNzA_7950944b-0de6-4147-86b8-60bc8a56e3d5"
      unitRef="number">0.070</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i48edc6c592494439969797a031f0a38a_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTIwNzc_0e596b0b-d60f-4d2f-ab04-3a3b1eb7c348"
      unitRef="number">0.100</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i48edc6c592494439969797a031f0a38a_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTIwNzc_2528fa11-bb6d-4da4-b549-4d216aa68c48"
      unitRef="number">0.100</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i94793ac34eb24e699f57a3960e391e71_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTIyNTY_50b297c2-dc87-47b6-bec4-bd0638427208"
      unitRef="number">0.45</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i94793ac34eb24e699f57a3960e391e71_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTIyNTY_646c7933-9f8c-4d7f-9976-805441528149"
      unitRef="number">0.45</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ifede6e1372dd4ddb9ca2270e1f8b8a13_D20210630-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTIyODY_4e30aec0-14c0-4653-879b-2e9b1ef5cc38"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i495d40d3ed894092a5e407185421dded_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTM3NDA_6b9e2006-43d6-4d25-85ef-be8d9a7f6375"
      unitRef="number">0.010</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i495d40d3ed894092a5e407185421dded_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTM3NjY_a6bc8c26-1d83-4b58-9e9f-4eea582ee488"
      unitRef="number">0.090</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i495d40d3ed894092a5e407185421dded_I20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTM5NDQ_5348fec6-c6f5-4ed4-a622-65a5ef9cd7fa"
      unitRef="number">0.10</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ie0b5d00c327249b888e21da2766eda53_D20211001-20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTQwMDU_ec85910e-8b7c-4eb5-9112-a458c5c1cc38"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:NumberOfReportingUnits
      contextRef="ib56d8698081a436cb05434bb225f22eb_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTQ5MDg_a73c9ec3-34c2-4c08-b35e-27b75b06d5cd"
      unitRef="reporting_unit">2</us-gaap:NumberOfReportingUnits>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i15ce718b5f734e61a6ad0bdd28c54691_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTYwODc_e508ec14-3c9d-440c-bff4-b339ccf8ec7c"
      unitRef="number">0.01</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i15ce718b5f734e61a6ad0bdd28c54691_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTYxMTM_75db041b-8318-4293-838e-b84d3c33cfef"
      unitRef="number">0.09</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i15ce718b5f734e61a6ad0bdd28c54691_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTY1MDU_51dbc716-dfd3-4bde-8e15-df17ab407df2"
      unitRef="number">0.02</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i5a8c0ca7ff6d40f5a4b99dd032ce969d_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTY1NjY_7717e669-b410-4732-b1f5-a139a3fd9196"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i56c650b8e02f446bbdb4b9a650860424_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU1NTc5MA_bfb6f9c0-30a6-420d-b384-f718655a2814"
      unitRef="number">0.01</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i56c650b8e02f446bbdb4b9a650860424_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU1NTc5NA_ee4e3b40-6fcf-4485-b1d4-4ac46ad9e8f6"
      unitRef="number">0.10</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate
      contextRef="i56c650b8e02f446bbdb4b9a650860424_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU2MjM4Ng_9bd1164b-4fdc-443d-a093-ab4af5057c73"
      unitRef="number">0.01</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i161c125a316c41338df59b517707ec98_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU1NTc5OQ_5b0d41c3-c57d-4517-bf0e-7946e2467788"
      unitRef="usd">83000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:NumberOfReportingUnits
      contextRef="id6fc6e77709e4c859b776fc4a4a569d6_D20220506-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU1NTg1Mw_8d11154a-6828-462f-8d23-502a4c9a55cc"
      unitRef="reporting_unit">3</us-gaap:NumberOfReportingUnits>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i09575f835d044c72a01f338fc66e8824_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU1NTgxMg_727ea1ec-389d-486e-b3b1-2d0bebdf5261"
      unitRef="number">0.02</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i9fd9c089632f4f5f8b22cfa9e437b633_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU1NTg1MA_5ccdad5d-b272-498b-8ef2-da941e150058"
      unitRef="number">0.03</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i09575f835d044c72a01f338fc66e8824_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU1NTgxNg_37bd09af-00ef-4b79-bbf3-c45a7820aec3"
      unitRef="number">0.090</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i9fd9c089632f4f5f8b22cfa9e437b633_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU1NTgyMg_0a4476a8-b59b-40d7-ab36-d4610968a2f2"
      unitRef="number">0.115</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i1a6c26cc64df4c86826a5f9b2862ceec_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU1NTgzNw_274a70cc-d598-4175-808f-ce7d155a9fee"
      unitRef="number">0.25</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ied74a18a6e8c464cbf9706fc4935c4ab_D20220506-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU1NTgyOA_2e23f23b-fd8f-49ca-8773-402e8805b73a"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i08e5c94f206e49029306d4605cb23f7b_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU1NTg0MQ_fe4ceff3-5400-4b3c-afe7-cfa336134a23"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfMTcyODE_57e65cff-d36c-47c3-8179-c80d6dabaa5c"
      unitRef="usd">4263000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icc599dddc6874659a5df85bf6a360251_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU2NjUyOA_c0d0ebb1-99fe-4d1f-a661-a629dcaadb08"
      unitRef="number">0.80</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie564ee44d1b6403eb498a73450791f9f_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82MS9mcmFnOjZhZmEzYjBkMmU5NDQyNTBiMWRmMzEzMzFkMGE0NzI5L3RleHRyZWdpb246NmFmYTNiMGQyZTk0NDI1MGIxZGYzMTMzMWQwYTQ3MjlfNDM5ODA0NjU2NjUzMw_0163723c-6722-448a-9109-c66c797c06cb"
      unitRef="usd">775000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RleHRyZWdpb246NzE4NDZkYjNiM2U2NDk0ZWI5MTlkOGUzZmU3NTk1OWVfOTg_640991fb-383c-4e2d-8ad2-dd579137e09e">ACCRUED AND OTHER CURRENT LIABILITIES&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal matters and related fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RleHRyZWdpb246NzE4NDZkYjNiM2U2NDk0ZWI5MTlkOGUzZmU3NTk1OWVfOTQ_bcc6ac58-0f0a-4b9e-a8f6-f758704772b1">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal matters and related fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <bhc:Legalsettlementsandrelatedfees
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfMS0yLTEtMS0xMTY3NzE_8c6b69ea-ec16-4c32-8d4d-2c8fa77fffd1"
      unitRef="usd">1536000000</bhc:Legalsettlementsandrelatedfees>
    <bhc:Legalsettlementsandrelatedfees
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfMS00LTEtMS0xMTY3NzE_c9c00d84-bd12-4b58-9157-08664cc988f3"
      unitRef="usd">1890000000</bhc:Legalsettlementsandrelatedfees>
    <bhc:AccruedProductRebateCurrent
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfMi0yLTEtMS0xMTY3NzE_7002aefa-006e-4dc2-a5a1-35715ae92962"
      unitRef="usd">962000000</bhc:AccruedProductRebateCurrent>
    <bhc:AccruedProductRebateCurrent
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfMi00LTEtMS0xMTY3NzE_6ebea32b-8ed4-48de-b716-745d7153f5be"
      unitRef="usd">908000000</bhc:AccruedProductRebateCurrent>
    <bhc:AccruedProductReturnCurrent
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfMy0yLTEtMS0xMTY3NzE_00f2715b-af6e-4291-8394-64c55abb1a2a"
      unitRef="usd">435000000</bhc:AccruedProductReturnCurrent>
    <bhc:AccruedProductReturnCurrent
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfMy00LTEtMS0xMTY3NzE_fabec835-18b1-4326-87ab-e78eaf834670"
      unitRef="usd">482000000</bhc:AccruedProductReturnCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfNC0yLTEtMS0xMTY3NzE_d6455143-e14b-40b0-9a7a-40dd9e6cf063"
      unitRef="usd">326000000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfNC00LTEtMS0xMTY3NzE_b56dd5f3-d1ff-417c-9161-50de15f4356e"
      unitRef="usd">328000000</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfNS0yLTEtMS0xMTY3NzE_239d2157-84c1-415e-9229-e0e62450cdf9"
      unitRef="usd">277000000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfNS00LTEtMS0xMTY3NzE_95adf48f-a1a2-47f9-b2d8-0a3df99f72d8"
      unitRef="usd">336000000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfNi0yLTEtMS0xMTY3NzE_f823d353-86fb-4a0a-bf4c-442382492ce2"
      unitRef="usd">59000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfNi00LTEtMS0xMTY3NzE_372ce993-77b2-4ff7-929a-74fdda82b12c"
      unitRef="usd">98000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfNy0yLTEtMS0xMTY3NzE_6d5c5a4c-cdff-4a4f-b27c-caba32e8bbbc"
      unitRef="usd">716000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfNy00LTEtMS0xMTY3NzE_c3c611dd-ca14-48db-a731-66923dd3bfbd"
      unitRef="usd">749000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfOC0yLTEtMS0xMTY3NzE_79eac357-94c9-4dd9-9f66-aba08982e569"
      unitRef="usd">4311000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82NC9mcmFnOjcxODQ2ZGIzYjNlNjQ5NGViOTE5ZDhlM2ZlNzU5NTllL3RhYmxlOmRhNmNjMTM1NWYxYTQ5NWI5YzY1MDYxODgxNGUzNjRkL3RhYmxlcmFuZ2U6ZGE2Y2MxMzU1ZjFhNDk1YjljNjUwNjE4ODE0ZTM2NGRfOC00LTEtMS0xMTY3NzE_4921d5b6-39f2-4493-80da-b93b70e51d15"
      unitRef="usd">4791000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTgzMjI_999c6708-2271-41c0-96f0-712c0b085915">FINANCING ARRANGEMENTS&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Credit Facilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;2018 Restated Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023 Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;2022 Amended Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027 Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;B+L Credit Facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;B+L Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;B+L Term Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.50% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.125% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.75% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.875% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Unsecured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.125%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Covenant Compliance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Credit Facilities (as defined below), the B+L Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes (as defined and described in the table above) and Senior Unsecured Notes (as defined and described in the table above) contain customary affirmative and negative covenants and specified events of default. These affirmative and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company&#x2019;s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. As of June&#160;30, 2022, the amount available for restricted payments under the &#x201c;builder basket&#x201d; in the Company&#x2019;s most restrictive indentures (as defined by those indentures) was approximately $14,100&#160;million (although such availability is subject to the Company&#x2019;s compliance with a 2.00:1.00 fixed charge coverage ratio). The 2027 Revolving Credit Facility (as defined below) also contains a financial &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;maintenance covenant that, requires the Company to maintain a first lien net leverage ratio of not greater than 4.00:1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2022, the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast for the next twelve months from the date of issuance of these financial statements, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations over that same period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to take steps to improve its operating results to seek to ensure continual compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company&#x2019;s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Secured Credit Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Senior Secured Credit Facilities under the 2018 Restated Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the &#x201c;Senior Secured Credit Facilities&#x201d; under the Company&#x2019;s Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018 (the &#x201c;2018 Restated Credit Agreement&#x201d;) with a syndicate of financial institutions and investors as lenders. Prior to the 2022 Amended Credit Agreement (as defined below), the 2018 Restated Credit Agreement provided for a revolving credit facility of $1,225 million, maturing on the earlier of June 1, 2023 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and Bausch Health Americas, Inc. (&#x201c;BHA&#x201d;) in an aggregate principal amount in excess of $1,000 million (the &#x201c;2023 Revolving Credit Facility&#x201d;) and term loan facilities of original principal amounts of $4,565 million and $1,500 million, maturing in June 2025 (the &#x201c;June 2025 Term Loan B Facility&#x201d;) and November 2025 (the &#x201c;November 2025 Term Loan B Facility&#x201d;), respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Senior Secured Credit Facilities under the 2022 Amended Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 10, 2022, the Company and certain of its subsidiaries as guarantors entered into a Second Amendment (the &#x201c;Second Amendment&#x201d;) to the Fourth Amended and Restated Credit and Guaranty Agreement (as amended by the Second Amendment, the &#x201c;2022 Amended Credit Agreement&#x201d;). The 2022 Amended Credit Agreement provides for a new term loan facility with an aggregate principal amount of $2,500&#160;million (the &#x201c;2027 Term Loan B Facility&#x201d;) maturing on February 1, 2027 and a new revolving credit facility of $975&#160;million (the &#x201c;2027 Revolving Credit Facility&#x201d;) that will mature on the earlier of February 1, 2027 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and BHA in an aggregate principal amount in excess of $1,000&#160;million. Borrowings under the 2027 Revolving Credit Facility can be made in U.S. dollars, Canadian dollars or Euros. After giving effect to the Second Amendment, the 2023 Revolving Credit Facility, June 2025 Term Loan B Facility and November 2025 Term Loan B Facility were refinanced (such refinancing, the &#x201c;Credit Agreement Refinancing&#x201d;), along with certain of the Company&#x2019;s existing senior notes, using net proceeds from the borrowings under the 2027 Term Loan B Facility, the B+L IPO and the B+L Debt Financing (as defined below) and available cash on hand. As of June 30, 2022, the Company had drawn $425&#160;million on the 2027 Revolving Credit Facility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the 2027 Term Loan B Facility bear interest at a rate per annum equal to, at the Company&#x2019;s option, either: (a) a forward-looking term rate determined by reference to the financing rate for borrowing U.S. dollars overnight collateralized by U.S. Treasury securities (&#x201c;term SOFR rate&#x201d;) for the interest period relevant to such borrowing&lt;/span&gt;&lt;span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or (b) a base rate determined by reference to the highest of: (i) the prime rate (as defined in the 2022 Amended Credit Agreement), (ii) the federal funds effective rate plus 1/2 of 1.00% and (iii) the term SOFR rate for a period of one month plus 1.00% (or if such rate shall not be ascertainable, 1.50%) (provided, however, that the term SOFR rate with respect to the 2027 Term Loan B Facility shall at no time be less than 0.50% per annum), in each case, plus an applicable margin. Borrowings under the 2027 Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at the Company&#x2019;s option, either: (a) the term SOFR rate (provided, however, that the term SOFR rate with respect to the 2027 Revolving Credit Facility shall at no time be less than 0.00% per annum) or (b) a base rate determined by reference to the highest of: (x) the prime rate (as defined in the 2022 Amended Credit Agreement), (y) the federal funds effective rate plus 1/2 of 1.00% or (z) the term SOFR rate for a period of one month plus 1.00%, (ii) Canadian dollars bear interest at a rate per annum equal to, at the Company&#x2019;s option, either: (a) the bankers&#x2019; acceptance rate for Canadian dollar deposits in the Toronto interbank market (the &#x201c;BA rate&#x201d;) for the interest period relevant to such borrowing (provided, however, that the BA rate shall at no time be less than 0.00% per annum) or (b) a prime rate determined by reference to the higher of: (x) the rate of interest last quoted by The Wall Street Journal as the &#x201c;Canadian Prime Rate&#x201d; or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (y) the one month BA rate calculated daily plus 1.00% (provided, however, that the prime rate shall at no time be less than 0.00% per annum) and (iii) euros bear interest at a rate per annum &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;equal to a term benchmark rate determined by reference to the cost of funds for euro deposits (&#x201c;EURIBOR&#x201d;) for the interest period relevant to such borrowing (provided, however, that such rate, shall at no time be less than 0.00% per annum in each case, plus an applicable margin). Term SOFR rate loans are subject to a credit spread adjustment ranging from 0.10%-0.25%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The applicable interest rate margin for borrowings under the 2027 Term Loan B Facility is 5.25% for term SOFR rate loans and 4.25% for U.S. dollar base rate loans. The applicable interest rate margin for borrowings under the 2027 Revolving Credit Facility ranges from 4.75% to 5.25% for term SOFR rate loans, BA rate loans and EURIBOR loans and&lt;/span&gt;&lt;span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.75% to 4.25% for U.S. dollar base rate loans and Canadian prime rate loans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company is required to pay commitment fees of 0.25%-0.50% per annum with respect to the unutilized commitments under the 2027 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on term SOFR rate borrowings under the 2027 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to certain exceptions and customary baskets set forth in the 2022 Amended Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, and net proceeds thresholds), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the 2022 Amended Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the 2022 Amended Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights, and net proceeds thresholds). These mandatory prepayments may be used to satisfy future amortization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortization rate for the 2027 Term Loan B Facility is 5.00% per annum, or $125&#160;million, payable in quarterly installments beginning on September 30, 2022. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of June 30, 2022, the remaining mandatory quarterly amortization payments for the 2027 Term Loan B Facility were $563&#160;million through December 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2022 Amended Credit Agreement permits the incurrence of incremental credit facility borrowings up to the greater of $1,000&#160;million and 40% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the 2022 Amended Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than 3.50:1.00, and, in the case of unsecured debt, either a total leverage ratio of not greater than 6.50:1.00 or an interest coverage ratio of not less than 2.00:1.00.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2022 Amended Credit Agreement provides that Bausch + Lomb shall initially be a &#x201c;restricted&#x201d; subsidiary subject to the terms of the 2022 Amended Credit Agreement covenants, but does not require Bausch + Lomb to guarantee the obligations under the 2022 Amended Credit Agreement. The 2022 Amended Credit Agreement permits the Company to designate Bausch + Lomb as an &#x201c;unrestricted&#x201d; subsidiary under the 2022 Amended Credit Agreement and no longer subject to the terms of the covenants thereunder provided that no event of default is continuing or will result from such designation and the total leverage ratio of Remainco (as defined in the 2022 Amended Credit Agreement) will not be greater than 7.60:1.00 on a pro forma basis. The Credit Agreement Refinancing contains provisions designed to facilitate the B+L Separation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Senior Secured Credit Facilities under the B+L Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 10, 2022, Bausch + Lomb entered into a credit agreement (the &#x201c;B+L Credit Agreement&#x201d;, and the credit facilities thereunder, the &#x201c;B+L Credit Facilities&#x201d;) providing for term loans of $2,500&#160;million with a five-year term to maturity (the &#x201c;B+L Term Facility&#x201d;) and a five-year revolving credit facility of $500&#160;million (the &#x201c;B+L Revolving Credit Facility&#x201d; and such financing, the &#x201c;B+L Debt Financing&#x201d;). The B+L Credit Facilities are secured by substantially all of the assets of Bausch + Lomb and its material, wholly-owned Canadian, U.S., Dutch and Irish subsidiaries, subject to certain exceptions. The term loans are denominated in U.S. dollars, and borrowings under the revolving credit facility will be made available in U.S. dollars, euros, pounds sterling and Canadian dollars. As of June 30, 2022, the B+L Revolving Credit Facility remains undrawn.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The B+L Revolving Credit Facility is a source of funding for Bausch + Lomb and its subsidiaries only. Absent the making of a dividend, which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to Bausch + Lomb&#x2019;s shareholders, proceeds from the B+L Revolving Credit Facility are not available to fund the operations, investing and financing activities of Bausch Health.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Borrowings under the B+L Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#x2019;s option, either: (a) the term SOFR rate for the interest period relevant to such borrowing or (b) a base rate, determined by reference to the highest of: (i) the prime rate (as defined in the B+L Credit Agreement), (ii) the federal funds &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;effective rate plus 1/2 of 1.00% and (iii) the term SOFR rate for a period of one month plus 1.00% (or if such rate shall not be ascertainable, 1.00%) (provided, however, that the term SOFR rate with respect to the B+L Revolving Credit Facility shall at no time be less than 0.00% per annum), (ii) Canadian dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#x2019;s option, either: (a) the BA rate for the interest period relevant to such borrowing (provided, however, that the BA rate shall at no time be less than 0.00% per annum) or (b) prime rate determined by reference to the higher of: (x) the rate of interest last quoted by The Wall Street Journal as the &#x201c;Canadian Prime Rate&#x201d; or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (y) the one month BA rate calculated daily plus 1.00% (provided, however, that the prime rate shall at no time be less than 0.00% per annum), (iii) euros bear interest at a rate per annum equal to EURIBOR for the interest period relevant to such borrowing (provided, however, that such rate shall at no time be less than 0.00% per annum) and (iv) pounds sterling bear interest at a rate per annum equal to the effective overnight interest rate for unsecured transaction in the Sterling Overnight Index Average (&#x201c;SONIA&#x201d;) (provided, however, that such rate, shall at no time be no less than 0.00% per annum, in each case, plus an applicable margin. Term SOFR rate loans are subject to a credit spread adjustment of 0.10% and sterling loans are subject to a credit spread adjustment of 0.0326%.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The applicable interest rate margins for borrowings under the B+L Revolving Credit Facility are: (i) between 0.75% to 1.75% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between 1.75% to 2.75% with respect to term SOFR rate, EURIBOR, SONIA or BA rate borrowings based on Bausch + Lomb&#x2019;s total net leverage ratio and (ii) after: (x) Bausch + Lomb&#x2019;s senior unsecured non-credit-enhanced long term indebtedness for borrowed money receives an investment grade rating from at least two of S&amp;amp;P, Moody&#x2019;s and Fitch and (y) the B+L Term Loan Facility has been repaid in full in cash (the &#x201c;IG Trigger&#x201d;), between 0.015% to 0.475% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between 1.015% to 1.475% with respect to term SOFR rate, EURIBOR, SONIA or BA rate borrowings based on Bausch + Lomb&#x2019;s debt rating. In addition, Bausch + Lomb is required to pay commitment fees of 0.25% per annum in respect of the unutilized commitments under the B+L Revolving Credit Facility, payable quarterly in arrears until the IG Trigger and a facility fee between 0.110% to 0.275% of the total revolving commitments, whether used or unused, based on Bausch + Lomb&#x2019;s debt rating and payable quarterly in arrears. Bausch + Lomb is also required to pay letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on term SOFR rate borrowings under the B+L Revolving Credit Facility on a per annum basis, payable quarterly in arrears, as well as customary fronting fees for the issuance of letters of credit and agency fees. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the B+L Term Facility bear interest at a rate per annum equal to, at Bausch + Lomb&#x2019;s option, either (i) the term SOFR rate for the interest period relevant to such borrowing (provided, however, that the term SOFR rate with respect to the B+L Term Facility shall at no time be less than 0.50% per annum), plus an applicable margin of 3.25% or (ii) a base rate determined by reference to the highest of (x) the prime rate (as defined in the B+L Credit Agreement), (y) the federal funds effective rate plus 1/2 of 1.00% and (z) the term SOFR rate for a period of one month plus 1.00% (or if such rate shall not be ascertainable, 2.25%) (provided, however, that the base rate with respect to the B+L Term Facility shall at no time be less than 0.50% per annum), plus an applicable margin of 2.25%. Term SOFR rate loans are subject to a credit spread adjustment of 0.10%.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to certain exceptions and customary baskets set forth in the B+L Credit Agreement, Bausch + Lomb is required to make mandatory prepayments of the loans under the B+L Term Facility under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the B+L Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the B+L Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortization rate for the B+L Term Facility is 1.00% per annum, or $25&#160;million, payable in quarterly installments beginning on September 30, 2022. Bausch + Lomb may direct that prepayments be applied to such amortization payments in order of maturity. As of June 30, 2022, the remaining mandatory quarterly amortization payments for the B+L Term Facility were $119&#160;million through March 2027. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Notes are guaranteed by each of the Company&#x2019;s subsidiaries that is a guarantor under the 2022 Amended Credit Agreement and existing Senior Unsecured Notes (together, the &#x201c;Note Guarantors&#x201d;). In connection with the closing of the B+L IPO, the redemption of the Company&#x2019;s 6.125% Senior Unsecured Notes due 2025 (the &#x201c;April 2025 Unsecured Notes&#x201d; and the related indenture, the &#x201c;April 2025 Unsecured Notes Indenture&#x201d;) (as discussed below) and the related release in respect of the 2018 Restated Credit Agreement, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#x2019;s obligations under the 2022 Amended Credit Agreement under the terms of the indentures governing the Senior Secured Notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#x2019;s and Note Guarantors&#x2019; respective existing and future unsubordinated indebtedness and senior to the Company&#x2019;s and Note Guarantors&#x2019; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;pari passu&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; with the Company&#x2019;s and the Note Guarantors&#x2019; respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#x2019;s and the Note Guarantors&#x2019; respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#x2019;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#x2019;s debt that is secured by assets that are not collateral.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#x2019;s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;4.875% Senior Secured Notes due 2028 - June 2021 Refinancing Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 8, 2021, the Company issued $1,600&#160;million aggregate principal amount of 4.875% Senior Secured Notes due June 2028 (the &#x201c;June 2028 Secured Notes&#x201d;) in a private placement. The proceeds and cash on hand were used to: (i) repurchase a portion and redeem the remainder of $1,600&#160;million of 7.00% Senior Secured Notes due 2024 (the &#x201c;March 2024 Secured Notes&#x201d;), representing the remaining outstanding principal balance of the March 2024 Secured Notes and (ii) pay all fees and expenses associated with these transactions (collectively, the &#x201c;June 2021 Refinancing Transactions&#x201d;). The June 2021 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $38&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#x2019;s carrying value. Interest on the June 2028 Secured Notes is payable semi-annually in arrears on each June 1 and December 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The June 2028 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after June 1, 2024, at the redemption prices set forth in the June 2028 Secured Notes indenture. The Company may redeem some or all of the June 2028 Secured Notes prior to June 1, 2024 at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of the redemption plus a &#x201c;make-whole&#x201d; premium. In addition, at any time prior to June 1, 2024, the Company may redeem up to 40% of the aggregate principal amount of the June 2028 Secured Notes using the net proceeds of certain equity offerings at the redemption price set forth in the June 2028 Secured Notes indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;6.125% Senior Secured Notes due 2027 - February 2022 Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 10, 2022, the Company issued $1,000&#160;million aggregate principal amount of 6.125% Senior Secured Notes due February 2027 (the &#x201c;February 2027 Secured Notes&#x201d;). The proceeds from the February 2027 Secured Notes, along with proceeds from the B+L IPO, the 2027 Term Loans and the B+L Debt Financing and cash on hand, were used to redeem the April 2025 Unsecured Notes and the Credit Agreement Refinancing as discussed below. The February 2027 Secured Notes accrue interest at a rate of 6.125% per year, payable semi-annually in arrears on each February and August. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The February 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after February 2024, at the redemption prices set forth in the indenture. The Company may redeem some or all of the February 2027 Secured Notes prior to February 2024 at a price equal to 100% of the principal amount thereof plus a &#x201c;make-whole&#x201d; premium. Prior to February 2024, the Company may redeem up to 40% of the aggregate principal amount of the February 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Unsecured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Unsecured Notes issued by the Company are the Company&#x2019;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the 2022 Amended Credit Agreement. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the 2022 Amended Credit Agreement. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes. In connection with the closing of the B+L IPO, the discharge of the April 2025 Unsecured Notes Indenture and the related release in respect of the 2018 Restated Credit Agreement, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Redemption of April 2025 Unsecured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 18, 2022, the Company issued conditional notices of redemption to redeem: (i) all of the April 2025 Unsecured Notes conditioned upon the completion of the Credit Agreement Refinancing and (ii) $370&#160;million in aggregate principal amount of the Company&#x2019;s outstanding 9.000% Senior Unsecured Notes due 2025 (the &#x201c;December 2025 Unsecured Notes&#x201d;) conditioned upon the receipt of aggregate proceeds of at least $7,000&#160;million from: (a) the B+L IPO, (b) the B+L Debt Financing, (c) the Credit Agreement Refinancing and (d) the issuance of the February 2027 Secured Notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the closing of the B+L IPO, the conditions of the redemption of its April 2025 Unsecured Notes were satisfied and the Company discharged the April 2025 Unsecured Notes Indenture using: (i) the net proceeds from the issuance of the February 2027 Secured Notes, (ii) the net proceeds from the B+L IPO, (iii) the net proceeds from the borrowings under the B+L Debt Financing and (iv) cash on hand. On May 10, 2022, the Company caused sufficient funds for the redemption in full of its April 2025 Unsecured Notes at a redemption price of 101.021% of the principal amount then outstanding to be irrevocably deposited with the Bank of New York Mellon, N.A., as trustee under the April 2025 Unsecured Notes Indenture, and the April 2025 Unsecured Notes Indenture was discharged. The April 2025 Unsecured Notes were redeemed on May 16, 2022. The redemption was accounted for as an extinguishment of debt. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 10, 2022, the Company notified the Trustee and holders of its outstanding December 2025 Unsecured Notes that the conditions to its previously announced redemption would not be satisfied, and the conditional redemption was cancelled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the closing of the B+L IPO, the discharge of the April 2025 Unsecured Notes Indenture and the related release in respect of the 2018 Restated Credit Agreement as described above, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Stated Rate of Interest&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average stated rate of interest for the Company&#x2019;s outstanding debt obligations as of June&#160;30, 2022 and December&#160;31, 2021 was 6.34% and 5.88%, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gain (Loss) on Extinguishment of Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended June 30, 2022, the Company repurchased and retired, outstanding Senior Unsecured Notes with an aggregate par value of $481&#160;million in the open market, for an aggregate cost of $300&#160;million. In connection with these repurchases, the Company recognized a gain of $176&#160;million on extinguishment of debt which represents the differences between the amounts paid to settle the extinguished debt and its carrying value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the repayment of: (i) June 2025 Term Loan B Facility, (ii) November 2025 Term Loan B Facility, (iii) 2023 Revolving Credit Facility and (iv) redemption of April 2025 Unsecured Notes the Company incurred a loss on extinguishment of debt of $63&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#x2019;s carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Maturities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may, from time to time, purchase outstanding debt for cash in open market purchases or privately negotiated transactions. Such repurchases or exchanges, if any, will depend on prevailing market conditions, future liquidity requirements, contractual restrictions and other factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of debt obligations for the remainder of 2022, the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized premiums, discounts and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTgzNDM_2a38f690-4b24-47a1-9c03-3977b7155099">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Credit Facilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;2018 Restated Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023 Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;2022 Amended Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027 Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;B+L Credit Facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;B+L Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;B+L Term Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.50% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.125% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.75% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.875% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Unsecured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.125%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="icc66dfaa572849969745a0c5f0b68d37_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMy00LTEtMS0xMTY3NzE_00158290-b0ab-4400-9a34-86ee8323eaca"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="icc66dfaa572849969745a0c5f0b68d37_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMy02LTEtMS0xMTY3NzE_3b1e15c6-a9f0-4c0d-96e6-131dc233d47a"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i793328a205eb4096950273313b00bd65_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMy04LTEtMS0xMTY3NzE_ea056399-cd19-4495-92f5-244d18e4e599"
      unitRef="usd">285000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i793328a205eb4096950273313b00bd65_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMy0xMC0xLTEtMTE2Nzcx_e3adc799-38a0-4442-a0ba-6b04b3eaa5ff"
      unitRef="usd">285000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6fa6b74354994e99b127ae89877febc7_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNC00LTEtMS0xMTY3NzE_e91478c3-3570-4c9e-bbd5-9c5514b77f0a"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i6fa6b74354994e99b127ae89877febc7_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNC02LTEtMS0xMTY3NzE_e498d01f-3e16-4453-b882-488f6d30ac82"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0edf0a7a93de4224aba9d200f79ca4dd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNC04LTEtMS0xMTY3NzE_0eeb4d2f-a868-4d9d-aa3b-7be89dfb2a5d"
      unitRef="usd">2829000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i0edf0a7a93de4224aba9d200f79ca4dd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNC0xMC0xLTEtMTE2Nzcx_c295f055-4712-47e3-be2d-fd48bceec5c7"
      unitRef="usd">2772000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic2335f26e5e14e98a36115419811c130_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNS00LTEtMS0xMTY3NzE_9061ff98-d31f-4541-8e67-3de968464faa"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ic2335f26e5e14e98a36115419811c130_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNS02LTEtMS0xMTY3NzE_dedcac5a-c598-4739-9018-c12328be9613"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6c45bbfd4f504c27b6226cc0c73a33f9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNS04LTEtMS0xMTY3NzE_85c66296-e29d-4ef9-b0be-e61db411cdb0"
      unitRef="usd">994000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i6c45bbfd4f504c27b6226cc0c73a33f9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNS0xMC0xLTEtMTE2Nzcx_7fad7743-c55e-4fa6-aee5-77144fe67d6d"
      unitRef="usd">984000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ieadee1866a824ef498fe7b558d0181c4_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNi00LTEtMS0xMjI4NDU_3668bb82-7a88-4a18-832f-8e828a718dac"
      unitRef="usd">425000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ieadee1866a824ef498fe7b558d0181c4_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNi02LTEtMS0xMjI4NDc_2a486171-8988-4156-9aac-a12a561b9ff6"
      unitRef="usd">425000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i40aff33e8b24488a834a063a1529422b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNi04LTEtMS0xMjI4NDk_725f246a-127f-4061-91b8-9c5992cc4ca4"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i40aff33e8b24488a834a063a1529422b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNi0xMC0xLTEtMTIyODUx_2ac6c6fd-fd0d-4920-9977-c4fa2f0b719c"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iafc837c840c1423691e83ffca1191fb0_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNy00LTEtMS0xMjI4NDU_41378132-69ea-485c-9aff-f10d493b75ee"
      unitRef="usd">2500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="iafc837c840c1423691e83ffca1191fb0_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNy02LTEtMS0xMjI4NDc_acc69f58-21d3-42b3-addf-f875027feb58"
      unitRef="usd">2448000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6cbc2b4901924769a731d568c6814714_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNy04LTEtMS0xMjI4NDk_99bf6191-18ea-41d6-814e-76cf2906d1ec"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i6cbc2b4901924769a731d568c6814714_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNy0xMC0xLTEtMTIyODUx_62d6d378-78df-4723-a2a4-d3f96a38b488"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2f38d4ca2bf94b95844417747e708aa1_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTEtNC0xLTEtMTI3OTky_ce6e1cd9-510f-4484-818a-b9ea4c777d3c"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i2f38d4ca2bf94b95844417747e708aa1_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTEtNi0xLTEtMTI3OTky_dc962bc2-ca0c-4ed0-ad93-985d5a1d9c0a"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia7c9cb43c0384e9db889a190dda21497_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTEtOC0xLTEtMTI3OTky_9fe22b7d-659f-4d23-bebf-52ee747d2af7"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ia7c9cb43c0384e9db889a190dda21497_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTEtMTAtMS0xLTEyNzk5Mg_59329de5-9745-4749-87f7-ec9cc590514f"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3b1a4f289c1e48948d7f02b9bee8c3b7_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfOS00LTEtMS0xMjEzMTg_92b0859d-5278-4c56-9a6b-90a2eb5c9146"
      unitRef="usd">2500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i3b1a4f289c1e48948d7f02b9bee8c3b7_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfOS02LTEtMS0xMjEzMjA_305a5e45-f832-442c-9e91-24816d53d8db"
      unitRef="usd">2446000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="idf103131598445f68811c80a255e6f67_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfOS04LTEtMS0xMjEzMjI_f67e6bcb-5c27-4b04-add2-be6a002c7c31"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="idf103131598445f68811c80a255e6f67_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfOS0xMC0xLTEtMTIxMzI0_d59f04ac-9d82-478f-bf98-d747162544c7"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i52543bc3134e4d3ab18b8abb808ab987_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNy0wLTEtMS0xMTY3NzEvdGV4dHJlZ2lvbjoyMGI1OTY0NDA0MWM0YzJhYmYwNTZlNGNlY2Y0ZTZiMF80_4f825db4-43da-4032-a96b-ee010edf2aea"
      unitRef="number">0.0550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i52543bc3134e4d3ab18b8abb808ab987_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNy00LTEtMS0xMTY3NzE_700cfea7-010f-47c0-8d9c-06a513ce53be"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i52543bc3134e4d3ab18b8abb808ab987_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNy02LTEtMS0xMTY3NzE_bb72e34f-fe5a-4211-a23e-7045a60439d3"
      unitRef="usd">1740000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ibfe50f19787342d2a1eba96ea86a16dc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNy04LTEtMS0xMTY3NzE_aa33ab7a-254e-4dd9-aaff-b24c50f665c7"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ibfe50f19787342d2a1eba96ea86a16dc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfNy0xMC0xLTEtMTE2Nzcx_afaf1632-54a4-4a45-a5dc-dc1aa13990a7"
      unitRef="usd">1739000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0d8d5f877595471594e7cd0d8a9a9bb3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfOC0wLTEtMS0xMTY3NzEvdGV4dHJlZ2lvbjo3MjEzZDE2NDAzY2I0NjEwODU0Yzg0M2Q4MmFmYjJiZV80_ec593a12-0ac5-47b7-98fe-8f585ddf4849"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0d8d5f877595471594e7cd0d8a9a9bb3_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfOC00LTEtMS0xMTY3NzE_0093d71b-1aba-493f-baa8-d6dd28687783"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i0d8d5f877595471594e7cd0d8a9a9bb3_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfOC02LTEtMS0xMTY3NzE_42c6af13-c050-46bd-9225-d500ab6cc8d8"
      unitRef="usd">986000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id0abb0ba205745ee88868776020e8f2c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfOC04LTEtMS0xMTY3NzE_09bb5bc8-0f48-4861-8d22-329e3919806d"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="id0abb0ba205745ee88868776020e8f2c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfOC0xMC0xLTEtMTE2Nzcx_8b70bfc6-99b9-4200-a99d-0279b9f238fd"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i833d75561bf74683841f8a1a38848570_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfOS0wLTEtMS0xMTY3NzEvdGV4dHJlZ2lvbjo3YzZmNzIwNDgyNmM0OTMzOTJmMzA1YWVkMTM0ZjE2NV80_7b9fe8d9-7281-401b-85b1-80499ccf1a1d"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i833d75561bf74683841f8a1a38848570_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfOS00LTEtMS0xMTY3NzE_aaa66a53-be18-4769-aa84-c2bbdc1bb912"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i833d75561bf74683841f8a1a38848570_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfOS02LTEtMS0xMTY3NzE_fdd018de-68ef-4758-908d-8d2f86c4324f"
      unitRef="usd">496000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8cea3fe80b2940b89f52022162775e03_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfOS04LTEtMS0xMTY3NzE_88f3302f-057e-4797-b512-4fe1079545c0"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i8cea3fe80b2940b89f52022162775e03_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfOS0xMC0xLTEtMTE2Nzcx_6e795e78-27d6-47d5-ad85-26e0242e0083"
      unitRef="usd">495000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i28a10e63f05e408188f20f7b9cdcf496_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTAtMC0xLTEtMTE2NzcxL3RleHRyZWdpb246OThmYmE1ZDc0YjQ0NDdlMDkxY2ViMzM5M2E1MDA3Y2JfNA_c9e1efa3-7451-4382-a856-5ac7cab4d1da"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i28a10e63f05e408188f20f7b9cdcf496_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTAtNC0xLTEtMTE2Nzcx_65b5061f-3e1d-4dbc-8a9a-940e293a28d1"
      unitRef="usd">1600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i28a10e63f05e408188f20f7b9cdcf496_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTAtNi0xLTEtMTE2Nzcx_e7f63134-1f08-4ddb-b50d-d897b9b35a8f"
      unitRef="usd">1581000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia55753b63d414228b384e230c86e775f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTAtOC0xLTEtMTE2Nzcx_0d42fb2a-8ac1-46b6-a14b-1fcbb8d0d021"
      unitRef="usd">1600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ia55753b63d414228b384e230c86e775f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTAtMTAtMS0xLTExNjc3MQ_794a2e1f-0a6b-43d3-8984-e758eddb315e"
      unitRef="usd">1580000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4a25c3e0cf7640eb931b7c3c9e6872cd_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTItMC0xLTEtMTE2NzcxL3RleHRyZWdpb246YzY3YWJjMGY3NzZmNDMxNTllZWRkMDNhMjhiOTIxNTJfNA_9e1acd8b-cfa0-4db7-bb06-c5400f730ed7"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4a25c3e0cf7640eb931b7c3c9e6872cd_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTItNC0xLTEtMTE2Nzcx_9a054a5d-a35b-4719-94b9-9d381dd42254"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i4a25c3e0cf7640eb931b7c3c9e6872cd_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTItNi0xLTEtMTE2Nzcx_2f9ff543-c268-43d4-8824-b074a2f3c535"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iee049418c13b4e299a8c83e2be11bc55_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTItOC0xLTEtMTE2Nzcx_9d93fecf-d24c-4e8f-965c-003aa7e5d1e1"
      unitRef="usd">2650000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="iee049418c13b4e299a8c83e2be11bc55_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTItMTAtMS0xLTExNjc3MQ_04f8afa3-7437-4e26-92b9-2bf52217c615"
      unitRef="usd">2640000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic8a3b188d15b4912ba75bc9ee39e79b0_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTMtMC0xLTEtMTE2NzcxL3RleHRyZWdpb246ZDZlYTZlYmQ2ODVhNDJkYjgzOTFkNmMxNDliOWFkMzBfNA_4dd0bfe5-6957-444f-bc9c-d37ff813a5df"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic8a3b188d15b4912ba75bc9ee39e79b0_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTMtNC0xLTEtMTE2Nzcx_b1cd3548-ade3-47ed-a4c8-c65ce681acfa"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ic8a3b188d15b4912ba75bc9ee39e79b0_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTMtNi0xLTEtMTE2Nzcx_67831e43-9b3c-4fb9-a1ed-233edae0f894"
      unitRef="usd">1485000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2a975e0e21154064a6bcc406c36b62b5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTMtOC0xLTEtMTE2Nzcx_43134513-6c89-4297-aa4f-77ea9958274c"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i2a975e0e21154064a6bcc406c36b62b5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTMtMTAtMS0xLTExNjc3MQ_11d53e1e-4de3-485b-9a53-8de700e146b2"
      unitRef="usd">1482000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iee91cc92408044d795d6bcf969858eb1_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTQtMC0xLTEtMTE2NzcxL3RleHRyZWdpb246ZDZjMTFiZTQ1MjAyNDAxY2E3ZTZjZTE2NTc2YTY4OWFfNA_6159fe7e-5a4d-47d0-8615-ee473767d10b"
      unitRef="number">0.0925</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iee91cc92408044d795d6bcf969858eb1_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTQtNC0xLTEtMTE2Nzcx_da6425d1-5e16-4f1f-9b0e-0963151d2c8e"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="iee91cc92408044d795d6bcf969858eb1_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTQtNi0xLTEtMTE2Nzcx_a426789f-4565-40c3-923e-af572e596dba"
      unitRef="usd">1490000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6f324ee7a47e4543b63557fd35984d09_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTQtOC0xLTEtMTE2Nzcx_e7b60115-c3cf-4c2c-8a22-07e357613008"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i6f324ee7a47e4543b63557fd35984d09_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTQtMTAtMS0xLTExNjc3MQ_f74a65a8-ea8f-49c8-b002-dbe7f9f2d9b6"
      unitRef="usd">1489000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if9165a4c4fa4438b9df24cf0a0792346_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTUtMC0xLTEtMTE2NzcxL3RleHRyZWdpb246YmNmMGFmNGU2ZGQxNDI2NTllZDBlNjQxZjRmZjY5MzlfNA_25d1f2ca-e1f4-427d-bf12-c428f437810e"
      unitRef="number">0.0850</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if9165a4c4fa4438b9df24cf0a0792346_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTUtNC0xLTEtMTE2Nzcx_7b4c7fde-9790-4459-ad92-43afb29b59a4"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="if9165a4c4fa4438b9df24cf0a0792346_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTUtNi0xLTEtMTE2Nzcx_a88195af-1ae0-49d8-90c0-25511e502380"
      unitRef="usd">1754000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if803056461c6486db832367a43895632_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTUtOC0xLTEtMTE2Nzcx_92b605e5-7a09-4c65-90d1-f53b7f32c2a6"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="if803056461c6486db832367a43895632_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTUtMTAtMS0xLTExNjc3MQ_82d4f366-69a6-4e24-bb5f-3b9dd2bb0f6d"
      unitRef="usd">1754000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i398c1b11a4d14d1a9a22642a4366b4f3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTYtMC0xLTEtMTE2NzcxL3RleHRyZWdpb246NmYxZjU2ODdlYjQ4NDEyODk2YjVmOTZiZTFiNmZiNTlfNA_22476f51-8372-4654-8002-69b8755dd8c3"
      unitRef="number">0.0700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i398c1b11a4d14d1a9a22642a4366b4f3_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTYtNC0xLTEtMTE2Nzcx_1c7cbc3e-1027-4979-8772-103020be8d1e"
      unitRef="usd">748000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i398c1b11a4d14d1a9a22642a4366b4f3_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTYtNi0xLTEtMTE2Nzcx_ac15610d-42cf-46e1-8d5e-135041b8f72f"
      unitRef="usd">742000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i13687ae43098477691509c97baced059_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTYtOC0xLTEtMTE2Nzcx_ca9a6d0c-772f-4dfb-98fa-e7d0b563a183"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i13687ae43098477691509c97baced059_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTYtMTAtMS0xLTExNjc3MQ_93103f1a-714e-4373-9730-521214431581"
      unitRef="usd">743000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7141189be3804bae89bd5a07b8eed649_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTctMC0xLTEtMTE2NzcxL3RleHRyZWdpb246NTNmNDYwZjgxZjUzNDg5ODkxMTA2NThhOTZlNDVjYzhfNA_8cdafb00-4b6a-4123-89a5-68f4fae9eff5"
      unitRef="number">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7141189be3804bae89bd5a07b8eed649_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTctNC0xLTEtMTE2Nzcx_38c64721-8a09-492c-8700-c3366ec90295"
      unitRef="usd">1176000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i7141189be3804bae89bd5a07b8eed649_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTctNi0xLTEtMTE2Nzcx_365c34e5-95f9-48e6-a319-e6664bb44f2d"
      unitRef="usd">1165000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic76bf6c1d1e74dbdac6341facf5d2281_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTctOC0xLTEtMTE2Nzcx_70c82755-8ff2-441f-a9e1-3a6e36a485f7"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ic76bf6c1d1e74dbdac6341facf5d2281_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTctMTAtMS0xLTExNjc3MQ_e939766e-ada8-4271-8226-ed71246ec882"
      unitRef="usd">1238000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2065ef23dc6d4584b71fd6c1feee2ce9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTgtMC0xLTEtMTE2NzcxL3RleHRyZWdpb246NDY2NzNhZTUxZDU0NDM0YzgzN2Y3ZGRjYjlmYmYwNjBfNA_d4648c0e-ab15-4519-9988-0017e997dc8f"
      unitRef="number">0.0625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2065ef23dc6d4584b71fd6c1feee2ce9_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTgtNC0xLTEtMTE2Nzcx_f786c7db-1a91-416d-ac02-85cefb1e9b40"
      unitRef="usd">1406000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i2065ef23dc6d4584b71fd6c1feee2ce9_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTgtNi0xLTEtMTE2Nzcx_6f7243cb-e49d-4ef4-a21c-6e44e00f07c6"
      unitRef="usd">1391000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia157a13c8e7444d9a15b0ef900f499ac_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTgtOC0xLTEtMTE2Nzcx_281cf3fe-2d63-4332-9e41-fd9b1ba074e0"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ia157a13c8e7444d9a15b0ef900f499ac_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTgtMTAtMS0xLTExNjc3MQ_28d63bb2-1095-4782-8eb3-d9ca6eea3dd5"
      unitRef="usd">1483000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i55d39b6dbdc64a07aafafbab0a66b4cf_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTktMC0xLTEtMTE2Nzcx_39606137-d83d-48a2-b04e-f8570f8c94ae"
      unitRef="number">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i55d39b6dbdc64a07aafafbab0a66b4cf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTktNC0xLTEtMTE2Nzcx_60e1c338-629d-4adb-affa-645a0ff05e35"
      unitRef="usd">834000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i55d39b6dbdc64a07aafafbab0a66b4cf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTktNi0xLTEtMTE2Nzcx_2c82f34e-f5a7-4d40-b06c-19abf42c99aa"
      unitRef="usd">826000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4db4028fafd541e2adcdd0f2a8acb446_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTktOC0xLTEtMTE2Nzcx_8dbcb600-9a50-40e9-8843-df930118b330"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i4db4028fafd541e2adcdd0f2a8acb446_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMTktMTAtMS0xLTExNjc3MQ_ca8b1a39-2aab-45e1-aea8-593fe5cec48e"
      unitRef="usd">990000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i14f52e507b3c4725b4e1096cc5b3092f_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjAtMC0xLTEtMTE2NzcxL3RleHRyZWdpb246YWUzZTU3NzliZDMxNGRmOThmNWMxMzRiOTA1NTllODJfNA_ce0da611-c867-4b59-9531-e12ab308b455"
      unitRef="number">0.0725</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i14f52e507b3c4725b4e1096cc5b3092f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjAtNC0xLTEtMTE2Nzcx_78bad7cd-98e8-4641-a92a-5e0e0a2ae9d3"
      unitRef="usd">745000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i14f52e507b3c4725b4e1096cc5b3092f_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjAtNi0xLTEtMTE2Nzcx_851a4a3e-d4be-4c68-a701-96da59f058b8"
      unitRef="usd">738000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7b92a3adf20a4c61a5df00eff00b36d1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjAtOC0xLTEtMTE2Nzcx_a7c5efdc-7884-426d-8559-68245e4df86e"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i7b92a3adf20a4c61a5df00eff00b36d1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjAtMTAtMS0xLTExNjc3MQ_eeafc356-47ba-46a1-9676-a0d18251d194"
      unitRef="usd">742000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2c2ba2913e7c4009a057680b01952716_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjEtMC0xLTEtMTE2NzcxL3RleHRyZWdpb246NmE2ZmRlNWY4MjMwNGJlYmJiNDc5MzM4NGI5ZmNjODNfNA_5f27e4f0-694b-4e64-9adb-edd30a396022"
      unitRef="number">0.0525</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2c2ba2913e7c4009a057680b01952716_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjEtNC0xLTEtMTE2Nzcx_8054216b-4e3b-4cd5-ab90-6211454c6748"
      unitRef="usd">1201000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i2c2ba2913e7c4009a057680b01952716_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjEtNi0xLTEtMTE2Nzcx_7a777636-83b0-4792-bd50-4c78fcdd6a49"
      unitRef="usd">1189000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iaa56bff66e564adaa6394ca261106b7c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjEtOC0xLTEtMTE2Nzcx_607bda83-f84b-4264-a49b-95906a864a10"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="iaa56bff66e564adaa6394ca261106b7c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjEtMTAtMS0xLTExNjc3MQ_37d6f8fa-2f76-4ce5-843a-cf179b71b9d8"
      unitRef="usd">1237000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifeef119d45684adb8aeab24feb20d75c_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjItMC0xLTEtMTE2Nzcx_1061ffc6-26dc-483c-ad96-711f4609da07"
      unitRef="number">0.0525</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ifeef119d45684adb8aeab24feb20d75c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjItNC0xLTEtMTE2Nzcx_fe783962-d0c3-4b2f-95e6-1d44f3d72238"
      unitRef="usd">909000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ifeef119d45684adb8aeab24feb20d75c_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjItNi0xLTEtMTE2Nzcx_f26bae09-42d1-4026-b284-c8cf5b7ac3b8"
      unitRef="usd">900000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id8fbf55e1f7641c9a02ee367f63c49ea_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjItOC0xLTEtMTE2Nzcx_fc2b8df1-f06d-4ab6-82e1-8b25ff922bea"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="id8fbf55e1f7641c9a02ee367f63c49ea_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjItMTAtMS0xLTExNjc3MQ_918e2fb0-b254-46d4-9fec-15f8c4c71b77"
      unitRef="usd">989000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic5eee7cc73d847faac3aa9d22d79a2c3_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjMtNC0xLTEtMTE2Nzcx_c4195bba-34d8-45ff-a293-4bf2dbe8555c"
      unitRef="usd">12000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ic5eee7cc73d847faac3aa9d22d79a2c3_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjMtNi0xLTEtMTE2Nzcx_76ba8597-ee0f-456e-aa2c-544460770505"
      unitRef="usd">12000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0c1392391ca546758b079e1238c10a9f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjMtOC0xLTEtMTE2Nzcx_eee81544-9ff1-4aff-aba8-311da86e03ee"
      unitRef="usd">12000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i0c1392391ca546758b079e1238c10a9f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjMtMTAtMS0xLTExNjc3MQ_e2f107fd-8397-4bd5-945f-f8d6649b2cb4"
      unitRef="usd">12000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjQtNC0xLTEtMTE2Nzcx_655598b4-bb64-453a-ad37-8e40749cd543"
      unitRef="usd">22056000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjQtNC0xLTEtMTE2Nzcx_e84a93f4-ffeb-43fb-9e35-5cb13074f5ac"
      unitRef="usd">22056000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjQtNi0xLTEtMTE2Nzcx_bf245a58-e5d7-4786-a02a-b66a5f8fe6c9"
      unitRef="usd">21814000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjQtOC0xLTEtMTE2Nzcx_fea7d0b2-a5d8-4ee2-8e62-e3902da16977"
      unitRef="usd">22870000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjQtMTAtMS0xLTExNjc3MQ_1b8a0475-ed6c-4f79-9b61-54d2df1253b9"
      unitRef="usd">22654000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjUtNi0xLTEtMTE2Nzcx_8a3823f4-c321-48d6-bbd4-bd859fd0c74f"
      unitRef="usd">150000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjUtMTAtMS0xLTExNjc3MQ_880002bb-0e34-4b08-87fc-16d21a4091bd"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjYtNi0xLTEtMTE2Nzcx_26912b6b-596b-4781-9229-996b8bbd826c"
      unitRef="usd">21664000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjcxNjRiMTk1YWRkNjRiNzRiMGE5OWFmOTQ1NzMyYjMxL3RhYmxlcmFuZ2U6NzE2NGIxOTVhZGQ2NGI3NGIwYTk5YWY5NDU3MzJiMzFfMjYtMTAtMS0xLTExNjc3MQ_c87c6b67-0e74-410b-9a51-099bd26ce45a"
      unitRef="usd">22654000000</us-gaap:LongTermDebtNoncurrent>
    <bhc:DebtInstrumentCovenantAmountAvailableForRestrictedPayments
      contextRef="ie97aa1338630440fa931939603c3afa8_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTIwMQ_ea17b170-9646-43e7-9dfa-3d80382429da"
      unitRef="usd">14100000000</bhc:DebtInstrumentCovenantAmountAvailableForRestrictedPayments>
    <bhc:DebtInstrumentCovenantTermsFixedChargeCoverageRatio
      contextRef="i9a193ea233134644af3474c6d58858b2_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTI3OA_96f993f0-ac3d-4039-bfa1-1d2cbf22d400"
      unitRef="number">2.00</bhc:DebtInstrumentCovenantTermsFixedChargeCoverageRatio>
    <bhc:DebtInstrumentCovenantComplianceSecuredLeverageRatio
      contextRef="i9a193ea233134644af3474c6d58858b2_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTU3NQ_5f32d9d2-6750-4552-bae7-76d2be6f819a"
      unitRef="number">4.00</bhc:DebtInstrumentCovenantComplianceSecuredLeverageRatio>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i70293a619f5141b8baf60127b5cdb2d3_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMzA3NA_6c57f4d9-134a-4723-aecb-2d87d322a8ea"
      unitRef="usd">1225000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold
      contextRef="i3dee274036df4695a83fc9e2f921cd2a_D20180601-20180601"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMzEzOQ_3301bd7e-612e-45d3-945a-050bc9490e5c">P91D</bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold>
    <bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold
      contextRef="i70293a619f5141b8baf60127b5cdb2d3_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMzMyNQ_37d36644-6e67-4c3e-8b0d-9833c3c814d8"
      unitRef="usd">1000000000</bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia3f9fb93db3f4b06852f02dd6bfe37ae_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMzQyNQ_e52410a1-70f9-480d-8eef-12d30ff820de"
      unitRef="usd">4565000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="icd3b61934fa0481cb903c6cad1023951_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMzQzMg_9f3f23fe-fb36-45dd-808f-ca5f3d6df8f8"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id684a5f342be4a9dacf6da92dfbae334_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjE0MQ_27239958-d136-4f64-8d22-a0db2f391ac7"
      unitRef="usd">2500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ie870cb7bef5c4e1f80f119d7291d6694_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjE1Nw_d1b51b10-3b4d-4e77-beb7-a7764755668d"
      unitRef="usd">975000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold
      contextRef="i6da3d0cbf2d147fc8ed6d47a33114b1b_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjIzOA_6d17ee68-ba0d-48d0-9465-16423984f55e">P91D</bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold>
    <bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold
      contextRef="ie870cb7bef5c4e1f80f119d7291d6694_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjE3MQ_68696f45-5680-41ce-9192-3ed90071d07a"
      unitRef="usd">1000000000</bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold>
    <us-gaap:LongTermDebt
      contextRef="ieadee1866a824ef498fe7b558d0181c4_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTA5OTUxMTYzNTQzNzg_b0f3a3ff-2bc4-4cdf-97dc-52ce5702ee8d"
      unitRef="usd">425000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="if697bdbf4b2341c28c62cc63991814b1_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjYwODYyNw_abae4672-a8e4-4313-8397-43902c425e13"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bhc:DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable
      contextRef="ic821cb350682455fb80a7cf379859436_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjYwODYzNA_6d7ae543-4755-4f16-b9bf-3ef7be46b866"
      unitRef="number">0.0150</bhc:DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="id3317da9d69b44a5a0f5530521c43d9a_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjYwODY0MQ_6542402c-79c3-4f1a-9875-da4c466958a3"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ib41ea84450c549cdbd5dd7eb01cb3125_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjYwODY0OA_bdf853d0-a1aa-4ba4-8206-bd377d230555"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i1b5b14287deb4a36811e3567b40c972b_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjYwODY1Ng_c14e6971-d5c4-4167-8c85-9055eab64063"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i3e01c970675a436bbf061ef17c476e22_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjYwODY2Mw_e6c56912-2bc1-47ba-946e-d7c98c23ab02"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="id1101765767e40daa36e42e2d05de9aa_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjYwODY3MQ_1cd9ccae-e3ac-47d4-a175-aa2068555d66"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i3e01c970675a436bbf061ef17c476e22_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjYwODY4Mg_17acd3da-4b76-4b6c-8e5c-e1bbecb74071"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ifdc5cac429d2406fad6f5db1a981f8e5_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTA5OTUxMTYzNDUyMjk_2660f3ec-e3fd-4cf3-b872-72232fe44c94"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate
      contextRef="ib41ea84450c549cdbd5dd7eb01cb3125_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTA5OTUxMTYzNDUyNDM_4c34329b-4028-44f9-9eba-016903071f7f"
      unitRef="number">0.0010</bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate>
    <bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate
      contextRef="ia8243ac81d9d44639387960613fa815a_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTA5OTUxMTYzNDUyNTA_3e7148d6-be76-4750-8fc7-59bd5f47c1eb"
      unitRef="number">0.0025</bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ic821cb350682455fb80a7cf379859436_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjMzMTY_1c9fcd0d-2d2e-4131-b634-6c61dfba59b2"
      unitRef="number">0.0525</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i6e609a7fc5194c08831552ad31cb3326_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjMzMjM_fb184b32-df2d-4dc6-8998-b32ac99eee47"
      unitRef="number">0.0425</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i084c2ea2f89c4a93a0688cf9fa993c87_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjMzMzM_a4776bc3-b9d8-4627-9da5-d8949660f9ac"
      unitRef="number">0.0475</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i3357e0f78c5d4623aa4578bb9c5bfb71_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjMzNDA_b7bbae5c-30c8-44b5-adf2-f28bad61ee59"
      unitRef="number">0.0525</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i8e66748d2095465691388b65def844ec_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjMzNDc_57a32710-f7a4-457c-bb5b-94d7117fcf51"
      unitRef="number">0.0375</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i84a6900222c6444eaa2f43c56b21657f_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjMzNTQ_38f68088-cc0d-413d-ad34-98a9f8f22b51"
      unitRef="number">0.0425</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i8ce4074fb09e40f88a53999eaedb2071_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjMzNjE_f9d2e64d-835b-4e10-a2f9-db7816f45e52"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="ia63076c25e4a4832b2cbf2122f93d974_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjMzNjg_1d1fea2e-3016-4460-b046-3645e9ded4b5"
      unitRef="number">0.0050</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments
      contextRef="i31d884d227e045f3b2a89fc5ec26f5bf_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjMzNzY_da48dc1c-dd26-431f-bdfe-fb555c32e6ec"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments
      contextRef="i31d884d227e045f3b2a89fc5ec26f5bf_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjMzODI_984b877e-6403-4328-b308-251fe8319e92"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments
      contextRef="i31d884d227e045f3b2a89fc5ec26f5bf_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjMzODg_9c8f8a82-3c0a-447e-867e-4dcd3ba2ff2b"
      unitRef="number">0.50</bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments
      contextRef="i31d884d227e045f3b2a89fc5ec26f5bf_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjMzOTM_bb9aa219-272e-485e-a301-a6f3f0bfdc2e"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments>
    <bhc:DebtInstrumentAnnualAmortizationRatePercentage
      contextRef="id684a5f342be4a9dacf6da92dfbae334_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjMzOTk_3f636865-05cf-4f3c-92e3-145872c01d6b"
      unitRef="number">0.0500</bhc:DebtInstrumentAnnualAmortizationRatePercentage>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="i88238e27384b4699bca91ad69cb37063_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjYxNDc4OQ_88b8bd92-cb3e-4d7c-bcab-487d92bbb255"
      unitRef="usd">125000000</us-gaap:DebtInstrumentPeriodicPayment>
    <bhc:DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization
      contextRef="i6b587afb6b2449d6abebb3e8259edaf4_D20220630-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjYwODY5MA_d12e1946-ac26-4642-8626-5710bcfdd724"
      unitRef="usd">563000000</bhc:DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization>
    <bhc:LineOfCreditFacilityThresholdForIncrementalBorrowings
      contextRef="ie870cb7bef5c4e1f80f119d7291d6694_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjM0MDY_d92a8d39-d08a-48b3-8d2b-f0fce6e87edd"
      unitRef="usd">1000000000</bhc:LineOfCreditFacilityThresholdForIncrementalBorrowings>
    <bhc:LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage
      contextRef="i6da3d0cbf2d147fc8ed6d47a33114b1b_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjM0MjI_94281e5a-6988-4c19-9b7a-625c42aeba53"
      unitRef="number">0.40</bhc:LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage>
    <bhc:DebtInstrumentCovenantTermsSecuredLeverageRatio
      contextRef="i317f673a636e4cfbbe6308e053f9a1b1_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjM0Mjc_be549c70-119e-49b4-a3e7-d72653acf6d9"
      unitRef="number">3.50</bhc:DebtInstrumentCovenantTermsSecuredLeverageRatio>
    <bhc:DebtInstrumentCovenantTotalLeverageRatioMaximum
      contextRef="i222693060eda48fcb8a8ff27a64972c7_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjM0MzM_3d1994b7-2c9b-4869-9070-b7b9798b034d"
      unitRef="number">6.50</bhc:DebtInstrumentCovenantTotalLeverageRatioMaximum>
    <bhc:DebtInstrumentCovenantInterestCoverageRatioMinimum
      contextRef="ie870cb7bef5c4e1f80f119d7291d6694_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxNjM0Mzk_c310da9b-eed9-4fbc-8e2e-67772dc35f2b"
      unitRef="number">2.00</bhc:DebtInstrumentCovenantInterestCoverageRatioMinimum>
    <bhc:DebtInstrumentCovenantTotalLeverageRatio
      contextRef="i1be7401b40834ec4b9897f7ca08a3bcc_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjYwODU1Nw_dafaa01a-bd5a-44ee-a80a-57c4e4363dc0"
      unitRef="number">7.60</bhc:DebtInstrumentCovenantTotalLeverageRatio>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if65afec1ca9042d88f04d82fb68476c8_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTA5OTUxMTYzNTg4MDA_0b233580-b87a-4af0-a86e-84d54629a70f"
      unitRef="usd">2500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="i0459e2e91fe04b5099b8551dc212bb5b_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjYwODU2OA_ad24caa4-8d3a-4dd7-bc1d-77faabe3cac7">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="i025e4c51c5f2476eaa7e7b81b3dd925e_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjYwODU4MQ_d813b513-c08d-4c72-8232-afc4a745f84e">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="iaf0a3be8d6bd4202945aa5df250dec6c_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTA5OTUxMTYzNTg4Mjk_21a7dc62-e14d-4e77-8e2b-3f16be208dd2"
      unitRef="usd">500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i13fb480b68044eeba4d131527e8279e9_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxODkyNDg_00b4c14e-927f-4dc1-bcfe-07399ef6a33b"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bhc:DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable
      contextRef="i13fb480b68044eeba4d131527e8279e9_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxODkyNTU_eb86fe24-02c4-494b-a593-0ec33756ebf4"
      unitRef="number">0.0100</bhc:DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i5197b5b99efa4eb8bf8f5a69128f60d6_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxODkyNjI_840ab0ad-35d4-43ea-9911-775905b0cf4f"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="id57f7f9d4d2d4e3e9eb4720166ca7a73_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxODkyNzA_b8ff4670-c41d-48bd-9544-fdef64727f24"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i37e23f9713ba4df0a3897cb703b32626_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxODkyNzg_2e850384-03e7-4e27-8b51-3704159568dd"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="id57f7f9d4d2d4e3e9eb4720166ca7a73_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxODkyODU_73886149-3898-4ce0-9509-ea0f43790574"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i9b4a82c59de848fd933f25769865c682_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxODkyOTM_db3d09fa-3c2d-4623-922b-d82acbac968d"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ic57a642f15b64fba9bd4ead705bdcd69_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjE4Nw_6244ee6b-5502-45e3-9b6a-dd341999e188"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate
      contextRef="i13fb480b68044eeba4d131527e8279e9_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjIwMw_3a61f4c1-a009-4b49-923c-527bf07e06fb"
      unitRef="number">0.0010</bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate>
    <bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate
      contextRef="i745d6bb83b7948309a5bca9ce9967c7f_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxODkzMDE_dbea80a6-dd2d-4dbd-8770-3964e83d6680"
      unitRef="number">0.000326</bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i794772c7b0a94cb4ae0831e44b12025a_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjIxMA_e4bb6ddd-9665-4b15-8a0a-e951b17392b4"
      unitRef="number">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="if00b75865db04bb2a36148fc758260df_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjIxNw_217c779a-6468-4c6e-a6aa-05abf68e9537"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i9fa8451ab2b24a2f9856257a3e56525b_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjIyNA_6a24ef68-ce41-4bce-b6eb-521bc91f496a"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i97fcf2fb2a11462b97034820ecfbea20_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjIzMQ_bb746617-94b4-4a6b-ac97-0085639a5264"
      unitRef="number">0.0275</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i89435b8df34c4e929c8786a5809ae39d_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjI2OQ_e12c7263-83fd-4ac7-8bcd-64bba8b032f7"
      unitRef="number">0.00015</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i6eb7b9d116404dcbb45abb5c29aab3db_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjI3Nw_e0dec408-20b9-468e-a743-556931bbb866"
      unitRef="number">0.00475</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia79343ddb46b49649e9595a3a81569bf_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjI4NQ_d95d7ac3-6353-4fee-a9e1-4950ef9b1bbb"
      unitRef="number">0.01015</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i7f27835a65de4739ba485d7737c8fcf1_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjI5Mw_938aa31c-19ab-4130-8ae8-da1abc482ae4"
      unitRef="number">0.01475</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i025e4c51c5f2476eaa7e7b81b3dd925e_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjMwMQ_cc7b32eb-6ce7-4dd8-9d03-4af83abe4510"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i4503aad9ff7046f7b027b10d33ee0a67_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjMwOA_b9e9e5d2-be5b-4fc5-a5b0-23c8288edc23"
      unitRef="number">0.00110</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i62be326ed1094f42a72cf8f28f3824e9_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjMxNg_2302187a-89be-4008-9ac3-aa0db3e4a556"
      unitRef="number">0.00275</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i3bcd09daf6ff45d1be1768c23751ced6_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxODkzMTA_6375df9d-5cb1-4bfe-beef-c837912d4639"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i586f734bb9414bcab81efe9583058179_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjMyNA_e88dbb61-a4e0-4fad-91ae-0d17a4cf8123"
      unitRef="number">0.0325</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i54647254f8ae45e6b7709b92695601f7_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxODkzMTc_2818c5e2-b798-4de0-baf2-d7bc8ade184f"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bhc:DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable
      contextRef="i54647254f8ae45e6b7709b92695601f7_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjMzMQ_f8005209-62b5-4119-9f37-510707c32972"
      unitRef="number">0.0225</bhc:DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i86c83d00da024414839c7b0495b95f61_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjMzOA_5d108e42-d904-40e5-9d47-a905ac26b3b9"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ife48262157f54a9f9411801fa38bef33_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxODkzMjQ_94b3cf49-48ff-4e08-8f36-b762f24bc9ba"
      unitRef="number">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate
      contextRef="i586f734bb9414bcab81efe9583058179_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjM1Mg_ca5f85e0-2aa1-48c2-a610-f14fe8584b3e"
      unitRef="number">0.0010</bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate>
    <bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments
      contextRef="i31491c26d42f4c55a76225f7c3e1437b_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjM1OQ_7e55f696-94f9-4c8a-b691-a13f95d21edf"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments
      contextRef="i31491c26d42f4c55a76225f7c3e1437b_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjM2NQ_e247ccb9-84ff-4984-a237-42bf00cecc17"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments
      contextRef="i31491c26d42f4c55a76225f7c3e1437b_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjM3MQ_37114c86-462e-4c36-b023-9b3b7855be60"
      unitRef="number">0.50</bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments
      contextRef="i31491c26d42f4c55a76225f7c3e1437b_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjM3Ng_b2a8a6f7-5aef-4613-912c-24832f26a76f"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments>
    <bhc:DebtInstrumentAnnualAmortizationRatePercentage
      contextRef="if65afec1ca9042d88f04d82fb68476c8_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjM4Mg_993b69fe-cd99-4dc6-a168-bd0fc4d4739c"
      unitRef="number">0.0100</bhc:DebtInstrumentAnnualAmortizationRatePercentage>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="i0459e2e91fe04b5099b8551dc212bb5b_D20220510-20220510"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjYxNDgwMw_1b54cf0d-edbb-49d9-a477-1a613fa2a278"
      unitRef="usd">25000000</us-gaap:DebtInstrumentPeriodicPayment>
    <bhc:DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization
      contextRef="ib72d5c0c9cae4427a65ac12763613c50_D20220630-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxODkzMzE_6c4f3cc5-1997-4e0e-b668-641809e3f4f9"
      unitRef="usd">119000000</bhc:DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4a25c3e0cf7640eb931b7c3c9e6872cd_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDM5ODA0NjU2MjYwMA_efd04024-0db0-43bf-aca9-c226b191bd71"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bhc:DebtInstrumentRedemptionPricePercentageChangeinControl
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTI1ODM_6c6bc2d7-d159-4e42-8e8f-010a3c1e85ac"
      unitRef="number">1.01</bhc:DebtInstrumentRedemptionPricePercentageChangeinControl>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i22e56e38486147d28bc2898f73182eef_I20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTI2NTI_6dc00983-a1ae-4cb9-9c50-593d0880d301"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i22e56e38486147d28bc2898f73182eef_I20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTI3NTg_b4fb28f6-d72b-48f0-a4f2-9e1cc794f1fa"
      unitRef="usd">1600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i22e56e38486147d28bc2898f73182eef_I20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTI3OTE_6dc00983-a1ae-4cb9-9c50-593d0880d301"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="if19b6a01b94c43baac9f6b2e2576cb33_D20210608-20210608"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTI5ODI_5a1b174d-e660-4b90-a032-a6dde21ad8dd"
      unitRef="usd">1600000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib2801d5faaff4cff805188a7408a18d9_I20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTI5ODg_c476163a-0678-4e23-8cdb-48f702b47be6"
      unitRef="number">0.0700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id15e04f207ca454ab4b3869196ecb3aa_D20210608-20210608"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTM0MjA_b9b1c377-dbf9-4728-b6d0-dfc09f96e266"
      unitRef="usd">-38000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i7ba95d1a1d8a4e50be9c80b6091f5c9f_D20210608-20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTM5NzU_fd5ddf17-c62d-473b-86af-4ee73867a5be"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="i670946275ba0478c9fa99c66c759a07f_D20210608-20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTQyMDA_e865fe7d-6b46-4e07-94c2-64f9d568d44e"
      unitRef="number">0.40</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i88c94d8d653b41e2bece3ba32629f570_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTQzOTU_47492366-f3fa-42c2-9545-df649840edea"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i88c94d8d653b41e2bece3ba32629f570_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTE1NDQ4NzIxOTAwOTg_e0b080fd-263e-47b4-ae6a-c7f62ddb42d9"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i88c94d8d653b41e2bece3ba32629f570_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTQ1MzY_c168c7c3-681d-4b66-a997-f9eb3ea4e43c"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i88c94d8d653b41e2bece3ba32629f570_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTUwMzM_c168c7c3-681d-4b66-a997-f9eb3ea4e43c"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="iaaa9e9d10abf4341b32b2669fa6bd9c5_D20220210-20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTU0MTI_e3ab605e-9d2a-4cf3-bba5-d6c09c87507d"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="ib171e1f6ad134f1e8a838ae91f96bdc6_D20220210-20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTU1Mjk_b2ac9acc-02f8-40f5-830a-435cf4316cff"
      unitRef="number">0.40</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <bhc:DebtInstrumentRedemptionPricePercentageChangeinControl
      contextRef="icacf3f32142f4f7793bba94c9b3e3ebe_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTY5MDE_a2391dab-72b7-4aed-b768-3fc663c56134"
      unitRef="number">1.01</bhc:DebtInstrumentRedemptionPricePercentageChangeinControl>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="ib86afa84ce1b41d5b48258b10accd8f9_I20220118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTA5OTUxMTYzNTk3MTY_fb2b55b8-dfee-42d1-ae2d-31a1df53a4aa"
      unitRef="usd">370000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib86afa84ce1b41d5b48258b10accd8f9_I20220118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTA5OTUxMTYzNTk3NDY_5dfba276-c56c-4e9e-807d-8a631a1ec9d5"
      unitRef="number">0.09000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bhc:DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet
      contextRef="ib86afa84ce1b41d5b48258b10accd8f9_I20220118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDk0NzgwMjQyNDM0NQ_8102f749-be57-4a58-b20a-fcb7b0635187"
      unitRef="usd">7000000000</bhc:DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i00eb5a1c1bb64566b2473aca50a87f8b_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTA5OTUxMTYzNTk3NjI_7754858d-e9ea-48f4-bb6e-684b4dd62d41"
      unitRef="number">1.01021</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTcxNjg_014c20bc-9cb8-421c-b32a-c2fd8d3bc880"
      unitRef="number">0.0634</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTcxNzU_64d5e06c-6853-4823-b404-a4ae43074ab3"
      unitRef="number">0.0588</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="ib99e0e69c7014f3db279170c3e995c4c_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDk0NzgwMjQyNjM5MA_c5b957b2-ccd9-4a0d-b8de-706a6ed64b23"
      unitRef="usd">481000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i79deb0713cde44578625b28d0e656766_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDk0NzgwMjQyNjQzOQ_ae5e8775-e854-4861-86fc-f01bf9fc7c94"
      unitRef="usd">300000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i79deb0713cde44578625b28d0e656766_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNDk0NzgwMjQyNjUxNQ_c924c56b-1ad5-4de1-80b8-c4aab5b66244"
      unitRef="usd">176000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i0acce2b828944f6db85708f4bd37bcd0_D20220510-20220510"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfNzE0NjgyNTY4MzA0OQ_66688355-bac8-4832-bede-0d3cfa6e1a66"
      unitRef="usd">-63000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RleHRyZWdpb246MjEwOWRmNGRiYzA2NDU1ODg0NmQ5NThhYmE0YTVmMjRfMTgzMzM_e0aeeeee-c5e4-42b1-848f-36cd0f3ea76f">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of debt obligations for the remainder of 2022, the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized premiums, discounts and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjI4MDRiNTk1NmYzOTQxYjM4YTI0NzA5MmM0YmJhYWFiL3RhYmxlcmFuZ2U6MjgwNGI1OTU2ZjM5NDFiMzhhMjQ3MDkyYzRiYmFhYWJfMS0xLTEtMS0xMTY3NzE_4335977c-2ece-4af3-bf19-0cdcf6db4990"
      unitRef="usd">75000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjI4MDRiNTk1NmYzOTQxYjM4YTI0NzA5MmM0YmJhYWFiL3RhYmxlcmFuZ2U6MjgwNGI1OTU2ZjM5NDFiMzhhMjQ3MDkyYzRiYmFhYWJfMi0xLTEtMS0xMTY3NzE_a7c2b9cd-4fa2-4093-91cc-3f003064f8bd"
      unitRef="usd">150000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjI4MDRiNTk1NmYzOTQxYjM4YTI0NzA5MmM0YmJhYWFiL3RhYmxlcmFuZ2U6MjgwNGI1OTU2ZjM5NDFiMzhhMjQ3MDkyYzRiYmFhYWJfMy0xLTEtMS0xMTY3NzE_c9cd00d7-79ec-48da-8ae6-3e7afd461003"
      unitRef="usd">150000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjI4MDRiNTk1NmYzOTQxYjM4YTI0NzA5MmM0YmJhYWFiL3RhYmxlcmFuZ2U6MjgwNGI1OTU2ZjM5NDFiMzhhMjQ3MDkyYzRiYmFhYWJfNC0xLTEtMS0xMTY3NzE_ca48ada5-69ed-447b-9540-eeef34eabc80"
      unitRef="usd">3400000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjI4MDRiNTk1NmYzOTQxYjM4YTI0NzA5MmM0YmJhYWFiL3RhYmxlcmFuZ2U6MjgwNGI1OTU2ZjM5NDFiMzhhMjQ3MDkyYzRiYmFhYWJfNS0xLTEtMS0xMTY3NzE_5b46250a-e438-45fa-bab3-33ddda1ed98b"
      unitRef="usd">1650000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjI4MDRiNTk1NmYzOTQxYjM4YTI0NzA5MmM0YmJhYWFiL3RhYmxlcmFuZ2U6MjgwNGI1OTU2ZjM5NDFiMzhhMjQ3MDkyYzRiYmFhYWJfNi0xLTEtMS0xMTY3NzE_59f51e73-4de7-42a2-94e3-0149c11f1b9b"
      unitRef="usd">8000000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjI4MDRiNTk1NmYzOTQxYjM4YTI0NzA5MmM0YmJhYWFiL3RhYmxlcmFuZ2U6MjgwNGI1OTU2ZjM5NDFiMzhhMjQ3MDkyYzRiYmFhYWJfNy0xLTEtMS0xMTY3NzE_23172efd-3c7a-4a31-9eaa-f6b965f543ac"
      unitRef="usd">8631000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjI4MDRiNTk1NmYzOTQxYjM4YTI0NzA5MmM0YmJhYWFiL3RhYmxlcmFuZ2U6MjgwNGI1OTU2ZjM5NDFiMzhhMjQ3MDkyYzRiYmFhYWJfOC0xLTEtMS0xMTY3NzE_655598b4-bb64-453a-ad37-8e40749cd543"
      unitRef="usd">22056000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjI4MDRiNTk1NmYzOTQxYjM4YTI0NzA5MmM0YmJhYWFiL3RhYmxlcmFuZ2U6MjgwNGI1OTU2ZjM5NDFiMzhhMjQ3MDkyYzRiYmFhYWJfOC0xLTEtMS0xMTY3NzE_e84a93f4-ffeb-43fb-9e35-5cb13074f5ac"
      unitRef="usd">22056000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjI4MDRiNTk1NmYzOTQxYjM4YTI0NzA5MmM0YmJhYWFiL3RhYmxlcmFuZ2U6MjgwNGI1OTU2ZjM5NDFiMzhhMjQ3MDkyYzRiYmFhYWJfOS0xLTEtMS0xMTY3NzE_70eda85e-f33c-4bc8-ad71-d42a2f824bea"
      unitRef="usd">242000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV82Ny9mcmFnOjIxMDlkZjRkYmMwNjQ1NTg4NDZkOTU4YWJhNGE1ZjI0L3RhYmxlOjI4MDRiNTk1NmYzOTQxYjM4YTI0NzA5MmM0YmJhYWFiL3RhYmxlcmFuZ2U6MjgwNGI1OTU2ZjM5NDFiMzhhMjQ3MDkyYzRiYmFhYWJfMTAtMS0xLTEtMTE2Nzcx_bf245a58-e5d7-4786-a02a-b66a5f8fe6c9"
      unitRef="usd">21814000000</us-gaap:LongTermDebt>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RleHRyZWdpb246NjQyNjA1YzE4OGQ4NGYwZGIxNzVlZWVmZTIwOWU3MmFfNDAw_8f5bd8eb-e0dd-42f2-b7fd-c6de6b4e590f">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which covers certain U.S. employees and employees in certain other countries. Net periodic (benefit) cost for the Company&#x2019;s defined benefit pension plans and postretirement benefit plan for the six months ended June 30, 2022 and 2021 consists of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Postretirement&lt;br/&gt;Benefit&lt;br/&gt;Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service credit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RleHRyZWdpb246NjQyNjA1YzE4OGQ4NGYwZGIxNzVlZWVmZTIwOWU3MmFfMzk2_9da17f62-df9f-4661-ad6f-b724504e49b4">Net periodic (benefit) cost for the Company&#x2019;s defined benefit pension plans and postretirement benefit plan for the six months ended June 30, 2022 and 2021 consists of: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Postretirement&lt;br/&gt;Benefit&lt;br/&gt;Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service credit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i4cd8cb835ea2462f98e5d1fadf8a2bf3_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfMy0yLTEtMS0xMTY3NzE_951c4457-404d-4ecc-a5ec-d9fea1cb9a23"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ia0860bb9611a474495df2c84fca443ea_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfMy00LTEtMS0xMTY3NzE_f7bb4dc2-c510-4429-9155-5a6bfe750435"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="iba8a2efe71f24a6fa3f18d4fe8dc0568_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfMy02LTEtMS0xMTY3NzE_7681ac87-3d09-40d4-b456-3573726fabc9"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i666ce213d28248b1853cff9f08dadf3c_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfMy04LTEtMS0xMTY3NzE_f13407b8-84c9-41c2-a9f4-620831ed12fe"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ia9f1c1de00ee4efcb8697ec7c3c5c449_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfMy0xMC0xLTEtMTE2Nzcx_ee293c7a-df99-434f-a320-9621fb4f10dd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i5ffeb2497315442bb679da042122c643_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfMy0xMi0xLTEtMTE2Nzcx_f24277a8-b59f-4bf3-98b5-5eaf3b7e1a20"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i4cd8cb835ea2462f98e5d1fadf8a2bf3_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNC0yLTEtMS0xMTY3NzE_a3ff0156-b054-48b9-bcb1-293bfd52b0cc"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ia0860bb9611a474495df2c84fca443ea_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNC00LTEtMS0xMTY3NzE_a722a3b7-e583-4360-b388-f91da35aadac"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="iba8a2efe71f24a6fa3f18d4fe8dc0568_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNC02LTEtMS0xMTY3NzE_d40c0da8-1c56-4ecf-8ecd-bceab5aca095"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i666ce213d28248b1853cff9f08dadf3c_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNC04LTEtMS0xMTY3NzE_7bc2842a-6cb7-4841-a18b-b094e8116ef0"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ia9f1c1de00ee4efcb8697ec7c3c5c449_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNC0xMC0xLTEtMTE2Nzcx_1afb30fe-85aa-489d-a662-1c96727f7014"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i5ffeb2497315442bb679da042122c643_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNC0xMi0xLTEtMTE2Nzcx_33e2c670-b545-480f-9e99-a2d66d393fdb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i4cd8cb835ea2462f98e5d1fadf8a2bf3_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNS0yLTEtMS0xMTY3NzE_9629d066-3f60-4abd-b365-a30c78e213cf"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ia0860bb9611a474495df2c84fca443ea_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNS00LTEtMS0xMTY3NzE_6b721bba-1ec5-4d2e-b6f7-73eb3e87c05e"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="iba8a2efe71f24a6fa3f18d4fe8dc0568_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNS02LTEtMS0xMTY3NzE_7f0df28a-c257-47b8-83f6-713c4e113379"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i666ce213d28248b1853cff9f08dadf3c_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNS04LTEtMS0xMTY3NzE_c4a7f091-52ad-4b52-b8aa-84d38429cd40"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ia9f1c1de00ee4efcb8697ec7c3c5c449_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNS0xMC0xLTEtMTE2Nzcx_510ac8f6-7e40-40fc-8119-a6718dd120c4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i5ffeb2497315442bb679da042122c643_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNS0xMi0xLTEtMTE2Nzcx_98610e0c-5242-425a-84fc-6258db19470a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i4cd8cb835ea2462f98e5d1fadf8a2bf3_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNi0yLTEtMS0xMTY3NzE_5bbf4e88-dcdb-4a2f-946f-b9365e5de330"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ia0860bb9611a474495df2c84fca443ea_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNi00LTEtMS0xMTY3NzE_778449ac-5671-4525-a7a4-3b6f625cf3a9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="iba8a2efe71f24a6fa3f18d4fe8dc0568_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNi02LTEtMS0xMTY3NzE_9fa6f21a-0847-49ee-9654-4e4f55e64f6f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i666ce213d28248b1853cff9f08dadf3c_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNi04LTEtMS0xMTY3NzE_0b699156-0a56-4d5c-bcac-465bcca82bf2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ia9f1c1de00ee4efcb8697ec7c3c5c449_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNi0xMC0xLTEtMTE2Nzcx_9e55a6cb-1cf8-41b1-85b8-c80b0fe271be"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i5ffeb2497315442bb679da042122c643_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNi0xMi0xLTEtMTE2Nzcx_5f33135b-738b-4b43-9df2-c5191e52e30c"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i4cd8cb835ea2462f98e5d1fadf8a2bf3_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNy0yLTEtMS0xMjIzNzk_4888db5d-b90a-4f7c-8375-dfb068b30e86"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ia0860bb9611a474495df2c84fca443ea_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNy00LTEtMS0xMjIzNzk_9ce816ee-7b6b-4305-9ee6-a9ed6657ef5a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="iba8a2efe71f24a6fa3f18d4fe8dc0568_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNy02LTEtMS0xMjIzNzk_06680c91-a004-44d6-9f9b-e336f8ed7e28"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i666ce213d28248b1853cff9f08dadf3c_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNy04LTEtMS0xMjIzNzk_be808ffe-f3d5-438f-b948-e0a31177ec17"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ia9f1c1de00ee4efcb8697ec7c3c5c449_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNy0xMC0xLTEtMTIyMzc5_8c19076e-0d2d-45e3-a109-9dd34f16cca1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i5ffeb2497315442bb679da042122c643_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNy0xMi0xLTEtMTIyMzc5_ee79ee03-a5ab-4d3b-af10-09cb293d6511"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i4cd8cb835ea2462f98e5d1fadf8a2bf3_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNy0yLTEtMS0xMTY3NzE_3e2a4bc8-ce22-47fb-9ec0-eb77592d43ca"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ia0860bb9611a474495df2c84fca443ea_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNy00LTEtMS0xMTY3NzE_2518e503-73ed-448e-b761-16ffaa375c97"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="iba8a2efe71f24a6fa3f18d4fe8dc0568_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNy02LTEtMS0xMTY3NzE_f6a8f77b-f90c-4288-a10a-824f8b04fecf"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i666ce213d28248b1853cff9f08dadf3c_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNy04LTEtMS0xMTY3NzE_7083a531-2561-4ae0-8df5-d2ce7e471c54"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ia9f1c1de00ee4efcb8697ec7c3c5c449_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNy0xMC0xLTEtMTE2Nzcx_5ede15fd-accb-40ae-9104-46a2e7c00274"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i5ffeb2497315442bb679da042122c643_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83My9mcmFnOjY0MjYwNWMxODhkODRmMGRiMTc1ZWVlZmUyMDllNzJhL3RhYmxlOmVkYmIyMzE2ZDlhYzQzZTk5YjI5Y2VjNTMzZmQxM2E2L3RhYmxlcmFuZ2U6ZWRiYjIzMTZkOWFjNDNlOTliMjljZWM1MzNmZDEzYTZfNy0xMi0xLTEtMTE2Nzcx_e67da3c2-1f58-4812-8593-d804e3a51256"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDUyNg_37becd6f-3978-464d-b411-3ac9cf84be66">SHARE-BASED COMPENSATION&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Bausch Health&#x2019;s Long-Term Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2014, shareholders approved the Company&#x2019;s 2014 Omnibus Incentive Plan (the &#x201c;2014 Plan&#x201d;) which replaced the Company&#x2019;s 2011 Omnibus Incentive Plan (the &#x201c;2011 Plan&#x201d;) for future equity awards granted by the Company. The Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan was equal to 18,000,000 common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or surrendered under the 2011 Plan and the Company&#x2019;s 2007 Equity Compensation Plan. The Company registered 20,000,000 common shares for issuance under the 2014 Plan. The 2014 Plan was amended and restated effective April 30, 2018 and April 28, 2020 to, among other things, increase the number of common shares authorized for issuance under the 2014 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective June 21, 2022, the Company further amended and restated the 2014 Plan, as subsequently amended and restated (the &#x201c;Amended and Restated 2014 Plan&#x201d;). Such amendment and restatement increased the number of common shares authorized for issuance under the Amended and Restated 2014 Plan by an additional 11,500,000 common shares, among other things.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximately 21,627,000 common shares were available for future grants under the Amended and Restated 2014 Plan as of June&#160;30, 2022. The Company uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with the Company&#x2019;s focus on improving its tangible capital usage and allocation while maintaining focus on improving total shareholder return over the long-term. The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based restricted share units (&#x201c;RSUs&#x201d;) and performance-based RSUs. Performance-based RSUs are comprised of awards that: (i) vest upon achievement of certain share price appreciation conditions that are based on total shareholder return (&#x201c;TSR&#x201d;), (ii) vest upon attainment of certain performance targets that are based on the Company&#x2019;s return on tangible capital (&#x201c;ROTC&#x201d;) and (iii) vest fully or partially upon attainment of certain goals that are linked to the B+L Separation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Bausch + Lomb Long-Term Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; + Lomb participated in Bausch Health&#x2019;s long-term incentive program prior to the establishment of the Bausch + Lomb Incentive Plan. Effective May 5, 2022, Bausch + Lomb established the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the &#x201c;B+L Plan&#x201d;). A total of 28,000,000 common shares of Bausch + Lomb are authorized under the B+L Plan. The B+L Plan provides for the grant of various types of awards including RSUs, stock appreciation rights, stock options, performance-based awards and cash awards. Under the Plan, the exercise price of awards, if any, is set on the grant date and may not be less than the fair market value per share on that date. Generally, stock options have a term of ten years and a three-year vesting period, subject to limited exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 5, 2022, in connection with the B+L IPO, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; + Lomb granted certain awards to certain eligible recipients (the &#x201c;IPO Founder Grants&#x201d;). Eligible recipients are individuals employed by Bausch + Lomb or employed by an affiliate of Bausch + Lomb. Approximately 3,900,000 IPO Founder Grants were issued to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; + Lomb executive officers and were awarded 50% in the form of stock options and 50% in the form of RSUs. Additionally, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; + Lomb granted approximately 5,700,000 stock options and RSUs to non-executive eligible recipients, of which approximately 4,300,000 were IPO Founder Grants. The options have a three-year graded vesting period and the RSUs vest 50% in the second year and 50% in the third year after the grant. Vesting of the IPO Founder Grants are contingent on the completion of the B+L Separation and expense recognition will begin near the time of the B+L Separation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximately 18,400,000 Bausch + Lomb common shares were available for future grants as of June&#160;30, 2022 under the B+L Plan. Bausch + Lomb uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components and classification of Bausch Health share-based compensation expenses related to stock options and RSUs for the three and six months ended June 30, 2022 and 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based awards granted for the six months ended June 30, 2022 and 2021 consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Bausch Health Share-Based Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,570,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,466,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,680,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,861,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TSR performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROTC performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;B+L Separation performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Bausch+ Lomb Share-Based Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,455,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,207,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, the remaining unrecognized compensation expenses related to all outstanding non-vested stock options, time-based RSUs and performance-based RSUs under the Amended and Restated 2014 Plan amounted to $139 million, which will be amortized over a weighted-average period of 1.74 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, the remaining unrecognized compensation expenses related to all outstanding non-vested stock options, time-based RSUs and performance-based RSUs under the B+L Plan amounted to $59&#160;million, which will be amortized over a weighted-average period of 1.77 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i1b4bf4e8fe81409981be4a7ea9e8c8b8_I20140531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDQ0_3886ecae-3f56-4d50-aa50-c71be74c8043"
      unitRef="shares">18000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i1b4bf4e8fe81409981be4a7ea9e8c8b8_I20140531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfODA0_8435523d-a697-414c-8b8c-dd14adea8d22"
      unitRef="shares">20000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i8fcb725d105e49e7b841b1a1b6ea5845_D20180430-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfMTE3Mg_4782b447-a80e-4fd3-9f6e-e846454337a1"
      unitRef="shares">11500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ib6c3216122874ca2a63bc8576f858181_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfMzAxOA_91e75de6-0bac-4663-9b57-87b4259ce14f"
      unitRef="shares">21627000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i9ddb299f73684060bea0bc507f71ef99_I20220505"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfMTE1NDQ4NzIwOTgyODk_43818a37-efab-4132-b748-0b27a7d595cd"
      unitRef="shares">28000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i5d0bb60ae16b4974b67f6d117230127a_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfMTE1NDQ4NzIwOTgzMDA_bbc43858-f4ee-4c70-b44a-0e2ff072119a">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i5d0bb60ae16b4974b67f6d117230127a_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfMTE1NDQ4NzIwOTgzMjU_5821f7fd-2da9-4c23-a710-96afac0caadf">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i1d3dfe74f4714b7a933c87137684aa03_D20220505-20220505"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDk0NzgwMjMzMjI4OQ_ba68fccf-139b-4e05-93bb-d8a764df7945"
      unitRef="shares">3900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent
      contextRef="id6202db2af2b4bafa11ccccaaf34418a_I20220505"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDk0NzgwMjMzMjMxOA_4c4eb670-8f49-4fc0-995e-8a7bfe279f03"
      unitRef="number">0.50</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent
      contextRef="i9090a13c2aa6459eaac11b6d545fcbe2_I20220505"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDk0NzgwMjMzMjMxMw_094e920b-fd9b-4003-93c7-8d4b0c6709bf"
      unitRef="number">0.50</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross
      contextRef="i9f3765198c384eddb84bb962d8f1d47c_D20220505-20220505"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDk0NzgwMjMzMjMwMQ_cfc568ef-6b23-4d5c-a141-21e62b2de662"
      unitRef="shares">5700000</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross
      contextRef="i224371ec19ea4a1fab4ab9edec1c44b2_D20220505-20220505"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDk0NzgwMjMzNjA0MA_ab2a90a8-1ef3-4df9-ba5c-2dcfc89747de"
      unitRef="shares">4300000</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i82c8f4dd25114f83975b0eb530968e3c_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDM5ODA0NjUyMTg4Mg_e0cdd94d-3e77-4e06-84ab-33e0cbf290a5">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i6be3a30d81ad44bdaad72c4d270fd4a4_D20220505-20220505"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDM5ODA0NjUyMTg4NA_e30fe6d3-2cc3-4db8-b103-e1a3bcf8808b"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i515efea05dbc4414985b6f9579a6bbce_D20220505-20220505"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDM5ODA0NjUyMTg4OQ_198b09a2-4987-4117-80c3-b0fcca6300a9"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i2a344934b62143ffb69252e4cddaf7f0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDM5ODA0NjUxNzcyOQ_ad22c7c3-f33d-4160-b293-a7e3a3085e7e"
      unitRef="shares">18400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDUxOQ_c46949b2-edb7-4b67-822f-402f86553f44">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components and classification of Bausch Health share-based compensation expenses related to stock options and RSUs for the three and six months ended June 30, 2022 and 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i33dd60c60854413ab4b719ac057cf817_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfMi0yLTEtMS0xMjAyNDE_108da141-ec19-4bf5-9dcf-0a9741f029ab"
      unitRef="usd">3000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibc3fb9c24a1a42d6a1abed1c7e372f2a_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfMi00LTEtMS0xMjAyNDM_e4e738b6-8331-4906-8c93-cd661021a8d3"
      unitRef="usd">3000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id4690e57d623418889d484725bb730c7_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfMi0yLTEtMS0xMTY3NzE_f67b568d-bf74-416a-9778-987e05e30499"
      unitRef="usd">7000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i41c4ed7db4b34d4bbdc90c34f51f1caa_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfMi00LTEtMS0xMTY3NzE_2b67bc57-b046-4e57-8ba6-69a465514af2"
      unitRef="usd">7000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie919cd08314e401e805d15dfd8c4b7f9_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfMy0yLTEtMS0xMjAyNDE_da88e60f-8dea-41d0-b564-eb86a2330d00"
      unitRef="usd">23000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id624e9058a214f69b2edf512f1e9c531_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfMy00LTEtMS0xMjAyNDM_ac0fe041-06ce-4fe8-8e3b-82346e3a5b98"
      unitRef="usd">28000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i79b44039ced246f8b01d5c45ecee92be_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfMy0yLTEtMS0xMTY3NzE_ad739d8a-ae38-46ca-a3db-325ccdc0eecb"
      unitRef="usd">51000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id7f366437a554f0881430dd47c95e590_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfMy00LTEtMS0xMTY3NzE_b9d14dbd-fd8f-4ede-856a-76d76ae2cda7"
      unitRef="usd">55000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfNC0yLTEtMS0xMjAyNDE_42657412-958e-48cf-b6d9-8dbd3f7ef77d"
      unitRef="usd">26000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfNC00LTEtMS0xMjAyNDM_ee60ce02-3d39-4eb7-a8a3-22a16584b9b1"
      unitRef="usd">31000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfNC0yLTEtMS0xMTY3NzE_af8b9ade-268c-42d2-b244-b2e8041dcc95"
      unitRef="usd">58000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfNC00LTEtMS0xMTY3NzE_5c92d8f6-c107-4525-97c0-9fd5529d0cce"
      unitRef="usd">62000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8324a3a87b5b4431a240a863bcd109e7_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfNi0yLTEtMS0xMjAyNDU_a00fd3cf-c7d2-4dd4-8eca-2da8d2ec616b"
      unitRef="usd">3000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i162c7abaff6441bcaafdcb7c3786380f_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfNi00LTEtMS0xMjAyNDc_722d63da-57da-4eb8-918b-1c7bf0f129f8"
      unitRef="usd">2000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia50d9a9309cc4eeabfd8a0b7ec06cbb9_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfNi0yLTEtMS0xMTY3NzE_75096a1c-7ea5-4bb3-91c7-a0baa7fbe8cc"
      unitRef="usd">6000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idd76194575be490ba80170f4fdd8bdeb_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfNi00LTEtMS0xMTY3NzE_b3bea723-1997-4f71-b330-fa12bf32607c"
      unitRef="usd">5000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8c788daa389d46c7ab261260e329fa06_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfNy0yLTEtMS0xMjAyNDU_c2b41a77-cc3b-4f15-97a5-4c3fb0c50af7"
      unitRef="usd">23000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id2a52a76022341358c404e2fb242b953_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfNy00LTEtMS0xMjAyNDc_fa86bb97-17b9-47d2-87db-331bfdfed3f6"
      unitRef="usd">29000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibd6d0843d657451284d1138fc8962e1a_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfNy0yLTEtMS0xMTY3NzE_c41dda70-6c78-43c9-8139-343fcc363d17"
      unitRef="usd">52000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia4c50767d19044e08e9feb4b807a2916_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfNy00LTEtMS0xMTY3NzE_0b85bd8f-4dcc-427b-a38b-1c001ee240d5"
      unitRef="usd">57000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfOC0yLTEtMS0xMjAyNDU_15e6f0e1-a676-4420-9e62-3ced831457de"
      unitRef="usd">26000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfOC00LTEtMS0xMjAyNDc_877cfe85-2aec-409d-b968-be50c55ffaaf"
      unitRef="usd">31000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfOC0yLTEtMS0xMTY3NzE_97dac505-8655-4d87-bda6-862bc1a0eaac"
      unitRef="usd">58000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOjI4MDgxYjgyNzcwMTQ3MTdhMmMyMWM4OGZjMmM1MDZhL3RhYmxlcmFuZ2U6MjgwODFiODI3NzAxNDcxN2EyYzIxYzg4ZmMyYzUwNmFfOC00LTEtMS0xMTY3NzE_21c2189f-1e04-4fe5-82e7-0784b7439795"
      unitRef="usd">62000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDUyMQ_80bc7d8f-0169-4ad5-ad6f-1419783aa23b">&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based awards granted for the six months ended June 30, 2022 and 2021 consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Bausch Health Share-Based Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,570,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,466,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,680,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,861,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TSR performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROTC performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;B+L Separation performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Bausch+ Lomb Share-Based Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,455,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,207,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="id4690e57d623418889d484725bb730c7_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMi0xLTEtMS0xMTY3NzE_2d6fb243-e071-4a89-985e-b9b1f12694a2"
      unitRef="shares">2570000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i41c4ed7db4b34d4bbdc90c34f51f1caa_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMi0zLTEtMS0xMTY3NzE_4aae76d3-d248-4bc8-a2ee-2e61afb92a02"
      unitRef="shares">1466000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="id4690e57d623418889d484725bb730c7_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMy0xLTEtMS0xMTY3NzE_39a84018-1b5c-4af7-a57b-a7fe5bafadfe"
      unitRef="usdPerShare">23.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i41c4ed7db4b34d4bbdc90c34f51f1caa_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMy0zLTEtMS0xMTY3NzE_c92ebda6-f435-41f5-ba69-7428cc444d7d"
      unitRef="usdPerShare">32.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id4690e57d623418889d484725bb730c7_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfNC0xLTEtMS0xMTY3NzE_ea780b5c-b8a7-4140-a15b-eafa2be154e7"
      unitRef="usdPerShare">6.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i41c4ed7db4b34d4bbdc90c34f51f1caa_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfNC0zLTEtMS0xMTY3NzE_d139a035-010a-434c-801c-1506ed5a5e31"
      unitRef="usdPerShare">11.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ifc74e57032d14542b4caf11d925a446c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfNi0xLTEtMS0xMTY3NzE_d38a60b6-c8f0-49b4-8911-b8f0d5ae495c"
      unitRef="shares">2680000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie6dc26b569a743babd2022197af82304_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfNi0zLTEtMS0xMTY3NzE_b7da8077-5719-43ee-9c92-7bb7a0d0096e"
      unitRef="shares">2861000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ifc74e57032d14542b4caf11d925a446c_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfNy0xLTEtMS0xMTY3NzE_4c7dae97-3b71-46a9-9e26-1c1bba2ff93f"
      unitRef="usdPerShare">18.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie6dc26b569a743babd2022197af82304_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfNy0zLTEtMS0xMTY3NzE_3dc0cace-2778-46c5-97ca-36b315f108e0"
      unitRef="usdPerShare">32.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i451c05ed9bb34dfd81236d9bd495bdd4_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfOS0xLTEtMS0xMTY3NzE_6528c2f0-fac4-4e1f-adb8-7d050b647b26"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i697b06c7bfab4c66b24bd5ee7d182aff_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfOS0zLTEtMS0xMTY3NzE_12f0dcde-191c-4d9c-a2eb-6cb0c71dff17"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i451c05ed9bb34dfd81236d9bd495bdd4_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMTAtMS0xLTEtMTE2Nzcx_3d045d91-b7a6-43b9-94ef-8b3d29b0ea22"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i697b06c7bfab4c66b24bd5ee7d182aff_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMTAtMy0xLTEtMTE2Nzcx_56da59fb-f913-4382-9485-a4e2ddebf015"
      unitRef="usdPerShare">56.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="icac063b2f1aa4b21b334538c17b2df50_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMTItMS0xLTEtMTE2Nzcx_f3859bd1-a8ac-40e0-b129-5a64174b2a28"
      unitRef="shares">369000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i557729c1fe0b4b1480972c1737bd0a7f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMTItMy0xLTEtMTE2Nzcx_85756cc2-46c6-47b6-bcdb-081acb90329f"
      unitRef="shares">413000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="icac063b2f1aa4b21b334538c17b2df50_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMTMtMS0xLTEtMTE2Nzcx_41d1a3b1-07fe-4d49-ba8b-8d89c35cbc1f"
      unitRef="usdPerShare">9.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i557729c1fe0b4b1480972c1737bd0a7f_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMTMtMy0xLTEtMTE2Nzcx_08a1f559-b324-4b52-be71-04cd801573b3"
      unitRef="usdPerShare">31.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie92ec71133c44dfc990b249053e5e02b_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMTUtMS0xLTEtMTE2Nzcx_5d283e8c-5325-45b5-8230-96dfa145d40a"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iadcde18252cb48d884cbe14183aa9c67_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMTUtMy0xLTEtMTE2Nzcx_861fcef3-3f76-436f-b826-12d9d168c19a"
      unitRef="shares">132000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie92ec71133c44dfc990b249053e5e02b_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMTYtMS0xLTEtMTE2Nzcx_77dc22b6-49e1-43ea-86e0-951638665a2d"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iadcde18252cb48d884cbe14183aa9c67_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMTYtMy0xLTEtMTE2Nzcx_31354c4e-4221-4779-b1cf-a27173ce075a"
      unitRef="usdPerShare">32.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i68d73c7e5e384257812c2170febe4778_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMjAtMS0xLTEtMTIxNzk0_f42b27d4-6285-4d06-be48-fd7c0eeca745"
      unitRef="shares">6455000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i5f24f78b6a854ff5ad91cc5ccdd5b4af_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMjAtMy0xLTEtMTIxNzk2_e66f10b1-d590-4fb3-8ea6-85d675483e12"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i68d73c7e5e384257812c2170febe4778_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMjEtMS0xLTEtMTIxNzk0_3ec64800-8e95-4ec6-b515-93637d7a9a09"
      unitRef="usdPerShare">18.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i5f24f78b6a854ff5ad91cc5ccdd5b4af_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMjEtMy0xLTEtMTIxNzk2_e44b030f-dad0-44e6-bcdc-0a1de62d3e00"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i68d73c7e5e384257812c2170febe4778_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMjItMS0xLTEtMTIxNzk0_bedfce7f-ab32-4e77-8bc8-7b20065d19e3"
      unitRef="usdPerShare">4.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5f24f78b6a854ff5ad91cc5ccdd5b4af_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMjItMy0xLTEtMTIxNzk2_a0b1d757-0600-482a-ab4e-1f34e44afde6"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iab029c733228479b92d1b8a6e2205965_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMjQtMS0xLTEtMTIxNzk4_f1ca2d36-1562-41c8-8868-4be8596b4ce8"
      unitRef="shares">3207000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="idd8a8752f1f749c88cde59232457ef50_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMjQtMy0xLTEtMTIxODAw_0f51090c-3155-4c88-8125-97268134449c"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iab029c733228479b92d1b8a6e2205965_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMjUtMS0xLTEtMTIxNzk4_bf6ed556-ba91-4055-8095-8cc05613c071"
      unitRef="usdPerShare">17.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="idd8a8752f1f749c88cde59232457ef50_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RhYmxlOmM0YzMyMDgzNjZkMDRhOWViMGZkYTU0NGRjMzM3NmY2L3RhYmxlcmFuZ2U6YzRjMzIwODM2NmQwNGE5ZWIwZmRhNTQ0ZGMzMzc2ZjZfMjUtMy0xLTEtMTIxODAw_00f75942-8ea4-4baa-8a36-6bb1d425a22d"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDQ0OQ_09271ad4-cb2c-4f01-ad94-972d20d2f8d3"
      unitRef="usd">139000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDUxMQ_a6694321-1f79-452a-98c3-e937d0a72f5a">P1Y8M26D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i2a344934b62143ffb69252e4cddaf7f0_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDM5ODA0NjUyMjA2OQ_648384a3-105c-42a6-a289-d53c6ac73cc2"
      unitRef="usd">59000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="idd08efb021e240aebc5ee605feba929f_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83Ni9mcmFnOjBiNDUzMzEwYTQwZDQ5MDg4OWFhNjEyYjM4YWI4MDU3L3RleHRyZWdpb246MGI0NTMzMTBhNDBkNDkwODg5YWE2MTJiMzhhYjgwNTdfNDM5ODA0NjUyMjA4Mg_88d94ed2-acea-4ba6-87b7-e6fee161a5dd">P1Y9M7D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83OS9mcmFnOjNkYTE3YjEwMzlhOTQ2MDE4Y2E3MjY5NWJhZTIxYmUzL3RleHRyZWdpb246M2RhMTdiMTAzOWE5NDYwMThjYTcyNjk1YmFlMjFiZTNfNDcy_5e6a25f1-41fc-463e-931f-b8ccf8d4cf0b">ACCUMULATED OTHER COMPREHENSIVE LOSS&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss consists of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,990)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,905)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension and postretirement benefit plan adjustments, net of income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company&#x2019;s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company&#x2019;s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the change in the Company&#x2019;s ownership interest in Bausch + Lomb, the carrying amount of accumulated other comprehensive income was adjusted to reflect the change in the ownership interest in Bausch + Lomb through a corresponding credit of $137&#160;million to equity attributable to the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83OS9mcmFnOjNkYTE3YjEwMzlhOTQ2MDE4Y2E3MjY5NWJhZTIxYmUzL3RleHRyZWdpb246M2RhMTdiMTAzOWE5NDYwMThjYTcyNjk1YmFlMjFiZTNfNDY5_41b248bb-b16a-44eb-8169-a52383c64cb4">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss consists of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,990)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,905)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension and postretirement benefit plan adjustments, net of income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i720ba0ebf9c2430f814fa6947f648cee_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83OS9mcmFnOjNkYTE3YjEwMzlhOTQ2MDE4Y2E3MjY5NWJhZTIxYmUzL3RhYmxlOjIzOTJkZDRiMTk1ZjQ1NGFiZDBhMjNhNWZlM2RjZmUyL3RhYmxlcmFuZ2U6MjM5MmRkNGIxOTVmNDU0YWJkMGEyM2E1ZmUzZGNmZTJfMS0yLTEtMS0xMTY3NzE_1b052883-d339-492c-81ba-78b87c622788"
      unitRef="usd">-1990000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i25c764472afe40a994fbab76db8f8203_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83OS9mcmFnOjNkYTE3YjEwMzlhOTQ2MDE4Y2E3MjY5NWJhZTIxYmUzL3RhYmxlOjIzOTJkZDRiMTk1ZjQ1NGFiZDBhMjNhNWZlM2RjZmUyL3RhYmxlcmFuZ2U6MjM5MmRkNGIxOTVmNDU0YWJkMGEyM2E1ZmUzZGNmZTJfMS00LTEtMS0xMTY3NzE_19c2bd0f-fb38-45fd-a911-ccf2bc8d0f03"
      unitRef="usd">-1905000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i488260ae8425453ebec7df5c26c9c934_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83OS9mcmFnOjNkYTE3YjEwMzlhOTQ2MDE4Y2E3MjY5NWJhZTIxYmUzL3RhYmxlOjIzOTJkZDRiMTk1ZjQ1NGFiZDBhMjNhNWZlM2RjZmUyL3RhYmxlcmFuZ2U6MjM5MmRkNGIxOTVmNDU0YWJkMGEyM2E1ZmUzZGNmZTJfMi0yLTEtMS0xMTY3NzE_24ccea8d-1c6a-4e7c-ac38-18a1ebbd445d"
      unitRef="usd">-12000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibdc7a899aaa242abbfc3fb10b5125784_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83OS9mcmFnOjNkYTE3YjEwMzlhOTQ2MDE4Y2E3MjY5NWJhZTIxYmUzL3RhYmxlOjIzOTJkZDRiMTk1ZjQ1NGFiZDBhMjNhNWZlM2RjZmUyL3RhYmxlcmFuZ2U6MjM5MmRkNGIxOTVmNDU0YWJkMGEyM2E1ZmUzZGNmZTJfMi00LTEtMS0xMTY3NzE_404fdaac-68e5-4b9a-b345-681ff8465fac"
      unitRef="usd">-19000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6b5d37c24d0e41cb994b6d343566c79e_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83OS9mcmFnOjNkYTE3YjEwMzlhOTQ2MDE4Y2E3MjY5NWJhZTIxYmUzL3RhYmxlOjIzOTJkZDRiMTk1ZjQ1NGFiZDBhMjNhNWZlM2RjZmUyL3RhYmxlcmFuZ2U6MjM5MmRkNGIxOTVmNDU0YWJkMGEyM2E1ZmUzZGNmZTJfMy0yLTEtMS0xMTY3NzE_a6365efa-767b-4759-a008-1bb45c85dc59"
      unitRef="usd">-2002000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a5f744b0e03413c9fa836c080e97ee8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83OS9mcmFnOjNkYTE3YjEwMzlhOTQ2MDE4Y2E3MjY5NWJhZTIxYmUzL3RhYmxlOjIzOTJkZDRiMTk1ZjQ1NGFiZDBhMjNhNWZlM2RjZmUyL3RhYmxlcmFuZ2U6MjM5MmRkNGIxOTVmNDU0YWJkMGEyM2E1ZmUzZGNmZTJfMy00LTEtMS0xMTY3NzE_e15d9fd0-8e01-45f4-bfbd-35ba569f3eec"
      unitRef="usd">-1924000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0faf02d0dab04ba2a12aed2a72ddb539_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV83OS9mcmFnOjNkYTE3YjEwMzlhOTQ2MDE4Y2E3MjY5NWJhZTIxYmUzL3RleHRyZWdpb246M2RhMTdiMTAzOWE5NDYwMThjYTcyNjk1YmFlMjFiZTNfNDM5ODA0NjUxMzQ1NA_0098220a-dd76-420a-9400-1f4697defbbb"
      unitRef="usd">137000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84Mi9mcmFnOjQ0MjdhMDc3NjQ2YzRmNTI4YjY3ZWQzMDE4NDI1YmMwL3RleHRyZWdpb246NDQyN2EwNzc2NDZjNGY1MjhiNjdlZDMwMTg0MjViYzBfMjM2_81e044af-f032-42c7-8d17-6df80c01121b">RESEARCH AND DEVELOPMENT&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. Research and development costs consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product related research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Quality assurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84Mi9mcmFnOjQ0MjdhMDc3NjQ2YzRmNTI4YjY3ZWQzMDE4NDI1YmMwL3RleHRyZWdpb246NDQyN2EwNzc2NDZjNGY1MjhiNjdlZDMwMTg0MjViYzBfMjMz_8cb9616a-2b46-4e93-8b8a-14207a8da998">Research and development costs consist of:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product related research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Quality assurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock>
    <bhc:ResearchAndDevelopmentExpenseProductRelated
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84Mi9mcmFnOjQ0MjdhMDc3NjQ2YzRmNTI4YjY3ZWQzMDE4NDI1YmMwL3RhYmxlOjVkMzJmZTFiN2JkNDRhNjJiOGFlZDQ1ZDZmMWQyNmQ3L3RhYmxlcmFuZ2U6NWQzMmZlMWI3YmQ0NGE2MmI4YWVkNDVkNmYxZDI2ZDdfMi0yLTEtMS0xMTY3NzE_6bb3674e-496a-4f08-a553-c3335f953bb9"
      unitRef="usd">120000000</bhc:ResearchAndDevelopmentExpenseProductRelated>
    <bhc:ResearchAndDevelopmentExpenseProductRelated
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84Mi9mcmFnOjQ0MjdhMDc3NjQ2YzRmNTI4YjY3ZWQzMDE4NDI1YmMwL3RhYmxlOjVkMzJmZTFiN2JkNDRhNjJiOGFlZDQ1ZDZmMWQyNmQ3L3RhYmxlcmFuZ2U6NWQzMmZlMWI3YmQ0NGE2MmI4YWVkNDVkNmYxZDI2ZDdfMi00LTEtMS0xMTY3NzE_86a9170c-834c-4fa0-b09e-bea8ebd5384f"
      unitRef="usd">109000000</bhc:ResearchAndDevelopmentExpenseProductRelated>
    <bhc:ResearchAndDevelopmentExpenseProductRelated
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84Mi9mcmFnOjQ0MjdhMDc3NjQ2YzRmNTI4YjY3ZWQzMDE4NDI1YmMwL3RhYmxlOjVkMzJmZTFiN2JkNDRhNjJiOGFlZDQ1ZDZmMWQyNmQ3L3RhYmxlcmFuZ2U6NWQzMmZlMWI3YmQ0NGE2MmI4YWVkNDVkNmYxZDI2ZDdfMi02LTEtMS0xMTY3NzE_2d4db56e-4d25-4abe-b255-b15583aa5780"
      unitRef="usd">241000000</bhc:ResearchAndDevelopmentExpenseProductRelated>
    <bhc:ResearchAndDevelopmentExpenseProductRelated
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84Mi9mcmFnOjQ0MjdhMDc3NjQ2YzRmNTI4YjY3ZWQzMDE4NDI1YmMwL3RhYmxlOjVkMzJmZTFiN2JkNDRhNjJiOGFlZDQ1ZDZmMWQyNmQ3L3RhYmxlcmFuZ2U6NWQzMmZlMWI3YmQ0NGE2MmI4YWVkNDVkNmYxZDI2ZDdfMi04LTEtMS0xMTY3NzE_8a46a1f6-5721-45fe-912e-d62178ee2457"
      unitRef="usd">214000000</bhc:ResearchAndDevelopmentExpenseProductRelated>
    <bhc:ResearchAndDevelopmentExpenseQualityAssurance
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84Mi9mcmFnOjQ0MjdhMDc3NjQ2YzRmNTI4YjY3ZWQzMDE4NDI1YmMwL3RhYmxlOjVkMzJmZTFiN2JkNDRhNjJiOGFlZDQ1ZDZmMWQyNmQ3L3RhYmxlcmFuZ2U6NWQzMmZlMWI3YmQ0NGE2MmI4YWVkNDVkNmYxZDI2ZDdfMy0yLTEtMS0xMTY3NzE_93e7fe58-64f1-4265-9fa9-b37ce9644806"
      unitRef="usd">7000000</bhc:ResearchAndDevelopmentExpenseQualityAssurance>
    <bhc:ResearchAndDevelopmentExpenseQualityAssurance
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84Mi9mcmFnOjQ0MjdhMDc3NjQ2YzRmNTI4YjY3ZWQzMDE4NDI1YmMwL3RhYmxlOjVkMzJmZTFiN2JkNDRhNjJiOGFlZDQ1ZDZmMWQyNmQ3L3RhYmxlcmFuZ2U6NWQzMmZlMWI3YmQ0NGE2MmI4YWVkNDVkNmYxZDI2ZDdfMy00LTEtMS0xMTY3NzE_673a2e51-33dc-4654-bc9b-162df899486c"
      unitRef="usd">6000000</bhc:ResearchAndDevelopmentExpenseQualityAssurance>
    <bhc:ResearchAndDevelopmentExpenseQualityAssurance
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84Mi9mcmFnOjQ0MjdhMDc3NjQ2YzRmNTI4YjY3ZWQzMDE4NDI1YmMwL3RhYmxlOjVkMzJmZTFiN2JkNDRhNjJiOGFlZDQ1ZDZmMWQyNmQ3L3RhYmxlcmFuZ2U6NWQzMmZlMWI3YmQ0NGE2MmI4YWVkNDVkNmYxZDI2ZDdfMy02LTEtMS0xMTY3NzE_382c68a8-2c88-4f21-8077-c94489567ee8"
      unitRef="usd">13000000</bhc:ResearchAndDevelopmentExpenseQualityAssurance>
    <bhc:ResearchAndDevelopmentExpenseQualityAssurance
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84Mi9mcmFnOjQ0MjdhMDc3NjQ2YzRmNTI4YjY3ZWQzMDE4NDI1YmMwL3RhYmxlOjVkMzJmZTFiN2JkNDRhNjJiOGFlZDQ1ZDZmMWQyNmQ3L3RhYmxlcmFuZ2U6NWQzMmZlMWI3YmQ0NGE2MmI4YWVkNDVkNmYxZDI2ZDdfMy04LTEtMS0xMTY3NzE_fca173df-17b0-42f6-979b-971074f67072"
      unitRef="usd">13000000</bhc:ResearchAndDevelopmentExpenseQualityAssurance>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84Mi9mcmFnOjQ0MjdhMDc3NjQ2YzRmNTI4YjY3ZWQzMDE4NDI1YmMwL3RhYmxlOjVkMzJmZTFiN2JkNDRhNjJiOGFlZDQ1ZDZmMWQyNmQ3L3RhYmxlcmFuZ2U6NWQzMmZlMWI3YmQ0NGE2MmI4YWVkNDVkNmYxZDI2ZDdfNC0yLTEtMS0xMTY3NzE_9dbc4cbc-ce5b-42f1-8a69-60094195ece2"
      unitRef="usd">127000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84Mi9mcmFnOjQ0MjdhMDc3NjQ2YzRmNTI4YjY3ZWQzMDE4NDI1YmMwL3RhYmxlOjVkMzJmZTFiN2JkNDRhNjJiOGFlZDQ1ZDZmMWQyNmQ3L3RhYmxlcmFuZ2U6NWQzMmZlMWI3YmQ0NGE2MmI4YWVkNDVkNmYxZDI2ZDdfNC00LTEtMS0xMTY3NzE_7bf9f4a6-c33f-4271-a1b3-906a87af4b5c"
      unitRef="usd">115000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84Mi9mcmFnOjQ0MjdhMDc3NjQ2YzRmNTI4YjY3ZWQzMDE4NDI1YmMwL3RhYmxlOjVkMzJmZTFiN2JkNDRhNjJiOGFlZDQ1ZDZmMWQyNmQ3L3RhYmxlcmFuZ2U6NWQzMmZlMWI3YmQ0NGE2MmI4YWVkNDVkNmYxZDI2ZDdfNC02LTEtMS0xMTY3NzE_71284e67-a92e-4f03-bf1f-b895ea05438d"
      unitRef="usd">254000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84Mi9mcmFnOjQ0MjdhMDc3NjQ2YzRmNTI4YjY3ZWQzMDE4NDI1YmMwL3RhYmxlOjVkMzJmZTFiN2JkNDRhNjJiOGFlZDQ1ZDZmMWQyNmQ3L3RhYmxlcmFuZ2U6NWQzMmZlMWI3YmQ0NGE2MmI4YWVkNDVkNmYxZDI2ZDdfNC04LTEtMS0xMTY3NzE_c0f4e492-620a-48ba-9cf5-1e6803516b9e"
      unitRef="usd">227000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RleHRyZWdpb246ZmIzMWE0OTI2NjZjNDA0NmFlYzI0ZGYyODE2NTk3OTRfMTg0_6ee773b7-84a1-42c4-874f-9ed4d943e68c">OTHER EXPENSE, NET&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expense, net consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.340%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Litigation and other matters&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale of assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired in-process research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain on sale of assets, net for the six months ended June 30, 2021, includes $25&#160;million related to the achievement of a milestone related to a certain product.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RleHRyZWdpb246ZmIzMWE0OTI2NjZjNDA0NmFlYzI0ZGYyODE2NTk3OTRfMTg4_9da40bad-541f-4ab1-abf3-cd33103013a0">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expense, net consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.340%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Litigation and other matters&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale of assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired in-process research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfMi0yLTEtMS0xMTY3NzE_a09cb18f-f801-43ba-959d-ec591450f370"
      unitRef="usd">-8000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfMi00LTEtMS0xMTY3NzE_12e4bdeb-f7ff-4175-a1bd-0004203d2ac6"
      unitRef="usd">-532000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfMi02LTEtMS0xMTY3NzE_436e184c-3c4d-456f-9dfa-91ec2802e7e7"
      unitRef="usd">-7000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfMi04LTEtMS0xMTY3NzE_a1a0114f-abf0-48c2-b491-394ee95718a7"
      unitRef="usd">-532000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfMy0yLTEtMS0xMTY3NzE_2aa2654e-7cd6-491c-b0f1-51183bf8b27c"
      unitRef="usd">-5000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfMy00LTEtMS0xMTY3NzE_39f10095-dc32-4b23-89a5-476309619af0"
      unitRef="usd">9000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfMy02LTEtMS0xMTY3NzE_e50f58a5-dea5-43d2-9a65-e15b9d2e02ca"
      unitRef="usd">-2000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfMy04LTEtMS0xMTY3NzE_4497e3cd-718e-4d44-b14b-dbb883664c3f"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNC0yLTEtMS0xMTY3NzE_4b55f6e8-7ac8-4d95-8654-e26255a171bb"
      unitRef="usd">3000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNC00LTEtMS0xMTY3NzE_d2ea90f5-df73-463f-8c77-b8e78b0d6c92"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNC02LTEtMS0xMTY3NzE_80a47af6-bab3-4ab5-98a5-375b0e357f36"
      unitRef="usd">3000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNC04LTEtMS0xMTY3NzE_8e3f9498-a069-4f2a-890b-53a060107584"
      unitRef="usd">23000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNS0yLTEtMS0xMTY3NzE_aa23b410-ca45-4537-ae32-e23807de6579"
      unitRef="usd">1000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNS00LTEtMS0xMTY3NzE_e4b4bb2e-7aff-4776-a77f-37bd90886230"
      unitRef="usd">1000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNS02LTEtMS0xMTY3NzE_ca019d33-a6c9-463a-a4ab-abada5810eb3"
      unitRef="usd">1000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNS04LTEtMS0xMTY3NzE_c189f441-1f0c-418c-9125-bb84203dd09b"
      unitRef="usd">3000000</us-gaap:ResearchAndDevelopmentInProcess>
    <bhc:OtherIncomeExpenseNet
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNi0yLTEtMS0xMzAyODM_593f3fb2-5756-4ba9-9fb2-75bfd8d995fe"
      unitRef="usd">-1000000</bhc:OtherIncomeExpenseNet>
    <bhc:OtherIncomeExpenseNet
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNi00LTEtMS0xMzAyODM_267e93a7-cb18-46ff-9b63-5195708bf973"
      unitRef="usd">0</bhc:OtherIncomeExpenseNet>
    <bhc:OtherIncomeExpenseNet
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNi02LTEtMS0xMzAyOTY_e7e31749-063a-45e5-8e3f-57aa2e18adb7"
      unitRef="usd">-1000000</bhc:OtherIncomeExpenseNet>
    <bhc:OtherIncomeExpenseNet
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNi04LTEtMS0xMzAyOTY_c923a648-c182-4e5b-bb35-ec805aaf7d70"
      unitRef="usd">0</bhc:OtherIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNi0yLTEtMS0xMTY3NzE_b3f37eb3-5a02-4986-8d05-37d01127f9a8"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNi00LTEtMS0xMTY3NzE_75b7f2a0-71b1-4b8f-8852-1b7399d898d2"
      unitRef="usd">-542000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNi02LTEtMS0xMTY3NzE_1e1deec3-03ca-4c8d-aa23-6f4ba0e32cb5"
      unitRef="usd">-2000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RhYmxlOjZkYjk5NjJmNjFiMTQ0Mzc4MGFmNDY4NmY5Yjg3MDBkL3RhYmxlcmFuZ2U6NmRiOTk2MmY2MWIxNDQzNzgwYWY0Njg2ZjliODcwMGRfNi04LTEtMS0xMTY3NzE_60168dbf-70e8-463b-96ea-b4907baf58bc"
      unitRef="usd">-512000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ib81ba7780e6c4af981ed3d93789a7a30_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84NS9mcmFnOmZiMzFhNDkyNjY2YzQwNDZhZWMyNGRmMjgxNjU5Nzk0L3RleHRyZWdpb246ZmIzMWE0OTI2NjZjNDA0NmFlYzI0ZGYyODE2NTk3OTRfMTA3_91dd3738-5d61-4bc5-ab6c-4c899f7a5a45"
      unitRef="usd">25000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfNzc3NQ_1ff392c0-e648-494e-ba41-6151751e6f08">INCOME TAXES &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For interim financial statement purposes, U.S. GAAP income tax expense/benefit related to ordinary income is determined by applying an estimated annual effective income tax rate against a company&#x2019;s ordinary income. Income tax expense/benefit related to items not characterized as ordinary income is recognized as a discrete item when incurred. The estimation of the Company&#x2019;s income tax provision requires the use of management forecasts and other estimates, application of statutory income tax rates, and an evaluation of valuation allowances. The Company&#x2019;s estimated annual effective income tax rate may be revised, if necessary, in each interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Benefit from income taxes for the six months ended June 30, 2022 was $6 million and included: (i) $16&#160;million of income tax expense for the Company&#x2019;s ordinary loss for the six months ended June 30, 2022 and (ii) $22 million of net income tax benefit for discrete items, which includes: (a) $39&#160;million of net income tax benefit recognized for changes in uncertain tax positions and (b) a $16&#160;million tax provision associated with filing certain tax returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Benefit from income taxes for the six months ended June 30, 2021 was $61 million and included: (i) $50 million of income tax benefit for the Company&#x2019;s ordinary loss for the six months ended June 30, 2021 and (ii) $11&#160;million of net income tax provision for discrete items, which includes: (a) a $54&#160;million of net income tax benefit associated with certain legal settlements, (b) a $46&#160;million tax provision related to potential and recognized withholding tax on intercompany dividends, (c) a $7&#160;million tax benefit related to a deduction for stock compensation and (d) a $4&#160;million tax provision associated with the filing of certain tax returns. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made. The valuation allowance against deferred tax assets was $2,277 million and $2,222 million as of June&#160;30, 2022 and December&#160;31, 2021, respectively. The increase was primarily due to losses in Canada. The Company will continue to assess the need for a valuation allowance on an ongoing basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 8, 2021, the Organisation for Economic Co-operation and Development (&#x201c;OECD&#x201d;)/G20 inclusive framework on Base Erosion and Profit Shifting (the &#x201c;Inclusive Framework&#x201d;) published a statement updating and finalizing the key &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;components of a two-pillar plan on global tax reform originally agreed on July 1, 2021, and a timetable for implementation by 2023. The timetable for implementation has since been extended to 2024. The Inclusive Framework plan has now been agreed to by 141 OECD members, including several countries which did not agree to the initial plan. Under pillar one, taxing rights over multinational businesses with global turnover above &#x20ac;20 billion and a profit margin above 10% will generally be re-allocated to market jurisdictions. Under pillar two, the Inclusive Framework has agreed on a global minimum corporate tax rate of 15% for companies with revenue above &#x20ac;750 million, calculated on a country-by-country basis. On October 30, 2021, the G20 formally endorsed the new global minimum corporate tax rate rules. The Inclusive Framework agreement must now be implemented by the OECD Members who have agreed to the plan, effective in 2023. On December 20, 2021, the OECD published model rules to implement the pillar two rules, which are generally consistent with agreements reached by the Inclusive Framework in October 2021. Some further guidance on the plan and rules has been published, with additional guidance expected to be published in 2023. The Company will continue to monitor the implementation of the Inclusive Framework agreement by the countries in which we operate. While the Company is unable to predict when and how the Inclusive Framework agreement will be enacted into law in these countries, it is possible that the implementation of the Inclusive Framework agreement, including the global minimum corporate tax rate could have a material effect on the Company&#x2019;s liability for corporate taxes and the Company&#x2019;s consolidated effective tax rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2022 and December&#160;31, 2021, the Company had $840 million and $927 million of unrecognized tax benefits, which included $44 million and $41 million of interest and penalties, respectively. Of the total unrecognized tax benefits as of June&#160;30, 2022, $179 million would reduce the Company&#x2019;s effective tax rate, if recognized. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits at June&#160;30, 2022 could decrease by approximately $14 million in the next 12 months as a result of the resolution of certain tax audits and other events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to be under examination by the Canada Revenue Agency. The Company&#x2019;s position as of June&#160;30, 2022 with regard to proposed audit adjustments was updated to reflect an updated assessment received for 2015 which would primarily result in a loss of tax attributes that are subject to a full valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, the Company undertook an internal restructuring in the form of what is commonly known as a Granite Trust transaction, which resulted in a recorded capital loss (the &#x201c;2017 capital loss&#x201d;). In the U.S., the 2014 tax year remains open to the extent of the portion of the 2017 capital loss carried back to that year. The Internal Revenue Service (&#x201c;IRS&#x201d;) is continuing its examination of the Company&#x2019;s annual tax filings for 2015 and 2016 and the Company&#x2019;s short period tax return for the period ended September 8, 2017, which was filed as a result of the Company&#x2019;s internal restructuring efforts during 2017. In 2021, the Company received a notice of proposed adjustment from the IRS that would disallow the 2017 capital loss. The Company intends to contest any proposed tax deficiency through the IRS administrative appeals process, and if necessary, appropriate litigation. If the Company were ultimately unsuccessful in defending its position, and all or a substantial portion of the 2017 capital loss deduction were disallowed, the Company estimates, in a worst-case scenario, that it could be liable for additional income taxes (excluding penalties and interest) of up to $2,100&#160;million, which could have an adverse effect on the Company&#x2019;s financial condition and results of operations. The Company intends to vigorously defend its position, including through appropriate litigation, if necessary, and ultimately believes it will sustain its deduction of the 2017 capital loss, and, accordingly, no income tax provision has been recorded. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2015 through 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s subsidiaries in Germany are under audit for tax years 2014 through 2016. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#x2019;s Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company settled its audit with the Australian Taxation Office for various years beginning in 2011 through 2017 with no material adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain affiliates of the Company in regions outside of Canada, the U.S., Germany and Australia are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#x2019;s Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfNzA2_416f30b3-9a64-4644-a285-a8b8bba4ace0"
      unitRef="usd">-6000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfNzI3_f8ccd1ef-6be3-45a8-9c92-1bb29e3709a3"
      unitRef="usd">16000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfODA0_9618e443-288a-4f92-973b-67f7ea9af17d"
      unitRef="usd">-22000000</bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfODcz_08432671-2606-476b-bc66-af4eeb890c26"
      unitRef="usd">-39000000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <bhc:EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfOTc3_939d8797-e807-4e87-9b3b-7784bd3b2957"
      unitRef="usd">16000000</bhc:EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfMTA2OQ_13d3a34e-9e11-4829-83ec-d9a6b17f2c12"
      unitRef="usd">-61000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfMTA5MA_e6a0e4f3-1c26-414b-a786-4b2f2fcb93f4"
      unitRef="usd">-50000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfNDM5ODA0NjUxOTY5Nw_7a3ba589-ece2-43b3-b96f-aa2b00611b5a"
      unitRef="usd">11000000</bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount>
    <bhc:EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfMTE2Mw_d211c3ec-e361-42cf-b9d1-9b59da299fa0"
      unitRef="usd">-54000000</bhc:EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount>
    <bhc:EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfNDM5ODA0NjUxOTcxMA_71af2cff-0adf-4c6d-ad69-4b500d9fb526"
      unitRef="usd">46000000</bhc:EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfMTI2NQ_73936c75-0377-4e97-bed1-95cd97186285"
      unitRef="usd">-7000000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <bhc:EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfNDM5ODA0NjUxOTcyMw_74780f33-7c3e-4645-a28c-d2653492ff7b"
      unitRef="usd">4000000</bhc:EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfMjIyOQ_ccea87ff-d07f-4ddd-8f25-a3c98a1ded68"
      unitRef="usd">2277000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfMjIzNg_77fc97e6-9571-42d3-8331-439ecb27dad3"
      unitRef="usd">2222000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfNDMwMQ_c949fd5e-7b2d-41ab-89db-452eb2518add"
      unitRef="usd">840000000</bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties>
    <bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfNDMwOA_3b9ea76a-54b9-4dae-9edf-8b1a93514c60"
      unitRef="usd">927000000</bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfNDM1Ng_6457c059-7e04-4daf-9d4d-9912fd76ffe0"
      unitRef="usd">44000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i318a5014ae1e41d09bf1de7db3ca0828_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfNDM2Mw_ddc03417-4529-4fcf-9f28-c7a732905909"
      unitRef="usd">41000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfNDQ1Ng_d3d07bb1-8c8c-462a-a014-b1385f6cad20"
      unitRef="usd">179000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfNDY2Mg_6ef876a2-6466-4ae2-896e-1cd2a3e8736d"
      unitRef="usd">14000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV84OC9mcmFnOmFiMzJiMDNlNjliMzRkNDY4NTQwOTZmZTNhYTdhYTE4L3RleHRyZWdpb246YWIzMmIwM2U2OWIzNGQ0Njg1NDA5NmZlM2FhN2FhMThfNjM4Ng_964e858b-ae12-44a9-9fda-2e9dc8d78ff6"
      unitRef="usd">2100000000</us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RleHRyZWdpb246MzU4MWUyYzAzNWE5NDVmOGFkNDJhZGIwMTc4MTAwNGNfOTY0_1d2a2287-7033-48e9-b56e-0d7456270ab0">LOSS PER SHARE&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per share attributable to Bausch Health Companies Inc. were calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted loss per share attributable to Bausch Health&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Companies Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June 30, 2022 and 2021, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately 1,184,000 and 4,558,000 common shares for the three months ended June 30, 2022 and 2021, respectively, and approximately 2,392,000 and 5,608,000 common shares for the six months ended June 30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;During the three and six months ended June 30, 2022, time-based RSUs, performance-based RSUs and stock options to purchase approximately 15,372,000 and 13,771,000 common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During the three and six months ended June 30, 2021, time-based RSUs, performance-based RSUs and stock options to purchase approximately 3,929,000 and 4,110,000 common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During the three months ended June 30, 2022, an additional 156,000 performance-based RSUs were not included in the computation of diluted earnings per share as the required performance conditions had not been met.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RleHRyZWdpb246MzU4MWUyYzAzNWE5NDVmOGFkNDJhZGIwMTc4MTAwNGNfOTYx_8f2460d7-6714-4339-a3ad-6ac59216dd9b">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per share attributable to Bausch Health Companies Inc. were calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted loss per share attributable to Bausch Health&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Companies Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfMi0xLTEtMS0xMTY3NzE_fdcb755b-b8d7-43eb-afb3-5324abaf372b"
      unitRef="usd">-145000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfMi0zLTEtMS0xMTY3NzE_6ec4e541-60ea-47a2-9ee6-91260de85c51"
      unitRef="usd">-595000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfMi01LTEtMS0xMTY3NzE_b62f4ba4-306b-4bc2-8d47-76dd85df3344"
      unitRef="usd">-214000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="ia4bd722a099c434c96732e1638d0eef9_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfMi03LTEtMS0xMTY3NzE_39538422-44d3-4314-bf14-91c29e1af5ed"
      unitRef="usd">-1205000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfMi03LTEtMS0xMTY3NzE_ce9cc730-46dc-4484-b836-fab046e2159f"
      unitRef="usd">-1205000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfMy0xLTEtMS0xMTY3NzE_3d856aa6-170a-4ffe-b302-9769db5dfec9"
      unitRef="shares">362200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfMy0xLTEtMS0xMTY3NzE_9641a01e-051d-4ebe-86b5-6c7e5d9b8a5e"
      unitRef="shares">362200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfMy0zLTEtMS0xMTY3NzE_0e735f3f-38c7-4f88-982d-c539356f7eeb"
      unitRef="shares">359100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfMy0zLTEtMS0xMTY3NzE_55194c8f-ea06-4c98-9298-a7f78d9f03c4"
      unitRef="shares">359100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfMy01LTEtMS0xMTY3NzE_1189b2fe-8ce8-4805-83e9-4426af4badf4"
      unitRef="shares">361500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfMy01LTEtMS0xMTY3NzE_50c56646-02e7-4ac0-a842-c089656bec94"
      unitRef="shares">361500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfMy03LTEtMS0xMTY3NzE_7bad3fef-e6f1-4b42-945d-48da57025ff2"
      unitRef="shares">358000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfMy03LTEtMS0xMTY3NzE_d87b09cc-e1da-4796-9cc5-866df4e19191"
      unitRef="shares">358000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfNy0xLTEtMS0xMTY3NzE_265ff4c3-528e-46a9-825e-7224c3c45718"
      unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfNy0xLTEtMS0xMTY3NzE_9cb90fc5-b0ab-44c2-bd7a-caeeb5a4b82f"
      unitRef="usdPerShare">-0.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfNy0zLTEtMS0xMTY3NzE_2cdeda4b-46b6-4bef-a17a-7faac1a766ff"
      unitRef="usdPerShare">-1.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfNy0zLTEtMS0xMTY3NzE_4f6e992a-5796-469f-8860-200a94372aa2"
      unitRef="usdPerShare">-1.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfNy01LTEtMS0xMTY3NzE_04b936c4-5ce7-4780-aae9-48ca049ea687"
      unitRef="usdPerShare">-0.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfNy01LTEtMS0xMTY3NzE_ec2ad1d5-0e9f-4569-a10e-d11f55843f6c"
      unitRef="usdPerShare">-0.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfNy03LTEtMS0xMTY3NzE_0365dda3-80f9-4b69-9099-b0f4ad685600"
      unitRef="usdPerShare">-3.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RhYmxlOmRkNjYwZGZkNGViZjQ0YTg4MWI2MTgwMTk2M2U3MDJjL3RhYmxlcmFuZ2U6ZGQ2NjBkZmQ0ZWJmNDRhODgxYjYxODAxOTYzZTcwMmNfNy03LTEtMS0xMTY3NzE_53ac96a1-7d4f-4861-99f2-521b57f21ebc"
      unitRef="usdPerShare">-3.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib67e20cff1f34666a7bda60fe85e0092_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RleHRyZWdpb246MzU4MWUyYzAzNWE5NDVmOGFkNDJhZGIwMTc4MTAwNGNfNDMx_962f85b0-7352-4d34-9737-0b51cf0b0272"
      unitRef="shares">1184000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icb9c38f8768a42babfa04ab70b2ba49b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RleHRyZWdpb246MzU4MWUyYzAzNWE5NDVmOGFkNDJhZGIwMTc4MTAwNGNfNDM4_1b784ce0-620a-4c94-b153-a6c0acf95931"
      unitRef="shares">4558000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7c6c606001c0400cac53065471f71ff1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RleHRyZWdpb246MzU4MWUyYzAzNWE5NDVmOGFkNDJhZGIwMTc4MTAwNGNfNzE0NjgyNTU4MTY2Nw_149401fe-6d1f-46b0-af44-8327c954a5e1"
      unitRef="shares">2392000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib34295b40b53420292196a9f2aa2100a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RleHRyZWdpb246MzU4MWUyYzAzNWE5NDVmOGFkNDJhZGIwMTc4MTAwNGNfNzE0NjgyNTU4MTY1MA_2e3d3e63-6795-4451-b89f-528682e52cb8"
      unitRef="shares">5608000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib34421622cb84c04846df6c8e22ebbed_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RleHRyZWdpb246MzU4MWUyYzAzNWE5NDVmOGFkNDJhZGIwMTc4MTAwNGNfNTgw_1d9f66e9-f4d7-4542-a4ce-1d5d9465f31b"
      unitRef="shares">15372000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3b78053555ef422d9b068388d75f6068_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RleHRyZWdpb246MzU4MWUyYzAzNWE5NDVmOGFkNDJhZGIwMTc4MTAwNGNfNTg3_4f7cce33-636f-48e3-b76d-69a24f7f0e61"
      unitRef="shares">13771000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5d86e8e57d7e44a4bdcd3c9f0a800e7d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RleHRyZWdpb246MzU4MWUyYzAzNWE5NDVmOGFkNDJhZGIwMTc4MTAwNGNfNzE0NjgyNTU4MjA4Mw_8bb48755-4dfe-4db1-ad82-1968133fee20"
      unitRef="shares">3929000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if9065eee32f34d6fa02a0d1a52cb32c9_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RleHRyZWdpb246MzU4MWUyYzAzNWE5NDVmOGFkNDJhZGIwMTc4MTAwNGNfNzE0NjgyNTU4MjEwOQ_c55abcbc-2e90-4e6d-84f8-1448ab299929"
      unitRef="shares">4110000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount
      contextRef="ie62c44e3a5424b748e2e6a9534f2057c_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RleHRyZWdpb246MzU4MWUyYzAzNWE5NDVmOGFkNDJhZGIwMTc4MTAwNGNfNzk3_265b33bc-ddcf-458b-b81f-c39824d787fd"
      unitRef="shares">156000</bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount>
    <bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount
      contextRef="ie62c44e3a5424b748e2e6a9534f2057c_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85MS9mcmFnOjM1ODFlMmMwMzVhOTQ1ZjhhZDQyYWRiMDE3ODEwMDRjL3RleHRyZWdpb246MzU4MWUyYzAzNWE5NDVmOGFkNDJhZGIwMTc4MTAwNGNfNzk3_ea6fd886-f28e-4256-afc9-244ea2bf6738"
      unitRef="shares">156000</bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNTM4NzA_c178d63d-4e48-4459-bdfd-08f4f1458956">LEGAL PROCEEDINGS&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described in Note 20, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company&#x2019;s Consolidated Financial Statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC and the CSA on February 23, 2022. Except as described below, there have been no material updates or developments with respect to any such proceedings or actions during the six months ended June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued. As of June 30, 2022, the Company&#x2019;s Consolidated Balance Sheets includes accrued current loss contingencies of $1,536 million related to matters which are both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company&#x2019;s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Governmental and Regulatory Inquiries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As referenced above, during the three months ended June 30, 2022, there have been no material updates or developments with respect to certain other proceedings or actions as described under &#x201c;Governmental and Regulatory Inquiries&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Note 20, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company&#x2019;s Consolidated Financial Statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC and the CSA on February 23, 2022. These matters include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investigation by the U.S. Attorney&#x2019;s Office for the District of Massachusetts - re OraPharma&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Company received a subpoena from the U.S. Attorney&#x2019;s Office for the District of Massachusetts, requesting materials including documents concerning the sales, marketing, coverage and reimbursement of Arestin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, including related support services, and other matters. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is cooperating with this investigation. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Securities and RICO Class Actions and Related Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. Securities Litigation - Opt-Out Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658). On January 31, 2021, the District Court issued an order granting final approval of this settlement. On February 4, 2021, Timber Hill LLC (&#x201c;Timber Hill&#x201d;) filed a notice of appeal of the Court&#x2019;s final approval order, which overruled its objections to the allocation of settlement proceeds as between common stock and options. On March 1, 2021, Cathy Lochridge filed a notice of appeal of the Court&#x2019;s final approval order, which overruled her objections as to the attorneys&#x2019; fees awarded to class counsel. On October 14, 2021, Timber Hill dismissed its appeal of the final approval order. On December 20, 2021, the Third Circuit denied Lochridge&#x2019;s appeal. On January 3, 2022, Lochridge filed a petition for rehearing of the appeal en banc. On May 12, 2022, the Third Circuit denied Lochridge&#x2019;s petition for rehearing en banc. The deadline for Lochridge to file a petition for a writ of certiorari with the U.S. Supreme Court is August 10, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2015, four putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#x2019;s business and prospects, including relating to drug pricing, the Company&#x2019;s use of specialty pharmacies, and the Company&#x2019;s relationship with Philidor Rx Services, LLC (&#x201c;Philidor&#x201d;). On May 31, 2016, the court entered an order consolidating the four actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658. On December 16, 2019, the Company, the current or former officers and directors, ValueAct, and the underwriters announced that they agreed to resolve the securities action for $1,210 million, subject to final court approval. This settlement received final approval from the court on January 31, 2021 and will resolve and discharge all claims against the Company in the class action. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. The settlement remains subject to appeal of the final court approval (as such appeal is further described above). In order to qualify for a settlement payment all persons and entities that purchased or otherwise acquired the Company securities during the class period must have submitted a proof of claim and release form by May 6, 2020. The settlement payments have been paid into an escrow account in accordance with the payment schedule outlined in the settlement agreement. These payments, less certain settlement expenses and attorneys&#x2019; fees, will remain in escrow until resolution of the appeal of the final court approval of the settlement agreement. The opt-out litigations discussed below remain ongoing. As of June 30, 2022, Restricted cash and other settlement deposits includes an aggregate $1,210&#160;million of: (i) payments in the escrow fund and (ii) certain disbursements for settlement expenses and attorney&#x2019;s fees. Disbursements for attorney&#x2019;s fees remain refundable until resolution of the appeal of the final court approval of the settlement agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 18-cv-10246), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company&#x2019;s common stock during the period January 4, 2013 through August 11, 2016. On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 15-cv-07658). On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the consolidated putative class action, thirty-seven groups of individual investors in the Company&#x2019;s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. These actions were captioned previously in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on February 23, 2022. Sixteen of the thirty-seven opt-out actions have been dismissed; and the total number of remaining opt-out actions pending in the District of New Jersey is twenty-one actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These individual shareholder actions assert claims under Sections 10(b), and 20(a) of the Exchange Act. Certain of these individual actions assert additional claims, including claims under Section 18 of the Exchange Act, Sections 11, 12(a)(2), and 15 of the Securities Act, common law fraud, negligent misrepresentation, and claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act. These claims are based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss were filed in many of these individual actions and the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud, and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) opt-out action, closing the case. On September 10, 2019, the Court granted defendants&#x2019; motion to dismiss all claims in the Bahaa Aly v. Valeant Pharmaceuticals International, Inc. (&#x201c;Aly&#x201d;) (Case No. 18-cv-17393) opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. On June 16, 2021, the Court of Appeals granted plaintiffs&#x2019; appeal in the Aly action. This action has been remanded to the District Court. On June 19, 2020, the Court entered stipulations of voluntary dismissal in the Catalyst, Mississippi, Connecticut, and Delaware actions. On July 13, 2020, the Court entered a stipulation of voluntary dismissal in the NYCERS action. On December 30, 2020, the Court entered a stipulation of voluntary dismissal in the BlueMountain action. On February 18, 2021, and March 10, 2021, the Court entered stipulations of voluntary dismissal in the T. Rowe, BloombergSen, Principal Funds, Pentwater, Lord Abbett, Equity Trustees, and UC Regents actions. On April 30, 2021, the Court entered a stipulation of voluntary dismissal in the Florida SBA action. On July 20, 2021, the Court entered a stipulation of voluntary dismissal in the Janus action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discovery in the opt-out actions has concluded. Motions for summary judgment were filed on August 1, 2022 but have not yet been fully briefed. Trial dates have not been set in any of the opt-out actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disputes the claims against it in the remaining individual opt-out complaints and intends to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Canadian Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, six putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec. The Company is also aware of two additional putative class actions that were filed with the applicable court but which have not been served on the Company and the factual allegations made in these actions are substantially similar to those outlined herein. These actions were captioned previously in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021, filed on February 23, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each of these putative class actions, other than the Catucci action in the Quebec Superior Court, was discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec Securities Act and authorized the class proceeding. On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After a hearing on November 11, 2019, the court approved a settlement in the Catucci action between the class members and the Company&#x2019;s auditors and the action was dismissed as against them. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 4, 2020, the Company entered into a settlement agreement with the plaintiffs in Catucci, on behalf of the class, pursuant to which it agreed to resolve the Catucci action for the amount of CAD 94,000,000 plus payment of an additional amount to cover notice and settlement administration costs and disbursements. As part of the settlement, the Company and the other defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. Court approval of the settlement was granted after a hearing on November 16, 2020. The Catucci action has now been dismissed against the Company, its current and former directors and officers, its underwriters and its insurers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action. On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, one of the entities which exercised its opt-out rights, the California State Teachers&#x2019; Retirement System (&#x201c;CalSTRS&#x201d;), served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers&#x2019; Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt-out proceedings. On that same date, CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 3, 2020, the Quebec Superior Court granted the applications of CalSTRS and BlackRock for leave to pursue their respective actions asserting claims under the Quebec Securities Act. On June 16, 2020, the Quebec Court of Appeal granted the defendants leave to appeal that decision. The appeal was heard on September 29, 2021 and, by judgment dated October 29, 2021, the appeals were dismissed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 8 and 9, 2020, respectively, CalSTRS amended its proceedings to, among other things, include a new alleged misrepresentation concerning the accounting treatment of &#x201c;price appreciation credits&#x201d; in respect of Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; during the period covered by the claims. A hearing was held on February 17, 2021 with respect to whether CalSTRS would be permitted to file the proposed amended proceedings.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 9, 2021, the Quebec Superior Court granted the Company&#x2019;s application to strike the new allegations from its Quebec Securities Act claim, but permitted the amendments to its claim under the Quebec Civil Code. On December 8, 2021, CalSTRS delivered its amended pleadings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 17, 2021, four additional opt-outs from the Catucci class issued a Statement of Claim in the Ontario Superior Court of Justice. That proceeding is captioned The Bank of Korea et al. v. Valeant Pharmaceuticals International Inc. et al. (Court File No. 21-006589666-0000). In addition, these plaintiffs also served and filed a motion for leave to pursue claims under the Ontario Securities Act. The allegations in this proceeding are similar to those made by the plaintiffs in the Catucci class action and the plaintiffs in the opt-out actions described above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Securities and RICO Class Actions and Related Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As referenced above, during the three months ended June 30, 2022, there have been no material updates or developments with respect to certain other proceedings or actions as described under &#x201c;Securities and RICO Class Actions and Related Matters&#x201d; in Note 20, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company&#x2019;s Consolidated Financial Statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC and the CSA on February 23, 2022. Such matters include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RICO Class Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between May 27, 2016 and September 16, 2016, three actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties (these actions were subsequently consolidated), alleging claims under the federal Racketeer Influenced Corrupt Organizations Act (&#x201c;RICO&#x201d;) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company-branded drugs between January 2, 2013 and November 9, 2015.&#160;The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding: (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured&#x2019;s consent to renew the prescription.&#160;The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute.&#160;On August 4, 2021, the Company executed a stipulation of settlement for this action and, on August 17, 2021, the Court preliminarily approved the settlement. On December 6, 2021 the Special Master overseeing this litigation issued a report and recommendation recommending final approval of the settlement, and on February 22, 2022 the settlement was approved by the district court. The time to appeal the district court&#x2019;s final approval order expired on March 24, 2022, and the settlement has resolved and discharged all claims against the Company in this action. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Insurance Coverage Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during two distinct policy periods, (i) 2013-14 and (ii) 2015-16. The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; Case No. 3:18-CV-00493). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the lawsuit, the Company seeks coverage for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (the &#x201c;Allergan Securities Litigation&#x201d;) (under the 2013-2014 coverage period) and (ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and the SEC Investigation and certain of the other investigations described under &#x201c;Complete or Inactive Matters&#x201d; in Note 20, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company&#x2019;s Consolidated Financial Statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021 and under &#x201c;Governmental and Regulatory Inquiries&#x201d; and &#x201c;Complete or Inactive Matters&#x201d; in Note 21, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company&#x2019;s Consolidated Financial Statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC and the CSA on February 19, 2020 (under the 2015-2016 coverage period).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 20, 2021, the Company entered into settlement agreements with the insurers in the 2015-2016 coverage period in which the Company agreed to resolve its claims for insurance coverage in connection with the U.S. Securities Litigation and the Canadian Securities Litigation and related opt-out litigation and related investigations matters described above. On that same day, the Company entered into settlement agreements with two of its insurers in the 2013-2014 coverage period in which the Company agreed to resolve its claims against those two insurers only for insurance coverage in connection with the Allergan Securities Litigation. As a result of all of the settlement agreements entered into with the insurers on July 20, 2021, the Company has received an aggregate sum of $213&#160;million. The Company&#x2019;s insurance claims with respect to the Allergan Securities Litigation against the remaining insurers in the 2013-2014 coverage period remain pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Hound Partners Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP, and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County that asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. The Company disputes the claims and intends to vigorously defend this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Antitrust&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Glumetza Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between August 2019 and July 2020, eight (8) putative antitrust class actions and four (4) non-class complaints naming the Company, Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., and Santarus, Inc. (for purposes of this subsection, collectively, the &#x201c;Company&#x201d;), among other defendants, were filed or transferred to the Northern District of California. Three (3) of the class actions were filed by plaintiffs seeking to represent a class of direct purchasers. The purported classes of direct purchasers filed a consolidated first amended complaint and a motion for class certification in April 2020. The court certified a direct purchaser class in August 2020. The putative class action complaints filed by end payer purchasers have all been voluntarily dismissed. Three (3) of the non-class complaints were filed by direct purchasers. The fourth non-class complaint, asserting claims based on both direct and indirect purchases, was filed by an insurer plaintiff in July 2020 and subsequently amended in September 2020. In December 2020, the court denied the Company&#x2019;s motion to dismiss as to the insurer plaintiff&#x2019;s direct claims but dismissed the insurer plaintiff&#x2019;s indirect claims. On February 2, 2021, the insurer plaintiff&#x2019;s motion for leave to amend its complaint was denied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These actions were consolidated and coordinated in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 3:19-cv-05822-WHA (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;). The lawsuits alleged that a 2012 settlement of a patent litigation regarding Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or grant any other company a license to do so. The complaints alleged that the settlement agreement resulted in higher prices for Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and its generic equivalent both prior to and after generic entry. Both the class and non-class plaintiffs sought damages under federal antitrust laws for claims based on direct purchases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 8, 2021, the insurer plaintiff filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#x201c;State Court Action&#x201d;) (discussed in further detail below, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;see Glumetza State-Law Insurer Litigations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). Defendants&#x2019; demurrer in the State Court Action was heard on September 22, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 26, 2021, the Company reached an agreement in principle and, thereafter, on September 14, 2021, executed a final settlement agreement to resolve the class plaintiffs&#x2019; claims for $300&#160;million, subject to court approval. On August 1, 2021, the Company also reached an agreement in principle to resolve the non-class direct purchaser plaintiffs&#x2019; claims, described above, for additional consideration. A final settlement agreement with the non-class direct purchaser plaintiffs was executed on August 6, 2021. As part of the settlements, the Company admitted no liability as to the claims against it and denied all allegations of wrongdoing. On September 20, 2021, the insurer plaintiff voluntarily dismissed its claims in the consolidated &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;federal action. By stipulation, the insurer plaintiff has asserted its direct opt-out claims in the State Court Action, resulting in the consolidation of all of its opt-out claims in the State Court Action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 22, 2021, the court granted preliminary approval of the class settlement agreement and vacated the October 2021 trial date and all other pre-trial deadlines in the consolidated actions. On February 3, 2022, the court granted final approval of the class settlement and ordered dismissal of the class plaintiffs&#x2019; claims. The deadline to appeal the final approval of the class settlement has now passed, and the settlements have resolved and discharged all asserted class and direct purchaser non-class claims against the Company in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Generic Pricing Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s subsidiaries, Oceanside Pharmaceuticals, Inc. (&#x201c;Oceanside&#x201d;), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (&#x201c;Bausch Health US&#x201d;), and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (&#x201c;Bausch Health Americas&#x201d;) (for the purposes of this paragraph, collectively, the &#x201c;Company&#x201d;), are defendants in multidistrict antitrust litigation (&#x201c;MDL&#x201d;) entitled In re: Generic Pharmaceuticals Pricing Antitrust Litigation, pending in the United States District Court for the Eastern District of Pennsylvania (MDL 2724, 16- MD-2724). The lawsuits seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company&#x2019;s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals. The lawsuits, which have been brought as putative class actions by direct purchasers, end payers, and indirect resellers, and as direct actions by direct purchasers, end payers, insurers, States, and various Counties, Cities, and Towns, have been consolidated into the MDL. There are also additional, separate complaints which have been consolidated in the same MDL that do not name the Company or any of its subsidiaries as a defendant. There are cases pending in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed in the cases. The cases have been placed in deferred status. The Company disputes the claims against it and continues to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, Bausch Health Companies Inc. and certain U.S. and Canadian subsidiaries (for the purposes of this paragraph, collectively the &#x201c;Company&#x201d;) have been named as defendants in a proposed class proceeding entitled Kathryn Eaton v. Teva Canada Limited, et al. in the Federal Court in Toronto, Ontario, Canada (Court File No. T-607-20). The plaintiff seeks to certify a proposed class action on behalf of persons in Canada who purchased generic drugs in the private sector, alleging that the Company and other defendants violated the Competition Act by conspiring to allocate the market, fix prices, and maintain the supply of generic drugs, and seeking damages under federal law. The proposed class action contains similar allegations to the In re: Generic Pharmaceuticals Pricing Antitrust Litigation pending in the United States Court for the Eastern District of Pennsylvania. The Company disputes the claims against it and intends to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These lawsuits cover products of both Bausch + Lomb and the Company&#x2019;s businesses. It is anticipated that Bausch + Lomb and the Company will split the fees and expenses associated with defending these claims, as well as any potential damages or other liabilities awarded in or otherwise arising from these claims, in the manner set forth in the Master Separation Agreement between Bausch Health and Bausch + Lomb.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Glumetza State-Law Insurer Litigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 8, 2021, the insurer plaintiff from the federal &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 3:19-cv-05822- WHA (N.D. Cal.) (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) (discussed in further detail above) filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#x201c;State Court Action&#x201d;). The State Court Action alleges that a 2012 settlement of a patent litigation regarding Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or grant any other company a license to do so. The State Court Action alleges that the settlement agreement resulted in higher prices for Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and its generic equivalent both prior to and after generic entry. On September 20, 2021, the parties stipulated that the insurer plaintiff&#x2019;s direct opt-out claims from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, discussed above, were deemed asserted in the State Court Action. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defendants&#x2019; demurrer in the State Court Action was heard on September 22, 2021. On November 29, 2021, the court denied the motion in part and granted it in part as to certain state law claims, with leave to amend. The insurer plaintiff did not amend the complaint. Defendants&#x2019; answers were filed on February 3, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On April 5, 2022, Health Care Service Corporation filed an action with similar substantive allegations and similar indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others. Defendants&#x2019; answers were filed on June 17, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disputes the claims and intends to vigorously defend these matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intellectual Property&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patent Litigation/Paragraph IV Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company (and/or certain of its affiliates) is also party to certain patent infringement proceedings in the United States and Canada, including as arising from claims filed by the Company (or that the Company anticipates filing within the required time periods) in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers respecting their pending applications for generic versions of certain products sold by or on behalf of the Company, including Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 550mg, Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Relistor&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Injection, Arazlo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and Nuvessa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States and Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in Canada, or other similar suits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 17, 2020, the Company and Alfasigma S.p.A. (&#x201c;Alfasigma&#x201d;) received a Notice of Paragraph IV Certification from Norwich Pharmaceuticals Inc. (&#x201c;Norwich&#x201d;), in which Norwich asserted that the U.S. patents listed in the FDA&#x2019;s Orange Book for the Company&#x2019;s Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Norwich&#x2019;s generic rifaximin tablets, 550 mg, for which an Abbreviated New Drug Application (&#x201c;ANDA&#x201d;) has been filed by Norwich. The Company, through its subsidiaries Salix Pharmaceuticals, Inc. and Bausch Health Ireland Limited, holds the New Drug Application for Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and owns or exclusively licenses (from Alfasigma) these patents.&#160;On March 26, 2020, certain of the Company&#x2019;s subsidiaries and Alfasigma filed suit against Norwich in the U.S. District Court for the District of Delaware (Case No. 20-cv-00430) pursuant to the Hatch-Waxman Act, alleging infringement by Norwich of one or more claims of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patents, thereby triggering a 30-month stay of the approval of Norwich&#x2019;s ANDA for rifaximin tablets, 550 mg. Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is protected by 26 patents covering the composition of matter and the use of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; listed in the FDA&#x2019;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange&#160;Book. Trial in this matter was held in March 2022. The court issued an Oral Order on July 28, 2022 indicating that the court will find certain U.S. Patents protecting the use of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (rifaximin) 550 mg tablets for the reduction in risk of hepatic encephalopathy (&#x201c;HE&#x201d;) recurrence valid and infringed and U.S. Patents protecting the composition, and use of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for treating inflammatory bowel syndrome with diarrhea (&#x201c;IBS-D&#x201d;) invalid (the &#x201c;Norwich Legal Decision&#x201d;). The Company remains confident in the strength of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents and intends to appeal the court&#x2019;s decision and vigorously defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (now Padagis LLC) (&#x201c;Padagis&#x201d;), in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#x2019;s Orange Book for Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate and tazarotene) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#x2019; generic lotion, for which an ANDA has been filed by Padagis. On August 28, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described below, regarding Padagis&#x2019; ANDA for generic Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate) lotion. The court scheduled a trial to begin on October 4, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Company received a Notice of Paragraph IV Certification from Taro Pharmaceuticals Inc. (&#x201c;Taro&#x201d;), in which Taro asserted that certain U.S. patents, each of which is listed in the FDA&#x2019;s Orange Book for Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate and tazarotene) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use, sale, offer for sale, or importation of Taro&#x2019;s generic lotion, for which an ANDA has been filed by Taro. On July 21, 2022, the Company filed suit against Taro pursuant to the Hatch-Waxman Act, alleging infringement by Taro of one or more claims of the Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patents and triggering a 30-month stay of the approval of the Taro ANDA. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company remains confident in the strength of the Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents and intends to vigorously defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Padagis, in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#x2019;s Orange Book for Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#x2019; generic halobetasol propionate lotion, for which an ANDA has been filed by Padagis. On May 1, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA for halobetasol propionate lotion. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described above, regarding Padagis&#x2019; ANDA for generic Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate and tazarotene) lotion. The court scheduled a trial to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;begin on October 4, 2022. The Company remains confident in the strength of the Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents and intends to vigorously pursue this matter and defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Company commenced litigation against MSN Laboratories Private Ltd. (&#x201c;MSN&#x201d;) and Mylan Pharmaceuticals Inc., (&#x201c;Mylan&#x201d;) alleging patent infringement by MSN&#x2019;s and Mylan&#x2019;s filing of their ANDA for generic Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (plecanatide) 3mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from each of MSN and Mylan, in which they had each asserted that the U.S. patents listed in the FDA&#x2019;s Orange Book for the Company&#x2019;s Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; tablets, 3 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of their respective generic plecanatide tablets, 3 mg. The filing of these suits triggered a 30-month stay of the approval of the MSN and Mylan ANDAs for plecanatide tablets. The Company remains confident in the strength of the Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents and intends to vigorously pursue this matter and defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;PreserVision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; AREDS Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PreserVision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; AREDS and PreserVision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; AREDS 2 are over the counter eye vitamin formulas for those with moderate-to-advanced age-related degeneration (&#x201c;AMD&#x201d;). The PreserVision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; U.S. formulation patent expired in March 2021, but a patent covering methods of using the formulation remains in force into 2026. Bausch + Lomb Incorporated (&#x201c;B&amp;amp;L Inc.&#x201d;) has filed patent infringement proceedings against 16 defendants claiming infringement of these patents and, in certain circumstances, related unfair competition and false advertising causes of action. Twelve of these proceedings were subsequently settled; two resulted in a default. One defendant filed a declaratory judgment action after B&amp;amp;L Inc. filed its suit, seeking declaratory judgment related to patent claims as well as false advertising and unfair competition claims. As of the date of this filing, there are two ongoing actions: (1) Bausch &amp;amp; Lomb Inc. &amp;amp; PF Consumer Healthcare 1 LLC v. ZeaVision LLC, C.A. No. 6:20-cv-06452-CJS (W.D.N.Y.); and (2) Bausch &amp;amp; Lomb Inc. &amp;amp; PF Consumer Healthcare 1 LLC v. SBH Holdings LLC, C.A. No. 20-cv-01463-VAC-CJB (D. Del.). Bausch + Lomb remains confident in the strength of these patents and B&amp;amp;L Inc. intends to continue to vigorously pursue these matters and defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patent Litigation against Certain Ocuvite and PreserVision &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 22, 2021, ZeaVision, LLC (&#x201c;ZeaVision&#x201d;) filed a complaint for patent infringement against certain of the Ocuvite&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and PreserVision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products in the Eastern District of Missouri (Case No. 4:21-cv-00739-RWS). On June 29, 2021, ZeaVision amended its complaint to assert a second patent against certain of the Ocuvite&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and PreserVision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products. On November 16, 2021, ZeaVision filed an additional complaint for patent infringement to assert a third patent against certain of the PreserVision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products (Case No. 4:21-cv-01352-RWS). On March 1, 2022, the cases were consolidated. On March 10, 2022, the court granted Bausch + Lomb&#x2019;s motion to stay all proceedings pending inter partes review. On July 1, 2022, ZeaVision filed a motion to partially lift the stay to allow Case No. 4:21-cv-01352-RWS to proceed, and Bausch + Lomb opposed the motion. The Company disputes the claims and intends to vigorously defend this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 16, 2021, B&amp;amp;L Inc. received a Notice of Paragraph IV Certification from Slayback Pharma LLC (&#x201c;Slayback&#x201d;), in which Slayback asserted that certain U.S. patents, each of which is listed in the FDA&#x2019;s Orange Book for Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (brimonidine tartrate solution) drops (the &#x201c;Lumify Patents&#x201d;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Slayback&#x2019;s generic drops, for which an ANDA has been filed by Slayback. B&amp;amp;L Inc., through its affiliate Bausch + Lomb Ireland Limited, exclusively licenses the Lumify Patents from Eye Therapies, LLC (&#x201c;Eye Therapies&#x201d;). On September 10, 2021, B&amp;amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Slayback pursuant to the Hatch-Waxman Act, alleging infringement by Slayback of one or more claims of the Lumify Patents, thereby triggering a 30-month stay of the approval of the Slayback ANDA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 20, 2022, B&amp;amp;L Inc. received a Notice of Paragraph IV Certification from Lupin Ltd. (&#x201c;Lupin&#x201d;), in which Lupin asserted that certain U.S. patents, each of which is listed in the FDA&#x2019;s Orange Book for Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (brimonidine tartrate solution) drops (the &#x201c;Lumify Patents&#x201d;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Lupin&#x2019;s generic brimonidine tartrate solution, for which its ANDA No. 216716 has been filed by Lupin. On February 2, 2022, B&amp;amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Lupin pursuant to the Hatch-Waxman Act, alleging patent infringement by Lupin of one or more claims of the Lumify Patents, thereby triggering a 30-month stay of the approval of the Lupin ANDA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;B&amp;amp;L Inc. remains confident in the strength of the Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related patents and B&amp;amp;L Inc. intends to vigorously defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Parties Review Proceedings at the U.S. Patent and Trademark Office&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, patents covering the Company&#x2019;s branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review (&#x201c;IPR&#x201d;) at the U.S. Patent &amp;amp; Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution. IPR challenges have been brought against patents covering the Company&#x2019;s branded pharmaceutical products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following Acrux DDS&#x2019;s IPR petition, the U.S. Patent and Trial Appeal Board (&#x201c;PTAB&#x201d;), in May 2017, instituted inter partes review for an Orange Book-listed patent covering Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (U.S. Patent No. 7,214,506 (the &#x201c;&#x2018;506 Patent&#x201d;)) and, on June 6, 2018, issued a written determination invalidating such patent. An appeal of this decision was filed on August 7, 2018. On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings. As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion. The &#x2018;506 Patent, therefore, remains valid and enforceable and expires in 2026. Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is covered by sixteen Orange Book-listed patents owned by the Company or its licensor, which expire in the years 2028 through 2035. In August and September 2018, the Company received notices of the filing of a number of ANDAs with paragraph IV certification, and has timely filed patent infringement suits against these ANDA filers, and, in addition, the Company has also commenced certain patent infringement proceedings in Canada against four separate defendants. All cases in U.S. regarding Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; have been settled. In Canada, two lawsuits remain pending against Apotex Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Mylan has filed IPR petitions for certain U.S. patents listed in the FDA Orange Book for Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (plecanatide). On March 21, 2022, Mylan filed a petition for IPR of U.S. Patent No. 7,041,786. On June 10, 2022, Mylan filed petitions for IPR of U.S. Patent Nos. 9,610,321, 9,616,097, 9,919,024, and 9,925,231. The Company remains confident in the strength of these patents and intends to vigorously defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Liability &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Products Liability Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since 2016, the Company has been named in a number of product liability lawsuits involving the Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; body powder product acquired in September 2012 from Johnson &amp;amp; Johnson; due to dismissals, twenty-nine (29) of such product liability suits currently remain pending. In three (3) cases pending in the Atlantic County, New Jersey Multi-County Litigation, agreed stipulations of dismissal have been entered by the Court, thus dismissing the Company from those cases. Potential liability (including its attorneys&#x2019; fees and costs) arising out of these remaining suits is subject to full indemnification obligations of Johnson &amp;amp; Johnson owed to the Company and its affiliates, and legal fees and costs will be paid by Johnson &amp;amp; Johnson. Twenty-eight (28) of these lawsuits filed by individual plaintiffs allege that the use of Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; caused the plaintiffs to develop ovarian cancer, mesothelioma or breast cancer. The allegations in these cases include failure to warn, design defect, manufacturing defect, negligence, gross negligence, breach of express and implied warranties, civil conspiracy concert in action, negligent misrepresentation, wrongful death, loss of consortium and/or punitive damages. The damages sought include compensatory damages, including medical expenses, lost wages or earning capacity, loss of consortium and/or compensation for pain and suffering, mental anguish anxiety and discomfort, physical impairment and loss of enjoyment of life. Plaintiffs also seek pre- and post-judgment interest, exemplary and punitive damages, and attorneys&#x2019; fees. Additionally, two proposed class actions have been filed in Canada against the Company and various Johnson &amp;amp; Johnson entities (one in the Supreme Court of British Columbia and one in the Superior Court of Quebec), on behalf of persons who have purchased or used Johnson &amp;amp; Johnson&#x2019;s Baby Powder or Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The class actions allege the use of the product increases certain health risks (British Columbia) or negligence in failing to properly test, failing to warn of health risks, and failing to remove the products from the market in a timely manner (Quebec). The plaintiffs in these actions are seeking awards of general, special, compensatory and punitive damages. On November 17, 2020, the British Columbia court issued a judgment declining to certify a class as to the Company or Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and at this time no appeal of that judgment has been filed. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 16, 2021, the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;plaintiff in the British Columbia class action filed a Second Amended Notice of Civil Claim and Application&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for Certification, removing the Company as a defendant; as a result, the British Columbia class action is concluded&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson, through one or more subsidiaries, has purported to have completed a Texas divisional merger with respect to any talc liabilities at Johnson &amp;amp; Johnson Consumer, Inc. (&#x201c;JJCI&#x201d;). LTL Management, LLC (&#x201c;LTL&#x201d;), the resulting entity of the divisional merger, assumed JJCI&#x2019;s talc liabilities and thereafter filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the Western District of North Carolina. Pursuant to court orders entered in November 2021, the case was transferred to the United States District Court for the District of New Jersey (the &#x201c;Bankruptcy Court&#x201d;), and substantially all cases related to Johnson &amp;amp; Johnson&#x2019;s talc liability were stayed for a period of sixty (60) days pursuant to a preliminary injunction. Notwithstanding the divisional merger and LTL&#x2019;s bankruptcy case, the Company and its affiliates continue to have indemnification claims and rights against Johnson &amp;amp; Johnson and LTL pursuant to the terms of the indemnification agreement entered into between JJCI and its affiliates and the Company and its affiliates, which indemnification agreement remains in effect. As a result, it is the Company&#x2019;s current expectation that it will not incur any material impairments with respect to its indemnification claims as a result of the divisional merger or the bankruptcy. In &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 2021, certain talc claimants filed motions to dismiss the bankruptcy case. Shortly thereafter, LTL filed a motion in the Bankruptcy Court to extend the 60-day preliminary injunction. On February 25, 2022, the Bankruptcy Court entered orders denying the motions to dismiss and extending the preliminary injunction staying substantially all cases subject to the indemnification agreement related to Johnson &amp;amp; Johnson&#x2019;s talc liability through at least June 29, 2022. The order denying the motions to dismiss and the order extending the preliminary injunction are subject to appeal and the bankruptcy court certified their appeals directly to the United States Court of Appeals for the Third Circuit. On May 11, 2022, the Third Circuit granted authorization for the parties to proceed with their direct appeals and on June 24, 2022, set an expedited briefing schedule to conclude on September 6, 2022. Further, pursuant to a court order dated March 18, 2022, the Bankruptcy Court directed certain talc claimants and LTL to mediate the issues related to the case in the hopes of achieving a global resolution. The Bankruptcy Court has also ordered separate mediation with respect to certain consumer protection claims against LTL by various state attorneys general. On May 4, 2022, the Bankruptcy Court extended LTL&#x2019;s exclusive period to file a chapter 11 plan until September 9, 2022, which the talc claimants have challenged by filing a motion to terminate the exclusivity period and requesting a hearing on such motion for September 14, 2022. On July 26, 2022, the Bankruptcy Court held a hearing to consider alternative paths to case resolution, and on July 28, 2022, authorized an abbreviated estimation process designed to determine the extent of the debtor&#x2019;s aggregate liability. Additionally, the Bankruptcy Court identified its proposed independent expert who will issue a report forecasting and estimating the volume and value of claims. Thereafter, the Bankruptcy Court will direct the parties to reconvene for mediation. On July 28, 2022, the Bankruptcy Court also ruled that it would leave in place the stay and injunction enjoining talc product liability cases from proceeding until at least the completion of the estimation process. Following the Bankruptcy Court&#x2019;s July 28 ruling, on August 2, 2022, LTL filed a motion to extend its exclusivity period until 30 days after the issuance of the independent expert&#x2019;s report, with a hearing on such motion requested for August 23, 2022. To the extent that any cases proceed during the pendency of the bankruptcy case, it is the Company&#x2019;s expectation that Johnson &amp;amp; Johnson, in accordance with the indemnification agreement, will continue to vigorously defend the Company in each of the remaining actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;General Civil Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. Securities Litigation - New Jersey Declaratory Judgment Lawsu&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;it&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 24, 2022, the Company and Bausch + Lomb were named in a declaratory judgment action in the Superior &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Court of New Jersey, Somerset County, Chancery Division, brought by certain individual investors in the Company&#x2019;s common shares and debt securities who are also maintaining individual securities fraud claims against the Company and certain current or former officers and directors as part of the U.S. Securities Litigation. This newly filed action seeks a declaratory judgment that the transfer of the Company assets to Bausch + Lomb would constitute a voidable transfer under New Jersey&#x2019;s Uniform Voidable Transactions Act and that Bausch + Lomb would become liable for damages awarded against the Company in the individual opt-out actions. The declaratory judgment action alleges that a transfer of assets from the Company to Bausch + Lomb would leave the Company with inadequate financial resources to satisfy these plaintiffs&#x2019; alleged securities fraud damages in the underlying individual opt-out actions. None of the plaintiffs in this declaratory judgment action have obtained a judgment against the Company in the underlying individual opt-out actions and the Company disputes the claims against it in those underlying actions. The underlying individual opt-out actions assert claims under Sections 10(b) and 20(a) of the Exchange Act, and certain actions assert claims under Section 18 of the Exchange Act. The allegations in those underlying individual opt out actions are made against the Company and several of its former officers and directors only and relate to, among other things, allegedly false and misleading statements made during the 2013-2016 time period by the Company and/or failures to disclose information about the Company&#x2019;s business and prospects including relating to drug pricing and the use of specialty pharmacies. On March 31, 2022, the Company and Bausch + Lomb removed the action to the U.S. District Court for the District of New Jersey. As a result, the New Jersey Superior Court action is closed and the case is now pending in the District of New Jersey (Case No. 22-cv-01823). On April 29, 2022, Plaintiffs filed a motion to remand. That motion is fully briefed and pending as of June 30, 2022. Other proceedings are in abeyance pending resolution of Plaintiffs&#x2019; remand motion. Both the Company and Bausch + Lomb dispute the claims in this declaratory judgment action and intend to vigorously defend this matter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;California Proposition 65 Related Matter&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson &amp;amp; Johnson (Gutierrez, et al. v. Johnson &amp;amp; Johnson, et al., Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the California Safe Cosmetics Act. This lawsuit was served on Bausch Health US in June 2019 and was subsequently removed to the United States District Court for the Southern District of California, where it is currently pending. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. Bausch Health US filed a motion to dismiss Plaintiffs&#x2019; claims, which was granted in April 2020 without prejudice. In May 2020, Plaintiffs filed an amended complaint and in June 2020, filed a motion for leave to amend the complaint further, which was granted. In August 2020, Plaintiffs filed &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Fifth Amended Complaint. On January 22, 2021, the Court granted the motion to dismiss with prejudice. On February 19, 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit Court of Appeals. On July 1, 2021, Appellants (Plaintiffs) filed their opening brief; Appellees&#x2019; response briefs were filed on October 8, 2021. This matter was stayed by the Ninth Circuit on December 7, 2021, due to the preliminary injunction entered by the Bankruptcy Court in the LTL bankruptcy proceeding. This stay included Appellants&#x2019; reply brief deadline, which was previously due to be filed on or before December 2, 2021. On March 9, 2022, the Ninth Circuit issued an order extending the stay through July 29, 2022. On July 29, 2022, Johnson &amp;amp; Johnson filed a status report in the Gutierrez appeal, outlining the developments since the last status report and the imposition of the current stay. Johnson &amp;amp; Johnson noted that following a July 26, 2022, hearing, the Bankruptcy Court left the preliminary injunction in place, and accordingly, asked the Ninth Circuit if Johnson &amp;amp; Johnson could have until December 19, 2022, to provide the next status report while the stay remains in place in this action. They also indicated they will inform the court if the status of the bankruptcy stay changes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New Mexico Attorney General Consumer Protection Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Bausch Health US were named in an action brought by State of New Mexico ex rel. Hector H. Balderas, Attorney General of New Mexico, in the County of Santa Fe New Mexico First Judicial District Court (New Mexico ex rel. Balderas v. Johnson &amp;amp; Johnson, et al., Civil Action No. D-101-CV-2020-00013, filed on January 2, 2020), alleging consumer protection claims against Johnson &amp;amp; Johnson and Johnson &amp;amp; Johnson Consumer, Inc., the Company and Bausch Health US related to Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and its alleged causal link to mesothelioma and other cancers. In April 2020, Bausch Health US filed a motion to dismiss, which in September 2020, the Court granted in part as to the New Mexico Medicaid Fraud Act and New Mexico Fraud Against Taxpayers Act claims and denied as to all other claims. The State of New Mexico brings claims against all defendants under the New Mexico Unfair Practices Act and other common law and equitable causes of action, alleging defendants engaged in wrongful marketing, sale and promotion of talcum powder products. The lawsuit seeks to recover the cost of the talcum powder products as well as the cost of treating asbestos-related cancers allegedly caused by those products. Bausch Health US filed its answer on November 16, 2020. On December 30, 2020 Johnson &amp;amp; Johnson filed a Motion for Partial Judgment on the Pleadings and on January 4, 2021, Bausch Health US filed a joinder to that motion, which was denied on March 8, 2021. Trial is scheduled to begin on March 6, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 14, 2022, LTL filed an adversary proceeding in the Bankruptcy Court (Case No. 21-30589, Adv. Pro. No. 22-01231) against the State of New Mexico ex rel. Hector H. Balderas, Attorney General, and a motion seeking an injunction barring the State of New Mexico from continuing to prosecute the action while the bankruptcy case is pending. On July 20, 2022, the Bankruptcy Court entered a consent order pursuant to which, among other things, a hearing on the injunction is scheduled for August 23, 2022, and the action is stayed pending further order on the injunction motion. The one exception is that the parties in the New Mexico case may continue to litigate the scheduling order extension in that case which has been scheduled for hearing August 24, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other General Civil Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As referenced above, during the three months ended June 30, 2022, there have been no material updates or developments with respect to certain proceedings or actions as described under &#x201c;General Civil Actions&#x201d; in Note 20, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company&#x2019;s Consolidated Financial Statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021. These matters include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Doctors Allergy Formula Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, Doctors Allergy Formula, LLC (&#x201c;Doctors Allergy&#x201d;), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, asserting breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas.&#160;Doctors Allergy claims its damages are not less than $23 million. Bausch Health Americas has asserted counterclaims against Doctors Allergy. Bausch Health Americas filed a motion seeking an order granting Bausch Health Americas summary judgment on its counterclaims against Plaintiff and dismissing Plaintiff&#x2019;s claims against it. The motion was fully briefed as of May 2021. The Court held a hearing on the motion on January 25, 2022. The motion remains pending. Bausch Health Americas disputes the claims against it and intends to continue to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation with Former Salix CEO&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, asserting claims for breach of contract and declaratory relief. On November 19, 2021, Logan amended her complaint to add a claim for breach of the implied covenant of good faith and fair dealing. The lawsuit arises out of the contractual termination &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of approximately $30 million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd. Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification. On June 20, 2019, the Court entered an order staying the claim for declaratory relief pending the final resolution of the breach of contract claim. Trial is scheduled to commence on April 10, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disputes the claims against it in each of these matters and intends to vigorously defend the matters.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LitigationReserveCurrent
      contextRef="ifa4f1d340e184a83a769da723d5d1bdf_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTM2Ng_74d2bd22-940d-41f9-96f4-09b8e245e46f"
      unitRef="usd">1536000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i30507c6e944f444ebabb56848a53aea3_D20151001-20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNDI0MQ_5e28abd5-12f3-4905-8f7d-9f9f81ec4bb7"
      unitRef="case">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i30507c6e944f444ebabb56848a53aea3_D20151001-20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNDc4Mg_4fd37d49-fc2a-4f1c-a337-b62a56b6dd8e"
      unitRef="case">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="ie30ec1de778c473aa24992db460e51ab_D20191216-20191216"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNTA4Mg_69865adc-a65d-4fb9-a376-2160fe315ad2"
      unitRef="usd">1210000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i74040cd3e59640bf9752be2e23b0ac69_D20220630-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNjI0NA_29fd8a47-6897-47f5-8faf-531cb436ba68"
      unitRef="usd">1210000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors
      contextRef="i4102d9065afe4932a90e498521bfa3cb_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNzYxNg_3536b414-9086-4ca5-a293-f59d0c97557f"
      unitRef="group">37</bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="i4102d9065afe4932a90e498521bfa3cb_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfODA2OQ_ebd0fa9f-3d2d-443b-821f-851b374233fb"
      unitRef="case">16</us-gaap:LossContingencyClaimsDismissedNumber>
    <bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors
      contextRef="i4102d9065afe4932a90e498521bfa3cb_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfODA3OQ_3536b414-9086-4ca5-a293-f59d0c97557f"
      unitRef="group">37</bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors>
    <bhc:LossContingencyPlaintiffsNumberofGroupsofInvestorsPending
      contextRef="i4102d9065afe4932a90e498521bfa3cb_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfODIxMA_7ef32d51-0696-498e-a1e2-fca20ba7facb"
      unitRef="group">21</bhc:LossContingencyPlaintiffsNumberofGroupsofInvestorsPending>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="ib9028ff993434533b2b5623750bbd556_D20150101-20151231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTA3NTg_3fae8ff6-5565-4305-a5d0-dabc101cf9ac"
      unitRef="case">6</us-gaap:LossContingencyNewClaimsFiledNumber>
    <bhc:LossContingencyNewClaimsFiledButNotYetServedNumber
      contextRef="i5274caaee15944b38fc2385088096f35_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTA5NzY_af1c1cdf-b0fc-4d92-ba97-456b9e8cd57f"
      unitRef="action">2</bhc:LossContingencyNewClaimsFiledButNotYetServedNumber>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="icb691d8ec4ac4d71aee1342723827741_D20200804-20200804"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTI1Mzk_20ed8e8d-29d5-449d-a870-2efe4bc5f965"
      unitRef="cad">94000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction
      contextRef="i757e35cf9f3d40a4b5c93f8ca62f5f21_I20190215"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTM5NjM_60f54884-00c7-45f6-ad89-204b378b24eb"
      unitRef="entity">1</bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction>
    <bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction
      contextRef="iaf7e31cd823147eabf32516dee47b2d9_I20210317"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTU5NDk_c570bfa3-3102-40f1-a7e0-80b4cc25503a"
      unitRef="entity">4</bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i5d58819753a6484caa4ffdf910353903_D20160527-20160916"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTY2OTk_83a49df5-c5bf-4ce9-afb6-8b64aca5ecd9"
      unitRef="action">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <bhc:LossContingencyNumberOfInsurancePolicyPeriods
      contextRef="i4305560891084775b5a8f280c90557dd_D20171207-20171207"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTkxNTU_d32ffc72-8e69-45be-bcb2-e2bcc772b693"
      unitRef="insurance_policy_period">2</bhc:LossContingencyNumberOfInsurancePolicyPeriods>
    <bhc:LossContingencySettlementAgreementsNumberOfInsurers
      contextRef="i74c5348c904e49149ebdc8edaa5089a9_I20210720"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMjExMjY_7b61bb05-d121-468b-962b-7d96aae65aea"
      unitRef="insured">2</bhc:LossContingencySettlementAgreementsNumberOfInsurers>
    <bhc:LossContingencySettlementAgreementsNumberOfInsurers
      contextRef="i74c5348c904e49149ebdc8edaa5089a9_I20210720"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMjEyNDI_5214f792-e4f1-42f2-bec4-53c336d66d16"
      unitRef="insured">2</bhc:LossContingencySettlementAgreementsNumberOfInsurers>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="iddba8dcdaa5c416aba241e33eece7d94_D20210720-20210720"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMjE0Nzk_a0c7cdee-c6ae-4df7-a93f-83b15c637a10"
      unitRef="usd">213000000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i59952c7ec62348a0bf0304c3e9c4aa1f_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMjIyMDM_31df8750-a0da-44aa-8634-7426078b73c6"
      unitRef="case">8</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i26aebd3fd2cf4b1b9c6310ad6e35e2e8_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMjIyNDc_171eb3cd-1f31-4f31-b4b6-2ed8b147e728"
      unitRef="case">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i9b5eea4e2b054fe9b33f5a1c2468e6be_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMjI1MjY_b9c33cf0-40d5-44ad-84ad-383477aeda0b"
      unitRef="case">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i2bacfb7cad21454aa0b7847ed301e366_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMjI5MzU_95e24895-f921-4fa4-9eda-bf20079bebcc"
      unitRef="case">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="ib1b9c6e509b24bc380ee524ca05ae442_D20210726-20210726"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMjQ2ODQ_90951482-6df4-41df-b7b3-9c93bb76e44a"
      unitRef="usd">300000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bhc:GainContingencyStayOfApprovalPeriod
      contextRef="i6a2d38205ea946e095aed8012d8b17c2_D20200326-20200326"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMzIxOTI_780e8878-f081-4967-8572-78919899e862">P30M</bhc:GainContingencyStayOfApprovalPeriod>
    <bhc:GainContingencyStayOfApprovalPeriod
      contextRef="i0ccb1877ab504b0da10aae4fbd2023a4_D20200828-20200828"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMzM1MTI_0cb4251d-48cc-49fa-81a6-15b559ce59d6">P30M</bhc:GainContingencyStayOfApprovalPeriod>
    <bhc:GainContingencyStayOfApprovalPeriod
      contextRef="ie0c3cf86c7f3419099a730b07b8db1b8_D20220721-20220721"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNDM5ODA0NjYxNzkzMg_f9dd2de9-17a8-469e-90f2-a512c9693eba">P30M</bhc:GainContingencyStayOfApprovalPeriod>
    <bhc:GainContingencyStayOfApprovalPeriod
      contextRef="i3ada237c7e9e4db3b48af8ba931e7f96_D20200501-20200501"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMzQ2MTY_a036df32-25d8-45ff-8b81-8b7c036d6622">P30M</bhc:GainContingencyStayOfApprovalPeriod>
    <bhc:GainContingencyStayOfApprovalPeriod
      contextRef="i19fa8a54dc9d4942b1269451e77f4405_D20210401-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMzU4NTA_67b66515-22ad-4ec7-8894-7000f871e32b">P30M</bhc:GainContingencyStayOfApprovalPeriod>
    <bhc:GainContingencyNumberOfDefendants
      contextRef="i163c3bd2391743dca52453bf7bb54c2d_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTE1NDQ4NzIxODAyNzA_bf3895d1-00b4-4022-9d9c-2e830721039d"
      unitRef="defendant">16</bhc:GainContingencyNumberOfDefendants>
    <bhc:GainContingencyNumberOfDefendants
      contextRef="ic0fbaa5244774f8785a4c3159850c238_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTE1NDQ4NzIxODAyNzM_d5547064-4758-4074-8c4a-432256a15194"
      unitRef="defendant">12</bhc:GainContingencyNumberOfDefendants>
    <bhc:GainContingencyNumberOfDefendants
      contextRef="i9fa2cc2f25c840c8aa8cd8f821e0e024_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTE1NDQ4NzIxODAyOTY_15f1fca9-c6f1-479b-a964-9276f7242158"
      unitRef="defendant">2</bhc:GainContingencyNumberOfDefendants>
    <bhc:GainContingencyNumberOfDefendants
      contextRef="i535a21de35094309b7dde211b4cc6c75_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTE1NDQ4NzIxODAzMTA_5250d590-f37a-41c7-bb82-df8aa11437f0"
      unitRef="defendant">1</bhc:GainContingencyNumberOfDefendants>
    <bhc:GainContingencyNumberOfDefendants
      contextRef="i5e13b85e78034bd58a4c8e9b49e1b7f8_D20220809-20220809"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNDM5ODA0NjU5OTk1Mw_971fcd40-6dc5-4d52-84c1-981bb61aa6af"
      unitRef="defendant">2</bhc:GainContingencyNumberOfDefendants>
    <bhc:GainContingencyStayOfApprovalPeriod
      contextRef="i699127da9e51419abf9760aca1b136de_D20220202-20220202"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTE1NDQ4NzIxODAyNDg_7277846d-9ac8-4c6e-8826-cd6ef79655a2">P30M</bhc:GainContingencyStayOfApprovalPeriod>
    <bhc:GainContingencyStayOfApprovalPeriod
      contextRef="i9baba49f62e74a14aed75dbbd081c3b4_D20220202-20220202"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTE1NDQ4NzIxODAzMjA_c011a54c-bbd7-4fde-ab16-e893becda9a9">P30M</bhc:GainContingencyStayOfApprovalPeriod>
    <bhc:GainContingencyNumberOfDefendants
      contextRef="ifac3480ee2d142bf905b63b471677601_D20180801-20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNDM5ODA0NjYxNzkzOQ_96489087-5d98-41de-bd8a-1c8144be7172"
      unitRef="defendant">4</bhc:GainContingencyNumberOfDefendants>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="ic187ba4416b64839ad042a51d60bfdd1_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNDM5ODA0NjYxNzk0OA_72af89c0-331b-41ef-afff-a0187c0327c7"
      unitRef="lawsuit">2</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ibf92d71d956242d2ae34c263d78aac0a_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMzk5MDc_1c368664-822a-42c2-a268-92b5d820923e"
      unitRef="case">29</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ife18e9be510b4194a3a4277ad67e7250_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfMTE1NDQ4NzIxODAzMzA_b3b7a130-d773-4569-b6c1-72bac74e4163"
      unitRef="case">3</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i8381d2aef44c4cb6bbf760cd8d3e40b8_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNDAyNTA_07b30fd2-16ac-4324-8db7-6b10ac588779"
      unitRef="case">28</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i768a63ca14b44cf0a9b21c5ad06e8cea_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNDEwOTc_d2dc7c05-8f8c-4359-aeda-5e85cd09df7d"
      unitRef="case">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ic0c00ea3613744deacee586a7d91e4c2_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNDEyMDk_af16dcab-ee2f-4bc0-bf9e-059020e2d77d"
      unitRef="case">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ibed3ef3f1abe40969ae83f8df49eaddc_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNDEyNTc_0e2842cf-536b-4aba-996d-24758fc8cd07"
      unitRef="case">1</us-gaap:LossContingencyPendingClaimsNumber>
    <bhc:LossContingencyStayOfApprovalPeriod
      contextRef="i256a9238c6d447949e96e0113ba7913c_D20211101-20211130"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNDI5MTg_a57f332b-19e8-4932-83e6-f338d8b6bc8c">P60D</bhc:LossContingencyStayOfApprovalPeriod>
    <bhc:LossContingencyStayOfApprovalMotionToExtendPeriod
      contextRef="ie1614b745c4246e89dd4a1987611b15c_D20211201-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNDM2OTc_70622136-a239-4736-a19f-3f4e39391cdf">P60D</bhc:LossContingencyStayOfApprovalMotionToExtendPeriod>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i3da2b3029b9e49809af6f64595c73392_D20180401-20180430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNTIyMjc_659e0c74-0a33-4ff7-bd15-b6c6cc11e161"
      unitRef="usd">23000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i521280a2735e43e2bc975a7b850cdd00_D20190128-20190128"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85NC9mcmFnOjkxNTE1NDFjNDYxNzRkNDg5NWUxMjRmYzQyZWNmZTZjL3RleHRyZWdpb246OTE1MTU0MWM0NjE3NGQ0ODk1ZTEyNGZjNDJlY2ZlNmNfNTMxNTA_3a9df1cb-7b5c-4abf-9962-7872858ace85"
      unitRef="usd">30000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RleHRyZWdpb246ODZkOGIyZDAzM2QxNDQzN2IzMmE4YzM5MDAxNWE3MTZfNDI0OQ_559e4b24-3553-4246-a558-f9242ea3f58f">SEGMENT INFORMATION&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reportable Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Company&#x2019;s previously announced plan to separate its Solta business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., the Company had begun managing its operations in a manner which was consistent with the organizational structure of the two separate entities as proposed by the Solta IPO. As a result, during the first quarter of 2022, the Company&#x2019;s Chief Executive Officer (&#x201c;CEO&#x201d;), who is the Company&#x2019;s Chief Operating Decision Maker, commenced managing the business differently through changes in its operating and reportable segments, which necessitated a realignment of the Company&#x2019;s historical segment structure. This realignment is consistent with how the Company&#x2019;s CEO currently: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports. Pursuant to these changes, effective in the first quarter of 2022, the Company operates in the following reportable segments: (i) Salix, (ii) International (formerly International Rx), (iii) Diversified Products, (iv) Solta Medical and (v) Bausch + Lomb. The new segment structure does not impact the Company&#x2019;s reporting units but realigns the two reporting units of the former Ortho Dermatologics segment whereby its medical dermatology reporting unit (Ortho Dermatologics) is now part of the current Diversified Products segment and the Solta reporting unit is now the sole reporting unit of the new Solta Medical segment. Prior period presentation of segment revenues and segment profits has been recast to conform to the current segment reporting structure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 16, 2022, the Company announced it was suspending plans for the Solta IPO; however, the Company is continuing to manage and operate the business in its current reportable segment structure. See Note 2, &#x201c;SIGNIFICANT ACCOUNTING POLICIES&#x201d; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a brief description of the Company&#x2019;s segments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Salix segment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; consists of sales in the U.S. of GI products. Sales of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; product line represented 81% and 80% of the Salix segment&#x2019;s revenues for the three and six months ended June 30, 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The International segment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; consists of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Diversified Products segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological) products and (iv) dentistry products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Solta Medical segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consists of global sales of Solta aesthetic medical devices. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Bausch + Lomb segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consists of global sales of Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals products.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment profit is based on operating income after the elimination of intercompany transactions, including between Bausch + Lomb and other segments. Certain costs, such as Amortization of intangible assets, Asset impairments, Goodwill impairments, Restructuring, integration, separation and IPO costs and Other (income) expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#x2019;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Revenues and Profits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment revenues and profits were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(717)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairments, including loss on assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, integration, separation and IPO costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(542)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(491)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenues by Segment and Product Category &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by segment and product category were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The top ten products for the six months ended June 30, 2022 and 2021 represented 48% and 43% of total revenues for the six months ended June 30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Geographic Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are attributed to a geographic region based on the location of the customer and were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Poland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Russia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Italy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;South Korea&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made and are reflected in the table above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Major Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customers that accounted for 10% or more of total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation (including McKesson Specialty)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health,&#160;Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportingUnits
      contextRef="i86a04889bcf044b38603f4f4ca1d8de4_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RleHRyZWdpb246ODZkOGIyZDAzM2QxNDQzN2IzMmE4YzM5MDAxNWE3MTZfMTI3NQ_86be53b1-7d0e-478a-ac21-c919f2b85868"
      unitRef="reporting_unit">2</us-gaap:NumberOfReportingUnits>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i99a74cae63104c7b82e2b04e1ad12241_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RleHRyZWdpb246ODZkOGIyZDAzM2QxNDQzN2IzMmE4YzM5MDAxNWE3MTZfNTQ5NzU1ODE0NTM5OQ_48e2ec32-727c-4d1e-a465-40ba5260532d"
      unitRef="number">0.81</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icc599dddc6874659a5df85bf6a360251_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RleHRyZWdpb246ODZkOGIyZDAzM2QxNDQzN2IzMmE4YzM5MDAxNWE3MTZfNTQ5NzU1ODE0NTQwNg_60a6b859-9b21-490c-a959-f84539184724"
      unitRef="number">0.80</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RleHRyZWdpb246ODZkOGIyZDAzM2QxNDQzN2IzMmE4YzM5MDAxNWE3MTZfNDIzOQ_bf91692c-10b0-45a3-ab4d-152519c286b3">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment revenues and profits were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(717)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairments, including loss on assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, integration, separation and IPO costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(542)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(491)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(772)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i135087334a5d4c22bfa9b973191edec2_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNC0xLTEtMS0xMTY3NzE_ae373f9d-c006-497e-83e1-d0b261c86275"
      unitRef="usd">501000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33f1397d8a6c4970be8e3744fa05b614_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNC0zLTEtMS0xMTY3NzE_124941ac-f317-43e4-bab8-99905ff47095"
      unitRef="usd">516000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa70c909ebed4960ac5793fab0872d29_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNC01LTEtMS0xMTY3NzE_174dafb2-8f33-4143-bd10-747a5ca5d72d"
      unitRef="usd">965000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1fd4b8f2dca420587be152cd56a71f1_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNC03LTEtMS0xMTY3NzE_1ee00fea-3a6f-4e7f-9622-b777a098833b"
      unitRef="usd">988000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6165a9798c56425cb4efb5a5f6723bfc_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNS0xLTEtMS0xMTY3NzE_9d893038-5aa3-4a48-bfcf-1a375cb49b13"
      unitRef="usd">233000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8bd4de5a193d4a029240767ca5a07233_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNS0zLTEtMS0xMTY3NzE_e5641113-fb86-47cd-bf24-a1ff59f4d9e7"
      unitRef="usd">313000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife570419c7bf420eb1abf7c964aaca40_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNS01LTEtMS0xMTY3NzE_c94354a8-3fbd-464f-87c1-46b9c8339cdb"
      unitRef="usd">477000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3029344c603341c39ead09035d7dfa4d_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNS03LTEtMS0xMTY3NzE_a45bf3ba-9915-4d26-9a27-243567f3d2b7"
      unitRef="usd">619000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0dd827b38d174dab9b133e198c4a8961_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNS0xLTEtMS0xMjU4Mjc_2662d752-fe8b-413e-9bea-414a260a8413"
      unitRef="usd">235000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58ecd7a903984152b7f6c2ae9bec8334_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNS0zLTEtMS0xMjU4MzA_cddb7ce7-4c8a-45bd-95ac-894dc6865a33"
      unitRef="usd">264000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib91d44ce63944098b3420f5c3736b8a9_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNS01LTEtMS0xMjU4MzI_a999feec-c3e8-4427-b34c-aeabcbe244de"
      unitRef="usd">484000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc157eb51cba40e89c5c61507c69e6e5_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNS03LTEtMS0xMjU4MzQ_04ebe07e-dd18-4894-9a51-6c4ff4b780a4"
      unitRef="usd">560000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66c6b838e58742c0aec7f7e50a13b045_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNi0xLTEtMS0xMTY3NzE_709d3bc7-f064-4282-ab64-95014e57fe3a"
      unitRef="usd">57000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ffd9a91d95843f5b57ffc1c00e8f083_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNi0zLTEtMS0xMTY3NzE_2d3789d1-7f7d-456c-9148-d82bed309342"
      unitRef="usd">73000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3dba412bc4484690b009184d4ba468c6_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNi01LTEtMS0xMTY3NzE_93d1d15b-d165-4691-b11a-a536ea556563"
      unitRef="usd">129000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52b7ac6f51a042f3af9aea0cd5d38c09_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfNi03LTEtMS0xMTY3NzE_907ec7d4-16d6-49a2-9eb4-f6a0fe53c340"
      unitRef="usd">145000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i641af432b0f64dcb834dccbe69309abd_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfOC0xLTEtMS0xMjU3ODk_a56d5eaa-f7b7-482d-b17f-4db0633f6945"
      unitRef="usd">941000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if41baecc67df46e3909a38e74cfc03c7_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfOC0zLTEtMS0xMjU3OTc_6f123455-1136-409e-9685-5cdf8eec7b35"
      unitRef="usd">934000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4ade95eb6964658bc80338e46f307dc_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfOC01LTEtMS0xMjU4MDA_bb7d3346-d373-465e-9690-3171cc07f24b"
      unitRef="usd">1830000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7050fd087c144698ee6de6deb8f7b08_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfOC03LTEtMS0xMjU4MDM_2d4670d8-1460-4c0c-aa1e-d2c26373088c"
      unitRef="usd">1815000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56f9693a8c8e416f9524496f13d18f13_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfOC0xLTEtMS0xMTY3NzE_c858ecf9-b1ac-42a1-a5f2-1f91c782b100"
      unitRef="usd">1967000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i457d6b1c8dad41d797d6f3caa45e3c46_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfOC0zLTEtMS0xMTY3NzE_bdbcbb62-c652-4e6e-811c-f4d2a9046700"
      unitRef="usd">2100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c0e69d16e47492cba77b50588ee0475_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfOC01LTEtMS0xMTY3NzE_a5102e2a-0791-4090-a603-b5dfd077a224"
      unitRef="usd">3885000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8193e2fcad6a491c9c98e5dadc6de63a_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfOC03LTEtMS0xMTY3NzE_46e8e764-dce0-4905-a2e9-88a668210c4a"
      unitRef="usd">4127000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="i135087334a5d4c22bfa9b973191edec2_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTEtMS0xLTEtMTE2Nzcx_cd3aaa67-d714-41ef-8083-d5939c54da5f"
      unitRef="usd">354000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i33f1397d8a6c4970be8e3744fa05b614_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTEtMy0xLTEtMTE2Nzcx_0294ac48-f975-4279-a3a6-677b9cbb9210"
      unitRef="usd">370000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iaa70c909ebed4960ac5793fab0872d29_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTEtNS0xLTEtMTE2Nzcx_50ad9540-7ea7-48b6-9735-41cdf2c666f0"
      unitRef="usd">676000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia1fd4b8f2dca420587be152cd56a71f1_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTEtNy0xLTEtMTE2Nzcx_ae50fc4d-0a5f-4c6c-af9f-98ca1ca1b42b"
      unitRef="usd">697000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6165a9798c56425cb4efb5a5f6723bfc_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTItMS0xLTEtMTE2Nzcx_5918dd2c-c9e6-4c7c-a421-14a51a37fbb8"
      unitRef="usd">66000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8bd4de5a193d4a029240767ca5a07233_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTItMy0xLTEtMTE2Nzcx_72f2feac-5354-4aac-ad7c-60358a978f0e"
      unitRef="usd">103000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ife570419c7bf420eb1abf7c964aaca40_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTItNS0xLTEtMTE2Nzcx_d4214b5c-8979-4dfb-a0f5-03bca7abf2c6"
      unitRef="usd">157000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3029344c603341c39ead09035d7dfa4d_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTItNy0xLTEtMTE2Nzcx_0176654c-0094-40e1-ab81-61b2dc6e6a08"
      unitRef="usd">212000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0dd827b38d174dab9b133e198c4a8961_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTMtMS0xLTEtMTI1OTAx_b8dc43b0-f0db-40cd-a8d6-56362baf4515"
      unitRef="usd">141000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i58ecd7a903984152b7f6c2ae9bec8334_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTMtMy0xLTEtMTI1OTAx_381141be-cb71-4e25-821c-cac750df0f86"
      unitRef="usd">162000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib91d44ce63944098b3420f5c3736b8a9_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTMtNS0xLTEtMTI1OTAx_fc97d941-7f01-40eb-81e8-9b335d1ea7e1"
      unitRef="usd">299000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifc157eb51cba40e89c5c61507c69e6e5_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTMtNy0xLTEtMTI1OTAx_ddde3be9-c9af-47f8-9f98-ed28cc738a30"
      unitRef="usd">362000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i66c6b838e58742c0aec7f7e50a13b045_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTQtMS0xLTEtMTMzNzYx_979f1d13-1c8a-4b74-ab10-a339326b57df"
      unitRef="usd">20000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0ffd9a91d95843f5b57ffc1c00e8f083_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTQtMy0xLTEtMTMzNzYx_296e3b78-9443-408b-a2d0-17219376d8bb"
      unitRef="usd">39000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3dba412bc4484690b009184d4ba468c6_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTQtNS0xLTEtMTMzNzYx_c544a1bb-99d4-460d-8fa3-c2d0debee42d"
      unitRef="usd">55000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i52b7ac6f51a042f3af9aea0cd5d38c09_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTQtNy0xLTEtMTMzNzYx_68552a99-b7d8-4c07-a746-1753bede8d8c"
      unitRef="usd">80000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i641af432b0f64dcb834dccbe69309abd_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTQtMS0xLTEtMTI1ODg4_b926d799-861e-45eb-ade4-49b0e9db7974"
      unitRef="usd">208000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if41baecc67df46e3909a38e74cfc03c7_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTQtMy0xLTEtMTI1ODg4_80a32614-f76f-49f3-b8b2-fa37dcec8d2e"
      unitRef="usd">213000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id4ade95eb6964658bc80338e46f307dc_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTQtNS0xLTEtMTI1ODg4_4dd2629b-1591-42fd-af39-966e463b7547"
      unitRef="usd">414000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie7050fd087c144698ee6de6deb8f7b08_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTQtNy0xLTEtMTI1ODg4_eeb7aa80-441a-4e39-a1d9-a60e815024b1"
      unitRef="usd">452000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i56f9693a8c8e416f9524496f13d18f13_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTUtMS0xLTEtMTE2Nzcx_f02b98c1-65a3-453b-8489-ae70241cdc8a"
      unitRef="usd">789000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i457d6b1c8dad41d797d6f3caa45e3c46_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTUtMy0xLTEtMTE2Nzcx_ca0f95d3-1aad-44f1-90a0-c253dcdb2154"
      unitRef="usd">887000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3c0e69d16e47492cba77b50588ee0475_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTUtNS0xLTEtMTE2Nzcx_29cf7f4d-ba18-464b-b426-b1929a125bff"
      unitRef="usd">1601000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8193e2fcad6a491c9c98e5dadc6de63a_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTUtNy0xLTEtMTE2Nzcx_65c09029-aafd-4167-9e3f-ac7c8614662b"
      unitRef="usd">1803000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iabd877b8ef23452c8e9fb08b70c21536_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTYtMS0xLTEtMTE2Nzcx_cda87e4d-2c85-4f6c-bac7-15aa72163917"
      unitRef="usd">-202000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic7fcbc8743ff4d28a9642d1d245a31c3_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTYtMy0xLTEtMTE2Nzcx_6a51e6bd-c25f-4037-8478-ec868f3bea3d"
      unitRef="usd">-199000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia26aedc76fcf44ae81e064729f28caf3_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTYtNS0xLTEtMTE2Nzcx_d9f4bcf3-827f-43d1-84ca-d485d327303e"
      unitRef="usd">-396000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i341826d4665e4f9691c35f15ba5167d5_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTYtNy0xLTEtMTE2Nzcx_334c4573-a78c-41ac-8be8-9cb395f8aabe"
      unitRef="usd">-380000000</us-gaap:OperatingIncomeLoss>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTctMS0xLTEtMTE2Nzcx_229f0dc4-dac3-4dd4-8d92-ddc720df547c"
      unitRef="usd">302000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTctMy0xLTEtMTE2Nzcx_03e245f8-e3e6-42cb-a84f-896b29c947e5"
      unitRef="usd">360000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTctNS0xLTEtMTE2Nzcx_8a93b5f5-271e-438b-919b-8ca70ca54b51"
      unitRef="usd">612000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTctNy0xLTEtMTE2Nzcx_3d173568-1200-4bb0-84cc-a4bdf033fc68"
      unitRef="usd">717000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTgtMS0xLTEtMTE2Nzcx_812d6f6e-eace-4391-ac93-dd99be3fa990"
      unitRef="usd">83000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTgtMy0xLTEtMTE2Nzcx_97111cbb-dfc8-4943-bb3f-000866a3fa61"
      unitRef="usd">0</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTgtNS0xLTEtMTE2Nzcx_17e7d943-5d86-4f98-8a56-da42bf98546c"
      unitRef="usd">83000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTgtNy0xLTEtMTE2Nzcx_46f60fae-6baf-4be7-b740-7487f6762616"
      unitRef="usd">469000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTktMS0xLTEtMTE2Nzcx_54319a37-5277-494f-b4b7-f658880cb127"
      unitRef="usd">6000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTktMy0xLTEtMTE2Nzcx_0272940b-af82-4b7b-8adf-ac088858a186"
      unitRef="usd">47000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTktNS0xLTEtMTE2Nzcx_8abfa467-9428-4b09-8962-83ad00984b3f"
      unitRef="usd">14000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMTktNy0xLTEtMTE2Nzcx_3d3f6336-3e44-46b5-85e3-7117d98953e0"
      unitRef="usd">195000000</us-gaap:AssetImpairmentCharges>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjAtMS0xLTEtMTE2Nzcx_3c0e84a4-d26c-45b6-bcf4-233f168ef30a"
      unitRef="usd">35000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjAtMy0xLTEtMTE2Nzcx_856d72c8-b8ab-46df-99f8-e0c9d665fb8c"
      unitRef="usd">9000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjAtNS0xLTEtMTE2Nzcx_a343e766-b0eb-4f96-a3e8-346b24b1509c"
      unitRef="usd">48000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjAtNy0xLTEtMTE2Nzcx_3897d03b-b729-40ac-9a57-19f303af4a73"
      unitRef="usd">21000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjEtMS0xLTEtMTE2Nzcx_1db2cb9c-4d71-41f3-b861-b05be39c883d"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjEtMy0xLTEtMTE2Nzcx_6864c787-a728-46f1-ae8c-3bd32c05f62e"
      unitRef="usd">-542000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjEtNS0xLTEtMTE2Nzcx_4a23adbb-982e-4136-a434-b2bc8bb6b9ef"
      unitRef="usd">-2000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjEtNy0xLTEtMTE2Nzcx_64d3ca97-9da4-456b-96b1-27a26dedeeb2"
      unitRef="usd">-512000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OperatingIncomeLoss
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjItMS0xLTEtMTE2Nzcx_cda0c98f-d578-4432-b049-8eb359a4862b"
      unitRef="usd">161000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjItMy0xLTEtMTE2Nzcx_e133e0e1-10ee-470e-a702-a1785ebfa360"
      unitRef="usd">-270000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjItNS0xLTEtMTE2Nzcx_71f78b7d-43bb-4d70-8980-5458de714a1c"
      unitRef="usd">446000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjItNy0xLTEtMTE2Nzcx_3ff38a6d-521a-4f61-8590-f691b519f152"
      unitRef="usd">-491000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjMtMS0xLTEtMTE2Nzcx_e7b58578-7dc9-4d91-9d28-a81de21ebd29"
      unitRef="usd">3000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjMtMy0xLTEtMTE2Nzcx_87190d3c-b5cf-4e9e-a534-b91399b4cdab"
      unitRef="usd">2000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjMtNS0xLTEtMTE2Nzcx_ee72c7e2-0833-48fb-bfab-b1fc79dad7a4"
      unitRef="usd">5000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjMtNy0xLTEtMTE2Nzcx_1e05124a-6e5d-4e85-b835-e72619c3eb55"
      unitRef="usd">4000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseDebt
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjQtMS0xLTEtMTE2Nzcx_5c5fba05-dac3-4363-99c0-7dcb48a973df"
      unitRef="usd">410000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjQtMy0xLTEtMTE2Nzcx_2d3aa0d8-ba07-4670-a767-c78e865fd92c"
      unitRef="usd">364000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjQtNS0xLTEtMTE2Nzcx_d13bf50d-4ad0-4f65-aa83-c5c69f58c662"
      unitRef="usd">772000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjQtNy0xLTEtMTE2Nzcx_ee80a332-dc87-45df-948f-c9b92098cf4d"
      unitRef="usd">732000000</us-gaap:InterestExpenseDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjUtMS0xLTEtMTE2Nzcx_6cd87c3f-84a3-462e-b5d5-3280b5f15ce4"
      unitRef="usd">113000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjUtMy0xLTEtMTE2Nzcx_52153aeb-8063-4608-b4e5-81ab5472de8e"
      unitRef="usd">-45000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjUtNS0xLTEtMTE2Nzcx_68631b75-8797-45b3-bf17-acfd5c4baae1"
      unitRef="usd">113000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjUtNy0xLTEtMTE2Nzcx_57548523-6bd8-4bc7-9dca-34edbdb902d5"
      unitRef="usd">-50000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjYtMS0xLTEtMTE2Nzcx_2069bc1a-6c16-4422-85aa-ae93ad8872ff"
      unitRef="usd">4000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjYtMy0xLTEtMTE2Nzcx_138b63cf-a6d2-46a1-8fe8-4f286cc11bb6"
      unitRef="usd">7000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjYtNS0xLTEtMTE2Nzcx_cd734b99-f6b8-42d4-9807-55ba392ac83d"
      unitRef="usd">-3000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjYtNy0xLTEtMTE2Nzcx_3a0ea119-994d-486a-98eb-bffb617a802e"
      unitRef="usd">8000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjctMS0xLTEtMTE2Nzcx_ab05a49b-41da-4d35-ba41-3f1e3a556b5d"
      unitRef="usd">-129000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjctMy0xLTEtMTE2Nzcx_30401f94-70cc-47bb-849b-76243771c5be"
      unitRef="usd">-670000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjctNS0xLTEtMTE2Nzcx_80827dcf-2190-4517-92b6-382e9601f7ac"
      unitRef="usd">-211000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmE4NzNiMTNkNzBkZjQ0MWJhMGRiNWJkMzY2ODVlYjIyL3RhYmxlcmFuZ2U6YTg3M2IxM2Q3MGRmNDQxYmEwZGI1YmQzNjY4NWViMjJfMjctNy0xLTEtMTE2Nzcx_f2274eef-e55b-4805-982c-fd1f1b1cb13b"
      unitRef="usd">-1261000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RleHRyZWdpb246ODZkOGIyZDAzM2QxNDQzN2IzMmE4YzM5MDAxNWE3MTZfNDIwNw_69807aff-6c47-4843-bba3-39978ab7479a">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by segment and product category were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i120c5c3448804817954acd3db4e441ce_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMi0xLTEtMS0xMTY3NzE_bda8bbe2-92d4-4e1b-9f0a-7645f948a16d"
      unitRef="usd">501000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f6e559fe09a4393a2f7b2d796409368_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMi0zLTEtMS0xMTY3NzE_68982229-3893-4987-ae51-951807a92a7a"
      unitRef="usd">69000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1917cf604f114f61a3027f48b8e509ba_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMi01LTEtMS0xMTY3NzE_4dee3819-6e7c-41fa-b6ce-87204771b1c9"
      unitRef="usd">197000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i304de3dee0ca46afbd4d773d5b73caeb_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMi03LTEtMS0xMTY3NzE_3090211a-2780-4f93-8feb-6a7d13dae659"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5bdd34908934731b3f7ed30e692ca37_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMi05LTEtMS0xMTY3NzE_fc5353e4-61d8-4c0d-9038-04b229ff6e29"
      unitRef="usd">117000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib94cfde72d4a4cceaa45cabf3b8613fe_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMi0xMS0xLTEtMTE2Nzcx_ddbefafb-ad06-4e39-bbdb-9fbd89872391"
      unitRef="usd">884000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i697b4e937dcf4444a2da425da4f9da4a_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMy0xLTEtMS0xMTY3NzE_f63b41b5-2c9b-4577-a636-f9f787289c6b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8bf870b296aa434ba035c90e0472f7b5_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMy0zLTEtMS0xMTY3NzE_31b2a64e-039f-450e-9fde-a9abd5464a2b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37722f9f64464a7789b7776cda56802e_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMy01LTEtMS0xMTY3NzE_eff6dc1f-9c6f-41d6-80c2-a66dc50920e6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68e196aa912c4a06b50fe1a7ff07c9c3_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMy03LTEtMS0xMTY3NzE_5b70ba4f-3d98-452e-9bb0-81bb9eae1796"
      unitRef="usd">57000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1535a26028ca41d681e4eb89f1cab0ef_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMy05LTEtMS0xMTY3NzE_3263e72a-cd97-4b8c-8cd5-4f417383f53d"
      unitRef="usd">392000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ac012d36aa744d285111dd5bfa0f49b_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMy0xMS0xLTEtMTE2Nzcx_2ce10cf1-82c1-449b-af7b-6774922489cb"
      unitRef="usd">449000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1532aea43eb6489e973b019623e7468c_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNC0xLTEtMS0xMTY3NzE_3397beaf-0948-47a0-871f-e7c1c47650db"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i40ac48836f7b4475b5d15a50602624db_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNC0zLTEtMS0xMTY3NzE_c0e177fe-dbd9-4e02-9064-76a9bc9e4aa9"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3591c7e9bf84e3b97a9bfacbd8fc4c0_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNC01LTEtMS0xMTY3NzE_ab9b89da-173c-4a5c-9420-28dc33148e1e"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9945eced06dd4de19098303f4b0695b2_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNC03LTEtMS0xMTY3NzE_19a05855-4ab1-4c1e-9fc0-68133e0812e3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6fdf97ea30640ada7e3f06ac163c2d4_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNC05LTEtMS0xMTY3NzE_23323842-6263-485c-920e-8d69be7c2d16"
      unitRef="usd">364000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i363714d873034daabe033fe4530323c5_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNC0xMS0xLTEtMTE2Nzcx_4e4c5997-8263-4d90-8565-937e1350b6e1"
      unitRef="usd">400000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18def26b9d7f4f769191fbb1b702e4e8_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNS0xLTEtMS0xMTY3NzE_98a07482-b702-4d17-b4d2-7a7040431304"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9dde17363f0241f99f397e9fc622e2dd_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNS0zLTEtMS0xMTY3NzE_53dd7d19-0ca9-4aef-814d-91147c622069"
      unitRef="usd">122000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e6d327e99e94ae6ac9c9222edaffe89_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNS01LTEtMS0xMTY3NzE_b6b44cf2-81cd-4623-b8d6-d6cdbd227c68"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2c6d5fc0df14fdd8c5d865fdd5a471f_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNS03LTEtMS0xMTY3NzE_08c12985-09aa-46a6-a99d-ae32d8947dc2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5244d54181f2446bb8ba651b7b0fbad7_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNS05LTEtMS0xMTY3NzE_92567e2d-8060-4002-ace6-6a6e1678b03d"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id527f274d97e461ab64689a5373f4d81_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNS0xMS0xLTEtMTE2Nzcx_c6f68e75-1dde-4bec-bec9-1960c32c1a42"
      unitRef="usd">214000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b3c647fe76d46f0bc12c314d43c29b1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNi0xLTEtMS0xMTY3NzE_288ce851-9c36-429b-a813-0b475246a839"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4daa40222c247d590b95cd5d1197454_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNi0zLTEtMS0xMTY3NzE_1d9cf92f-6548-46d0-820e-4e7216cddf6c"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00857c1731c645e18fc5b267ac5193c4_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNi01LTEtMS0xMTY3NzE_8af81b68-c37d-4bc2-8bfe-8edcbce3735b"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id70a3d87ffc848f3a702d8181bb0aac1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNi03LTEtMS0xMTY3NzE_7a26b107-8f3b-4bec-a63c-a6947ccb8a50"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9098718d68eb4191b04c1220647b46ac_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNi05LTEtMS0xMTY3NzE_35d737c7-1988-4bb0-a099-9e571deee3cf"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98252b07170a475c86a2d0a8454ebb3e_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNi0xMS0xLTEtMTE2Nzcx_8737fdf3-b7f6-409e-a342-653e6934585a"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d0cc468650a4f8eb079db9c1f1d724f_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNy0xLTEtMS0xMTY3NzE_1858ba28-beaa-48e5-9574-76bab7a2dc2f"
      unitRef="usd">501000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb0c495400cf41aaabcb4ebdf8cc8c54_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNy0zLTEtMS0xMTY3NzE_f718e38e-265b-47b0-890c-a1c0907408d1"
      unitRef="usd">233000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52b3e89147934577b98cf490c2dc6e6d_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNy01LTEtMS0xMTY3NzE_4ec1471e-6d55-4e0e-8d2f-c123082c49bc"
      unitRef="usd">235000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad533e12c8984d1aabaf4ca2ea7f295f_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNy03LTEtMS0xMTY3NzE_1158312b-8e5e-48e1-8ee6-d2258966bf37"
      unitRef="usd">57000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8a84b3f2b824ca7bb450377f0288abe_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNy05LTEtMS0xMTY3NzE_b0373f60-3692-4173-835d-31518fe0ea0d"
      unitRef="usd">941000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfNy0xMS0xLTEtMTE2Nzcx_af3d1a41-6ee1-40f3-8da0-4890cec65df3"
      unitRef="usd">1967000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id997cc25c0184d418316a9c77c4792d5_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTAtMS0xLTEtMTE2Nzcx_d340eb31-7cf0-46b2-9950-2af08dc452bf"
      unitRef="usd">514000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i175f3c9ffed049e683076ff08bfebbbd_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTAtMy0xLTEtMTE2Nzcx_bc3c8dda-31da-480e-8a91-5e87b9079825"
      unitRef="usd">67000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia439123672ce49b5b793b5103844ab11_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTAtNS0xLTEtMTE2Nzcx_c9e1bb91-c473-4f0b-ac50-c97f35b4f603"
      unitRef="usd">223000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3a10c843c354c3eb832c610df7c4cec_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTAtNy0xLTEtMTE2Nzcx_8b4d4ac4-62e2-429d-b220-85578080caeb"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i094e2621cd8646149b22d5835913eff4_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTAtOS0xLTEtMTE2Nzcx_48b0a06b-cff8-42c8-9a0c-3e1938cb45d2"
      unitRef="usd">138000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8d1a68df38d4361a9ac80a5d0b7650d_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTAtMTEtMS0xLTExNjc3MQ_3f06222f-8705-4c65-a4c4-301fc488a10f"
      unitRef="usd">942000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f1a30d7d1d8412cb4ef23629b723985_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTEtMS0xLTEtMTE2Nzcx_ef047b2a-7309-42cb-88df-40b23aef54a4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i55e9e9d493b84ce3b937b48d26431696_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTEtMy0xLTEtMTE2Nzcx_55e92d37-619b-4952-8ceb-a7da1f43c139"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia453e822304242f5817dad90b1b13517_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTEtNS0xLTEtMTE2Nzcx_fd26091d-65d8-4121-b8a1-b525cb175cac"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf81fc999e7d4614a4ac10b31038913c_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTEtNy0xLTEtMTE2Nzcx_8fa4644d-0ca3-4bd3-8b49-921df4f0b425"
      unitRef="usd">73000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie523d947f1fa44f2a62fe53506efc11d_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTEtOS0xLTEtMTE2Nzcx_50f3876a-3e68-4039-98c7-f0e81b7e3a62"
      unitRef="usd">397000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45ab7ba925334c48973d75b0c877af73_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTEtMTEtMS0xLTExNjc3MQ_9d0b9f50-80ff-448a-8f22-85dcea6084be"
      unitRef="usd">470000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic38842b1d031468aaa7b2c3123e44ef8_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTItMS0xLTEtMTE2Nzcx_d7cb240d-09af-42c7-a08a-4d0abfacc2d1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i636acc71a6ad4a25a53a6db7c8380b4c_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTItMy0xLTEtMTE2Nzcx_321138be-569e-4168-b923-4ec5e4b313da"
      unitRef="usd">32000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71427b5dcdf84da295d3722e33c25b53_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTItNS0xLTEtMTE2Nzcx_0bdb3fab-7f2a-4ced-b366-207279c120e3"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieda5739af68749139a002f6bbc8b7968_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTItNy0xLTEtMTE2Nzcx_215b7eca-33fe-49b1-af67-6b175a996745"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8cc095d5494b464eba663d1927c92206_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTItOS0xLTEtMTE2Nzcx_42b10a94-45d3-4c9b-9b53-58afb9491362"
      unitRef="usd">325000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ff22abce45548b7ae5bae24b04a665a_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTItMTEtMS0xLTExNjc3MQ_9cc5dd2f-5266-4838-8778-7ed9d86d6e9b"
      unitRef="usd">359000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6117b7192764a0b83f96ffa1cb7174b_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTMtMS0xLTEtMTE2Nzcx_45bff8fd-49f3-4c5a-b168-b735e38aedd2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66e4cb2eef1c497aba28c323a09b369d_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTMtMy0xLTEtMTE2Nzcx_eb785002-8a1e-485c-b50c-be3f5098002c"
      unitRef="usd">206000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7885ad991d8747f994509e41120e1156_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTMtNS0xLTEtMTE2Nzcx_5b4b219b-09e7-4108-98d0-45797b521246"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i033175b733ff4d76ac19b4af757b2c72_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTMtNy0xLTEtMTE2Nzcx_477375fe-dbdb-4af4-bdf8-74181dcce6e1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a94cf1fdbb647919430b66b2c3f4818_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTMtOS0xLTEtMTE2Nzcx_b0cdb3a0-b333-488e-8be0-96cd20f16dc4"
      unitRef="usd">68000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa1d61d59efe430d99d872a21dbbb93f_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTMtMTEtMS0xLTExNjc3MQ_1fde9fb9-ebd5-49b2-a00a-6d32f8f9ea37"
      unitRef="usd">305000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58fa049f1be9491d86f8e95d6a2c5777_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTQtMS0xLTEtMTE2Nzcx_a4e6d993-9422-44ff-b7ae-583f478c2b37"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie753b580b8874261b8650c0a68ba8d70_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTQtMy0xLTEtMTE2Nzcx_b705fc3d-30f0-46b0-abee-686800dbece1"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5c02cb63e5b4aa3a0984f648ed39900_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTQtNS0xLTEtMTE2Nzcx_0a5c1884-00ad-4fe7-9f82-906e4c915161"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iecf369ea76514f31b38a239710bbca0f_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTQtNy0xLTEtMTE2Nzcx_e17170c5-941c-496c-b00e-7b677e6336ac"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8530b669e5514873aea052a84f77f1e8_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTQtOS0xLTEtMTE2Nzcx_a31855be-c52e-4116-b2ae-9854e5432518"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i13a41399fcd14f7c86e4befc31b9bed4_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTQtMTEtMS0xLTExNjc3MQ_40819100-2337-47f7-9731-36fb5850b393"
      unitRef="usd">24000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96c50519eebe43e28fe0e6f1d4c9fcf4_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTUtMS0xLTEtMTE2Nzcx_6d75aa30-9468-4f70-abbe-37b1d3183cc3"
      unitRef="usd">516000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96c60e82572346049ef163998e5a970d_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTUtMy0xLTEtMTE2Nzcx_99258768-9b72-41a1-8b21-2e2e616dd93e"
      unitRef="usd">313000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0da421ef8e5c446692c399776ebed030_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTUtNS0xLTEtMTE2Nzcx_9f18191f-0a84-472d-a8bf-c04bc189bb01"
      unitRef="usd">264000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0702da316be6440e840ce3f2f1780427_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTUtNy0xLTEtMTE2Nzcx_dbae25e0-627f-48f6-9c46-87b238381119"
      unitRef="usd">73000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iddbe6a4096ff457cb62338fc9c69d310_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTUtOS0xLTEtMTE2Nzcx_fc3077ae-1b13-4be0-8b2c-6978b9828d38"
      unitRef="usd">934000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTUtMTEtMS0xLTExNjc3MQ_1ea2f6ce-3fbe-4128-976e-34ea68ae43fa"
      unitRef="usd">2100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie25fd17d002a4da395da4369a027c307_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTgtMS0xLTEtMTIwMjUx_451b208f-9c08-48f1-98c3-489020f7ab02"
      unitRef="usd">965000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4ef1ddaae604d258905581fe15e36d0_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTgtMy0xLTEtMTIwMjUx_40b7bfa5-0877-4fce-87d8-b3d30333e12f"
      unitRef="usd">134000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5239df425024a3e9d3b04b6422f8d1c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTgtNS0xLTEtMTIwMjUx_fa283c57-6605-4346-aec5-92c1de1ca313"
      unitRef="usd">402000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i425a979e48b04f06b178c9b31d745920_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTgtNy0xLTEtMTIwMjUx_3a54f786-a17b-4ee0-ae79-1e3895162431"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1b2fa78c45a42dd8e6d9fc4f37b7f8f_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTgtOS0xLTEtMTIwMjUx_d1201ad8-50ff-449d-b209-2e986c8e0ddd"
      unitRef="usd">227000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd114af7b13347929658a839ced9cb43_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTgtMTEtMS0xLTEyMDI1MQ_3df6b0ee-7ad6-4b8c-bd2d-eed2923db96f"
      unitRef="usd">1728000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c7ae506423648cf912c0b4dafc6bb92_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTktMS0xLTEtMTIwMjUx_cbe67007-efa0-4519-930a-7f55be796059"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4fa22ed31f5d47d78586f590cb5b2296_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTktMy0xLTEtMTIwMjUx_9631a82f-53c2-461e-b39b-d7ebcadef455"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if81393d129bb4f80a2217b7c9d4c8957_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTktNS0xLTEtMTIwMjUx_42990302-79bf-4a22-9b73-f18d4141bb63"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08b72bf14f6c499fbdab27dad66f293c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTktNy0xLTEtMTIwMjUx_6f68fc23-e7f1-4335-8237-99db267062e5"
      unitRef="usd">129000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2e2aafd1b5e4899a9552e3dacb16fce_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTktOS0xLTEtMTIwMjUx_3971c81a-1b1c-42de-94a0-28510081f644"
      unitRef="usd">778000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iffba9783b7fe44a6935ad5a994bbbee4_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMTktMTEtMS0xLTEyMDI1MQ_a7a0f14d-08ae-48af-9179-fe201f554f5f"
      unitRef="usd">907000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id62f002563a345a4b90b427b6746a4ba_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjAtMS0xLTEtMTIwMjUx_7b11a988-44a9-4795-be5e-3bcd17e72dac"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff8125862d7c4fa8b63656e4caef3fea_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjAtMy0xLTEtMTIwMjUx_d0fd2be5-222b-41b5-871e-4ebdb19fe274"
      unitRef="usd">73000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1843b2170f054dfda4d14d6b65d9e07e_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjAtNS0xLTEtMTIwMjUx_53c3b653-c61f-4fc7-8591-da522e4d4ab9"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i875a6c5886a44cbe9f224b9739a1d650_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjAtNy0xLTEtMTIwMjUx_5bddb27a-06d5-4231-8970-2d92e478c98e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife0400651f12423ea171a23fe5b7b728_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjAtOS0xLTEtMTIwMjUx_a6de463a-317f-417d-9673-7d69aeb4296b"
      unitRef="usd">699000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9906ce0703774a55b40a2d2cbed1fa6f_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjAtMTEtMS0xLTEyMDI1MQ_5ef6c6b7-fd33-4670-b740-9955cb44b118"
      unitRef="usd">775000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ba7a99462cd4381a45f105bbdc6d784_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjEtMS0xLTEtMTIwMjUx_ff126052-30bc-4d11-84ec-fa204ce8b1e3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39805184860940d5bd360342cd8f0cf6_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjEtMy0xLTEtMTIwMjUx_eb9e0a3a-c6f6-476b-ab67-c116652411e1"
      unitRef="usd">255000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf03874e602d4ffa881dc7e9af5ec89f_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjEtNS0xLTEtMTIwMjUx_d35912ee-d022-4b55-8419-4126fbd5bc4f"
      unitRef="usd">67000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic07dceb99d094428b0107fdfd7ea2ded_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjEtNy0xLTEtMTIwMjUx_ff7cb827-4e72-4be4-8351-562fe54642fa"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b8d25aa564b48688828b7b52a248072_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjEtOS0xLTEtMTIwMjUx_e5cb3c7c-6d9d-437d-9bbb-bc0f66c900db"
      unitRef="usd">113000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa7024726e6548129771c398104f4234_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjEtMTEtMS0xLTEyMDI1MQ_7c6a1660-fbbd-4346-9e15-db872909c3bb"
      unitRef="usd">435000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i09631ce9f39243a38774112d96ca119c_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjItMS0xLTEtMTIwMjUx_62d46704-b5a2-49a8-a0d5-a60ddb283805"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36c7f7595c284373909f23141e52949e_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjItMy0xLTEtMTIwMjUx_b6aac767-0ae1-4777-95be-bde0ab4cf9bb"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4105a97cccf946db9ca58a8b45433ea7_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjItNS0xLTEtMTIwMjUx_84cd1077-f2cf-4154-b37d-75fe92e90ec5"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57f06f60daf14282b059eb9c693125a2_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjItNy0xLTEtMTIwMjUx_c20f214e-b352-4717-a43f-6e3c7789ec8c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05e092a9ec4e49c6a71e8efa4a8d7087_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjItOS0xLTEtMTIwMjUx_bfe6d5b8-6fde-4bca-8bac-db03aef252e8"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4002b0e7cb584f409ca3835643a996ce_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjItMTEtMS0xLTEyMDI1MQ_30b3a77d-63f6-45ca-bc63-a24a312a743b"
      unitRef="usd">40000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c7b76190d5140fd9da04108a1ed24e5_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjMtMS0xLTEtMTIwMjUx_362e336b-dae4-4e40-b2f8-3f46054001eb"
      unitRef="usd">965000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i430a37ccee354cf9b59987d97e781a8f_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjMtMy0xLTEtMTIwMjUx_6e69c83e-20c5-4fe0-9b15-678cad3c3338"
      unitRef="usd">477000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iecd0285b18fe41da9fc167864657bccb_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjMtNS0xLTEtMTIwMjUx_acaa3093-000a-4166-a879-d2616866772c"
      unitRef="usd">484000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i864ee40a0f6549cab4f16fffdd93c3fd_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjMtNy0xLTEtMTIwMjUx_cb2da099-891e-4ceb-92d3-b8ded43c1d20"
      unitRef="usd">129000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86bd562069224eb1a2aa48a2a7c117a3_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjMtOS0xLTEtMTIwMjUx_db98482a-faf4-4715-892a-6e11818b82b6"
      unitRef="usd">1830000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjMtMTEtMS0xLTEyMDI1MQ_e1046a74-5d4b-4b0f-a811-4163ad3a224b"
      unitRef="usd">3885000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ecff54947c94ec5a731ac192a3eac6f_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjYtMS0xLTEtMTIwMjUz_aa0971e4-e45c-488c-a3c2-7511dd09733c"
      unitRef="usd">984000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie837436aa8784d168ff0c0b936ad7cbe_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjYtMy0xLTEtMTIwMjUz_76bd7c2a-b9a2-4ae2-9b55-da91a14e5eda"
      unitRef="usd">126000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5f965033d67432c81edaee2da1a1977_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjYtNS0xLTEtMTIwMjUz_208b5bcf-04ba-4840-a0a0-12ad005d12b0"
      unitRef="usd">465000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0bde276d18e442d082198091776c5340_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjYtNy0xLTEtMTIwMjUz_23269b90-9119-4d8c-941b-7b038bf78ba6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i406023bd6e5f421284bd2cc748d58de8_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjYtOS0xLTEtMTIwMjUz_cf624fa8-af18-4fef-9a8b-89f1a2cda153"
      unitRef="usd">259000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86081bcd6aa54f46bf54174fe6157caf_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjYtMTEtMS0xLTEyMDI1Mw_e6df5cf3-eb96-49b3-89f3-60bcdae1a1ed"
      unitRef="usd">1834000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d9741cc605c4351b5b3308c245d8cae_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjctMS0xLTEtMTIwMjUz_35c6b019-4bf0-4b5e-b097-461cbbf74ef8"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8bfae50f3756423ca86237fa9b199c6f_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjctMy0xLTEtMTIwMjUz_d07f6312-ab68-44fe-b1e2-a9dc1a245456"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie00839f31b7c419293449f6db9edd59a_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjctNS0xLTEtMTIwMjUz_176d90ad-d770-4ac0-90a6-ee4656ad09aa"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64314cb261074ff9adb800d48da61982_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjctNy0xLTEtMTIwMjUz_c8b2a975-0fd2-4273-aca0-ef866ed9439d"
      unitRef="usd">145000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i895071e19f56442e8979c066881d9317_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjctOS0xLTEtMTIwMjUz_728681d2-bb2b-42d5-91b9-8ee14eb0c66e"
      unitRef="usd">779000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia36c07693d1f4df588ce2d80fa89ff6e_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjctMTEtMS0xLTEyMDI1Mw_6475b61c-cd91-452d-8162-d78da67d1cc6"
      unitRef="usd">924000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib42a147c0c7b4941bae23485591fe3e2_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjgtMS0xLTEtMTIwMjUz_fa2b41f0-75bc-40d3-a113-77bf4216768c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c9e5781756f4250be2a94d03142b737_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjgtMy0xLTEtMTIwMjUz_858281b7-5ecc-4bfa-bd9b-e77377cd9e42"
      unitRef="usd">57000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98b834d54e804d5ea61ab8adaffb5153_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjgtNS0xLTEtMTIwMjUz_0c6a1d19-21f1-4726-a57f-70658c1e698e"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3fbc6006e021429bb57b14e5be7faea9_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjgtNy0xLTEtMTIwMjUz_a9f7a9df-28cc-47b7-9ded-a616f55dfb02"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a5341f0ece54bcca5e06f9dbc2c5aa7_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjgtOS0xLTEtMTIwMjUz_a9955295-e5bf-4ec7-8732-398352d9376f"
      unitRef="usd">645000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4be2243ad7b746ff8509e04bcc66e578_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjgtMTEtMS0xLTEyMDI1Mw_0a93bc00-2dd8-40e5-bb74-61039a796780"
      unitRef="usd">706000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28cd923a4f904a5da05278a0549bb209_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjktMS0xLTEtMTIwMjUz_edb7063a-772f-46de-b91d-272702e8ebae"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a79025dcf9b4067a64a869b30e5d82f_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjktMy0xLTEtMTIwMjUz_5076d355-4344-4ed8-9a33-58a425b9ec35"
      unitRef="usd">418000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85da69a1931c49e8b2e5ce17cb63defa_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjktNS0xLTEtMTIwMjUz_6c67f1ab-f0e4-42a3-bf25-6ef342cd3a67"
      unitRef="usd">78000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c72a40331c64039b9c3787b46aac39c_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjktNy0xLTEtMTIwMjUz_5392a353-aea5-4af7-986f-a96136d05704"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf5411fb6d544cfd8fd5bf410f862cbc_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjktOS0xLTEtMTIwMjUz_8c50d5ec-7590-4b9e-8084-96e15431b96b"
      unitRef="usd">119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5a9a936aaad4510ab5bf3d9d20d705c_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMjktMTEtMS0xLTEyMDI1Mw_bd8907ec-0afb-40ab-8f13-9a7eae8ddd6d"
      unitRef="usd">615000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73af0e3646d5483ab230a7ecb7d39952_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMzAtMS0xLTEtMTIwMjUz_221a775d-43d5-4889-b502-349d23b192ae"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia56d626754214d8bb30c6d8a7af45bde_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMzAtMy0xLTEtMTIwMjUz_3740ed77-8988-4794-944a-c4f862b59bd2"
      unitRef="usd">18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18484995d42c4a828a942edcda3b3121_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMzAtNS0xLTEtMTIwMjUz_8729a268-e5d6-4e2b-a157-be1ce80096f1"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i13c03a791f84448bb0b7d082960d3002_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMzAtNy0xLTEtMTIwMjUz_7384102c-2d65-4cae-bb99-44a98ae35a68"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ed7a35687114a9980b0c5849d0ae283_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMzAtOS0xLTEtMTIwMjUz_c922de73-e6d1-4ae7-aaaa-b536624b8d79"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id15af34d73934993bcabdfba417f3137_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMzAtMTEtMS0xLTEyMDI1Mw_27f627f9-607a-426f-9f0a-34166fb7036e"
      unitRef="usd">48000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id018321b208247d78d77fe559ea5026b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMzEtMS0xLTEtMTIwMjUz_0e818661-df85-4000-873a-794b5c3c4da0"
      unitRef="usd">988000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04f8b4bf53f849b2a0c2101807367a6e_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMzEtMy0xLTEtMTIwMjUz_2ebec953-a97f-497e-9222-0ee3fbbccd81"
      unitRef="usd">619000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99757cb9fe65492481f94c5710ab5f19_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMzEtNS0xLTEtMTIwMjUz_cb7c6b2f-00ba-4eb7-8569-c1c5ac27d941"
      unitRef="usd">560000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib382d5d0d22742d48bc99e77c138c9e1_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMzEtNy0xLTEtMTIwMjUz_872c324b-699f-4e25-b146-cd0691502725"
      unitRef="usd">145000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20309133d4fc442aa35447c20bd22671_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMzEtOS0xLTEtMTIwMjUz_749db3b2-f03b-4427-8b4f-cd85d6d17467"
      unitRef="usd">1815000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOmEwODY0NjlkZGIzMTQ5YzFiZmNlYjlhOGYzMjhmZWJjL3RhYmxlcmFuZ2U6YTA4NjQ2OWRkYjMxNDljMWJmY2ViOWE4ZjMyOGZlYmNfMzEtMTEtMS0xLTEyMDI1Mw_e97b4887-4c01-42cd-b17b-d68dfd33f3cd"
      unitRef="usd">4127000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <bhc:ConcentrationRiskNumberOfProducts
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RleHRyZWdpb246ODZkOGIyZDAzM2QxNDQzN2IzMmE4YzM5MDAxNWE3MTZfMzgxMw_663e2b7d-0b86-46b6-8700-a6126593587a"
      unitRef="product">10</bhc:ConcentrationRiskNumberOfProducts>
    <bhc:ConcentrationRiskNumberOfProducts
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RleHRyZWdpb246ODZkOGIyZDAzM2QxNDQzN2IzMmE4YzM5MDAxNWE3MTZfMzgxMw_f61456e1-87f5-4f3c-b0ed-57a8abf89429"
      unitRef="product">10</bhc:ConcentrationRiskNumberOfProducts>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2cfaca18cad64ba8b05f366fe634d9ef_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RleHRyZWdpb246ODZkOGIyZDAzM2QxNDQzN2IzMmE4YzM5MDAxNWE3MTZfMzg0OA_41a44d96-a4ae-4d51-a630-dbff65a093d6"
      unitRef="number">0.48</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4deb7698e4954a5b8d104244e7a7dc24_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RleHRyZWdpb246ODZkOGIyZDAzM2QxNDQzN2IzMmE4YzM5MDAxNWE3MTZfMzg1NQ_3df4630f-534c-450e-bd88-e3f708ef57f2"
      unitRef="number">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RleHRyZWdpb246ODZkOGIyZDAzM2QxNDQzN2IzMmE4YzM5MDAxNWE3MTZfNDI0NQ_9bbf1d77-f9fa-4f2b-90ef-cdc94b1342ed">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are attributed to a geographic region based on the location of the customer and were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Poland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Russia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Italy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;South Korea&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9362d500d1bd48e4b930877c7401396e_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMi0xLTEtMS0xMTY3NzE_c34706c7-3abe-4d49-861c-57d2c3f007f1"
      unitRef="usd">1190000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i456aa1b7ef8e4440b7cb8b6579de00b4_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMi0zLTEtMS0xMTY3NzE_3f31c9a3-baa7-4807-a015-9ac85c246769"
      unitRef="usd">1216000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5171d1e65dcd4cbdb5cc14e47de1aa9b_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMi01LTEtMS0xMTY3NzE_07876f8a-74b2-402d-a6dd-68c8ce9f6e63"
      unitRef="usd">2305000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9ff5741a13c41598bd951eb6df22a49_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMi03LTEtMS0xMTY3NzE_7ce513bd-ba68-4f77-885e-94b1a402f4e6"
      unitRef="usd">2378000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9c0f8ff2e5749af9aff83169945c02a_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMy0xLTEtMS0xMTY3NzE_4a7fe09e-12de-4947-b848-86ae2034c4b4"
      unitRef="usd">74000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43c8fbd8ff914b6ca19f0386f21d064b_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMy0zLTEtMS0xMTY3NzE_1c25c747-16e7-4f68-aa1b-c2edc7b4d8df"
      unitRef="usd">119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14ff28c4ec8a4de49643e94dca541c07_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMy01LTEtMS0xMTY3NzE_9e8e002e-21b4-4bfc-9552-4bea5d5b3745"
      unitRef="usd">177000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia381cdacc8be46eca693495fb7945846_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMy03LTEtMS0xMTY3NzE_0987c3b2-6172-451d-af02-158c3ca37374"
      unitRef="usd">229000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe893c791888473889bea0f1c91bcd39_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfNC0xLTEtMS0xMTY3NzE_1eca24f2-758f-45c6-a58f-5a99d73c01f1"
      unitRef="usd">88000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia641b1adcc574ee0ab038b7fa110e50a_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfNC0zLTEtMS0xMTY3NzE_ae38732a-0c42-43ac-b3b3-4f0bb8ab66b5"
      unitRef="usd">87000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7834297d0db94dfe9f7141a9f3078f4d_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfNC01LTEtMS0xMTY3NzE_f399425c-19e0-4783-ad00-3b5ce1087e48"
      unitRef="usd">166000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i591e4832b4f54fbb9d7adb9df692f736_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfNC03LTEtMS0xMTY3NzE_36cca8b1-7d47-4517-8700-49248628e006"
      unitRef="usd">163000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ed4f56387c146ce93bc623b05db992f_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfNS0xLTEtMS0xMTY3NzE_0eab6f88-810e-4bac-b4d0-1a402efa54be"
      unitRef="usd">63000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f1990f6b2cd456e92b332bb89de592f_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfNS0zLTEtMS0xMTY3NzE_e8332418-b999-4093-8719-b0aa2e441ed3"
      unitRef="usd">71000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60c79a94ccae45868e7311a72fb1d515_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfNS01LTEtMS0xMTY3NzE_2af1d1b8-0bdd-4cb8-a723-3cfffc17f341"
      unitRef="usd">139000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i884265fef55745918deccdac9bcfa489_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfNS03LTEtMS0xMTY3NzE_8e72c82c-314c-421e-b0b0-f79876965bbc"
      unitRef="usd">133000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i069927ecb29c4fe080759394b3c8dc0c_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfNi0xLTEtMS0xMTY3NzE_1680506e-fee2-4688-b573-bd12a2bb1a70"
      unitRef="usd">69000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ced9f4e29364491b1408b971112bc7c_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfNi0zLTEtMS0xMTY3NzE_2b36cc30-7b59-4a1b-88af-60e22ff6939e"
      unitRef="usd">56000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibdc9dc66188149c59e6c7ce0524d38b6_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfNi01LTEtMS0xMTY3NzE_245b9ec2-ef99-4a18-8125-95d1b9fdad44"
      unitRef="usd">130000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6bf2b6a85341450abb18712f9efb5eda_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfNi03LTEtMS0xMTY3NzE_b5e6ec90-43b0-49d0-8dd3-6e4685d451eb"
      unitRef="usd">125000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7053004fc5084f679e0978de05d595ea_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfOC0xLTEtMS0xMjAyNTc_f54d26fa-5ea5-4c1b-9902-65df1f9d3d7d"
      unitRef="usd">58000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31517ff0a8fc467a97fb7a044c926728_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfOC0zLTEtMS0xMjAyNTc_ba79a3f7-81d1-446f-885a-1bd266934712"
      unitRef="usd">56000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70de35ed376b493a9c17e9a01ab991c0_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfNy01LTEtMS0xMTY3NzE_47243fde-5986-4f02-98e3-1ce443a9ef6d"
      unitRef="usd">115000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib63abbc4e400433b9f6ec4a807834bce_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfNy03LTEtMS0xMTY3NzE_5bb86458-969d-4393-9ac0-f9b13dc41cc4"
      unitRef="usd">110000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60d3cf48dd964670a527396a7fe4eb90_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfOC0xLTEtMS0xMTY3NzE_8ebf242e-70ca-4a3c-9c8c-483b6c638caf"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73244b3c309e4530819a1d26aa067e4b_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfOC0zLTEtMS0xMTY3NzE_56ad4409-083c-4fb1-afcd-f9791914833b"
      unitRef="usd">55000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie300b629f5f74f4a92f1b3212fe0f30e_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfOC01LTEtMS0xMTY3NzE_0704be8a-5b1b-482a-8839-1c59fbd0c8b7"
      unitRef="usd">101000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6948cd6efdde4ea5884d6a6035885001_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfOC03LTEtMS0xMTY3NzE_698bda67-2aad-468c-9ad4-e2ceed1df946"
      unitRef="usd">115000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idce9b5dcada741cfa3553faf07a2ab29_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfOS0xLTEtMS0xMTY3NzE_67817234-d96a-4219-8430-924d843afca5"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17e0e178db084c9caca62884ab5d8e93_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfOS0zLTEtMS0xMTY3NzE_5c60cff2-4293-4db1-b511-8b992c30507e"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e2d85cd6a68443cb41d6924d9e95324_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfOS01LTEtMS0xMTY3NzE_804adf56-181a-4bd9-89ab-bf00735c6aa6"
      unitRef="usd">80000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i42b0806f1ff343be83a859afbca2a621_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfOS03LTEtMS0xMTY3NzE_d4d424ed-f757-4cf0-bf53-a9a529eb4f25"
      unitRef="usd">70000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i443d6ce9e17f413aa131fd871f9a563c_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTAtMS0xLTEtMTE2Nzcx_2a15964a-5266-4ba5-b92a-357171235392"
      unitRef="usd">29000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i084806bf6a674211835a0bd79f97abba_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTAtMy0xLTEtMTE2Nzcx_3a05883d-82f0-41ff-8333-7d9553c80dc9"
      unitRef="usd">27000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a390cca570a48afb39f787bcd7cada6_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTAtNS0xLTEtMTE2Nzcx_5af733fa-67ae-4ec1-9f8f-8e9d4d5f4bf6"
      unitRef="usd">57000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i869eb22b61c947cda0c17505c748ba31_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTAtNy0xLTEtMTE2Nzcx_66f7a0b3-cebb-434a-aad1-9776547cb29c"
      unitRef="usd">52000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99dbbb9db6434a699d016c9c43e9044f_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTEtMS0xLTEtMTE2Nzcx_f9814006-3010-4de7-9809-e63ac9823570"
      unitRef="usd">38000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icce4f70058be4e0b99727594cbdf1550_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTEtMy0xLTEtMTE2Nzcx_6420318e-4f4c-414b-b20c-edf7aa35fd71"
      unitRef="usd">33000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e85ab61967049ef95c26fe225814698_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTEtNS0xLTEtMTE2Nzcx_78ab9e09-7ad8-4df7-af35-c9c053e4516f"
      unitRef="usd">63000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i007fd7d6bf5e4f9e867874fad1935ed7_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTEtNy0xLTEtMTE2Nzcx_11e2386b-e92e-4e67-8cea-66bacb62a478"
      unitRef="usd">64000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5eb5ee1718564d8b976f1851830b7dbd_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTItMS0xLTEtMTE2Nzcx_7ce3c18e-d49f-4a21-ad80-73b76086355e"
      unitRef="usd">23000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i059deee3380c481ca365b22d8012a26f_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTItMy0xLTEtMTE2Nzcx_8b959554-be91-4cfe-9cbe-c90a50930346"
      unitRef="usd">23000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcc32b6fa5394db2a95a6046a14c34da_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTItNS0xLTEtMTE2Nzcx_d8b58977-8210-4f0e-984c-32a58fd911f9"
      unitRef="usd">44000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb02cd70b47347f8b7ffdf5647ef00c0_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTItNy0xLTEtMTE2Nzcx_f4de623b-df91-493b-9fc9-d8013c21ad3f"
      unitRef="usd">42000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7079eca37c44de7aacc67bf6c5a6511_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTMtMS0xLTEtMTE2Nzcx_bc185f28-efe5-41a0-965f-42736d8ef7dd"
      unitRef="usd">23000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b1368ef6dc84e9b8b1bacbf9cd7dd96_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTMtMy0xLTEtMTE2Nzcx_6491dcb6-040c-4db9-8af0-7d8f8319ecd7"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib74d8519f3d64c62a7f44ecee5857716_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTMtNS0xLTEtMTE2Nzcx_8a92935c-f541-4b26-b58e-2d4a07a9de31"
      unitRef="usd">43000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iefa92bbaed9340e4a7f6b8cfcdecb6ef_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTMtNy0xLTEtMTE2Nzcx_e4231835-c271-4d5f-bbcf-96023a3020ae"
      unitRef="usd">38000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70e4a3d5230a4ff8b71fd4c1597f8ffe_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTUtMS0xLTEtMTIwMjU3_d14096cc-d4ae-47cd-b46e-843b216c095b"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b528c8c45d94928a7607bd144197d86_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTUtMy0xLTEtMTIwMjU3_f5671031-56fa-4517-9acc-18444dc71f2d"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if74073e3926d4398abab160d9cbb64e6_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTQtNS0xLTEtMTE2Nzcx_f1789ff2-cf7f-4004-b19e-c7942f3c529e"
      unitRef="usd">39000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c750ce60d174c2d8ea17243fca49290_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTQtNy0xLTEtMTE2Nzcx_bab293a7-ef61-464b-9d81-7196f1f15bed"
      unitRef="usd">40000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i420e7b1dee5c49dbb3ab84d5bf60a017_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTUtMS0xLTEtMTE2Nzcx_bf9e6436-c715-4413-bed8-c61cabbaf459"
      unitRef="usd">207000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id551f20a7c294526a90193e44a7d481b_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTUtMy0xLTEtMTE2Nzcx_5cfabef9-1113-4f0a-b3b1-3020c774867a"
      unitRef="usd">288000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e57a428831244d0addaf1c93da509e0_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTUtNS0xLTEtMTE2Nzcx_7e844d4f-57b0-45a6-b668-05edd857c05f"
      unitRef="usd">426000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f42c8f52d064fceaa8822b15b9cebc7_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTUtNy0xLTEtMTE2Nzcx_1eb81315-e1d5-4beb-bf59-56434e113ace"
      unitRef="usd">568000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTYtMS0xLTEtMTE2Nzcx_ed537a04-1468-43a1-9b6b-31fb1b3bed10"
      unitRef="usd">1967000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9582b2f1b2d14fa2acf092f058010739_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTYtMy0xLTEtMTE2Nzcx_3c8ddb0e-3681-4c8e-83f4-aa19a2f9111b"
      unitRef="usd">2100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTYtNS0xLTEtMTE2Nzcx_cc84c395-63a2-413f-b3ad-5fb50ae16a99"
      unitRef="usd">3885000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i507b73cee6da4c61a623f2b81a6d0f4b_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjcyZjY0ODc2NThhMTRiNGU5MTY0ZWRlZWFhMGYwYWJkL3RhYmxlcmFuZ2U6NzJmNjQ4NzY1OGExNGI0ZTkxNjRlZGVlYWEwZjBhYmRfMTYtNy0xLTEtMTE2Nzcx_a464da9d-3847-4436-ae0a-592a10d1f5b9"
      unitRef="usd">4127000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RleHRyZWdpb246ODZkOGIyZDAzM2QxNDQzN2IzMmE4YzM5MDAxNWE3MTZfNDI0OA_903bfadd-acb3-4269-8f61-96a60ee7c787">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customers that accounted for 10% or more of total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation (including McKesson Specialty)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health,&#160;Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0cf345d189714dc1bec54dec30d5fe8a_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjRhN2Q5ODA3ODdmZTQzMzA5ZmJjYzIwYTNmNTk1NjdhL3RhYmxlcmFuZ2U6NGE3ZDk4MDc4N2ZlNDMzMDlmYmNjMjBhM2Y1OTU2N2FfMi0xLTEtMS0xMTY3NzE_56ae6aeb-0157-4a85-8ff2-c33515db1f7f"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i648582730a944818a8954c08f4676c96_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjRhN2Q5ODA3ODdmZTQzMzA5ZmJjYzIwYTNmNTk1NjdhL3RhYmxlcmFuZ2U6NGE3ZDk4MDc4N2ZlNDMzMDlmYmNjMjBhM2Y1OTU2N2FfMi0zLTEtMS0xMTY3NzE_052fa874-247f-4560-93ed-c345016f0609"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i227c1b875ad04673a4bb23d3cb69932a_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjRhN2Q5ODA3ODdmZTQzMzA5ZmJjYzIwYTNmNTk1NjdhL3RhYmxlcmFuZ2U6NGE3ZDk4MDc4N2ZlNDMzMDlmYmNjMjBhM2Y1OTU2N2FfMy0xLTEtMS0xMTY3NzE_4fb62638-dc55-418e-a3fc-c8aa5f1662b7"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i640e2ab4eb224f69a463e994c0e65ae1_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjRhN2Q5ODA3ODdmZTQzMzA5ZmJjYzIwYTNmNTk1NjdhL3RhYmxlcmFuZ2U6NGE3ZDk4MDc4N2ZlNDMzMDlmYmNjMjBhM2Y1OTU2N2FfMy0zLTEtMS0xMTY3NzE_2ea2e8cf-30b7-4a1c-b3fd-fd817144475a"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7ba3dd5c6bf14d8ea672f7543ae52430_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjRhN2Q5ODA3ODdmZTQzMzA5ZmJjYzIwYTNmNTk1NjdhL3RhYmxlcmFuZ2U6NGE3ZDk4MDc4N2ZlNDMzMDlmYmNjMjBhM2Y1OTU2N2FfNC0xLTEtMS0xMTY3NzE_de1e9c67-8c19-418c-82a7-0d8ff6077375"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i555a31f9bb61484a89ccf486fcac5905_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV85Ny9mcmFnOjg2ZDhiMmQwMzNkMTQ0MzdiMzJhOGMzOTAwMTVhNzE2L3RhYmxlOjRhN2Q5ODA3ODdmZTQzMzA5ZmJjYzIwYTNmNTk1NjdhL3RhYmxlcmFuZ2U6NGE3ZDk4MDc4N2ZlNDMzMDlmYmNjMjBhM2Y1OTU2N2FfNC0zLTEtMS0xMTY3NzE_76d80014-78d5-4b01-abdc-4a72db333dbf"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i6cb3866345124864badac5670e1d0aaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xMDAvZnJhZzo4M2U5NTA5NTAyY2E0MTg3YTUwN2U0MGVjZGZhNjFhMy90ZXh0cmVnaW9uOjgzZTk1MDk1MDJjYTQxODdhNTA3ZTQwZWNkZmE2MWEzXzExNTQ0ODcyMTIwOTE4_3dd67c32-f40c-4849-a1bd-c516d86d4555">SUBSEQUENT EVENT Cross-Currency SwapsDuring July 2022, the Company entered into cross-currency swaps, with aggregate notional amounts of $1,000&#160;million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its Consolidated Financial Statements from adverse movements in exchange rates. The euro-denominated net investment being hedged is the Company&#x2019;s investment in certain Bausch + Lomb euro-denominated subsidiaries.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i83b432d29b6b47c8a7c436116ed24dae_I20220731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc2MmZiYTIyOTM2OTQyNjI5NGM0NDI0YzIwMTVhMDFhL3NlYzo3NjJmYmEyMjkzNjk0MjYyOTRjNDQyNGMyMDE1YTAxYV8xMDAvZnJhZzo4M2U5NTA5NTAyY2E0MTg3YTUwN2U0MGVjZGZhNjFhMy90ZXh0cmVnaW9uOjgzZTk1MDk1MDJjYTQxODdhNTA3ZTQwZWNkZmE2MWEzXzExNTQ0ODcyMTIwOTIw_2c62f5bd-68ab-4403-b290-ca54bdaafe51"
      unitRef="usd">1000000000</us-gaap:DerivativeNotionalAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>114
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M_'['H0/8?E O3=J79*M_ 5!+ P04    " #\A E52QN <& "  #=!0  &
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;*U4;6_:,!#^*U8F3:W4D5>@91 )
M E5;=2TJW?9AV@>3',2J8V>V@>[?SW9"!%+H.FE?$M_YGN?NL7TWW''Q(G,
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MLWB_.8;H_+76D^]N_2@8_CY!_,J?W^'O&WMBQ8Z!_5I;!K"E'N+.Q)8NV<5
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MPM,.JJT Q&X%>+-E.GE54:ORYAN&3G1Q?P(Y!S;G")N4;="0V)1M5!!$)F/
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M;^[2T+6BA\< U6.(JL:QU-H)T&!)Y\).1<1ZA -P-W4'5 \;W]SEP0ERV6.
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M.:MR)BA_9YVO5F8<,Z77A#FX &!E/^3JD$4=X0]]\?^:T>%?G*>ZK+D8%@9
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M_5]XDO!\;U$."_(,YYIFF7T[Z!Y42[5$]&"Y)[@R;?\Z(>KXC0QBQRLN.;,
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M\G>"_J8R<_XV;V2JRLSX<JHD/)4&X/W88)GAAAC$CS7?_ =02P,$%     @
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M2SW%3S?4Q%$[ SI?*65?%L[!_K,P^@U02P,$%     @ _(0)52XK-K>-'@
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ML:5R_!J#X^$F>U&")11*-$J%5*6=-Y^I2\=2YX#Y;O.JJ3HG>CP9&F\#LP+
M)_ />*K=5_KH87?#F8<DIXJ!M5&ICBO8([B*]?LN-"0Q[ZQI\RX\T6JT;C+1
M3-?B]H1-NV@G>T0/XJ#FCXI:$]OZD7>37?A6.C>&W;*DTA=A.:AK.9S1J9V+
M,J\B6"&QE4=[>!LA^@W(4(F05\2I-#N*RJUU>)S)PD2ORJYS/Z5_WCT^F>LM
MJ%,E,/2+KBIP,?+[6E%8%GFEH'A?72JO!<2RKCQ+VFSX!\DU<!*J5/FX[GE\
MO&V YY% '8H*2THP>><6B%57<AGEA/6DLOQ&U5CH%JT(1"-4ESFZ<],<YGY'
M,D#E< :MZMX#6"Y6"%&,6:#5F)>A##69WL"V@#H3I1L-1\8=:]Q]0<('+P G
MISZ*\DI=RU*E*G NXTL#>R=PRZJ4'30-CLR5$R.O'N^+>Y^COHMK*N\&KY_T
M*!"$?7FOL*E>[KU691-H]N;BMJM^IGX/[^8CG.Y6QGU8Y%22&F^*%+]S[8.T
M2Y33)+G3V5=F;J^5%A01E?438E.Y[:X=GL@KB?M0/_&69MR!2?O:Z#)1O&I>
MAD9]3\6-!%MLSUCBW.D7=,U@)00&J)%?YMI@Q.O^TH*N%RJR2) $TXH-Q:=+
M(@<H&+36\*SBS?3EE^UM08^T94#[2$Y<W?Q%$2X0Y="X$L521Z7,Y7<>R<I
M!J89,,R"I-#1$S?W9&IVMK$)L9CKX*;.491+<ZTI,21=-5B6"=?*1LUCXB0*
MN,8O]H)0EN?W."/I)M1$*H2LQ&\'7Z TUSYYP5?B"/UV;>KI#$RF%**\[XR
M,<<A1OZ&U(=G.5<<(:\FEL',K,T[ZY&"*$HQAHE]<IGS="]?FY@C]H[K1_*R
M)6S8B0BM:IIG6Q1+%]F*0'/T1==@YMXC%THET.MR?+A1CH<;!3DE'[#J'M6O
M,8DDB^D+/.OXH2$U V)D](B0K]U9]?*(FDWC[D;K(GVY[V!/'F>9V-7V2_\^
M[,I;@G0@T@VEFFBRNKT2&4^F9-OI8R?R\*,'K8+[''2F>^/[V+EPZ)-[T5?K
M%4)66PZWUI:;@/)?*N"J%?^75LU24X\FV-O3U;L,JKT\U01L_/-8UF-HN:VI
MKIE#3S6[RK<GT&)$?=]A@V;H16*A9\V*0]N2A7:',#B*1?'A]G+73(F RS<\
M; '+=Y.\[JP/$KT[B=B^-1H)Y(&TLYS=7B9^;IWX*65?W[*M_'M:V>?L3T=H
MU(F$U']20DM%Q4Q@KR/VU2A+:HO1_9$!)R7W*M*#&1!D$">N3?4$C:&HK,"-
M>3<O_-\]QCW8#@<8S'0BD.WKQ,)Y;/=$RZT'5#N7[R;D (##Q^'CO8F?.8<F
M6L.[5,Y+\D:EH=S<;&N<HH;@G=(!*,7EW?CJUVU"\/^7HNQ7?BOTZ& 63&BW
MA6F:0JZVD91D9ZD40+40")&DC*Q046!'E.YQX9#-PK6#?2V@\6:3>P![[N:9
M>J@*0R/JS3VC:8_!9PY2,ZH4(25*@78SCS%Q;(AP,U&;8>%)M38!W]4ZX9XQ
MT&L-Z0# _LFY-4G%)JNT->WA1"+PK5##AR7B_%=(M>?B#MO73,6K:P+,!=NJ
M4%.TNG_NF=ZJF(,=^M(%CU"TVZGP6W2X)59CV;#V?H4^ V G,6A/Z;<X@TI+
M]! 1R0Q9+B 40[@4;(1LO+V()3/&'H-JO_7U 6AQ#D6UCV4W3O0W["QM;/%&
MJ/K#OR.V]YKNB)&S4E3SN8@$U=F:"\MJNZ+KFS?OCG0TZ@8>5K,-1X/AN#]4
MG'HL*0M)18Z%LE@'=J]O4',">^:LS$=^%_Q7EG\-/O DP?C Q\'E@&HVRQPO
MH. ._K:A"7OX>2L*NE-.FJ0\:9IMHF$I/Z4U1;MTYEYIXN"07NFS=?QPPZZC
M."?&P8=?%&YPK4YZ@=Y"XNQ$KZ0+3&6@P]CJG3#@IMSB:]W(EDQA 1&/O971
M*555BVAXVCEX[NBA&D(BY,4D(;/A1S/%_&HS>DO:#V"=_8/>; R3ZT-(-W)U
MURJL8 *]2+YWNC%3C14J&F?UM+3I4\[-%] V"Z+\8+!Y,2R2RMG@9"(+:4\'
MT^E/]9<B_(R^ZL%O65$<(BN^:W"5?&6P345CB9MY/9%T1GJNX79L.;6I^&8U
M(')WA1UV1\NU_RRW2=_]R73DFD RK@)B5-ZQ&DI9X7;75U/NG[B7T+<S$);Y
M&MB+^J*B;)'2.0MPU=3UZOOXBDKGFO&.+(4\H&Z2$T4M-5&TY":*[9,3]'JI
M1@JB54#8NA%]"+K_0GNEUC=?::_U>O_]^59IY]O:[YZI_J"TD'.1U']&6DB]
MHUFH6([CQH7*_,%H7REKQD/K;C7D M(X63U(A);X30]Z X+*LX(>2OD"-*"L
M;W"R=%@*+JG2[<:_2:^SL $#NH("#!'@^X#L&XXG7V0))LWK7D*E2D<2 4YI
M+"^-(/=4G?4A1Q8 J$B]J??]Z;B3#(W,&=W0X.$K:WG1MC7:G$RO%49X PJF
M_=&\1%CO*:S+:^K]9*0W,N<RPHK1(%:H-W$7SVKOV;ZN3Q;L!^>GDNSQ_:H4
M U4?3H.3<#*DC_BVV3/Y]#R8DG_SQ4XY#<\ #OGNU\8RU;M??T]5;2N/MWVW
M^,%X,CYL?Z6LQ?:^?JMLV^O;CX&H>?F6E>S5"WI3Y1NP/]"IA2E?[HWVG*=X
MBN3EWN7HV>5X[QAZVN:O7JQ!&WY09T\3/H>N>')T3Q:#Z"]EML8AP?XORVQ%
M'Y>< ::Q ?P^ST >J"\XP1V8O@3>J_\%4$L#!!0    ( /R$"56P1$Q-> ,
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MQO4Y:)&I[. 9>XO7NH3 GYV;W(?=0>#NE'QI,%\/MB/Y.6(!FJS2#-SJN.0
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MA\?] )3OFWYB9.5ZU9TTU/F<F-.O!I55H/V%E&8SL0Z:G]?D+U!+ P04
M" #\A E5EXW;I[ ,  "G(P  &0   'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6S-6MMR&[D1_144U[ME5]'B1;3D]455LGR)M\J1R_)F4Y7* S@#DEC-#+@
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M?Z6V/I U3VX$DPA,Q!5GIXOD?E)_>T<\""!P'53!)!\>27R$XV%-:-)#TF1
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M*S_OW8$4U4#$7+IQ7T\F"E2:&>,E@CQ4 ,"E'\",BV36H#ZNHEU8W^BZ%#?
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M;/4'Q^[[0_1WZJ%&!*3)':RTL?9FY XOV8C**PN5ZZ(F]J2^H34V>"1@K6;
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MD &:R4&;84[/9%K">'<(='5)$"M[WE-HRKX*.A!%L@F'<7@G:%FD6K*AX:U
MG%C4E<_VUW7;O\,D 86\?>.B=]GV!>OMQ#1(2XVR3[B^"+G/G-=EG=OV8QMW
M3>,6%,JH%@;5CPX-4#%,XPT*89I.U*3A9KGT2;OEE(O97J&PT8ZG"W,.Q7NQ
MQ-._@F4[\=-Y-LFKP7.F7W#)$ITKH'83&ZQBE,E+Z>XO0$O3X43DB7KFC'#Q
MVH0&&D:5*E':C:AXM3^G89'ADNKT0#/#JE"_*Y.ECFE/$=J4W>&AVS^$]F37
M5)J:>2J;3L&CBL(JY[!B[IG'*GS!AA=TI,ZN?@C6D5?'U 4(\^@KMU7UX.7P
M=/?B%_"9#E\<[-ALLYY@N,H@DI\K=TH)S('W7U&T@-)ST!,;3')Q^$PBX$UO
M*<>T%:5& =*A5:^<N[+;!<SO&$L"W8WX1)="*K-AMW7]IBP>5M$O5A?WY_2Q
M_<X&(U<IE*V,.O" CCG.JC(.&Q64U T98B#Z#=Q"V!#=X>%CZ*<M5$W*S.1P
MXNC]WHU;*$1WD:WHY%GTC]<5>SI]3YP)_QRZE6#.W?$VN]%J ',C<[)B8-!A
M+RF*-^6Z/-VB[K7[[O7Q$5Q&167=K5(*V@,<^J0(X<.3?_S,F:GY(@,=GJ&X
MSDVZT+MTT"1?Y7RTZK^B-S1XGC=TZ.V>_O)CJ_#^E]!Y^$]+9TR./8/.IFBX
M)8Q'N^1+MH5Q?9EG3V5'7UU'Y49ETNV&"FM[Q0<8+@9^9J>FP\8EN>S3-]&Z
MO37Z84.YE"7;YH))O7>;O9C.YN+@=DLI=&NX=""KE39:?2&A 1+HH_!ZZ-VO
M<K^ W@[&8,0/.[6]%7FV>N9Z;#8?5!SC;QHD6[9^*W$5$JO+?\5&EF8P:HY:
M\S=N5\V<3IP<@:.N=V\'\4<KS][,F5SM0-OCDPZ HE\._-0UU1NW-9S;BWXL
M<!?*C2CK'-\WH#@\P>8T;C]W#7[>K  \@+7I@ !N.D^\Q[@#NSQ\'YF_]<P%
M)H5R+(*BP)][=AWD[D!\V1.R]Z F3 =0Z#WEWO8_R#*1]%Q>KUBHS&YI3UU\
MP?ZSL$H5!_7U&] V5X:']=TNVFS"T(186*7@69[ZI&>7)G.7/-8R443OI$'J
M20L%B@4=R!YMG^XXW]Z>(]V#J2A3@Q&2O,AWS3%7MDH]%W,3Q[8NSYW(U$/;
M,0">J-.]M3?93Z!PI\"<15.9C454GMN4F'JKW.%H&&HTFZ0*.BI;YT ]Y.J)
M+M=W^'$T%S:+@ST$8#5!O*N))!"JY?EC05&://"&7'4$+C;&8S'&Y%<P]@5H
MPQHE=%ATP,TR)8B,C5>RCVB+F\V!3D2/LN;PEJF&[CQK)3"(+TY4">MLLG1>
MM#%O)9?T6F/Z?>*5OG!9G"OVX])5_1AUUQZ(2>%Y7&E>[M\][?&7)1I*Q$*L
M9.E/D ^J!9-!:1&S 04#/%[VO+,VO8P<+M$:NJ,L@+;O:2#N5BK8#:=T-+%N
MD:6^U7P5>P=?C-'#,\; \0J2SPHQ5Z+ZX7:;\@^J$(C.5\'!<:8@(FF?"] V
M=#W;!6W%:6=T]BT],T,"@$ZNX'/SFY8J)JWO%Z*,?&N^OHV^U"A1QIP?[)U>
MP%/OWU?ARPN?3LQGXC/FT^[]9D4<!Q&,%[3)\P@4T>[??SP+_.LGM>8.&O."
M.Y4MU6 [B-I^Y,,F3H*(FD[8=HW92'RWY )P[0K:,X%OM.MDI*79$TZGR>1>
M;3?NC0$J9Z+)$ZZ4<Z7WIIF>XHY"'X 9N8-6$P-.=2J 5B\%1%RT@N:M>:_#
MBAI5\I+-P.A1WA,/<Z-9M$=DPG)V[N!]WHL,&])GB^OZ1E*45 L=D&DO.B\T
M&M7*#+<O6TWA*WT.,.GPN7:(31K,F6)<9:.( WW2UAZAJ)QN%!57RFI"YU9M
ML5^A&]^V&[UW6EN$NUCM+ ,92X4&9;%?-K@NJ:C#5;X<<(4A-\HY41=;<N<Y
MJ=P[-*S&G)8^ZA\LJ5M2:FL7@>.5)H"3I2H"*;KL[(Y.Y1SC3J6=9F<X:VN]
MM'+R_.GC/N>CI.+)-!0?A/&\1Y1/K=?)?N*O..S''23JY4@X0M_+_JT=$FTV
M-!/W8/-W!X/^8_7:!^I=MW9:MF9*E2N/3[<U0"<K'0"Q;M1QMW"?%)1W^@4L
MN$KU6?-8*K:!8-:;?-)(B!WL2KCDT['AAK7;/EK??/CB[1U*IU V;/"X#N'
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M1NV1@CU#D14EOH"4=PPI+S1T2$+]H(M4$!GY_HM(@;\#P!R"6CM(@2-;7\:
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MO1GDCD;J,*Y3B7$R77R9_?';T>\"*56J2A>H-$2$ZQ6)I"F!^NPA@84,*[$
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M'L<B%XZ%,3@Z%E#"\ '2T<RZD!W[T!XE"DQD5W)Y$XJDRZU4\-M'5UI'M<N
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MJHG[V[RTPC#D41V#40V^H#!7P:W>W'?0ZSN1]6X/W^+ITLN?C7'S#L%IEL>
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M3 E]"R1 23CL*%.>+$N1B\6CQ;302Q1#!H9QT&*DZ'N7&KL)3(5F.1R'#=#
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MSVA,&@%\/Q=8/9L'8Z ]]8W_ 5!+ P04    " #\A E55>@HQ3(#  !7!P
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MG=?G 2A?QOW$R,J5SJ4T5(C=<$,O'RHK0/LK*<U^8@TT;^GP+U!+ P04
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MW"YU'ED/<?6+%I4=G.9"TQAFERN:>U$: ?J^$$)O7XR#W20]^@E02P,$%
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M5'"A*8J3=?*+5)+;7GR$LU;S^CIHU*O@H@&S>GXPD4 AJ55H,H7./$*!J\Q
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ML:[KN+JNI>HZ^[IMB]2T0@=H/VII/_IO:9]47=M\O*SA8&U(T50;5//%+(=
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M=Q2CU[3-9Z!F4)N%^_0R-C5@=X\SK2;:\@+,/QI3KP>LH/T6=_8?4$L#!!0
M   ( /R$"56S5ZK+R0(  (<&   9    >&PO=V]R:W-H965T<R]S:&5E=#0R
M+GAM;+5576_30!#\*RLC(1 A=IPFT))8:M)6!)4DJBE]J'@XV^OX5/O.W)V3
MAE_/GIV:%*5Y0.+%OJ^9G=E;KT<;J1YTAFC@L<B%'CN9,>69Z^HXPX+IKBQ1
MT$XJ5<$,3=7*U:5"EM2@(G=]SQNZ!>/""4;UVE(%(UF9G M<*M!543"UG6 N
M-V.GYSPMW/!59NR"&XQ*ML(0S6VY5#1S6Y:$%R@TEP(4IF/GO'<V&=KS]8'O
M'#=Z;PS6223E@YW,DK'C64&88VPL Z/7&J>8YY:(9/S<<3IM2 O<'S^Q7]7>
MR4O$-$YE?L<3DXV=CPXDF+(J-S=R\QEW?@:6+Y:YKI^PV9WU'(@K;62Q Y."
M@HOFS1YW>=@#^/X+ '\'\&O=3:!:Y04S+!@IN0%E3Q.;'=16:S2)X\)>2F@4
M[7+"F>#B,IS>S);?9HLY+*Y@<AO.YI=A".]ASI1B-F7PY@(-X[E^.W(-A;1
M-][13QIZ_P7Z+Y7H0M_K@._Y/L2R$D9MG].XI+B5[;>R_9JW_P+O0JV8X+^8
MO=D.3*70,N<):RY:)+!4J%&89D&F<,4%$S%G.82TB%151L/]>:2-HKKX<<A8
M(^#DL #[K9SIDL4X=DH;2ZW1"5Z_Z@V]3T?L]5M[_6/LP;PJ(E16>),RCAJX
M@$W&XPQ(.S=;H.^2[@?U(>T-^Z!FMY_E.NAYWLA='Y!TTDHZ.2IIPBKJ"/ .
MKF41'8IY%/Z/^1JTX@9'R^%9 73@&K4&DS$!=YG,\RTL-@(3"*M(\X13[^G
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M'0U(PD,<HP4%+(DB2+]/4$@.0\W4CAU+O-UQV:&/!GNX12O$G_<+*I[T B7
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MI7*49Q\MLAO)5NFI_(Q)R:+T<HDD0*X[J.=SQN3V1@^0?SKJ_ -02P,$%
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MB*=C^4(9Z^P7]H5MPX$PU48F!9AVD'"1_[/'(@\' .*I!G@%P'L.:+\":!6
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M<+FUPS7!0-\8P/NE$/IM8CY0_$>C]Q]02P,$%     @ _(0)54O!A6:Z @
MS@8  !D   !X;"]W;W)K<VAE971S+W-H965T-3@N>&ULK55=;]HP%/TK5UDU
MM5+;?$!9UT&D\*4Q :J@= _3'DQR :].3&T'.FD_?K83,M"@ZD-?$CN^Y]CG
M^-Z;YI:+)[E"5/"2LDRVG)52ZSO7E?$*4R*O^1HSO;+@(B5*3\72E6N!)+&@
ME+F!YS7<E-#,"9OVV[T(FSQ7C&9X+T#F:4K$[S8ROFTYOK/[,*'+E3(?W+"Y
M)DN<HIJM[X6>N15+0E/,).49"%RTG,B_Z]1-O UXI+B5>V,P2N:</YG)(&DY
MGCD0,HR582#ZM<$.,F:(]#&>2TZGVM( ]\<[]K[5KK7,B<0.9]]IHE8MY]:!
M!!<D9VK"MU^QU'-C^&+.I'W"MHSU'(ASJ7A:@O4)4IH5;_)2^K '\.LG $$)
M"-X*J)6 FA5:G,S*ZA)%PJ;@6Q F6K.9@?7&HK4:FIE;G"JA5ZG&J; ?#2;P
M& UG/1CUHNELTAOUQ@]3B,9=Z _&T;@SB(8P&$\?)K-BY0HB*5%)(%D"0TKF
ME%%%4<((B<P%)F!N!\8\NYI@G M!LR6TB:0%HD^H@$?"<@2^@"'/EE<*10I=
MG*M+&!,AB+E8..^B(I3)"[WA;-J%\[,+. .:P8@RIA- -EVE]1L5;EQJ;1=:
M@Q-:O^79-=2\2PB\(#@"[[P.[V*LX;Z%^X=P5[M>61]4U@>6KWZ"3SLD*H-(
M\DM?MBX/!7]@B!MD'S_X#>_+L7.V7^4U=7\GUR3&EJ,+6Z+8H!,6;,=$OQ/9
M@06URH*:9:^=RKXJ&2[?DE7_\LE$'?A7)-B/H=X !@I3^?.8<;7W-.Z=R Z,
MJU?&U5_-'6O<9E=%K*JB1%?1,>$%6\.RF<:^"?V&7]=9O-E7]']4$#1N/U=1
MQ5'=O6YC.OV(B"7-)#!<:)QW_>G& 5%TSV*B^-HVH#E7NIW9X4K_<%"8 +V^
MX%SM)J:G5;^P\"]02P,$%     @ _(0)5<"X.F&7 @  V@8  !D   !X;"]W
M;W)K<VAE971S+W-H965T-3DN>&ULK55=;]HP%/TK5E9-K;0U7Q#:#B*UT&I,
M:E=!/QZF/9CD E8=.[,-:?_]KI,THA#0'O:2^..><\^YCF_ZA50O>@E@R&O&
MA1XX2V/R"]?5R1(RJD]E#@)WYE)EU.!4+5R=*Z!I"<JX&WA>Y&:4"2?NEVOW
M*N[+E>%,P+TB>I5E5+U= 9?%P/&=]X4)6RR-77#C?DX7, 7SF-\KG+D-2\HR
M$)I)013,!\ZE?S&,;'P9\,2@T!MC8IW,I'RQDW$Z<#PK"#@DQC)0?*UA")Q;
M(I3QI^9TFI06N#E^9[\IO:.7&=4PE/R9I68Y<,X<DL*<KKB9R.([U'ZZEB^1
M7)=/4E2QO8Y#DI4V,JO!J"!CHGK3U[H.&P!_'R"H <&_ L(:$)9&*V6EK1$U
M-.XK61!EHY'-#LK:E&ATPX0]Q:E1N,L09^+QW=/UW<//R?AZ2KZ2H<QR*4 8
M3>2<C,4:AU(QT.1X!(8RKD\PZG$Z(L=')^2(,$%N&>=X'KKO&I1C2=VD3GU5
MI0[VI/ZQ$J<D]+Z0P N"%OCP,'P$"<+]$NY_A+M8A*8205.)H.0+]U6B=OM&
M1DPG7.J5 O+K<J:-PF_M=YN_BK#33FCOWX7.:0(#!R^8!K4&)_[\R8^\;VUN
M_Q/9!^]AXST\Q!Y/:($?E0'%*&\]R0H>E7#;&-9QZ&'1UYL&=F."WGD3\T%7
MI]'5.:CK&5N _<AR)1/0K<HJ@NY&5C_H;"EKB?&#=F7=1EGWH+(;)AC>NI0L
MI$Q;A75WDD:=LRUA+3'>'F%1(RPZ*.Q!&LHWKVZ;MFCGJ'RO%VZ)VPTZ/P^W
MQ+D;G<=V_5NJ%DQHPF&.*.^TA]Y4U4FKB9%YV8QFTF!K*X=+_/F L@&X/Y?2
MO$]L?VM^9_%?4$L#!!0    ( /R$"56NWR'+.P4  "8?   9    >&PO=V]R
M:W-H965T<R]S:&5E=#8P+GAM;+5987/:.!#]*QJN<]/.76)+,@9RP PA;8Z;
M),V4]/I9@ !?;,N516CNUY]L' M;LH],E2\)AMW'>^M=OS4>[AE_3+>4"O C
M"N-TU-D*D5PX3KK<THBDYRRAL?QDS7A$A#SD&R=-."6K/"D*'>2ZOA.1(.Z,
MA_E[]WP\9#L1!C&]YR#=11'ASY<T9/M1!W9>WO@2;+8B>\,9#Q.RH7,JOB;W
M7!XY)<HJB&B<!BP&G*Y'G0F\F&(_2\@C_@[H/CUZ#3(I"\8>LX/9:M1Q,T8T
MI$N101#Y[XE.:1AF2)+']P*T4WYGEGC\^@7]4RY>BEF0E$Y9^"U8B>VHT^^
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M)?SGD_8KBUK4\[.SUBN+J-4Q.W.3*/#L%_'O#DNJX_0^EQC9R=Z=' T7H)I
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M??;V*]$F(THS2Z7)/@SMV8=/#[&@7W>Q(/%MMMQ<;W_O& VW^[U+!\U(H)I
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M3%K6GP;U0(O2=M>UT-BK[>4>/Z= F@!\OA5"OPY,PVX_T-)_ 5!+ P04
M" #\A E5FMB+Z0,.  "FJ   &0   'AL+W=O<FMS:&5E=',O<VAE970V-2YX
M;6R]G6MSV[@9A?\*1]UV-K,;B_=+:GO&$9!M=A(W$V_:S[0,VYQ(I$M2]FYG
M?WPI63:(BR!".FP^))8EG$.=5WFAA^#E]*FJOS?WC+7.[\M%V9Q-[MOVX=UT
MVLSOV3)O3JH'5G;/W%;U,F^[A_7=M'FH67ZS&;1<3'W7C:?+O"@GYZ>;WWVI
MST^K5;LH2O:E=IK5<IG7?[QGB^KI;.)-7G[QM;B[;]>_F)Z?/N1W[(JUWQZ^
MU-VCZ:O*3;%D95-4I5.SV[/)A?>.>EZP'K%YR;\*]M3T?G;6[^6ZJKZO'WR\
M.9NXZTUB"S9OUQIY]\\CF['%8BW5;<A_MJJ35]/UP/[/+^H?-N^^>S?7><-F
MU>+?Q4U[?S9))\X-N\U7B_9K]?0/MGU'T5IO7BV:S=_.T_:U[L29KYJV6FX'
M=UNP+,KG?_/?MTGT!GCAC@'^=H _=$"P'1 ,'1!N!X1#!T3; 9NW/GU^[YO@
M2-[FYZ=U]>34ZU=W:NL?-NEO1G=Y%>7ZDW+5UMVS13>N/?_P\?+B<O;Q\A?G
MXNO7B\M?Z&=Z^=N5\]:Y>O[H.-6M,ZO*IEH4-WG+;IQ/57GWMF7UTB'LNG5^
M)*S-BT7SIAOR[8HX/_[PQOG!*4KG<[%8=)^$YG3:=INY-IO.MYOT_GF3_!V;
M].NJ/'$"]V?'=WU?,WQF'OZ!79\XWN[AQ#R<L'GG[FV&>YKA=,#&NZEN^+0K
MS6M]_-?Z^!N]8(<>C_NFB_MGI^R:1U>259DOJ[HM_MM59/V$<U,T\VI5MKJX
MGQU"O<.Z%;UK'O(Y.YMTO:9A]2.;G/_M+U[L_ET7/E*,(,4H2$PH4_!:IL"D
M?OZE+LIY\9 OG(OEKC(\*\0;A74#?SSW?3>*3Z>/_7R-/K;YZBS3Q!4M*<A2
M""Y\#2XT!O=;U7:A+81/N2Z\9Y6H_TZ\U NE\(Q>MN%I+/TXDBPIR%((+WH-
M+S*&]XDUS3MGMJIK5K;.P[HA='-OUQ[VYQDI;\Z+I,_%S&ANFZ9J*'\,079"
MDO%KDK$QR<NJ?#L_),=8\[F,8_ES:32W35)CJ?E<@BR%-)/7-!/S?^IU8I^J
MO'3>.Q_R>;$HVC\<LF).-SNR]<P8Z:(T:MI.4T@Q@A2C(#&A,.EK8=+1OTVD
MR#(AQ0A2C(+$A#)EKV7*COXVD>WKIS.CAVVVJIV?^IG4<T".0F:>RTG&A7R5
MV,J8HC,[V6:G,?23Q)?"0WF*Z?4XT#NL9U]6CVQYS>J=?=LL;-L1H&H$JD91
M:F*). IZX[.@!X5!J!J!JE&4FE@L#H3>\42XE3!V(B@/:@RS3/[FB+(4@^-
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M=EE>Y-__(VN>45SSYOERL_N_][WYV[,3;[[=E/FJ>7!U!*O%>O\U_;VIA/(
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MA@D[%6""9@@H3: T2=%T8=H,8<).!;#CG(7IGPK0O62##BLIFEYSY19IR%P
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MA>['#ALJ4#A# R54")XK5- ^=BQIJOV W)5CHP44)S&<KF^H1 LA'"V$;+2
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M422,(6$<"1,@F*&Y\49S8V@!/48J#PD+D#"*A#$DC"-A @0SE'>T4=[1_UU
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MAX^];Y4/=3N@M !*HU :@](XE"90-%."M0WBVVT0\-H8>[;6"MV_%=/>:I8
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M!AJ#- WP_4I@)*UNC(/ZV'SV#5!+ P04    " #\A E5[(XPW#T"   @!0
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M82"M@SG?":%/ANV2[E-,_@)02P,$%     @ _(0)5=.:/A7K P  %18  !D
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MU1.LJHU"K,I'--V(HA!)^7+)F4RZZ@/R_;D0Q>.&"M \1VSR#U!+ P04
M" #\A E5E-O/!1\$   1&0  &0   'AL+W=O<FMS:&5E=',O<VAE970W-2YX
M;6S%F>]OVC@8Q_\5*YM.F[0V/R"!]@ )B*?MI&X5N=Y>NXF!J(G-; .]__YL
M)P02TJSM6=T;2,SS?.S'SZ-O\IC1GK('OL98@,<\(WQLK8787-LVC]<X1_R2
M;C"1ORPIRY&0MVQE\PW#*-%.>69[CA/8.4J)-1GIL5LV&=&MR%*";QG@VSQ'
M[-\9SNA^;+G686"1KM9"#=B3T0:M<(3%W>:6R3N[HB1IC@E/*0$,+\?6U+V&
M;J <M,4_*=[SDVN@0KFG]$'=?$W&EJ-6A#,<"X5 \FN'YSC+%$FNXV<)M:HY
ME>/I]8'^60<O@[E'',]I]B--Q'IL#2V0X"7:9F)!]U]P&9"O>#'-N/X$^]+6
ML4"\Y8+FI;-<09Z2XAL]EAMQXB Y[0Y>Z> U'?I/./1*A]YS9^B7#OWGSN"7
M#CITNXA=;UR(!)J,&-T#IJPE35WHW=?><K]2H@HE$DS^FDH_,8F^3!?P8C:-
M8 CFWV]NX;=H^O?7[]_ !8B*V@%T":(U8OA")20!<YK+*N5(YQD^JFL,/H18
MH#3C'Z7?712"#^\_@O<@)> FS3)IR$>VD*M5<]IQN;)9L3+OB97UP TE8LT!
M) E.6OS#;O^@P]^6NU1ME7?8JIG7"?QK2RY!S_D$/,?S6M8S?[Z[VQ;._YL=
MOGKVVF;TJKKI:5[O"9ZJ DHP$1P@DH X0YRGRS0NRD*6##\IF?BT9'!1,FT%
M44S9;Y]22>8UWZ 8CRVIB1RS';8F?[QS ^?/MFR8A(4F8= 0K):W?I6W?A=]
M$KTB+04QT$3UX-E-O&!D[TXW^]RDY]9-PG,3?U@W@><F@5>9U,+UJW#]SG 7
M<@,1B]>Z2!.\DP_&C7S,B4.XK;K4B7QI&9J$A29AT!"LEI>@RDOP]O(1F,R;
M25AH$@8-P6IY&U1Y&QB7CX+HGVI#0SW.+;R&>)Q;-!0(GEOX[=(QK$(==H<J
M7UY3LOH$5IA@AC)=J"B1[V I%PRI]]M.%>FDO[0:3<)"DS!H"%9+T565HJNW
M5Y$KDWDS"0M-PJ A6"UOKG/L.ASC.E(B:S+15)(VFZN&EK38^ V]@6TV@W8]
M<4]:+;<[:$'C!T WXLF&J-/_I;5GE!8:I4%3M'HFO&,FO+<7CG).4]DS20N-
MTJ I6CU[Q];3[>R07B<>O5^^A?S:)&PQ&325H\ND'O"Q9W.[F[9%=->N%YUN
M+ZXXD[30* V:HM43<.PB7?\WZ(71/M,H+31*@Z9H]>P=>TVWLR5ZG5X$YX<>
M9X+18C-L*L:YC>\V):/%IMF\V"='O#EF*WVVSF4X6R**4[MJM#J_G^I3Z\;X
MS+V>NRWCH3KOUT?*1WSQ9\$-8JN4<)#AI9S*N1S(;++B_+VX$72C#YCOJ1 T
MUY=KC!+,E('\?4FI.-RH":I_02;_ 5!+ P04    " #\A E581V ^Q\%  #<
M'   &0   'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6R]66MOXC@4_2L6NUK-
M:+9)[(0 74 "VMV9U71:0;OSV24&HB8Q:QOH2/OCUWF0D)<%':M?F@?WGMQC
M^]BG]O! V0O?$"+ :QA$?-39"+&]-DV^W) 0<X-N221_65$68B$?V=KD6T:P
MER2%@8DLRS5#[$>=\3!Y]\#&0[H3@1^1!P;X+@PQ^S$E 3V,.K!S?#'WUQL1
MOS#'PRU>DP413]L')I_,',7S0Q)QGT: D=6H,X'7,QO%"4G$/SXY\)-[$%-Y
MIO0E?OCBC3I67!$)R%+$$%A>]F1&@B!&DG7\FX%V\F_&B:?W1_0_$_*2S#/F
M9$:#[[XG-J-.OP,\LL*[0,SIX3/)"'5CO"4->/(7'+)8JP.6.RYHF"7+"D(_
M2J_X-6N(DP2)TYR L@1437!:$NPLP4Z(II4EM&ZPP.,AHP? XFB)%M\D;9-D
M2S9^%'?C0C#YJR_SQ'CQ>3*_O9I.%K<W8'9_]W#[;3%Y_'+_#5R!1=JS@*[
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MMBQ+C]+2!T&WR6G4,Q6"ALGMAF"/L#A _KZB5!P?X@_D!YKC_P%02P,$%
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M E4S:\8)EJK+-Z9(.> P!Y'$M"W+-0F.J>%U\[$9][HLDTE,8<:1R C!_.L
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M%#U-"6?\R^MWX16$GV?AQ3P\A(OP&E["!5.*V03"08"&I5R_H-6/\P .GK^
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MI@$^7PBA7R^,@^*<>_H_4$L#!!0    ( /R$"545TY7OEP,  +T,   9
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M1C4'U5Q4\U#-K[6.KW$$&Q9IOF+<3F-39*5W%UF]><*[L=3J;SD+1NNL4,U
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MNS0MGNZ4'3RFV5_5ZEW^'U!+ P04    " #\A E5.8-\)K<#  #%$@  &0
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MLB:BZI\G=:.2I):J=?S>H(/--NO"]U^_Z>[ZR5=/YB$JU$V6_#N>EO.+P>E
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MD)A+8AZ)^20F22P@L1#".MDS1NUINA'=+#8B%#-4LU'-0347U3Q4\U%-HEJ
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M[*UCLA_);(>]7;&WZ]\_R?1)*$'RI3Y,]J'6ZM^*6IIUK)DYO5>A'_3=U1Z
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MAR+3,>-P)XG*DH3*WQ.(Q6[D=)S]P)RM(VT&W/$PI6NX!_TUO9/8<TN6)4N
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MHIGUT[:0.KV+6R)XXZ3M]VV) &)ZMD(T8VBW:RL$%,2W*(3V3M1MGJZ3J!B
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MFL2BF1705H\?9!$E1[6)J#2!2I-8-+-^VB;R_9=2<FAQHRT//X\10(SOV_(
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M94#Q^WV2Y,]?RAVLW]TP_!=02P,$%     @ _(0)521V'] F P  - P  !D
M  !X;"]W;W)K<VAE971S+W-H965T.38N>&ULM5==;]HP%/TK5B9-K=21#RC0
M#B(![5:VT5;0;0_3'MSD AZ)G=D.M/]^MA-2@@):I?0%_''O\3G'-^'2VS"^
M$DL B9[BB(J^M90RN;1M$2PAQJ+!$J!J9\YXC*6:\H4M$@XX-$EQ9'N.T[9C
M3*CE]\S:/?=[+)41H7#/D4CC&//G(41LT[=<:[LP)8NEU NVWTOP F8@OR?W
M7,WL B4D,5!!&$4<YGUKX%Z.7)-@(GX0V(B=,=)2'AE;Z<DX[%N.9@01!%)#
M8/6UAA%$D492//[FH%9QID[<'6_1/QGQ2LPC%C!BT4\2RF7?ZEHHA#E.(SEE
MFQO(!9UKO(!%PGRB31[K6"A(A61QGJP8Q(1FW_@I-V(G0>%4)WAY@K>?T#J0
MT,P3FD9HQLS(NL(2^SW.-HCK:(6F!\8;DZW4$*JO<2:YVB4J3_JSZ\^3Z]L'
M-+[]=#>=#![&=[?H YK@/XRCD3D>N$ G5R QB<2IVIO"&F@*0@VW 6C$: !4
M<FRN9DK$JF=+Q4Z?80<YDV'&Q#O I(TFC,JE0-<TA+"<;RM5A31O*VWH'07\
MDM(&:CIGR',\KX+/Z/_3W2-TFH7338/7.H W4$81P5(>P!#X JARC2<L\ZS*
MKJ-P^O&^% D.H&^IYU< 7X/EOW_GMIV/55IK BLI;Q7*6P:]>4!Y7C%G>V6%
M?GU3@6@L(1:_JPQHU6E 36 E \X+ \Z/7GWY\5!5L$()<+VDWI15RC.X"P.G
M7\1KWVFX[9Z]WE54&=0I@DI,VP73]E&FD^ K",%*M8E." VB-"1T@8K]60(!
MP9%\/JWB?_20U]Y<36 E/SJ%'YTW*=U.G0;4!%8RH%L8T*VW=+M55=G<*]W*
MH'9UZ5X43"^.,\5<E2B.T VHNER>91:,:="HHGD4Z[475!-82;;KO/R".V]2
MHSEL31[4A58V8:>-<>NMTQQOKP;=O4*MCO+V*M7>Z;]B_=NNVU*! I92F?4K
MQ6K1^@Y,P[>W/M0ML>GK7F"R?GJ"^8)0@2*8*TBGT5%O?YZUJ-E$LL1T>8],
MJNLWPZ5JZX'K +4_9TQN)_J XH^"_P]02P,$%     @ _(0)5='Q%&6C @
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ _(0)56H_1S<@!P  $4
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M(8Q)\\TALM"0_0#"D7K5V[Z)+#1DME!+O>HEB?NAEVT$TT86LIDMU(KYJT)
M-[5M9"&;?2WT^TA8 _!LI*HDI9C(0C:SA5Y5 '6#ZYNN=AM5+]0]FA;;R$+V
MNQYF>Q-/BHDL9+_WZ39-.E'K9".F1;ZDY2L;6<AFME ;9JR6NR*M4E4VAA"R
MD,U=%VK!=.MGZHI=637R31M9R&:V4!NFGU5JLU'+:M<80O#I&V8+M6'J7KG:
M+2LQ21N8R$(V]Y&$%LRQRE2A!Y&7THU#!UG(.<'1A/9"M8,LY#!;J!TS5NO]
M0ZKTT3H'6<CA/IW0BCE*R^3UDLU!%G*XUT*HT1O9NX,LY'"OA5HQ(_6DLIT2
M=Q036<AY_Q/7&O,V^3LOA+<K*2:RD//.IZ]?)1\4$UG(V5NHN_]R^?G32MVG
MF5H%^D^4^OHRV2RGA:A?ZCOU#'-0/[%RO]ML/'TMS"9YLGIYHOWE:?S/_P%0
M2P,$%     @ _(0)5;0I?LS" @  "CD  !H   !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<\W:O6ZC0!A&X5NQN(#@^9]9Q:FV2;O*#5C.V(YB&PM8;7+W
M:SF%?= 6VT2\%1H0'Z=ZA& >?]7#>GSK3L/^[3PL/HZ'T[!J]N-X_M&VPV9?
MC^OAH3O7T^7*MNN/Z_&R['?M>;UY7^]J:Y?+V/;W,YJGQ_N9BY?/<_V?B=UV
M^[:I/[O-[V,]C?\8W/[I^O=A7^O8+%[6_:Z.JZ;].-Q.#^WU8!XNDYO%\^NJ
MZ9]?3=/.'6019.</<@AR\P=Y!/GY@P*"POQ!$4%Q_J"$H#1_4$90GC^H(*C,
M'V26E'$ID#3!6D!K0ZZ-@->&8!L!L0W)-@)F&Z)M!-0V9-L(N&T(MQ&0VY!N
M(V"W(=Y&0&]+O:V WI9Z6P&][>1E6T!O2[VM@-Z6>EL!O2WUM@)Z6^IM!?2V
MU-L*Z&VIMQ70VU)O*Z"WH]Y.0&]'O9V WHYZ.P&]W>1CB8#>CGH[ ;T=]78"
M>COJ[03T=M3;">CMJ+<3T-M1;R>@MZ?>7D!O3[V]@-Z>>GL!O3WU]@)Z^\G'
M;@&]/?7V GI[ZNT%]/;4VPOH[:FW%]#;4V\OH'>@WD% [T"]@X#>@7H' ;T#
M]0X">@?J'03T#I.?E0)Z!^H=!/0.U#L(Z!VH=Q#0.U#O(*!WI-Y10.](O:.
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M\O^XVY]02P$"% ,4    " #\A E5!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( /R$"56HA< L[P
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( /R$"5697)PC$ 8  )PG   3              "  <T!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ _(0)54UO8R+Z!0  SA\  !@
M             ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( /R$"55I\CQ0AP8  # ;   8              " @3X.  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #\A E52QN <& "  #=
M!0  &               @('[%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ _(0)5<[[S& ?"   <"P  !@              ("!D1<
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( /R$"56"^\LI
M&00  (8/   8              " @>8?  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    " #\A E5WV:T$A8+   49   &
M@($U)   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ _(0)
M598- !H%"0  WBD  !@              ("!@2\  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( /R$"57VDINNH ,  !P(   8
M      " @;PX  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M" #\A E54/H%Z'4/   !*P  &               @(&2/   >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ _(0)59'0D$K2"P  :1\  !D
M             ("!/4P  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    " #\A E52>E3@QL&  !.#0  &0              @(%&6   >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( /R$"54,E4T[Y04
M 'P0   9              " @9A>  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ _(0)58:R,X)Z#0  N"D  !D              ("!
MM&0  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #\A E5
MOJ3+[&H"   \!0  &0              @(%E<@  >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( /R$"54)V4(-)QD  $!C   9
M      " @09U  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ _(0)599:/1#; @  (@8  !D              ("!9(X  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #\A E5+BLVMXT>  #(@0
M&0              @(%VD0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( /R$"56P1$Q-> ,  %<(   9              " @3JP  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ _(0)528YB@P3
M"@  [1X  !D              ("!Z;,  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    " #\A E51,/5D-L#  "V"   &0
M@($SO@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( /R$
M"55NG]L@R@(  ( &   9              " @47"  !X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ _(0)58M!!+@, P  R 8  !D
M         ("!1L4  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
M    " #\A E5EXW;I[ ,  "G(P  &0              @(&)R   >&PO=V]R
M:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( /R$"57!7'9AI ,  /8(
M   9              " @7#5  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
M4$L! A0#%     @ _(0)56M'^&AY)0  N8<  !D              ("!2]D
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " #\A E58US^
M"X8-   ;(P  &0              @('[_@  >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;%!+ 0(4 Q0    ( /R$"57H^@=)[P(  %X&   9
M  " @;@, 0!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
M_(0)59$J<BXF#   PB$  !D              ("!W@\! 'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    " #\A E5BBAV8- $  #""P  &0
M            @($[' $ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( /R$"55_:V/G- 8  $\4   9              " @4(A 0!X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ _(0)58O"]UV% @
M7 4  !D              ("!K2<! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    " #\A E54#>])KT%  ">$0  &0              @(%I
M*@$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( /R$"54Y
MWS9BZ0(  !$&   9              " @5TP 0!X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ _(0)5:=CW(1#!0   0X  !D
M     ("!?3,! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /R$"54HW-U1VP(  #\&   9              "
M@9=& 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ _(0)
M5=L4L)KF @  B08  !D              ("!J4D! 'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6Q02P$"% ,4    " #\A E5%K3/%Z<'  "7$P  &0
M        @('&3 $ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0
M   ( /R$"56S5ZK+R0(  (<&   9              " @:14 0!X;"]W;W)K
M<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ _(0)5=M5%-O_!   9"$
M !D              ("!I%<! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q0
M2P$"% ,4    " #\A E59RY+AE0%   Z*P  &0              @(':7 $
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( /R$"5598W-B
M@@4  (<?   9              " @65B 0!X;"]W;W)K<VAE971S+W-H965T
M-#4N>&UL4$L! A0#%     @ _(0)58J3ML(, P  T0@  !D
M ("!'F@! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " #\
MA E5E]U%VW<#   7#   &0              @(%A:P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( /R$"54SZDJ;+00  'H5   9
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M970U,BYX;6Q02P$"% ,4    " #\A E5DP6ZOY<"  !^!0  &0
M    @('1A0$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    (
M /R$"54#=)U#3@,  (D+   9              " @9^( 0!X;"]W;W)K<VAE
M971S+W-H965T-30N>&UL4$L! A0#%     @ _(0)5> &ZPR' P  :PL  !D
M             ("!)(P! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"
M% ,4    " #\A E5?%[57B(#  "+"@  &0              @('BCP$ >&PO
M=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( /R$"55ADLT_=00
M -T0   9              " @3N3 0!X;"]W;W)K<VAE971S+W-H965T-3<N
M>&UL4$L! A0#%     @ _(0)54O!A6:Z @  S@8  !D              ("!
MYY<! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " #\A E5
MP+@Z89<"  #:!@  &0              @('8F@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4Y+GAM;%!+ 0(4 Q0    ( /R$"56NWR'+.P4  "8?   9
M      " @::= 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%
M  @ _(0)51=,&PJ%$0  [P8! !D              ("!&*,! 'AL+W=O<FMS
M:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " #\A E5J70$P0P#  !5"@
M&0              @('4M $ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+
M 0(4 Q0    ( /R$"57_Y[%"; @  (Q0   9              " @1>X 0!X
M;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ _(0)5<B2# Y0
M P  K D  !D              ("!NL ! 'AL+W=O<FMS:&5E=',O<VAE970V
M-"YX;6Q02P$"% ,4    " #\A E5FMB+Z0,.  "FJ   &0
M@(%!Q $ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( /R$
M"563-<7CJ0(  $0'   9              " @7O2 0!X;"]W;W)K<VAE971S
M+W-H965T-C8N>&UL4$L! A0#%     @ _(0)5;3*A>RU%P  YD<! !D
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M=#<Q+GAM;%!+ 0(4 Q0    ( /R$"549KA 44@,  -\+   9
M  " @18! @!X;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @
M_(0)53#HJ\J.!   ]Q4  !D              ("!GP0" 'AL+W=O<FMS:&5E
M=',O<VAE970W,RYX;6Q02P$"% ,4    " #\A E5 :+X!BL(  !33   &0
M            @(%D"0( >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4
M Q0    ( /R$"564V\\%'P0  !$9   9              " @<81 @!X;"]W
M;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @ _(0)56$=@/L?!0
MW!P  !D              ("!'!8" 'AL+W=O<FMS:&5E=',O<VAE970W-BYX
M;6Q02P$"% ,4    " #\A E5.RVXX3($  "%&P  &0              @(%R
M&P( >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( /R$"55E
M#@4DT@(  .X(   9              " @=L? @!X;"]W;W)K<VAE971S+W-H
M965T-S@N>&UL4$L! A0#%     @ _(0)56Q:4RD& P  S0D  !D
M     ("!Y"(" 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /R$"57*W[;UVP,  %,3   9              "
M@1$W @!X;"]W;W)K<VAE971S+W-H965T.#0N>&UL4$L! A0#%     @ _(0)
M59.SU M% @  =@0  !D              ("!(SL" 'AL+W=O<FMS:&5E=',O
M<VAE970X-2YX;6Q02P$"% ,4    " #\A E5EQ@7HUD*  "4AP  &0
M        @(&?/0( >&PO=V]R:W-H965T<R]S:&5E=#@V+GAM;%!+ 0(4 Q0
M   ( /R$"54Y@WPFMP,  ,42   9              " @2]( @!X;"]W;W)K
M<VAE971S+W-H965T.#<N>&UL4$L! A0#%     @ _(0)55K^JT)1"@  J9<
M !D              ("!'4P" 'AL+W=O<FMS:&5E=',O<VAE970X."YX;6Q0
M2P$"% ,4    " #\A E5>=4I1+H$  #X(   &0              @(&E5@(
M>&PO=V]R:W-H965T<R]S:&5E=#@Y+GAM;%!+ 0(4 Q0    ( /R$"5560J]'
MVP(  '\)   9              " @99; @!X;"]W;W)K<VAE971S+W-H965T
M.3 N>&UL4$L! A0#%     @ _(0)54CF"SXV P  %PP  !D
M ("!J%X" 'AL+W=O<FMS:&5E=',O<VAE970Y,2YX;6Q02P$"% ,4    " #\
MA E5,T4$X=P*  "A:@  &0              @($58@( >&PO=V]R:W-H965T
M<R]S:&5E=#DR+GAM;%!+ 0(4 Q0    ( /R$"55N?S77_0P  !:7   9
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M970Y-RYX;6Q02P$"% ,4    " #\A E53J90!D0#  "4%   #0
M    @ $,BP( >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( /R$"567BKL<P
M !,"   +              "  7N. @!?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M /R$"55J/T<W( <  !%    /              "  62/ @!X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " #\A E5M"E^S,("   *.0  &@
M@ &QE@( >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #\
MA E5C,4FGTX"   G-P  $P              @ &KF0( 6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     :0!I -8<   JG (    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>721</ContextCount>
  <ElementCount>374</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>195</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>18</UnitCount>
  <MyReports>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - REVENUE RECOGNITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/REVENUERECOGNITION</Role>
      <ShortName>REVENUE RECOGNITION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - LICENSING AGREEMENTS AND DIVESTITURE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURE</Role>
      <ShortName>LICENSING AGREEMENTS AND DIVESTITURE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2113105 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS</Role>
      <ShortName>RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2115106 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2127107 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INVENTORIES</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2130108 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2136109 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES</Role>
      <ShortName>ACCRUED AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2139110 - Disclosure - FINANCING ARRANGEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS</Role>
      <ShortName>FINANCING ARRANGEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2149111 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2152112 - Disclosure - SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION</Role>
      <ShortName>SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2157113 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2161114 - Disclosure - RESEARCH AND DEVELOPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT</Role>
      <ShortName>RESEARCH AND DEVELOPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2164115 - Disclosure - OTHER EXPENSE, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSENET</Role>
      <ShortName>OTHER EXPENSE, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2168116 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2170117 - Disclosure - LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LOSSPERSHARE</Role>
      <ShortName>LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2174118 - Disclosure - LEGAL PROCEEDINGS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGS</Role>
      <ShortName>LEGAL PROCEEDINGS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2181119 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATION</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2189120 - Disclosure - SUBSEQUENT EVENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SUBSEQUENTEVENT</Role>
      <ShortName>SUBSEQUENT EVENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - REVENUE RECOGNITION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/REVENUERECOGNITIONTables</Role>
      <ShortName>REVENUE RECOGNITION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/REVENUERECOGNITION</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2316302 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2328303 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INVENTORIESTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/INVENTORIES</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2331304 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2337305 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables</Role>
      <ShortName>ACCRUED AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2340306 - Disclosure - FINANCING ARRANGEMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables</Role>
      <ShortName>FINANCING ARRANGEMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2350307 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2353308 - Disclosure - SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables</Role>
      <ShortName>SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2358309 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2362310 - Disclosure - RESEARCH AND DEVELOPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables</Role>
      <ShortName>RESEARCH AND DEVELOPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2365311 - Disclosure - OTHER EXPENSE, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSENETTables</Role>
      <ShortName>OTHER EXPENSE, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/OTHEREXPENSENET</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2371312 - Disclosure - LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LOSSPERSHARETables</Role>
      <ShortName>LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/LOSSPERSHARE</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2382313 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/SEGMENTINFORMATION</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails</Role>
      <ShortName>DESCRIPTION OF BUSINESS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - REVENUE RECOGNITION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails</Role>
      <ShortName>REVENUE RECOGNITION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - REVENUE RECOGNITION - Variable Consideration Provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails</Role>
      <ShortName>REVENUE RECOGNITION - Variable Consideration Provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails</Role>
      <ShortName>REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails</Role>
      <ShortName>LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails</Role>
      <ShortName>RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2421412 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2422413 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2423414 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2424415 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2425416 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2426417 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2429418 - Disclosure - INVENTORIES - Components of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails</Role>
      <ShortName>INVENTORIES - Components of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2432419 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2433420 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2434421 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2435422 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2438423 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2441424 - Disclosure - FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2442425 - Disclosure - FINANCING ARRANGEMENTS - Covenant Compliance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Covenant Compliance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2443426 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2444427 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Senior Secured Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2445428 - Disclosure - FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2446429 - Disclosure - FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2447430 - Disclosure - FINANCING ARRANGEMENTS - Gain (Loss) on Extinguishment of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Gain (Loss) on Extinguishment of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2448431 - Disclosure - FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2451432 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2454433 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2455434 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2456435 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2459436 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2460437 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2463438 - Disclosure - RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails</Role>
      <ShortName>RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2466439 - Disclosure - OTHER EXPENSE, NET - Summary of Other Expense, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails</Role>
      <ShortName>OTHER EXPENSE, NET - Summary of Other Expense, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2467440 - Disclosure - OTHER EXPENSE, NET - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails</Role>
      <ShortName>OTHER EXPENSE, NET - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2469441 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2472442 - Disclosure - LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails</Role>
      <ShortName>LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2473443 - Disclosure - LOSS PER SHARE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails</Role>
      <ShortName>LOSS PER SHARE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2475444 - Disclosure - LEGAL PROCEEDINGS - Legal Proceeds and Governmental and Regulatory Inquiries (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - Legal Proceeds and Governmental and Regulatory Inquiries (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2476445 - Disclosure - LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2477446 - Disclosure - LEGAL PROCEEDINGS - Antitrust (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - Antitrust (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>2478447 - Disclosure - LEGAL PROCEEDINGS - Intellectual Property (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - Intellectual Property (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>2479448 - Disclosure - LEGAL PROCEEDINGS - Product Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - Product Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>2480449 - Disclosure - LEGAL PROCEEDINGS - General Civil Actions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - General Civil Actions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>2483450 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails</Role>
      <ShortName>SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>2484451 - Disclosure - SEGMENT INFORMATION - Segment Revenues and Profit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails</Role>
      <ShortName>SEGMENT INFORMATION - Segment Revenues and Profit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>2485452 - Disclosure - SEGMENT INFORMATION - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails</Role>
      <ShortName>SEGMENT INFORMATION - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>2486453 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1</Role>
      <ShortName>SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>2487454 - Disclosure - SEGMENT INFORMATION - Revenue by Geographic Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails</Role>
      <ShortName>SEGMENT INFORMATION - Revenue by Geographic Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>2488455 - Disclosure - SEGMENT INFORMATION - Major Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails</Role>
      <ShortName>SEGMENT INFORMATION - Major Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="bhc-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>2490456 - Disclosure - SUBSEQUENT EVENT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SUBSEQUENTEVENTNarrativeDetails</Role>
      <ShortName>SUBSEQUENT EVENT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="bhc-20220630.htm">bhc-20220630.htm</File>
    <File>bhc-20220630.xsd</File>
    <File>bhc-20220630_cal.xml</File>
    <File>bhc-20220630_def.xml</File>
    <File>bhc-20220630_lab.xml</File>
    <File>bhc-20220630_pre.xml</File>
    <File>exhibit1010spurremployment.htm</File>
    <File>exhibit1011spurremployment.htm</File>
    <File>exhibit107bauschpharmacfoe.htm</File>
    <File>exhibit108bauschpharmagcem.htm</File>
    <File>exhibit109spurremploymenta.htm</File>
    <File>exhibit311q22022.htm</File>
    <File>exhibit312q22022.htm</File>
    <File>exhibit321q22022.htm</File>
    <File>exhibit322q22022.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1498">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>120
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bhc-20220630.htm": {
   "axisCustom": 0,
   "axisStandard": 46,
   "contextCount": 721,
   "dts": {
    "calculationLink": {
     "local": [
      "bhc-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bhc-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "bhc-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bhc-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bhc-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bhc-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 760,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 4,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 9
   },
   "keyCustom": 74,
   "keyStandard": 300,
   "memberCustom": 118,
   "memberStandard": 75,
   "nsprefix": "bhc",
   "nsuri": "http://www.bauschhealth.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information",
     "role": "http://www.bauschhealth.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - REVENUE RECOGNITION",
     "role": "http://www.bauschhealth.com/role/REVENUERECOGNITION",
     "shortName": "REVENUE RECOGNITION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - LICENSING AGREEMENTS AND DIVESTITURE",
     "role": "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURE",
     "shortName": "LICENSING AGREEMENTS AND DIVESTITURE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113105 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS",
     "role": "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS",
     "shortName": "RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115106 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127107 - Disclosure - INVENTORIES",
     "role": "http://www.bauschhealth.com/role/INVENTORIES",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130108 - Disclosure - INTANGIBLE ASSETS AND GOODWILL",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136109 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES",
     "role": "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES",
     "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139110 - Disclosure - FINANCING ARRANGEMENTS",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS",
     "shortName": "FINANCING ARRANGEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149111 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152112 - Disclosure - SHARE-BASED COMPENSATION",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION",
     "shortName": "SHARE-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ifa4f1d340e184a83a769da723d5d1bdf_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ifa4f1d340e184a83a769da723d5d1bdf_I20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2157113 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2161114 - Disclosure - RESEARCH AND DEVELOPMENT",
     "role": "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT",
     "shortName": "RESEARCH AND DEVELOPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2164115 - Disclosure - OTHER EXPENSE, NET",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSENET",
     "shortName": "OTHER EXPENSE, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2168116 - Disclosure - INCOME TAXES",
     "role": "http://www.bauschhealth.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2170117 - Disclosure - LOSS PER SHARE",
     "role": "http://www.bauschhealth.com/role/LOSSPERSHARE",
     "shortName": "LOSS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2174118 - Disclosure - LEGAL PROCEEDINGS",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGS",
     "shortName": "LEGAL PROCEEDINGS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2181119 - Disclosure - SEGMENT INFORMATION",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATION",
     "shortName": "SEGMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2189120 - Disclosure - SUBSEQUENT EVENT",
     "role": "http://www.bauschhealth.com/role/SUBSEQUENTEVENT",
     "shortName": "SUBSEQUENT EVENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - REVENUE RECOGNITION (Tables)",
     "role": "http://www.bauschhealth.com/role/REVENUERECOGNITIONTables",
     "shortName": "REVENUE RECOGNITION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ifa4f1d340e184a83a769da723d5d1bdf_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316302 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328303 - Disclosure - INVENTORIES (Tables)",
     "role": "http://www.bauschhealth.com/role/INVENTORIESTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331304 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337305 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Tables)",
     "role": "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables",
     "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340306 - Disclosure - FINANCING ARRANGEMENTS (Tables)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables",
     "shortName": "FINANCING ARRANGEMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2350307 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2353308 - Disclosure - SHARE-BASED COMPENSATION (Tables)",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables",
     "shortName": "SHARE-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2358309 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2362310 - Disclosure - RESEARCH AND DEVELOPMENT (Tables)",
     "role": "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables",
     "shortName": "RESEARCH AND DEVELOPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2365311 - Disclosure - OTHER EXPENSE, NET (Tables)",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSENETTables",
     "shortName": "OTHER EXPENSE, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostsAndExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2371312 - Disclosure - LOSS PER SHARE (Tables)",
     "role": "http://www.bauschhealth.com/role/LOSSPERSHARETables",
     "shortName": "LOSS PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2382313 - Disclosure - SEGMENT INFORMATION (Tables)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ifa4f1d340e184a83a769da723d5d1bdf_I20220630",
      "decimals": "-2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfCountriesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails",
     "shortName": "DESCRIPTION OF BUSINESS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ifa4f1d340e184a83a769da723d5d1bdf_I20220630",
      "decimals": "-2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfCountriesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ifa4f1d340e184a83a769da723d5d1bdf_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i1441c284542b4be69c98952b98de6886_I20220601",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - REVENUE RECOGNITION - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
     "shortName": "REVENUE RECOGNITION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i4f09824df81c4936b5ccd49a133e7471_D20220101-20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i318a5014ae1e41d09bf1de7db3ca0828_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - REVENUE RECOGNITION - Variable Consideration Provisions (Details)",
     "role": "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails",
     "shortName": "REVENUE RECOGNITION - Variable Consideration Provisions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesDeductions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i318a5014ae1e41d09bf1de7db3ca0828_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details)",
     "role": "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails",
     "shortName": "REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i318a5014ae1e41d09bf1de7db3ca0828_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ic98d97b553c347bba74a30a630426fa0_D20210331-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
     "shortName": "LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ic98d97b553c347bba74a30a630426fa0_D20210331-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails",
     "shortName": "RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i73006e60a9e74841887814ddcaca7dc1_D20220101-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ib1d5ed0948004c6da2b0030b9c2d5c61_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ib1d5ed0948004c6da2b0030b9c2d5c61_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:HighlyLiquidInvestmentsMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:HighlyLiquidInvestmentsMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i9e40ec51c8e14dcf8242bf19258f7e98_D20220101-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForProceedsFromHedgeInvestingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i9e40ec51c8e14dcf8242bf19258f7e98_D20220101-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForProceedsFromHedgeInvestingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i54705085633648acb51a31a97ced439a_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i54705085633648acb51a31a97ced439a_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i5073339adb074151bb1c3f96161a4030_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421412 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i5073339adb074151bb1c3f96161a4030_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i5073339adb074151bb1c3f96161a4030_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422413 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i5073339adb074151bb1c3f96161a4030_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i0beb279eb94a4ed9a49020c90d93ed68_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423414 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i0beb279eb94a4ed9a49020c90d93ed68_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "id76bfb01eac947359aab3481b8c4cc1a_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "rate",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424415 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "id76bfb01eac947359aab3481b8c4cc1a_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "rate",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i318a5014ae1e41d09bf1de7db3ca0828_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425416 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i318a5014ae1e41d09bf1de7db3ca0828_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6085cb4d390c424680c3eafd241edadf_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426417 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6085cb4d390c424680c3eafd241edadf_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ifa4f1d340e184a83a769da723d5d1bdf_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429418 - Disclosure - INVENTORIES - Components of Inventories (Details)",
     "role": "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails",
     "shortName": "INVENTORIES - Components of Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ifa4f1d340e184a83a769da723d5d1bdf_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i1ca51f98774641caa2fa73733729ac9b_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT",
     "shortName": "CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i1ca51f98774641caa2fa73733729ac9b_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ifa4f1d340e184a83a769da723d5d1bdf_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432419 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ifa4f1d340e184a83a769da723d5d1bdf_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433420 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ifa4f1d340e184a83a769da723d5d1bdf_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434421 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ifa4f1d340e184a83a769da723d5d1bdf_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i318a5014ae1e41d09bf1de7db3ca0828_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435422 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ic5e21899f1044f7fa7cb214f91d5655c_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ifa4f1d340e184a83a769da723d5d1bdf_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:Legalsettlementsandrelatedfees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438423 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details)",
     "role": "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails",
     "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ifa4f1d340e184a83a769da723d5d1bdf_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:Legalsettlementsandrelatedfees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtInstrumentCarryingAmount",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ifa4f1d340e184a83a769da723d5d1bdf_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441424 - Disclosure - FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
     "shortName": "FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6fa6b74354994e99b127ae89877febc7_I20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ie97aa1338630440fa931939603c3afa8_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentCovenantAmountAvailableForRestrictedPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442425 - Disclosure - FINANCING ARRANGEMENTS - Covenant Compliance (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
     "shortName": "FINANCING ARRANGEMENTS - Covenant Compliance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ie97aa1338630440fa931939603c3afa8_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentCovenantAmountAvailableForRestrictedPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ifa4f1d340e184a83a769da723d5d1bdf_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443426 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
     "shortName": "FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ia3f9fb93db3f4b06852f02dd6bfe37ae_I20180601",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentRedemptionPricePercentageChangeinControl",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444427 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Notes (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
     "shortName": "FINANCING ARRANGEMENTS - Senior Secured Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i22e56e38486147d28bc2898f73182eef_I20210608",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentRedemptionPricePercentageChangeinControl",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445428 - Disclosure - FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
     "shortName": "FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ib86afa84ce1b41d5b48258b10accd8f9_I20220118",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentRepurchasedFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ifa4f1d340e184a83a769da723d5d1bdf_I20220630",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtWeightedAverageInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446429 - Disclosure - FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
     "shortName": "FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ifa4f1d340e184a83a769da723d5d1bdf_I20220630",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtWeightedAverageInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447430 - Disclosure - FINANCING ARRANGEMENTS - Gain (Loss) on Extinguishment of Debt (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails",
     "shortName": "FINANCING ARRANGEMENTS - Gain (Loss) on Extinguishment of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ifa4f1d340e184a83a769da723d5d1bdf_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448431 - Disclosure - FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails",
     "shortName": "FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ifa4f1d340e184a83a769da723d5d1bdf_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i4cd8cb835ea2462f98e5d1fadf8a2bf3_D20220101-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451432 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i4cd8cb835ea2462f98e5d1fadf8a2bf3_D20220101-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ifa4f1d340e184a83a769da723d5d1bdf_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454433 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "SHARE-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ifa4f1d340e184a83a769da723d5d1bdf_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455434 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails",
     "shortName": "SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "id4690e57d623418889d484725bb730c7_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456435 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details)",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails",
     "shortName": "SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "id4690e57d623418889d484725bb730c7_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ifa4f1d340e184a83a769da723d5d1bdf_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459436 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of Accumulated Other Comprehensive Loss (Details)",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of Accumulated Other Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i720ba0ebf9c2430f814fa6947f648cee_I20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460437 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ResearchAndDevelopmentExpenseProductRelated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463438 - Disclosure - RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details)",
     "role": "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails",
     "shortName": "RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ResearchAndDevelopmentExpenseProductRelated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - DESCRIPTION OF BUSINESS",
     "role": "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS",
     "shortName": "DESCRIPTION OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466439 - Disclosure - OTHER EXPENSE, NET - Summary of Other Expense, Net (Details)",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails",
     "shortName": "OTHER EXPENSE, NET - Summary of Other Expense, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnDispositionOfAssets1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467440 - Disclosure - OTHER EXPENSE, NET - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails",
     "shortName": "OTHER EXPENSE, NET - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ib81ba7780e6c4af981ed3d93789a7a30_D20210101-20210630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GainLossOnDispositionOfAssets1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2469441 - Disclosure - INCOME TAXES - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2472442 - Disclosure - LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details)",
     "role": "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails",
     "shortName": "LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ib67e20cff1f34666a7bda60fe85e0092_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2473443 - Disclosure - LOSS PER SHARE - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails",
     "shortName": "LOSS PER SHARE - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ib67e20cff1f34666a7bda60fe85e0092_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ifa4f1d340e184a83a769da723d5d1bdf_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationReserveCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2475444 - Disclosure - LEGAL PROCEEDINGS - Legal Proceeds and Governmental and Regulatory Inquiries (Details)",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails",
     "shortName": "LEGAL PROCEEDINGS - Legal Proceeds and Governmental and Regulatory Inquiries (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ifa4f1d340e184a83a769da723d5d1bdf_I20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationReserveCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i4102d9065afe4932a90e498521bfa3cb_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "group",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2476445 - Disclosure - LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails",
     "shortName": "LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i4102d9065afe4932a90e498521bfa3cb_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "group",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i59952c7ec62348a0bf0304c3e9c4aa1f_D20190801-20200730",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "case",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2477446 - Disclosure - LEGAL PROCEEDINGS - Antitrust (Details)",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
     "shortName": "LEGAL PROCEEDINGS - Antitrust (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i59952c7ec62348a0bf0304c3e9c4aa1f_D20190801-20200730",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "case",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6a2d38205ea946e095aed8012d8b17c2_D20200326-20200326",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:GainContingencyStayOfApprovalPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2478447 - Disclosure - LEGAL PROCEEDINGS - Intellectual Property (Details)",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
     "shortName": "LEGAL PROCEEDINGS - Intellectual Property (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6a2d38205ea946e095aed8012d8b17c2_D20200326-20200326",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:GainContingencyStayOfApprovalPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i256a9238c6d447949e96e0113ba7913c_D20211101-20211130",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:LossContingencyStayOfApprovalPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2479448 - Disclosure - LEGAL PROCEEDINGS - Product Liability (Details)",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
     "shortName": "LEGAL PROCEEDINGS - Product Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i256a9238c6d447949e96e0113ba7913c_D20211101-20211130",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:LossContingencyStayOfApprovalPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i3da2b3029b9e49809af6f64595c73392_D20180401-20180430",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2480449 - Disclosure - LEGAL PROCEEDINGS - General Civil Actions (Details)",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails",
     "shortName": "LEGAL PROCEEDINGS - General Civil Actions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i3da2b3029b9e49809af6f64595c73392_D20180401-20180430",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ib56d8698081a436cb05434bb225f22eb_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unitRef": "reporting_unit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2483450 - Disclosure - SEGMENT INFORMATION - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
     "shortName": "SEGMENT INFORMATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2484451 - Disclosure - SEGMENT INFORMATION - Segment Revenues and Profit (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails",
     "shortName": "SEGMENT INFORMATION - Segment Revenues and Profit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i56f9693a8c8e416f9524496f13d18f13_D20220401-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2485452 - Disclosure - SEGMENT INFORMATION - Disaggregation of Revenue (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
     "shortName": "SEGMENT INFORMATION - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "ib94cfde72d4a4cceaa45cabf3b8613fe_D20220401-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ConcentrationRiskNumberOfProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2486453 - Disclosure - SEGMENT INFORMATION - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1",
     "shortName": "SEGMENT INFORMATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i6cb3866345124864badac5670e1d0aaf_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ConcentrationRiskNumberOfProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "if72062e9d1124e26a01bfeb4ed5f1ae1_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2487454 - Disclosure - SEGMENT INFORMATION - Revenue by Geographic Area (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails",
     "shortName": "SEGMENT INFORMATION - Revenue by Geographic Area (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i9362d500d1bd48e4b930877c7401396e_D20220401-20220630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i0cf345d189714dc1bec54dec30d5fe8a_D20220101-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2488455 - Disclosure - SEGMENT INFORMATION - Major Customers (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
     "shortName": "SEGMENT INFORMATION - Major Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i0cf345d189714dc1bec54dec30d5fe8a_D20220101-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i80db1e595e9640d1885c3342cd690c01_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2490456 - Disclosure - SUBSEQUENT EVENT - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/SUBSEQUENTEVENTNarrativeDetails",
     "shortName": "SUBSEQUENT EVENT - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220630.htm",
      "contextRef": "i83b432d29b6b47c8a7c436116ed24dae_I20220731",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 195,
   "tag": {
    "bhc_A9.00SeniorNotesdueDecember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "9.00% Senior Notes due December 2025 [Member]",
        "label": "9.00% Senior Notes due December 2025 [Member]",
        "terseLabel": "9.00% Senior Notes due December 2025"
       }
      }
     },
     "localname": "A9.00SeniorNotesdueDecember2025Member",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AccountsReceivableAllowanceForForeignExchangeAndOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Allowance For Foreign Exchange And Other",
        "label": "Accounts Receivable, Allowance For Foreign Exchange And Other",
        "negatedTerseLabel": "Foreign exchange and other"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForForeignExchangeAndOther",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AccretionForTimeValueOfMoneyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion For Time Value Of Money [Member]",
        "label": "Accretion For Time Value Of Money [Member]",
        "terseLabel": "Accretion for the time value of money"
       }
      }
     },
     "localname": "AccretionForTimeValueOfMoneyMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AccruedAndOtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued And Other Current Liabilities",
        "label": "Accrued And Other Current Liabilities [Member]",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedAndOtherCurrentLiabilitiesMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AccruedProductRebateCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the current portion of accrued product rebates.",
        "label": "Accrued Product Rebate Current",
        "terseLabel": "Product rebates"
       }
      }
     },
     "localname": "AccruedProductRebateCurrent",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AccruedProductReturnCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Product Return Current",
        "terseLabel": "Product returns"
       }
      }
     },
     "localname": "AccruedProductReturnCurrent",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]",
        "label": "Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]",
        "terseLabel": "LICENSING AGREEMENTS AND DIVESTITURE"
       }
      }
     },
     "localname": "AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All Reporting Units, Excluding Ortho Dermatologics, Vision Care, Surgical And Ophthalmic",
        "label": "All Reporting Units, Excluding Ortho Dermatologics, Vision Care, Surgical And Ophthalmic [Member]",
        "terseLabel": "All Reporting Units, Excluding Ortho Dermatologics, Vision Care, Surgical and Ophthalmic"
       }
      }
     },
     "localname": "AllReportingUnitsExcludingOrthoDermatologicsVisionCareSurgicalAndOphthalmicMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AllowancesForLossesOnAccountsReceivableAndInventories": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.",
        "label": "Allowances for Losses on Accounts Receivable and Inventories",
        "terseLabel": "Allowances for losses on trade receivable and inventories"
       }
      }
     },
     "localname": "AllowancesForLossesOnAccountsReceivableAndInventories",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AmerisourceBergenCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the major customer of the entity, AmerisourceBergen Corporation.",
        "label": "Amerisource Bergen Corporation [Member]",
        "terseLabel": "AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AmerisourceBergenCorporationMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.",
        "label": "Amortization of Intangible Assets Excluding Amortization Allocated to Revenues Cost of Good Sold",
        "negatedLabel": "Amortization of intangible assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AmounPharmaceuticalCompanySAEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amoun Pharmaceutical Company S.A.E",
        "label": "Amoun Pharmaceutical Company S.A.E [Member]",
        "terseLabel": "Amoun"
       }
      }
     },
     "localname": "AmounPharmaceuticalCompanySAEMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AnnualAmortizationOfIntangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Amortization Of Intangible Assets",
        "label": "Annual Amortization Of Intangible Assets",
        "terseLabel": "Finite lived intangible assets, annual amortization expense"
       }
      }
     },
     "localname": "AnnualAmortizationOfIntangibleAssets",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ApotexIncLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Apotex Inc. Litigation",
        "label": "Apotex Inc. Litigation [Member]",
        "terseLabel": "Apotex Inc. Litigation"
       }
      }
     },
     "localname": "ApotexIncLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AssetImpairmentChargesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Impairment Charges",
        "label": "Asset Impairment Charges [Member]",
        "terseLabel": "Asset impairments, including loss on assets held for sale"
       }
      }
     },
     "localname": "AssetImpairmentChargesMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BLCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "B+L Credit Agreement",
        "label": "B+L Credit Agreement [Member]",
        "terseLabel": "B+L Credit Agreement"
       }
      }
     },
     "localname": "BLCreditAgreementMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base Rate Factor, Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate",
        "label": "Base Rate Factor, Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "terseLabel": "Base Rate Factor, SOFR"
       }
      }
     },
     "localname": "BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BauschLombInternationalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bausch Lomb/International [Member]",
        "label": "Bausch + Lomb/International [Member]",
        "terseLabel": "Bausch + Lomb/ International"
       }
      }
     },
     "localname": "BauschLombInternationalMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BauschLombMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bausch + Lomb",
        "label": "Bausch + Lomb [Member]",
        "terseLabel": "Bausch + Lomb"
       }
      }
     },
     "localname": "BauschLombMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BauschLombToBeDistributedToOtherLegalEntitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bausch + Lomb. To Be Distributed To Other Legal Entities",
        "label": "Bausch + Lomb. To Be Distributed To Other Legal Entities [Member]",
        "terseLabel": "Bausch + Lomb. To Be Distributed To Other Legal Entities"
       }
      }
     },
     "localname": "BauschLombToBeDistributedToOtherLegalEntitiesMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BrandedandOtherGenericProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Branded and Other Generic Products [Member]",
        "label": "Branded and Other Generic Products [Member]",
        "terseLabel": "Branded and Other Generics"
       }
      }
     },
     "localname": "BrandedandOtherGenericProductsMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement which may include cash and shares.",
        "label": "Business Acquisition, Contingent Consideration Fair Value Disclosure",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationFairValueDisclosure",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination.",
        "label": "Business Combination, Contingent Consideration Arrangements Change in Amount of Contingent Consideration Asset Cash",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_BusinessCombinationContingentConsiderationNoncurrentLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Noncurrent Liability",
        "label": "Business Combination, Contingent Consideration, Noncurrent Liability",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationNoncurrentLiability",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_CanadianBankersAcceptanceRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Canadian Bankers Acceptance Rate",
        "label": "Canadian Bankers Acceptance Rate [Member]",
        "terseLabel": "BA Rate"
       }
      }
     },
     "localname": "CanadianBankersAcceptanceRateMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CanadianSecuritiesLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Canadian Securities Litigation",
        "label": "Canadian Securities Litigation [Member]",
        "terseLabel": "Canadian Securities Litigation"
       }
      }
     },
     "localname": "CanadianSecuritiesLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CardinalHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the major customer of the entity, Cardinal Health, Inc.",
        "label": "Cardinal Health Inc [Member]",
        "terseLabel": "Cardinal Health,\u00a0Inc."
       }
      }
     },
     "localname": "CardinalHealthIncMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ConcentrationRiskNumberOfProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk, Number Of Products",
        "label": "Concentration Risk, Number Of Products",
        "terseLabel": "Number of products represented of total revenue"
       }
      }
     },
     "localname": "ConcentrationRiskNumberOfProducts",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_CustomerTopTenProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer, Top Ten Products",
        "label": "Customer, Top Ten Products [Member]",
        "terseLabel": "Customer, Top Ten Products"
       }
      }
     },
     "localname": "CustomerTopTenProductsMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold",
        "label": "Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold",
        "terseLabel": "Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold"
       }
      }
     },
     "localname": "DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Alternate Term, Principal Amount Maturity Threshold",
        "label": "Debt Instrument, Alternate Term, Principal Amount Maturity Threshold",
        "terseLabel": "Alternate term, principal amount maturity threshold"
       }
      }
     },
     "localname": "DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentAnnualAmortizationRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Annual Amortization Rate, Percentage",
        "label": "Debt Instrument, Annual Amortization Rate, Percentage",
        "terseLabel": "Annual amortization rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentAnnualAmortizationRatePercentage",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Basis Spread On Variable Rate, If Rate Not Ascertainable",
        "label": "Debt Instrument, Basis Spread On Variable Rate, If Rate Not Ascertainable",
        "terseLabel": "Variable rate, if rate not ascertainable (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Amount Available For Restricted Payments",
        "label": "Debt Instrument, Covenant, Amount Available For Restricted Payments",
        "terseLabel": "Amount available for restricted payments"
       }
      }
     },
     "localname": "DebtInstrumentCovenantAmountAvailableForRestrictedPayments",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Secured Leverage Ratio",
        "label": "Debt Instrument, Covenant Compliance, Secured Leverage Ratio",
        "terseLabel": "Secured leverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantComplianceSecuredLeverageRatio",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "terseLabel": "Interest coverage ratio (not less than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantInterestCoverageRatioMinimum",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met",
        "label": "Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met",
        "terseLabel": "Debt covenant, redemption and discharge condition, amount, if circumstances met"
       }
      }
     },
     "localname": "DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio",
        "label": "Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio",
        "terseLabel": "Fixed charge coverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsFixedChargeCoverageRatio",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Secured Leverage Ratio",
        "label": "Debt Instrument, Covenant Terms, Secured Leverage Ratio",
        "terseLabel": "Secured leverage ratio (not greater than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsSecuredLeverageRatio",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantTotalLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Total Leverage Ratio",
        "label": "Debt Instrument, Covenant, Total Leverage Ratio",
        "terseLabel": "Total leverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTotalLeverageRatio",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Total Leverage Ratio",
        "label": "Debt Instrument, Covenant, Total Leverage Ratio, Maximum",
        "terseLabel": "Total leverage ratio (not greater than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTotalLeverageRatioMaximum",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Credit Spread Adjustment on Variable Rate",
        "label": "Debt Instrument, Credit Spread Adjustment on Variable Rate",
        "terseLabel": "Credit spread adjustment (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentCreditSpreadAdjustmentOnVariableRate",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Periodic Payment, Remaining Quarterly Amortization",
        "label": "Debt Instrument, Periodic Payment, Remaining Quarterly Amortization",
        "terseLabel": "Remaining quarterly amortization payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentRedemptionPricePercentageChangeinControl": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption Price, Percentage, Change in Control",
        "label": "Debt Instrument, Redemption Price, Percentage, Change in Control",
        "terseLabel": "Redemption price percentage to change in control (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageChangeinControl",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DeclaratoryJudgementActionLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Declaratory Judgement Action Litigation",
        "label": "Declaratory Judgement Action Litigation [Member]",
        "terseLabel": "Declaratory Judgement Action Litigation"
       }
      }
     },
     "localname": "DeclaratoryJudgementActionLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DefaultJudgementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Default Judgement",
        "label": "Default Judgement [Member]",
        "terseLabel": "Default Judgement"
       }
      }
     },
     "localname": "DefaultJudgementMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DeferredIncomeTaxNoncashExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.",
        "label": "Deferred Income Tax Noncash Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxNoncashExpenseBenefit",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DerivativeGainExcludedComponent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative, Gain, Excluded Component",
        "label": "Derivative, Gain, Excluded Component",
        "negatedTerseLabel": "Gain excluded from hedge effectiveness"
       }
      }
     },
     "localname": "DerivativeGainExcludedComponent",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DeviceProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Device Products [Member]",
        "label": "Device Products [Member]",
        "terseLabel": "Devices"
       }
      }
     },
     "localname": "DeviceProductsMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DiscontinuedProductLinesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discontinued Product Lines",
        "label": "Discontinued Product Lines [Member]",
        "terseLabel": "Discontinued Product Lines"
       }
      }
     },
     "localname": "DiscontinuedProductLinesMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DiversifiedProductsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Diversified Products Segment [Member]",
        "label": "Diversified Products Segment [Member]",
        "terseLabel": "Diversified Products"
       }
      }
     },
     "localname": "DiversifiedProductsSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DoctorsAllergyFormulaLLCLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Doctors Allergy Formula, LLC Litigation [Member]",
        "label": "Doctors Allergy Formula, LLC Litigation [Member]",
        "terseLabel": "Doctors Allergy Formula, LLC Litigation"
       }
      }
     },
     "localname": "DoctorsAllergyFormulaLLCLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Discrete Items, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Discrete Items, Amount",
        "terseLabel": "Income tax provision (benefit) for discrete items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Expense Filing Tax Returns, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Expense Filing Tax Returns, Amount",
        "terseLabel": "Provision related to filing certain tax returns"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Legal Settlements, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Legal Settlements, Amount",
        "negatedTerseLabel": "Income tax benefit for legal settlements"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationLegalSettlementsAmount",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Withholding Tax, Intercompany Dividends, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Withholding Tax, Intercompany Dividends, Amount",
        "terseLabel": "Provision related to withholding tax, intercompany dividends"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationWithholdingTaxIntercompanyDividendsAmount",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]",
        "label": "Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "Time-based RSUs, Performance-based RSUs and Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_EuropeInterbankOfferedRateEURIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Europe Interbank Offered Rate (EURIBOR)",
        "label": "Europe Interbank Offered Rate (EURIBOR) [Member]",
        "terseLabel": "EURIBOR"
       }
      }
     },
     "localname": "EuropeInterbankOfferedRateEURIBORMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Adjustments, Changes In Estimates Of Other Future Payments [Member]",
        "label": "Fair Value Adjustments, Changes In Estimates Of Other Future Payments [Member]",
        "terseLabel": "Fair value adjustments due to changes in estimates of other future payments"
       }
      }
     },
     "localname": "FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Finite Lived and Indefinite Lived Intangible Assets [Line Items]",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_GainContingencyNumberOfDefendants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Number Of Defendants",
        "label": "Gain Contingency, Number Of Defendants",
        "terseLabel": "Number of defendants"
       }
      }
     },
     "localname": "GainContingencyNumberOfDefendants",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_GainContingencyStayOfApprovalPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Stay Of Approval, Period",
        "label": "Gain Contingency, Stay Of Approval, Period",
        "terseLabel": "Stay of approval, period"
       }
      }
     },
     "localname": "GainContingencyStayOfApprovalPeriod",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_GainLossRelatedToLitigationSettlementGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) Related to Litigation Settlement, Gross payments not offset by insurance proceeds.",
        "label": "Gain (Loss) Related To Litigation Settlement, Gross",
        "negatedLabel": "Adjustments to accrued legal settlements"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlementGross",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_GlumetzaAntitrustLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glumetza Antitrust Class Actions Litigation [Member]",
        "label": "Glumetza Antitrust Litigation [Member]",
        "terseLabel": "Glumetza Antitrust Litigation"
       }
      }
     },
     "localname": "GlumetzaAntitrustLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glumetza Antitrust Litigation, Non-Class Complaints [Member]",
        "label": "Glumetza Antitrust Litigation, Non-Class Complaints [Member]",
        "terseLabel": "Glumetza Antitrust Litigation, Non-Class Complaints"
       }
      }
     },
     "localname": "GlumetzaAntitrustLitigationNonClassComplaintsMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill, Impairment Loss, Not Included In Asset Impairment Charges",
        "label": "Goodwill, Impairment Loss, Not Included In Asset Impairment Charges",
        "negatedTerseLabel": "Goodwill impairments",
        "terseLabel": "Goodwill impairments",
        "verboseLabel": "Goodwill impairments"
       }
      }
     },
     "localname": "GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_HighlyLiquidInvestmentsMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Highly Liquid Investments, Maturity Period",
        "label": "Highly Liquid Investments, Maturity Period",
        "terseLabel": "Highly liquid investments, maturity period (or less)"
       }
      }
     },
     "localname": "HighlyLiquidInvestmentsMaturityPeriod",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_IPOAndOverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IPO And Over-Allotment Option",
        "label": "IPO And Over-Allotment Option [Member]",
        "terseLabel": "IPO and Over-Allotment Option"
       }
      }
     },
     "localname": "IPOAndOverAllotmentOptionMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_IPOFoundersGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IPO Founders Grants",
        "label": "IPO Founders Grants [Member]",
        "terseLabel": "IPO Founders Grants"
       }
      }
     },
     "localname": "IPOFoundersGrantsMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_InsuranceCoverageLawsuitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance Coverage Lawsuit [Member]",
        "label": "Insurance Coverage Lawsuit [Member]",
        "terseLabel": "Insurance Coverage Lawsuit"
       }
      }
     },
     "localname": "InsuranceCoverageLawsuitMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_InterestSettlementOnCrossCurrencySwaps": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Settlement On Cross-Currency Swaps",
        "label": "Interest Settlement On Cross-Currency Swaps",
        "terseLabel": "Interest settlements from cross-currency swaps"
       }
      }
     },
     "localname": "InterestSettlementOnCrossCurrencySwaps",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_InternationalRxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International Rx",
        "label": "International Rx [Member]",
        "terseLabel": "International",
        "verboseLabel": "International"
       }
      }
     },
     "localname": "InternationalRxMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_Legalsettlementsandrelatedfees": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal settlements and related fees",
        "label": "Legal settlements and related fees",
        "terseLabel": "Legal matters and related fees"
       }
      }
     },
     "localname": "Legalsettlementsandrelatedfees",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of annual excess cash flow with any excess amounts after the prepayment of the loans.",
        "label": "Line of Credit Facility, Percentage of Consolidated Excess Cash Flow Payable as Mandatory Prepayments",
        "terseLabel": "Percentage of annual excess cash flow"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of net cash proceeds from asset sales outside ordinary course of business payable as mandatory prepayments.",
        "label": "Line of Credit Facility, Percentage of Net Cash Proceeds from Asset Sales Outside Ordinary Course of Business Payable as Mandatory Prepayments",
        "terseLabel": "Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of net cash proceeds of insurance and condemnation proceeds for property or asset (losses) which is payable as mandatory prepayment.",
        "label": "Line of Credit Facility, Percentage of Net Cash Proceeds of Insurance and Condemnation Proceeds from Property or Asset Losses Payable as Mandatory Prepayments",
        "terseLabel": "Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of net cash proceeds from the incurrence of debt payable as mandatory prepayments.",
        "label": "Line of Credit Facility, Percentage of Net Proceeds from Incurrence of Debt Payable as Mandatory Pre-payments",
        "terseLabel": "Percentage of cash proceeds from incurrence of debt"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Threshold For Incremental Borrowings",
        "label": "Line Of Credit Facility, Threshold For Incremental Borrowings",
        "terseLabel": "Threshold for incremental borrowings"
       }
      }
     },
     "localname": "LineOfCreditFacilityThresholdForIncrementalBorrowings",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility Threshold For Incremental Borrowings, Percentage",
        "label": "Line Of Credit Facility Threshold For Incremental Borrowings, Percentage",
        "terseLabel": "Incremental borrowings interest rate"
       }
      }
     },
     "localname": "LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LitigationSettlementNumberOfObjectorsAppeals": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Number of Objectors' Appeals",
        "label": "Litigation Settlement, Number of Objectors' Appeals",
        "terseLabel": "Settlement, escrow fund included in restricted cash, number of objectors' appeals"
       }
      }
     },
     "localname": "LitigationSettlementNumberOfObjectorsAppeals",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LitigationwithFormerSalixCEOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation with Former Salix CEO [Member]",
        "label": "Litigation with Former Salix CEO [Member]",
        "terseLabel": "Litigation with Former Salix CEO"
       }
      }
     },
     "localname": "LitigationwithFormerSalixCEOMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_LossContingencyNewClaimsFiledButNotYetServedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency New Claims Filed But Not Yet Served Number",
        "label": "Loss Contingency New Claims Filed But Not Yet Served Number",
        "terseLabel": "Number of suits filed but not yet served"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledButNotYetServedNumber",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action",
        "label": "Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action",
        "terseLabel": "Number of entities, exercised opt-out right, pursuing action"
       }
      }
     },
     "localname": "LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyNumberOfInsurancePolicyPeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Insurance Policy Periods",
        "label": "Loss Contingency, Number Of Insurance Policy Periods",
        "terseLabel": "Number of distinct insurance policy periods"
       }
      }
     },
     "localname": "LossContingencyNumberOfInsurancePolicyPeriods",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Plaintiffs, Number of Groups of Investors",
        "label": "Loss Contingency, Plaintiffs, Number of Groups of Investors",
        "terseLabel": "Number of groups of investors filing action"
       }
      }
     },
     "localname": "LossContingencyPlaintiffsNumberofGroupsofInvestors",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending",
        "label": "Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending",
        "terseLabel": "Number of groups of investors filing action, remain pending"
       }
      }
     },
     "localname": "LossContingencyPlaintiffsNumberofGroupsofInvestorsPending",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencySettlementAgreementsNumberOfInsurers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Settlement Agreements, Number Of Insurers",
        "label": "Loss Contingency, Settlement Agreements, Number Of Insurers",
        "terseLabel": "Settlement agreements, number of insurers"
       }
      }
     },
     "localname": "LossContingencySettlementAgreementsNumberOfInsurers",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyStayOfApprovalMotionToExtendPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Stay Of Approval, Motion To Extend, Period",
        "label": "Loss Contingency, Stay Of Approval, Motion To Extend, Period",
        "terseLabel": "Stay of approval, motion to extend, period"
       }
      }
     },
     "localname": "LossContingencyStayOfApprovalMotionToExtendPeriod",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_LossContingencyStayOfApprovalPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Stay Of Approval, Period",
        "label": "Loss Contingency, Stay Of Approval, Period",
        "terseLabel": "Stay of approval, period"
       }
      }
     },
     "localname": "LossContingencyStayOfApprovalPeriod",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lumify Paragraph I V Proceedings Lupin ANDA Litigation",
        "label": "Lumify Paragraph I V Proceedings Lupin ANDA Litigation [Member]",
        "terseLabel": "Lumify Paragraph I V Proceedings Lupin ANDA Litigation"
       }
      }
     },
     "localname": "LumifyParagraphIVProceedingsLupinANDALitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lumify Paragraph I V Proceedings Slayback ANDA Litigation",
        "label": "Lumify Paragraph I V Proceedings Slayback ANDA Litigation [Member]",
        "terseLabel": "Lumify Paragraph I V Proceedings Slayback ANDA Litigation"
       }
      }
     },
     "localname": "LumifyParagraphIVProceedingsSlaybackANDALitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_MSNLaboratoriesPrivateLtdLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MSN Laboratories Private Ltd. Litigation",
        "label": "MSN Laboratories Private Ltd. Litigation [Member]",
        "terseLabel": "MSN Laboratories Private Ltd. Litigation"
       }
      }
     },
     "localname": "MSNLaboratoriesPrivateLtdLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_McKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the major customer of the entity, McKesson Corporation.",
        "label": "Mc Kesson Corporation [Member]",
        "terseLabel": "McKesson Corporation (including McKesson Specialty)"
       }
      }
     },
     "localname": "McKessonCorporationMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_MeasurementInputWeightedAverageDiscountRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Weighted-Average Discount Rate [Member]",
        "label": "Measurement Input, Weighted-Average Discount Rate [Member]",
        "terseLabel": "Measurement Input, Weighted Average Risk-Adjusted Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputWeightedAverageDiscountRateMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_MilestonePaymentRelatedToCertainProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Related To Certain Product [Member]",
        "label": "Milestone Payment Related To Certain Product [Member]",
        "terseLabel": "Milestone Payment Related To Certain Product"
       }
      }
     },
     "localname": "MilestonePaymentRelatedToCertainProductMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NewRestatedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Restated Credit Agreement",
        "label": "New Restated Credit Agreement [Member]",
        "terseLabel": "New Restated Credit Agreement"
       }
      }
     },
     "localname": "NewRestatedCreditAgreementMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NonExecutiveEligibleRecipientsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Executive Eligible Recipients",
        "label": "Non-Executive Eligible Recipients [Member]",
        "terseLabel": "Non-Executive Eligible Recipients"
       }
      }
     },
     "localname": "NonExecutiveEligibleRecipientsMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NorwichPharmaceuticalsIncLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Norwich Pharmaceuticals Inc. Litigation",
        "label": "Norwich Pharmaceuticals Inc. Litigation [Member]",
        "terseLabel": "Norwich Pharmaceuticals Inc. Litigation"
       }
      }
     },
     "localname": "NorwichPharmaceuticalsIncLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OmnibusIncentivePlan2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Omnibus Incentive Plan 2014 [Member]",
        "label": "Omnibus Incentive Plan 2014 [Member]",
        "terseLabel": "2014 Plan"
       }
      }
     },
     "localname": "OmnibusIncentivePlan2014Member",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OrthoDermatologicsReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ortho Dermatologics Reporting Unit [Member]",
        "label": "Ortho Dermatologics Reporting Unit [Member]",
        "terseLabel": "Ortho Dermatologics Reporting Unit"
       }
      }
     },
     "localname": "OrthoDermatologicsReportingUnitMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OrthoDermatologicsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ortho Dermatologics Segment [Member]",
        "label": "Ortho Dermatologics Segment [Member]",
        "verboseLabel": "Ortho Dermatologics"
       }
      }
     },
     "localname": "OrthoDermatologicsSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Countries [Member]",
        "label": "Other Countries [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCountriesMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Income (Expense), Net",
        "label": "Other Income (Expense), Net",
        "terseLabel": "Other, Net"
       }
      }
     },
     "localname": "OtherIncomeExpenseNet",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_OtherLongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents long-term debt obligations not elsewhere enumerated.",
        "label": "Other Long Term Debt [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLongTermDebtMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Revenues [Member]",
        "label": "Other Revenues [Member]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "OtherRevenuesMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OutLicensedTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the rights to receive cash flows under an out-license arrangement (for example, license fees, milestone payments and royalties).",
        "label": "Out Licensed Technology [Member]",
        "terseLabel": "Technology and other"
       }
      }
     },
     "localname": "OutLicensedTechnologyMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OvertheCounterProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Over the Counter Products [Member]",
        "label": "Over the Counter Products [Member]",
        "terseLabel": "OTC"
       }
      }
     },
     "localname": "OvertheCounterProductsMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PadagisLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Padagis Litigation",
        "label": "Padagis Litigation [Member]",
        "terseLabel": "Padagis Litigation"
       }
      }
     },
     "localname": "PadagisLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PartnerRelationshipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to existing arrangements with various other entities, for which the entity provides regulatory, compliance, sales, marketing and distribution functions.",
        "label": "Partner Relationships [Member]",
        "terseLabel": "Partner relationships"
       }
      }
     },
     "localname": "PartnerRelationshipsMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PatentInfringementLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent Infringement Litigation",
        "label": "Patent Infringement Litigation [Member]",
        "terseLabel": "Patent Infringement Litigation"
       }
      }
     },
     "localname": "PatentInfringementLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment For Contingent Consideration Liability, Including Accretion, Operating Activities",
        "label": "Payment For Contingent Consideration Liability, Including Accretion, Operating Activities",
        "negatedLabel": "Payments of contingent consideration adjustments, including accretion"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pending Litigation, Agreed Stipulations Of Dismissal Submitted",
        "label": "Pending Litigation, Agreed Stipulations Of Dismissal Submitted [Member]",
        "terseLabel": "Pending Litigation, Agreed Stipulations of Dismissal Submitted"
       }
      }
     },
     "localname": "PendingLitigationAgreedStipulationsOfDismissalSubmittedMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance-Based Restricted Stock Units",
        "label": "Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "Performance-Based Restricted Stock Units"
       }
      }
     },
     "localname": "PerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PerrigoIsraelPharmaceuticalsLtdLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Perrigo Israel Pharmaceuticals, Ltd. Litigation",
        "label": "Perrigo Israel Pharmaceuticals, Ltd. Litigation [Member]",
        "terseLabel": "Perrigo Israel Pharmaceuticals, Ltd. Litigation"
       }
      }
     },
     "localname": "PerrigoIsraelPharmaceuticalsLtdLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PharmaceuticalProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical Products [Member]",
        "label": "Pharmaceutical Products [Member]",
        "terseLabel": "Pharmaceuticals"
       }
      }
     },
     "localname": "PharmaceuticalProductsMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PlaintiffsDirectPurchasersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plaintiffs, Direct Purchasers [Member]",
        "label": "Plaintiffs, Direct Purchasers [Member]",
        "terseLabel": "Plaintiffs, Direct Purchasers"
       }
      }
     },
     "localname": "PlaintiffsDirectPurchasersMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PreserVisionAREDSPatentLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PreserVision\u00ae AREDS Patent Litigation",
        "label": "PreserVision\u00ae AREDS Patent Litigation [Member]",
        "terseLabel": "PreserVision\u00ae AREDS Patent Litigation"
       }
      }
     },
     "localname": "PreserVisionAREDSPatentLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PriceAppreciationCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price Appreciation Credit [Member]",
        "label": "Price Appreciation Credit [Member]",
        "terseLabel": "Price Appreciation Credit"
       }
      }
     },
     "localname": "PriceAppreciationCreditMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Issuance Initial Public Offering, Net Of Costs, Related Party",
        "label": "Proceeds from Issuance Initial Public Offering, Net Of Costs, Related Party",
        "terseLabel": "Net proceeds from B+L initial public offering, net of costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOfferingNetOfCostsRelatedParty",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ProductBrandsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the rights to non-patented product brands.",
        "label": "Product Brands [Member]",
        "terseLabel": "Product brands"
       }
      }
     },
     "localname": "ProductBrandsMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RICOClassActionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RICO Class Actions",
        "label": "RICO Class Actions [Member]",
        "terseLabel": "RICO Class Actions"
       }
      }
     },
     "localname": "RICOClassActionsMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ROTCPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ROTC Performance-Based Restricted Stock Units [Member]",
        "label": "ROTC Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "ROTC performance-based RSUs"
       }
      }
     },
     "localname": "ROTCPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate",
        "label": "Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate",
        "terseLabel": "Reporting unit, impairment test, estimated cash flows, discount rate"
       }
      }
     },
     "localname": "ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reporting Unit, Impairment Test, Estimated Cash Flows, Increase (Decrease) In Discount Rate",
        "label": "Reporting Unit, Impairment Test, Estimated Cash Flows, Increase (Decrease) In Discount Rate",
        "terseLabel": "Reporting unit, impairment test, estimated cash flows, change in discount rate"
       }
      }
     },
     "localname": "ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_ReportingUnitImpairmentTestLongTermGrowthRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reporting Unit, Impairment Test, Long-Term Growth Rate",
        "label": "Reporting Unit, Impairment Test, Long-Term Growth Rate",
        "terseLabel": "Reporting unit, impairment test, long-term growth rate"
       }
      }
     },
     "localname": "ReportingUnitImpairmentTestLongTermGrowthRate",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_ReportingUnitsExcludingOrthoDermatologicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reporting Units Excluding Ortho Dermatologics",
        "label": "Reporting Units Excluding Ortho Dermatologics [Member]",
        "terseLabel": "Reporting Units Excluding Ortho Dermatologics"
       }
      }
     },
     "localname": "ReportingUnitsExcludingOrthoDermatologicsMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ResearchAndDevelopmentExpenseProductRelated": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Expense, Product Related",
        "label": "Research And Development Expense, Product Related",
        "terseLabel": "Product related research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseProductRelated",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ResearchAndDevelopmentExpenseQualityAssurance": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Expense, Quality Assurance",
        "label": "Research And Development Expense, Quality Assurance",
        "terseLabel": "Quality assurance"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseQualityAssurance",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ReserveForChargebacksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Chargebacks [Member]",
        "label": "Reserve For Chargebacks [Member]",
        "terseLabel": "Chargebacks"
       }
      }
     },
     "localname": "ReserveForChargebacksMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForCustomerReturnsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Customer Returns [Member]",
        "label": "Reserve For Customer Returns [Member]",
        "terseLabel": "Returns"
       }
      }
     },
     "localname": "ReserveForCustomerReturnsMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForDiscountsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Discounts And Allowances [Member]",
        "label": "Reserve For Discounts And Allowances [Member]",
        "terseLabel": "Discounts and Allowances"
       }
      }
     },
     "localname": "ReserveForDiscountsAndAllowancesMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForDistributionFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Distribution Fees [Member]",
        "label": "Reserve For Distribution Fees [Member]",
        "terseLabel": "Distribution Fees"
       }
      }
     },
     "localname": "ReserveForDistributionFeesMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForRebatesAdvertisingCreditsPortionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Rebates, Advertising Credits Portion [Member]",
        "label": "Reserve For Rebates, Advertising Credits Portion [Member]",
        "terseLabel": "Rebates, Advertising Credits Portion"
       }
      }
     },
     "localname": "ReserveForRebatesAdvertisingCreditsPortionMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Rebates [Member]",
        "label": "Reserve For Rebates [Member]",
        "terseLabel": "Rebates"
       }
      }
     },
     "localname": "ReserveForRebatesMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure",
        "label": "Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure",
        "terseLabel": "Restricted cash and other settlement deposits"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_RestrictedCashAndOtherSettlementDepositsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash And Other Settlement Deposits, Current",
        "label": "Restricted Cash And Other Settlement Deposits, Current",
        "terseLabel": "Restricted cash and other settlement deposits",
        "verboseLabel": "Restricted cash and other settlement deposits"
       }
      }
     },
     "localname": "RestrictedCashAndOtherSettlementDepositsCurrent",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash And Other Settlement Deposits, Current",
        "label": "Restricted Cash And Other Settlement Deposits, Current [Member]",
        "terseLabel": "Restricted Cash And Other Settlement Deposits, Current"
       }
      }
     },
     "localname": "RestrictedCashAndOtherSettlementDepositsCurrentMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RestructuringAndIntegrationCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring And Integration Costs",
        "label": "Restructuring And Integration Costs [Member]",
        "terseLabel": "Restructuring and Integration Costs"
       }
      }
     },
     "localname": "RestructuringAndIntegrationCostsMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring And Related Activities And Initial Public Offering Costs Disclosure",
        "label": "Restructuring And Related Activities And Initial Public Offering Costs Disclosure [Text Block]",
        "terseLabel": "RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_RestructuringChargesAndInitialPublicOfferingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Charges And Initial Public Offering Costs",
        "label": "Restructuring Charges And Initial Public Offering Costs",
        "negatedTerseLabel": "Restructuring, integration, separation and IPO costs",
        "terseLabel": "Restructuring, integration, separation and IPO costs"
       }
      }
     },
     "localname": "RestructuringChargesAndInitialPublicOfferingCosts",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_RevenuesNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net revenues during the period in the normal course of business.",
        "label": "Revenues Net [Member]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenuesNetMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RevolvingCreditFacilityDueFebruary2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving Credit Facility Due February 2027",
        "label": "Revolving Credit Facility Due February 2027 [Member]",
        "terseLabel": "Revolving Credit Facility Due February 2027"
       }
      }
     },
     "localname": "RevolvingCreditFacilityDueFebruary2027Member",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RevolvingCreditFacilityDueJune2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving Credit Facility Due June 2023 [Member]",
        "label": "Revolving Credit Facility Due June 2023 [Member]",
        "terseLabel": "Revolving Credit Facility Due June 2023"
       }
      }
     },
     "localname": "RevolvingCreditFacilityDueJune2023Member",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RevolvingCreditFacilityDueMay2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving Credit Facility Due May 2027",
        "label": "Revolving Credit Facility Due May 2027 [Member]",
        "terseLabel": "Revolving Credit Facility Due May 2027"
       }
      }
     },
     "localname": "RevolvingCreditFacilityDueMay2027Member",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SOFRCDORAndEURIBORRatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SOFR, CDOR and EURIBOR Rates",
        "label": "SOFR, CDOR and EURIBOR Rates [Member]",
        "terseLabel": "SOFR, CDOR and EURIBOR Rates"
       }
      }
     },
     "localname": "SOFRCDORAndEURIBORRatesMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SOFRCDOREURIBORAndSONIARatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SOFR, CDOR, EURIBOR and SONIA Rates",
        "label": "SOFR, CDOR, EURIBOR and SONIA Rates [Member]",
        "terseLabel": "SOFR, CDOR, EURIBOR and SONIA Rates"
       }
      }
     },
     "localname": "SOFRCDOREURIBORAndSONIARatesMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SONIARateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SONIA Rate",
        "label": "SONIA Rate [Member]",
        "terseLabel": "SONIA Rate"
       }
      }
     },
     "localname": "SONIARateMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SaleOfStockNumberOfAdditionalSharesAvailableForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Number Of Additional Shares Available For Issuance",
        "label": "Sale Of Stock, Number Of Additional Shares Available For Issuance",
        "terseLabel": "Number of additional shares available for issuance (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfAdditionalSharesAvailableForIssuance",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bhc_SaleOfStockOverAllotmentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Over-Allotment, Term",
        "label": "Sale of Stock, Over-Allotment, Term",
        "terseLabel": "Underwriters option to purchase additional shares, term"
       }
      }
     },
     "localname": "SaleOfStockOverAllotmentTerm",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_SalixSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Salix Segment [Member]",
        "label": "Salix Segment [Member]",
        "terseLabel": "Salix"
       }
      }
     },
     "localname": "SalixSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the carrying value of amortizable and nonamortizable intangibles assets, in total and by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Schedule of Finite Lived and Indefinite Lived Intangible Asset by Major Class [Table]",
        "terseLabel": "Schedule of Finite Lived and Indefinite Lived Intangible Asset by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_ScheduleOfOtherIncomeAndExpensesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Schedule Of Other Income And Expenses [Table]",
        "label": "Schedule Of Other Income And Expenses [Line Items]",
        "terseLabel": "Schedule Of Other Income And Expenses [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfOtherIncomeAndExpensesLineItems",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_ScheduleOfOtherIncomeAndExpensesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Other Income And Expenses [Table]",
        "label": "Schedule Of Other Income And Expenses [Table]",
        "terseLabel": "Schedule Of Other Income And Expenses [Table]"
       }
      }
     },
     "localname": "ScheduleOfOtherIncomeAndExpensesTable",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Excluded From Computation Of Earnings Per Share, Performance Conditions Not Met, Amount",
        "label": "Securities Excluded From Computation Of Earnings Per Share, Performance Conditions Not Met, Amount",
        "terseLabel": "Excluded from computation of earnings per share, performance conditions not met (in shares)"
       }
      }
     },
     "localname": "SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bhc_SeniorNotes500DueFebruary2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 5.00%, Due February 2029",
        "label": "Senior Notes, 5.00%, Due February 2029 [Member]",
        "terseLabel": "5.00% Senior Notes Due February 2029"
       }
      }
     },
     "localname": "SeniorNotes500DueFebruary2029Member",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes500DueJanuary2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.00% Senior Notes Due January 2028 [Member]",
        "label": "Senior Notes, 5.00%, Due January 2028 [Member]",
        "terseLabel": "5.00% Senior Notes Due January 2028"
       }
      }
     },
     "localname": "SeniorNotes500DueJanuary2028Member",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes525DueFebruary2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 5.25%, Due February 2031",
        "label": "Senior Notes, 5.25%, Due February 2031 [Member]",
        "terseLabel": "5.25% Senior Notes Due February 2031"
       }
      }
     },
     "localname": "SeniorNotes525DueFebruary2031Member",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes525DueJanuary2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.25% Senior Notes Due January 2030 [Member]",
        "label": "Senior Notes, 5.25%, Due January 2030 [Member]",
        "terseLabel": "5.25% Senior Notes Due January 2030"
       }
      }
     },
     "localname": "SeniorNotes525DueJanuary2030Member",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes6125DueApril2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.125% Senior Notes due April 2025 [Member]",
        "label": "Senior Notes, 6.125%, Due April 2025 [Member]",
        "terseLabel": "6.125% Senior Notes Due April 2025"
       }
      }
     },
     "localname": "SeniorNotes6125DueApril2025Member",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes625DueFebruary2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 6.25%, Due February 2029",
        "label": "Senior Notes, 6.25%, Due February 2029 [Member]",
        "terseLabel": "6.25% Senior Notes Due February 2029"
       }
      }
     },
     "localname": "SeniorNotes625DueFebruary2029Member",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes700DueJanuary2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes 7.00 Percent Due January 2028 [Member]",
        "label": "Senior Notes, 7.00%, Due January 2028 [Member]",
        "terseLabel": "7.00 % Senior Notes Due January 2028"
       }
      }
     },
     "localname": "SeniorNotes700DueJanuary2028Member",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes700DueMarch2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 7.00%, Due March 2024",
        "label": "Senior Notes, 7.00%, Due March 2024 [Member]",
        "terseLabel": "7.00% Senior Notes, Due March 2024"
       }
      }
     },
     "localname": "SeniorNotes700DueMarch2024Member",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes725DueMay2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes 7.25 Percent Due May 2029 [Member]",
        "label": "Senior Notes, 7.25%, Due May 2029 [Member]",
        "terseLabel": "7.25 % Senior Notes Due May 2029"
       }
      }
     },
     "localname": "SeniorNotes725DueMay2029Member",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes850DueJanuary2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "8.50% Senior Notes Due January 2027 [Member]",
        "label": "Senior Notes, 8.50%, Due January 2027 [Member]",
        "terseLabel": "8.50% Senior Notes Due January 2027"
       }
      }
     },
     "localname": "SeniorNotes850DueJanuary2027Member",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes900DueDecember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "9.00% Senior Notes due December 2025 [Member]",
        "label": "Senior Notes, 9.00%, Due December 2025 [Member]",
        "terseLabel": "9.00% Senior Notes Due December 2025"
       }
      }
     },
     "localname": "SeniorNotes900DueDecember2025Member",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes925DueApril2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "9.25% Senior Notes Due April 2026 [Member]",
        "label": "Senior Notes, 9.25%, Due April 2026 [Member]",
        "verboseLabel": "9.25% Senior Notes Due April 2026"
       }
      }
     },
     "localname": "SeniorNotes925DueApril2026Member",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured4875NotesDueJune2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 4.875% Notes Due June 2028",
        "label": "Senior Secured 4.875% Notes Due June 2028 [Member]",
        "terseLabel": "4.875% Senior Notes Due June 2028"
       }
      }
     },
     "localname": "SeniorSecured4875NotesDueJune2028Member",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured5.50NotesDueNovember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 5.50% Notes Due November 2025 [Member]",
        "label": "Senior Secured 5.50% Notes Due November 2025 [Member]",
        "terseLabel": "5.50% Senior Notes Due November 2025"
       }
      }
     },
     "localname": "SeniorSecured5.50NotesDueNovember2025Member",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured5.75NotesDueAugust2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 5.75% Notes Due August 2027 [Member]",
        "label": "Senior Secured 5.75% Notes Due August 2027 [Member]",
        "verboseLabel": "5.75% Senior Notes Due August 2027"
       }
      }
     },
     "localname": "SeniorSecured5.75NotesDueAugust2027Member",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured6125NotesDueFebruary2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 6.125% Notes Due February 2027",
        "label": "Senior Secured 6.125% Notes Due February 2027 [Member]",
        "terseLabel": "6.125% Senior Notes Due February 2027"
       }
      }
     },
     "localname": "SeniorSecured6125NotesDueFebruary2027Member",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecuredCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Credit Facilities [Member]",
        "label": "Senior Secured Credit Facilities [Member]",
        "terseLabel": "Senior Secured Credit Facilities"
       }
      }
     },
     "localname": "SeniorSecuredCreditFacilitiesMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecuredCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Credit Facility",
        "label": "Senior Secured Credit Facility [Member]",
        "terseLabel": "Senior Secured Credit Facility"
       }
      }
     },
     "localname": "SeniorSecuredCreditFacilityMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeparationAndInitialPublicOfferingCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Separation And Initial Public Offering Costs",
        "label": "Separation And Initial Public Offering Costs [Member]",
        "terseLabel": "Separation and IPO Costs"
       }
      }
     },
     "localname": "SeparationAndInitialPublicOfferingCostsMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeparationPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Separation Performance-Based Restricted Stock Units",
        "label": "Separation Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "B+L Separation performance-based RSUs"
       }
      }
     },
     "localname": "SeparationPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Award Type, Percent",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Award Type, Percent",
        "terseLabel": "Incentive stock plan, award type, percent"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsAwardTypePercent",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Grants In Period, Gross",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Grants In Period, Gross",
        "terseLabel": "Incentive stock plan, grants in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsGrantsInPeriodGross",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bhc_ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement, Option And Restricted Stock Units RSUs",
        "label": "Share-Based Payment Arrangement, Option And Restricted Stock Units RSUs [Member]",
        "terseLabel": "Options and RSUs"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shower To Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma Or Breast Cancer",
        "label": "Shower To Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma Or Breast Cancer [Member]",
        "terseLabel": "Shower to Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma or Breast Cancer"
       }
      }
     },
     "localname": "ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ShowerToShowerProductLiabilityLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shower to Shower Product Liability Litigation [Member]",
        "label": "Shower To Shower Product Liability Litigation [Member]",
        "terseLabel": "Shower to Shower Product Liability Litigation"
       }
      }
     },
     "localname": "ShowerToShowerProductLiabilityLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SoltaMedicalSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Solta Medical Segment",
        "label": "Solta Medical Segment [Member]",
        "terseLabel": "Solta Medical"
       }
      }
     },
     "localname": "SoltaMedicalSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Research And Development Expense [Table Text Block]",
        "label": "Summary Of Research And Development Expense [Table Text Block]",
        "terseLabel": "Summary of research and development"
       }
      }
     },
     "localname": "SummaryOfResearchAndDevelopmentExpenseTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Valuation And Qualifying Accounts [Table Text Block]",
        "label": "Summary Of Valuation And Qualifying Accounts [Table Text Block]",
        "terseLabel": "Summary of variable consideration provisions"
       }
      }
     },
     "localname": "SummaryOfValuationAndQualifyingAccountsTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_TSRPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TSR Performance-Based Restricted Stock Units [Member]",
        "label": "TSR Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "TSR Performance-Based Restricted Stock Units"
       }
      }
     },
     "localname": "TSRPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TaroPharmaceuticalsIncLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Taro Pharmaceuticals Inc. Litigation",
        "label": "Taro Pharmaceuticals Inc. Litigation [Member]",
        "terseLabel": "Taro Pharmaceuticals Inc. Litigation"
       }
      }
     },
     "localname": "TaroPharmaceuticalsIncLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermFacilityDueMay2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Facility Due May 2027",
        "label": "Term Facility Due May 2027 [Member]",
        "terseLabel": "Term Facility Due May 2027"
       }
      }
     },
     "localname": "TermFacilityDueMay2027Member",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermLoanBFacilityDueFebruary2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B Facility Due February 2027",
        "label": "Term Loan B Facility Due February 2027 [Member]",
        "terseLabel": "Term Loan B Facility Due February 2027"
       }
      }
     },
     "localname": "TermLoanBFacilityDueFebruary2027Member",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermLoanBFacilityDueJune2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B Facility Due June 2025 [Member]",
        "label": "Term Loan B Facility Due June 2025 [Member]",
        "verboseLabel": "Term Loan B Facility Due June 2025"
       }
      }
     },
     "localname": "TermLoanBFacilityDueJune2025Member",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermLoanBFacilityDueNovember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B Facility Due November 2025 [Member]",
        "label": "Term Loan B Facility Due November 2025 [Member]",
        "terseLabel": "Term Loan B Facility Due November 2025"
       }
      }
     },
     "localname": "TermLoanBFacilityDueNovember2025Member",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TimeBasedRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents stock awards in the form of time-based restricted stock units (RSUs) to certain directors, officers and other eligible employees pursuant to the company's incentive compensation plan.",
        "label": "Time Based RSU [Member]",
        "terseLabel": "Time-based RSUs"
       }
      }
     },
     "localname": "TimeBasedRSUMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. Dollar Base Rate and Canadian Dollar Prime Rate",
        "label": "U.S. Dollar Base Rate and Canadian Dollar Prime Rate [Member]",
        "terseLabel": "U.S. Dollar Base Rate and Canadian Dollar Prime Rate"
       }
      }
     },
     "localname": "USDollarBaseRateAndCanadianDollarPrimeRateMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_UnitedStatesandPuertoRicoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United States and Puerto Rico [Member]",
        "label": "United States and Puerto Rico [Member]",
        "terseLabel": "U.S. and Puerto Rico"
       }
      }
     },
     "localname": "UnitedStatesandPuertoRicoMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross amount of unrecognized tax benefits including interest and penalties pertaining to uncertain tax positions taken in tax returns as of the balance sheet date.",
        "label": "Unrecognized Tax Benefits, Including Interest and Penalties",
        "terseLabel": "Unrecognized tax benefits including interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncludingInterestAndPenalties",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ValeantUSSecuritiesLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valeant US Securities Litigation [Member]",
        "label": "Valeant US Securities Litigation [Member]",
        "terseLabel": "US Securities Litigation"
       }
      }
     },
     "localname": "ValeantUSSecuritiesLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ViolationofCanadianProvincialSecuritiesLegislationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Violation of Canadian Provincial Securities Legislation [Member]",
        "label": "Violation of Canadian Provincial Securities Legislation [Member]",
        "terseLabel": "Violation of Canadian Provincial Securities Legislation"
       }
      }
     },
     "localname": "ViolationofCanadianProvincialSecuritiesLegislationMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vision Care, Surgical And Ophthalmic Reporting Units",
        "label": "Vision Care, Surgical And Ophthalmic Reporting Units [Member]",
        "terseLabel": "Vision Care, Surgical And Ophthalmic Reporting Units"
       }
      }
     },
     "localname": "VisionCareSurgicalAndOphthalmicReportingUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_XifaxanBrandedProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xifaxan Branded Products",
        "label": "Xifaxan Branded Products [Member]",
        "terseLabel": "Xifaxan Branded Products"
       }
      }
     },
     "localname": "XifaxanBrandedProductsMember",
     "nsuri": "http://www.bauschhealth.com/20220630",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "Canada"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_DE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GERMANY",
        "terseLabel": "Germany"
       }
      }
     },
     "localname": "DE",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_ES": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SPAIN",
        "terseLabel": "Spain"
       }
      }
     },
     "localname": "ES",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_FR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FRANCE",
        "terseLabel": "France"
       }
      }
     },
     "localname": "FR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_GB": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM",
        "terseLabel": "United Kingdom"
       }
      }
     },
     "localname": "GB",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IT": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ITALY",
        "terseLabel": "Italy"
       }
      }
     },
     "localname": "IT",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_KR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "KOREA, REPUBLIC OF",
        "terseLabel": "South Korea"
       }
      }
     },
     "localname": "KR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_MX": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MEXICO",
        "terseLabel": "Mexico"
       }
      }
     },
     "localname": "MX",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_PL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "POLAND",
        "terseLabel": "Poland"
       }
      }
     },
     "localname": "PL",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_RU": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RUSSIAN FEDERATION",
        "terseLabel": "Russia"
       }
      }
     },
     "localname": "RU",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S. Plan"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Smaller Reporting Company"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r124",
      "r176",
      "r189",
      "r190",
      "r191",
      "r192",
      "r194",
      "r196",
      "r200",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r290",
      "r292",
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r124",
      "r176",
      "r189",
      "r190",
      "r191",
      "r192",
      "r194",
      "r196",
      "r200",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r290",
      "r292",
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r56",
      "r58",
      "r122",
      "r123",
      "r301",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer [Member]",
        "terseLabel": "Executive Officer"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r207",
      "r361",
      "r365",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r271",
      "r273",
      "r274",
      "r275",
      "r300",
      "r336",
      "r456",
      "r461",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r688",
      "r692",
      "r712",
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r271",
      "r273",
      "r274",
      "r275",
      "r300",
      "r336",
      "r456",
      "r461",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r688",
      "r692",
      "r712",
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r207",
      "r361",
      "r365",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r203",
      "r273",
      "r274",
      "r361",
      "r363",
      "r644",
      "r687",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r203",
      "r273",
      "r274",
      "r361",
      "r363",
      "r644",
      "r687",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r258",
      "r271",
      "r273",
      "r274",
      "r275",
      "r300",
      "r336",
      "r397",
      "r456",
      "r461",
      "r492",
      "r493",
      "r494",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r688",
      "r692",
      "r712",
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r258",
      "r271",
      "r273",
      "r274",
      "r275",
      "r300",
      "r336",
      "r397",
      "r456",
      "r461",
      "r492",
      "r493",
      "r494",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r688",
      "r692",
      "r712",
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r57",
      "r58",
      "r122",
      "r123",
      "r301",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r204",
      "r205",
      "r361",
      "r364",
      "r690",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r204",
      "r205",
      "r361",
      "r364",
      "r690",
      "r701",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r209",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA-BC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BRITISH COLUMBIA",
        "terseLabel": "BRITISH COLUMBIA"
       }
      }
     },
     "localname": "CA-BC",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CA-QC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "QUEBEC",
        "terseLabel": "QUEBEC"
       }
      }
     },
     "localname": "CA-QC",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NJ": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW JERSEY",
        "terseLabel": "NEW JERSEY",
        "verboseLabel": "New Jersey"
       }
      }
     },
     "localname": "NJ",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "ACCRUED AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r40",
      "r630"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Employee compensation and benefit costs"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r21",
      "r651",
      "r670"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r62",
      "r67",
      "r74",
      "r75",
      "r76",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Pension and postretirement benefit plan adjustments, net of income taxes"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails",
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r27",
      "r65",
      "r66",
      "r67",
      "r672",
      "r697",
      "r698"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r74",
      "r75",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income Loss [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails",
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r64",
      "r67",
      "r74",
      "r75",
      "r76",
      "r132",
      "r133",
      "r134",
      "r554",
      "r626",
      "r693",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails",
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r60",
      "r67",
      "r74",
      "r75",
      "r76",
      "r554",
      "r614",
      "r615",
      "r616",
      "r617",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r503",
      "r504",
      "r505",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Employee withholding taxes related to share-based awards"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r464",
      "r507",
      "r508"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r31",
      "r210",
      "r215",
      "r216",
      "r220"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Recovery",
        "terseLabel": "Recoveries"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "negatedTerseLabel": "Write-offs"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r110",
      "r320",
      "r331",
      "r332",
      "r623"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization and write-off of debt premiums, discounts and issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Dilutive effect of potential common shares (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Anti-dilutive shares not included in the computation of diluted earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r110",
      "r250"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "negatedLabel": "Asset impairments, including loss on assets held for sale",
        "terseLabel": "Asset impairments, including loss on assets held for sale",
        "verboseLabel": "Asset impairments, including loss on assets held for sale"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r19",
      "r119",
      "r184",
      "r191",
      "r198",
      "r213",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r293",
      "r295",
      "r296",
      "r547",
      "r556",
      "r607",
      "r628",
      "r630",
      "r649",
      "r669"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r12",
      "r39",
      "r119",
      "r213",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r293",
      "r295",
      "r296",
      "r547",
      "r556",
      "r607",
      "r628",
      "r630"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r487",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r566",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r109",
      "r540"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r538",
      "r539"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Current portion included in Accrued and other current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Fair value, contingent consideration obligations, discount rate"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r538",
      "r539"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Non-current portion"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r10",
      "r15",
      "r112"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r106",
      "r112",
      "r113"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, restricted cash and other settlement deposits, end of period",
        "periodStartLabel": "Cash, cash equivalents, restricted cash and other settlement deposits, beginning of period",
        "totalLabel": "Cash, cash equivalents, restricted cash and other settlement deposits, end of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r106",
      "r612"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents, restricted cash and other settlement deposits"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r49",
      "r655",
      "r678"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 18)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common shares available for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r132",
      "r133",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "terseLabel": "Common shares, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r24",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r24",
      "r630"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common shares, no par value, unlimited shares authorized, 361,571,921 and 359,405,748 issued and outstanding at June 30, 2022 and December\u00a031, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r70",
      "r72",
      "r73",
      "r84",
      "r661",
      "r683"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Bausch Health Companies Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r70",
      "r72",
      "r83",
      "r545",
      "r546",
      "r560",
      "r660",
      "r682"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Comprehensive income attributable to noncontrolling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r70",
      "r72",
      "r82",
      "r544",
      "r560",
      "r659",
      "r681"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r81",
      "r94",
      "r658",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r166",
      "r167",
      "r207",
      "r605",
      "r606",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r166",
      "r167",
      "r207",
      "r605",
      "r606",
      "r699",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r166",
      "r167",
      "r207",
      "r605",
      "r606",
      "r699",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r166",
      "r167",
      "r207",
      "r605",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r166",
      "r167",
      "r207",
      "r605",
      "r606",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]",
        "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]"
       }
      }
     },
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable": {
     "auth_ref": [
      "r555",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent which may have occurred during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary.",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]",
        "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]"
       }
      }
     },
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r115",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractualRightsMember": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights that arise from a contractual arrangement with a third party (not including franchise rights and license agreements).",
        "label": "Contractual Rights [Member]",
        "terseLabel": "Product rights/patents"
       }
      }
     },
     "localname": "ContractualRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r194",
      "r200",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r89",
      "r644"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrencySwapMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.",
        "label": "Currency Swap [Member]",
        "terseLabel": "Currency Swap"
       }
      }
     },
     "localname": "CurrencySwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r164",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r117",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r314",
      "r321",
      "r322",
      "r324",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "FINANCING ARRANGEMENTS"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r118",
      "r124",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r329",
      "r330",
      "r331",
      "r332",
      "r624",
      "r650",
      "r652",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r22",
      "r325",
      "r652",
      "r668"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Principal Amount",
        "totalLabel": "Total debt obligations"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r297",
      "r329",
      "r330",
      "r622",
      "r624",
      "r625"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r312",
      "r329",
      "r330",
      "r604"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r46",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Stated interest rate on debt (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]",
        "verboseLabel": "Long-term debt, net of unamortized debt discount"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r47",
      "r118",
      "r124",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r329",
      "r330",
      "r331",
      "r332",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "auth_ref": [
      "r47",
      "r665"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments including both interest and principal payments.",
        "label": "Debt Instrument, Periodic Payment",
        "terseLabel": "Quarterly installment payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period Two"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of principal amount of debt redeemed.",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "terseLabel": "Maximum percentage of principal amount that can be redeemed"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of the original debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchased Face Amount",
        "terseLabel": "Repurchased principal amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r47",
      "r118",
      "r124",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r323",
      "r329",
      "r330",
      "r331",
      "r332",
      "r339",
      "r340",
      "r341",
      "r342",
      "r621",
      "r622",
      "r624",
      "r625",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r310",
      "r326",
      "r329",
      "r330",
      "r623"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Unamortized premiums, discounts and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Weighted average interest rate"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r519"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Unrecognized tax benefit, amount possible to decrease in next twelve months"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r513",
      "r514"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "verboseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r513",
      "r514"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r522"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Valuation allowance against deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r375",
      "r413",
      "r440",
      "r446",
      "r447"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedTerseLabel": "Amortization of net loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r375",
      "r414",
      "r441",
      "r446",
      "r447"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Amortization of prior service credit and other"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r375",
      "r412",
      "r439",
      "r446",
      "r447"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedTerseLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r375",
      "r379",
      "r411",
      "r438",
      "r446",
      "r447"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r409",
      "r436",
      "r446",
      "r447"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic (benefit) cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r377",
      "r410",
      "r437",
      "r446",
      "r447"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r110",
      "r252"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization of intangible assets"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r54",
      "r55",
      "r58",
      "r604"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Foreign currency exchange contracts"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeNet": {
     "auth_ref": [
      "r604"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives.",
        "label": "Derivative, Fair Value, Net",
        "terseLabel": "Net fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r58",
      "r567",
      "r568",
      "r574",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r565",
      "r567",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r565",
      "r567",
      "r574",
      "r580",
      "r581",
      "r583",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain": {
     "auth_ref": [
      "r573",
      "r575"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain",
        "negatedTerseLabel": "Gain related to settlements"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r573",
      "r575"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Gain (loss) related to changes in fair value"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss": {
     "auth_ref": [
      "r573",
      "r575"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized loss of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Loss",
        "negatedTerseLabel": "Loss related to settlements"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r54",
      "r55",
      "r58",
      "r604"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Foreign currency exchange contracts"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Aggregate notional amounts"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r361",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r466",
      "r467",
      "r498",
      "r499",
      "r501",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r251",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": {
     "auth_ref": [
      "r3",
      "r4",
      "r7",
      "r255"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents",
        "terseLabel": "Cash and cash equivalents, held for sale"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r6",
      "r9"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Revenue associated with products for disposal"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r452",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r451",
      "r455",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r85",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r145",
      "r147",
      "r149",
      "r150",
      "r151",
      "r155",
      "r156",
      "r589",
      "r590",
      "r662",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic loss per share attributable to Bausch Health Companies Inc. (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r85",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r147",
      "r149",
      "r150",
      "r151",
      "r155",
      "r156",
      "r589",
      "r590",
      "r662",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted loss per share attributable to Bausch Health Companies Inc. (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r612"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and other"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r509",
      "r516"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount",
        "negatedTerseLabel": "Tax benefit related to stock compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Components and classification of share-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r500"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Remaining unrecognized compensation expense related to non-vested awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average service period over which compensation cost is expected to be recognized (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "terseLabel": "Revenue, Major Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r74",
      "r75",
      "r76",
      "r132",
      "r133",
      "r134",
      "r136",
      "r142",
      "r144",
      "r158",
      "r214",
      "r338",
      "r343",
      "r503",
      "r504",
      "r505",
      "r524",
      "r525",
      "r588",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r619",
      "r626",
      "r693",
      "r694",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails",
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "verboseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r591",
      "r592",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r312",
      "r329",
      "r330",
      "r398",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r446",
      "r592",
      "r634",
      "r635",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r591",
      "r592",
      "r594",
      "r595",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r312",
      "r398",
      "r400",
      "r405",
      "r446",
      "r592",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r312",
      "r329",
      "r330",
      "r398",
      "r400",
      "r405",
      "r446",
      "r592",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r312",
      "r329",
      "r330",
      "r398",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r446",
      "r592",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "verboseLabel": "Reconciliation of contingent payment obligations measured on a recurring basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r596",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r596",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r597"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": {
     "auth_ref": [
      "r598"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "verboseLabel": "Foreign currency translation adjustment included in other comprehensive loss"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r599"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Payments/Settlements"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r596"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r312",
      "r329",
      "r330",
      "r398",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r446",
      "r634",
      "r635",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r591",
      "r592",
      "r594",
      "r595",
      "r600",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Nonrecurring adjustment"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r601",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.",
        "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]",
        "terseLabel": "Federal Funds"
       }
      }
     },
     "localname": "FederalFundsEffectiveSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite lived intangible assets, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r17",
      "r242"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization and Impairments"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r237",
      "r239",
      "r242",
      "r245",
      "r645",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r242",
      "r646"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r237",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r242",
      "r645"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Finite-lived intangible assets",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "terseLabel": "Finite-lived intangible assets:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r608",
      "r609",
      "r610",
      "r611"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign exchange and other"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r111",
      "r610",
      "r611"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Foreign exchange loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r58",
      "r398",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign currency exchange contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r451",
      "r455",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "Non-U.S. Plans"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of entity's patents that another entity has allegedly infringed.",
        "label": "Gain Contingency, Patents Allegedly Infringed upon, Number",
        "terseLabel": "Number of lawsuits pending"
       }
      }
     },
     "localname": "GainContingencyPatentsAllegedlyInfringedUponNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Net gain on sale of assets",
        "negatedTerseLabel": "Gain on sale of assets, net",
        "verboseLabel": "Milestone achievement, included in net (loss) gain on sale of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r269"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedTerseLabel": "Litigation and other matters"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r110",
      "r333",
      "r334"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "(Gain) loss on extinguishment of debt",
        "negatedTerseLabel": "Loss on extinguishment of debt",
        "terseLabel": "Gain (loss) on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r16",
      "r222",
      "r224",
      "r231",
      "r235",
      "r630",
      "r648"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance at the end of the period",
        "periodStartLabel": "Balance at the beginning of the period",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "INTANGIBLE ASSETS AND GOODWILL"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "negatedTerseLabel": "Foreign exchange and other"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r224",
      "r231",
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Accumulated goodwill impairment charges"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r110",
      "r223",
      "r228",
      "r234",
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedLabel": "Impairment",
        "verboseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Realignment of segment goodwill"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Change in the carrying amount of goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r565",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "B+L IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r110",
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "terseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r110",
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "verboseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r79",
      "r184",
      "r190",
      "r194",
      "r197",
      "r200",
      "r647",
      "r656",
      "r663",
      "r685"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r452",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r254",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r120",
      "r517",
      "r521",
      "r523",
      "r526",
      "r528",
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss": {
     "auth_ref": [
      "r519"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated amount of loss resulting from an adverse tax position.",
        "label": "Income Tax Examination, Estimate of Possible Loss",
        "terseLabel": "Estimate of possible loss, income tax examination (up to)"
       }
      }
     },
     "localname": "IncomeTaxExaminationEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r121",
      "r143",
      "r144",
      "r182",
      "r515",
      "r527",
      "r529",
      "r686"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Benefit from income taxes",
        "negatedTerseLabel": "(Provision for) benefit from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r516"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Income tax expense (benefit) on ordinary loss"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "auth_ref": [
      "r516"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount",
        "negatedLabel": "Tax benefit related to changes in uncertain tax positions"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Shareholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r238",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "terseLabel": "Indefinite-lived intangible assets:"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r238",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r236",
      "r240"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "terseLabel": "Total intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r92",
      "r318",
      "r328",
      "r331",
      "r332"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "negatedLabel": "Interest expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total Inventories"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r11",
      "r38",
      "r630"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r91",
      "r177"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "terseLabel": "LEGAL PROCEEDINGS"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r43",
      "r119",
      "r192",
      "r213",
      "r282",
      "r283",
      "r284",
      "r287",
      "r288",
      "r289",
      "r291",
      "r293",
      "r295",
      "r296",
      "r548",
      "r556",
      "r557",
      "r607",
      "r628",
      "r629"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r30",
      "r119",
      "r213",
      "r607",
      "r630",
      "r654",
      "r675"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r45",
      "r119",
      "r213",
      "r282",
      "r283",
      "r284",
      "r287",
      "r288",
      "r289",
      "r291",
      "r293",
      "r295",
      "r296",
      "r548",
      "r556",
      "r557",
      "r607",
      "r628",
      "r629",
      "r630"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Facility fee (as a percent)"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Commitment fee (as a percent)"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LitigationReserveCurrent": {
     "auth_ref": [
      "r49",
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.",
        "label": "Estimated Litigation Liability, Current",
        "terseLabel": "Current accrued loss contingencies"
       }
      }
     },
     "localname": "LitigationReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded from other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded from Other Party",
        "terseLabel": "Aggregate amount to be received"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedFromOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Settlement, agreed to pay",
        "verboseLabel": "Settlement, escrow fund included in restricted cash and other settlement deposits"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r22",
      "r311",
      "r327",
      "r329",
      "r330",
      "r652",
      "r671"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Total long-term debt",
        "verboseLabel": "Amount drawn under credit facility"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt",
        "verboseLabel": "Less: Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r124",
      "r280",
      "r316"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r124",
      "r280",
      "r316"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r124",
      "r280",
      "r316"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r124",
      "r280",
      "r316"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r124",
      "r280",
      "r316"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r124",
      "r280",
      "r316"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Non-current portion of long-term debt",
        "verboseLabel": "Non-current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r47",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r278",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r278",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyClaimsDismissedNumber": {
     "auth_ref": [
      "r270",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims dismissed.",
        "label": "Loss Contingency, Claims Dismissed, Number",
        "terseLabel": "Number of claims dismissed"
       }
      }
     },
     "localname": "LossContingencyClaimsDismissedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r269",
      "r270",
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Damages sought"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r278",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r270",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Number of suits filed",
        "verboseLabel": "Number of putative antitrust class actions filed"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r270",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of lawsuits pending"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r53",
      "r119",
      "r213",
      "r282",
      "r287",
      "r288",
      "r289",
      "r295",
      "r296",
      "r607",
      "r653",
      "r674"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Ownership percentage by parent"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r159",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows From Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows From Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r106",
      "r108",
      "r111"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows From Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r9",
      "r68",
      "r71",
      "r76",
      "r80",
      "r111",
      "r119",
      "r135",
      "r137",
      "r138",
      "r139",
      "r140",
      "r143",
      "r144",
      "r148",
      "r184",
      "r190",
      "r194",
      "r197",
      "r200",
      "r213",
      "r282",
      "r283",
      "r284",
      "r287",
      "r288",
      "r289",
      "r291",
      "r293",
      "r295",
      "r296",
      "r590",
      "r607",
      "r657",
      "r679"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss attributable to Bausch Health Companies Inc.",
        "totalLabel": "Net loss attributable to Bausch Health Companies Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r68",
      "r71",
      "r76",
      "r143",
      "r144",
      "r551",
      "r559"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Net income attributable to noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r343",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfCountriesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of countries in which the entity operates as of balance sheet date.",
        "label": "Number of Countries in which Entity Operates",
        "terseLabel": "Number of countries in which entity operates"
       }
      }
     },
     "localname": "NumberOfCountriesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r184",
      "r190",
      "r194",
      "r197",
      "r200"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating income (loss)",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r194",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segment"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r63",
      "r65",
      "r544",
      "r553"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent",
        "negatedLabel": "Pension and postretirement benefit plan adjustments, net of income taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": {
     "auth_ref": [
      "r61",
      "r65",
      "r572",
      "r577",
      "r586"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax",
        "terseLabel": "Gain excluded from assessment of hedge effectiveness"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r576"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Gain (loss) recognized in Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r69",
      "r72",
      "r74",
      "r75",
      "r77",
      "r81",
      "r338",
      "r613",
      "r618",
      "r619",
      "r658",
      "r680"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive (loss) income",
        "totalLabel": "Other comprehensive (loss) income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive (loss) income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r371",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "OTHER EXPENSE, NET"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENET"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedTotalLabel": "Other expense (income), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 8.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedTerseLabel": "Other expense, net",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r421",
      "r422",
      "r424",
      "r427",
      "r431",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Postretirement Benefit Plan"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Bausch Health Companies\u00a0Inc. Shareholders\u2019 Deficit"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Payments of acquisition-related contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "negatedTerseLabel": "Payments of accrued legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromHedgeInvestingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.",
        "label": "Payments for (Proceeds from) Hedge, Investing Activities",
        "terseLabel": "Payments or receipts in settlement of cross-currency swaps"
       }
      }
     },
     "localname": "PaymentsForProceedsFromHedgeInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r104",
      "r261"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "terseLabel": "Restructuring payments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payments of financing costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Payments of employee withholding taxes related to share-based awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Payments for intangible and other assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r212"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r397",
      "r399",
      "r405",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r446",
      "r448",
      "r449",
      "r450",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r372",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r421",
      "r422",
      "r424",
      "r427",
      "r431",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r450",
      "r451",
      "r457",
      "r458",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Pension Benefit Plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r487",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r487",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Cash proceeds from divestiture"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity.",
        "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested",
        "terseLabel": "Proceeds from sale of assets and businesses, net of costs to sell"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Issuance of long-term debt, net of discounts"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r98",
      "r103"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product Concentration Risk"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r9",
      "r68",
      "r71",
      "r76",
      "r105",
      "r119",
      "r135",
      "r143",
      "r144",
      "r184",
      "r190",
      "r194",
      "r197",
      "r200",
      "r213",
      "r282",
      "r283",
      "r284",
      "r287",
      "r288",
      "r289",
      "r291",
      "r293",
      "r295",
      "r296",
      "r544",
      "r550",
      "r552",
      "r559",
      "r560",
      "r590",
      "r607",
      "r663"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "netLabel": "Net (loss) income",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r253",
      "r630",
      "r664",
      "r677"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r86",
      "r217"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r630",
      "r676",
      "r700"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayments of long-term debt",
        "terseLabel": "Repayments of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r233",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]",
        "terseLabel": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [
      "r233",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]",
        "terseLabel": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fair value of reporting unit in excess of carrying amount.",
        "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount",
        "terseLabel": "Fair value of reporting value, greater than its carrying value"
       }
      }
     },
     "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]",
        "terseLabel": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r512"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development",
        "totalLabel": "Research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "terseLabel": "RESEARCH AND DEVELOPMENT"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "auth_ref": [
      "r260",
      "r263",
      "r266",
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "terseLabel": "Costs incurred"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r110",
      "r259",
      "r264",
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring, integration, separation, and IPO costs"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r260",
      "r261",
      "r266",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Cost-rationalization and integration initiatives"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r261",
      "r265"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "terseLabel": "Liabilities associated with restructuring, integration and separation costs"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r26",
      "r343",
      "r630",
      "r673",
      "r696",
      "r698"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r132",
      "r133",
      "r134",
      "r136",
      "r142",
      "r144",
      "r214",
      "r503",
      "r504",
      "r505",
      "r524",
      "r525",
      "r588",
      "r693",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r424",
      "r427",
      "r432",
      "r433",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r451",
      "r455",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r424",
      "r427",
      "r432",
      "r433",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r451",
      "r455",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r421",
      "r422",
      "r424",
      "r427",
      "r431",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r457",
      "r458",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r421",
      "r422",
      "r424",
      "r427",
      "r431",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r457",
      "r458",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r175",
      "r176",
      "r189",
      "r195",
      "r196",
      "r203",
      "r204",
      "r207",
      "r360",
      "r361",
      "r644"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Price appreciation credits"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r116",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from specified business segment for satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer, Segment Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer, Segment Benchmark"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerSegmentBenchmarkMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r362",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUE RECOGNITION"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Shares sold, net proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.",
        "label": "Sale of Stock, Percentage of Ownership after Transaction",
        "terseLabel": "Percentage of shares held"
       }
      }
     },
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price of shares sold (in usd per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Summary of activity in allowance for credit losses"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued and other current liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r67",
      "r618",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of the components of Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r533",
      "r534",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Summary of the components and classification of share-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of long-term debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r430",
      "r431",
      "r434",
      "r435",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of assets and liabilities associated with derivatives, included in the Consolidated Balance Sheets"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock": {
     "auth_ref": [
      "r582",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of gains and losses on derivative instruments included in an entity's trading activities.",
        "label": "Schedule of Derivative Instruments Included in Trading Activities [Table Text Block]",
        "terseLabel": "Schedule of foreign exchange contracts on the Consolidated Statements of Operations and Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of calculation of net loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r496",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of revenues by segment and product category"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r591",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of components and classification of financial assets and liabilities measured at fair value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r237",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of finite-lived intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of changes in the carrying amount of goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r244",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of indefinite-lived intangible assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r14",
      "r35",
      "r36",
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of the components of inventories, net"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of long-term debt maturities"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Components of net periodic benefit cost"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for net investment hedges of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of effect of hedging instruments on financial statements"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of other expense, net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r266",
      "r267",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "terseLabel": "Schedule of customers that accounted for 10% or more of total revenue"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "auth_ref": [
      "r88",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "terseLabel": "Schedule of revenue attributed to a geographic region"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r78",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r184",
      "r187",
      "r193",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r184",
      "r187",
      "r193",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of segment revenues and profit"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r478",
      "r485",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Summary of share-based awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r463",
      "r465",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r487",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of estimated aggregate amortization expense for each of the five succeeding years"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Senior Secured Notes"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.",
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "terseLabel": "SOFR Rate"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r172",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r189",
      "r190",
      "r191",
      "r192",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r207",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r235",
      "r263",
      "r268",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r184",
      "r188",
      "r194",
      "r198",
      "r199",
      "r200",
      "r201",
      "r203",
      "r206",
      "r207",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENT INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment reporting information"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative",
        "verboseLabel": "Separation and IPO-related costs included in selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "verboseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Incentive stock plan, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Maximum shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for future grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures [Abstract]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r487",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Vesting Period, Second Year after Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Vesting Period, Third Year after Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Award vesting rights, percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Incentive stock plan, term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r114",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r5",
      "r172",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r189",
      "r190",
      "r191",
      "r192",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r207",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r235",
      "r256",
      "r263",
      "r268",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r51",
      "r74",
      "r75",
      "r76",
      "r132",
      "r133",
      "r134",
      "r136",
      "r142",
      "r144",
      "r158",
      "r214",
      "r338",
      "r343",
      "r503",
      "r504",
      "r505",
      "r524",
      "r525",
      "r588",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r619",
      "r626",
      "r693",
      "r694",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails",
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r158",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-Based Payment Arrangement [Member]",
        "terseLabel": "Stock Options and RSUs"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures [Abstract]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r23",
      "r24",
      "r338",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Common shares issued under share-based compensation plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r23",
      "r24",
      "r338",
      "r343"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Proceeds from B+L initial public offering, net of costs (Note 2)",
        "verboseLabel": "Adjustment to reflect change in ownership interest in Bausch + Lomb"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r23",
      "r24",
      "r343",
      "r486"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Common shares issued under share-based compensation plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r24",
      "r28",
      "r29",
      "r119",
      "r211",
      "r213",
      "r607",
      "r630"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Bausch Health Companies Inc. shareholders\u2019 deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Equity (Deficit)"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r75",
      "r119",
      "r132",
      "r133",
      "r134",
      "r136",
      "r142",
      "r213",
      "r214",
      "r343",
      "r503",
      "r504",
      "r505",
      "r524",
      "r525",
      "r542",
      "r543",
      "r558",
      "r588",
      "r607",
      "r613",
      "r614",
      "r619",
      "r626",
      "r694",
      "r695"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total equity (deficit)",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r620",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r620",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r620",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r620",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r631",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENT"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Corporate brands"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Bausch + Lomb Trademark"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r260",
      "r261",
      "r266",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnfavorableRegulatoryActionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A enacted or proposed action, ruling or regulation that is likely to or possibly will have an adverse effect on the entity's financial position or results of operations, excluding tax matters.",
        "label": "Unfavorable Regulatory Action [Member]",
        "terseLabel": "Unfavorable Regulatory Action"
       }
      }
     },
     "localname": "UnfavorableRegulatoryActionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r518"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized tax benefits related to interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r520"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Portion of unrecognized tax benefits, if recognized, would reduce the Company's effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]",
        "terseLabel": "Senior Unsecured Notes",
        "verboseLabel": "Unsecured Debt"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSGainLossonExtinguishmentofDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r163",
      "r168",
      "r169",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r125",
      "r130"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Reserve ending balance",
        "periodStartLabel": "Reserve beginning balance",
        "terseLabel": "Cooperative advertising credits included in rebates"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": {
     "auth_ref": [
      "r128"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account",
        "terseLabel": "Current period provisions",
        "verboseLabel": "Sales return provisions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedTerseLabel": "Payments and credits"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r487",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r487",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r146",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted weighted-average common shares outstanding (in shares)",
        "verboseLabel": "Diluted weighted-average common shares (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r145",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic weighted-average common shares outstanding (in shares)",
        "verboseLabel": "Basic weighted-average common shares (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 18
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "https://asc.fasb.org/topic&trid=49130413"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "https://asc.fasb.org/topic&trid=2122503"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4M",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591554-111686"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "184",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5634876-113961"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "https://asc.fasb.org/subtopic&trid=2197926"
  },
  "r715": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r716": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r717": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r718": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r719": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r720": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "https://asc.fasb.org/topic&trid=2134417"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>121
<FILENAME>0000885590-22-000039-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000885590-22-000039-xbrl.zip
M4$L#!!0    ( /R$"57-&5W"=20% -,Z.  0    8FAC+3(P,C(P-C,P+FAT
M;>R]69<;1ZXM_'Y^A3\_WVK'@)B\NGV7K,%'?54EMP;[2"^]  1"1:N*58=D
M:?"O_Q"L02I9;LL6BV2FZ$'BD$PF<V\ &S$ ?_^_;XZ/OGHEL_GD9/J/K^W?
MS-=?_=_O_O[_[>W]S_>/'GQUYX3/CF6Z^.KV3' A]:O7D\7A5S]7F;_\JLU.
MCK_Z^63V<O(*]_:6G[E]<OIV-GEQN/C*&><^>'/VK<F27,:R5T*@/7 2]THK
MLI>">%^=CVSK_WGQ;>0&OJ#LA>S<'GB.>YB1]UH6:C6)I";_IWZ;HFN$SA4?
M"[CH"C"  W;&!C1V^;6'"_UU^@NG\V_YY&RZF+W]Q]>'B\7IM]]\\X9F1W^;
M"__MQ<FK;R[>_*9?]M<7'YB\N3KV]>O7?UL>?S)[H<=8_\UD>C292K]'EX?K
M\Y>_]P'CO^EO$\[EZNSS$W V_8=/7!QQ\8%K![[VR\-L*>6;-_TWOKOFQ<?/
M^.YZOUG,<#IO)[-C7"CF_2>;/>/V[-4/IT.^=A+"LSD?'@H>+0[_QB?'R[MD
MHC>7'YC/WGUKPSDMOU%?_.!V+O;T=E\[\^7M_T]79\.>R7O>7IZG_Z0ZN0[C
MQ3V+WYR_^?ZAD_]TAZ?S!4[Y"I/YXG3V<7[T=Z[]FC>_@?L:)OW=RT//YGLO
M$$]_>X<NWKAVWBJ3CU^!OG'] N:3CWV]_B[[S?_L/WC,AW*,>]=^X;='.'WQ
MCZ]ENO?T\==J&X+UN[\?RP*_ZN?9D_\]F[SZQ]>W3Z8+M?B])V]/]6-\_NP?
M7R_DS>*;)=6^^>Z__NN__KZ8+([D.Z7*WB4;_O[-^6M__^;\S'12WW[W]SIY
M]=5\\?9(_O%UG<Q/C_#MM].3J>CW3]Y\VP^4V?G#2:TR73[4]P_4Z\PF?/[U
M;Q:/I/WCZTED\CE&#\$ZR!$(*W*(R8BM!K']^\[R4JRQ>^\8.L7C_M4R^?;N
M5*_O[6W]-3,\NC^M\N;_R=NOOYI4/77U/[VE.R>O'KA'KY[Y_;/ZR]U7SW\H
MOSS\A=W^\?/)LR?WWSY\LN\>/OG7VX-?[H>#'_;-P9W[YMFO]U_O/_GI</_.
MO<,'_N#HV:\G_N"7?QX_.[[[=O^7E[\>_/+2[/_R3#_[Z)>#._K9'_;?[M^Y
M:Y\]N?7FV4_9/'#/WS[[F>/^SS\=/?_AGR\?WGGJGO_\S!_\<._PV9,7;Y\]
M^?[EP9-_OGSFGK[>/WX*![\\?55_N#>A'Y[&_3L'D_T?[K]Y=OS\^/F3E_[@
MSBU[\/,_7SZ_\Z]?]]W3H-]Y>/#D^2_[/]^_^,Q/^EUA^OS)R>M]=__ULU_N
M3?231P^?L-F_\]0^.W[T\N#._J]Z+OU]=^W!\?Z;9T?YUP=/[B[V'YLW^O>;
M@U_8[__KWS464D]>]K)DHQZ:ZAZ6U/9\:.Q*\"66^/5W1O_).82BU+@&ZTVB
M?/ML-E.([TWFC$?/!&=WI_6.AJZOOSIW*OH-;Q;?5GUE[UB_]G"OXHX$?T@"
M\Q$24!2?"LL>"-@]""7O%5O\'K, 8--W2_OZ.^N^\7:-^%\JEG<$N*>OS'<0
M_Q'$]F-V7E(.'G$OF135SA/LH1#ML4)>K'54HO_ZNP[#QA#^4<]_4G<8?Q+&
M[B,89V>K5Q6]9Z/->\ F*<96]EJB;,3%0(6^_NY?ZT3XEL);EQ ?X8OKCKM-
MWDC=:WC4E?0.[O\,M_\(W%B\9]+0S0[]'D!0KRW1[BEB!H+"U+R&[GNW'CR^
M^SN(WYLA=VW^U=ET<H[W].R89/;U=0Y8\J4Z9B1QD/3OD#Q2]LF@A@W""PX$
M:_8N'WS]516>'"NX__CZ_L&]2TI<Z.1O[P@M[JN@G2W-_WN<3^:/3S4OK0^G
M/^%L@G0DCS2N:Z;0'8-^<,]MEB-O]'RO+WGR[-=GBM4M\_#./CS_^:[R1'GQ
MY.6;_>-'1_M/GCGERN3@UR/]CI=7/#GX]>#EP<__,ON_OH3G/^Q;_0Y[X/YY
M>.#V]7N?'S[[^9E]]LN+<'#\[$.>^'WW+]OY]/#)X<MGOS[5W_/4ZW7[9[_J
M=1[?.WS^RT^3AW=>NN='^?5[/'G[\,XMMW_KWY2;J\1ACYI7B2<M*4^(]TP$
M]EF?2NL2[V_ADB67M/B3-$&3&$T)RC^&ZDHNXHFL)X>8HL".)G],D^=W[MMG
M2A5U"T?[Q_\*!W=^.MZ_\^*-4N3ELV/]_"\O_?ZO/QWI:Q_0Y/3E_B\__;+O
M'DWV?W[Z]OF=E^;@YV>O']ZYJQ1Y-'G^Y)9>,_]Z\//3UP_O?4B3NZ\?JD+(
M*@&;Z@*;NQ($<GL=PKUF$HA8U8%45D$3B@U*A!!\1F@U9Q=\8!N"\;%8M#N:
M? )-GMP*SY\\>[U_I[Y\^$0CU1V-&C_?.]S_85\I\B\X^.%?;SJ-GC_Y,.J<
M*G6.C@Y^N?7ZP"F]?F&CQ]IG/]]]_>S76V\/[KPPS^_<ZS0ZVO^--[D;#E[_
MVZ= M7'<<R2:*V3-&A%CV'/->FZ9*1*L@B:9G$^-1)QR,II*SI&!;"%&YQRW
M'4W^F";/E@&#7RO,;_9_?:KPWE51<N^7YS\\M<^/U8OH>?3_</ ;<7)Z^/ '
MO:9?;[F#7^_^>O#DOME_LO_KLY\[I7XZ?O[STS?/GK#^_](^^PU-[L/^BW\+
M!8Z4ZYZS3K5H!;^7-=?8*\Y7([%4SN9W:/+-]3&DF329R91E_I&1KSXZ]^U\
M.4*FM/EJ.5KW[>+MJ:(WGQR?'O7ALN5KA[/.JO<'N?[V9E[U#-]</\7YU[_[
MSHM+F)^<S9;/E@.1WUXP]9P=?T4B7YY(EB-9E\\FM3]O$YE]M;P@^>@0Z^W[
M_^_ZB,R''_[N\J7K9S]=YE>7S^8+G"WZ<,HRZ=O3BS/V\G/OWKNZS/K>H7'/
MFW=?<?[.Y?/++_GFVHWZZ'TK8K/U 4!8 *62>A (A6LNWF1;_WU_>;NR@2VX
M7>?#KXN+.Y#W#%R=Z.*=3[L#W>DM?_[\$)565[_L6'!^-I/O+@!8OGEYBLOW
M+I_W<WSTCC8-J)H"@C(O V:OLJM43&IRH5KUVA=W=#L(>/V.OL^IOWA'SY;V
M?/V67<R\?/OT\9T_?3>]S1B,"A_-H4%-N2A!JZ2J\A9-=GEY-ZUUWF[7W;1[
MUNUY^]?NYK4[$'JPS^*3#Q'01W5FP=F<]298#<%Q?7RZ, MYT4/W^=.J7_;F
M]&C"D\6^= 'Q59WHN^>SGY<Q_QY.9C_AT9E\__;JX7_K&7'&AV\?R"LYNO5F
MHE;XF^/O3T_/%O/E$?;\]'__YJ/?^M<N9O^<A,N1D9G\[YG&FK>_<R7O'3I_
M)'PVFTVF+_[@DK[YX'ZMT1RO$8AM=.C!%];@[PV7Q#[%4)5-59S/%Z$1UA@:
M_RR3YK/%MS_.3NH9+Q[.'LOLU83E.E(7[ZX>D@]#-*P]1 M4;D5]'445WM5E
MTRSGAFA4:;.E)7[V$C^[P^_W\;.?CI]=&7X.I37,-1M3P8 MK3':5*/*+E25
MM0%I.E3\-B*14]*\MM90P)B>!&>HDDOP1G-P#L9?V)_=V=^GV-^GXK<Z^V-)
MA4/)A<A"JBD;38O%:ZZ#ZD.]'U/\NS6M%V\_7!S*;(SAL&H<K$ J820 ET@Q
M1]M")A-C"R&/*1RN%\Z-1$<$<5QJMB5%\-87TS**APP.HPJ<,47'M5OG^H.E
M%>O%VL"8/=3 V2;-746#92XM0AA3L%R[=:X_=K:D%N>D5&N=&FI$8ZD)@=30
M+(K=0.P<1) J(3MRS9*K%AHZY&:*:VH%2OWDRP:"U""B03")DF>16!$X6HS.
M-T=9'U33@#;@/K;53M\?<OU19H_[:/75O:B35_H;WC]TN>H$%R=7#O%/CL[^
MYO/]Q3LR/3F>3#]VVHM?_X=CZ-=.\<WUJ_^CP6%1JT+P0M5X*!8S5Z<2L-H"
M ,B7DQ?^Y@>'_VR,N8PDCQ<*>/_,W?\]ZZNI3XY/3Z9]D/%ZP-'7CT^FCQ<G
M_/*F!QW]:D:M2U"57FUM&B0T6C1-M @JYDI.@@,8#32W:IWT*5,\^A$G]?[T
M-IY.%G@T$)BHAN#99P?)02R6**7N?Y/Q)HKFQF.!Z9$L<#*5>A=GT\GTQ7P@
M^+2:N)BDH3!D:(*96JK&""A&D6$\^-QB/CL^.^J;XI9BNA\WD\-^ME=R?\HG
MQS(0R )[!# Q<R*(A-GH7UBM0^-J+#P:R'[$OC-D(*B +QJ,.%CG5#'$5I"J
M,\4VMDXXI=&@<G R[3]\=G)TI'[NOMX"%6!#08F\JH8BH'$HJJ!C:A9,C36A
M!9\<K0^EC3E\8,>H>ESZ8#6@WHQH8J.,'%WE(4S6;JN VORH@&G8- B8BF2
MT*$&!:D.DZN5PL6HP+C W418WSS0$J49VS*["N"RIRX&8D@!L@]9POB OBDQ
ML'DL?4P90[/1H@-3%$J"TA>79H..O(P/RW5)B,UC:U(S"8.IF3,HRJ3XJBKT
M";U-)6UB>/N&L;W1D:3- YH3A6J"E!@\Y%0Q,R:)$<DW0ABA?+KY@8UM0-4;
MD9RK(P;GJ=A@F0N[[$RUI6[_$MAML,X;65RJT='&9LBXG"$RY5!!2$$RU=<0
MS6B@V= X[XI@TM0Q,?O2R#GPZ#2=#)B2BS&%G-T %I%OC3N\$7RBABV?V$$U
M I:I%*!8/?@0(Z<BH\%G"\9Y5P19L9&;LSF0RZ"Y7A^J:9K;AR9J6]&-!K+U
MC/.N"!50=<"^&9]M 0\E>T."JA5RLI)&)!4V,\Z[*G?7YX4U_JB'LU!*)JIH
M6T5,P#[F\]%X.X+1^'4).KNZZ:OL2JY%6%-@B+GF$#EBQE:08PEU--!L0M"M
M#J;D$XIOGEUA *EHQ$2,!E3854AY-#"M5="M#I\:(TIJJ0_^ E.@' USDN1"
MB!JA1H//I@7=ZB #GSSFV*TJ@B5+4<&SI@EXB<PP&LC6(.A6APIQ(,Y X%R!
M!J&@A]RB9Z_9*U\LIQ@#*AL0=*M#*59L$!&<[8,_CI$T&/6Q(,@$(=GUH;2I
M.V"B2J7@?(+2>MD'<NKWG;=5XW/EB@/8EK1-VG8+EJ(G$B<6G)@$-O8T/XK&
M!TN:74* \0&ZF948&P&W;T@JTBS4E$"]%!JK+U2H8@LD7\<'[EHFZ#>"I?%Z
M7ZW8IO(-D)BR00N@P+)ZWSB$#:%;EQ-M'M446Y:<J1C5?H"IN*:BHD1-=8LU
MU,:'ZD:676P&VP0M<*J<-;EJSN0$&- $DTS-%D9HL9M?![<1H&U,[$6E<$"G
MJ0 @2JR2"H$WR5&Y2 N&C^\:QWE7-2/L6'*SK!&S+XC7O)I4]WBVSE UMHT&
MF@V-\ZX(IM ,D4-(:CWZ!U/UEFTQ-E:68F@T,*U[G'=%^&!MCC6_KQ B1$>4
M"6IQJ9CB)6,=#3Y;,,Z[,L_G,ZLII1 \]-45-=0476VB2$;$T4"VGG'>%:%B
MFD,5^S%8%U3X42\#X-&F5G(##FDTJ&QFG'=5BUX@%8_L044=2"REA82^1".^
M6+D:Y]V.L@PW<@<X1IN%F"'GWL8A*ULQFV+$%A\(UE>0=C22=E65<G-"JJ'D
M6&H" YRK2;Z%(B&1UY@\&F@V(VE7!5,EFUBEDG>B26%L1-86KA1<3=Q\&PU,
M:Y:TJ\+'8V@)@(P8#]9S:9A]9).-E"2RQI+;HY>TJX*LY%+128T-"#0_S&!<
M2T%2 &O[7-58(%N+I%T5*C:6J'$G5*P%LFW%V]ZZB[PF\^H#S6A0V8BD715*
M$%-JQD$)?8@%1%5<BJ!*KG??I H#*$"YK?+APYUCZR]'Z4JUOH0L!@621<U4
M+!,O6QJA#V,$=^,S#9NI.]JB0UM[VY\(UM6"R635F2;5$H(=0AG9+0F%F\>2
M 5L)%C61BY HH0T^>'"&N>B+F^CE-)( NGEL"8&<2VR]:B+TG"GGIO 6JM(B
MUO%AN]8=]QN(L,[%BCWY, 6<JSEX"4!("1QK&C(^0->_XWX#X90Q:,*24P(-
MIZSX-DP^>9]<02[GTXYF!*G+ND8YS<KRE>C "L? -62PU?6J"-8%0Q0HE!)'
M \TF1CE7!Y-UW"<:(W-5&XJI-&Y-<F9-15BS_M' M-91SE6:4=8L,(CAJ!ZN
MF>PL6*"B0K/51CP:?#8]RKDZR+I01)$LO@9HP*5J0*H4!9%B]&4TD*UAE'.%
MJ'AA2VAL+ 8\]EZ5$OI4J#'LRL5TSAA0V< HY^I0XB#.YE*:-0 MJ9IC4H_7
MBJTAAK!&=[>Q@!QSJP[)9%^@LEZ@*>*\&-M$_7\90&>:;=*V'RXN7G]OFM 7
MD8LA@TII4D Y-E]L G!H-$Z,#]"-;=#:0-.^+%R9V5/)4 353UG*U;H8LD5*
MXP-W71NTUH\E M7DU"A+8?"]9U_R3FSTN1J1-D+/N_X-6AMH#>:R52V>U=.*
M9DX.4_8Y-[ EHF."\:&ZJ0U:&_"^A0 "]FT& @FDJWHGJ81:-<#:-CYL-S]M
MNAG73+&O>V\EQ=C7/I02 IJ8;4UL^*I9R1;BV[LT/GP]E=G\<')ZCB4=\K??
MXYE>QX.38[K1Q.RS2J%==6Z;GO5KN;JSUUNGG>K#RQ-\K'':;\[&)V?JG-[^
MYG3]MER\]RGGNYXT!9-K\P2>U,4;0=!GA8U4EVPH\6)V)UBS=_E@VXARY0C.
M:#ZI$YR]?8Q'\K M\Z+K3N#^CP]O?C(G[%GS*4;^P:&?,YFC,5E\'RXS$:1J
M;N3%]<[EX$IF+!=&OL/N#RS^?3@^JZ=7=9)- .<B^-K(6L\M&VC1QGQ5='XD
M-O7PE<QN'1V=+/JI'Y[V]'6,-F:J)C9J5>HN+42C<&:-H\5&O>-9 ;X -5Y-
M@YOM'0[=4E#CGYD%?W?HYW3Q=:4&0<LANFZ=5%0815=(&B=\5TQVA^6?E4YF
M)2.Z )9=!O6D!"2Q<,DE.$6I2LPY;B\\6R!>5X) JYX-!>]]5BQJS-1EA83@
M4K5ZZP?@]38 Q>8=6V_G+L 4BS'0.Z.D2"GH/45O<Y,Z -P^P<-U'%46WIK6
M+R1>!1\LYZ3Z4M6D"4'%O:,0HW'@LH2X_1M.?L*C,^SP=+1>XY1EKO ]DKG,
M7LG\R=M3>0?MQ:OW3F9W)O-E@MN/???!H>P_L285YXUP7].@&1DY29EBKM0@
MIC!6T&Z?S1<GQS)[)(NSV70H:'E5@^S%%J( )K;2$I&-XAU(H^3'BM8C(75*
M0T$);.@U(W*SX,!SH4+-8@,*)EJP.%:4;A_B[(4BQ2^'@E1@""G99L0U2"5G
M-C:0))O(-4-VK$AIR%K,)G36/WA/!F188B)5FQP&R$ZP!<.IDNN%-UW$ :WV
MWVZIL?DM (@%FP/V?6=LWWH58UOV#:NEA"A#VJFSI0)E\Q@'K_FZ)H#-<X/"
M-8,'1T8-655.=7[T&-^8K-D\MLQ1DDJ!6B2!6-/72 NS(<\Q!CM^;&]4#&T>
M7X+>YHP*:M((/@(V8\B0".223!L_OC<OH;8 Y.0,E^)MR=1QI5A5@*E -M55
MNJBW-DYLUSVBL[KN=J88STZMD2  2"@82_55M7.,IFWSHIHM%TPWTS&2G2(D
M/?6,FH$V;#X8";GJC9641XO6.D9T5M@QTH?6JRXV,09RM;E1]2GFOK"EQB'T
M]=Q"$7,S]F2#Q-Q06FI Z'*M!1F"KYI1J/(<*U)K'=%9'5S54@/)IE .4(TE
M%E]B=EYBM9 'T,#]L]S?K?I*9HO)?#)]<7LF=;*8_W@R6\\:B)7 Y]4Q"I@2
MV/8^DRT')VQ32*&&3/X2/KN]$[C#A,^N9@$%-%.R@]JR92@^4F"N4-!ZKUG[
MU5K ;4[B^@**'V<G]8P7#V>/%9X)OX?8C[/^]/1T)CQ9HGP.TQAS-6#L)7 @
M&6Z0R*"+H'&O&9L3)1A 18'!Y&JKVQ5<0@F28@@V!G!LBK52N=B"3C/M+&,%
M;9VYV@K1BB8%!]0\1*B)"]=*EK DXW,0/U:TUI&KK0XE#Z:2ZY:5,HA:$=E,
MF5#_MU%UYEA16E>NMCJDQ'$.D8%<M)!RH="JI@&42]!'L8X5J;7F:BNL662H
MN5Q,0%^ K3["4)U$%E+-P4/:EKG=4F/S&S.CBP5CRBTF N%6*D%RIC)+D6;\
MZ*%>[^S[1C"&G)-8*E :0A)32K"],Z9#S]&U(>V@WS)9LWEL([-C<2[8UE2I
M&LP:9EDTPT>POM;18[N^V?>-X.LS2Y*2DY<*N;A<U56KTTX8;%:;'CV^:YY]
MWPC(EK,U@55:>894$KI>5IXKU!H*U@&TK]UNF74S[1W9."E-$7)=,JF-4H,6
M$;W)*00S5M#6NY]B9?UMP?MB,4E.%H@:-I9:/9/%&H(?K8FM9S_%RF;?)2@8
M+65NL6^V11]Z7SW#1M5,RVZL**UO/\7*[$F 3$;Q)3&44BA@+E1+SM&X?-F\
M;7Q(K7D_Q>KZJ4;-_8P/N3G(O:LJN9C19_(.V(P6KHU.WZX.OIQ-<4WS=>LL
MI" 8-=F+CH-ZQ>#BQ6[ W>S[JN%;T>P[^U@L@:9N&M:2!K;B)+42R".%Y,(
MDKAMG'W?4,G"7$LBE2GL(1%A4I5B4"$#IS[67&#I_066?GOG-,[+#5X5+OP>
MC[I=/CX46?2$[*H(<$_3CDYZ(;?Y]V_UR>G)'(]^F)V<G<[U%$=G5>URF<KI
M%4W/I#[4V[EDP?P=0VX=:Z+WH\J<8V31Z,EXU$L?XO3MXUMW_X GG_R#KEW;
M[2.<S_4.\;G;N5:+YMJ!YT_TLMOWR]H.!R>+C_^:FZ>S?V_^Y@_H_/ZAGS-^
M:% 06E6A;2!Z+I*BR@,AWY3I_G+\'[;8-?T.G1^<O(_\DH/SN2SN*^DFLW[
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M'R$C4[#H+19-22OX@A<* 0:@$'8D'@")/Q0;GUK$875B0UAB*L[:D!I(ISJ
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MRSIG5U:X%KPR8 LJMC1?BA"S(Z=!!C1SRF"]&P4TFYE=61U(Q4F0EEJJ;*$
M4(HFIY <.T*%;!0@K7MV977P2//6A1316PML$*5"B<P9<Q+R R@OL&6IRPWM
M>DFF9K4B/:F* T#7FN,<D\008W4#6'ZVC?)Z\XO1<J0:H@)6G%-5;M$A0M8_
M$UN;T(\5V#%B65AENRI#4X,%TVJI:,":C'V#&@RJ/</&I?SFT01OT"=F$1^
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MK7IG0-N0 *E(U5<8@-R.SL.D\Z!"R2 M)SO.#6IUP5IHV9<4J&_Z\J;$+'[
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MD!B939G,"$]EE5GR0:6DF2)F@DZXW  +4K_D:E%M(YA'EGPN&Y<DRY9#1NW
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M8J()M? :#IOOU,;R"ALIX[0_^<\TSE)WMA&H2BH4/":IF"-.YKR),0G./81
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MB0B9 G#+8S#)858I6-=\#[,T8'I8(51@)H;DG8MDI$!83Q RF6)SDXC!I-@
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M'X[HO;IAV!^.GOR#5?_[:?YC=<J3\;#?BXN?9D]B:XS18X\PDCO9IW>HOG=
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M*TGN3C3/AQ2HO3@8#A[L\@;U-V/" 43539HL'FBONB[[,EHAC3 F!):(YQN
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MKBD$V]=N=5J!FU,SA8#IH,85[:"M'/ ^DR5JVE[%S]0)]M3#]7Z8&R[6(BK
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MAA9?.3F8G%5M9J6N^?]&DZ*.!#0(O8!*_G66*F06(K268F,Z>3DX\8AV_2O
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M6D#/EP&^.O!U W[9!R[4_VX5>988P9.$X8R1)$L8D80D1"91G/(HYG_'V58
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M"60__XJ\;*(ZQ4B!KK]"[E??B[T#, ?@;7+&2U<%,AY<\'+PB0]G>AM ;U@
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M\ U>'Q^]._[]8&_W9']O\.X$_G.X?W3R;G#\\^#XS?[;W9,#^$#OW^)%,1K
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M.]Y39W_M_>OR_8DDG<S-%_C\^5%Q^,MO\.SR\F@/GOG#:?K7WMOBZ)=]<I3
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MDOP   \* ,L60*2IB5F>H1@VT-; :D1UGJ-(I3&7) ;(!A> ;&?QNNIO'AP
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M:Q,Y\Z"U$( \6K!4*V$:H0U3+$2MBII<DE+06+&QXIUFQ562KHPTE&260;B
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M);']Y[(NN"9$3HDEX"$28#0)/,8$QK/ = %J"FEK&UT_TH,:@#<F,-T ?"T
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M+GG,J3;'Y>)NG9;>$!E1*]Z\H^&HQBUJTF@]S7*%H[ ;Z][<L);X.BGMQV*
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MNHR6KFX#AX\)#A<-8"-%FH@\BP7/$L!$3F)-1!XSGBB=BM1:SA .)5T^HO=
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M8;19DN-#H#=V$7J-Y*4D_G\#M?"6<P>NA@M^S+8S#BWL\E6<KD6X [P&U.S
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M HZL5PT.$ 2A)% /7N]=@*G:(-E]MS=5$HL1OT5"S5Y\"H.SSG2" G"AI'_
MAV[44N=1LE:1#6>_%"0,, =$/ XC!R\%"YK#<N/*AJ+FI9I&1OW<&WP'_,5K
M)LJS5HH'O4$/&67^9XP.1D[!"PTVNAD'E@BAO\)\QSSN\V/=ZTRF]79K;[(#
M48X]K37C.\#&04W(R10#@TY@<-4:+*QC(%7)S"%4",8<V)?G,89:@37&>EB
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MP%H#:\\:UKBBQG!'I=:)(*F7/M.:IHXSX;S.> -K]PAK;!'6;"J4R;F* <,
MUC3V6C=)'C/O$LV$]4*3%QM2B ;6&EA[SK F:"),DN6>"B:XD5IJ3Q6(1T)2
M*JAJ8.T>84TLPII*-#?&9['A,H^%URR65J6QS3+I4ZLD-?S%!LV6FY\WL-;
MVC."M<2(),NH)XYYD<D\-X0FVF4TT\P331M8NT=8.VMMD;, ;0<[K'UASKYJ
MPC$2JN/<)BP6+,]B!:YGG&*V9&)S#6L(7NAEW8P;6&M@[5G &J>Y2@@5RE$G
MJ"5HK%D'@L.-(CG+[QC6'D,W]D>#><4"YBE/3 ;**4XR0<"6PQ;N66( ^)RQ
M&>-6)&C+K>4I?RRP=^-]91_^[S%M'6_-G?68R3._U9;QPOPO34M@-Z/A2KA_
MS+@GJ".IMC1C*A$Y<\HG(#Q6,Z&T8:E:>7SE]@!8YN[8@UXH(%*?;FD@[R:0
M=[Z\A2I 88F$Y+$U 'N"9"3.$T_BC#"L]R,-%_3%!LORG\6[U;#R2RVY1I*O
M)\E*2>69@*66B2#&R#3U+%<FL5(FJ;.-)#] 25[:-<P(E8Z#JZ8X$['($A?+
M),EB!_+,P>?.<LU>;*0_'89J!/G!"G+"34($]YX;+Z2QN>"":0+*F!IC&?]-
M@MRX*'<FY4N;:-YQHUUJ8I$3'PO+30QP+6,K<YZXS--4!P^%\;01]"<KZ,:D
M+H.I6^DRX2A1.DV=,41SDZ8);03]T0GZTK92QIFEB>-QDCL2PR*GL?*9B3.E
M4IXEQ'.E4= ):TSSIROH&K0YX5HJ89C@J5">$$VT<R*7&?! 8YH_0%E>WDM)
MM$B31-LX2[T"K6UEK,$<CS57$A95YHDR(,RD$>6G*\JW*O?2Z.P'+>>+^P=I
MSB1U1L094VBB2Q]+!F+OB).<.YUR+U]LL+6,/B0W_+9'SQ[1%L$[=5[6E@KU
MZ ;.%J/;[0Y<L3M\+;1;0;['@79_/-SM@>U)O=$&Q6Z 8NVMY2T!0Q@GQM#8
MBQR,E3Q3<:Y2X%XK'  8URHE+S8X6=X"7:HB<4,$N<^\CD9R[VD[H)'<VTKN
M\A: U)YYF\0)]3(6"?8#-L3'B>"&RRRQ"4O0S<@:R7V2DON;X_^SDMNX%7<F
MULL'9[($(SX&\\IY+$1*XEQ*$3/'>9((1HA!L5Y;E6/>"/93$.S?'.]O5/)M
M97<IC"]R1RE:SRR<#C%)"L8T2+&U6LJ<<B$POT9FR[MUC>0^!<G]S0'\1G)O
M*[G+07N6..HL+$Q&+:;&,1=K)V7,))6IT[DC4KW8$(WD/DW)_<WQ^L:8_D5B
MO1BCUZEF)#,^-@GFR1$O8G"12,S!=28B2U.6>(S1IV2YOL:]2/8SR.!?4?SM
MTI*\=[0O>=5]U<&,JM [A[6SO3&6C5_HM_[L#GK=/7T>M,JXB:V7,6*DY%3F
M&LT[G5I'4O#=B6569^4!UY]6%,T!UULH@OWE;0YEG)*I2F*7,1:++!-Q3K($
M]$!"/<E3I<)9+[D<++W=3NW="<P]9W0TR-D@YQTC)Y&$8PMSK44BA$ND2J7E
M5E"7IL1+TR#G/2+GTC:33[5W/$UC8=,$<]#!,4ZTBC/C,N5L0G1"P#'F/UT:
MH$'.!CD;Y/QQFHUA@)8.JZFD(I->>9X0E^38Z<QE^5TC9Q.9N#-87=KFRY1F
M7(-!RDW.8Y$K'2M)2(S)%UHZ0=.4AHS_.TL>;("U =8&6"\)__+$.VV,=X2(
MW-+<:\NS-)>.&PO6:6.2WB-V+A?A$]QRS0 [\PSL4L=UG"NI8JF%H5I;;W5R
M)Y7@&^1LD+-!SJO*E[HT]\KYS NM6&ZM5$8DW!K+TC1ID/,>D7-YFUL*(Y3,
M?&Q9QF(AG(@U2[/8&N93G_@D(Y<DC3;0V4!G YUW"9U>"4\M%\317*B<JPPL
M386%YQ)+P8IIO/F'BZN+>092,N,< 4/4I!3<>:%C*06-&<\L<4J)-$O1G9<9
M?3+(&E(5_@J=TC=NV*R=7]:L_4XEEI*K1):AR.YV36>,G8&+;E0UW,0_L65]
MV3M>Z=X)_'N />Y[_=#A'C_;0)TAD+$^9!C9,=S3BPS,IW?L!L.HYR/5[P]Z
M9R!F(]<YC_[K!@ !*."%RXG4>2(LH=HX+M.<<9=:*G+2 ,1U :+C_O/A_,LG
MV]=,I.V+0Q!J>,^;';YW\/?W]IL/QZU/KSNM;YLPQD, "GC&I\^B=?#: Q"<
MMC:_*B6=3QF)F<8THMRQ6"<2:[\[KXF _V$W"[%\HK_NN1R.HMYD[7G*$R>(
M3,"C%4;[/&'.T"S!<SVYYO7:4](4FOV5:]\^_:I2(8UR.DY=DL6",AE+)7FL
M4I(:+PF7)G^Q<6D%I@D#!#"8RW0*3+'0^'(M&KAAWQF$F,[Y6G1Z5)BC@#T#
MYSOP/> 4/$K!QRJ%$!][,% 6KS"N.$'(&JY%73>J46RKUPWHK_#F:LFC_2/G
M1L/UZ.#(P<-/\5\W<?L\D3FV<<FI$9*G.C'&"JDHYRX3&;TB7W*W_7J143^X
M$]<=N]>#WC&,=X1C^%2,CK8J*-TY0Y &K-T<#AW\OSU09_-LZXLS9^,+-^A-
M.)8\.X[=I>W#KZG-&/5:QJE58(QDR@&S@EFBLY0!+VLI7?9BH]M;1JO^H #6
M0(T%2Q5@8T:U#5#3(3\-B[/H&-;H:!BY+BK..:Y>GU@RP22HWM$>PR(6IOR,
MK%1T2UQ:83I4VIFGH+[[O6&!E[T<N$[0NZ]."SLZJJWMF;LJ2X-,;U$:V'X\
MNOR6I:[!]V2!Y LDF_GWT: >3%\=NE@/G/H>*P]C?:DZI^I\^.*O>;,++*Q9
M^BU._7XF&$71JBG.K5ZP5N<'5'T9+GD9(*S^JIP662?X_MJ8Y6GX'"6B_._"
MY](YF^6]$AUD;CD865Y33H355A,O+)58R%U:QI,7U[=K\\OLVI4O3G)N16;0
ML,N%=")GJ77:&\N8YXEB<%]I@"[1J*/Z0_>R_N.5+8;]CCI_670#Z<--K^8'
MFO27K/DPT/+G*9L I0*K5"G(U9NKG]?#3PL>2OD;)^LTN?QG^/66OR5"W.K.
M'PU6KJ?T=D]MQMJ,M1GK56--K_74*XXZ7'EHZ2:7+E^[(LA:V@#W$TW,5D83
M]\'2:I66ULZ2I47G0D;7I.:]QI;S>M*E1B]&\#)SG9-<X,A4?M1PZ53.S['.
M3:)D]\4K^;5X9;L8EF7?_D</_MH US+\=^KV7^=<S76(\:R(^L&-QH/K]19I
M:+=$NQ!+;6AW"]J5!1TQ^-_0[Y9@.!H4>HS.5L#!UZ[AQ%M1\J '6OHFEL:=
M=+]ZR'O?*\ZOSL5PZ:^H-7EGQ'UBZ07/MA.A,(I(P41&C!>9)HJEPHC$$YIG
M.A/E60#2-%B=21#X]O'\RYMV ;]??+[8/&UM?RB^?-I-X![>>O/^O 5O__SM
MWV_MBTYG,4&@??#/]\]L%^;0_M;:WCQMO_FG\_E;I]/Z9N#=NQ<M!L_]U.)[
MG_[%9H-+YT\]98E-31)G@F6Q<)+%2F4&^T83SY),,8_I_K+I&]W VK.&-9G(
MQ&5IDM T$<P02:FS1E*IF'4D=PVLW2.L+1T.=5GF<V]X[(C$PZ$NCY7Q>:R]
M2!W!XVI4OMA(LJ9O= -KSQO64I(E3&C/12IL9J2Q5E.M9$9XGCC>P-H]PMK2
MX4PBJ#(Y3V-!+(V%<3S.M38Q\3QC.LM3Z]B+C2R3#:PUL/:<88V#@&B&-EN6
M"P?VF::YSK6"?V@J==[ VCW"VM*Y26>Y$2H%,!/>QH)BQ7A/=*R$R4F>P,HI
M!TYH+AI8:V#M.<.:8R9/4B,T2ZG(<JD3;_-$Z%PF\%=J&UB[1UA;/M0(*Y7F
MCLDXI0QPC=L\EM*+V N3&.&Y\PYP+6^<T ;6GC6LF<0QFH-H4"*$S[S*C&94
M>$EMDB;)76\9/.$S);\?\Q8/''J79%F*QRNDRF/!:!(KHU0LI#>4"4VLRO#
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MU0V5),UE,LT\HN5L2([5DV3&:3[9P&$#74S9KO*(*B)4.>:84M>99BKA*,.
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M.^WV0C]VEG-Y:L?_?#K?^Q*.'>6RN7D@MM_#=S;?GL+W:?,]+%'OM\A7^I7
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MQY7B7S^\?;_QH?'GIYW?W[[=W&J^_UR]3WY=>P%K)PP\<*?3_*,#-GL/;I6
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M4KXCFZ"Q;VS[U)[W5_Y]<]V$)?+Z -[N^_/TL-%H3.OBC>D;A_!?:]#HS6%
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MDGM.-.-@1&IAE:61!@/_6446N:]7@&<>X)F@;I19I2,SR"4<$7<T( >SA&(
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MK.N[#IG&$#02KKQP_6AYJ[83NYU.' K+>*.OL7'4/>DT/N<K1@3S80R389^
M'TLJ N84<R<<C50QPPB)0#B+J#VMJ&V=-0_V-2?>NP"(1FQ$/'D#Y@RQ2*8
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M<>MTP"S"(DP35=@51EU3?6Y=U^>#TWV&#1'4<*0TAQ4Y< 7V<8HH1(VUQ\S
MU!5]7E)]GF<K&UN-D[/ R$+B*B7@TMAAJB)P;"SH+ OT_;:RBP;/I<$3[@HP
MU=PJQI$GN80&!0TVV C$) \I: 86$:S(P,'+9O72*.X\"W%R(@5L@XL6)C\8
MX1TLP(3)J +QLQQ!E87X&=3X]MF\P$H2IS4R7L-"K)Q'QEB*(HG<):.L%HN+
M6%Z@/B\HE\[2GK]O7>:??XS4.C/!W)01?7$PMX"3]NDP=S5_'[K]?L&W1>#;
M^>2A.LR6=-(YQ 1UB&M%4?8:0]%)98FDUG"_:(?Q&GE.%CU^[+/UHL>/H<?X
MQA'<[L=]Q7 N9N:1<BXB;C1!6FB,C% N&"^]MZ[H\<O7XT<[42]Z_!AZ/'&4
M3EA,Q.B 3' $UF.GD=.6(VH"!SM$D1#*>OP*]/C1CM*+'C^&'O,;>GRQL2^<
M%)%RH-08<\1E"+ ><XRP<41ZK8EWMNCQDNKQ7*[HCW7 ?EN1B\+.H["3^2!L
MTMB*Q%$(+)^X 7G.^WO(8T8"MUZJ7-*8R\GL7;/OUQ=%K>V"^V@'YV7!?1S]
MO7EBCO<] 1-7>(&HY0'Q_Y^]-V]JZUCW1K^*BCKGUDZ]M'?/0_)>JMC&]G$J
M$HF#DPO_4#V"L) X$H3AT]^GER30!$@@&8$[E1#0L%:O[N?WS(/E'-E(#"*2
M&V>2EY2*(G'?/I"7$# O0/Z.0&Z,I;(=\4/%E&241.2P- !D!T#6\)L5)&&?
MB"5<%R"_4B OHCJO+(1>5.?G(78R1JX8<<!>";(N3RK B2!'#4,B=\0S5EBG
MUDEU7E)I^CKWR/C8Z<*?>>1S?]QN-1^WDS-'2N'Y:XR&#\[S_46W&]O^>J\+
MC].JYJQ]LLUVT4>6Q-U %YD>P\*493ABQ*N^WL(&E/M\(\JDDE9'CG/9^?HE
M !5L+UD=65F(?!YP%Q O N*I<G,;9.["'U&>G  VA7( 8AN1D'!RDBM%==K8
M4M.5;B47=UVANPY!\2*6OQ>BIP+EP6*&I<5(\ 0VAV8*.6<L4MKD)K4<.[66
M>;D%VTL6RRN+E!>QO&P03U6@&TI!,I.(%%4!<9\4,I%Y))B/@DF>,^PWMB0M
M8OG50'<=0N-%+'\O1$\4HG^[/N1PJ(J -(XN>^^=Y\A* +<%F$M.C)*,%;G\
M]L&]LGAZ ??W _=8C/T;.72461)= EQ3,*.5,<@D15%DP3/.@R.N-'KZ <"]
M^J+THGPO'<U3%>IYCHLP,2&I1![&2P2R>=2XL"1$3;$P>1@O)07(KPO(:Q%C
M+P!>/H"G:M-#<(R!./8NCS!+"0#LO$<6IQ1$,%SET!0A:])B8DDEZ>L1=U<S
MH?<?V[)M'S=K.]''4Q>[-48V:QDY+UV%_KP9(&O'XQ915@(C7G/JHU7<VEQ=
MI;V32FF%B16J&H:Q &<KYL4R^-F?,R+M7''&*$6@ED3$A0K(6?@1=;288@5,
MSORHP\L*U.<:5"@X6*=45M-N K4F8AU"-!J+Z"W!SX-ZZ0'_++Q/!>5)D%)&
MYA"<EP.\<XP<*#1@B7"B .XL>%'U@)^AP!2T%[2GI!@6 H@E$JZ<<@$;&8U0
MFA'F/"EH?T&TTTFT1Q&4(E2!3,<*<2<3LD'F^CHX.R8\EI9M;+%-(J;3A O:
M"]H3=9C(&!@UB2LM##%*2V*H-E$'*Q='>P'T(H">"MXGK$7(A>W$X2HQEB+0
MX!WR'&1WI,98HC>V-'WV )<"YS<(9QX\MTEXA8WGDDM-'05SG ?M-">,%CBO
M%L[3!? L"6(QMBA0 7C.32Z=Q!XQSK7QP&L%51M;RA1EO.!Y&L^&1A&32BIX
MP@WG3DFLE5#44V<!W<7+]E(XGXP::(>SMIV0,[AJ3,V142F [2U(I %''XN;
MK6#] :S'Q @5"@PV0KC'UL; C?1>6ZVB8ZX8WB\)^*DXO\&<2\$(4KF/-6A8
M%&G&(B+*^ 06N7 \;FS132:>/>FIP/T-PIT1;04FW.:>YR1@XQ()407'O,6:
MZ@+W%X7[I'SGCG*JN,B]YD"/3S(@$RFH]480J5@TB=J-+4(W^>O!>YDF7ZVA
M3)-_"4]%5#AH,&V R7'EN*4I4:^EBE)(&?HI4G28(D6Q9+A,\GAAOCAC?+PW
MV&F"!7*>8\29]T@+(Y$CA/DH04ERI6#P!X"SEF#H2H"IH91'1RRUEFOXJ3PA
MRK("YW6$\T3#^_W#I'+)&.5("BH1QZ#E.&<=4DI'+KW3+I8ZHQ\ SL8KIR0Q
M. C"<0HF6,P)UI;$ /@6!<[K".>)<O[Z87 T: SBF EN$8^)(A,X059HH:5T
MEHKE-?TK<%Y;.'.&+5/9K 1"\,DX88Q6P:BH-+$Z%3BO(YPGVM_7#XD'U5IH
M(%TI<[*/SD4)\",XGEMX"A==D<ZO%<X+-<V2((ZU-LXGS+EC6F*6>.+>DJ!#
MY'/@N8RO73V I[,!/,AC'5)"(CG0KRD%!'-!$68T.(PC2&@W.QN@].985^ N
MA%L>(\<6)RFX\=;Q1"0\=6Y[YUD*RY;#!:Z+P77*Z9^<B4;G>+YBB-M D(9?
MX4_'C4X61\IS*>"SD_$*9M<6L]$'3+5P1*<<I[,F>2(5(%D*Y;QW!;,OBMGI
MN+PF3,"_B& ; :D2(ZU\0AP;0Z)UJ6J;+34KF'VSF)4^Z\22<4$H!Z@Z&ZP7
M4N%( K:VV+MKBN6I%OA>JQ H181E(<P30TY+AZ0EU#C'!59KV26ZC(DO8^)?
M<PR]#.59/G\;'1-_<\0:-U\/%6'6& VJ"L@GQ%6DR$5!D&/":!654V9YP?,R
MDV=M<;RRX'G!\2IPC"=Q;"038!H:I"JOGB(!:48<LE;XX((2AI>QM#\ CE<6
M-2\X7@6.Z12.G00$\X14%!CQ$#C2%FL$-B.1A!)A;!D3_P/@>&7A\H+C5>"8
M3^+8.4FX5 09'ACBT0ND*?PIN632>8F]+$-K?P <+R%,7G#\_7 \VO:>-VX\
M.?22$\NH1A+(%7$F*=(B1(2M"2YA.-_H"I!_!""O*&Y>@+P:(#<G@*RH3"1W
MG33"!02\.+>CY!QY$W R"J"LEM?BO@!Y?3/75A9-+].GGX78D7GQ'-3HJT.;
MB+(\2:0XM8CKQ)')':D<)4II.$*9Z,;6C"CZBPR?+CA=,DY7%D$O.'T>3IMC
M.+TY-&#*2"%S3CB E5OE0;+JB!(7<$Z<2 TGLS8X+4/B2SWY*XN%E\E8WS\^
M/B@NQXJ%Y 5%W##X(8)$0-P$&5 7393!:)'6,?VG8'OI]2XK"I"7>3JK"XX/
M0"PC4\'0@*)/>9P.P-D9K9"6(1JP(X)E 10462I>7@UTUR$D7L3R"X3)<U6Y
M/Z2 VZ!<[GR7!.(A$N2\"RB0A%E,VEA:JLI?*[87$<LKBY,7L;RZ&/EP+)1+
M29AD4?8>($ZL08X;C)A7W"INX#\ L2A#XE\/=-<A,E[$\DM$R_,<:7$8LUYM
M-$;1*#"7B0_]P97"8>#-TJKHEA<M+^!>8W"O*%I>P/T2$71XGNV;0Y%<=9+(
MZ@A*M\ ).>)H[B\O)9=2<TT+N-\^N)<00"]#XE\NNCXH;,UFDV Z(AQS\W@:
M3-;#"9*>$>$-Y3+)C2V&"Y!?%Y#7(L1> +S"L/L P!A($Q//D (^C+BV @0S
MG!1/0DC'J! &=&V"UZ21TX\T)/[7BW:L,5P-B*>KJ#^?LV]_?S-^9G!DH7/A
M6O&V=__SAEZL6\+#?SUQKL$R]F>MA<$BPT# 1,>:61GR6!EK+0,V@G4P@1B=
M7'\8R (BH-AA2V#\N^^G4Q*T]4KSY)#E.?9A'?R6L@2 E[4W#BRQN*(Q7TO
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MY.P<RUENJ6/;&W$6K3M1?!ZL=&?@EOK<+F0R02:T?E+GC:-#XP(ADCO$4_!
M)BP@BPU#UG&;!!;**S:;88#8'LQMFC6 <5HYWIRLYQKQ;C[FV1R;H="^I<3;
MGJCC7LV'Q_*,F21KT7)[PDA:=<=M(HDG5%A&I.>$,1V2,$X0I;"*WNB!AXH/
M/503P"P=MY?)J7?_.!0.!TX\0UZH@#@<!'()1Z0,EQ$NKU2NU-#L333??M"D
M>>M=M$=\)?V ![#(ZYH<=1Y4?H.Q?;BU?WKG'?]M.+RM:RMF>';A6DW?NOXI
M<[K.Q='Q)#,96 Z9I[A.5=7:-R'Z\_K@6IG5Y:' 0\^(NP;&U,TY%1/<.%_B
M*';..F"@5#FKMTZ5(6ON=\+.&7)#=T4>*P?,N9]>/9K(T9MRVUC7[=B0&S@/
MPE?9)KKM@CW(./QRT>LU[;^_?NO:W+,:EI;@\7/=^:CE,V)(;=X-"QS.1V[!
M+H;.Y< @[5V<G>7'!UMJ:#$!BZHZ8@]6.&%[S=JS$5_:6;?IJT3*>PZQ,OC:
M@[/L6\Z3$J#O QH<\-TLU<^_[^:(6ZQ(J+K-T^M_'W;=/"TG.("B*:,"*6(B
MS_4;3BEXB5MNA31!#L2*P'*F6"DYP<L3*T=YC+T&Q8X(;I'45",N:4(Z4(8$
MII9[8X7P?F.K4I#F3A"^+WE^RH\WU:MALN?#V("_7CRS%7 ?TK\&/&O:MS>2
MD+]YEU%?U2#<Y> OU#;_#8B:QUP_O3O?SVQ&];B#,.__:&/ZR2T>2W!:5GMD
M;(0223,1,.=>48M) A466(^,6A?_T@J9RE4>;T15M"1ZQ'1.==(R(L<<& H!
MN^C D*"2S Z^+]Y0TZ1@/-9&,IIX@D-WE/ID0;HPY21CY:A7*#^V#T$\!!M$
M0(XJBKC1#NF8* K6<!*)P%B 63)ME?2/>J)+\MKAO'@2Y\-\X^@0T!9P'F*(
M<4R(.V60<PG,52ZLTC3W06/+FU^W:M27@Y_KX*^!V6/+N9)6(P?*/.(X*&0=
MDRAP2;"1VM*<:47(N^G.A_^]LJ:I]VN6@TY@SVBA2JST5'HO>4A@PH#B+*U(
MQE$M*=S>/TI[);]O:01XT[@\I(I;A;U'01@P88@22&.=D(\J$"&L23&"MC&#
M_);49S,&6 '1%F2.YY)[EXS"V:@U3(!EZQ:W:4LRWY.XT>[V(8V4)<H<2@%(
M@!MOD5:* 5^BH!%@X12S;[#EYKP.Q>8@46\P2>NNY\%S&CK>QB(6,9\W\\"]
M/!<L?\Y7H1V (AB+XSZHN^& ]KQV6;D0FNU<U7\>[VLY5V5$S,HN/\U[DCT0
M=^ZR&;F](]Q@ 1Z =13>\ 3HCMQ@:AB6( &Q\ X(4KE'PB6%!RR)!^#Z'X<I
M<A\3Z)X"\ "J*//(IJ@0*(B,2<*XI6R^W-[[NGWF8%LWO)5.GX"^TT'BWZS
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M,LI@Q+DPR 9#$6<V.6J<,+9*UE'/+\PI,?XW#^1B,:P,N%,^.ZV)$38A8B,
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M>>SW&GA9$UZ6**%: P%1YQ".C"/NL$9:)8^(#)18C@V(@"R&-27TCP<$,K]
M!L)NKXO\G6B:34K"C]^PN[C'-<V_ZA 6)>5M?"</[:AOZC.^W<[\+*+\+BP"
M #._3)HW?J7;B/3/2P9)2T.HDPX)D_OG*DV0H=0@ __48#MH*GT)FDFY8:_2
MK9CGH?B8&P1_&'#5(/A#,\8:!+\;!%\VIU@K+YU48)0I,,H(=GF>.$'8&!<
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M_G@U)W!(R(&V\!79!(O]W79.[=G@R;_GM6Q0J&<W</'=?\P;MEJ+9+!XZ'6
M:7Y!]8?EDM^+_C#^J'HM#-2<B:0.03%9_MT2O/ISX=]5 '66^"KXP$%'Q1)
M,K9<$.>X4X;0$%*,A-I:M,)O8MC.(DU:GK FB@L=N:'8.?B3IA IA:LQ??)(
MS9YC8-UAAE\_5;V+<IP52U#FLMHR(T>R6"D_*3H:,'Q_4"FOH,##7^(LK&1E
MK-L;M@Z+LILU*GB]!R-MIL9K;6O]%1MQD\7-)[;[_D D1H,)%$F5Y_@*09&S
MH+0H&:B+,FEB0%_A*\5-)5&F\F IF1V#C>- #[$ \2$;*7!DH R'HIGT1I59
MEHV(G L+Q%0,U)P"V^D!):6Q8.KD'_4K^V)&&$VMUB6_&0SA:N"[3N?93^"[
MF!H^K7F;9\RUV:[(AOR"\I?MV"O.J(A@.!+@^WQUMAM;/0?O7)EPU3G7C]G*
M%E(^R6ZY=IS%#&9!]'90_E)6U85]:PU/8P>L(S#MAT>PBG[ON'P7BET,)O9@
M,"HKJ<Y],$M,@SRUL-@<6V#=GX"VFRUP6.IQ9<'>Y#TS\1Q'P+#)6\)9?&OG
M!4S?MI75ILIU, !:S<9[NQ=^!@J:.<6)X"N;.LS.@<$PGI1_M8_!-LTV;?;I
MP-O#MH"F"#)BU*G.8!#CU_QG[ Y&_3B^%6SZ38\$(*(LH?)#C$W_<MIAY./T
MN++LZ91ORGY63UEF 4TSZ4$D "$= MU6KJ;\+G!Z8-FV)_XF-QJTLYLD#K)
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M,HAK("L=8T($F!ZGI"D.8+'P+2%72]M"*.L<N0_, =8PGBSFFGAG,//2VT"
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M.P>6*R6=!QO !%#*),U=V*U 01MNLJ5@K,^TMZ00[5]9<5_3C<F$BC@I[46
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M^?S&BX,/Y^>G+U5>JGYMM:KIBK,@UWG4/H92O%09LB5GKJ@R"^8U+*I=DMT
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M!6^$(&!C:2Z(=12V)(]#T$+2/&,F"BGHBM3]AI@V24QGN]L'TE(>@6J0CYP
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M]/0"64M%:PU/E9=CIK)ZBE&YX#:6#I]E%DIQ9.2_;:TA4>MRV\MF>UZ0LF7
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MQWSB!G&=$@)E3".=F 3!)6FBH"$;9U<AS_W7)&Q.>V]RRV\%*V3G\,!;D;0
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MHQ.6>.*<Y$)*P!'%K+<"6ZV27F-V3!.ZOJG&\.7M@5*":Z$# EW!YK)3CN!
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M]2%^ZW6^Y0VMG2V3::B36$3_F@E"]],>+X=Z(W5@ZQC.DPQ."X5UXBXPY7S
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M>&-<Y^#^/%KCK0?#E'=VLI8[2AQC7##MB7(T)(%?22RWCM8\Q()MSI+WQ+0
M[XX@JVW>-RIBY @U2%C)B0))L50OK3)I%BR[KD[!?7R,$$(I:CQ)$3ON"-?8
M* H(P90+V*HZHOM.,&*:Y6JAA/2>YEP%</"5D\CYX!#6Q'IG,*,F+:URPA8,
M(][;G':=@5MGHLV)7SR0^M7QBS>"[(U9]L=)()8Y@K!*$?' #?C'VB$=M/%,
M> =D8&G5K/!%FJFK,W!KW+L-[CV0SM:X]W9P;YK18FU)$@+0CE&.N!,4N:@
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MNI<O,N[-?&HGE"/PP[:'%Q=<?K'M=O<$Q"+VJ]>9;OP=1N[(GA4NVU%XQ1B
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MR^5D%0L^.J["CU6_NK-\+JL,PXUG'H"!Z;<R^+L(W!WZKIJE ;L!=^#5'>:
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M24MOZ ?#7@YKC92MFO5(T.6V- 3 ,$'OH+>_=[HGG4KY/O8L '(L=GHY\CN
M;_U*=<?N4S4R5432CE*EX)NWQZUL.<K!FIQES2V^<G0\QYI+U93-RD5VJG>"
M<WDYS&?1Y@RFHYSWD^..G7$PN9PTN<"&XVYO,LPW\Z@R\ZJ58[O6?Z]N 6^>
M;SZ.?8^Z:ZPSV['WHP66=SSOO/EY^V)*N.RP4A7++@7)G]3!:\K<C.K#Y'>J
M<NCZEY*?@0L^R&NC?_T#>+]QXM1EPMW%>I_1D6H6:3L>#ZI8>CGQGL5DI%HP
MKO#L<>V>J^@Z6Y9GK@ !ZX"F](M0?<VW+X=O-B)WH> VSR_EOH0G7:+'!6Y4
MJRW+X.SG[6I<*@P(K7ZIM/-']"J[R:WMA!(82^)0$O6SR\?E/@M@X7TK0R'<
ML=<=[A]</-6&'.2%]RRGVS-1B< @\N4YZ[F:_;M:KZ?D,H!2.7+;!@3=+P<?
MNN)*;Q8GX#04>69L1'J&G?[0YYL .F6]R8ELG3 6HS$8CZ8; ;_*K!& M?[
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MWMZ=(AVX0DJ&H$5(C'$.GNN<=54UG-5P]F[@S'(7%*46&^,YX]Y(Q6@DDNF
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M!*=]M\4_#A-6MVV$5VQ*=N_)!>?=%FC5;2UPH1H8M0"BY:;9@T_[W_?IH\S
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M\39:D&":JFX7R@4T"E@>6"+Y32HC]VZK@4'EI@Y+=I,Z[I4&#K8B!DEG]?4
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MAS,8N!_DF8IF"2@;T>>((!-4Q@4J03BBE"4B0Q<M/>,$SJAAR@+-40F(-.A
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M%5TT169+N5V(SUB(S2:^4$38L!TMH7<J4TD)62SN9G,RL:S7"BX+GLMK^$%
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MK+:R*B1I*-58P!!GYXN+K?W\^2NN#NX!_M0@3"/]VQ4WR"63#62'*%51&V=
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M& S4EHX1*OVUA11_\?-*'5!F'*C%5A!+T6Q7L$N#_LY03V,T2#%3!T^G\.]
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MS?7!6M:Z3>0->A0@.<.X* 6\S*H<\^M.[_M4TG'>@(/%B[[AJP%AEU0"@H)
MN!$VG?:B:ZHA<$6I*>PES+%M\%7%KSNB$CW(-7$T;H_75G![[)51+J2-S:CK
M,T-\G;5Y0NAR,:B)V0-%VO#U',2!"S+U2Z.B16%7BJJ=+W'<-"?2Z;ZM?MY
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M422*;*4QXVAF\2L^K>=6?05:!B$B&.9I)A8\'($CTPH>CJDC!$5A>3?]600
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MXI!^0Z?3;D&0<&(! (>6WO&/&9PN#>UQ11B&?Q)!\ID\LXTDANJ8A+&WY>6
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MP%UB"D;*GF(+^S86..W]&]''#D88L&.1/@RU%27JY%\8O7_O@(?;7.IRET+
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MHU;.1).SCLT"B__P*+DY)0L'T-<,]!JUUZWH?L@#(* P?"C]/TZBY'2ZF5C
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M!WCGGOP>D%TW9"<N>DC!&8Z"T8A=^[-3W$Q4PKO%9UE"44O#ZMY%X,ZC-'U
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MKOA> TJ5;X8 3Q=OMNTWM:AW=7]O$.-JQ.C.$Z/3J*TQI&Q,?2:'J,/4*JM
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M//D1Y%X/P">Y7Q--U-F+Y#99_/N0%6M=5>008PVNGY$;-=D/ .;)+^+C6+W
M/$5'E;2W)#8[QF;JB)?/$<Z3>#DYD[SGJK*W_32D"8JM>-"8/%0/SGJ3-K=6
M+.080+Y+0#:.P(C$;KF(O8XYB5+C*MZ88>1:QA2!.0+Y@L@[Z&105E]9YZ*"
MV$1Z1V>4"XU]\IH=]N.0ZYHT>H,%V1\;#O 09@ \L%;_HB>]]@9KY0JNVM2J
MKJ&9(LYCRV.DR0S)Z%_3N'PHT1,Y+4Y";Y?68@_GB<APD4T1Q>%R=GWJ\:JZ
MXA8FEPP.>H@<%'1-UD?K(/31P\T$$4BI>L(XQHW,DX/.!RH0K4]1Z*</;Q#/
MAHQ*;&7)JJW!A%+0U5XDN^K8S<%!@X-NH%*X$%A3FW!.!@@!;18&BC&(+BK:
MC6S('#EHD@W!9KI/UI2F!.*2V:(H<5-9 V>3D%D;<<G"JC[9X*#!03? 05';
M0LX$K@% %!'H7%VSS<2DP8X:J5ERT'D=5'I[!5^U"C8V!:D%A1F"2I&M2RX9
M8W#USO&#@@8%W4112!'N(=#] #_XF#E8YU++F ,69X8,FB,%39),+3L=>UUF
M'P>DH)_'$%<LJX Q,2:;BDN;6^B&#)H33 <'+<-!/ED6T<.VY\?(4FX:;=,^
M::.CPYNO9]D]>JW*WJ%:OLD@J%5C11<<6ZED6\A5N<8]#VZ30G&VE8-*(5$%
MUT@\M4>R>^9$4LL$VLF;G6QQ6'#39YXX.Y54_W#M3BZP[!WQ3CU[\9=XE?&&
MXPW_Y T_,P?\X:F7:N"5JS#Z_BV9H'BA"?I^^\W&,WG6JX.-)XM>7O\XVJT;
M3C_:$#-BS]#)0SBY]NTK$@N7Z]'BBB9'US[U41^$\KKBA[\WDJQ:WXJ)16M+
M4,BA+P0N(&D;NZ^QD&16Y-E"DMGA%MZ^ZOKE5)6 ?-Y?_]5;N8FFUJDIS#KU
MR)3I0]7ZJ7W45K=(K*VXA6%=_6!OPU^\PL5\S,4<##@8<)N@-E,*40T:BO4"
M&>^3:=7XZD+1@P'GR(!OSS.@YLB-O-(I1@5-_,\42U+LBM/.N6ILV]PR*P?&
M!@,.!KSW#.BMP]+ >FV!7,7B6 ,'L+:E8O)@P!DRX//S&K"132[[J$+07H&#
MH*CVTV4VFU)-)F?<YA;H=?5P& PX&/"^,*!0'V'$"DF(K^D^%2=E9&=*!(_V
MAC3@.&B['F8\KPT=>6@Q"1^:R IJU<*,$96I+J$WP8);^]C1P8Z#'>\+._:$
M;2-A1/ $MI346T6U#,U%CBVUH0]GR((OSNO#8F2)2%QB?SSV'8MBJU'9BBGD
M5'4I97/+VG@?&7#PW."Y3P^?+\;T%N)LG(.(%H-/E!SF6C SN)M7@:,\Y8IA
MP@_E*7+]3\VS[WYVI076M:I()2C@E!476U2MQ:)UA3'T0.&C:-?56NE&ZE;N
MPR2NK^N_M_.E6JW>[S82-O=9?CJ =0%2;FALU@R%6@[,:(<W>F<HZ+=IKC9S
M#5'KJ&JC/FC$H$*G2<76N\=$#-KCF&TP5VSVLE5;BS/-%X@E)I]"\Z@S>[:B
M& 8V[Q(VST>*,#A#J8_B=-DJ"*8J=LBJQ,J92FW@/W=,]L#F]<<IDG'HQ,]%
M9FA)"U+[^,J,!7)"?T.U3 .;:\'F)+\%%E$[;55$;@ID<7L_ J>:204,&.;@
M!C;GBDV=.%IN!EK(@-BX$-M8Q <+S:(;.>998O"\?0PMI):M4S4VH\ YKY)U
M42$6MJ)J@ZUB'X6 !_YFAK]FJR5JQ;"OD! )O;?5%<IL0LMUX&^&^)O$\'OO
MYYP,]>.?68$M52&(%VF3EQV13 L FULQCJ%<L\-?8\*8',=6 2B@\U0\(0(S
MUPH#?S/$WP7A8XJD1<44I1/U@<W4%)J(JE59O.8]--\VMU"OF$4;0[DN.93K
MY>,QB>NC+1Z";5I;'QRYGJIGU RVMY.'(#_1\'_O"O?\^M4T;AS9&,*4E)@/
M5!#1*ZZ^*L>YF%BC+6-<P(. >6O)6)^"+3%#H\3!!=]GPE!MKM4;@OF \VIP
M/N]*%]V*%0 K:RTK$+],I6A$4E0N;%#T1(3/:"8UD'R'D&P2.+8FZJ8]E%8(
MBDC+P,$7K#H.IWR.2)X$IKW+3I;,J1Q,ZT?/HDH>C2KDK:U0@!@WMP:0[S&0
M4_04LD])=#9DKMBL%?D='?99W'Z<'[A3 #]OJCV7PC:2TJ$/XK;.J(11*UM0
M\-U/BJ0ZE/<#@'FK6EXC>-.,E6U0R41#5C2WY\C1IF&O9PCG21"=0JD0'"EG
M>AM7$XO"$)V*)2!5!HN!-[<"KIC$&E"^2U!&U"&+QM8N1B#O&3398L5V%],H
MC#,M<X3R!?%X7UO(@:-JQ3D%0<PR1] *T?O, &SZU+T8U]7Y9I1LGT'<W_=I
MT7!-OFZ\.'Q5]S>^J;OR4GE4<7NFV/-[P>8"+AD"WXSVS"6'$M,-9?R&3[ &
MYGDRC<8WD8!!>ZN<YJR@&/$)H&;9=59#KHE-'=5HL\6FPZ2]29""1M!%'#P7
MM -!:FHZMQNJXAX87 V#Y_WRRE@UB9#/H04%,; B#E%E8T+P%HRI?2:,7]'V
M#_Q=?Z:Z:9<BU*!M@=8H)5-RK$C-UYQPJ.\YXF\2^"[.H[&UJB)KI("]%QMH
ML/?\#HV%53,T<:1OH11FP._/#SKK6+*P)Q8Q?V 3]_;[K;02JSC!M0QI>I=@
M>=XLMA8S)QL5U#ZND2NHY+Q1/MA6/02PO0'_D*;SQ*;F5*PG\@%8]&E*2? 9
MV5NRD'2\H<._ X,K87 28ZX^L\LQJU"P*' ]QLS,BK-N(634NO#FEEEU9.K
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M0_&<5&BE*N!,*LF&5H6UH]JLMS7U257WV/0\>"3+"XA)K#&S3]! BXATR?D
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M^SM;$4-Z8',9V1<R2W(FO<0/&4O<U&5.G":1Z[I>*B(Q./:;Q\@KCKV78H+
M=^PH#<"Q1QA^'//<#AWI>7D>@F26.(EV8.2GR\AI)I),A*$;QRY+1)#($-A7
M.H'',C].P\&QWSQ&7G7L69 F4GBVS!-B9 RZ>X&=!.#N)WG&,\;0';BO'E<#
M)V\@)X=I[J4ACP.?N2QP.!AB<>1Z>2+S-) 9'QS[S>/D%<<>3BJ4(G%LYJ>8
MI\\<.\XRWPXEV-E!QK#A G"R=U_]2(:,_9?Q(6SS5,@A8W\E\,\)?,=AN0B<
MF.5AE$@GB>(,[(@L2 (Y%-EOFO Y[$+Q_]J^/#@6?^8!R[PPYS8<6& S ?Y
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M\X&W]WE_LLO^^+P?[.]L7QS\ONOO'W_,<<V'VW\FCI_FP- VAS.PF1<F=HS
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M -2"8[=XALRG]PMV!IA\KF7P%,7<6!\CQA7Q\][U4WC_NH:5TN9P*^=%U1Z
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M?F$,%SPL=0SP4ED!RG\.QT#65O,W-#!GL-@+.*4Y^BVNXUCT8BJF\D0Y!-T
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M[9'H#Y607%36+Z58U)B0_PW+=!XM OI:7MB;@E9QPY%U+C'S.*;$ 4@[;DU
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M]U*;B#;L.%KJ"P;RK^WGH#%*V&P:(<;MP"UJ1"T68XYX)9HM1.-(8?E8E*&
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M?\UX@?UOS VP$0XJ1T$>4I<U.SA?>L79F N9ELJ5F:_=!?)J^AM!^IVRK"H
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M^V;8O:_8/:QQ.84/['..8=M9.;Z<4'=[U?;;-'M,2S5FI51!8JT":!I9+Z&
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M!H69,O3^__#)[*<=TR8*)&MMBL*QYC*SL8FS G7D8%(KN\(8R$V])@4YJ?^
MGG*.Q%M2=ZH%WEA23(@O3IH%S(H9J:BF-02O"+NA1J&2_:]"3 OZ*::O+"ZH
MFAW^JI&*,P-]5FT)SW!^XPDW(QA-PW<<ZH(S5/2Y$]B2#@J/'I/5<HQOK:PF
MJD0LIM/R3,UE,:]JFHX]XFE\UY*(+N"9EM4$]D[0MM"\GD6->-%ZU$6,JA"@
MFN!+0W]A"[$]P;CA*-6H9#SF::D'W#1#@>M.)X"V$%17K$RS?Y2]!FBXAJ73
MIDA?W3U]2EI/Y)PVY&HZ4 U**H3FSG& >?<QJDP5SDO.S?.:)+KN\X01L@GU
MHE-SKD>=K/CYJ:IAU:-Z]1@DJG=]:3TO7NA)P$U;NA%\")^J'"R.+[UL^@,@
MY]"]FEQM35?#Y0*#:.;JHLKL&:_FEZ ?+DN$7%1PV1GUD<@+:J= .XW#3*LB
MU2WSP+U%OQO6 AXO6(T<IWE]H+9S^J^=D^H?^H1?8DRODO]=%)7RLR?\$XY8
MNE3;JX9U8Q+16LQTK387I]AIKQGYKA'/W;WGXU$G+TW3P%O*P &9$KT8^80Y
M;V7(+0<!M* TL)I<B\T#L_Z<;2R%;I)&FO-Z7*9@YAB#IP/1 D[3=F_[UTCJ
M#OY\,<4Q5FAB$*ZN&:.!M#5IRIWAF,?PFVFW86'3EQ#7VI$-[1H+O:K=2PD2
M%S$'>U.QU0B(+H/JUD=+ L.$:*8T!/AH3F%J B2H!M 8*IJNB(1)(8!',<.P
M-&V<SRMXH>D5[2;5CC83N-N[=KJ;T*A%<SM@=-"I"$C6&S4SF'J\'>G+3]/R
M?(II#(R=UT@6JD7EJ+NI:AB);[MJ1I<JK=?M&JF[2G>DEZK/[#>+7)E?N]K=
M)%\GC(@84]4L4\7&EK>R'52Y&&,[J#E""$C%@IV*6,S^Q%M$:F;%R63]?JWN
MTBII::1H42L$J&& DW&9HF>Y2F6*PE[]\[<]O343T[I@"J<]7C?:HM,^%/8"
M?ZJ>;23A;,RGQ"<S#N8Y?M_44  9R_7W;*(R8\E)9ZR'1&L.U"MH=W3I\E:I
M=>.>-5I,S;AXO87MQG8W\\D*T]X0P&ND*1=:C_7HR A2JDX\0'Q4\5_KS23]
MY_562T]4=>/&?5FD8.M7V"?6P>%OCF\]!P\P'R_*JCR5%Y?C$C&7\L6(!BH"
MZ\(VVV+,ZU56S'!$GVFB060XD<B$"-A&V29,-REZHHE_FX1JW<!)=W;;GE3P
MG%*H^8JJID(6:3G!CK<G!#7*+NL<MK8/1WW3_%YU30(%-P,A]I:#)+&.U'Q#
MDDLC_<H$,U6&0D:5,!UQIFRR=5/8VV.M<:IM/=>V/;(#557AK\L9>1D9G_.V
M#+I53Z"8EB<ZZA;GW6$U=WZ@%EH]H:Q$R@%8? CSRL',Z0V<]'2S]58N+Y?1
MK^]=LI2TN(5TEPU\JP'07TVKR U *%8;[R!W41E^O77^WQI]+QPVTFOO@Q[H
M2464A51X*OEX?MK:^$]6/+6VGI%.-\LA:A=68]3H50&.!]7]:E/),%US2<.Z
M7RZOX#3^ ^YX-62SOJI?.1AX?"(*U-Y3/$XYQ^[EF*Z<52#50) 7&56ZX-1B
M<LOJ!?A!U*/[Q17*8FLXD:\_$;0-49* NI!SQ.&U^VV4L"AQ^64--C"<CG75
M$1KW0!OX2R?*^P7WX+]8/38D@["[CJ/71]8^^AZ*%LIJ.-[;'R^9 AV/V1TU
MH9-&QPW,\_79NE4Z7]1--J)C :!;P14V3V9RPE=LQ<69A"VH^P"+QWTR#]KP
M8\FRN\J9?\2#MF^RG8P#H"VG7CQLC?6T)@RP#][%(BWJTP(A/."0H$U> ?&^
MUBA'[2(9]WLYZB2M_6/;]=%-@W=$XIB4&3EGJ"5L%5<N*W+7)S/P%K)N9%D%
MU.H9&NHEQM4MUVY'WF/9[&Q>ZE&W,ZS"@?N"(T33./AB7A:3"7H'QF-K,;#%
M-!_SR405]J3E.8[P5!?1&RS&0NHP/)Q6PY0TD*0SMAY1MRH9\^OQ:^.AJ:"7
M!$=X0:Q-VI-76<&%F55/ >>Q;'6K>G-P<+0S5,EZ,<:0)$[J4OQWIE9V+IN1
M(UD3M?*L9L1)2^2=$23KNKA^8:J3>7_+5.<>^7%-$@2C4'O3O.)@NX"WM6@%
M\I,3&9T9.?C6 @L<34X+.<C,Y5&,COF+A6PR&TW.4#O"O0TL>ANHC) )6)2]
M<  \5C$0YJBX2GW^CM BT*=@4W*A&H!@!1ZJ(YR!AY>\+[&B"F5Z]Q+<E3_*
MZI/J:P.7O;T$I9HNJI/>9;\5>$ 83*=V,,T2FJU 9%@ODF V9,MZFG1P#.<I
MY5RW! <YR['$V4*K9:HL>]J382S!7<<2-.T7^N7#(Q78HCX.;D1,!^I-&-4-
M#Z6F^-SZP8T"S/B-40U3ZQP;ITAT&)$:1M>ZN3TZ44;KK'*5"K#)"6C7NJC-
M=:LWP/#;O%1I6J/WL8]3O_T)[-$""^")UU$9T\@-BO\54VKHJYHM<?$);8#E
M#:!T;UHUX.;^S:F;)L::LS9"HU*^Q514I,?)<D #Y.KW?;+,VTU'-MWZ=<9G
MF8F'YB_WTVGT&D[N9E@4-W>-R)9M1]8/GN<T_-PR\6)V4O&,].QZ;:<!%_HR
MPP.9"0_CW00'5M,:;TG)#Z-$[Z]VLC/!=?O7#]MO#__S&+?RX4'0)D\^INY[
MN+,:_JEI5PFW 1&]A(AV!T3T5RKP!SJQCH1&::P&.\CQV);8[G!<U*=+S>"Z
M80P4WN_ P/J-8,V/4= \M,P>#?MWI_WSK.='OQV-+#-79)IU*J-?X&3Z_.TC
M+01ZZ*VU_%A;%&/8Q?FPA5^1^AH\O*IKD5XQKE>[*0?E6>.FQ.2F-+.PK1]\
MIW5,$!S5-BY:"1 81*SR;+"A7D?)*7MNQ9'!!:]XZ(6LN_#8&06[M3N_=$N,
M*<QQ)*B9XP>>D)KRF$HY;?VMD8$KK0V4>Z-^@+T#J^[K:0/]U@X4YC+JY1YP
M(XQ?JHCB%[[J>JCJ2A &7ZTVP=&;[_MM1I/?Q!]L*WI0!C&35PEJM:C;>&:+
M FL"FDVL>X4E&H!YRPF4-S.GH8E1XUS_;]V),'?+""SE%+0MS]OP<]T?)X_9
M8G7)7V5:MTU IK"W0*]G9DHL+EO-@J.O\3J@?@O$M%1=!)T1;+%58ZH3"!U>
MONFCC@ T4U377R2?J0;;2#2$5M<3$S*:P0D[,JL*( .4)#UPK0&AC;2?ID+[
MR!^SLE!!_=Z#=&Z\6Y+2S=4>GYI!=UV*7]ZJM!M%>1 2?^!,3;_/;XNU;,#6
M*@>CNDHWTOJ'I)7C=(T.ES;AH:N3+O-.5J YB2$G\,UR MGU.KN5)BOJ%7G^
M.EYI0*Z=.&1-A#-%%:GJ#%!F8>5?0U@]L7<%C9B9A4J]YG.<DO576:W^MA]S
M;),%&/#OZZZE8*7,<Q7^Z1"OGA];G^*+:UG0'\:E+FC$!(Z"4H)4JFF::D>>
MIJSXO0]:7I.:;0YRM&1/K"1,#>";>&N9)JAZ$46!0 6B%3 (B'*J0MG*7#VI
MRG-$+C>%&N=X(M*LI4\8O8I5.OX6^]QD8;\>W1!<@V[8V,.^%=[AV<^[>6ZF
M9UK[?,JI$/X0MO(UG^%-K".3D[>^(0,\J#VXAQX R#;1MGM!2GSU/V^Q;($K
M)$B+;= IT,^F *:@WDK%!,40;VI?3PF: PMI[H  *\4B( %IOJI06XRW&NE2
MDYD"N%)O68EFVXD"4[3%VAUMK7\_HK(&A/^<2M6]@,1T9\8$1\P1/OVR?3TS
M+84D929GDHZ"BKG'I< %Z-O30U&2ZGH?E.' L7)Z,L?GJ:8*6':'ZD+.%1K)
MJ%ECNQ559U"KUD.=>FB5[-6_Z:U7 2AK]*=(RRGY0-JMDCEU4]82@EZJLW_-
M[K9)X&9+FUK*YDR6#XM:M6/G9U20J'=4>?M<6Z\7Q60QP1SS @'.55FK<&NO
M)H/7M52R:635Y4@3"M=V\J55IG_I_=#*"U4LE?4VRWC$2N?><%<[,IUC=V93
M%XT'>4C*XQ>@B:G @SD&LZA6)5G?L.G$0TLI4$VA0C3)"RD61#ISR2<4B2CF
MVIP#281\K[HQK$RE,DS=0*TT?1;8)$6)KF(B6VE' 1+]N*8300OL4M](-4N<
MS_5*\*"VK&T"7!)84369PS=7?)_AF5;],YUWSE"O9\(_-1"/]L[].OI.4\QB
M#O9ZOK(L)<KWWAV2DSLFY!@9>GPBZ6W;^DY\6'F.4\N4[#1EOK>6*RTHCI9#
M2G:-5GFB_N=.V]1<Q\PZ%-,Q."9H<$@57EFAR_12@8A:XBNGK9@T"/IE+=T=
MK= <O YN=+P<LF[5P",Q+FM]]WUPL%QGI!=.(".JJ#;,1&1K6JRTY&L:2J@)
M.N;9$XX.R[Q+\>U/\T9T*7#2&5:8B47=>4WP7D#36Q7UIP-_;J>M.J^+"S47
MCSP4>!\J<_2;E1OFI<5KE#$_ 1+'ZGK4/U.,<8TM/@'GK?&=:(EE.M8%BC76
M-A+A7U"C#CBO'^).G!?++$ML*E._?+14?$MCF;KT'Y3HJ^S5]0)'"Z@J,W54
M3>,C4%?M =L/6N;0S)#HL*%J 8J07"-N5QWI5MRV.D5QZKCX[P(DX_Q2NWI(
M8KH27TE!TU&FO3FRI,SN0"97M"AKFA''0RMBW8J8*88YG%J_R+2BOOFM1.OJ
MS0((&%,W+H6"&Z:^5DJ$6ZX7_ CR=HKS:(Y +F/!"#'$-]Z 6S+J@[)<!HJN
MV7S8^,AZCANO2XO[W_3VT!0;;]9>WL4'^8J^X@,KK[)RURYY>5_'$<04\QX.
MY+8'LHTY+7E6E(M:1>#!;JM-9-R(U];6[ [7;&S-O&N>JEA]*WJGDB;!"9I*
MW'2],+:LR>IAM[*",NR8A&YSWYCMLS&(HPM+9^2FZ#X5Y%>?@UDJL0\:X?O
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M6A7U3@!$XI9P0-1!B+B1C?AP!9=DG)1IY*5Y,,PJ#?8@8R'G@GE/\3 PG^^
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M1,K.]K;QP?X$#DH\L<6LA@^ [TD%0RM.KC G1;X1'1(.^&)6AN3*68%<CX%
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M6BHI+C(S29B'XLBMG!DARAK3%@GLX2[/C" /7-IQ^T64BQG0 U4:XW#V?IC
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M@NP@A  WQ>HT[;FT;<@0=WL1RS9#J5:CN<;XQ%+:J=ZPSF@AO]L6FZ_ 9TX
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M[Y8NN,DQBEGO1+[EW=@Y,._=^R^V5Z(HY^[40)%FMQU:)FM.T4')<R%$?J\
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M[EU4C'3^M_*[M\[NG6>YBA+/>FMN7H'UWW[SUMF\]TDO"?M^[U;?.]@ZSG7
M?_5(??=[N,8>OM.1W\#;;."%G>#6"#[H\7"2)][Z6TL3?@@Q4:C\.;+>[B57
MX>=4^XC!6KOW,<S3!.ND[F?$S];OWP6\J3_QBF^]S9N,4Q^L6G/SX'%8R]KS
MN[>&\4*PE44_R3SSK<5\O_?@3G]DK,-Z7['Z*F\$?X2I^CN)/ .NQ8!_ZBCJ
M%CD<'XQQ]*_W?A_7V<=_Z5C][<_@]7;OZ6W:H\[2_'\:)Y7[D-\ZIP96$_T_
M\'13'ZU::_^P"&]$I>+<8+-L!9;/+MW-*>WW;_7],Y:-%_Y;"G\2QOG3QH1=
ML9&)6I2QB^"5H*]^OM<YWDN28=<NI]H]PNC! \9@G-6)X4)..B6U9>>VS^/<
M,A'F"Q9O4W4'O^RKRZ=;"/"H7@&!9YGF,FHS*CO[OE9M--4ST$38956.@&S]
M9 KU\R0GN%?I5^!^L28U 3LXN])91;-4G+XZG)\^0_N4TW*NG?$FL1UT5R)M
MX;.N$K0835]9"0G C2'47>$HP(9I ID_,(87>!F'.0X8P-X"PM>RH^CY]<_I
M:&O;WC/XX7 CSSDSG\%@-DAOI-.0V>?9$64+:CEW)S/<8[F0(!YHL!47?IBF
M/\9>)L"M[LRCU<&7-KT[.%],SMIQD@MV,^[A@E;(&0<P_DRME\$41:;E%D2<
MQE)03Z8T(>$KK=.%F( \<33GR:C4I=0(/B(FA3/)\*EIUD?EPQV")6H$7T'>
M4R"E=\+6M(_L3OX+I^P^669\U&.>M_#I;=V&VD;!K&G9LP\3;K-F]2^V"H,'
MN.WQ2VAU#D<@V,(E/!R;7:>":%4#K;W8+&N9<X*.0@:I80A7,]YH-LYK5O00
M&G501"6P(<V>L; -U7.5#AV$/R:<3 M3PR=RQ'V[=A!GOIN&V3=["'(_+LZ$
M]!;DQEJ0RT]S8DB'.;V].R58X;_"@?JN_'FYSGG9;C9'C(!T< #_:H!M/@$Q
M#?UFKA-;."N2;AKZS5NO1"HM(H3@\KNWSNZ]+T:@R9_JWCVZW?8%EI/EB6\G
M7><0.8__DEFJ;N@!M_4W1-/SZ=@UBQYE,$0900(S=:0)#'V'(-XMM)7\ :PA
M!C:FJ_$: R7X NS5RX0GPMX DE;&F6;A>]4I;! PSP?&I,6HD&/UV]'7SKLL
MZ!4ALYA)F/VYP%YU#+DG:_RN&#Y](&-LI55MLD2MN+VV-:^YUVS]%.R\ ^\4
M?</["7PL'Y"N0M.;&3*O"7YP4IF(@(.D<<A GT8"#0D<U9E'3^BQ61)=:3MQ
MDO^1%#DB]:(P\B]P4D"$"'2%BO@WB)0*Q)SP3Z7GS3\C_A7_RVP:__1YJ-(1
M"'5!7)#)I,OW>7_/0M>5-Y@AE[^#\#%F(B/*&^^Y'&WO?C^A+A)88V >A6YB
M$N^:$(DV&(X$Y$OE0N77!>;#*@#)WNVYU4GE'@D-3EO$,GZ<LCYX%&F51B'0
MN2!J6]C/,.T5(YD^]J)1DK0<E8,/%R!PH)0$;U20)A,5Y9/= 7")/3DP1",(
MFIZDM^]9SH8<B,0IZCU-..1FUI*=E/;V[%3FP^&X3H/(3<++4W#";!02:G7D
M!O <Y&]/J=M3BN*A431'U<$_<@'I]IM]V\T&UAVAJ8Q[_:1#L=X:W61K]#/X
M59=A]N)18R.[P:=RJDM#!B6YUIB<"SBPZ".LOT>8W)]5"OI?C8?!^1\!PI3;
M,45\;'S6:1I>)L%YEBH=!76C,6![,4ZN ]F$X/W[UR^L!2F_- 8D@75RWLQ<
MCH,24CMAP]@:9*'8I!,:S)79*A@!*H<OPK%FY_Q]HO%"P2L<*83^J)>$.ZU\
M@+U,NCI7X*G0D84C)'+](H@J H&Q!8&VEC'N#; E-5;:]#1ET20)9X>.=[6-
M=MAQ#A0I26G.N#/<J8'C'FF0C(J$@RV+ 0=8\W+V2NU"D3>8G6 ;3[M='%]!
M1@YN%<T$.F5(=Q(%B^7]D5F-T+QQ8!R-7QF$$:]:EK+'DFBF2-7$D*_.BC"W
M<1PC"^,BS0H5VSE>OZJ\-]S]4WW'\16G"):.:=G+J=A0^6I*OL6T/Z,$)QA%
M*BS=-"\,=RD,5CTAHVMD6M"4V(E%6/G[S=T1/&,(RU(3ZR<;DUQ^-E1#OB*6
M7,BU4BGP"4>9C',..NR7+(;*E&.[.#^QAQ/00/*(J>WX'+D 7G&-G%L-5O3M
M>OHTWZ>+7*VCY+J!DP=42BG<FKC9E1NY\XFU.U>O#"*N_E;H&L16V^X%I\AR
MR@1NJR072ELE50X31FI]ZN4)LD_''0E<&@IL-,/S!CQ*2UZ0Y:F.+_-A39](
M8DCDP<PE-^,LK\!\2),BBR:LWV2^+D_0831O/=!XS[SPS[,QVQ](=K9&/Z]G
MMCOV^NZC6NR?S#3C_;LSU_G+'M[.]FK_H=1^8R/,Z]EV-!H#B\UB,_']>,-,
M8\^_Z_/OY[LUA(E/'L["5=WD2J]BX?JP[+T%$.[4I/U3BR5[LR'KI?_6;C!)
M%QTXCL$OECV6 R]CV?LA98?-63OBAY1YQ\X[=DLX=E_!5MZ DJ#?P!JG0^@.
M/#K\I'K:!=[1*ZMT\(H9"1:ZT7M]&WMN;IS7UR"?KP&L,- ISUOEG]/*5'7@
M%,-QQ!/K>(3X #+S.?[!>9+VC<X@L?0M/$&ZW[N!]^L&,@.O[ $2;=C]\X;[
M4S/<M]=R>Z".Q6=KN5$OHZB.X'U9<[@#FEQ=;42,7FIJ* [5.JP>4F$<RLQ[
MM^%9CBOYA."] K\(Q[9CR>7;]XVJ^297E1:<')YXB)$55CW#S$/G'F/&G,-E
M^G[;6ZO'6C2RU28V.*:^F%I]/_7^S*GOI_BDH1U=+>7^,A[:--+7^N8U@K;$
M7'V+=;N:&@'*_OS,-.C?6$SJ6>$6IGJ*FX>4>($**P"-E1/:.'#':4;5U',Z
M(4RA]2HUUIY2=T*IAA4WU?L6)]?@35R*&)'WA.@<0C3I0>E;DPA]&$^&^Q"8
MY:O?_?[?R_Z3I2_N%5?%\T'CQ!&*. \CQE2;2%_0"5<(E>>9BK*$6[NR4L[F
MMW:AE-W<VN5)?B\D-UU?,<&_7>0$"U1V?OVFXD*EIEKU>.D.L&K1F(TZC=0W
MM(PP@!/#A1AI&JL)0R;!DP5S"#@G&^B4+%90QP7<,N<@)7#Q$FJFN+$#\?9?
M5AX=<UK;?@EVPA?+][<]<;Y^5 =,F+@A3+UTHQNB/F%%(8:4*(:Y$SHD XXJ
M\B%X9'\[O>R>8O=#,9N2Z"F,,H.;)(>0D ](BL%MD63=2^)D%/8R)J?U=YF<
M&)(FH<\*CC!/TW&O*KU=>(, =QE0!KZ9>0'UA-$)X0">R K*\(35J@;3 !,D
M=.ZAAV<8#T]0>N9--Y-N(J<-E@7^7Q\Y$UR"/ V[14[UU@-TYVN:RX?;GFJX
M[;XE<<7]G1MNNP 63OY^[ ZV\]B6\2R#IJ"D:IP-S22%<SL:J"R\'*D&A6)*
M%)89X3G^Y&HPCG]7QN(P4WN%/GP&4@HJA3-Q)K\D6(>5$!VHIE;'.I+=25 ^
MDM)E@S 2C$!S.GEO\Q[#,]*)=3BKW+3&4)5X'7(/Y2Q--(\">,(R]?@=Y<P-
M?RT+DN%#0P_*)=P[58D/"35]>.BQ2>%C1!M(A#4"1>79O3A@9 3/QXLVE_SW
M%C2Z^72\BP".L%@U?I/B!JR$3.0Y[-XX;*U(SEZ%L$_+M7?!M^:X^96(:C_L
MWUU -<SJR6C>2!]9\)&%^XTL?$S2Z[ W?.S00EG(,\<77!!*F%&**E^UN#);
M+G+""?,J4\WC%A:GMO?]>70']8[E=ON@S*,%93XF5U)09?L[59GF@R,N'Z))
M9FM4I1J.3]=*5;L1G6L- @,/X*NH6!@$=L\3\19$9*6.[=?L<_..MP\M77I
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MX&ARI,D5PUSU4M((%F4\0V5!K[#I /S#99I<PPO(PB0[E+AD+_C395]X$:V
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MGE4$]8O.\K3HY45*K5%AG.O+E#+]C2#38Y66$%/GGS_!?F3/+<*Z[XL=-YM
M/NRPV?1IK^KJ>0(]L*OGN\,WFT#M53ND/(%\*>I6!E=YU)YF).=&$.OUFJ.>
MK%.T7C;9NZX/2Z6#CB^@VVP*[1RL <+OJ?-0QZF7GHVFSX$O$-YP"NT<M)I/
M,GAZ&[]ARP;%M!K'S35#)QLS!LA3=_[@O?V59Q1XZCX5ZNX<'*X^UMG3=>/I
MNM_H[*^9;_#4W7CJ=AJ'ZR*E>NIN/'5W6HW6T0IP?0]%V3L*X&YTV':LL9 @
MOL12V&2D@QTLA+W53*HM8\[6X9HH>!NC>.[0W]XRVNZTCU9WQCU=-YZNG7TO
MLUM+V\Z:#0J>MAM/VYW.R>J5I9ZN&T_7D_U-G9K^#*9KG\>Y3G66BX7_S&J$
M?7W61M/'PZ%N-GU\?>-FT\>W0&PV?3R8\&;3YQ'UVS.(+EO34^J"GU=)\$[G
MD4I]?"'6,M397Z40P%/GH65G!4 <3YP')L[1D:_1WF#J['OJ;"YU.D^S_/<)
M6)OO5!A+_0(B><%"8>%%F T1[ O'(_1U][F-[&KY .AF4VBGLP(:M2?. XO/
M@6_ WW *>06WX13:.5C!X/'$>>CBQD<4GV<0 'V;I/ CVJ*]H8HO-<%U)0B5
M\+Q"H1YT<;/IXR%E-YL^._L^HN-IXVFS*FU6==\\?1ZZ\^M)(\ENLNGY'@<:
M=/4 +%#3VY6K[_I6&+%;5I:\TVIO8->A[R>]-5T/5VGK\G1]*G0]Z*Q9KN5I
MN_&TW6FO8@IXNCX9NK8:[4-/V2VD;*O1/-A4G*1G$%K>^9PF5V&&,R# QG\!
MIGZL!V$>#-)D='N#_PE[E+[F=F.)<^3CS)M-H)WC(R\]FTH</YAQP^FS)NB(
M)]"#E:*L4&OGH\VK;.U'G=,(71]==BS1?1]=WD:Z'IRLD/'U='TJ=.T<K-FL
M[6F[\;3=:3=7+[/W=-U\NK8:[:;/]6TA94]6'@/M8\MW:LU+"%GE>1IVBUQU
M(QWD21 G\/LX3Y,(;KNDL<2(\/#,@LR^.7US:>.;GS>7-AYQ8W-ILT*PPM/F
MH4,.GC8;2YO'T6G/**8\98.^4D76&P:_:A7EP^!U,H*UA?#:\[BWMZ:[P-_Y
MRSY0HY\4^![S>;?SJS9M3W]\Q/W9;#%NK0'$<'>;\\B!!B\E7DJ6S'UX*?%2
MXJ7DADS2[>IBO:1X27D>DK+3;JT]C=5+B9>29R(EF.7T=I>7$R\G-^2,;]<?
M^HB20N&\GRG"!?_MAU?__+_P/T'8_\\?PJ/#]J"KVNV3_<.33ONP?=+I=3KM
M3J_=;!VH9DO];^OXZ ?W+OG<D4HOP]A\U3%LH?P&/^.XRN-_%5D>#B9W3;=6
MTQ".GOA+F,/K>A52'M5)V492?AVF6@<?X+IA%KR)^[H?_%;$.MAO-H)VL]WF
MJ%\*O\Z3(!_JX(8;6H'EB8W>IH6;\D5?Z;B Y]WEM_"O0MBQ./^EW=D[.B#=
M>[_?-R6_0G0MT=S)?_R?XW;KZ&46I.:;@=C!. WA>^#%P:6.<7 Q4)GZW<9I
MTB]Z()@JTED#KXM[X5A%<&48$W\@YIH:ZP)$$!^E,@0$?G?>"$"N1RJ'+[R<
M- B>34]T,*30<@/N4CD<87$69H@@_$NP$[X(NJDB_AH/%=S:HV>J"%Z[$\)?
M:67X$GB4N=+\;M8=<,NGKZ_-%V1TWTYX]2(8Z3Y>!0N\"GNP 3M8=Z'@(R,<
MI0$WAW&>JJ171"JUOTO&0UAS-(*79050'A^@_UV$8\) QF<KG<%>P *R^AM>
M[ 6?<)O*/8==C(J^#F C0Q7W&+X.B(N7FZN8 +C%(-FP"JP*P<MZR2Y\TRC)
ML4,1]KKR@51"@M]2?UA)8:&;I95#)WH$<#0MGC\"W[*WI6+QJ7!(<JU!#GYL
M-4X.CP)X5X2[B]OQ8[L!AZ#]U2!)A>U1+8Y8+>H9>A3O1?W8@%=D8]W+PRL=
MH23 AO=P[S5N_H^M_7WS;&"R-#C\:2] <;4770.5^@6F9UA(\.4AB'*/D;?A
MJ;"M>9%J9H!^F"$/A'%!I",*_WC4*=]1,D(]^Y/ =CC/PSM/1W"H(^;W;P7<
MT#YLR">10.)*BGB@KI*4'E&N:B#HC+TB334H#,W+.&S-6@;PXYLB3<8L!*=9
MJ$14\1W.;L%U5TE4C.1AK9),Y;-XH^P]*&CT61? @M\;P1E\79J%@Q"H]=D5
MFXLDRA7(S"5*,SY_D.D\Z.+BG">9U\M#)5OVC^!],NJ:FXEZF7:60(P%1VH>
MDMHLGPT,;QZ/CXSAM_!#! S<QT_JH<#3EYZP\35[[Q:L9$O%%L6#43\M*>23
MG4.-]"G_$A3D( 2J+BNZ#3H249"*+(,_PCL&14H*O*]S%49&A9:"#6="-X/C
M %^7X:^ *_&D;3=?TG];[9?!%SU.4A:V"UG9%W>YGWF9=%OK94WG3I%0=F3_
M$+9LG&0AOO*75$<*E_/R.NSG0S'>W;N$XLWR%M4%F[O(Y]_BL *<0KE.'XGJ
MAX>S=H3_=YB:U8S5I=[M@AA]VU4#6.PO*KI6D^R'GZO\#ZSN;F#]V_D+__E_
MNRG<MY@.XL!4=T%^R:8Y^33F5_RFYEX3/]KX-_N']'-PT.'_UG[^87.MZA6=
MC]<J&X(2AA.JB$7SGD91<HTF$-A8K\&*N]3H3/+?X$H^H5"<WFH'<6&[%-HI
MZ+$,#LL,%J]2:Z%5C5KX;1^N2,&$ %<[RZJF.:DL4$)_@?+!$U %5W!"Z'S"
M%AY>2-8 /%JE:7A%QF1.9T[E.7M\U%@(#*LUZ4BSC\&WI;J77,9T6H'%P4=]
M#F?2=9@/13W2!<9.G;%J<UB.R]<9R[B'K-*OL(IR6*57LDK#V#TEKPPT7G,]
M#.%0)/=&A7TTKN"P[8<Y^[;],,6]XET'JP >@V=U%.%_4WAT+GHYU6 -Q?9Y
M/>"/[L)'XDU K-KS]\"T@4,'5C,HT ZHG"\?DQS.GX8Y,[Z\^>/-Q]_?!%_>
MO/[T[N/YU_-/'^58,'9:$:N"WTN%XN$(_+N8- WY;F_#&#8*#([@(H=?D%73
M(**(&Q@8(Q&7 D=AF"=IQEQW$^G1D[M244$;A'>@P3BBGPK\'-@^U&MX-7$M
M/&5$MBAL&U:^PY^OX!#%@W /#CUT4M1X#)L5\E6\H\QCI3=Z/=0QD*>TF)1A
M)>O17@\3X"G@JS10/7#-^(2#+P47<T=V]L_3U[*3+V /02/3;AJO*6/F[6DX
MIX$JY0.!>K_3U5F!+& N;^"*<)VPOV$>,1>8]9/[1M<[S[%&2&DLDRL,ZRH_
M+4'#$"P#H,D$?Q@2]^=T7V5-Y^X:W67Q,IV-%*M37<)W9?RD/,G1177EQCB-
M*#_X:6-%[P<FP87B3EEG$SY4*WA)[0-I38;\L [L=("G).X>I^@WBX6%TDWM
M#@,B*+Z\W :TZU)Q'JI_8T56>KMCN"[I(QJ\UGWX8E!LE^ @$^>@N9?! OO(
M;0;9IZLBTB0!FTRP E2:(U8VL&#C$]6EF#83M"8^V&YFJOJD[71XA?>QC,Q\
MP[1:H >*TB-5H'J]M(!_1J'JAA'L(ZK)+3WX_@3I$<<X@(>![2;Z!M@5GAA?
M BL/$M@K<H7X5"060(4&S(NBG5G6A%VF6$R&026*J@"W7J9J)*HO FL[8J>Y
M9#SNO-E-V;"'S2_/FQ!W"#:,7CY&X[V(B1YX$YB0X0@^U1YH<DSL!?A149;0
MH:B1/W.2:/H^>A1%'2)VSX?A6)0.?\($U3"^W)%SC"!<A?J:EHOG*KL^\MEV
MJYCK-%Z%'QB.<;])'4LDE]F;8SR3,?GW(2T1?7X4=RLTCJ1D=(RG?=9M*9X#
M>J8!@AM9MR;D_!0G9^70";O."N_$HS_[Y:YCS>R-35GRD1IG^A?SCY>PF^-(
M37X)8^)@NNEE]84@0O4T!+V0_USZ%V#/DX\A]<7R9OGS'OVIEEKAOQWL[QVW
MYO^YN==:\V\'G<Y:=RY:[,E>LW7RK-?:WFL=KT>M+=K7]G+KN:'>_L;>AQ4N
M;;=^J F[B.^-J<>74U&0ATG/WIR_:MZ0U*MD;!]PKT_J6[U4BG?#]QE/I[D-
MN?NK??&SV[G6.JSXJ%4CQS>&N>:4%8$9+\'Z;*JXZ'9RMT4L0;FE^?WM=R5.
M6[EWGWOY5$.69RS/6'?/6$^Z'?+F, 3/MYYV9Y?AGGNJMMSX8LHE=W7=:LK-
M+99<\L/W&YVFGZ?Q]/"3EB0OA7$VC[R/L14_>37IU>0MU.3QR>;)D5>37DW>
MJYI\TC!W2WZQDSY:/6NTUJ&R+%3.$L^X,[?0+W([%WE'/C&IKB/*OV^T,)_-
MJ<*Z#^-OE1/S*1Z*G36AL)^H4?,$2=39:S\*B1[?,/'\L90('ZSIM'@1?C@1
M7G6BT[:(\!WY%D_%,OG"-7?WZC \,6S-947$C]3:< JU5K9#[H9$CZ_$/'\L
M)<'[7H(WFT+/5X*?68#D"W>+>6=JY9T[/%AS&(UWIAY,BYWLK7K2;(LWY1ED
M*1EN>QG><!*UCO8>)VCU^#+\S"(B#H2"]ZE6WKV#@R/O5&TVB5J'>ZNFT+;%
MJ_(,LI0,[_O0YH:3J'7@(R//(S)R5D?E\?[5Z@IM59O$NU</'NA]'!(]OCKS
M_+&<6^$E>+,IU/(5(UM<C?Z5D,Y*8+O']JJVKM6CT3E8TRG?F$X>3][YE0;M
MO>/-H^[CJT[/6G>A.5IKUK%XS;'YY.TT]U8U?9^%YG@.H!H?[Z2MSS?8+M"=
M)YTUXPX;HSL]>1>$_=9M1-INW>E9Z]8;VFXTC]:,=WC-L?GD/3A9V>IZ%IKC
M.82ZJG/F'MM=?8+"TUX5LV2#JP=6 S^8,9WU02 :MI2/'J=*Z0GQT7-P@K_<
M1A'[X=T/ J3VA*=W+Q\I.+Q=I.#IC[K?E&=XJ?52NZR7#O_U4GN[9Y"1\3.-
M[/GGMDW/>KUX1**=6RC##"M#$V?/3*39?3A,#9')<1K7[+&-/)<)T\(_T7,P
MS?/3'4S&=N8APXO;>_ON4L9): =S\;BT6\V#$F[9187X2^?@9EKOMHX?C=(T
MLO#0JH&'7T)UNUJ=/>+Z>;RW$AO!33IU1WBGP XQSL?FO\RZ$5_'?S5+"%(:
M0(D\:*8WTNS(L&='%LI41%C;UZ2;JM&D!Q?]')SI[VJD\Z'*DE@W@G<XXCO_
M6]W+7A_BOBVQV5/SG)%K=_?W9HP9ZX*TX .025I'G4?DD1_^&9R^XYF^0,TL
M\3NXW@[.&!7_2[ 3O@B&<*$5"!8$Y/=_A0/U7<5^N]=GV)T0MK<ZE;6RV=/:
M9X;>22CT*EK'U3:@VD"_)*CBZ-[?04.%F:?76O1ZZ8_\QSSRQ:A<Z80O8C \
MXTO=WPL^ 7/Q+%:5P34:?E11,-$JK8VGAN/8&H-@\.$X99P#RX-4O^/DU9"F
MLN)T:!XT#2Y V MUW M%1&7"-8-,Y^H;SYJM0E+7AK<VQ+2$9S<"L(N#.,F#
M"-[& [Y9#<NT;'P_CS>%)^ /9J2O,[N9)L["4TF_X*S@,"]HZJP[H!4G&^/O
MQN"$V<7#'7C+B(J6\>$)3SJ&?YNAZ>9KANI*P__T>1;W8*!9@97WXN^9'/R9
M@?Z.\Y)AJS0]B_8_2) T]*\>T@!/\!C'TM,LVX&Z2E)PHB:B(6'98*#)D/?_
MS]Z7/[>-'(W^*R@_.R57*"[!FU:R55K9ZT\I6_*3O$G>3U\-@2&)& 2X."0K
M?_WK[IG!19 B*%*\)I6U)!*8H^_NZ>F6[:&5W?4;BT.0?'\UOOC3(2X\C*<\
MTSF:2 <L_]BE=3+CSQA8,(*APS#FV.>:P<A.8)^C)GP".3H#2*&M%P=J.\_X
M&"8U<T\[K \Y6(L*;B-8/W;914/3D?UXA3$Y!QY!OR4*6;I2U(8:W[_&1DZ>
M(L60C[%!,>UN!OO^2>W1X?VWIJD:PU783;,F*';D4G=Y0W 33JTZK]O&*(:E
M<T7'M"P8  3@#Q[5YFSJ]#V;3Y'<1(-=M1Y@.@+,"!X'[!I7M_^\_HB__[#]
M1P]Q!VYCIAU\LB316UGXE #B@JR>D]A2VK2Z*)SG5%+2-!=;A6;>D@*^D;["
MAJ'OQM'B5^9Z;NU(J'=[91 1_TX"M9H9"-3S(8B^'^=L!(O]P-Q']A2^^26O
M[D"S90%8W+O8X:]_&P;PWG(\I)V/,U"0'](C'RA I#Y2/5P;C52IPAKH;Z/3
M%C\+?[_1JOKU536%?2JI:FGU9KQQD,@@?+*A&72M%UC%\G4Q<XE+#FXW2;=Y
MEUP[,6N37PV4Q=!U=,1B+=A=SESN@3&IH;>&.T;!GH#]U]7!GK6(K\RR7"7J
MN8: _1=W7;#* DWIZZ'JCH/O=7YI?'4L0,T,U!RO-[HUXS<^PVP[#=0UQ<?'
MV!\&CJ/AMR;\A$ 0 @(L.W1&"P<?^DA#1QP/V(W)'5IOP)61GZ?#5E*CFI=>
MP$OW7_Y-,DL[>R^3^8M.N!,JO1VY_D]F.5[-N'%&W':8I4^>MG$PNY*UOE34
M+,Y2T*+FY0>[RX1Z NBO3QC>]+0-OW8((&(/A^M7[AQ^VK[<<1);F@0)XSXX
M%J^>#/F,M;E(08AS,SJOBTH.8M6)\M3YJ5-]7D9]=/H;R!-=SZ=3=T['L]QR
MZ.#6L *PE**P>B)K?7T.GN?7K7-GKQ0^GW[.N!=F;BKM]5;$J:03P736"IN[
M\D,ZC?_L^W9HW/NN;9SQGS+3PV!3'\CVOX((*+]X.F-.@$?X%%-Q@/V]L8/Y
M\RP$NR]\OTD@[5-"N033F, 4(IA2@98F7<,\,291Q$D.S QL6P;;'%\0XUAR
MG,32>N3&+ Y V&'Z1>!/17Z',*AY>&$$_A-SHR?XX$E _1%S%WZ0!"T\:O,,
MQ\(<^<7 ;X[K1"J+AO\9.S,<\2)CCF.J"BTPD/D1!K,1%V)FF%'E[\ H=:,$
M)M'3#(4<P.2!!4_&D$>/G'NH*1Q\II#?HH0^R/":\>"C45^3&W9D4KY2 2!X
M !T@B.(@X)[U))/=1R[MMG0M@HHQQPG@7IF0ZR](H#\T2GX$O+SM]!I) @X"
MZ&VWT4X^>/D%!J#.]/["VU8R= V)K?M.9%LES^"*2O+>1999/AL5_P+D<,H@
M"VCXRZD?8Y8/K W>;G95XE.2RYK, Y0EZ ZGXP^.'X<X7Y(=E>:;X6LJU2L[
M?8$PB3%$,I6:)%R<*B5-H#RC N<X\IY*"H("YR24CUP&*P]#V#HFL;E,Y.,E
MKEU^;.3NL/QP+0_5!4M"48<;1=XCH&:G7#E=K30%[4C9[=J3Q/?;7]AT=O'%
MN/:L.M&WY\-2'9$NN""M#Q 11C"OJR27-,*%(88&F0N6B6$QH"_*\\)G$%")
M$<UF(>(!'_WJN S8[1HL@R>E#8 SB9HP%1&,?9DB*DWN_-0VBY@!5FP8AT1<
ML':+0C:D-#Q8T!1)),M'83R<.I&DCMS^B=Y@76JG=>,WRF:%>;+/H5]D]BYP
M191$Z!K_PT$Y3&AO]VS$ 5B7\/$3++X&FR2XVAR>G5+^*,T!D TE1=J.37FK
M3*2"BNQ/&@7 "4HJV02F)WI/!)LHS.1G>D)8IGFO@#D4<P@,PXNG0X$TUX_R
MH:RKN53/1P?6)3(D\UFA,D.R;OP/J.0'9!8_%OF2()>'L6>K!5HL3K39HQ_\
M0$;%486^P^1*$!]X%IX2FF\_R<3<<(881U$VD1"-HPGH=:%X<[C"?&/,L64$
M4GC]%S^0N:V8)8EICV2+\#2AE9)[13*SA%0*&P%[;@L@94TA(=YP&P"8M_)6
MMM) 2V22T%9&YDF5ZUDA+;9N_!X'>$T!A!/ PX_'DW)2_ SC> \P%]@J]X":
MB7'% @R2L82I,NG9<G.X+@ 2DCO8(<"K4Y[H+I%F*GG.0^<6Z;>FW.0L%-D#
M R8>BDG@?9*WA%I,605XN*0TDBF9H''B_'1UEA^[@@]^<#XSXID@&[F0QXD#
MQ.CQ,1.Z.TUK1EI-[]80E2E<)CBD;3B(RW&U3%Y P*7DU<A!.W".!@,^!?_?
M%L\D(I)L9F322Z1X_/Y>??4%)!H11PHFYHFK* 6IFNBEQXF/^/<5*S%,>89A
M<!,A!_JV4>%FG@<Z$-6S;2X%;WYL2MT/.(KX;!IQ 2.4PTP)UO#;*!9C*B2"
M#(?GHJ=3LDA+XDOY")$LXR1,J^:@WA+7;>$W<_/7;1OUYOQUVP.);%0,!]QS
M$*)XQ>,S'KZ PJ4@M@WJ%&.!)!*,;<1#]H@<[S^3Y+FDRPZXSWE/_X/!IS/7
M?^*<;H3 4]*Q#$,?'7 @-!(?:313N-,$V1&H"M!;-="28^;BO1HR.X2.X-;$
M@WV.@0@G,6P%"1/DKE)S0GJQ/#Y&L2=N'%PD]@;HI1!%$DTA0[;BW@^J6(8.
M-+D"%PE;P<^I3VM0V[Z@<"N8!\(-\BTKGF7?+(8;+#\ Y88&Q_)00^8RH*2O
MPGYH?.$09N\\T6V;Q/^XYV KT]SGR@7!H:Z_W29_TSA2GZ&%3"R-ZX!IQ7=
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M=.*6FX(2=9NO 8F=1/G%.6*G=JAMLU%LA]I.RU5D;D0@Z7GG5-8U1W54Z#+
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MEF:?'<//0/0!4BW/1,=Q\A*FSD\<C;/ H]J@X)']!ZRYT':LY"Q.^$FJG'Q
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MYN##((^J03S-OZ]]CGBB[/OZIQ$[W?SW7 'E;81#GGMO8;6%H[[+5FWS^\U
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M$2"#A3TXEG1&E61QN1<:%DHJ2JS YU!UNC(CQ6*SE>RU.>D%LPNAA4).C.6
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M/V@N5PU7+)P (X>4R"2V?8D7BJ6%?D77FK%RJ/CNH[H9C/#\G?/P2.D94/]
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M)R0AD'AMG#3 PT@@"B(:84VHHD$B"2&2!8&POI+MI,5[U+<1_&L3NPSC$."
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M^9A.O1]@B<RS>-Z4Q(19 $#L1N+H=>0*X1 \H<@&E8&\G.%3Q9#YL>F>2KG
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M(ZG5:.T.1:?@)FU(;W!1SO0%&N,9>VM%\T*6$&L!QFT_QH)DA0+YIWX?>A,
MVF^1 7*]MV:,?7,P.HSB )I;-+?4!N;+\@TUMVAN.15N.6M5R*;:&S8A._87
M*K7ZZY[7KJ41R^HNEE>SO4WN&ES.I_0<5>7PE:]:B)+@W4;%;C54^QF["+-
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M#@:?GM\F:NMH,WMXHSU6F@-,UP!&B %/30S._WJO*'NEB;!O#O5@8P%\:^8
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M6?BY-@9960)6;2R<ZU>?FB><@ 'V+1A(P$/CY,Y//Y[8TM[;0MXPRK-H7FX
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M_W1D[>*DP<T M9W/>1(XVN]:KCL#VJZI[EF.LVWO]T2?4PU\[7W :WWE]=0
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MZ,TJ^6EA,"#F37I;R3A-"+>#P;!4'%/"\UX,/]MG/KS'1O/7]YD/.X!IU]8
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MC^R"3=$JT0$[=* 'Z12BE/Q7\N5:Y9 *;)1,1[AUQ4:S7K&77 ZD A/<N./
M(]Y,/])H[WIEYY<LM (3+;A_Z_K(WJ=O21X"%8RPN)JAATO.JYP/%>!6Q98F
MT+"$IV2@,977#WPX:OK\!CU=M=V >@PF/IY^2).50XY(#7DJ?+3!8 07O,\$
MF_\#.\R\= /J79Z!*,.H0'.K;\0#)8<H'@5T!F6Y<%@OY_X<V0MB;DRN1(GN
MA$J!/=H9]!\83YA-%^7,2^\!YW^NP%2*:VWD0\W5<"@PZ3R--IY3[,%# ]"
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M![#QN8*;?"[WF_A/L5:^N$%SXSG==^/Q-5JM,^]749%SUA(\3:AV Z/@"=?
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MMCB+D1-!P>B LQ6$QMGR%HS7W!!OK.2UEV<[(^G2AE*=IPLO('9+AM87=2D
M/TQQ'NQ;JJ%,GD)>N'U^<+-2JIZ[)*T$%@WZ)Q[UE%&&@\].&Y(48V);BF#3
ML71J2]H9N[?*B&T84.M9@5DQH8("F;4'D00!7)X:<$A,A.3QG]JT;M7VWR@W
M*ABN&&\ZEY90#<\S6)?0#$E!6F6)EM)6GHQN9I_ODF4OY:^O()_MFHE,44U<
M9!"I0636:$#?"@=(%$UH14>5:R>/U>K3L;W(]>YPJKI,=W=2N'?VV[NCDS^J
MGA#>?F;K)X.+T=>KDE(*.*,"^=+'3WMS_7%2@C5O[^SWT([],NO(QR)'U1(%
M!(I6ABCQ>1:5#00OA1;E2-K4OGY:'EW%'<Y%EY72!))K;);HP1E13!C&?$[6
M2%H["K2;.UQ+W'AA\UIEZBN674,5%_IN[K#=#WSO"<-CB"R!5:6F,;6E"V6I
M&&*RUID'DDCM.*P7X'1IJ]H2.6H)IU[H^(/TB7?]H1N&FRC5DL33G\QZ!/6(
MBNAY\=+]0S,0I4VC%=Q :47L%$/_K'X3CB6Q=2F;:DL\:D5L;><C$,VBXZ6'
MD#5HT)?.C08M.9"1*F8B3:EZX9'U\Q&V%>6Q+<)L+I(=)SKY;!C)F4,V'M4C
MXPP<R:G41F1!Z&32XQCBGS?1J672;$]053CUYFK2'S99I!<>-6&9OUF@RJ>"
M:H3.7IP'J^R-QPY?+6@G"!>_Q5%<%$UYDI_[DS+(,MF]Y%WV"IW#3!T%48ZY
MK;,)J J6&\J,37P) FX';9=2KK; U@Y2H$Z*\F P^HI[>RJW,C<Q=S=]&^]Z
MTS3)1K/>)646<Z)*1$F!$ER&0J4 -OB(7+1$"HLC6"X'>9V'=RG!:PO$:U]
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MG94*:C<U:\Z^NDM4P,Y;KHP![7 .A,^I]#K'[[C/)F8JDGMD=RT,L5KN:3]
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MH=W=]!LN@4DN* \LN&0"S5J:VL<(W\/4+6NF.G^>E+6O*:**NUU,^7ED3Z>
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MZ52.#@A7<A868B(SP 4C(=/ 7*B=Y;,>TB[=D'2(;BL+<7>$:V(O(Q?)*!^
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M&Y\,_2@5[VD^N\)][=?V1HN/1,]J<N'871G=A:&ET5 ;\-W1B!R$0D?/:$L
M-W$?B929!/=(F-T5MF?.MIU0V5T*BDTH6##\.1R-#L^^NN%TX1!.9K./D_GA
MN"REO"R+I5W]?/_434_2;""T-JGX\9E&?&_0F0?O,P6=A0G>H[>H20.>/1G
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M\MD3I%NUW%-FM''EZ@W$ V>]L\R%8JAP[1S1V)PR($ N(W&6T-K>R T +XL
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MOVS2;4&['30R+%:Q?%W>+GKM/J7I<!+_X4;GZ6/Z<_&3V<!XJ@R7 H1C^$?
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M<._#X<=R+K+\]J+GUXWCAZ'SPQ$^OYRAN5)&%MW\G1M.RWR.-!F[SZED"%$
M;]QLN,%%%7VBJW2$M36!WCKP$EIY*KA")C*A4_:&HURI)5GG*!P?] ET,Y_F
M\O.7,/;NA7$TOGPT_L+'R7AZ \E5/*J4I30Q#8I3? \-QS=2F0 Z&I\E5TJ2
M1A<FM?"#JBY@4P]QB>$2TE4IZ)Z?+6X1'S@N*,9**!>C&<9/Y<HTJR)DIFE0
M3D8A&UV^W4)"CX+J?[_8'NMN.Y=U-=;! =Z^FYWB\LM_#OY]/OSF1HNS@;N
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M9N=!;;339^J_":[7?![42F]-SP">(O0^29&-UKP$<]:J4@HJ SB"H9[W@;+
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M.?/#I4U<H]\+T#]6D$N OD V$-%3*JD '77QH<O4S.PS4&=MT+&,3JV]G52
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M0W&-B> :=3*@B,PB^!B3K1WAKX'RLOE00_Z50_E/;CH?I^GGM)Q+.3L=?KU
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MH'2BE#*62?7I('= ;+P)GGUUPVDY2SVZTZ.U=&1'Y44=^.R#(0X-=? 4_\!
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M-2H606O&E7#*&I5M&&H1KP5T/'K?7=X#D%4_T-W2*I.2**::*"<'CMPIH$B
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MUUP@VF:,#C63QM9+F.!9S/4F1JFD38XJ;ZSA:F\V-]">^J:JA5Y[&<YV2AG
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MB()K:)Y4T'0&>\MT.81-]PF5?RC7?SM._+>?ZS]@$9MF<(X7I9F1H=;"4CP
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M+OMV,O]8]?"F+ 0TM"!#+C KY!@P[:)D/EM'"RXEB>S(8VA=7;-7J#.TC;9
MW+>4<*RE_#*=X>3R^MGM;%9I$3_,X'H."WK/*GJ5_"F23K F +,NMO <F+%
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M-;,L6HH9=*Q)9IU2[:SW"H6Q'INS"QPE\5B5 P]B?R."^= U!]4A^L;R\/W
M@JN%E^N\5%$+RQRO2A0N,&]X99R4+H /QG:K8MKCZ6\5X.$)TH<W@&EK(!K'
M@<NVV1]%6KK+781JF /8*LCX.8!&0$V'TO)H)H#D!,MB@64!@FEO.?/*&693
MDA0*6U'66_L? _0[4@%C(M]'N8TS K^3&C$O%CN'Z_SV%F<WTW>3-%TU;W"?
MH/)*(]0=3I%HH1+9VH+"QL2C3EW85O:\9MR\0",@IL-HL:'/FFK_U>SKQ;/7
M%SX990(B*T$$IHM'!MPH9H"#PN)R2KO( N:8_O5R^N7?ED^\^X27?_C^!7]_
MWV,&]$"M-?PPOTGPA+Q;+;PNP*Q(IC+T)UJ 34QQ$!0)10#<-9N\)VY/S@*W
M?EIK6$^QDN#MJXNDD)ND/:LI08I28V3>T;<O@I').@U:[2K?[8?;VU?G@%M/
MK36\ 5M)\-O?:0&Z\"PMX^2]TP)\C28=D,XSYRI+'<,N/Z<?;K_]_1QPZZFU
MAM0X*PE^>7<A*>07E;!=1!)#%ZN9+X8S9PS0;[((8E?6LQ]NO[P[!]QZ:NT^
M;N98W/[R]J*V*T9?R"D"6WG,4#*0Y%8;([A4JHZZV%5,T ^WO[P]!]QZ:NT^
M;O98W)Z_N* 8IZ!RGOE4I\3)XEA(N3".3@9'/\QI%UER/]R>OS@'W'IJ[3YN
M[EC<?GUZD2P:G4UF]0J4%D!N;5 JLX3)&ATBF+)K,F(_W'Y]>@ZX]=3:?=S\
ML;B]^_V"Q R@C6,I+,C-5&$45%($&2D\ 3I?%;;#[=WOYX!;3ZW=QRT<B]N+
M]Q>VEFXFI9C+05+D#_3M"TX1I/$%445MPJX2V'ZXO7A_#KCUU-J&N/OHA,G+
M#Q<%'=@0(HF CFG+ [FTDC,E(/%L+?#<[H-[^>$<@.NIM0W '9TQ^>N[BY*3
MYDJ2,[2@@02HN38RH&Q5BMDDFU5J!MQ?SR(2Z*FU#< =Q<JTX)U9<$7-)M^(
M9Z3GEO[#.C>M3A@7GBPI!>9 JY =Q9G8A8UVT[,?,V1-]+4!0#5:^=F?:RQ;
M5IUM?O)@Q68=%K).V5.*]:YH;N@(DU)3= V%6R&E$0EQ$V7/YI<<5\+RXOIF
M<O/UOR89EY?>?WK)JV^5%3Y[Q3$KYGV=+AID9E$HPQ+XQ$OFUB6_8R<]I%:E
MHVB#,KK8(!1P22Z^J$D1J24++I&SG] $X] &NROE_O@978:PCU[$+GT0&+3$
MZYXFGG[]\P?Y].L[_#R=W4RN+U<34^XJ0XITEJ153$"@2+\(S4(A1XC<([ J
M)&5XZ]:W!F*/5>PUAH6-C>)#%WAU;C9,CM1GDV4@,))2*YN6%8H5%WW !$*O
M3X$]VX[OT6VD;V-X'ZP>HL.WBWS_; P_&-&^K;Z'P/$09I-#(8\7 O/6U?R.
MI=]E$5D [JV2Z'/H-+KBY,WEV,;P0:VE#PJ#-X9;B25[)VI-% D3/9 PBH+8
MG &4D!G6&6H>;6-X+[WO; SOH[1QR&6^\2Q9$$8:6PBB!&2YW+'HM6?)&:FB
M,<(TGZ9Z@OQU)^A@'(30&*0S/_ Q=1'MGS1W/2'L069VB/Y'IKES+LKB$S)5
M*"K4$2WSB,BBDP"!VYJX?NRF<03-W5"6T4?M0UC$<K?<QK9&AU\20=9)+YK$
MJX=LS''!A)\" '#;GC5UMT@GX'\<"M^Z6334_? L-=:9 #XY)E,EA^8<&"CC
MF'!">1,EWALP^LA9:A[*U6B@_]'(;+H(]=.0V?1"J!.SR2'J'8_,)F)T25N6
MC"/;KK-H:"/4=")"M+'0+MCM:#@MS/N1V;2'O(]6&^<0GI 4D_GT=I;P*<XN
M\?K9=$:[VN)86EV*)Z=\+4)!G@2MUQ3FE4[,&XT^"JES[%)$L/]-)T-LTP>.
MZ6"Z;'B\5^E^2W_%^7RZ0:@4<[*6_-J<R,/52 XO>1^.F9R\M"&"Y[P#P%M?
M\-AQ;:.YUBQ4,,N3:[CZCT6)Q<OKM+(P X7+PIERHF:SDB'G5&IF(0GR5TDB
MWV4RUY;'/W8H6VAM:QJG?=W/[T_?O_C;[R]>?WCQG_3+^N2I0^I]]CRQ59U/
M'\'7ZWLHAO(%,%$DI34XP%H/66J]N.$0R\6^AQ]9MW ;Y_B_M^3.OR"W_^;5
M]Z$K20K#R41LJ"8G/="W'FTE)LW D^9%8!?7IT\QPA99CAZZ0^?4EX7.7D\K
MP'#UY%.MA+O0.@@/.;*")=:D.C*0M+.%4(SG@!EC\TEC6V1Y@(GW+9"_-VZG
MA:J'*,_Y\V+O(E>?0@RADN^%VH&HZHC";!UMK5Y85RLM0^LQ7)OD&*N 9A#
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M'5XM;ESF'R>?%]^ #YZ\INQ8*"HSK9UB$')AF:,H,61RJUKG'PZ3]*S=CL9
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M5<X')>AG&;J,9%Y_[GB'Y'':G392S=;3;TO9^_+']9<(<_SW?_E_4$L#!!0
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M,$X(\I.4\#0F-O-_H!QS(XF-&FH+D&\5@4NEB?S%1I76_<:./(8.E1G#3#
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M(9RCO<R-8AHAP5;*@=%KQQ$U(YB+<1J94NPALB:,7@@<4<3Q/B8EA5XUG]-
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MN?.;8P=XC$PDS0F@$A%LP] ';&Y/062^?74 U60Q#FWZS.I98@-0D&6[LZG
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M:/K<0+T*'TWVT__&P-#TDC_@G+66[O6J*7O49*S?7+FAD% _8PP27]U;\%C
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M4NT#[\0T(H[34'93A16 AO:KS;$QJEO4J?\%]8F.MSM:':).M=KUAKH?[!G
MI/;TRHN\ZIR*9T7%%7DN![:L@?[A;??('7Y3/YK_P#F[_N=&^I6[&I=%>2GN
M\1EGMZ]EZJ<_91,J9] =S],56[B.1V(/):K,I N1$R204,1AF C,.:<HB<P"
MGT82?&H$5$K'F?GQTN@CKF?[3'$<AS[(4OK4Z0W:2H.6UF7MH]9SM>:@5'T&
M*N5;!8*+^O+Q6NH/:@!FH() I5^K0+ 8W#7RL-D*"AM+['&#R48>C(,@M+'[
M[[?6'4M5<?_PK<DT[3I)PMT ^I%TBY&7>#!)F M%G'A^0,,@3KC) M79V]16
M%2F88>VG;C#UN-\:1 ,3]HD<-+\IU'X?H R4%BZ6&+&[KU%I3$OM]]RC]Y+Y
M"<=G_H27!5]+D[MD)IRQG)?9'P3GQ<)APO<CE\+(IYYD"X9A@A,7QB&*D?1]
M(Z*?BJR[JZE112DM>,%KU5F9$[86%BAI]3?BSP!\_C##'FP#TT>%6$O2X5#3
M/[BPA]Y(1Q87H&AT9J$'3,=IQ9D&1CNGT%.D?4*A^4;?JP.9NIZ0EY_)?5K\
MX\/;!Y[1YQ><_Z/< /,"2AAU&93F%H&(X0 2%@40)8+&A(G(<9") 7:NPZD1
MZYZ\0 D,MO+V.IPXB[B>E683QX&9]A((>X3:Z^%B+9;^3'<C!\OK*7\8#:_Y
MGKG%]I&3]<Z5G"_EG,TD=ZE8F":6\2-^*^ZD)YD_KIKLMNP+7F_RT@N]_DEY
M4=P*^41&TU>\+.^/KA_E !;/JR5;A+$J141"&+D1AM+0BV'"!8,18W'H.9R$
MB780XN#23HW>MBH"^>?+#&3;D'HF]02O2E%U1:9H5%4V9JFKVK_BI;;JZ==&
MWZ:,P;K16-^*&OY3.6^^3NH#&/K86.K:VJR<@=W'\%A^#+NH<:4S*)4&CZMM
M2G &&KUE,Z#27#V]U1U4RH/'*7X,^E;YI#Z*D0S[*7T<1I[":(/5X6P,+\-H
M_LIH<+9=GO$Z[><U?2OXK;@NUJE<#*5_[R:Q[Q$'J8187%H@CK1 $H=!AW@N
M\CQ&0C\P\9'VFY^:R2"E4RO^5CXS]^<=='K.3G] !EY"WV,Q W>K94K?P%_U
MGX-4"C\.AR6/YEWCH_HOQQ5[[ZV<>*KG!@@NGN<94W^H<Z_O>*GV6([4%U\(
M/\9QX$4P<:5W@1+N0X(C IDO/1#L,_FQF.V$Z/8\-0)0$@.^$]EP_T,;<,V-
MD"%@''I'1"&H-DK+O[3$G@$E."@E!SO1+6Z/F*)E:Y]$N]]Q-TQ,X3C8.3%N
MH!]-=24W;Q(7W*D<OZML/W_!'59)/^=$&E.8KA<,4Z%*C4(O#C%$(640>]2!
MV FHAP5RA*-U0F99KJE17!6V0_<2BORV+(L%I#T*--@:/3U&_ 5C,C!?GBWA
ML)_?I5;N(,]+I1_XJ]'0HDEF&7-+K&M+JE$YV3*4[QG;=O-]TZ9_EXVM\K=[
M_$.ZK3Q/\;)81 E%/!8)Q$0@B'@80A6>"VD2.B3 6"3(-\N:?J27J7&ME$UM
M*E?"F69./X:B'DM>C,W G+>5;P840EL15?RH_%1M9D_O ,):\O1C?8R<.[U#
MS</4Z5T/]ZP=TQB%7SA6%J':VOK/=/W\+5N1@N??%<O<9*^;=7'/E4[I,BWW
M>-4_-WF>9D\?<)$6GU-,RMOC95N+.'8YB0(!$8ZD5XHB!..$$B@")#G$9YY/
MZ.*U#-1\6.-\K4<<@\AJ,KG>2SS<//M0%;N> <*?TJRLG*W.L[HCLT<<8((D
M*@[%,/%)!!%598,<G\KQ3I 3$A)Z$:\'^#IC_U;#V\@[PN!RZ6Q/:ECU%JE?
M/E #+W*[W8X9:*D(?D@=05M)4&D)]M6<@:V>H%1T!K:J5LU:+&HTY%#8JGDT
MB(SCED0:$N:#BDF#=M;S[M]&=OW/C93D6MD@A:'S?^KU"4WZG8B@DG$0C_P<
M$+;N+IWJ9MR[1F>4/;@;=.YY2]&DN^S7[B*(>,21B&$@!)&6*DX@(4X"(^P1
MGS,OB#VCJSQ=G4W-Q]T/@<Q5".3K5MH+XT?;&&L>F5A";NA3DH.XT7;&_ %#
M1H_ ,52X:+NK7QLJ>D3ILV&BQ]X9^<;[R828F_7S*D__Q=DB9DD<JW@,7.;7
MH8$/L20<&$4X$(X;\P0;$<^ LDZ-M\;(L#S&)Z!I.TUC8(<VORZ_Z+[[+(ZD
M$][J/(%[[?H#\ZNOLFM(^N]Q>UT?<FL7U@VZ['M:0W/I(?*/O/KS)IO3LCA@
M4=?6G&=,_B3?<-;X@BDO%H@D@L24P9"%:F\619#@A,(@=IS$%_)_Q.BPO9\8
M4UM3&IG!:U,0%E<REQ$QJ_*H=[D3W_1$J-=(Z1X9#8W_X&=*E>#@MT8%%<\
MMB-2JU$.1*T(^*PQ%#W.G"Y!TMJA5"\A1CZUN@2HPV.MBUKK39ZK%_Z(?^Z"
MH514;!D4NP@8"=R04$AB(B *U:8 CB+('!]33$3BF&T*='4V-2*\^7IU^^4:
M/,[_O^L'8Y8[#:DVEUD!:GC&4E$^4LY6."3X:Y"P:AU([%'/Z:[&)IBS2A^A
MD?/OF%\5O>>O*NXF>U+I0FY>7G&:*Q/OD1?K)MJ[#+3\M%S]*%37BKGNY4\7
MV)/L0;@'14!\B!@-(8Z"&+HQ<H@3>MC5JTA^D113HY>M(F C-9F!=*L+6$ME
M9H WZ@"JPI"%4F@&6*T2R.6O]._K]1^\;KX:;4@&)K+=:'PK1V.G!G@L1V.K
M2144_JD:C48;<#_2:.C?BAQE5$:Z[3CHZ!A=7[P8U8YKB?W;'NVZX<7JMZ\1
M7MY8SX3OG*S_DZ=/S[+]^7>>XR?>% XLYU@4AM+F=4+(,<(0.;XJFQ3'4%#B
ML!@)QPLCHX3OW?U-;6%J1 6XDG5;'M5@R=&%6L\8M@C@P,N(DG0&M@C6PFY+
MEEHB(D-<;*5Z/]/;N*G>]50_2/6N^5I_8MG=BZ[2;Z:TW@I=J/CP +L"AIA+
M7]H//(A]]4\'AP+%B7"QT07%SMZF1BK_L<&Y[&>I\I(4:[Q<EHOW:R6LX29B
M-\SZE&(%O!$(92_/0R-J<^9CETW.0F*12T[W-3J3G%7[&(^<?ZEGE$[.6;K>
M%B%;O> T6X0$>WX881B'+I$VB>=#$CL(^F&"/!PQ(K#16<6Q3J;&&96,NU)X
M?U5BFB9T.P:G'DE<"M+ W&",CWGH30< MD)NCG4Q;JA-AY('(39=SYIOJ?U-
M6B++M\_I/S<I4W=:BG6Y'#:)4NJ: )'O<B]R(LC=.( H<C%, NF/4(Z$&SK2
M?- [I]3N<6I$4 D-EJ74TH#8BCW;I3NKK@Z WU8Y6/+"I'RXWB"<WP:S#NW
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MJ#4"E4K5<Y52,Z.RAG9&2=^B&W6T1K+Y1ADU(]/0&LH=QN/E?8QF7EJ#HVV
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MM?PVNU?IRW/)QQ]PD1;?LA51M[Q5NJ";['6SWK]=\\A_KC](@/ZQ""(G87'
M(8I)(IW;)($)#1GDKALB[(:QXQLYMT,(.352?:#/G&VJH)Q\3V3U$]J$I*W5
M7XN4\3IE]XHLZZWF KS4D  5.J :J6 !1.$"-H7Z>Y$^9:E(J2HDL&E!)0TI
MB54!?E.IZI? -PRL&N0STF3_7_QQ#+TT2/6JI*8ST-(0?&D-]E9)4&HY VT]
M0:GHN[N/X*_'\G=*8U"J;-%4'G)$;"TP0X@X[NHS(,@'2].0??7-+9T]J0H;
MJO;&%[S>Y*50]_P5OY6Q4K?B3HI$TU>\O,G48OE)+JR+)/ 8#BB"3H@\E3N$
MPP2Y$?29AP5#+'(]WRS?= \IIK;RR,D1F6:>[@.^'IT/#NG ?*WDATH!H#28
M@5J'M]I<5]+:S$Y] 5C6,E;WD6'D+-87P'28V?J2QOJQW3U723\XN\9Y)HFV
M.;A(?!H1CU/H)7$,D8MB&!/A0APA[#"/^H12$SH[WLW4^.I].4;C#*\GT-3C
MI\LQ&IB &@%!(^$ 1SO=(%@BEA.=C,H<W8J^IX8S3_>\,525XI4$HS8!LJ>;
M3*SRE]*8^KS-94 "%R?2LX:.P*XT;)P08B;MG(#'*!$T"(0P8@*=3J?&"TWE
MZ+P16OJT6ZD-[PGI8*['%[:1')@]&A"W\H*6P /EC3"!R-8E()TNQ[W\8P#"
MP:4?DW?-(PZ_I$M>K%<9OZM,G/LJ*]GCZJI*1E;'T-3+*/%#Q.-$$A!7":@I
M"2&)?01=Q\$LP"A("-,-/33J>6I\M!4>U-*#6GSPN *U DWDEWXHG=E@='/4
MH! /3%0FZ/:(6#2#63]T<3"X1XIAM N[431C+^@ZPAK-VALMOK&7FNU QWX-
M]#-.F[1$VSYVH>\/?+U>EL7E%DZ G=CQB%P(E)_J8:(2?:I=.">2JX4?>R%I
MKGT^ZANI6IUKS:']ZYZ/(RP..U%;\8YRR58+DYFMJC<$>L:J/41'S#92YS2[
MW^5*;8&[$]N>O6J$DB6#5:_/42U6(QC>FZQF+_<\(]@U*9?%3=$D$">4.]AC
MTE?V*$0$<1@G<0 I"G$4"#\.N):!VMW-U*S1]IPHQ>Q9/N4$J)J;^Q=#-?3N
MO3E*YIOVG2#8VI4_WLFXV^Z=BA[LJW<_W:/\RNWCU1W/2U=8ROL!%YS=2\LH
M3U4L59DBXUN6;F\!)!&C24(P#+D0$#$10T(2!(/$18&3<":M%.UJ+$9=3XTJ
ME/3@=2<^)$I^</_PS:1@BQGZYQW5X3 =>D->P=F2''ZHX-S*7B7A :7T?>J[
MF"%M4.YE,,3'JOYB%WFS<C"]P.NJ#F/6X'C%8GHINE<[IE\+_8S"J]7+BUIB
M9*/-A!!)PCQ)_ %21<@5^\<A2V#$"6)^'$?2=S6Q!P]ZF!J_5P+6F;[,K+]#
M]/0,OXLP&9B?&SA**K!_5GI2=4N6WF'[HQIY)]5[;]^=?M#<M'O@6;K*OZ[6
MO B\X..&_[\XV^#\S7-\I_XN!?9$R$(',BHX1!YB*BR"0NRR(/&Y)X) .P/"
M^>ZF-L6#/[S@?X!*;E *#J38H)8;*,'U#0P-M,^;;W8Q'/P4= ?<#)1@S@X
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M;%[49<I:='5&^=H(KX*7I/1@_8S7@,J92#C(:U7,:.SBD=1CN3''9V 25*J
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M(PY)0 7$-!&!&Q/JA5H>>D<?4[/+&S%!)2=0@H)24CU>Z8*SFZ(M@30P(??
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ML101Y+6,^GNTQZ [OZE](2 #4U*%12->CXWK8Z#H[U5?",Y(V].F(!GM1W=
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MI@7$R;QE>F_WC-CC2_G;IS]Y)AM>E@6O7B0-JFC M23"ZY^OTL/B"TX"EM
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M^'7E 6\//:ZO^QVF]KS:[SW3L^O/P3#YWTBVU+?XGX54S^CD%S^4A*2Q!WG
M)$0B"91>2#F,0L08$H1$-+)JZ&,^]]0$09/=(G[6S9BW=0 L^^Q8P&\F! 8"
M=6 9T9DMI G?YA71DGJWZ4$],'/5SL9BYG$[U=A#LM>$IL<0_838K5AG>5EZ
MXT9]J^[5(%]63VJ.N1])'Z-8P"@.,401(9"&<0)]1$2:"$:)M+J%.S31U,33
MCDZ@"06:4O!'1:ME)["#V)J)(Q>(#2Q[^H%E+62.(>%(HAR<9E3Q<8S9M[+B
MZ/,]VZ.4P=9WRG 655!BU9&Y_@9'%',1IQ@*S"*ESX@ 8JK;G*8R]5(<4N%;
MI6MWSC8U$5%G'&RI!0VY/>5$-]1FPL(9@ -+C!.PLV]W8H*)JR8GG7.-V]K$
MA.V]AB9&+YW8'M6P1[-ZX&JE2WFW6NU]RY;B4M%6S 6G/ @$A@FCI8N=0BJ)
M^H<'/-31S6D<]^J-ZH*ZJ8FJWOW7]5-M-IN&[)I34++:MRVJDR\!479SZ D.
M.2(I1-@C,,4408]($>H )X;Q_(?(Z6KR7X,VE?__BV#[13"T[#]J<8>V_3]B
M5?OWQ76)ONNFN$YH^YB.N"YA/=@.U^DD]G?QVN=QOEKJUNW:(Z(4E9=K>?;\
MG*]^D,5-&=8XQYZ4B 4A)))H4R1E$#.JS).(">+YOA]X1OW0#.>;VEFO:=2Q
M]*2F<F95.]44Y./WZ8ZA&UB$EMU_6^3.0(GCM01G6QQO!L#1_(+<,9XCW8@[
MP-7J MP"I8X;;Y-11KOBMF"I?:=M\]JI05&E?+][S@51A\#?2)[IC/Q;941>
M2OWOU6I]5C"1KY41J?\RIT&0(!(R*+'6VWUEQF&21#"(4N%[&,=8&-=L/8F2
MJ0GOAF(=(:64N4R6/P =*$7:=(-/1.EX6K+K'H&]0Z=LU^VXU!]M-08^#_8B
M>2K-N.(%7"_!=J5NRY6ZE.4/9?_R5SR-M31](ZT&7**/"KIROE0GA&#UA-<X
M&LMV_ \*S.H)P^$8K;X#]NV:VJ<[O;ZDG:=">@EFNN6+G^C6J1)2+!&,:4J%
M'P4RQEZ/<EG]*3+:P>/7S2I#%')153)9KUK-(*R[H_9>*S,OTL#0CW6^-4RT
M1&=1RL0='TKG #4G[:=F93R)RVZIIP+JK&5J;T)&[IMZ*F#[S5-/'M%.LG*1
MS<_4(%P/]'5!'N8X%2+R)(7"#Q$LK0., V48Q+XN3R.%#*2)3; W\M1T_"UQ
M0%-G)MSVX>J652>!,+#H,>3?6(P<Y/4=J5 (]NO#ZL>_JG<J@:!^V,F!_9%&
MV=8'&6AVZ>$'>M[$9LML+;ZIW<XOE7J^?-"MD$O/[O="R,WB6R;%W).$!CSR
ME%$>28A8&,-4!#$DH0@#SX\8]8UL=)M)I[95*YK!0A.MZW765-?=06=@4U*N
M_BX-[3RK%3"\U'*,Z]!W526YL*07[ BN[JUFH*(9?.M"U/[FR0(B5Q=*)E..
M>T]D <+>]8_-N[T+$>N^43?YZD?&!?_\HD96DUTN?XA"^S#/F-).RNNF>8RY
ME\9I "-?A+IV7:B$DLZ<1W$@?!%$G$J;MGOF4UO)IQ%Z[.G"MV43/26(M(!2
M_U_3#,B6:.OZPJ;K8":?AD%W8"FE@2U;VS5D _H"/GVO4/X%;(D'9\=A[E-+
MV!(Q=T6$32<>NWJP)2#OE VV':&OIZCMI?JJOEUG3[HPW!S[U!.Z0UT4DP0B
M(1DD*8N@[TGN1=C'@F,;=>K01%-3H6[R;,FR9[( I*3/UIES $Y35\WI((U]
MT:"I!&?=6/5PL70#X<R!<F":D=TCW<SN.S^./&\G"LI"D/G+_-]OYS%+O20,
M=3T?RB#"<01Q6-:P2V5,0BD";!2DNAMR:MO[;K59/X)_7^6"F.WL%CK=>[@?
MSP/OUG^_OKTXFX';BYOOG[]=GH/KKZ?OT7U&.QP7]</59JQ_V>W#UE"C[+A]
MTIN]]<Y?>M:P?AW&<"7^/%^0[*GXFBT$O]J4R=VI9)$GO1"*%*MMEBC3(-7_
MA#3T/(]@XC.CEE 6<TYM'U94Z;BO8I.M"R UJ99EK0V0#M/02[PP@"BDL2YH
MF"BK2S<Y2'R&8L(Y3JE=P+5CK,<)H]ZA_;Q95[<H1+&@3A!=Y69!B@)4>9J#
M+829_N,8W(&%ZWZLF"(85!2#DF3U24FTP^+CY@BYJD)N,..XY<C-(=BK2V[Q
MJOL^L]N>HBPB)))<PC35S0P(#6&*O!0F81J3.,;"9XF-0\ADTJFY@JJ&HNQ5
M0]%/B[(94M6.REWWURWNB?0YI2C1=W145Z^,(?4" B,<LP@E#.$@=-6M=ZJ]
M=S\"=S/A[QK-@:6_04?<L1O;?D";VNDUG3VEA>R)#6%;]7G?CK[K&!Z)(,2A
M![&GVQ$RXD.:, Y3PE-!N,^".+*1_1US34WDO]XK6N;LM1P\4&Y+;ZQ?K6MP
M'UP#,WGD"-F!Q9"A )KMM1BL2DHY+==]#"YW);L/SC1VV>YC++]3NOOH*_W<
M=Y?W<X\)$A 1041C#R*!8V7M,@3#&,LX05S(P"B3;#?DU+272R6E#-M&MW Q
M<]S9<3OPMKZ\/_OVG^Y\=3O>3O;5J:%&]=7M2'_KJVO]Q3XA2'>#^;8BR\]-
M>^(O&_'7S5(H?J.Z!J,?1T3P1$(I NT-3Y7A$*0^3(/(2SR6B$@8.H_,)IR>
MWZAL;:2)!I]WS<<5W4 3#C3EYNDB!H!W[U/W( Z\AX^CUZ.BO0&,YJDU;N$<
M*7_&!:Q6&3+F*'6DP1@,,EJNBSE#[806B[?LQ'&1K^>[^O?GI!!G/[-B'K(X
M)J'28;!$2IOAVD@22, (12DE,D@1-6KY^?[P4]-L6FTN-(G@#TVDH5PX &"W
M.#T=EJ'=ZW:(&&_I;L:[;!3U9LL^4;_MM*,#@XZRI;L9:K;PD:?L-:@[]BCX
M9B&N92O<\FS)+Y?*T#@8@/GYY7?R7ZO\7%\ZW9>9H&D2,N(E$<385_L\T@T[
ML2]AB*B44EDME!C7OW!$T]2$0\.6-N;K&.\J(%D7Q-GQ!MZ/4M:Q@"6#H.00
M_%'R:*%SN%KIX_K=!ZS?P%+L_Y&E,]<I/V )QTK<S@JV6.G207HQUX\",)+G
M+SJL]H>N-516L7E:Y>OLOTLGFU[AY6K9_FB7DU%LDS*R)2B]K^7S:KV?RO4N
M;^5_!6?M7T%6E#<W*QW7JR;;R_#0C6ETA/424 $>\M7FN4Q.?1#E7045C&S4
M0:I^>0%$<5%D3]F"Y#,@LNJ!%_VW+ =+LBZY;'VD7]24*JY7SZ)LB+,LMCB4
MCMJ7PRY:*WW;\3>H0REW-=-HFKMC:-KJO>NA736NNB]O)D2KI<D\""E%:40A
M8S* "'D"8AHQZ(61U'E>4C>#/:E=U?ZD4U,)2@K!0K0[5)W:&ND=J(\?V4,
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M1E/_[!ELJX4]WK9,(EP_Y_/S,_CY?![+,/$"GT,<<:[KK?L0!YS"(&04^W%
M$L^H,\MNR*FI@)]O+^\O[_X"SJ^_??_]\^6989K@#J)NN=R/\8%EKC'/YHF
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M[V*J78R^\[D>Y>B%&JD\$6Y$7E;F4I16F4C;_+$[G3[V76>/U:=8$*(D\),
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M=M?/HE)5'":J#+A"CH3]$!2.>C(,"/';8V3(J?KZP7>7HG5#\7D8<2QP%,"
MZ2H_/HT@Y0F'3!\929I$!%E5>GQGCJG)_!:)MF[N??Q,/=PGH3*P[&S'7?S1
MT.=0+^W@WID;>W^&D3W8!UG<=UX??K1G$]I\I4ZC]<N-6M6UDA]:8CSK^U*=
M31#A)/!0A*&D<0213"*8<HITDDC@Q9&0B9U1VS79U'9Z0^NL;(V\+@]XT= [
M \N.? %[H,TD@2OX!A8).^1NMLA=[)!SFFEA HFK9K5=4XW;L-: Z;VFM2;O
MV <N58K*-J?MGOS4JLJMT)PH055JN7_/UH^/JP57JJ_Z^Z4NC5.W(_^2_<BX
M6')=B%69R_,D$9%@/(2!GW@0Q5X B8@E]#WLQSS"/C(/<7)*V02%TX^LT/?(
M^:YKZ)\[;G3U 5V)8,<0X U'YG$];A>W6\9]Z)*-8E^VTGEU)8/2PGS-VPRT
MN-,/S4";0;#E< 8J'C]J*<V#N3YL24<*^QI_::TBQ0:!OR.FS.U\HT6?#0)3
M.TYMF GZ:?RWHND@?2V_K=1D(G_2.8]SY$=^$A =8)P(B' B=65( <.4)M1'
M*8E%:-99_MA41AMYU%[R.TJU&W"A:(4*_R? %;5V>OY!>'TB6.S%& J?!A %
M,H(DEAC&:5EXA$0!-XI#< +NB+K*"-":F4\N !M84WB-E282:BK+E'5W1M,Q
M(!P93 >G&=58.L;L6T/IZ//]I.X=>Q1\LQ KV=&/XNMFO<G%.UTIRCHAK60_
M@1+*0P0IUJGBC F81IX'F<\BCU)?D,"J#IM+XJ8F?AK>RGNZ;21NTR!8 -)B
M"(B*(R!7.1"$/>J7UH_J=ZWA%1L%M"@5N!=!<DL'L-,O@)G ^ZAE'5A(ME>T
ML^./4J8K[EXU_ $U?W4UI6'"*8: WI%8=DK:J*)\"%#?BO]!YNC9A(UD^=_(
M8B-^%T3G&^I#21L)WY<KJB/7]5R7R^>-O@5L&Q+JMTV>*S%5!J-L$PU^(]E2
M)[@K$V2QX9JI"Y(OU6/%/ R2B&H7?RAY I'O49CZ*(0XX1%C"#%)[5JVC47Y
MU Z;,_;/359DFA?8>.:VN3%K_6.A++F\1UC<>%\&L[-EDDL\\,&C>08ETS/0
M8KMTO((VXZ#B?,\'M&4>E-S/VEE &H&FSE^# E ?-3@X;$LW]M*Y:F(W&MWC
MMKP;>SGV&N2-3D#/L,>GY\7J18BR_O7ULR:A3B42?BCC- B@$+IX:RHDQ-@3
MD.NFOT$2Q"*(K((7#\TTM?.F*MZ^>NX.)K-$T^P <(+1T);"(\F;DO<WE54/
MSO)<1U15=]$5W0,D<QU%QU50W<%YQ@V-.\;N7H#;T1=Z%D-=/6DCG^EK[J9N
M1B0"*@,!(ZQ+Z@620$+#$)*$^ESXPHN%T:7RX2FF)A4:"LOX"\OZH_OXF8F#
MTU 96 Z\ F2 W7Z8>5<E//<G&+<JYT$&]PIM'G[2OH'9?;9>"%U_K0Q>V)"%
M5DMNM5VES[O'[/E^526 J5F5UC%/_)0E98(GEARBF')( C^&$9<$1Q'COF]4
MDZ''W%.3 27YVD.V8P#\49%JT?K,=@&Z9<7 L XL1'HA:M4TK2<V)_13LYUQ
MM%9K/:%H=V'K.T0_Q:,L$U;=[C=%PVJ?X*Y@V,Y_3Q(<\E2))TP0TX&U&*9(
M()@@WT/"EQX*K1QN5K-/3515!1@O_N/FXNKN8@:N+N[M=!8[Z,W4F<$ '5A(
M5<40ZUBD777$YLIC1_Q !1%[X>9(2;*;>U3]J1<L;U6K?H.<5(PP*8MJ_94L
MZYI:N'&X,%\2&BMSBNKB5RE+(8X##IF0(?%('/C$*%O4;+JI":SD5\\#[]0B
MK G7E=YPK^IYA^#NEEGN01S:+?.J5EZRJY77!O"T.H2'D.Q5AM !HA]0A; $
M5M<19]KM90]OWY*$1] RJTAX:)"/*$AXA*$#]0B/O>6BV<^MX.+IN>X6F:UX
M;8612&#!(@_BA F( LRTQRN"7A*A(,9QC FS\G@93#HU&;W7&&9']JPNKF]I
M#ULM@:'3S#&P0[O17&!Z8C.=;I &Z9AS8,H/;(O3#4)W[YLC[YY@_5ZMEJNJ
MLL'RH5)3:_5T+N* ^"$1D$D10L12#U)*$N@QC@(O83&)O&V+L=6:+"RLWH.S
M&FV<-QW$MG,/;:$U@8:?JFZQO_1(*#V"N86=>QJ$8QJV;4JWO1%K8@^WUNUG
MQ1Y%Q:79>GBR\>W4HXR_:Y@>?ZMGX8EVH#]'.!9^%$#"$8'(DTJ0(.1K]8;%
MD?"8B*+YVER"],Z;&$%0E,+HI'R)5]!A&3'J41^FB? @BH($ICAB4,1Q+$A"
M!4V3^0^1TY5QN8Z>X+4G&0Z^*E<*\)S\N02;I?K" 98+GJV!)*P,5#D!3#/A
M.M$DDZ'22@9,)?FX]!&3E!&':2*?R4(WFKI[%&+]32.N]+2SGUDQ1S&*0UUI
M/@XDABCA'*8QHS A,F \86E K*(8#DTT-3NNIA.4A(*&4O"'IM72<#N(K=EN
M=H'8P#N['U@]:D5V(^&L.N2!:4:N!]G-['X%R"//]Q0,FR);"MV>[HEFRW+4
M;:>Z]7D[KGP;B*DT,E;W4J!Q& 2Q,KL4 A(B0A D,4L@]U.?^)*S))96TN,4
M:J8F8A1EL"8-/.N4#NN2M2>MC:'T&0OQH454S0=H,3+;=<5<@U>\O(J0W_'C
M4)2Y@-65O#N)EG&%H@O8]B2GDT%[IN<2'2M21J/>Y!D3-R(O@X?G42@I2RF#
M0<1]B+"V.,,DA3IC/_6X0$G K5)M#TPT-:%8$J>CG0I-70&*U8)K;Q78%%PW
M7JX^/^QSL4/93 :ZP&[HJTU2Q8B51,Y A:*B$Y2$.LPO/0*%JUS10].,F_=Y
MA-F]',YCS_>]>\NS'Z2JXM)XTXNKU?J+*+*'I?8?GQ5_$?RA=(!M'VC28729
M/QY$:<+B%.*RA6,L8Y@JPPU2%)(DCA-?^%9A7R=3-#6I4R7!+<HDN%9ELZ:B
MMOJCU#EX/W2VDNVMW:F+9WJE-^*2#'[?U_#2NO4K='0!V+$#2 %JAMI/O4IH
M=%STT1G&SJX+3Z5GY+M$1_#M7S2Z&KAW2W7=DG!;8TL432_!4%F[GH<B&,B(
M*<$;<4@CKG[R0QZE<432T,I[=G"FJ0G4^HYLK4D$SU6;8^N^Y@= -1.(3J :
M6- UO<5W-?QT8)KSOHQ'H7#7^/O /&/W\.YF]YUVW$=>Z&G<Z8Y06M;H;( Z
M?%89F<^Y>!3*JFRJ\FWKLHL8!P+1"'+?(TI:!%RI:4ID>"SU0Q^G-&56TL)R
M_JG)D"WYVK!Y17>S80P*OSM9&$,S<3BXA[8>72!M;TOVP\N5B6DY^[B69S]H
M]@S2GL/89TS^3GYF3YNG.MHY#?V8)%C9FU%"(8I8!"GA.EP"$1%2A&,2F.9#
MOAIY:B*J)LX\L?$U3MURY23N!Y88-5T.H[D/<GM"FN'K\49+(GR7C7:*X/L/
MG%;@\5I6685_S[C:UG*5/]7%4GZ(Y49\501>_%1;8DD6YYMBK79]7GQ^N<E7
M?,/6A9(+=R+_D3%1[#+6?/4M\!,/PX 3'R(>,$@I\V',$8NI%_B)[%7MT3FE
M4Y,*[4*!><55 >@+*,1#><CJ_+CGBA^@MH-X6.6604'#+;JAJC.%I1Q8Q-5,
M +VW0<,&V/*A%[3AI%S1AI=1ZCL.!KSC8H_NZ?R0RH^#P7VH#.1P$_9V<6V>
M-J5CO(RZ?4>+K'UIUU)9T// PS3Q9009"94I2WFL-,!8%\K"RI!EPJ/,JC*6
MY?Q3.Q%:Y%<-. %[967IFP=K]YC5@A@[S8:">7A7VA;A*F;_73NV=2^@3V?%
M@U,W6Q_PW#G?K&8?VR77!YIW''6]AK&3>:SJX3Z_^39G,DF(5#JOLE@CB'3(
M/PY3I1$G*"#,BSP1&ZG NR&G)IEN5NI7;B9[6L!TBY-^[ XL(6ZNOYU=?3E]
MN^\S]\X.+@3[]6'UXU_KAZL-7/^RV[NMH4;9COND-SOLG;_8%W#X(K3.T6@A
MM8\C8K$Z\F,*6>CKD@W2@ZGG)5!$04HP)L2+B6G)AO<FF-J&JFBTZ';V+FK=
M^\L%%H/?X?\H0Y :"\F^JL*[N)C743@5GY$J)UCC9%4>H0N$CH(([[XV6@F$
M+J+;10\ZGSO5F=8$A;8JJRL+J_5;:>3/4Q3Y"1)*I@DL(8I3H12$!$'"&?(3
M+TDDL>I4:TO U*1?V_6U#;ENLS#3?I/6![6WQ/8"SW:=;-U:[M$?^@K/.? G
M^*;LT'/N<C*<_H,\27;@''8068[3-X1AQ?ZAS2QE8Y4G8:M ;T!C/TI$ +G4
MFIU'):11&L(D)8AARA-"C30[@[DF)^;*^N=5_>C*^WM[]]VV,5,'M(;BR@U@
M0TNF[F+H Y1%-L#%61#!X9E&#A@XRO)^<,#Q5_H)C7-2/.I( _4?W>[[!UGH
M>,NS]3G)\Y=L^5 V?9AS/_ 22F.8)'X $:8IQ(QP&,1Q&FE]-$RM^E(:S3HU
M0:*I+>4'TS^('=UVLL0,<3.IXAS'@>7+%L+RAQ;),T#6H*&ZZI_C3L98H>1(
MVIC-.:K<L8+AK02R>[F?++I<_E"#KO*7OZ_R?UPNE;7(E,XT]TF"$J6MP"0@
M%"*2$J6[! Q*W8-8>#Y-[>ZGWI]F:M)&$Z>369XK\NQDS $DS83*Z?@,+$6V
M!,Y @U)-Y S\EG==SUF+CFXL',F* Y.,*ARZ&7TK#8X\W?/>NNR;V&0.>#[S
M8RXX]*@N4$E#']+8(S#Q,/*B@'LA#6S*.+T:W6JSCU;'J2DP0$I2+>^87X%G
MMM%[0S+P_FX:L[I/KGB/85=WNJ_&'O?&]CVV]NYCWWVH;Y9K1[)6;1;+ "4$
M"PQ#*G1<<4BA,B 2R *./4J1B+A17+'%G%,[PH\E0-IFIQX'W6S?.X9R\-NI
M;A2'Z-5D#I"S]-#C,XZ< &H,P7Z*I_FK?0V%U[V6K\3ZXJ?N)*FF^FVUXG]F
MB\4V(8AZB"=AFL @U8H$1Q'$7AQ#&::<)#Y7DL@J4\MF\JE)I$K/R'8]T/NH
M&E;HFYH<PV ZN"&RUTQ>!ZM]VM(.&N)_&20KJP]LSFP6BZE'MF3L0=FW;WJ,
MT?/61JS7"\&_9>OL@;0ZK$J41%ZJ^STE.(0H]'V8A@F&-$0D#4F<(LL;F_?G
MF9J$JLD$.SHM;VH.P&EX2W,Z2$/?T.SA,\2E3#<,KBYD#LPR[F5,-ZM[%S%'
M'N\G ^JKMN+K*O\F'LBBFJ7\:.ZSR/?2B,)0"J6^>&D*2<!CZ"644RH%Y4&\
MK8MO+@XZIC3ZMK\IBC]&]&M-L8Z:('4QAH4F'10[VNV$11?N9@+C5!A'"J=M
MH).K')1T@CL#S*SEA@$:CF1'UTRCR@\#EM_*$)-7^LF11C5INL#E@A3BBZC^
M.X]\S))$:11^D"*(TIA"*F(&11 C&DF._= J_JUSMJGI%;>"+)15VA1.:-([
M'VH>[.1&-\YFDL,9>@/+CH;.&=CVC2Q)!)\:8ATVU3 "Q9$(Z9YK5"%BQ/9;
M,6+VTFF5I%L1:M_4!Y=K\53,J4=3$H8"1BCP(9)1##$7RCPAS*-^&K,PLJI0
MV#79U,3(>^&:X ]-+BCIM2TWWX6SF1QQA=[ 8J0_<+WK-7<AXK@<\[M3?4BU
MY2ZF#Q53[GS'3H!PD<VK;.B[)[)8-#/,DRC"$@<)3,*(0X12'RK#14 B/#^E
M010'GI$3]L#X4Q,3)7'JL+P59;'XY4.9X4J6AJ4C#J'8+1$<8#.P$*BH R5Y
MV\CWTS?^$<8[4O[4F]4V5S_L=O>A\4;9T$>8:?;PL<?ZG?M7&^W-N);;[^WW
M9:9L81S2A$=8=Z&G$B*!,4P%$C!, HF\A" _QC8G_OO33&T35U16A6&:;;S1
MA-J=\0<P-3O=3T=JX"V] VDGZ[YW@F1]GG=CX.@D/S#)J&=X-Z-O3^\C3_<3
M %])EI>AG+\K*V*3EUZ)K[GXYT8LV4O3.EB&8>@%'D3$4_H_%4RGW".8QC+V
MHDC2!%G%8QK,.371T*(4;$GMV2O8!'(S8>$8R($E1T\,K<6'!2J.9(G)C*,*
M%@L(WDH9FU=/S>.]$NO/8BEDMCY?%>NBS(G;53NCF*748PCZ-,%*[+ 8IEX:
M0/7M\B7R4>I)VB]]MW/>J8D>;4BLELU%R%*L=:>5;,4S!FC%!&"*B[XYNMUK
M8'B+ZA[9H6]56QFY.H*C)AJ45(]4),X(*^?YM]VS?E#:K1$4A[-MS5ZW+)R[
M?L[G5W^=AQ&2$8T8Y#C2R2A$]]@D :0I(Q1S/Q%F103J\:8F7:XN_@[^>G%[
M=_&?AG5R:U@030C!(H$A"I29J+'!) J@X"34-]@H#8E9Y^ >P(S3+/A*_ G^
MJI? T(G30-,M,WNP.[1%=_PK8%XH^#5W'9X8_60EN?1/K=+ ]0CC% 1^3>ZV
M#/";C_OI.74]R&(;&IG$B$3$YU!&4NT9'9.:2AY YF.)$?=('%NUC7L[P=1D
M2T.?G6JR!YN9#G(*& -OL(:T04)"#_'M2''8&WY4#>$0<V]5@8//]72*9,ML
M+;YE/W3?D;W T+GT0NI3*F! _!2B5,00IVD(B9=&/D<HC(/0)E.M>SJK73U"
MZII6E[>)VV=/NC:=I?^C&]TX87&@9"&,:20@BGQM\=$ 8AH%H1_RT)?,RMOD
M#MT19&9%+5QH<D^-VS\"M*&/R1E\ TO9&KF24O!^H+Y#'Y,1*J[<2]V3C>M9
M,F)\SZED]I9]54OM A>\;*52D"6_V8A\O;K-V*J. D]2)GB ,.2$>!!)P924
M)@DDRH0+(AY*SZR.B<%<4Y,DWW^]^[4LO5$1"C2EY@4>CP';+3P<PS6PY*@H
M!16I;R'K41SS&';F=3(=8CA2R<P3L;0JH&F(3D<MS6,CC%96TY"5=H5-TU=Z
M.NFSAV4F,T:6ZS-6%B!6ZM[-:I&QK-V1Q$MP(BA+(!.>OA_4CK$8<677DH2G
MB(7J 2L?O=&T4Q.U=Y>_75U^O3P_N[H'9^?GU]^O[B^O?@,WU]\NSR\O[BQ=
M\V;(&WKFG>,YM&-^1S#840P:DL$?PSCEK6!RY9,WFW1<E[P5$'L>>;NW^TFF
MBZ?GQ>I%B+J+2EG!L"Q@V"Z7=[5:_A"%SDC_D^2\*-.@VW_7]P17J_5_BO6M
M8"M%]7\+/J<LTCWP!)18<(B"4)GT(A00)RBFA#%&B+ 19H-1.C7Y=ROTM7 5
M+I5OJ2S;J#1L /%3_RS:'=R7JR6L> >D9-Y.4 [W13"3K9-8WJ'%<7=]4&55
M-_R!DL%9>8-:=H-_$6NPXVEVS%5D+;,'A]^1F!^.SE%/AL'A?GN8##]ACR8:
MV0\E3M41)WA3VOZN2BRK33OD!7&HM%Y(/(DABA.A>\K'4 C"O= 3L6]6>\1D
MLJF= BUZMRT3+#I*'(/VN,?!)6 #R]7WL (UL7W:<1P#SZ(UAT,0QVK3<1*8
M=CT[#-'IZM]Q;(CQ>GD8,O.JKX?I._;"]5;\6"U^*"WR/!<\6W\E+%MDZY<O
M&_%5T'Q#\A>%95)_H96BCG 82,C"4-^EAPBF7%)=Z2E*!>-^%!KIZK833TWH
M;FD'%?&@H1XH\D%#/] ,F(L3JY4X+I>'PG?X:WM3:'N(;"N,S<7W4%B/),I=
M?)VM!'H?O#J$N]5PHPGZ/DRVA7ZO]_NTJ*/K7>' LT790W<M[D7^=)-G2Y8]
MDT5E1?Y.UIM<47"OEJ)X7"WX7*9>BE).H.1$*=[8"]510!F4C.HR& @C"\6[
M/QU3.QZVQ /UWZ<9>&[H!Z1D #S5'(!UPX)-$[C^ZV6@S8^S"D,K^HJ+5NW2
M&=BMR'VY(EM>:@<):+@!]^.NB$WWOE%69K0F?P.ND&5#P)-Q[>P;V'_T$=L+
MG@S!ZRZ$IP]G?XZ=5<7*:OOH5E U95.H/4*^C",O@7Z .40Q2V :!S'T(AY[
M?I*0-#&JI7)DGJF=0S6-("^)M' +=6%Y_ QQA-# 9T1-9>.[ !6=1ZOA6V%E
M+MT=83::P?"LABNSX]:/8MM1H<R07BW;I0.?7W\%?W4CLPW0ZI#)76^/)G,-
M6&C+5)/'>\C,Q>)U7ONV_.YUOGY<?5$26ZW"8O60L>)O6:%=^R07=YM<?:!D
M^))?/S^N'\GB*6.US>R1*,*Q"&$4)CY$1(:0HCB"*<.AYV'?\Y!1'/$@U$U-
M/BL&W]9SF(%=5>N22_"*S1FH&-6QX&(&&E[+D*\=MQ;"R_D7P.!X^,AE'?I0
M<;:B9Z]6M(>KR_W26IQF'[G$(YV!0RVUHQ-RJ!7H.E>=SSG>:3P47*_.\,$F
MZ1?3]?OJ1QE/<KG4I2?*[:)(7/U)%%R%FNY6J7CY#U'<KA:+KZM<W_7/!0OB
M1!>VE1[U($()AQ@1!HF/U#$?2!DE5BU*>] PM5/\[N(<-%GQ,^ 'T$MGH.%+
M=\W;<@9VK%4=DFOFP!^:/5#S9UG8IL\J=A_2(ZW-P$?Q>,MB'41U K".PJ/Z
M4#!JX-,)$+T-:3IEJ+Z-DUZ7";Y<UH&YQ:U@(ONA*V7,8Q+SB(8IE*&O)"E#
M.N35E] 781"&)%06DV@Z#IC)4I-IC3;HZZX# XO/^YQP':#:4&C=)LD :S-Y
MYPR_L=HB[94(UV*MH1GLB';9"LD<(F<MD RF'+GUD3D(^RV/+-ZU+PI\)UCI
M4/<#>I^MU3??QS@EH5+54JGSNK'2W%+,4T@9B9 7>VJS&Q72>6_PJ2EB)5':
M^>@'G^@OH"'7O!CP'GK=<N-43 :6#[9P6!4"/L1WKRK >X.-5@+X$!OM^K\'
MGSFU$-\7(;.EX'41K1NU>,67K&"+E:X 6-73FD=2_1^.$(Q0PG1=!@K3B"8P
MC.+$8TG 6&#53<1J]JEM\';]N)I\T-20*QD +0[J>G*6UI3=ZICI%8-A/K0%
MY13N$VKV6<#FO'*?R=P?5+_/ I;#5?QL!NE;D6N=515-]>AWSZMEL<J_Z>57
MEEA=>=<G(B(1"2 +L80H\!'$1%M$ 1*8!A'W0JLVC 9S3DVX[4@N-Q>HB08-
MU3WK'IN@;R;&'&,ZL/ Z'<X>1<&, 7)6)^SXC".7#C.&8+^:F/FK_0116:;T
M;,DOJJ388B[3F" E7&# =?-71 BDH200,:RD41PPA(5-2;&W$UB)F!&*B%5]
MJ>N<8$L_RQYX9D+C%$@&EA!5U6'M\+TXAHBU*#C$MJ-]OS?\J)O\$'-O=_3!
MYWJW;RW]@VK$,AJ&+';5*BGR LS#%"(2"X@DDS"5:B?[04 ##\<>]ZRNI3KF
MFIK>T)!:?I,;8DV*7EJ#;+;C'4$W\.;OC5J?;JW'\'#7K?7@3&-W:SW&\CO=
M6H^^8B<V2J]J_C+__3_FG$0AIEQW8TT#B'BL2XP$&/H)(:$7I0E.C$H [X:<
MFA#X7?PT+C37 J9[1_=C=^"-^_O%?UR>7Y^^/?>9ZW!=U@]7F[#^9;?_6D.-
MLLWV26]VTSM_Z7G65G&F:C?6A2#*]J=-'!C&7LIC G&DNPP&7$*<Z)H+,D2,
M!>J#U*HS4==D4]MH57?>O%>-[4Y0#0]71U -?;K64=_Z<*T);1H;NZL,8(.)
MJQ.V:ZIQCU@#IO?.6)-W>EYJ;&A1=BM:7ZB=L?ZV[:X;1X+PD!+(4T&5K* "
MXI@',.$T\AGU(B\-K.XO#DPT-3FQHQ.4A)[0O?@@MH:W#PX0&_JBH1=8]A<*
M1Y!P=7=P:)IQKPF.,+MW(W#L^9Z"X=T"4JUB9I]?=H_4M<[*JE+7S_K!XC?U
MX+JX7-Z4W;?FOJ>L>D*5ZAYZRLY/,(8DB264(I$IHLK21YZ5.'%*WM2$4$F=
MX.!3M@2%9J/XQ5+TN%T]0X'U86LRM)AKE?5KL]:N[0?H"WBW_%]5YZ]F<08J
M)G6\5\5F66E?7]1^7>529&M]>>=0<@ZR)*[DK5OBQI72@P"[)]N'F:7?B? Z
M.WRGS2 _IB'U?!BQ((+(3R5,?<ZAIXS-&.E06=/>9D=FLI$(X_0\^[9:/D!=
M*@1P1?*L;#>IMO)&O:.S17155_T'P+."V7=^.02XY%BB( EA*#%2@*M3E:28
M0M^+L"\BGL1Q:'.6.H![E(*)KRM/G*"8'P+6[)AS -? YU4OI*S/EB,X.#HD
M#LTRJK0_PNI;L7WL\;[A.*T4M+.?63&/(AR$. JA)Y(8HO]+W;LV-XXK:<)_
M!1$;LUL=*YSA!22!=S^Y7*X>QU:5ZW6YY\1$?U#@ZN(<6?(1)7=Y?OT")"71
MNE  !=*<B'.ZW38)9#X@'B02B4R:$4AD2F!()%$93F.2.=5^.NAA;!3P]MHF
M^-/(Z!Q6LX^BW:R_")N>Y[L;+!W"8TZH[BT89K_]@4-?3JAW&.ARZL%N$_KC
MNM#44!3:MF/YO#+MYJ*L\W3%_[G.B[S\E=LIKENC(_J(-X*#AN35(:^1'32$
M[^6TMQMNGF: 8^>#3H]NP.S/G8ZM=/1=K1;\'[=%L9;BTWIIBFJ4^Y]RJU0<
MWU--(Q73!(L0BBR,]%J*,LB2((()"EB@$F4.G)T<5.XRC&VUU;(]+38.*)"7
MNNB]C1Z'ZG>0E9Z.-W4KGLOP\NY^JPXC9^F<ZG<\AO! %:"2?U(YFHK)<8=3
ML]X$5?I#:;B6/'J6NN/IRWW408)A?43=(3IP!%W05.>@/?,)%>:B@=[-Z*[-
MM>LR,G":1"J(9)S C!FNQ I#*I(0QDAQ$H1A%N'8[09T2V]6LW#0B\\;88VK
M1^G%;,Z-Z<V-L,XQ>R<QM@PKN!"WP6+VMH!5OHE:T++\C4=WMP4<_D+V3O8T
M=,C>.96/A.R=?<4])=U7_G^U?6=JR"SU-JFDH#I")E5)1!.39SK4G(%4B"$.
M$@D3%HN4!BI#S.J.4&LO8S.>-H*"AJ3&+MJDF=K^_<>SY#F=K5XM3:5VK-MI
MPQN"/1/&5PZ.H.>>2NTT3O8IT;S@]3[I/9_H?RZ6@*^+U>))FX&:?<UO]9_S
MU>L$'/M"/:7Y/(M92S*RT^\.EE3LK/C-Y&#G'W;GTA_KIR>Z?+U3N\0W<_'_
MK^DL5Z^:/#:9)\I+GKL:IR$/4QP(!E-BKIP'F8!4IA2J5"">28EIQ&QYMI,$
M8^/@6@GSX;_096YDU6;:O,CU*-3;U>7BI4S8YI!CN=O@G"?FWB'O>X]:HWVG
MFAFZY@+L=-CEN*DNG0.;\K2>!L">\7L?B(%6@[X&Q&DIN C,EF6B6[N#+2$7
MJ=U<7BYKJ*/_M"I1MCWOV.45:)0RCY. \B"!8<8E1%'"(.5Q!--,9BDF L61
MF[_T?)^C6UYN?O]Z\^T!W'[[?'?_]>KA]NZ;H[?3 F=+[Z9?]/I>*>IB@[MS
MRYV\?94LMP?(EWO2HL=AW9'V$!RX'QU>=;=V;Y22?)6_R-LYUQN5!_KKGJZD
MJ4 [-Y6S2M+[(A_I[(=<K6:E9[NHRI!,(QZ)U,01QU+;O8C$"#*$-"E)1AE'
MD<0XW7@B'^PLW^[2=/!4/@Q 4Y4>8$5_ 58G 5)Z6S@S.H!BIX2] 7;!@)TW
M@WO&?QB&VRH!:O2U&L#H =XJ,@&E*J"AR]G2WSZ'P]XH'F98!K*,^QP>)^OX
M<E1;3.0+&A_,3KX<@*:Q[*&U;A9S>X+BCW1F?C5E810H$D50TDRO5@)'$)N+
M=22)(QS&5,:9T_U;JU['9C5?+Q;/I?M%SSXJ7J0V*(KR_*PLEFEN1A@7N13F
MBH13_2NWL4!ADL8B22!/9%HE+J,JP#!0-$':I) 9EM/GZI1U19>K=QJ1?0GZ
M]!V70FH;X3&?S\V(L$K</M!/$J[WC4$ $\6HMMN0@#B))0Q0D&5(QHA16J-_
M,[<\0^X)^TW__2,OYZ)GV.TVD]Z!['L[>:Q@P-DB ?X6\DZX>=IEVO4YZ#[3
M"8;]G:;;RUW=6S/]U\??]69H699GN1)/^3PWH8=F5=IDO=HFS:!Q* ,.,9&)
MV6*&IG"*WG$F>C4/]!]4BMVN-SGU[S+/AKGT5(L_ 8^5 N6LHF]4Z)BJSFU@
M;#UC/8'=NX^L1OGW!LIO9=^FO^LA-T<GV+QYSESZ'MB'U@&60V]:ET;<:PK<
ME ?]5T(LR\#K*L-0D'*F8AI %60*(DHC2%,906T*\X"AA.A-BFU=@6,=C&V[
M4<D(:B$GH!;3OK; 413;N<<'-GT[J!QA<:HQT*9[ISH#1QL<K-9 FSK->@.M
MSW4S56P<&L?#?V]^:=.IT"_4"<)KAU],@@3%1,&$2JRG/Q:0I6$,,X+UU.>A
MR.+ P6'>EYPC=:4_-'SH2SDSW8+5 A0F.OO-/0@WN\?[*-N91N\R:&/SOYL_
MU"LN^%"K\YO%S0K?F\>^!L.33>9=O$'-MK[ W;?L>NNGV^KQ65N5*_E%RR-N
MYRO][>9L)LL[=\;K;1)4U'V7G_]_2+I\^&LQS0(1:B.1P%1(;2'B((!4,0RS
MD(14(4F#2+IXJ3M),38S4D\(Y$;JW<"W8^[>(>V9GBOY8:D V&E07?6=E'S,
MS=K:5&8"C!Y *^*/="_"T1.S=I-A4/J\"*9]CKRL,??HDM\7"_%7/IO=/CW3
M?%DFY%@4Q;?%ZK8^:+J=E[WO_GZM&?I1%B8WO1"49U I1"&*N-XJ\Y 8@QDA
M3",49=;QU)VE&!L1;A0!^592A\B1[H,19F&6L-1<.L82(L$4I &*8! 1%66A
MWLG(Q,X-.]AP#...?:\!B5&<L"Q-] A$!*),"4BIB/7LD E32481QXZA5_V.
MRO#;Q?<:FG8C8K#OOV<C8J/#!.RD!$:-"="*@(TF^H<ZA4CCL5J;(0;#/L1J
MD$$9*,*JS\%QBK"Z&-26 *ON;0\67W6Q^LWPJLL;ZRD7<>&4!_/O,G_\J9>
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M'JQ-Q"@+!=&L! D)I=ZU8 *)R;^2X82'VI() VH5(7V)$&/;T&SUJ*ZN5YJ
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M[J)OJV57T:W=P?8;%ZG=W(E<UI![Z9WKQ8M<;HL]Q)D@+$@()%F20B19!DG
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M#-"AS_$15RWV_G5(H"4'6G1@9+>/LK2%OIVI>@*T=XZRP;+#_2];4.V#57L
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M+[U]#W\MZN,03E&2"95"3DEBHA,T2V!A2L4@D5"5,90Y[> M^QT;:>Q=79N
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M[8]T,.AL/ZW@_B1O>;+;W+Z7SXNE.2+]8YZOZA#4((XX02B&(4VUJ<]QH,V
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M=7K_QS3C.) IYC#&H8!(26W#J4Q FK DQ2&.,V'%.[LFQ\8J]^NBR*D=5S2
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M0!G)(IYAQ:V2YK5U,K:%<R<C*(6L/7D=XF</X+1TAUX(4M^.3U=\.D7'G@+
M8TSL01>#1\*>4O)8_.O)9SN$S-U]OK_^='=?YZ*_FHL?=]]NKTQZ^JVUG"$4
MF,S%,N'45"XWIZQ"0!$%* HC@B-IY8BTZVYT%* EG@ C\P344E=W^HW<91D%
MESBY\VB?M[/]8M@W0YR'KTL@W'D<':+?O.(Y5,C;!9^E6Z2;-3IMX6WG&QDN
MILU:H3>!;/9O>3L+VEK]:1AF*L "4DI3B'"80,*3&-(DB8D4/(E"ISB7EK[&
M1K_'CSDZ7HELP[CSX= (MUE=0?-Q,M33#JRMI_<^%SJW-[-YI6MZ\P?ZZU88
MGZG*>;GDU(E3(A'B4*8IS&*,3$JZ#)*44(BS+.",I:G$B5N*\Q,]C8TPZN3=
M6EKP5MQS*54< 6[G"Z^P]>V4Z8I8AW3G9]"X(.7YJ98'3GM^1L'#U.?G7NAF
M3?PQ5_1EL32;PWOYN)Z9@7FMLI#6]C'#G,9)1&%  J9W=3R!#$<,DBA*19AD
M:4*(BTUQML>Q$45#8+"3N$[5ZF97G$?;SKKPBF'/K-$*7P]W):VQ\61PG.]O
M4+/#6OU]X\/^Q8Z^8E-$^^/Y.ML?]^ML5SQWI\J_%E?KU<_%,O\O*:9QG- P
M#$SPKLED+ED 24)"2*0,XQAGF 5.I1B\2S@V)OM*?^5/ZR=0E'("NA44?,CG
M]6\=JV;['U5+?_=[CE7?KC C&BPE!TWM0$,]4SZK^5RM(BAUW&0%+#-25&.]
M4]2CR[VO,?#EK_<NW[#._K[@/3@IZ*VCKB5Y\L7RN]3_%/>2F[SX6YOW2OSG
MNBB3,W^2!5_F98;F*999Q'FB(,I" 5$8RRJM.D[3,$@4#?2RX%:3QTV L?'\
MOM".=S6<\;>C[#Y1[9F1]^6=E+Q,EU6TOZD MI$?_/E],<OY:S]W.+I"Z*U4
MCV/W ]?JZ0;.8;&>CNUTO;):%CPTI8%,VECC[/M[OOJYJ7RX]3M'+$%9DB90
M,2XA"D(&J:DBD<9!AB663&9.%6(M^QT?MU451<MB61O!P5]:\FUMT<YN?]NA
ML..['@#NG>:\8-OA<JP34MYNR]KU.O#U62<H#N_3NKW>)7727-/C#\G72RF2
MOR7!M\5*%I_6\MOBI703:)R33>(DR9DR82 HD-@D15.0$85@$L5<T)"D06!=
M:LRAW[%1EI'V7T"E "C%!EINL!$<&,E=<OO8#T [4?4(:]\[Y K+6FQ0 7P"
MV4[ID^PA=DF>U O4@Z5.\@FY8PXE9^!:,RC9MS9@_B1G%=]F3W)_O6-2[GR>
MK^27_$6*6_W-S1]S-I-5NN^K)U.?^[_*[] D!9\7\EX^T7PNC(_@<UYP.OL/
M29?35%&I4KU3EP(3B%)%()9A $44H82'BC 5.>7NOERFL2T96R&-"\]\PHXI
MO3V,DIV1.S#V/:\KE3:P5 ?L]*G*$S2*&#15FX W@U7I!8QB'K.)^T/95])Q
M#Q(-FYO<'X0'*<P]-NUND.^*5YJ-VN?%4MOY/^@L_W5]<U?;*%E(XBCB$8P8
M"2!2(H4LX &,,!51HJ*0!U8W,NRZ&QN7-FJIEEO92F90"@VTU/9VH074YRUN
MOP#V3(CGL.M@7%N :&]3^P5S(%/Z<E"=S&=[C%JL9HM&!C.6[15JVL@.;W5U
MY!::R?G/J[GX)%_D;/%LOJ6:]6]^\=E:E%7>_[G.EV:E*(O"FUIAQ6JJJ HC
MDJ;FNAR#* HHI&$00Y)%(L:($1(YY?"Y0):QT?=&E?+6@M@IX^K:[3XXG(8B
MXRB$"34ALE(P4VL(P3BEE&<ID82&T]5B16?C&IRM1,,/#N#V><%]#)&M1WX0
MX'OWTC<P;^@!:D7 AZTJ8*,+R.>@UJ;,;GTZRJ>#\_YB4+TY]+M+,K"3_V+(
M#AW_ES=Y89FV1O*[KY*:RPOB;GYO?%(F??='6N3%'_,%*^3RQ009WLZ?URO]
M9PV9?JM<F*_IC)O 0_WC_6(VTVNTB3*9HH3A,#$9[2*10)3$$608Q9 G1&1Q
MAF,<.=56Z5WBL2VAN[IGDS?I)C=*FS*,6[5!J?<$-#4'I>K@K>X3T-"^8\FY
MWKX92^_5F+Z$OGU;_7\$X$^C.JAU[Z.:7M_CY+LD7V_ROD]=O[[A/UD<L/>.
M.U:2*-,B\]<??]'GS749%&5"R!!F"'.(B$PA2RF&F0JX2@.AURJG*[B'78QM
M==E("(R(C@4D#O&S(^[+4.F9:=\ TL,-E]/*^RH@<=C!L 4D3BIX4$#B]),=
M9S0M?IK_FS1)+W2F;>A"F]:K96[.?<P?M(']]A>-)ZN@P=LY7VJ.DI]D]6_]
MWY7UK<WPGR:DVN0"N%%*\M54)HEB'&60,H(@HEQ!HE("8T2$##B)&!(NKH5A
MQ1^;-^*;7.F-;B6VV?%RK=^D_">0.S4G8+E%H/KC+L]](5>K677!0LCG19&[
M.C$&_GXLV7*T7T7?3%Q^ .:?X*;Y >R4!=4CY@O8^^7;-RH4P 8&\&$#Q&\3
ML,4";, H\ZJ "@Z/O/\NP^AK31E6^&'7JW<9F(.U\'VD<#^Q-KZJY8O4)OB]
M9(U,3"3D5 0B@33(&$2)MIHQD1QF-.%4V\^FF('M,?6)/L9F.]?"V9^>GL+N
M_+FS!T0&<&QK"8W_ -0R=CA?/H60_:&R!Z0&.DGNA)C3X?$9+%I.C$^].=@Q
M\1G1FV?#YQ[MMI?XN"[R>>ED?V+YO/)"+.8K3:?ZR] _%;ENJ_SUQKWQ6CLW
MS*=3^C"F04QH&LD$2F5"=P3!D%$5P9B10&+!! ^=KC9ZD&EL'%HZ-E\JQR;?
MZF)^W"D#%FQ6G_YK8T[D!3?)EX$I8.YFW_L84SNC?>"1ZIG;-]J ACH3L%,(
MO-%HYZ%^G8"&5I4+VI]%[1%C3V:R#XD&M7T]0KAOT/IL>HAH=Q/(^5D_.^4H
M"$6F#=DLD\8''"M(B8BA"C.! I$%-+,J&W&9&&/C:?VM9WV&L6_AMSS[ZQW4
MO@_T.@6K&T6 T>2]HM/WD7R7@/2M$"..0=\'ZK*P\X/6NB:2O);F7NGL=B[D
MK_\K7Z>4QRE#G$(LA,G 06/]DZ&]1 I$@P!ANYRS)WL8&X_5:1!K*4$I)M!R
MNB:,W >RG;:\P-,S(SDCTR$QY GM+T@(N=_BP(D@3RATF #RU(/=3)LKW:;(
M9VM31*N\.%@>KG_3H_MI82ZH3",:XICJV4Q9*$W>1ZJ-&"Y@+%4FXR3F2#GE
MFSC7X=BF>5->L!-X HS(X,]*:,<$$V=!MS-=?$+9,R5<B**S+6(+C2>KXVQW
M@]H7MLKO6Q+6[W7/6%]ES;F=\\63U-:*-$>P4Q9DB0@2"1E%VF! *H,4,PZ#
M4&),3%7CR"F!XZF.QD8M&[G,8;46TSTW_5$T[;C#!T8]<\9.1%#):(Y8*RG]
M9J1OP\%C.OJCW0R>B[Y-V6.)Z%N?OS!4_&/34?-Y698IXJ]7O_)BRKB(PPC%
M,,@8@0@'#.(XPS"A$8X5YBI1HE.P]^D^QT8/38?G5E#PIQ'5T=ZP =S26^(7
MQIX9I!."W:.2SV/B.ZZXI<?WB0P^#\')V%Z+5]UC#*Z>%ROY2[/7[MKGYAPX
M8BPB>C>3)'$ $1,<DHP@2'":R"2*0D:LDU*=[&5LE%():I;3OX&=K/:'ZJ?A
M;*</;R#UO4TYBD^'Z(.6[\XZ_L +8 -%(#A^6$ZQ!V=Q:(D^./WN8/$'9\5O
M1B"<?]B= [_^^*9I9;$T$.O]W/=E_D)7\LM*''Z;%"'*LA@BKO0_L@1!QC(-
M:QQH5N2!8-0Z\LJZU[%QI!8<-"4'M>A R]Z-->T'X#R+]@)KWV:8):(=>-;A
MV[;FW5X@'HB'+_YXG9C9&:D6IK9O:S#F=E:OR>3N+WN/3= 6-?W/Q?+:Y*XN
M]WA88I11(F":&GZ7$8)4901&BO(8L3 3F'L*2-CO>VPLWWIJ7IBR&J7\H%2@
MVZ;;86 L-]_]P-TS^WM%VF=0PBG,^H]$..AY+.$'IR!QB#DXV43'\\EMJOWB
M7LXT@XJ'Q0/]9;)9_US,S)V$SXOE\<HE4R&S,*:A@CS(!$1Q(B'1)FR9*C]"
MDB NV'0N'\M6'4XPNXMD-2U)-2T/!.OQP/[I>;9XE;+,0U;K %;TE[8?EI6&
M8+6H"D-!5M89HN;6M..=N$N&THX@^QZ9X>L^;>LY[:KP3,#F6@Y0FC9-&<Z&
M@N!N&^'L\33U<EQ]';1>(,FP9["70W9P/.NAR8XU^_A/*=8S69=X:JL159PJ
M$O5@$C),4XPD4R&' 4L2B%*D-*%$"I(L%#334R-RN\?@3;*QV:<;Q;:UVVKB
M/54(KMA5@F.'E># GZ62CA:LOV&WH^]W&<R^R?Q@'-L+^A6M%?W.CJ-[\3[?
MF/LJVN=-KF&+]?F&\Z!(G_<.NBT)=R9/PA7GR[44C:P\52*.U3053)$X2V$0
MT@@BP@-(591"I )*$LQ3B9RB!MN[&QMYE]*Z<>T9/.T(U!]*/;-B*2BH)6VF
M(9N 6EA_#&<'BB?:.M/9H%QDI_@^P5B^U8TU]N]E/>AF2@<84JG$:6 NM)IT
M6:D0$,>*PB3+,L1('$GIQ!>G.AH;4QQ<:@1&TD[^QI/8VG&'#\3Z/D?J!)8S
M89Q#PA-5G.QF4)(XI^P^/9Q]OALQ?%F8^YWUI4ZN^>;CZS>ZTAW=J=VOJT U
MS 3C.,L@3PG3IH7(($DR"B7F3%L6H<APYD(5]EV/C3R,Y* A(ZCD[L0>#@-@
MQR?]P-HSPW1$U)EBW,'Q1#H.'0]*0^Z [!-3AQ:Z7GVL+^F(D&6I%"&,)1<0
M"1Q#3&+]4Q8$(48L#@*KT]3]AL=&,_5U/K>K3@=HM;/&)1CTS FVZG>XQ'CV
M+I+MW<4A;QF=$O_PIN)%MX9,,]>ZD:NEI-<+(:<)E8P*BJ&01$^R- @AI2*%
M)):*A &B26P5L+O?\-BFVW5925X+!XQT]K/M#5CG9UM7"'J>;9;:.TVV8ZIV
MFFQO&AILLAT3OSG9COZ]XVE[E39@4^"<XHB(5*]KJ6 ((D1CR)10,)%A9DIW
MRBA 3G=_WS0_MHE72>=XIOT6,,MCZLXP]#SYZI"</FJ[']?9UZGPV\:'/>@]
MJMC!V>WQI[K47=_<RZVJN4A1%7E_TGOQ\@#@3MW0Y5R;NR:79^G_U_]6B^43
MU>IH2UCD9?:S;XO55[FZ>C+YSZ:"B9@(R6"4A:;V&(D@H1&%."41CR*AK5GK
MN.\^!!P;4VPT ^9S 'RGFSGED[5VX-DDDC;Z3<R/&PU-0KI:13!?K,"37($/
M^;QZLCA=D&F8+Z&=P,8POGV?UV[5 ]M1-@J"AH;@3H&-CB8C='5>6R:'WH[R
M3E%3'1U\-:F8*F7?>81="M6_[T@/5M'^W4;<*=B^S^%HB<OOI=O!0OC[!*T9
M[=]K/QU+6#2C DS*[U5>^>T_Y06?+8P7?VNW<JY8&B $PSC,(.(!A@RQ6/\G
MY[$24@;2R:?NT/?8UO:=K."CG$N5VQG$%P^!W=:A)V![7E0[8NI>&<$='5]E
M#1QZ'K8F@3LD!P4%.C31]11P_JCG^-,GR<J#Q=IUG'!"$YPHF*F(092&#&(>
M1C!E&1(*1UC)T.W$[U@W8R,B(R4T8@(CYZ0^Z^Z4;^P$KK8'>9>BU?NAG0;J
MP16H#F=V;3AX.Y\[VLG 9W%MBAZ>N[4^W3'@7!M-)<7<J1^K!?^'B6_74\X4
M*EF];I=,F8DXQIH(&!6:%W@20&W%9%#1"*$HSE1($J=@<IM>QT836Z'+"..&
MV/\+5()WME[L!L&.1+Q#V[<;P >J[L'8+BCY"K2VZG/8(&H7& X"I)U>=G?
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M2T#33!]?DQ8%(1DIXM)M3V@QZ_PVB+=]*@&M$)\7H8"7R-M1CF<T [-.KV!
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MC3JPZJQ3>7NA3%AOJHW:P3Y7V<KU)[FY+G65;O.^%/><0IYQDH""EPCHOB3
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MN;K7W8Y7J?D=#%=?)?#P ><@4V\RN^]7=2E-TO?Y -*8I;A J "<ZM[7,B>
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M1*R%$]TZ3NK)N0G8',2(BIBM>!C01*AE>/Q9%A'V*>+Q%UP$YZVSV@OO/:N
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M-,WGHX4!?Y^NBMV^%>* :T^M9 R\],B:#0$,UPX"]X*JY&F.]CM^SQ;+]M,
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M47H'GY[AG[\>?3H[/?EP\OGHR\'9,?YTQS/OE0_MY+Q;AX%*9]TR(76'P3O
M)<&C)5RB X1^MW!:@',.G:)(D]#:B<!J]TM]A93= \O5!YZ5& /#8FOYHCLV
M!@[EF3 !*ZP$I11#KX]8\;3'8KUS>T%!O^=7#7T_C_*VEG"/)]5L.B]]<>)U
MF)],3]/TZS"D@V_#V2!K[H/"&)-XB7&&$!RL3A&4M\YPYJ.S:YU.N, #=.#?
M[I'QVMJ-^#9;Z'%24:AM@&(1*"XYF+V?7+KA>!!DBHL&6]*62^YD!7@7,RA7
M)L<ZHI1;ZX'V>LAX3D _\*BCT^< V5' #3BY*T9^39<^30>6EB83QJ.';E <
MH4P,%0JEHYCG.J-O16M?@SPBH'=T[*K0YTW+MI1N.]"XE\CB+G#%2W0232J+
MP*G2N'&H F., UF&"!+ERE20;I#R(CW]Q#^= V=WV3> H[LS&2.*=(Q?S@9)
MR>BH)J ,Q9"-4H,AFR\U6(0:'@*-O/:KD.=4-!(S;^^I5!)P Q#YDKZF\?6#
M6O44N9*">G!>)A V1[!,&9 Y">%P/^E4.\1Y2D,CCNR6.GU62K2#@-L!R >4
M4RD<+RS\?3B_.+R>S3$6G-XU;BR=E/"?6*I2;%;,Q.C 2)/13,H 3F0":'VU
MI=I(_%8W&-J$S'YAMALN7@999TIJ (>'D]GBJ%]UNKZ7&^%"1*TE1%5Z1!*+
MFU/+4J] 0B:*1E?]TOXU6AHYU^H8KBH";P0X)[FT%'WH*9Y.1G$0B?%*,PKH
M$EK<<@1C4!5*"5U4'$,%DA3I #HO4].O.:JC[1<@5$'T#8#H-"V*2GY)XS1U
M(V3F(%X.Q\,BH_GP:UI);8#!A>8NE#G,R(L0J;RC"@20Z"@9DQ3->FWO>BW*
M^K5,G8"K Y4T +0OJ!DDH$P?>H^'^FBRZ+2^8N;^' __O!XNWIYCN!H673)F
M\P$&NBF7=Z6!: ;"6PW&"P9,4*U<C#96?_&_ [G]/ASH!)+[4E[/D\D.+DOY
MW7\O='62GW9SO^?SP:\=C!8?B9[GY-;QO3\<%@<"C8;:@/M4(Z<@%"U%RI8
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MTKB*>VUEN0')SJ)Q%0:-:U ,))$\\Z03R[4?6;U-T5KX,C\$OCI0P>: LDM
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M #"KZ;!=F"[VWBL<<D9C$!C;R^1P(W)"P0==$E/2.T>D-+)^J<.F5/9;#-@
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M\C(E_9:MM0?#W=75J\OJ+\+@E\DD_CX<C>[96&3M)_-EKJJ([Q4V0Y8QH>C
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M Y#<8K AD">;% 4EO59:*<M<=?]I7>+ZS<=UAK=NE-/$*)A'X?3;T?3JA>.
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M["?N#@#S2-?L(I@Q(4A(CN2AM/2 II"-SB;&6(+,I?7@Y3TZV'=]"[+_>==
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M,?3MEQS.#MV%>CK"YZG$/I B#E)V;4FGCB5@AAG:PD*"Y_1%1E6B,]D5TWI
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MW XYTTFZ7PB]WIPMOM51GJ]P\_7-Z>K/[42"U?GR;,LD[1%T(7%@7%E017%
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MF^N"(O*$"4,2(3L,%SZ-XYF!=E[ZQ#5%Z:VS%T^0LZ\5H<^K=7Z;RR6V'T\
M7F!8G"[.%MLUM[[=C3_Z665U857//I/87]*G_O-$^ERL\QY<O;]2R=<.OIK5
M&3$ZEJ25;#X=H"T'\\9UK7!WU[+-J.6>&X0\:URV6;E=RGZ'?O+A[.1#K!S
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M@&2#35*-0-4?_SF=+!>A9M7/RVS^M99N//EKUYQPFA7.#5EKVM?4*$Z>J)#
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ML>4^Y@(R<1Z1"6EMEZCX#DN/L#56#RAJPOB!KZ;7U3W$^;?J$-8)92M5G*1
MKY,#\D1KJZ=<(_HL@T6EA7&F!-ZB*^-C:X\LM64_JV5OY@X,C@_X[6J>OM0;
M^CJ8=9^DZXEV-B>6%8-4:FLIZ1EXKZHFC8))D9,,+9J\=M[0<-?8_C*?]2V
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ML(]'MW?@\L )'^?SY9?9&ZR':'8Y^SQ)USS9I"5(:W1"(Z$(73N2%4^F*?>
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M&1IK!4!_S_^MW-?-&.';-R?UEP[YKRCL=\6#TFYQ.>4S6%-R*4)3#0!D[F/
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M0.?=J(3=(%S.RB2?0(LI#HC>3@TXEWZ;@<4$TXKYM)2N+D@[P@AO2!\V-1Z
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MQ/V5<AWG LPA^$>7L="J3OR\5"7;8T1*A619=:L$T!;1/3Y]<3%P;&LXU$'
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MJ6,SQJ>>/;&/]?8Y>Q$@YS#L_ME4M98"09)U-U142RQ3S)?F.?6)(*M#PS\
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M1%WI(Z0W1+UU-WN8K%\W5H+F'+TZQAR";>7M!^[I0$3EX-?=Z8J6$F'Z,]H
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MSI0?T;BZL24)9KFK7+>AY?CA?B=YQL/9:X\?GCZZ&S!@(#'3I6Q/2'UX3Z!
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M3,6U9<-JF31:2%E%P@U_5W4(EHGD&X]"JY&M1;J)M1;L?\D/8W\)XL\"4\"
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M(L")1,RS3R/:^O'^V-R*9LZ6]C+V[;)@Q G8-5B^"TMBJR =^=\M*)BJ(%B
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MCV '%RH2E2U*W6AL*&2=%"!)@H]W!7T@N!OM -3X0D?F&%GW3[]1KMUT*Z1
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M93.T_G=4I OXS[2>92__/U!+ P04    " #]A E5<#2[GV=8  !8IP( '@
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M_H#MC87LRF(K1>20A6$WSW5WJJ*J-?HI#<&A#G"<]VY]M84&R&3+#)!?%*9
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MZ^-6'10T_,LF^BJ=HY'@%SX6#!TJ(93R]#N$3X*:A9U$UBD8F!/^'@-2_.]
M2^/>L4H"48+@K,"PW"?!HX('M')$:3&O47M.P/"PL0Y0+ 7H\R7O9939Y*S
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M8W&OXT69&6LBRRS50F<8K3;X%6+2FY*BUJVY61?1;J6#^,KU"9X'R+4K.WV
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MS%W?:.C>^*&M-D0K]: =/M&!>Z>=5W/R?KW+>GV7MW_P5!\\U>&UBKB3I_H
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M,%%Q[I'BLHM7$3Z6'0:+6&K36+%6<,^6T; 39!<%(\G>]*P[_<6XZB9\RS;
MIHVL"5X9-[:-TOGVTGO_(\-$6X)Q9:WQ]LR$89D?@"(R XN<NF"'_I)PDIQ#
MA#Q%\O/[8J0>[Y*1RCT0P$%[7Q8UG]\MVZH@$$G^K79G:H7B2+E6?>5A0F<
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M<&@]@4Z&;$9Z<P0K..O$+U%LD!2XO&AOWI6%_8MTXJOO1^6K;=SZ;P<1>_8
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M?Y!K#!MB30<K"DQ5D.37>!.+B-WP4"8R(NI'CO2--<8CN7(#V9^Q2*1,8]N
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M;>U]67?;5I;N^_T5:->M:FDMR)%D>4K27DN6E<1U$]O+<CK=3[T.@4/RQ"#
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M0]MK#LRAL?"L;T*!8*3!Q=1(T<:?:84[9*;5:F'\JZETM3J;QP8U\9EEFN'
M-G"-'2XZ/ 0(PS4)HNS(X@R8''WK0^MJ5\WH1"[>J7#K0#>&[ZB\%-J<E,2+
MO+G03Z&5EJ5W8/_'PG J$9*8V&QNBX3QEO"V<XVO'D?,BCE7)CUIYG33LEBH
MK%Z<C$'A16Z%.?(DP0Q:??N5;6DU:[+:S+%^R4AG/G^1KH[Q5[!7T1&"S8F)
MFCB:%2D(N)CKC:E1"A.54K8JPNID2\)O$Q7!)TAEFJG%(=-[CTSOQ2'3NR^9
M7CPK,4=#D?</81(9G..".*LP)EDI/.)FAJA^WYTKS+2P\;)&$#J0MC2CVF>C
M9CP<H^;BX>FC#8D+A4DLE*T_$?WS>Q+(VV\D%U JM\NBT@(Y-9FTJILU6%)T
M=XHZ9059CUS?<O=H5<'X.'0?OGDW7N@JL0S5,'QVNB2F/$%$(JX+V'0Y\Y6U
MZ$(^'E8)7U:H]-)E&/; K:2A;*]VZ[:@^@[];N09D))T"]DD$^BC,+/]*LM.
M- 4V :39ZK#.'P$'F(W=KK/<@ON3XQ9*2W4G)..F1'96^TML55$6&<>RR"[Q
M-PU;L05WM2V_*P.SI4J;929J!'1!Y:C<$Q^S5(]#.2=.H[.49WO=8'(O+V@[
M!VW?*/-$+4:E3(U27+(Q9[0%Z/</91GV6 U,AJ,&=@ED_V3W0/9[ K%_NC,0
M^Y],E8"J5;DNFFW;*GLLP78)0'_3))AUM3T].-RZNWOCXF+@>^-L2'LCT&X^
MJ^*JYD>&V0&:N92R6R:=IG1$J2,P7L9FN0B?6\RTMA:UBZC1Z!&$8*=.V65S
MZ%LV!Y&*@&H2G;6)R*>@<!C]%3;4A$5 .KW(DZ,C:XEQK7_8@#?&B"NXU<E4
M83!LILN);2;,C8#%?G1..P7."!E04OL<;#C,O'D>+M"BPK'@7'29EOIPQZXA
M!EF6E#&A-T"//VP];;E]+ #"4RFQ-7LU53DWV[YB(WA7NE,'DS$$QT:)@XA;
MREC:*.I7BJV!8#W*]I:P#!P,92>D^:J]02DRW@14V>N@U<L[@I(1L"&%CRT.
MZ+TZ?NNQ\S)@'[<:6@@YB=NX^RU1SX<G4=](B4(G7YU;P@7R!(4/AG#,7HSY
M#BL^\4G=C1E+37^'F:*XCXZ+A'+B^[(QHPN&^W6%M=HU5VF(R!P)1T11"GE8
MS$U\2/94B>N\%/C1^[VC'@UO1_7JZ%6:F-D#HJ!#3FO+N'TB[$66KZVS/_;;
M1M\IE/R; BNHMFR4?R=E2:%MTHVDYC30JH.\#AH"$GC#LCPQJ3#=U&_MEK[3
M$;\Z/NN##R@<>S$9P%^]B>IA[4+H"9_H/$H;T,>(8<V%,$=V/J8PN2B%(W*5
ML'!<Z;)F\ LW%"AUW90Y8U?FM26@PEX5,"$U)OB(_,FD/;T')/9->!CYKN*&
M!#P@>!SUH. V6<B=27TJ?.NL0__Y^_2?%\XFDRP5O@5;@\Q_OS3(:Y:'<:KO
M.2(+OQ2VSI:9AKU-@J?@KNML\+6;T"&?I$U:2BRP8[L#%UR@@/Q(I;V$:$*]
MU9@B^QWG13"&KHS%1C.-N'6$<#IR=WH2]A)0.T@###=*/1[+SJ1^:>3NR1Y?
MIP,..7V;TW]\R.G_[CG]X5@*NU01\QK^.<O1*W4*==LIZ1 HY8IC#(]SS."I
M:9&E+2JS<D:)M#5M1RF.-%I*S8T#SEJNLJ$\FB5Z))DJ':9[?&\D1B=9:"DF
MD7#97@A>/64Q%4>1"J''YA+9@/R.Y/ =L2OW,%&&1(*"NZ]U$B:V35XU7&OK
M.J<RUUNHRS2FRZ5!!#B1B'GV:41;/]X?FUO1S-G27L:^71:,. &[!LMW84EL
M%:0C_[L#!5,5! MP/( 4_:B$A:X%:%Q!1ZHD?5HU3%06,)$Z#O>I#880S :6
MDVVDD64N[$=MCK30F0KBF)2OWPJQWPB>Q'M9TY/?Y=O,MM-<1.']>W-)[9AT
MW*F*GU]@VZ&P@=\,2"SV"H<[&2I;J#-D9J?6A=R5;,QA1?6)W; .2*'5L#;D
MOATQH?!49\+]87=^/T"''TN0U!8(V8>KVF]":&J*_-O"8&O;4=UBJ>6L<V05
MD:94 *B#,U2Y[@T<VC2$F)"(?V=FZ/C1%/CPF:U8EJ&[SG-[? )WJ1;@/2@N
MQ3C[*^I-,H!C&$IP49D5!3Y+,]J![E55]'S+E5GQ0"?H^59-]T%7\ST'O;W5
MQ(EK>]:B^V<B;8Z->&TCD9&@PMT;[3FU,LGD.RRL0$RVBH3"H?3R1GHAJ02C
M([:[2VA3HUZ!PSXV8RRYP <?/7Y\C-$6;'^VNC=>$)>,7H&2.@3J=E-<3(L[
M=&:V.S4=%'6+A#ZTY.S&[NV",56V+Y#UL\UR8Z =:%^,S4BV+,*= ?FFJ%%
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MVW)2&PPHA#]/K+'4P2^B! [QCYYCJH<'(H#K"9!G%:P0"QBUMJ+)PTY8GM_
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MW&<SM/X[*M(%_-^TGF4O_C]02P,$%     @ _80)5=6Y%DF4"   5R<  !0
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ML[8[*Q?R[RPE9 H!?T<HUQ1%-7=G/WLL3+*Y+EM>DS'5\ZQIJ<+AD#/'H<X
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M'W"M_3!E[2==^=5_B.8^B?OP/U!+ P04    " #]A E5N"JG S,&  ":&0
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M,#(R,#8S,%]D968N>&UL4$L! A0#%     @ _80)5=5<GY6[? $ 6"\/ !0
M             ( !AC$& &)H8RTR,#(R,#8S,%]L86(N>&UL4$L! A0#%
M  @ _80)582"WO<F_   #3D+ !0              ( !<ZX' &)H8RTR,#(R
M,#8S,%]P<F4N>&UL4$L! A0#%     @ _80)53J?*"?L$@  K98  !X
M         ( !RZH( &5X:&EB:70Q,#$P<W!U<G)E;7!L;WEM96YT+FAT;5!+
M 0(4 Q0    ( /V$"56X4'Q+NT\  +]E @ >              "  ?.]" !E
M>&AI8FET,3 Q,7-P=7)R96UP;&]Y;65N="YH=&U02P$"% ,4    " #]A E5
M<#2[GV=8  !8IP( '@              @ 'J#0D 97AH:6)I=#$P-V)A=7-C
M:'!H87)M86-F;V4N:'1M4$L! A0#%     @ _80)5:DFW5==6P  )+4" !X
M             ( !C68) &5X:&EB:70Q,#AB875S8VAP:&%R;6%G8V5M+FAT
M;5!+ 0(4 Q0    ( /V$"56E-I EL4\  "9D @ >              "  2;"
M"0!E>&AI8FET,3 Y<W!U<G)E;7!L;WEM96YT82YH=&U02P$"% ,4    " #]
MA E5U;D6290(  !7)P  %               @ $3$@H 97AH:6)I=#,Q,7$R
M,C R,BYH=&U02P$"% ,4    " #]A E59<%L#YX(  !M)P  %
M    @ '9&@H 97AH:6)I=#,Q,G$R,C R,BYH=&U02P$"% ,4    " #]A E5
MN"JG S,&  ":&0  %               @ &I(PH 97AH:6)I=#,R,7$R,C R
M,BYH=&U02P$"% ,4    " #]A E5\)L%2T@&  #%&0  %
M@ $.*@H 97AH:6)I=#,R,G$R,C R,BYH=&U02P4&      \ #P (!   B# *
#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
